

APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

38th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2018

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2017.

38th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2018

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

CONTENTS

	<i>PAGE</i>
PREFACE TO THIRTY EIGHTH EDITION.....	iv
1.0 INTRODUCTION	vi
1.1 Content and Exclusion	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Further Guidance on Bioequivalence	ix
1.4 Reference Listed Drug and Reference Standard.....	ix
1.5 General Policies and Legal Status	x
1.6 Practitioner/User Responsibilities	xi
1.7 Therapeutic Equivalence Evaluations Codes	xiii
1.8 Description of Certain Special Situations	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiv
1.11 Discontinued Section	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition	xxv
2.0 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY EIGHTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the FD&C Act for periods of exclusivity and provides patent information concerning the listed drugs. The *Addendum* also provides additional information that may be helpful to those submitting an NDA or ANDA to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Office of Generic Drugs, Center for Drug Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade name (proprietary name) or established name (if no trade name exists) and by applicant name (holder of the approved application), which have been abbreviated for this publication. Established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in (21 CFR 299.4(e)). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list.

Distributors or repackagers of products listed in the Orange Book are not identified.

1.2 Therapeutic Equivalence-Related Terms

¹ Newly approved products are added to parts 1, 2, or 3, of the Orange Book, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredients, are of the same dosage form and route of administration, and are formulated to contain the same amount of active ingredient and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity).² They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).³ Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.⁴

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the Orange Book, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain).* Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that

2 See generally 21 CFR 314.3(b).

3 See generally 21 CFR 314.3(b).

4 See generally 21 CFR 314.3(b).

products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).⁵ Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Section 505 (j)(8)(B) of the FD&C Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under

⁵ See generally 21 CFR 314.3(b).

similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.⁶

1.4 Reference Listed Drug and Reference Standard

A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.⁷

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and FDA has determined it was not withdrawn for reasons of safety or effectiveness, and FDA selects an ANDA as the reference standard), the reference listed drug and the reference standard may be different.

⁶ We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm>; see generally 21 CFR part 320.

⁷ 21 CFR 314.94(a)(3)(i).

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent the FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource drug products listed under the same heading with two or more reference listed drugs.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may

be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. For example, there may also be allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by other than the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*. Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is

permitted by regulation to appear on the label, even when the manufacturer is not the applicant or marketer.

Although the products in the Orange Book are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations in the Orange Book are, in most cases, correct.

To relate firm name information on a product label to that in the Orange Book, the following should be noted: the applicant's name always appears in the Orange Book. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the manufacturer or marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears in the Orange Book and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears in the Orange Book and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears in the Orange Book; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the Orange Book, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that in the Orange Book, the following should be noted: if the applicant is the marketer, the applicant's name appears in the Orange Book and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears in the Orange Book. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the applicant to appear in the Orange Book. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears in the Orange Book.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an application that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)) or satisfied by a showing that an acceptable *in vitro* dissolution standard is met. A

therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

- (2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in

somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference listed drug products that are not identified as bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code

as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug

products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms*, the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.⁸ In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as xmg/vial.

After the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), which amended the FD&C Act, it became evident that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book now displays the strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. If this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1gm/20mL (50mg/mL) and 3gm/60mL (50mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products

⁸ The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products

in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium tablet drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (CEDIPROF NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (CEDIPROF NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (CEDIPROF NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-Tabs (Lloyd NDA 021116) tablets.⁹

The chart outlines TE codes for all 0.025 mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One

⁹ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) is currently listed in the Discontinued Drug Product List section of the Orange Book and Mylan's levothyroxine product (ANDA 076187) has been selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
THYRO-TABS	LLOYD	0.025MG	N/A ¹⁰	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient (in a fixed combination drug product), or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA for a drug that is the same as a drug product approved in a petitioned ANDA should utilize the drug product approved in the petitioned ANDA as a reference standard. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.¹¹ (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C

¹⁰ Thyro-Tabs is in the Discontinued Drug Product List and therefore no longer is assigned a TE code.

¹¹ If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its right to the exclusivity protection, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable, pursuant to the NDA holder's exclusivity being waived. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such

information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons***". The determinations listed in Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.¹² Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in a product's marketing status that would result in the product being moved to the Discontinued Drug

¹² See, e.g., Section 506I(d) of the FD&C Act.

Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the Orange Book, but rather intends to apply the change prospectively to drug products added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov. If you do not have access to email, you can contact the Orange Book Staff by mail at:

FDA/CDER Orange Book Staff
Office of Generic Drug Policy
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the [Orange Book](#) home page by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>
REFERENCE LISTED DRUG* (+)	→	<u>AP</u> +! PAGE PHARMA <u>25MG/ML</u> <u>N013111</u> <u>001</u> AUG 22, 1983
REFERENCE STANDARD * (!)	→	<u>AP</u> +! <u>50MG/ML</u> <u>N013111</u> <u>002</u> AUG 22, 1983
		<u>AP</u> +! <u>75MG/ML</u> <u>N013111</u> <u>003</u> AUG 22, 1983
		<u>AP</u> +! <u>100MG/ML</u> <u>N013111</u> <u>004</u> JAN 04, 1989
	→	<u>MEPERIDINE HCL</u>
THERAPEUTIC EQUIVALENCE (TE)	→	<u>AP</u> GREENBERG PHARM <u>25MG/ML</u> <u>A064890</u> 001 FEB 29, 1987
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u> <u>50MG/ML</u> <u>A064890</u> 002 FEB 29, 1987
		<u>AP</u> <u>75MG/ML</u> <u>A064890</u> 003 FEB 29, 1987
		<u>AP</u> <u>100MG/ML</u> <u>A064890</u> 004 MAR 08, 1992
SINGLE SOURCE PRODUCT (NO TE CODE)		! TIMOKIM LLC 10MG/ML A099225 001 DEC 12, 1995
		<u>AP</u> JOHNSON MED <u>25MG/ML</u> <u>A099226</u> <u>001</u> NOV 27, 1993
		! KENDRA PHARM 150MG/ML A079444 001 OCT 31, 1999
APPLICANT	→	↑
AVAILABLE STRENGTH(S) OF A PRODUCT	→	↑
APPLICATION NUMBER AND PRODUCT NUMBER	→	↑
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→	↑
APPROVAL DATE	→	↑

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4


MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>
PRODUCT INFORMATION	→	TABLET; ORAL
		HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL
		REINWALD LABS 25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107 001	Sep 26, 2016
-----------	---------------------	------------------------	--------------------	--------------

ZIAGEN

AA	+! VIIV HLTHCARE	EQ 20MG BASE/ML	N020978 001	Dec 17, 1998
-----------	------------------	------------------------	--------------------	--------------

TABLET;ORAL

ABACAVIR SULFATE

AB	APOTEX INC	EQ 300MG BASE	A201570 001	Dec 17, 2012
-----------	------------	----------------------	--------------------	--------------

AB	AUROBINDO PHARMA LTD	EQ 300MG BASE	A077844 001	Dec 17, 2012
-----------	----------------------	----------------------	--------------------	--------------

AB	CIPLA LTD	EQ 300MG BASE	A078119 001	Nov 21, 2017
-----------	-----------	----------------------	--------------------	--------------

AB	HETERO LABS LTD III	EQ 300MG BASE	A091560 001	Sep 13, 2013
-----------	---------------------	----------------------	--------------------	--------------

AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012
-----------	------------------	----------------------	--------------------	--------------

AB	STRIDES PHARMA	EQ 300MG BASE	A091050 001	Oct 28, 2016
-----------	----------------	----------------------	--------------------	--------------

ZIAGEN

AB	+! VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998
-----------	------------------	----------------------	--------------------	--------------

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551 001	Aug 22, 2014
----	---------------	----------------------------------	-------------	--------------

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A206151 001	Mar 28, 2017
-----------	----------------------	----------------------------	--------------------	--------------

AB	CIPLA LTD	EQ 600MG BASE;300MG	A091144 001	Mar 28, 2017
-----------	-----------	----------------------------	--------------------	--------------

AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990 001	Mar 28, 2017
-----------	-----------	----------------------------	--------------------	--------------

AB	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246 001	Sep 29, 2016
-----------	-----------------	----------------------------	--------------------	--------------

EPZICOM

AB	+! VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652 001	Aug 02, 2004
-----------	------------------	----------------------------	--------------------	--------------

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912 001	Dec 05, 2013
-----------	-----------	----------------------------------	--------------------	--------------

TRIZIVIR

AB	+! VIIV HLTHCARE	EQ 300MG BASE;150MG;300MG	N021205 001	Nov 14, 2000
-----------	------------------	----------------------------------	--------------------	--------------

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743 001	Apr 28, 2017
----	-------------------	------------------------	-------------	--------------

ABEMACICLIB

TABLET;ORAL

VERZENIO

+	ELI LILLY AND CO	50MG	N208716 001	Sep 28, 2017
---	------------------	------	-------------	--------------

+		100MG	N208716 002	Sep 28, 2017
---	--	-------	-------------	--------------

+		150MG	N208716 003	Sep 28, 2017
---	--	-------	-------------	--------------

+!		200MG	N208716 004	Sep 28, 2017
----	--	-------	-------------	--------------

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+!	JANSSEN BIOTECH	250MG	N202379 001	Apr 28, 2011
----	-----------------	-------	-------------	--------------

+		500MG	N202379 002	Apr 14, 2017
---	--	-------	-------------	--------------

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

+!	ASTRAZENECA	100MG	N210259 001	Oct 31, 2017
----	-------------	-------	-------------	--------------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	BARR LABS DIV TEVA	333MG	A200143 001	Nov 18, 2013
-----------	--------------------	--------------	--------------------	--------------

AB	! GLENMARK GENERICS	333MG	A202229 001	Jul 16, 2013
-----------	---------------------	--------------	--------------------	--------------

AB	MYLAN PHARMS INC	333MG	A200142 001	Mar 11, 2014
-----------	------------------	--------------	--------------------	--------------

AB	ZYDUS PHARMS USA INC	333MG	A205995 001	May 26, 2017
-----------	----------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACARBOSE

TABLET; ORAL

ACARBOSE

<u>AB</u>	EMCURE PHARMS LTD	<u>25MG</u>	<u>A202271 001</u>	Feb 07, 2012
<u>AB</u>		<u>50MG</u>	<u>A202271 002</u>	Feb 07, 2012
<u>AB</u>		<u>100MG</u>	<u>A202271 003</u>	Feb 07, 2012
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A078441 001</u>	May 14, 2009
<u>AB</u>		<u>50MG</u>	<u>A078441 002</u>	May 14, 2009
<u>AB</u>		<u>100MG</u>	<u>A078441 003</u>	May 14, 2009
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091053 001</u>	Jan 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091053 002</u>	Jan 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091053 003</u>	Jan 06, 2011
<u>AB</u>	STRIDES PHARMA	<u>25MG</u>	<u>A090912 001</u>	Jul 27, 2011
<u>AB</u>		<u>50MG</u>	<u>A090912 002</u>	Jul 27, 2011
<u>AB</u>		<u>100MG</u>	<u>A090912 003</u>	Jul 27, 2011
<u>AB</u>	VIRTUS PHARM	<u>25MG</u>	<u>A091343 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A091343 002</u>	Oct 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A091343 003</u>	Oct 17, 2013
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077532 001</u>	May 07, 2008
<u>AB</u>		<u>50MG</u>	<u>A077532 002</u>	May 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077532 003</u>	May 07, 2008
<u>AB</u>	WEST-WARD PHARMS INT	<u>25MG</u>	<u>A078470 001</u>	May 07, 2008
<u>AB</u>		<u>50MG</u>	<u>A078470 002</u>	May 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A078470 003</u>	May 07, 2008
<u>PRECOSE</u>				
<u>AB</u>	+! BAYER HLTHCARE	<u>25MG</u>	<u>N020482 004</u>	May 29, 1997
<u>AB</u>	+	<u>50MG</u>	<u>N020482 001</u>	Sep 06, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020482 002</u>	Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047 001</u>	Dec 30, 1999
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A075047 002</u>	Dec 30, 1999
<u>AB</u>	MYLAN	<u>EQ 200MG BASE</u>	<u>A074288 001</u>	Apr 24, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074288 002</u>	Apr 24, 1995
<u>SECTRAL</u>				
<u>AB</u>	+ PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917 001</u>	Dec 28, 1984
<u>AB</u>	+!	<u>EQ 400MG BASE</u>	<u>N018917 003</u>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

ACETAMINOPHEN

<u>AP</u>	CUSTOPHARM INC	<u>1GM/100ML (10MG/ML)</u>	<u>A202605 001</u>	Jun 13, 2016
<u>AP</u>	SANDOZ INC	<u>1GM/100ML (10MG/ML)</u>	<u>A204052 001</u>	Mar 22, 2016
<u>OFIRMEV</u>				
<u>AP</u>	+! MALLINCKRODT IP	<u>1GM/100ML (10MG/ML)</u>	<u>N022450 001</u>	Nov 02, 2010
	ACETAMINOPHEN FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767 001	Oct 28, 2015

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BUTALBITAL AND ACETAMINOPHEN

MIKART INC 300MG; 50MG

A207313 001 Dec 27, 2017

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

<u>AA</u>	CNTY LINE PHARMS	<u>325MG; 50MG</u>	<u>A205120 001</u>	Oct 30, 2015
<u>AA</u>	LARKEN LABS INC	<u>325MG; 50MG</u>	<u>A203484 002</u>	Dec 04, 2015
<u>AA</u>	MIKART INC	<u>300MG; 50MG</u>	<u>A207386 001</u>	Nov 15, 2016
<u>AA</u>	! NEXGEN PHARMA	<u>300MG; 50MG</u>	<u>A090956 001</u>	Aug 23, 2011
<u>AA</u>	TEDOR PHARMA INC	<u>300MG; 50MG</u>	<u>A207635 001</u>	Jun 05, 2017
<u>BUTAPAP</u>				
<u>AA</u>	! MIKART	<u>325MG; 50MG</u>	<u>A089987 001</u>	Oct 26, 1992
	ALLZITAL LARKEN LABS INC	325MG; 25MG	A203484 001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	! NEXGEN PHARMA	<u>300MG; 50MG; 40MG</u>	<u>A040885 001</u>	Nov 16, 2009
<u>AB</u>	NUVO PHARM INC	<u>300MG; 50MG; 40MG</u>	<u>A207118 001</u>	Oct 28, 2016
<u>AB</u>	TEDOR PHARMA INC	<u>300MG; 50MG; 40MG</u>	<u>A206615 001</u>	Aug 04, 2017
	! MAYNE PHARMA INC	325MG; 50MG; 40MG	A089007 001	Mar 17, 1986

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

! MIKART 325MG/15ML;50MG/15ML;40MG/15ML

A040387 001 Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	ACTAVIS LABS UT INC	<u>325MG;50MG;40MG</u>	<u>A088616</u>	<u>001</u>	Nov 09, 1984
<u>AA</u>	CNTY LINE PHARMS	<u>325MG;50MG;40MG</u>	<u>A204984</u>	<u>001</u>	Jan 10, 2017
<u>AA</u>	HIKMA PHARMS	<u>325MG;50MG;40MG</u>	<u>A089718</u>	<u>001</u>	Jun 12, 1995
<u>AA</u>	LANNETT HOLDINGS INC	<u>325MG;50MG;40MG</u>	<u>A200243</u>	<u>001</u>	Sep 13, 2012
<u>AA</u>	MIKART	<u>325MG;50MG;40MG</u>	<u>A089175</u>	<u>001</u>	Jan 21, 1987
<u>AA</u>	SPECGX LLC	<u>325MG;50MG;40MG</u>	<u>A087804</u>	<u>001</u>	Jan 24, 1985
<u>AA</u>	! VINTAGE PHARMS	<u>325MG;50MG;40MG</u>	<u>A040511</u>	<u>001</u>	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<u>AB</u>	NEXGEN PHARMA INC	<u>325MG;50MG;40MG;30MG</u>	<u>A076560</u>	<u>001</u>	Jun 10, 2004
<u>AB</u>	VINTAGE PHARMS	<u>325MG;50MG;40MG;30MG</u>	<u>A075929</u>	<u>001</u>	Apr 22, 2002
	<u>FIORICET W/ CODEINE</u>				
<u>AB</u>	+! ACTAVIS LABS UT INC	<u>325MG;50MG;40MG;30MG</u>	<u>N020232</u>	<u>001</u>	Jul 30, 1992
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

WRASER PHARMS LLC 320.5MG;30MG;16MG

A204785 001 Nov 26, 2014

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

LARKEN LABS INC 325MG;30MG;16MG

A204209 001 Sep 30, 2016

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	HI TECH PHARMA	<u>120MG/5ML;12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
<u>AA</u>	MIKART	<u>120MG/5ML;12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	! PHARM ASSOC	<u>120MG/5ML;12MG/5ML</u>	<u>A087508</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>120MG/5ML;12MG/5ML</u>	<u>A091238</u>	<u>001</u>	Nov 10, 2011
<u>AA</u>	WOCKHARDT BIO AG	<u>120MG/5ML;12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u>	AUROLIFE PHARMA LLC	<u>300MG;15MG</u>	<u>A202800</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;30MG</u>	<u>A202800</u>	<u>002</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;60MG</u>	<u>A202800</u>	<u>003</u>	Apr 15, 2013
<u>AA</u>	! SPECGX LLC	<u>300MG;15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	SUN PHARM INDS LTD	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	! VINTAGE	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
	<u>TYLENOL W/ CODEINE NO. 3</u>				
<u>AA</u>	! JANSSEN PHARMS	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>	
	<u>TYLENOL W/ CODEINE NO. 4</u>				
<u>AA</u>	JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	! MIKART	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>	PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>	VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
	! MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	! PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

ANEXSIA 5/325

<u>AA</u>	SPECGX LLC	<u>325MG; 5MG</u>	<u>A040409 001</u>	Oct 20, 2000
-----------	------------	-------------------	--------------------	--------------

ANEXSIA 7.5/325

<u>AA</u>	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040405 001</u>	Sep 08, 2000
-----------	------------	---------------------	--------------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	ABHAI LLC	<u>300MG; 5MG</u>	<u>A209036 001</u>	Jun 21, 2017
-----------	-----------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A209036 002</u>	Jun 21, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A209036 003</u>	Jun 21, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A209037 001</u>	Jun 21, 2017
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A209037 002</u>	Jun 21, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A209037 003</u>	Jun 21, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	ACTAVIS LABS FL INC	<u>300MG; 5MG</u>	<u>A206470 001</u>	Jun 02, 2016
-----------	---------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A206470 002</u>	Jun 02, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A206470 003</u>	Jun 02, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	AMNEAL PHARMS	<u>300MG; 5MG</u>	<u>A207137 001</u>	Nov 29, 2016
-----------	---------------	-------------------	--------------------	--------------

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG; 5MG</u>	<u>A206869 001</u>	Jun 23, 2017
-----------	------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A040736 001</u>	Aug 25, 2006
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040746 002</u>	May 10, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A040746 001</u>	Aug 25, 2006
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 5MG</u>	<u>A201013 001</u>	Apr 11, 2012
-----------	---------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201013 002</u>	Apr 11, 2012
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A201013 003</u>	Apr 11, 2012
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	LANNETT HOLDINGS INC	<u>300MG; 5MG</u>	<u>A207171 001</u>	Jun 20, 2017
-----------	----------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A207171 002</u>	Jun 20, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A207171 003</u>	Jun 20, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A207172 001</u>	Jun 22, 2017
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207172 002</u>	Jun 22, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A207172 003</u>	Jun 22, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	LARKEN LABS INC	<u>325MG; 5MG</u>	<u>A202935 002</u>	Jun 15, 2016
-----------	-----------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202935 003</u>	Jun 15, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A202935 004</u>	Jun 15, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	!	MIKART	<u>300MG; 5MG</u>	<u>A040658 001</u>	Jan 19, 2006
-----------	---	--------	-------------------	--------------------	--------------

<u>AA</u>	!		<u>300MG; 7.5MG</u>	<u>A040658 002</u>	Mar 24, 2006
-----------	---	--	---------------------	--------------------	--------------

<u>AA</u>	!		<u>300MG; 10MG</u>	<u>A040658 003</u>	Jun 23, 2004
-----------	---	--	--------------------	--------------------	--------------

<u>AA</u>	!		<u>325MG; 2.5MG</u>	<u>A040846 001</u>	Jun 09, 2010
-----------	---	--	---------------------	--------------------	--------------

<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A040432 001</u>	Jan 22, 2003
-----------	--	--	---------------------	--------------------	--------------

<u>AA</u>	NOVEL LABS INC	<u>300MG; 5MG</u>	<u>A206142 001</u>	Nov 14, 2016
-----------	----------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A206142 002</u>	Nov 14, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A206142 003</u>	Nov 14, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A206245 001</u>	Dec 01, 2016
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A206245 002</u>	Dec 01, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A206245 003</u>	Dec 01, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	PAR PHARM	<u>300MG; 5MG</u>	<u>A205001 001</u>	Jul 05, 2016
-----------	-----------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A205001 002</u>	Jul 05, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A205001 003</u>	Jul 05, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A202991 001</u>	Apr 12, 2016
-----------	---------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202991 002</u>	Apr 12, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A202991 003</u>	Apr 12, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	SPECGX LLC	<u>300MG; 5MG</u>	<u>A206718 001</u>	Mar 31, 2017
-----------	------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A206718 002</u>	Mar 31, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A206718 003</u>	Mar 31, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A040400 001</u>	Jul 26, 2000
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 5MG</u>	<u>A090118 001</u>	Dec 23, 2008
-----------	--------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118 002</u>	Dec 23, 2008
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118 003</u>	Dec 23, 2008
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	TRIS PHARMA INC	<u>300MG; 5MG</u>	<u>A202214 004</u>	Mar 15, 2016
-----------	-----------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A202214 005</u>	Mar 15, 2016
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A202214 006</u>	Mar 15, 2016
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A202214 001</u>	Mar 27, 2013
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202214 002</u>	Mar 27, 2013
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A202214 003</u>	Mar 27, 2013
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	UPSHER-SMITH LABS	<u>325MG; 5MG</u>	<u>A206484 001</u>	Mar 24, 2017
-----------	-------------------	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A206484 002</u>	Mar 24, 2017
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A206484 003</u>	Mar 24, 2017
-----------	--	--------------------	--------------------	--------------

<u>AA</u>	VINTAGE PHARMS	<u>300MG; 5MG</u>	<u>A090415 001</u>	Jan 24, 2011
-----------	----------------	-------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A090415 002</u>	Jan 24, 2011
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>300MG; 10MG</u>	<u>A090415 003</u>	Jan 24, 2011
-----------	--	--------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 5MG</u>	<u>A040655 001</u>	Jan 19, 2006
-----------	--	-------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656 001</u>	Jan 19, 2006
-----------	--	---------------------	--------------------	--------------

<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355 001</u>	May 31, 2000
-----------	--	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	WES PHARMA INC	<u>325MG; 5MG</u>	<u>A210211 001</u>	Oct 30, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210211 002</u>	Oct 30, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210211 003</u>	Oct 30, 2017

NORCO

<u>AA</u>	APIL	<u>325MG; 2.5MG</u>	<u>A040148 004</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG; 5MG</u>	<u>A040099 001</u>	Jun 25, 1997
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040148 005</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG; 7.5MG</u>	<u>A040148 003</u>	Sep 12, 2000
<u>AA</u>	!	<u>325MG; 10MG</u>	<u>A040148 001</u>	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	! SPECGX LLC	<u>325MG/5ML; 5MG/5ML</u>	<u>A040680 001</u>	Sep 29, 2006
-----------	--------------	---------------------------	--------------------	--------------

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

<u>AA</u>	VINTAGE PHARMS	<u>325MG/5ML; 5MG/5ML</u>	<u>A203573 001</u>	Dec 18, 2014
-----------	----------------	---------------------------	--------------------	--------------

TABLET; ORAL

OXYCET

<u>AA</u>	SPECGX LLC	<u>325MG; 5MG</u>	<u>A087463 001</u>	Dec 07, 1983
-----------	------------	-------------------	--------------------	--------------

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<u>A201447 001</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201447 002</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201447 003</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201447 004</u>	Apr 12, 2013
<u>AA</u>	ALVOGEN MALTA	<u>325MG; 5MG</u>	<u>A202677 003</u>	Mar 08, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202677 001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677 002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS	<u>325MG; 5MG</u>	<u>A040777 001</u>	Nov 27, 2007
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 7.5MG</u>	<u>A040778 002</u>	Jun 27, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778 001</u>	Nov 27, 2007
<u>AA</u>	ASCENT PHARMS INC	<u>325MG; 2.5MG</u>	<u>A207419 001</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A207419 002</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207419 003</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207419 004</u>	Mar 22, 2017
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972 001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201972 002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201972 003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201972 004</u>	Jul 15, 2013
<u>AA</u>	CHEMO RESEARCH SL	<u>325MG; 5MG</u>	<u>A207574 001</u>	Dec 13, 2016
<u>AA</u>	LANNETT HOLDINGS INC	<u>325MG; 5MG</u>	<u>A207333 001</u>	Sep 25, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207333 002</u>	Sep 25, 2017
<u>AA</u>	MAYNE PHARMA INC	<u>325MG; 2.5MG</u>	<u>A090177 001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177 002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177 003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177 004</u>	Oct 20, 2008
<u>AA</u>	NESHER PHARMS	<u>325MG; 2.5MG</u>	<u>A210079 001</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A210079 002</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210079 003</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210079 004</u>	Dec 28, 2017
<u>AA</u>	NOVEL LABS INC	<u>325MG; 2.5MG</u>	<u>A204407 001</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A204407 002</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A204407 003</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A204407 004</u>	Feb 24, 2017
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278 001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278 002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278 003</u>	Aug 28, 2014
<u>AA</u>	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040545 001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545 002</u>	Jun 30, 2004
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535 001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535 002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535 003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535 004</u>	Dec 26, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105 001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734 002</u>	Jul 11, 2013
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171 001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535 001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535 002</u>	Sep 05, 2003

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCT

AA	!	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
AA	!		<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
AA	!		<u>325MG; 7.5MG</u>	<u>A040330</u>	<u>003</u>	Nov 23, 2001
AA	!		<u>325MG; 10MG</u>	<u>A040330</u>	<u>004</u>	Nov 23, 2001

ROXICET

AA		WEST-WARD PHARMS INT	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
	!	OXYCODONE AND ACETAMINOPHEN MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
	!		300MG; 5MG	A040608	002	Dec 30, 2005
	!		300MG; 7.5MG	A040608	003	Dec 30, 2005
	!		300MG; 10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
AB		AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
AB		APOTEX INC	<u>325MG; 37.5MG</u>	<u>A078778</u>	<u>001</u>	Apr 07, 2014
AB		AUROBINDO PHARMA LTD	<u>325MG; 37.5MG</u>	<u>A207152</u>	<u>001</u>	Mar 22, 2017
AB		MACLEODS PHARMS LTD	<u>325MG; 37.5MG</u>	<u>A206885</u>	<u>001</u>	May 02, 2017
AB		MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
AB		MYLAN	<u>325MG; 37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
AB		PAR PHARM	<u>325MG; 37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
AB		SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
AB		ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012

ULTRACET

AB	+	JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001
-----------	---	----------------	----------------------	----------------	------------	--------------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779</u>	<u>001</u>	Jul 14, 2011
AB		NOSTRUM LABS INC	<u>500MG</u>	<u>A204691</u>	<u>001</u>	Mar 29, 2016
AB		NOVAST LABS LTD	<u>500MG</u>	<u>A203434</u>	<u>001</u>	Sep 30, 2016
AB		ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008

DIAMOX

AB	+	TEVA BRANDED PHARM	<u>500MG</u>	<u>N012945</u>	<u>001</u>	
-----------	---	--------------------	--------------	----------------	------------	--

TABLET; ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMA	<u>125MG</u>	<u>A205530</u>	<u>001</u>	Oct 27, 2016
AB			<u>250MG</u>	<u>A205530</u>	<u>002</u>	Oct 27, 2016
AB		LANNETT	<u>250MG</u>	<u>A084840</u>	<u>001</u>	
AB		STRIDES PHARMA	<u>125MG</u>	<u>A209734</u>	<u>001</u>	Nov 20, 2017
AB			<u>250MG</u>	<u>A209734</u>	<u>002</u>	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	<u>125MG</u>	<u>A089753</u>	<u>002</u>	Jun 22, 1988
AB		TARO	<u>125MG</u>	<u>A040195</u>	<u>001</u>	May 28, 1997
AB	!		<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP		PAR STERILE PRODUCTS	<u>EQ 500MG BASE/VIAL</u>	<u>A205358</u>	<u>001</u>	Jun 20, 2017
AP		SAGENT AGILA	<u>EQ 500MG BASE/VIAL</u>	<u>A200880</u>	<u>001</u>	May 09, 2012
AP		WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
AP	!	X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008

ACETAZOLAMIDE SODIUM

AP		EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202693</u>	<u>001</u>	Dec 19, 2014
-----------	--	-------------------	---------------------------	----------------	------------	--------------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
AT		BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
AT		ICU MEDICAL INC	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>AT</u>	! WOCKHARDT BIO AG	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	
-----------	----------------	-----------	----------------	------------	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%;1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982
-----------	----------------------	--------------	----------------	------------	--------------

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	TARO	<u>2%;1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%;1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

<u>AT</u>	+! HI TECH PHARMA	<u>2%;1%</u>	<u>N012770</u>	<u>001</u>	
-----------	-------------------	--------------	----------------	------------	--

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983
----	----------------	-------	---------	-----	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993
----	-----------------	-----------	---------	-----	--------------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

<u>AP</u>	+! CUMBERLAND PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>N021539</u>	<u>001</u>	Jan 23, 2004
-----------	----------------------	----------------------------	----------------	------------	--------------

ACETYLCYSTEINE

<u>AP</u>	AKORN INC	<u>6GM/30ML (200MG/ML)</u>	<u>A203173</u>	<u>001</u>	Mar 24, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>6GM/30ML (200MG/ML)</u>	<u>A207358</u>	<u>001</u>	Feb 29, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>6GM/30ML (200MG/ML)</u>	<u>A200644</u>	<u>001</u>	Nov 07, 2012
<u>AP</u>	MYLAN INSTITUTIONAL	<u>6GM/30ML (200MG/ML)</u>	<u>A203624</u>	<u>001</u>	Jun 19, 2015
<u>AP</u>	SAGENT PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>A091684</u>	<u>001</u>	Oct 31, 2017

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u>	ALVOGEN INC	<u>10%</u>	<u>A204674</u>	<u>001</u>	Feb 11, 2014
<u>AN</u>		<u>20%</u>	<u>A203853</u>	<u>001</u>	Jun 21, 2012
<u>AN</u>	HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>		<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>	! LUITPOLD	<u>10%</u>	<u>A072489</u>	<u>001</u>	Jul 28, 1995
<u>AN</u>	!	<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995

TABLET, EFFERVESCENT;ORAL

CETYLEV

+	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016
+!		2.5GM	N207916	002	Jan 29, 2016

ACITRETIN

CAPSULE;ORAL

ACITRETIN

<u>AB</u>	BARR LABS INC	<u>10MG</u>	<u>A091455</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>25MG</u>	<u>A091455</u>	<u>002</u>	Apr 04, 2013
<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A202552</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>17.5MG</u>	<u>A202552</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A202552</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>		<u>25MG</u>	<u>A202552</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A202148</u>	<u>001</u>	Sep 10, 2015
<u>AB</u>		<u>25MG</u>	<u>A202148</u>	<u>002</u>	Sep 10, 2015
<u>AB</u>	SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A204633</u>	<u>001</u>	May 22, 2015
<u>AB</u>		<u>17.5MG</u>	<u>A204633</u>	<u>002</u>	May 22, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A204633</u>	<u>003</u>	May 22, 2015
<u>AB</u>		<u>25MG</u>	<u>A204633</u>	<u>004</u>	May 22, 2015
<u>AB</u>	TEVA PHARMS USA	<u>17.5MG</u>	<u>A202897</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>22.5MG</u>	<u>A202897</u>	<u>002</u>	Apr 04, 2013

SORIATANE

<u>AB</u>	+ STIEFEL LABS INC	<u>10MG</u>	<u>N019821</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	+	<u>17.5MG</u>	<u>N019821</u>	<u>003</u>	Aug 06, 2009
<u>AB</u>	+	<u>22.5MG</u>	<u>N019821</u>	<u>004</u>	Aug 06, 2009

PRESCRIPTION DRUG PRODUCT LIST

ACITRETIN

CAPSULE;ORAL

SORIATANE

AB	+		25MG	<u>N019821</u>	<u>002</u>	Oct 28, 1996
-----------	----------	--	-------------	-----------------------	-------------------	--------------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

	+	ASTRAZENECA PHARMS	0.4MG/INH	N202450	001	Jul 23, 2012
--	----------	--------------------	-----------	---------	-----	--------------

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

	+	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994
--	----------	---------------------	----------	---------	-----	--------------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	!	APOTEX INC	200MG	<u>A075677</u>	<u>001</u>	Sep 28, 2005
AB		BOSCOGEN	200MG	<u>A075090</u>	<u>001</u>	Jan 26, 1999
AB		CADILA PHARMS LTD	200MG	<u>A201445</u>	<u>001</u>	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	200MG	<u>A206261</u>	<u>001</u>	Aug 16, 2017
AB		DAVA PHARMS INC	200MG	<u>A074833</u>	<u>001</u>	Apr 22, 1997
AB		TEVA	200MG	<u>A074578</u>	<u>001</u>	Apr 22, 1997
AB		ZYDUS PHARMS USA INC	200MG	<u>A204313</u>	<u>001</u>	Mar 25, 2016

ZOVIRAX

AB	+	MYLAN PHARMS INC	200MG	<u>N018828</u>	<u>001</u>	Jan 25, 1985
-----------	----------	------------------	--------------	-----------------------	-------------------	--------------

CREAM;TOPICAL

ZOVIRAX

	+	VIB	5%	N021478	001	Dec 30, 2002
--	----------	-----	----	---------	-----	--------------

OINTMENT;TOPICAL

ACYCLOVIR

AB		AMNEAL PHARMS	5%	<u>A204605</u>	<u>001</u>	Jun 18, 2014
AB		FOUGERA PHARMS INC	5%	<u>A206633</u>	<u>001</u>	May 11, 2016
AB		G AND W LABS INC	5%	<u>A205591</u>	<u>001</u>	Nov 13, 2017
AB		GLENMARK PHARMS LTD	5%	<u>A205510</u>	<u>001</u>	Jul 31, 2017
AB		MYLAN PHARMS INC	5%	<u>A202459</u>	<u>001</u>	Apr 03, 2013
AB		TARO	5%	<u>A205469</u>	<u>001</u>	Dec 21, 2016
AB		TOLMAR	5%	<u>A206437</u>	<u>001</u>	Jul 31, 2017

ZOVIRAX

AB	+	VALEANT BERMUDA	5%	<u>N018604</u>	<u>001</u>	Mar 29, 1982
-----------	----------	-----------------	-----------	-----------------------	-------------------	--------------

SUSPENSION;ORAL

ACYCLOVIR

AB		ACTAVIS MID ATLANTIC	200MG/5ML	<u>A074738</u>	<u>001</u>	Apr 28, 1997
-----------	--	-------------------------	------------------	-----------------------	-------------------	--------------

AB		HI TECH PHARMA	200MG/5ML	<u>A077026</u>	<u>001</u>	Jun 07, 2005
-----------	--	----------------	------------------	-----------------------	-------------------	--------------

ZOVIRAX

AB	+	MYLAN PHARMS INC	200MG/5ML	<u>N019909</u>	<u>001</u>	Dec 22, 1989
-----------	----------	------------------	------------------	-----------------------	-------------------	--------------

TABLET;BUCCAL

SITAVIG

	+	EPI HLTH	50MG	N203791	001	Apr 12, 2013
--	----------	----------	------	---------	-----	--------------

TABLET;ORAL

ACYCLOVIR

AB		APOTEX INC	400MG	<u>A077309</u>	<u>001</u>	Sep 29, 2005
AB			800MG	<u>A077309</u>	<u>002</u>	Sep 29, 2005
AB		CADILA PHARMS LTD	400MG	<u>A202168</u>	<u>001</u>	Nov 15, 2013
AB			800MG	<u>A202168</u>	<u>002</u>	Nov 15, 2013
AB		CARLSBAD	400MG	<u>A075382</u>	<u>001</u>	Apr 30, 1999
AB			800MG	<u>A075382</u>	<u>002</u>	Apr 30, 1999
AB		DAVA PHARMS INC	400MG	<u>A074946</u>	<u>001</u>	Nov 19, 1997
AB			800MG	<u>A074946</u>	<u>002</u>	Nov 19, 1997
AB		HERITAGE PHARMS INC	400MG	<u>A074891</u>	<u>001</u>	Oct 31, 1997
AB			800MG	<u>A074891</u>	<u>002</u>	Oct 31, 1997
AB		HETERO LABS LTD V	400MG	<u>A203834</u>	<u>001</u>	Oct 29, 2013
AB			800MG	<u>A203834</u>	<u>002</u>	Oct 29, 2013
AB		MYLAN PHARMS INC	400MG	<u>A075211</u>	<u>001</u>	Sep 28, 1998
AB			800MG	<u>A075211</u>	<u>002</u>	Sep 28, 1998
AB		TEVA	400MG	<u>A074556</u>	<u>002</u>	Apr 22, 1997
AB			800MG	<u>A074556</u>	<u>003</u>	Apr 22, 1997
AB		ZYDUS PHARMS USA INC	400MG	<u>A204314</u>	<u>001</u>	Aug 19, 2014
AB			800MG	<u>A204314</u>	<u>002</u>	Aug 19, 2014

PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

AB	+	MYLAN PHARMS INC	400MG	N020089 001	Apr 30, 1991
AB	+	!	800MG	N020089 002	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701 001	Oct 11, 2013
AP	!	FRESENIUS KABI USA	EQ 50MG BASE/ML	A074930 001	May 13, 1998
AP	!		EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998
AP		HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771 001	Feb 29, 2016
AP	!		EQ 1GM BASE/VIAL	A205771 002	Feb 29, 2016
AP		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606 001	Jun 13, 2017
AP			EQ 1GM BASE/VIAL	A206606 002	Jun 13, 2017

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	!	VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009
---	---	-----------------	-------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB		FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010
-----------	--	----------------	-------------	--------------------	--------------

DIFFERIN

AB	+	!	GALDERMA LABS LP	0.1%	N020748 001	May 26, 2000
-----------	---	---	------------------	-------------	--------------------	--------------

GEL; TOPICAL

ADAPALENE

AB		ACTAVIS MID ATLANTIC	0.3%	A201000 001	Oct 27, 2014
AB		GLENMARK GENERICS	0.1%	A091314 001	Jul 01, 2010
AB		PLIVA HRVATSKA DOO	0.1%	A090962 001	Jun 02, 2010
AB		TARO	0.3%	A208322 001	Jun 23, 2016
AB		TOLMAR	0.3%	A200298 001	Jun 14, 2012

DIFFERIN

AB	+	!	GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007
-----------	---	---	------------------	-------------	--------------------	--------------

LOTION; TOPICAL

DIFFERIN

+	!	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
---	---	------------------	------	-------------	--------------

SOLUTION; TOPICAL

ADAPALENE

AB		CALL INC	0.1%	A203981 001	Sep 23, 2016
AB	!		0.1%	A204593 001	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790 001	Sep 30, 2015
-----------	--	----------------------	------------------	--------------------	--------------

EPIDUO

AB	+	!	GALDERMA LABS LP	0.1%;2.5%	N022320 001	Dec 08, 2008
-----------	---	---	------------------	------------------	--------------------	--------------

EPIDUO FORTE

+	!	GALDERMA LABS	0.3%;2.5%	N207917 001	Jul 15, 2015
---	---	---------------	-----------	-------------	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

AB		SIGMAPHARM LABS LLC	10MG	A202051 001	Aug 29, 2013
-----------	--	---------------------	-------------	--------------------	--------------

HEPSERA

AB	+	!	GILEAD	10MG	N021449 001	Sep 20, 2002
-----------	---	---	--------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP	+	!	ASTELLAS	3MG/ML	N019937 002	Oct 30, 1989
-----------	---	---	----------	---------------	--------------------	--------------

ADENOSINE

AP		AKORN	3MG/ML	A078076 001	Oct 31, 2008
AP		FRESENIUS KABI USA	3MG/ML	A077133 001	Apr 27, 2005
AP		GLAND PHARMA LTD	3MG/ML	A077283 001	Jun 14, 2007
AP		LUITPOLD	3MG/ML	A090010 001	Apr 28, 2009
AP		MYLAN LABS LTD	3MG/ML	A078640 001	Mar 21, 2014
AP			3MG/ML	A078686 001	May 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

<u>AP</u>	WEST-WARD PHARMS INT	<u>3MG/ML</u>	<u>A076404 001</u>	Jun 16, 2004
<u>AP</u>		<u>3MG/ML</u>	<u>A076500 001</u>	Jun 16, 2004
	SOLUTION; IV (INFUSION)			
	<u>ADENOSINE</u>			
<u>AP</u>	AKORN	<u>60MG/20ML (3MG/ML)</u>	<u>A090450 001</u>	Oct 02, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090450 002</u>	Oct 02, 2014
<u>AP</u>	AUROBINDO PHARMA LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A205331 001</u>	Nov 02, 2017
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A205331 002</u>	Nov 02, 2017
<u>AP</u>	EMCURE PHARMS LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A202313 001</u>	Sep 15, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A202313 002</u>	Sep 15, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077897 001</u>	Nov 27, 2017
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A077897 002</u>	Nov 27, 2017
<u>AP</u>	HOSPIRA INC	<u>60MG/20ML (3MG/ML)</u>	<u>A203883 001</u>	Mar 24, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A203883 002</u>	Mar 24, 2014
<u>AP</u>	SAGENT STRIDES	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	! TEVA PHARMS USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>	!	<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
+		EQ 30MG BASE	N201292 002	Jul 12, 2013
+	!	EQ 40MG BASE	N201292 003	Jul 12, 2013

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	IMPAX LABS INC	200MG	N020666 001	Jun 11, 1996
---	----------------	-------	-------------	--------------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
---	---------------	---------	-------------	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

+	ISO TEX	100uCi/10ML (10uCi/ML)	N017836 003	Jun 08, 2004
+		500uCi/0.5ML	N017836 001	
+	!	1,000uCi/ML	N017836 002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837 001	
+	!	1mCi/VIAL	N017837 002	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004	
		PROVENTIL-HFA				
BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503 001	Aug 15, 1996	
		VENTOLIN HFA				
BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001	
		POWDER, METERED; INHALATION				
		PROAIR RESPICLICK				
		+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636 001	Mar 31, 2015
		SOLUTION; INHALATION				

ACCUNEB

<u>AN</u>	+	MYLAN SPECIALITY LP	<u>EQ 0.021% BASE</u>	<u>N020949 002</u>	Apr 30, 2001
<u>AN</u>	+	!	<u>EQ 0.042% BASE</u>	<u>N020949 001</u>	Apr 30, 2001

ALBUTEROL SULFATE

<u>AN</u>		AUROBINDO PHARMA LTD	<u>EQ 0.083% BASE</u>	<u>A206224 001</u>	Oct 17, 2017
<u>AN</u>	!	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050 001</u>	Jun 18, 1998
<u>AN</u>		HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A074543 001</u>	Jan 15, 1998
<u>AN</u>		NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355 002</u>	Mar 31, 2010

PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A076355 001</u>	Jun 28, 2004
<u>AN</u>	!	<u>EQ 0.083% BASE</u>	<u>A074880 001</u>	Sep 17, 1997
<u>AN</u>		<u>EQ 0.5% BASE</u>	<u>A075664 001</u>	Jun 26, 2001
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839 001</u>	Dec 16, 2008
<u>AN</u>	SUN PHARMA GLOBAL	<u>EQ 0.083% BASE</u>	<u>A207857 001</u>	Jul 21, 2017
<u>AN</u>	WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772 001</u>	Sep 25, 2007
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077772 002</u>	Sep 25, 2007

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241 001</u>	May 12, 2010
<u>AA</u>	G AND W LABS INC	<u>EQ 2MG BASE/5ML</u>	<u>A074454 001</u>	Sep 25, 1995
<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749 001</u>	Jan 30, 1998
<u>AA</u>	!	<u>EQ 2MG BASE/5ML</u>	<u>A073419 001</u>	Mar 30, 1992
<u>AA</u>	VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105 001</u>	Dec 27, 2006
<u>AA</u>	VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788 001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A072894 002</u>	Jan 17, 1991
<u>AB</u>	!	<u>EQ 4MG BASE</u>	<u>A072894 001</u>	Jan 17, 1991
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 2MG BASE</u>	<u>A072637 002</u>	Dec 05, 1989
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A072637 001</u>	Dec 05, 1989

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A078092 002</u>	Jan 29, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078092 001</u>	Jan 29, 2007

VOSPIRE ER

<u>AB</u>	DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130 002</u>	Sep 26, 2002
<u>AB</u>	!	<u>EQ 8MG BASE</u>	<u>A076130 003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	CIPLA LTD	<u>EQ 0.083% BASE;0.017%</u>	<u>A077559 001</u>	Dec 31, 2007
<u>AN</u>	NEPHRON	<u>EQ 0.083% BASE;0.017%</u>	<u>A076749 001</u>	Dec 31, 2007
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A202496 001</u>	Oct 01, 2012
<u>AN</u>	SUN PHARMA GLOBAL	<u>EQ 0.083% BASE;0.017%</u>	<u>A207875 001</u>	Aug 07, 2017
<u>AN</u>	TEVA PHARMS	<u>EQ 0.083% BASE;0.017%</u>	<u>A076724 001</u>	Dec 31, 2007
<u>AN</u>	WATSON LABS TEVA	<u>EQ 0.083% BASE;0.017%</u>	<u>A077063 001</u>	Dec 31, 2007

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747 001	Oct 07, 2011
---	---	-------------------------	------------------------------	-------------	--------------

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	!	ALLERGAN	0.25%	N022134 001	Jul 28, 2010
---	---	----------	-------	-------------	--------------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973 001</u>	Jul 12, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079061 001</u>	Jun 23, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076587 001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884 001</u>	Jul 18, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079227 001</u>	Jul 30, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076730 001</u>	Jul 29, 2004

ALECTINIB HYDROCHLORIDE

CAPSULE; ORAL

ALECENSA

+	!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434 001	Dec 11, 2015
---	---	-------------------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

! WEST-WARD PHARMS
INT

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013

TABLET;ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A077982 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982 004</u>	Aug 04, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124 003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258 001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258 002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258 003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258 004</u>	Sep 24, 2009
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A076768 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768 004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768 005</u>	Aug 04, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079049 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079049 004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049 002</u>	Aug 04, 2008
<u>AB</u>	IMPAX LABS INC	<u>EQ 5MG BASE</u>	<u>A075710 001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710 002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710 003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710 004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710 005</u>	Feb 06, 2008
<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A090557 001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557 002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557 003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557 004</u>	Feb 18, 2010
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584 004</u>	Aug 04, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022 001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022 002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022 003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022 004</u>	Sep 10, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984 003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+! MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560 005</u>	Oct 20, 2000
	TABLET, EFFERVESCENT;ORAL			
	BINOSTO			
	+! MISSION PHARMA	EQ 70MG BASE	N202344 001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+ MERCK

EQ 70MG BASE;2,800 IU

N021762 001 Apr 07, 2005

+!

EQ 70MG BASE;5,600 IU

N021762 002 Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

<u>AP</u>	+! AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353 001</u>	Dec 29, 1986
	<u>ALFENTANIL</u>			
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221 001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013 001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060 001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284 001</u>	Jan 17, 2012
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079014 001</u>	Jul 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079057</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079056</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	UNICHEM LABS LTD	<u>10MG</u>	<u>A203192</u>	<u>001</u>	Jan 28, 2016

UROXATRAL

<u>AB</u>	+! CONCORDIA PHARMS INC	<u>10MG</u>	<u>N021287</u>	<u>001</u>	Jun 12, 2003
-----------	----------------------------	-------------	----------------	------------	--------------

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET;ORAL

TEKTURNA

+!	NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017
----	--------------	----------------	---------	-----	--------------

TABLET;ORAL

TEKTURNA

+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007
---	--------------	---------------	---------	-----	--------------

+!		EQ 300MG BASE	N021985	002	Mar 05, 2007
----	--	---------------	---------	-----	--------------

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
---	--------------	----------------------	---------	-----	--------------

+		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008
---	--	--------------------	---------	-----	--------------

+!		EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
----	--	----------------------	---------	-----	--------------

+!		EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008
----	--	--------------------	---------	-----	--------------

ALITRETINOIN

GEL;TOPICAL

PANRETIN

+!	EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999
----	-----------	--------------	---------	-----	--------------

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154</u>	<u>001</u>	May 06, 2013
<u>AB</u>		<u>300MG</u>	<u>A203154</u>	<u>002</u>	May 06, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	INDOCO REMEDIES	<u>100MG</u>	<u>A204467</u>	<u>001</u>	Jul 28, 2016
<u>AB</u>		<u>300MG</u>	<u>A204467</u>	<u>002</u>	Jul 28, 2016
<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637</u>	<u>002</u>	Mar 16, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A078390</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	SUN PHARM INDUSTRIES	<u>100MG</u>	<u>A071450</u>	<u>002</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
<u>AB</u>	ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A210117</u>	<u>001</u>	Oct 12, 2017
<u>AB</u>		<u>300MG</u>	<u>A210117</u>	<u>002</u>	Oct 12, 2017

LOPURIN

<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987

ZYLOPRIM

<u>AB</u>	+ CASPER PHARMA LLC	<u>100MG</u>	<u>N016084</u>	<u>001</u>	
<u>AB</u>	+!	<u>300MG</u>	<u>N016084</u>	<u>002</u>	

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004
-----------	-------------------------	---------------------------	----------------	------------	--------------

ALOPRIM

<u>AP</u>	+! MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u>	May 17, 1996
-----------	------------------------	---------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+	IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017
+	!	300MG; 200MG	N209203	002	Aug 18, 2017

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	<u>EQ 6.25MG BASE</u>	<u>A205523</u>	<u>001</u>	Mar 03, 2016
AB		<u>EQ 12.5MG BASE</u>	<u>A205523</u>	<u>002</u>	Mar 03, 2016
AB	MYLAN PHARMS INC	<u>EQ 6.25MG BASE</u>	<u>A205171</u>	<u>001</u>	Nov 09, 2015
AB		<u>EQ 12.5MG BASE</u>	<u>A205171</u>	<u>002</u>	Nov 09, 2015
AB	TEVA PHARMS USA	<u>EQ 6.25MG BASE</u>	<u>A078027</u>	<u>001</u>	Jul 07, 2015
AB		<u>EQ 12.5MG BASE</u>	<u>A078027</u>	<u>002</u>	Jul 07, 2015

AXERT

AB	+	JANSSEN PHARMS	<u>EQ 6.25MG BASE</u>	<u>N021001</u>	<u>001</u>	May 07, 2001
AB	+	!	<u>EQ 12.5MG BASE</u>	<u>N021001</u>	<u>002</u>	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+	!	EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE; 500MG	N203414	001	Jan 25, 2013
+	!	EQ 12.5MG BASE; 1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 15MG BASE	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE; EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 12.5MG BASE; EQ 45MG BASE	N022426	006	Jan 25, 2013
+		EQ 25MG BASE; EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE; EQ 30MG BASE	N022426	002	Jan 25, 2013
+	!	EQ 25MG BASE; EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	<u>EQ 0.5MG BASE</u>	<u>A206647</u>	<u>001</u>	Dec 22, 2016
AB		<u>EQ 1MG BASE</u>	<u>A206647</u>	<u>002</u>	Dec 22, 2016
AB	WEST-WARD PHARMS INT	<u>EQ 0.5MG BASE</u>	<u>A200652</u>	<u>001</u>	May 04, 2015
AB		<u>EQ 1MG BASE</u>	<u>A200652</u>	<u>002</u>	May 04, 2015

LOTRONEX

AB	+	SEBELA IRELAND LTD	<u>EQ 0.5MG BASE</u>	<u>N021107</u>	<u>002</u>	Dec 23, 2003
AB	+	!	<u>EQ 1MG BASE</u>	<u>N021107</u>	<u>001</u>	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1 .2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000
---	------------	---	---------	-----	--------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1 .2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003
---	------------	--	---------	-----	--------------

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

!	WEST-WARD PHARMS INT	1MG/ML	A074312	001	Oct 31, 1993
---	-------------------------	--------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342 001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342 002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342 003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342 004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741 001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741 002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741 003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741 004</u>	Jan 19, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.25MG</u>	<u>A203346 001</u>	Jul 31, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A203346 002</u>	Jul 31, 2015
<u>AB</u>		<u>1MG</u>	<u>A203346 003</u>	Jul 31, 2015
<u>AB</u>		<u>2MG</u>	<u>A203346 004</u>	Jul 31, 2015
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174 001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174 002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174 003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174 004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215 001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215 002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215 003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215 004</u>	Jan 27, 1994
<u>AB</u>	NATCO PHARMA LTD	<u>0.25MG</u>	<u>A200739 001</u>	Apr 15, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A200739 002</u>	Apr 15, 2015
<u>AB</u>		<u>1MG</u>	<u>A200739 003</u>	Apr 15, 2015
<u>AB</u>		<u>2MG</u>	<u>A200739 004</u>	Apr 15, 2015
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112 001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112 002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112 003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909 001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082 001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082 002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082 003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082 004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491 001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491 002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491 003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491 004</u>	Dec 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248 001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248 002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248 003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248 004</u>	Sep 17, 2010

XANAX

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276 001</u>	
<u>AB</u>	+	<u>0.5MG</u>	<u>N018276 002</u>	
<u>AB</u>	+!	<u>1MG</u>	<u>N018276 003</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N018276 004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056 001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056 002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056 003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056 004</u>	Feb 13, 2007
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387 001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387 002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387 003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387 004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469 001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469 002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469 003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469 004</u>	Sep 29, 2011
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077725 001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725 002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725 004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725 003</u>	Jul 31, 2006
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449 001</u>	Nov 12, 2008
<u>AB</u>		<u>1MG</u>	<u>A078449 004</u>	Dec 23, 2015
<u>AB</u>		<u>2MG</u>	<u>A078449 002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449 003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>0.5MG</u>	<u>A090871 001</u>	Jun 07, 2011

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

LTD

<u>AB</u>		<u>1MG</u>	<u>A090871 002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871 003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871 004</u>	Jun 07, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>0.5MG</u>	<u>A078489 001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489 002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489 003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489 004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434 001</u>	Jan 17, 2003
<u>AB</u>	+		<u>1MG</u>	<u>N021434 002</u>	Jan 17, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021434 003</u>	Jan 17, 2003
<u>AB</u>	+		<u>3MG</u>	<u>N021434 004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561 001</u>	Mar 16, 2010
<u>AB</u>			<u>0.5MG</u>	<u>A078561 002</u>	Mar 16, 2010
<u>AB</u>			<u>1MG</u>	<u>A078561 003</u>	Mar 16, 2010
<u>AB</u>			<u>2MG</u>	<u>A078561 004</u>	Mar 16, 2010
<u>AB</u>		PAR PHARM	<u>0.25MG</u>	<u>A078088 001</u>	Jan 09, 2009
<u>AB</u>			<u>0.5MG</u>	<u>A078088 002</u>	Jan 09, 2009
<u>AB</u>	!		<u>1MG</u>	<u>A078088 003</u>	Jan 09, 2009
<u>AB</u>			<u>2MG</u>	<u>A078088 004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>		TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196 001</u>	Apr 30, 1999
<u>AP</u>		WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>A074815 001</u>	Jan 20, 1998

CAVERJECT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379 001</u>	Jul 06, 1995
<u>AP</u>	+		<u>0.02MG/VIAL</u>	<u>N020379 002</u>	Jul 06, 1995
<u>AP</u>	+		<u>0.04MG/VIAL</u>	<u>N020379 004</u>	May 19, 1997

EDEX

<u>AP</u>	+	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649 002</u>	Jun 12, 1997
<u>AP</u>	+		<u>0.02MG/VIAL</u>	<u>N020649 003</u>	Jun 12, 1997
<u>AP</u>	+		<u>0.04MG/VIAL</u>	<u>N020649 004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484 001</u>	
-----------	---	-------------------------	-----------------	--------------------	--

CAVERJECT

	+	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379 003	Jun 27, 1996
--	---	-------------------------	--------------	-------------	--------------

CAVERJECT IMPULSE

		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212 001	Jun 11, 2002
			0.02MG/VIAL	N021212 002	Jun 11, 2002

EDEX

	+	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649 005	Jul 30, 1998
	+		0.02MG/VIAL	N020649 006	Jul 30, 1998
	+		0.04MG/VIAL	N020649 007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

	+	MYLAN SPECIALITY LP	0.125MG	N020700 001	Nov 19, 1996
	+		0.25MG	N020700 002	Nov 19, 1996
	+		0.5MG	N020700 003	Nov 19, 1996
	+		1MG	N020700 004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

	+	EISAI INC	50MG	N019926 001	Dec 26, 1990
--	---	-----------	------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+! CUBIST PHARMS 12MG N021775 001 May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A208966</u>	<u>001</u>	Jun 21, 2017
<u>AB</u>		BIONPHARMA INC	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008
<u>AB</u>		HERITAGE PHARMA	<u>100MG</u>	<u>A209171</u>	<u>001</u>	Jun 12, 2017
<u>AB</u>		LANNETT HOLDINGS INC	<u>100MG</u>	<u>A209221</u>	<u>001</u>	Jun 15, 2017
<u>AB</u>		NEWGEN PHARMS LLC	<u>100MG</u>	<u>A207570</u>	<u>001</u>	Sep 30, 2016
<u>AB</u>	!	SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u>	Feb 18, 1987
<u>AB</u>		STRIDES PHARMA	<u>100MG</u>	<u>A209047</u>	<u>001</u>	Jun 07, 2017
<u>AB</u>		USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986
<u>AB</u>		WATSON LABS INC	<u>100MG</u>	<u>A208107</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>		ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A208278</u>	<u>001</u>	May 31, 2016

CAPSULE, EXTENDED RELEASE; ORAL

GOCOVRI

+ ADAMAS PHARMA EQ 68.5MG BASE N208944 001 Aug 24, 2017
+! EQ 137MG BASE N208944 002 Aug 24, 2017

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	!	CMP PHARMA INC	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002
<u>AA</u>	!	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	!	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993
<u>AA</u>	!	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995
<u>AA</u>	!	WOCKHARDT BIO AG	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>		NEWGEN PHARMS LLC	<u>100MG</u>	<u>A207571</u>	<u>001</u>	Jan 31, 2017
<u>AB</u>		STRIDES PHARMA	<u>100MG</u>	<u>A209035</u>	<u>001</u>	Jun 09, 2017
<u>AB</u>	!	USL PHARMA	<u>100MG</u>	<u>A076186</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		WATSON LABS INC	<u>100MG</u>	<u>A208096</u>	<u>001</u>	Dec 15, 2016

AMBRISENTAN

TABLET; ORAL

LETAIRIS

+ GILEAD 5MG N022081 001 Jun 15, 2007
+! 10MG N022081 002 Jun 15, 2007AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.1%</u>	<u>A076065</u>	<u>001</u>	May 15, 2003
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076229</u>	<u>001</u>	May 31, 2002

LOTION; TOPICAL

AMCINONIDE

! FOUGERA PHARMS 0.1% A076329 001 Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.1%</u>	<u>A076096</u>	<u>001</u>	Nov 19, 2002
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076367</u>	<u>001</u>	Mar 19, 2003

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A204363</u>	<u>001</u>	Jul 17, 2017
<u>AP</u>		SUN PHARMA GLOBAL	<u>500MG/VIAL</u>	<u>A077126</u>	<u>001</u>	Mar 14, 2008

ETHYOL

<u>AP</u>	+	CLINIGEN HLTHCARE	<u>500MG/VIAL</u>	<u>N020221</u>	<u>001</u>	Dec 08, 1995
-----------	---	-------------------	-------------------	----------------	------------	--------------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

<u>AP</u>	!	EMCURE PHARMS LTD	<u>EQ 250MG BASE/ML</u>	<u>A204040</u>	<u>001</u>	Dec 12, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A205605</u>	<u>001</u>	Dec 09, 2015
<u>AP</u>			<u>EQ 250MG BASE/ML</u>	<u>A205604</u>	<u>001</u>	Dec 09, 2015
<u>AP</u>		SAGENT PHARMS	<u>EQ 250MG BASE/ML</u>	<u>A203323</u>	<u>001</u>	May 12, 2016
<u>AP</u>		TEVA PHARMS USA	<u>EQ 250MG BASE/ML</u>	<u>A064045</u>	<u>002</u>	Sep 28, 1993
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A063313</u>	<u>001</u>	Apr 11, 1994

PRESCRIPTION DRUG PRODUCT LIST

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATEAP EQ 250MG BASE/ML A063315 001 Apr 11, 1994AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDEAB ! PAR PHARM 5MG A070346 001 Jan 22, 1986AB SIGMAPHARM LABS LLC 5MG A079133 001 Jan 30, 2009AB WINDLAS HLTHCARE 5MG A204180 001 Aug 07, 2015MIDAMORAB + PADDOCK LLC 5MG N018200 001AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEAB BARR EQ 5MG ANHYDROUS; 50MG A071111 001 May 10, 1988AB ! MYLAN EQ 5MG ANHYDROUS; 50MG A073209 001 Oct 31, 1991AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN 15% (150GM/1000ML) A091112 001 Apr 13, 2012

15% (300GM/2000ML) A091112 002 Apr 13, 2012

AMINOSYN 10%

ICU MEDICAL INC 10% (10GM/100ML) N017673 003

AMINOSYN 10% (PH6)

ICU MEDICAL INC 10% (10GM/100ML) N017673 008 Nov 18, 1985

AMINOSYN 3.5%

ICU MEDICAL INC 3.5% (3.5GM/100ML) N017789 004

AMINOSYN 5%

ICU MEDICAL INC 5% (5GM/100ML) N017673 001

AMINOSYN 7%

ICU MEDICAL INC 7% (7GM/100ML) N017673 002

AMINOSYN 7% (PH6)

ICU MEDICAL INC 7% (7GM/100ML) N017673 006 Nov 18, 1985

AMINOSYN 8.5%

ICU MEDICAL INC 8.5% (8.5GM/100ML) N017673 004

AMINOSYN 8.5% (PH6)

ICU MEDICAL INC 8.5% (8.5GM/100ML) N017673 007 Nov 18, 1985

AMINOSYN II 10%

ICU MEDICAL INC 10% (10GM/100ML) N019438 005 Apr 03, 1986

AMINOSYN II 10% IN PLASTIC CONTAINER

ICU MEDICAL INC 10% (10GM/100ML) N020015 001 Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU MEDICAL INC 15% (15GM/100ML) N020041 001 Dec 19, 1991

AMINOSYN II 7%

ICU MEDICAL INC 7% (7GM/100ML) N019438 003 Apr 03, 1986

AMINOSYN II 8.5%

ICU MEDICAL INC 8.5% (8.5GM/100ML) N019438 004 Apr 03, 1986

AMINOSYN-HBC 7%

ICU MEDICAL INC 7% (7GM/100ML) N019374 001 Jul 12, 1985

AMINOSYN-HF 8%

ICU MEDICAL INC 8% (8GM/100ML) A020345 001 Apr 04, 1996

AMINOSYN-PF 10%

ICU MEDICAL INC 10% (10GM/100ML) N019492 002 Oct 17, 1986

AMINOSYN-PF 7%

ICU MEDICAL INC 7% (7GM/100ML) N019398 001 Sep 06, 1985

AMINOSYN-RF 5.2%

ICU MEDICAL INC 5.2% (5.2GM/100ML) N018429 001

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE 15% (15GM/100ML) A020512 001 Aug 30, 1996

FREAMINE HBC 6.9%

B BRAUN 6.9% (6.9GM/100ML) N016822 006 May 17, 1983

FREAMINE III 10%

B BRAUN 10% (10GM/100ML) N016822 005

FREAMINE III 8.5%

B BRAUN 8.5% (8.5GM/100ML) N016822 004

HEPATAMINE 8%

B BRAUN 8% (8GM/100ML) N018676 001 Aug 03, 1982

NEPHRAMINE 5.4%

B BRAUN 5.4% (5.4GM/100ML) N017766 001

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984
TROPHAMINE				
+! B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984
TROPHAMINE 10%				
+! B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE				
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG /100ML;150MG/100ML;200MG/100ML;120MG/10 0ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+! BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER				
+ FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;	N200656	006	Aug 25, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

	174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9 GM/100ML (2053ML)		
+!	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9 GM/100ML (2566ML)	N200656 007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5 GM/100ML (1440ML)	N200656 001	Aug 25, 2014
+	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5 GM/100ML (1920ML)	N200656 002	Aug 25, 2014
+	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)	N200656 003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 10GM/100ML	N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 25GM/100ML	N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 5GM/100ML	N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%; 110MG/100ML; 230MG/100ML; 10MG/100ML; 440MG/100ML; 690MG/100ML	N016822 007	Jul 01, 1988
---------	--	-------------	--------------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N017789 003	
-----------------	--	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%; 54MG/100ML; 40MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML	N016822 003	
---------	---	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
-----------------	--	-------------	--------------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437 005	Apr 03, 1986
-----------------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC 7%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017789 002

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017673 005
LAMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID**AP** LUITPOLD 250MG/ML **A071192 001** Dec 01, 1987AMINOCAPROIC ACID IN PLASTIC CONTAINER**AP** ! HOSPIRA 250MG/ML **A070010 001** Mar 09, 1987

SYRUP; ORAL

AMICAR**AA** +! CLOVER PHARMS 1.25GM/5ML **N015230 002**AMINOCAPROIC ACID**AA** AKORN 1.25GM/5ML **A074759 001** Sep 02, 1998

TABLET; ORAL

AMICAR**AB** + CLOVER PHARMS 500MG **N015197 001**AMINOCAPROIC**AB** AKORN 500MG **A075602 001** May 24, 2001

AMICAR

+! CLOVER PHARMS 1GM N015197 002 Jun 24, 2004

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION; ORAL

GLEOLAN

+! NXDC 1.5GM/VIAL N208630 001 Jun 06, 2017

GEL; TOPICAL

AMELUZ

+! BIOFRONTERA 10% N208081 001 May 10, 2016

SOLUTION; TOPICAL

LEVULAN

+! DUSA 20% N020965 001 Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE**AP** ! HOSPIRA 25MG/ML **A087242 001** Oct 26, 1983**AP** LUITPOLD 25MG/ML **A087600 001**AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

! JACOBUS 4GM/PACKET A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE**AP** ! AKORN 50MG/ML **A076232 001** Jul 05, 2006**AP** AUROBINDO PHARMA 50MG/ML **A204550 001** Oct 25, 2017

LTD

AP ! FRESENIUS KABI USA 50MG/ML **A075761 001** Oct 15, 2002**AP** ! GLAND PHARMA LTD 50MG/ML **A077161 001** Apr 20, 2005**AP** HIKMA FARMACEUTICA 50MG/ML **A077234 001** Feb 25, 2008**AP** ! HOSPIRA 50MG/ML **A075955 001** Oct 18, 2002**AP** HOSPIRA INC 50MG/ML **A203884 001** Nov 25, 2013**AP** 50MG/ML **A203885 001** Nov 25, 2013**AP** ! MYLAN INSTITUTIONAL 50MG/ML **A076217 001** Oct 15, 2002**AP** WOCKHARDT 50MG/ML **A077610 001** Oct 30, 2008**AP** 50MG/ML **A077834 001** Oct 30, 2008NEXTERONE**AP** + BAXTER HLTHCARE 50MG/ML **N022325 001** Dec 24, 2008

+! 150MG/100ML (1.5MG/ML) N022325 002 Nov 16, 2010

+! 360MG/200ML (1.8MG/ML) N022325 003 Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE**AB** APOTEX INC 200MG **A078578 001** Nov 06, 2008**AB** AUROBINDO PHARMA 200MG **A204742 001** Jun 03, 2016

LTD

AB MAYNE PHARMA INC 100MG **A075389 002** Dec 28, 2017**AB** 200MG **A075389 001** Jan 25, 2001

PRESCRIPTION DRUG PRODUCT LIST

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<u>AB</u>		<u>400MG</u>	<u>A075389 003</u>	Dec 28, 2017
<u>AB</u>	MURTY PHARMS	<u>100MG</u>	<u>A077069 003</u>	Oct 04, 2016
<u>AB</u>		<u>200MG</u>	<u>A077069 001</u>	Apr 08, 2005
<u>AB</u>		<u>400MG</u>	<u>A077069 002</u>	Apr 08, 2005
<u>AB</u>	! SANDOZ	<u>200MG</u>	<u>A075315 001</u>	Dec 23, 1998
<u>AB</u>		<u>400MG</u>	<u>A075315 002</u>	Jun 30, 2000
<u>AB</u>	TARO PHARM	<u>100MG</u>	<u>A075424 002</u>	Dec 18, 2002
<u>AB</u>		<u>200MG</u>	<u>A075424 001</u>	Mar 30, 2001
<u>AB</u>		<u>400MG</u>	<u>A076362 001</u>	Nov 29, 2002
<u>AB</u>	TEVA PHARMS	<u>200MG</u>	<u>A074739 001</u>	Nov 30, 1998
<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A079029 001</u>	Sep 16, 2008

PACERONE

<u>AB</u>	UPSHER-SMITH LABS	<u>100MG</u>	<u>A075135 002</u>	Apr 12, 2005
<u>AB</u>		<u>200MG</u>	<u>A075135 001</u>	Apr 30, 1998
	AMIODARONE HYDROCHLORIDE TARO PHARM	300MG	A076362 002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A202446 001</u>	Jun 04, 2014
<u>AB</u>		<u>25MG</u>	<u>A202446 002</u>	Jun 04, 2014
<u>AB</u>		<u>50MG</u>	<u>A202446 003</u>	Jun 04, 2014
<u>AB</u>		<u>75MG</u>	<u>A202446 004</u>	Jun 04, 2014
<u>AB</u>		<u>100MG</u>	<u>A202446 005</u>	Jun 04, 2014
<u>AB</u>		<u>150MG</u>	<u>A202446 006</u>	Jun 04, 2014
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009 002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009 003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009 001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009 004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009 005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009 006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969 001</u>	
<u>AB</u>	!	<u>25MG</u>	<u>A085966 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968 001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971 001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967 001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970 001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218 001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218 002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218 003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218 004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218 005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218 006</u>	Sep 11, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A210086 001</u>	Oct 06, 2017
<u>AB</u>		<u>25MG</u>	<u>A210086 002</u>	Oct 06, 2017
<u>AB</u>		<u>50MG</u>	<u>A210086 003</u>	Oct 06, 2017
<u>AB</u>		<u>75MG</u>	<u>A210086 004</u>	Oct 06, 2017
<u>AB</u>		<u>100MG</u>	<u>A210086 005</u>	Oct 06, 2017
<u>AB</u>		<u>150MG</u>	<u>A210086 006</u>	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986
	!	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443 002	Nov 10, 1988
		10MG;4MG	A071443 003	Nov 10, 1988
	!	25MG;2MG	A071443 004	Nov 10, 1988
	!	25MG;4MG	A071443 005	Nov 10, 1988
	!	50MG;4MG	A071443 001	Nov 10, 1988

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553 003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925 001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925 002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925 003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477 001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477 002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477 003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719 001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719 002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719 003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021 001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021 002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021 003</u>	Jul 17, 2007
<u>AB</u>	CHINA RESOURCES	<u>EQ 2.5MG BASE</u>	<u>A090752 003</u>	May 16, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090752 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752 002</u>	Apr 15, 2011
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073 001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073 002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073 003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692 001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692 002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692 003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552 001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552 002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552 003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771 001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771 002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771 003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955 001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A206367 001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955 002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206367 002</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955 003</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206367 003</u>	Dec 10, 2015
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043 001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043 002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043 003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380 001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380 002</u>	Apr 13, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A076418 001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418 002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418 003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453 001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453 002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453 003</u>	Jul 02, 2009
<u>AB</u>	POLYGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207821 001</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207821 002</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207821 003</u>	Jul 11, 2016
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2.5MG BASE</u>	<u>A078231 001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231 002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231 003</u>	Nov 30, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A077974 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974 003</u>	Jul 09, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846 001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846 002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846 003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573 001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573 002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573 003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245 001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245 002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245 003</u>	Oct 21, 2013
<u>AB</u>	UPSHER-SMITH LABS	<u>EQ 2.5MG BASE</u>	<u>A077759 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759 003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414 001</u>	Apr 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414 003</u>	Apr 07, 2010
<u>AB</u>	VIVIMED GLOBAL	<u>EQ 2.5MG BASE</u>	<u>A077516 001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516 002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516 003</u>	Jul 11, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671 001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671 002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671 003</u>	Jul 19, 2007
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 2.5MG BASE</u>	<u>A077262 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262 003</u>	Jul 09, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500 001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500 002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500 003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226 003</u>	Jul 09, 2007
<u>NORVASC</u>				
<u>AB</u>	+ PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787 001</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N019787 002</u>	Jul 31, 1992
<u>AB</u>	+!	<u>EQ 10MG BASE</u>	<u>N019787 003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874 001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874 002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874 003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874 004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874 005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874 006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874 007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874 008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874 009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874 010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874 011</u>	Mar 07, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465 001</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013
<u>CADUET</u>				
<u>AB</u>	+ PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
<u>AB</u>	+!	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431 001</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A091431 002</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A091431 003</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091431 004</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A091431 005</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A091431 006</u>	Dec 30, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239 001</u>	Sep 05, 2012

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

LTD

<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A202239 002</u>	Sep 05, 2012	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A202239 003</u>	Sep 05, 2012	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202239 004</u>	Sep 05, 2012	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202239 005</u>	Sep 05, 2012	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202239 006</u>	Sep 05, 2012	
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183 001</u>	Apr 15, 2010	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183 002</u>	Apr 15, 2010	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183 003</u>	Apr 15, 2010	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A090149 001</u>	Jul 05, 2011	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183 004</u>	Apr 15, 2010	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090149 002</u>	Jul 05, 2011	
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466 001</u>	Feb 05, 2010	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466 002</u>	Feb 05, 2010	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466 003</u>	Feb 05, 2010	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078466 005</u>	Jul 05, 2011	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466 004</u>	Feb 05, 2010	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078466 006</u>	Jul 05, 2011	
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375 001</u>	May 21, 2010	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077375 002</u>	May 21, 2010	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077375 003</u>	May 21, 2010	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A079047 001</u>	Jul 05, 2011	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077375 004</u>	May 21, 2010	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A079047 002</u>	Jul 05, 2011	
<u>AB</u>	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381 001</u>	Jul 29, 2010	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078381 002</u>	Jul 29, 2010	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381 003</u>	Jul 29, 2010	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078381 005</u>	Jul 29, 2010	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078381 004</u>	Jul 29, 2010	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381 006</u>	Jul 29, 2010	
<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179 001</u>	May 18, 2007	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179 002</u>	May 18, 2007	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179 003</u>	May 18, 2007	
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A077179 005</u>	Jul 05, 2011	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179 004</u>	May 18, 2007	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A077179 006</u>	Jul 05, 2011	
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890 001</u>	Oct 14, 2010	
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890 002</u>	Oct 14, 2010	
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890 003</u>	Oct 14, 2010	
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890 004</u>	Oct 14, 2010	
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364 001</u>	Jul 05, 2011	
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364 002</u>	Jul 05, 2011	
LOTREL					
<u>AB</u>	+	<u>NOVARTIS</u>	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364 002</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;10MG</u>	<u>N020364 003</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;20MG</u>	<u>N020364 004</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;40MG</u>	<u>N020364 007</u>	Apr 11, 2006
<u>AB</u>	+		<u>EQ 10MG BASE;20MG</u>	<u>N020364 005</u>	Jun 20, 2002
<u>AB</u>	+	!	<u>EQ 10MG BASE;40MG</u>	<u>N020364 006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A206137 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A206137 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A206137 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A206137 004</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A206137 005</u>	Oct 26, 2016
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A202491 001</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A202491 002</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A202491 003</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A202491 004</u>	Nov 03, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A202491 005</u>	Nov 03, 2016
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A203580 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A203580 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A203580 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A203580 004</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A203580 005</u>	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

<u>AB</u>	+	DAIICHI SANKYO	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>N200175 001</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>N200175 002</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;25MG;40MG</u>	<u>N200175 003</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>N200175 004</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 10MG BASE;25MG;40MG</u>	<u>N200175 005</u>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG;12.5MG;160MG</u>	<u>A206180 001</u>	Dec 19, 2017
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A206180 002</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A206180 003</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A206180 004</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A206180 005</u>	Dec 19, 2017
<u>AB</u>		LUPIN LTD	<u>5MG;12.5MG;160MG</u>	<u>A200797 001</u>	Jun 03, 2015
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A200797 002</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A200797 003</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A200797 004</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A200797 005</u>	Jun 03, 2015
<u>AB</u>		PAR PHARM	<u>5MG;12.5MG;160MG</u>	<u>A201087 001</u>	Jun 01, 2015
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A201087 002</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A201087 003</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A201087 004</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A201087 005</u>	Jun 01, 2015
<u>AB</u>		TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435 001</u>	Sep 25, 2012
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A200435 002</u>	Sep 25, 2012
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A200435 005</u>	Sep 25, 2012
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A200435 003</u>	Sep 25, 2012
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A200435 004</u>	Sep 25, 2012
<u>AB</u>		TORRENT PHARMS LTD	<u>5MG;12.5MG;160MG</u>	<u>A201593 001</u>	Jun 03, 2015
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A201593 002</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A201593 003</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A201593 004</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A201593 005</u>	Jun 03, 2015
		<u>EXFORGE HCT</u>			
<u>AB</u>	+	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314 001</u>	Apr 30, 2009
<u>AB</u>	+		<u>5MG;25MG;160MG</u>	<u>N022314 002</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;12.5MG;160MG</u>	<u>N022314 003</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;25MG;160MG</u>	<u>N022314 004</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;25MG;320MG</u>	<u>N022314 005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207216 001</u>	Oct 28, 2016
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A207216 002</u>	Oct 28, 2016
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A207216 003</u>	Oct 28, 2016
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A207216 004</u>	Oct 28, 2016
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207073 001</u>	Jul 17, 2017
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A207073 002</u>	Jul 17, 2017
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A207073 003</u>	Jul 17, 2017
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A207073 004</u>	Jul 17, 2017
<u>AB</u>		ALKEM LABS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A209042 001</u>	Aug 14, 2017
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A209042 002</u>	Aug 14, 2017
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A209042 003</u>	Aug 14, 2017
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A209042 004</u>	Aug 14, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206906 001</u>	May 15, 2017
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A206906 002</u>	May 15, 2017
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A206906 003</u>	May 15, 2017
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A206906 004</u>	May 15, 2017
<u>AB</u>		GLENMARK PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207807 001</u>	Jul 05, 2017
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A207807 002</u>	Jul 05, 2017
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A207807 003</u>	Jul 05, 2017
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A207807 004</u>	Jul 05, 2017
<u>AB</u>		JUBILANT GENERICS	<u>EQ 5MG BASE;20MG</u>	<u>A207450 001</u>	May 15, 2017
<u>AB</u>			<u>EQ 5MG BASE;40MG</u>	<u>A207450 002</u>	May 15, 2017
<u>AB</u>			<u>EQ 10MG BASE;20MG</u>	<u>A207450 003</u>	May 15, 2017
<u>AB</u>			<u>EQ 10MG BASE;40MG</u>	<u>A207450 004</u>	May 15, 2017
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206884 001</u>	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

<u>AB</u>		<u>EQ 5MG BASE; 40MG</u>	<u>A206884 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE; 20MG</u>	<u>A206884 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A206884 004</u>	Oct 26, 2016
<u>AB</u>	MICRO LABS	<u>EQ 5MG BASE; 20MG</u>	<u>A207435 001</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 5MG BASE; 40MG</u>	<u>A207435 002</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE; 20MG</u>	<u>A207435 003</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A207435 004</u>	Nov 02, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE; 20MG</u>	<u>A091154 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE; 40MG</u>	<u>A091154 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE; 20MG</u>	<u>A091154 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A091154 004</u>	Oct 26, 2016
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE; 20MG</u>	<u>A202933 001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 5MG BASE; 40MG</u>	<u>A202933 002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE; 20MG</u>	<u>A202933 003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A202933 004</u>	Nov 25, 2016
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 5MG BASE; 20MG</u>	<u>A207771 001</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 5MG BASE; 40MG</u>	<u>A207771 002</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE; 20MG</u>	<u>A207771 003</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A207771 004</u>	Sep 22, 2017
<u>AZOR</u>				
<u>AB</u>	+	DAIICHI SANKYO	<u>EQ 5MG BASE; 20MG</u>	<u>N022100 001</u> Sep 26, 2007
<u>AB</u>	+		<u>EQ 5MG BASE; 40MG</u>	<u>N022100 002</u> Sep 26, 2007
<u>AB</u>	+		<u>EQ 10MG BASE; 20MG</u>	<u>N022100 003</u> Sep 26, 2007
<u>AB</u>	+		<u>EQ 10MG BASE; 40MG</u>	<u>N022100 004</u> Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	MARINA BIOTECH	EQ 2.5MG BASE; 3.5MG	N205003 001	Jan 21, 2015
+		EQ 5MG BASE; 7MG	N205003 002	Jan 21, 2015
+		EQ 10MG BASE; 14MG	N205003 003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE; 40MG</u>	<u>A205234 001</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 5MG BASE; 80MG</u>	<u>A205234 003</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A205234 002</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 10MG BASE; 80MG</u>	<u>A205234 004</u>	Nov 17, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE; 40MG</u>	<u>A201586 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE; 80MG</u>	<u>A201586 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A201586 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE; 80MG</u>	<u>A201586 004</u>	Jan 08, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE; 40MG</u>	<u>A202516 001</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 5MG BASE; 80MG</u>	<u>A202516 003</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A202516 002</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE; 80MG</u>	<u>A202516 004</u>	Aug 26, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE; 40MG</u>	<u>A202517 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE; 80MG</u>	<u>A202517 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE; 40MG</u>	<u>A202517 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE; 80MG</u>	<u>A202517 004</u>	Jan 08, 2014
<u>TWYNSTA</u>				
<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE; 40MG</u>	<u>N022401 001</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 5MG BASE; 80MG</u>	<u>N022401 003</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 10MG BASE; 40MG</u>	<u>N022401 002</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 10MG BASE; 80MG</u>	<u>N022401 004</u> Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE; 160MG</u>	<u>A202713 001</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 5MG BASE; 320MG</u>	<u>A202713 003</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE; 160MG</u>	<u>A202713 002</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE; 320MG</u>	<u>A202713 004</u>	Apr 03, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE; 160MG</u>	<u>A206512 001</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 5MG BASE; 320MG</u>	<u>A206512 002</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE; 160MG</u>	<u>A206512 003</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE; 320MG</u>	<u>A206512 004</u>	Apr 22, 2016

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE;160MG</u>	<u>A205137 001</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A205137 003</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A205137 002</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A205137 004</u>	Sep 16, 2016
<u>AB</u>	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090245 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090245 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090245 004</u>	Mar 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE;160MG</u>	<u>A090483 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090483 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090483 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090483 004</u>	Mar 30, 2015
<u>AB</u>	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202829 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202829 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202829 004</u>	Mar 30, 2015
<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011 001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090011 003</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090011 002</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090011 004</u>	Mar 28, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE;160MG</u>	<u>A091235 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A091235 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A091235 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A091235 004</u>	Mar 30, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202377 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202377 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202377 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202377 004</u>	Mar 30, 2015
<u>EXFORGE</u>				
<u>AB</u>	+ NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990 002</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 5MG BASE;320MG</u>	<u>N021990 004</u>	Jun 20, 2007
<u>AB</u>	+!	<u>EQ 10MG BASE;160MG</u>	<u>N021990 003</u>	Jun 20, 2007
<u>AB</u>	+!	<u>EQ 10MG BASE;320MG</u>	<u>N021990 005</u>	Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779 001</u>	Oct 19, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-</u> <u>37.5mCi/ML)</u>	<u>A204352 001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<u>AP</u>	+! FEINSTEIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119 001</u>	Aug 23, 2007
<u>AP</u>	GEN HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A207025 001</u>	Feb 03, 2016
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465 001</u>	Oct 23, 2014
<u>AP</u>	IBA MOLECULAR N AM	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667 001</u>	Apr 22, 2015
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514 001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938 001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321 001</u>	Feb 25, 2013
<u>AP</u>	MIDWEST MEDCL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204457 001</u>	Nov 18, 2015
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535 001</u>	Nov 20, 2014
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510 001</u>	Nov 02, 2015
<u>AP</u>	SPECTRON MRC LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455 001</u>	Apr 23, 2015
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812 001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496 001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203933 001</u>	Jun 27, 2014
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506 001</u>	Feb 07, 2014
	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687 001	Dec 17, 2015
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543 001	Dec 14, 2012
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515 001	Feb 04, 2015
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547 001	Aug 14, 2015
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366 001	Sep 19, 2014
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356 001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

!	HOSPIRA	5MEQ/ML	A088366 001	Jun 13, 1984
---	---------	---------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774 001</u>	May 01, 2002
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A075883 001</u>	Apr 10, 2003
<u>AB</u>		WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829 001</u>	Feb 07, 2006

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570 001</u>	Jun 23, 2004
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A076216 001</u>	May 28, 2004
<u>AB</u>		WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575 001</u>	Jun 11, 2002

AMOXAPINE

TABLET; ORAL

AMOXAPINE

		WATSON LABS	25MG	A072688 001	Aug 28, 1992
			50MG	A072689 001	Aug 28, 1992
			100MG	A072690 001	Aug 28, 1992
	!		150MG	A072691 001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>		AM ANTIBIOTICS	<u>250MG</u>	<u>A062058 001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062058 002</u>	
<u>AB</u>		AUROBINDO	<u>250MG</u>	<u>A065271 001</u>	Nov 09, 2005
<u>AB</u>			<u>500MG</u>	<u>A065271 002</u>	Nov 09, 2005
<u>AB</u>		DAVA PHARMS INC	<u>250MG</u>	<u>A062884 001</u>	Feb 25, 1988
<u>AB</u>			<u>500MG</u>	<u>A062881 001</u>	Feb 25, 1988
<u>AB</u>		HIKMA PHARMS	<u>250MG</u>	<u>A065291 001</u>	Feb 05, 2007
<u>AB</u>			<u>500MG</u>	<u>A065291 002</u>	Feb 05, 2007
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A064076 001</u>	Sep 30, 1994
<u>AB</u>			<u>500MG</u>	<u>A064076 002</u>	Sep 30, 1994
<u>AB</u>		TEVA	<u>250MG</u>	<u>A061926 001</u>	
<u>AB</u>	!		<u>500MG</u>	<u>A061926 003</u>	

AMOXIL

<u>AB</u>		DR REDDYS LABS INC	<u>250MG</u>	<u>A062216 001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062216 004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>200MG/5ML</u>	<u>A065334 001</u>	Dec 28, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065334 002</u>	Dec 28, 2006
<u>AB</u>		AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030 001</u>	Sep 15, 2014
<u>AB</u>			<u>250MG/5ML</u>	<u>A204030 002</u>	Sep 15, 2014
<u>AB</u>		DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927 001</u>	Nov 25, 1988
<u>AB</u>			<u>250MG/5ML</u>	<u>A062927 002</u>	Nov 25, 1988
<u>AB</u>		HIKMA	<u>125MG/5ML</u>	<u>A065322 002</u>	Jun 19, 2006
<u>AB</u>			<u>200MG/5ML</u>	<u>A065325 002</u>	Jun 19, 2006
<u>AB</u>			<u>250MG/5ML</u>	<u>A065322 001</u>	Jun 19, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065325 001</u>	Jun 19, 2006
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065387 001</u>	Mar 26, 2007
<u>AB</u>			<u>200MG/5ML</u>	<u>A065378 001</u>	Mar 26, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065387 002</u>	Mar 26, 2007
<u>AB</u>			<u>400MG/5ML</u>	<u>A065378 002</u>	Mar 26, 2007
<u>AB</u>		TEVA	<u>125MG/5ML</u>	<u>A061931 001</u>	
<u>AB</u>			<u>200MG/5ML</u>	<u>A065119 001</u>	Dec 04, 2002
<u>AB</u>	!		<u>250MG/5ML</u>	<u>A061931 002</u>	
<u>AB</u>	!		<u>400MG/5ML</u>	<u>A065119 002</u>	Dec 04, 2002
<u>AB</u>		WOCKHARDT BIO AG	<u>400MG/5ML</u>	<u>A065319 002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>		TEVA	<u>50MG/ML</u>	<u>A061931 003</u>	Dec 01, 1982
-----------	--	------	----------------	--------------------	--------------

AMOXIL

<u>AB</u>		DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226 005</u>	
<u>AB</u>			<u>125MG/5ML</u>	<u>A062226 001</u>	
<u>AB</u>			<u>250MG/5ML</u>	<u>A062226 002</u>	

LAROTID

<u>AB</u>		DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226 003</u>	
<u>AB</u>			<u>250MG/5ML</u>	<u>A062226 004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>500MG</u>	<u>A065256 001</u>	Nov 09, 2005
<u>AB</u>			<u>875MG</u>	<u>A065256 002</u>	Nov 09, 2005
<u>AB</u>		HIKMA	<u>875MG</u>	<u>A065255 001</u>	Mar 29, 2006

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228 001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228 002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056 001</u>	Sep 18, 2000
<u>AB</u>	!	<u>875MG</u>	<u>A065056 002</u>	Sep 18, 2000

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	TEVA	125MG	A064013 002	Sep 11, 1995
	!	250MG	A064013 001	Dec 22, 1992

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+!	VERNALIS R AND D LTD	775MG	N050813 001	Jan 23, 2008
----	----------------------	-------	-------------	--------------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	RISING PHARMS INC	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A206006 001</u>	Oct 07, 2016
<u>AB</u>	SANDOZ INC	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A202588 001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A200218 001</u>	Aug 30, 2013

PREVPAC

<u>AB</u>	+!	TAKEDA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>N050757 001</u>	Dec 02, 1997
-----------	----	-------------------	---	--------------------	--------------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN

+!	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG	N050824 001	Feb 08, 2011
----	--------------	--	-------------	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A201090 001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A201090 002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A201091 001</u>	Dec 20, 2011
<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065191 002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065191 001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065373 001</u>	Nov 09, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065066 001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065066 002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065098 001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065098 002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065358 001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065089 001</u>	May 25, 2004
<u>AB</u>	!	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065089 002</u>	May 25, 2004
<u>AB</u>	!	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065162 001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT BIO AG	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>A065431 001</u>	Nov 25, 2008
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065420 001</u>	Dec 02, 2013

AUGMENTIN '250'

<u>AB</u>	+!	DR REDDYS LABS INC	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>N050575 002</u>	Aug 06, 1984
		AUGMENTIN '125'			
	+	DR REDDYS LABS INC	125MG/5ML; EQ 31.25MG BASE/5ML	N050575 001	Aug 06, 1984

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG; EQ 125MG BASE</u>	<u>A091569 001</u>	Jan 20, 2012	
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A091569 002</u>	Jan 20, 2012	
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A091568 001</u>	Jan 20, 2012	
<u>AB</u>	HIKMA PHARMS	<u>875MG; EQ 125MG BASE</u>	<u>A203824 001</u>	Aug 23, 2016	
<u>AB</u>	MICRO LABS LTD INDIA	<u>250MG; EQ 125MG BASE</u>	<u>A205707 001</u>	Dec 30, 2016	
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A205707 002</u>	Dec 30, 2016	
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A204755 003</u>	Dec 30, 2016	
<u>AB</u>	!	SANDOZ	<u>250MG; EQ 125MG BASE</u>	<u>A065189 001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A065064 001</u>	Mar 15, 2002	
<u>AB</u>	!	<u>875MG; EQ 125MG BASE</u>	<u>A065063 001</u>	Mar 14, 2002	
<u>AB</u>	!	SANDOZ INC	<u>500MG; EQ 125MG BASE</u>	<u>A065117 001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A065093 001</u>	Nov 21, 2002	
<u>AB</u>	TEVA	<u>500MG; EQ 125MG BASE</u>	<u>A065101 001</u>	Oct 30, 2002	

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002
	AUGMENTIN '875'			
AB	+ DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996
	TABLET, CHEWABLE; ORAL			
	AMOXICILLIN AND CLAVULANATE POTASSIUM			
	TEVA	200MG;EQ 28.5MG BASE	A065205 001	Feb 09, 2005
	!	400MG;EQ 57MG BASE	A065205 002	Feb 09, 2005
	TABLET, EXTENDED RELEASE; ORAL			
	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	SANDOZ	1GM;EQ 62.5MG BASE	A090227 001	Apr 21, 2010
	AUGMENTIN XR			
AB	+! DR REDDYS LABS INC	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE; ORAL

ADZENYS ER

+! NEOS THERAPS INC EQ 1.25MG BASE/ML N204325 001 Sep 15, 2017

DYANAVEL XR

+! TRIS PHARMA INC EQ 2.5MG BASE/ML N208147 001 Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

+ NEOS THERAPS EQ 3.1MG BASE N204326 001 Jan 27, 2016

+ EQ 6.3MG BASE N204326 002 Jan 27, 2016

+ EQ 9.4MG BASE N204326 003 Jan 27, 2016

+ EQ 12.5MG BASE N204326 004 Jan 27, 2016

+ EQ 15.7MG BASE N204326 005 Jan 27, 2016

+! EQ 18.8MG BASE N204326 006 Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10**AB** + SHIRE **2.5MG;2.5MG;2.5MG;2.5MG** **N021303 001** Oct 11, 2001ADDERALL XR 15**AB** + SHIRE **3.75MG;3.75MG;3.75MG;3.75MG** **N021303 006** May 22, 2002ADDERALL XR 20**AB** + SHIRE **5MG;5MG;5MG;5MG** **N021303 002** Oct 11, 2001ADDERALL XR 25**AB** + SHIRE **6.25MG;6.25MG;6.25MG;6.25MG** **N021303 004** May 22, 2002ADDERALL XR 30**AB** +! SHIRE **7.5MG;7.5MG;7.5MG;7.5MG** **N021303 003** Oct 11, 2001ADDERALL XR 5**AB** + SHIRE **1.25MG;1.25MG;1.25MG;1.25MG** **N021303 005** May 22, 2002DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**AB** ACTAVIS ELIZABETH **1.25MG;1.25MG;1.25MG;1.25MG** **A077302 001** Jun 22, 2012**AB** **2.5MG;2.5MG;2.5MG;2.5MG** **A077302 002** Jun 22, 2012**AB** **3.75MG;3.75MG;3.75MG;3.75MG** **A077302 003** Jun 22, 2012**AB** **5MG;5MG;5MG;5MG** **A077302 004** Jun 22, 2012**AB** **6.25MG;6.25MG;6.25MG;6.25MG** **A077302 005** Jun 22, 2012**AB** **7.5MG;7.5MG;7.5MG;7.5MG** **A077302 006** Jun 22, 2012**AB** IMPAX LABS **1.25MG;1.25MG;1.25MG;1.25MG** **A076852 001** Feb 16, 2016**AB** **2.5MG;2.5MG;2.5MG;2.5MG** **A076852 002** Feb 16, 2016**AB** **3.75MG;3.75MG;3.75MG;3.75MG** **A076852 003** Feb 16, 2016**AB** **5MG;5MG;5MG;5MG** **A076852 004** Feb 16, 2016**AB** **6.25MG;6.25MG;6.25MG;6.25MG** **A076852 005** Feb 16, 2016**AB** **7.5MG;7.5MG;7.5MG;7.5MG** **A076852 006** Feb 16, 2016**AB** TEVA **1.25MG;1.25MG;1.25MG;1.25MG** **A077488 001** Apr 29, 2013**AB** **2.5MG;2.5MG;2.5MG;2.5MG** **A077488 002** Apr 29, 2013**AB** **3.75MG;3.75MG;3.75MG;3.75MG** **A077488 003** Apr 29, 2013**AB** **5MG;5MG;5MG;5MG** **A077488 004** Apr 29, 2013**AB** **6.25MG;6.25MG;6.25MG;6.25MG** **A077488 005** Apr 29, 2013**AB** **7.5MG;7.5MG;7.5MG;7.5MG** **A077488 006** Apr 29, 2013DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**AB** BARR LABS INC **1.25MG;1.25MG;1.25MG;1.25MG** **A076536 001** Feb 12, 2013**AB** **2.5MG;2.5MG;2.5MG;2.5MG** **A076536 002** Feb 12, 2013**AB** **3.75MG;3.75MG;3.75MG;3.75MG** **A076536 003** Feb 12, 2013**AB** **5MG;5MG;5MG;5MG** **A076536 004** Feb 12, 2013**AB** **6.25MG;6.25MG;6.25MG;6.25MG** **A076536 005** Feb 12, 2013**AB** **7.5MG;7.5MG;7.5MG;7.5MG** **A076536 006** Feb 12, 2013

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MYDAYIS

+	SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
AB		1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB	ALVOGEN MALTA	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017
AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	MYLAN PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
AB		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440</u>	<u>007</u>	Oct 07, 2003
<u>AB</u>	SUN PHARM INDUSTRIES	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480</u>	<u>001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480</u>	<u>002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480</u>	<u>003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480</u>	<u>004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480</u>	<u>005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480</u>	<u>006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480</u>	<u>007</u>	Sep 09, 2003
<u>AB</u>	SUNRISE PHARM INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A209799</u>	<u>001</u>	Dec 28, 2017
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A209799</u>	<u>002</u>	Dec 28, 2017
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A209799</u>	<u>003</u>	Dec 28, 2017
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A209799</u>	<u>004</u>	Dec 28, 2017
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A209799</u>	<u>005</u>	Dec 28, 2017
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A209799</u>	<u>006</u>	Dec 28, 2017
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A209799</u>	<u>007</u>	Dec 28, 2017

AMPHETAMINE SULFATE

TABLET; ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012
!		10MG	A200166	002	Aug 09, 2012

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

!	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992
---	--------------	-----------	---------	-----	--------------

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995
---	---------------------	--------	---------	-----	--------------

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+	ASTELLAS	50MG/VIAL	N050740	001	Aug 11, 1997
---	----------	-----------	---------	-----	--------------

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 500MG BASE/VIAL</u>	<u>A090884</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090884</u>	<u>002</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090884</u>	<u>003</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090889</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 125MG BASE/VIAL</u>	<u>A065499</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	<u>A062772</u>	<u>006</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062772</u>	<u>007</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062772</u>	<u>003</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A202864</u>	<u>001</u>	Sep 04, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A202864</u>	<u>002</u>	Sep 04, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202864</u>	<u>003</u>	Sep 04, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202864</u>	<u>004</u>	Sep 04, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202865</u>	<u>001</u>	Sep 04, 2015
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A201404</u>	<u>001</u>	Dec 20, 2013
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>	MYLAN LABS LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A201025</u>	<u>001</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A201025</u>	<u>002</u>	Apr 09, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A201025 003</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201025 004</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202198 001</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 125MG BASE/VIAL</u>	<u>A090583 001</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A090583 002</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090583 003</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090583 004</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090583 005</u>	Nov 27, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090581 001</u>	Oct 20, 2015
<u>AP</u>	! SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395 001</u>	
<u>AP</u>	!	<u>EQ 250MG BASE/VIAL</u>	<u>A061395 002</u>	
<u>AP</u>	!	<u>EQ 500MG BASE/VIAL</u>	<u>A061395 003</u>	
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A061395 004</u>	
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A061395 005</u>	
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A061395 006</u>	

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738 001</u>	Feb 19, 1987
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062738 002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406 001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406 002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403 001</u>	Dec 23, 2009
<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406 001</u>	Dec 07, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406 002</u>	Dec 07, 2015
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339 001</u>	Sep 20, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176 001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176 002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188 001</u>	Nov 25, 2005
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375 001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653 001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375 002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653 002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646 001</u>	Dec 21, 2011
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222 001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222 002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314 001</u>	Nov 27, 2006
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316 001</u>	Jun 29, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316 002</u>	Jun 29, 2007
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024 001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024 002</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197 001</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579 001</u>	Jan 08, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579 002</u>	Jan 08, 2016
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578 001</u>	Jan 11, 2016
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240 001</u>	Jul 25, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074 001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074 002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076 001</u>	Mar 19, 2002

UNASYN

<u>AP</u>	! PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901 002</u>	Feb 27, 1992
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901 001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608 002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608 001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608 005</u>	Dec 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB	DAVA PHARMS INC	EQ 250MG BASE	A062883 001	Feb 25, 1988
AB	!	EQ 500MG BASE	A062882 001	Feb 25, 1988
AB	SANDOZ	EQ 250MG BASE	A064082 001	Aug 29, 1995
AB		EQ 500MG BASE	A064082 002	Aug 29, 1995
FOR SUSPENSION; ORAL				
AMPICILLIN TRIHYDRATE				
	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989
	!	EQ 250MG BASE/5ML	A062982 002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997
<u>ANAGRELIDE HYDROCHLORIDE</u>				
AB	BARR	EQ 0.5MG BASE	A076530 001	Apr 18, 2005
AB		EQ 1MG BASE	A076530 002	Apr 18, 2005
AB	IMPAX LABS	EQ 0.5MG BASE	A076910 001	Apr 18, 2005
AB		EQ 1MG BASE	A076910 002	Apr 18, 2005
AB	IVAX SUB TEVA PHARMS	EQ 0.5MG BASE	A076468 001	Apr 18, 2005
AB	!	EQ 1MG BASE	A076468 002	Apr 18, 2005
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151 001	Jun 30, 2017
AB		EQ 1MG BASE	A209151 002	Jun 30, 2017

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010
AB	APOTEX INC	1MG	A200654 001	May 11, 2012
AB	CIPLA LTD	1MG	A091164 001	Jun 28, 2010
AB	DR REDDYS LABS LTD	1MG	A090732 001	Jun 28, 2010
AB	FRESENIUS KABI ONCOL	1MG	A090088 001	Jun 28, 2010
AB	MYLAN	1MG	A091051 001	Jun 28, 2010
AB	NATCO PHARMA LTD	1MG	A079220 001	Jun 28, 2010
AB	SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010
AB	TEVA PHARMS	1MG	A078058 001	Jun 28, 2010
AB	WEST-WARD PHARMS INT	1MG	A078485 001	Jun 28, 2010
AB	ZYDUS PHARMS USA INC	1MG	A078921 001	Jun 28, 2010
<u>ARIMIDEX</u>				
AB	+! ASTRAZENECA PHARMS	1MG	N020541 001	Dec 27, 1995

ANGIOTENSIN II

SOLUTION; IV (INFUSION)

GIAPREZA

	+! LA JOLLA PHARM CO	2.5MG/ML (2.5MG/ML)	N209360 001	Dec 21, 2017
	+!	5MG/2ML (2.5MG/ML)	N209360 002	Dec 21, 2017

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

	+! VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
	+!	100MG/VIAL	N021632 002	Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

	+ BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
	+!	5MG	N202155 002	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	+! US WORLDMEDS	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004
--	-----------------	--------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE	A077764 001	Mar 12, 2009
IOPIDINE				
AT	+! NOVARTIS PHARMS CORP	EQ 0.5% BASE	N020258 001	Jul 30, 1993
	+!	EQ 1% BASE	N019779 001	Dec 31, 1987

APREMILAST

TABLET;ORAL

OTEZLA

+	CELGENE CORP	10MG	N205437 001	Mar 21, 2014
+		20MG	N205437 002	Mar 21, 2014
+!		30MG	N205437 003	Mar 21, 2014

APREPITANT

CAPSULE;ORAL

APREPITANT

AB	GLENMARK PHARMS LTD	40MG	A207777 001	Oct 12, 2017
AB		80MG	A207777 002	Oct 12, 2017
AB		125MG	A207777 003	Oct 12, 2017
AB	SANDOZ	40MG	A090999 001	Sep 24, 2012
AB		80MG	A090999 002	Sep 24, 2012
AB		125MG	A090999 003	Sep 24, 2012
EMEND				
AB	+ MERCK	40MG	N021549 003	Jun 30, 2006
AB	+	80MG	N021549 001	Mar 26, 2003
AB	+!	125MG	N021549 002	Mar 26, 2003

EMULSION;IV (INFUSION)

CINVANTI

+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296 001	Nov 09, 2017
----	-------------------	-----------------------	-------------	--------------

FOR SUSPENSION;ORAL

EMEND

+!	MSD MERCK CO	125MG/KIT	N207865 001	Dec 17, 2015
----	--------------	-----------	-------------	--------------

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

BROVANA

+!	SUNOVION	EQ 0.015MG BASE/2ML	N021912 001	Oct 06, 2006
----	----------	---------------------	-------------	--------------

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811 001	Mar 23, 2015
AP	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012
AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120 001	Sep 21, 2016
AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626 001	Jun 30, 2014
AP	+! NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665 001	Jun 30, 2014
	+! HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049 002	Sep 30, 2016

INJECTABLE;IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570 001	May 22, 2017
AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011
ARGATROBAN IN 0.9% SODIUM CHLORIDE				
	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769 001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE				
	+! EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434 001	Jun 29, 2011

ARGININE HYDROCHLORIDE

INJECTABLE;INJECTION

R-GENE 10

+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931 001	
----	----------------------	------------	-------------	--

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013
+		300MG	N202971 003	Sep 29, 2014
+!		400MG/VIAL	N202971 002	Feb 28, 2013
+		400MG	N202971 004	Sep 29, 2014

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

<u>AA</u>	!	AMNEAL PHARMS	<u>1MG/ML</u>	<u>A203906</u>	<u>001</u>	Aug 14, 2015
<u>AA</u>		APOTEX INC	<u>1MG/ML</u>	<u>A204094</u>	<u>001</u>	Sep 30, 2015
<u>AA</u>		SILARX PHARMS INC	<u>1MG/ML</u>	<u>A204171</u>	<u>001</u>	Aug 14, 2015

TABLET;ORAL

ABILIFY

<u>AB</u>	+	OTSUKA	<u>2MG</u>	<u>N021436</u>	<u>006</u>	Nov 15, 2002
<u>AB</u>	+		<u>5MG</u>	<u>N021436</u>	<u>005</u>	Nov 15, 2002
<u>AB</u>	+		<u>10MG</u>	<u>N021436</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>	+		<u>15MG</u>	<u>N021436</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>	+		<u>20MG</u>	<u>N021436</u>	<u>003</u>	Nov 15, 2002
<u>AB</u>	+		<u>30MG</u>	<u>N021436</u>	<u>004</u>	Nov 15, 2002

ARIPIPIRAZOLE

<u>AB</u>		ACCORD HLTHCARE	<u>2MG</u>	<u>A206251</u>	<u>001</u>	Dec 07, 2016
<u>AB</u>			<u>5MG</u>	<u>A206251</u>	<u>002</u>	Dec 07, 2016
<u>AB</u>			<u>10MG</u>	<u>A206251</u>	<u>003</u>	Dec 07, 2016
<u>AB</u>			<u>15MG</u>	<u>A206251</u>	<u>004</u>	Dec 07, 2016
<u>AB</u>			<u>20MG</u>	<u>A206251</u>	<u>005</u>	Dec 07, 2016
<u>AB</u>			<u>30MG</u>	<u>A206251</u>	<u>006</u>	Dec 07, 2016
<u>AB</u>		AJANTA PHARMA LTD	<u>2MG</u>	<u>A206174</u>	<u>001</u>	Sep 12, 2016
<u>AB</u>			<u>5MG</u>	<u>A206174</u>	<u>002</u>	Sep 12, 2016
<u>AB</u>			<u>10MG</u>	<u>A206174</u>	<u>003</u>	Sep 12, 2016
<u>AB</u>			<u>15MG</u>	<u>A206174</u>	<u>004</u>	Sep 12, 2016
<u>AB</u>			<u>20MG</u>	<u>A206174</u>	<u>005</u>	Sep 12, 2016
<u>AB</u>			<u>30MG</u>	<u>A206174</u>	<u>006</u>	Sep 12, 2016
<u>AB</u>		ALEMBIC PHARMS LTD	<u>2MG</u>	<u>A202101</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>			<u>5MG</u>	<u>A202101</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>			<u>10MG</u>	<u>A202101</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>			<u>15MG</u>	<u>A202101</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>			<u>20MG</u>	<u>A202101</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>			<u>30MG</u>	<u>A202101</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>		AMNEAL PHARMS	<u>2MG</u>	<u>A204838</u>	<u>001</u>	Jun 17, 2016
<u>AB</u>			<u>5MG</u>	<u>A204838</u>	<u>002</u>	Jun 17, 2016
<u>AB</u>			<u>10MG</u>	<u>A204838</u>	<u>003</u>	Jun 17, 2016
<u>AB</u>			<u>15MG</u>	<u>A204838</u>	<u>004</u>	Jun 17, 2016
<u>AB</u>			<u>20MG</u>	<u>A204838</u>	<u>005</u>	Jun 17, 2016
<u>AB</u>			<u>30MG</u>	<u>A204838</u>	<u>006</u>	Jun 17, 2016
<u>AB</u>		APOTEX INC	<u>2MG</u>	<u>A078583</u>	<u>001</u>	Jul 24, 2015
<u>AB</u>			<u>5MG</u>	<u>A078583</u>	<u>002</u>	Jul 24, 2015
<u>AB</u>			<u>10MG</u>	<u>A078583</u>	<u>003</u>	Jul 24, 2015
<u>AB</u>			<u>15MG</u>	<u>A078583</u>	<u>004</u>	Jul 24, 2015
<u>AB</u>			<u>20MG</u>	<u>A078583</u>	<u>005</u>	Jul 24, 2015
<u>AB</u>			<u>30MG</u>	<u>A078583</u>	<u>006</u>	Jul 24, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>2MG</u>	<u>A203908</u>	<u>001</u>	Oct 08, 2015
<u>AB</u>			<u>5MG</u>	<u>A203908</u>	<u>002</u>	Oct 08, 2015
<u>AB</u>			<u>10MG</u>	<u>A203908</u>	<u>003</u>	Oct 08, 2015
<u>AB</u>			<u>15MG</u>	<u>A203908</u>	<u>004</u>	Oct 08, 2015
<u>AB</u>			<u>20MG</u>	<u>A203908</u>	<u>005</u>	Oct 08, 2015
<u>AB</u>			<u>30MG</u>	<u>A203908</u>	<u>006</u>	Oct 08, 2015
<u>AB</u>		HETERO LABS LTD V	<u>2MG</u>	<u>A205064</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>			<u>5MG</u>	<u>A205064</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>			<u>10MG</u>	<u>A205064</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>			<u>15MG</u>	<u>A205064</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>			<u>20MG</u>	<u>A205064</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>			<u>30MG</u>	<u>A205064</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>2MG</u>	<u>A204111</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>			<u>5MG</u>	<u>A204111</u>	<u>002</u>	Oct 07, 2016
<u>AB</u>			<u>10MG</u>	<u>A204111</u>	<u>003</u>	Oct 07, 2016
<u>AB</u>			<u>15MG</u>	<u>A204111</u>	<u>004</u>	Oct 07, 2016
<u>AB</u>			<u>20MG</u>	<u>A204111</u>	<u>005</u>	Oct 07, 2016
<u>AB</u>			<u>30MG</u>	<u>A204111</u>	<u>006</u>	Oct 07, 2016
<u>AB</u>		ORCHID HLTHCARE	<u>2MG</u>	<u>A202683</u>	<u>001</u>	May 23, 2017
<u>AB</u>			<u>5MG</u>	<u>A202683</u>	<u>002</u>	May 23, 2017
<u>AB</u>			<u>10MG</u>	<u>A202683</u>	<u>003</u>	May 23, 2017
<u>AB</u>			<u>15MG</u>	<u>A202683</u>	<u>004</u>	May 23, 2017
<u>AB</u>			<u>20MG</u>	<u>A202683</u>	<u>005</u>	May 23, 2017
<u>AB</u>			<u>30MG</u>	<u>A202683</u>	<u>006</u>	May 23, 2017
<u>AB</u>		PRINSTON INC	<u>2MG</u>	<u>A205363</u>	<u>001</u>	Dec 04, 2017
<u>AB</u>			<u>5MG</u>	<u>A205363</u>	<u>002</u>	Dec 04, 2017
<u>AB</u>			<u>10MG</u>	<u>A205363</u>	<u>003</u>	Dec 04, 2017

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

<u>AB</u>		<u>15MG</u>	<u>A205363 004</u>	Dec 04, 2017
<u>AB</u>		<u>20MG</u>	<u>A205363 005</u>	Dec 04, 2017
<u>AB</u>		<u>30MG</u>	<u>A205363 006</u>	Dec 04, 2017
<u>AB</u>	SANTOS BIOTECH	<u>2MG</u>	<u>A091279 001</u>	Jan 09, 2017
<u>AB</u>		<u>5MG</u>	<u>A091279 002</u>	Jan 09, 2017
<u>AB</u>		<u>10MG</u>	<u>A091279 003</u>	Jan 09, 2017
<u>AB</u>		<u>15MG</u>	<u>A091279 004</u>	Jan 09, 2017
<u>AB</u>		<u>20MG</u>	<u>A091279 005</u>	Jan 09, 2017
<u>AB</u>		<u>30MG</u>	<u>A091279 006</u>	Jan 09, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>2MG</u>	<u>A206383 001</u>	Sep 29, 2016
<u>AB</u>		<u>5MG</u>	<u>A206383 002</u>	Sep 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A206383 003</u>	Sep 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A206383 004</u>	Sep 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A206383 005</u>	Sep 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A206383 006</u>	Sep 29, 2016
<u>AB</u>	TEVA PHARMS USA	<u>2MG</u>	<u>A078607 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A078607 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A078608 001</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A078708 001</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A078708 002</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A078708 003</u>	Apr 28, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>2MG</u>	<u>A201519 001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519 003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519 002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519 006</u>	Apr 28, 2015

ABILIFY MYCITE KIT

+	OTSUKA PHARM CO LTD	2MG	N207202 001	Nov 13, 2017
+	!	5MG	N207202 002	Nov 13, 2017
+		10MG	N207202 003	Nov 13, 2017
+		15MG	N207202 004	Nov 13, 2017
+		20MG	N207202 005	Nov 13, 2017
+		30MG	N207202 006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

ARIPIPIRAZOLE

<u>AB</u>	!	ALEMBOIC PHARMS LTD	<u>10MG</u>	<u>A202102 001</u>	Apr 28, 2015
<u>AB</u>			<u>15MG</u>	<u>A202102 002</u>	Apr 28, 2015
<u>AB</u>		ORCHID HLTHCARE	<u>10MG</u>	<u>A202547 001</u>	Dec 11, 2017
<u>AB</u>			<u>15MG</u>	<u>A202547 002</u>	Dec 11, 2017

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533 001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533 002	Oct 05, 2015
+	!	882MG/3.2ML (275.63MG/ML)	N207533 003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533 004	Jun 05, 2017

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>		LUPIN LTD	<u>50MG</u>	<u>A200751 001</u>	Nov 28, 2016
<u>AB</u>			<u>150MG</u>	<u>A200751 003</u>	Nov 28, 2016
<u>AB</u>			<u>200MG</u>	<u>A200751 004</u>	Nov 28, 2016
<u>AB</u>			<u>250MG</u>	<u>A200751 005</u>	Nov 28, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A200043 001</u>	Jun 01, 2012
<u>AB</u>			<u>150MG</u>	<u>A200043 002</u>	Jun 01, 2012
<u>AB</u>			<u>250MG</u>	<u>A200043 003</u>	Jun 01, 2012
<u>AB</u>		NATCO PHARMA LTD	<u>50MG</u>	<u>A202768 001</u>	Nov 28, 2016
<u>AB</u>			<u>150MG</u>	<u>A202768 002</u>	Nov 28, 2016
<u>AB</u>			<u>200MG</u>	<u>A202768 005</u>	Sep 28, 2017
<u>AB</u>			<u>250MG</u>	<u>A202768 003</u>	Nov 28, 2016

NUVIGIL

<u>AB</u>	+	CEPHALON	<u>50MG</u>	<u>N021875 001</u>	Jun 15, 2007
<u>AB</u>	+		<u>150MG</u>	<u>N021875 003</u>	Jun 15, 2007
<u>AB</u>	+		<u>200MG</u>	<u>N021875 005</u>	Mar 26, 2009
<u>AB</u>	+	!	<u>250MG</u>	<u>N021875 004</u>	Jun 15, 2007

ARMODAFINIL

		NATCO PHARMA LTD	100MG	A202768 004	Sep 28, 2017
--	--	------------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+! CEPHALON

1MG/ML

N021248 001 Sep 25, 2000

+!

2MG/ML

N021248 002 Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+! NOVARTIS

20MG; 120MG

N022268 001 Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE**AP** HOSPIRA4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG
BASE/ML)**A079138 001** Jun 18, 2010SEPTOCAINE**AP** +! DEPROCO4%;EQ 0.0085MG BASE/1.7ML (4%;EQ
0.005MG BASE/ML)**N022010 001** Mar 30, 2006**AP** +!4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG
BASE/ML)**N020971 001** Apr 03, 2000ULTACAN**AP** HANSAMED INC4%;EQ 0.0085MG BASE/1.7ML (4%;EQ
0.005MG BASE/ML)**A201751 001** Jul 11, 2017ULTACAN FORTE**AP** HANSAMED INC4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG
BASE/ML)**A201750 001** Jul 11, 2017

ORABLOC

+ PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG
BASE/ML)

N022466 001 Feb 26, 2010

+!

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG
BASE/ML)

N022466 002 Feb 26, 2010

ASCORBIC ACID

SOLUTION; IV (INFUSION)

ASCOR

+! MCGUFF

25,000MG/50ML (500MG/ML)

N209112 001 Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+! SANDOZ INC

80MG/VIAL; 0.02MG/VIAL; 400
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VI
AL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/
VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+! SANDOZ INC

80MG/VIAL; 0.02MG/VIAL; 400
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VI
AL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/
VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021646 001 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;
VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+! HOSPIRA

80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/
VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL;
0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG
BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A;
VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+! HOSPIRA

200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIA
L; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL
; 10MG/VIAL; 0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+! HOSPIRA

200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5
ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5
ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0
.15MG/5ML

N021643 001 Feb 18, 2004

PRESCRIPTION DRUG PRODUCT LIST

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+! SALIX PHARMS 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+ FOREST LABS LLC EQ 2.5 BASE N022117 003 Mar 12, 2015

+ EQ 5MG BASE N022117 001 Aug 13, 2009

+! EQ 10MG BASE N022117 002 Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+! NEW HAVEN PHARMS 162.5MG N200671 001 Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL**AA** +! ALLERGAN SALES LLC **325MG;50MG;40MG** **N017534 005** Apr 16, 1986LANORINAL**AA** LANNETT **325MG;50MG;40MG** **A086996 002** Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE**AA** ! HIKMA INTL PHARMS **325MG;50MG;40MG** **A086162 002** Feb 16, 1984**AA** PII **325MG;50MG;40MG** **A204195 001** Sep 22, 2016ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE**AB** MAYNE PHARMA INC **325MG;50MG;40MG;30MG** **A203335 001** Oct 30, 2015BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE**AB** NEXGEN PHARMA INC **325MG;50MG;40MG;30MG** **A075231 001** Nov 30, 2001**AB** STEVENS J **325MG;50MG;40MG;30MG** **A074951 001** Aug 31, 1998FIORINAL W/CODEINE**AB** +! ALLERGAN SALES LLC **325MG;50MG;40MG;30MG** **N019429 003** Oct 26, 1990ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+! SUN PHARM 356.4MG;30MG;16MG N011483 004 Sep 06, 1983

INDUSTRIES

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ 385MG;30MG;25MG A074654 001 Dec 31, 1996

! 770MG;60MG;50MG A074654 002 Dec 31, 1996

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN**AB** ! HERITAGE PHARMS INC **325MG;200MG** **A089594 001** Mar 31, 1989**AB** NOVAST LABS LTD **325MG;200MG** **A040832 001** Jan 07, 2010**AB** OXFORD PHARMS **325MG;200MG** **A040252 001** Dec 10, 1997**AB** SANDOZ **325MG;200MG** **A040116 001** Apr 25, 1996ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE**AB** INGENUS PHARMS NJ **325MG;200MG;16MG** **A040860 001** Jan 07, 2010**AB** ! SANDOZ **325MG;200MG;16MG** **A040118 001** Apr 16, 1996ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX**AB** +! BOEHRINGER **25MG;200MG** **N020884 001** Nov 22, 1999

INGELHEIM

ASPIRIN AND DIPYRIDAMOLE**AB** AMNEAL PHARMS **25MG;200MG** **A206392 001** Mar 08, 2016**AB** BARR **25MG;200MG** **A078804 001** Aug 14, 2009**AB** IMPAX LABS INC **25MG;200MG** **A206964 001** Jan 18, 2017**AB** PAR PHARM INC **25MG;200MG** **A207944 001** Jan 18, 2017**AB** SANDOZ INC **25MG;200MG** **A206739 001** Jan 18, 2017**AB** ZYDUS PHARMS USA **25MG;200MG** **A206753 001** Aug 29, 2017

INC

PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

! STEVENS J

325MG;400MG

A081145 001 Jan 31, 1995

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

+ ARALEZ PHARMS

81MG;40MG

N205103 001 Sep 14, 2016

+!

325MG;40MG

N205103 002 Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN**AA** ACTAVIS LABS FL INC325MG;4.8355MGA090084 001 Mar 22, 2011**AA** MAYNE PHARMA INC325MG;4.8355MGA091670 001 Mar 16, 2011PERCODAN**AA** +! ENDO PHARMS325MG;4.8355MGN007337 007 Aug 05, 2005ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE**AB** TEVA PHARMS USAEQ 150MG BASEA091673 002 Apr 22, 2014**AB**EQ 200MG BASEA091673 003 Apr 22, 2014**AB**EQ 300MG BASEA091673 004 Apr 22, 2014REYATAZ**AB** + BRISTOL MYERSEQ 150MG BASEN021567 002 Jun 20, 2003

SQUIBB

AB +EQ 200MG BASEN021567 003 Jun 20, 2003**AB** +!EQ 300MG BASEN021567 004 Oct 16, 2006

ATAZANAVIR SULFATE

TEVA PHARMS USA

EQ 100MG BASE

A091673 001 Apr 22, 2014

POWDER;ORAL

REYATAZ

+! BRISTOL MYERS

EQ 50MG BASE/PACKET

N206352 001 Jun 02, 2014

SQUIBB

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+! BRISTOL-MYERS

EQ 300MG BASE;150MG

N206353 001 Jan 29, 2015

SQUIBB

ATENOLOL

TABLET;ORAL

ATENOLOL**AB** ALVOGEN MALTA25MGA073646 001 Jul 31, 1992**AB**50MGA072303 001 Jul 15, 1988**AB**100MGA072304 001 Jul 15, 1988**AB** AUROBINDO PHARMA25MGA078512 001 Oct 31, 2007**AB**50MGA078512 002 Oct 31, 2007**AB**100MGA078512 003 Oct 31, 2007**AB** DAVA PHARMS INC50MGA073542 001 Dec 19, 1991**AB**100MGA073543 001 Dec 19, 1991**AB** IPCA LABS LTD25MGA077877 001 Dec 27, 2006**AB**50MGA077877 002 Dec 27, 2006**AB**100MGA077877 003 Dec 27, 2006**AB** MYLAN25MGA073457 002 Apr 26, 1999**AB**50MGA073457 003 Jan 24, 1992**AB**100MGA073457 001 Jan 24, 1992**AB** SANDOZ25MGA074052 001 May 01, 1992**AB**50MGA073025 001 Sep 17, 1991**AB**100MGA073026 001 Sep 17, 1991**AB** SUN PHARM INDS INC25MGA078210 001 Jul 10, 2007**AB**50MGA078210 002 Jul 10, 2007**AB**100MGA078210 003 Jul 10, 2007**AB** SUN PHARM25MGA074499 001 Jul 30, 1997

INDUSTRIES

AB50MGA073475 001 Mar 30, 1993**AB**100MGA073476 001 Mar 30, 1993**AB** TEVA25MGA074056 003 Jul 19, 2004**AB**50MGA074056 001 Jan 18, 1995**AB**100MGA074056 002 Jan 18, 1995**AB** UNIQUE PHARM LABS25MGA077443 001 Sep 13, 2006**AB**50MGA077443 002 Sep 13, 2006**AB**100MGA077443 003 Sep 13, 2006

PRESCRIPTION DRUG PRODUCT LIST

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900 001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900 002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900 003</u>	Jan 28, 2005

TENORMIN

<u>AB</u>	+ ALVOGEN MALTA	<u>25MG</u>	<u>N018240 004</u>	Apr 09, 1990
<u>AB</u>	+	<u>50MG</u>	<u>N018240 001</u>	
<u>AB</u>	+!	<u>100MG</u>	<u>N018240 002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	ALVOGEN MALTA	<u>50MG; 25MG</u>	<u>A072301 001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302 001</u>	May 31, 1990
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203 001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203 002</u>	Oct 31, 1993
<u>AB</u>	SUN PHARM INDUSTRIES	<u>50MG; 25MG</u>	<u>A073582 002</u>	Apr 29, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582 001</u>	Apr 29, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665 001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665 002</u>	Jul 02, 1992

TENORETIC 100

<u>AB</u>	+! ALVOGEN MALTA	<u>100MG; 25MG</u>	<u>N018760 001</u>	Jun 08, 1984
-----------	------------------	--------------------	--------------------	--------------

TENORETIC 50

<u>AB</u>	+ ALVOGEN MALTA	<u>50MG; 25MG</u>	<u>N018760 002</u>	Jun 08, 1984
-----------	-----------------	-------------------	--------------------	--------------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A078983 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A078983 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A078983 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A078983 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A078983 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A078983 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A078983 007</u>	May 30, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079016 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079016 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079016 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079016 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079016 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079016 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079016 007</u>	May 30, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A079019 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079019 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079019 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079019 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079019 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079019 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079019 007</u>	May 30, 2017
<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A079022 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079022 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079022 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079022 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079022 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079022 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079022 007</u>	May 30, 2017

STRATTERA

<u>AB</u>	+ LILLY	<u>10MG</u>	<u>N021411 002</u>	Nov 26, 2002
<u>AB</u>	+	<u>18MG</u>	<u>N021411 003</u>	Nov 26, 2002
<u>AB</u>	+	<u>25MG</u>	<u>N021411 004</u>	Nov 26, 2002
<u>AB</u>	+	<u>40MG</u>	<u>N021411 005</u>	Nov 26, 2002
<u>AB</u>	+!	<u>60MG</u>	<u>N021411 006</u>	Nov 26, 2002
<u>AB</u>	+	<u>80MG</u>	<u>N021411 007</u>	Feb 14, 2005
<u>AB</u>	+	<u>100MG</u>	<u>N021411 008</u>	Feb 14, 2005

PRESCRIPTION DRUG PRODUCT LIST

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548 004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650 001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650 002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650 003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357 001</u>	Jul 17, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A204846 001</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204846 002</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204846 003</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204846 004</u>	Jan 09, 2017
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 10MG BASE</u>	<u>A091624 001</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624 002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624 003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624 004</u>	Apr 05, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226 004</u>	May 29, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575 004</u>	May 29, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A205519 001</u>	May 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205519 002</u>	May 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205519 003</u>	May 19, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205519 004</u>	May 19, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477 004</u>	Nov 30, 2011
<u>AB</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A205300 001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205300 002</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205300 003</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205300 004</u>	Mar 27, 2017

LIPITOR

<u>AB</u>	+ PFIZER	<u>EQ 10MG BASE</u>	<u>N020702 001</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020702 002</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020702 003</u>	Dec 17, 1996
<u>AB</u>	+!	<u>EQ 80MG BASE</u>	<u>N020702 004</u>	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	<u>EQ 10MG BASE;10MG</u>	<u>A206084 001</u>	Apr 26, 2017
		<u>EQ 20MG BASE;10MG</u>	<u>A206084 002</u>	Apr 26, 2017
		<u>EQ 40MG BASE;10MG</u>	<u>A206084 003</u>	Apr 26, 2017
	!	<u>EQ 80MG BASE;10MG</u>	<u>A206084 004</u>	Apr 26, 2017

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>	AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960 001</u>	Mar 18, 2014
<u>AB</u>	APOTEX INC	<u>750MG/5ML</u>	<u>A209750 001</u>	Oct 11, 2017
<u>AB</u>	PADDOCK LLC	<u>750MG/5ML</u>	<u>A207833 001</u>	Apr 28, 2017

MEPRON

<u>AB</u>	+! GLAXOSMITHKLINE LLC	<u>750MG/5ML</u>	<u>N020500 001</u>	Feb 08, 1995
-----------	------------------------	------------------	--------------------	--------------

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>62.5MG;25MG</u>	<u>A091211 002</u>	Apr 06, 2015
<u>AB</u>		<u>250MG;100MG</u>	<u>A091211 001</u>	Jan 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>62.5MG;25MG</u>	<u>A202362 001</u>	May 27, 2014
<u>AB</u>		<u>250MG;100MG</u>	<u>A202362 002</u>	May 27, 2014

MALARONE

<u>AB</u>	+! GLAXOSMITHKLINE	<u>250MG;100MG</u>	<u>N021078 001</u>	Jul 14, 2000
-----------	--------------------	--------------------	--------------------	--------------

MALARONE PEDIATRIC

<u>AB</u>	+ GLAXOSMITHKLINE	<u>62.5MG;25MG</u>	<u>N021078 002</u>	Jul 14, 2000
-----------	-------------------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A206011 001</u>	Apr 08, 2015
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A090761 001</u>	Oct 18, 2012
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A206096 001</u>	Jun 22, 2017
<u>AP</u>	NANJING KING-FRIEND	<u>10MG/ML</u>	<u>A091489 001</u>	Feb 17, 2012
<u>AP</u>	! WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A074901 001</u>	Jul 18, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A206010 001</u>	Apr 08, 2015
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A090782 001</u>	Oct 18, 2012
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A206001 001</u>	Apr 07, 2017
<u>AP</u>	NANJING KING-FRIEND	<u>10MG/ML</u>	<u>A091488 001</u>	Feb 17, 2012
<u>AP</u>	! WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A074900 001</u>	Jul 18, 1997

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
+!		EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
+!		EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
+!		EQ 2MG SULFATE/0.7ML	N017106 001	

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146 004	Aug 17, 2017
+!		1MG/10ML (0.1MG/ML)	N021146 005	Aug 17, 2017

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146 002	Jul 09, 2001
+!		0.5MG/5ML (0.1MG/ML)	N021146 001	Jul 09, 2001
+!		1MG/10ML (0.1MG/ML)	N021146 003	Jul 09, 2001

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+!	AKORN	1%	N206289 001	Jul 18, 2014
	ISOPTO ATROPINE			
	NOVARTIS PHARMS CORP	1%	N208151 001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+!	SEBELA IRELAND LTD	0.025MG; 1MG	N017744 002	
----	--------------------	--------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	WEST-WARD PHARMS INT	0.025MG/5ML; 2.5MG/5ML	A087708 001	May 03, 1982
---	----------------------	------------------------	-------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<u>AA</u>	ANI PHARMS INC	<u>0.025MG; 2.5MG</u>	<u>A086727 001</u>	
<u>AA</u>	LANNETT	<u>0.025MG; 2.5MG</u>	<u>A085372 001</u>	
<u>AA</u>	MYLAN	<u>0.025MG; 2.5MG</u>	<u>A085762 001</u>	
<u>AA</u>	PAR PHARM	<u>0.025MG; 2.5MG</u>	<u>A040357 001</u>	May 02, 2000

LOMOTIL

<u>AA</u>	+! GD SEARLE LLC	<u>0.025MG; 2.5MG</u>	<u>N012462 001</u>	
-----------	------------------	-----------------------	--------------------	--

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+!	MERIDIAN MEDCL	2.1MG/0.7ML; 600MG/2ML	N021983 001	Sep 28, 2006
----	----------------	------------------------	-------------	--------------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+!	SEBELA IRELAND LTD	3MG	N018689 001	May 24, 1985
----	--------------------	-----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AVANAFIL

TABLET; ORAL

STENDRA

+	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012
+		100MG	N202276	002	Apr 27, 2012
+	!	200MG	N202276	003	Apr 27, 2012

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	CEREXA	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015
---	--------	-------------------------	---------	-----	--------------

AXITINIB

TABLET; ORAL

INLYTA

+	PF PRISM CV	1MG	N202324	001	Jan 27, 2012
+	!	5MG	N202324	002	Jan 27, 2012

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016

VIDAZA

AP	+	!	CELGENE	100MG/VIAL	N050794	001	May 19, 2004
-----------	---	---	---------	-------------------	----------------	------------	--------------

AZATHIOPRINE

TABLET; ORAL

AZASAN

AB	AAIPHARMA LLC	25MG	A075252	002	Feb 03, 2003
AB		50MG	A075252	001	Jun 07, 1999
AB		75MG	A075252	003	Feb 03, 2003
AB		100MG	A075252	004	Feb 03, 2003

AZATHIOPRINE

AB	AMNEAL PHARMS LLC	50MG	A074069	001	Feb 16, 1996
AB	MYLAN	50MG	A075568	001	Dec 13, 1999
AB	ZYDUS PHARMS USA	25MG	A077621	002	Sep 05, 2008
AB		50MG	A077621	001	Mar 15, 2007
AB		75MG	A077621	003	Sep 05, 2008
AB		100MG	A077621	004	Sep 05, 2008

IMURAN

AB	+	!	SEBELA IRELAND LTD	50MG	N016324	001
-----------	---	---	--------------------	-------------	----------------	------------

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

!	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995
---	-------------------------	--------------------	---------	-----	--------------

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015
---	----------------	-----	---------	-----	--------------

CREAM; TOPICAL

AZELEX

+	ALLERGAN	20%	N020428	001	Sep 13, 1995
---	----------	-----	---------	-----	--------------

GEL; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002
---	----------------	-----	---------	-----	--------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A203660	001	Nov 08, 2016
AT	APOTEX INC	0.05%	A078621	001	Aug 03, 2009
AT	!	SANDOZ INC	A202305	001	May 31, 2012
AT	SUN PHARMA GLOBAL	0.05%	A078738	001	Jun 21, 2010

SPRAY, METERED; NASAL

ASTELIN

AB	+	!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996
-----------	---	---	---------------------	------------------------------	----------------	------------	--------------

ASTEPRO

AB	+	!	MYLAN SPECIALITY LP	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009
-----------	---	---	---------------------	-------------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156 001	Aug 18, 2017
AB	AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660 001	Aug 28, 2017
AB		EQ 0.1876MG BASE/SPRAY	A208199 001	Dec 15, 2017
AB	APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954 001	Apr 30, 2009
AB		EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012
AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176 001	Jul 28, 2015
AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743 001	May 08, 2014
AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012
AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609 001	Mar 17, 2017
AB	WEST-WARD PHARMS INT	EQ 0.125MG BASE/SPRAY	A091444 001	Oct 24, 2014
AB		EQ 0.1876MG BASE/SPRAY	A207243 001	Sep 22, 2017
AB	ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409 001	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712 001	Apr 28, 2017
	DYMISTA			
AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011
+		EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331 001	Dec 20, 2011
+		EQ 40MG MEDOXOMIL;25MG	N202331 002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488 001	May 15, 2015
AB		EQ 200MG BASE/5ML	A065488 002	May 15, 2015
AB	PLIVA	EQ 100MG BASE/5ML	A065246 002	Jul 05, 2006
AB		EQ 200MG BASE/5ML	A065246 001	Jul 05, 2006
AB	TEVA PHARMS	EQ 100MG BASE/5ML	A065419 001	Jun 24, 2008
AB		EQ 200MG BASE/5ML	A065419 002	Jun 24, 2008

ZITHROMAX

AB	+	PFIZER	EQ 100MG BASE/5ML	N050710 001	Oct 19, 1995
AB	+		EQ 200MG BASE/5ML	N050710 002	Oct 19, 1995
	+		EQ 1GM BASE/PACKET	N050693 001	Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797 001	Jun 10, 2005
---	-------------	-----------------	-------------	--------------

INJECTABLE;INJECTION

AZITHROMYCIN

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294 001	Jun 19, 2015
AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A065179 001	Dec 13, 2005
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A065501 001	Nov 09, 2009
AP	HOSPIRA	EQ 500MG BASE/VIAL	A065500 001	Jun 26, 2009
AP		EQ 500MG BASE/VIAL	A065511 001	Jun 26, 2009
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732 001	Jan 26, 2017
AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A065506 001	Mar 24, 2009
AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923 001	Apr 02, 2013

ZITHROMAX

AP	+	PFIZER	EQ 500MG BASE/VIAL	N050733 001	Jan 30, 1997
-----------	---	--------	---------------------------	--------------------	--------------

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+	OAK PHARMS INC	1%	N050810 001	Apr 27, 2007
---	----------------	----	-------------	--------------

TABLET;ORAL

AZITHROMYCIN

AB	APOTEX CORP	EQ 250MG BASE	A065507 001	Jul 13, 2011
AB		EQ 500MG BASE	A065509 001	Jul 13, 2011
AB		EQ 600MG BASE	A065508 001	Jul 13, 2011
AB	LUPIN LTD	EQ 250MG BASE	A065398 001	May 15, 2015

PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065399 001</u>	May 15, 2015
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065400 001</u>	May 15, 2015
<u>AB</u>	MYLAN	<u>EQ 600MG BASE</u>	<u>A065360 001</u>	Jan 08, 2007
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065218 001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209 001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150 001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	+	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002
<u>AB</u>	+	!	<u>EQ 600MG BASE</u>	<u>N050730 001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+! GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
-----------	---	-------------------------	-----------------	--------------------	--------------

<u>AP</u>	+	!	<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986
-----------	---	---	-----------------	--------------------	--------------

AZTREONAM

<u>AP</u>		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010

AZACTAM IN PLASTIC CONTAINER

+! BRISTOL MYERS
SQUIBB

20MG/ML

N050632 002 May 24, 1989

+!

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

FRESENIUS KABI USA

500MG/VIAL

A065439 001 Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>		X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153 001</u>	May 09, 1997
-----------	--	--------------	--------------------------	--------------------	--------------

BACITRACIN

<u>AP</u>		AKORN	<u>50,000 UNITS/VIAL</u>	<u>A206719 001</u>	Oct 20, 2017
-----------	--	-------	--------------------------	--------------------	--------------

<u>AP</u>		FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116 001</u>	Dec 03, 2002
-----------	--	--------------------	--------------------------	--------------------	--------------

<u>AP</u>	!	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733 002</u>	
-----------	---	-------------------------	--------------------------	--------------------	--

<u>AP</u>		SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211 001</u>	May 11, 2010
-----------	--	----------------	--------------------------	--------------------	--------------

<u>AP</u>		XELLIA PHARMS APS	<u>50,000 UNITS/VIAL</u>	<u>A203177 001</u>	Aug 25, 2014
-----------	--	-------------------	--------------------------	--------------------	--------------

PHARMACIA AND
UPJOHN

10,000 UNITS/VIAL

A060733 001

OINTMENT; OPHTHALMIC

BACITRACIN

! PERRIGO CO
TENNESSEE

500 UNITS/GM

A061212 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<u>AT</u>		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213 001</u>	Jul 25, 2012
-----------	--	-------	---	--------------------	--------------

<u>AT</u>	!	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068 001</u>	Oct 30, 1995
-----------	---	-----------------	---	--------------------	--------------

OINTMENT; TOPICAL

CORTISPORIN

+! MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984

PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>	AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088 001</u>	Feb 06, 2004
<u>AT</u>	! BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064 001</u>	Oct 30, 1995
<u>AT</u>	PERRIGO CO TENNESSEE	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A060764 002</u>	

NEOSPORIN

<u>AT</u>	+ CASPER PHARMA LLC	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050417 001</u>	
-----------	---------------------	--	--------------------	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<u>AT</u>	AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028 001</u>	Jan 30, 1995
<u>AT</u>	! BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046 001</u>	Jan 26, 1995
<u>AT</u>	PERRIGO CO TENNESSEE	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022 001</u>	Feb 27, 2002

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

!	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002
---	-------------------------	--	---------	-----

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

<u>AP</u>	EMERALD INTL LTD	<u>0.05MG/ML</u>	<u>A091193 001</u>	May 03, 2016
<u>AP</u>		<u>0.5MG/ML</u>	<u>A091193 002</u>	May 03, 2016
<u>AP</u>		<u>2MG/ML</u>	<u>A091193 003</u>	May 03, 2016

GABLOFEN

<u>AP</u>	PIRAMAL CRITICAL	<u>0.05MG/ML</u>	<u>N022462 001</u>	Nov 19, 2010
<u>AP</u>		<u>0.5MG/ML</u>	<u>N022462 002</u>	Nov 19, 2010
<u>AP</u>		<u>2MG/ML</u>	<u>N022462 003</u>	Nov 19, 2010

LIORESAL

<u>AP</u>	+! SAOL THERAPS RES LTD	<u>0.05MG/ML</u>	<u>N020075 003</u>	Nov 07, 1996
<u>AP</u>	+!	<u>0.5MG/ML</u>	<u>N020075 001</u>	Jun 17, 1992
<u>AP</u>	+!	<u>2MG/ML</u>	<u>N020075 002</u>	Jun 17, 1992

GABLOFEN

+!	PIRAMAL CRITICAL	1MG/ML	N022462	004 Jun 22, 2012
----	------------------	--------	---------	------------------

TABLET;ORAL

BACLOFEN

<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A077971 001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971 002</u>	Oct 26, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234 001</u>	Jul 21, 1988
<u>AB</u>	!	<u>20MG</u>	<u>A072235 001</u>	Jul 21, 1988
<u>AB</u>	LANNETT	<u>10MG</u>	<u>A077241 002</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241 001</u>	Dec 20, 2005
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A077121 002</u>	Jul 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A090334 001</u>	Feb 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090334 002</u>	Feb 18, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078401 002</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401 001</u>	Sep 18, 2009
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A077088 002</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088 001</u>	Oct 31, 2007
<u>AB</u>	RUBICON RES PVT LTD	<u>10MG</u>	<u>A209102 002</u>	Nov 28, 2017
<u>AB</u>		<u>20MG</u>	<u>A209102 003</u>	Nov 28, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A077862 001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077862 002</u>	Aug 14, 2006
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A074584 001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584 002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077068 002</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068 001</u>	Aug 30, 2005
<u>AB</u>	RUBICON RES PVT LTD	5MG	A209102	001 Nov 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	APOTEX INC	750MG	A077883 001	Dec 28, 2007
AB	MYLAN	750MG	A077807 001	Dec 28, 2007
AB	WEST-WARD PHARMS INT	750MG	A077806 001	Dec 28, 2007

COLAZAL

AB	+ !	VALEANT PHARMS INTL	750MG	N020610 001	Jul 18, 2000
-----------	------------	---------------------	--------------	--------------------	--------------

TABLET; ORAL

BALSALAZIDE DISODIUM

AB	PAR PHARM INC	1.1GM	A206336 001	Sep 08, 2015
-----------	---------------	--------------	--------------------	--------------

GIAZO

AB	+ !	VALEANT PHARMS INTL	1.1GM	N022205 001	Feb 03, 2012
-----------	------------	---------------------	--------------	--------------------	--------------

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

+ !	BRACCO	98% (334GM/BOTTLE)	N208036 001	Jan 11, 2016
------------	--------	--------------------	-------------	--------------

E-Z-PAQUE

+ !	BRACCO	96% (169GM/BOTTLE)	N208036 002	Apr 07, 2017
------------	--------	--------------------	-------------	--------------

PASTE; ORAL

VARIBAR

+ !	BRACCO	40% (92GM/230ML)	N208844 001	Oct 14, 2016
------------	--------	------------------	-------------	--------------

SUSPENSION; ORAL

LIQUID E-Z-PAQUE

+ !	BRACCO	60% (213GM/355ML)	N208143 003	Mar 01, 2017
------------	--------	-------------------	-------------	--------------

READI-CAT 2

+ !	BRACCO	2% (9GM/450ML)	N208143 001	Jan 15, 2016
------------	--------	----------------	-------------	--------------

READI-CAT 2 SMOOTHIES

+ !	BRACCO	2% (9GM/450ML)	N208143 002	Jan 15, 2016
------------	--------	----------------	-------------	--------------

TAGITOL V

+ !	BRACCO	40% (8GM/20ML)	N208143 005	Aug 04, 2017
------------	--------	----------------	-------------	--------------

VARIBAR NECTAR

+ !	BRACCO	40% (96GM/240ML)	N208143 004	Jul 07, 2017
------------	--------	------------------	-------------	--------------

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

+ !	WYETH PHARMS PFIZER	EQ 20MG BASE;0.45MG	N022247 001	Oct 03, 2013
------------	---------------------	---------------------	-------------	--------------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ !	TEVA BRANDED PHARM	0.04MG/INH	N020911 002	Sep 15, 2000
------------	--------------------	------------	-------------	--------------

QVAR 80

+ !	TEVA BRANDED PHARM	0.08MG/INH	N020911 001	Sep 15, 2000
------------	--------------------	------------	-------------	--------------

QVAR REDHALER

+	NORTON WATERFORD	0.04MG/INH	N207921 001	Aug 03, 2017
----------	------------------	------------	-------------	--------------

+ !		0.08MG/INH	N207921 002	Aug 03, 2017
------------	--	------------	-------------	--------------

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813 002	Dec 17, 2014
----------	--------------------	------------------	-------------	--------------

+ !		0.08MG/ACTUATION	N202813 001	Mar 23, 2012
------------	--	------------------	-------------	--------------

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ !	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389 001	Jul 27, 1987
------------	-----------------	-------------------------	-------------	--------------

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

+ !	JANSSEN THERAP	EQ 100MG BASE	N204384 001	Dec 28, 2012
------------	----------------	---------------	-------------	--------------

BELINOSTAT

POWDER; IV (INFUSION)

BELEODAQ

+ !	SPECTRUM PHARMS	500MG/VIAL	N206256 001	Jul 03, 2014
------------	-----------------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A076820 001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820 002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820 003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820 004</u>	Feb 03, 2006
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128 001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128 002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128 003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128 004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212 001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212 002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212 003</u>	May 22, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333 004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430 004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402 004</u>	Feb 11, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076344 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344 004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211 004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848 001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848 002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848 003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848 004</u>	May 23, 2008

LOTENSIN

<u>AB</u>	+ US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851 001</u>	Jun 25, 1991
<u>AB</u>	+ I	<u>10MG</u>	<u>N019851 002</u>	Jun 25, 1991
<u>AB</u>	+ I	<u>20MG</u>	<u>N019851 003</u>	Jun 25, 1991
<u>AB</u>	+ I	<u>40MG</u>	<u>N019851 004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG; 6.25MG</u>	<u>A078794 001</u>	Aug 21, 2014
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A078794 002</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A078794 003</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 25MG</u>	<u>A078794 004</u>	Aug 21, 2014
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631 004</u>	Feb 11, 2004

LOTENSIN HCT

<u>AB</u>	+ US PHARMS HOLDINGS I	<u>10MG; 12.5MG</u>	<u>N020033 002</u>	May 19, 1992
<u>AB</u>	+ I	<u>20MG; 12.5MG</u>	<u>N020033 004</u>	May 19, 1992
<u>AB</u>	+ I	<u>20MG; 25MG</u>	<u>N020033 003</u>	May 19, 1992

PRESCRIPTION DRUG PRODUCT LIST

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>25MG/VIAL</u>	<u>A205574 001</u>	May 19, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205574 002</u>	May 19, 2016
<u>AP</u>	BRECKENRIDGE PHARM	<u>25MG/VIAL</u>	<u>A205447 001</u>	Dec 29, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205447 002</u>	Dec 29, 2016
<u>AP</u>	GLENMARK PHARMS LTD	<u>25MG/VIAL</u>	<u>A204771 001</u>	Mar 24, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204771 002</u>	Mar 24, 2016
<u>AP</u>	HOSPIRA INC	<u>25MG/VIAL</u>	<u>A204086 001</u>	May 20, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204086 002</u>	May 20, 2016
<u>AP</u>	INNOPHARMA LICENSING	<u>25MG/VIAL</u>	<u>A205476 001</u>	Mar 24, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205476 002</u>	Mar 24, 2016
<u>TREANDA</u>				
<u>AP</u>	+! CEPHALON	<u>25MG/VIAL</u>	<u>N022249 002</u>	May 01, 2009
<u>AP</u>	+!	<u>100MG/VIAL</u>	<u>N022249 001</u>	Mar 20, 2008

SOLUTION; IV (INFUSION)

BENDEKA

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194 001	Dec 07, 2015
TREANDA				
+!	CEPHALON	45MG/0.5ML (90MG/ML)	N022249 003	Sep 13, 2013
+!		180MG/2ML (90MG/ML)	N022249 004	Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	+ KING PHARMS LLC	<u>5MG;40MG</u>	<u>N018647 001</u>	May 25, 1983
<u>AB</u>	+!	<u>5MG;80MG</u>	<u>N018647 002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG;40MG</u>	<u>A077833 001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG;80MG</u>	<u>A077833 002</u>	Mar 30, 2007

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALTAFLUOR BENOX

+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582 001	Dec 14, 2017
----	--------------------	------------	-------------	--------------

BENZNIDAZOLE

TABLET; ORAL

BENZNIDAZOLE

+	CHEMO RESEARCH SL	12.5MG	N209570 001	Aug 29, 2017
+!		100MG	N209570 002	Aug 29, 2017

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	APOTEX INC	<u>100MG</u>	<u>A091310 001</u>	Jan 16, 2015
<u>AA</u>		<u>200MG</u>	<u>A091310 002</u>	Jan 16, 2015
<u>AA</u>	BIONPHARMA INC	<u>100MG</u>	<u>A081297 001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297 002</u>	Oct 30, 2007
<u>AA</u>	CSPC NBP PHARM CO	<u>200MG</u>	<u>A202765 001</u>	Jul 31, 2015
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851 001</u>	Nov 09, 2009
<u>AA</u>		<u>150MG</u>	<u>A040851 002</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851 003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682 001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682 002</u>	Jul 30, 2007
<u>AA</u>	STRIDES PHARMA	<u>100MG</u>	<u>A091133 001</u>	Jul 30, 2015
<u>AA</u>		<u>200MG</u>	<u>A091133 002</u>	Jul 30, 2015
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587 001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587 002</u>	Mar 19, 2008
<u>AA</u>	! THE PHARMA NETWORK	<u>100MG</u>	<u>A040627 001</u>	Mar 30, 2007
<u>AA</u>	!	<u>200MG</u>	<u>A040749 001</u>	Jul 25, 2007
<u>AA</u>	! THEPHARMANETWORK LLC	<u>150MG</u>	<u>A201209 001</u>	Sep 24, 2014
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597 001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597 002</u>	Jun 08, 2007
<u>TESSALON</u>				
<u>AA</u>	+ PFIZER	<u>100MG</u>	<u>N011210 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

AB	+ !	DOW PHARM	2.5%;EQ 1.2% BASE	N050819 001	Oct 23, 2008
-----------	------------	-----------	--------------------------	--------------------	--------------

BENZACLIN

AB	+ !	VALEANT BERMUDA	5%;EO 1% BASE	N050756 001	Dec 21, 2000
-----------	------------	-----------------	----------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	2.5%;EO 1.2% BASE	A205128 001	Jun 19, 2015
-----------	--	---------------------	--------------------------	--------------------	--------------

AB		MYLAN PHARMS INC	5%;EO 1% BASE	A065443 001	Aug 11, 2009
-----------	--	------------------	----------------------	--------------------	--------------

AB		PERRIGO ISRAEL	5%;EO 1% BASE	A202440 001	Sep 21, 2015
-----------	--	----------------	----------------------	--------------------	--------------

AB			5%;1.2%	A090979 001	Jun 26, 2012
-----------	--	--	----------------	--------------------	--------------

AB		TARO	5%;1.2%	A206218 001	Dec 15, 2017
-----------	--	------	----------------	--------------------	--------------

AB		TOLMAR	5%;EO 1% BASE	A204087 001	Jun 27, 2017
-----------	--	--------	----------------------	--------------------	--------------

AB			5%;1.2%	A203688 001	Aug 25, 2016
-----------	--	--	----------------	--------------------	--------------

DUAC

AB	+ !	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002
-----------	------------	---------	----------------	--------------------	--------------

ONEXTON

+ !	DOW PHARM	3.75%;EQ 1.2% BASE	N050819 002	Nov 24, 2014
------------	-----------	---------------------------	--------------------	--------------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+ !	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984
-----------	------------	--------------	--------------	--------------------	--------------

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	5%;3%	A065385 001	Sep 18, 2015
-----------	--	------	--------------	--------------------	--------------

AB		TOLMAR	5%;3%	A065112 001	Mar 29, 2004
-----------	--	--------	--------------	--------------------	--------------

AKTIPAK

+ !	CUTANEA	5%;3%	N050769 001	Nov 27, 2000
------------	---------	--------------	--------------------	--------------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		ANDA REPOSITORY	50MG	A040578 001	Apr 17, 2006
-----------	--	-----------------	-------------	--------------------	--------------

AA		EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012
-----------	--	-------------------	-------------	--------------------	--------------

AA		EPIC PHARMA LLC	50MG	A090346 001	Dec 15, 2015
-----------	--	-----------------	-------------	--------------------	--------------

AA	!	KVK TECH	50MG	A090968 001	Jul 20, 2010
-----------	----------	----------	-------------	--------------------	--------------

AA		MIKART	25MG	A090473 001	Sep 15, 2010
-----------	--	--------	-------------	--------------------	--------------

AA			50MG	A090473 002	Sep 15, 2010
-----------	--	--	-------------	--------------------	--------------

AA		SPECGX LLC	50MG	A040773 001	Apr 25, 2007
-----------	--	------------	-------------	--------------------	--------------

AA		TEDOR PHARM	25MG	A040747 002	Nov 20, 2015
-----------	--	-------------	-------------	--------------------	--------------

AA			50MG	A040747 001	Mar 30, 2007
-----------	--	--	-------------	--------------------	--------------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	1MG/ML	A090233 001	Jul 28, 2009
-----------	--	--------------------	---------------	--------------------	--------------

AP		HIKMA FARMACEUTICA	1MG/ML	A090287 001	Aug 31, 2009
-----------	--	--------------------	---------------	--------------------	--------------

AP		LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010
-----------	--	----------	---------------	--------------------	--------------

AP		NAVINTA LLC	1MG/ML	A091525 001	Feb 05, 2013
-----------	--	-------------	---------------	--------------------	--------------

COGENTIN

AP	+ !	OAK PHARMS AKORN	1MG/ML	N012015 001	
-----------	------------	------------------	---------------	--------------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

AA		ASPEN GLOBAL INC	0.5MG	A204713 001	Apr 14, 2015
-----------	--	------------------	--------------	--------------------	--------------

AA			1MG	A204713 002	Apr 14, 2015
-----------	--	--	------------	--------------------	--------------

AA			2MG	A204713 003	Apr 14, 2015
-----------	--	--	------------	--------------------	--------------

AA		EPIC PHARMA LLC	0.5MG	A072264 001	Feb 27, 1989
-----------	--	-----------------	--------------	--------------------	--------------

AA			1MG	A072265 001	Feb 27, 1989
-----------	--	--	------------	--------------------	--------------

AA			2MG	A072266 001	Feb 27, 1989
-----------	--	--	------------	--------------------	--------------

AA		INVAGEN PHARMS	0.5MG	A090294 001	Mar 29, 2010
-----------	--	----------------	--------------	--------------------	--------------

AA			1MG	A090294 002	Mar 29, 2010
-----------	--	--	------------	--------------------	--------------

AA			2MG	A090294 003	Mar 29, 2010
-----------	--	--	------------	--------------------	--------------

AA		LEADING PHARMA LLC	0.5MG	A090168 001	Nov 28, 2012
-----------	--	--------------------	--------------	--------------------	--------------

AA			1MG	A090168 002	Nov 28, 2012
-----------	--	--	------------	--------------------	--------------

AA			2MG	A090168 003	Nov 28, 2012
-----------	--	--	------------	--------------------	--------------

AA		PLIVA	0.5MG	A089058 001	Aug 10, 1988
-----------	--	-------	--------------	--------------------	--------------

AA			1MG	A089059 001	Aug 10, 1988
-----------	--	--	------------	--------------------	--------------

AA			2MG	A089060 001	Aug 10, 1988
-----------	--	--	------------	--------------------	--------------

AA	!	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996
-----------	----------	------------	--------------	--------------------	--------------

AA	!		1MG	A040103 002	Dec 12, 1996
-----------	----------	--	------------	--------------------	--------------

AA	!		2MG	A040103 003	Dec 12, 1996
-----------	----------	--	------------	--------------------	--------------

AA		VINTAGE	0.5MG	A040715 001	Aug 27, 2007
-----------	--	---------	--------------	--------------------	--------------

AA			1MG	A040715 002	Aug 27, 2007
-----------	--	--	------------	--------------------	--------------

AA			2MG	A040715 003	Aug 27, 2007
-----------	--	--	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

OXFORD PHARMS

0.5MG

A040706 002 Feb 14, 2008

1MG

A040706 003 Feb 14, 2008

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+! SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+! ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+! BAUSCH AND LOMB INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+! ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+! BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+! ORPHAN EUROPE

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATEAB LUITPOLD3MG/ML; EQ 3MG BASE/MLA090747 001 Jul 31, 2009CELESTONE SOLUSPANAB +! MERCK SHARP DOHME3MG/ML; EQ 3MG BASE/MLN014602 001BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATEAB ACTAVIS MIDEQ 0.05% BASEA070885 001 Feb 03, 1987

ATLANTIC

AB +! FOUGERA PHARMSEQ 0.05% BASEN019137 001 Jun 26, 1984AB TAROEQ 0.05% BASEA073552 001 Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB FOUGERA PHARMSEQ 0.05% BASEA076215 001 Dec 09, 2003AB GLENMARK GENERICSEQ 0.05% BASEA078930 001 Sep 23, 2008AB PERRIGO NEW YORKEQ 0.05% BASEA076592 001 Dec 09, 2003AB TAROEQ 0.05% BASEA076543 001 Dec 09, 2003AB TOLMAREQ 0.05% BASEA076603 001 Jan 23, 2004DIPROLENE AFAB +! MERCK SHARP DOHMEEQ 0.05% BASEN019555 001 Apr 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB ! FOUGERA PHARMSEQ 0.05% BASEA075276 001 May 13, 2003AB TAROEQ 0.05% BASEA076508 001 Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATEAB ACTAVIS MIDEQ 0.05% BASEA070281 001 Jul 31, 1985

ATLANTIC

AB ! FOUGERA PHARMS INCEQ 0.05% BASEA070275 001 Aug 12, 1985AB G AND W LABS INCEQ 0.05% BASEA071467 001 Aug 10, 1987AB PERRIGO NEW YORKEQ 0.05% BASEA072538 001 Jan 31, 1990

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATEAB FOUGERA PHARMSEQ 0.05% BASEA077111 001 May 21, 2007AB TAROEQ 0.05% BASEA077477 001 May 21, 2007DIPROLENEAB +! MERCK SHARP DOHMEEQ 0.05% BASEN019716 001 Aug 01, 1988

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A071012 001	Feb 03, 1987
AB	+ ! FOUGERA PHARMS INC	EQ 0.05% BASE	N019141 001	Sep 04, 1984
AB	TARO	EQ 0.05% BASE	A074271 001	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995
AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999
AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004
AB	TELIGENT PHARMA INC	EQ 0.05% BASE	A206118 001	Nov 09, 2017

DIPROLENE

AB	+ ! MERCK SHARP DOHME	EQ 0.05% BASE	N018741 001	Jul 27, 1983
SPRAY; TOPICAL				
SERNIVO				
	+ ! PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079 001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

	+ ! LEO PHARMA AS	0.064%; 0.005%	N207589 001	Oct 16, 2015
--	--------------------------	-----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	0.064%; 0.005%	A200174 001	Dec 12, 2014
AB	TOLMAR	0.064%; 0.005%	A201615 001	Jan 14, 2013

TACLONEX

AB	+ ! LEO PHARMA AS	0.064%; 0.005%	N021852 001	Jan 09, 2006
SUSPENSION; TOPICAL				
TACLONEX				
	+ ! LEO PHARMA AS	0.064%; 0.005%	N022185 001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE; 1%	A076002 001	Aug 02, 2002
AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A075502 001	Jun 05, 2001
AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894 001	Oct 30, 2015
AB	TARO	EQ 0.05% BASE; 1%	A075673 001	May 29, 2001

LOTRISONE

AB	+ ! MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N018827 001	Jul 10, 1984
LOTION; TOPICAL				

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A076516 001	Jun 16, 2005
AB	TARO	EQ 0.05% BASE; 1%	A076493 001	Jul 28, 2004

LOTRISONE

AB	+ ! MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010 001	Dec 08, 2000
-----------	------------------------------	--------------------------	--------------------	--------------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO UK FINCO	0.12%	A078337 001	Nov 26, 2012
AB	RICONPHARMA LLC	0.12%	A207144 001	May 24, 2017
AB	TARO PHARM	0.12%	A208204 001	May 24, 2017

LUXIQ

AB	+ ! MYLAN PHARMS INC	0.12%	N020934 001	Feb 28, 1999
-----------	-----------------------------	--------------	--------------------	--------------

CREAM; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	N018642 001	Mar 24, 1983
-----------	------------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

AB	+ ! FOUGERA PHARMS INC	EQ 0.1% BASE	N018861 001	Aug 31, 1983
-----------	-------------------------------	---------------------	--------------------	--------------

DERMABET

AB	TARO	EQ 0.1% BASE	A072041 001	Jan 06, 1988
-----------	------	---------------------	--------------------	--------------

VALNAC

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070050 001	Oct 10, 1984
-----------	-------------------------	---------------------	--------------------	--------------

LOTION; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072 001	Jun 27, 1985
-----------	------------------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	+!	FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018866 001</u>	Aug 31, 1983
<u>AB</u>		STI PHARMA LLC	<u>EQ 0.1% BASE</u>	<u>A070052 001</u>	Jul 31, 1985

OINTMENT; TOPICAL

BETA-VAL

<u>AB</u>		G AND W LABS INC	<u>EQ 0.1% BASE</u>	<u>A070069 001</u>	Dec 19, 1985
-----------	--	------------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<u>A070051 001</u>	Oct 10, 1984
<u>AB</u>	+!	FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018865 001</u>	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

<u>AT</u>		AKORN	<u>EQ 0.5% BASE</u>	<u>A075386 001</u>	Jun 30, 2000
<u>AT</u>		MEDIMETRIKS PHARMS	<u>EQ 0.5% BASE</u>	<u>A075630 001</u>	Apr 12, 2001
<u>AT</u>		WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694 001</u>	Nov 16, 2009

BETOPTIC

<u>AT</u>	+!	ALCON	<u>EQ 0.5% BASE</u>	<u>N019270 001</u>	Aug 30, 1985
-----------	----	-------	---------------------	--------------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

	+!	NOVARTIS PHARMS CORP	EQ 0.25% BASE	N019845 001	Dec 29, 1989
--	----	----------------------	---------------	-------------	--------------

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>		EPIC PHARMA	<u>10MG</u>	<u>A075541 001</u>	Oct 22, 1999
<u>AB</u>	!		<u>20MG</u>	<u>A075541 002</u>	Oct 22, 1999
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A078962 001</u>	Jun 27, 2008
<u>AB</u>			<u>20MG</u>	<u>A078962 002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>		AMNEAL PHARM	<u>5MG</u>	<u>A040855 001</u>	Nov 21, 2007
<u>AA</u>			<u>10MG</u>	<u>A040855 002</u>	Nov 21, 2007
<u>AA</u>			<u>25MG</u>	<u>A040855 003</u>	Nov 21, 2007
<u>AA</u>			<u>50MG</u>	<u>A040855 004</u>	Nov 21, 2007
<u>AA</u>		ECI PHARMS LLC	<u>5MG</u>	<u>A040725 001</u>	Oct 26, 2007
<u>AA</u>			<u>10MG</u>	<u>A040726 001</u>	Oct 26, 2007
<u>AA</u>			<u>25MG</u>	<u>A040727 001</u>	Oct 26, 2007
<u>AA</u>			<u>50MG</u>	<u>A040728 001</u>	Oct 26, 2007
<u>AA</u>		HERITAGE PHARMA	<u>5MG</u>	<u>A091256 001</u>	May 04, 2010
<u>AA</u>			<u>10MG</u>	<u>A091256 002</u>	May 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A091256 003</u>	May 04, 2010
<u>AA</u>			<u>50MG</u>	<u>A091256 004</u>	May 04, 2010
<u>AA</u>		LANNETT HOLDINGS INC	<u>5MG</u>	<u>A040677 002</u>	Mar 27, 2008
<u>AA</u>			<u>10MG</u>	<u>A040677 003</u>	Mar 27, 2008
<u>AA</u>			<u>25MG</u>	<u>A040677 004</u>	Mar 27, 2008
<u>AA</u>			<u>50MG</u>	<u>A040677 001</u>	Mar 27, 2008
<u>AA</u>		UPSHER-SMITH LABS	<u>5MG</u>	<u>A040633 001</u>	Jun 01, 2005
<u>AA</u>			<u>10MG</u>	<u>A040634 001</u>	Jun 01, 2005
<u>AA</u>			<u>25MG</u>	<u>A040635 001</u>	Jun 01, 2005
<u>AA</u>			<u>50MG</u>	<u>A040636 001</u>	Jun 01, 2005
<u>AA</u>		WOCKHARDT	<u>5MG</u>	<u>A040532 001</u>	Sep 29, 2003
<u>AA</u>			<u>10MG</u>	<u>A040533 001</u>	Sep 29, 2003
<u>AA</u>			<u>25MG</u>	<u>A040534 001</u>	Sep 29, 2003
<u>AA</u>			<u>50MG</u>	<u>A040518 001</u>	Sep 29, 2003
<u>DUVOID</u>					
<u>AA</u>		BI-COASTAL PHARMA	<u>10MG</u>	<u>A086262 001</u>	
<u>AA</u>			<u>25MG</u>	<u>A086263 001</u>	
<u>AA</u>			<u>50MG</u>	<u>A085882 003</u>	
<u>URECHOLINE</u>					
<u>AA</u>	!	ODYSSEY PHARMS	<u>5MG</u>	<u>A089095 001</u>	Dec 19, 1985
<u>AA</u>	!		<u>10MG</u>	<u>A088440 001</u>	May 29, 1984
<u>AA</u>	!		<u>25MG</u>	<u>A088441 001</u>	May 29, 1984
<u>AA</u>	!		<u>50MG</u>	<u>A089096 001</u>	Dec 19, 1985

PRESCRIPTION DRUG PRODUCT LIST

BETRIXABAN

CAPSULE; ORAL

BEVYXXA

+	PORTOLA PHARMS INC	40MG	N208383 001	Jun 23, 2017
+	!	80MG	N208383 002	Jun 23, 2017

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE**AB** BIONPHARMA INC **75MG****A203174 001** Aug 12, 2014TARGRETIN**AB** +! VALEANT LUXEMBOURG **75MG****N021055 001** Dec 29, 1999

GEL; TOPICAL

TARGRETIN

+! VALEANT LUXEMBOURG 1%

N021056 001 Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE**AB** ACCORD HLTHCARE **50MG****A078917 001** Jul 06, 2009**AB** APOTEX INC **50MG****A200274 001** May 21, 2015**AB** FRESSENIUS KABI **50MG****A079045 001** May 13, 2010

ONCOL

AB MYLAN **50MG****A079185 001** Jul 06, 2009**AB** SANDOZ **50MG****A078575 001** Jul 06, 2009**AB** SANTOS BIOTECH **50MG****A091011 001** Jun 10, 2015**AB** SUN PHARMA GLOBAL **50MG****A079110 001** Jul 06, 2009**AB** TEVA **50MG****A076932 001** Jul 06, 2009**AB** WATSON LABS TEVA **50MG****A078634 001** Aug 28, 2009**AB** ZYDUS PHARMS USA **50MG****A079089 001** Jul 06, 2009

INC

CASODEX**AB** +! ASTRAZENECA PHARMS **50MG****N020498 001** Oct 04, 1995BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST**AT** APOTEX INC **0.03%****A090449 001** Jul 20, 2015**AT** ! LUPIN LTD **0.03%****A203991 001** Feb 20, 2015**AT** SANDOZ INC **0.03%****A202565 001** May 05, 2015

LUMIGAN

+! ALLERGAN 0.01%

N022184 001 Aug 31, 2010

SOLUTION/DROPS; TOPICAL

BIMATOPROST**AT** APOTEX INC **0.03%****A201894 001** Dec 01, 2014**AT** SANDOZ INC **0.03%****A202719 001** Apr 19, 2016LATISSE**AT** +! ALLERGAN **0.03%****N022369 001** Dec 24, 2008BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

!	NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	A202217 001	Aug 20, 2014
		; N/A, 5.6GM		

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+! FOREST LABS LLC 140MG; 125MG; 125MG

N050786 001 Sep 28, 2006

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE**AB** AUROBINDO PHARMA **5MG****A077910 001** Dec 27, 2006**AB** **10MG****A077910 002** Dec 27, 2006**AB** MYLAN **5MG****A075831 001** Dec 14, 2005**AB** ! **10MG****A075831 002** Dec 14, 2005**AB** ORIT LABS LLC **5MG****A204891 001** Jan 11, 2017**AB** **10MG****A204891 002** Jan 11, 2017**AB** SANDOZ **5MG****A075643 001** Nov 16, 2000**AB** **10MG****A075643 002** Nov 16, 2000**AB** TEVA PHARMS **5MG****A075644 001** Jun 26, 2001**AB** **10MG****A075644 002** Jun 26, 2001**AB** UNICHEM PHARMS **5MG****A078635 001** Aug 18, 2009

(USA)

AB **10MG****A078635 002** Aug 18, 2009

PRESCRIPTION DRUG PRODUCT LIST

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>2.5MG; 6.25MG</u>	<u>A075768 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075768 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075768 003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG; 6.25MG</u>	<u>A075579 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075579 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075579 003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG; 6.25MG</u>	<u>A079106 001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A079106 002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A079106 003</u>	Jul 28, 2010
<u>ZIAC</u>				
<u>AB</u>	+ TEVA BRANDED PHARM	<u>2.5MG; 6.25MG</u>	<u>N020186 003</u>	Mar 26, 1993
<u>AB</u>	+	<u>5MG; 6.25MG</u>	<u>N020186 001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG; 6.25MG</u>	<u>N020186 002</u>	Mar 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

<u>AP</u>	+	THE MEDICINES CO	<u>250MG/VIAL</u>	<u>N020873 001</u>	Dec 15, 2000
<u>BIVALIRUDIN</u>					
<u>AP</u>		ACCORD HLTHCARE	<u>250MG/VIAL</u>	<u>A206551 001</u>	Nov 22, 2017
<u>AP</u>		APOTEX INC	<u>250MG/VIAL</u>	<u>A204876 001</u>	Jul 06, 2017
<u>AP</u>		DR REDDYS LABS LTD	<u>250MG/VIAL</u>	<u>A201577 001</u>	May 26, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>250MG/VIAL</u>	<u>A090189 001</u>	Oct 28, 2016
<u>AP</u>		HOSPIRA INC	<u>250MG/VIAL</u>	<u>A090811 001</u>	Jul 14, 2015
<u>AP</u>			<u>250MG/VIAL</u>	<u>A090816 001</u>	Jul 14, 2015
SOLUTION; IV (INFUSION)					
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE					
	+	CELERITY PHARMS	250MG/50ML (5MG/ML)	N208374 001	Dec 21, 2017
	+		500MG/100ML (5MG/ML)	N208374 002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185 001</u>	Jan 28, 2008
<u>AP</u>	!		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185 002</u>	Jan 28, 2008
<u>AP</u>		HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031 001</u>	Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031 002</u>	Mar 10, 2000
<u>AP</u>		TEVA PHARMS USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033 001</u>	Jun 27, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033 002</u>	Jun 27, 2000
<u>AP</u>		WEST-WARD PHARMS	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042 002</u>	Oct 17, 2001
<u>AP</u>		INT	<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042 001</u>	Oct 17, 2001

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+! MILLENNIUM PHARMS 3.5MG/VIAL

N021602 001 May 13, 2003

POWDER; INTRAVENOUS

BORTEZOMIB

FRESENIUS KABI USA 3.5MG/VIAL

N205004 001 Nov 06, 2017

BOSENTAN

TABLET; ORAL

TRACLEER

+ ACTELION PHARMS LTD 62.5MG

N021290 001 Nov 20, 2001

+! 125MG

N021290 002 Nov 20, 2001

TABLET, FOR SUSPENSION; ORAL

TRACLEER

+! ACTELION PHARMS 32MG

N209279 001 Sep 05, 2017

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+! PF PRISM CV EQ 100MG BASE

N203341 001 Sep 04, 2012

+ EQ 400MG BASE

N203341 003 Oct 27, 2017

+ EQ 500MG BASE

N203341 002 Sep 04, 2012

PRESCRIPTION DRUG PRODUCT LIST

BREXPIRAZOLE

TABLET; ORAL

REXULTI

+	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015
+		0.5MG	N205422	002	Jul 10, 2015
+		1MG	N205422	003	Jul 10, 2015
+	!	2MG	N205422	004	Jul 10, 2015
+		3MG	N205422	005	Jul 10, 2015
+		4MG	N205422	006	Jul 10, 2015

BRIGATINIB

TABLET; ORAL

ALUNBRIG

+	ARIAD	30MG	N208772	001	Apr 28, 2017
+	!	90MG	N208772	002	Apr 28, 2017
+		180MG	N208772	003	Oct 02, 2017

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+	!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013
---	---	------------------	---------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	!	ALLERGAN	0.15%	N021262	001	Mar 16, 2001	
			BRIMONIDINE TARTRATE					
AT			AKORN	0.2%	A076439	001	Mar 14, 2006	
AT		!	BAUSCH AND LOMB	0.2%	A076260	001	May 28, 2003	
AT			INDOCO REMEDIES	0.2%	A091691	001	Nov 18, 2014	
AT			SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	
AT				0.2%	A078075	001	Jan 30, 2008	
			QOLIANA					
AT			SANDOZ INC	0.15%	N021764	001	May 22, 2006	
			ALPHAGAN P					
		+	!	ALLERGAN	0.1%	N021770	001	Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+	!	NOVARTIS PHARMS	0.2%; 1%	N204251	001	Apr 19, 2013
			CORP			

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+	!	ALLERGAN	0.2%; EQ 0.5% BASE	N021398	001	Oct 30, 2007
---	---	----------	--------------------	---------	-----	--------------

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+	!	NOVARTIS PHARMS	1%	N020816	001	Apr 01, 1998
			CORP			

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+	!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016
---	---	---------	--------------------	---------	-----	--------------

SOLUTION; ORAL

BRIVIACT

+	!	UCB INC	10MG/ML	N205838	001	May 12, 2016
---	---	---------	---------	---------	-----	--------------

TABLET; ORAL

BRIVIACT

+		UCB INC	10MG	N205836	001	May 12, 2016
+			25MG	N205836	002	May 12, 2016
+			50MG	N205836	003	May 12, 2016
+			75MG	N205836	004	May 12, 2016
+	!		100MG	N205836	005	May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT1			AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
AT1		!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014
AT1			PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015
AT2			APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014
AT2		!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014

PRESCRIPTION DRUG PRODUCT LIST

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMSITE

+! SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016

PROLENSA

+! BAUSCH AND LOMB EQ 0.07% ACID N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATEAB ! MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005AB ZYDUS PHARMS USA EQ 5MG BASE A078899 001 Jul 30, 2008

INC

PARLODELAB + US PHARMS HOLDINGS EQ 5MG BASE N017962 002 Mar 01, 1982

I

TABLET;ORAL

BROMOCRIPTINE MESYLATEAB MYLAN EQ 2.5MG BASE A076962 001 Sep 24, 2004AB ! PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008AB SANDOZ INC EQ 2.5MG BASE A074631 001 Jan 13, 1998PARLODELAB + US PHARMS HOLDINGS EQ 2.5MG BASE N017962 001

I

CYCLOSET

+! VEROSCIENCE EQ 0.8MG BASE N020866 001 May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DMAA ! WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5ML A088811 001 Jun 07, 1985BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDEAA ACELLA PHARMS LLC 2MG/5ML;10MG/5ML;30MG/5ML A203375 001 Sep 20, 2016AA PADDOCK LLC 2MG/5ML;10MG/5ML;30MG/5ML A205292 001 Jul 15, 2014AA TARO PHARM 2MG/5ML;10MG/5ML;30MG/5ML A205112 001 Feb 27, 2017AA VINTAGE PHARMS 2MG/5ML;10MG/5ML;30MG/5ML A202940 001 Jul 21, 2014BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

+! VALEANT PHARMS INTL 2MG/ACTUATION N205613 001 Oct 07, 2014

CAPSULE;ORAL

BUDESONIDEAB ALVOGEN MALTA 3MG A206724 001 Nov 23, 2016AB AMNEAL PHARMS 3MG A206200 001 Jul 31, 2017AB APPCO PHARMA LLC 3MG A207367 001 Apr 07, 2017AB BARR LABS DIV TEVA 3MG A090379 001 Apr 02, 2014AB MAYNE PHARMA 3MG A206623 001 Apr 08, 2016AB MYLAN 3MG A090410 001 May 16, 2011AB SCIECURE PHARMA INC 3MG A209041 001 Sep 28, 2017AB ZYDUS PHARMS USA 3MG A206134 001 May 04, 2017

INC

ENTOCORT ECAB +! PERRIGO PHARMA INTL 3MG N021324 001 Oct 02, 2001

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

+ ASTRAZENECA 0.08MG/INH N021949 001 Jul 12, 2006

+! 0.16MG/INH N021949 002 Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDEAN APOTEX INC 0.25MG/2ML A078202 001 Mar 30, 2009AN 0.5MG/2ML A078202 002 Mar 30, 2009AN CIPLA LTD 0.25MG/2ML A205710 001 Nov 16, 2017AN 0.5MG/2ML A205710 002 Nov 16, 2017AN 1MG/2ML A205710 003 Nov 16, 2017AN IMPAX LABS INC 0.25MG/2ML A078404 001 Jul 31, 2012AN 0.5MG/2ML A078404 002 Jul 31, 2012AN SANDOZ INC 0.25MG/2ML A201966 003 Sep 27, 2013AN 0.5MG/2ML A201966 002 Sep 27, 2013AN 1MG/2ML A201966 001 Sep 27, 2013AN TEVA PHARMS 0.25MG/2ML A077519 001 Nov 18, 2008AN 0.5MG/2ML A077519 002 Nov 18, 2008AN TEVA PHARMS USA 1MG/2ML A204548 001 Mar 08, 2016

PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

SUSPENSION; INHALATION

PULMICORT RESPULES

<u>AN</u>	+	ASTRAZENECA PHARMS	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000
<u>AN</u>	+		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000
<u>AN</u>	+	!	<u>1MG/2ML</u>	<u>N020929</u>	<u>003</u>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

UCERIS

	+	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013
--	---	---------------------	-----	---------	-----	--------------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

	+	ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929	001	Jul 21, 2006
	+		0.16MG/INH; 0.0045MG/INH	N021929	002	Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	!	ATHENEX INC	<u>0.25MG/ML</u>	<u>A074441</u>	<u>001</u>	Jan 27, 1995
<u>AP</u>		HOSPIRA	<u>0.25MG/ML</u>	<u>A074332</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>		WEST-WARD PHARMS INT	<u>0.25MG/ML</u>	<u>A079196</u>	<u>001</u>	Apr 30, 2008

TABLET; ORAL

BUMETANIDE

<u>AB</u>		AMNEAL PHARMS CO	<u>0.5MG</u>	<u>A209724</u>	<u>001</u>	Oct 18, 2017
<u>AB</u>			<u>1MG</u>	<u>A209724</u>	<u>002</u>	Oct 18, 2017
<u>AB</u>			<u>2MG</u>	<u>A209724</u>	<u>003</u>	Oct 18, 2017
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>			<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>			<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996
<u>AB</u>			<u>1MG</u>	<u>A074700</u>	<u>002</u>	Nov 21, 1996
<u>AB</u>	!		<u>2MG</u>	<u>A074700</u>	<u>003</u>	Nov 21, 1996
		<u>BUMEX</u>				
<u>AB</u>	+	VALIDUS PHARMS	<u>0.5MG</u>	<u>N018225</u>	<u>002</u>	Feb 28, 1983
<u>AB</u>	+		<u>1MG</u>	<u>N018225</u>	<u>001</u>	Feb 28, 1983
<u>AB</u>	+		<u>2MG</u>	<u>N018225</u>	<u>003</u>	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
	+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A207183</u>	<u>001</u>	May 13, 2016
<u>AP</u>			<u>0.5%</u>	<u>A207183</u>	<u>002</u>	May 13, 2016
<u>AP</u>		HOSPIRA	<u>0.25%</u>	<u>A070583</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070586</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070590</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>N018053</u>	<u>002</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070584</u>	<u>001</u>	Feb 17, 1986
<u>AP</u>			<u>0.5%</u>	<u>A070597</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>A070609</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>N018053</u>	<u>001</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070585</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>			<u>0.75%</u>	<u>N018053</u>	<u>003</u>	
<u>AP</u>		SAGENT AGILA	<u>0.25%</u>	<u>A091503</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>			<u>0.5%</u>	<u>A091503</u>	<u>002</u>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895</u>	<u>001</u>	Nov 05, 2013
<u>AP</u>			<u>0.5%</u>	<u>A203895</u>	<u>002</u>	Nov 05, 2013
<u>AP</u>			<u>0.75%</u>	<u>A203895</u>	<u>003</u>	Nov 05, 2013
<u>AP</u>		SAGENT AGILA	<u>0.25%</u>	<u>A091487</u>	<u>002</u>	Oct 18, 2011
<u>AP</u>			<u>0.5%</u>	<u>A091487</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>			<u>0.75%</u>	<u>A091487</u>	<u>003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>001</u>	
<u>AP</u>	+		<u>0.5%</u>	<u>N016964</u>	<u>006</u>	

PRESCRIPTION DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	<u>+</u> !	<u>HOSPIRA</u>	<u>0.25%</u>	<u>N016964</u>	<u>012</u>	
<u>AP</u>	<u>+</u> !		<u>0.5%</u>	<u>N016964</u>	<u>005</u>	
<u>AP</u>	<u>+</u> !		<u>0.75%</u>	<u>N016964</u>	<u>009</u>	

SENSORCAINE

<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	<u>May 21, 1986</u>
<u>AP</u>			<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070553</u>	<u>001</u>	<u>May 21, 1986</u>
<u>AP</u>			<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070554</u>	<u>001</u>	<u>May 21, 1986</u>
<u>AP</u>			<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>0.75%</u>	<u>A207266</u>	<u>001</u>	<u>Jul 25, 2016</u>
		<u>CORP</u>				
<u>AP</u>		<u>HOSPIRA</u>	<u>0.75%</u>	<u>A071810</u>	<u>001</u>	<u>Dec 11, 1987</u>

MARCAINE

<u>AP</u>	<u>+</u> !	<u>HOSPIRA</u>	<u>0.75%</u>	<u>N018692</u>	<u>001</u>	<u>May 04, 1984</u>
-----------	------------	----------------	--------------	----------------	------------	---------------------

SENSORCAINE

<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>0.75%</u>	<u>A071202</u>	<u>001</u>	<u>Apr 15, 1987</u>
-----------	--	---------------------------	--------------	----------------	------------	---------------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	<u>!</u>	<u>HOSPIRA</u>	<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	<u>Jun 16, 1988</u>
<u>AP</u>			<u>0.5%;0.005MG/ML</u>	<u>A071170</u>	<u>001</u>	<u>Jun 16, 1988</u>
	<u>!</u>		<u>0.25%;0.005MG/ML</u>	<u>A071165</u>	<u>001</u>	<u>Jun 16, 1988</u>
			<u>0.25%;0.005MG/ML</u>	<u>A071167</u>	<u>001</u>	<u>Jun 16, 1988</u>

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>		<u>SEPTODONT</u>	<u>0.5%;0.0091MG/ML</u>	<u>A077250</u>	<u>001</u>	<u>Sep 27, 2006</u>
-----------	--	------------------	-------------------------	----------------	------------	---------------------

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

<u>AP</u>	<u>+</u> !	<u>HOSPIRA</u>	<u>0.5%;0.0091MG/ML</u>	<u>N022046</u>	<u>001</u>	<u>Jul 13, 1983</u>
-----------	------------	----------------	-------------------------	----------------	------------	---------------------

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	<u>+</u> !	<u>HOSPIRA</u>	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>004</u>	
<u>AP</u>	<u>+</u> !		<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>008</u>	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	<u>+</u> !	<u>HOSPIRA</u>	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>013</u>	
<u>AP</u>	<u>+</u> !		<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>007</u>	
<u>AP</u>	<u>+</u> !		<u>0.75%;0.0091MG/ML</u>	<u>N016964</u>	<u>010</u>	

SENSORCAINE

<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>0.25%;0.0091MG/ML</u>	<u>A070966</u>	<u>001</u>	<u>Oct 13, 1987</u>
<u>AP</u>			<u>0.25%;0.0091MG/ML</u>	<u>A070967</u>	<u>001</u>	<u>Oct 13, 1987</u>
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>A070968</u>	<u>001</u>	<u>Oct 13, 1987</u>
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>N018304</u>	<u>004</u>	<u>Sep 02, 1983</u>
<u>AP</u>			<u>0.75%;0.0091MG/ML</u>	<u>N018304</u>	<u>005</u>	<u>Sep 02, 1983</u>

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

<u>+</u>	<u>PURDUE PHARMA LP</u>	<u>5MCG/HR</u>	<u>N021306</u>	<u>001</u>	<u>Jun 30, 2010</u>
<u>+</u>		<u>7.5MCG/HR</u>	<u>N021306</u>	<u>005</u>	<u>Jun 30, 2014</u>
<u>+</u>		<u>10MCG/HR</u>	<u>N021306</u>	<u>002</u>	<u>Jun 30, 2010</u>
<u>+</u>		<u>15MCG/HR</u>	<u>N021306</u>	<u>004</u>	<u>Jul 25, 2013</u>
<u>+</u> !		<u>20MCG/HR</u>	<u>N021306</u>	<u>003</u>	<u>Jun 30, 2010</u>

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS

SUBLOCADE

<u>+</u>	<u>INDIVIOR INC</u>	<u>100MG/0.5ML (100MG/0.5ML)</u>	<u>N209819</u>	<u>001</u>	<u>Nov 29, 2017</u>
<u>+</u> !		<u>300MG/1.5ML (200MG/ML)</u>	<u>N209819</u>	<u>002</u>	<u>Nov 29, 2017</u>

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

<u>+</u>	<u>BDSI</u>	<u>EQ 0.075MG BASE</u>	<u>N207932</u>	<u>001</u>	<u>Oct 23, 2015</u>
<u>+</u>		<u>EQ 0.15MG BASE</u>	<u>N207932</u>	<u>002</u>	<u>Oct 23, 2015</u>
<u>+</u>		<u>EQ 0.3MG BASE</u>	<u>N207932</u>	<u>003</u>	<u>Oct 23, 2015</u>
<u>+</u>		<u>EQ 0.45MG BASE</u>	<u>N207932</u>	<u>004</u>	<u>Oct 23, 2015</u>
<u>+</u>		<u>EQ 0.6MG BASE</u>	<u>N207932</u>	<u>005</u>	<u>Oct 23, 2015</u>
<u>+</u>		<u>EQ 0.75MG BASE</u>	<u>N207932</u>	<u>006</u>	<u>Oct 23, 2015</u>
<u>+</u> !		<u>EQ 0.9MG BASE</u>	<u>N207932</u>	<u>007</u>	<u>Oct 23, 2015</u>

PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

PROBUPHINE

+! BRAEBURN PHARMS INC EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016

INJECTABLE; INJECTION

BUPRENEX**AP** +! INDIVIOR INCEQ 0.3MG BASE/MLN018401 001BUPRENORPHINE HYDROCHLORIDE**AP** HOSPIRAEQ 0.3MG BASE/MLA074137 001 Jun 03, 1996**AP** LUITPOLDEQ 0.3MG BASE/MLA078331 001 Mar 27, 2007**AP** PAR STERILEEQ 0.3MG BASE/MLA206586 001 Jul 28, 2015

PRODUCTS

AP WEST-WARD PHARMSEQ 0.3MG BASE/MLA076931 001 Mar 02, 2005

INT

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE**AB** ACTAVIS ELIZABETHEQ 2MG BASEA090819 001 Feb 19, 2015**AB**EQ 8MG BASEA090819 002 Feb 19, 2015**AB**

BARR

EQ 2MG BASEA090360 001 May 07, 2010**AB**EQ 8MG BASEA090360 002 May 07, 2010**AB**

ETHYPHARM

EQ 2MG BASEA090622 001 Sep 24, 2010**AB**EQ 8MG BASEA090622 002 Sep 24, 2010**AB**

MYLAN PHARMS INC

EQ 2MG BASEA201066 001 Mar 06, 2015**AB**EQ 8MG BASEA201066 002 Mar 06, 2015**AB**

RHODES PHARMS

EQ 2MG BASEA207276 001 Mar 27, 2017**AB**EQ 8MG BASEA207276 002 Mar 27, 2017**AB**

SANDOZ INC

EQ 2MG BASEA090279 001 Jun 10, 2015**AB**EQ 8MG BASEA090279 002 Jun 10, 2015**AB**

SUN PHARM INDS LTD

EQ 2MG BASEA201760 001 Jan 29, 2016**AB**EQ 8MG BASEA201760 002 Jan 29, 2016**AB**

WEST-WARD PHARMS

EQ 2MG BASEA078633 001 Oct 08, 2009

INT

AB

!

EQ 8MG BASEA078633 002 Oct 08, 2009BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL

BUNAVAIL

+ BDSI

EQ 2.1MG BASE;EQ 0.3MG BASE

N205637 001 Jun 06, 2014

+

EQ 4.2MG BASE;EQ 0.7MG BASE

N205637 002 Jun 06, 2014

+!

EQ 6.3MG BASE;EQ 1MG BASE

N205637 003 Jun 06, 2014

FILM; BUCCAL, SUBLINGUAL

SUBOXONE

+ INDIVIOR INC

EQ 2MG BASE;EQ 0.5MG BASE

N022410 001 Aug 30, 2010

+

EQ 4MG BASE;EQ 1MG BASE

N022410 003 Aug 10, 2012

+

EQ 8MG BASE;EQ 2MG BASE

N022410 002 Aug 30, 2010

+!

EQ 12MG BASE;EQ 3MG BASE

N022410 004 Aug 10, 2012

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE**AB** ACTAVIS ELIZABETHEQ 2MG BASE;EQ 0.5MG BASEA091422 001 Feb 22, 2013**AB**

!

EQ 8MG BASE;EQ 2MG BASEA091422 002 Feb 22, 2013**AB**

AMNEAL PHARMS

EQ 8MG BASE;EQ 2MG BASEA203136 002 Feb 22, 2013**AB**

ETHYPHARM USA CORP

EQ 2MG BASE;EQ 0.5MG BASEA204431 001 Oct 16, 2015**AB**EQ 8MG BASE;EQ 2MG BASEA204431 002 Oct 16, 2015**AB**

KREMERS URBAN

EQ 2MG BASE;EQ 0.5MG BASEA205022 001 Sep 19, 2016

PHARMS

ABEQ 8MG BASE;EQ 2MG BASEA205022 002 Sep 19, 2016**AB**

SPECGX LLC

EQ 2MG BASE;EQ 0.5MG BASEA207000 001 Dec 13, 2017**AB**EQ 8MG BASE;EQ 2MG BASEA207000 002 Dec 13, 2017**AB**

SUN PHARM INDS LTD

EQ 8MG BASE;EQ 2MG BASEA201633 002 Aug 05, 2016**AB**

TEVA PHARMS USA

EQ 2MG BASE;EQ 0.5MG BASEA091149 001 Sep 08, 2014**AB**EQ 8MG BASE;EQ 2MG BASEA091149 002 Sep 08, 2014**AB**

WEST-WARD PHARMS

EQ 2MG BASE;EQ 0.5MG BASEA203326 001 Jun 27, 2014

INT

ABEQ 8MG BASE;EQ 2MG BASEA203326 002 Jun 27, 2014BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE**AB** AMNEAL PHARMSEQ 2MG BASE;EQ 0.5MG BASEA203136 001 Feb 22, 2013**AB**

SUN PHARM INDS LTD

EQ 2MG BASE;EQ 0.5MG BASEA201633 001 Aug 05, 2016

ZUBSOLV

+ OREXO US INC

EQ 0.7MG BASE;EQ 0.18MG BASE

N204242 006 Oct 04, 2016

+

EQ 1.4MG BASE;EQ 0.36MG BASE

N204242 001 Jul 03, 2013

+

EQ 2.9MG BASE;EQ 0.71MG BASE

N204242 005 Jun 04, 2015

+

EQ 5.7MG BASE;EQ 1.4MG BASE

N204242 002 Jul 03, 2013

+

EQ 8.6MG BASE;EQ 2.1MG BASE

N204242 003 Dec 11, 2014

+!

EQ 11.4MG BASE;EQ 2.9MG BASE

N204242 004 Dec 11, 2014

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+	!	522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	APOTEX INC	75MG	A076143	001	Jan 17, 2006
AB	!	100MG	A076143	002	Jan 17, 2006
AB	HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016
AB		100MG	A206975	002	Aug 19, 2016
AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017
AB		100MG	A207389	002	Sep 18, 2017
AB	MYLAN	75MG	A075491	001	Apr 17, 2000
AB		100MG	A075491	002	Apr 17, 2000
AB	SANDOZ	75MG	A075584	001	Feb 07, 2000
AB		100MG	A075584	002	Feb 07, 2000

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	100MG	A079095	001	Mar 24, 2009
AB1		150MG	A079095	002	Mar 24, 2009
AB1		200MG	A079095	003	Mar 24, 2009
AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011
AB1		150MG	A091459	002	Jun 09, 2011
AB1		200MG	A091459	003	Jun 09, 2011
AB1	IMPAX LABS	100MG	A075913	001	Jan 28, 2004
AB1		150MG	A075913	002	Mar 22, 2004
AB1		200MG	A076711	001	Dec 03, 2004
AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016
AB1		150MG	A206674	002	Feb 09, 2016
AB1		200MG	A206674	003	Feb 09, 2016
AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013
AB1		150MG	A202774	002	Oct 11, 2013
AB1		200MG	A202774	003	Oct 11, 2013
AB1	MYLAN	100MG	A090325	001	Apr 08, 2010
AB1		150MG	A090325	002	Apr 08, 2010
AB1		200MG	A090325	003	Apr 08, 2010
AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015
AB1		150MG	A202304	002	May 26, 2015
AB1		200MG	A202304	003	May 26, 2015
AB1	SANDOZ	100MG	A075932	001	Nov 25, 2003
AB1		150MG	A075932	002	Mar 22, 2004
AB1		200MG	A075932	003	Jun 22, 2005
AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016
AB1		150MG	A205794	002	Mar 01, 2016
AB1		200MG	A205794	003	Mar 01, 2016
AB1	SUN PHARMA GLOBAL	100MG	A078866	001	Apr 06, 2010
AB1		150MG	A078866	002	Apr 06, 2010
AB1		200MG	A078866	003	Apr 06, 2010
AB1	TORRENT PHARMS LTD	100MG	A203969	001	Oct 31, 2014
AB1		150MG	A203969	002	Oct 31, 2014
AB1		200MG	A203969	003	Oct 31, 2014
AB1	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010
AB1		150MG	A077455	002	Mar 12, 2008
AB1		200MG	A077455	003	Jul 19, 2010

WELLBUTRIN SR

AB1	+	GLAXOSMITHKLINE	100MG	N020358	002	Oct 04, 1996
AB1	+		150MG	N020358	003	Oct 04, 1996
AB1	+	!	200MG	N020358	004	Jun 14, 2002

BUPROPION HYDROCHLORIDE

AB2	ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009
AB2	ANCHEN PHARMS	150MG	A091520	001	Jun 09, 2011
AB2	IMPAX LABS	150MG	A075914	001	May 27, 2004
AB2	JUBILANT GENERICS	150MG	A202775	001	Oct 11, 2013
AB2	MYLAN	150MG	A090941	001	May 03, 2010
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008
AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016

ZYBAN

AB2	+	GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997
------------	---	-----------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	ANBISON LAB CO LTD	<u>150MG</u>	<u>A207224</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>		<u>300MG</u>	<u>A207224</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	INVAGEN PHARMS	<u>150MG</u>	<u>A206556</u>	<u>001</u>	Aug 26, 2016
<u>AB3</u>		<u>300MG</u>	<u>A206556</u>	<u>002</u>	Aug 26, 2016
<u>AB3</u>	JUBILANT GENERICS	<u>150MG</u>	<u>A207459</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>		<u>300MG</u>	<u>A207459</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>	LUPIN LTD	<u>150MG</u>	<u>A090693</u>	<u>001</u>	Apr 06, 2017
<u>AB3</u>		<u>300MG</u>	<u>A090693</u>	<u>002</u>	Apr 06, 2017
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	SCIEGEN PHARMS INC	<u>150MG</u>	<u>A207479</u>	<u>001</u>	Apr 12, 2017
<u>AB3</u>		<u>300MG</u>	<u>A207479</u>	<u>002</u>	Apr 12, 2017
<u>AB3</u>	SINOTHERAPEUTICS INC	<u>150MG</u>	<u>A208652</u>	<u>001</u>	Aug 21, 2017
<u>AB3</u>		<u>300MG</u>	<u>A208652</u>	<u>002</u>	Aug 21, 2017
<u>AB3</u>	SUN PHARMA GLOBAL	<u>150MG</u>	<u>A200695</u>	<u>001</u>	Dec 18, 2014
<u>AB3</u>	TWI PHARMS INC	<u>150MG</u>	<u>A210081</u>	<u>001</u>	Nov 03, 2017
<u>AB3</u>		<u>300MG</u>	<u>A210081</u>	<u>002</u>	Nov 03, 2017
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>	ZYDUS PHARMS USA INC	<u>300MG</u>	<u>A201567</u>	<u>001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	+	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>	+	!	<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
		FORFIVO XL				
	+	!	ALVOGEN	450MG	N022497	001 Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	!	OREXIGEN	90MG; 8MG	N200063	001	Sep 10, 2014
---	---	----------	-----------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557</u>	<u>001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557</u>	<u>002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557</u>	<u>003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557</u>	<u>004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557</u>	<u>005</u>	Dec 30, 2014
<u>AB</u>	AMNEAL PHARMS CO	<u>5MG</u>	<u>A208829</u>	<u>001</u>	May 24, 2017
<u>AB</u>		<u>7.5MG</u>	<u>A208829</u>	<u>002</u>	May 24, 2017
<u>AB</u>		<u>10MG</u>	<u>A208829</u>	<u>003</u>	May 24, 2017
<u>AB</u>		<u>15MG</u>	<u>A208829</u>	<u>004</u>	May 24, 2017
<u>AB</u>		<u>30MG</u>	<u>A208829</u>	<u>005</u>	May 24, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A204582</u>	<u>001</u>	Sep 18, 2015
<u>AB</u>		<u>10MG</u>	<u>A204582</u>	<u>002</u>	Sep 18, 2015
<u>AB</u>		<u>15MG</u>	<u>A204582</u>	<u>003</u>	Sep 18, 2015
<u>AB</u>		<u>30MG</u>	<u>A204582</u>	<u>004</u>	Sep 18, 2015
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076008</u>	<u>003</u>	Mar 01, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>7.5MG</u>	<u>A076008</u>	<u>002</u>	Jul 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A076008</u>	<u>004</u>	Mar 01, 2002
<u>AB</u>		<u>15MG</u>	<u>A076008</u>	<u>005</u>	Mar 28, 2001
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	ORION CORP ORION	<u>5MG</u>	<u>A202087</u>	<u>001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087</u>	<u>002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087</u>	<u>003</u>	Dec 16, 2015

PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A202087 004</u>	Dec 16, 2015
<u>AB</u>	OXFORD PHARMS	<u>30MG</u>	<u>A078302 001</u>	Dec 17, 2007
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202330 001</u>	Aug 25, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202330 005</u>	Feb 17, 2017
<u>AB</u>		<u>10MG</u>	<u>A202330 002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330 003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330 004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022 001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022 002</u>	Feb 28, 2002
<u>AB</u>	!	<u>15MG</u>	<u>A075022 003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022 004</u>	Mar 25, 2004
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078888 001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888 002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888 003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888 004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	ACTAVIS LLC	<u>6MG/ML</u>	<u>A205139 001</u>	Dec 08, 2017
<u>AP</u>	AMNEAL PHARMS CO	<u>6MG/ML</u>	<u>A209580 001</u>	Dec 18, 2017
<u>AP</u>	LUITPOLD PHARMS INC	<u>6MG/ML</u>	<u>A202259 001</u>	Dec 22, 2015
<u>AP</u>	PHARMASCIENCE INC	<u>6MG/ML</u>	<u>A207050 001</u>	Mar 24, 2017
<u>AP</u>	SANDOZ INC	<u>6MG/ML</u>	<u>A205106 001</u>	Jul 07, 2017

BUSULFEX

<u>AP</u>	+! OTSUKA PHARM	<u>6MG/ML</u>	<u>N020954 001</u>	Feb 04, 1999
-----------	-----------------	---------------	--------------------	--------------

MYLERAN

<u>AP</u>	ASPEN GLOBAL INC	<u>6MG/ML</u>	<u>A208536 001</u>	Nov 20, 2017
-----------	------------------	---------------	--------------------	--------------

TABLET; ORAL

MYLERAN

+!	ASPEN GLOBAL	2MG	N009386	001
----	--------------	-----	---------	-----

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

+!	MYLAN SPECIALITY LP	30MG	N000793	004
----	---------------------	------	---------	-----

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+!	MYLAN	1%	N020524	001	Oct 18, 1996
----	-------	----	---------	-----	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

!	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012
---	----------------	----	---------	-----	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400 001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400 002</u>	May 01, 2009
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A075046 001</u>	Aug 12, 1998

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626 001</u>	Jan 23, 1997
<u>AP</u>		<u>2MG/ML</u>	<u>A074626 002</u>	Jan 23, 1997
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A075045 001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045 002</u>	Aug 12, 1998

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	APOTEX INC	<u>1MG/SPRAY</u>	<u>A075499 001</u>	Dec 04, 2002
<u>AB</u>	!	<u>1MG/SPRAY</u>	<u>A075759 001</u>	Aug 08, 2001
<u>AB</u>	WEST-WARD PHARMS INT	<u>1MG/SPRAY</u>	<u>A075824 001</u>	Mar 12, 2002

PRESCRIPTION DRUG PRODUCT LIST

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

+! SANOFI AVENTIS US 60MG/1.5ML (40MG/ML) N201023 001 Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A078035</u>	<u>001</u>	Apr 21, 2008
AB	APOTEX CORP	<u>0.5MG</u>	<u>A201503</u>	<u>001</u>	Mar 08, 2013
AB	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007
AB	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A202947</u>	<u>001</u>	Dec 02, 2013
AB	! PAR PHARM	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

+ EXELIXIS EQ 20MG BASE N203756 001 Nov 29, 2012

+! EQ 80MG BASE N203756 002 Nov 29, 2012

TABLET; ORAL

CABOMETYX

+ EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016

+ EQ 40MG BASE N208692 002 Apr 25, 2016

+! EQ 60MG BASE N208692 003 Apr 25, 2016

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFECIT

AP	+! WEST-WARD PHARMS INT	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999
-----------	----------------------------	---	-----------------------	-------------------	--------------

CAFFEINE CITRATE

AP	AUROBINDO PHARMA LTD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A205013</u>	<u>001</u>	Sep 22, 2015
AP	EXELA PHARMA SCIENCE	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006
AP	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007
AP	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007
AP	MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A207400</u>	<u>001</u>	Dec 14, 2017
AP	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827</u>	<u>001</u>	Aug 29, 2012
AP	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u>	<u>001</u>	Sep 30, 2009

SOLUTION; ORAL

CAFECIT

AA	+! WEST-WARD PHARMS INT	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>002</u>	Apr 12, 2000
-----------	----------------------------	---	-----------------------	-------------------	--------------

CAFFEINE CITRATE

AA	EXELA PHARMA SCS LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006
AA	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008
AA	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u>	<u>001</u>	Nov 20, 2009
AA	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102</u>	<u>001</u>	Aug 29, 2012
AA	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

! HORIZON PHARMA 100MG; 2MG A086557 001 Oct 04, 1983

TABLET; ORAL

CAFERGOT

AA	! SANDOZ	<u>100MG; 1MG</u>	<u>A084294</u>	<u>001</u>	
-----------	----------	-------------------	-----------------------	-------------------	--

ERGOTAMINE TARTRATE AND CAFFEINE

AA	HIKMA INTL PHARMS	<u>100MG; 1MG</u>	<u>A040510</u>	<u>001</u>	Sep 17, 2004
AA	MIKART	<u>100MG; 1MG</u>	<u>A040590</u>	<u>001</u>	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+! OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+! MAYNE PHARMA 0.005% N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENE

AB	GLENMARK PHARMS	<u>0.005%</u>	<u>A205772</u>	<u>001</u>	Jun 09, 2015
AB	TOLMAR	<u>0.005%</u>	<u>A200935</u>	<u>001</u>	May 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX**AB** +! LEO PHARMA AS **0.005%** **N020554 001** Jul 22, 1996

OINTMENT; TOPICAL

CALCIPOTRIENE

! GLENMARK PHARMS INC 0.005% A090633 001 Mar 24, 2010

SOLUTION; TOPICAL

CALCIPOTRIENE**AT** FOUGERA PHARMS **0.005%** **A078305 001** May 06, 2008**AT** G AND W LABS INC **0.005%** **A078468 001** Mar 24, 2011**AT** HI TECH PHARMA **0.005%** **A077579 001** Nov 19, 2009**AT** NOVEL LABS INC **0.005%** **A207163 001** Dec 26, 2017**AT** ! TOLMAR **0.005%** **A077029 001** Nov 20, 2009CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+! MYLAN IRELAND LTD 200 IU/ML N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON**AB** ! APOTEX INC **200 IU/SPRAY** **A076396 001** Nov 17, 2008**AB** PAR PHARM **200 IU/SPRAY** **A076979 001** Jun 08, 2009CALCITRIOL

CAPSULE; ORAL

CALCITRIOL**AB** AMNEAL PHARMS **0.25MCG** **A203289 002** Jun 14, 2017**AB** **0.5MCG** **A203289 001** Jun 14, 2017**AB** BIONPHARMA INC **0.25MCG** **A091174 001** May 24, 2013**AB** **0.5MCG** **A091174 002** May 24, 2013**AB** STRIDES PHARMA **0.25MCG** **A091356 001** Dec 12, 2014**AB** **0.5MCG** **A091356 002** Dec 12, 2014**AB** TEVA **0.25MCG** **A075765 001** Oct 12, 2001**AB** **0.5MCG** **A075765 002** Oct 12, 2001**AB** WEST-WARD PHARMS **0.25MCG** **A076917 001** Mar 27, 2006

INT

ROCALTROL**AB** + VALIDUS PHARMS **0.25MCG** **N018044 001****AB** +! **0.5MCG** **N018044 002**

INJECTABLE; INJECTION

CALCITRIOL

! AKORN 0.001MG/ML A078066 001 Jan 29, 2008

OINTMENT; TOPICAL

VECTICAL

+! GALDERMA LABS LP 3MCG/GM N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL**AA** WEST-WARD PHARMS **1MCG/ML** **A076242 001** Jul 18, 2003

INT

ROCALTROL**AA** +! VALIDUS PHARMS **1MCG/ML** **N021068 001** Nov 20, 1998CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE**AB** AMNEAL PHARMS **667MG** **A201658 001** Oct 06, 2014**AB** CHARTWELL RX **667MG** **A091312 001** Jun 01, 2012**AB** ECI PHARMS LLC **667MG** **A203298 001** Jul 26, 2016**AB** HERITAGE PHARMS INC **667MG** **A202315 001** Jun 29, 2015**AB** INVAGEN PHARMS **667MG** **A203135 001** Feb 07, 2013**AB** LUPIN LTD **667MG** **A202127 001** Jul 09, 2015**AB** NOSTRUM LABS INC **667MG** **A203179 001** Oct 26, 2015**AB** WEST-WARD PHARMS **667MG** **A077728 001** Feb 26, 2008

INT

PHOSLO GELCAPS**AB** +! FRESENIUS MEDCL **667MG** **N021160 003** Apr 02, 2001

SOLUTION; ORAL

PHOSLYRA

+! FRESENIUS MEDCL 667MG/5ML N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATE**AB** HERITAGE PHARMS INC **667MG** **A202885 001** Jan 22, 2015**AB** INVAGEN PHARMS **667MG** **A202420 001** Feb 05, 2013

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

AB	!	PADDOCK LLC	667MG	A091561 001	Apr 13, 2011
-----------	---	-------------	--------------	--------------------	--------------

ELIPHOS

AB		CYPRESS PHARM	667MG	A078502 001	Nov 25, 2008
-----------	--	---------------	--------------	--------------------	--------------

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10%

AP		LUITPOLD PHARMS INC	100MG/ML	A209088 001	Jul 27, 2017
-----------	--	---------------------	-----------------	--------------------	--------------

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	+	HOSPIRA	100MG/ML	N021117 001	Jan 28, 2000
-----------	---	---------	-----------------	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

AT	+	ALCON	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N018469 001	
-----------	---	-------	---	--------------------	--

ENDOSOL EXTRA

AT	+	AKORN	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N020079 001	Nov 27, 1991
-----------	---	-------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 010	Oct 10, 2008
---	----------------------	---	-------------	--------------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 011	Oct 10, 2008
---	----------------------	---	-------------	--------------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 013	Oct 10, 2008
---	----------------------	--	-------------	--------------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 006	Oct 25, 2006
---	----------------------	--	-------------	--------------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 002	Oct 25, 2006
---	----------------------	---	-------------	--------------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 003	Oct 25, 2006
---	----------------------	--	-------------	--------------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 015	Oct 10, 2008
---	----------------------	---	-------------	--------------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 004	Oct 25, 2006
---	----------------------	--	-------------	--------------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 014	Oct 10, 2008
---	----------------------	--	-------------	--------------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 001	Oct 25, 2006
---	----------------------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML	N018883 001	Nov 30, 1984
-----------	--	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT		FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	N018883 004	Nov 30, 1984
-----------	--	-----------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020171 001</u>	Aug 19, 1992
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML</u>	<u>N018883 002</u>	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N018883 005</u>	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020171 002</u>	Aug 19, 1992
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;5.567MG/100ML;392MG/100ML</u>	<u>N018883 003</u>	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;5.538MG/100ML;448MG/100ML</u>	<u>N018883 006</u>	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;5.538MG/100ML;448MG/100ML</u>	<u>N020171 003</u>	Aug 19, 1992
-----------	-----------------	---	--------------------	--------------

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML</u>	<u>N017512 001</u>	
-----------	-----------------	---	--------------------	--

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML</u>	<u>N017512 003</u>	
-----------	-----------------	---	--------------------	--

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;5.567MG/100ML;392MG/100ML</u>	<u>N017512 002</u>	
-----------	-----------------	---	--------------------	--

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020183 001</u>	Dec 04, 1992
-----------	-----------------	---	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML</u>	<u>N017512 007</u>	Jul 09, 1984
-----------	-----------------	---	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML</u>	<u>N017512 008</u>	Jul 09, 1984
-----------	-----------------	---	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;5.567MG/100ML;392MG/100ML</u>	<u>N017512 009</u>	Jul 09, 1984
-----------	-----------------	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 004</u>	
-----------	-----------------	---	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020163 001</u>	Dec 04, 1992
-----------	--	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N017512 005</u>	
-----------	-----------------	---	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML</u>	<u>N020163 002</u>	Dec 04, 1992
-----------	--	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;5.538MG/100ML;448MG/100ML</u>	<u>N017512 006</u>	
-----------	-----------------	---	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;5.538MG/100ML;448MG/100ML</u>	<u>N020163 003</u>	Dec 04, 1992
-----------	--	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML	N020183 002	Dec 04, 1992
--	-----------------	--	-------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML	N020183 003	Dec 04, 1992
--	-----------------	--	-------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;5.538MG/100ML;448MG/100ML	N020183 004	Dec 04, 1992
--	-----------------	--	-------------	--------------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5.67MG/100ML;392MG/100ML	N017512 010	Nov 18, 1985
--	-----------------	--	-------------	--------------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5.38MG/100ML;448MG/100ML	N017512 011	Nov 18, 1985
--	-----------------	--	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTT'S B SOLUTION

+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9	N020577	001	Sep 27, 1996
		MG/ML;7.3MG/ML;0.2MG/ML			

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/1	N020000	001	Apr 17, 1992
		00ML			

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	<u>+</u>	<u>ICU MEDICAL INC</u>	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/1</u>	<u>N017608</u>	<u>001</u>
			<u>00ML;310MG/100ML</u>		

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>		<u>B BRAUN</u>	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/1</u>	<u>N019634</u>	<u>003</u>	Feb 24, 1988
			<u>00ML;310MG/100ML</u>			

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>20MG/100ML;5GM/100ML;30MG/100ML;600MG/1</u>	<u>N016679</u>	<u>001</u>
			<u>00ML;310MG/100ML</u>		

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/</u>	<u>N019367</u>	<u>006</u>	Apr 05, 1985
			<u>100ML;310MG/100ML</u>			

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>20MG/100ML;5GM/100ML;179MG/100ML;600MG/</u>	<u>N019367</u>	<u>004</u>	Apr 05, 1985
			<u>100ML;310MG/100ML</u>			

<u>AP</u>			<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/</u>	<u>N019367</u>	<u>005</u>	Apr 05, 1985
			<u>100ML;310MG/100ML</u>			

<u>AP</u>		<u>ICU MEDICAL INC</u>	<u>20MG/100ML;5GM/100ML;179MG/100ML;600MG/</u>	<u>N019685</u>	<u>002</u>	Oct 17, 1988
			<u>100ML;310MG/100ML</u>			

<u>AP</u>			<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/</u>	<u>N019685</u>	<u>008</u>	Oct 17, 1988
			<u>100ML;310MG/100ML</u>			

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/</u>	<u>N019367</u>	<u>007</u>	Apr 05, 1985
			<u>100ML;310MG/100ML</u>			

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/</u>	<u>N019367</u>	<u>008</u>	Apr 05, 1985
			<u>100ML;310MG/100ML</u>			

<u>AP</u>		<u>ICU MEDICAL INC</u>	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/</u>	<u>N019685</u>	<u>004</u>	Oct 17, 1988
			<u>100ML;310MG/100ML</u>			

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG	N019634	001	Feb 24, 1988
		/100ML;160MG/100ML			

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/	N019367	002	Apr 05, 1985
		100ML;310MG/100ML			

		20MG/100ML;5GM/100ML;179MG/100ML;600MG/	N019367	003	Apr 05, 1985
		100ML;310MG/100ML			

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/	N019367	001	Apr 05, 1985
		100ML;310MG/100ML			

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;	N018895	001	Jul 20, 1984
		16.1MG/ML			

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

<u>AT</u>		<u>AKORN</u>	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6</u>	<u>A075503</u>	<u>001</u>	Sep 27, 2006
			<u>.4MG/ML;1.7MG/ML</u>			

<u>AT</u>		<u>B BRAUN</u>	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6</u>	<u>A091387</u>	<u>001</u>	Feb 03, 2010
			<u>.4MG/ML;1.7MG/ML</u>			

BSS

<u>AT</u>	<u>+</u> !	<u>ALCON</u>	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6</u>	<u>N020742</u>	<u>001</u>	Dec 10, 1997
			<u>.4MG/ML;1.7MG/ML</u>			

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026 002	Jan 13, 2015
----	----------------------	--	-------------	--------------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026 001	Jan 13, 2015
----	----------------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A075323 001</u>	Apr 21, 2000
-----------	-----------------	---	---------------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

AT	+! HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>N018608 001</u>	Feb 26, 1982
-----------	------------	---	---------------------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992
-----------	---------	---	---------------------------	--------------

AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	
-----------	-----------------	---	---------------------------	--

AP	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	
-----------	-----------------	---	---------------------------	--

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156 001</u>	
-----------	---------	---	---------------------------	--

AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495 001</u>	Feb 19, 1982
-----------	-----------------	---	---------------------------	--------------

AT	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635 001</u>	
-----------	-----------------	---	---------------------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632 001</u>	Feb 29, 1988
-----------	---------	--	---------------------------	--------------

AP	+! BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682 001</u>	
-----------	--------------------	--	---------------------------	--

AP	ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641 001</u>	
-----------	-----------------	--	---------------------------	--

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681 001</u>	Dec 27, 1982
-----------	------------	--	---------------------------	--------------

AT	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494 001</u>	Feb 19, 1982
-----------	-----------------	--	---------------------------	--------------

AT	+!	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921 001</u>	Apr 03, 1984
-----------	----	--	---------------------------	--------------

AT	+! ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416 001</u>	Jan 17, 1986
-----------	--------------------	--	---------------------------	--------------

CALCIUM GLUCONATE

SOLUTION; IV (INFUSION)

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418 001	Jun 15, 2017
----	--------------------	---------------------	-------------	--------------

+!		5GM/50ML (100MG/ML)	N208418 002	Jun 15, 2017
----	--	---------------------	-------------	--------------

+!		10GM/100ML (100MG/ML)	N208418 003	Jun 15, 2017
----	--	-----------------------	-------------	--------------

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+!	ONY	35MG/ML	N020521 001	Jul 01, 1998
----	-----	---------	-------------	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013
---	----------------	-------	-------------	--------------

+!		300MG	N204042 002	Mar 29, 2013
----	--	-------	-------------	--------------

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG; 500MG	N204353 001	Aug 08, 2014
---	----------------	-------------	-------------	--------------

+		50MG; 1GM	N204353 002	Aug 08, 2014
---	--	-----------	-------------	--------------

+		150MG; 500MG	N204353 003	Aug 08, 2014
---	--	--------------	-------------	--------------

+!		150MG; 1GM	N204353 004	Aug 08, 2014
----	--	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+	!	150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

<u>AB</u>	+	ASTRAZENECA	<u>4MG</u>	<u>N020838</u>	<u>001</u>	Jun 04, 1998
<u>AB</u>	+		<u>8MG</u>	<u>N020838</u>	<u>002</u>	Jun 04, 1998
<u>AB</u>	+		<u>16MG</u>	<u>N020838</u>	<u>003</u>	Jun 04, 1998
<u>AB</u>	+	!	<u>32MG</u>	<u>N020838</u>	<u>004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

<u>AB</u>		ALEMBIC PHARMS LTD	<u>32MG</u>	<u>A209119</u>	<u>001</u>	Jun 20, 2017
<u>AB</u>		APOTEX INC	<u>4MG</u>	<u>A202079</u>	<u>001</u>	Jan 10, 2014
<u>AB</u>			<u>8MG</u>	<u>A202079</u>	<u>002</u>	Jan 10, 2014
<u>AB</u>			<u>16MG</u>	<u>A202079</u>	<u>003</u>	Jan 10, 2014
<u>AB</u>			<u>32MG</u>	<u>A202079</u>	<u>004</u>	Jan 10, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>4MG</u>	<u>A203813</u>	<u>001</u>	Dec 05, 2016
<u>AB</u>			<u>8MG</u>	<u>A203813</u>	<u>002</u>	Dec 05, 2016
<u>AB</u>			<u>16MG</u>	<u>A203813</u>	<u>003</u>	Dec 05, 2016
<u>AB</u>			<u>32MG</u>	<u>A203813</u>	<u>004</u>	Dec 05, 2016
<u>AB</u>		SANDOZ	<u>4MG</u>	<u>A078702</u>	<u>001</u>	May 03, 2013
<u>AB</u>			<u>8MG</u>	<u>A078702</u>	<u>002</u>	May 03, 2013
<u>AB</u>			<u>16MG</u>	<u>A078702</u>	<u>003</u>	May 03, 2013
<u>AB</u>			<u>32MG</u>	<u>A078702</u>	<u>004</u>	May 03, 2013
<u>AB</u>		ZYDUS PHARMS USA INC	<u>4MG</u>	<u>A091390</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>			<u>8MG</u>	<u>A091390</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>			<u>16MG</u>	<u>A091390</u>	<u>003</u>	Aug 23, 2017
<u>AB</u>			<u>32MG</u>	<u>A091390</u>	<u>004</u>	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

<u>AB</u>	+	ASTRAZENECA	<u>16MG;12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>	+		<u>32MG;12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	!	<u>32MG;25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX INC	<u>16MG;12.5MG</u>	<u>A202884</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A202884</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;25MG</u>	<u>A202884</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>		DR REDDYS LABS LTD	<u>16MG;12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>			<u>32MG;25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>16MG;12.5MG</u>	<u>A204100</u>	<u>001</u>	Feb 27, 2015
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A204100</u>	<u>002</u>	Feb 27, 2015
<u>AB</u>			<u>32MG;25MG</u>	<u>A204100</u>	<u>003</u>	Feb 27, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>16MG;12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>			<u>32MG;25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012
<u>AB</u>		ZYDUS PHARMS USA INC	<u>16MG;12.5MG</u>	<u>A203466</u>	<u>001</u>	Nov 27, 2017
<u>AB</u>			<u>32MG;12.5MG</u>	<u>A203466</u>	<u>002</u>	Nov 27, 2017
<u>AB</u>			<u>32MG;25MG</u>	<u>A203466</u>	<u>003</u>	Nov 27, 2017

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015
---	----------------	-----------	---------	-----	--------------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

<u>AB</u>		ACCORD HLTHCARE	<u>150MG</u>	<u>A202593</u>	<u>001</u>	Apr 23, 2015
<u>AB</u>			<u>500MG</u>	<u>A202593</u>	<u>002</u>	Apr 23, 2015
<u>AB</u>		ALKEM LABS LTD	<u>150MG</u>	<u>A207652</u>	<u>001</u>	Nov 24, 2017
<u>AB</u>			<u>500MG</u>	<u>A207652</u>	<u>002</u>	Nov 24, 2017
<u>AB</u>		AMNEAL PHARMS	<u>150MG</u>	<u>A204741</u>	<u>001</u>	Feb 28, 2017
<u>AB</u>			<u>500MG</u>	<u>A204741</u>	<u>002</u>	Feb 28, 2017
<u>AB</u>		MYLAN PHARMS INC	<u>150MG</u>	<u>A090943</u>	<u>001</u>	Aug 08, 2014
<u>AB</u>			<u>500MG</u>	<u>A090943</u>	<u>002</u>	Aug 08, 2014

PRESCRIPTION DRUG PRODUCT LIST

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	SHILPA MEDICARE LTD	<u>150MG</u>	<u>A207456 001</u>	Dec 12, 2016
<u>AB</u>		<u>500MG</u>	<u>A207456 002</u>	Dec 12, 2016
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649 001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649 002</u>	Sep 16, 2013
<u>AB</u>	WEST-WARD PHARMS INT	<u>150MG</u>	<u>A200483 001</u>	Jul 14, 2016
<u>AB</u>		<u>500MG</u>	<u>A200483 002</u>	Jul 14, 2016
<u>XELODA</u>				
<u>AB</u>	+ HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896 001</u>	Apr 30, 1998
<u>AB</u>	+!	<u>500MG</u>	<u>N020896 002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

<u>AP</u>	+! AKORN	<u>EQ 1GM BASE/VIAL</u>	<u>N050095 001</u>	
<u>CAPREOMYCIN SULFATE</u>				
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202634 001</u>	Nov 27, 2017

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+! ACORDA

8%

N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG</u>	<u>A074505 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505 004</u>	Feb 13, 1996
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A074434 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434 003</u>	Feb 13, 1996
<u>AB</u>	!	<u>100MG</u>	<u>A074434 004</u>	Feb 13, 1996
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A074477 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074477 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074477 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074477 004</u>	Feb 13, 1996
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322 004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386 001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386 002</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386 003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386 004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT LTD	<u>12.5MG</u>	<u>A074532 001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532 002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532 003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532 004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	G AND W LABS INC	<u>25MG;15MG</u>	<u>A074827 001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827 002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827 003</u>	Dec 29, 1997
<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896 001</u>	Dec 29, 1997
<u>AB</u>	!	<u>25MG;25MG</u>	<u>A074896 002</u>	Dec 29, 1997
<u>AB</u>	!	<u>50MG;15MG</u>	<u>A074896 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896 003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+! ALCON

0.01%

N016968 001

PRESCRIPTION DRUG PRODUCT LIST

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986 001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986 002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986 003</u>	Nov 25, 2011
<u>AB</u>	MYLAN IRELAND LTD	<u>100MG</u>	<u>A076697 001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697 002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697 003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106 001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106 002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106 003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592 001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592 002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592 003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	+ SHIRE	<u>100MG</u>	<u>N020712 003</u>	Sep 30, 1997
<u>AB</u>	+	<u>200MG</u>	<u>N020712 001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712 002</u>	Sep 30, 1997

EQUETRO

+	VALIDUS PHARMS	100MG	N021710 001	Dec 10, 2004
+		200MG	N021710 002	Dec 10, 2004
+		300MG	N021710 003	Dec 10, 2004

SOLUTION;IV (INFUSION)

CARNEXIV

+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030 001	Oct 07, 2016
---	---------------------	----------------------	-------------	--------------

SUSPENSION;ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT BIO AG	<u>100MG/5ML</u>	<u>A075714 001</u>	Jun 05, 2002
-----------	------------------	------------------	--------------------	--------------

TEGRETOL

<u>AB</u>	+	NOVARTIS	<u>100MG/5ML</u>	<u>N018927 001</u>	Dec 18, 1987
-----------	---	----------	------------------	--------------------	--------------

TERIL

<u>AB</u>	TARO PHARM	<u>100MG/5ML</u>	<u>A076729 001</u>	Sep 20, 2004
-----------	------------	------------------	--------------------	--------------

TABLET;ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948 001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649 001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272 002</u>	Dec 07, 2005

EPITOL

<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541 001</u>	Sep 17, 1986
-----------	------	--------------	--------------------	--------------

TEGRETOL

<u>AB</u>	+	NOVARTIS	<u>200MG</u>	<u>N016608 001</u>
-----------	---	----------	--------------	--------------------

CARBAMAZEPINE

	TORRENT PHARMS	100MG	A077272 001	Dec 07, 2005
		300MG	A077272 003	Dec 07, 2005
		400MG	A077272 004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687 001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712 001</u>	Jul 05, 2001

EPITOL

<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524 001</u>	Jul 29, 1992
-----------	------	--------------	--------------------	--------------

TEGRETOL

<u>AB</u>	+	NOVARTIS	<u>100MG</u>	<u>N018281 001</u>
-----------	---	----------	--------------	--------------------

CARBAMAZEPINE

!	TARO PHARM INDS	200MG	A075687 002	Jul 29, 2002
---	-----------------	-------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115 001</u>	Mar 31, 2009
<u>AB</u>		<u>200MG</u>	<u>A078115 002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115 003</u>	Mar 31, 2009

TEGRETOL-XR

<u>AB</u>	+	NOVARTIS	<u>100MG</u>	<u>N020234 001</u>	Mar 25, 1996
<u>AB</u>	+		<u>200MG</u>	<u>N020234 002</u>	Mar 25, 1996
<u>AB</u>	+		<u>400MG</u>	<u>N020234 003</u>	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

<u>AB</u>	ALVOGEN MALTA	<u>25MG</u>	<u>A204291 001</u>	Jan 08, 2016
<u>AB</u>	AMERIGEN PHARMS LTD	<u>25MG</u>	<u>A203261 001</u>	Mar 10, 2014
<u>AB</u>	EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205304 001</u>	Feb 17, 2016
<u>AB</u>	NOVEL LABS INC	<u>25MG</u>	<u>A204763 001</u>	Oct 20, 2017

PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA

TABLET; ORAL

LODOSYN

AB	+!	ATON	25MG	N017830	001	
-----------	-----------	------	-------------	----------------	------------	--

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012
AB			37.5MG;200MG;150MG	A079085	002	May 10, 2012
AB		WOCKHARDT LTD	12.5MG;200MG;50MG	A090786	001	Nov 20, 2012
AB			18.75MG;200MG;75MG	A090833	001	Nov 20, 2012
AB			25MG;200MG;100MG	A090833	002	Nov 20, 2012
AB			31.25MG;200MG;125MG	A090833	003	Nov 20, 2012
AB			37.5MG;200MG;150MG	A090833	004	Nov 20, 2012
AB			50MG;200MG;200MG	A090833	005	Nov 20, 2012
STALEVO 100						
AB	+	ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003
STALEVO 125						
AB	+	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008
STALEVO 150						
AB	+	ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003
STALEVO 200						
AB	+!	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007
STALEVO 50						
AB	+!	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003
STALEVO 75						
AB	+	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
+		36.25MG;145MG	N203312	002	Jan 07, 2015
+		48.75MG;195MG	N203312	003	Jan 07, 2015
+!		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION; ENTERAL

DUOPA

+!	ABEVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015
-----------	------------	-------------------	---------	-----	--------------

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	10MG;100MG	A074260	001	Sep 03, 1993
AB			25MG;100MG	A074260	002	Sep 03, 1993
AB			25MG;250MG	A074260	003	Sep 03, 1993
AB		APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008
AB			25MG;100MG	A077120	002	Jun 02, 2008
AB			25MG;250MG	A077120	003	Jun 02, 2008
AB		MAYNE PHARMA	10MG;100MG	A073618	001	Aug 28, 1992
AB			25MG;100MG	A073589	001	Aug 28, 1992
AB			25MG;250MG	A073607	001	Aug 28, 1992
AB		MYLAN	10MG;100MG	A090324	001	Sep 28, 2009
AB			25MG;100MG	A090324	002	Sep 28, 2009
AB			25MG;250MG	A090324	003	Sep 28, 2009
AB		SUN PHARM INDS	10MG;100MG	A078536	001	Oct 28, 2008
AB			25MG;100MG	A078536	002	Oct 28, 2008
AB			25MG;250MG	A078536	003	Oct 28, 2008
SINEMET						
AB	+	MERCK SHARP DOHME	10MG;100MG	N017555	001	
AB	+		25MG;100MG	N017555	003	
AB	+!		25MG;250MG	N017555	002	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	25MG;100MG	A202323	001	Feb 08, 2013
AB			50MG;200MG	A202323	002	Feb 08, 2013
AB		APOTEX	25MG;100MG	A076212	001	Jun 16, 2004
AB			50MG;200MG	A076212	002	Jun 16, 2004
AB		IMPAX LABS	25MG;100MG	A076521	001	May 14, 2004
AB			50MG;200MG	A076521	002	May 14, 2004
AB		MYLAN	25MG;100MG	A075091	002	Apr 21, 2000
AB			50MG;200MG	A075091	001	Sep 30, 1999
AB		SUN PHARM INDS	25MG;100MG	A077828	001	Aug 23, 2007
AB			50MG;200MG	A077828	002	Aug 23, 2007

PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

SINEMET CR

AB	+	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992
AB	+	!	50MG;200MG	N019856 001	May 30, 1991

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB		MYLAN	10MG;100MG	A078893 001	Sep 18, 2008
AB			25MG;100MG	A078893 002	Sep 18, 2008
AB		!	25MG;250MG	A078893 003	Sep 18, 2008
AB		SUN PHARMA GLOBAL	10MG;100MG	A078690 001	Jul 31, 2009
AB			25MG;100MG	A078690 002	Jul 31, 2009
AB			25MG;250MG	A078690 003	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

AA		CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010
AA		!	4MG/5ML	A040458 001	Apr 25, 2003
AA		VINTAGE PHARMS	4MG/5ML	A040814 001	Feb 26, 2008

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

+	!	TRIS PHARMA INC	4MG/5ML	N022556 001	Mar 28, 2013
---	---	-----------------	---------	-------------	--------------

TABLET;ORAL

CARBINOXAMINE MALEATE

AA		CYPRESS PHARM	4MG	A090417 001	Aug 23, 2010
AA		INVAGEN PHARMS	4MG	A090435 001	Apr 15, 2010
AA		!	4MG	A040442 001	Mar 19, 2003
AA		MISSION PHARMACAL CO	4MG	A090756 001	May 27, 2011
AA		VINTAGE PHARMS	4MG	A040639 002	May 30, 2008
		MIKART INC	6MG	A207484 001	May 31, 2016

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775 001	Feb 09, 2017
AP			150MG/15ML (10MG/ML)	A206775 002	Feb 09, 2017
AP			450MG/45ML (10MG/ML)	A206775 003	Feb 09, 2017
AP			600MG/60ML (10MG/ML)	A206775 004	Feb 09, 2017
AP		AKORN	50MG/5ML (10MG/ML)	A090475 001	Jul 29, 2009
AP			150MG/15ML (10MG/ML)	A090475 002	Jul 29, 2009
AP			450MG/45ML (10MG/ML)	A090475 003	Jul 29, 2009
AP			600MG/60ML (10MG/ML)	A091268 002	Jul 28, 2010
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007
AP			150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007
AP			450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007
AP			600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007
AP		FRESENIUS KABI ONCOL	50MG/5ML (10MG/ML)	A077432 001	Sep 29, 2006
AP			150MG/15ML (10MG/ML)	A077432 002	Sep 29, 2006
AP			450MG/45ML (10MG/ML)	A077432 003	Sep 29, 2006
AP		FRESENIUS KABI USA	450MG/45ML (10MG/ML)	A077247 003	Oct 21, 2004
AP			450MG/45ML (10MG/ML)	A077266 003	Feb 15, 2006
AP			600MG/60ML (10MG/ML)	A077266 004	Feb 15, 2006
AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324 001	Feb 15, 2017
AP			150MG/15ML (10MG/ML)	A207324 002	Feb 15, 2017
AP			450MG/45ML (10MG/ML)	A207324 003	Feb 15, 2017
AP			600MG/60ML (10MG/ML)	A207324 004	Feb 15, 2017
AP		HOSPIRA	50MG/5ML (10MG/ML)	A076517 001	Oct 14, 2004
AP			150MG/15ML (10MG/ML)	A076517 002	Oct 14, 2004
AP			450MG/45ML (10MG/ML)	A076517 003	Oct 14, 2004
AP			600MG/60ML (10MG/ML)	A077059 001	Nov 23, 2004
AP		INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487 001	Apr 26, 2017
AP			150MG/15ML (10MG/ML)	A208487 002	Apr 26, 2017
AP			450MG/45ML (10MG/ML)	A208487 003	Apr 26, 2017
AP			600MG/60ML (10MG/ML)	A208487 004	Apr 26, 2017
AP		MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998 001	Apr 24, 2007
AP			150MG/15ML (10MG/ML)	A077998 002	Apr 24, 2007
AP			450MG/45ML (10MG/ML)	A077998 003	Apr 24, 2007
AP		MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063 001	Nov 09, 2011
AP			150MG/15ML (10MG/ML)	A091063 002	Nov 09, 2011
AP			450MG/45ML (10MG/ML)	A091063 003	Nov 09, 2011
AP			600MG/60ML (10MG/ML)	A091063 004	Nov 09, 2011

PRESCRIPTION DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>		NANJING KING-FRIEND	<u>50MG/5ML (10MG/ML)</u>	<u>A077096 001</u>	Jun 14, 2005
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077096 002</u>	Jun 14, 2005
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077096 003</u>	Jun 14, 2005
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077096 004</u>	Jun 03, 2013
<u>AP</u>	!	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269 001</u>	Oct 14, 2004
<u>AP</u>	!		<u>150MG/15ML (10MG/ML)</u>	<u>A077269 002</u>	Oct 14, 2004
<u>AP</u>	!		<u>450MG/45ML (10MG/ML)</u>	<u>A077269 003</u>	Oct 14, 2004
<u>AP</u>	!		<u>600MG/60ML (10MG/ML)</u>	<u>A077269 004</u>	Dec 28, 2007
<u>AP</u>		PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631 001</u>	Dec 02, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A078631 002</u>	Dec 02, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A078631 003</u>	Dec 02, 2008
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A078631 004</u>	Dec 02, 2008
<u>AP</u>		SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A078280 001</u>	May 08, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A078280 002</u>	May 08, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A078280 003</u>	May 08, 2008
<u>AP</u>		SANJA PHARMS CO	<u>50MG/5ML (10MG/ML)</u>	<u>A205487 001</u>	Mar 28, 2016
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A205487 002</u>	Mar 28, 2016
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A205487 003</u>	Mar 28, 2016
<u>AP</u>		SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926 001</u>	Sep 19, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077926 002</u>	Sep 19, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077926 003</u>	Sep 19, 2008
<u>AP</u>	!	TEVA PHARMS USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077139 001</u>	Sep 21, 2005
<u>AP</u>	!		<u>150MG/15ML (10MG/ML)</u>	<u>A077139 002</u>	Sep 21, 2005
<u>AP</u>	!		<u>450MG/45ML (10MG/ML)</u>	<u>A077139 003</u>	Sep 21, 2005
<u>AP</u>	!		<u>600MG/60ML (10MG/ML)</u>	<u>A077139 004</u>	Sep 21, 2005
<u>AP</u>		WEST-WARD PHARMS INT	<u>50MG/5ML (10MG/ML)</u>	<u>A077244 001</u>	Oct 15, 2004
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077244 002</u>	Oct 15, 2004
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077244 003</u>	Oct 15, 2004
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077244 004</u>	Jan 20, 2006
	!	MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478 001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+	!	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989 001	
---	---	-------------------------	-------------------	-------------	--

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+		ONYX THERAP	30MG/VIAL	N202714 002	Jun 03, 2016
+	!		60MG/VIAL	N202714 001	Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+	!	ORPHAN EUROPE	200MG	N022562 001	Mar 18, 2010
---	---	---------------	-------	-------------	--------------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

+		FOREST RES INST INC	EQ 1.5MG BASE	N204370 001	Sep 17, 2015
+			EQ 3MG BASE	N204370 002	Sep 17, 2015
+			EQ 4.5MG BASE	N204370 003	Sep 17, 2015
+	!		EQ 6MG BASE	N204370 004	Sep 17, 2015

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>		ACCELRX LABS	<u>350MG</u>	<u>A040576 001</u>	Jun 07, 2005
<u>AA</u>		AUROBINDO PHARMA	<u>350MG</u>	<u>A040792 001</u>	Aug 06, 2009
<u>AA</u>		HIKMA INTL PHARMS	<u>350MG</u>	<u>A040124 001</u>	Jan 24, 1996
<u>AA</u>		INGENUS PHARMS NJ	<u>350MG</u>	<u>A040823 001</u>	Oct 22, 2008
<u>AA</u>		NATCO PHARMA LTD	<u>350MG</u>	<u>A090988 001</u>	Oct 28, 2014
<u>AA</u>		ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085 001</u>	Oct 28, 2014
<u>AA</u>		SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374 001</u>	Jan 27, 2014
<u>AA</u>		STRIDES PHARMA	<u>350MG</u>	<u>A205513 002</u>	Nov 12, 2015
<u>AA</u>		SUN PHARM INDUSTRIES	<u>350MG</u>	<u>A089346 001</u>	Oct 17, 1991
<u>AA</u>		VINTAGE PHARMS	<u>350MG</u>	<u>A040245 001</u>	Sep 08, 1997
<u>AA</u>		WATSON LABS	<u>350MG</u>	<u>A087499 001</u>	Apr 20, 1982

PRESCRIPTION DRUG PRODUCT LIST

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	WILSHIRE PHARMS INC	350MG	A205126 002	Jul 08, 2015
-----------	---------------------	--------------	--------------------	--------------

SOMA

AA	+	MYLAN SPECIALITY LP	350MG	N011792 001
-----------	---	---------------------	--------------	--------------------

CARISOPRODOL

AB	AUROBINDO PHARMA	250MG	A040792 002	Nov 08, 2016
-----------	------------------	--------------	--------------------	--------------

AB	NOSTRUM LABS INC	250MG	A207237 001	May 11, 2017
-----------	------------------	--------------	--------------------	--------------

AB	STRIDES PHARMA	250MG	A205513 001	Nov 12, 2015
-----------	----------------	--------------	--------------------	--------------

AB	WILSHIRE PHARMS INC	250MG	A205126 001	Jul 08, 2015
-----------	---------------------	--------------	--------------------	--------------

SOMA

AB	+	MYLAN SPECIALITY LP	250MG	N011792 004	Sep 13, 2007
-----------	---	---------------------	--------------	--------------------	--------------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637 001	Sep 23, 1996
---	------------------	-------	-------------	--------------

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422 001	
---	-------------------	------------	-------------	--

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

AT	BAUSCH AND LOMB	1%	A075546 001	Jan 20, 2000
-----------	-----------------	-----------	--------------------	--------------

AT	!	SANDOZ INC	1%	A075476 001	Jan 03, 2000
-----------	---	------------	-----------	--------------------	--------------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB	APOTEX INC	3.125MG	A078165 001	Sep 05, 2007
-----------	------------	----------------	--------------------	--------------

AB		6.25MG	A078165 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078165 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078165 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	AUROBINDO PHARMA	3.125MG	A078332 001	Sep 05, 2007
-----------	------------------	----------------	--------------------	--------------

AB		6.25MG	A078332 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078332 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078332 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	BEXIMCO USA	3.125MG	A078384 001	Sep 05, 2007
-----------	-------------	----------------	--------------------	--------------

AB		6.25MG	A078384 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078384 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078384 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	CIPLA LTD	3.125MG	A077474 001	Sep 05, 2007
-----------	-----------	----------------	--------------------	--------------

AB		6.25MG	A077474 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A077474 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A077474 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	DR REDDYS LABS LTD	3.125MG	A076649 001	Sep 05, 2007
-----------	--------------------	----------------	--------------------	--------------

AB		6.25MG	A076649 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A076649 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A076649 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	GLENMARK GENERICS	3.125MG	A078251 001	Sep 05, 2007
-----------	-------------------	----------------	--------------------	--------------

AB		6.25MG	A078251 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078251 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078251 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	LUPIN	3.125MG	A078217 001	Sep 05, 2007
-----------	-------	----------------	--------------------	--------------

AB		6.25MG	A078217 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078217 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078217 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	MYLAN	3.125MG	A077316 001	Sep 05, 2007
-----------	-------	----------------	--------------------	--------------

AB		6.25MG	A077316 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A077316 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A077316 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	SANDOZ	3.125MG	A078227 001	Sep 05, 2007
-----------	--------	----------------	--------------------	--------------

AB		6.25MG	A078227 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A078227 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A078227 004	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	SUN PHARM INDS INC	3.125MG	A077346 004	Sep 05, 2007
-----------	--------------------	----------------	--------------------	--------------

AB		6.25MG	A077346 001	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A077346 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		25MG	A077346 003	Sep 05, 2007
-----------	--	-------------	--------------------	--------------

AB	SUN PHARM INDS LTD	3.125MG	A076989 001	Sep 05, 2007
-----------	--------------------	----------------	--------------------	--------------

AB		6.25MG	A076989 002	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

AB		12.5MG	A076989 003	Sep 05, 2007
-----------	--	---------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007
	<u>COREG</u>			
<u>AB</u>	+ SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>	+	<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+!	<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>	+	<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

CARVEDILOL PHOSPHATE

<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A090132 001</u>	Oct 25, 2017
<u>AB</u>		<u>20MG</u>	<u>A090132 002</u>	Oct 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A090132 003</u>	Oct 25, 2017
<u>AB</u>		<u>80MG</u>	<u>A090132 004</u>	Oct 25, 2017
	<u>COREG CR</u>			
<u>AB</u>	+ SMITHKLINE BEECHAM	<u>10MG</u>	<u>N022012 001</u>	Oct 20, 2006
<u>AB</u>	+	<u>20MG</u>	<u>N022012 002</u>	Oct 20, 2006
<u>AB</u>	+!	<u>40MG</u>	<u>N022012 003</u>	Oct 20, 2006
<u>AB</u>	+	<u>80MG</u>	<u>N022012 004</u>	Oct 20, 2006

CASPOFUNGIN ACETATE

POWDER; IV (INFUSION)

CANCIDAS

<u>AP</u>	+! MERCK	<u>50MG/VIAL</u>	<u>N021227 001</u>	Jan 26, 2001
<u>AP</u>	+!	<u>70MG/VIAL</u>	<u>N021227 002</u>	Jan 26, 2001

CASPOFUNGIN ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N206110 001</u>	Dec 30, 2016
<u>AP</u>		<u>70MG/VIAL</u>	<u>N206110 002</u>	Dec 30, 2016
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/VIAL</u>	<u>A207092 001</u>	Sep 29, 2017
<u>AP</u>		<u>70MG/VIAL</u>	<u>A207092 002</u>	Sep 29, 2017
<u>AP</u>	MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A207650 001</u>	Sep 29, 2017
<u>AP</u>		<u>70MG/VIAL</u>	<u>A207650 002</u>	Sep 29, 2017

CEFACTOR

CAPSULE; ORAL

CEFACTOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350 001</u>	Apr 03, 2007
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A065350 002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146 001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146 002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACTOR

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012
		EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012
	!	EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACTOR

	TEVA	EQ 375MG BASE	A065058 001	Sep 04, 2002
	!	EQ 500MG BASE	A065058 002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352 001</u>	Jan 25, 2007
<u>AB</u>	CSPC OUYI PHARM CO	<u>EQ 500MG BASE</u>	<u>A205072 001</u>	Jul 28, 2017
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311 001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392 001</u>	May 29, 2007

PRESCRIPTION DRUG PRODUCT LIST

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB	ORCHID HLTHCARE	EQ 500MG BASE	A065309 001	Sep 18, 2006
AB	! TEVA PHARMS	EQ 500MG BASE	A065282 001	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349 001	Apr 25, 2013
AB		EQ 500MG BASE/5ML	A065349 002	Apr 25, 2013
AB	HIKMA PHARMS	EQ 250MG BASE/5ML	A091036 001	Nov 28, 2012
AB		EQ 500MG BASE/5ML	A091036 002	Nov 28, 2012
AB	LUPIN	EQ 250MG BASE/5ML	A065396 001	Feb 21, 2008
AB	!	EQ 500MG BASE/5ML	A065396 002	Feb 21, 2008
AB	ORCHID HLTHCARE	EQ 250MG BASE/5ML	A065307 002	Oct 16, 2006
AB		EQ 500MG BASE/5ML	A065307 003	Oct 16, 2006

TABLET;ORAL

CEFADROXIL

AB	HIKMA	EQ 1GM BASE	A065260 001	Mar 30, 2006
AB	ORCHID HLTHCARE	EQ 1GM BASE	A065301 001	Sep 18, 2006
	! TEVA PHARMS	EQ 1GM BASE	A062774 001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP	ACS DOBFAR	EQ 500MG BASE/VIAL	A065303 001	Oct 22, 2008
AP		EQ 1GM BASE/VIAL	A065303 002	Oct 22, 2008
AP		EQ 10GM BASE/VIAL	A065306 001	Oct 22, 2008
AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A065047 001	Sep 18, 2001
AP		EQ 1GM BASE/VIAL	A065047 002	Sep 18, 2001
AP		EQ 10GM BASE/VIAL	A065143 001	Oct 18, 2004
AP	! HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005
AP	!	EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005
AP	!	EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005
AP		EQ 1GM BASE/VIAL	A201654 001	Feb 03, 2016
AP	!	EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005
AP	QILU PHARM CO LTD	EQ 1GM BASE/VIAL	A203661 001	Dec 28, 2015
AP	SANDOZ	EQ 500MG BASE/VIAL	A062831 001	Dec 09, 1988
AP		EQ 1GM BASE/VIAL	A062831 002	Dec 09, 1988
AP		EQ 1GM BASE/VIAL	A065345 001	May 09, 2007
AP		EQ 10GM BASE/VIAL	A062831 003	Sep 25, 1992

KEFZOL

AP	ACS DOBFAR	EQ 500MG BASE/VIAL	A061773 002	
AP		EQ 1GM BASE/VIAL	A061773 003	
AP		EQ 10GM BASE/VIAL	A061773 004	

ANCEF IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
!		EQ 20MG BASE/ML	A063002 002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+	! B BRAUN	EQ 1GM BASE/VIAL	N050779 002	Jul 27, 2000
+		EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012

CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306 002	Aug 18, 2014
!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141 001	Nov 29, 2006
!		EQ 300GM BASE/VIAL	A065141 002	Nov 29, 2006

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131 001	Aug 07, 2015
	CORP			

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB	AUROBINDO PHARMA	300MG	A065434 001	Jan 07, 2008
AB	LUPIN	300MG	A065264 001	May 19, 2006
AB	ORCHID HLTHCARE	300MG	A065418 001	Jul 18, 2007
AB	!	300MG	A065330 001	Apr 06, 2007
AB	TEVA PHARMS	300MG	A065368 001	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB	AUROBINDO PHARMA	125MG/5ML	A065473 001	Dec 14, 2007
AB		250MG/5ML	A065473 002	Dec 14, 2007
AB	LUPIN	125MG/5ML	A065259 001	May 31, 2006
AB		250MG/5ML	A065259 002	May 07, 2007
AB	ORCHID HLTHCARE	125MG/5ML	A065429 001	Jul 18, 2007

PRESCRIPTION DRUG PRODUCT LIST

CEFDINIR

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>		<u>250MG/5ML</u>	<u>A065429 002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337 001</u>	Apr 06, 2007
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065337 002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332 001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332 002</u>	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441 001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441 002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065369 001</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065369 002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268 001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369 003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268 002</u>	Jul 30, 2012
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A203704 001</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203704 002</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203704 003</u>	Feb 01, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091048 001</u>	Jan 04, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091048 002</u>	Jan 04, 2017

MAXIPIME

<u>AP</u>	+!	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679 001</u>	Jan 18, 1996
<u>AP</u>	+!		<u>EQ 1GM BASE/VIAL</u>	<u>N050679 002</u>	Jan 18, 1996
<u>AP</u>	+!		<u>EQ 2GM BASE/VIAL</u>	<u>N050679 003</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

EQ 1GM BASE/VIAL

N050821 001 May 06, 2010

EQ 2GM BASE/VIAL

N050821 002 May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 1GM BASE/50ML (EQ 20MG BASE/ML)

N050817 001 Aug 05, 2008

+!

EQ 2GM BASE/100ML (EQ 20MG BASE/ML)

N050817 002 Aug 05, 2008

CEFIXIME

CAPSULE; ORAL

SUPRAX

+! LUPIN LTD

400MG

N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

CEFIXIME

<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG/5ML</u>	<u>A204835 001</u>	Apr 14, 2015
<u>AB</u>		<u>200MG/5ML</u>	<u>A204835 002</u>	Apr 14, 2015
<u>AB</u>	BELCHER PHARMS LLC	<u>100MG/5ML</u>	<u>A206938 001</u>	Feb 06, 2017
<u>AB</u>		<u>200MG/5ML</u>	<u>A206938 002</u>	Feb 06, 2017
<u>AB</u>		<u>500MG/5ML</u>	<u>A206939 001</u>	Feb 06, 2017
<u>AB</u>	SANDOZ INC	<u>100MG/5ML</u>	<u>A206144 001</u>	Nov 17, 2017
<u>AB</u>		<u>200MG/5ML</u>	<u>A206144 002</u>	Nov 17, 2017

SUPRAX

<u>AB</u>	+!	LUPIN LTD	<u>500MG/5ML</u>	<u>N202091 001</u>	Feb 20, 2013
<u>AB</u>		LUPIN PHARMS	<u>100MG/5ML</u>	<u>A065129 001</u>	Feb 23, 2004
<u>AB</u>			<u>200MG/5ML</u>	<u>A065355 001</u>	Apr 10, 2007

TABLET; ORAL

SUPRAX

! LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

!

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065072 001</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065072 002</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065072 003</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065071 001</u>	Nov 20, 2002
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065197 001</u>	Aug 29, 2006

CEFOTAXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065290 001</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065290 002</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065293 001</u>	Aug 10, 2006

PRESCRIPTION DRUG PRODUCT LIST

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203132 001</u>	Feb 19, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065290 003</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065293 002</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203132 002</u>	Feb 19, 2016
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065292 001</u>	Aug 10, 2006
<u>AP</u>	LUPIN	<u>EQ 500MG BASE/VIAL</u>	<u>A065124 001</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065124 002</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065124 003</u>	Sep 24, 2003
<u>AP</u>	WOCKHARDT	<u>EQ 500MG BASE/VIAL</u>	<u>A065197 002</u>	Jun 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065197 003</u>	Jun 20, 2008
<u>CLAFORAN</u>				
<u>AP</u>	+!	US PHARM HOLDINGS	<u>EQ 500MG BASE/VIAL</u>	<u>N050547 001</u>
<u>AP</u>	+!		<u>EQ 1GM BASE/VIAL</u>	<u>N050547 002</u>
<u>AP</u>	+!		<u>EQ 2GM BASE/VIAL</u>	<u>N050547 003</u>
<u>AP</u>	+!		<u>EQ 10GM BASE/VIAL</u>	<u>N050547 004</u> Dec 29, 1983

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

<u>AP</u>	+	TELGENT	<u>EQ 1GM BASE/VIAL</u>	<u>N050588 001</u> Dec 27, 1985
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050588 002</u> Dec 27, 1985

CEFOTETAN

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374 001</u> Aug 09, 2007
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065374 002</u> Aug 09, 2007
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A065375 001</u> Aug 09, 2007
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A091031 001</u> Oct 26, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091031 002</u> Oct 26, 2011
<u>AP</u>		WEST-WARD PHARM CORP	<u>EQ 10GM BASE/VIAL</u>	<u>A091030 001</u> Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

	+!	B BRAUN	EQ 1GM BASE/VIAL	N065430 001 Aug 09, 2007
	+!		EQ 2GM BASE/VIAL	N065430 002 Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	!	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414 001</u> Jun 12, 2009
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065414 002</u> Jun 12, 2009
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A065415 001</u> May 19, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238 001</u> Mar 12, 2010
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065238 002</u> Mar 12, 2010
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065239 001</u> Mar 02, 2010
<u>AP</u>		HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313 001</u> Jan 23, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065313 002</u> Jan 23, 2006
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065312 001</u> Feb 13, 2006
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 1GM BASE/VIAL</u>	<u>A065051 001</u> Sep 11, 2000
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065051 002</u> Sep 11, 2000
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065050 001</u> Sep 11, 2000
<u>CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER</u>				
<u>AP</u>	+!	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N065214 001</u> Mar 10, 2006
<u>AP</u>	+!		<u>EQ 2GM BASE/VIAL</u>	<u>N065214 002</u> Mar 10, 2006

MEFOXIN IN PLASTIC CONTAINER

	!	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001 Jan 25, 1993
	!		EQ 40MG BASE/ML	A063182 002 Jan 25, 1993

POWDER; IV (INFUSION)

CEFOXITIN IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A200938 001 Nov 16, 2015
--	--	--------------	---------------	--------------------------

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409 001</u> Jun 08, 2007
<u>AB</u>			<u>EQ 100MG BASE/5ML</u>	<u>A065409 002</u> Jun 08, 2007
<u>AB</u>		SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031 001</u> Jan 14, 2009
<u>AB</u>	!		<u>EQ 100MG BASE/5ML</u>	<u>A090031 002</u> Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370 001</u> Jun 11, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065370 002</u> Jun 11, 2007

PRESCRIPTION DRUG PRODUCT LIST

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388 001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388 002</u>	Nov 14, 2007
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462 001</u>	May 28, 2008
<u>AB</u>	!	<u>EQ 200MG BASE</u>	<u>A065462 002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351 001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351 002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381 001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381 002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261 001</u>	Dec 19, 2005
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065261 002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284 002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284 001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257 001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257 002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236 001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236 002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327 001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327 002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340 001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340 002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276 001</u>	Dec 08, 2005
<u>AB</u>	!	<u>500MG</u>	<u>A065276 002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267 001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267 002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235 001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235 002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208 001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208 002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428 001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428 002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

+	CEREXA	400MG/VIAL	N200327 001	Oct 29, 2010
+	!	600MG/VIAL	N200327 002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640 001</u>	Nov 20, 1985
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062640 002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640 003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640 004</u>	Feb 03, 1992
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196 001</u>	Oct 15, 2008

FORTAZ

<u>AP</u>	+	!	TELIGENT	<u>500MG/VIAL</u>	<u>N050578 001</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>1GM/VIAL</u>	<u>N050578 002</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>2GM/VIAL</u>	<u>N050578 003</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>6GM/VIAL</u>	<u>N050578 004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662 001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662 002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032 001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662 003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032 002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662 004</u>	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

+	B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011
+	!	EQ 2GM BASE	N050823 002	Jun 13, 2011

PRESCRIPTION DRUG PRODUCT LIST

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+	!	TELIGENT	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+	!		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)

ZERBAXA

+	!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014
---	---	-------------------	-------------------------------------	---------	-----	--------------

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>		ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		BEDFORD	<u>EQ 10GM BASE/VIAL</u>	<u>A065475</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>		HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065232</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		LUPIN	<u>EQ 10GM BASE/VIAL</u>	<u>A065263</u>	<u>001</u>	Sep 12, 2006
<u>AP</u>	!	SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	!	SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>		WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLIX CONTAINER

<u>AP</u>	+	!	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	+	!		<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

CEFTRIAXONE SODIUM

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 10GM BASE/VIAL</u>	<u>A090701</u>	<u>001</u>	Oct 04, 2017
<u>AP</u>		SAGENT PHARMS	<u>EQ 10GM BASE/VIAL</u>	<u>A091117</u>	<u>001</u>	Jan 20, 2017
		CEFTRIAXONE				
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014
		CEFTRIAXONE IN PLASTIC CONTAINER				
	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>		AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065342</u>	<u>002</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065342</u>	<u>003</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065342</u>	<u>004</u>	Jan 10, 2008
<u>AP</u>		HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065230</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065230</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065230</u>	<u>003</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065230</u>	<u>004</u>	Aug 02, 2005
<u>AP</u>		LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125</u>	<u>001</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065125</u>	<u>002</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065125</u>	<u>003</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065125</u>	<u>004</u>	Sep 30, 2003
<u>AP</u>		QILU PHARM CO LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A203702</u>	<u>001</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A203702</u>	<u>002</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A203702</u>	<u>003</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A203702</u>	<u>004</u>	Jun 29, 2016
<u>AP</u>	!	SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169</u>	<u>001</u>	May 09, 2005
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A065169</u>	<u>002</u>	May 09, 2005
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A065169</u>	<u>003</u>	May 09, 2005
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065169</u>	<u>004</u>	May 09, 2005
<u>AP</u>		WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065391</u>	<u>002</u>	Apr 12, 2007
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065391</u>	<u>003</u>	Apr 12, 2007

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

+		GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+	!		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

CEFUROXIME AXETIL

TABLET; ORAL

CEFTIN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605 001</u>	Dec 28, 1987
<u>AB</u>	+		<u>EQ 250MG BASE</u>	<u>N050605 002</u>	Dec 28, 1987
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N050605 003</u>	Dec 28, 1987

CEFUROXIME AXETIL

<u>AB</u>		ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496 001</u>	Jun 07, 2010
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065496 002</u>	Jun 07, 2010
<u>AB</u>		ANI PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065190 001</u>	Oct 18, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065190 002</u>	Oct 18, 2004
<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A065069 001</u>	Oct 02, 2002
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065069 002</u>	Oct 02, 2002
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308 001</u>	Mar 29, 2006
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065308 002</u>	Mar 29, 2006
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065308 003</u>	Mar 29, 2006
<u>AB</u>		LUPIN	<u>EQ 250MG BASE</u>	<u>A065135 001</u>	Jul 25, 2003
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065135 002</u>	Jul 25, 2003
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359 001</u>	Feb 15, 2008
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065359 002</u>	Feb 15, 2008
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065359 003</u>	Feb 15, 2008
<u>AB</u>		WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166 001</u>	Jul 29, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065166 002</u>	Jul 29, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065166 003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>		ACS DOBFAR SPA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004
<u>AP</u>		HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483 002</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503 001</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484 001</u>	Oct 15, 2008

ZINACEF

<u>AP</u>	+	TELIGENT	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
<u>AP</u>	+		<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

	+	TELIGENT	<u>EQ 30MG BASE/ML</u>	<u>N050643 002</u>	Apr 28, 1989
--	---	----------	------------------------	--------------------	--------------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>		ACS DOBFAR SPA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997
<u>AB</u>		HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004

ZINACEF

<u>AB</u>	+	TELIGENT	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983
-----------	---	----------	---------------------------	--------------------	--------------

CEFUROXIME SODIUM

<u>AP</u>		HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483 001</u>	Oct 15, 2008
-----------	--	-------------	---------------------------	--------------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>	+	GD SEARLE	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
<u>AB</u>	+		<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
<u>AB</u>	+		<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
<u>AB</u>	+		<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>		ALEMBIC PHARMS LTD	<u>50MG</u>	<u>A204519 001</u>	Aug 21, 2015
<u>AB</u>			<u>100MG</u>	<u>A204519 002</u>	Aug 21, 2015
<u>AB</u>			<u>200MG</u>	<u>A204519 003</u>	Aug 21, 2015
<u>AB</u>			<u>400MG</u>	<u>A204519 004</u>	Aug 21, 2015
<u>AB</u>		APOTEX INC	<u>50MG</u>	<u>A204197 001</u>	Jun 02, 2015
<u>AB</u>			<u>100MG</u>	<u>A204197 002</u>	Jun 02, 2015
<u>AB</u>			<u>200MG</u>	<u>A204197 003</u>	Jun 02, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206827 001</u>	Feb 01, 2016
<u>AB</u>			<u>100MG</u>	<u>A206827 002</u>	Feb 01, 2016
<u>AB</u>			<u>200MG</u>	<u>A206827 003</u>	Feb 01, 2016
<u>AB</u>			<u>400MG</u>	<u>A206827 004</u>	Feb 01, 2016
<u>AB</u>		CIPLA LTD	<u>50MG</u>	<u>A207446 001</u>	Sep 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

CELECOXIB

CAPSULE;ORAL

CELECOXIB

<u>AB</u>		<u>100MG</u>	<u>A207446 002</u>	Sep 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207446 003</u>	Sep 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207446 004</u>	Sep 23, 2015
<u>AB</u>	JUBILANT GENERICS	<u>50MG</u>	<u>A207061 001</u>	Apr 04, 2017
<u>AB</u>		<u>100MG</u>	<u>A207061 002</u>	Apr 04, 2017
<u>AB</u>		<u>200MG</u>	<u>A207061 003</u>	Apr 04, 2017
<u>AB</u>		<u>400MG</u>	<u>A207061 004</u>	Apr 04, 2017
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240 001</u>	Oct 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202240 002</u>	Jun 09, 2015
<u>AB</u>		<u>200MG</u>	<u>A202240 003</u>	Jun 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A202240 004</u>	Jun 09, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A204590 001</u>	Mar 16, 2016
<u>AB</u>		<u>100MG</u>	<u>A204590 002</u>	Mar 16, 2016
<u>AB</u>		<u>200MG</u>	<u>A204590 003</u>	Mar 16, 2016
<u>AB</u>		<u>400MG</u>	<u>A204590 004</u>	Mar 16, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A078857 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A078857 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A078857 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A078857 004</u>	Feb 11, 2015
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898 002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898 003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898 004</u>	May 30, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A207677 001</u>	Dec 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207677 002</u>	Dec 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207677 003</u>	Dec 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207677 004</u>	Dec 23, 2015
<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562 001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562 004</u>	Feb 11, 2015

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836 001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836 002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836 004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253 001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253 002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713 001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713 002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215 001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215 002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229 001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229 002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248 001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248 002</u>	Jun 28, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791 001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791 002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702 001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152 001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152 002</u>	Feb 24, 2005
<u>KEFLEX</u>				
<u>AB</u>	+ PRAGMA PHARMS LLC	<u>EQ 250MG BASE</u>	<u>N050405 002</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050405 003</u>	
<u>AB</u>	+!	<u>EQ 750MG BASE</u>	<u>N050405 005</u>	May 12, 2006

CEPHALEXIN

ALKEM LABS LTD

FOR SUSPENSION;ORAL

CEPHALEXIN

<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234 001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234 002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326 001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326 002</u>	Jul 10, 2006
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703 001</u>	Feb 13, 1987
<u>AB</u>	!	<u>EQ 250MG BASE/5ML</u>	<u>A062703 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336 001</u>	Jul 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB		<u>EQ 250MG BASE/5ML</u>	<u>A065336 002</u>	Jul 25, 2007
	TABLET; ORAL			
	CEPHALEXIN			
	TEVA	EQ 250MG BASE	A063023 001	Jan 12, 1989
	!	EQ 500MG BASE	A063024 001	Jan 12, 1989

CERITINIB

CAPSULE; ORAL

ZYKADIA

+	!	NOVARTIS PHARMS CORP	150MG	N205755 001	Apr 29, 2014
---	---	-------------------------	-------	-------------	--------------

CETIRIZINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ZERVIAE

+	!	EYEVANCE PHARMS	EQ 0.24% BASE	N208694 001	May 30, 2017
---	---	-----------------	---------------	-------------	--------------

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA		ALLIED PHARMA INC	<u>5MG/5ML</u>	<u>A090191 001</u>	Nov 12, 2009
AA		AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766 001</u>	Oct 07, 2009
AA		BIO PHARM INC	<u>5MG/5ML</u>	<u>A078870 001</u>	Apr 27, 2009
AA		BRECKENRIDGE PHARM	<u>5MG/5ML</u>	<u>A078488 001</u>	Oct 06, 2008
AA	!	PERRIGO R AND D	<u>5MG/5ML</u>	<u>A078398 001</u>	Jun 17, 2008
AA		SILARX	<u>5MG/5ML</u>	<u>A078876 001</u>	May 11, 2012
AA		TARO	<u>5MG/5ML</u>	<u>A076601 001</u>	Jun 20, 2008
AA		TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279 001</u>	May 27, 2008
AA		VINTAGE	<u>5MG/5ML</u>	<u>A078496 001</u>	Sep 25, 2009

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+	!	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000
---	---	----------------	-------------------	-------------	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB		APOTEX INC	<u>30MG</u>	<u>A091260 001</u>	Aug 25, 2011
AB		NOVEL LABS INC	<u>30MG</u>	<u>A204746 001</u>	Dec 30, 2016
AB		RISING PHARMS INC	<u>30MG</u>	<u>A203775 001</u>	Jun 04, 2014
AB		WEST-WARD PHARMS INT	<u>30MG</u>	<u>A091591 001</u>	Jul 08, 2013

EVOXAC

AB	+	!	DAIICHI SANKYO INC	<u>30MG</u>	<u>N020989 002</u>	Jan 11, 2000
-----------	---	---	--------------------	--------------------	---------------------------	--------------

CHENODIOL

TABLET; ORAL

CHENODIOL

!		NEXGEN PHARMA	250MG	A091019 001	Oct 22, 2009
---	--	---------------	-------	-------------	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	!	ASPEN GLOBAL INC	2MG	N010669 002	
---	---	------------------	-----	-------------	--

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

!		FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982
---	--	--------------------	------------------	-------------	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	<u>5MG</u>	<u>A084768 001</u>	
AB			<u>10MG</u>	<u>A083116 001</u>	
AB			<u>25MG</u>	<u>A084769 001</u>	

LIBRIUM

AB		VALEANT PHARM INTL	<u>5MG</u>	<u>A085461 001</u>	
AB			<u>10MG</u>	<u>A085472 001</u>	
AB	!		<u>25MG</u>	<u>A085475 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

LIBRAX

+! VALEANT PHARMS 5MG; 2.5MG N012750 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	0.12%	A074356 001	May 07, 1996
AT	LYNE	0.12%	A074291 001	Dec 28, 1995
AT	TEVA	0.12%	A074522 001	Dec 15, 1995
AT	WOCKHARDT BIO AG	0.12%	A075006 001	Mar 03, 2004
AT	XTTRIUM	0.12%	A077789 001	Jun 18, 2009

PAROEX

AT	SUNSTAR AMERICAS	0.12%	A076434 001	Nov 29, 2005
-----------	------------------	--------------	--------------------	--------------

PERIDEX

AT	+! 3M	0.12%	N019028 001	Aug 13, 1986
-----------	-------	--------------	--------------------	--------------

PERIOGARD

AT	COLGATE PALMOLIVE CO	0.12%	A073695 001	Jan 14, 1994
AT	COLGATE-PALMOLIVE CO	0.12%	A203212 001	Jan 28, 2016

TABLET; DENTAL

PERIOCHIP

+! DEXCEL PHARMA 2.5MG N020774 001 May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP	HOSPIRA	2%	A087447 001	Apr 16, 1982
AP		3%	A087446 001	Apr 16, 1982
AP	WEST-WARD PHARMS INT	2%	A040273 001	Sep 09, 1998
AP		3%	A040273 002	Sep 09, 1998

NESACAINE

AP	+ FRESENIUS KABI USA	2%	N009435 002	
-----------	----------------------	-----------	--------------------	--

NESACAINE-MPF

AP	+! FRESENIUS KABI USA	2%	N009435 006	May 02, 1996
AP	+!	3%	N009435 007	May 02, 1996

NESACAINE

+! FRESENIUS KABI USA 1% N009435 001

SOLUTION; INTRATHECAL

CLOROTEKAL

+ B BRAUN MEDICAL INC 50MG/5ML (10MG/ML) N208791 001 Sep 26, 2017

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	! HIKMA PHARMS	EQ 150MG BASE	A083082 001	
AA		EQ 300MG BASE	A083082 002	Sep 17, 1999
AA	IPCA LABS LTD	EQ 150MG BASE	A090610 001	Dec 03, 2009
AA		EQ 300MG BASE	A090249 001	Dec 03, 2009
AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011
AA	!	EQ 300MG BASE	A090612 001	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+! SALIX PHARMS 250MG/5ML N011870 001

TABLET; ORAL

CHLOROTHIAZIDE

! MYLAN 250MG A084217 002
500MG A084217 001CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090896 001	Oct 16, 2009
AP	LUITPOLD	EQ 500MG BASE/VIAL	A202561 001	Apr 22, 2013
AP	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	A202493 001	Jun 18, 2014
AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462 001	May 29, 2015
AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011

DIURIL

AP	+! OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145 005	
-----------	---------------------	---------------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	ACELLA PHARMS LLC	4MG/5ML;5MG/5ML	A206891 001	Jun 09, 2017
-----------	-------------------	------------------------	--------------------	--------------

VITUZ

AA	+! CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013
-----------	------------------	------------------------	--------------------	--------------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	BIO-PHARM INC	4MG/5ML;5MG/5ML;60MG/5ML	A206660 001	May 15, 2017
-----------	---------------	---------------------------------	--------------------	--------------

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	4MG/5ML;5MG/5ML;60MG/5ML	A204627 001	Apr 29, 2014
-----------	-------------	---------------------------------	--------------------	--------------

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657 001	Aug 03, 2015
-----------	------------------	---------------------------------	--------------------	--------------

ZUTRIPRO

AA	+! CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011
-----------	------------------	---------------------------------	--------------------	--------------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

+!	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768 001	Apr 30, 2015
----	----------------------	--------------------------------------	-------------	--------------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007
--	------------	----------------------------------	-------------	--------------

!		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007
---	--	-----------------------------------	-------------	--------------

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	TRIS PHARMA INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091632 001	Oct 01, 2010
-----------	-----------------	--	--------------------	--------------

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	NEOS THERAP INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012
-----------	-----------------	--	--------------------	--------------

TUSSIONEX PENNKINETIC

AB	+! UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N019111 001	Dec 31, 1987
-----------	------------	--	--------------------	--------------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

!	WEST-WARD PHARMS INT	25MG/ML	A083329 001	
---	----------------------	---------	-------------	--

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	USL PHARMA	10MG	A083386 001	
!		25MG	A084112 001	
		50MG	A084113 001	
!		100MG	A084114 001	
		200MG	A084115 001	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

AB	ANI PHARMS INC	100MG	A088921 001	Apr 12, 1985
-----------	----------------	--------------	--------------------	--------------

AB		250MG	A088922 001	Apr 12, 1985
-----------	--	--------------	--------------------	--------------

AB	MYLAN	100MG	A088549 002	Jun 01, 1984
-----------	-------	--------------	--------------------	--------------

AB		250MG	A088549 001	Jun 01, 1984
-----------	--	--------------	--------------------	--------------

DIABINESE

AB	+ PFIZER	100MG	N011641 003	
-----------	----------	--------------	--------------------	--

AB	+!	250MG	N011641 006	
-----------	----	--------------	--------------------	--

GLUCAMIDE

AB	ANI PHARMS INC	250MG	A088641 001	Oct 11, 1984
-----------	----------------	--------------	--------------------	--------------

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	MYLAN	25MG	A086831 002	
-----------	-------	-------------	--------------------	--

AB	!	50MG	A086831 001	
-----------	---	-------------	--------------------	--

AB	RICONPHARMA LLC	25MG	A206904 001	Mar 30, 2017
-----------	-----------------	-------------	--------------------	--------------

AB		50MG	A206904 002	Mar 30, 2017
-----------	--	-------------	--------------------	--------------

AB	SUN PHARM INDUSTRIES	25MG	A089286 002	Jul 21, 1986
-----------	----------------------	-------------	--------------------	--------------

AB		50MG	A089286 001	Jul 21, 1986
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CHLORZOXAZONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN	15MG; 0.1MG	A071325 003	Feb 09, 1987
	15MG; 0.2MG	A071325 002	Feb 09, 1987
!	15MG; 0.3MG	A071325 001	Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	BARR	500MG	A089895 001	May 04, 1988	
AA	!	WATSON LABS	500MG	A089859 001	May 04, 1988
		MIKART	375MG	A040861 001	Jun 01, 2010
	!		750MG	A040861 002	Jun 01, 2010
	!	MIKART INC	250MG	A207483 001	Jun 24, 2016

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	PAR PHARM	EQ 4GM RESIN/PACKET	A077204 001	Aug 26, 2005	
AB		EQ 4GM RESIN/SCOOPFUL	A077204 002	Aug 26, 2005	
AB	!	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A074557 002	Aug 15, 1996	

CHOLESTYRAMINE LIGHT

AB	PAR PHARM	EQ 4GM RESIN/PACKET	A077203 001	Aug 26, 2005	
AB		EQ 4GM RESIN/SCOOPFUL	A077203 002	Aug 26, 2005	
AB	!	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A074558 002	Aug 15, 1996	
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL	A202902 001	Apr 25, 2017	

PREVALITE

AB	UPSHER-SMITH LABS	EQ 4GM RESIN/PACKET	A073263 001	Feb 22, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A073263 002	Oct 30, 1997

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

+	RTRX	50MG	N205750 001	Mar 17, 2015
+	!	250MG	N205750 002	Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

AP	GLOBAL ISOTOPES LLC	4-33.1mCi/ML	A206319 001	Nov 13, 2015	
AP	+	MCPRF	4-33.1mCi/ML	N203155 001	Sep 12, 2012
AP	UCSF RODIOPHARM	4-33.1mCi/ML	A208444 001	Nov 20, 2017	
AP	WA UNIV SCH MED	4-33.1mCi/ML	A208413 001	Jan 10, 2017	
	UNIV TX MD ANDERSON	4-100mCi/ML	A205690 001	Oct 29, 2015	

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	ACTAVIS ELIZABETH	EQ 45MG FENOFIBRIC ACID	A200920 001	Oct 07, 2015
AB		EQ 135MG FENOFIBRIC ACID	A200920 002	Oct 07, 2015
AB	ALEMIC PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A208705 001	May 12, 2017
AB		EQ 135MG FENOFIBRIC ACID	A208705 002	May 12, 2017
AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573 002	Jul 18, 2013
AB		EQ 135MG FENOFIBRIC ACID	A201573 001	Jul 18, 2013
AB	IMPAX LABS INC	EQ 45MG FENOFIBRIC ACID	A200264 001	Sep 07, 2016
AB		EQ 135MG FENOFIBRIC ACID	A200264 002	Sep 07, 2016
AB	LUPIN LTD	EQ 45MG FENOFIBRIC ACID	A200750 001	Dec 04, 2013
AB		EQ 135MG FENOFIBRIC ACID	A200750 002	Dec 04, 2013
AB	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013
AB		EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013

TRILIPIX

AB	+	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008
AB	+	!	EQ 135MG FENOFIBRIC ACID	N022224 002	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+	!	EMD SERONO	EQ 0.25MG /0.5ML	N021149 002	Oct 06, 2003
---	---	------------	------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA EQ 0.004MG CHROMIUM/ML N018961 001 Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+! ASTRAZENECA PHARMS 0.08MG/INH N021658 002 Jan 10, 2008

+! 0.16MG/INH N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+! ASTRAZENECA PHARMS 0.037MG/INH N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+! ASTRAZENECA PHARMS 0.05MG/INH N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS **0.77%** **A076435 001** Dec 29, 2004**AB** G AND W LABS INC **0.77%** **A078463 001** Dec 20, 2010**AB** GLENMARK PHARMS **0.77%** **A090273 001** Nov 10, 2009**AB** PERRIGO NEW YORK **0.77%** **A077364 001** Mar 03, 2006**AB** TARO **0.77%** **A076790 001** Apr 12, 2005LOPROX**AB** +! MEDIMETRIKS PHARMS **0.77%** **N018748 001** Dec 30, 1982

GEL; TOPICAL

CICLOPIROX**AB** +! CNTY LINE PHARMS **0.77%** **N020519 001** Jul 21, 1997**AB** FOUGERA PHARMS **0.77%** **A077896 001** Jun 10, 2008**AB** GLENMARK GENERICS **0.77%** **A091595 001** Feb 29, 2012**AB** PADDOCK LLC **0.77%** **A078266 001** Jan 07, 2009

SHAMPOO; TOPICAL

CICLOPIROX**AT** ACTAVIS MID **1%** **A090490 001** Nov 24, 2009

ATLANTIC

AT FOUGERA PHARMS **1%** **A090146 001** May 25, 2010**AT** PERRIGO CO **1%** **A078594 001** Feb 16, 2010**AT** TARO **1%** **A090269 001** Feb 23, 2011LOPROX**AT** +! MEDICIS **1%** **N021159 001** Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROX**AT** ACTAVIS MID **8%** **A078046 001** Sep 18, 2007

ATLANTIC

AT AKORN **8%** **A078975 001** Feb 17, 2010**AT** APOTEX INC **8%** **A078172 001** Sep 18, 2007**AT** CIPLA LTD **8%** **A078124 001** Sep 18, 2007**AT** G AND W LABS **8%** **A078233 001** Sep 18, 2007**AT** HI TECH PHARMA **8%** **A078270 001** Sep 18, 2007**AT** PERRIGO NEW YORK **8%** **A077623 001** Sep 18, 2007**AT** TARO PHARM INDS **8%** **A078144 001** Sep 18, 2007**AT** TOLMAR **8%** **A077687 001** Sep 18, 2007PENLAC**AT** +! VALEANT BERMUDA **8%** **N021022 001** Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS **0.77%** **A076422 001** Aug 06, 2004**AB** PERRIGO NEW YORK **0.77%** **A077676 001** Dec 15, 2006**AB** TARO **0.77%** **A077092 001** Aug 10, 2005LOPROX**AB** +! MEDIMETRIKS PHARMS **0.77%** **N019824 001** Dec 30, 1988CIDOFVIR

INJECTABLE; INJECTION

CIDOFVIR**AP** EMCURE PHARMS LTD **EQ 75MG BASE/ML** **A202501 001** Jul 26, 2012**AP** ! MYLAN INSTITUTIONAL **EQ 75MG BASE/ML** **A201276 001** Jun 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

<u>AP</u>	ACS DOBFAR	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>A090577 001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A090577 002</u>	Dec 21, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>A090825 001</u>	Nov 16, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A090825 002</u>	Nov 16, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A091007 001</u>	Nov 16, 2011
<u>PRIMAXIN</u>				
<u>AP</u>	+! MERCK	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>N050587 001</u>	Nov 26, 1985
<u>AP</u>	+!	<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>N050587 002</u>	Nov 26, 1985

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030 001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030 002</u>	Dec 10, 2004
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708 001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708 002</u>	Sep 28, 2009
<u>AB</u>	CHARTWELL RX	<u>50MG</u>	<u>A077722 001</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A077831 001</u>	Sep 24, 2012
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310 001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021 001</u>	Nov 23, 2004
<u>AB</u>	! TEVA	<u>50MG</u>	<u>A077027 001</u>	Nov 24, 2004
<u>AB</u>	!	<u>100MG</u>	<u>A077027 002</u>	Nov 24, 2004
<u>AB</u>	WEST-WARD PHARMS INT	<u>50MG</u>	<u>A077024 001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024 002</u>	May 17, 2005

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890 001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890 002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890 003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890 004</u>	Dec 18, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246 003</u>	May 17, 1994
<u>AB</u>	!	<u>800MG</u>	<u>A074246 004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566 001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151 003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463 001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC

EQ 300MG BASE/2ML

A074428 001 Apr 25, 1996

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS INC	<u>EQ 300MG BASE/5ML</u>	<u>A074610 001</u>	Sep 26, 1996
<u>AA</u>	! HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664 001</u>	Oct 28, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553 001</u>	Jan 27, 1997
<u>AA</u>	WOCKHARDT BIO AG	<u>EQ 300MG BASE/5ML</u>	<u>A074757 001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

+ AMGEN

EQ 30MG BASE

N021688 001 Mar 08, 2004

+

EQ 60MG BASE

N021688 002 Mar 08, 2004

+!

EQ 90MG BASE

N021688 003 Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

<u>AB</u>	+ BAYER HLTHCARE	<u>250MG/5ML</u>	<u>N020780 001</u>	Sep 26, 1997
<u>AB</u>	+!	<u>500MG/5ML</u>	<u>N020780 002</u>	Sep 26, 1997

CIPROFLOXACIN

<u>AB</u>	LUPIN LTD	<u>250MG/5ML</u>	<u>A200563 001</u>	Mar 05, 2014
<u>AB</u>		<u>500MG/5ML</u>	<u>A200563 002</u>	Mar 05, 2014

INJECTABLE; INJECTION

CIPROFLOXACIN

<u>AP</u>	! BAXTER HLTHCARE	<u>200MG/20ML (10MG/ML)</u>	<u>A078062 001</u>	Apr 29, 2008
-----------	-------------------	-----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

CORP

<u>AP</u>	!		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>		BAXTER HLTHCARE CORP	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>	!	HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	!		<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+	!	OTONOMY INC	6% (60MG/ML)	N207986	001	Dec 10, 2015
---	---	-------------	--------------	---------	-----	--------------

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+	!	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369	001	Mar 30, 1998
---	---	-------------------------	--------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	!	NOVARTIS PHARMS CORP	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990
-----------	---	---	-------------------------	---------------------	----------------	------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>		RISING PHARMS INC	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>		TELLIGENT	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>		WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRAKAL

+	!	WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009
---	---	---------------	--------------	---------	-----	--------------

TABLET; ORAL

CIPRO

<u>AB</u>	+	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
<u>AB</u>	+		<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>	+	!	<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
<u>AB</u>	+		<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>		CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	TARO PHARM	<u>EQ 100MG BASE</u>	<u>A076912 001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912 002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912 003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912 004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639 001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639 002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639 003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794 001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794 004</u>	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+! LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

+! NOVARTIS PHARMS EQ 0.2% BASE; 1% N020805 001 Feb 10, 1998
CORPCIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

<u>AB</u>	ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166 002</u>	Nov 27, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166 001</u>	Nov 27, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701 001</u>	Mar 26, 2007
<u>AB</u>	! MYLAN PHARMS INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183 001</u>	Mar 22, 2007
<u>AB</u>	!	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183 002</u>	Mar 22, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

+! NOVARTIS PHARMS 0.3%; 0.1% N021537 001 Jul 18, 2003
CORPCISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A205873 001</u>	Jun 16, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203183 001</u>	Feb 26, 2015
<u>AP</u>	JIANGSU HENGRUI MED	<u>EQ 2MG BASE/ML</u>	<u>A209334 001</u>	Aug 30, 2017
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159 001</u>	Feb 03, 2012

CISATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A205872 001</u>	Jun 16, 2017
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A205872 002</u>	Jun 16, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203182 001</u>	Feb 26, 2015
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A203182 002</u>	Feb 26, 2015
<u>AP</u>	JIANGSU HENGRUI MED	<u>EQ 2MG BASE/ML</u>	<u>A204960 001</u>	Jan 27, 2017
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A204960 002</u>	Sep 19, 2017
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154 001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154 002</u>	Feb 03, 2012

NIMBEX

+! ABBVIE EQ 2MG BASE/ML N020551 001 Dec 15, 1995

NIMBEX PRESERVATIVE FREE+! ABBVIE EQ 2MG BASE/ML N020551 003 Dec 15, 1995
+! EQ 10MG BASE/ML N020551 002 Dec 15, 1995CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>1MG/ML</u>	<u>A206774 001</u>	Aug 18, 2015
<u>AP</u>	! FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735 001</u>	Jul 16, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A207323 001</u>	Mar 17, 2017
<u>AP</u>	+ HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057 004</u>	Nov 08, 1988
<u>AP</u>	MYLAN LABS LTD	<u>1MG/ML</u>	<u>A091062 001</u>	Apr 18, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>1MG/ML</u>	<u>A074656 001</u>	May 16, 2000
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A075036 001</u>	Nov 07, 2000

PRESCRIPTION DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812</u>	<u>001</u>	Aug 28, 2006
<u>AA</u>	HETERO LABS LTD III	<u>EQ 10MG BASE/5ML</u>	<u>A201450</u>	<u>001</u>	Dec 15, 2015
<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629</u>	<u>001</u>	Jun 15, 2006
<u>AA</u>	! WEST-WARD PHARMS INT	<u>EQ 10MG BASE/5ML</u>	<u>A077043</u>	<u>001</u>	Dec 13, 2004

TABLET;ORAL

CELEXA

<u>AB</u>	+ FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822</u>	<u>001</u>	Apr 27, 2000
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020822</u>	<u>002</u>	Jul 17, 1998
<u>AB</u>	+!	<u>EQ 40MG BASE</u>	<u>N020822</u>	<u>003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289</u>	<u>003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A077044</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045</u>	<u>003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045</u>	<u>002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045</u>	<u>001</u>	Apr 29, 2005
<u>AB</u>	G AND W LABS INC	<u>EQ 10MG BASE</u>	<u>A077048</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048</u>	<u>002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048</u>	<u>003</u>	Nov 16, 2004
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534</u>	<u>001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534</u>	<u>002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534</u>	<u>003</u>	Oct 03, 2006
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205407</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205407</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205407</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077042</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232</u>	<u>002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A077032</u>	<u>001</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077032</u>	<u>002</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077032</u>	<u>003</u>	Nov 12, 2004
<u>AB</u>	TORPHARM	<u>EQ 20MG BASE</u>	<u>A077046</u>	<u>002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046</u>	<u>003</u>	Nov 24, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216</u>	<u>003</u>	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990
---	-----------------	---	---------	-----	--------------

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535	001	Jul 16, 2012
---	--------------------	--------------------------------------	---------	-----	--------------

SOLUTION;ORAL

CLENPIQ

+	FERRING PHARMS INC	12GM/160ML;3.5GM/160ML;10MG/160ML	N209589	001	Nov 28, 2017
---	--------------------	-----------------------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+! EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A

N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE**AP** ! FRESENIUS KABI USA1MG/ML**A076571 001** Apr 22, 2004**AP** MYLAN LABS LTD1MG/ML**A200510 001** Oct 06, 2011**AP** WEST-WARD PHARMS
INT1MG/ML**A075405 001** Feb 28, 2000CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN**AB** + ABBVIE125MG/5ML**N050698 001** Dec 23, 1993**AB** +!250MG/5ML**N050698 002** Dec 23, 1993CLARITHROMYCIN**AB** SANDOZ125MG/5ML**A065283 002** Sep 04, 2007**AB**250MG/5ML**A065283 003** Sep 04, 2007**AB** SUN PHARM INDS LTD125MG/5ML**A065382 001** Aug 30, 2007**AB**250MG/5ML**A065382 002** Aug 30, 2007

TABLET; ORAL

BIAXIN**AB** +! ABBVIE250MG**N050662 001** Oct 31, 1991**AB** +!500MG**N050662 002** Oct 31, 1991CLARITHROMYCIN**AB** ALLIED PHARMA INC250MG**A202710 001** Jun 10, 2013**AB**500MG**A202710 002** Jun 10, 2013**AB** APOTEX CORP250MG**A065384 001** Aug 20, 2007**AB**500MG**A065384 002** Aug 20, 2007**AB** AUROBINDO250MG**A065489 001** Jul 25, 2012**AB**500MG**A065489 002** Jul 25, 2012**AB** HEC PHARM USA INC250MG**A203584 001** Sep 28, 2015**AB**500MG**A203584 002** Sep 28, 2015**AB** SANDOZ250MG**A065144 001** Oct 18, 2005**AB**500MG**A065136 001** Aug 25, 2005**AB** SUN PHARM INDS LTD250MG**A065174 001** Sep 24, 2004**AB**500MG**A065174 002** Sep 24, 2004**AB** TEVA250MG**A065155 001** May 31, 2005**AB**500MG**A065155 002** May 31, 2005**AB** WEST-WARD PHARMS250MG**A065178 002** May 25, 2004**AB**500MG**A065178 001** May 25, 2004**AB** WOCHKHARDT250MG**A065266 001** May 31, 2006**AB**500MG**A065266 002** May 31, 2006

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN**AB** ACTAVIS LABS FL INC500MG**A065145 001** Jun 24, 2004**AB** ALLIED PHARMA INC500MG**A203243 001** Feb 29, 2016**AB** LUPIN LTD500MG**A202532 001** Sep 15, 2015**AB** ! MAYNE PHARMA500MG**A065154 001** May 18, 2005CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE**AA** ! TEVAEQ 0.5MG BASE/5ML**A073399 001** Jun 30, 1994**AA** WOCHKHARDTEQ 0.5MG BASE/5ML**A074863 001** Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

! TEVA

2.68MG

A073283 001 Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+! CHIESI USA INC

25MG/50ML (0.5MG/ML)

N022156 001 Aug 01, 2008

+!

50MG/100ML (0.5MG/ML)

N022156 002 Aug 01, 2008

+!

125MG/250ML (0.5MG/ML)

N022156 003 Nov 08, 2013

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

AB	+	PHARMACIA AND UPJOHN	EQ 75MG BASE	N050162 001	
AB	+		EQ 150MG BASE	N050162 002	
AB	+		EQ 300MG BASE	N050162 003	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

AB		AUROBINDO PHARMA	EQ 150MG BASE	A065442 001	Aug 26, 2009
AB			EQ 300MG BASE	A065442 002	Aug 26, 2009
AB		EPIC PHARMA LLC	EQ 150MG BASE	A065194 001	Mar 22, 2004
AB			EQ 300MG BASE	A065194 002	Mar 22, 2004
AB		G AND W LABS INC	EQ 150MG BASE	A063029 001	Sep 20, 1989
AB			EQ 300MG BASE	A063029 002	Aug 05, 2005
AB		LANNETT	EQ 75MG BASE	A065243 002	Aug 12, 2005
AB			EQ 300MG BASE	A065243 001	Aug 12, 2005
AB		SUN PHARM INDS LTD	EQ 150MG BASE	A065061 001	Feb 02, 2001
AB			EQ 300MG BASE	A065061 002	Feb 02, 2001
AB		WATSON LABS	EQ 150MG BASE	A063083 001	Jul 31, 1991
AB			EQ 300MG BASE	A063083 002	Mar 18, 2003
AB		ZYDUS PHARMS USA	EQ 75MG BASE	A065217 001	Jan 31, 2005
AB			EQ 150MG BASE	A065217 002	Jan 31, 2005
AB			EQ 300MG BASE	A065217 003	Jan 31, 2005

CLINDAMYCIN HYDROCHLORIDE

AB		LANNETT	EQ 150MG BASE	A065243 003	Aug 12, 2005
-----------	--	---------	----------------------	--------------------	--------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	!	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A062644 001	Apr 07, 1986
-----------	----------	-------------------------	-------------------------	--------------------	--------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513 001	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013
AA		LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012
AA		MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063 001	May 25, 2016
AA		ORIT LABS LLC	EQ 75MG BASE/5ML	A206958 001	May 05, 2017
AA		PADDOCK LLC	EQ 75MG BASE/5ML	A090902 001	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PERRIGO UK FINCO	1%	A090785 001	Mar 31, 2010
-----------	--	------------------	-----------	--------------------	--------------

EVOCLIN

AT	+	MYLAN PHARMS INC	1%	N050801 001	Oct 22, 2004
-----------	----------	------------------	-----------	--------------------	--------------

CREAM; VAGINAL

CLEOCIN

AB	+	PHARMACIA AND UPJOHN	EQ 2% BASE	N050680 002	Mar 02, 1998
-----------	----------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004
-----------	--	----------------	-------------------	--------------------	--------------

CLINDESSE

+		PERRIGO PHARMA INTL	EQ 2% BASE	N050793 001	Nov 30, 2004
----------	--	---------------------	-------------------	--------------------	--------------

GEL; TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N050615 001	Jan 07, 1987
-----------	----------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000
-----------	--	----------------	-------------------	--------------------	--------------

CLINDAGEL

BT	+	PRECISION DERMAT	EQ 1% BASE	N050782 001	Nov 27, 2000
-----------	----------	------------------	-------------------	--------------------	--------------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A062803 001	Oct 16, 1987
-----------	--	-------------------------	-------------------------	--------------------	--------------

AP	+		EQ 150MG BASE/ML	N050441 001	
-----------	----------	--	-------------------------	--------------------	--

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989
-----------	----------	-------------------------	-----------------------	--------------------	--------------

AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989
-----------	----------	--	------------------------	--------------------	--------------

AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991
-----------	----------	--	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AP		ALVOGEN INC	EQ 150MG BASE/ML	A062800 001	Jul 24, 1987
-----------	--	-------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A062801 001	Jul 24, 1987
-----------	--	--	-------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943 001</u>	Sep 29, 1988
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346 001</u>	Mar 29, 2007
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347 001</u>	May 09, 2007
<u>AP</u>	MYLAN LABS LTD	<u>EQ 150MG BASE/ML</u>	<u>A204748 001</u>	Oct 10, 2017
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A204749 001</u>	Oct 10, 2017
<u>AP</u>	SAGENT PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A090108 001</u>	Sep 30, 2011
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A090109 001</u>	Sep 30, 2011
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 150MG BASE/ML</u>	<u>A062889 001</u>	Apr 25, 1988
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065206 001</u>	Sep 24, 2004

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048 001</u>	Apr 04, 2013
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A203048 002</u>	Apr 04, 2013
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A203048 003</u>	Apr 04, 2013
<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 6MG BASE/ML</u>	<u>A208084 001</u>	Jun 28, 2017
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A208084 002</u>	Jun 28, 2017
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A208084 003</u>	Jun 28, 2017
<u>AP</u>	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692 001</u>	May 31, 2012
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A201692 002</u>	May 31, 2012
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A201692 003</u>	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+! ABRAXIS PHARM EQ 900MG BASE/100ML N050635 001 Dec 22, 1989

LOTION; TOPICAL

CLEOCIN T

<u>AB</u>	+! PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600 001</u>	May 31, 1989
-----------	----------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067 001</u>	Jan 31, 2002
	SOLUTION; IV (INFUSION)			
	CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE			
	+! BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083 001	Apr 20, 2017
	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083 002	Apr 20, 2017
	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083 003	Apr 20, 2017

SOLUTION; TOPICAL

CLEOCIN T

<u>AT</u>	+! PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 001</u>	
-----------	----------------------------	-------------------	--------------------	--

CLINDA-DERM

<u>AT</u>	PADDOCK LLC	<u>EQ 1% BASE</u>	<u>A063329 001</u>	Sep 30, 1992
-----------	-------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AT</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065254 001</u>	Feb 14, 2006
<u>AT</u>	FOUGERA PHARMS INC	<u>EQ 1% BASE</u>	<u>A064159 001</u>	Jun 05, 1997
<u>AT</u>	G AND W LABS INC	<u>EQ 1% BASE</u>	<u>A062811 001</u>	Sep 01, 1988
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050 001</u>	Nov 30, 1995
<u>AT</u>	TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184 001</u>	Mar 31, 2004
<u>AT</u>	TELIGENT PHARMA INC	<u>EQ 1% BASE</u>	<u>A206945 001</u>	Dec 30, 2016
<u>AT</u>	VINTAGE PHARMS	<u>EQ 1% BASE</u>	<u>A203343 001</u>	May 29, 2015
<u>AT</u>	WOCKHARDT	<u>EQ 1% BASE</u>	<u>A063304 001</u>	Jul 15, 1997

SUPPOSITORY; VAGINAL

CLEOCIN

+! PHARMACIA AND UPJOHN 100MG N050767 001 Aug 13, 1999

SWAB; TOPICAL

CLEOCIN

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 002</u>	Feb 22, 1994
-----------	---------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AT</u>	AKORN	<u>EQ 1% BASE</u>	<u>A065513 001</u>	Jun 17, 2010
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049 001</u>	May 25, 2000

CLINDETS

<u>AT</u>	PERRIGO CO	<u>EQ 1% BASE</u>	<u>A064136 001</u>	Sep 30, 1996
-----------	------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>1.2%;0.025%</u>	<u>A202564 001</u>	Jun 12, 2015
-----------	-------------------------	--------------------	--------------------	--------------

ZIANA

<u>AB</u>	+! MEDICIS	<u>1.2%;0.025%</u>	<u>N050802 001</u>	Nov 07, 2006
-----------	------------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010
----	---	-----------------	-------------	---------	-----	--------------

CLOBAZAM

SUSPENSION; ORAL

ONFI

+	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012
---	---------------------	----------	---------	-----	--------------

TABLET; ORAL

ONFI

+	LUNDBECK PHARMS LLC	10MG	N202067	002	Oct 21, 2011
---	---------------------	------	---------	-----	--------------

+		20MG	N202067	003	Oct 21, 2011
---	--	------	---------	-----	--------------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		INGENUS PHARMS LLC	<u>0.05%</u>	<u>A206805</u>	<u>001</u>	Jul 31, 2017
------------	--	--------------------	--------------	-----------------------	-------------------	--------------

AB1		PERRIGO ISRAEL	<u>0.05%</u>	<u>A077763</u>	<u>001</u>	Mar 10, 2008
------------	--	----------------	--------------	-----------------------	-------------------	--------------

OLUX

AB1	+	MYLAN PHARMS INC	<u>0.05%</u>	<u>N021142</u>	<u>001</u>	May 26, 2000
------------	---	------------------	--------------	-----------------------	-------------------	--------------

CLOBETASOL PROPIONATE

AB2		PERRIGO ISRAEL	<u>0.05%</u>	<u>A201402</u>	<u>001</u>	Aug 14, 2012
------------	--	----------------	--------------	-----------------------	-------------------	--------------

OLUX E

AB2	+	MYLAN PHARMS INC	<u>0.05%</u>	<u>N022013</u>	<u>001</u>	Jan 12, 2007
------------	---	------------------	--------------	-----------------------	-------------------	--------------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		FOUGERA PHARMS INC	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
------------	--	--------------------	--------------	-----------------------	-------------------	--------------

AB1		G AND W LABS INC	<u>0.05%</u>	<u>A074139</u>	<u>001</u>	Aug 03, 1994
------------	--	------------------	--------------	-----------------------	-------------------	--------------

AB1		MYLAN PHARMS INC	<u>0.05%</u>	<u>A075338</u>	<u>001</u>	Feb 09, 2001
------------	--	------------------	--------------	-----------------------	-------------------	--------------

AB1		TARO	<u>0.05%</u>	<u>A074249</u>	<u>001</u>	Jul 08, 1996
------------	--	------	--------------	-----------------------	-------------------	--------------

CORMAX

AB1	!	HI TECH PHARMA	<u>0.05%</u>	<u>A074220</u>	<u>001</u>	May 16, 1997
------------	---	----------------	--------------	-----------------------	-------------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A075430</u>	<u>001</u>	May 26, 1999
------------	---	----------------	--------------	-----------------------	-------------------	--------------

AB2		TARO	<u>0.05%</u>	<u>A075633</u>	<u>001</u>	May 17, 2000
------------	--	------	--------------	-----------------------	-------------------	--------------

AB2		TELIGENT PHARMA INC	<u>0.05%</u>	<u>A209411</u>	<u>001</u>	Aug 21, 2017
------------	--	---------------------	--------------	-----------------------	-------------------	--------------

EMBELINE E

AB2		HI TECH PHARMA	<u>0.05%</u>	<u>A075325</u>	<u>001</u>	Dec 24, 1998
------------	--	----------------	--------------	-----------------------	-------------------	--------------

IMPOYZ

+	PROMIUS PHARMA LLC	0.025%	N209483	001	Nov 28, 2017
---	--------------------	--------	---------	-----	--------------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A075368</u>	<u>001</u>	Feb 15, 2000
-----------	---	----------------	--------------	-----------------------	-------------------	--------------

AB		PERRIGO CO	<u>0.05%</u>	<u>A075027</u>	<u>001</u>	Oct 31, 1997
-----------	--	------------	--------------	-----------------------	-------------------	--------------

AB		TARO	<u>0.05%</u>	<u>A075279</u>	<u>001</u>	May 28, 1999
-----------	--	------	--------------	-----------------------	-------------------	--------------

AB		TELIGENT PHARMA INC	<u>0.05%</u>	<u>A208881</u>	<u>001</u>	Mar 06, 2017
-----------	--	---------------------	--------------	-----------------------	-------------------	--------------

EMBELINE

AB		HI TECH PHARMA	<u>0.05%</u>	<u>A076141</u>	<u>001</u>	Apr 12, 2002
-----------	--	----------------	--------------	-----------------------	-------------------	--------------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078223</u>	<u>001</u>	Dec 04, 2008
-----------	--	----------------------	--------------	-----------------------	-------------------	--------------

AB		LUPIN LTD	<u>0.05%</u>	<u>A209147</u>	<u>001</u>	Sep 22, 2017
-----------	--	-----------	--------------	-----------------------	-------------------	--------------

AB		TARO	<u>0.05%</u>	<u>A200302</u>	<u>001</u>	Jul 02, 2012
-----------	--	------	--------------	-----------------------	-------------------	--------------

AB		TELIGENT PHARMA INC	<u>0.05%</u>	<u>A208667</u>	<u>001</u>	Nov 29, 2016
-----------	--	---------------------	--------------	-----------------------	-------------------	--------------

CLOBEX

AB	+	GALDERMA LABS LP	<u>0.05%</u>	<u>N021535</u>	<u>001</u>	Jul 24, 2003
-----------	---	------------------	--------------	-----------------------	-------------------	--------------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A074407</u>	<u>001</u>	Feb 23, 1996
-----------	---	----------------	--------------	-----------------------	-------------------	--------------

AB		G AND W LABS INC	<u>0.05%</u>	<u>A074089</u>	<u>001</u>	Feb 16, 1994
-----------	--	------------------	--------------	-----------------------	-------------------	--------------

AB		GLENMARK PHARMS	<u>0.05%</u>	<u>A208933</u>	<u>001</u>	Mar 20, 2017
-----------	--	-----------------	--------------	-----------------------	-------------------	--------------

AB		MYLAN PHARMS INC	<u>0.05%</u>	<u>A075057</u>	<u>001</u>	Aug 12, 1998
-----------	--	------------------	--------------	-----------------------	-------------------	--------------

AB		TARO	<u>0.05%</u>	<u>A074248</u>	<u>001</u>	Jul 12, 1996
-----------	--	------	--------------	-----------------------	-------------------	--------------

AB		ZYDUS PHARMS USA INC	<u>0.05%</u>	<u>A210199</u>	<u>001</u>	Oct 27, 2017
-----------	--	----------------------	--------------	-----------------------	-------------------	--------------

EMBELINE

AB		HI TECH PHARMA	<u>0.05%</u>	<u>A074221</u>	<u>001</u>	Mar 31, 1995
-----------	--	----------------	--------------	-----------------------	-------------------	--------------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078854</u>	<u>001</u>	Jun 07, 2011
-----------	--	----------------------	--------------	-----------------------	-------------------	--------------

AB		HI-TECH PHARMACAL	<u>0.05%</u>	<u>A209871</u>	<u>001</u>	Oct 27, 2017
-----------	--	-------------------	--------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012
-----------	----------------	--------------	--------------------	--------------

CLOBEX

AB	+! GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004
-----------	------------------	--------------	--------------------	--------------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999
AT	G AND W LABS INC	0.05%	A074331 001	Dec 15, 1995
AT	MACLEODS PHARMS LTD	0.05%	A209361 001	Oct 25, 2017
AT	NOVEL LABS INC	0.05%	A206075 001	Nov 23, 2015
AT	TARO	0.05%	A075224 001	Nov 16, 1998
AT		0.05%	A075363 001	Dec 29, 2000
AT	TOLMAR	0.05%	A076977 001	Aug 05, 2005
AT	WOCKHARDT BIO AG	0.05%	A075205 001	Nov 13, 1998

EMBELINE

AT	! HI TECH PHARMA	0.05%	A074222 001	Dec 06, 1995
-----------	------------------	--------------	--------------------	--------------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT	AKORN	0.05%	A207218 001	Apr 28, 2017
AT	PADDOCK LLC	0.05%	A090898 001	Jun 16, 2011
AT	ZYDUS PHARMS USA INC	0.05%	A206378 001	Feb 16, 2017

CLOBEX

AT	+! GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005
-----------	---------------------	--------------	--------------------	--------------

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+! PROMIUS PHARMA LLC 0.1%

N017765 001

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029 001	May 09, 2017
AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857 001	Nov 06, 2017
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375 001	Nov 06, 2017
AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775 001	Dec 06, 2017
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860 001	Nov 06, 2017

CLOLAR

AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673 001	Dec 28, 2004
-----------	------------	---------------------------	--------------------	--------------

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

AB	+! SANOFI AVENTIS US	50MG	N016131 002	
-----------	----------------------	-------------	--------------------	--

CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	A075528 001	Aug 30, 1999
-----------	-----------	-------------	--------------------	--------------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+! SPECGX LLC	25MG	N019906 001	Dec 29, 1989
AB	+	50MG	N019906 002	Dec 29, 1989
AB	+	75MG	N019906 003	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB	MYLAN	25MG	A074947 001	Apr 30, 1998
AB		50MG	A074947 002	Apr 30, 1998
AB		75MG	A074947 003	Apr 30, 1998
AB	SANDOZ	25MG	A074364 001	Mar 29, 1996
AB		25MG	A074953 001	Jun 25, 1997
AB		50MG	A074364 002	Mar 29, 1996
AB		50MG	A074953 002	Jun 25, 1997
AB		75MG	A074364 003	Mar 29, 1996
AB		75MG	A074953 003	Jun 25, 1997
AB	TARO	25MG	A074694 001	Dec 31, 1996
AB		50MG	A074694 002	Dec 31, 1996
AB		75MG	A074694 003	Dec 31, 1996
AB	TEVA	25MG	A074958 001	Aug 26, 1997
AB		50MG	A074958 002	Aug 26, 1997
AB		75MG	A074958 003	Aug 26, 1997
AB	ZYDUS PHARMS USA INC	25MG	A208961 001	Dec 27, 2017
AB		50MG	A208961 002	Dec 27, 2017

PRESCRIPTION DRUG PRODUCT LIST

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>75MG</u>	<u>A208961</u>	<u>003</u>	Dec 27, 2017
-----------	--	-------------	----------------	------------	--------------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150</u>	<u>001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150</u>	<u>002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150</u>	<u>003</u>	Oct 05, 1998
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	SUN PHARM INDS INC	<u>0.5MG</u>	<u>A075423</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423</u>	<u>003</u>	Apr 27, 2001
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	+	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>
<u>AB</u>	+	!	<u>1MG</u>	<u>N017533</u>	<u>002</u>
<u>AB</u>	+		<u>2MG</u>	<u>N017533</u>	<u>003</u>

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	!	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654</u>	<u>002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654</u>	<u>003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654</u>	<u>004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654</u>	<u>005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	----------------	------------	--------------

CATAPRES-TTS-2

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	----------------	------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984
-----------	---	-------------------------	-------------------	----------------	------------	--------------

CLONIDINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873</u>	<u>001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873</u>	<u>002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873</u>	<u>003</u>	May 06, 2014
<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	MAYNE PHARMA	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010

PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1MG/10ML (0.1MG/ML)</u>	<u>A091104 001</u>	Oct 08, 2009
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A091104 002</u>	Oct 08, 2009
<u>AP</u>	ZYDUS PHARMS USA INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601 002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	+ MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615 001</u>	Oct 02, 1996
<u>AP</u>	+!	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615 002</u>	Apr 27, 1999

TABLET;ORAL

CATAPRES

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407 001</u>	
<u>AB</u>	+	<u>0.2MG</u>	<u>N017407 002</u>	
<u>AB</u>	+!	<u>0.3MG</u>	<u>N017407 003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976 001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368 001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368 002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368 003</u>	Dec 06, 2011
<u>AB</u>	FRONTIDA BIOPHARM	<u>0.1MG</u>	<u>A070925 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923 001</u>	Sep 04, 1987
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099 001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099 002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099 003</u>	Aug 27, 2009
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317 002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317 003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317 001</u>	Jun 09, 1987
<u>AB</u>	PRINSTON INC	<u>0.1MG</u>	<u>A077901 001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901 002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901 003</u>	Mar 09, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>0.1MG</u>	<u>A090329 001</u>	Jul 03, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A090329 002</u>	Jul 03, 2014
<u>AB</u>		<u>0.3MG</u>	<u>A090329 003</u>	Jul 03, 2014
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895 001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895 002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895 003</u>	Aug 26, 2009
<u>AB</u>	YUNG SHIN PHARM	<u>0.1MG</u>	<u>A202297 001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297 002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297 003</u>	Jun 13, 2013
	CHARTWELL MOLECULES	0.1MG	A071785 002	Apr 05, 1988
		0.2MG	A071785 003	Apr 05, 1988

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320 001</u>	May 15, 2015
<u>AB1</u>	AJANTA PHARMA LTD	<u>0.1MG</u>	<u>A209686 001</u>	Nov 20, 2017
<u>AB1</u>	AMNEAL PHARMS NY	<u>0.1MG</u>	<u>A210052 001</u>	Nov 20, 2017
<u>AB1</u>	LUPIN LTD	<u>0.1MG</u>	<u>A209285 001</u>	Oct 23, 2017
<u>AB1</u>	XIAMEN LP PHARM CO	<u>0.1MG</u>	<u>A209757 001</u>	Nov 20, 2017

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984 001</u>	Sep 30, 2013
------------	---------------	--------------	--------------------	--------------

KAPVAY

<u>AB1</u>	+! CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331 003</u>	Sep 28, 2010
------------	----------------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015
------------	-------------------	--------------	----------------	------------	--------------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013
AB		EQ 300MG BASE	A202925	002	Mar 27, 2013
AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012
AB	AMNEAL PHARMS	EQ 75MG BASE	A203751	001	Apr 11, 2014
AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012
AB		EQ 300MG BASE	A076274	002	Mar 04, 2014
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012
AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012
AB		EQ 300MG BASE	A077665	002	May 17, 2012
AB	SCIEGEN PHARMS INC	EQ 75MG BASE	A204165	001	Sep 15, 2014
AB		EQ 300MG BASE	A204165	002	Sep 15, 2014
AB	SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012
AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012
AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266	001	Aug 14, 2012
AB		EQ 300MG BASE	A202266	002	Nov 20, 2012
AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686	001	Oct 10, 2012

PLAVIX

AB	+	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997
AB	+	!	EQ 300MG BASE	N020839	002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017
		7.5MG	A072112	003	Aug 11, 2017

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	MYLAN	3.75MG	A071858	002	Jul 17, 1987
AB		7.5MG	A071858	003	Jul 17, 1987
AB		15MG	A071858	001	Jul 17, 1987
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000
AB		7.5MG	A075731	002	Apr 27, 2000
AB		15MG	A075731	001	Apr 27, 2000

GEN-XENE

AB	ALRA	3.75MG	A071787	001	Apr 26, 1988
AB		7.5MG	A071788	001	Apr 26, 1988
AB		15MG	A071789	001	Apr 26, 1988

TRANXENE

AB	+	RECORDATI RARE	7.5MG	N017105	007
AB	+	!	15MG	N017105	008

CLOTTRIMAZOLE

CREAM;TOPICAL

CLOTTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338	001	Sep 02, 2008	
AB	GLENMARK PHARMS	1%	A090219	001	Aug 03, 2010	
AB	!	TARO	1%	A072640	001	Aug 31, 1993

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT	!	TARO	1%	A074580	001	Jul 29, 1996
AT		TEVA	1%	A073306	001	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTTRIMAZOLE

AB	PADDOCK LLC	10MG	A076763	001	Oct 28, 2005	
AB	!	WEST-WARD PHARMS INT	10MG	A076387	001	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+! TASMAN PHARMA

50MG/ML

N203479 001 Feb 06, 2013

TABLET; ORAL

CLOZAPINE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A202873</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A202873</u>	<u>002</u>	Nov 25, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A206433</u>	<u>001</u>	Nov 29, 2016
<u>AB</u>		<u>50MG</u>	<u>A206433</u>	<u>002</u>	Nov 29, 2016
<u>AB</u>		<u>100MG</u>	<u>A206433</u>	<u>003</u>	Nov 29, 2016
<u>AB</u>		<u>200MG</u>	<u>A206433</u>	<u>004</u>	Nov 29, 2016
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A074949</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>25MG</u>	<u>A074949</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949</u>	<u>004</u>	Apr 25, 2005
<u>AB</u>		<u>50MG</u>	<u>A076809</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949</u>	<u>002</u>	Nov 26, 1997
<u>AB</u>		<u>100MG</u>	<u>A076809</u>	<u>002</u>	Dec 16, 2005
<u>AB</u>		<u>200MG</u>	<u>A076809</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	MAYNE PHARMA	<u>25MG</u>	<u>A203807</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>50MG</u>	<u>A203807</u>	<u>003</u>	Aug 22, 2017
<u>AB</u>		<u>100MG</u>	<u>A203807</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>		<u>200MG</u>	<u>A203807</u>	<u>004</u>	Aug 22, 2017
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075417</u>	<u>003</u>	Apr 15, 2010
<u>AB</u>		<u>25MG</u>	<u>A075417</u>	<u>001</u>	May 27, 1999
<u>AB</u>		<u>50MG</u>	<u>A075417</u>	<u>004</u>	Apr 15, 2010
<u>AB</u>		<u>100MG</u>	<u>A075417</u>	<u>002</u>	May 27, 1999
<u>AB</u>		<u>200MG</u>	<u>A075417</u>	<u>005</u>	Apr 15, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>		<u>200MG</u>	<u>A075713</u>	<u>004</u>	Nov 07, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A209480</u>	<u>001</u>	Dec 06, 2017
<u>AB</u>		<u>50MG</u>	<u>A209480</u>	<u>002</u>	Dec 06, 2017
<u>AB</u>		<u>100MG</u>	<u>A209480</u>	<u>003</u>	Dec 06, 2017
<u>AB</u>		<u>200MG</u>	<u>A209480</u>	<u>004</u>	Dec 06, 2017

CLOZARIL

<u>AB</u>	+ HERITAGE LIFE	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+!	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

<u>AB</u>	BARR LABS INC	<u>25MG</u>	<u>A090308</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A090308</u>	<u>002</u>	Nov 25, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A201824</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>100MG</u>	<u>A201824</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A203039</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>200MG</u>	<u>A203039</u>	<u>002</u>	Nov 25, 2015

FAZACLO ODT

<u>AB</u>	+ JAZZ PHARMS III	<u>25MG</u>	<u>N021590</u>	<u>001</u>	Feb 10, 2004
<u>AB</u>	+!	<u>100MG</u>	<u>N021590</u>	<u>002</u>	Feb 10, 2004
<u>AB</u>	+	<u>150MG</u>	<u>N021590</u>	<u>005</u>	Jul 09, 2010
<u>AB</u>	+	<u>200MG</u>	<u>N021590</u>	<u>006</u>	Jul 09, 2010
	+	12.5MG	N021590	004	May 30, 2007

COBICISTAT

TABLET; ORAL

TYBOST

+! GILEAD SCIENCES INC 150MG

N203094 001 Sep 24, 2014

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG; EQ 800MG BASE

N205395 001 Jan 29, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

GENVOYA

+! GILEAD SCIENCES INC 150MG; 150MG; 200MG; EQ 10MG BASE

N207561 001 Nov 05, 2015

PRESCRIPTION DRUG PRODUCT LIST

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+! GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE

TABLET; ORAL

COTELLIC

+! GENENTECH INC EQ 20MG BASE N206192 001 Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION; NASAL

GOPRELTO

+! GENUS LIFESCIENCES 4% N209963 001 Dec 14, 2017

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** VINTAGE 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040660 001** Dec 07, 2006PROMETH VC W/ CODEINE**AA** ! ACTAVIS MID 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A088764 001** Oct 31, 1984
ATLANTICPROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** HI-TECH PHARMA CO 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040674 001** Dec 23, 2014PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** AMNEAL PHARMS 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A200963 001** Aug 26, 2015CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE**AA** ! ACTAVIS MID 10MG/5ML; 6.25MG/5ML **A088763 001** Oct 31, 1984
ATLANTIC**AA** AMNEAL PHARMS 10MG/5ML; 6.25MG/5ML **A200894 001** Apr 24, 2013**AA** HI TECH PHARMA 10MG/5ML; 6.25MG/5ML **A040151 001** Aug 26, 1997**AA** NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML **A090180 001** Mar 17, 2010**AA** TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML **A200386 001** Jun 29, 2012**AA** WOCKHARDT BIO AG 10MG/5ML; 6.25MG/5ML **A088875 001** Dec 17, 1984PROMETHAZINE WITH CODEINE**AA** VINTAGE 10MG/5ML; 6.25MG/5ML **A040650 001** Jan 31, 2006CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

! STI PHARMA LLC 10MG/5ML; 30MG/5ML; 1.25MG/5ML A088704 001 Mar 22, 1985

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE**AB** LANNETT HOLDINGS 15MG **A203046 001** Jun 13, 2014
INC**AB** 30MG **A203046 002** Jun 13, 2014**AB** 60MG **A203046 003** Jun 13, 2014**AB** + WEST-WARD PHARMS 15MG **N022402 001** Jul 16, 2009
INT**AB** + 30MG **N022402 002** Jul 16, 2009**AB** +! 60MG **N022402 003** Jul 16, 2009COLCHICINE

CAPSULE; ORAL

MITIGARE

+! HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014

TABLET; ORAL

COLCRYS

+! TAKEDA PHARMS USA 0.6MG N022352 001 Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID**AB** ! WATSON LABS 0.5MG; 500MG **A084279 001**PROBENECID AND COLCHICINE**AB** INGENUS PHARMS NJ 0.5MG; 500MG **A040618 001** May 13, 2008

PRESCRIPTION DRUG PRODUCT LIST

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

+ DAIICHI SANKYO

1.875GM/PACKET

N022362 001 Oct 02, 2009

+!

3.75GM/PACKET

N022362 002 Oct 02, 2009

TABLET; ORAL

WELCHOL

+! DAIICHI SANKYO

625MG

N021176 001 May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID**AB** + PHARMACIA UPJOHN5GM/SCOOPFULN017563 003 Sep 22, 1995**AB** +!5GM/PACKETN017563 004 Sep 22, 1995COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS5GM/SCOOPFULA077277 001 May 02, 2006**AB**5GM/PACKETA077277 002 May 02, 2006

FLAVORED COLESTID

+ PHARMACIA UPJOHN

5GM/PACKET

N017563 001

+

5GM/SCOOPFUL

N017563 002

TABLET; ORAL

COLESTID**AB** +! PHARMACIA UPJOHN1GMN020222 001 Jul 19, 1994COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS1GMA077510 001 Oct 24, 2006COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM**AP** EMCURE PHARMS LTDEQ 150MG BASE/VIALA202359 001 Sep 28, 2012**AP** FRESENIUS KABI USAEQ 150MG BASE/VIALA065364 001 Apr 17, 2008**AP** PADDOCK LLCEQ 150MG BASE/VIALA065177 001 Mar 19, 2004**AP** SAGENT PHARMSEQ 150MG BASE/VIALA201365 001 Feb 19, 2014**AP** X GEN PHARMSEQ 150MG BASE/VIALA064216 001 Feb 26, 1999**AP** XELLIA PHARMS APSEQ 150MG BASE/VIALA205356 001 May 29, 2015COLY-MYCIN M**AP** +! PAR STERILEEQ 150MG BASE/VIALN050108 002

PRODUCTS

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+! ENDO PHARMS INC

EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG
BASE/ML; 0.5MG/ML

N050356 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+! CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008

COPANLISIB DIHYDROCHLORIDE

POWDER; IV (INFUSION)

ALIQOPA

+! BAYER HEALTHCARE

60MG/VIAL

N209936 001 Sep 14, 2017

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+! COOPERSURGICAL

309MG/COPPER

N018680 001 Nov 15, 1984

CORTICORELIN OVINE TRIFLUORATE

INJECTABLE; INJECTION

ACTHREL

+! FERRING

EQ 0.1MG BASE/VIAL

N020162 001 May 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+! MALLINCKRODT ARD

80 UNITS/ML

N008372 008

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

! HIKMA INTL PHARMS

25MG

A080776 002

PRESCRIPTION DRUG PRODUCT LIST

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+ !	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001	
-----------	------------	-------------------------	--------------------	----------------	------------	--

COSYNTROPIN

AP		MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009
AP		SANDOZ	0.25MG/VIAL	A202147	001	Jun 29, 2012

CRISABOROLE

OINTMENT; TOPICAL

EUCRISA

+ !	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016
------------	-------------------	----	---------	-----	--------------

CRIZOTINIB

CAPSULE; ORAL

XALKORI

+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
----------	-------------	-------	---------	-----	--------------

+ !		250MG	N202570	002	Aug 26, 2011
------------	--	-------	---------	-----	--------------

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+ !	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012
------------	-----------------	-------	---------	-----	--------------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA		AILEX PHARMS LLC	100MG/5ML	A209264	001	Oct 16, 2017
-----------	--	------------------	------------------	----------------	------------	--------------

AA		MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013
-----------	--	-------------------------	------------------	----------------	------------	--------------

AA		RISING PHARMS INC	100MG/5ML	A202583	001	Oct 27, 2011
-----------	--	-------------------	------------------	----------------	------------	--------------

GASTROCROM

AA	+ !	MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996
-----------	------------	---------------------	------------------	----------------	------------	--------------

SOLUTION; INHALATION

CROMOLYN SODIUM

AN		AILEX PHARMS LLC	10MG/ML	A209453	001	Oct 16, 2017
-----------	--	------------------	----------------	----------------	------------	--------------

AN		MYLAN SPECIALITY LP	10MG/ML	A074209	001	Apr 26, 1994
-----------	--	---------------------	----------------	----------------	------------	--------------

AN	!	TEVA PHARMS	10MG/ML	A075271	001	Jan 18, 2000
-----------	----------	-------------	----------------	----------------	------------	--------------

AN		WOCKHARDT BIO AG	10MG/ML	A075346	001	Oct 25, 1999
-----------	--	------------------	----------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT	!	AKORN	4%	A074706	001	Apr 29, 1998
-----------	----------	-------	-----------	----------------	------------	--------------

AT		ALCON	4%	A075282	001	Jun 16, 1999
-----------	--	-------	-----------	----------------	------------	--------------

CROTAMITON

CREAM; TOPICAL

EURAX

+ !	RANBAXY	10%	N006927	001	
------------	---------	-----	---------	-----	--

LOTION; TOPICAL

CROTAN

AT		MARNEL PHARMS	10%	A087204	001	
-----------	--	---------------	------------	----------------	------------	--

EURAX

AT	+ !	RANBAXY	10%	N009112	003	
-----------	------------	---------	------------	----------------	------------	--

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ !	HOSPIRA	EQ 0.4MG COPPER/ML	N018960	001	Jun 26, 1986
------------	---------	--------------------	---------	-----	--------------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	!	LUITPOLD	1MG/ML	A080737	001	
-----------	----------	----------	---------------	----------------	------------	--

AP		MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017
-----------	--	----------------	---------------	----------------	------------	--------------

AP		SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015
-----------	--	-------------------------	---------------	----------------	------------	--------------

AP		WEST-WARD PHARMS INT	1MG/ML	A080515	002	
-----------	--	-------------------------	---------------	----------------	------------	--

VIBISONE

AP	!	FRESENIUS KABI USA	1MG/ML	A080557	003	
-----------	----------	--------------------	---------------	----------------	------------	--

SPRAY, METERED; NASAL

NASCOBAL

+ !	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005
------------	-----------------	-------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

+	TEVA PHARMS INTL	15MG			
+	!	30MG			

N021777	001	Feb 01,	2007
N021777	002	Feb 01,	2007

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>5MG</u>	<u>A071611</u>	<u>002</u>	Feb 03,	2006
<u>AB</u>			<u>7.5MG</u>	<u>A071611</u>	<u>003</u>	Feb 03,	2006
<u>AB</u>			<u>10MG</u>	<u>A071611</u>	<u>001</u>	May 03,	1989
<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26,	2008
<u>AB</u>			<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26,	2008
<u>AB</u>		FRONTIDA BIOPHARM	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06,	2006
<u>AB</u>			<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23,	1995
<u>AB</u>		INVAGEN PHARMS	<u>5MG</u>	<u>A090478</u>	<u>001</u>	Jul 23,	2010
<u>AB</u>			<u>10MG</u>	<u>A090478</u>	<u>002</u>	Jul 23,	2010
<u>AB</u>		JUBILANT CADISTA	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19,	2006
<u>AB</u>			<u>7.5MG</u>	<u>A077563</u>	<u>003</u>	Aug 25,	2017
<u>AB</u>			<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19,	2006
<u>AB</u>		KVK TECH	<u>5MG</u>	<u>A078048</u>	<u>001</u>	Feb 28,	2011
<u>AB</u>			<u>10MG</u>	<u>A078048</u>	<u>002</u>	Feb 28,	2011
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A073144</u>	<u>002</u>	Feb 03,	2006
<u>AB</u>			<u>7.5MG</u>	<u>A073144</u>	<u>003</u>	Mar 25,	2013
<u>AB</u>	!		<u>10MG</u>	<u>A073144</u>	<u>001</u>	May 30,	1991
<u>AB</u>		ORIT LABS LLC	<u>5MG</u>	<u>A078218</u>	<u>002</u>	Jun 19,	2015
<u>AB</u>			<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18,	2008
<u>AB</u>		OXFORD PHARMS	<u>5MG</u>	<u>A077209</u>	<u>002</u>	Feb 03,	2006
<u>AB</u>			<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04,	2005
<u>AB</u>		PLIVA	<u>10MG</u>	<u>A074421</u>	<u>001</u>	Sep 29,	1995
<u>AB</u>		PRINSTON INC	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28,	2007
<u>AB</u>			<u>10MG</u>	<u>A077797</u>	<u>002</u>	Feb 28,	2007
<u>AB</u>		RUBICON RES PVT LTD	<u>5MG</u>	<u>A208170</u>	<u>001</u>	May 31,	2017
<u>AB</u>			<u>7.5MG</u>	<u>A208170</u>	<u>002</u>	May 31,	2017
<u>AB</u>			<u>10MG</u>	<u>A208170</u>	<u>003</u>	May 31,	2017
<u>AB</u>		SUN PHARM INDS LTD	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12,	2008
<u>AB</u>			<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12,	2008
<u>AB</u>			<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12,	2008

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>		AKORN	<u>1%</u>	<u>A040164</u>	<u>001</u>	Jan 13,	1997
-----------	--	-------	-----------	----------------	------------	---------	------

CYCLOGYL

<u>AT</u>	!	NOVARTIS PHARMS	<u>0.5%</u>	<u>A084109</u>	<u>001</u>		
-----------	---	-----------------	-------------	----------------	------------	--	--

CORP

<u>AT</u>	!		<u>1%</u>	<u>A084110</u>	<u>001</u>		
-----------	---	--	-----------	----------------	------------	--	--

CYCLOPENTOLATE HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>0.5%</u>	<u>A205937</u>	<u>001</u>	Dec 09,	2015
-----------	--	-----------	-------------	----------------	------------	---------	------

PENTOLAIR

<u>AT</u>		BAUSCH AND LOMB	<u>1%</u>	<u>A040075</u>	<u>001</u>	Apr 29,	1994
-----------	--	-----------------	-----------	----------------	------------	---------	------

CYCLOGYL

!		NOVARTIS PHARMS	<u>2%</u>	A084108	001		
---	--	-----------------	-----------	---------	-----	--	--

CORP

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!		NOVARTIS PHARMS	<u>0.2%;1%</u>	A084300	001		
---	--	-----------------	----------------	---------	-----	--	--

CORP

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

+		WEST-WARD PHARMS	25MG	N203856	001	Sep 16,	2013
---	--	------------------	------	---------	-----	---------	------

INT

+	!		50MG	N203856	002	Sep 16,	2013
---	---	--	------	---------	-----	---------	------

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	!	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745</u>	<u>001</u>	May 21,	2008
-----------	---	-----------------	-------------------	----------------	------------	---------	------

<u>AP</u>	!		<u>1GM/VIAL</u>	<u>A040745</u>	<u>002</u>	May 21,	2008
-----------	---	--	-----------------	----------------	------------	---------	------

<u>AP</u>	!		<u>2GM/VIAL</u>	<u>A040745</u>	<u>003</u>	May 21,	2008
-----------	---	--	-----------------	----------------	------------	---------	------

<u>AP</u>		JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A204555</u>	<u>001</u>	Oct 31,	2014
-----------	--	---------------------	-------------------	----------------	------------	---------	------

<u>AP</u>			<u>1GM/VIAL</u>	<u>A204555</u>	<u>002</u>	Oct 31,	2014
-----------	--	--	-----------------	----------------	------------	---------	------

<u>AP</u>			<u>2GM/VIAL</u>	<u>A204555</u>	<u>003</u>	Oct 31,	2014
-----------	--	--	-----------------	----------------	------------	---------	------

PRESCRIPTION DRUG PRODUCT LIST

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

! PURDUE GMP

250MG

A060593 001

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINEAB1 IVAX SUB TEVA
PHARMS25MGA065110 003 Mar 29, 2005AB1 50MG A065110 001 Mar 29, 2005AB1 100MG A065110 002 Mar 29, 2005AB1 MAYNE PHARMA 25MG A065044 002 Dec 20, 2000AB1 100MG A065044 001 Dec 20, 2000AB1 SANDOZ 25MG A065017 002 Jan 13, 2000AB1 100MG A065017 001 Jan 13, 2000GENGRAFAB1 ABBVIE25MGA065003 001 May 12, 2000AB1 50MG A065003 002 May 12, 2000AB1 100MG A065003 003 May 12, 2000NEORALAB1 + NOVARTIS25MGN050715 001 Jul 14, 1995AB1 +! 100MG N050715 002 Jul 14, 1995CYCLOSPORINEAB2 APOTEX25MGA065040 001 May 09, 2002AB2 100MG A065040 002 May 09, 2002SANDIMMUNEAB2 + NOVARTIS25MGN050625 001 Mar 02, 1990AB2 +! 100MG N050625 002 Mar 02, 1990BX + 50MG N050625 003 Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+! ALLERGAN

0.05%

N050790 001 Dec 23, 2002

RESTASIS MULTIDOSE

+! ALLERGAN

0.05%

N050790 002 Oct 27, 2016

INJECTABLE; INJECTION

CYCLOSPORINEAP LUITPOLD50MG/MLA065151 001 Oct 07, 2003AP WEST-WARD PHARMS 50MG/ML A065004 001 Oct 29, 1999SANDIMMUNEAP +! NOVARTIS50MG/MLN050573 001 Nov 14, 1983

SOLUTION; ORAL

CYCLOSPORINEAB1 ABBVIE100MG/MLA065025 001 Mar 03, 2000AB1 IVAX SUB TEVA 100MG/ML A065078 001 Mar 25, 2005AB1 PHARMS 100MG/ML A065054 001 Dec 18, 2001AB1 MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001NEORALAB1 +! NOVARTIS100MG/MLN050716 001 Jul 14, 1995CYCLOSPORINEAB2 WOCHKHARDT BIO AG100MG/MLA065133 001 Sep 17, 2004SANDIMMUNEAB2 +! NOVARTIS100MG/MLN050574 001 Nov 14, 1983CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDEAA BIO-PHARM INC2MG/5MLA204823 001 Dec 27, 2016AA ! LYNE 2MG/5ML A040668 001 Jun 28, 2006AA PHARM ASSOC 2MG/5ML A091295 001 Mar 28, 2013AA SILARX PHARMS INC 2MG/5ML A203191 001 Jul 13, 2017

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDEAA AILEX PHARMS LLC4MGA207555 001 Jan 31, 2017AA APEX PHARMS INC 4MG A207783 001 Dec 29, 2016AA APPCO PHARMA LLC 4MG A206553 001 Nov 29, 2016AA COREPHARMA 4MG A040537 001 Sep 30, 2003AA INGENUS PHARMS NJ 4MG A205087 001 Sep 23, 2015AA ! IVAX SUB TEVA 4MG A087056 001AA PHARMSAA PAR PHARM 4MG A087129 001AA SANTOS BIOTECH 4MG A040644 001 May 30, 2006AA ZYDUS PHARMS USA 4MG A208938 001 May 19, 2017

PRESCRIPTION DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

INC

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

+ MYLAN

EQ 50MG BASE

N020392 001 Aug 15, 1994

+!

EQ 150MG BASE

N020392 002 Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+ HORIZON PHARMA USA

EQ 25MG BASE

N203389 001 Apr 30, 2013

+!

EQ 75MG BASE

N203389 002 Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+! LEADIANT BIOSCI INC

EQ 0.44% BASE

N200740 001 Oct 02, 2012

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE**AP** ! FRESENIUS KABI USA**100MG/ML****A076512 001** Jan 15, 2004**AP** HONG KONG**20MG/ML****A206190 001** Nov 09, 2017**AP** ! HOSPIRA**20MG/ML****A071868 001** Jun 04, 1990**AP** !**20MG/ML****A072168 001** Aug 31, 1990**AP** !**20MG/ML****A072945 001** Feb 28, 1994**AP****100MG/ML****A075383 001** Nov 22, 1999**AP** MYLAN LABS LTD**20MG/ML****A200914 001** Dec 13, 2011**AP****20MG/ML****A200915 001** Dec 13, 2011**AP****100MG/ML****A201784 001** Jan 30, 2012**AP** MYLAN PHARMS INC**20MG/ML****A200916 001** Dec 13, 2011

WEST-WARD PHARMS

100MG/VIAL

A071471 001 Aug 02, 1989

INT

!

500MG/VIAL

A071472 001 Aug 02, 1989

!

1GM/VIAL

A074245 001 Aug 31, 1994

!

2GM/VIAL

A074245 002 Aug 31, 1994

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+! PACIRA PHARMS INC

10MG/ML

N021041 001 Apr 01, 1999

CYTARABINE; DAUNORUBICIN

POWDER; IV (INFUSION)

VYXEOS

+! CELATOR PHARMS

100MG; 44MG

N209401 001 Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

+ BOEHRINGER

EQ 75MG BASE

N022512 001 Oct 19, 2010

INGELHEIM

+

EQ 110MG BASE

N022512 003 Nov 20, 2015

+!

EQ 150MG BASE

N022512 002 Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

+ NOVARTIS PHARMS

EQ 50MG BASE

N202806 001 May 29, 2013

CORP

+!

EQ 75MG BASE

N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE**AP** ! FRESENIUS KABI USA**200MG/VIAL****A075371 002** Aug 27, 1999**AP** HOSPIRA**200MG/VIAL****A075940 001** Oct 18, 2001**AP** TEVA PHARMS USA**200MG/VIAL****A075259 002** Aug 27, 1998**AP** !**500MG/VIAL****A075259 001** Sep 22, 2000**AP** WEST-WARD PHARMS**200MG/VIAL****A075812 001** Jun 15, 2001

INT

AP**500MG/VIAL****A075812 002** Oct 31, 2002

!

FRESENIUS KABI USA

100MG/VIAL

A075371 001 Aug 27, 1999

PRESCRIPTION DRUG PRODUCT LIST

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843 001	Jul 24, 2015
+	!	EQ 60MG BASE	N206843 002	Jul 24, 2015
+		EQ 90MG BASE	N206843 003	Apr 13, 2016

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	!	RECORDATI RARE	0.5MG/VIAL	N050682 001	
DACTINOMYCIN						
AP			LUITPOLD PHARMS INC	0.5MG/VIAL	A202562 001	Aug 23, 2013
AP			MYLAN LABS LTD	0.5MG/VIAL	A203385 001	Nov 09, 2017

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+	!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883 001	May 23, 2014
---	---	--------------------	--------------------	-------------	--------------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+	!	ACORDA	10MG	N022250 001	Jan 22, 2010
DALFAMPRIDINE						
AB			ACTAVIS LABS FL INC	10MG	A206836 001	Jan 23, 2017
AB			AUROBINDO PHARMA LTD	10MG	A206811 001	Jan 23, 2017

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	!	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748 001	Sep 21, 1999
---	---	-------------	------------------------	-------------	--------------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

+		PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287 001	Dec 22, 1994
+			5,000IU/0.2ML (25,000IU/ML)	N020287 003	Mar 18, 1996
+			7,500IU/0.3ML (25,000IU/ML)	N020287 005	Apr 04, 2002
+			10,000IU/ML (10,000IU/ML)	N020287 004	Jan 30, 1998
+			12,500IU/0.5ML (25,000IU/ML)	N020287 009	May 01, 2007
+			15,000IU/0.6ML (25,000IU/ML)	N020287 010	May 01, 2007
+			18,000IU/0.72ML (25,000IU/ML)	N020287 011	May 01, 2007
+	!		95,000IU/3.8ML (25,000IU/ML)	N020287 006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

AB			BARR	50MG	A074582 003	May 29, 1998
AB				100MG	A074582 002	May 29, 1998
AB	!			200MG	A074582 001	Aug 09, 1996
AB			LANNETT	50MG	A077246 002	Apr 19, 2007
AB				100MG	A077246 003	Apr 19, 2007
AB				200MG	A077246 001	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB	+		PAR STERILE PRODUCTS	25MG	N017443 001	
AB	+			50MG	N017443 003	
AB	+	!		100MG	N017443 002	

DANTROLENE SODIUM

AB			ELITE LABS INC	25MG	A076686 001	Oct 24, 2005
AB				50MG	A076686 002	Oct 24, 2005
AB				100MG	A076686 003	Oct 24, 2005
AB			IMPAX LABS	25MG	A076856 001	Mar 01, 2005
AB				50MG	A076856 002	Mar 01, 2005
AB				100MG	A076856 003	Mar 01, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+	!	EAGLE PHARMS	250MG/VIAL	N205579 001	Jul 22, 2014
---	---	--------------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTRIUUM

AP	+!	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001	
-----------	-----------	----------------------	------------------	----------------	------------	--

DANTROLENE SODIUM

AP		HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017
-----------	--	--------------	------------------	----------------	------------	--------------

AP		MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016
-----------	--	---------------------	------------------	----------------	------------	--------------

REVONTO

AP		US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007
-----------	--	--------------	------------------	----------------	------------	--------------

DAPAGLIFLOZIN PROPANEDIOL

TABLET; ORAL

FARXIGA

	+	ASTRAZENECA AB	EQ 5MG BASE	N202293	001	Jan 08, 2014
--	----------	----------------	-------------	---------	-----	--------------

	+!		EQ 10MG BASE	N202293	002	Jan 08, 2014
--	-----------	--	--------------	---------	-----	--------------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

	+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017
--	----------	----------------	--------------------	---------	-----	--------------

	+		EQ 5MG BASE; 500MG	N205649	001	Oct 29, 2014
--	----------	--	--------------------	---------	-----	--------------

	+		EQ 5MG BASE; 1GM	N205649	002	Oct 29, 2014
--	----------	--	------------------	---------	-----	--------------

	+		EQ 10MG BASE; 500MG	N205649	003	Oct 29, 2014
--	----------	--	---------------------	---------	-----	--------------

	+!		EQ 10MG BASE; 1GM	N205649	004	Oct 29, 2014
--	-----------	--	-------------------	---------	-----	--------------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

	+!	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017
--	-----------	----------------	---------------------------	---------	-----	--------------

DAPSONE

GEL; TOPICAL

ACZONE

AB	+!	ALLERGAN	5%	N021794	001	Jul 07, 2005
-----------	-----------	----------	-----------	----------------	------------	--------------

DAPSONE

AB		TARO	5%	A209506	001	Oct 16, 2017
-----------	--	------	-----------	----------------	------------	--------------

ACZONE

	+!	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016
--	-----------	--------------	------	---------	-----	--------------

TABLET; ORAL

DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017
-----------	--	-------------	-------------	----------------	------------	--------------

AB			100MG	A204380	002	Mar 23, 2017
-----------	--	--	--------------	----------------	------------	--------------

AB		ALVOGEN	25MG	A205429	001	Jan 07, 2016
-----------	--	---------	-------------	----------------	------------	--------------

AB			100MG	A205429	002	Jan 07, 2016
-----------	--	--	--------------	----------------	------------	--------------

AB		JACOBUS	25MG	A086841	001	
-----------	--	---------	-------------	----------------	------------	--

AB	!		100MG	A086842	001	
-----------	----------	--	--------------	----------------	------------	--

AB		NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016
-----------	--	------------------	-------------	----------------	------------	--------------

AB			100MG	A203887	002	May 06, 2016
-----------	--	--	--------------	----------------	------------	--------------

AB		NOVITIUM PHARMA	25MG	A206505	001	Dec 01, 2016
-----------	--	-----------------	-------------	----------------	------------	--------------

AB			100MG	A206505	002	Dec 01, 2016
-----------	--	--	--------------	----------------	------------	--------------

AB		VIRTUS PHARMS	25MG	A204074	001	May 10, 2016
-----------	--	---------------	-------------	----------------	------------	--------------

AB			100MG	A204074	002	May 10, 2016
-----------	--	--	--------------	----------------	------------	--------------

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

AP	+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003
-----------	-----------	-------------------	-------------------	----------------	------------	--------------

DAPTOMYCIN

AP		CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016
-----------	--	------------------	-------------------	----------------	------------	--------------

AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014
-----------	--	-------------	-------------------	----------------	------------	--------------

AP		TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016
-----------	--	-----------------	-------------------	----------------	------------	--------------

CUBICIN RF

	+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016
--	-----------	-------------------	------------	---------	-----	--------------

POWDER; IV (INFUSION)

DAPTOMYCIN

	+!	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017
--	-----------	---------------	------------	---------	-----	--------------

	+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017
--	-----------	-------------------	------------	---------	-----	--------------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017
-----------	--	---------------------	----------------------	----------------	------------	--------------

AB			EQ 15MG BASE	A207302	002	Jul 28, 2017
-----------	--	--	---------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207681 001</u>	Dec 08, 2017
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A207681 002</u>	Dec 08, 2017
<u>AB</u>	ANCHEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A091190 001</u>	Mar 13, 2015
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A091190 002</u>	Mar 13, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 7.5MG BASE</u>	<u>A206743 001</u>	Sep 19, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A206743 002</u>	Sep 19, 2016
<u>AB</u>	CIPLA LTD	<u>EQ 7.5MG BASE</u>	<u>A207664 001</u>	Sep 01, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A207664 002</u>	Sep 01, 2016
<u>AB</u>	JUBILANT GENERICS	<u>EQ 7.5MG BASE</u>	<u>A205550 001</u>	Oct 12, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A205550 002</u>	Oct 12, 2016
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A205209 001</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A205209 002</u>	Nov 17, 2016
<u>ENABLEX</u>				
<u>AB</u>	+ APIL	<u>EQ 7.5MG BASE</u>	<u>N021513 001</u>	Dec 22, 2004
<u>AB</u>	+!	<u>EQ 15MG BASE</u>	<u>N021513 002</u>	Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION;ORAL

PREZISTA

+! JANSSEN PRODS EQ 100MG BASE/ML N202895 001 Dec 16, 2011

TABLET;ORAL

DARUNAVIR ETHANOLATE

<u>AB</u>	TEVA PHARMS USA	<u>EQ 600MG BASE</u>	<u>A202118 001</u>	Nov 21, 2017
<u>PREZISTA</u>				
<u>AB</u>	+ JANSSEN PRODS	<u>EQ 600MG BASE</u>	<u>N021976 002</u>	Feb 25, 2008
	+	EQ 75MG BASE	N021976 004	Dec 18, 2008
	+	EQ 150MG BASE	N021976 005	Dec 18, 2008
	+!	EQ 800MG BASE	N021976 006	Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

+! ABBVIE INC EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG N206619 001 Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE;ORAL

VIEKIRA XR

+! ABBVIE INC EQ 200MG BASE;8.33MG;50MG;33.33MG N208624 001 Jul 22, 2016

DASATINIB

TABLET;ORAL

DASATINIB

<u>AB</u>	APOTEX INC	<u>20MG</u>	<u>A202103 001</u>	Jun 10, 2016
<u>AB</u>		<u>50MG</u>	<u>A202103 002</u>	Jun 10, 2016
<u>AB</u>		<u>70MG</u>	<u>A202103 003</u>	Jun 10, 2016
<u>AB</u>		<u>100MG</u>	<u>A202103 004</u>	Jun 10, 2016
<u>SPRYCEL</u>				
<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N021986 001</u>	Jun 28, 2006
<u>AB</u>	+	<u>50MG</u>	<u>N021986 002</u>	Jun 28, 2006
<u>AB</u>	+	<u>70MG</u>	<u>N021986 003</u>	Jun 28, 2006
<u>AB</u>	+!	<u>100MG</u>	<u>N021986 004</u>	May 30, 2008
	+	80MG	N021986 005	Oct 28, 2010
	+	140MG	N021986 006	Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 20MG BASE/VIAL</u>	<u>A064103 001</u>	Feb 03, 1995
-----------	------------------------	--------------------------	--------------------	--------------

DAUNORUBICIN HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/VIAL</u>	<u>A065000 001</u>	May 25, 1999
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A065035 001</u>	Jan 24, 2000
<u>AP</u>	+! WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>N050731 001</u>	Jan 30, 1998
	FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034 001	Nov 20, 2001

PRESCRIPTION DRUG PRODUCT LIST

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

AP	+!	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006
-----------	-----------	---------------------	------------------	----------------	------------	--------------

DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017
AP		CHEMI SPA	50MG/VIAL	A206033	001	Sep 22, 2017
AP		CIPLA LTD	50MG/VIAL	A208601	001	Nov 16, 2017
AP		DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013
AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017
AP		SANDOZ INC	50MG/VIAL	A202969	001	Aug 28, 2014

POWDER; INTRAVENOUS

DECITABINE

+!	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014
-----------	-------------------	-----------	---------	-----	--------------

DEFERASIROX

GRANULE; ORAL

JADENU SPRINKLE

+	NOVARTIS PHARMS	90MG	N207968	001	May 18, 2017
+	CORP	180MG	N207968	002	May 18, 2017
+!		360MG	N207968	003	May 18, 2017

TABLET; ORAL

JADENU

+	NOVARTIS PHARMS	90MG	N206910	001	Mar 30, 2015
+	CORP	180MG	N206910	002	Mar 30, 2015
+!		360MG	N206910	003	Mar 30, 2015

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016
AB			250MG	A203560	002	Jan 26, 2016
AB			500MG	A203560	003	Jan 26, 2016
AB	+	NOVARTIS	125MG	N021882	001	Nov 02, 2005
AB	+		250MG	N021882	002	Nov 02, 2005
AB	+!		500MG	N021882	003	Nov 02, 2005

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+!	APOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015
-----------	---------------	----------	---------	-----	--------------

TABLET; ORAL

FERRIPROX

+!	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011
-----------	---------------	-------	---------	-----	--------------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	500MG/VIAL	A078718	001	Sep 15, 2009
AP			2GM/VIAL	A078718	002	Sep 15, 2009
AP		GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017
AP			2GM/VIAL	A207384	002	Sep 29, 2017
AP		HOSPIRA	500MG/VIAL	A076019	001	Mar 17, 2004
AP			2GM/VIAL	A076019	002	Mar 17, 2004
AP		WEST-WARD PHARMS	500MG/VIAL	A078086	001	May 30, 2007
AP		INT	2GM/VIAL	A078086	002	May 30, 2007
AP	+!	NOVARTIS	500MG/VIAL	N016267	001	
AP	+!		2GM/VIAL	N016267	002	May 25, 2000

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)

DEFITELIO

+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016
-----------	-----------------	-----------------------	---------	-----	--------------

DEFLAZACORT

SUSPENSION; ORAL

EMFLAZA

+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017
-----------	------------	------------	---------	-----	--------------

TABLET; ORAL

EMFLAZA

+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
+		18MG	N208684	002	Feb 09, 2017

PRESCRIPTION DRUG PRODUCT LIST

DEFLAZACORT

TABLET; ORAL

EMFLAZA

+

30MG

N208684 003 Feb 09, 2017

+!

36MG

N208684 004 Feb 09, 2017

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

+ FERRING

EQ 80MG BASE/VIAL

N022201 001 Dec 24, 2008

+!

EQ 120MG BASE/VIAL

N022201 002 Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER; IV (INFUSION)

BAXDELA

+! MELINTA

EQ 300MG BASE/VIAL

N208611 001 Jun 19, 2017

TABLET; ORAL

BAXDELA

+! MELINTA

EQ 450MG BASE

N208610 001 Jun 19, 2017

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+ VIIV HLTHCARE

100MG

N020705 001 Apr 04, 1997

+!

200MG

N020705 002 Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	AKORN	150MG	A065389 001	Dec 01, 2008
AB		300MG	A065389 002	Dec 01, 2008
AB	AMNEAL PHARM	150MG	A065425 001	Feb 27, 2008
AB	!	300MG	A065425 002	Feb 27, 2008
AB	BARR	150MG	A065171 001	Dec 13, 2004
AB		300MG	A065171 002	Dec 13, 2004
AB	EPIC PHARMA LLC	150MG	A065447 001	Aug 18, 2015
AB		300MG	A065447 002	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

KYBELLA

+! KYTHERA BIOPHARMS

20MG/2ML (10MG/ML)

N206333 001 Apr 29, 2015

DESFLURANE

LIQUID; INHALATION

SUPRANE

+! BAXTER HLTHCARE

99.9%

N020118 001 Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	10MG	A074430 001	Feb 09, 1996
AB		25MG	A071601 001	Jun 05, 1987
AB		50MG	A071588 001	Jun 05, 1987
AB		75MG	A071602 001	Oct 05, 1987
AB		100MG	A071766 001	Oct 05, 1987
AB		150MG	A074430 002	Feb 09, 1996
AB	AMNEAL PHARMS CO	10MG	A208105 001	Mar 17, 2016
AB		25MG	A208105 002	Mar 17, 2016
AB		50MG	A208105 003	Mar 17, 2016
AB		75MG	A208105 004	Mar 17, 2016
AB		100MG	A208105 005	Mar 17, 2016
AB		150MG	A208105 006	Mar 17, 2016
AB	COREPHARMA	10MG	A205153 001	Oct 28, 2016
AB		25MG	A205153 002	Oct 28, 2016
AB		50MG	A205153 003	Oct 28, 2016
AB		75MG	A205153 004	Oct 28, 2016
AB		100MG	A205153 005	Oct 28, 2016
AB		150MG	A205153 006	Oct 28, 2016
AB	HERITAGE PHARMS INC	10MG	A207433 001	May 05, 2016
AB		25MG	A207433 002	May 05, 2016
AB		50MG	A207433 003	May 05, 2016
AB		75MG	A207433 004	May 05, 2016
AB		100MG	A207433 005	May 05, 2016
AB		150MG	A207433 006	May 05, 2016
AB	INGENUS PHARMS LLC	10MG	A204963 001	Dec 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>25MG</u>	<u>A204963</u>	<u>002</u>	Dec 26, 2017
<u>AB</u>		<u>50MG</u>	<u>A204963</u>	<u>003</u>	Dec 26, 2017
<u>AB</u>		<u>75MG</u>	<u>A204963</u>	<u>004</u>	Dec 26, 2017
<u>AB</u>		<u>100MG</u>	<u>A204963</u>	<u>005</u>	Dec 26, 2017
<u>AB</u>		<u>150MG</u>	<u>A204963</u>	<u>006</u>	Dec 26, 2017
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>25MG</u>	<u>A072100</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988

NORPRAMIN

<u>AB</u>	+	US PHARM HOLDINGS	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>	+		<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>	+		<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>	+		<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>	+		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

		25MG	A071803	002	Dec 08, 1987
		50MG	A071803	003	Dec 08, 1987
		75MG	A071803	004	Dec 08, 1987
		150MG	A071803	005	May 29, 1997

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	!	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003
---	---	-------------------------	-----------	---------	-----	--------------

DESLOMATADINE

SOLUTION; ORAL

CLARINEX

<u>AA</u>	+	!	MERCK SHARP DOHME	<u>0.5MG/ML</u>	<u>N021300</u>	<u>001</u>	Sep 01, 2004
-----------	---	---	-------------------	-----------------	----------------	------------	--------------

DESLOMATADINE

<u>AA</u>			TARO PHARM	<u>0.5MG/ML</u>	<u>A202936</u>	<u>001</u>	May 26, 2016
<u>AA</u>			TARO PHARM INDS	<u>0.5MG/ML</u>	<u>A202592</u>	<u>001</u>	Jun 30, 2015

TABLET; ORAL

CLARINEX

<u>AB</u>	+	!	MERCK SHARP DOHME	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001
-----------	---	---	-------------------	------------	----------------	------------	--------------

DESLOMATADINE

<u>AB</u>			BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>			DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>			LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>			MYLAN PHARMS INC	<u>5MG</u>	<u>A078351</u>	<u>001</u>	Feb 10, 2012
<u>AB</u>			ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>			PERRIGO R AND D	<u>5MG</u>	<u>A078361</u>	<u>001</u>	Dec 22, 2011
<u>AB</u>			SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>			SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>	+		MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005
<u>AB</u>	+	!		<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002

DESLOMATADINE

<u>AB</u>			REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>				<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLOMATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+	!	MERCK SHARP DOHME	<u>5MG;240MG</u>	<u>N021605</u>	<u>001</u>	Mar 03, 2005
-----------	---	---	-------------------	------------------	----------------	------------	--------------

DESLOMATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

<u>AB</u>			DR REDDYS LABS LTD	<u>5MG;240MG</u>	<u>A078366</u>	<u>001</u>	Apr 26, 2011
			CLARINEX-D 12 HOUR				
	+	!	MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

PRESCRIPTION DRUG PRODUCT LIST

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

AP	+ !	FERRING PHARMS INC	0.004MG/ML	N018938	001	Mar 30, 1984
-----------	------------	--------------------	-------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

AP		SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017
-----------	--	---------------	-------------------	----------------	------------	--------------

AP			0.004MG/ML	A204751	001	Aug 22, 2017
-----------	--	--	-------------------	----------------	------------	--------------

AP		SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013
-----------	--	--------------------	-------------------	----------------	------------	--------------

SOLUTION; NASAL

DDAVP

AB	+ !	FERRING PHARMS INC	0.01%	N017922	001	
-----------	------------	--------------------	--------------	----------------	------------	--

DESMOPRESSIN ACETATE

AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

AB	+ !	FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996
-----------	------------	--------------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

AB	!	BAUSCH AND LOMB	0.01MG/SPRAY	A074830	001	Jan 25, 1999
-----------	----------	-----------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		APOTEX INC	0.01MG/SPRAY	A076703	001	Jan 27, 2005
-----------	--	------------	---------------------	----------------	------------	--------------

AB		SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013
-----------	--	-------------------	---------------------	----------------	------------	--------------

AB		ZYDUS PHARMS USA	0.01MG/SPRAY	A091345	001	Oct 03, 2017
-----------	--	------------------	---------------------	----------------	------------	--------------

INC

MINIRIN

AB	+ !	FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
-----------	------------	---------	---------------------	----------------	------------	--------------

NOCTIVA

+		AVADEL SPECIT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
----------	--	---------------	-----------------	---------	-----	--------------

+ !			0.00166MG/SPRAY	N201656	002	Mar 03, 2017
------------	--	--	-----------------	---------	-----	--------------

STIMATE (NEEDS NO REFRIGERATION)

+ !		FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007
------------	--	--------------------	--------------	---------	-----	--------------

TABLET; ORAL

DDAVP

AB	+	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995
-----------	----------	--------------------	--------------	----------------	------------	--------------

AB	+ !		0.2MG	N019955	002	Sep 06, 1995
-----------	------------	--	--------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

AB		ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005
-----------	--	---------------------	--------------	----------------	------------	--------------

AB			0.2MG	A076470	002	Jul 01, 2005
-----------	--	--	--------------	----------------	------------	--------------

AB		APOTEX INC	0.1MG	A077414	001	Mar 07, 2006
-----------	--	------------	--------------	----------------	------------	--------------

AB			0.2MG	A077414	002	Mar 07, 2006
-----------	--	--	--------------	----------------	------------	--------------

AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015
-----------	--	---------------------	--------------	----------------	------------	--------------

AB			0.2MG	A201831	002	May 28, 2015
-----------	--	--	--------------	----------------	------------	--------------

AB		HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017
-----------	--	-----------------	--------------	----------------	------------	--------------

AB			0.2MG	A207880	002	May 26, 2017
-----------	--	--	--------------	----------------	------------	--------------

AB		IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006
-----------	--	----------------	--------------	----------------	------------	--------------

AB			0.2MG	A077122	002	Jan 25, 2006
-----------	--	--	--------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	0.1MG	A200653	001	Jun 27, 2014
-----------	--	------------------	--------------	----------------	------------	--------------

AB			0.2MG	A200653	002	Jun 27, 2014
-----------	--	--	--------------	----------------	------------	--------------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

AB		LUPIN LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202226	001	Aug 12, 2015
-----------	--	-----------	------------------------------------	----------------	------------	--------------

CYCLESSA

AB	+ !	ASPEN GLOBAL INC	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N021090	001	Dec 20, 2000
-----------	------------	------------------	--	----------------	------------	--------------

DESOGEN

AB		ORGANON USA INC	0.15MG; 0.03MG	N020071	002	Dec 10, 1992
-----------	--	-----------------	-----------------------	----------------	------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	0.15MG, N/A; 0.02MG, 0.01MG	A209170	001	Jun 05, 2017
-----------	--	-----------------	------------------------------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	0.15MG, N/A; 0.02MG, 0.01MG	A206853	001	Mar 22, 2017
-----------	--	------------------	------------------------------------	----------------	------------	--------------

LTD

AB	!	DURAMED PHARMS BARR	0.15MG; 0.03MG	A075256	002	Aug 12, 1999
-----------	----------	---------------------	-----------------------	----------------	------------	--------------

AB		MAYNE PHARMA	0.15MG, N/A; 0.02MG, 0.01MG	A076916	001	Dec 29, 2008
-----------	--	--------------	------------------------------------	----------------	------------	--------------

AB			0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	A077182	001	Jan 24, 2006
-----------	--	--	--	----------------	------------	--------------

AB		MYLAN LABS LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202296	001	Aug 30, 2013
-----------	--	----------------	------------------------------------	----------------	------------	--------------

AB			0.15MG; 0.03MG	A202085	001	May 20, 2015
-----------	--	--	-----------------------	----------------	------------	--------------

AB		NOVAST LABS LTD	0.15MG; 0.03MG	A091234	001	Jul 12, 2013
-----------	--	-----------------	-----------------------	----------------	------------	--------------

AB		WATSON LABS	0.15MG; 0.03MG	A076915	001	Jul 29, 2005
-----------	--	-------------	-----------------------	----------------	------------	--------------

EMOQUETTE

AB		VINTAGE PHARMS LLC	0.15MG; 0.03MG	A076675	001	Feb 25, 2011
-----------	--	--------------------	-----------------------	----------------	------------	--------------

ENSKYCE

AB		LUPIN LTD	0.15MG; 0.03MG	A201887	001	Mar 07, 2013
-----------	--	-----------	-----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

ISIBLOOM

AB	LABS LEON FARMA	0.15MG;0.03MG	A202789 001	Aug 12, 2015
-----------	-----------------	----------------------	--------------------	--------------

KALLIGA

AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG	A207081 001	May 17, 2017
-----------	----------------------	----------------------	--------------------	--------------

KARIVA

AB	! BARR	0.15MG,N/A;0.02MG,0.01MG	A075863 001	Apr 05, 2002
-----------	--------	---------------------------------	--------------------	--------------

KIMIDESS

AB	VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681 001	Apr 30, 2015
-----------	----------------	---------------------------------	--------------------	--------------

PIMTREA

AB	NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247 001	Aug 01, 2013
-----------	-----------------	---------------------------------	--------------------	--------------

VELIVET

AB	DURAMED PHARMS BARR	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A076455 001	Feb 24, 2004
-----------	---------------------	---	--------------------	--------------

VIORELE

AB	GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346 001	Apr 02, 2012
-----------	-------------------	---------------------------------	--------------------	--------------

VOLNEA

AB	LABS LEON FARMA	0.15MG,N/A;0.02MG,0.01MG	A202689 001	Sep 09, 2016
-----------	-----------------	---------------------------------	--------------------	--------------

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+	!	AQUA PHARMS	0.05%	N021978 001	Sep 19, 2006
---	---	-------------	-------	-------------	--------------

CREAM; TOPICAL

DESONIDE

AB	G AND W LABS INC	0.05%	A074027 001	Sep 28, 1992
-----------	------------------	--------------	--------------------	--------------

AB	GLENMARK PHARMS	0.05%	A209729 001	Jul 24, 2017
-----------	-----------------	--------------	--------------------	--------------

AB	+	!	PERRIGO NEW YORK	0.05%	N017010 001
-----------	---	---	------------------	--------------	--------------------

AB	TARO	0.05%	A073548 001	Jun 30, 1992
-----------	------	--------------	--------------------	--------------

DESOWEN

AB	GALDERMA LABS LP	0.05%	N019048 001	Dec 14, 1984
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

DESONATE

+	!	BAYER HLTHCARE	0.05%	N021844 001	Oct 20, 2006
---	---	----------------	-------	-------------	--------------

LOTION; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002
-----------	----------------	--------------	--------------------	--------------

AB	GLENMARK PHARMS	0.05%	A209494 001	Sep 26, 2017
-----------	-----------------	--------------	--------------------	--------------

AB	TARO PHARM	0.05%	A202161 001	Oct 31, 2014
-----------	------------	--------------	--------------------	--------------

AB	TELLIGENT PHARMA INC	0.05%	A207855 001	Sep 28, 2017
-----------	----------------------	--------------	--------------------	--------------

DESOWEN

AB	!	GALDERMA LABS LP	0.05%	A072354 001	Jan 24, 1992
-----------	---	------------------	--------------	--------------------	--------------

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001
-----------	----------------	--------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	0.05%	A209996 001	Sep 15, 2017
-----------	---------------------	--------------	--------------------	--------------

AB	HI-TECH PHARMACAL	0.05%	A208836 001	Mar 27, 2017
-----------	-------------------	--------------	--------------------	--------------

AB	+	!	PERRIGO NEW YORK	0.05%	N017426 001
-----------	---	---	------------------	--------------	--------------------

AB	TARO	0.05%	A074254 001	Aug 03, 1994
-----------	------	--------------	--------------------	--------------

DESOWEN

AB	GALDERMA LABS LP	0.05%	A071425 001	Jun 15, 1988
-----------	------------------	--------------	--------------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A205082 001	Sep 04, 2015
-----------	----------------------	--------------	--------------------	--------------

AB	AKORN	0.05%	A203787 001	Jan 06, 2017
-----------	-------	--------------	--------------------	--------------

AB		0.25%	A203234 001	Jun 12, 2015
-----------	--	--------------	--------------------	--------------

AB	FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010
-----------	----------------	--------------	--------------------	--------------

AB	LUPIN ATLANTIS	0.05%	A208163 001	Jan 10, 2017
-----------	----------------	--------------	--------------------	--------------

AB		0.25%	A208164 001	Jan 09, 2017
-----------	--	--------------	--------------------	--------------

AB	PERRIGO NEW YORK	0.25%	A076510 001	Jul 01, 2003
-----------	------------------	--------------	--------------------	--------------

TOPICORT

AB	!	TARO	0.05%	A073210 001	Nov 30, 1990
-----------	---	------	--------------	--------------------	--------------

AB	!		0.25%	A073193 001	Nov 30, 1990
-----------	---	--	--------------	--------------------	--------------

GEL; TOPICAL

DESOXIMETASONE

AB	AKORN	0.05%	A090727 001	Mar 10, 2011
-----------	-------	--------------	--------------------	--------------

AB	PERRIGO NEW YORK	0.05%	A077552 001	Jan 09, 2006
-----------	------------------	--------------	--------------------	--------------

AB	RISING PHARMS INC	0.05%	A204675 001	Aug 12, 2016
-----------	-------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DESOXIMETASONE

GEL; TOPICAL

TOPICORT

AB	! TARO	0.05%	A074904	001	Jul 14, 1998
-----------	---------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A204965	001	Nov 07, 2016
AB	AKORN	0.25%	A201005	001	Apr 24, 2014
AB	FOUGERA PHARMS	0.25%	A078657	001	Sep 28, 2012
AB	G AND W LABS INC	0.25%	A206740	001	Dec 23, 2016
AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013
AB	LUPIN ATLANTIS	0.05%	A208044	001	Dec 12, 2016
AB		0.25%	A208104	001	Dec 01, 2016
AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015
AB	RISING PHARMS INC	0.25%	A204272	001	Nov 30, 2016
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016
AB	ZYDUS PHARMS USA INC	0.25%	A205206	001	Sep 19, 2017

TOPICORT

AB	+ ! TARO	0.05%	N018594	001	Jan 17, 1985
AB	!	0.25%	A074286	001	Jun 07, 1996

SPRAY; TOPICAL

DESOXIMETASONE

AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017
-----------	----------------	--------------	----------------	------------	--------------

TOPICORT

AT	+ ! TARO	0.25%	N204141	001	Apr 11, 2013
-----------	-----------------	--------------	----------------	------------	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+ ! ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+ !	100MG	N204150	002	Mar 04, 2013
	KHEDEZLA				
BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC		100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

	+ ! SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
	+ !	EQ 100MG BASE	N205583	002	Jan 28, 2014

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016
AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A204082	002	Aug 28, 2017
AB		EQ 50MG BASE	A204082	001	Feb 16, 2016
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A204020	001	Oct 11, 2017
AB		EQ 100MG BASE	A204020	002	Oct 11, 2017

PRISTIQ

AB	+ WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014
AB	+ !	EQ 50MG BASE	N021992	001	Feb 29, 2008
AB	+ !	EQ 100MG BASE	N021992	002	Feb 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+	!	12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

!	WEST-WARD PHARMS	1MG/ML	A088252	001	Sep 01, 1983
---	------------------	--------	---------	-----	--------------

INT

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011
AA	!	STI PHARMA LLC	0.5MG/5ML	A084754	001
AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011
AA	WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
---	----------	-------	---------	-----	--------------

SOLUTION; ORAL

DEXAMETHASONE

!	WEST-WARD PHARMS	0.5MG/5ML	A088248	001	Sep 01, 1983
---	------------------	-----------	---------	-----	--------------

INT

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

+	NOVARTIS PHARMS	0.1%	N013422	001	
---	-----------------	------	---------	-----	--

CORP

TABLET; ORAL

DEXAMETHASONE

AB	ECR	1.5MG	A040700	001	Aug 15, 2008
AB	LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017
AB	WEST-WARD PHARMS	1.5MG	A084610	001	
	INT				
BP	PAR PHARM	0.5MG	A088148	001	Apr 28, 1983
BP		0.75MG	A088160	001	Apr 28, 1983
BP		4MG	A088238	001	Apr 28, 1983
BP		6MG	A088481	001	Nov 28, 1983
BP	WEST-WARD PHARMS	0.5MG	A084611	001	
	INT				
BP		0.75MG	A084613	001	
BP		1MG	A088306	001	Sep 15, 1983
BP		2MG	A087916	001	Aug 26, 1982
BP		4MG	A084612	001	
BP	!	6MG	A088316	001	Sep 15, 1983
BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	AUROBINDO PHARMA	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015
	LTD				
AP	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001	
AP		EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015
AP	!	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005
AP	!	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	Jul 21, 1982
AP	MYLAN LABS LTD	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008
AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008
AP	WEST-WARD PHARMS	EQ 4MG PHOSPHATE/ML	A084282	001	
	INT				
AP	!	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	!	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003
-----------	---	--------------------	-----------------------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	
AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985

PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+ !	NOVARTIS PHARMS CORP	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065 002</u>	
-----------	------------	-------------------------	--	--------------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063 001</u>	Jul 25, 1994
-----------	--	-----------------	--	--------------------	--------------

AT		PERRIGO CO TENNESSEE	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938 001</u>	Jul 31, 1989
-----------	--	-------------------------	--	--------------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135 001</u>	Sep 13, 1995
-----------	--	-----------------	--	--------------------	--------------

MAXITROL

AT	+ !	NOVARTIS PHARMS CORP	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023 002</u>	
-----------	------------	-------------------------	--	--------------------	--

AT		SANDOZ INC	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341 001</u>	May 22, 1984
-----------	--	------------	--	--------------------	--------------

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+ !		NOVARTIS PHARMS CORP	0.1%;0.3%	N050616 001	Sep 28, 1988
------------	--	-------------------------	-----------	-------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	+ !	NOVARTIS PHARMS CORP	<u>0.1%;0.3%</u>	<u>N050592 001</u>	Aug 18, 1988
-----------	------------	-------------------------	------------------	--------------------	--------------

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134 001</u>	Oct 27, 1999
-----------	--	-----------------	------------------	--------------------	--------------

TOBRADEX ST

+ !		NOVARTIS PHARMS CORP	0.05%;0.3%	N050818 001	Feb 13, 2009
------------	--	-------------------------	------------	-------------	--------------

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

!		WOCKHARDT BIO AG	2MG/5ML	A088251 001	Mar 23, 1984
----------	--	------------------	---------	-------------	--------------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	+ !	TAKEDA PHARMS USA	<u>60MG</u>	<u>N022287 002</u>	Jan 30, 2009
-----------	------------	-------------------	-------------	--------------------	--------------

DEXLANSOPRAZOLE

AB		PAR PHARM INC	<u>60MG</u>	<u>A202294 001</u>	Apr 19, 2017
-----------	--	---------------	-------------	--------------------	--------------

DEXILANT

+		TAKEDA PHARMS USA	30MG	N022287 001	Jan 30, 2009
----------	--	-------------------	------	-------------	--------------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204023 001</u>	Feb 09, 2016
-----------	--	-----------------	---	--------------------	--------------

AP		ACTAVIS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204686 001</u>	Oct 17, 2016
-----------	--	-------------	---	--------------------	--------------

AP		AKORN INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585 001</u>	Nov 24, 2014
-----------	--	-----------	---	--------------------	--------------

AP		AUROBINDO PHARMA LTD	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205867 001</u>	Mar 17, 2016
-----------	--	-------------------------	---	--------------------	--------------

AP		FRESENIUS KABI USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A201072 001</u>	Sep 18, 2015
-----------	--	--------------------	---	--------------------	--------------

AP		JIANGSU HENGRUI MED	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A209065 001</u>	Sep 19, 2017
-----------	--	---------------------	---	--------------------	--------------

AP		LUITPOLD PHARMS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203773 001</u>	May 12, 2017
-----------	--	---------------------	---	--------------------	--------------

AP		MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881 001</u>	Aug 18, 2014
-----------	--	---------------------	---	--------------------	--------------

AP		PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972 001</u>	Aug 18, 2014
-----------	--	-------------------------	---	--------------------	--------------

AP		SANDOZ INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A091465 001</u>	Jun 14, 2016
-----------	--	------------	---	--------------------	--------------

AP		SUN PHARM INDS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202126 001</u>	Aug 20, 2015
-----------	--	--------------------	---	--------------------	--------------

AP		TEVA PHARMS USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205272 001</u>	Nov 28, 2017
-----------	--	-----------------	---	--------------------	--------------

AP		WEST-WARD PHARMS INT	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205046 001</u>	Apr 26, 2017
-----------	--	-------------------------	---	--------------------	--------------

PRECEDEX

AP	+ !	HOSPIRA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038 001</u>	Dec 17, 1999
-----------	------------	---------	---	--------------------	--------------

+ !			EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038 004	Nov 14, 2014
------------	--	--	--------------------------------------	-------------	--------------

+ !			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038 002	Mar 13, 2013
------------	--	--	---------------------------------------	-------------	--------------

+ !			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038 003	Mar 13, 2013
------------	--	--	--	-------------	--------------

SOLUTION;IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

+ !		HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628 002	Oct 21, 2015
------------	--	-----------------	--------------------------------------	-------------	--------------

+			EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628 001	Oct 21, 2015
----------	--	--	--	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A079108 001</u>	Aug 05, 2015
<u>AB</u>		<u>10MG</u>	<u>A079108 002</u>	Aug 05, 2015
<u>AB</u>		<u>15MG</u>	<u>A079108 003</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A079108 004</u>	Dec 21, 2015
<u>AB</u>		<u>25MG</u>	<u>A203614 001</u>	Jul 05, 2017
<u>AB</u>		<u>30MG</u>	<u>A079108 005</u>	Nov 21, 2013
<u>AB</u>		<u>35MG</u>	<u>A203614 002</u>	Jul 05, 2017
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>15MG</u>	<u>A078992 003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992 004</u>	Nov 18, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A204266 001</u>	Aug 25, 2015
<u>AB</u>		<u>10MG</u>	<u>A204266 002</u>	Aug 25, 2015
<u>AB</u>		<u>15MG</u>	<u>A204266 003</u>	Aug 25, 2015
<u>AB</u>		<u>20MG</u>	<u>A204266 004</u>	Dec 21, 2015
<u>AB</u>		<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>		<u>40MG</u>	<u>A204266 007</u>	Aug 25, 2015
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A202842 001</u>	Nov 30, 2016
<u>AB</u>		<u>10MG</u>	<u>A202842 002</u>	Nov 30, 2016
<u>AB</u>		<u>15MG</u>	<u>A202842 003</u>	Nov 30, 2016
<u>AB</u>		<u>20MG</u>	<u>A202842 004</u>	Nov 30, 2016
<u>AB</u>		<u>25MG</u>	<u>A202842 005</u>	Nov 30, 2016
<u>AB</u>		<u>30MG</u>	<u>A202842 006</u>	Nov 30, 2016
<u>AB</u>		<u>35MG</u>	<u>A202842 007</u>	Nov 30, 2016
<u>AB</u>		<u>40MG</u>	<u>A202842 008</u>	Nov 30, 2016
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908 004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013
<u>AB</u>		<u>25MG</u>	<u>A202731 001</u>	Jul 05, 2017
<u>AB</u>		<u>30MG</u>	<u>A202731 003</u>	May 19, 2014
<u>AB</u>		<u>35MG</u>	<u>A202731 004</u>	Jul 05, 2017
<u>AB</u>		<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013
<u>FOCALIN XR</u>				
<u>AB</u>	+ NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>	+	<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>	+	<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>	+	<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>	+	<u>25MG</u>	<u>N021802 008</u>	Apr 21, 2011
<u>AB</u>	+	<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>	+	<u>35MG</u>	<u>N021802 007</u>	Apr 21, 2011
<u>AB</u>	+	<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>2.5MG</u>	<u>A206931 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A206931 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A206931 003</u>	Dec 04, 2015
<u>AB</u>	LANNETT CO INC	<u>2.5MG</u>	<u>A209468 001</u>	Sep 25, 2017
<u>AB</u>		<u>5MG</u>	<u>A209468 002</u>	Sep 25, 2017
<u>AB</u>		<u>10MG</u>	<u>A209468 003</u>	Sep 25, 2017
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A204534 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A204534 003</u>	Dec 04, 2015
<u>AB</u>	RHODES PHARMS	<u>2.5MG</u>	<u>A208756 001</u>	Nov 20, 2017
<u>AB</u>		<u>5MG</u>	<u>A208756 002</u>	Nov 20, 2017
<u>AB</u>		<u>10MG</u>	<u>A208756 003</u>	Nov 20, 2017
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A201231 001</u>	Sep 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A201231 002</u>	Sep 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A201231 003</u>	Sep 24, 2015
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107 003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107 001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107 002</u>	Jan 29, 2007
<u>AB</u>	TRIS PHARMA INC	<u>2.5MG</u>	<u>A207901 001</u>	Aug 26, 2016
<u>AB</u>		<u>5MG</u>	<u>A207901 002</u>	Aug 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A207901 003</u>	Aug 26, 2016
<u>FOCALIN</u>				
<u>AB</u>	+ NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>	+	<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001

PRESCRIPTION DRUG PRODUCT LIST

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A207321 001</u>	Nov 28, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004

ZINECARD

<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995
<u>AP</u>	+!	<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995
	TOTECT			
	+! CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025 001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	+ IMPAX LABS INC	<u>5MG</u>	<u>N017078 001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017078 002</u>	
<u>AB</u>	+!	<u>15MG</u>	<u>N017078 003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901 001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901 002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901 003</u>	Nov 30, 2012
<u>AB</u>	MAYNE PHARMA	<u>5MG</u>	<u>A076137 001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137 002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137 003</u>	Jan 18, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A206735 001</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206735 002</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206735 003</u>	Jan 27, 2016
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A209111 001</u>	Jun 27, 2017
<u>AB</u>		<u>10MG</u>	<u>A209111 002</u>	Jun 27, 2017
<u>AB</u>		<u>15MG</u>	<u>A209111 003</u>	Jun 27, 2017
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076353 001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353 002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353 003</u>	May 06, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A205673 001</u>	Oct 31, 2017
<u>AB</u>		<u>10MG</u>	<u>A205673 002</u>	Oct 31, 2017
<u>AB</u>		<u>15MG</u>	<u>A205673 003</u>	Oct 31, 2017

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	! OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776 001</u>	Jan 29, 2008
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644 001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893 001</u>	Jul 31, 2013
<u>AA</u>		<u>10MG</u>	<u>A202893 002</u>	Jul 31, 2013
<u>AA</u>	AVANTHI INC	<u>5MG</u>	<u>A203548 001</u>	Nov 23, 2015
<u>AA</u>		<u>10MG</u>	<u>A203548 002</u>	Nov 23, 2015
<u>AA</u>	BARR	<u>5MG</u>	<u>A040361 001</u>	Jan 31, 2001
<u>AA</u>	!	<u>10MG</u>	<u>A040361 002</u>	Jan 31, 2001
<u>AA</u>	MIKART	<u>5MG</u>	<u>A090533 002</u>	Oct 25, 2011
<u>AA</u>		<u>10MG</u>	<u>A090533 004</u>	Oct 25, 2011
<u>AA</u>	NESHER PHARMS	<u>5MG</u>	<u>A206588 001</u>	Mar 28, 2016
<u>AA</u>		<u>10MG</u>	<u>A206588 002</u>	Mar 28, 2016
<u>AA</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204330 001</u>	Mar 16, 2016
<u>AA</u>		<u>10MG</u>	<u>A204330 002</u>	Mar 16, 2016
<u>AA</u>	SPECGX LLC	<u>5MG</u>	<u>A040436 001</u>	Jan 29, 2002
<u>AA</u>		<u>10MG</u>	<u>A040436 002</u>	Jan 29, 2002
<u>AA</u>	SUNRISE PHARM INC	<u>5MG</u>	<u>A210059 001</u>	Oct 18, 2017
<u>AA</u>		<u>10MG</u>	<u>A210059 002</u>	Oct 18, 2017
	MIKART	2.5MG	A090533 001	Oct 25, 2011
		7.5MG	A090533 003	Oct 25, 2011
		15MG	A090533 005	Oct 25, 2011
		20MG	A090533 006	Oct 25, 2011
		30MG	A090533 007	Oct 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

AA	G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762 001	Oct 31, 1984
	<u>PROMETHAZINE DM</u>			
AA	! VINTAGE	15MG/5ML; 6.25MG/5ML	A040649 001	Feb 14, 2006
	<u>PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE</u>			
AA	HI TECH PHARMA	15MG/5ML; 6.25MG/5ML	A040027 001	Jul 31, 1996
	<u>PROMETHAZINE W/ DEXTROMETHORPHAN</u>			
AA	WOCKHARDT BIO AG	15MG/5ML; 6.25MG/5ML	A088864 001	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB	ACTAVIS ELIZABETH	20MG; 10MG	A202934 001	Oct 10, 2017
	<u>NUDEXTA</u>			
AB	+! AVANIR PHARMS	20MG; 10MG	N021879 001	Oct 29, 2010

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+! B BRAUN	10GM/100ML	N019626 004	Feb 02, 1988
AP	+! BAXTER HLTHCARE	10GM/100ML	N016694 001	
AP	+! ICU MEDICAL INC	10GM/100ML	N018080 001	

DEXTROSE 20% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	20GM/100ML	N017521 004	
AP	+! ICU MEDICAL INC	20GM/100ML	N018564 001	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	30GM/100ML	N017521 003	
AP	+! ICU MEDICAL INC	30GM/100ML	N019345 001	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	40GM/100ML	N017521 002	
AP	+! ICU MEDICAL INC	40GM/100ML	N018562 001	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+! B BRAUN	50MG/ML	N016730 002	
AP	+!	5GM/100ML	N016730 001	
AP	+!	5GM/100ML	N019626 002	Feb 02, 1988
AP	+! BAXTER HLTHCARE	50MG/ML	N016673 003	Oct 30, 1985
AP	+!	50MG/ML	N020179 002	Dec 07, 1992
AP	+!	5GM/100ML	N016673 001	
AP	+!	5GM/100ML	N020179 001	Dec 07, 1992
AP	FRESENIUS KABI USA	50MG/ML	A207449 001	Oct 21, 2016
AP	+! HOSPIRA	50MG/ML	N019222 001	Jul 13, 1984
AP	+!	5GM/100ML	N019466 001	Jul 15, 1985
AP	+!	5GM/100ML	N019479 001	Sep 17, 1985
AP	+! ICU MEDICAL INC	50MG/ML	N016367 002	

DEXTROSE 50% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	50GM/100ML	N017521 001	
AP	+!	50GM/100ML	N020047 001	Jul 02, 1991
AP	+! ICU MEDICAL INC	50GM/100ML	N018563 001	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	70GM/100ML	N017521 006	Mar 26, 1982
AP	+!	70GM/100ML	N020047 003	Jul 02, 1991
AP	+! ICU MEDICAL INC	70GM/100ML	N018561 001	Mar 23, 1982
AP	+!	70GM/100ML	N019893 001	Dec 26, 1989

DEXTROSE 25%

+!	HOSPIRA	250MG/ML	N019445 002	Nov 23, 1998
----	---------	----------	-------------	--------------

DEXTROSE 50%

+	HOSPIRA	500MG/ML	N019445 003	Sep 03, 2014
---	---------	----------	-------------	--------------

DEXTROSE 50% IN PLASTIC CONTAINER

+	HOSPIRA	500MG/ML	N019445 001	Jun 03, 1986
---	---------	----------	-------------	--------------

DEXTROSE 60% IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	60GM/100ML	N017521 005	Mar 26, 1982
----	-----------------	------------	-------------	--------------

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385 001	
--	-----------------	---	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610	001
-----------------	---	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873	001	Jun 10, 1993
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484	001
-----------------	---	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513	001	May 08, 1986
-----------------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609	001
-----------------	--	---------	-----

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML	N017634	001
----	---	-----------------	------------------------	---------	-----

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003
----	---	-----------------	------------------------	---------	-----

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML	N017634	002
----	---	-----------------	------------------------	---------	-----

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML; 150MG/100ML	N019699	004	Sep 29, 1989
----	--	---------	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML; 300MG/100ML	N019699	006	Sep 29, 1989
----	--	---------	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003
----	--	-----------------	------------------------	---------	-----

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634	004
---	-----------------	-----------------------	---------	-----

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 149MG/100ML	N018371	001
-----------------	------------------------	---------	-----

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002
-----------------	------------------------	---------	-----

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP		BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037	006	Apr 13, 1982
----	--	-----------------	------------------------------------	---------	-----	--------------

AP		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	007	Apr 13, 1982
----	--	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP		BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037	004
----	--	-----------------	-------------------------------------	---------	-----

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	008	Apr 13, 1982
----	--	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP		BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037	001
----	--	-----------------	-------------------------------------	---------	-----

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP		BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037	005	Apr 13, 1982
----	--	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP		BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037	009	Apr 13, 1982
----	--	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP		BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037	002
----	--	-----------------	------------------------------------	---------	-----

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	003
----	--	-----------------	-------------------------------------	---------	-----

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 330MG/100ML	N018629	005	Mar 23, 1982
----	--	-----------------	------------------------------------	---------	-----	--------------

AP		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 330MG/100ML	N018629	002	Mar 23, 1982
----	--	-----------------	-------------------------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;330MG/100ML</u>	<u>N018629 003</u> Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N018629 004</u> Mar 23, 1982
<u>AP</u>		<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N018629 006</u> Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;330MG/100ML</u>	<u>N018629 007</u> Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N018629 008</u> Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N018629 001</u> Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 010</u>
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;200MG/100ML</u>	<u>N019630 008</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N019630 014</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N019630 020</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019630 026</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N019630 010</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N019630 016</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N019630 022</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019630 028</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N019630 012</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N019630 018</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N019630 024</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019630 030</u> Feb 17, 1988
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N018008 005</u> Apr 28, 1982
<u>AP</u>		<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 006</u> Apr 28, 1982
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 005</u> Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 009</u> Jul 05, 1983
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019308 004</u> Apr 05, 1985
<u>AP</u>		<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 002</u> Apr 05, 1985
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 002</u> Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 004</u> Mar 24, 1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 006</u> Mar 28, 1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 006</u> Mar 24, 1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 007</u> Apr 28, 1982
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 010</u> Jul 05, 1983
<u>AP</u>		<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 007</u> Mar 28, 1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 005</u> Apr 05, 1985
<u>AP</u>		<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 003</u> Apr 05, 1985
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 005</u> Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 008</u> Mar 24, 1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008 008</u> Apr 28, 1982
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362 002</u>
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019308 006</u> Apr 05, 1985
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691 007</u> Mar 24, 1988
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 009</u> Apr 28, 1982
<u>AP</u>	<u>ICU MEDICAL INC</u>	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362 003</u>

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 007</u>	Apr 05, 1985
<u>AP</u>	ICU MEDICAL INC	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 009</u>	Mar 24, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 004</u>	
<u>AP</u>	ICU MEDICAL INC	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 008</u>	Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 004</u>	Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 001</u>	Apr 05, 1985
<u>AP</u>	ICU MEDICAL INC	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 001</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 003</u>	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;200MG/100ML N019630 031 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;450MG/100ML N019630 037 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N019630 043 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N019630 001 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N019630 007 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N019630 013 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N019630 039 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N019630 045 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;110MG/100ML;300MG/100ML N019630 050 May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;110MG/100ML N019630 003 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;200MG/100ML N019630 009 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;330MG/100ML N019630 015 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;450MG/100ML N019630 021 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;900MG/100ML N019630 027 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;200MG/100ML N019630 034 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;450MG/100ML N019630 040 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;900MG/100ML N019630 046 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;150MG/100ML;300MG/100ML N019630 051 May 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML		N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML		N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML		N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML		N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML		N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML		N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML		N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML		N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML		N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER		
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML		N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML		N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER		
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML		N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 002	Jul 05, 1983
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML		N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 001	Jan 17, 1986
ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML		N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML		N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML		N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML		N018365 001	
+ ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML		N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML		N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML		N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML		N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML		N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML		N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML		N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 005	Mar 28, 1988
ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML		N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER		
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 005	Mar 28, 1988
ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML		N018876 009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631 004</u>	Feb 24, 1988
AP	+! BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631 007</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631 008</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631 009</u>	Feb 24, 1988
AP	ICU MEDICAL INC	<u>5GM/100ML;450MG/100ML</u>	<u>N017607 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631 010</u>	Feb 24, 1988
AP	+! ICU MEDICAL INC	<u>5GM/100ML;900MG/100ML</u>	<u>N017585 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N016689 001
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N016687 001
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N016683 001
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N016678 001
	DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;110MG/100ML	N019631 011 Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;200MG/100ML	N019631 012 Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;330MG/100ML	N019631 013 Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;450MG/100ML	N019631 014 Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;900MG/100ML	N019631 015 Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001 Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002 Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003 Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005 Feb 24, 1988
	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016 Jan 19, 1990
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;110MG/100ML	N019631 006 Feb 24, 1988
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER		
	+! ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606 001
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799 001

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

	+ BRACCO	30%	N010040 018
	CYSTOGRAFIN DILUTE		
	+ BRACCO	18%	N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOGRAFIN-76

	+! BRACCO	66%;10%	N010040 001
--	-----------	---------	-------------

SOLUTION; ORAL, RECTAL

GASTROGRAFIN

AA	+! BRACCO	66%;10%	N011245 003
	<u>MD-GASTROVIEW</u>		
AA	LIEBEL-FLARSHEIM	66%;10%	A087388 001

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

	+! BRACCO	52.7%;26.8%	N011324 002
--	-----------	-------------	-------------

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/ML	A204433 001 Apr 14, 2014
-----------	----------------------	---------------	---------------------------------

DIAZEPAM INTENSOL

AA	! WEST-WARD PHARMS INT	5MG/ML	A071415 001 Apr 03, 1987
-----------	------------------------	---------------	---------------------------------

GEL; RECTAL

DIASTAT

	+ VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)	N020648 001 Jul 29, 1997
	DIASTAT ACUDIAL		
	+ VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)	N020648 007 Sep 15, 2005
	+!	20MG/4ML (5MG/ML)	N020648 006 Sep 15, 2005

PRESCRIPTION DRUG PRODUCT LIST

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

! HOSPIRA

10MG/2ML (5MG/ML)

A072079 001 Dec 20, 1988

!

50MG/10ML (5MG/ML)

A071583 001 Oct 13, 1987

SOLUTION; ORAL

DIAZEPAM**AA** LANNETT HOLDINGS
INC**5MG/5ML****A206477 001** Jun 24, 2016**AA** ! WEST-WARD PHARMS
INT**5MG/5ML****A070928 001** Apr 03, 1987

TABLET; ORAL

DIAZEPAM**AB** BARR**2MG****A070152 001** Nov 01, 1985**AB****10MG****A070154 001** Nov 01, 1985**AB** IVAX SUB TEVA
PHARMS**2MG****A071307 001** Dec 10, 1986**AB****5MG****A071321 001** Dec 10, 1986**AB****10MG****A071322 001** Dec 10, 1986**AB** MAYNE PHARMA**2MG****A071134 001** Feb 03, 1987**AB****5MG****A071135 001** Feb 03, 1987**AB****10MG****A071136 001** Feb 03, 1987**AB** MYLAN**2MG****A070325 002** Sep 04, 1985**AB****5MG****A070325 003** Sep 04, 1985**AB****10MG****A070325 001** Sep 04, 1985**AB** VINTAGE PHARMS**2MG****A077749 001** Mar 31, 2006**AB****5MG****A077749 002** Mar 31, 2006**AB****10MG****A077749 003** Mar 31, 2006VALIUM**AB** + ROCHE**2MG****N013263 002****AB** +**5MG****N013263 004****AB** +!**10MG****N013263 006**

DIAZEPAM

DAVA PHARMS INC

2MG

A070228 002 Sep 26, 1985

5MG

A070228 003 Sep 26, 1985

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+! TEVA BRANDED PHARM

50MG/ML

N017453 001

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

+! STRONGBRIDGE US

50MG

N011366 002 Aug 07, 2015

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

+ IROKO PHARMS LLC

18MG

N204592 001 Oct 18, 2013

+!

35MG

N204592 002 Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+! INST BIOCHEM

1.3%

N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM**AB** BIONPHARMA INC**25MG****A204648 001** Feb 23, 2016ZIPSOR**AB** +! DEPOMED INC**25MG****N022202 001** Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA**AB** +! DEPOMED INC**50MG****N022165 001** Jun 17, 2009DICLOFENAC POTASSIUM**AB** PAR FORM**50MG****A202964 001** May 02, 2016

TABLET; ORAL

DICLOFENAC POTASSIUM**AB** APOTEX**50MG****A076561 001** Mar 18, 2004**AB** ! MYLAN**50MG****A075463 001** Jul 26, 1999**AB** SANDOZ**50MG****A075229 001** Nov 20, 1998**AB** TEVA**50MG****A075219 001** Aug 06, 1998

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	ACTAVIS MID ATLANTIC	3%	A206493 001	Dec 02, 2015
AB	AMNEAL PHARMS	1%	A208077 001	Mar 18, 2016
AB	GLENMARK PHARMS LTD	3%	A208301 001	Sep 13, 2016
AB	TARO	3%	A206298 001	Apr 28, 2016

DICLOFENAC SODIUM

AB	TOLMAR	3%	A200936 001	Oct 28, 2013
-----------	--------	-----------	--------------------	--------------

SOLARAZE

AB	+! FOUGERA PHARMS	3%	N021005 001	Oct 16, 2000
-----------	-------------------	-----------	--------------------	--------------

VOLTAREN

AB	+! GLAXOSMITHKLINE CONS	1%	N022122 001	Oct 17, 2007
-----------	-------------------------	-----------	--------------------	--------------

SOLUTION; INTRAVENOUS

DYLOJECT

+!	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396 001	Dec 23, 2014
----	--------------------	-----------------------	-------------	--------------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	AMNEAL PHARMS	1.5%	A206116 001	Sep 02, 2016
AT	ANDA REPOSITORY	1.5%	A202393 001	Nov 24, 2014
AT	! APOTEX INC	1.5%	A202027 001	May 27, 2014
AT	LUPIN LTD	1.5%	A204132 001	Aug 20, 2015
AT	NOVEL LABS INC	1.5%	A205878 001	Dec 09, 2015
AT	RICONPHARMA LLC	1.5%	A206715 001	Aug 07, 2017
AT	TARO	1.5%	A203818 001	Nov 26, 2014
AT	TELIGENT PHARMA INC	1.5%	A202769 001	Jul 08, 2015
AT	WATSON LABS INC	1.5%	A202852 001	Nov 24, 2014

PENNSAID

+!	HORIZON PHARMA	2%	N204623 001	Jan 16, 2014
----	----------------	----	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT	AKORN	0.1%	A077845 001	Apr 17, 2008
AT	ALTAIRE PHARMS INC	0.1%	A203383 001	Nov 16, 2015
AT	BAUSCH AND LOMB	0.1%	A078792 001	Dec 28, 2007
AT	RISING PHARMS INC	0.1%	A078553 001	Dec 28, 2007
AT	SANDOZ INC	0.1%	A078031 001	Feb 06, 2008

VOLTAREN

AT	+! NOVARTIS	0.1%	N020037 001	Mar 28, 1991
-----------	-------------	-------------	--------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ACTAVIS ELIZABETH	50MG	A074514 001	Mar 26, 1996
AB		75MG	A074514 002	Mar 26, 1996
AB	CARLSBAD	25MG	A075185 002	Nov 13, 1998
AB		50MG	A075185 003	Nov 13, 1998
AB		75MG	A075185 001	Nov 13, 1998
AB	MYLAN PHARMS INC	50MG	A075281 002	Feb 12, 2002
AB		75MG	A075281 003	Feb 12, 2002
AB	! SANDOZ	25MG	A074376 001	Sep 28, 1995
AB	!	50MG	A074376 002	Sep 28, 1995
AB	!	75MG	A074394 001	Nov 30, 1995
AB	UNIQUE PHARM LABS	25MG	A090066 001	Dec 01, 2010
AB		50MG	A090066 002	Dec 01, 2010
AB		75MG	A077863 003	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	! DEXCEL LTD	100MG	A076201 001	Nov 06, 2002
AB	MYLAN	100MG	A076152 001	Dec 13, 2001
AB	VPNA	100MG	A075492 001	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	+ GD SEARLE LLC	50MG; 0.2MG	N020607 001	Dec 24, 1997
AB	+!	75MG; 0.2MG	N020607 002	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB	ACTAVIS LABS FL INC	50MG; 0.2MG	A201089 001	Jul 09, 2012
AB		75MG; 0.2MG	A201089 002	Jul 09, 2012
AB	AMNEAL PHARMS	50MG; 0.2MG	A203995 001	Nov 25, 2016
AB		75MG; 0.2MG	A203995 002	Nov 25, 2016
AB	EXELA HOLDINGS	50MG; 0.2MG	A200540 001	Mar 14, 2014
AB		75MG; 0.2MG	A200540 002	Mar 14, 2014

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	SANDOZ	50MG;0.2MG	A200158 001	May 09, 2013
AB		75MG;0.2MG	A200158 002	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

AB	SANDOZ	EQ 250MG BASE	A061454 001	
AB	!	EQ 500MG BASE	A061454 003	
AB	TEVA	EQ 250MG BASE	A062286 001	Jun 03, 1982
AB		EQ 500MG BASE	A062286 002	Jun 03, 1982
	SANDOZ	EQ 125MG BASE	A061454 002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

AB	+!	FOREST LABS INC	10MG	N007409 003	Oct 15, 1984
-----------	----	-----------------	-------------	--------------------	--------------

DICYCLOMINE HYDROCHLORIDE

AB		LANNETT	10MG	A084285 001	
AB		MYLAN	10MG	A040319 001	Sep 07, 1999
AB		WATSON LABS	10MG	A085082 001	Jun 19, 1986

INJECTABLE; INJECTION

BENTYL

AP	+!	FOREST LABS INC	10MG/ML	N008370 001	Oct 15, 1984
-----------	----	-----------------	----------------	--------------------	--------------

BENTYL PRESERVATIVE FREE

AP	+!	FOREST LABS INC	10MG/ML	N008370 002	Oct 15, 1984
-----------	----	-----------------	----------------	--------------------	--------------

DICYCLOMINE HYDROCHLORIDE

AP		LUITPOLD PHARMS INC	10MG/ML	A208353 001	Feb 17, 2017
-----------	--	---------------------	----------------	--------------------	--------------

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP		WEST-WARD PHARMS	10MG/ML	A040465 001	Jun 30, 2003
-----------	--	------------------	----------------	--------------------	--------------

INT

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

! MIKART

10MG/5ML

A040169 001 Mar 24, 2005

TABLET;ORAL

BENTYL

AB	+!	FOREST LABS INC	20MG	N007409 001	Oct 15, 1984
-----------	----	-----------------	-------------	--------------------	--------------

DICYCLOMINE HYDROCHLORIDE

AB		LANNETT	20MG	A040230 001	Feb 26, 1999
AB		MYLAN	20MG	A040317 001	Sep 07, 1999
AB		WATSON LABS	20MG	A085223 001	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AB		AUROBINDO PHARMA	125MG	A090094 001	Sep 24, 2008
AB			200MG	A090094 002	Sep 24, 2008
AB			250MG	A090094 003	Sep 24, 2008
AB			400MG	A090094 004	Sep 24, 2008
AB		BARR	200MG	A077167 001	Dec 03, 2004
AB			250MG	A077167 002	Dec 03, 2004
AB			400MG	A077167 003	Dec 03, 2004

VIDEX EC

AB	+	BRISTOL MYERS SQUIBB	125MG	N021183 001	Oct 31, 2000
AB	+		200MG	N021183 002	Oct 31, 2000
AB	+		250MG	N021183 003	Oct 31, 2000
AB	+!		400MG	N021183 004	Oct 31, 2000

FOR SOLUTION;ORAL

VIDEX

+! BRISTOL-MYERS
SQUIBB

10MG/ML

N020156 001 Oct 09, 1991

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

+! BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A

N022252 001 May 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	AVANTHI INC	25MG	A201212 001	Dec 22, 2010
AA	LANNETT HOLDINGS INC	25MG	A200177 001	Jul 18, 2011

TENUATE

AA	+ !	ACTAVIS LABS UT INC	25MG	N011722 002
-----------	------------	---------------------	-------------	--------------------

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

AB	LANNETT HOLDINGS INC	75MG	A091680 001	Oct 24, 2011
-----------	-------------------------	-------------	--------------------	--------------

TENUATE DOSPAN

AB	+ !	ACTAVIS LABS UT INC	75MG	N012546 001
-----------	------------	---------------------	-------------	--------------------

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	!	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002
BX	!	TARO	0.05%	A075508 001	Apr 24, 2000

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	AKORN	0.05%	A206572 001	Jul 24, 2015	
AB	FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999	
AB	RICONPHARMA LLC	0.05%	A207440 001	Feb 27, 2017	
AB	!	TARO	0.05%	A075331 001	May 14, 1999

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	HERITAGE PHARMA	500MG	A202845 001	Mar 08, 2012	
AB	!	TEVA	500MG	A073673 001	Jul 31, 1992
AB	ZYDUS PHARMS USA INC	500MG	A203547 001	Jun 16, 2017	

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+ !	NOVARTIS PHARMS CORP	0.05%	N022212 001	Jun 23, 2008
--	------------	-------------------------	-------	-------------	--------------

DIGOXIN

ELIXIR; ORAL

DIGOXIN

	+ !	WEST-WARD PHARMS INT	0.05MG/ML	N021648 001	Aug 26, 2004
--	------------	-------------------------	-----------	-------------	--------------

INJECTABLE; INJECTION

DIGOXIN

AP	SANDOZ INC	0.25MG/ML	A040481 001	Aug 21, 2003
AP	WEST-WARD PHARMS INT	0.25MG/ML	A083391 001	

LANOXIN

AP	+ !	COVIS PHARMA BV	0.25MG/ML	N009330 002
-----------	------------	-----------------	------------------	--------------------

LANOXIN PEDIATRIC

	+ !	COVIS PHARMA BV	0.1MG/ML	N009330 004
--	------------	-----------------	----------	-------------

TABLET; ORAL

DIGOXIN

AB	HIKMA INTL PHARMS	0.125MG	A077002 002	Oct 30, 2007
AB		0.25MG	A077002 001	Oct 30, 2007
AB	IMPAX LABS	0.125MG	A078556 001	Jul 20, 2009
AB		0.25MG	A078556 002	Jul 20, 2009
AB	MYLAN PHARMS INC	0.125MG	A040282 001	Dec 23, 1999
AB		0.25MG	A040282 002	Dec 23, 1999
AB	STEVENS J	0.125MG	A076268 001	Jul 26, 2002
AB		0.25MG	A076268 002	Jul 26, 2002
AB	SUN PHARM INDS INC	0.125MG	A076363 001	Jan 31, 2003
AB		0.25MG	A076363 002	Jan 31, 2003

LANOXIN

AB	+	CONCORDIA PHARMS INC	0.125MG	N020405 002	Sep 30, 1997
-----------	----------	-------------------------	----------------	--------------------	--------------

AB	+ !		0.25MG	N020405 004	Sep 30, 1997
	+		0.0625MG	N020405 001	Sep 30, 1997
	+		0.1875MG	N020405 003	Sep 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

<u>AP</u>	<u>+!</u>	<u>VALEANT</u>	<u>1MG/ML</u>	<u>N005929</u>	<u>001</u>	
<u>DIHYDROERGOTAMINE MESYLATE</u>						
<u>AP</u>		<u>HIKMA PHARMS</u>	<u>1MG/ML</u>	<u>A206621</u>	<u>001</u>	Sep 15, 2017
<u>AP</u>		<u>PADDOCK LLC</u>	<u>1MG/ML</u>	<u>A040475</u>	<u>001</u>	Apr 28, 2003
<u>AP</u>		<u>WEST-WARD PHARMS</u>	<u>1MG/ML</u>	<u>A040453</u>	<u>001</u>	Jun 09, 2003
INT						
SPRAY, METERED; NASAL						
MIGRANAL						
	<u>+!</u>	<u>VALEANT</u>	<u>0.5MG/INH</u>	<u>N020148</u>	<u>001</u>	Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>		<u>APOTEX</u>	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>			<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>			<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>		<u>MYLAN</u>	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>			<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>	<u>!</u>		<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998
<u>CARDIZEM CD</u>						
<u>AB3</u>	<u>+</u>	<u>VALEANT INTL</u>	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>	<u>+</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>	<u>+</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>	<u>+</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	<u>+!</u>		<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999
<u>CARTIA XT</u>						
<u>AB3</u>		<u>ACTAVIS LABS FL INC</u>	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>			<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>			<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>			<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998
<u>DILTIAZEM HYDROCHLORIDE</u>						
<u>AB3</u>		<u>ACTAVIS ELIZABETH</u>	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>		<u>PAR PHARM</u>	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>			<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>			<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>			<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>		<u>SUN PHARM INDS LTD</u>	<u>120MG</u>	<u>A203023</u>	<u>001</u>	Jun 08, 2017
<u>AB3</u>			<u>180MG</u>	<u>A203023</u>	<u>002</u>	Jun 08, 2017
<u>AB3</u>			<u>240MG</u>	<u>A203023</u>	<u>003</u>	Jun 08, 2017
<u>AB3</u>			<u>300MG</u>	<u>A203023</u>	<u>004</u>	Jun 08, 2017
<u>AB3</u>			<u>360MG</u>	<u>A203023</u>	<u>005</u>	Jun 08, 2017
<u>AB3</u>		<u>SUN PHARMA GLOBAL</u>	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>			<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>			<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>			<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>			<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>		<u>VALEANT PHARMS</u>	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
NORTH						
<u>AB3</u>			<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>			<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>			<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB3</u>		<u>ZYDUS PHARMS USA</u>	<u>120MG</u>	<u>A206534</u>	<u>001</u>	Aug 08, 2017
INC						
<u>AB3</u>			<u>180MG</u>	<u>A206534</u>	<u>002</u>	Aug 08, 2017
<u>AB3</u>			<u>240MG</u>	<u>A206534</u>	<u>003</u>	Aug 08, 2017
<u>AB3</u>			<u>300MG</u>	<u>A206534</u>	<u>004</u>	Aug 08, 2017
<u>AB3</u>			<u>360MG</u>	<u>A206534</u>	<u>005</u>	Aug 08, 2017
<u>AB4</u>		<u>SANDOZ</u>	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>			<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>			<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>			<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>			<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>			<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>		<u>SUN PHARMA GLOBAL</u>	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>			<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>			<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>			<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>			<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010
<u>AB4</u>		<u>ZYDUS PHARMS USA</u>	<u>120MG</u>	<u>A206641</u>	<u>001</u>	Aug 11, 2017
INC						
<u>AB4</u>			<u>180MG</u>	<u>A206641</u>	<u>002</u>	Aug 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB4</u>		<u>240MG</u>	<u>A206641 003</u>	Aug 11, 2017
<u>AB4</u>		<u>300MG</u>	<u>A206641 004</u>	Aug 11, 2017
<u>AB4</u>		<u>360MG</u>	<u>A206641 005</u>	Aug 11, 2017
<u>AB4</u>		<u>420MG</u>	<u>A206641 006</u>	Aug 11, 2017

DILTZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395 001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395 002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395 003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395 004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395 005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401 001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401 002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401 003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401 004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401 005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	+ VALEANT PHARMS NORTH	<u>120MG</u>	<u>N020401 001</u>	Sep 11, 1995
<u>AB4</u>	+	<u>180MG</u>	<u>N020401 002</u>	Sep 11, 1995
<u>AB4</u>	+	<u>240MG</u>	<u>N020401 003</u>	Sep 11, 1995
<u>AB4</u>	+	<u>300MG</u>	<u>N020401 004</u>	Sep 11, 1995
<u>AB4</u>	+	<u>360MG</u>	<u>N020401 005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401 006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	!	MYLAN	120MG	A074910 003	May 02, 1997
			60MG	A074910 001	May 02, 1997
			90MG	A074910 002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075086 001</u>	Apr 09, 1998	
<u>AP</u>	!	ATHENEX INC	<u>5MG/ML</u>	<u>A074617 001</u>	Feb 28, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651 001</u>	Aug 09, 2012
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941 001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749 001</u>	Nov 21, 2001
<u>AP</u>		WEST-WARD PHARMS	<u>5MG/ML</u>	<u>A078538 001</u>	Dec 17, 2008
		INT			
	!	HOSPIRA	100MG/VIAL	A075853 001	Dec 17, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	+	VALEANT INTL	<u>30MG</u>	<u>N018602 001</u>	Nov 05, 1982
<u>AB</u>	+		<u>60MG</u>	<u>N018602 002</u>	Nov 05, 1982
<u>AB</u>	+		<u>90MG</u>	<u>N018602 003</u>	Dec 08, 1986
<u>AB</u>	+		<u>120MG</u>	<u>N018602 004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>30MG</u>	<u>A072838 004</u>	Nov 05, 1992
<u>AB</u>			<u>60MG</u>	<u>A072838 003</u>	Nov 05, 1992
<u>AB</u>			<u>90MG</u>	<u>A072838 002</u>	Nov 05, 1992
<u>AB</u>			<u>120MG</u>	<u>A072838 001</u>	Nov 05, 1992
<u>AB</u>		TEVA	<u>30MG</u>	<u>A074185 001</u>	May 31, 1995
<u>AB</u>			<u>60MG</u>	<u>A074185 002</u>	May 31, 1995
<u>AB</u>			<u>90MG</u>	<u>A074185 003</u>	May 31, 1995
<u>AB</u>			<u>120MG</u>	<u>A074185 004</u>	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

<u>AB</u>	+	VALEANT INTL	<u>120MG</u>	<u>N021392 001</u>	Feb 06, 2003
<u>AB</u>	+		<u>180MG</u>	<u>N021392 002</u>	Feb 06, 2003
<u>AB</u>	+		<u>240MG</u>	<u>N021392 003</u>	Feb 06, 2003
<u>AB</u>	+		<u>300MG</u>	<u>N021392 004</u>	Feb 06, 2003
<u>AB</u>	+		<u>360MG</u>	<u>N021392 005</u>	Feb 06, 2003
<u>AB</u>	+		<u>420MG</u>	<u>N021392 006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686 006</u>	Mar 15, 2010
<u>AB</u>			<u>180MG</u>	<u>A077686 005</u>	Mar 15, 2010
<u>AB</u>			<u>240MG</u>	<u>A077686 004</u>	Mar 15, 2010
<u>AB</u>			<u>300MG</u>	<u>A077686 003</u>	Mar 15, 2010
<u>AB</u>			<u>360MG</u>	<u>A077686 002</u>	Mar 15, 2010
<u>AB</u>			<u>420MG</u>	<u>A077686 001</u>	Mar 15, 2010

PRESCRIPTION DRUG PRODUCT LIST

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

! FRESENIUS KABI USA 50MG/ML

A040519 001 Jun 23, 2004

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+! AKORN 10%

N005939 001

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

+ BIOGEN IDEC INC 120MG

N204063 001 Mar 27, 2013

+! 240MG

N204063 002 Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE**AT** MYLAN INSTITUTIONAL **50%****A076185 001** Nov 29, 2002**RIMSO-50****AT** +! MYLAN INSTITUTIONAL **50%****N017788 001**DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+! PHARMACIA AND 0.5MG/3GM

N019617 001 Dec 09, 1992

UPJOHN

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+! FERRING PHARMS INC 10MG

N020411 001 Mar 30, 1995

SUPPOSITORY; VAGINAL

PROSTIN E2

+! PHARMACIA AND 20MG

N017810 001

UPJOHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! BARR 50MG

A080738 001

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE**AP** APP PHARMS **50MG/ML****A040466 001** May 28, 2002**AP** HOSPIRA **50MG/ML****A040140 001** Nov 20, 1998**AP** MYLAN INSTITUTIONAL **50MG/ML****A040498 001** Jul 12, 2005**AP** ! WEST-WARD PHARMS **50MG/ML****A080817 002**

INT

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE**AP** FRESENIUS KABI USA **50MG/ML****A091526 001** Mar 26, 2013DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE**AP** ! ATHENEX INC **5MG/ML****A074939 001** Apr 13, 1998**AP** FRESENIUS KABI USA **5MG/ML****A074956 001** Sep 30, 1998**AP** WEST-WARD PHARMS **5MG/ML****A074521 001** Oct 18, 1996

INT

TABLET; ORAL

DIPYRIDAMOLE**AB** BARR **25MG****A087184 001** Oct 03, 1990**AB** **50MG****A087716 001** Oct 03, 1990**AB** **75MG****A087717 001** Oct 03, 1990**AB** IMPAX LABS **25MG****A040782 001** Jul 18, 2007**AB** **50MG****A040782 002** Jul 18, 2007**AB** **75MG****A040782 003** Jul 18, 2007**AB** MURTY PHARMS **25MG****A040733 001** Feb 13, 2007**AB** **50MG****A040733 002** Feb 13, 2007**AB** **75MG****A040733 003** Feb 13, 2007**AB** ZYDUS PHARMS USA **25MG****A040874 001** Jan 28, 2008

INC

AB **50MG****A040874 002** Jan 28, 2008**AB** **75MG****A040874 003** Jan 28, 2008

PRESCRIPTION DRUG PRODUCT LIST

DIPYRIDAMOLE

TABLET; ORAL

PERSANTINE

AB	+	BOEHRINGER INGELHEIM	25MG	<u>N012836 003</u>	Dec 22, 1986
AB	+		50MG	<u>N012836 004</u>	Feb 06, 1987
AB	+		75MG	<u>N012836 005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AB		MAYNE PHARMA	<u>EQ 100MG BASE</u>	<u>A070173 001</u>	May 31, 1985
AB			<u>EQ 150MG BASE</u>	<u>A070173 002</u>	May 31, 1985
AB		TEVA	<u>EQ 100MG BASE</u>	<u>A070101 001</u>	Feb 22, 1985
AB			<u>EQ 150MG BASE</u>	<u>A070102 001</u>	Feb 22, 1985

NORPACE

AB	+	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447 001</u>	
AB	+		<u>EQ 150MG BASE</u>	<u>N017447 002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

	+	GD SEARLE LLC	EQ 100MG BASE	N018655 001	Jul 20, 1982
	+		EQ 150MG BASE	N018655 002	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB		ODYSSEY PHARMS	250MG	<u>A088482 001</u>	Dec 08, 1983
AB	!		500MG	<u>A088483 001</u>	Dec 08, 1983

DISULFIRAM

AB		CHARTWELL MOLECULES	250MG	<u>A091563 001</u>	Dec 31, 2012
AB			500MG	<u>A091563 002</u>	Dec 31, 2012
AB		MYLAN PHARMS INC	250MG	<u>A203916 001</u>	Mar 04, 2015
AB			500MG	<u>A203916 002</u>	Mar 04, 2015
AB		SIGMAPHARM LABS LLC	250MG	<u>A091619 001</u>	Mar 28, 2011
AB			500MG	<u>A091619 002</u>	Mar 28, 2011
AB		WEST-WARD PHARMS INT	250MG	<u>A202652 001</u>	Feb 05, 2014
AB			500MG	<u>A202652 002</u>	Feb 05, 2014

DISULFIRAM

AB		ALVOGEN MALTA	250MG	<u>A091681 001</u>	Aug 08, 2013
-----------	--	---------------	--------------	---------------------------	--------------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680 001</u>	Sep 12, 1989
-----------	---	--------	--------------------------------------	---------------------------	--------------

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979 001</u>	Jan 23, 2009
AB		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407 001</u>	Mar 28, 2011
AB		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919 001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

AB	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723 003</u>	Oct 26, 1984
AB	+		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723 001</u>	Mar 10, 1983
AB	+		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723 002</u>	Mar 10, 1983

DIVALPROEX SODIUM

AB		ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080 001</u>	Feb 25, 2011
AB		ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411 001</u>	Nov 03, 2008
AB		AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554 001</u>	Apr 21, 2011
AB			<u>EQ 250MG VALPROIC ACID</u>	<u>A090554 002</u>	Apr 21, 2011
AB			<u>EQ 500MG VALPROIC ACID</u>	<u>A090554 003</u>	Apr 21, 2011
AB		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755 001</u>	Jul 29, 2008
AB			<u>EQ 250MG VALPROIC ACID</u>	<u>A078755 002</u>	Jul 29, 2008
AB			<u>EQ 500MG VALPROIC ACID</u>	<u>A078755 003</u>	Jul 29, 2008
AB		LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790 001</u>	Jul 29, 2008
AB			<u>EQ 250MG VALPROIC ACID</u>	<u>A078790 002</u>	Jul 29, 2008
AB			<u>EQ 500MG VALPROIC ACID</u>	<u>A078790 003</u>	Jul 29, 2008
AB		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062 001</u>	Mar 17, 2009
AB			<u>EQ 250MG VALPROIC ACID</u>	<u>A090062 002</u>	Mar 17, 2009
AB			<u>EQ 500MG VALPROIC ACID</u>	<u>A090062 003</u>	Mar 17, 2009
AB		NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615 003</u>	Jul 29, 2008
AB			<u>EQ 250MG VALPROIC ACID</u>	<u>A077615 002</u>	Jul 29, 2008
AB			<u>EQ 500MG VALPROIC ACID</u>	<u>A077615 001</u>	Jul 29, 2008
AB		ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853 001</u>	Nov 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853 002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853 003</u>	Nov 25, 2008
<u>AB</u>	PRINSTON INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210 001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210 002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210 003</u>	Nov 30, 2009
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290 001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597 003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941 003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163 001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163 002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163 003</u>	Apr 05, 2011
<u>AB</u>	UPSHER-SMITH LABS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182 003</u>	Jul 29, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296 001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296 002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296 003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100 001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100 002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100 003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	+	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168 002</u>	May 31, 2002
<u>AB</u>	+	!	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168 001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730 001</u>	May 29, 2015
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A203730 002</u>	May 29, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445 001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445 002</u>	Aug 04, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419 001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419 002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161 001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791 001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791 002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567 001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567 002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070 001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705 002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705 001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239 002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>	!	<u>EQ 12.5MG BASE/ML</u>	<u>A074292 001</u>	Feb 16, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

PRESCRIPTION DRUG PRODUCT LIST

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	+	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012
<u>AP</u>		ACTAVIS LLC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013
<u>AP</u>		DFB ONCOLOGY LTD	<u>20MG/ML (20MG/ML)</u>	<u>A206177 001</u>	Jan 20, 2017
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A206177 002</u>	Jan 20, 2017
<u>AP</u>		DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014
<u>AP</u>	+	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+		<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+		<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>		INGENUS PHARMS LLC	<u>20MG/2ML (10MG/ML)</u>	<u>A207563 001</u>	Aug 31, 2017
<u>AP</u>			<u>80MG/8ML (10MG/ML)</u>	<u>A207563 002</u>	Aug 31, 2017
<u>AP</u>			<u>160MG/16ML (10MG/ML)</u>	<u>A207563 003</u>	Aug 31, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>20MG/ML (20MG/ML)</u>	<u>A207252 001</u>	Aug 09, 2017
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A207252 002</u>	Aug 09, 2017
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>A207252 003</u>	Aug 09, 2017
<u>AP</u>		SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011
<u>AP</u>			<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011
<u>AP</u>			<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011
<u>AP</u>		TEVA PHARMS USA	<u>20MG/ML (20MG/ML)</u>	<u>A203877 001</u>	Sep 16, 2015
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A203877 002</u>	Sep 16, 2015

TAXOTERE

<u>AP</u>	+	SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

DOCETAXEL

+		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011
+			80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011
		ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
		DFB ONCOLOGY LTD	200MG/10ML (20MG/ML)	A206177 003	Jan 20, 2017
+		HOSPIRA INC	20MG/ML (20MG/ML)	N022234 004	Jun 23, 2016
+			80MG/4ML (20MG/ML)	N022234 005	Jun 23, 2016
+			160MG/8ML (20MG/ML)	N022234 007	Jan 24, 2017
!		JIANGSU HENGRUI MED	40MG/ML	A203170 001	Feb 15, 2017

SOLUTION; IV (INFUSION)

DOCETAXEL

		EAGLE PHARMS	20MG/ML (20MG/ML)	N205934 001	Dec 22, 2015
			80MG/4ML (20MG/ML)	N205934 002	Dec 22, 2015
			160MG/8ML (20MG/ML)	N205934 003	Dec 22, 2015

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

<u>AB</u>		MAYNE PHARMA INC	<u>0.125MG</u>	<u>A207058 001</u>	Jun 06, 2016
<u>AB</u>			<u>0.25MG</u>	<u>A207058 002</u>	Jun 06, 2016
<u>AB</u>			<u>0.5MG</u>	<u>A207058 003</u>	Jun 06, 2016

TIKOSYN

<u>AB</u>	+	PFIZER	<u>0.125MG</u>	<u>N020931 001</u>	Oct 01, 1999
<u>AB</u>	+		<u>0.25MG</u>	<u>N020931 002</u>	Oct 01, 1999
<u>AB</u>	+		<u>0.5MG</u>	<u>N020931 003</u>	Oct 01, 1999

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+		VIIV HLTHCARE	EQ 10MG BASE	N204790 002	Jun 09, 2016
+			EQ 25MG BASE	N204790 003	Jun 09, 2016
+	!		EQ 50MG BASE	N204790 001	Aug 12, 2013

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

JULUCA

+	!	VIIV HLTHCARE	EQ 50MG BASE; EQ 25MG BASE	N210192 001	Nov 21, 2017
---	---	---------------	----------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	+	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	!	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
<u>AB</u>	+	!	<u>23MG</u>	<u>N022568</u>	<u>001</u>	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		ACI HEALTHCARE LTD	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011
<u>AB</u>		ACTAVIS ELIZABETH	<u>23MG</u>	<u>A202415</u>	<u>001</u>	Dec 17, 2015
<u>AB</u>		ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201724</u>	<u>001</u>	Feb 25, 2013
<u>AB</u>			<u>10MG</u>	<u>A201724</u>	<u>002</u>	Feb 25, 2013
<u>AB</u>		APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
<u>AB</u>			<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
<u>AB</u>		AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
<u>AB</u>		CADILA PHARMS LTD	<u>5MG</u>	<u>A204609</u>	<u>001</u>	Sep 19, 2017
<u>AB</u>			<u>10MG</u>	<u>A204609</u>	<u>002</u>	Sep 19, 2017
<u>AB</u>		CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u>		CSPC OUYI PHARM CO	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>			<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>		DEXCEL PHARMA	<u>23MG</u>	<u>A203713</u>	<u>001</u>	Feb 19, 2016
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u>			<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>		HETERO LABS LTD V	<u>5MG</u>	<u>A203034</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>			<u>10MG</u>	<u>A203034</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>		INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>			<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u>			<u>23MG</u>	<u>A203419</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		JUBILANT GENERICS	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u>		LUPIN LTD	<u>23MG</u>	<u>A202782</u>	<u>001</u>	Oct 30, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>			<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>			<u>23MG</u>	<u>A202631</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u>			<u>23MG</u>	<u>A202656</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>		OSMOTICA PHARM US	<u>23MG</u>	<u>A203114</u>	<u>001</u>	Jan 26, 2016
<u>AB</u>		PAR PHARM	<u>23MG</u>	<u>A202542</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>		PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>		PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>		SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>			<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>		SUN PHARM INDS LTD	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>			<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>			<u>23MG</u>	<u>A204293</u>	<u>001</u>	Jun 05, 2015
<u>AB</u>		TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>		TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>		TWI PHARMS INC	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		UNICHEM LABS LTD	<u>5MG</u>	<u>A203656</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>			<u>10MG</u>	<u>A203656</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>		VIVIMED GLOBAL	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>		WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>		ZHEJIANG HISUN PHARM	<u>23MG</u>	<u>A202410</u>	<u>001</u>	Mar 24, 2017
<u>AB</u>		ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>			<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012
<u>AB</u>			<u>23MG</u>	<u>A203162</u>	<u>001</u>	Aug 31, 2017

PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

ARICEPT ODT

<u>AB</u>	+	EISAI INC	<u>5MG</u>	<u>N021720 001</u>	Oct 18, 2004
<u>AB</u>	+	!	<u>10MG</u>	<u>N021720 002</u>	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		BARR	<u>5MG</u>	<u>A078388 002</u>	Nov 26, 2010
<u>AB</u>			<u>10MG</u>	<u>A078388 001</u>	Nov 26, 2010
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787 001</u>	Dec 14, 2012
<u>AB</u>			<u>10MG</u>	<u>A201787 002</u>	Dec 14, 2012
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A091198 001</u>	May 10, 2011
<u>AB</u>			<u>10MG</u>	<u>A091198 002</u>	May 10, 2011
<u>AB</u>		UNICHEM LABS LTD	<u>5MG</u>	<u>A204831 001</u>	Nov 10, 2016
<u>AB</u>			<u>10MG</u>	<u>A204831 002</u>	Nov 10, 2016
<u>AB</u>		ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175 001</u>	May 10, 2011
<u>AB</u>			<u>10MG</u>	<u>A090175 002</u>	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS	<u>10MG;14MG</u>	<u>A208328 001</u>	Jan 27, 2017
<u>AB</u>			<u>10MG;28MG</u>	<u>A208328 002</u>	Jan 27, 2017

NAMZARIC

<u>AB</u>	+	FOREST LABS LLC	<u>10MG;14MG</u>	<u>N206439 001</u>	Dec 23, 2014
<u>AB</u>	+	!	<u>10MG;28MG</u>	<u>N206439 002</u>	Dec 23, 2014
	+		10MG;7MG	N206439 003	Jul 18, 2016
	+		10MG;21MG	N206439 004	Jul 18, 2016

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	!	HOSPIRA	<u>40MG/ML</u>	<u>N018132 001</u>
<u>AP</u>	+			<u>80MG/100ML</u>	<u>N018132 002</u>
<u>AP</u>	+			<u>80MG/ML</u>	<u>N018132 004</u>
<u>AP</u>	+			<u>160MG/100ML</u>	<u>N018132 003</u>
<u>AP</u>	!		LUITPOLD	<u>40MG/ML</u>	<u>A070799 001</u>
<u>AP</u>	!			<u>80MG/ML</u>	<u>A070820 001</u>

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	!	B BRAUN	<u>80MG/100ML</u>	<u>N019099 002</u>
<u>AP</u>	+			<u>320MG/100ML</u>	<u>N019099 004</u>

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	!	B BRAUN	<u>160MG/100ML</u>	<u>N019099 003</u>
-----------	---	---	---------	--------------------	--------------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	!	BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615 001</u>
<u>AP</u>	+			<u>160MG/100ML</u>	<u>N019615 002</u>
<u>AP</u>	+			<u>320MG/100ML</u>	<u>N019615 003</u>
<u>AP</u>	+		HOSPIRA	<u>80MG/100ML</u>	<u>N018826 001</u>
<u>AP</u>	+			<u>160MG/100ML</u>	<u>N018826 002</u>
<u>AP</u>	+			<u>320MG/100ML</u>	<u>N018826 003</u>

DOPAMINE HYDROCHLORIDE

!		LUITPOLD	160MG/ML	A070826 001	Feb 11, 1987
---	--	----------	----------	-------------	--------------

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	40MG/100ML	N019099 001	Oct 15, 1986
---	---	---------	------------	-------------	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	640MG/100ML	N019615 004	Mar 27, 1987
---	---	-----------------	-------------	-------------	--------------

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>		BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143 001</u>	Jun 25, 2009
<u>AT</u>		HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846 001</u>	Oct 28, 2008
<u>AT</u>		LUITPOLD	<u>EQ 2% BASE</u>	<u>A079186 001</u>	Nov 18, 2009
<u>AT</u>		SANDOZ INC	<u>EQ 2% BASE</u>	<u>A078748 001</u>	Nov 06, 2008
<u>AT</u>			<u>EQ 2% BASE</u>	<u>A078981 001</u>	Apr 13, 2009
<u>AT</u>		TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756 001</u>	Dec 04, 2008
<u>AT</u>		WATSON LABS INC	<u>EQ 2% BASE</u>	<u>A202053 001</u>	Sep 11, 2014

TRUSOPT

<u>AT</u>	+	MERCK	<u>EQ 2% BASE</u>	<u>N020408 001</u>	Dec 09, 1994
-----------	---	-------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT	+ !	OAK PHARMS INC	EQ 2% BASE;EQ 0.5% BASE	N020869 001	Apr 07, 1998
<u>DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE</u>					
AT		AKORN INC	EQ 2% BASE;EQ 0.5% BASE	A203058 001	Sep 22, 2014
AT		BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037 001	Jul 14, 2009
AT		HI TECH PHARMA	EQ 2% BASE;EQ 0.5% BASE	A077847 001	Oct 28, 2008
AT		SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749 001	Nov 06, 2008
AT		SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604 001	Nov 18, 2009
AT		TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704 001	Sep 28, 2009
AT		WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054 001	Sep 03, 2014
AT		ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180 001	Dec 04, 2013
COSOPT PF					
	+ !	OAK PHARMS INC	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+ !	WEST-WARD PHARMS INT	20MG/ML	N014879 001	
<u>DOXAPRAM HYDROCHLORIDE</u>					
AP		ATHENEX INC	20MG/ML	A076266 001	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB	+ !	PFIZER	EQ 1MG BASE	N019668 001	Nov 02, 1990
AB	+		EQ 2MG BASE	N019668 002	Nov 02, 1990
AB	+		EQ 4MG BASE	N019668 003	Nov 02, 1990
AB	+		EQ 8MG BASE	N019668 004	Nov 02, 1990

DOXAZOSIN MESYLATE

AB		ACCORD HLTHCARE	EQ 1MG BASE	A202824 001	Jun 11, 2014
AB			EQ 2MG BASE	A202824 002	Jun 11, 2014
AB			EQ 4MG BASE	A202824 003	Jun 11, 2014
AB			EQ 8MG BASE	A202824 004	Jun 11, 2014
AB		APOTEX	EQ 1MG BASE	A075580 001	Oct 18, 2000
AB			EQ 2MG BASE	A075580 002	Oct 18, 2000
AB			EQ 4MG BASE	A075580 003	Oct 18, 2000
AB			EQ 8MG BASE	A075580 004	Oct 18, 2000
AB		DAVA PHARMS INC	EQ 1MG BASE	A076161 001	Jun 10, 2004
AB			EQ 2MG BASE	A076161 002	Jun 10, 2004
AB			EQ 4MG BASE	A076161 003	Jun 10, 2004
AB			EQ 8MG BASE	A076161 004	Jun 10, 2004
AB		MYLAN	EQ 1MG BASE	A075509 001	Oct 19, 2000
AB			EQ 2MG BASE	A075509 002	Oct 19, 2000
AB			EQ 4MG BASE	A075509 003	Oct 19, 2000
AB			EQ 8MG BASE	A075509 004	Oct 19, 2000
AB		PLIVA	EQ 1MG BASE	A075750 001	Jun 08, 2001
AB			EQ 2MG BASE	A075750 002	Jun 08, 2001
AB			EQ 4MG BASE	A075750 003	Jun 08, 2001
AB			EQ 8MG BASE	A075750 004	Jun 08, 2001
AB		TEVA	EQ 1MG BASE	A075536 001	Oct 18, 2000
AB			EQ 2MG BASE	A075536 002	Oct 18, 2000
AB			EQ 4MG BASE	A075536 003	Oct 18, 2000
AB			EQ 8MG BASE	A075536 004	Oct 18, 2000
AB		ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719 001	Jul 07, 2017
AB			EQ 2MG BASE	A208719 002	Jul 07, 2017
AB			EQ 4MG BASE	A208719 003	Jul 07, 2017
AB			EQ 8MG BASE	A208719 004	Jul 07, 2017

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

	+	PFIZER	EQ 4MG BASE	N021269 001	Feb 22, 2005
	+ !		EQ 8MG BASE	N021269 002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB		AMNEAL PHARMS CO	EQ 10MG BASE	A207482 001	Jun 28, 2017
AB			EQ 25MG BASE	A207482 002	Jun 28, 2017
AB			EQ 50MG BASE	A207482 003	Jun 28, 2017
AB			EQ 75MG BASE	A207482 004	Jun 28, 2017
AB			EQ 100MG BASE	A207482 005	Jun 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
	! PAR PHARM	EQ 150MG BASE	A071669 001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>	! TEVA PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A071609 001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT BIO AG	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+! MYLAN PHARMS INC

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013

SILENOR

<u>AB</u>	+ PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+!	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	RISING PHARMS INC	<u>0.5MCG</u>	<u>A201518 001</u>	Sep 09, 2016
<u>AB</u>		<u>1MCG</u>	<u>A201518 002</u>	Sep 09, 2016
<u>AB</u>		<u>2.5MCG</u>	<u>A201518 003</u>	Sep 09, 2016
<u>AB</u>	WEST-WARD PHARMS INT	<u>0.5MCG</u>	<u>A091433 001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433 002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433 003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	+ GENZYME CORP	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>	+	<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+!	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AKORN INC	<u>2MCG/ML (2MCG/ML)</u>	<u>A203929 002</u>	Mar 28, 2016
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203929 001</u>	May 07, 2015
<u>AP</u>	AMNEAL PHARMS CO	<u>2MCG/ML (2MCG/ML)</u>	<u>A208974 001</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208974 002</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208975 001</u>	May 24, 2017
<u>AP</u>	HIKMA PHARMS	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333 001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926 001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	+ GENZYME CORP	<u>2MCG/ML (2MCG/ML)</u>	<u>N021027 002</u>	Apr 06, 2000
<u>AP</u>	+!	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622 001</u>	Jun 27, 2014
<u>AP</u>		<u>200MG/100ML</u>	<u>A203622 002</u>	Jun 27, 2014
<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515 001</u>	Nov 08, 2012
<u>AP</u>	AMNEAL PHARMS CO	<u>20MG/VIAL</u>	<u>A208888 001</u>	Feb 17, 2017
<u>AP</u>		<u>50MG/VIAL</u>	<u>A208888 002</u>	Feb 17, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209825 001</u>	Aug 11, 2017
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A200901 001</u>	Feb 14, 2012
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170 001</u>	Oct 28, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>2MG/ML</u>	<u>N050629 001</u>	Dec 23, 1987
<u>AP</u>	+!	<u>200MG/100ML</u>	<u>N050629 002</u>	May 03, 1988

PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	!	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>		<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
	+ PHARMACIA AND UPJOHN	150MG/75ML	N050629 003	Mar 28, 2011

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	+ JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995
<u>AB</u>	+	<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>	DR REDDYS LABS LTD	<u>20MG/10ML (2MG/ML)</u>	<u>A208657 001</u>	May 15, 2017
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A208657 002</u>	May 15, 2017
<u>AB</u>	!	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>	Feb 04, 2013
<u>AB</u>	!	<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A209165 001</u>	Jul 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209165 002</u>	Jul 28, 2017
<u>AB</u>	G AND W LABS INC	<u>EQ 50MG BASE</u>	<u>A204446 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204446 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204446 003</u>	May 28, 2015
<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065 001</u>	Feb 17, 2011
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234 001</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234 002</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234 003</u>	Mar 05, 2014
<u>AB</u>	MAYNE PHARMA INC	<u>EQ 50MG BASE</u>	<u>A209396 001</u>	Sep 29, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A209396 002</u>	Sep 29, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209396 003</u>	Sep 29, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778 001</u>	Jun 08, 2012
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055 001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055 002</u>	Dec 01, 2000
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A065055 003</u>	Jul 15, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053 001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053 003</u>	Sep 10, 2003
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053 002</u>	Nov 22, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 50MG BASE</u>	<u>A205115 001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A205115 002</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A205115 003</u>	Feb 18, 2016

MONODOX

<u>AB</u>	+ AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641 002</u>	Feb 10, 1992
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N050641 003</u>	Oct 18, 2006
<u>AB</u>	+!	<u>EQ 100MG BASE</u>	<u>N050641 001</u>	Dec 29, 1989

ORACEA

+! GALDERMA LABS LP 40MG

N050805 001 May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+! PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>	
-----------	-----------	-------------------------	--------------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE

TABLET; ORAL

DOXYCYCLINE

AB	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377 001</u>	Nov 07, 2006
AB		<u>EQ 75MG BASE</u>	<u>A065377 002</u>	Nov 07, 2006
AB		<u>EQ 100MG BASE</u>	<u>A065377 003</u>	Nov 07, 2006
AB		<u>EQ 150MG BASE</u>	<u>A065427 001</u>	Jun 07, 2007
AB	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070 001</u>	Dec 15, 2000
AB		<u>EQ 75MG BASE</u>	<u>A065070 003</u>	Dec 30, 2002
AB		<u>EQ 100MG BASE</u>	<u>A065070 002</u>	Dec 15, 2000
AB	!	<u>EQ 150MG BASE</u>	<u>A065070 004</u>	Jul 14, 2005
AB	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006
AB		<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006
AB		<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006
AB	ZYDUS PHARMS USA INC	<u>EQ 50MG BASE</u>	<u>A209582 001</u>	Sep 28, 2017
AB		<u>EQ 75MG BASE</u>	<u>A209582 002</u>	Sep 28, 2017
AB		<u>EQ 100MG BASE</u>	<u>A209582 003</u>	Sep 28, 2017
AB		<u>EQ 150MG BASE</u>	<u>A209582 004</u>	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+! PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
AB		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
AB	AMNEAL PHARMS	<u>EQ 100MG BASE</u>	<u>A207289 001</u>	Jun 27, 2016
AB	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
AB		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
AB	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
AB		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984
AB	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675 001</u>	Jul 10, 1986
AB	MYLAN	<u>EQ 50MG BASE</u>	<u>A062337 001</u>	Mar 29, 1982
AB		<u>EQ 100MG BASE</u>	<u>A062337 002</u>	Mar 29, 1982
AB	SUN PHARM INDUSTRIES	<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986

VIBRAMYCIN

AB	+! PFIZER	<u>EQ 100MG BASE</u>	<u>N050007 002</u>	
	ACTICLATE CAP			
	+! AQUA PHARMS	EQ 75MG BASE	N208253 001	Apr 26, 2016
	DOXYCYCLINE HYCLATE			
	! HIKMA INTL PHARMS	EQ 20MG BASE	A065103 001	May 13, 2005

INJECTABLE; INJECTION

DOXY 100

AP	! FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475 001</u>	Dec 09, 1983
-----------	----------------------	---------------------------	--------------------	--------------

DOXY 200

AP	! FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A062475 002</u>	Dec 09, 1983
-----------	----------------------	---------------------------	--------------------	--------------

DOXYCYCLINE

AP	MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A091406 001</u>	Aug 21, 2012
AP	! WEST-WARD PHARMS INT	<u>EQ 100MG BASE/VIAL</u>	<u>A062569 001</u>	Mar 09, 1988
AP	ZYDUS PHARMS USA INC	<u>EQ 100MG BASE/VIAL</u>	<u>A207757 001</u>	Sep 28, 2017
AP		<u>EQ 200MG BASE/VIAL</u>	<u>A207757 002</u>	Sep 28, 2017

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+! TOLMAR

50MG

N050751 001 Sep 03, 1998

TABLET; ORAL

ACTICLATE

AB	+ AQUA PHARMS LLC	<u>EQ 75MG BASE</u>	<u>N205931 001</u>	Jul 25, 2014
AB	+!	<u>EQ 150MG BASE</u>	<u>N205931 002</u>	Jul 25, 2014

DOXYCYCLINE HYCLATE

AB	ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421 001</u>	Feb 02, 1983
AB	AMNEAL PHARMS CO	<u>EQ 75MG BASE</u>	<u>A209372 001</u>	Oct 06, 2017
AB		<u>EQ 150MG BASE</u>	<u>A209372 002</u>	Oct 06, 2017
AB	CARIBE HOLDINGS	<u>EQ 100MG BASE</u>	<u>A062269 002</u>	Nov 08, 1982
AB	CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505 001</u>	Sep 11, 1984
AB	! HIKMA INTL PHARMS	<u>EQ 100MG BASE</u>	<u>A065095 001</u>	Jul 02, 2003
AB	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163 001</u>	May 13, 2005

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	!	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277 001</u>	Nov 10, 2005
<u>AB</u>		LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287 001</u>	Feb 28, 2006
<u>AB</u>		LUPIN LTD	<u>EQ 75MG BASE</u>	<u>A208818 001</u>	Sep 27, 2017
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A208818 002</u>	Sep 27, 2017
<u>AB</u>		MAYNE PHARMA INC	<u>EQ 75MG BASE</u>	<u>A208765 001</u>	Jun 14, 2017
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A208765 002</u>	Jun 14, 2017
<u>AB</u>		MYLAN	<u>EQ 100MG BASE</u>	<u>A062432 001</u>	Feb 15, 1983
<u>AB</u>		NOVEL LABS INC	<u>EQ 100MG BASE</u>	<u>A207558 001</u>	Sep 06, 2017
<u>AB</u>		SUN PHARM INDUSTRIES	<u>EQ 20MG BASE</u>	<u>A065134 001</u>	May 13, 2005
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A062677 001</u>	Jul 10, 1986
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 100MG BASE</u>	<u>A207773 001</u>	Oct 30, 2017
		CARIBE HOLDINGS	EQ 50MG BASE	A062269 003	

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>	+	MAYNE PHARMA	<u>EQ 50MG BASE</u>	<u>N050795 006</u>	Dec 19, 2014
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 80MG BASE</u>	<u>N050795 004</u>	Apr 11, 2013
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>N050795 005</u>	Apr 11, 2013

DOXYCYCLINE HYCLATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013
<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A090431 003</u>	May 23, 2016
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090431 001</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A090431 004</u>	Apr 29, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090431 002</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A090431 005</u>	May 19, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052 001</u>	Feb 08, 2012
<u>AB</u>		PRINSTON INC	<u>EQ 150MG BASE</u>	<u>A207494 001</u>	Nov 15, 2016
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A207494 002</u>	Nov 15, 2016
		DORYX MPC			
	+	MAYNE PHARMA	EQ 120MG BASE	N050795 008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

<u>AB</u>	+	DUCHESNAY	<u>10MG;10MG</u>	<u>N021876 001</u>	Apr 08, 2013
-----------	---	-----------	------------------	--------------------	--------------

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>10MG;10MG</u>	<u>A205811 001</u>	Aug 19, 2016
<u>AB</u>		PAR PHARM INC	<u>10MG;10MG</u>	<u>A208518 001</u>	Dec 06, 2017

TABLET, EXTENDED RELEASE; ORAL

BONJESTA

	+	DUCHESNAY	20MG;20MG	N209661 001	Nov 07, 2016
--	---	-----------	-----------	-------------	--------------

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>		AKORN INC	<u>2.5MG</u>	<u>A079217 001</u>	Jun 20, 2014
<u>AB</u>			<u>5MG</u>	<u>A079217 002</u>	Jun 20, 2014
<u>AB</u>			<u>10MG</u>	<u>A079217 003</u>	Jun 20, 2014
<u>AB</u>		SVC PHARMA	<u>2.5MG</u>	<u>A078292 001</u>	Jun 27, 2008
<u>AB</u>			<u>5MG</u>	<u>A078292 002</u>	Jun 27, 2008
<u>AB</u>			<u>10MG</u>	<u>A078292 003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	+	ABBVIE	<u>2.5MG</u>	<u>N018651 001</u>	May 31, 1985
<u>AB</u>	+		<u>5MG</u>	<u>N018651 002</u>	May 31, 1985
<u>AB</u>	+		<u>10MG</u>	<u>N018651 003</u>	May 31, 1985

SOLUTION; ORAL

SYNDROS

	+	INSYS DEV CO INC	5MG/ML	N205525 001	Mar 23, 2017
--	---	------------------	--------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+! SANOFI AVENTIS US EQ 400MG BASE N022425 001 Jul 01, 2009

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL**AP** EUROHLTH INTL SARL 2.5MG/ML **A208197 001** Dec 14, 2017**AP** HOSPIRA 2.5MG/ML **A071981 001** Feb 29, 1988**AP** LUITPOLD 2.5MG/ML **A072123 001** Oct 24, 1988INAPSINE**AP** +! AKORN INC 2.5MG/ML **N016796 001**DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

+ BAYER HLTHCARE 0.25MG; 0.5MG N021355 001 Feb 29, 2012

+! 0.5MG; 1MG N021355 002 Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL**AB** BARR 3MG; 0.02MG **A078515 001** Mar 30, 2009**AB** CYNDEA PHARMA 3MG; 0.02MG **A209423 001** Dec 22, 2017**AB** GLENMARK PHARMS LTD 3MG; 0.02MG **A204296 001** Aug 17, 2015**AB** MYLAN LABS LTD 3MG; 0.02MG **A202594 001** Oct 22, 2015**AB** PII 3MG; 0.02MG **A203291 001** Jul 18, 2017**AB** WATSON LABS 3MG; 0.02MG **A078833 001** Nov 28, 2011LORYNA**AB** LABS LEON FARMA 3MG; 0.02MG **A079221 001** Mar 28, 2011MELAMISA**AB** NOVAST LABS LTD 3MG; 0.02MG **A202016 001** Jan 26, 2016NIKKI**AB** LUPIN LTD 3MG; 0.02MG **A201661 001** May 27, 2014YAZ**AB** +! BAYER HLTHCARE 3MG; 0.02MG **N021676 001** Mar 16, 2006

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL**AB** ACCORD HLTHCARE 3MG; 0.03MG **A207245 001** Nov 22, 2016**AB** APOTEX INC 3MG; 0.03MG **A205876 001** Sep 21, 2016**AB** BARR 3MG; 0.03MG **A077527 001** May 09, 2008**AB** GLENMARK PHARMS LTD 3MG; 0.03MG **A204848 001** Mar 25, 2016**AB** LUPIN LTD 3MG; 0.03MG **A201663 001** Dec 18, 2012**AB** MAYNE PHARMA 3MG; 0.03MG **A090081 001** Sep 07, 2010**AB** MYLAN LABS LTD 3MG; 0.03MG **A202131 001** May 04, 2015SYEDA**AB** LABS LEON FARMA 3MG; 0.03MG **A090114 001** Mar 28, 2011YAELA**AB** NOVAST LABS LTD 3MG; 0.03MG **A202015 001** Nov 19, 2014YASMIN**AB** +! BAYER HLTHCARE 3MG; 0.03MG **N021098 001** May 11, 2001DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ**AB** BAYER HLTHCARE 3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG **N022532 001** Sep 24, 2010DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM**AB** WATSON LABS INC 3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG **A203593 001** Oct 11, 2016**AB** 3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG **A203594 001** Oct 11, 2016SAFYRAL**AB** +! BAYER HLTHCARE 3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG **N022574 001** Dec 16, 2010TYDEMY**AB** LUPIN LTD 3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG **A205948 001** Dec 12, 2017DROXIDOPA

CAPSULE; ORAL

NORTHERA

+ LUNDBECK NA LTD 100MG N203202 001 Feb 18, 2014

+ 200MG N203202 002 Feb 18, 2014

+! 300MG N203202 003 Feb 18, 2014

PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

<u>AB</u>	+	LILLY	<u>EQ 20MG BASE</u>	<u>N021427 001</u>	Aug 03, 2004
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N021427 002</u>	Aug 03, 2004
<u>AB</u>	+	!	<u>EQ 60MG BASE</u>	<u>N021427 004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776 001</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090776 002</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090776 003</u>	Dec 17, 2013
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A208706 001</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A208706 002</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A208706 003</u>	Jan 06, 2017
<u>AB</u>		ALEMbic PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A202949 001</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202949 002</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202949 003</u>	Jun 09, 2014
<u>AB</u>		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197 001</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203197 002</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203197 003</u>	Aug 26, 2015
<u>AB</u>		ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780 001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090780 002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090780 003</u>	Oct 28, 2015
<u>AB</u>		APOTEX INC	<u>EQ 20MG BASE</u>	<u>A202045 001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202045 002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202045 003</u>	Jun 11, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090778 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090778 003</u>	Dec 11, 2013
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 20MG BASE</u>	<u>A203088 001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203088 002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203088 003</u>	Jun 11, 2014
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A090723 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090723 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090723 003</u>	Dec 11, 2013
<u>AB</u>		HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A204343 001</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204343 002</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204343 003</u>	Aug 03, 2016
<u>AB</u>		INVENTIA HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202336 001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202336 002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202336 003</u>	Oct 28, 2015
<u>AB</u>		LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090694 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090694 004</u>	Dec 11, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204815 001</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204815 002</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204815 003</u>	Mar 23, 2017
<u>AB</u>		PRINSTON INC	<u>EQ 20MG BASE</u>	<u>A206653 001</u>	May 18, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A206653 002</u>	May 18, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A206653 003</u>	May 18, 2017
<u>AB</u>		SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A090745 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090745 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090745 003</u>	Dec 11, 2013
<u>AB</u>		TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090783 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090783 003</u>	Dec 11, 2013
<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
<u>AB</u>		ZYDUS HLTHCARE	<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
<u>AB</u>		LUPIN LTD	EQ 40MG BASE	A090694 003	Dec 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

DUTASTERIDE

CAPSULE; ORAL

AVODART

AB	+ !	GLAXOSMITHKLINE	0.5MG	N021319	001	Nov 20, 2001
-----------	------------	-----------------	--------------	----------------	------------	--------------

DUTASTERIDE

AB		ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015
AB		AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015
AB		APOTEX INC	0.5MG	A204292	001	Nov 24, 2015
AB		ASCENT PHARMS INC	0.5MG	A206574	001	Oct 21, 2016
AB		AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015
AB		BARR	0.5MG	A090095	001	Dec 21, 2010
AB		BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015
AB		BRECKENRIDGE PHARM	0.5MG	A204705	001	Nov 20, 2015
AB		HAUPT PHARMA	0.5MG	A207935	001	Oct 13, 2017
AB		HUMANWELL PURACAP	0.5MG	A209909	001	Nov 21, 2017
AB		INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016
AB		MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017
AB		MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016
AB		RISING PHARMS INC	0.5MG	A202530	001	Nov 20, 2015
AB		STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015
AB		VINTAGE PHARMS LLC	0.5MG	A202421	001	Nov 20, 2015
AB		WEST-WARD PHARMS INT	0.5MG	A202204	001	Nov 23, 2015
AB		ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	0.5MG; 0.4MG	A202975	001	Nov 20, 2015
AB		ANCHEN PHARMS	0.5MG; 0.4MG	A202509	001	Feb 26, 2014

JALYN

AB	+ !	GLAXOSMITHKLINE	0.5MG; 0.4MG	N022460	001	Jun 14, 2010
-----------	------------	-----------------	---------------------	----------------	------------	--------------

ECHOTHIOPHATE IODIDEFOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

+ !	WYETH PHARMS INC	0.125%	N011963	001		
------------	------------------	--------	---------	-----	--	--

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+ !	CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	
------------	-------------------	----	---------	-----	--------------	--

CREAM; TOPICAL

ECONAZOLE NITRATE

AB		FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002
AB	!	PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004
AB		TARO	1%	A076005	001	Nov 26, 2002
AB		TELLIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004

SPECTAZOLE

AB	+	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982
-----------	----------	---------------	-----------	----------------	------------	--------------

EDARAVONE

SOLUTION; IV (INFUSION)

RADICAVA

+ !	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	
------------	-------------------	-----------------------	---------	-----	--------------	--

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+ !	MEDICIS	200MG/ML	N008922	001		
------------	---------	----------	---------	-----	--	--

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

+	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015	
+		EQ 30MG BASE	N206316	002	Jan 08, 2015	
+ !		EQ 60MG BASE	N206316	003	Jan 08, 2015	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

!	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	
----------	---------------------	---------	---------	-----	--------------	--

PRESCRIPTION DRUG PRODUCT LIST

EFAVIRENZ

CAPSULE; ORAL

EFAVIRENZ

AB	AUROBINDO PHARMA LTD	50MG	A078064 001	Dec 15, 2017
-----------	----------------------	-------------	--------------------	--------------

AB		200MG	A078064 003	Dec 15, 2017
-----------	--	--------------	--------------------	--------------

SUSTIVA

AB	+ BRISTOL MYERS SQUIBB	50MG	N020972 001	Sep 17, 1998
-----------	------------------------	-------------	--------------------	--------------

AB	+!	200MG	N020972 003	Sep 17, 1998
-----------	----	--------------	--------------------	--------------

EFAVIRENZ

	AUROBINDO PHARMA LTD	100MG	A078064 002	Dec 15, 2017
--	----------------------	-------	-------------	--------------

TABLET; ORAL

EFAVIRENZ

AB	MYLAN PHARMS INC	600MG	A091471 001	Feb 17, 2016
-----------	------------------	--------------	--------------------	--------------

SUSTIVA

AB	+! BRISTOL MYERS SQUIBB	600MG	N021360 002	Feb 01, 2002
-----------	-------------------------	--------------	--------------------	--------------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+!	GILEAD	600MG; 200MG; 300MG	N021937 001	Jul 12, 2006
----	--------	---------------------	-------------	--------------

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+!	DOW PHARM	10%	N203567 001	Jun 06, 2014
----	-----------	-----	-------------	--------------

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+!	SKINMEDICA	13.9%	N021145 001	Jul 27, 2000
----	------------	-------	-------------	--------------

ELBASVIR; GRAZOPREVIR

TABLET; ORAL

ZEPATIER

+!	MERCK SHARP DOHME	50MG; 100MG	N208261 001	Jan 28, 2016
----	-------------------	-------------	-------------	--------------

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A205186 001	Aug 29, 2017
-----------	-------------------	---------------------	--------------------	--------------

AB		EQ 40MG BASE	A205186 002	Aug 29, 2017
-----------	--	---------------------	--------------------	--------------

AB	MYLAN PHARMS INC	EQ 20MG BASE	A205152 001	Aug 11, 2017
-----------	------------------	---------------------	--------------------	--------------

AB		EQ 40MG BASE	A205152 002	Aug 11, 2017
-----------	--	---------------------	--------------------	--------------

AB	TEVA PHARMS USA	EQ 20MG BASE	A202040 001	Jun 27, 2017
-----------	-----------------	---------------------	--------------------	--------------

AB		EQ 40MG BASE	A202040 002	Jun 27, 2017
-----------	--	---------------------	--------------------	--------------

AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409 001	Jun 16, 2017
-----------	----------------------	---------------------	--------------------	--------------

AB		EQ 40MG BASE	A206409 002	Jun 16, 2017
-----------	--	---------------------	--------------------	--------------

RELPAK

AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016 001	Dec 26, 2002
-----------	------------------	---------------------	--------------------	--------------

AB	+!	EQ 40MG BASE	N021016 002	Dec 26, 2002
-----------	----	---------------------	--------------------	--------------

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+!	GENZYME CORP	EQ 84MG BASE	N205494 001	Aug 19, 2014
----	--------------	--------------	-------------	--------------

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+!	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027 001	Aug 24, 2015
----	----------------------	---------------------	-------------	--------------

TABLET; ORAL

PROMACTA

+	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291 004	Oct 20, 2011
---	----------------------	----------------	-------------	--------------

+		EQ 25MG ACID	N022291 001	Nov 20, 2008
---	--	--------------	-------------	--------------

+		EQ 50MG ACID	N022291 002	Nov 20, 2008
---	--	--------------	-------------	--------------

+!		EQ 75MG ACID	N022291 003	Sep 08, 2009
----	--	--------------	-------------	--------------

+!		EQ 100MG ACID	N022291 005	Nov 16, 2012
----	--	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ELUXADOLINE

TABLET; ORAL

VIBERZI

+	ALLERGAN HOLDINGS	75MG	N206940 001	May 27, 2015
+	!	100MG	N206940 002	May 27, 2015

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+	NOVARTIS PHARMS	0.05%	N020706 001	Dec 29, 1997
	CORP			

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

+	BOEHRINGER	10MG	N204629 001	Aug 01, 2014
	INGELHEIM			
+	!	25MG	N204629 002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

+	BOEHRINGER	10MG; 5MG	N206073 001	Jan 30, 2015
	INGELHEIM			
+	!	25MG; 5MG	N206073 002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

+	BOEHRINGER	5MG; 500MG	N206111 001	Aug 26, 2015
	INGELHEIM			
+		5MG; 1GM	N206111 002	Aug 26, 2015
+		12.5MG; 500MG	N206111 003	Aug 26, 2015
+	!	12.5MG; 1GM	N206111 004	Aug 26, 2015

TABLET, EXTENDED RELEASE; ORAL

SYNJARDY XR

+	BOEHRINGER	5MG; 1GM	N208658 001	Dec 09, 2016
	INGELHEIM			
+		10MG; 1GM	N208658 002	Dec 09, 2016
+		12.5MG; 1GM	N208658 003	Dec 09, 2016
+	!	25MG; 1GM	N208658 004	Dec 09, 2016

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+	GILEAD	200MG	N021500 001	Jul 02, 2003
---	--------	-------	-------------	--------------

SOLUTION; ORAL

EMTRIVA

+	GILEAD	10MG/ML	N021896 001	Sep 28, 2005
---	--------	---------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351 001	Mar 01, 2016
---	---------------------	-----------------------------------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; 300MG	N202123 001	Aug 10, 2011
---	---------------------	----------------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+	GILEAD SCIENCES INC	200MG; EQ 25MG BASE	N208215 001	Apr 04, 2016
---	---------------------	---------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	200MG; 300MG	A090894 001	Jun 08, 2017
-----------	-----------------	---------------------	--------------------	--------------

TRUVADA

AB	+	GILEAD	200MG; 300MG	N021752 001	Aug 02, 2004
	+		100MG; 150MG	N021752 002	Mar 10, 2016
	+		133MG; 200MG	N021752 003	Mar 10, 2016
	+		167MG; 250MG	N021752 004	Mar 10, 2016

PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+! SILVERGATE PHARMS

1MG/ML

N204308 001 Aug 13, 2013

SOLUTION;ORAL

EPANED

+! SILVERGATE PHARMS

1MG/ML

N208686 001 Sep 20, 2016

TABLET;ORAL

ENALAPRIL MALEATE

<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A075178 002</u>	Mar 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075178 001</u>	Mar 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075178 003</u>	Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178 004</u>	Mar 23, 2001
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075480 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480 004</u>	Aug 22, 2000
<u>AB</u>	SANDOZ INC	<u>2.5MG</u>	<u>A075496 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075496 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075459 001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459 002</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657 001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657 002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657 003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657 004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479 004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT LTD	<u>2.5MG</u>	<u>A075483 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483 004</u>	Aug 22, 2000
<u>VASOTEC</u>				
<u>AB</u>	+ VALEANT PHARMS	<u>2.5MG</u>	<u>N018998 005</u>	Jul 26, 1988
	NORTH			
<u>AB</u>	+	<u>5MG</u>	<u>N018998 001</u>	Dec 24, 1985
<u>AB</u>	+	<u>10MG</u>	<u>N018998 002</u>	Dec 24, 1985
<u>AB</u>	+!	<u>20MG</u>	<u>N018998 003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486 001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486 002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909 001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909 002</u>	Oct 15, 2001
<u>AB</u>	G AND W LABS INC	<u>5MG;12.5MG</u>	<u>A075727 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727 002</u>	Sep 18, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624 002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788 002</u>	Sep 18, 2001
<u>VASERETIC</u>				
<u>AB</u>	+ VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221 003</u>	Jul 12, 1995
<u>AB</u>	+!	<u>10MG;25MG</u>	<u>N019221 001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	! ATHENEX INC	<u>1.25MG/ML</u>	<u>A075634 001</u>	Aug 22, 2000
<u>AP</u>	HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687 001</u>	Dec 23, 2008
<u>AP</u>	! HOSPIRA	<u>1.25MG/ML</u>	<u>A075458 001</u>	Aug 22, 2000
<u>AP</u>	TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578 001</u>	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

+ CELGENE CORP

EQ 50MG BASE

N209606 001 Aug 01, 2017

+!

EQ 100MG BASE

N209606 002 Aug 01, 2017

PRESCRIPTION DRUG PRODUCT LIST

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+! ROCHE

90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUMAB SANDOZ INC300MG/3ML (100MG/ML)A078660 001 Nov 28, 2011LOVENOXAB + SANOFI AVENTIS US300MG/3ML (100MG/ML)N020164 009 Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)AP AMPHASTAR PHARM30MG/0.3ML (100MG/ML)A076684 001 Sep 19, 2011AP40MG/0.4ML (100MG/ML)A076684 002 Sep 19, 2011AP60MG/0.6ML (100MG/ML)A076684 003 Sep 19, 2011AP80MG/0.8ML (100MG/ML)A076684 004 Sep 19, 2011AP100MG/ML (100MG/ML)A076684 005 Sep 19, 2011AP120MG/0.8ML (150MG/ML)A076684 006 Sep 19, 2011AP150MG/ML (150MG/ML)A076684 007 Sep 19, 2011AP SANDOZ30MG/0.3ML (100MG/ML)A077857 002 Jul 23, 2010AP40MG/0.4ML (100MG/ML)A077857 003 Jul 23, 2010AP60MG/0.6ML (100MG/ML)A077857 004 Jul 23, 2010AP80MG/0.8ML (100MG/ML)A077857 005 Jul 23, 2010AP100MG/ML (100MG/ML)A077857 001 Jul 23, 2010AP120MG/0.8ML (150MG/ML)A077857 006 Jul 23, 2010AP150MG/ML (150MG/ML)A077857 007 Jul 23, 2010AP TEVA30MG/0.3ML (100MG/ML)A076726 001 Jun 23, 2014AP40MG/0.4ML (100MG/ML)A076726 002 Jun 23, 2014AP60MG/0.6ML (100MG/ML)A076726 003 Jun 23, 2014AP80MG/0.8ML (100MG/ML)A076726 004 Jun 23, 2014AP100MG/ML (100MG/ML)A076726 005 Jun 23, 2014AP120MG/0.8ML (150MG/ML)A076726 006 Jun 23, 2014AP150MG/ML (150MG/ML)A076726 007 Jun 23, 2014LOVENOX (PRESERVATIVE FREE)AP + SANOFI AVENTIS US30MG/0.3ML (100MG/ML)N020164 001 Mar 29, 1993AP +40MG/0.4ML (100MG/ML)N020164 002 Jan 30, 1998AP +60MG/0.6ML (100MG/ML)N020164 003 Mar 27, 1998AP +80MG/0.8ML (100MG/ML)N020164 004 Mar 27, 1998AP +!100MG/ML (100MG/ML)N020164 005 Mar 27, 1998AP +120MG/0.8ML (150MG/ML)N020164 007 Jun 02, 2000AP +150MG/ML (150MG/ML)N020164 008 Jun 02, 2000ENTACAPONE

TABLET; ORAL

COMTANAB +! ORION PHARMA200MGN020796 001 Oct 19, 1999ENTACAPONEAB AJANTA PHARMA LTD200MGA205792 001 Aug 31, 2017AB AUROBINDO PHARMA200MGA203437 001 Jun 19, 2015

LTD

AB MACLEODS PHARMS LTD200MGA207210 001 Jun 05, 2017AB SUN PHARMA GLOBAL200MGA090690 001 Jul 16, 2012AB WOCKHARDT LTD200MGA078941 001 Aug 16, 2012ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+! BRISTOL MYERS

0.05MG/ML

N021798 001 Mar 29, 2005

SQUIBB

TABLET; ORAL

BARACLUDEAB + BRISTOL MYERS0.5MGN021797 001 Mar 29, 2005

SQUIBB

AB +!1MGN021797 002 Mar 29, 2005ENTECAVIRAB ACCORD HLTHCARE0.5MGA205824 001 Aug 25, 2017AB1MGA205824 002 Aug 25, 2017AB AMNEAL PHARMS0.5MGA206652 001 Nov 12, 2015AB1MGA206652 002 Nov 12, 2015AB AUROBINDO PHARMA0.5MGA206217 001 Aug 26, 2015

LTD

AB1MGA206217 002 Aug 26, 2015AB CIPLA LTD0.5MGA206872 001 Dec 06, 2016AB1MGA206872 002 Dec 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

ENTECAVIR

TABLET; ORAL

ENTECAVIR

<u>AB</u>	HETERO LABS LTD V	<u>0.5MG</u>	<u>A205740 001</u>	Aug 21, 2015
<u>AB</u>		<u>1MG</u>	<u>A205740 002</u>	Aug 21, 2015
<u>AB</u>	PAR PHARM INC	<u>0.5MG</u>	<u>A206294 001</u>	Nov 23, 2016
<u>AB</u>		<u>1MG</u>	<u>A206294 002</u>	Nov 23, 2016
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A208782 001</u>	Oct 10, 2017
<u>AB</u>		<u>1MG</u>	<u>A208782 002</u>	Oct 10, 2017
<u>AB</u>	SANDOZ INC	<u>0.5MG</u>	<u>A206672 001</u>	May 11, 2017
<u>AB</u>		<u>1MG</u>	<u>A206672 002</u>	May 11, 2017
<u>AB</u>	TEVA PHARMS USA	<u>0.5MG</u>	<u>A202122 001</u>	Aug 26, 2014
<u>AB</u>		<u>1MG</u>	<u>A202122 002</u>	Aug 26, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A206745 001</u>	Jun 23, 2017
<u>AB</u>		<u>1MG</u>	<u>A206745 002</u>	Jun 23, 2017

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+	ASTELLAS	40MG	N203415 001	Aug 31, 2012
---	----------	------	-------------	--------------

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

<u>AP</u>	+	FLAMEL IRELAND LTD	<u>50MG/ML (50MG/ML)</u>	<u>N208289 001</u>	Apr 29, 2016
-----------	---	--------------------	--------------------------	--------------------	--------------

EPHEDRINE SULFATE

<u>AP</u>		AKORN INC	<u>50MG/ML (50MG/ML)</u>	<u>N208609 001</u>	Mar 01, 2017
<u>AP</u>		SANDOZ INC	<u>50MG/ML (50MG/ML)</u>	<u>A209784 001</u>	Aug 23, 2017

SOLUTION; IV (INFUSION)

CORPHEDRA

		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943 001	Jan 27, 2017
--	--	-------------------------	-------------------	-------------	--------------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

<u>AT</u>	+	ALLERGAN	<u>0.05%</u>	<u>N021565 001</u>	Oct 16, 2003
-----------	---	----------	--------------	--------------------	--------------

EPINASTINE HYDROCHLORIDE

<u>AT</u>		AKORN	<u>0.05%</u>	<u>A204055 001</u>	May 05, 2017
<u>AT</u>		APOTEX	<u>0.05%</u>	<u>A090919 001</u>	Oct 31, 2011
<u>AT</u>		BRECKENRIDGE PHARM	<u>0.05%</u>	<u>A090870 001</u>	Mar 14, 2011
<u>AT</u>		SANDOZ INC	<u>0.05%</u>	<u>A203384 001</u>	Dec 07, 2016
<u>AT</u>		SOMERSET THERAPS LLC	<u>0.05%</u>	<u>A090951 001</u>	Oct 31, 2011
<u>AT</u>		SUN PHARM INDS	<u>0.05%</u>	<u>A091626 001</u>	Oct 31, 2011

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENACLICK

BX	+	IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009
BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009

EPIPEN

BX	+	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430 001	Dec 22, 1987
----	---	---------------------	----------------	-------------	--------------

EPIPEN JR.

BX	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430 002	Dec 22, 1987
----	---	---------------------	-----------------	-------------	--------------

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012

ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200 001	Dec 07, 2012
+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640 001	Dec 18, 2013

AUVI-Q

+	KALEO INC	EQ 0.1MG/DELIVERY	N201739 003	Nov 17, 2017
---	-----------	-------------------	-------------	--------------

SYMJEPI

+	ADAMIS PHARMS CORP	0.3MG/0.3ML (0.3MG/0.3ML)	N207534 001	Jun 15, 2017
---	--------------------	---------------------------	-------------	--------------

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029 001	Jul 29, 2014
--	--	--------------------	---------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

! DEPROCO

EQ 0.02MG BASE/ML;2%

A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

! DEPROCO

EQ 0.01MG BASE/ML;2%

A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL**AP** +! DENTSPLY PHARM 0.005MG/ML;4%**N021383 001**PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE**AP** SEPTODONT INC 0.005MG/ML;4%**A078959 001** Aug 30, 2011EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE**AP** EASTMAN KODAK 0.01MG/ML;2%**A040057 002** Feb 26, 1993**AP** 0.02MG/ML;2%**A040057 001** Feb 26, 1993**AP** HOSPIRA 0.005MG/ML;0.5%**A089635 001** Jun 21, 1988**AP** 0.005MG/ML;1.5%**A088571 001** Sep 13, 1985**AP** 0.005MG/ML;1.5%**A089645 001** Jun 21, 1988**AP** 0.005MG/ML;2%**A089651 001** Jun 21, 1988**AP** 0.01MG/ML;1%**A089644 001** Jun 21, 1988**AP** 0.01MG/ML;2%**A078772 001** May 12, 2008**AP** 0.01MG/ML;2%**A089646 001** Jun 21, 1988**AP** 0.02MG/ML;2%**A078772 002** May 12, 2008OCTOCAINE**AP** ! SEPTODONT 0.01MG/ML;2%**A084048 001****AP** ! 0.02MG/ML;2%**A084048 002**KYLOCAINE W/ EPINEPHRINE**AP** +! FRESENIUS KABI USA 0.005MG/ML;0.5%**N006488 012****AP** +! 0.005MG/ML;1.5%**N006488 017****AP** +! 0.005MG/ML;2%**N006488 019** Nov 13, 1986**AP** +! 0.01MG/ML;1%**N006488 004****AP** +! 0.02MG/ML;2%**N006488 005**

+! 0.005MG/ML;1%

N006488 018 Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE**AP** +! PFIZER INC 200MG/100ML (2MG/ML)**N050778 001** Sep 15, 1999**AP** + 50MG/25ML (2MG/ML)**N050778 002** Sep 15, 1999EPIRUBICIN HYDROCHLORIDE**AP** ACTAVIS TOTOWA 10MG/5ML (2MG/ML)**A065445 001** Sep 18, 2008**AP** 50MG/25ML (2MG/ML)**A065445 002** Sep 18, 2008**AP** 200MG/100ML (2MG/ML)**A065445 003** Sep 18, 2008**AP** AKORN INC 50MG/25ML (2MG/ML)**A090163 001** Jun 24, 2009**AP** CIPLA LTD 50MG/25ML (2MG/ML)**A065361 001** Oct 22, 2007**AP** 200MG/100ML (2MG/ML)**A065361 002** Oct 22, 2007**AP** FRESENIUS KABI 200MG/100ML (2MG/ML)**A065411 001** Aug 20, 2007

ONCOL

AP 50MG/25ML (2MG/ML)**A065411 002** Aug 20, 2007**AP** FRESENIUS KABI USA 10MG/5ML (2MG/ML)**A065408 001** Oct 15, 2007**AP** 50MG/25ML (2MG/ML)**A065408 002** Oct 15, 2007**AP** 150MG/75ML (2MG/ML)**A065408 003** Oct 15, 2007**AP** 200MG/100ML (2MG/ML)**A065408 004** Oct 15, 2007**AP** HISUN PHARM 50MG/25ML (2MG/ML)**A090075 001** Mar 25, 2010

HANGZHOU

AP 200MG/100ML (2MG/ML)**A090075 002** Mar 25, 2010**AP** HOSPIRA 10MG/5ML (2MG/ML)**A065343 001** Apr 19, 2007**AP** 150MG/75ML (2MG/ML)**A065343 003** Apr 19, 2007**AP** 200MG/100ML (2MG/ML)**A065343 004** Apr 19, 2007**AP** IMPAX LABS INC 50MG/25ML (2MG/ML)**A065331 001** Aug 09, 2007**AP** 200MG/100ML (2MG/ML)**A065331 002** Aug 09, 2007**AP** MYLAN LABS LTD 50MG/25ML (2MG/ML)**A091599 001** Mar 12, 2012**AP** 200MG/100ML (2MG/ML)**A091599 002** Mar 12, 2012**AP** WEST-WARD PHARMS 50MG/25ML (2MG/ML)**A065289 001** Jun 27, 2007

INT

AP 200MG/100ML (2MG/ML)**A065289 002** Jun 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A206922</u>	<u>001</u>	Jul 13, 2017
<u>AB</u>		<u>50MG</u>	<u>A206922</u>	<u>002</u>	Jul 13, 2017
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A203896</u>	<u>001</u>	Feb 02, 2017
<u>AB</u>		<u>50MG</u>	<u>A203896</u>	<u>002</u>	Feb 02, 2017
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008

INSPRA

<u>AB</u>	+ GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+!	<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008

FLOLAN

<u>AP</u>	+! GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995
<u>AP</u>	+!	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995
	VELETRI				
	+ ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260</u>	<u>002</u>	Jun 28, 2012
	+!	<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260</u>	<u>001</u>	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012</u>	<u>001</u>	Nov 16, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A202012</u>	<u>002</u>	Nov 16, 2011

TEVETEN

<u>AB</u>	+ ABBEVIE	<u>EQ 400MG BASE</u>	<u>N020738</u>	<u>005</u>	Dec 22, 1997
<u>AB</u>	+!	<u>EQ 600MG BASE</u>	<u>N020738</u>	<u>006</u>	May 27, 1999

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

<u>AP</u>	ACCORD HLTHCARE	<u>2MG/ML</u>	<u>A205557</u>	<u>001</u>	Nov 06, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A205557</u>	<u>002</u>	Nov 06, 2017
<u>AP</u>	AKORN	<u>2MG/ML</u>	<u>A204589</u>	<u>001</u>	Apr 18, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A204589</u>	<u>002</u>	Apr 18, 2017
<u>AP</u>	AMNEAL PHARMS	<u>2MG/ML</u>	<u>A205581</u>	<u>001</u>	Dec 08, 2016
<u>AP</u>		<u>75MG/100ML</u>	<u>A205581</u>	<u>002</u>	Dec 08, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206127</u>	<u>001</u>	Dec 08, 2015
<u>AP</u>		<u>75MG/100ML</u>	<u>A206127</u>	<u>002</u>	Dec 08, 2015
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A090854</u>	<u>001</u>	Jun 12, 2015

INTEGRILIN

<u>AP</u>	+! SCHERING	<u>2MG/ML</u>	<u>N020718</u>	<u>001</u>	May 18, 1998
<u>AP</u>	+!	<u>75MG/100ML</u>	<u>N020718</u>	<u>002</u>	May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+! US PHARM HOLDINGS	<u>50,000 IU</u>	<u>N003444</u>	<u>001</u>	
-----------	----------------------	------------------	----------------	------------	--

ERGOCALCIFEROL

<u>AA</u>	ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833</u>	<u>001</u>	May 20, 2009
<u>AA</u>	SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004</u>	<u>001</u>	Jul 14, 2010
<u>AA</u>	STRIDES PHARMA	<u>50,000 IU</u>	<u>A090455</u>	<u>001</u>	Aug 03, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865</u>	<u>001</u>	Dec 29, 2009

VITAMIN D

<u>AA</u>	BIONPHARMA INC	<u>50,000 IU</u>	<u>A080704</u>	<u>001</u>	
-----------	----------------	------------------	----------------	------------	--

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

	! SUN PHARM INDUSTRIES	<u>1MG</u>	<u>A081113</u>	<u>001</u>	Oct 31, 1991
--	------------------------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

! TERSERA THERAPS LLC 2MG

A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

HALAVEN

+! EISAI INC 1MG/2ML (0.5MG/ML)

N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

TARCEVA

+ OSI PHARMS EQ 25MG BASE

N021743 001 Nov 18, 2004

+ EQ 100MG BASE

N021743 002 Nov 18, 2004

+! EQ 150MG BASE

N021743 003 Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)

INVANZ

+! MERCK SHARP DOHME EQ 1GM BASE/VIAL

N021337 001 Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

+ MERCK SHARP DOHME 5MG

N209803 001 Dec 19, 2017

+! 15MG

N209803 002 Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

+ MERCK SHARP DOHME 2.5MG;500MG

N209806 001 Dec 19, 2017

+ 2.5MG;1GM

N209806 002 Dec 19, 2017

+ 7.5MG;500MG

N209806 003 Dec 19, 2017

+! 7.5MG;1GM

N209806 004 Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STELUJAN

+ MERCK SHARP DOHME 5MG;EQ 100MG BASE

N209805 001 Dec 19, 2017

+! 15MG;EQ 100MG BASE

N209805 002 Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC**AB** +! MAYNE PHARMA **250MG****N050536 001**ERYTHROMYCIN**AB** ARBOR PHARMS LLC **250MG****A062746 001** Dec 22, 1986

GEL;TOPICAL

ERYGEL**AT** +! MYLAN PHARMS INC **2%****N050617 001** Oct 21, 1987ERYTHROMYCIN**AT** FOUGERA PHARMS **2%****A064184 001** Sep 30, 1997**AT** PERRIGO CO **2%****A063211 001** Jan 29, 1993**AT** TELIGENT PHARMA INC **2%****A208154 001** Jul 19, 2017

OINTMENT;OPHTHALMIC

ERYTHROMYCIN**AT** AKORN **0.5%****A064030 001** Jul 18, 1996**AT** BAUSCH AND LOMB **0.5%****A064067 001** Jul 29, 1994**AT** ! PERRIGO CO **0.5%****A062447 001** Sep 26, 1983

TENNESSEE

SOLUTION;TOPICAL

ERYTHROMYCIN**AT** ! PERRIGO NEW YORK **2%****A063038 001** Jan 11, 1991**AT** TELIGENT PHARMA INC **2%****A208100 001** Nov 20, 2017**AT** WOCKHARDT BIO AG **2%****A062825 001** Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN**AT** AKORN **2%****A090215 001** May 12, 2010**AT** ! PERRIGO CO **2%****A064126 001** Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

ARBOR PHARMS LLC 250MG

A061621 001

! 500MG

A061621 002

PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN

TABLET, COATED PARTICLES;ORAL

PCE

+ ARBOR PHARMS LLC

333MG

N050611 001 Sep 09, 1986

+!

500MG

N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

ARBOR PHARMS LLC

250MG

A062298 001

333MG

A062298 003 Mar 29, 1982

!

500MG

A062298 002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

+ ARBOR PHARMS LLC

EQ 200MG BASE/5ML

N050207 001

ERYPED

+ ARBOR PHARMS LLC

EQ 200MG BASE/5ML

N050207 003 Mar 30, 1987

+!

EQ 400MG BASE/5ML

N050207 002

TABLET;ORAL

E.E.S. 400

BX ! ARBOR PHARMS LLC

EQ 400MG BASE

A061905 002 Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX ! ARBOR PHARMS LLC

EQ 400MG BASE

A061904 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCINAP HOSPIRAEQ 500MG BASE/VIALA062638 001 Oct 31, 1986AP +!EQ 500MG BASE/VIALN050609 001 Sep 24, 1986

!

EQ 1GM BASE/VIAL

A062638 002 Oct 31, 1986ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

! ARBOR PHARMS LLC

EQ 250MG BASE

A060359 001

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATEAA AMNEAL PHARMSEQ 5MG BASE/5MLA202227 001 Mar 14, 2012AA ANTRIM PHARMS LLCEQ 5MG BASE/5MLA203967 001 May 26, 2015AA AUROBINDO PHARMAEQ 5MG BASE/5MLA079062 001 Apr 02, 2012

LTD

AA HETERO LABS LTD IIIEQ 5MG BASE/5MLA202221 001 Jun 12, 2012AA MACLEODS PHARMS LTDEQ 5MG BASE/5MLA202754 001 Mar 31, 2016AA SILARX PHARMS INCEQ 5MG BASE/5MLA090477 001 Jun 12, 2013AA TAROEQ 5MG BASE/5MLA079121 001 May 03, 2012LEXAPROAA +! FOREST LABSEQ 5MG BASE/5MLN021365 001 Nov 27, 2002

TABLET;ORAL

ESCITALOPRAM OXALATEAB ACCORD HLTHCAREEQ 5MG BASEA202389 001 Sep 11, 2012ABEQ 10MG BASEA202389 002 Sep 11, 2012ABEQ 20MG BASEA202389 003 Sep 11, 2012AB AMNEAL PHARMSEQ 5MG BASEA205619 001 May 17, 2017ABEQ 10MG BASEA205619 002 May 17, 2017ABEQ 20MG BASEA205619 003 May 17, 2017AB APOTEX INCEQ 5MG BASEA078777 001 Sep 11, 2012ABEQ 10MG BASEA078777 002 Sep 11, 2012ABEQ 20MG BASEA078777 003 Sep 11, 2012AB AUROBINDO PHARMAEQ 5MG BASEA090432 001 Sep 11, 2012

LTD

ABEQ 10MG BASEA090432 002 Sep 11, 2012ABEQ 20MG BASEA090432 003 Sep 11, 2012AB HIKMA PHARMSEQ 5MG BASEA078766 001 Sep 11, 2012ABEQ 10MG BASEA078766 002 Sep 11, 2012ABEQ 20MG BASEA078766 003 Sep 11, 2012AB INVAGEN PHARMSEQ 5MG BASEA078604 001 Sep 11, 2012ABEQ 10MG BASEA078604 002 Sep 11, 2012ABEQ 20MG BASEA078604 003 Sep 11, 2012AB JUBILANT GENERICSEQ 5MG BASEA202280 001 Sep 12, 2012ABEQ 10MG BASEA202280 002 Sep 12, 2012ABEQ 20MG BASEA202280 003 Sep 12, 2012AB LUPIN LTDEQ 5MG BASEA078169 001 Sep 11, 2012ABEQ 10MG BASEA078169 002 Sep 11, 2012

PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078169 003</u>	Sep 11, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A202210 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202210 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202210 003</u>	Sep 11, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A078032 001</u>	Aug 28, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078032 002</u>	Aug 28, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078032 003</u>	Aug 28, 2015
<u>AB</u>	STI PHARMA LLC	<u>EQ 5MG BASE</u>	<u>A077512 001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077512 002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077512 003</u>	Sep 12, 2012
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE</u>	<u>A076765 001</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076765 002</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076765 003</u>	Mar 14, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A090939 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939 003</u>	Sep 11, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A077734 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077734 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077734 003</u>	Sep 11, 2012
<u>LEXAPRO</u>				
<u>AB</u>	+ FOREST LABS	<u>EQ 5MG BASE</u>	<u>N021323 001</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N021323 002</u>	Aug 14, 2002
<u>AB</u>	+!	<u>EQ 20MG BASE</u>	<u>N021323 003</u>	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIOM

+	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
+		400MG	N022416 002	Nov 08, 2013
+		600MG	N022416 003	Nov 08, 2013
+	!	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+!	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386 006</u>	Feb 25, 2003
<u>ESMOLOL HYDROCHLORIDE</u>					
<u>AP</u>		AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A205520 001</u>	Jul 23, 2015
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005
<u>AP</u>		LUITPOLD PHARMS INC	<u>10MG/ML</u>	<u>A201126 001</u>	Feb 20, 2015
<u>AP</u>		MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005
<u>AP</u>		WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	!	BAXTER HLTHCARE	2GM/100ML	N019386 005 Jan 27, 2003
BREVIBLOC IN PLASTIC CONTAINER					
	+	!	BAXTER HLTHCARE	1GM/100ML	N019386 004 Feb 16, 2001
SOLUTION; INTRAVENOUS					
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703 002 Apr 07, 2016
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER					
	+	!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703 001 Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A208333 001</u>	Oct 20, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A208333 002</u>	Oct 20, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A205606 001</u>	Apr 21, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205606 002</u>	Apr 21, 2016
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A078279 001</u>	Sep 25, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078279 002</u>	Sep 25, 2015
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078003 001</u>	Jan 26, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078003 002</u>	Jan 26, 2015
<u>AB</u>		KREMERS URBAN PHARMS	<u>EQ 20MG BASE</u>	<u>A205563 001</u>	Sep 01, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205563 002</u>	Sep 01, 2017
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A078936 001</u>	Aug 02, 2015

PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		EQ 40MG BASE	A078936 002	Aug 03, 2015
AB	TORRENT PHARMS LTD	EQ 20MG BASE	A203636 001	Oct 19, 2015
AB		EQ 40MG BASE	A203636 002	Oct 19, 2015

NEXIUM

AB	+	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153 001	Feb 20, 2001
AB	+	!	EQ 40MG BASE	N021153 002	Feb 20, 2001

ESOMEPRAZOLE MAGNESIUM

BX	HETERO LABS LTD III	EQ 20MG BASE	A202784 001	Sep 21, 2015
BX		EQ 40MG BASE	A202784 002	Sep 21, 2015

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

+	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
+		EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011
+		EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008
+		EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006
+	!	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A202461 001	Sep 27, 2013
AB		EQ 20MG BASE;500MG	A202461 002	Sep 27, 2013

VIMOVO

AB	+	HORIZON PHARMA USA	EQ 20MG BASE;375MG	N022511 002	Apr 30, 2010
AB	+	!	EQ 20MG BASE;500MG	N022511 001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379 001	Sep 25, 2015	
AP	!	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A204657 002	Aug 10, 2016
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181 001	Mar 06, 2017	
AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686 002	May 17, 2017	
AP	SUN PHARMA GLOBAL	EQ 40MG BASE/VIAL	A200882 002	Mar 18, 2013	

NEXIUM IV

AP	+	ASTRAZENECA PHARMS	EQ 40MG BASE/VIAL	N021689 002	Mar 31, 2005
-----------	---	--------------------	--------------------------	--------------------	--------------

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+	R2 PHARMA LLC	49.3MG	N202342 002	Aug 06, 2013
---	---------------	--------	-------------	--------------

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB	MAYNE PHARMA	1MG	A074921 001	Jul 10, 1997
AB	!	2MG	A074921 002	Jul 10, 1997
AB	PAR PHARM	1MG	A074826 001	Jul 03, 1997
AB		2MG	A074826 002	Jul 03, 1997
AB	WATSON LABS	1MG	A074818 001	Aug 19, 1997
AB		2MG	A074818 002	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	!	ALLERGAN SALES LLC	0.01%	A086069 001	Jan 31, 1984
-----------	---	--------------------	--------------	--------------------	--------------

ESTRADIOL

AB	MYLAN PHARMS INC	0.01%	A208788 001	Dec 29, 2017
-----------	------------------	--------------	--------------------	--------------

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB	+	BAYER HLTHCARE	0.0375MG/24HR	N020375 005	May 27, 2003
AB	+		0.06MG/24HR	N020375 006	May 27, 2003

ESTRADIOL

AB	MYLAN TECHNOLOGIES	0.0375MG/24HR	A075182 004	Jul 20, 2006
AB		0.06MG/24HR	A075182 005	Jul 20, 2006
AB1		0.025MG/24HR	A201675 001	Dec 19, 2014
AB1		0.0375MG/24HR	A201675 002	Dec 19, 2014
AB1		0.05MG/24HR	A201675 003	Dec 19, 2014
AB1		0.075MG/24HR	A201675 004	Dec 19, 2014
AB1		0.1MG/24HR	A201675 005	Dec 19, 2014

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE-DOT

<u>AB1</u>	+	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538</u>	<u>009</u>	May 03, 2002
<u>AB1</u>	+		<u>0.0375MG/24HR</u>	<u>N020538</u>	<u>005</u>	Jan 08, 1999
<u>AB1</u>	+		<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>	+		<u>0.075MG/24HR</u>	<u>N020538</u>	<u>007</u>	Jan 08, 1999
<u>AB1</u>	+!		<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	+	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>	+		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>	+		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+!		<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>			<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>			<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>			<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

ALORA

BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002
BX			0.05MG/24HR	N020655	001	Dec 20, 1996
BX			0.075MG/24HR	N020655	002	Dec 20, 1996
BX			0.1MG/24HR	N020655	003	Dec 20, 1996

MENOSTAR

	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
--	----	----------------	--------------	---------	-----	--------------

MINIVELLE

	+	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014
	+		0.0375MG/24HR	N203752	001	Oct 29, 2012
	+		0.05MG/24HR	N203752	003	Oct 29, 2012
	+		0.075MG/24HR	N203752	002	Oct 29, 2012
	+!		0.1MG/24HR	N203752	004	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

	+	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
	+		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
	+!		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

	+!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
--	----	---------------------	---------------------------	---------	-----	--------------

ESTROGEL

	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
--	----	-------------------	---------------------------	---------	-----	--------------

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

	+!	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
--	----	-------------------------	---------------	---------	-----	--------------

SPRAY;TRANSDERMAL

EVAMIST

	+!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007
--	----	---------------------	--------------	---------	-----	--------------

TABLET;ORAL

ESTRADIOL

<u>AB</u>		BARR LABS INC	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>			<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
<u>AB</u>	!		<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
<u>AB</u>		EPIC PHARMA INC	<u>0.5MG</u>	<u>A040275</u>	<u>001</u>	Dec 29, 1998
<u>AB</u>			<u>1MG</u>	<u>A040275</u>	<u>002</u>	Dec 29, 1998
<u>AB</u>			<u>2MG</u>	<u>A040275</u>	<u>003</u>	Dec 29, 1998
<u>AB</u>		MAYNE PHARMA	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
<u>AB</u>			<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
<u>AB</u>			<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996
<u>AB</u>		MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
<u>AB</u>			<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
<u>AB</u>			<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999

TABLET;VAGINAL

ESTRADIOL

<u>AB</u>		AMNEAL PHARMS	<u>10MCG</u>	<u>A205256</u>	<u>001</u>	May 29, 2015
<u>AB</u>		TEVA PHARMS USA	<u>10MCG</u>	<u>A206388</u>	<u>001</u>	Jul 21, 2017

VAGIFEM

<u>AB</u>	+!	NOVO NORDISK INC	<u>10MCG</u>	<u>N020908</u>	<u>002</u>	Nov 25, 2009
-----------	----	------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

+ APIL

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003

+!

EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

! PHARMACIA AND
UPJOHN

5MG/ML

A085470 003

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+! EXELTIS USA INC

0.25%

N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGENAO +! PAR STERILE
PRODUCTS20MG/MLN009402 004AO +!
ESTRADIOL VALERATE40MG/MLN009402 003AO LUITPOLD20MG/MLA090920 001 Jan 19, 2010AO40MG/MLA090920 002 Jan 19, 2010

DELESTROGEN

+! PAR STERILE
PRODUCTS

10MG/ML

N009402 002

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+! BAYER HLTHCARE

0.045MG/24HR; 0.015MG/24HR

N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

+ NOVEN PHARMS INC

0.05MG/24HR; 0.14MG/24HR

N020870 001 Aug 07, 1998

+!

0.05MG/24HR; 0.25MG/24HR

N020870 002 Aug 07, 1998

TABLET; ORAL

ACTIVELLAAB + AMNEAL PHARMS LLC0.5MG; 0.1MGN020907 002 Dec 28, 2006AB +!
AMABELZ1MG; 0.5MGN020907 001 Nov 18, 1998AB LUPIN LTD0.5MG; 0.1MGA203339 001 Jun 20, 2016AB1MG; 0.5MGA203339 002 Jun 20, 2016ESTRADIOL AND NORETHINDRONE ACETATEAB BARR1MG; 0.5MGA079193 001 May 11, 2010AB BRECKENRIDGE PHARM0.5MG; 0.1MGA078324 002 Jun 09, 2011AB1MG; 0.5MGA078324 001 Apr 17, 2008AB MYLAN LABS LTD0.5MG; 0.1MGA207261 001 Feb 10, 2017AB1MG; 0.5MGA207261 002 Feb 10, 2017AB TEVA PHARMS USA0.5MG; 0.1MGA200747 001 Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

! BARR

1MG, 1MG; N/A, 0.09MG

A076812 001 Apr 29, 2005

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+! PHARMACIA AND
UPJOHN

EQ 140MG PHOSPHATE

N018045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+! WYETH PHARMS INC

0.625MG/GM

N020216 001

INJECTABLE; INJECTION

PREMARIN

+! WYETH PHARMS INC

25MG/VIAL

N010402 001

TABLET; ORAL

PREMARIN

+ WYETH PHARMS INC

0.3MG

N004782 003

+

0.45MG

N004782 006 Jul 16, 2003

PRESCRIPTION DRUG PRODUCT LIST

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

+	!	0.625MG	N004782	004	
+	!	0.9MG	N004782	005	Jan 26, 1984
+	!	1.25MG	N004782	001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+	!	WYETH PHARMS INC	0.625MG, 0.625MG; N/A, 5MG	N020527	002	Nov 17, 1995
---	---	------------------	----------------------------	---------	-----	--------------

PREMPRO

+	!	WYETH PHARMS INC	0.3MG; 1.5MG	N020527	005	Jun 04, 2003
+	!		0.45MG; 1.5MG	N020527	004	Mar 12, 2003
+	!		0.625MG; 2.5MG	N020527	001	Nov 17, 1995
+	!		0.625MG; 5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

		MONARCH PHARMS	0.3MG	A084951	001	
			0.625MG	A084948	001	
			1.25MG	A084950	001	
	!		2.5MG	A084949	001	

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

		MYLAN	0.75MG	A040359	001	Aug 26, 1999
			1.5MG	A040359	002	Aug 26, 1999

OGEN 5

		PHARMACIA AND UPJOHN	6MG	A083220	004	
--	--	----------------------	-----	---------	-----	--

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB		AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016
AB			2MG	A208451	002	Sep 15, 2016
AB			3MG	A208451	003	Sep 15, 2016
AB		DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014
AB			2MG	A091024	002	Apr 15, 2014
AB			3MG	A091024	003	Apr 15, 2014
AB		GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014
AB			2MG	A091166	002	Apr 15, 2014
AB			3MG	A091166	003	Apr 15, 2014
AB		LUPIN LTD	1MG	A091124	001	Sep 13, 2011
AB			2MG	A091124	002	Sep 13, 2011
AB			3MG	A091124	003	Sep 13, 2011
AB		MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015
AB			2MG	A202929	002	Jan 30, 2015
AB			3MG	A202929	003	Jan 30, 2015
AB		MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013
AB			2MG	A091151	002	Mar 26, 2013
AB			3MG	A091151	003	Mar 26, 2013
AB		ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014
AB			2MG	A091113	002	Jun 10, 2014
AB			3MG	A091113	003	Jun 10, 2014
AB		SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013
AB			2MG	A091103	002	Apr 03, 2013
AB			3MG	A091103	003	Apr 03, 2013
AB		TEVA	1MG	A091169	001	May 23, 2011
AB			2MG	A091169	002	May 23, 2011
AB			3MG	A091169	003	May 23, 2011
AB		WEST-WARD PHARMS INT	1MG	A091153	001	Apr 15, 2014
AB			2MG	A091153	002	Apr 15, 2014
AB			3MG	A091153	003	Apr 15, 2014
		LUNESTA				
AB	+	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004
AB	+		2MG	N021476	002	Dec 15, 2004
AB	+		3MG	N021476	003	Dec 15, 2004

PRESCRIPTION DRUG PRODUCT LIST

ETELICALCETIDE

SOLUTION; INTRAVENOUS

PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION; IV (INFUSION)

EXONDYS 51

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+	!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIIN

AP	+	!	ATON	<u>EQ 50MG BASE/VIAL</u>	<u>N016093</u>	<u>001</u>
-----------	---	---	------	--------------------------	----------------	------------

ETHACRYNATE SODIUM

AP			MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A204634</u>	<u>001</u>	Aug 23, 2016
AP			PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A205473</u>	<u>001</u>	Jul 29, 2015
AP			ZYDUS PHARMS USA INC	<u>EQ 50MG BASE/VIAL</u>	<u>A207758</u>	<u>001</u>	Nov 17, 2017

ETHACRYNIC ACID

TABLET; ORAL

EDECRIIN

AB	+	!	ATON	<u>25MG</u>	<u>N016092</u>	<u>001</u>
-----------	---	---	------	-------------	----------------	------------

ETHACRYNIC ACID

AB			EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205609</u>	<u>001</u>	Jun 30, 2016
AB			PAR PHARM INC	<u>25MG</u>	<u>A208501</u>	<u>001</u>	Jul 21, 2017
AB			WEST-WARD PHARMS INT	<u>25MG</u>	<u>A207262</u>	<u>001</u>	Feb 23, 2017

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB			AKORN	<u>100MG</u>	<u>A075095</u>	<u>001</u>	Nov 30, 1999
AB				<u>400MG</u>	<u>A075095</u>	<u>002</u>	Nov 30, 1999
AB			BARR	<u>400MG</u>	<u>A076057</u>	<u>001</u>	Nov 26, 2001
AB			LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u>	Jun 17, 2009
AB				<u>400MG</u>	<u>A078939</u>	<u>002</u>	Jun 17, 2009

MYAMBUTOL

AB	+		STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>
AB	+	!		<u>400MG</u>	<u>N016320</u>	<u>003</u>

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+	!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988
---	---	-----------	---------	---------	-----	--------------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB			MYLAN LABS LTD	<u>0.035MG;1MG</u>	<u>A204703</u>	<u>001</u>	Jul 28, 2016
AB				<u>0.05MG;1MG</u>	<u>A204704</u>	<u>001</u>	Feb 09, 2016
			<u>KELNOR</u>				
AB			BARR	<u>0.035MG;1MG</u>	<u>A076785</u>	<u>001</u>	May 23, 2005
			<u>ZOVIA 1/35E-28</u>				
AB			MAYNE PHARMA	<u>0.035MG;1MG</u>	<u>A072721</u>	<u>001</u>	Dec 30, 1991
			<u>ZOVIA 1/50E-28</u>				
AB	!		WATSON LABS	<u>0.05MG;1MG</u>	<u>A072723</u>	<u>001</u>	Dec 30, 1991

ETHINYL ESTRADIOL; ETNOGESTREL

RING; VAGINAL

NUVARING

+	!	ORGANON SUB MERCK	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001
---	---	-------------------	--------------------------	---------	-----	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

ASHLYNA

AB			GLENMARK GENERICS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203163</u>	<u>001</u>	Feb 23, 2015
			<u>DAYSEE</u>				
AB			LUPIN LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A091467</u>	<u>001</u>	Apr 10, 2013
			<u>FAYOSIM</u>				
AB			LUPIN LTD	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	<u>A205943</u>	<u>001</u>	Mar 29, 2016

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

AB	LABS LEON FARMA	<u>0.03MG;0.15MG</u>	A079064 001	Sep 27, 2010
-----------	-----------------	----------------------	--------------------	--------------

JAIMIESS

AB	LABS LEON FARMA	<u>0.03MG,0.01MG;0.15MG,N/A</u>	A203770 001	Dec 27, 2017
-----------	-----------------	---------------------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	A203871 001	Nov 13, 2015
-----------	---------------	----------------------	--------------------	--------------

AB		<u>0.03MG,0.01MG;0.15MG,N/A</u>	A203872 001	Dec 22, 2015
-----------	--	---------------------------------	--------------------	--------------

AB	GLENMARK GENERICS	<u>0.02MG;0.09MG</u>	A202791 001	Apr 09, 2015
-----------	-------------------	----------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.03MG;0.15MG</u>	A203164 001	Jun 12, 2015
-----------	---------------------	----------------------	--------------------	--------------

AB	LUPIN LTD	<u>0.02MG,0.01MG;0.1MG,N/A</u>	A091674 001	Oct 26, 2011
-----------	-----------	--------------------------------	--------------------	--------------

AB		<u>0.03MG;0.15MG</u>	A091440 001	Oct 23, 2012
-----------	--	----------------------	--------------------	--------------

AB	MAYNE PHARMA	<u>0.02MG,0.01MG;0.1MG,N/A</u>	A200407 001	Oct 25, 2011
-----------	--------------	--------------------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	A200490 001	Apr 21, 2015
-----------	----------------	----------------------	--------------------	--------------

AB	! WATSON LABS	<u>0.02MG;0.09MG</u>	A079218 001	Jun 06, 2011
-----------	---------------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	LABS LEON FARMA	<u>0.02MG,0.01MG;0.1MG,N/A</u>	A205131 001	Dec 14, 2017
-----------	-----------------	--------------------------------	--------------------	--------------

AB	MAYNE PHARMA	<u>0.03MG,0.01MG;0.15MG,N/A</u>	A078834 001	May 31, 2011
-----------	--------------	---------------------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.02MG,0.15MG;</u>	A206053 001	Oct 02, 2017
-----------	----------------	-----------------------	--------------------	--------------

		<u>0.025MG,0.15MG;0.03MG,0.15MG;</u>		
--	--	--------------------------------------	--	--

AB		<u>0.02MG,0.01MG;0.1MG,N/A</u>	A200493 001	Jun 17, 2015
-----------	--	--------------------------------	--------------------	--------------

AB		<u>0.03MG,0.01MG;0.15MG,N/A</u>	A200492 001	May 27, 2015
-----------	--	---------------------------------	--------------------	--------------

LO SIMPESE

AB	AUROBINDO PHARMA LTD	<u>0.02MG,0.01MG;0.01MG,N/A</u>	A206852 001	Apr 28, 2017
-----------	----------------------	---------------------------------	--------------------	--------------

LOSEASONIQUE

AB	TEVA BRANDED PHARM	<u>0.02MG,0.01MG;0.1MG,N/A</u>	N022262 001	Oct 24, 2008
-----------	--------------------	--------------------------------	--------------------	--------------

QUARTETTE

AB	+! TEVA BRANDED PHARM	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	N204061 001	Mar 28, 2013
-----------	-----------------------	--	--------------------	--------------

QUASENSE

AB	WATSON LABS	<u>0.03MG;0.15MG</u>	A077101 001	Sep 06, 2006
-----------	-------------	----------------------	--------------------	--------------

SEASONALE

AB	+! TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	N021544 001	Sep 05, 2003
-----------	-----------------------	----------------------	--------------------	--------------

SEASONIQUE

AB	+! TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.15MG,N/A</u>	N021840 001	May 25, 2006
-----------	-----------------------	---------------------------------	--------------------	--------------

SETLAKIN

AB	NOVAST LABS LTD	<u>0.03MG;0.15MG</u>	A090716 001	Sep 15, 2014
-----------	-----------------	----------------------	--------------------	--------------

SIMPESE

AB	AUROBINDO PHARMA LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	A206851 001	Apr 07, 2017
-----------	----------------------	---------------------------------	--------------------	--------------

TABLET; ORAL-28

ALTAVERA

AB	LABS LEON FARMA	<u>0.03MG;0.15MG</u>	A079102 001	Aug 03, 2010
-----------	-----------------	----------------------	--------------------	--------------

AYUNA

AB	AUROBINDO PHARMA LTD	<u>0.03MG;0.15MG</u>	A206866 001	Sep 23, 2016
-----------	----------------------	----------------------	--------------------	--------------

ELIFEMME

AB	LABS LEON FARMA	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	A202507 001	Dec 04, 2015
-----------	-----------------	--	--------------------	--------------

ENPRESSE-28

AB	DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	A075809 002	Jul 16, 2001
-----------	---------------------	--	--------------------	--------------

KURVELO

AB	LUPIN LTD	<u>0.03MG;0.15MG</u>	A091408 001	Oct 17, 2012
-----------	-----------	----------------------	--------------------	--------------

LEVONEST

AB	NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	A090719 001	Dec 29, 2010
-----------	-----------------	--	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	A201095 001	Dec 08, 2014
-----------	---------------	----------------------	--------------------	--------------

AB	LUPIN LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	A200248 001	Nov 19, 2015
-----------	-----------	--	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	A091663 001	Dec 21, 2012
-----------	----------------	----------------------	--------------------	--------------

LEVORA 0.15/30-28

AB	! MAYNE PHARMA	<u>0.03MG;0.15MG</u>	A073594 001	Dec 13, 1993
-----------	----------------	----------------------	--------------------	--------------

MARLISSA

AB	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	A091452 001	Feb 29, 2012
-----------	-------------------	----------------------	--------------------	--------------

MYZILRA

AB	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	A077502 001	Nov 23, 2011
-----------	--------------------	--	--------------------	--------------

PORTIA-28

AB	BARR	<u>0.03MG;0.15MG</u>	A075866 002	May 23, 2002
-----------	------	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

TRIVORA-28

AB	!	MAYNE PHARMA	<u>0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG</u>	A074538	002	Dec 18, 1997
-----------	---	--------------	---	----------------	------------	--------------

AFIRMELLE

AB1		AUROBINDO PHARMA LTD	<u>0.02MG; 0.1MG</u>	A206886	001	Nov 14, 2016
------------	--	----------------------	----------------------	----------------	------------	--------------

AVIANE-28

AB1		DURAMED PHARMS BARR	<u>0.02MG; 0.1MG</u>	A075796	001	Apr 30, 2001
------------	--	---------------------	----------------------	----------------	------------	--------------

FALMINA

AB1		NOVAST LABS LTD	<u>0.02MG; 0.1MG</u>	A090721	001	Mar 28, 2012
------------	--	-----------------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		AMNEAL PHARMS	<u>0.02MG; 0.1MG</u>	A201108	001	Feb 05, 2014
------------	--	---------------	----------------------	----------------	------------	--------------

AB1		LUPIN LTD	<u>0.02MG; 0.1MG</u>	A091425	001	Jan 18, 2013
------------	--	-----------	----------------------	----------------	------------	--------------

AB1	!	MAYNE PHARMA	<u>0.02MG; 0.1MG</u>	A076625	001	Nov 18, 2004
------------	---	--------------	----------------------	----------------	------------	--------------

AB1		MYLAN LABS LTD	<u>0.02MG; 0.1MG</u>	A200245	001	Oct 09, 2013
------------	--	----------------	----------------------	----------------	------------	--------------

ORSYTHIA

AB1		VINTAGE PHARMS LLC	<u>0.02MG; 0.1MG</u>	A077099	001	May 11, 2011
------------	--	--------------------	----------------------	----------------	------------	--------------

VIENVA

AB1		LABS LEON FARMA	<u>0.02MG; 0.1MG</u>	A201088	001	May 21, 2015
------------	--	-----------------	----------------------	----------------	------------	--------------

LESSINA-28

AB2		BARR	<u>0.02MG; 0.1MG</u>	A075803	002	Mar 20, 2002
------------	--	------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	!	MAYNE PHARMA	<u>0.02MG; 0.1MG</u>	A077681	001	May 31, 2006
------------	---	--------------	----------------------	----------------	------------	--------------

AB2		MYLAN LABS LTD	<u>0.02MG; 0.1MG</u>	A202247	001	Dec 08, 2014
------------	--	----------------	----------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

XULANE

!	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR		A200910	001	Apr 16, 2014
---	--------------------	---------------------------	--	---------	-----	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

AB		ALLERGAN SALES LLC	<u>0.035MG; 1MG</u>	N017565	001	
-----------	--	--------------------	---------------------	----------------	------------	--

NORTREL 1/35-21

AB		BARR	<u>0.035MG; 1MG</u>	A072693	001	Feb 28, 1992
-----------	--	------	---------------------	----------------	------------	--------------

NORTREL 7/7/7

		BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	A075478	001	Aug 30, 2002
--	--	------	--	---------	-----	--------------

TABLET; ORAL-28

ALYACEN 1/35

AB		GLENMARK GENERICS	<u>0.035MG; 1MG</u>	A091634	001	Jan 19, 2012
-----------	--	-------------------	---------------------	----------------	------------	--------------

ALYACEN 7/7/7

AB		GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	A091636	001	Jan 19, 2012
-----------	--	-------------------	--	----------------	------------	--------------

ARANELLE

AB		BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG</u>	A076783	001	Sep 29, 2004
-----------	--	------	---	----------------	------------	--------------

BALZIVA-28

AB		BARR	<u>0.035MG; 0.4MG</u>	A076238	001	Apr 22, 2004
-----------	--	------	-----------------------	----------------	------------	--------------

BREVICON 28-DAY

AB		ALLERGAN SALES LLC	<u>0.035MG; 0.5MG</u>	N017743	001	
-----------	--	--------------------	-----------------------	----------------	------------	--

BRIELLYN

AB		GLENMARK GENERICS	<u>0.035MG; 0.4MG</u>	A090538	001	Mar 22, 2011
-----------	--	-------------------	-----------------------	----------------	------------	--------------

CYCLAFEM 0.5/35

AB		VINTAGE PHARMS	<u>0.035MG; 0.5MG</u>	A203413	001	Dec 16, 2015
-----------	--	----------------	-----------------------	----------------	------------	--------------

CYCLAFEM 1/35

AB		VINTAGE PHARMS LLC	<u>0.035MG; 1MG</u>	A076337	001	Nov 12, 2010
-----------	--	--------------------	---------------------	----------------	------------	--------------

CYCLAFEM 7/7/7

AB		VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	A076338	001	Nov 16, 2010
-----------	--	--------------------	--	----------------	------------	--------------

CYONANZ

AB		AUROBINDO PHARMA LTD	<u>0.035MG; 0.5MG</u>	A207055	001	Oct 21, 2016
-----------	--	----------------------	-----------------------	----------------	------------	--------------

DASETTA 1/35

AB		NOVAST LABS LTD	<u>0.035MG; 1MG</u>	A090948	001	Dec 22, 2011
-----------	--	-----------------	---------------------	----------------	------------	--------------

DASETTA 7/7/7

AB		NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	A090946	001	Dec 22, 2011
-----------	--	-----------------	--	----------------	------------	--------------

GILDAGIA

AB		VINTAGE PHARMS	<u>0.035MG; 0.4MG</u>	A078376	001	Nov 06, 2012
-----------	--	----------------	-----------------------	----------------	------------	--------------

MODICON 28

AB	+	JANSSEN PHARMS	<u>0.035MG; 0.5MG</u>	N017735	001	
-----------	---	----------------	-----------------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

<u>AB</u>	ACCORD HLTHCARE	<u>0.035MG;1MG</u>	<u>A206864</u>	<u>001</u>	Apr 28, 2017
<u>AB</u>	MAYNE PHARMA	<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987
<u>AB</u>	! MYLAN LABS LTD	<u>0.035MG;0.4MG</u>	<u>A200897</u>	<u>001</u>	May 11, 2015
<u>AB</u>	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010
<u>AB</u>	WATSON LABS TEVA	<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987

NORINYL 1+35 28-DAY

<u>AB</u>	ALLERGAN SALES LLC	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	
-----------	--------------------	--------------------	----------------	------------	--

NORTREL 0.5/35-28

<u>AB</u>	BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992
-----------	------	----------------------	----------------	------------	--------------

NORTREL 1/35-28

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992
-----------	------	--------------------	----------------	------------	--------------

NORTREL 7/7/7

<u>AB</u>	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002
-----------	------	---	----------------	------------	--------------

NYLIA 1/35

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG;1MG</u>	<u>A207056</u>	<u>001</u>	Oct 21, 2016
-----------	----------------------	--------------------	----------------	------------	--------------

NYLIA 7/7/7

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A207054</u>	<u>001</u>	Oct 21, 2016
-----------	----------------------	---	----------------	------------	--------------

ORTHO-NOVUM 1/35-28

<u>AB</u>	+! JANSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	
-----------	-------------------	--------------------	----------------	------------	--

ORTHO-NOVUM 7/7/7-28

<u>AB</u>	+! JANSSEN PHARMS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984
-----------	-------------------	---	----------------	------------	--------------

PHILITH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011
-----------	-----------------	----------------------	----------------	------------	--------------

PIRMELLA 1/35

<u>AB</u>	LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512</u>	<u>001</u>	Apr 24, 2013
-----------	-----------	--------------------	----------------	------------	--------------

PIRMELLA 7/7/7

<u>AB</u>	LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510</u>	<u>001</u>	Apr 24, 2013
-----------	-----------	---	----------------	------------	--------------

TRI-NORINYL 28-DAY

<u>AB</u>	+! MAYNE PHARMA	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
-----------	-----------------	--	----------------	------------	--------------

VYFEMLA

<u>AB</u>	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013
-----------	-----------	----------------------	----------------	------------	--------------

WERA

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012
-----------	-----------------	----------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL

! MYLAN LABS LTD 0.05MG;1MG A203006 001 Aug 05, 2013

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

	WATSON LABS TEVA	<u>0.035MG,0.035MG;0.5MG,1MG</u>	A071044	001	Apr 01, 1988
--	------------------	----------------------------------	---------	-----	--------------

TABLET, CHEWABLE; ORAL

FEMCON FE

<u>AB</u>	+! APIL	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
-----------	---------	----------------------	----------------	------------	--------------

KAITLIB FE

<u>AB</u>	LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448</u>	<u>001</u>	Dec 17, 2015
-----------	-----------	----------------------	----------------	------------	--------------

NEXESTA FE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG;0.4MG</u>	<u>A207535</u>	<u>001</u>	Feb 02, 2017
-----------	----------------------	----------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>0.035MG;0.4MG</u>	<u>A207066</u>	<u>001</u>	Mar 29, 2017
-----------	-----------------	----------------------	----------------	------------	--------------

<u>AB</u>	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
-----------	---------------	----------------------	----------------	------------	--------------

<u>AB</u>	+! APIL	<u>0.025MG;0.8MG</u>	<u>N022573</u>	<u>001</u>	Dec 22, 2010
-----------	---------	----------------------	----------------	------------	--------------

<u>AB</u>	BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
-----------	------	----------------------	----------------	------------	--------------

<u>AB</u>	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A091332</u>	<u>001</u>	Mar 23, 2016
-----------	-----------	----------------------	----------------	------------	--------------

<u>AB</u>	MYLAN LABS LTD	<u>0.025MG;0.8MG</u>	<u>A203371</u>	<u>001</u>	Apr 23, 2014
-----------	----------------	----------------------	----------------	------------	--------------

<u>AB</u>		<u>0.035MG;0.4MG</u>	<u>A202086</u>	<u>001</u>	Apr 01, 2015
-----------	--	----------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

TAYTULLA

	+! APIL	0.02MG;1MG	N204426	001	Apr 19, 2013
--	---------	------------	---------	-----	--------------

TABLET; ORAL

AUROVELA 24 FE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207504</u>	<u>001</u>	Jun 15, 2017
-----------	----------------------	-------------------	----------------	------------	--------------

BLISOVI 24 FE

<u>AB</u>	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A091398</u>	<u>001</u>	Oct 28, 2015
-----------	-----------	-------------------	----------------	------------	--------------

FEMHRT

<u>AB</u>	APIL	<u>0.0025MG;0.5MG</u>	<u>N021065</u>	<u>001</u>	Jan 14, 2005
-----------	------	-----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FYAVOLV

AB	LUPIN LTD	<u>0.005MG;1MG</u>	<u>A204213 002</u>	Dec 10, 2015
AB		<u>0.0025MG;0.5MG</u>	<u>A204213 001</u>	Dec 10, 2015

GILDESS 24 FE

AB	VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293 001</u>	Dec 01, 2014
-----------	----------------	-------------------	--------------------	--------------

LARIN 24 FE

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202994 001</u>	Feb 18, 2015
-----------	-----------------	-------------------	--------------------	--------------

LERIBANE

AB	NOVAST LABS LTD	<u>0.0025MG;0.5MG</u>	<u>A203435 002</u>	Jun 03, 2016
-----------	-----------------	-----------------------	--------------------	--------------

AB		<u>0.005MG;1MG</u>	<u>A203435 001</u>	Jun 03, 2016
-----------	--	--------------------	--------------------	--------------

LO LOESTRIN FE

AB	+! APIL	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>N022501 001</u>	Oct 21, 2010
-----------	---------	------------------------------	--------------------	--------------

LOESTRIN 24 FE

AB	+ APIL	<u>0.02MG;1MG</u>	<u>N021871 001</u>	Feb 17, 2006
-----------	--------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	! BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221 001</u>	Nov 06, 2009
-----------	-----------------	--------------------	--------------------	--------------

AB	GLENMARK GENERICS	<u>0.0025MG;0.5MG</u>	<u>A203038 001</u>	Apr 02, 2015
-----------	-------------------	-----------------------	--------------------	--------------

AB		<u>0.005MG;1MG</u>	<u>A203038 002</u>	Apr 02, 2015
-----------	--	--------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.0025MG;0.5MG</u>	<u>A207260 001</u>	Feb 02, 2017
-----------	----------------	-----------------------	--------------------	--------------

AB		<u>0.005MG;1MG</u>	<u>A207259 001</u>	Dec 27, 2016
-----------	--	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	MYLAN LABS LTD	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>A205049 001</u>	May 31, 2016
-----------	----------------	------------------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	! AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267 001</u>	Sep 01, 2009
-----------	-----------------	-------------------	--------------------	--------------

AB	BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938 001</u>	Dec 01, 2014
-----------	---------------	-------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A204847 001</u>	Nov 17, 2017
-----------	---------------------	-------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202742 001</u>	Oct 30, 2014
-----------	----------------	-------------------	--------------------	--------------

TABLET; ORAL-21

AUROVELA 1.5/30

AB	AUROBINDO PHARMA LTD	<u>0.03MG;1.5MG</u>	<u>A207581 001</u>	Jun 26, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA 1/20

AB	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207506 001</u>	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

GILDESS 1.5/30

AB	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075 002</u>	Jul 24, 2012
-----------	--------------------	---------------------	--------------------	--------------

GILDESS 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 002</u>	Jul 24, 2012
-----------	--------------------	-------------------	--------------------	--------------

JUNEL 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076381 001</u>	May 30, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076380 001</u>	May 30, 2003
-----------	------	-------------------	--------------------	--------------

LARIN 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A202996 001</u>	Mar 20, 2014
-----------	-----------------	---------------------	--------------------	--------------

LARIN 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202995 001</u>	Dec 04, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

AB	APIL	<u>0.03MG;1.5MG</u>	<u>N017875 001</u>	
-----------	------	---------------------	--------------------	--

LOESTRIN 21 1/20

AB	APIL	<u>0.02MG;1MG</u>	<u>N017876 001</u>	
-----------	------	-------------------	--------------------	--

MICROGESTIN 1.5/30

AB	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 002</u>	Jul 30, 2003
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

AB	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 002</u>	Jul 30, 2003
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206969 001</u>	Jan 20, 2016
-----------	---------------------	-------------------	--------------------	--------------

AB	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202771 001</u>	Nov 06, 2013
-----------	----------------	-------------------	--------------------	--------------

AB		<u>0.03MG;1.5MG</u>	<u>A202770 001</u>	Feb 19, 2015
-----------	--	---------------------	--------------------	--------------

TRI-LEGEST 21

	BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076405 001</u>	Oct 26, 2007
--	------	--	--------------------	--------------

TABLET; ORAL-28

AUROVELA FE 1.5/30

AB	AUROBINDO PHARMA LTD	<u>0.03MG;1.5MG</u>	<u>A207580 001</u>	Jun 15, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA FE 1/20

AB	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207505 001</u>	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

BLISOVI FE 1.5/30

AB	LUPIN LTD	<u>0.03MG;1.5MG</u>	<u>A201585 001</u>	Nov 18, 2015
-----------	-----------	---------------------	--------------------	--------------

BLISOVI FE 1/20

AB	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A201584 001</u>	Nov 18, 2015
-----------	-----------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

ESTROSTEP FE

AB	+! APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130 002	Oct 09, 1996
-----------	----------------	---	--------------------	--------------

GILDESS FE 1.5/30

AB	VINTAGE PHARMS LLC	0.03MG; 1.5MG	A077075 001	Apr 28, 2005
-----------	--------------------	----------------------	--------------------	--------------

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	0.02MG; 1MG	A077077 001	May 20, 2005
-----------	--------------------	--------------------	--------------------	--------------

HAILEY FE 1/20

AB	GLENMARK PHARMS LTD	0.02MG; 1MG	A206597 001	Nov 21, 2017
-----------	---------------------	--------------------	--------------------	--------------

JUNEL FE 1.5/30

AB	BARR	0.03MG; 1.5MG	A076064 001	Sep 18, 2003
-----------	------	----------------------	--------------------	--------------

JUNEL FE 1/20

AB	BARR	0.02MG; 1MG	A076081 001	Sep 18, 2003
-----------	------	--------------------	--------------------	--------------

LARIN FE 1.5/30

AB	NOVAST LABS LTD	0.03MG; 1.5MG	A091453 001	Aug 23, 2013
-----------	-----------------	----------------------	--------------------	--------------

LARIN FE 1/20

AB	NOVAST LABS LTD	0.02MG; 1MG	A091454 001	Aug 26, 2013
-----------	-----------------	--------------------	--------------------	--------------

LOESTRIN FE 1.5/30

AB	+! APIL	0.03MG; 1.5MG	N017355 001	
-----------	----------------	----------------------	--------------------	--

LOESTRIN FE 1/20

AB	+ APIL	0.02MG; 1MG	N017354 001	
-----------	---------------	--------------------	--------------------	--

MICROGESTIN FE 1.5/30

AB	MAYNE PHARMA	0.03MG; 1.5MG	A075548 001	Feb 05, 2001
-----------	--------------	----------------------	--------------------	--------------

MICROGESTIN FE 1/20

AB	MAYNE PHARMA	0.02MG; 1MG	A075647 001	Feb 05, 2001
-----------	--------------	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	MAYNE PHARMA	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076629 001	Mar 18, 2010
-----------	--------------	---	--------------------	--------------

AB	MYLAN LABS LTD	0.02MG; 1MG	A202772 001	Nov 14, 2013
-----------	----------------	--------------------	--------------------	--------------

AB		0.03MG; 1.5MG	A202741 001	Feb 20, 2015
-----------	--	----------------------	--------------------	--------------

TRI-LEGEST FE

AB	BARR	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076105 001	Oct 26, 2007
-----------	------	---	--------------------	--------------

TABLET, CHEWABLE; ORAL

MIBELAS 24 FE

AB	LUPIN ATLANTIS	0.02MG; 1MG	A206287 001	May 24, 2016
-----------	----------------	--------------------	--------------------	--------------

MINASTRIN 24 FE

AB	+! APIL	0.02MG; 1MG	N203667 001	May 08, 2013
-----------	----------------	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	0.02MG; 1MG	A207514 001	Sep 11, 2017
-----------	---------------	--------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	0.02MG; 1MG	A210369 001	Dec 26, 2017
-----------	---------------------	--------------------	--------------------	--------------

AB	MYLAN LABS LTD	0.02MG; 1MG	A206120 001	Sep 12, 2017
-----------	----------------	--------------------	--------------------	--------------

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

+!	APIL	0.01MG, 0.01MG, N/A; 1MG, N/A, N/A	N204654 001	Jul 24, 2013
-----------	------	---	--------------------	--------------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A200494 001	Jun 17, 2011
-----------	-------------------	---	--------------------	--------------

TABLET; ORAL-28

ESTARYLLA

AB	LABS LEON FARMA	0.035MG; 0.25MG	A090794 001	Jan 30, 2013
-----------	-----------------	------------------------	--------------------	--------------

MILI

AB	AUROBINDO PHARMA LTD	0.035MG; 0.25MG	A205449 001	Jul 07, 2016
-----------	----------------------	------------------------	--------------------	--------------

MONO-LINYAH

AB	NOVAST LABS LTD	0.035MG; 0.25MG	A090523 001	May 23, 2012
-----------	-----------------	------------------------	--------------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A203870 001	Nov 12, 2015
-----------	---------------	---	--------------------	--------------

AB		0.035MG; 0.25MG	A203865 001	Oct 27, 2015
-----------	--	------------------------	--------------------	--------------

AB		0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A203873 001	May 12, 2016
-----------	--	---	--------------------	--------------

AB	GLENMARK GENERICS	0.035MG; 0.25MG	A200538 001	Apr 05, 2012
-----------	-------------------	------------------------	--------------------	--------------

AB	GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A204057 001	Feb 23, 2016
-----------	-----------------	---	--------------------	--------------

AB	LUPIN LTD	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A205588 001	Apr 26, 2016
-----------	-----------	---	--------------------	--------------

AB		0.035MG; 0.25MG	A205630 001	Oct 27, 2016
-----------	--	------------------------	--------------------	--------------

AB	LUPIN PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A200541 001	Jun 25, 2012
-----------	--------------	---	--------------------	--------------

AB	MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A202132 001	Sep 09, 2015
-----------	----------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A201897 001</u>	Jan 27, 2016
AB		<u>0.035MG; 0.25MG</u>	<u>A201896 001</u>	Jan 27, 2016
AB	OC PHARMA	<u>0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG</u>	<u>A200383 001</u>	Apr 07, 2015
AB		<u>0.035MG; 0.25MG</u>	<u>A200384 001</u>	Apr 07, 2015
	<u>ORTHO CYCLEN-28</u>			
AB	+! JANSSEN PHARMS	<u>0.035MG; 0.25MG</u>	<u>N019653 002</u>	Dec 29, 1989
	<u>ORTHO TRI-CYCLEN</u>			
AB	+! JANSSEN PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N019697 001</u>	Jul 03, 1992
	<u>ORTHO TRI-CYCLEN LO</u>			
AB	+! JANSSEN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N021241 001</u>	Aug 22, 2002
	<u>PREVIFEM</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG; 0.25MG</u>	<u>A076334 001</u>	Jan 09, 2004
	<u>SPRINTEC</u>			
AB	BARR	<u>0.035MG; 0.25MG</u>	<u>A075804 001</u>	Sep 25, 2002
	<u>TRI LO SPRINTEC</u>			
AB	BARR LABS INC	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076784 001</u>	Jun 29, 2009
	<u>TRI-ESTARYLLA</u>			
AB	LABS LEON FARMA	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090793 001</u>	Jan 30, 2013
	<u>TRI-LINYAH</u>			
AB	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090524 001</u>	May 30, 2012
	<u>TRI-LO-ESTARYLLA</u>			
AB	LABS LEON FARMA	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A091232 001</u>	Jun 29, 2015
	<u>TRI-LO-MILI</u>			
AB	AUROBINDO PHARMA LTD	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205762 001</u>	Nov 04, 2016
	<u>TRI-MILI</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205441 001</u>	Jul 06, 2016
	<u>TRI-PREVIFEM</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076335 001</u>	Mar 26, 2004
	<u>TRI-SPRINTEC</u>			
AB	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A075808 001</u>	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840 001</u>	Nov 30, 2001
	TABLET; ORAL-28			
	<u>CRYSELLE</u>			
AB	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840 002</u>	Nov 30, 2001
	<u>ELINEST</u>			
AB	NOVAST LABS LTD	<u>0.03MG; 0.3MG</u>	<u>A091105 001</u>	Mar 28, 2012
	<u>LOW-OGESTREL-28</u>			
AB	MAYNE PHARMA	<u>0.03MG; 0.3MG</u>	<u>A075288 002</u>	Jul 28, 1999
	OGESTREL 0.5/50-28			
	! WATSON LABS	0.05MG; 0.5MG	A075406 002	Dec 15, 1999

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190 001	
----	---------	---	-------------	--

ETHIONAMIDE

TABLET; ORAL

TRECTOR

+!	WYETH PHARMS INC	250MG	N013026 002	
----	------------------	-------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

<u>AB</u>	AKORN	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
<u>AB</u>	BIONPHARMA INC	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>	HERITAGE PHARMS INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012

ZARONTIN

<u>AB</u>	<u>+</u> ! PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	
-----------	------------------------	--------------	----------------	------------	--

SYRUP; ORAL

ETHOSUXIMIDE

<u>AA</u>	MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
<u>AA</u>	TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993

ZARONTIN

<u>AA</u>	<u>!</u> PARKE-DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	
-----------	----------------------	------------------	----------------	------------	--

ETHOTOIN

TABLET; ORAL

PEGANONE

<u>+</u> !	RECORDATI RARE	250MG	N010841	001	
------------	----------------	-------	---------	-----	--

ETIDRONATE DISODIUM

TABLET; ORAL

ETIDRONATE DISODIUM

	MYLAN	200MG	A075800	001	Jan 24, 2003
<u>!</u>		400MG	A075800	002	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	ANI PHARMS INC	<u>200MG</u>	<u>A075126</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	<u>!</u>	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	<u>!</u>	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	<u>!</u>	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	<u>+</u> ! HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	--------------------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206126</u>	<u>001</u>	Feb 24, 2017
<u>AP</u>	EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209058</u>	<u>001</u>	Apr 18, 2017
<u>AP</u>	HIKMA FARMACEUTICA	<u>2MG/ML</u>	<u>A202354</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>	LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A201044</u>	<u>001</u>	Feb 07, 2017
<u>AP</u>	PAR STERILE PRODUCTS	<u>2MG/ML</u>	<u>A091297</u>	<u>001</u>	Jun 20, 2012
<u>AP</u>	WEST-WARD PHARMS	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996

PRESCRIPTION DRUG PRODUCT LIST

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

INT

AP	ZYDUS PHARMS USA INC	2MG/ML	A202360 001	Jul 18, 2014
-----------	-------------------------	---------------	--------------------	--------------

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529 002	May 31, 2011
---	-----------------	--------------	-------------	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

!	MYLAN	50MG	A075635 001	Sep 19, 2001
---	-------	------	-------------	--------------

INJECTABLE; INJECTION

ETOPOSIDE

AP	ACCORD HLTHCARE	20MG/ML	A074513 001	Mar 14, 1996	
AP	!	FRESENIUS KABI USA	20MG/ML	A074983 001	Sep 30, 1998
AP	MYLAN LABS LTD	20MG/ML	A203507 001	Nov 20, 2017	
AP		20MG/ML	A204927 001	Oct 31, 2017	
AP	TEVA PHARMS USA	20MG/ML	A074529 001	Jul 24, 1996	
AP	WEST-WARD PHARMS INT	20MG/ML	A074290 001	Jul 17, 1995	

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457 001	May 17, 1996
---	-------------------------	--------------------	-------------	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

+	JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012
+		100MG	N022187 001	Jan 18, 2008
+		200MG	N022187 002	Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

+	NOVARTIS	2.5MG	N022334 003	Jul 09, 2010
+		5MG	N022334 001	Mar 30, 2009
+		7.5MG	N022334 004	Mar 30, 2012
+		10MG	N022334 002	Mar 30, 2009

ZORTRESS

+	NOVARTIS	0.25MG	N021560 001	Apr 20, 2010
+		0.5MG	N021560 002	Apr 20, 2010
+		0.75MG	N021560 003	Apr 20, 2010

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

+	NOVARTIS PHARM	2MG	N203985 001	Aug 29, 2012
+		3MG	N203985 002	Aug 29, 2012
+		5MG	N203985 003	Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753 001	Oct 21, 1999
-----------	---	-------------------------	-------------	--------------------	--------------

EXEMESTANE

AB		ALVOGEN MALTA	25MG	A200898 001	Jul 28, 2014
AB		MYLAN PHARMS INC	25MG	A203315 001	Mar 10, 2017
AB		UPSHER-SMITH LABS	25MG	A209208 001	Jul 26, 2017
AB		WEST-WARD PHARMS INT	25MG	A077431 001	Apr 01, 2011

EXENATIDE

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON BCISE

+	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210 001	Oct 20, 2017
---	----------------	-------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+! ASTRAZENECA AB 2MG/VIAL N022200 001 Jan 27, 2012

BYDUREON PEN

+! ASTRAZENECA AB 2MG N022200 002 Feb 28, 2014

INJECTABLE; SUBCUTANEOUS

BYETTA

+! ASTRAZENECA AB 300MCG/1.2ML (250MCG/ML) N021773 001 Apr 28, 2005

+! 600MCG/2.4ML (250MCG/ML) N021773 002 Apr 28, 2005

EZETIMIBE

TABLET; ORAL

EZETIMIBEAB ALKEM LABS LTD 10MG A209234 001 Dec 21, 2017AB AMNEAL PHARMS CO 10MG A208803 001 Jun 12, 2017AB APOTEX INC 10MG A208332 001 Jun 12, 2017AB AUROBINDO PHARMA LTD 10MG A209838 001 Aug 25, 2017AB GLENMARK PHARMS LTD 10MG A078560 001 Jun 26, 2015AB OHM LABS INC 10MG A207311 001 Jun 12, 2017AB SANDOZ INC 10MG A203931 001 Jun 12, 2017AB TEVA PHARMS USA 10MG A078724 001 Jun 12, 2017AB WATSON LABS INC 10MG A200831 001 Jun 12, 2017AB ZYDUS PHARMS USA 10MG A204331 001 Jun 12, 2017

INC

ZETIAAB +! MSD INTL GMBH 10MG N021445 001 Oct 25, 2002EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATINAB ALKEM LABS LTD 10MG; 10MG A209222 001 Dec 22, 2017AB 10MG; 20MG A209222 002 Dec 22, 2017AB 10MG; 40MG A209222 003 Dec 22, 2017AB 10MG; 80MG A209222 004 Dec 22, 2017AB AMNEAL PHARMS CO 10MG; 10MG A208831 001 Nov 21, 2017AB 10MG; 20MG A208831 002 Nov 21, 2017AB 10MG; 40MG A208831 003 Nov 21, 2017AB 10MG; 80MG A208831 004 Nov 21, 2017AB DR REDDYS LABS SA 10MG; 10MG A200909 001 Apr 26, 2017AB 10MG; 20MG A200909 002 Apr 26, 2017AB 10MG; 40MG A200909 003 Apr 26, 2017AB 10MG; 80MG A200909 004 Apr 26, 2017AB IMPAX LABS INC 10MG; 10MG A201890 001 Apr 26, 2017AB 10MG; 20MG A201890 002 Apr 26, 2017AB 10MG; 40MG A201890 003 Apr 26, 2017AB 10MG; 80MG A201890 004 Apr 26, 2017AB WATSON LABS INC 10MG; 10MG A202968 001 Apr 26, 2017AB 10MG; 20MG A202968 002 Apr 26, 2017AB 10MG; 40MG A202968 003 Apr 26, 2017AB 10MG; 80MG A202968 004 Apr 26, 2017VYTORINAB + MSD INTL 10MG; 10MG N021687 001 Jul 23, 2004AB + 10MG; 20MG N021687 002 Jul 23, 2004AB + 10MG; 40MG N021687 003 Jul 23, 2004AB +! 10MG; 80MG N021687 004 Jul 23, 2004FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIRAB APOTEX 125MG A091480 001 Jul 22, 2011AB 250MG A091480 002 Jul 22, 2011AB 500MG A091480 003 Jul 22, 2011AB AUROBINDO PHARMA LTD 125MG A091114 001 Mar 21, 2011AB 250MG A091114 002 Mar 21, 2011AB 500MG A091114 003 Mar 21, 2011AB CIPLA LTD 125MG A078278 001 Mar 21, 2011AB 250MG A078278 002 Mar 21, 2011AB 500MG A078278 003 Mar 21, 2011AB HETERO LABS LTD V 125MG A202438 001 Sep 10, 2014AB 250MG A202438 002 Sep 10, 2014AB 500MG A202438 003 Sep 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	<u>125MG</u>	<u>A201022</u>	<u>001</u>	Jan 12, 2012
AB		<u>250MG</u>	<u>A201022</u>	<u>002</u>	Jan 12, 2012
AB		<u>500MG</u>	<u>A201022</u>	<u>003</u>	Jan 12, 2012
AB	MYLAN	<u>125MG</u>	<u>A201333</u>	<u>001</u>	Mar 24, 2011
AB		<u>250MG</u>	<u>A201333</u>	<u>002</u>	Mar 24, 2011
AB		<u>500MG</u>	<u>A201333</u>	<u>003</u>	Mar 24, 2011
AB	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
AB		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
AB	!	<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007
AB	WEST-WARD PHARMS INT	<u>125MG</u>	<u>A090128</u>	<u>001</u>	Mar 21, 2011
AB		<u>250MG</u>	<u>A090128</u>	<u>002</u>	Mar 21, 2011
AB		<u>500MG</u>	<u>A090128</u>	<u>003</u>	Mar 21, 2011

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB	HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995</u>	<u>001</u>	May 30, 2014
AB	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
AB	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010
AB	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012

PEPCID

AB	+!	SALIX PHARMS	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987
-----------	----	--------------	-----------------	----------------	------------	--------------

INJECTABLE; INJECTION

FAMOTIDINE

AP	ATHENEX INC	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001	
AP		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001	
AP	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001	
AP	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008	
AP	!	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP	ATHENEX INC	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001	
AP		<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001	
AP	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001	
AP	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008	
AP	!	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001
---	-----------------	----------	---------	-----	--------------

TABLET; ORAL

FAMOTIDINE

AB	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
AB		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
AB	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
AB		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
AB	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206530</u>	<u>001</u>	Dec 22, 2015
AB		<u>40MG</u>	<u>A206530</u>	<u>002</u>	Dec 22, 2015
AB	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
AB	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
AB	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
AB	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
AB	PERRIGO R AND D	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
AB		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
AB	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
AB	WOCKHARDT LTD	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
AB		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001

PEPCID

AB	+	VALEANT PHARMS NORTH	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
AB	+	!	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

PRESCRIPTION DRUG PRODUCT LIST

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+! HORIZON PHARMA 26.6MG; 800MG N022519 001 Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

ULORIC

+ TAKEDA PHARMS USA 40MG N021856 001 Feb 13, 2009

+! 80MG N021856 002 Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATEAB AMNEAL PHARMS 600MG/5ML A202385 001 Dec 16, 2011AB TARO PHARM 600MG/5ML A206314 001 Jun 16, 2017FELBATOLAB +! MYLAN SPECIALITY LP 600MG/5ML N020189 003 Jul 29, 1993

TABLET; ORAL

FELBAMATEAB ALVOGEN MALTA 400MG A204595 001 Jan 11, 2016AB 600MG A204595 002 Jan 11, 2016AB AMNEAL PHARMS 400MG A201680 001 Sep 13, 2011AB 600MG A201680 002 Sep 13, 2011AB IMPAX LABS INC 400MG A202284 001 Nov 04, 2015AB 600MG A202284 002 Nov 04, 2015AB TARO PHARM 400MG A207093 001 Apr 20, 2017AB 600MG A207093 002 Apr 20, 2017AB ZYDUS PHARMS USA 400MG A208970 001 May 30, 2017

INC

AB 600MG A208970 002 May 30, 2017FELBATOLAB + MYLAN SPECIALITY LP 400MG N020189 001 Jul 29, 1993AB +! 600MG N020189 002 Jul 29, 1993FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINEAB AUROBINDO PHARMA LTD 2.5MG A203417 001 Jan 17, 2013AB 5MG A203417 002 Jan 17, 2013AB 10MG A203417 003 Jan 17, 2013AB GLENMARK GENERICS 2.5MG A090365 001 Dec 17, 2010AB 5MG A090365 002 Dec 17, 2010AB 10MG A090365 003 Dec 17, 2010AB HERITAGE PHARMS INC 2.5MG A201964 001 Nov 08, 2013AB 5MG A201964 002 Nov 08, 2013AB 10MG A201964 003 Nov 08, 2013AB JUBILANT GENERICS 2.5MG A203983 001 Aug 19, 2016AB 5MG A203983 002 Aug 19, 2016AB 10MG A203983 003 Aug 19, 2016AB MYLAN 2.5MG A078855 001 Apr 17, 2008AB 5MG A078855 002 Apr 17, 2008AB ! 10MG A078855 003 Apr 17, 2008AB ORCHID HLTHCARE 2.5MG A203032 001 May 21, 2015AB 5MG A203032 002 May 21, 2015AB 10MG A203032 003 May 21, 2015AB SUN PHARM INDS LTD 2.5MG A091200 001 Dec 13, 2013AB 5MG A091200 002 Dec 13, 2013AB 10MG A091200 003 Dec 13, 2013AB SUN PHARM INDUSTRIES 2.5MG A075896 001 Nov 02, 2004AB 5MG A075896 002 Nov 02, 2004AB 10MG A075896 003 Nov 02, 2004AB TORRENT PHARMS LTD 2.5MG A202170 001 Nov 28, 2011AB 5MG A202170 002 Nov 28, 2011AB 10MG A202170 003 Nov 28, 2011AB VINTAGE PHARMS LLC 2.5MG A200815 001 Oct 28, 2011AB 5MG A200815 002 Oct 28, 2011AB 10MG A200815 003 Oct 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

<u>AB</u>	+	LUPIN ATLANTIS	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
<u>AB</u>	+	!	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004

FENOFIBRATE

<u>AB</u>		SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>			<u>130MG</u>	<u>A201748</u>	<u>002</u>	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

<u>AB</u>		APOTEX INC	<u>43MG</u>	<u>A202252</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>			<u>130MG</u>	<u>A202252</u>	<u>002</u>	Jul 26, 2013
<u>AB</u>		CNTY LINE PHARMS	<u>67MG</u>	<u>A207805</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>			<u>134MG</u>	<u>A207805</u>	<u>002</u>	Nov 16, 2017
<u>AB</u>			<u>200MG</u>	<u>A207805</u>	<u>003</u>	Nov 16, 2017
<u>AB</u>		DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012
<u>AB</u>			<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012
<u>AB</u>		GLENMARK PHARMS LTD	<u>67MG</u>	<u>A205566</u>	<u>001</u>	Apr 07, 2017
<u>AB</u>			<u>134MG</u>	<u>A205566</u>	<u>002</u>	Apr 07, 2017
<u>AB</u>			<u>200MG</u>	<u>A205566</u>	<u>003</u>	Apr 07, 2017
<u>AB</u>		IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003
<u>AB</u>			<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003
<u>AB</u>		!	<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003
<u>AB</u>		INVAGEN PHARMS	<u>67MG</u>	<u>A207378</u>	<u>001</u>	Mar 28, 2017
<u>AB</u>			<u>134MG</u>	<u>A207378</u>	<u>002</u>	Mar 28, 2017
<u>AB</u>			<u>200MG</u>	<u>A207378</u>	<u>003</u>	Mar 28, 2017
<u>AB</u>		MYLAN PHARMS INC	<u>43MG</u>	<u>A202579</u>	<u>001</u>	Jan 10, 2013
<u>AB</u>			<u>67MG</u>	<u>A202676</u>	<u>001</u>	Oct 23, 2012
<u>AB</u>			<u>130MG</u>	<u>A202579</u>	<u>002</u>	Jan 10, 2013
<u>AB</u>			<u>134MG</u>	<u>A202676</u>	<u>002</u>	Oct 23, 2012
<u>AB</u>			<u>200MG</u>	<u>A202676</u>	<u>003</u>	Oct 23, 2012
<u>AB</u>		RHODES PHARMS	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>			<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>			<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002

ANTARA (MICRONIZED)

+	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013
+		90MG	N021695	005	Oct 18, 2013

LIPOFEN

+	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
+	!	150MG	N021612	003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>48MG</u>	<u>A205118</u>	<u>001</u>	May 05, 2016
<u>AB</u>			<u>145MG</u>	<u>A205118</u>	<u>002</u>	May 05, 2016
<u>AB</u>		CIPLA LTD	<u>48MG</u>	<u>A208709</u>	<u>001</u>	Dec 15, 2016
<u>AB</u>			<u>145MG</u>	<u>A208709</u>	<u>002</u>	Dec 15, 2016
<u>AB</u>		CNTY LINE PHARMS	<u>54MG</u>	<u>A207803</u>	<u>001</u>	Dec 19, 2017
<u>AB</u>			<u>160MG</u>	<u>A207803</u>	<u>002</u>	Dec 19, 2017
<u>AB</u>		HETERO LABS LTD III	<u>48MG</u>	<u>A204598</u>	<u>001</u>	Jul 12, 2016
<u>AB</u>			<u>145MG</u>	<u>A204598</u>	<u>002</u>	Jul 12, 2016
<u>AB</u>		IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		!	<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>		LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>			<u>54MG</u>	<u>A204019</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>			<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011
<u>AB</u>			<u>160MG</u>	<u>A204019</u>	<u>002</u>	Aug 17, 2015
<u>AB</u>		MYLAN	<u>40MG</u>	<u>A204475</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>			<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007
<u>AB</u>			<u>120MG</u>	<u>A204475</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>			<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007
<u>AB</u>		MYLAN PHARMS INC	<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>			<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>		RHODES PHARMS	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005
<u>AB</u>			<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005
<u>AB</u>		SUN PHARM INDS LTD	<u>48MG</u>	<u>A200884</u>	<u>001</u>	Sep 07, 2017
<u>AB</u>			<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>			<u>145MG</u>	<u>A200884</u>	<u>002</u>	Sep 07, 2017
<u>AB</u>			<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>		VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012
<u>AB</u>			<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

<u>AB</u>	+	SANTARUS INC	<u>40MG</u>	<u>N022118</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>	+	!	<u>120MG</u>	<u>N022118</u>	<u>002</u>	Aug 10, 2007

TRICOR

<u>AB</u>	+	ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>	+	!	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004

TRIGLIDE

BX	+	!	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005
			FENOFIBRATE				
			SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	+	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009
	+	!	105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	!	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997
-----------	---	---	---------	------------------------	----------------	------------	--------------

FENOLDOPAM MESYLATE

<u>AP</u>		SANDOZ INC	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005
<u>AP</u>		WEST-WARD PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004
		INT				

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

	+	!	XSPIRE PHARMA	EQ 200MG BASE	N017604	003	
	+			EQ 400MG BASE	N017604	004	Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

	!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988
--	---	---------------	---------------	---------	-----	--------------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>	+	JANSSEN PHARMS	<u>100MCG/HR</u>	<u>N019813</u>	<u>001</u>	Aug 07, 1990
-----------	---	----------------	------------------	----------------	------------	--------------

DURAGESIC-12

<u>AB</u>	+	JANSSEN PHARMS	<u>12.5MCG/HR</u>	<u>N019813</u>	<u>005</u>	Feb 04, 2005
-----------	---	----------------	-------------------	----------------	------------	--------------

DURAGESIC-25

<u>AB</u>	+	!	JANSSEN PHARMS	<u>25MCG/HR</u>	<u>N019813</u>	<u>004</u>	Aug 07, 1990
-----------	---	---	----------------	-----------------	----------------	------------	--------------

DURAGESIC-50

<u>AB</u>	+	JANSSEN PHARMS	<u>50MCG/HR</u>	<u>N019813</u>	<u>003</u>	Aug 07, 1990
-----------	---	----------------	-----------------	----------------	------------	--------------

DURAGESIC-75

<u>AB</u>	+	JANSSEN PHARMS	<u>75MCG/HR</u>	<u>N019813</u>	<u>002</u>	Aug 07, 1990
-----------	---	----------------	-----------------	----------------	------------	--------------

FENTANYL-100

<u>AB</u>		3M DRUG DELIVERY	<u>100MCG/HR</u>	<u>A202097</u>	<u>005</u>	Nov 04, 2016
<u>AB</u>		ACTAVIS LABS UT INC	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007
<u>AB</u>		AVEVA	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008
<u>AB</u>		LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006
<u>AB</u>		MAYNE PHARMA	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007
<u>AB</u>		MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>		SPECGX LLC	<u>100MCG/HR</u>	<u>A077154</u>	<u>004</u>	Feb 09, 2011

FENTANYL-12

<u>AB</u>		3M DRUG DELIVERY	<u>12.5MCG/HR</u>	<u>A202097</u>	<u>001</u>	Nov 04, 2016
<u>AB</u>		AVEVA	<u>12.5MCG/HR</u>	<u>A077449</u>	<u>005</u>	Sep 11, 2015
<u>AB</u>		MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007
<u>AB</u>		SPECGX LLC	<u>12.5MCG/HR</u>	<u>A077154</u>	<u>005</u>	Jun 11, 2015

FENTANYL-25

<u>AB</u>		3M DRUG DELIVERY	<u>25MCG/HR</u>	<u>A202097</u>	<u>002</u>	Nov 04, 2016
<u>AB</u>		ACTAVIS LABS UT INC	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>		AVEVA	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008
<u>AB</u>		LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006
<u>AB</u>		MAYNE PHARMA	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>		MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		SPECGX LLC	<u>25MCG/HR</u>	<u>A077154</u>	<u>001</u>	Feb 09, 2011

FENTANYL-37

<u>AB</u>		AVEVA	<u>37.5MCG/HR</u>	<u>A077449</u>	<u>006</u>	Dec 06, 2017
-----------	--	-------	-------------------	----------------	------------	--------------

FENTANYL-50

<u>AB</u>		3M DRUG DELIVERY	<u>50MCG/HR</u>	<u>A202097</u>	<u>003</u>	Nov 04, 2016
<u>AB</u>		ACTAVIS LABS UT INC	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-50

<u>AB</u>	AVEVA	<u>50MCG/HR</u>	<u>A077449 002</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051 002</u>	Aug 04, 2006
<u>AB</u>	MAYNE PHARMA	<u>50MCG/HR</u>	<u>A077062 002</u>	Aug 20, 2007
<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258 002</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>50MCG/HR</u>	<u>A077154 002</u>	Feb 09, 2011

FENTANYL-62

<u>AB</u>	AVEVA	<u>62.5MCG/HR</u>	<u>A077449 007</u>	Dec 06, 2017
-----------	-------	-------------------	--------------------	--------------

FENTANYL-75

<u>AB</u>	3M DRUG DELIVERY	<u>75MCG/HR</u>	<u>A202097 004</u>	Nov 04, 2016
<u>AB</u>	ACTAVIS LABS UT INC	<u>75MCG/HR</u>	<u>A076709 003</u>	Aug 20, 2007
<u>AB</u>	AVEVA	<u>75MCG/HR</u>	<u>A077449 003</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051 003</u>	Aug 04, 2006
<u>AB</u>	MAYNE PHARMA	<u>75MCG/HR</u>	<u>A077062 003</u>	Aug 20, 2007
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258 003</u>	Jan 28, 2005
<u>AB</u>	SPECGX LLC	<u>75MCG/HR</u>	<u>A077154 003</u>	Feb 09, 2011

FENTANYL-87

<u>AB</u>	AVEVA	<u>87.5MCG/HR</u>	<u>A077449 008</u>	Dec 06, 2017
	FENTANYL-37			
	MYLAN TECHNOLOGIES	37.5MCG/HR	A076258 006	Dec 29, 2014
	FENTANYL-62			
	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258 007	Dec 29, 2014
	FENTANYL-87			
	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258 008	Dec 29, 2014

SPRAY;SUBLINGUAL

SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788 001	Jan 04, 2012
+		0.2MG	N202788 002	Jan 04, 2012
+	!	0.4MG	N202788 003	Jan 04, 2012
+		0.6MG	N202788 004	Jan 04, 2012
+		0.8MG	N202788 005	Jan 04, 2012
+		1.2MG	N202788 006	Aug 30, 2012
+		1.6MG	N202788 007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115 001</u>	Jan 12, 1985
-----------	---------	--------------------------	--------------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786 001</u>	Sep 24, 1991
<u>AP</u>	+!	WEST-WARD PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>N019101 001</u>
		INT		Jul 11, 1984

SUBLIMAZE PRESERVATIVE FREE

<u>AP</u>	+!	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619 001</u>
-----------	----	-------	--------------------------	--------------------

SPRAY, METERED;NASAL

LAZANDA

+	ELEFSEE PHARMS INTL	EQ 0.1MG BASE	N022569 001	Jun 30, 2011
+		EQ 0.3MG BASE	N022569 003	Dec 21, 2015
+	!	EQ 0.4MG BASE	N022569 002	Jun 30, 2011

TABLET;BUCCAL, SUBLINGUAL

FENTORA

+	CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006
+		EQ 0.2MG BASE	N021947 002	Sep 25, 2006
+	!	EQ 0.4MG BASE	N021947 003	Sep 25, 2006
+		EQ 0.6MG BASE	N021947 004	Sep 25, 2006
+		EQ 0.8MG BASE	N021947 005	Sep 25, 2006

TABLET;SUBLINGUAL

ABSTRAL

<u>AB</u>	+	SENTYNL THERAPS INC	<u>EQ 0.1MG BASE</u>	<u>N022510 001</u>	Jan 07, 2011
<u>AB</u>	+		<u>EQ 0.2MG BASE</u>	<u>N022510 002</u>	Jan 07, 2011
<u>AB</u>	+		<u>EQ 0.3MG BASE</u>	<u>N022510 003</u>	Jan 07, 2011
<u>AB</u>	+!		<u>EQ 0.4MG BASE</u>	<u>N022510 004</u>	Jan 07, 2011
<u>AB</u>	+		<u>EQ 0.6MG BASE</u>	<u>N022510 005</u>	Jan 07, 2011
<u>AB</u>	+		<u>EQ 0.8MG BASE</u>	<u>N022510 006</u>	Jan 07, 2011

FENTANYL CITRATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 0.1MG BASE</u>	<u>A207338 001</u>	Nov 17, 2017
<u>AB</u>		<u>EQ 0.2MG BASE</u>	<u>A207338 002</u>	Nov 17, 2017
<u>AB</u>		<u>EQ 0.3MG BASE</u>	<u>A207338 003</u>	Nov 17, 2017
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A207338 004</u>	Nov 17, 2017
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A207338 005</u>	Nov 17, 2017
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A207338 006</u>	Nov 17, 2017

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>	+	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747 001</u>	Nov 04, 1998
<u>AB</u>	+	!	<u>EQ 0.4MG BASE</u>	<u>N020747 002</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 0.6MG BASE</u>	<u>N020747 003</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 0.8MG BASE</u>	<u>N020747 004</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 1.2MG BASE</u>	<u>N020747 005</u>	Nov 04, 1998
<u>AB</u>	+		<u>EQ 1.6MG BASE</u>	<u>N020747 006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>		PAR PHARM	<u>EQ 0.2MG BASE</u>	<u>A077312 001</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.4MG BASE</u>	<u>A077312 002</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>A077312 003</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>A077312 004</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.2MG BASE</u>	<u>A077312 005</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.6MG BASE</u>	<u>A077312 006</u>	Oct 30, 2009
<u>AB</u>		SPECGX LLC	<u>EQ 0.2MG BASE</u>	<u>A078907 001</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.4MG BASE</u>	<u>A078907 002</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.6MG BASE</u>	<u>A078907 003</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 0.8MG BASE</u>	<u>A078907 004</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.2MG BASE</u>	<u>A078907 005</u>	Oct 30, 2009
<u>AB</u>			<u>EQ 1.6MG BASE</u>	<u>A078907 006</u>	Oct 30, 2009

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+	!	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338 001	May 22, 2006
---	---	------------------	--------------------------	-------------	--------------

FERRIC CARBOXYMALTOS

INJECTABLE; INTRAVENOUS

INJECTAFER

+	!	LUITPOLD PHARMS INC	750MG IRON/15ML (50MG IRON/ML)	N203565 001	Jul 25, 2013
---	---	---------------------	--------------------------------	-------------	--------------

FERRIC CITRATE

TABLET; ORAL

AURYXIA

+	!	KERYX BIOPHARMS	EQ 210MG IRON	N205874 001	Sep 05, 2014
---	---	-----------------	---------------	-------------	--------------

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	!	HEYL CHEMISCH	500MG	N021626 001	Oct 02, 2003
---	---	---------------	-------	-------------	--------------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION; INTRAVENOUS

TRIFERIC

+	!	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551 001	Apr 25, 2016
---	---	----------------------	-------------------	-------------	--------------

SOLUTION; IV (INFUSION)

TRIFERIC

+	!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317 001	Jan 23, 2015
---	---	----------------------	----------------------------------	-------------	--------------

+			272MG IRON/50ML (5.44MG IRON/ML)	N206317 002	Sep 04, 2015
---	--	--	----------------------------------	-------------	--------------

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	!	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180 001	Jun 30, 2009
---	---	-----------------	--------------------------------------	-------------	--------------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>4MG</u>	<u>A205007 001</u>	Feb 17, 2017
<u>AB</u>			<u>8MG</u>	<u>A205007 002</u>	Feb 17, 2017
<u>AB</u>		ZYDUS PHARMS USA INC	<u>4MG</u>	<u>A204946 001</u>	Oct 03, 2017
<u>AB</u>			<u>8MG</u>	<u>A204946 002</u>	Oct 03, 2017
		<u>TOVIAZ</u>			
<u>AB</u>	+	PFIZER	<u>4MG</u>	<u>N022030 001</u>	Oct 31, 2008
<u>AB</u>	+	!	<u>8MG</u>	<u>N022030 002</u>	Oct 31, 2008

PRESCRIPTION DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+ !	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006
-----------	------------	-------------------	-----------------	----------------	------------	--------------

FEXOFENADINE HYDROCHLORIDE

AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012
-----------	--	----------------------	-----------------	----------------	------------	--------------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB		BARR	30MG	A076191	001	Aug 31, 2005
-----------	--	------	-------------	----------------	------------	--------------

AB			60MG	A076191	002	Aug 31, 2005
-----------	--	--	-------------	----------------	------------	--------------

AB			180MG	A076191	003	Aug 31, 2005
-----------	--	--	--------------	----------------	------------	--------------

AB		DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006
-----------	--	--------------------	-------------	----------------	------------	--------------

AB			60MG	A076502	002	Apr 11, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			180MG	A076502	003	Apr 11, 2006
-----------	--	--	--------------	----------------	------------	--------------

AB		MYLAN	30MG	A077081	002	Apr 11, 2008
-----------	--	-------	-------------	----------------	------------	--------------

AB			60MG	A077081	003	Apr 11, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB			180MG	A077081	001	Apr 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

AB		TEVA	30MG	A076447	001	Sep 01, 2005
-----------	--	------	-------------	----------------	------------	--------------

AB			60MG	A076447	002	Sep 01, 2005
-----------	--	--	-------------	----------------	------------	--------------

AB			180MG	A076447	003	Sep 01, 2005
-----------	--	--	--------------	----------------	------------	--------------

FIDAXOMICIN

TABLET; ORAL

DIFICID

+ !	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011
------------	-------------------	-------	---------	-----	--------------

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

+ !	NOVARTIS PHARMS CORP	0.3%	N206307	001	Dec 17, 2014
------------	----------------------	------	---------	-----	--------------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB		ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013
-----------	--	-----------------	------------	----------------	------------	--------------

AB			5MG	A090121	001	Feb 23, 2010
-----------	--	--	------------	----------------	------------	--------------

AB		ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013
-----------	--	----------------	------------	----------------	------------	--------------

AB		ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007
-----------	--	---------------------	------------	----------------	------------	--------------

AB		ALKEM LABS LTD	1MG	A207750	001	Jan 06, 2017
-----------	--	----------------	------------	----------------	------------	--------------

AB			5MG	A204304	001	Jan 05, 2017
-----------	--	--	------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	5MG	A078341	001	Oct 30, 2007
-----------	--	------------------	------------	----------------	------------	--------------

AB		AUROBINDO PHARMA LTD	1MG	A203687	001	Nov 05, 2013
-----------	--	----------------------	------------	----------------	------------	--------------

AB		CIPLA LTD	1MG	A077335	001	Nov 20, 2014
-----------	--	-----------	------------	----------------	------------	--------------

AB		DR REDDYS LABS INC	1MG	A076436	001	Jul 28, 2006
-----------	--	--------------------	------------	----------------	------------	--------------

AB		DR REDDYS LABS LTD	5MG	A076437	001	Feb 28, 2007
-----------	--	--------------------	------------	----------------	------------	--------------

AB		GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006
-----------	--	--------------------	------------	----------------	------------	--------------

AB		HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013
-----------	--	---------------------	------------	----------------	------------	--------------

AB			5MG	A090061	001	Jun 07, 2010
-----------	--	--	------------	----------------	------------	--------------

AB		MYLAN	5MG	A077578	001	Dec 18, 2006
-----------	--	-------	------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	1MG	A078161	001	Nov 05, 2013
-----------	--	------------------	------------	----------------	------------	--------------

AB		SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013
-----------	--	-------------------	------------	----------------	------------	--------------

AB			5MG	A090507	001	Aug 16, 2011
-----------	--	--	------------	----------------	------------	--------------

AB		TEVA	1MG	A076905	001	Nov 05, 2013
-----------	--	------	------------	----------------	------------	--------------

AB			5MG	A076511	001	Dec 15, 2006
-----------	--	--	------------	----------------	------------	--------------

AB		ZYDUS PHARMS USA INC	5MG	A078900	001	Dec 28, 2009
-----------	--	----------------------	------------	----------------	------------	--------------

PROPECIA

AB	+ !	MERCK	1MG	N020788	001	Dec 19, 1997
-----------	------------	-------	------------	----------------	------------	--------------

PROSCAR

AB	+ !	MERCK	5MG	N020180	001	Jun 19, 1992
-----------	------------	-------	------------	----------------	------------	--------------

FINGOLIMOD

CAPSULE; ORAL

GILENYA

+ !	NOVARTIS	0.5MG	N022527	001	Sep 21, 2010
------------	----------	-------	---------	-----	--------------

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

+ !	FRESENIUS KABI USA	3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)	N207648	001	Jul 13, 2016
------------	--------------------	--	---------	-----	--------------

+ !		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)	N207648	002	Jul 13, 2016
------------	--	--	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

+!

3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML
(500ML)

N207648 003 Jul 13, 2016

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE**AB** EPIC PHARMA**100MG****A076835 001** Nov 30, 2005**AB** ! PADDOCK LLC**100MG****A076831 001** Dec 16, 2004FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE**AB** AMNEAL PHARM**50MG****A075442 001** Jul 31, 2001**AB****100MG****A075442 002** Jul 31, 2001**AB****150MG****A075442 003** Jul 31, 2001**AB** ANI PHARMS INC**50MG****A075882 001** Oct 28, 2002**AB****100MG****A075882 002** Oct 28, 2002**AB****150MG****A075882 003** Oct 28, 2002**AB** AUROBINDO PHARMA
LTD**50MG****A202821 001** Nov 03, 2017**AB****100MG****A202821 002** Nov 03, 2017**AB****150MG****A202821 003** Nov 03, 2017**AB** SUN PHARM INDS LTD**50MG****A076421 001** Mar 28, 2003**AB****100MG****A076421 002** Mar 28, 2003**AB****150MG****A076421 003** Mar 28, 2003**AB** WEST-WARD PHARMS
INT**50MG****A076278 001** Jan 14, 2003**AB****100MG****A076278 002** Jan 14, 2003**AB** !**150MG****A076278 003** Jan 14, 2003TAMBOCOR**AB** + CNTY LINE PHARMS**50MG****N018830 004** Aug 23, 1988**AB** +**100MG****N018830 001** Oct 31, 1985**AB** +**150MG****N018830 003** Jun 03, 1988FLIBANSERIN

TABLET; ORAL

ADDYI

+! SPROUT PHARMS

100MG

N022526 001 Aug 18, 2015

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+! PIRAMAL IMAGING

30ML (1.4-135mCi/ML)

N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+! AVID RADIOPHARMS
INC

10-30ML (13.5-51mCi/ML)

N202008 002 Apr 06, 2012

+! 10-50ML (13.5-51mCi/ML)

N202008 003 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE**AP** FRESENIUS KABI USA**500MG/VIAL****A075837 001** Feb 22, 2001**AP** PHARMAFORCE**500MG/VIAL****A203008 001** Nov 22, 2017**AP** ! WEST-WARD PHARMS
INT**500MG/VIAL****A075387 001** Apr 16, 2000FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+! BLUE EARTH

9-221mCi/ML

N208054 001 May 27, 2016

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN**AB** + PFIZER**50MG/5ML****N020090 001** Dec 23, 1993**AB** +!**200MG/5ML****N020090 002** Dec 23, 1993FLUCONAZOLE**AB** AUROBINDO PHARMA
LTD**50MG/5ML****A079150 001** Sep 18, 2009**AB****200MG/5ML****A079150 002** Sep 18, 2009**AB** IVAX SUB TEVA
PHARMS**50MG/5ML****A077523 001** Sep 12, 2007

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

<u>AB</u>		<u>200MG/5ML</u>	<u>A077523 002</u>	Sep 12, 2007
<u>AB</u>	WEST-WARD PHARMS	<u>50MG/5ML</u>	<u>A076246 001</u>	Jul 29, 2004
	INT			
<u>AB</u>		<u>200MG/5ML</u>	<u>A076246 002</u>	Jul 29, 2004

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078764 001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078764 002</u>	Jan 30, 2012
<u>AP</u>	! HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304 001</u>	Jul 29, 2004
<u>AP</u>	!	<u>400MG/200ML (2MG/ML)</u>	<u>A076304 002</u>	Jul 29, 2004
<u>AP</u>	RENAISSANCE SSA LLC	<u>200MG/100ML (2MG/ML)</u>	<u>A077988 001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077988 002</u>	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A077947 001</u>	May 26, 2010
	CORP			
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077947 002</u>	May 26, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076145 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145 002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736 001</u>	Aug 23, 2005
<u>AP</u>	WEST-WARD PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A076087 001</u>	Jul 29, 2004
	INT			
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087 003</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	! ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104 001</u>	Jul 30, 2009
<u>AP</u>	!	<u>400MG/200ML (2MG/ML)</u>	<u>A079104 002</u>	Jul 30, 2009
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766 002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078698 001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078698 002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303 001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303 002</u>	Jul 29, 2004
<u>AP</u>	RENAISSANCE SSA LLC	<u>200MG/100ML (2MG/ML)</u>	<u>A077909 001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909 002</u>	May 26, 2010
<u>AP</u>	WEST-WARD PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107 001</u>	Jul 30, 2008
	INT			
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107 002</u>	Jul 30, 2008
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%			
	WEST-WARD PHARMS	100MG/50ML (2MG/ML)	A076087 002	Sep 26, 2008
	INT			
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	RENAISSANCE SSA LLC	100MG/50ML (2MG/ML)	A077909 003	Apr 20, 2015

TABLET; ORAL

DIFLUCAN

<u>AB</u>	+ PFIZER	<u>50MG</u>	<u>N019949 001</u>	Jan 29, 1990
<u>AB</u>	+	<u>100MG</u>	<u>N019949 002</u>	Jan 29, 1990
<u>AB</u>	+	<u>150MG</u>	<u>N019949 004</u>	Jun 30, 1994
<u>AB</u>	+!	<u>200MG</u>	<u>N019949 003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665 004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731 001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731 002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731 003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731 004</u>	Oct 07, 2008
<u>AB</u>	DR REDDYS LABS INC	<u>50MG</u>	<u>A076658 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076658 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076658 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076658 004</u>	Jul 29, 2004
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253 001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253 002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253 003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253 004</u>	Jan 25, 2006
<u>AB</u>	HARRIS PHARM	<u>50MG</u>	<u>A078423 001</u>	Mar 07, 2011
<u>AB</u>		<u>100MG</u>	<u>A078423 002</u>	Mar 07, 2011
<u>AB</u>		<u>150MG</u>	<u>A078423 003</u>	Mar 07, 2011
<u>AB</u>		<u>200MG</u>	<u>A078423 004</u>	Mar 07, 2011
<u>AB</u>	IVAX SUB TEVA	<u>50MG</u>	<u>A076077 001</u>	Jul 29, 2004
	PHARMS			
<u>AB</u>		<u>100MG</u>	<u>A076077 002</u>	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>150MG</u>	<u>A076957</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A208963</u>	<u>001</u>	Feb 16, 2017
<u>AB</u>		<u>100MG</u>	<u>A208963</u>	<u>002</u>	Feb 16, 2017
<u>AB</u>		<u>150MG</u>	<u>A208963</u>	<u>003</u>	Feb 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A208963</u>	<u>004</u>	Feb 16, 2017

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	+	VALEANT	<u>250MG</u>	<u>N017001</u>	<u>001</u>
<u>AB</u>	+	!	<u>500MG</u>	<u>N017001</u>	<u>002</u>

FLUCYTOSINE

<u>AB</u>		NOVEL LABS INC	<u>250MG</u>	<u>A204652</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>			<u>500MG</u>	<u>A204652</u>	<u>002</u>	Jul 07, 2017
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011
<u>AB</u>		WEST-WARD PHARMS INT	<u>250MG</u>	<u>A206550</u>	<u>001</u>	Oct 17, 2017
<u>AB</u>			<u>500MG</u>	<u>A206550</u>	<u>002</u>	Oct 17, 2017

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>		ACTAVIS LLC	<u>50MG/2ML (25MG/ML)</u>	<u>A203738</u>	<u>001</u>	Feb 28, 2017	
<u>AP</u>		ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009	
<u>AP</u>		CUSTOPHARM INC	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003	
<u>AP</u>	!	FRESENIUS KABI USA	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007	
<u>AP</u>			<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007	
<u>AP</u>	!	HOSPIRA	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007	
<u>AP</u>		MUSTAFA NEVZAT ILAC	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010	
<u>AP</u>		MYLAN LABS LTD	<u>50MG/2ML (25MG/ML)</u>	<u>A200647</u>	<u>001</u>	Dec 21, 2011	
<u>AP</u>			<u>50MG/VIAL</u>	<u>A200648</u>	<u>001</u>	Oct 16, 2012	
<u>AP</u>		SAGENT PHARMS	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004	
<u>AP</u>	+	!	SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>		3D IMAGING DRUG	<u>20-300mCi/ML</u>	<u>A203778</u>	<u>001</u>	Oct 30, 2015	
<u>AP</u>		BIOMEDCL RES FDN	<u>20-300mCi/ML</u>	<u>A203710</u>	<u>001</u>	May 01, 2015	
<u>AP</u>			<u>20-300mCi/ML</u>	<u>A203837</u>	<u>001</u>	May 01, 2015	
<u>AP</u>		BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014	
<u>AP</u>		CARDINAL HEALTH 414	<u>20-300mCi/ML</u>	<u>A203603</u>	<u>001</u>	Nov 13, 2015	
<u>AP</u>		CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014	
<u>AP</u>		CPDC	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014	
<u>AP</u>		ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014	
<u>AP</u>	+	!	FEINSTEIN	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>	+	!		<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>		GLOBAL ISOTOPES LLC	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014	
<u>AP</u>	!	HOUSTON CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013	
<u>AP</u>		JUBILANT DRAXIMAGE	<u>20-300mCi/ML</u>	<u>A203920</u>	<u>001</u>	Jun 23, 2015	
<u>AP</u>		KETTERING MEDCTR	<u>4-40mCi/ML</u>	<u>A204759</u>	<u>001</u>	Oct 27, 2015	
<u>AP</u>		KREITCHMAN PET CTR	<u>10-100mCi/ML</u>	<u>A203942</u>	<u>001</u>	Apr 11, 2016	

PRESCRIPTION DRUG PRODUCT LIST

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	MEM SLOAN-KETTERING	<u>20-300mCi/ML</u>	<u>A208679</u>	<u>001</u>	Dec 08, 2016
<u>AP</u>	METHODIST HOSP RES	<u>20-300mCi/ML</u>	<u>A203904</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	MIDWEST MEDCL	<u>20-200mCi/ML</u>	<u>A203736</u>	<u>001</u>	Nov 19, 2015
<u>AP</u>	MIPS CRF	<u>20-300mCi/ML</u>	<u>A204472</u>	<u>001</u>	Sep 11, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	! QUEEN HAMAMATSU PET	<u>10-100mCi/ML</u>	<u>A203771</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	SOFIE	<u>20-300mCi/ML</u>	<u>A203591</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	! UCLA BIOMEDICAL	<u>4-40mCi/ML</u>	<u>A203811</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV MICHIGAN	<u>20-300mCi/ML</u>	<u>A204531</u>	<u>001</u>	Jul 17, 2015
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>20-300mCi/ML</u>	<u>A204498</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
	UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	! IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	MYLAN LABS LTD	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	! SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ INC	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005
<u>AP</u>	WEST-WARD PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
	INT				
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+! MYLAN SPECIALITY LP 0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	! BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	! APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+		<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+		<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

+	ALIMERA SCIENCES INC	0.19MG		N201923	001	Sep 26, 2014
---	----------------------	--------	--	---------	-----	--------------

RETISERT

+	BAUSCH AND LOMB	0.59MG		N021737	001	Apr 08, 2005
---	-----------------	--------	--	---------	-----	--------------

OIL; TOPICAL

DERMA-SMOOTH/FS

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>001</u>	Feb 03, 1988
<u>AT</u>	+		<u>0.01%</u>	<u>N019452</u>	<u>002</u>	Nov 09, 2005

FLUOCINOLONE ACETONIDE

<u>AT</u>		AKORN	<u>0.01%</u>	<u>A091514</u>	<u>001</u>	Jun 25, 2015
<u>AT</u>		IDENTI PHARMS INC	<u>0.01%</u>	<u>A201759</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>			<u>0.01%</u>	<u>A201764</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		LYNE	<u>0.01%</u>	<u>A090982</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>			<u>0.01%</u>	<u>A203377</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		PERRIGO ISRAEL	<u>0.01%</u>	<u>A202847</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>			<u>0.01%</u>	<u>A202848</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>		TARO	<u>0.01%</u>	<u>A202368</u>	<u>001</u>	May 19, 2016
<u>AT</u>			<u>0.01%</u>	<u>A209336</u>	<u>001</u>	May 19, 2016

OIL/DROPS; OTIC

DERMOTIC

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>003</u>	Nov 09, 2005
-----------	---	-------------	--------------	----------------	------------	--------------

FLUOCINOLONE ACETONIDE

<u>AT</u>		AKORN	<u>0.01%</u>	<u>A202705</u>	<u>001</u>	Sep 09, 2016
<u>AT</u>		IDENTI PHARMS INC	<u>0.01%</u>	<u>A091306</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		LYNE	<u>0.01%</u>	<u>A203378</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		PERRIGO ISRAEL	<u>0.01%</u>	<u>A202849</u>	<u>001</u>	Jul 17, 2017

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		FOUGERA PHARMS INC	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		G AND W LABS	<u>0.025%</u>	<u>A089524</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994

SYNALAR

<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>	
-----------	---	--------------------	---------------	----------------	------------	--

SHAMPOO; TOPICAL

CAPEX

+	GALDERMA LABS LP	0.01%		N020001	001	Aug 27, 1990
---	------------------	-------	--	---------	-----	--------------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		ACTAVIS LABS UT INC	<u>0.01%</u>	<u>A208386</u>	<u>001</u>	Oct 21, 2016
<u>AT</u>		FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		G AND W LABS INC	<u>0.01%</u>	<u>A207441</u>	<u>001</u>	Sep 28, 2016
<u>AT</u>		GAVIS PHARMS LLC	<u>0.01%</u>	<u>A206422</u>	<u>001</u>	Sep 02, 2015
<u>AT</u>		GLASSHOUSE PHARMS	<u>0.01%</u>	<u>A209596</u>	<u>001</u>	Dec 26, 2017
<u>AT</u>		TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985

SYNALAR

<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>	
-----------	---	--------------------	--------------	----------------	------------	--

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+	GALDERMA LABS LP	0.01%; 4%; 0.05%		N021112	001	Jan 18, 2002
---	------------------	------------------	--	---------	-----	--------------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

!	MEDIMETRIKS PHARMS	0.025%; EQ 3.5MG BASE/GM		A060700	001	
---	--------------------	--------------------------	--	---------	-----	--

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

<u>AB</u>		FOUGERA PHARMS INC	<u>0.1%</u>	<u>A200735</u>	<u>001</u>	Jul 14, 2014
<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A091282</u>	<u>001</u>	Jul 14, 2014
<u>AB</u>		PERRIGO ISRAEL	<u>0.1%</u>	<u>A090256</u>	<u>001</u>	Jan 14, 2014
<u>AB</u>		TARO	<u>0.1%</u>	<u>A200734</u>	<u>001</u>	Jul 14, 2014

VANOS

<u>AB</u>	+	MEDICIS	<u>0.1%</u>	<u>N021758</u>	<u>001</u>	Feb 11, 2005
-----------	---	---------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

<u>AB1</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
<u>AB1</u>	G AND W LABS INC	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A071500</u>	<u>001</u>	Jun 10, 1987
<u>AB1</u>	+!	<u>0.05%</u>	<u>N019117</u>	<u>001</u>	Jun 26, 1984
<u>AB1</u>	TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u>	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

<u>AB2</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076586</u>	<u>001</u>	Jun 23, 2004
<u>AB2</u>	G AND W LABS INC	<u>0.05%</u>	<u>A074204</u>	<u>001</u>	Jun 13, 1995
<u>AB2</u>	! TARO	<u>0.05%</u>	<u>A072494</u>	<u>001</u>	Jan 19, 1989
<u>AB2</u>	TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u>	Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE

<u>AB</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N017373</u>	<u>001</u>	
<u>AB</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A072933</u>	<u>001</u>	Dec 30, 1994
<u>AB</u>	G AND W LABS INC	<u>0.05%</u>	<u>A072537</u>	<u>001</u>	Feb 07, 1989
<u>AB</u>	! TARO	<u>0.05%</u>	<u>A074935</u>	<u>001</u>	Jul 29, 1997

OINTMENT; TOPICAL

FLUOCINONIDE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A074905</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A207538</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>	! TARO	<u>0.05%</u>	<u>A075008</u>	<u>001</u>	Jun 30, 1999
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A073481</u>	<u>001</u>	Dec 27, 1991

LIDEX

<u>AB</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N016909</u>	<u>002</u>	
-----------	--------------------	--------------	----------------	------------	--

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A072934</u>	<u>001</u>	Feb 27, 1995
<u>AT</u>	G AND W LABS INC	<u>0.05%</u>	<u>A071535</u>	<u>001</u>	Dec 02, 1988
<u>AT</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A206003</u>	<u>001</u>	Jul 21, 2017
<u>AT</u>	! TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
<u>AT</u>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u>	Feb 07, 1989

LIDEX

<u>AT</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984
-----------	--------------------	--------------	----------------	------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	+ AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008
-----------	---------	---	----------------	------------	--------------

FLUORESCITE

<u>AP</u>	+! NOVARTIS PHARMS CORP	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
	AK-FLUOR 25%				
	+! AKORN	<u>EQ 500MG BASE/2ML (EQ 250MG BASE/ML)</u>	<u>N022186</u>	<u>002</u>	Aug 08, 2008

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

+!	ALLERGAN	0.1%	<u>N017760</u>	<u>001</u>	Sep 04, 1985
----	----------	------	----------------	------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

+!	ALLERGAN	0.1%	<u>N016851</u>	<u>002</u>	Jul 28, 1982
----	----------	------	----------------	------------	--------------

FML FORTE

	ALLERGAN	0.25%	<u>N019216</u>	<u>001</u>	Apr 23, 1986
--	----------	-------	----------------	------------	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

+!	NOVARTIS PHARMS CORP	0.1%	<u>N019079</u>	<u>001</u>	Feb 11, 1986
----	-------------------------	------	----------------	------------	--------------

FLUOROURACIL

CREAM; TOPICAL

CARAC

<u>AB</u>	+! VALEANT PHARMS NORTH	<u>0.5%</u>	<u>N020985</u>	<u>001</u>	Oct 27, 2000
-----------	----------------------------	-------------	----------------	------------	--------------

EFUDEX

<u>AB</u>	+! VALEANT PHARM INTL	<u>5%</u>	<u>N016831</u>	<u>003</u>	
-----------	-----------------------	-----------	----------------	------------	--

FLUOROURACIL

<u>AB</u>	MYLAN PHARMS INC	<u>0.5%</u>	<u>A203122</u>	<u>001</u>	Apr 20, 2015
<u>AB</u>	SPEAR PHARMS	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
<u>AB</u>	TARO	<u>5%</u>	<u>A090368</u>	<u>001</u>	Mar 05, 2010

PRESCRIPTION DRUG PRODUCT LIST

FLUOROURACIL

CREAM; TOPICAL

FLUOROPLEX

+! AQUA PHARMS

1%

N016988 001

TOLAK

+! HILL DERMACEUTICALS

4%

N022259 001 Sep 18, 2015

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	!	ACCORD HLTHCARE	<u>500MG/10ML (50MG/ML)</u>	<u>A040743 002</u>	Apr 26, 2007
<u>AP</u>	!		<u>1GM/20ML (50MG/ML)</u>	<u>A040743 001</u>	Apr 26, 2007
<u>AP</u>	!		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798 002</u>	Apr 26, 2007
<u>AP</u>	!		<u>5GM/100ML (50MG/ML)</u>	<u>A040798 001</u>	Apr 26, 2007
<u>AP</u>	!	FRESENIUS KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279 002</u>	Sep 30, 1998
<u>AP</u>	!		<u>1GM/20ML (50MG/ML)</u>	<u>A040279 001</u>	Sep 30, 1998
<u>AP</u>	!		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278 001</u>	Sep 30, 1998
<u>AP</u>	!		<u>5GM/100ML (50MG/ML)</u>	<u>A040278 002</u>	Sep 30, 1998
<u>AP</u>		GLAND PHARMA LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A210123 001</u>	Oct 27, 2017
<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A210123 002</u>	Oct 27, 2017
<u>AP</u>			<u>2.5GM/50ML (50MG/ML)</u>	<u>A210124 001</u>	Dec 26, 2017
<u>AP</u>			<u>5GM/100ML (50MG/ML)</u>	<u>A210124 002</u>	Dec 26, 2017
<u>AP</u>		MYLAN LABS LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A202668 001</u>	Jul 17, 2012
<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A202668 002</u>	Jul 17, 2012
<u>AP</u>			<u>2.5GM/50ML (50MG/ML)</u>	<u>A202669 001</u>	Jul 17, 2012
<u>AP</u>			<u>5GM/100ML (50MG/ML)</u>	<u>A202669 002</u>	Jul 17, 2012
<u>AP</u>		SAGENT PHARMS	<u>500MG/10ML (50MG/ML)</u>	<u>A203608 001</u>	May 11, 2017
<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A203608 002</u>	May 11, 2017
<u>AP</u>			<u>2.5GM/50ML (50MG/ML)</u>	<u>A203609 001</u>	Feb 17, 2016
<u>AP</u>			<u>5GM/100ML (50MG/ML)</u>	<u>A203609 002</u>	Feb 17, 2016
<u>AP</u>	!	TEVA PHARMS USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040333 001</u>	Jan 27, 2000
<u>AP</u>	!		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334 001</u>	Feb 25, 2000
<u>AP</u>	!		<u>5GM/100ML (50MG/ML)</u>	<u>A040334 002</u>	Feb 25, 2000

SOLUTION; TOPICAL

EFUDEX

<u>AT</u>	+	VALEANT PHARM INTL	<u>2%</u>	<u>N016831 001</u>	
<u>AT</u>	+		<u>5%</u>	<u>N016831 002</u>	

FLUOROURACIL

<u>AT</u>		TARO PHARM	<u>2%</u>	<u>A076526 001</u>	Nov 05, 2003
<u>AT</u>			<u>5%</u>	<u>A076526 002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223 003</u>	Mar 19, 2009
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619 003</u>	Jan 31, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 40MG BASE</u>	<u>A075465 003</u>	Aug 02, 2001
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336 003</u>	Oct 01, 2012
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245 003</u>	Sep 28, 2004
<u>AB</u>		PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922 003</u>	Dec 16, 2004
<u>AB</u>		SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049 003</u>	Jan 29, 2002
<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 40MG BASE</u>	<u>A204597 003</u>	Mar 16, 2015
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A076990 001</u>	Dec 13, 2004
<u>AB</u>		TEVA	<u>EQ 40MG BASE</u>	<u>A075452 003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+	ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936 003</u>	Jun 15, 1999
-----------	---	------------------	---------------------	--------------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>		ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223 001</u>	Mar 19, 2009
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A090223 002</u>	Mar 19, 2009
<u>AB1</u>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619 001</u>	Jan 31, 2008
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A078619 002</u>	Jan 31, 2008
<u>AB1</u>		BARR	<u>EQ 10MG BASE</u>	<u>A074803 002</u>	Jan 30, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A074803 001</u>	Aug 02, 2001
<u>AB1</u>		DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465 001</u>	Jan 29, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075465 002</u>	Jan 29, 2002
<u>AB1</u>		HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336 001</u>	Oct 01, 2012
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A201336 002</u>	Oct 01, 2012
<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245 002</u>	Jan 31, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075245 001</u>	Jan 31, 2002
<u>AB1</u>		LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464 001</u>	Jan 30, 2002
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075464 002</u>	Jan 30, 2002
<u>AB1</u>		SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049 001</u>	Aug 02, 2001
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075049 002</u>	Jan 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A204597 001</u>	Mar 16, 2015
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A204597 002</u>	Mar 16, 2015
<u>AB1</u>	SPECGX LLC	<u>EQ 10MG BASE</u>	<u>A075658 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001 002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	+ ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 006</u>	Dec 23, 1992
<u>AB1</u>	+ FLUOXETINE HYDROCHLORIDE	<u>EQ 20MG BASE</u>	<u>N018936 001</u>	Dec 29, 1987

MYLAN
!

EQ 10MG BASE

A078045 001 Nov 17, 2008

EQ 20MG BASE

A078045 002 Nov 17, 2008

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237 001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572 001</u>	Mar 22, 2010

PROZAC WEEKLY

<u>AB</u>	+! LILLY	<u>EQ 90MG BASE</u>	<u>N021235 001</u>	Feb 26, 2001
-----------	----------	---------------------	--------------------	--------------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE/5ML</u>	<u>A079209 001</u>	Mar 20, 2009
<u>AA</u>	! PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015 001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849 001</u>	Feb 09, 2007
<u>AA</u>	SPECGX LLC	<u>EQ 20MG BASE/5ML</u>	<u>A075920 001</u>	Jan 29, 2002
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506 001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT BIO AG	<u>EQ 20MG BASE/5ML</u>	<u>A075514 001</u>	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A208698 001</u>	Apr 05, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A208698 002</u>	Apr 05, 2017
<u>AB</u>	+! ALVOGEN	<u>EQ 60MG BASE</u>	<u>N202133 001</u>	Oct 06, 2011
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006 001</u>	Jan 30, 2002
<u>AB</u>	INVENTIA HLTHCARE	<u>EQ 60MG BASE</u>	<u>A209695 001</u>	Nov 20, 2017
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755 001</u>	Aug 02, 2001
<u>AB</u>	!	<u>EQ 20MG BASE</u>	<u>A075755 002</u>	Aug 02, 2001
<u>AB</u>	PAR FORM	<u>EQ 10MG BASE</u>	<u>A203836 001</u>	Aug 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203836 002</u>	Aug 19, 2016
<u>AB</u>	PAR PHARM INC	<u>EQ 60MG BASE</u>	<u>A209419 001</u>	Nov 16, 2017
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872 001</u>	Jan 29, 2002
<u>AB1</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A206937 001</u>	Oct 21, 2016
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A206937 002</u>	Oct 21, 2016

SARAFEM

<u>AB1</u>	+ APIL	<u>EQ 10MG BASE</u>	<u>N021860 001</u>	May 19, 2006
<u>AB1</u>	+ FLUOXETINE HYDROCHLORIDE	<u>EQ 15MG BASE</u>	<u>N021860 002</u>	May 19, 2006
<u>AB1</u>	+! SARAFEM	<u>EQ 20MG BASE</u>	<u>N021860 003</u>	May 19, 2006

SELFEMRA

<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151 001</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>A200151 002</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A200151 003</u>	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742 001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742 002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742 003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742 004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742 005</u>	Nov 02, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901 005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901 001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901 003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901 002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901 004</u>	Nov 16, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074 001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528 001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528 002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528 003</u>	Jun 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		<u>EQ 50MG BASE;EQ 12MG BASE</u>	A077528 004	Jun 19, 2012
	SYMBYAX			
AB	+	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	N021520 001 Apr 09, 2007
AB	+		<u>EQ 25MG BASE;EQ 6MG BASE</u>	N021520 002 Dec 24, 2003
AB	+		<u>EQ 25MG BASE;EQ 12MG BASE</u>	N021520 004 Dec 24, 2003
AB	+	!	<u>EQ 50MG BASE;EQ 6MG BASE</u>	N021520 003 Dec 24, 2003
AB	+		<u>EQ 50MG BASE;EQ 12MG BASE</u>	N021520 005 Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

! USL PHARMA

10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO		AUROBINDO PHARMA LTD	<u>25MG/ML</u>	A207739 001 Oct 17, 2017
AO	!	FRESENIUS KABI USA	<u>25MG/ML</u>	A071413 001 Jul 14, 1987
AO		PAR STERILE PRODUCTS	<u>25MG/ML</u>	A203732 001 Jul 03, 2014
AO		WEST-WARD PHARMS INT	<u>25MG/ML</u>	A074531 001 Aug 30, 1996

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

! FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		LANNETT	<u>1MG</u>	A089743 002 Aug 25, 1988
AB			<u>2.5MG</u>	A089743 003 Aug 25, 1988
AB			<u>5MG</u>	A089743 004 Aug 25, 1988
AB			<u>10MG</u>	A089743 001 Aug 25, 1988
AB		MYLAN	<u>1MG</u>	A089804 002 Aug 12, 1988
AB			<u>2.5MG</u>	A089804 003 Aug 12, 1988
AB			<u>5MG</u>	A089804 004 Aug 12, 1988
AB	!		<u>10MG</u>	A089804 001 Aug 12, 1988
AB		SANDOZ	<u>1MG</u>	A089586 002 Oct 16, 1987
AB			<u>2.5MG</u>	A089586 003 Oct 16, 1987
AB			<u>5MG</u>	A089586 004 Oct 16, 1987
AB			<u>10MG</u>	A089586 001 Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

AT	+	!	AQUA PHARMS	<u>0.05%</u>	N012806 002		
			FLURANDRENOLIDE				
AT			CINTEX SVCS	<u>0.05%</u>	A205342 001 Apr 13, 2016		
			CORDRAN SP				
			+	!	AQUA PHARMS	<u>0.025%</u>	N012806 003

LOTION; TOPICAL

CORDRAN

AT	+	!	AQUA PHARMS	<u>0.05%</u>	N013790 001
			FLURANDRENOLIDE		
AT			CINTEX SVCS	<u>0.05%</u>	A205343 001 Dec 22, 2016
AT			PERRIGO UK FINCO	<u>0.05%</u>	A207133 001 Aug 30, 2016

OINTMENT; TOPICAL

CORDRAN

AT	+	!	AQUA PHARMS	<u>0.05%</u>	N012806 001		
			FLURANDRENOLIDE				
AT			TELIGENT PHARMA INC	<u>0.05%</u>	A207851 001 Dec 30, 2016		
			CORDRAN				
			+	!	ALLERGAN SALES LLC	<u>0.004MG/SQ CM</u>	N016455 001

PRESCRIPTION DRUG PRODUCT LIST

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

!

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN**AB** MYLAN**50MG****A074358 001** Jun 20, 1994**AB** !**100MG****A074358 002** Jun 20, 1994**AB** SUN PHARM INDS INC**50MG****A075058 001** Apr 27, 2001**AB****100MG****A075058 002** Apr 27, 2001**AB** TEVA**100MG****A074431 001** May 31, 1995FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM**AT** BAUSCH AND LOMB**0.03%****A074447 001** Jan 04, 1995OCUFEN**AT** +! ALLERGAN**0.03%****N019404 001** Dec 31, 1986FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE**AB** ACTAVIS LABS FL INC**125MG****A075820 001** Sep 18, 2001**AB** ! CIPLA LTD**125MG****A075780 001** Sep 19, 2001**AB** PAR PHARM**125MG****A075298 001** Sep 18, 2001FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+! GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013

+!

121.5mCi/30ML (4.05mCi/ML)

N203137 002 Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUTY ELLIPTA

+! GLAXOSMITHKLINE

0.1MG/INH

N205625 001 Aug 20, 2014

+!

0.2MG/INH

N205625 002 Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

TRELEGY ELLIPTA

+! GLAXOSMITHKLINE

0.1MG/INH;EQ 0.0625MG BASE/INH;EQ
0.025MG BASE/INH

N209482 001 Sep 18, 2017

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+! GLAXO GRP LTD

0.1MG/INH;EQ 0.025MG BASE/INH

N204275 001 May 10, 2013

+!

0.2MG/INH;EQ 0.025MG BASE/INH

N204275 002 Apr 30, 2015

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+! GLAXO GRP LTD

0.044MG/INH

N021433 003 May 14, 2004

+!

0.11MG/INH

N021433 002 May 14, 2004

+!

0.22MG/INH

N021433 001 May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATE**AB** FOUGERA PHARMS**0.05%****A076451 001** May 14, 2004**AB** G AND W LABS**0.05%****A077055 001** Jun 30, 2006**AB** ! PERRIGO NEW YORK**0.05%****A076793 001** May 14, 2004**AB** TOLMAR**0.05%****A076633 001** May 14, 2004

LOTION; TOPICAL

CUTIVATE**AB** +! FOUGERA PHARMS**0.05%****N021152 001** Mar 31, 2005FLUTICASONE PROPIONATE**AB** GLENMARK GENERICS**0.05%****A090759 001** May 02, 2011**AB** PERRIGO ISRAEL**0.05%****A091553 001** Jul 30, 2013

OINTMENT; TOPICAL

CUTIVATE**AB** +! FOUGERA PHARMS**0.005%****N019957 001** Dec 14, 1990FLUTICASONE PROPIONATE**AB** FOUGERA PHARMS**0.005%****A076300 001** May 14, 2004**AB** G AND W LABS**0.005%****A077168 001** Mar 03, 2006

PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB	PERRIGO NEW YORK	0.005%	A076668	001	May 14, 2004
	POWDER; INHALATION				
	ARMONAIR RESPICLICK				
	+ TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017
	+	0.113MG/INH	N208798	002	Jan 27, 2017
	+	0.232MG/INH	N208798	003	Jan 27, 2017
	FLOVENT DISKUS 100				
	+! GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000
	FLOVENT DISKUS 250				
	+! GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
	FLOVENT DISKUS 50				
	+! GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000
	SPRAY, METERED; NASAL				

FLUTICASONE PROPIONATE

AB	APOTEX INC	0.05MG/SPRAY	A077538	001	Sep 12, 2007
AB	HI TECH PHARMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008
AB	! WEST-WARD PHARMS	0.05MG/SPRAY	A076504	001	Feb 22, 2006
	INT				
AB	WOCKHARDT BIO AG	0.05MG/SPRAY	A078492	001	Jan 09, 2012
	XHANCE				
	+! OPTNOSE US	0.093MG	N209022	001	Sep 18, 2017

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

	+! GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+	0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+	0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50

	+! GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
--	------------------	------------------------------	---------	-----	--------------

ADVAIR DISKUS 250/50

	+! GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
--	------------------	-------------------------------	---------	-----	--------------

ADVAIR DISKUS 500/50

	+! GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000
--	------------------	------------------------------	---------	-----	--------------

AIRDUO RESPICLICK

	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012
AB	!	EQ 40MG BASE	A090595	002	Apr 11, 2012
AB	TEVA PHARMS	EQ 20MG BASE	A078407	001	Jun 12, 2012
AB		EQ 40MG BASE	A078407	002	Jun 12, 2012

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016
	LESCOL XL				
AB	+! NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013
AB	!	150MG	A091482	002	Nov 18, 2013
AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013
AB		150MG	A091476	002	Mar 13, 2013
AB	TORRENT PHARMS LTD	100MG	A203240	001	Oct 31, 2014
AB		150MG	A203240	002	Oct 31, 2014

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001
AB		50MG	A075897	002	Jan 25, 2001
AB		100MG	A075897	003	Jan 25, 2001
AB	APOTEX	25MG	A075902	001	May 07, 2001
AB		50MG	A075902	002	May 07, 2001
AB		100MG	A075902	003	May 07, 2001

PRESCRIPTION DRUG PRODUCT LIST

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889 001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889 002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889 003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893 001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893 002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893 003</u>	Sep 10, 2002
<u>AB</u>	UPSHER-SMITH LABS	<u>25MG</u>	<u>A075888 001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888 002</u>	Nov 29, 2000
<u>AB</u>	!	<u>100MG</u>	<u>A075888 003</u>	Nov 29, 2000
	<u>LUVOX</u>			
<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519 001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519 002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519 003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

! FRESENIUS KABI USA 5MG/ML A089202 001 Feb 18, 1986

TABLET; ORAL

FOLIC ACID

<u>AA</u>	AIPING PHARM INC	<u>1MG</u>	<u>A091145 001</u>	Jul 12, 2013
<u>AA</u>	!	<u>1MG</u>	<u>A040625 001</u>	Jul 21, 2005
<u>AA</u>	CADILA PHARMS LTD	<u>1MG</u>	<u>A202437 001</u>	Jan 27, 2014
<u>AA</u>	HIKMA PHARMS	<u>1MG</u>	<u>A080600 001</u>	
<u>AA</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090035 001</u>	Jun 09, 2009
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A040796 001</u>	Jan 12, 2009
<u>AA</u>	NUVO PHARM INC	<u>1MG</u>	<u>A204418 001</u>	Jul 28, 2015
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040756 001</u>	Jun 04, 2010
<u>AA</u>	!	<u>1MG</u>	<u>A080680 001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+	!	ORGANON USA INC	300 IU/0.36ML	N021211 001	Mar 23, 2004
+	!		600 IU/0.72ML	N021211 002	Mar 23, 2004
+	!		900 IU/1.08ML	N021211 004	Feb 11, 2005

GONAL-F

+	!	EMD SERONO	450 IU/VIAL	N020378 005	Mar 26, 2004
+			1,050 IU/VIAL	N020378 004	Feb 28, 2001

GONAL-F RFF

+	!	EMD SERONO	75 IU/VIAL	N021765 002	Mar 25, 2004
---	---	------------	------------	-------------	--------------

GONAL-F RFF REDI-JECT

+	!	EMD SERONO	300 IU/0.5ML	N021684 001	May 25, 2004
+	!		450 IU/0.75ML	N021684 002	May 25, 2004
+	!		900 IU/1.5ML	N021684 003	May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<u>AP</u>	+	!	PAR PHARM INC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696 001</u>	Dec 04, 1997
-----------	---	---	---------------	-----------------------------	--------------------	--------------

FOMEPIZOLE

<u>AP</u>			LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368 001</u>	Dec 14, 2007
<u>AP</u>			MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639 001</u>	Mar 03, 2008
<u>AP</u>			NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537 001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

<u>AP</u>	+	!	MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345 001</u>	Dec 07, 2001
<u>AP</u>	+	!		<u>5MG/0.4ML</u>	<u>N021345 002</u>	May 28, 2004
<u>AP</u>	+	!		<u>7.5MG/0.6ML</u>	<u>N021345 003</u>	May 28, 2004
<u>AP</u>	+	!		<u>10MG/0.8ML</u>	<u>N021345 004</u>	May 28, 2004

FONDAPARINUX SODIUM

<u>AP</u>			AUROBINDO PHARMA LTD	<u>2.5MG/0.5ML</u>	<u>A206918 001</u>	Dec 26, 2017
<u>AP</u>				<u>5MG/0.4ML</u>	<u>A206918 002</u>	Dec 26, 2017
<u>AP</u>				<u>7.5MG/0.6ML</u>	<u>A206918 003</u>	Dec 26, 2017
<u>AP</u>				<u>10MG/0.8ML</u>	<u>A206918 004</u>	Dec 26, 2017
<u>AP</u>			DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316 001</u>	Jul 11, 2011
<u>AP</u>				<u>5MG/0.4ML</u>	<u>A091316 002</u>	Jul 11, 2011
<u>AP</u>				<u>7.5MG/0.6ML</u>	<u>A091316 003</u>	Jul 11, 2011
<u>AP</u>				<u>10MG/0.8ML</u>	<u>A091316 004</u>	Jul 11, 2011

PRESCRIPTION DRUG PRODUCT LIST

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFORMIST

+! MYLAN SPECLT 0.02MG/2ML N022007 001 May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+! ASTRAZENECA PHARMS 0.0048MG/INH;0.0090MG/INH N208294 001 Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+! MERCK SHARP DOHME 0.005MG/INH;0.1MG/INH N022518 001 Jun 22, 2010

+! 0.005MG/INH;0.2MG/INH N022518 002 Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+! VIIV HLTHCARE EQ 50MG BASE/ML N022116 001 Jun 14, 2007

TABLET; ORAL

FOSAMPRENAVIR CALCIUM**AB** MYLAN PHARMS INC **EQ 700MG BASE** **A204060 001** Apr 15, 2016LEXIVA**AB** +! VIIV HLTHCARE **EQ 700MG BASE** **N021548 001** Oct 20, 2003FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND**AP** +! MERCK AND CO INC **EQ 150MG BASE/VIAL** **N022023 002** Nov 12, 2010FOSAPREPITANT DIMEGLUMINE**AP** FRESENIUS KABI USA **EQ 150MG BASE/VIAL** **A206197 001** Jun 09, 2016FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR

+! CLINIGEN HLTHCARE 2.4GM/100ML N020068 001 Sep 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM**AB** APOTEX INC **10MG** **A076906 001** May 17, 2005**AB** **20MG** **A076906 002** May 17, 2005**AB** **40MG** **A076906 003** May 17, 2005**AB** AUROBINDO PHARMA LTD **10MG** **A091163 001** Mar 30, 2011**AB** **20MG** **A091163 002** Mar 30, 2011**AB** **40MG** **A091163 003** Mar 30, 2011**AB** INVAGEN PHARMS **10MG** **A077222 001** Apr 20, 2005**AB** **20MG** **A077222 002** Apr 20, 2005**AB** **40MG** **A077222 003** Apr 20, 2005**AB** PRINSTON INC **10MG** **A205670 001** Aug 29, 2016**AB** **20MG** **A205670 002** Aug 29, 2016**AB** **40MG** **A205670 003** Aug 29, 2016**AB** TEVA **10MG** **A076139 001** Nov 25, 2003**AB** **20MG** **A076139 002** Nov 25, 2003**AB** ! **40MG** **A076139 003** Nov 25, 2003**AB** UPSHER-SMITH LABS **10MG** **A076483 001** Apr 23, 2004**AB** **20MG** **A076483 002** Apr 23, 2004**AB** **40MG** **A076483 003** Apr 23, 2004FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE**AB** AUROBINDO PHARMA **10MG;12.5MG** **A079245 001** Jul 09, 2009**AB** **20MG;12.5MG** **A079245 002** Jul 09, 2009**AB** EMCURE PHARMS INDIA **10MG;12.5MG** **A079025 001** Sep 17, 2010**AB** ! **20MG;12.5MG** **A079025 002** Sep 17, 2010**AB** INVAGEN PHARMS **10MG;12.5MG** **A090228 001** Jul 09, 2009**AB** **20MG;12.5MG** **A090228 002** Jul 09, 2009**AB** SANDOZ **10MG;12.5MG** **A076961 001** Sep 28, 2005**AB** **20MG;12.5MG** **A076961 002** Sep 28, 2005

PRESCRIPTION DRUG PRODUCT LIST

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	<u>+!</u> PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450 001</u>	Aug 05, 1996
-----------	-----------------------	--------------------------------	--------------------	--------------

FOSPHENYTOIN SODIUM

<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476 001</u>	Mar 18, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052 001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765 001</u>	Dec 02, 2009
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277 001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099 001</u>	May 13, 2010
<u>AP</u>	MYLAN LABS LTD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736 001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417 001</u>	Mar 18, 2008
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481 001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989 001</u>	Aug 06, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137 001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	<u>+!</u> ENDO PHARMS	<u>EQ 2.5MG BASE</u>	<u>N021006 001</u>	Nov 08, 2001
-----------	-----------------------	----------------------	--------------------	--------------

FROVATRIPTAN SUCCINATE

<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A204730 001</u>	Mar 11, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A202931 001</u>	Aug 28, 2014

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+! ASTRAZENECA

50MG/ML

N021344 001 Apr 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	AMNEAL PHARMS CO	<u>10MG/ML</u>	<u>A207552 001</u>	Jul 20, 2016
<u>AP</u>	BAXTER HLTHCARE CORP	<u>10MG/ML</u>	<u>A202747 001</u>	Jan 27, 2014
<u>AP</u>	EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428 001</u>	Aug 26, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902 001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241 001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667 001</u>	May 28, 1982
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941 001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	<u>!</u> WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A070434 001</u>	Apr 22, 1987
<u>AA</u>	WOCKHARDT BIO AG	<u>10MG/ML</u>	<u>A070655 001</u>	Oct 02, 1987
	WEST-WARD PHARMS INT	40MG/5ML	A070433 001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010 001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010 002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010 003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413 001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413 002</u>	Nov 30, 1983
<u>AB</u>	LEADING PHARMA LLC	<u>20MG</u>	<u>A077293 001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293 002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293 003</u>	Nov 09, 2005
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487 001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487 002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082 001</u>	Oct 29, 1986
<u>AB</u>	PRINSTON INC	<u>20MG</u>	<u>A076796 001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796 002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796 003</u>	Mar 26, 2004
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569 002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569 001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569 005</u>	Aug 14, 1984
<u>AB</u>	WEST-WARD PHARMS INT	<u>20MG</u>	<u>N018823 001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823 002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086 001</u>	Jan 24, 1986

LASIX

<u>AB</u>	<u>+</u> US PHARM HOLDINGS	<u>20MG</u>	<u>N016273 002</u>	
<u>AB</u>	<u>+</u>	<u>40MG</u>	<u>N016273 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

FUROSEMIDE

TABLET; ORAL

LASIX

AB	+!	80MG	N016273	003	
-----------	-----------	-------------	----------------	------------	--

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	ACTAVIS ELIZABETH	100MG	A075350	001	Sep 12, 2003
AB		300MG	A075350	002	Sep 12, 2003
AB		400MG	A075350	003	Sep 12, 2003
AB	ALKEM	100MG	A090858	001	Dec 17, 2010
AB		300MG	A090858	002	Dec 17, 2010
AB		400MG	A090858	003	Dec 17, 2010
AB	AMNEAL PHARMS NY	100MG	A078428	001	Jul 25, 2007
AB		300MG	A078428	002	Jul 25, 2007
AB		400MG	A078428	003	Jul 25, 2007
AB	APOTEX INC	100MG	A075360	001	Apr 06, 2005
AB		300MG	A075360	002	Apr 06, 2005
AB		400MG	A075360	003	Apr 06, 2005
AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008
AB		300MG	A078787	002	Jan 31, 2008
AB		400MG	A078787	003	Jan 31, 2008
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017
AB		300MG	A207099	002	Mar 24, 2017
AB		400MG	A207099	003	Mar 24, 2017
AB	INVAGEN PHARMS	100MG	A090705	001	Dec 30, 2009
AB		300MG	A090705	002	Dec 30, 2009
AB		400MG	A090705	003	Dec 30, 2009
AB	JIANGSU HENGRUI MED	100MG	A091008	001	Oct 26, 2017
AB		300MG	A091008	002	Oct 26, 2017
AB		400MG	A091008	003	Oct 26, 2017
AB	MARKSANS PHARMA	100MG	A090007	001	Jul 21, 2011
AB		300MG	A090007	002	Jul 21, 2011
AB		400MG	A090007	003	Jul 21, 2011
AB	MYLAN	100MG	A090158	001	Feb 14, 2011
AB		300MG	A090158	002	Feb 14, 2011
AB		400MG	A090158	003	Feb 14, 2011
AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016
AB		300MG	A204989	002	Feb 18, 2016
AB		400MG	A204989	003	Feb 18, 2016
AB	SUN PHARM INDS LTD	100MG	A077242	001	Aug 24, 2006
AB		300MG	A077242	002	Aug 24, 2006
AB		400MG	A077242	003	Aug 24, 2006
AB	TARO PHARM	100MG	A077261	001	Aug 02, 2013
AB		300MG	A077261	002	Aug 02, 2013
AB		400MG	A077261	003	Aug 02, 2013
AB	TEVA PHARMS	100MG	A075435	001	Oct 08, 2004
AB		300MG	A075435	002	Oct 08, 2004
AB		400MG	A075435	003	Oct 08, 2004
NEURONTIN					
AB	+ PFIZER PHARMS	100MG	N020235	001	Dec 30, 1993
AB	+	300MG	N020235	002	Dec 30, 1993
AB	+!	400MG	N020235	003	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403	001	May 01, 2012
AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012
AA	HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011
AA	TARO	250MG/5ML	A076672	001	Jul 03, 2013
AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016

NEURONTIN

AA	+! PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000
-----------	-----------------------	------------------	----------------	------------	--------------

TABLET; ORAL

GABAPENTIN

AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013
AB		800MG	A203244	001	Jul 12, 2013
AB	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004
AB		800MG	A075694	002	Oct 21, 2004
AB	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015
AB		800MG	A206402	002	Dec 23, 2015
AB	APOTEX INC	100MG	A077894	001	Oct 10, 2006

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

TABLET; ORAL

GABAPENTIN

<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>	CSPC OUYI PHARM CO	<u>600MG</u>	<u>A207057</u>	<u>001</u>	Oct 26, 2017
<u>AB</u>		<u>800MG</u>	<u>A207057</u>	<u>002</u>	Oct 26, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764</u>	<u>001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764</u>	<u>002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>600MG</u>	<u>A205101</u>	<u>001</u>	Feb 04, 2016
<u>AB</u>		<u>800MG</u>	<u>A205101</u>	<u>002</u>	Feb 04, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	TEVA PHARMS USA	<u>600MG</u>	<u>A205807</u>	<u>001</u>	Mar 10, 2017
<u>AB</u>		<u>800MG</u>	<u>A205807</u>	<u>002</u>	Mar 10, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926</u>	<u>001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926</u>	<u>002</u>	Feb 11, 2011

NEURONTIN

<u>AB</u>	+	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>	+	GRALISE	<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998
BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011
BX	+		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBILTABLET, EXTENDED RELEASE; ORAL
HORIZANT

+	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011
+		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GDAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

PRESCRIPTION DRUG PRODUCT LIST

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+	!	BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+	!		469.01MG/ML	N021037	001	Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	!	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013
+	!		1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017
+	!		3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013
+	!		5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013
+	!		7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+	!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992
+	!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	!	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+	!		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+	!		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+	!		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+	!		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+	!	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+	!		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+	!		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+	!		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+	!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
+	!		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016
AB			EQ 16MG BASE	A204895	002	Aug 05, 2016
AB			EQ 24MG BASE	A204895	003	Aug 05, 2016
AB		BARR	EQ 8MG BASE	A078189	001	Sep 15, 2008
AB			EQ 16MG BASE	A078189	002	Sep 15, 2008
AB			EQ 24MG BASE	A078189	003	Sep 15, 2008
AB		MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011
AB			EQ 16MG BASE	A090900	002	Jan 24, 2011
AB			EQ 24MG BASE	A090900	003	Jan 24, 2011
AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011
AB			EQ 16MG BASE	A090178	002	Feb 02, 2011
AB			EQ 24MG BASE	A090178	003	Feb 02, 2011
AB		WATSON LABS	EQ 8MG BASE	A079028	001	Dec 15, 2008
AB			EQ 16MG BASE	A079028	002	Dec 15, 2008
AB			EQ 24MG BASE	A079028	003	Dec 15, 2008

RAZADYNE ER

AB	+	!	JANSSEN PHARMS	EQ 8MG BASE	N021615	001	Apr 01, 2005
AB	+	!		EQ 16MG BASE	N021615	002	Apr 01, 2005
AB	+	!		EQ 24MG BASE	N021615	003	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

!	!	WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009
---	---	----------------------	--------	---------	-----	--------------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		APOTEX INC	EQ 4MG BASE	A077781	001	Sep 27, 2011
AB			EQ 8MG BASE	A077781	002	Sep 27, 2011
AB			EQ 12MG BASE	A077781	003	Sep 27, 2011
AB		AUROBINDO PHARMA	EQ 4MG BASE	A090957	001	Mar 29, 2011

PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

LTD

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
<u>AB</u>	BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590 001</u>	May 29, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077590 002</u>	May 29, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077590 003</u>	May 29, 2009
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587 001</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077587 002</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077587 003</u>	Jul 09, 2009
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
<u>AB</u>	YABAO PHARM	<u>EQ 4MG BASE</u>	<u>A077604 001</u>	Feb 06, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077604 002</u>	Feb 06, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077604 003</u>	Feb 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011
<u>RAZADYNE</u>				
<u>AB</u>	+! JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
<u>AB</u>	+	<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478	001
BS	MALLINKRODT NUCLEAR	2mCi/ML	N018058	001

GALLIUM DOTATATE GA-68

POWDER; INTRAVENOUS

NETSPOT

+!	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016
----	-------------	---------------	---------	-----	--------------

GANCICLOVIR

GEL; OPHTHALMIC

ZIRGAN

+!	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009
----	-----------------	-------	---------	-----	--------------

GANCICLOVIR

SOLUTION; IV (INFUSION)

GANCICLOVIR

+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017
----	-------------------------	----------------------	---------	-----	--------------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

<u>AP</u>	+! ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661 001</u>	Jun 23, 1989
<u>GANCICLOVIR</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658 001</u>	Jun 21, 2010
<u>AP</u>	LUITPOLD PHARMS INC	<u>EQ 500MG BASE/VIAL</u>	<u>A202624 001</u>	Sep 18, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A204560 001</u>	Nov 17, 2017
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 500MG BASE/VIAL</u>	<u>A204950 001</u>	Dec 06, 2016
<u>GANCICLOVIR SODIUM</u>				
<u>AP</u>	PHARMASCIENCE INC	<u>EQ 500MG BASE/VIAL</u>	<u>A207645 001</u>	Dec 08, 2017

PRESCRIPTION DRUG PRODUCT LIST

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

+! ORGANON USA INC EQ 250MCG BASE/0.5ML N021057 001 Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACINAT HI-TECH PHARMA CO 0.5% A203189 001 Sep 03, 2014AT LUPIN LTD 0.5% A202653 001 Aug 28, 2013AT SANDOZ INC 0.5% A204227 001 Jul 11, 2016ZYMAXIDAT +! ALLERGAN 0.5% N022548 001 May 18, 2010

ZYMAR

+! ALLERGAN 0.3% N021493 001 Mar 28, 2003

GEFITINIB

TABLET; ORAL

IRESSA

+! ASTRAZENECA PHARMS 250MG N206995 001 Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDEAP ACCORD HLTHCARE EQ 200MG BASE/VIAL A091594 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A091594 002 Jul 25, 2011AP EQ 2GM BASE/VIAL A091594 003 Jul 25, 2011AP ACTAVIS INC 200MG/5.26ML (38MG/ML) A204549 001 Apr 11, 2016AP 1GM/26.3ML (38MG/ML) A204549 002 Apr 11, 2016AP 2GM/52.6ML (38MG/ML) A204549 003 Apr 11, 2016AP ACTAVIS TOTOWA EQ 200MG BASE/VIAL A079160 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A079160 002 Jul 25, 2011AP EQ 2GM BASE/VIAL A079160 003 Jul 28, 2016AP APOTEX INC 200MG/5.26ML (38MG/ML) A206776 001 May 23, 2017AP 1GM/26.3ML (38MG/ML) A206776 002 May 23, 2017AP 2GM/52.6ML (38MG/ML) A206776 003 May 23, 2017AP CIPLA LTD EQ 200MG BASE/VIAL A078759 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A078759 002 Jul 25, 2011AP DR REDDYS LABS LTD EQ 200MG BASE/VIAL A091365 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A091365 002 Jul 25, 2011AP EQ 2GM BASE/VIAL A202997 001 May 07, 2013AP EMCURE PHARMS LTD EQ 200MG BASE/VIAL A202063 001 Sep 11, 2012AP EQ 1GM BASE/VIAL A202063 002 Sep 11, 2012AP FRESENIUS KABI EQ 200MG BASE/VIAL A090799 001 Jul 25, 2011AP ONCOL EQ 1GM BASE/VIAL A090799 002 Jul 25, 2011AP EQ 2GM BASE/VIAL A090799 003 May 16, 2011AP FRESENIUS KABI USA EQ 2GM BASE/VIAL A090242 003 May 16, 2011AP GLAND PHARMA LTD EQ 200MG BASE/VIAL A204520 001 Jan 05, 2016AP EQ 1GM BASE/VIAL A204520 002 Jan 05, 2016AP HAMELN RDS GMBH EQ 200MG BASE/VIAL A090663 001 Sep 10, 2012AP EQ 1GM BASE/VIAL A090663 002 Sep 10, 2012AP HOSPIRA EQ 200MG BASE/VIAL A078339 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A078339 002 Jul 25, 2011AP +! HOSPIRA INC 200MG/5.26ML (38MG/ML) N200795 001 Aug 04, 2011AP +! 1GM/26.3ML (38MG/ML) N200795 002 Aug 04, 2011AP ! EQ 2GM BASE/VIAL A079183 001 Nov 15, 2010AP +! 2GM/52.6ML (38MG/ML) N200795 003 Aug 04, 2011AP JIANGSU HANSONH EQ 200MG BASE/VIAL A202485 001 May 07, 2013AP PHARM EQ 1GM BASE/VIAL A202485 002 May 07, 2013AP LUITPOLD PHARMS INC EQ 200MG BASE/VIAL A202031 001 May 07, 2013AP EQ 1GM BASE/VIAL A202031 002 May 07, 2013AP MYLAN LABS LTD EQ 200MG BASE/VIAL A200145 001 Jul 25, 2011AP 200MG/5.26ML (38MG/ML) A205242 001 Dec 06, 2017AP EQ 1GM BASE/VIAL A200145 002 Jul 25, 2011AP 1GM/26.3ML (38MG/ML) A205242 002 Dec 06, 2017AP EQ 2GM BASE/VIAL A200145 003 Jul 25, 2011AP 2GM/52.6ML (38MG/ML) A205242 003 Dec 06, 2017AP SUN PHARMA GLOBAL EQ 200MG BASE/VIAL A078433 001 Jul 25, 2011AP EQ 1GM BASE/VIAL A078433 002 Jul 25, 2011AP TEVA PHARMS EQ 200MG BASE/VIAL A077983 002 Jan 25, 2011AP EQ 1GM BASE/VIAL A077983 001 Jan 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509 001	May 15, 1996
AP	+		EQ 1GM BASE/VIAL	N020509 002	May 15, 1996

SOLUTION; IV (INFUSION)

GEMCITABINE HYDROCHLORIDE

+	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604 002	Aug 03, 2017
+		1.5GM/15ML (100MG/ML)	N209604 003	Aug 03, 2017
+		2GM/20ML (100MG/ML)	N209604 004	Aug 03, 2017
+		200MG/2ML (100MG/ML)	N209604 001	Aug 03, 2017

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		APOTEX	600MG	A075034 001	Jul 20, 1998
AB		AUROBINDO PHARMA LTD	600MG	A202726 001	Sep 16, 2015
AB		CADILA PHARMS LTD	600MG	A203266 001	Jun 17, 2016
AB		CARIBE HOLDINGS	600MG	A078012 001	Mar 26, 2007
AB		CHARTWELL MOLECULES	600MG	A074270 001	Sep 27, 1993
AB		HIKMA PHARMS	600MG	A078599 001	Aug 16, 2010
AB		IMPAX PHARMS	600MG	A078207 001	Jun 01, 2007
AB		INVAGEN PHARMS	600MG	A077836 001	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	600MG	A079072 001	Sep 13, 2010
AB		SUN PHARM INDS INC	600MG	A079239 001	Dec 29, 2008
AB		TEVA	600MG	A074256 001	Oct 31, 1993
LOPID					
AB	+	PFIZER PHARMS	600MG	N018422 003	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

AB	+	LG CHEM LTD	EQ 320MG BASE	N021158 001	Apr 04, 2003
-----------	----------	-------------	----------------------	--------------------	--------------

GEMIFLOXACIN MESYLATE

AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466 001	Jun 15, 2015
-----------	--	-----------------	----------------------	--------------------	--------------

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT		G AND W LABS INC	EQ 0.1% BASE	A064056 001	Apr 29, 1994
AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307 001	

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366 002	Feb 06, 1986
AP	!		EQ 40MG BASE/ML	A062366 001	Aug 04, 1983
AP		HOSPIRA	EQ 10MG BASE/ML	A062420 001	Aug 15, 1983
AP			EQ 10MG BASE/ML	A062612 004	Feb 20, 1986
AP			EQ 40MG BASE/ML	A062420 002	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373 007	Sep 07, 1982
AP			EQ 1.6MG BASE/ML	A062373 008	Sep 07, 1982
AP			EQ 80MG BASE/100ML	A062373 002	Sep 07, 1982
AP			EQ 100MG BASE/100ML	A062373 005	Sep 07, 1982
AP		HOSPIRA	EQ 1.2MG BASE/ML	A062414 001	Aug 15, 1983
AP			EQ 1.6MG BASE/ML	A062414 003	Aug 15, 1983
AP			EQ 80MG BASE/100ML	A062414 008	Aug 15, 1983
AP			EQ 100MG BASE/100ML	A062414 010	Aug 15, 1983
	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373 009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373 006	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	!	AKORN	EQ 0.3% BASE	A064093 001	Aug 31, 1995
AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024 001	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533 001	Oct 05, 1984
AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062351 001	Feb 18, 1982
AT		TARO	EQ 0.1% BASE	A062477 001	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	!	ALLERGAN	EQ 0.3% BASE	A062452 001	Oct 10, 1984
-----------	----------	----------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GENTAK

AT	AKORN	EQ 0.3% BASE	A064163 001	Oct 12, 2001
-----------	-------	---------------------	--------------------	--------------

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	A062635 001	Jan 08, 1987
-----------	-------	---------------------	--------------------	--------------

AT	BAUSCH AND LOMB	EQ 0.3% BASE	A064048 001	May 11, 1994
-----------	-----------------	---------------------	--------------------	--------------

AT	PERRIGO CO	EQ 0.3% BASE	A065121 001	Jan 30, 2004
-----------	------------	---------------------	--------------------	--------------

AT	TENNESSEE			
-----------	-----------	--	--	--

AT	SANDOZ INC	EQ 0.3% BASE	A062196 001	
-----------	------------	---------------------	--------------------	--

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;0.6%	N050612 001	Dec 01, 1989
---	----------	-------------------	-------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;1%	N050586 001	Jun 10, 1988
---	----------	-----------------	-------------	--------------

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002
-----------	---	-----------------	----------------	--------------------	--------------

AP	+		40MG/ML	N020622 003	Jan 28, 2014
-----------	---	--	----------------	--------------------	--------------

GLATIRAMER ACETATE

AP	MYLAN PHARMS INC	20MG/ML	A091646 001	Oct 03, 2017
-----------	------------------	----------------	--------------------	--------------

AP		40MG/ML	A206936 001	Oct 03, 2017
-----------	--	----------------	--------------------	--------------

GLATOPIA

AP	SANDOZ INC	20MG/ML	A090218 001	Apr 16, 2015
-----------	------------	----------------	--------------------	--------------

GLECAPREVIR; PIBRENTASVIR

TABLET;ORAL

MAVYRET

+	ABBVIE INC	100MG;40MG	N209394 001	Aug 03, 2017
---	------------	------------	-------------	--------------

GLIMEPIRIDE

TABLET;ORAL

AMARYL

AB	+	SANOFI AVENTIS US	1MG	N020496 001	Nov 30, 1995
-----------	---	-------------------	------------	--------------------	--------------

AB	+		2MG	N020496 002	Nov 30, 1995
-----------	---	--	------------	--------------------	--------------

AB	+		4MG	N020496 003	Nov 30, 1995
-----------	---	--	------------	--------------------	--------------

GLIMEPIRIDE

AB	ACCORD HLTHCARE	1MG	A078181 001	Aug 23, 2007
-----------	-----------------	------------	--------------------	--------------

AB		2MG	A078181 002	Aug 23, 2007
-----------	--	------------	--------------------	--------------

AB		4MG	A078181 003	Aug 23, 2007
-----------	--	------------	--------------------	--------------

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012
-----------	----------------------	------------	--------------------	--------------

AB		2MG	A202759 002	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB		4MG	A202759 003	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB	CARLSBAD	1MG	A077911 001	Sep 22, 2009
-----------	----------	------------	--------------------	--------------

AB		2MG	A077911 002	Sep 22, 2009
-----------	--	------------	--------------------	--------------

AB		4MG	A077911 003	Sep 22, 2009
-----------	--	------------	--------------------	--------------

AB	DR REDDYS LABS LTD	1MG	A077091 001	Oct 06, 2005
-----------	--------------------	------------	--------------------	--------------

AB		2MG	A077091 002	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB		4MG	A077091 003	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB	INDOCO REMEDIES	1MG	A202112 001	Apr 17, 2013
-----------	-----------------	------------	--------------------	--------------

AB		2MG	A202112 002	Apr 17, 2013
-----------	--	------------	--------------------	--------------

AB		4MG	A202112 003	Apr 17, 2013
-----------	--	------------	--------------------	--------------

AB	INVAGEN PHARMS	1MG	A077295 001	Oct 06, 2005
-----------	----------------	------------	--------------------	--------------

AB		2MG	A077295 002	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB		4MG	A077295 003	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB	MYLAN	1MG	A077624 001	Nov 28, 2005
-----------	-------	------------	--------------------	--------------

AB		2MG	A077624 002	Nov 28, 2005
-----------	--	------------	--------------------	--------------

AB		4MG	A077624 003	Nov 28, 2005
-----------	--	------------	--------------------	--------------

AB	PRINSTON INC	1MG	A077370 001	Dec 23, 2005
-----------	--------------	------------	--------------------	--------------

AB		2MG	A077370 002	Dec 23, 2005
-----------	--	------------	--------------------	--------------

AB		4MG	A077370 003	Dec 23, 2005
-----------	--	------------	--------------------	--------------

AB		8MG	A077370 004	Dec 23, 2005
-----------	--	------------	--------------------	--------------

AB	TEVA	1MG	A076802 001	Oct 06, 2005
-----------	------	------------	--------------------	--------------

AB		2MG	A076802 002	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB		4MG	A076802 003	Oct 06, 2005
-----------	--	------------	--------------------	--------------

AB	VIVA HLTHCARE	1MG	A091220 001	Jun 29, 2012
-----------	---------------	------------	--------------------	--------------

AB		2MG	A091220 002	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB		4MG	A091220 004	Jun 29, 2012
-----------	--	------------	--------------------	--------------

AB		8MG	A091220 006	Jun 29, 2012
-----------	--	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

3MG

A091220 003 Jun 29, 2012

6MG

A091220 005 Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT**AB** +! TAKEDA PHARMS USA **2MG;30MG****N021925 001** Jul 28, 2006**AB** + **4MG;30MG****N021925 002** Jul 28, 2006PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE**AB** SANDOZ **2MG;30MG****A201049 001** Jan 04, 2013**AB** **4MG;30MG****A201049 002** Jan 04, 2013GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

! TEVA PHARMS USA 1MG;4MG

A078709 001 Apr 01, 2016

2MG;4MG

A078709 002 Apr 01, 2016

2MG;8MG

A078709 004 Apr 01, 2016

4MG;4MG

A078709 003 Apr 01, 2016

4MG;8MG

A078709 005 Apr 01, 2016

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE**AB** ACCORD HLTHCARE **5MG****A074550 001** Sep 11, 1997**AB** **10MG****A074550 002** Sep 11, 1997**AB** ANI PHARMS INC **5MG****A074497 001** Aug 31, 1995**AB** **10MG****A074497 002** Aug 31, 1995**AB** APOTEX **5MG****A075795 001** Jun 13, 2001**AB** **10MG****A075795 002** Jun 13, 2001**AB** MYLAN **5MG****A074226 001** May 10, 1994**AB** **10MG****A074226 002** May 10, 1994**AB** SANDOZ **5MG****A074305 001** Apr 07, 1995**AB** **10MG****A074305 002** Apr 07, 1995**AB** SUN PHARM INDS INC **5MG****A077820 001** Jul 11, 2006**AB** **10MG****A077820 002** Jul 11, 2006**AB** WATSON LABS TEVA **5MG****A074223 001** Feb 27, 1995**AB** **10MG****A074223 002** Feb 27, 1995GLUCOTROL**AB** + PFIZER **5MG****N017783 001** May 08, 1984**AB** +! **10MG****N017783 002** May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE**AB** AUROBINDO PHARMA LTD **2.5MG****A206928 001** May 12, 2017**AB** **5MG****A206928 002** May 12, 2017**AB** **10MG****A206928 003** May 12, 2017**AB** MYLAN PHARMS INC **2.5MG****A202298 001** May 19, 2015**AB** **5MG****A202298 002** May 19, 2015**AB** **10MG****A202298 003** May 19, 2015**AB** PAR PHARM **5MG****A076159 002** Sep 20, 2013**AB** **10MG****A076159 001** Sep 20, 2013**AB** UNIQUE PHARM LABS **2.5MG****A204720 001** Dec 29, 2016**AB** **5MG****A204720 002** Dec 29, 2016**AB** **10MG****A204720 003** Dec 29, 2016**AB** WATSON LABS **2.5MG****A076467 003** Mar 27, 2006**AB** **5MG****A076467 001** Sep 08, 2003**AB** **10MG****A076467 002** Nov 07, 2003GLUCOTROL XL**AB** + PFIZER **2.5MG****N020329 003** Aug 10, 1999**AB** + **5MG****N020329 001** Apr 26, 1994**AB** +! **10MG****N020329 002** Apr 26, 1994GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE**AB** EPIC PHARMA LLC **2.5MG;250MG****A077507 001** Oct 27, 2005**AB** **2.5MG;500MG****A077507 002** Oct 27, 2005**AB** **5MG;500MG****A077507 003** Oct 27, 2005**AB** HERITAGE PHARMS INC **2.5MG;250MG****A078728 001** Jun 23, 2010**AB** **2.5MG;500MG****A078728 002** Jun 23, 2010**AB** **5MG;500MG****A078728 003** Jun 23, 2010

PRESCRIPTION DRUG PRODUCT LIST

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	MYLAN	<u>2.5MG;250MG</u>	<u>A078083 001</u>	Apr 12, 2007
AB		<u>2.5MG;500MG</u>	<u>A078083 002</u>	Apr 12, 2007
AB		<u>5MG;500MG</u>	<u>A078083 003</u>	Apr 12, 2007
AB	SUN PHARM INDS INC	<u>2.5MG;250MG</u>	<u>A077620 001</u>	Jan 11, 2008
AB		<u>2.5MG;500MG</u>	<u>A077620 002</u>	Jan 11, 2008
AB		<u>5MG;500MG</u>	<u>A077620 003</u>	Jan 11, 2008
AB	TEVA PHARMS	<u>2.5MG;250MG</u>	<u>A077270 001</u>	Oct 28, 2005
AB		<u>2.5MG;500MG</u>	<u>A077270 002</u>	Oct 28, 2005
AB	!	<u>5MG;500MG</u>	<u>A077270 003</u>	Oct 28, 2005
AB	ZYDUS PHARMS USA INC	<u>2.5MG;250MG</u>	<u>A078905 001</u>	Jan 31, 2011
AB		<u>2.5MG;500MG</u>	<u>A078905 002</u>	Jan 31, 2011
AB		<u>5MG;500MG</u>	<u>A078905 003</u>	Jan 31, 2011

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N201849 001 May 08, 2015

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL N020918 001 Jun 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+! LILLY 1MG/VIAL N020928 001 Sep 11, 1998

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

AB	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591 001</u>	Dec 22, 1997
AB		<u>3MG</u>	<u>A074591 002</u>	Dec 22, 1997
AB		<u>4.5MG</u>	<u>A074591 003</u>	Dec 22, 1997
AB		<u>6MG</u>	<u>A074591 004</u>	Dec 22, 1997
AB	HIKMA	<u>1.5MG</u>	<u>A075890 001</u>	Jul 31, 2003
AB		<u>3MG</u>	<u>A075890 002</u>	Jul 31, 2003
AB		<u>6MG</u>	<u>A075890 003</u>	Jul 31, 2003
AB	MYLAN	<u>1.5MG</u>	<u>A074792 001</u>	Jun 26, 1998
AB		<u>3MG</u>	<u>A074792 002</u>	Jun 26, 1998
AB		<u>6MG</u>	<u>A074792 003</u>	Aug 17, 1999
AB	TEVA	<u>1.5MG</u>	<u>A074686 001</u>	Apr 20, 1999
AB		<u>3MG</u>	<u>A074686 002</u>	Apr 20, 1999
AB		<u>4.5MG</u>	<u>A074686 003</u>	Apr 20, 1999
AB		<u>6MG</u>	<u>A074686 004</u>	Apr 20, 1999

GLYNASE

AB	+ PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051 001</u>	Mar 04, 1992
AB	+	<u>3MG</u>	<u>N020051 002</u>	Mar 04, 1992
AB	+!	<u>6MG</u>	<u>N020051 004</u>	Sep 24, 1993

GLYBURIDE

AB1	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537 001</u>	Oct 18, 2007
AB1		<u>2.5MG</u>	<u>A077537 002</u>	Oct 18, 2007
AB1		<u>5MG</u>	<u>A077537 003</u>	Oct 18, 2007
AB1	EPIC PHARMA LLC	<u>1.25MG</u>	<u>A076257 001</u>	Jun 27, 2002
AB1		<u>2.5MG</u>	<u>A076257 002</u>	Jun 27, 2002
AB1		<u>5MG</u>	<u>A076257 003</u>	Jun 27, 2002
AB1	HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937 001</u>	Feb 28, 2011
AB1		<u>2.5MG</u>	<u>A090937 002</u>	Feb 28, 2011
AB1		<u>5MG</u>	<u>A090937 003</u>	Feb 28, 2011
AB1	PHARMADAX INC	<u>1.25MG</u>	<u>A203581 001</u>	Apr 14, 2016
AB1		<u>2.5MG</u>	<u>A203581 002</u>	Apr 14, 2016
AB1		<u>5MG</u>	<u>A203581 003</u>	Apr 14, 2016
AB1	TEVA	<u>1.25MG</u>	<u>A074388 001</u>	Aug 29, 1995
AB1		<u>2.5MG</u>	<u>A074388 002</u>	Aug 29, 1995
AB1	!	<u>5MG</u>	<u>A074388 003</u>	Aug 29, 1995
AB1	ZYDUS PHARMS USA INC	<u>1.25mg</u>	<u>A206749 001</u>	May 10, 2016
AB1		<u>2.5mg</u>	<u>A206749 002</u>	May 10, 2016
AB1		<u>5MG</u>	<u>A206749 003</u>	May 10, 2016

PRESCRIPTION DRUG PRODUCT LIST

GLYBURIDE

TABLET; ORAL

DIABETA

<u>AB2</u>	+	SANOFI AVENTIS US	<u>1.25MG</u>	<u>N017532</u>	<u>001</u>	May 01, 1984
<u>AB2</u>	+		<u>2.5MG</u>	<u>N017532</u>	<u>002</u>	May 01, 1984
<u>AB2</u>	+	!	<u>5MG</u>	<u>N017532</u>	<u>003</u>	May 01, 1984

GLYBURIDE

<u>AB2</u>		IMPAX LABS INC	<u>1.25MG</u>	<u>A206079</u>	<u>001</u>	Sep 30, 2015
<u>AB2</u>			<u>2.5MG</u>	<u>A206079</u>	<u>002</u>	Sep 30, 2015
<u>AB2</u>			<u>5MG</u>	<u>A206079</u>	<u>003</u>	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>		AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		!	<u>2.5MG;500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>			<u>5MG;500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>		HERITAGE PHARMS INC	<u>1.25MG;250MG</u>	<u>A079009</u>	<u>001</u>	Jun 03, 2009
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A079009</u>	<u>002</u>	Jun 03, 2009
<u>AB</u>			<u>5MG;500MG</u>	<u>A079009</u>	<u>003</u>	Jun 03, 2009
<u>AB</u>		IMPAX LABS INC	<u>1.25MG;250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>			<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004
<u>AB</u>		ZYDUS PHARMS USA INC	<u>1.25MG;250MG</u>	<u>A206748</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A206748</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>			<u>5MG;500MG</u>	<u>A206748</u>	<u>003</u>	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	!	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013
---	---	---------------------	----------	---------	-----	--------------

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>	
-----------	--	-----------------	--------------------	----------------	------------	--

GLYCINE 1.5% IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>	
<u>AT</u>		ICU MEDICAL INC	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>		AMNEAL PHARMS CO	<u>0.2MG/ML</u>	<u>A208973</u>	<u>001</u>	Jun 15, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>0.2MG/ML</u>	<u>A209328</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>		!	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
<u>AP</u>		LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
<u>AP</u>		SOMERSET THERAPS LLC	<u>0.2MG/ML</u>	<u>A207639</u>	<u>001</u>	Jun 23, 2017

POWDER; INHALATION

SEEBRI

+	!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015
---	---	---------------------	-------------	---------	-----	--------------

SOLUTION; INHALATION

LONHALA MAGNAIR KIT

+	!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017
---	---	---------------	----------	---------	-----	--------------

SOLUTION; ORAL

CUVPOSA

+	!	MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010
---	---	-------------	---------	---------	-----	--------------

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>		APPCO PHARMA LLC	<u>1MG</u>	<u>A207201</u>	<u>001</u>	Jan 03, 2017
<u>AA</u>			<u>2MG</u>	<u>A207201</u>	<u>002</u>	Jan 03, 2017
<u>AA</u>		AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>			<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>		LEADING PHARMA LLC	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>			<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012
<u>AA</u>		NATCO PHARMA LTD	<u>1MG</u>	<u>A091413</u>	<u>001</u>	Jun 20, 2016
<u>AA</u>			<u>2MG</u>	<u>A091413</u>	<u>002</u>	Jun 20, 2016
<u>AA</u>		PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>			<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006

PRESCRIPTION DRUG PRODUCT LIST

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	RISING PHARMS INC	<u>1MG</u>	<u>A040821 001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821 002</u>	Dec 29, 2008
<u>AA</u>	SANTOS BIOTECH	<u>1MG</u>	<u>A091182 001</u>	Feb 03, 2014
<u>AA</u>		<u>2MG</u>	<u>A091182 002</u>	Feb 03, 2014
<u>AA</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844 001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844 002</u>	Aug 18, 2009
<u>AA</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A090020 001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020 002</u>	Oct 19, 2011

ROBINUL

<u>AA</u>	+! CASPER PHARMA LLC	<u>1MG</u>	<u>N012827 001</u>	
-----------	----------------------	------------	--------------------	--

ROBINUL FORTE

<u>AA</u>	+! CASPER PHARMA LLC	<u>2MG</u>	<u>N012827 002</u>	
-----------	----------------------	------------	--------------------	--

GLYCOPYRROLATE

	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012
--	---------------	-------	-------------	--------------

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

	+! SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930 001	Oct 29, 2015
--	------------------------	--------------------------	-------------	--------------

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+! FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016 007</u>	
-----------	------------	--------------------------	--------------------	--

<u>AP</u>	+! FRESENIUS KABI USA	<u>10,000 UNITS/VIAL</u>	<u>N017067 002</u>	
-----------	-----------------------	--------------------------	--------------------	--

PREGNYL

<u>AP</u>	+! ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692 001</u>	
-----------	--------------------	--------------------------	--------------------	--

CHORIONIC GONADOTROPIN

	+! FERRING	5,000 UNITS/VIAL	N017016 006	
--	------------	------------------	-------------	--

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+! TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726 001	Dec 29, 1989
--	------------------------	---------------	-------------	--------------

	+!	EQ 10.8MG BASE	N020578 001	Jan 11, 1996
--	----	----------------	-------------	--------------

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	AMRING PHARMS	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A065187 001</u>	Oct 28, 2005
-----------	---------------	---	--------------------	--------------

<u>AT</u>	! BAUSCH AND LOMB	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A064047 001</u>	Jan 31, 1996
-----------	-------------------	---	--------------------	--------------

NEOSPORIN

<u>AT</u>	! MONARCH PHARMS	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A060582 001</u>	
-----------	------------------	---	--------------------	--

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+! KYOWA KIRIN	3.1MG/24HR	N022198 001	Sep 12, 2008
--	----------------	------------	-------------	--------------

INJECTION, EXTENDED RELEASE; SUBCUTANEOUS

SUSTOL

	+! HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445 001	Aug 09, 2016
--	----------------------	-------------------------	-------------	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119 001</u>	Sep 10, 2009
-----------	-----------	--	--------------------	--------------

<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078 001</u>	Sep 14, 2009
-----------	--	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078 002</u>	Sep 14, 2009
-----------	--	---	--------------------	--------------

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A204238 001</u>	Jul 06, 2016
-----------	----------------------	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204238 002</u>	Jul 06, 2016
-----------	--	---	--------------------	--------------

<u>AP</u>	BIONPHARMA INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863 001</u>	Jun 30, 2008
-----------	----------------	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880 001</u>	Jun 30, 2008
-----------	--	---	--------------------	--------------

<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262 001</u>	Dec 31, 2007
-----------	-----------	--	--------------------	--------------

<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258 001</u>	Jun 30, 2008
-----------	--	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258 002</u>	Jun 30, 2008
-----------	--	---	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522 001</u>	Dec 31, 2007
-----------	--------------------	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090 001</u>	Jun 30, 2008
-----------	--	---	--------------------	--------------

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629 001</u>	Dec 23, 2009
-----------	--------------------	--	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629 002</u>	Dec 23, 2009
-----------	--	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274 001</u>	Sep 22, 2010
AP	MYLAN ASI	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137 002</u>	Apr 09, 2010
AP	MYLAN LABS LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A203454 001</u>	Apr 04, 2017
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A203454 002</u>	Apr 04, 2017
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A203453 001</u>	Jan 31, 2017
AP	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136 001</u>	Apr 09, 2010
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136 002</u>	Apr 09, 2010
AP	SANDOZ INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534 001</u>	Apr 30, 2009
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531 001</u>	Apr 30, 2009
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835 001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531 002</u>	Apr 30, 2009
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835 002</u>	Jun 30, 2008
AP	! TEVA PHARMS USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392 001</u>	Dec 31, 2007
AP	!	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963 001</u>	Jan 03, 2008
AP	!	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297 001</u>	Jun 30, 2008
AP	WEST-WARD PHARMS INT	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913 001</u>	Jun 26, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186 001</u>	Jun 30, 2008
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187 001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177 001</u>	Dec 31, 2007
AP	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	BIONPHARMA INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
AP	! FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
AB	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
AB	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
AB	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725 001</u>	Jan 30, 2008
AB	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
AB	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
AB	TARO PHARM	<u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010
AB	! TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080 001</u>	Dec 31, 2007
AB	WEST-WARD PHARMS INT	<u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

AB	! ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
AB	CHARTWELL RX	<u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
AB	CIPLA LTD	<u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
AB	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

AB	! SANDOZ INC	<u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
AB	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
	SANDOZ INC	<u>250MG</u>	<u>A091592 001</u>	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

AB	+ VALEANT PHARMS INC	<u>125MG</u>	<u>N050475 001</u>	
AB	+!	<u>250MG</u>	<u>N050475 002</u>	

GRISEOFULVIN, ULTRAMICROSIZE

AB	COREPHARMA	<u>125MG</u>	<u>A204371 001</u>	Jan 09, 2014
AB		<u>250MG</u>	<u>A204371 002</u>	Jan 09, 2014

GRISEOFULVIN, ULTRAMICROSIZE

AB	SIGMAPHARM LABS LLC	<u>125MG</u>	<u>A202545 001</u>	Oct 22, 2012
AB		<u>250MG</u>	<u>A202545 002</u>	Oct 22, 2012

PRESCRIPTION DRUG PRODUCT LIST

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

MISSION PHARMACAL 200MG/5ML; 2.5MG/5ML
CO

N022424 001 May 14, 2015

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+! MISSION PHARMACAL 200MG/5ML; 2.5MG/5ML; 30MG/5ML
CO

N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

ANI PHARMS INC EQ 4MG BASE
! EQ 8MG BASEA074149 001 Apr 07, 1995
A074149 002 Apr 07, 1995GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109 001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109 002</u>	Nov 25, 1998
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 1MG BASE</u>	<u>A074673 001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673 002</u>	Feb 28, 1997
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A074796 001</u>	Jan 27, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074796 002</u>	Jan 27, 1997
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145 001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145 002</u>	Oct 17, 1995
<u>TENEX</u>				
<u>AB</u>	+ PROMIUS PHARMA	<u>EQ 1MG BASE</u>	<u>N019032 001</u>	Oct 27, 1986
<u>AB</u>	+!	<u>EQ 2MG BASE</u>	<u>N019032 002</u>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A200881 001</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A200881 002</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A200881 003</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200881 004</u>	Oct 05, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202578 001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202578 002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A202578 003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202578 004</u>	Jun 02, 2015
<u>AB</u>	SANDOZ INC	<u>EQ 1MG BASE</u>	<u>A202568 001</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202568 002</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A202568 003</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202568 004</u>	Jun 03, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 1MG BASE</u>	<u>A205689 001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205689 002</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205689 003</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205689 004</u>	Nov 16, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 1MG BASE</u>	<u>A201382 001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201382 002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201382 003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201382 004</u>	Jun 02, 2015
<u>AB</u>	TWI PHARMS INC	<u>EQ 1MG BASE</u>	<u>A201408 001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201408 002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201408 003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201408 004</u>	Jun 02, 2015
<u>INTUNIV</u>				
<u>AB</u>	+ SHIRE	<u>EQ 1MG BASE</u>	<u>N022037 001</u>	Sep 02, 2009
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N022037 002</u>	Sep 02, 2009
<u>AB</u>	+	<u>EQ 3MG BASE</u>	<u>N022037 003</u>	Sep 02, 2009
<u>AB</u>	+!	<u>EQ 4MG BASE</u>	<u>N022037 004</u>	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE
MERCK SHARP DOHME

125MG

N001546 001

PRESCRIPTION DRUG PRODUCT LIST

HALCINONIDE

CREAM; TOPICAL

HALOG

+! RANBAXY 0.1% N017556 001

OINTMENT; TOPICAL

HALOG

+! SUN PHARM INDS INC 0.1% N017824 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A077001 001</u>	Dec 16, 2004
<u>AB</u>	! G AND W LABS	<u>0.05%</u>	<u>A078162 001</u>	Apr 24, 2007
<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077123 001</u>	Dec 16, 2004
<u>AB</u>	TARO	<u>0.05%</u>	<u>A077227 001</u>	Aug 04, 2005

ULTRAVATE

<u>AB</u>	+ SUN PHARM INDS LTD	<u>0.05%</u>	<u>N019967 001</u>	Dec 27, 1990
-----------	----------------------	--------------	--------------------	--------------

LOTION; TOPICAL

ULTRAVATE

	+! SUN PHARM INDUSTRIES	0.05%	N208183 001	Nov 06, 2015
--	-------------------------	-------	-------------	--------------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	! G AND W LABS	<u>0.05%</u>	<u>A077721 001</u>	Sep 07, 2006
<u>AB</u>	G AND W LABS INC	<u>0.05%</u>	<u>A077109 001</u>	Jun 14, 2005
<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A076872 001</u>	Dec 16, 2004
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076994 001</u>	Dec 16, 2004

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019968 001</u>	Dec 17, 1990
-----------	-----------	--------------	--------------------	--------------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278 006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278 004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278 001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278 005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278 002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278 003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206 001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207 001</u>	Nov 17, 1986
<u>AB</u>	!	<u>2MG</u>	<u>A071208 001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209 001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210 001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211 001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580 003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580 004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580 005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+! JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701 001</u>	Jan 14, 1986
<u>AO</u>	+!	<u>EQ 100MG BASE/ML</u>	<u>N018701 002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893 001</u>	Dec 19, 1997
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893 002</u>	Dec 19, 1997
<u>AO</u>	GLAND PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A205241 001</u>	May 12, 2017
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A205241 002</u>	May 12, 2017
<u>AO</u>	MYLAN LABS LTD	<u>EQ 50MG BASE/ML</u>	<u>A075440 001</u>	Feb 28, 2000
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440 002</u>	Feb 28, 2000
<u>AO</u>	TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393 001</u>	May 11, 1999
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393 002</u>	May 11, 1999
<u>AO</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074811 001</u>	Jan 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305 001</u>	Sep 28, 1998

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037 001</u>	Feb 26, 1993
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364 001</u>	Sep 28, 1993
<u>AA</u>	! TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617 001</u>	Dec 01, 1988

PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	<u>+!</u>	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
<u>HALOPERIDOL</u>						
<u>AP</u>		AKORN	<u>EQ 5MG BASE/ML</u>	<u>A204849</u>	<u>001</u>	Sep 06, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	<u>+!</u>	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A206552</u>	<u>001</u>	Jun 10, 2016
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	<u>+!</u>		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>		GLAND PHARMA LTD	<u>5,000 UNITS/ML</u>	<u>A205323</u>	<u>001</u>	Feb 06, 2017
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>		MYLAN LABS LTD	<u>1,000 UNITS/ML</u>	<u>A203851</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A203851</u>	<u>002</u>	Nov 30, 2017
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203851</u>	<u>003</u>	Nov 30, 2017
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203852</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091659</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202733</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202957</u>	<u>002</u>	Jun 12, 2014
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203198</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203198</u>	<u>002</u>	Jun 12, 2014
<u>AP</u>	<u>+!</u>	WEST-WARD PHARMS INT	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>+!</u>	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>		HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>+!</u>	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>+!</u>	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985
<u>AP</u>			<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989
<u>AP</u>			<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>+!</u>	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985

PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	N017029 010	Apr 28, 1986
AP		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	A090810 001	Jun 30, 2010
AP		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	A202732 001	Jun 12, 2014
HEPARIN SODIUM					
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100 001	Apr 28, 1983
	+	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011
	+		5,000 UNITS/ML	N201370 002	Jul 21, 2011
	+		10,000 UNITS/ML	N201370 003	Jul 21, 2011
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
		HOSPIRA	5,000 UNITS/100ML	N019339 001	Mar 27, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
		HOSPIRA	5,000 UNITS/100ML	N018916 006	Jan 31, 1984
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
		HOSPIRA	5,000 UNITS/100ML	N018916 007	Jan 31, 1984
			10,000 UNITS/100ML	N018916 008	Jan 31, 1984
HEPARIN SODIUM PRESERVATIVE FREE					
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 019	Nov 22, 2010
	!	HOSPIRA	10,000 UNITS/ML	A089522 001	May 04, 1987
	+	PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE; TOPICAL

PRE-OP

AT	+	DAVIS AND GECK	<u>480MG</u>	N017433 001	
-----------	---	----------------	--------------	--------------------	--

PRE-OP II

AT	+	DAVIS AND GECK	<u>480MG</u>	N017433 002	
-----------	---	----------------	--------------	--------------------	--

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010
--	---	---------------	------------	-------------	--------------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

	+	ENDO PHARM	50MG	N022058 001	May 03, 2007
--	---	------------	------	-------------	--------------

VANTAS

	+	ENDO PHARM	50MG	N021732 001	Oct 12, 2004
--	---	------------	------	-------------	--------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	<u>1.5MG/5ML; 5MG/5ML</u>	A207487 001	Feb 21, 2017
AA		ACTAVIS MID ATLANTIC	<u>1.5MG/5ML; 5MG/5ML</u>	A088017 001	Jul 05, 1983
AA		BIO-PHARM INC	<u>1.5MG/5ML; 5MG/5ML</u>	A204765 001	Mar 06, 2017
AA	!	HI TECH PHARMA	<u>1.5MG/5ML; 5MG/5ML</u>	A040613 001	Feb 08, 2008
AA		NOVEL LABS INC	<u>1.5MG/5ML; 5MG/5ML</u>	A203535 001	Feb 13, 2017
AA		PADDOCK LLC	<u>1.5MG/5ML; 5MG/5ML</u>	A205731 001	Feb 15, 2017
AA		WOCKHARDT BIO AG	<u>1.5MG/5ML; 5MG/5ML</u>	A088008 001	Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA		AVANTHI INC	<u>1.5MG; 5MG</u>	A207176 001	Aug 07, 2017
AA		NOVEL LABS INC	<u>1.5MG; 5MG</u>	A091528 001	Apr 20, 2011
TUSSIGON					
AA	!	KING PHARMS	<u>1.5MG; 5MG</u>	A088508 001	Jul 30, 1985

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

	+	AMPHASTAR PHARM	150 UNITS/ML	N021665 001	Oct 26, 2004
--	---	-----------------	--------------	-------------	--------------

VITRASE

	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640 002	Dec 02, 2004
--	---	-----------------	----------------	-------------	--------------

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

	+	HALOZYME THERAP	150 UNITS/ML	N021859 001	Dec 02, 2005
--	---	-----------------	--------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	!	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>		FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>		LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997
<u>AP</u>		MYLAN INSTITUTIONAL	<u>20MG/ML</u>	<u>A204680</u>	<u>001</u>	Apr 28, 2016
<u>AP</u>		NAVINTA LLC	<u>20MG/ML</u>	<u>A202938</u>	<u>001</u>	Mar 28, 2013
<u>AP</u>		X-GEN PHARMS INC	<u>20MG/ML</u>	<u>A203110</u>	<u>001</u>	Jun 29, 2015

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>		ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AA</u>			<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AA</u>			<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AA</u>			<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012
<u>AA</u>		CADILA PHARMS LTD	<u>25MG</u>	<u>A203845</u>	<u>001</u>	Sep 18, 2014
<u>AA</u>			<u>50MG</u>	<u>A203845</u>	<u>002</u>	Sep 18, 2014
<u>AA</u>			<u>100MG</u>	<u>A203845</u>	<u>003</u>	Sep 18, 2014
<u>AA</u>		GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>			<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>			<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>			<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>		HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>			<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>			<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>		HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>			<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>			<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>			<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>		INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>			<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>			<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>			<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>		PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>			<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>			<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>			<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	!	PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	!		<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!		<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!		<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>		STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>			<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>			<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013
<u>AA</u>		TECH ORGANIZED	<u>10MG</u>	<u>A205236</u>	<u>001</u>	May 26, 2017
<u>AA</u>			<u>25MG</u>	<u>A205236</u>	<u>002</u>	May 26, 2017
<u>AA</u>			<u>50MG</u>	<u>A205236</u>	<u>003</u>	May 26, 2017
<u>AA</u>			<u>100MG</u>	<u>A205236</u>	<u>004</u>	May 26, 2017

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

		PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
	!		50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

	+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
--	---	------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>		APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>		IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>		PRINSTON INC	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>		SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
-----------	---------	---------------	----------------	------------	--------------

MICROZIDE

AB	+! ALLERGAN SALES LLC	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	-----------------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
-----------	-----------------	---------------	----------------	------------	--------------

AB		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
-----------	--	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
-----------	--	-------------	----------------	------------	--------------

AB	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
-----------	-------------------	---------------	----------------	------------	--------------

AB	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
-----------	--------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
-----------	--	-------------	----------------	------------	--------------

AB	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
-----------	------------------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
-----------	--	-------------	----------------	------------	--------------

AB	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
-----------	-----------------	-------------	----------------	------------	--

AB		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
-----------	--	-------------	----------------	------------	--

AB	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
-----------	---------------------	-------------	----------------	------------	--

AB		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
-----------	--	-------------	----------------	------------	--

AB	HIKMA INTL PHARMS	<u>50MG</u>	<u>A084878</u>	<u>001</u>	
-----------	-------------------	-------------	----------------	------------	--

AB	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
-----------	---------------	---------------	----------------	------------	--------------

AB		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
-----------	--	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
-----------	--	-------------	----------------	------------	--------------

AB	IVAX SUB TEVA	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
-----------	---------------	-------------	----------------	------------	--

AB	PHARMS				
-----------	--------	--	--	--	--

AB	!	<u>50MG</u>	<u>A083177</u>	<u>002</u>	
-----------	---	-------------	----------------	------------	--

AB	LEADING PHARMA LLC	<u>12.5MG</u>	<u>A040702</u>	<u>003</u>	May 10, 2017
-----------	--------------------	---------------	----------------	------------	--------------

AB		<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
-----------	--	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
-----------	--	-------------	----------------	------------	--------------

AB	MYLAN PHARMS INC	<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
-----------	------------------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
-----------	--	-------------	----------------	------------	--------------

AB	PRINSTON INC	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
-----------	--------------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002
-----------	--	-------------	----------------	------------	--------------

AB	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040857</u>	<u>001</u>	May 30, 2008
-----------	--------------------	---------------	----------------	------------	--------------

AB		<u>25MG</u>	<u>A040810</u>	<u>001</u>	Mar 27, 2007
-----------	--	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040810</u>	<u>002</u>	Mar 27, 2007
-----------	--	-------------	----------------	------------	--------------

AB	TECH ORGANIZED	<u>25MG</u>	<u>A203018</u>	<u>001</u>	Jul 23, 2014
-----------	----------------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A203018</u>	<u>002</u>	Jul 23, 2014
-----------	--	-------------	----------------	------------	--------------

AB	UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
-----------	---------	-------------	----------------	------------	--------------

AB		<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008
-----------	--	-------------	----------------	------------	--------------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+! SANOFI AVENTIS US	<u>12.5MG; 150MG</u>	<u>N020758</u>	<u>002</u>	Sep 30, 1997
-----------	----------------------	----------------------	----------------	------------	--------------

AB	+!	<u>12.5MG; 300MG</u>	<u>N020758</u>	<u>003</u>	Aug 31, 1998
-----------	----	----------------------	----------------	------------	--------------

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A091370</u>	<u>001</u>	Oct 15, 2012
-----------	--------------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A091370</u>	<u>002</u>	Oct 15, 2012
-----------	--	----------------------	----------------	------------	--------------

AB		<u>25MG; 300MG</u>	<u>A091370</u>	<u>003</u>	Oct 12, 2016
-----------	--	--------------------	----------------	------------	--------------

AB	APOTEX INC	<u>12.5MG; 150MG</u>	<u>A201505</u>	<u>001</u>	Oct 15, 2012
-----------	------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A201505</u>	<u>002</u>	Oct 15, 2012
-----------	--	----------------------	----------------	------------	--------------

AB	ATLAS PHARMS LLC	<u>12.5MG; 150MG</u>	<u>A203036</u>	<u>001</u>	Jan 15, 2016
-----------	------------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A203036</u>	<u>002</u>	Jan 15, 2016
-----------	--	----------------------	----------------	------------	--------------

AB		<u>25MG; 300MG</u>	<u>A203036</u>	<u>003</u>	Jan 15, 2016
-----------	--	--------------------	----------------	------------	--------------

AB	AUROBINDO PHARMA	<u>12.5MG; 150MG</u>	<u>A203630</u>	<u>001</u>	Feb 22, 2013
-----------	------------------	----------------------	----------------	------------	--------------

AB	LTD				
-----------	-----	--	--	--	--

AB		<u>12.5MG; 300MG</u>	<u>A203630</u>	<u>002</u>	Feb 22, 2013
-----------	--	----------------------	----------------	------------	--------------

AB		<u>25MG; 300MG</u>	<u>A203630</u>	<u>003</u>	Mar 31, 2016
-----------	--	--------------------	----------------	------------	--------------

AB	DR REDDYS LABS LTD	<u>12.5MG; 150MG</u>	<u>A203500</u>	<u>001</u>	Sep 27, 2012
-----------	--------------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A203500</u>	<u>002</u>	Sep 27, 2012
-----------	--	----------------------	----------------	------------	--------------

AB	HISUN PHARM	<u>12.5MG; 150MG</u>	<u>A207896</u>	<u>001</u>	Oct 14, 2016
-----------	-------------	----------------------	----------------	------------	--------------

AB	HANGZHOU				
-----------	----------	--	--	--	--

AB		<u>12.5MG; 300MG</u>	<u>A207896</u>	<u>002</u>	Oct 14, 2016
-----------	--	----------------------	----------------	------------	--------------

AB	LUPIN LTD	<u>12.5MG; 150MG</u>	<u>A201524</u>	<u>001</u>	Feb 27, 2013
-----------	-----------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A201524</u>	<u>002</u>	Feb 27, 2013
-----------	--	----------------------	----------------	------------	--------------

AB	MACLEODS PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A202414</u>	<u>001</u>	Sep 27, 2012
-----------	---------------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A202414</u>	<u>002</u>	Sep 27, 2012
-----------	--	----------------------	----------------	------------	--------------

AB	MYLAN PHARMS INC	<u>12.5MG; 150MG</u>	<u>A077969</u>	<u>001</u>	Sep 27, 2012
-----------	------------------	----------------------	----------------	------------	--------------

AB		<u>12.5MG; 300MG</u>	<u>A077969</u>	<u>002</u>	Sep 27, 2012
-----------	--	----------------------	----------------	------------	--------------

AB		<u>25MG; 300MG</u>	<u>A077969</u>	<u>003</u>	Jul 20, 2016
-----------	--	--------------------	----------------	------------	--------------

AB	PRINSTON INC	<u>12.5MG; 150MG</u>	<u>A203072</u>	<u>001</u>	May 09, 2014
-----------	--------------	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		<u>12.5MG;300MG</u>	<u>A203072 002</u>	May 09, 2014
AB	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446 001</u>	Sep 27, 2012
AB		<u>12.5MG;300MG</u>	<u>A077446 002</u>	Sep 27, 2012
AB	TEVA	<u>12.5MG;150MG</u>	<u>A077369 001</u>	Mar 30, 2012
AB		<u>12.5MG;300MG</u>	<u>A077369 002</u>	Mar 30, 2012
AB	UNICHEM LABS LTD	<u>12.5MG;150MG</u>	<u>A207018 001</u>	Sep 19, 2017
AB		<u>12.5MG;300MG</u>	<u>A207018 002</u>	Sep 19, 2017
AB	WEST-WARD PHARMS INT	<u>12.5MG;150MG</u>	<u>A090351 001</u>	Oct 15, 2012
AB		<u>12.5MG;300MG</u>	<u>A090351 002</u>	Oct 15, 2012
AB		<u>25MG;300MG</u>	<u>A090351 003</u>	Jun 08, 2017

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674 001</u>	Oct 05, 2004
AB		<u>12.5MG;20MG</u>	<u>A076674 002</u>	Oct 05, 2004
AB		<u>25MG;20MG</u>	<u>A076674 003</u>	Oct 05, 2004
AB	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606 001</u>	Mar 14, 2006
AB		<u>12.5MG;20MG</u>	<u>A077606 002</u>	Mar 14, 2006
AB		<u>25MG;20MG</u>	<u>A077606 003</u>	Mar 14, 2006
AB	HIKMA INTL PHARMS	<u>12.5MG;10MG</u>	<u>A076265 001</u>	Jul 08, 2002
AB		<u>12.5MG;20MG</u>	<u>A076265 002</u>	Jul 08, 2002
AB		<u>25MG;20MG</u>	<u>A076265 003</u>	Jul 08, 2002
AB	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A204058 001</u>	May 23, 2017
AB		<u>12.5MG;20MG</u>	<u>A204058 002</u>	May 23, 2017
AB		<u>25MG;20MG</u>	<u>A204058 003</u>	May 23, 2017
AB	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776 001</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A075776 002</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A075776 003</u>	Jul 01, 2002
AB	LUPIN	<u>12.5MG;10MG</u>	<u>A077912 001</u>	Sep 27, 2006
AB		<u>12.5MG;20MG</u>	<u>A077912 002</u>	Sep 27, 2006
AB		<u>25MG;20MG</u>	<u>A077912 003</u>	Sep 27, 2006
AB	MYLAN	<u>12.5MG;10MG</u>	<u>A076113 001</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A076113 002</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A076113 003</u>	Jul 01, 2002
AB	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230 001</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A076230 002</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A076230 003</u>	Jul 01, 2002
AB	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262 001</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A076262 002</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
AB	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007 001</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A076007 002</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A076007 003</u>	Jul 01, 2002
AB	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
AB		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
AB		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002
ZESTORETIC				
AB	+ ALVOGEN MALTA	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
AB	+!	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
AB	+!	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

AB	+ MERCK SHARP DOHME	<u>12.5MG;50MG</u>	<u>N020387 001</u>	Apr 28, 1995
AB	+	<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
AB	+!	<u>25MG;100MG</u>	<u>N020387 002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
AB		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
AB		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
AB	APOTEX	<u>12.5MG;50MG</u>	<u>A090150 001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A090150 002</u>	Aug 11, 2010
AB		<u>25MG;100MG</u>	<u>A090150 003</u>	Oct 06, 2010
AB	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
AB		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
AB		<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
AB	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		12.5MG;100MG	A201845 002	Sep 18, 2012
AB		25MG;100MG	A201845 003	Sep 18, 2012
AB	IPCA LABS LTD	12.5MG;50MG	A201682 001	Mar 01, 2013
AB		12.5MG;100MG	A201682 002	Mar 01, 2013
AB		25MG;100MG	A201682 003	Mar 01, 2013
AB	LUPIN LTD	12.5MG;50MG	A078245 001	Oct 06, 2010
AB		12.5MG;100MG	A078245 002	May 21, 2010
AB		25MG;100MG	A078245 003	Oct 06, 2010
AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012
AB		12.5MG;100MG	A202289 002	Aug 09, 2012
AB		25MG;100MG	A202289 003	Aug 09, 2012
AB	MYLAN	12.5MG;50MG	A091652 001	Oct 06, 2010
AB		12.5MG;100MG	A091652 002	Apr 06, 2010
AB		25MG;100MG	A091652 003	Oct 06, 2010
AB	PRINSTON INC	12.5MG;50MG	A204901 001	Nov 06, 2017
AB		12.5MG;100MG	A204901 002	Nov 06, 2017
AB		25MG;100MG	A204901 003	Nov 06, 2017
AB	SANDOZ	12.5MG;50MG	A077948 001	Oct 06, 2010
AB		12.5MG;100MG	A077948 003	Aug 19, 2010
AB		25MG;100MG	A077948 002	Oct 06, 2010
AB	TEVA PHARMS	12.5MG;50MG	A077157 001	Apr 06, 2010
AB		12.5MG;100MG	A077157 002	Apr 06, 2010
AB		25MG;100MG	A077157 003	Apr 06, 2010
AB	TORRENT PHARMS	12.5MG;50MG	A090528 001	Oct 06, 2010
AB		12.5MG;100MG	A090528 003	Apr 06, 2010
AB		25MG;100MG	A090528 002	Oct 06, 2010
AB	UNICHEM LABS LTD	12.5MG;50MG	A204832 001	Jul 21, 2017
AB		12.5MG;100MG	A204832 002	Jul 21, 2017
AB		25MG;100MG	A204832 003	Jul 21, 2017
AB	WEST-WARD PHARMS INT	12.5MG;50MG	A077732 002	Oct 06, 2010
AB		12.5MG;100MG	A077732 001	Apr 06, 2010
AB		25MG;100MG	A077732 003	Oct 06, 2010
AB	ZYDUS PHARMS USA INC	12.5MG;50MG	A078385 001	Oct 06, 2010
AB		25MG;100MG	A078385 002	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070265 002	Jan 23, 1986
!		25MG;250MG	A070265 001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

+	CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006
+		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006
+	!	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	+	US PHARMS HOLDINGS I	25MG;50MG	N018303 001	Dec 31, 1984
AB	+	!	25MG;100MG	N018303 002	Dec 31, 1984
<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>					
AB		ALEMBIC PHARMS LTD	25MG;50MG	A202870 001	Nov 06, 2013
AB			25MG;100MG	A202870 002	Nov 06, 2013
AB			50MG;100MG	A202870 003	Nov 06, 2013
AB		MYLAN	25MG;50MG	A076792 001	Aug 20, 2004
AB			25MG;100MG	A076792 002	Aug 20, 2004
AB			50MG;100MG	A076792 003	Aug 20, 2004
AB		SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012
AB			25MG;100MG	A090654 002	Jan 19, 2012
AB			50MG;100MG	A090654 003	Jan 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718 001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090718 002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG;15MG</u>	<u>A090718 003</u>	Mar 17, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>12.5MG;7.5MG</u>	<u>A202150 001</u>	Mar 07, 2014
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A202150 002</u>	Mar 07, 2014
<u>AB</u>		<u>25MG;15MG</u>	<u>A202150 003</u>	Mar 07, 2014
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980 001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980 003</u>	Mar 07, 2007
<u>AB</u>	!	<u>25MG;15MG</u>	<u>A076980 002</u>	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

<u>AB</u>	+	DAIICHI SANKYO	<u>12.5MG;20MG</u>	<u>N021532 002</u>	Jun 05, 2003
<u>AB</u>	+		<u>12.5MG;40MG</u>	<u>N021532 003</u>	Jun 05, 2003
<u>AB</u>	+	!	<u>25MG;40MG</u>	<u>N021532 005</u>	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;20MG</u>	<u>A204233 001</u>	Apr 24, 2017
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A204233 002</u>	Apr 24, 2017
<u>AB</u>		<u>25MG;40MG</u>	<u>A204233 003</u>	Apr 24, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG;20MG</u>	<u>A205391 001</u>	Apr 24, 2017
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A205391 002</u>	Apr 24, 2017
<u>AB</u>		<u>25MG;40MG</u>	<u>A205391 003</u>	Apr 24, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;20MG</u>	<u>A078827 001</u>	Oct 26, 2016
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A078827 002</u>	Oct 26, 2016
<u>AB</u>		<u>25MG;40MG</u>	<u>A078827 003</u>	Oct 26, 2016
<u>AB</u>	PRINSTON INC	<u>12.5MG;20MG</u>	<u>A207804 001</u>	Apr 24, 2017
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A207804 002</u>	Apr 24, 2017
<u>AB</u>		<u>25MG;40MG</u>	<u>A207804 003</u>	Apr 24, 2017
<u>AB</u>	TEVA PHARMS USA	<u>12.5MG;20MG</u>	<u>A200532 001</u>	Apr 24, 2017
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A200532 002</u>	Apr 24, 2017
<u>AB</u>		<u>25MG;40MG</u>	<u>A200532 003</u>	Apr 24, 2017
<u>AB</u>	TORRENT PHARMS LTD	<u>12.5MG;20MG</u>	<u>A206515 001</u>	May 03, 2017
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A206515 002</u>	May 03, 2017
<u>AB</u>		<u>25MG;40MG</u>	<u>A206515 003</u>	May 03, 2017

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG;40MG</u>	<u>A072042 001</u>	Mar 14, 1988	
<u>AB</u>		<u>25MG;80MG</u>	<u>A072043 001</u>	Mar 14, 1988	
<u>AB</u>	!	MYLAN	<u>25MG;40MG</u>	<u>A070947 002</u>	Mar 04, 1987
<u>AB</u>	!		<u>25MG;80MG</u>	<u>A070947 001</u>	Apr 01, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	+	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125 001</u>	Dec 28, 1999
<u>AB</u>	+		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125 002</u>	Dec 28, 1999
<u>AB</u>	+	!	<u>25MG;EQ 20MG BASE</u>	<u>N020125 003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524 001</u>	Mar 12, 2013
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A091524 002</u>	Mar 12, 2013
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A091524 003</u>	Mar 12, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450 001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078450 002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078450 003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A201356 001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A201356 002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A201356 003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093 001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A077093 002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A077093 003</u>	Mar 28, 2005

QUINARETIC

<u>AB</u>	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374 001</u>	Mar 31, 2004
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374 002</u>	Mar 31, 2004
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A076374 003</u>	Mar 31, 2004

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	+	GD SEARLE LLC	25MG; 25MG	<u>N012616</u>	<u>004</u>	Dec 30, 1982
-----------	----------	---------------	-------------------	-----------------------	-------------------	--------------

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	25MG; 25MG	<u>A086513</u>	<u>001</u>	
-----------	--	-------	-------------------	-----------------------	-------------------	--

AB		SUN PHARM INDUSTRIES	25MG; 25MG	<u>A089534</u>	<u>001</u>	Jul 02, 1987
-----------	--	-------------------------	-------------------	-----------------------	-------------------	--------------

ALDACTAZIDE

+	!	GD SEARLE LLC	50MG; 50MG	<u>N012616</u>	<u>005</u>	Dec 30, 1982
----------	----------	---------------	-------------------	-----------------------	-------------------	--------------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	+	BOEHRINGER INGELHEIM	12.5MG; 40MG	<u>N021162</u>	<u>001</u>	Nov 17, 2000
-----------	----------	-------------------------	---------------------	-----------------------	-------------------	--------------

AB	+		12.5MG; 80MG	<u>N021162</u>	<u>002</u>	Nov 17, 2000
-----------	----------	--	---------------------	-----------------------	-------------------	--------------

AB	+	!		<u>N021162</u>	<u>003</u>	Apr 19, 2004
-----------	----------	----------	--	-----------------------	-------------------	--------------

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG; 40MG	<u>A203010</u>	<u>001</u>	Feb 25, 2014
-----------	--	--------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A203010</u>	<u>002</u>	Feb 25, 2014
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A203010</u>	<u>003</u>	Feb 25, 2014
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		AUROBINDO PHARMA LTD	12.5MG; 40MG	<u>A208727</u>	<u>001</u>	Dec 15, 2016
-----------	--	-------------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A208727</u>	<u>002</u>	Dec 15, 2016
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A208727</u>	<u>003</u>	Dec 15, 2016
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		LUPIN LTD	12.5MG; 40MG	<u>A091351</u>	<u>001</u>	Aug 07, 2014
-----------	--	-----------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A091351</u>	<u>002</u>	Aug 07, 2014
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A091351</u>	<u>003</u>	Aug 07, 2014
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		MACLEODS PHARMS LTD	12.5MG; 40MG	<u>A204169</u>	<u>001</u>	Nov 02, 2015
-----------	--	---------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A204169</u>	<u>002</u>	Nov 02, 2015
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A204169</u>	<u>003</u>	Nov 02, 2015
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		MYLAN PHARMS INC	12.5MG; 40MG	<u>A091648</u>	<u>001</u>	Feb 25, 2014
-----------	--	------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A091648</u>	<u>002</u>	Feb 25, 2014
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A091648</u>	<u>003</u>	Feb 25, 2014
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		PRINSTON INC	12.5MG; 40MG	<u>A209028</u>	<u>001</u>	Nov 06, 2017
-----------	--	--------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A209028</u>	<u>002</u>	Nov 06, 2017
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A209028</u>	<u>003</u>	Nov 06, 2017
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		TORRENT PHARMS LTD	12.5MG; 40MG	<u>A201192</u>	<u>001</u>	Feb 25, 2014
-----------	--	--------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A201192</u>	<u>002</u>	Feb 25, 2014
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A201192</u>	<u>003</u>	Feb 25, 2014
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		ZYDUS PHARMS USA INC	12.5MG; 40MG	<u>A204221</u>	<u>001</u>	Aug 15, 2017
-----------	--	-------------------------	---------------------	-----------------------	-------------------	--------------

AB			12.5MG; 80MG	<u>A204221</u>	<u>002</u>	Aug 15, 2017
-----------	--	--	---------------------	-----------------------	-------------------	--------------

AB			25MG; 80MG	<u>A204221</u>	<u>003</u>	Aug 15, 2017
-----------	--	--	-------------------	-----------------------	-------------------	--------------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+	!	GLAXOSMITHKLINE LLC	25MG; 37.5MG	<u>N016042</u>	<u>003</u>	Mar 03, 1994
-----------	----------	----------	---------------------	---------------------	-----------------------	-------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED PHARMS BARR	25MG; 37.5MG	<u>A075052</u>	<u>001</u>	Jun 18, 1999
-----------	--	---------------------	---------------------	-----------------------	-------------------	--------------

AB		IVAX SUB TEVA PHARMS	25MG; 50MG	<u>A074259</u>	<u>001</u>	Mar 30, 1995
-----------	--	-------------------------	-------------------	-----------------------	-------------------	--------------

AB		LANNETT HOLDINGS INC	25MG; 37.5MG	<u>A201407</u>	<u>001</u>	Dec 09, 2011
-----------	--	-------------------------	---------------------	-----------------------	-------------------	--------------

AB		MYLAN	25MG; 37.5MG	<u>A074701</u>	<u>001</u>	Jun 07, 1996
-----------	--	-------	---------------------	-----------------------	-------------------	--------------

AB		SANDOZ	25MG; 37.5MG	<u>A074821</u>	<u>001</u>	Jun 05, 1997
-----------	--	--------	---------------------	-----------------------	-------------------	--------------

AB	!		25MG; 50MG	<u>A073191</u>	<u>001</u>	Jul 31, 1991
-----------	----------	--	-------------------	-----------------------	-------------------	--------------

TABLET; ORAL

MAXZIDE

AB	+	!	MYLAN PHARMS INC	50MG; 75MG	<u>N019129</u>	<u>001</u>	Oct 22, 1984
-----------	----------	----------	------------------	-------------------	-----------------------	-------------------	--------------

MAXZIDE-25

AB	+		MYLAN PHARMS INC	25MG; 37.5MG	<u>N019129</u>	<u>003</u>	May 13, 1988
-----------	----------	--	------------------	---------------------	-----------------------	-------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS INC	50MG; 75MG	<u>A073467</u>	<u>001</u>	Jan 31, 1996
-----------	--	----------------	-------------------	-----------------------	-------------------	--------------

AB		APOTEX INC	25MG; 37.5MG	<u>A071251</u>	<u>002</u>	May 05, 1998
-----------	--	------------	---------------------	-----------------------	-------------------	--------------

AB			50MG; 75MG	<u>A071251</u>	<u>001</u>	Apr 17, 1988
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		PLIVA	25MG; 37.5MG	<u>A074026</u>	<u>001</u>	Apr 26, 1996
-----------	--	-------	---------------------	-----------------------	-------------------	--------------

AB		SANDOZ	25MG; 37.5MG	<u>A073281</u>	<u>001</u>	Apr 30, 1992
-----------	--	--------	---------------------	-----------------------	-------------------	--------------

AB			50MG; 75MG	<u>A072011</u>	<u>001</u>	Jun 17, 1988
-----------	--	--	-------------------	-----------------------	-------------------	--------------

AB		WATSON LABS	25MG; 37.5MG	<u>A073449</u>	<u>001</u>	Sep 23, 1993
-----------	--	-------------	---------------------	-----------------------	-------------------	--------------

AB			50MG; 75MG	<u>A071851</u>	<u>001</u>	Nov 30, 1988
-----------	--	--	-------------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

<u>AB</u>	+	NOVARTIS	<u>12.5MG; 80MG</u>	<u>N020818</u>	<u>001</u>	Mar 06, 1998
<u>AB</u>	+		<u>12.5MG; 160MG</u>	<u>N020818</u>	<u>002</u>	Mar 06, 1998
<u>AB</u>	+		<u>12.5MG; 320MG</u>	<u>N020818</u>	<u>004</u>	Apr 28, 2006
<u>AB</u>	+		<u>25MG; 160MG</u>	<u>N020818</u>	<u>003</u>	Jan 17, 2002
<u>AB</u>	+	!	<u>25MG; 320MG</u>	<u>N020818</u>	<u>005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG; 80MG</u>	<u>A201662</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A201662</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A201662</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A201662</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A201662</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>		APOTEX INC	<u>12.5MG; 80MG</u>	<u>A203026</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A203026</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A203026</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A203026</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A203026</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG; 80MG</u>	<u>A202519</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A202519</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A202519</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A202519</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A202519</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>		LUPIN LTD	<u>12.5MG; 80MG</u>	<u>A078946</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A078946</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A078946</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A078946</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A078946</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>12.5MG; 80MG</u>	<u>A203145</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A203145</u>	<u>002</u>	Apr 19, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A203145</u>	<u>003</u>	Apr 19, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A203145</u>	<u>004</u>	Apr 19, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A203145</u>	<u>005</u>	Apr 19, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>12.5MG; 80MG</u>	<u>A078020</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A078020</u>	<u>002</u>	Sep 21, 2012
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A078020</u>	<u>004</u>	Sep 21, 2012
<u>AB</u>			<u>25MG; 160MG</u>	<u>A078020</u>	<u>003</u>	Sep 21, 2012
<u>AB</u>			<u>25MG; 320MG</u>	<u>A078020</u>	<u>005</u>	Sep 21, 2012
<u>AB</u>		PRINSTON INC	<u>12.5MG; 80MG</u>	<u>A206083</u>	<u>001</u>	Feb 08, 2016
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A206083</u>	<u>002</u>	Feb 08, 2016
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A206083</u>	<u>003</u>	Feb 08, 2016
<u>AB</u>			<u>25MG; 160MG</u>	<u>A206083</u>	<u>004</u>	Feb 08, 2016
<u>AB</u>			<u>25MG; 320MG</u>	<u>A206083</u>	<u>005</u>	Feb 08, 2016
<u>AB</u>		WATSON LABS TEVA	<u>12.5MG; 80MG</u>	<u>A091519</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 160MG</u>	<u>A091519</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG; 320MG</u>	<u>A091519</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 160MG</u>	<u>A091519</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG; 320MG</u>	<u>A091519</u>	<u>005</u>	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	!	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013
+			15MG	N202880	002	Oct 25, 2013
+			20MG	N202880	003	Oct 25, 2013
+			30MG	N202880	004	Oct 25, 2013
+			40MG	N202880	005	Oct 25, 2013
+			50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

+	!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
+			30MG	N206627	002	Nov 20, 2014
+			40MG	N206627	003	Nov 20, 2014
+			60MG	N206627	004	Nov 20, 2014
+			80MG	N206627	005	Nov 20, 2014
+			100MG	N206627	006	Nov 20, 2014
+			120MG	N206627	007	Nov 20, 2014

VANTRELA ER

+		TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017
+			30MG	N207975	002	Jan 17, 2017
+			45MG	N207975	003	Jan 17, 2017

PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

+ 60MG
+ 90MGN207975 004 Jan 17, 2017
N207975 005 Jan 17, 2017HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	ACTAVIS LABS FL INC	<u>7.5MG;200MG</u>	<u>A076604 001</u>	Dec 31, 2003
<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642 002</u>	Mar 18, 2004
<u>AB</u>	!	<u>7.5MG;200MG</u>	<u>A076642 001</u>	Oct 12, 2004
<u>AB</u>	AUROLIFE PHARMA LLC	<u>7.5MG;200MG</u>	<u>A204575 001</u>	Jun 02, 2016
<u>AB</u>	SUN PHARM INDS INC	<u>2.5MG;200MG</u>	<u>A091633 001</u>	May 28, 2013
<u>AB</u>		<u>5MG;200MG</u>	<u>A091633 002</u>	May 28, 2013
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A091633 003</u>	May 28, 2013
<u>AB</u>		<u>10MG;200MG</u>	<u>A091633 004</u>	May 28, 2013
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023 001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727 001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723 001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723 002</u>	Nov 06, 2006

REPREXAIN

<u>AB</u>	AMNEAL PHARMS NY	<u>2.5MG;200MG</u>	<u>A076642 003</u>	Oct 19, 2007
<u>AB</u>		<u>10MG;200MG</u>	<u>A076642 004</u>	Oct 19, 2007

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AA</u>	MAYNE PHARMA INC	<u>5MG/5ML; 60MG/5ML</u>	<u>A205658 001</u>	Nov 17, 2015
<u>AA</u>	PADDOCK LLC	<u>5MG/5ML; 60MG/5ML</u>	<u>A204658 001</u>	Apr 29, 2014

REZIRA

<u>AA</u>	+! CYPRESS PHARM	<u>5MG/5ML; 60MG/5ML</u>	<u>N022442 001</u>	Jun 08, 2011
-----------	------------------	--------------------------	--------------------	--------------

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>2.5%</u>	<u>A080706 007</u>	Jan 05, 2016
<u>AT</u>		<u>1%</u>	<u>A080706 006</u>	

ANUSOL HC

<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250 001</u>	Jun 06, 1984
-----------	--------------	-------------	--------------------	--------------

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795 001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682 001</u>	Mar 10, 1988
<u>AT</u>	! FOUGERA PHARMS INC	<u>1%</u>	<u>A080693 003</u>	
<u>AT</u>	!	<u>2.5%</u>	<u>A089414 001</u>	Dec 16, 1986
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025 001</u>	
<u>AT</u>	RISING PHARMS INC	<u>2.5%</u>	<u>A040879 001</u>	Aug 20, 2010
<u>AT</u>	TARO	<u>2.5%</u>	<u>A088799 001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503 001</u>	Mar 12, 2004

ENEMA;RECTAL

COLOCORT

<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172 001</u>	Dec 03, 1999
-----------	-------------	-------------------	--------------------	--------------

CORTENEMA

<u>AB</u>	+! ANI PHARMS	<u>100MG/60ML</u>	<u>N016199 001</u>	
-----------	---------------	-------------------	--------------------	--

HYDROCORTISONE

<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171 001</u>	May 27, 1994
-----------	-------------	-------------------	--------------------	--------------

LOTION;TOPICAL

HYDROCORTISONE

<u>AT</u>	! FOUGERA PHARMS	<u>2.5%</u>	<u>A040351 001</u>	Jul 25, 2000
<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247 001</u>	Jul 23, 1999
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417 001</u>	Jul 30, 2003

STIE-CORT

<u>AT</u>	PERRIGO CO	<u>2.5%</u>	<u>A089074 001</u>	Nov 26, 1985
-----------	------------	-------------	--------------------	--------------

ALA-SCALP

	CROWN LABS	2%	A083231 001	
--	------------	----	-------------	--

OINTMENT;TOPICAL

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796 001</u>	Oct 13, 1982
<u>AT</u>	! FOUGERA PHARMS	<u>1%</u>	<u>A080692 001</u>	
<u>AT</u>	! FOUGERA PHARMS INC	<u>2.5%</u>	<u>A081203 001</u>	May 28, 1993
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027 001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086257 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

OINTMENT; TOPICAL

HYDROCORTISONE IN ABSORBASE**AT** CMP PHARMA INC **1%** **A088138 001** Sep 06, 1985

SOLUTION; TOPICAL

TEXACORT

! MISSION PHARMA 2.5%

A081271 001 Apr 17, 1992

TABLET; ORAL

CORTEF**AB** + PHARMACIA AND **5MG** **N008697 003**
UPJOHN**AB** + **10MG** **N008697 001****AB** +! **20MG** **N008697 002**HYDROCORTISONE**AB** HIKMA INTL PHARMS **5MG** **A083365 002** Feb 23, 2015**AB** **10MG** **A083365 003** Feb 23, 2015**AB** **20MG** **A083365 001****AB** IMPAX LABS INC **5MG** **A040646 001** Mar 30, 2007**AB** **10MG** **A040646 002** Mar 30, 2007**AB** **20MG** **A040646 003** Mar 30, 2007**AB** PII **5MG** **A207029 001** Apr 27, 2017**AB** **10MG** **A207029 002** Apr 27, 2017**AB** **20MG** **A207029 003** Apr 27, 2017**AB** VINTAGE **5MG** **A040761 001** Jul 16, 2007**AB** **10MG** **A040761 002** Jul 16, 2007**AB** **20MG** **A040761 003** Jul 16, 2007HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+! MYLAN SPECIALITY LP 10%

N017351 001 Feb 10, 1982

CREAM; TOPICAL

MICORT-HC

SEBELA IRELAND LTD 2.5%

A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+! MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MYLAN SPECIALITY LP 1%;1% A086457 001

PROCTOFOAM HC

BX MYLAN SPECIALITY LP 1%;1% A086195 001

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%;1%

A083778 001

1%;1%

A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%;1%

A085980 001

2.5%;1%

A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO 1%;10%

A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS **0.1%** **A076654 001** Aug 03, 2005LOCOID**AB1** +! PRECISION DERMAT **0.1%** **N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** ACTAVIS MID **0.1%** **A205134 001** Dec 08, 2017

ATLANTIC

AB2 GLENMARK GENERICS **0.1%** **A202145 001** Sep 27, 2013LOCOID LIPOCREAM**AB2** +! PRECISION DERMAT **0.1%** **N020769 001** Sep 08, 1997

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE**AB** TELIGENT PHARMA INC **0.1%** **A209556 001** Nov 21, 2017

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

LOCOID

AB	+ !	PRECISION DERMAT	0.1%	N022076	001	May 18, 2007
-----------	------------	------------------	-------------	----------------	------------	--------------

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

AB		TARO	0.1%	A076842	001	Dec 27, 2004
-----------	--	------	-------------	----------------	------------	--------------

LOCOID

AB	+ !	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982
-----------	------------	------------------	-------------	----------------	------------	--------------

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT		TARO PHARM INDS	0.1%	A076364	001	Jan 14, 2004
-----------	--	-----------------	-------------	----------------	------------	--------------

LOCOID

AT	+ !	PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987
-----------	------------	------------------	-------------	----------------	------------	--------------

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ !	FOUGERA PHARMS	0.1%	N020453	001	Feb 28, 1997
------------	----------------	------	---------	-----	--------------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

SOLU-CORTEF

+ !	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001
------------	----------------------	--------------------	---------	-----

+ !		EQ 250MG BASE/VIAL	N009866	002
------------	--	--------------------	---------	-----

+ !		EQ 500MG BASE/VIAL	N009866	003
------------	--	--------------------	---------	-----

+ !		EQ 1GM BASE/VIAL	N009866	004
------------	--	------------------	---------	-----

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		PERRIGO NEW YORK	0.2%	A075666	001	May 24, 2000
-----------	--	------------------	-------------	----------------	------------	--------------

AB	!	TARO	0.2%	A075042	001	Aug 25, 1998
-----------	----------	------	-------------	----------------	------------	--------------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

!	TARO	0.2%	A075043	001	Aug 25, 1998
----------	------	------	---------	-----	--------------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

AT	+ !	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001
-----------	------------	----------------	--	----------------	------------

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005
-----------	--	---------------	--	----------------	------------	--------------

AT		BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053	001	Dec 29, 1995
-----------	--	-----------------	--	----------------	------------	--------------

AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983
-----------	--	------------	--	----------------	------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988
----------	------------	-------------------------------------	---------	-----	--------------

SUSPENSION/DROPS; OTIC

CASPORYN HC

AT	+ !	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001
-----------	------------	-------------------	--	----------------	------------

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006
-----------	--	---------------	--	----------------	------------	--------------

AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985
-----------	--	------------	--	----------------	------------	--------------

OTICAIR

AT		BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996
-----------	--	-----------------	--	----------------	------------	--------------

HYDROGEN PEROXIDE

SOLUTION; TOPICAL

ESKATA

+ !	ACLARIS THERAPS INC	40%	N209305	001	Dec 14, 2017
------------	---------------------	-----	---------	-----	--------------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+ !	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009
-----------	------------	--------------------	---------------	----------------	------------	--------------

AP	+ !		2MG/ML	N019034	004	Apr 30, 2009
-----------	------------	--	---------------	----------------	------------	--------------

AP	+ !		4MG/ML	N019034	005	Apr 30, 2009
-----------	------------	--	---------------	----------------	------------	--------------

DILAUDID-HP

AP	+ !	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984
-----------	------------	--------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

AP		AKORN	10MG/ML	A078228	001	Apr 14, 2010
-----------	--	-------	----------------	----------------	------------	--------------

AP			10MG/ML	A078261	001	Apr 14, 2010
-----------	--	--	----------------	----------------	------------	--------------

AP		BARR	10MG/ML	A076444	001	Apr 25, 2003
-----------	--	------	----------------	----------------	------------	--------------

AP		HOSPIRA INC	1MG/ML	N200403	001	Dec 01, 2011
-----------	--	-------------	---------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

<u>AP</u>		<u>2MG/ML</u>	<u>N200403</u>	<u>002</u>	Dec 01, 2011
<u>AP</u>		<u>4MG/ML</u>	<u>N200403</u>	<u>003</u>	Dec 01, 2011
<u>AP</u>		<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>	Jun 17, 2008

SOLUTION; ORAL

DILAUDID

<u>AA</u>	<u>+</u>	<u>RHODES PHARMS</u>	<u>5MG/5ML</u>	<u>N019891</u>	<u>001</u>	Dec 07, 1992
-----------	----------	----------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<u>AA</u>		<u>ASCENT PHARMS INC</u>	<u>5MG/5ML</u>	<u>A210176</u>	<u>001</u>	Oct 27, 2017
<u>AA</u>		<u>WEST-WARD PHARMS</u>	<u>5MG/5ML</u>	<u>A074653</u>	<u>001</u>	Jul 29, 1998

INT

TABLET; ORAL

DILAUDID

<u>AB</u>	<u>+</u>	<u>RHODES PHARMS</u>	<u>2MG</u>	<u>N019892</u>	<u>003</u>	Nov 09, 2007
<u>AB</u>	<u>+</u>		<u>4MG</u>	<u>N019892</u>	<u>002</u>	Nov 09, 2007
<u>AB</u>	<u>+</u>		<u>8MG</u>	<u>N019892</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>AUROLIFE PHARMA LLC</u>	<u>2MG</u>	<u>A205814</u>	<u>001</u>	May 13, 2016
<u>AB</u>			<u>4MG</u>	<u>A205814</u>	<u>002</u>	May 13, 2016
<u>AB</u>			<u>8MG</u>	<u>A205814</u>	<u>003</u>	May 13, 2016
<u>AB</u>		<u>ELITE LABS</u>	<u>8MG</u>	<u>A076723</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>		<u>LANNETT</u>	<u>2MG</u>	<u>A077471</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>			<u>2MG</u>	<u>A078439</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>			<u>4MG</u>	<u>A077471</u>	<u>003</u>	Dec 09, 2009
<u>AB</u>			<u>4MG</u>	<u>A078439</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>			<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>		<u>SPECGX LLC</u>	<u>2MG</u>	<u>A076855</u>	<u>002</u>	Sep 19, 2007
<u>AB</u>			<u>4MG</u>	<u>A076855</u>	<u>003</u>	Sep 19, 2007
<u>AB</u>			<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>		<u>WEST-WARD PHARMS</u>	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>INT</u>				
<u>AB</u>			<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL

EXALGO

<u>AB</u>	<u>+</u>	<u>SPECGX LLC</u>	<u>8MG</u>	<u>N021217</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>	<u>+</u>		<u>12MG</u>	<u>N021217</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>	<u>+</u>		<u>16MG</u>	<u>N021217</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>	<u>+</u>		<u>32MG</u>	<u>N021217</u>	<u>004</u>	Aug 24, 2012

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>ACTAVIS LABS FL INC</u>	<u>8MG</u>	<u>A202144</u>	<u>001</u>	May 12, 2014
<u>AB</u>			<u>12MG</u>	<u>A202144</u>	<u>002</u>	May 12, 2014
<u>AB</u>			<u>16MG</u>	<u>A202144</u>	<u>003</u>	May 12, 2014
<u>AB</u>			<u>32MG</u>	<u>A202144</u>	<u>004</u>	Jun 30, 2016
<u>AB</u>		<u>OSMOTICA</u>	<u>8MG</u>	<u>A205629</u>	<u>001</u>	Jul 07, 2016
<u>AB</u>			<u>12MG</u>	<u>A205629</u>	<u>002</u>	Jul 07, 2016
<u>AB</u>			<u>16MG</u>	<u>A205629</u>	<u>003</u>	Jul 07, 2016
<u>AB</u>			<u>32MG</u>	<u>A205629</u>	<u>004</u>	Jul 07, 2016
<u>AB</u>		<u>PADDOCK LLC</u>	<u>8MG</u>	<u>A204278</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>			<u>12MG</u>	<u>A204278</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>			<u>16MG</u>	<u>A204278</u>	<u>003</u>	Apr 06, 2015
<u>AB</u>			<u>32MG</u>	<u>A204278</u>	<u>004</u>	Sep 20, 2017

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

<u>+</u>	<u>SERB SA</u>	<u>5GM/VIAL (5GM/KIT)</u>	<u>N022041</u>	<u>001</u>	Apr 08, 2011
----------	----------------	---------------------------	----------------	------------	--------------

HYDROXOCOBALAMIN

<u>!</u>	<u>ACTAVIS LLC</u>	<u>1MG/ML</u>	<u>A085998</u>	<u>001</u>	
----------	--------------------	---------------	----------------	------------	--

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

<u>+</u>	<u>AKORN</u>	<u>1%;0.25%</u>	<u>N019261</u>	<u>001</u>	Jan 30, 1992
----------	--------------	-----------------	----------------	------------	--------------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>		<u>HIKMA PHARMS</u>	<u>200MG</u>	<u>A040760</u>	<u>001</u>	Aug 15, 2007
<u>AB</u>		<u>IPCA LABS LTD</u>	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>MYLAN</u>	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
<u>AB</u>		<u>SANDOZ</u>	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		<u>TEVA PHARMS</u>	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133 001	Nov 30, 1995
AB	ZYDUS PHARMS USA INC	200MG	A040657 001	Sep 21, 2007

PLAQUENIL

AB	+! CONCORDIA PHARMS INC	200MG	N009768 001	
-----------	----------------------------	--------------	--------------------	--

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

!	ASPEN GLOBAL INC	250MG/ML	A200271 001	Aug 24, 2015
---	------------------	----------	-------------	--------------

SOLUTION; INTRAMUSCULAR

MAKENA

+!	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011
----	-----------------	-----------------------	-------------	--------------

MAKENA PRESERVATIVE FREE

+!	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945 002	Feb 19, 2016
----	-----------------	---------------------	-------------	--------------

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+!	ATON	5MG	N018771 001	
----	------	-----	-------------	--

HYDROXYUREA

CAPSULE; ORAL

HYDREA

AB	+! BRISTOL MYERS SQUIBB	500MG	N016295 001	
-----------	----------------------------	--------------	--------------------	--

HYDROXYUREA

AB	BARR	500MG	A075143 001	Oct 16, 1998
-----------	------	--------------	--------------------	--------------

AB	PAR PHARM	500MG	A075340 001	Feb 24, 1999
-----------	-----------	--------------	--------------------	--------------

DROXIA

+	BRISTOL MYERS SQUIBB	200MG	N016295 002	Feb 25, 1998
---	-------------------------	-------	-------------	--------------

+		300MG	N016295 003	Feb 25, 1998
---	--	-------	-------------	--------------

+		400MG	N016295 004	Feb 25, 1998
---	--	-------	-------------	--------------

TABLET; ORAL

SIKLOS

+	ADDMEDICA SAS	100MG	N208843 001	Dec 21, 2017
---	---------------	-------	-------------	--------------

+		1GM	N208843 002	Dec 21, 2017
---	--	-----	-------------	--------------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

AP	!	FRESENIUS KABI USA	25MG/ML	A087329 001
-----------	---	--------------------	----------------	--------------------

AP	!		50MG/ML	A087329 002
-----------	---	--	----------------	--------------------

AP		LUITPOLD	25MG/ML	A087408 001
-----------	--	----------	----------------	--------------------

AP			50MG/ML	A087408 002
-----------	--	--	----------------	--------------------

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	!	HI TECH PHARMA	10MG/5ML	A040010 001	Oct 28, 1994
-----------	---	----------------	-----------------	--------------------	--------------

AA		SILARX PHARMS INC	10MG/5ML	A201674 001	Aug 21, 2013
-----------	--	-------------------	-----------------	--------------------	--------------

AA	!	VINTAGE PHARMS	10MG/5ML	A040391 001	Apr 10, 2002
-----------	---	----------------	-----------------	--------------------	--------------

AA	!	WOCKHARDT BIO AG	10MG/5ML	A087294 001	Apr 12, 1982
-----------	---	------------------	-----------------	--------------------	--------------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	10MG	A040808 001	Sep 24, 2008
-----------	--	--------------	-------------	--------------------	--------------

AB			25MG	A040808 002	Sep 24, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040808 003	Sep 24, 2008
-----------	--	--	-------------	--------------------	--------------

AB		ECI PHARMS LLC	10MG	A040804 001	Jun 30, 2008
-----------	--	----------------	-------------	--------------------	--------------

AB			25MG	A040804 002	Jun 30, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040804 003	Jun 30, 2008
-----------	--	--	-------------	--------------------	--------------

AB		ELITE LABS INC	10MG	A040604 002	Dec 28, 2004
-----------	--	----------------	-------------	--------------------	--------------

AB			25MG	A040604 003	Dec 28, 2004
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040604 001	Dec 28, 2004
-----------	--	--	-------------	--------------------	--------------

AB		HERITAGE PHARMA	10MG	A204279 001	Aug 20, 2014
-----------	--	-----------------	-------------	--------------------	--------------

AB			25MG	A204279 002	Aug 20, 2014
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A204279 003	Aug 20, 2014
-----------	--	--	-------------	--------------------	--------------

AB		HETERO LABS LTD III	10MG	A040805 001	May 29, 2008
-----------	--	---------------------	-------------	--------------------	--------------

AB			25MG	A040805 002	May 29, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040805 003	May 29, 2008
-----------	--	--	-------------	--------------------	--------------

AB		INVAGEN PHARMS	10MG	A040812 001	Mar 12, 2008
-----------	--	----------------	-------------	--------------------	--------------

AB			25MG	A040812 002	Mar 12, 2008
-----------	--	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A040812</u>	<u>003</u>	Mar 12, 2008
<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A040786</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040787</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040788</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A091176</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>25MG</u>	<u>A091176</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A091176</u>	<u>003</u>	Jun 07, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040840</u>	<u>002</u>	Mar 31, 2008
<u>AB</u>		<u>25MG</u>	<u>A040840</u>	<u>003</u>	Mar 31, 2008
<u>AB</u>		<u>50MG</u>	<u>A040840</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>	NUVO PHARM	<u>10MG</u>	<u>A207120</u>	<u>001</u>	Mar 29, 2017
<u>AB</u>		<u>50MG</u>	<u>A207122</u>	<u>001</u>	Mar 29, 2017
<u>AB</u>	NUVO PHARM INC	<u>25MG</u>	<u>A207121</u>	<u>001</u>	Mar 29, 2017
<u>AB</u>	!	<u>10MG</u>	<u>A088617</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	!	<u>25MG</u>	<u>A088618</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	!	<u>50MG</u>	<u>A088619</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	PRINSTON INC	<u>10MG</u>	<u>A040579</u>	<u>001</u>	May 27, 2005
<u>AB</u>		<u>25MG</u>	<u>A040574</u>	<u>001</u>	May 27, 2005
<u>AB</u>		<u>50MG</u>	<u>A040580</u>	<u>001</u>	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>	HERITAGE PHARMA	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A201507</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>EQ 50MG HYDROCHLORIDE</u>	<u>A201507</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>	IMPAX LABS INC	<u>EQ 25MG HCL</u>	<u>A040156</u>	<u>001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156</u>	<u>002</u>	Jul 15, 1996
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479</u>	<u>001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183</u>	<u>001</u>	
<u>VISTARIL</u>					
<u>AB</u>	+	<u>EQ 25MG HCL</u>	<u>N011459</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459</u>	<u>004</u>	
	HYDROXYZINE PAMOATE				
	BARR	<u>EQ 100MG HCL</u>	<u>A088488</u>	<u>001</u>	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

<u>AP</u>	+	<u>EQ 3MG BASE/3ML</u>	<u>N021858</u>	<u>001</u>	Jan 06, 2006
<u>IBANDRONATE SODIUM</u>					
<u>AP</u>	ACCORD HLTHCARE	<u>EQ 3MG BASE/3ML</u>	<u>A206058</u>	<u>001</u>	Feb 05, 2016
<u>AP</u>	APOTEX INC	<u>EQ 3MG BASE/3ML</u>	<u>A204222</u>	<u>001</u>	Oct 16, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 3MG BASE/3ML</u>	<u>A205332</u>	<u>001</u>	Aug 19, 2015
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A203987</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>	MYLAN LABS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A202671</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 3MG BASE/3ML</u>	<u>A202235</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A090853</u>	<u>001</u>	Feb 14, 2014

TABLET; ORAL

BONIVA

<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N021455</u>	<u>002</u>	Mar 24, 2005
<u>IBANDRONATE SODIUM</u>					
<u>AB</u>	APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A204502</u>	<u>001</u>	Mar 11, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A206887</u>	<u>001</u>	Oct 31, 2017
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 150MG BASE</u>	<u>A078996</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>	WATSON LABS TEVA	<u>EQ 150MG BASE</u>	<u>A079003</u>	<u>001</u>	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017
	+		140MG	N205552	001	Nov 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS 800MG/8ML (100MG/ML) N022348 002 Jun 11, 2009

SUSPENSION; ORAL

IBUPROFENAB ! ACTAVIS MID 100MG/5ML A074978 001 Mar 25, 1998

ATLANTIC

AB HI-TECH PHARMACAL 100MG/5ML A205647 001 Nov 03, 2016AB PERRIGO R AND D 100MG/5ML A076925 001 Sep 23, 2004AB TARO 100MG/5ML A209204 001 Jun 23, 2017

TABLET; ORAL

IBU-TABAB ALRA 400MG A071058 001 Aug 11, 1988AB 600MG A071059 001 Aug 11, 1988IBUPROFENAB AIPING PHARM INC 400MG A202413 001 Nov 23, 2016AB 600MG A202413 002 Nov 23, 2016AB 800MG A202413 003 Nov 23, 2016AB AMNEAL PHARMS NY 400MG A071334 001 Nov 25, 1986AB 400MG A078558 001 Jun 18, 2007AB 600MG A071335 001 Nov 25, 1986AB 600MG A078558 002 Jun 18, 2007AB 800MG A071935 001 Oct 13, 1987AB 800MG A078558 003 Jun 18, 2007AB CONTRACT PHARMACAL 400MG A071268 002 Oct 15, 1986AB 600MG A071268 001 Oct 15, 1986AB 800MG A071268 003 Jul 01, 1988AB DR REDDYS LA 400MG A075682 001 Nov 14, 2001AB 600MG A075682 002 Nov 14, 2001AB ! 800MG A075682 003 Nov 14, 2001AB DR REDDYS LABS INC 400MG A076112 001 Oct 31, 2001AB 600MG A076112 002 Oct 31, 2001AB 800MG A076112 003 Oct 31, 2001AB GRANULES INDIA LTD 400MG A091625 001 Sep 15, 2015AB 600MG A091625 002 Sep 15, 2015AB 800MG A091625 003 Sep 15, 2015AB MARKSANS PHARMA 400MG A090796 001 Dec 21, 2010AB 600MG A090796 002 Dec 21, 2010AB 800MG A090796 003 Dec 21, 2010AB PERRIGO R AND D 400MG A077114 001 Jul 18, 2005AB 600MG A077114 002 Jul 18, 2005AB 800MG A077114 003 Jul 18, 2005AB STRIDES PHARMA 400MG A078329 001 Feb 05, 2009AB 600MG A078329 002 Feb 05, 2009AB 800MG A078329 003 Feb 05, 2009AB VINTAGE PHARMS 400MG A071644 001 Feb 01, 1988IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYISINEAP EXELA PHARMA EQ 20MG BASE/2ML (EQ 10MG BASE/ML) A202402 001 Mar 30, 2016

SCIENCE

NEOPROFENAP +! RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFENAB ACTAVIS ELIZABETH 400MG; 5MG A078769 001 Jan 04, 2008AB ! BARR LABS INC 400MG; 5MG A078316 001 Nov 29, 2007IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERTAP +! PHARMACIA AND 0.1MG/ML N020491 001 Dec 28, 1995

UPJOHN

IBUTILIDE FUMARATEAP LUITPOLD 0.1MG/ML A090240 001 Jan 11, 2010AP MYLAN INSTITUTIONAL 0.1MG/ML A090643 001 Jan 11, 2010AP 0.1MG/ML A090924 001 Jan 11, 2010

PRESCRIPTION DRUG PRODUCT LIST

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+! SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N022150 001 Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+! BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 500MG N202057 002 Feb 16, 2017

+! 1GM N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFSAP +! PHARMACIA AND 1MG/ML N050734 001 Feb 17, 1997
UPJOHNIDARUBICIN HYDROCHLORIDEAP FRESENIUS KABI USA 1MG/ML A065440 001 Aug 04, 2009AP MYLAN LABS LTD 1MG/ML A200144 001 Oct 11, 2012AP WEST-WARD PHARMS 1MG/ML A065275 001 Dec 14, 2006

INT

AP 1MG/ML A065288 001 May 15, 2007IDARUBICIN HYDROCHLORIDE PFSAP TEVA PHARMS USA 1MG/ML A065036 001 May 01, 2002IDELALISIB

TABLET; ORAL

ZYDELIG

+ GILEAD SCIENCES INC 100MG N205858 001 Jul 23, 2014

+! 150MG N205858 002 Jul 23, 2014

IFOSFAMIDE

INJECTABLE; INJECTION

IFEXAP + BAXTER HLTHCARE 1GM/VIAL N019763 001 Dec 30, 1988AP + 3GM/VIAL N019763 002 Dec 30, 1988IFOSFAMIDEAP ! FRESENIUS KABI USA 1GM/VIAL A076078 001 May 28, 2002AP 1GM/20ML (50MG/ML) A090181 001 Sep 22, 2009AP ! 3GM/VIAL A076078 002 May 28, 2002AP 3GM/60ML (50MG/ML) A090181 002 Sep 22, 2009AP MYLAN LABS LTD 1GM/20ML (50MG/ML) A201689 001 Nov 26, 2012AP 3GM/60ML (50MG/ML) A201689 002 Nov 26, 2012AP ! TEVA PHARMS USA 1GM/20ML (50MG/ML) A076657 001 Apr 04, 2007AP ! 3GM/60ML (50MG/ML) A076657 002 Apr 04, 2007AP WEST-WARD PHARMS 1GM/20ML (50MG/ML) A076619 001 Jun 29, 2011

INT

AP 3GM/60ML (50MG/ML) A076619 002 Jun 29, 2011ILOPERIDONE

TABLET; ORAL

FANAPTAB +! VANDA PHARMS INC 1MG N022192 001 May 06, 2009AB + 2MG N022192 002 May 06, 2009AB + 4MG N022192 003 May 06, 2009AB + 6MG N022192 004 May 06, 2009AB + 8MG N022192 005 May 06, 2009AB + 10MG N022192 006 May 06, 2009AB + 12MG N022192 007 May 06, 2009ILOPERIDONEAB INVENTIA HLTHCARE 1MG A207231 001 Nov 28, 2016AB 2MG A207231 002 Nov 28, 2016AB 4MG A207231 003 Nov 28, 2016AB 6MG A207231 004 Nov 28, 2016AB 8MG A207231 005 Nov 28, 2016AB 10MG A207231 006 Nov 28, 2016AB 12MG A207231 007 Nov 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	!	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
+	!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

<u>AB</u>	+	NOVARTIS	<u>EQ 100MG BASE</u>	<u>N021588</u>	<u>001</u>	Apr 18, 2003
<u>AB</u>	+	!	<u>EQ 400MG BASE</u>	<u>N021588</u>	<u>002</u>	Apr 18, 2003

IMATINIB MESYLATE

<u>AB</u>		APOTEX INC	<u>EQ 100MG BASE</u>	<u>A079179</u>	<u>001</u>	Aug 05, 2016
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A079179</u>	<u>002</u>	Aug 05, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 100MG BASE</u>	<u>A204644</u>	<u>001</u>	Jun 21, 2017
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A204644</u>	<u>002</u>	Jun 21, 2017
<u>AB</u>		SUN PHARMA GLOBAL	<u>EQ 100MG BASE</u>	<u>A078340</u>	<u>001</u>	Dec 03, 2015
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A078340</u>	<u>002</u>	Dec 03, 2015
<u>AB</u>		TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A204285</u>	<u>001</u>	Aug 04, 2016
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A204285</u>	<u>002</u>	Aug 04, 2016

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

+		GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+	!		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>		LEADING PHARMA LLC	<u>10MG</u>	<u>A040903</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>			<u>25MG</u>	<u>A040903</u>	<u>002</u>	Oct 24, 2012
<u>AB</u>			<u>50MG</u>	<u>A040903</u>	<u>003</u>	Oct 24, 2012
<u>AB</u>		LUPIN LTD	<u>10MG</u>	<u>A090441</u>	<u>002</u>	Mar 11, 2010
<u>AB</u>			<u>25MG</u>	<u>A090441</u>	<u>003</u>	Mar 11, 2010
<u>AB</u>			<u>50MG</u>	<u>A090441</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		PAR PHARM	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>			<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>			<u>50MG</u>	<u>A088276</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>			<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>A084937</u>	<u>001</u>	
<u>AB</u>		SPECGX LLC	<u>10MG</u>	<u>A087846</u>	<u>002</u>	May 22, 1984
<u>AB</u>			<u>25MG</u>	<u>A087846</u>	<u>003</u>	May 22, 1984
<u>AB</u>		SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>			<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>			<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990

TOFRANIL

<u>AB</u>	!	SPECGX LLC	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984
		IMIPRAMINE HYDROCHLORIDE				
		OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008
			25MG	A040751	002	Feb 28, 2008

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>		LUPIN LTD	<u>EQ 75MG HCL</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 100MG HCL</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 125MG HCL</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 150MG HCL</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	!	WEST-WARD PHARMS INT	<u>EQ 75MG HCL</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 100MG HCL</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 125MG HCL</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 150MG HCL</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	!	MEDICIS	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
-----------	---	---	---------	-----------	----------------	------------	--------------

IMIQUIMOD

<u>AB</u>		APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>		FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		G AND W LABS INC	<u>5%</u>	<u>A200481</u>	<u>001</u>	Apr 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012
AB	PERRIGO ISRAEL	5%	A078837 001	Sep 07, 2010
AB	STRIDES PHARMA	5%	A202002 001	Jun 24, 2014
AB	TARO	5%	A200173 001	Apr 15, 2011
AB	TOLMAR	5%	A091044 001	Feb 28, 2011
ZYCLARA				
+	MEDICIS	2.5%	N022483 002	Jul 15, 2011
+		3.75%	N022483 001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

!	WEST-WARD PHARMS	EQ 5MG BASE/ML	A075513 001	May 09, 2000
	INT			

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383 001	Jul 01, 2011
---	---------------------	---------------	-------------	--------------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB	ACTAVIS ELIZABETH	1.25MG	A074722 001	Jun 17, 1996
AB		2.5MG	A074722 002	Jun 17, 1996
AB	AMERIGEN PHARMS LTD	1.25MG	A075201 001	Dec 04, 1998
AB		2.5MG	A075201 002	Dec 04, 1998
AB	ANI PHARMS INC	1.25MG	A074299 002	Apr 29, 1996
AB		2.5MG	A074299 001	Jul 27, 1995
AB	MYLAN	1.25MG	A074461 002	Mar 26, 1997
AB	!	2.5MG	A074461 001	Mar 27, 1996

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

+	MERCK SHARP DOHME	EQ 200MG BASE	N020685 003	Mar 13, 1996
+		EQ 400MG BASE	N020685 001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862 001	Dec 29, 1992
	INDIUM IN 111 CHLORIDE			
+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841 001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044 001	Dec 24, 1985
---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707 001	Feb 18, 1982
---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314 001	Jun 02, 1994
---	---------------------	---------	-------------	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AP	+	AKORN	25MG/VIAL	N011525 001
<u>INDOCYANINE GREEN</u>				
AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811 001 Nov 21, 2007

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	GLENMARK GENERICS	25MG	A091276 001	Dec 22, 2010
AB		50MG	A091276 002	Dec 22, 2010
AB	HERITAGE PHARMS INC	25MG	N018851 001	May 18, 1984
AB		50MG	N018851 002	May 18, 1984
AB	HETERO LABS LTD III	25MG	A091240 001	Apr 12, 2011

PRESCRIPTION DRUG PRODUCT LIST

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

<u>AB</u>		<u>50MG</u>	<u>A091240 002</u>	Apr 12, 2011
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A070719 001</u>	Feb 12, 1986
<u>AB</u>		<u>50MG</u>	<u>A070756 001</u>	Feb 12, 1986
<u>AB</u>	JUBILANT GENERICS	<u>25MG</u>	<u>A205215 001</u>	Aug 25, 2017
<u>AB</u>		<u>50MG</u>	<u>A205215 002</u>	Aug 25, 2017
<u>AB</u>	MYLAN	<u>25MG</u>	<u>N018858 001</u>	Apr 20, 1984
<u>AB</u>	!	<u>50MG</u>	<u>A070624 001</u>	Sep 04, 1985
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A070673 001</u>	Apr 29, 1987
<u>AB</u>		<u>50MG</u>	<u>A070674 001</u>	Apr 29, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A091401 001</u>	Mar 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A091401 002</u>	Mar 28, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A090403 001</u>	Nov 15, 2010
<u>AB</u>		<u>50MG</u>	<u>A090403 002</u>	Nov 15, 2010
	TIVORBEX			
	+ IROKO PHARMS LLC	20MG	N204768 001	Feb 24, 2014
	+!	40MG	N204768 002	Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A091549 001</u>	Dec 01, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A204243 001</u>	Dec 27, 2016
<u>AB</u>	AVANTHI INC	<u>75MG</u>	<u>A079175 001</u>	Mar 06, 2009
<u>AB</u>	CHARTWELL RX	<u>75MG</u>	<u>A200529 001</u>	Nov 30, 2010
<u>AB</u>	GLENMARK PHARMS LTD	<u>75MG</u>	<u>A203501 001</u>	Jun 22, 2017
<u>AB</u>	HETERO LABS LTD III	<u>75MG</u>	<u>A201807 001</u>	Sep 28, 2012
<u>AB</u>	JUBILANT GENERICS	<u>75MG</u>	<u>A202706 001</u>	Oct 05, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A202139 001</u>	Mar 20, 2014
<u>AB</u>	NOVAST LABS LTD	<u>75MG</u>	<u>A204853 001</u>	May 08, 2017
<u>AB</u>	!	<u>75MG</u>	<u>A074464 001</u>	May 28, 1998
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A202711 001</u>	Sep 25, 2017

INJECTABLE; INJECTION

INDOMETHACIN

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

! G AND W LABS 50MG A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+! IROKO PHARMS 25MG/5ML N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCINAP +! RECORDATI RARE EQ 1MG BASE/VIAL N018878 001 Jan 30, 1985INDOMETHACIN SODIUMAP HOSPIRA INC EQ 1MG BASE/VIAL A204118 001 Apr 19, 2016AP NAVINTA LLC EQ 1MG BASE/VIAL A206561 001 Jul 19, 2017AP WEST-WARD PHARMS EQ 1MG BASE/VIAL A078713 001 Jul 16, 2008

INT

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

+! LEO LABS 0.015% N202833 001 Jan 23, 2012

+! 0.05% N202833 002 Jan 23, 2012

INSULIN ASPART

SOLUTION; IV (INFUSION), SUBCUTANEOUS

FIASP

+! NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML) N208751 001 Sep 29, 2017

SOLUTION; SUBCUTANEOUS

FIASP FLEXTOUCH

+! NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N208751 002 Sep 29, 2017

PRESCRIPTION DRUG PRODUCT LISTINSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+	NOVO NORDISK INC	700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)	N021172 001	Nov 01, 2001
---	------------------	---	-------------	--------------

NOVOLOG MIX 70/30 FLEXPEN

+	NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 004	May 03, 2002
---	------------------	--	-------------	--------------

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986 001	Jun 07, 2000
---	------------------	--------------------------------	-------------	--------------

NOVOLOG FLEXPEN

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 003	Jan 19, 2001
---	------------------	------------------------------	-------------	--------------

NOVOLOG FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 005	Oct 31, 2013
---	------------------	------------------------------	-------------	--------------

NOVOLOG PENFILL

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 002	Jun 07, 2000
---	------------------	------------------------------	-------------	--------------

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

RYZODEG 70/30

+	NOVO NORDISK INC	90 UNITS/3ML; 210 UNITS/3ML (30 UNITS/ML; 70 UNITS/ML)	N203313 001	Sep 25, 2015
---	------------------	--	-------------	--------------

INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

TRESIBA

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314 001	Sep 25, 2015
---	------------------	------------------------------	-------------	--------------

+		600 UNITS/3ML (200 UNITS/ML)	N203314 002	Sep 25, 2015
---	--	------------------------------	-------------	--------------

INSULIN DEGLUDEC; LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

XULTOPHY 100/3.6

+	NOVO NORDISK INC	300 UNITS/3ML; 10.8MG/3ML (100 UNITS/ML; 3.6MG/ML)	N208583 001	Nov 21, 2016
---	------------------	--	-------------	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536 001	Jun 16, 2005
---	------------------	--------------------------------	-------------	--------------

LEVEMIR FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 005	Oct 31, 2013
---	------------------	------------------------------	-------------	--------------

INSULIN GLARGINE

SOLUTION; SUBCUTANEOUS

BASAGLAR

	ELI LILLY AND CO	300 UNITS/3ML (100 UNITS/ML)	N205692 001	Dec 16, 2015
--	------------------	------------------------------	-------------	--------------

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+	SANOFI AVENTIS US	100 UNITS/ML	N021081 001	Apr 20, 2000
---	-------------------	--------------	-------------	--------------

LANTUS SOLOSTAR

+	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081 002	Apr 27, 2007
---	-------------------	------------------------------	-------------	--------------

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538 001	Feb 25, 2015
---	--------------------	-----------------------------	-------------	--------------

INSULIN GLARGINE; LIXISENATIDE

SOLUTION; SUBCUTANEOUS

SOLIQUA 100/33

+	SANOFI-AVENTIS US	300 UNITS/3ML; 99MCG/3ML (100 UNITS/ML; 33MCG/ML)	N208673 001	Nov 21, 2016
---	-------------------	---	-------------	--------------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

APIDRA

+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629 001	Apr 16, 2004
---	-------------------	--------------------------------	-------------	--------------

+		300 UNITS/3ML (100 UNITS/ML)	N021629 002	Dec 20, 2005
---	--	------------------------------	-------------	--------------

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

+	SANOFI AVENTIS US	300 UNITS/3ML	N021629 003	Feb 24, 2009
---	-------------------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS

HUMULIN R

+! LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994

HUMULIN R KWIKPEN

+! LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015

INSULIN LISPRO

SOLUTION;IV (INFUSION), SUBCUTANEOUS

ADMELOG

+ SANOFI-AVENTIS US 1000 UNITS/10ML (100 UNITS/ML) N209196 001 Dec 11, 2017

ADMELOG SOLOSTAR

+ SANOFI-AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N209196 002 Dec 11, 2017

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG MIX 50/50

+! LILLY 50 UNITS/ML;50 UNITS/ML N021018 001 Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+! LILLY 50 UNITS/ML;50 UNITS/ML N021018 002 Sep 06, 2007

HUMALOG MIX 75/25

+! LILLY 75 UNITS/ML;25 UNITS/ML N021017 001 Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+! LILLY 75 UNITS/ML;25 UNITS/ML N021017 002 Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG

+! LILLY 100 UNITS/ML N020563 001 Jun 14, 1996

HUMALOG KWIKPEN

+! LILLY 100 UNITS/ML N020563 003 Sep 06, 2007

SOLUTION;SUBCUTANEOUS

HUMALOG KWIKPEN

+! ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

+ MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014

+! 8 UNITS/INH N022472 002 Jun 27, 2014

+ 12 UNITS/INH N022472 003 Apr 17, 2015

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS

ADREVIEW

+! GE HEALTHCARE 10mCi/5ML (2mCi/ML) N022290 001 Sep 19, 2008

IODIXANOL

INJECTABLE;INJECTION

VISIPAQUE 270

+! GE HEALTHCARE 55% N020351 001 Mar 22, 1996

VISIPAQUE 320

+! GE HEALTHCARE 65.2% N020351 002 Mar 22, 1996

65.2% N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

DATSCAN

+! GE HLTHCARE INC 5mCi/2.5ML (2mCi/ML) N022454 001 Jan 14, 2011

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

INTERPHARMA PRAHA

9.7GM/BOT N205383 001 Mar 26, 2015

AS

INJECTABLE;INJECTION

OMNIPAQUE 140

+! GE HEALTHCARE 30.2% N018956 005 Nov 30, 1988

SOLUTION;INJECTION, ORAL

OMNIPAQUE 350

+! GE HEALTHCARE 75.5% N018956 004 Dec 26, 1985

75.5% N020608 003 Oct 24, 1995

SOLUTION;INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+! GE HEALTHCARE 38.8% N018956 001 Dec 26, 1985

PRESCRIPTION DRUG PRODUCT LIST

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240

+	!	GE HEALTHCARE	51.8%	N018956 002	Dec 26, 1985
			51.8%	N020608 001	Oct 24, 1995

OMNIPAQUE 300

+	!	GE HEALTHCARE	64.7%	N018956 003	Dec 26, 1985
			64.7%	N020608 002	Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300

AP	+	!	BRACCO	61%	N018735 002	Dec 31, 1985
-----------	---	---	--------	------------	--------------------	--------------

ISOVUE-370

AP	+	!	BRACCO	76%	N018735 003	Dec 31, 1985
-----------	---	---	--------	------------	--------------------	--------------

SCANLUX-300

AP			SANOCHEMIA CORP USA	61%	A090394 001	Jun 18, 2010
-----------	--	--	---------------------	------------	--------------------	--------------

SCANLUX-370

AP			SANOCHEMIA CORP USA	76%	A090394 002	Jun 18, 2010
-----------	--	--	---------------------	------------	--------------------	--------------

ISOVUE-200

+	!	BRACCO	41%	N018735 006	Jul 07, 1987
---	---	--------	-----	-------------	--------------

ISOVUE-250

+	!	BRACCO	51%	N018735 007	Jul 06, 1992
+	!		51%	N020327 002	Oct 12, 1994

ISOVUE-300

+	!	BRACCO	61%	N020327 003	Oct 12, 1994
---	---	--------	-----	-------------	--------------

ISOVUE-370

+	!	BRACCO	76%	N020327 004	Oct 12, 1994
---	---	--------	-----	-------------	--------------

ISOVUE-M 200

+	!	BRACCO	41%	N018735 001	Dec 31, 1985
---	---	--------	-----	-------------	--------------

ISOVUE-M 300

+	!	BRACCO	61%	N018735 004	Dec 31, 1985
---	---	--------	-----	-------------	--------------

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+	!	BAYER HLTHCARE	49.9%	N021425 003	Mar 12, 2004
+	!		62.3%	N021425 001	Sep 20, 2002
+	!		76.9%	N021425 002	Sep 20, 2002

ULTRAVIST 240

+	!	BAYER HLTHCARE	49.9%	N020220 003	May 10, 1995
---	---	----------------	-------	-------------	--------------

ULTRAVIST 300

+	!	BAYER HLTHCARE	62.3%	N020220 002	May 10, 1995
---	---	----------------	-------	-------------	--------------

ULTRAVIST 370

+	!	BAYER HLTHCARE	76.9%	N020220 001	May 10, 1995
---	---	----------------	-------	-------------	--------------

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+	!	LIEBEL-FLARSHEIM	60%	N013295 001	
---	---	------------------	-----	-------------	--

CONRAY 30

+	!	LIEBEL-FLARSHEIM	30%	N016983 001	
---	---	------------------	-----	-------------	--

CONRAY 43

+	!	LIEBEL-FLARSHEIM	43%	N013295 002	
---	---	------------------	-----	-------------	--

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

		LIEBEL-FLARSHEIM	17.2%	N017057 002	
--	--	------------------	-------	-------------	--

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

		ISOTEX	250-300uCi/ML	N017279 001	
--	--	--------	---------------	-------------	--

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	!	LIEBEL-FLARSHEIM	51%	N019710 002	Dec 30, 1988
---	---	------------------	-----	-------------	--------------

OPTIRAY 300

+	!	LIEBEL-FLARSHEIM	64%	N019710 004	Jan 22, 1992
+	!		64%	N020923 004	May 13, 1999

OPTIRAY 320

+	!	LIEBEL-FLARSHEIM	68%	N019710 001	Dec 30, 1988
+	!		68%	N020923 002	May 29, 1998

PRESCRIPTION DRUG PRODUCT LIST

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 350

+	!	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992
+	!		74%	N020923	003	May 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+	!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004
---	---	-------------------------	-------------	---------	-----	--------------

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

<u>AN</u>		AUROBINDO PHARMA LTD	<u>0.02%</u>	<u>A206543</u>	<u>001</u>	Oct 27, 2016
<u>AN</u>		LANDELA PHARM	<u>0.02%</u>	<u>A077072</u>	<u>001</u>	Jul 19, 2005
<u>AN</u>		NEPHRON	<u>0.02%</u>	<u>A075562</u>	<u>001</u>	Sep 27, 2001
<u>AN</u>	!	RITEDOSE CORP	<u>0.02%</u>	<u>A075693</u>	<u>001</u>	Jan 26, 2001
<u>AN</u>		SUN PHARMA GLOBAL	<u>0.02%</u>	<u>A207903</u>	<u>001</u>	Jan 03, 2017
<u>AN</u>		WATSON LABS	<u>0.02%</u>	<u>A076291</u>	<u>001</u>	May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

<u>AB</u>	+	!	BOEHRINGER INGELHEIM	<u>0.021MG/SPRAY</u>	<u>N020393</u>	<u>001</u>	Oct 20, 1995
-----------	---	---	-------------------------	----------------------	----------------	------------	--------------

<u>AB</u>	+	!		<u>0.042MG/SPRAY</u>	<u>N020394</u>	<u>001</u>	Oct 20, 1995
-----------	---	---	--	----------------------	----------------	------------	--------------

IPRATROPIUM BROMIDE

<u>AB</u>		BAUSCH AND LOMB	<u>0.021MG/SPRAY</u>	<u>A076025</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>			<u>0.042MG/SPRAY</u>	<u>A076103</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		MYLAN SPECIALITY LP	<u>0.021MG/SPRAY</u>	<u>A075552</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>			<u>0.042MG/SPRAY</u>	<u>A075553</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		WEST-WARD PHARMS INT	<u>0.021MG/SPRAY</u>	<u>A076664</u>	<u>001</u>	Nov 05, 2003
<u>AB</u>			<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	+		SANOFI AVENTIS US	<u>75MG</u>	<u>N020757</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+			<u>150MG</u>	<u>N020757</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	!		<u>300MG</u>	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>		ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>150MG</u>	<u>A091236</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>300MG</u>	<u>A091236</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		APOTEX INC	<u>75MG</u>	<u>A200832</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>150MG</u>	<u>A200832</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>300MG</u>	<u>A200832</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		CIPLA LTD	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>			<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>			<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A203161</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A203161</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		HISUN PHARM HANGZHOU	<u>75MG</u>	<u>A206194</u>	<u>001</u>	Jun 14, 2016
<u>AB</u>			<u>150MG</u>	<u>A206194</u>	<u>002</u>	Jun 14, 2016
<u>AB</u>			<u>300MG</u>	<u>A206194</u>	<u>003</u>	Jun 14, 2016
<u>AB</u>		JUBILANT GENERICS	<u>75MG</u>	<u>A203534</u>	<u>001</u>	Feb 23, 2015
<u>AB</u>			<u>150MG</u>	<u>A203534</u>	<u>002</u>	Feb 23, 2015
<u>AB</u>			<u>300MG</u>	<u>A203534</u>	<u>003</u>	Feb 23, 2015
<u>AB</u>		LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>			<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>			<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>		PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

IRBESARTAN

TABLET; ORAL

IRBESARTAN

<u>AB</u>		<u>300MG</u>	<u>A203071 003</u>	Sep 27, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466 003</u>	Sep 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A204774 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A204774 003</u>	Dec 07, 2015
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159 001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>75MG</u>	<u>A203020 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A203020 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A203020 003</u>	Dec 07, 2015
<u>AB</u>	WEST-WARD PHARMS INT	<u>75MG</u>	<u>A090201 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201 003</u>	Oct 15, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	<u>+</u> !	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	<u>+</u> !		<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996
<u>AP</u>	<u>+</u> !		<u>300MG/15ML (20MG/ML)</u>	<u>N020571 003</u>	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
<u>AP</u>		ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A078589 003</u>	Nov 18, 2015
<u>AP</u>		AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
<u>AP</u>		CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219 001</u>	Feb 20, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077219 002</u>	Feb 20, 2008
<u>AP</u>		DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953 001</u>	Apr 15, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078953 002</u>	Apr 15, 2010
<u>AP</u>		EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
<u>AP</u>		FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078188 002</u>	Feb 27, 2008
<u>AP</u>		FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010
<u>AP</u>		HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
<u>AP</u>		HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
<u>AP</u>	<u>!</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
<u>AP</u>		INGENUS PHARMS LLC	<u>40MG/2ML (20MG/ML)</u>	<u>A206935 001</u>	May 26, 2017
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A206935 002</u>	May 26, 2017
<u>AP</u>		INTAS PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A203054 001</u>	Aug 31, 2017
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A203054 002</u>	Aug 31, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
<u>AP</u>		MUSTAFA NEVZAT ILAC	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 001</u>	May 13, 2011
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
<u>AP</u>		PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122 001</u>	Oct 31, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078122 002</u>	Oct 31, 2008
<u>AP</u>		QILU PHARM CO LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A203380 001</u>	May 03, 2016
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A203380 002</u>	May 03, 2016
<u>AP</u>			<u>300MG/15ML (20MG/ML)</u>	<u>A203380 003</u>	May 03, 2016
<u>AP</u>		SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805 001</u>	Apr 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078805 002</u>	Apr 21, 2008
<u>AP</u>		TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 001</u>	Feb 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008
<u>AP</u>	WEST-WARD PHARMS INT	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
	INJECTABLE, LIPOSOMAL; IV (INFUSION)			
	ONIVYDE			
	+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793 001 Oct 22, 2015

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP		LUITPOLD	EQ 50MG IRON/ML	N040024 001 Feb 23, 1996
		INFED		
BP	+!	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441 001
		PROFERDEX		
BP		NEW RIVER	EQ 50MG IRON/ML	N017807 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	+	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002 Mar 20, 2005
	+!		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135 001 Nov 06, 2000
	+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135 004 Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

	+!	ASTELLAS	186MG	N207500 001 Mar 06, 2015
--	----	----------	-------	--------------------------

POWDER; IV (INFUSION)

CRESEMBA

	+!	ASTELLAS	372MG	N207501 001 Mar 06, 2015
--	----	----------	-------	--------------------------

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

	+!	VALIDUS PHARMS INC	10MG	N011961 001
--	----	--------------------	------	-------------

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+!	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624 001</u>
		<u>ISOFLURANE</u>		
<u>AN</u>		HALOCARBON PRODS	<u>99.9%</u>	<u>A075225 001</u> Oct 20, 1999
<u>AN</u>		HOSPIRA	<u>99.9%</u>	<u>A074097 001</u> Jan 25, 1993
<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416 001</u> Sep 30, 1994
<u>AN</u>		PIRAMAL ENT	<u>99.9%</u>	<u>A074502 001</u> Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

	!	SANDOZ INC	100MG/ML	A040648 001 Jul 05, 2005
--	---	------------	----------	--------------------------

SYRUP; ORAL

ISONIAZID

	!	CMP PHARMA INC	50MG/5ML	A088235 001 Nov 10, 1983
--	---	----------------	----------	--------------------------

TABLET; ORAL

ISONIAZID

<u>AA</u>		BARR	<u>100MG</u>	<u>A080936 001</u>
<u>AA</u>			<u>300MG</u>	<u>A080937 002</u>
<u>AA</u>		MIKART	<u>100MG</u>	<u>A040090 001</u> Jun 26, 1997
<u>AA</u>			<u>300MG</u>	<u>A040090 002</u> Jun 26, 1997
<u>AA</u>	+!	SANDOZ	<u>100MG</u>	<u>N008678 002</u>
<u>AA</u>	+!		<u>300MG</u>	<u>N008678 003</u>
<u>AA</u>		THEPHARMANETWORK LLC	<u>100MG</u>	<u>A202610 001</u> Oct 29, 2014
<u>AA</u>			<u>300MG</u>	<u>A202610 002</u> Oct 29, 2014
		<u>LANIAZID</u>		
<u>AA</u>		LANNETT	<u>300MG</u>	<u>A089776 001</u> Jun 13, 1988

PRESCRIPTION DRUG PRODUCT LIST

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+! SANOFI AVENTIS US 50MG; 300MG; 120MG N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

! SANOFI AVENTIS US 150MG; 300MG A061884 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE**AP** NEXUS PHARMS **0.2MG/ML** **A206961 001** Aug 02, 2017ISUPREL**AP** +! HOSPIRA **0.2MG/ML** **N010515 001**ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+! AUXILIUM PHARMS LLC 40MG N019790 001 Sep 02, 1988

TABLET; ORAL

ISORDIL**AB** + VALEANT PHARMS **5MG** **N012093 007** Jul 29, 1988

NORTH

ISOSORBIDE DINITRATE**AB** HIKMA INTL PHARMS **5MG** **A086067 001** Oct 29, 1987**AB** **10MG** **A086066 001** Oct 29, 1987**AB** **20MG** **A088088 001** Nov 02, 1987**AB** **30MG** **A040591 001** Jan 10, 2007**AB** PAR PHARM **5MG** **A086923 001** Mar 12, 1987**AB** **10MG** **A086925 001** Mar 12, 1987**AB** **20MG** **A087537 001** Oct 02, 1987**AB** ! **30MG** **A087946 001** Jan 12, 1988**AB** SANDOZ **5MG** **A086221 001** Jan 07, 1988**AB** **10MG** **A086223 001** Jan 07, 1988**AB** **20MG** **A089367 001** Apr 07, 1988

ISORDIL

+! VALEANT PHARMS 40MG N012093 001 Jul 29, 1988

NORTH

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

! SUN PHARM INDS INC 40MG A040009 001 Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE**AB** ACTAVIS ELIZABETH **10MG** **A075037 002** Oct 30, 1998**AB** **20MG** **A075037 001** Oct 30, 1998**AB** ANI PHARMS INC **20MG** **A075147 001** Nov 27, 1998**AB** HIKMA PHARMS **20MG** **A075361 001** Oct 05, 2000MONOKET**AB** + LANNETT CO INC **10MG** **N020215 002** Jun 30, 1993**AB** +! **20MG** **N020215 001** Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE**AB** ACCORD HLTHCARE **30MG** **A209684 001** Oct 24, 2017**AB** **60MG** **A209684 002** Oct 24, 2017**AB** **120MG** **A209684 003** Oct 24, 2017**AB** DEXCEL LTD **30MG** **A075522 002** Sep 20, 2016**AB** **60MG** **A075522 001** Apr 17, 2000**AB** HIKMA PHARMS **30MG** **A076813 002** Mar 30, 2006**AB** **60MG** **A076813 001** Jan 07, 2005**AB** KREMERS URBAN **30MG** **A075155 002** Jan 13, 2000

PHARMS

AB **60MG** **A075155 001** Oct 30, 1998**AB** ! **120MG** **A075155 003** Aug 04, 2000**AB** NESHER PHARMS **30MG** **A075395 001** Mar 16, 2000**AB** **60MG** **A075395 002** Mar 16, 2000**AB** **120MG** **A075395 003** Mar 16, 2000**AB** TORRENT PHARMS **30MG** **A200270 001** Jun 03, 2011**AB** **60MG** **A200495 001** Jun 03, 2011**AB** **120MG** **A200495 002** Jun 03, 2011**AB** VINTAGE PHARMS **30MG** **A090598 001** Aug 11, 2010**AB** **60MG** **A090598 002** Aug 11, 2010

PRESCRIPTION DRUG PRODUCT LIST

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		120MG	A090598 003	Aug 11, 2010
-----------	--	--------------	--------------------	--------------

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831 001	Feb 02, 2016
-----------	----------------------	-----------	--------------------	--------------

AP	! MYLAN INSTITUTIONAL	1%	A090874 001	Jul 20, 2010
-----------	-----------------------	-----------	--------------------	--------------

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

AB	MYLAN PHARMS INC	10MG	A075945 001	Nov 08, 2002
-----------	------------------	-------------	--------------------	--------------

AB		20MG	A075945 002	Nov 08, 2002
-----------	--	-------------	--------------------	--------------

AB		40MG	A075945 003	Nov 08, 2002
-----------	--	-------------	--------------------	--------------

CLARAVIS

AB	TEVA PHARMS USA	10MG	A076356 001	Apr 11, 2003
-----------	-----------------	-------------	--------------------	--------------

AB		20MG	A076135 002	Apr 11, 2003
-----------	--	-------------	--------------------	--------------

AB		30MG	A076135 003	May 11, 2006
-----------	--	-------------	--------------------	--------------

AB	!	40MG	A076135 001	Apr 11, 2003
-----------	---	-------------	--------------------	--------------

ISOTRETINOIN

AB	AMNEAL PHARMS NY	10MG	A207792 001	Sep 29, 2017
-----------	------------------	-------------	--------------------	--------------

AB		20MG	A207792 002	Sep 29, 2017
-----------	--	-------------	--------------------	--------------

AB		30MG	A207792 003	Sep 29, 2017
-----------	--	-------------	--------------------	--------------

AB		40MG	A207792 004	Sep 29, 2017
-----------	--	-------------	--------------------	--------------

MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012
-----------	----------------	-------------	--------------------	--------------

AB		20MG	A076485 002	Jan 19, 2012
-----------	--	-------------	--------------------	--------------

AB		30MG	A076485 004	Aug 25, 2015
-----------	--	-------------	--------------------	--------------

AB		40MG	A076485 003	Jan 19, 2012
-----------	--	-------------	--------------------	--------------

ZENATANE

AB	DR REDDYS LABS LTD	10MG	A202099 001	Mar 25, 2013
-----------	--------------------	-------------	--------------------	--------------

AB		20MG	A202099 002	Mar 25, 2013
-----------	--	-------------	--------------------	--------------

AB		30MG	A202099 004	Feb 23, 2015
-----------	--	-------------	--------------------	--------------

AB		40MG	A202099 003	Mar 25, 2013
-----------	--	-------------	--------------------	--------------

ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951 001	May 25, 2012
----	---	--------------------	------	-------------	--------------

BX	+		20MG	N021951 002	May 25, 2012
----	---	--	------	-------------	--------------

BX	+		30MG	N021951 003	May 25, 2012
----	---	--	------	-------------	--------------

BX	+	!	40MG	N021951 004	May 25, 2012
----	---	---	------	-------------	--------------

	+		25MG	N021951 005	Aug 15, 2014
--	---	--	------	-------------	--------------

	+		35MG	N021951 006	Aug 15, 2014
--	---	--	------	-------------	--------------

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169 001	Apr 24, 2006
-----------	----------------	--------------	--------------------	--------------

AB		5MG	A077169 002	Apr 24, 2006
-----------	--	------------	--------------------	--------------

AB	WATSON LABS TEVA	2.5MG	A077317 001	Jan 05, 2006
-----------	------------------	--------------	--------------------	--------------

AB	!	5MG	A077317 002	Jan 05, 2006
-----------	---	------------	--------------------	--------------

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991 001	May 26, 2016
-----------	-----------------	--------------	--------------------	--------------

AB	ALEMBIC PHARMS LTD	100MG	A206741 001	Dec 13, 2016
-----------	--------------------	--------------	--------------------	--------------

AB	ALKEM LABS LTD	100MG	A208591 001	Jun 12, 2017
-----------	----------------	--------------	--------------------	--------------

AB	AMNEAL PHARMS	100MG	A205080 001	Sep 26, 2016
-----------	---------------	--------------	--------------------	--------------

AB	JUBILANT GENERICS	100MG	A203445 001	Feb 23, 2017
-----------	-------------------	--------------	--------------------	--------------

AB	MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012
-----------	------------------	--------------	--------------------	--------------

AB	PAR PHARM INC	100MG	A205724 001	Dec 13, 2016
-----------	---------------	--------------	--------------------	--------------

AB	SANDOZ	100MG	A076104 001	May 28, 2004
-----------	--------	--------------	--------------------	--------------

AB	ZYDUS PHARMS USA INC	100MG	A204672 001	Sep 19, 2017
-----------	----------------------	--------------	--------------------	--------------

SPORANOX

AB	+	!	JANSSEN PHARMS	100MG	N020083 001	Sep 11, 1992
-----------	---	---	----------------	--------------	--------------------	--------------

SOLUTION;ORAL

SPORANOX

	+	!	JANSSEN PHARMS	10MG/ML	N020657 001	Feb 21, 1997
--	---	---	----------------	---------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ITRACONAZOLE

TABLET; ORAL

ONMEL

+! SEBELA IRELAND LTD 200MG N022484 001 Apr 29, 2010

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

+ AMGEN INC EQ 5MG BASE N206143 001 Apr 15, 2015

+! EQ 7.5MG BASE N206143 002 Apr 15, 2015

IVACAFTOR

GRANULE; ORAL

KALYDECO

+ VERTEX PHARMS INC 50MG/PACKET N207925 001 Mar 17, 2015

+! 75MG/PACKET N207925 002 Mar 17, 2015

TABLET; ORAL

KALYDECO

+! VERTEX PHARMS 150MG N203188 001 Jan 31, 2012

IVACAFTOR; LUMACAFTOR

TABLET; ORAL

ORKAMBI

+ VERTEX PHARMS INC 125MG;100MG N206038 002 Sep 28, 2016

+! 125MG;200MG N206038 001 Jul 02, 2015

IVERMECTIN

CREAM; TOPICAL

SOOLANTRA

+! GALDERMA LABS LP 1% N206255 001 Dec 19, 2014

LOTION; TOPICAL

SKLICE

+! ARBOR PHARMS LLC 0.5% N202736 001 Feb 07, 2012

TABLET; ORAL

IVERMECTIN**AB** EDENBRIDGE PHARMS **3MG****A204154 001** Oct 24, 2014STROMEKTOL**AB** +! MERCK SHARP DOHME **3MG****N050742 002** Oct 08, 1998IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+! R-PHARM US LLC 15MG/VIAL N022065 001 Oct 16, 2007

+! 45MG/VIAL N022065 002 Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

+ MILLENNIUM PHARMS EQ 2.3MG BASE N208462 001 Nov 20, 2015

+ EQ 3MG BASE N208462 002 Nov 20, 2015

+! EQ 4MG BASE N208462 003 Nov 20, 2015

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

FRESENIUS KABI USA EQ 500MG BASE/2ML A065111 001 Dec 17, 2002

! EQ 1GM BASE/3ML A065111 002 Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR**AP** +! PAR STERILE PRODUCTS**EQ 10MG BASE/ML****N016812 001****AP** +!**EQ 50MG BASE/ML****N016812 002****AP** +!**EQ 100MG BASE/ML****N016812 003**KETAMINE HYDROCHLORIDE**AP** HOSPIRA**EQ 50MG BASE/ML****A074549 001** Jun 27, 1996**AP****EQ 100MG BASE/ML****A074549 002** Jun 27, 1996**AP**

MYLAN INSTITUTIONAL

EQ 10MG BASE/ML**A076092 001** Sep 30, 2008**AP****EQ 50MG BASE/ML****A076092 002** Dec 28, 2001**AP****EQ 100MG BASE/ML****A076092 003** Oct 25, 2002**AP**

WEST-WARD PHARMS

EQ 50MG BASE/ML**A074524 001** Mar 22, 1996**AP**

INT

EQ 100MG BASE/ML**A074524 002** Mar 22, 1996

PRESCRIPTION DRUG PRODUCT LIST

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

EXTINA**AT** +! MYLAN PHARMS INC **2%** **N021738 001** Jun 12, 2007KETOCONAZOLE**AT** PERRIGO ISRAEL **2%** **A091550 001** Aug 25, 2011
CREAM;TOPICALKETOCONAZOLE**AB** FOUGERA PHARMS **2%** **A076294 001** Apr 28, 2004**AB** ! TEVA **2%** **A075581 001** Apr 25, 2000KETOZOLE**AB** TARO **2%** **A075638 001** Dec 18, 2002

GEL;TOPICAL

XOLEGEL+! AQUA PHARMS **2%** N021946 001 Jul 28, 2006

SHAMPOO;TOPICAL

KETOCONAZOLE**AB** PERRIGO NEW YORK **2%** **A076419 001** Jan 07, 2004**AB** TOLMAR **2%** **A076942 001** Apr 11, 2005NIZORAL**AB** +! JANSSEN PHARMS **2%** **N019927 001** Aug 31, 1990

TABLET;ORAL

KETOCONAZOLE**AB** MYLAN **200MG** **A075597 001** Dec 23, 1999**AB** TARO **200MG** **A075319 001** Jun 15, 1999**AB** ! TEVA **200MG** **A075273 001** Jun 15, 1999KETOPROFEN

CAPSULE;ORAL

KETOPROFEN**AB** HERITAGE PHARMS INC **50MG** **A074014 002** Jan 29, 1993**AB** **75MG** **A074014 003** Jan 29, 1993**AB** MYLAN **50MG** **A074035 002** Dec 31, 1996**AB** **75MG** **A074035 003** Dec 31, 1996**AB** TEVA **50MG** **A073516 001** Dec 22, 1992**AB** ! **75MG** **A073517 001** Dec 22, 1992

HERITAGE PHARMS INC 25MG A074014 001 Jan 29, 1993

CAPSULE, EXTENDED RELEASE;ORAL

KETOPROFEN**AB** ACTAVIS LABS FL INC **100MG** **A075270 002** Mar 24, 1999**AB** **150MG** **A075270 003** Mar 24, 1999**AB** **200MG** **A075270 001** Mar 24, 1999**AB** MYLAN **100MG** **A075679 003** Feb 20, 2002**AB** **150MG** **A075679 002** Feb 20, 2002**AB** ! **200MG** **A075679 001** Feb 20, 2002KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE**AP** AMPHASTAR PHARM **15MG/ML** **A076209 001** Jul 21, 2004**AP** **30MG/ML** **A076209 002** Jul 21, 2004**AP** CYCLE PHARMS LTD **30MG/ML** **A209900 001** Sep 15, 2017**AP** FRESENIUS KABI USA **15MG/ML** **A075784 001** Jan 11, 2002**AP** **15MG/ML** **A203242 001** Oct 07, 2015**AP** **30MG/ML** **A075784 002** Jan 11, 2002**AP** **30MG/ML** **A203242 002** Oct 07, 2015**AP** GLAND PHARMA LTD **15MG/ML** **A204216 001** Nov 01, 2016**AP** **30MG/ML** **A204216 002** Nov 01, 2016**AP** ! HOSPIRA **15MG/ML** **A074802 001** Jun 05, 1997**AP** **15MG/ML** **A074993 001** Jan 27, 1999**AP** ! **30MG/ML** **A074802 002** Jun 05, 1997**AP** **30MG/ML** **A074993 002** Jan 27, 1999**AP** SAGENT PHARMS **15MG/ML** **A091065 001** Nov 27, 2013**AP** **30MG/ML** **A091065 002** Nov 27, 2013**AP** SANDOZ INC **30MG/ML** **A076271 002** Oct 06, 2004**AP** WOCKHARDT **15MG/ML** **A077942 001** Mar 27, 2007**AP** **30MG/ML** **A077942 002** Mar 27, 2007

SOLUTION/DROPS;OPHTHALMIC

ACULAR**AT** +! ALLERGAN **0.5%** **N019700 001** Nov 09, 1992ACULAR LS**AT** +! ALLERGAN **0.4%** **N021528 001** May 30, 2003

PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434 001</u>	Nov 05, 2009
<u>AT</u>	ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721 001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109 001</u>	Nov 05, 2009
<u>AT</u>	SANDOZ INC	<u>0.5%</u>	<u>A076583 001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017 001</u>	Nov 05, 2009

ACUVAIL

+! ALLERGAN

0.45%

N022427 001 Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

+! EGALET US INC

15.75MG/SPRAY

N022382 001 May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	! MYLAN	<u>10MG</u>	<u>A074761 001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284 001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754 001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

+! OMEROS

EQ 0.3% BASE;EQ 1% BASE

N205388 001 May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

+ EMMAUS MEDCL

5GM/PACKET

N208587 001 Jul 07, 2017

NUTRESTORE

+! EMMAUS MEDCL

5GM/PACKET

N021667 001 Jun 10, 2004

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431 001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524 001</u>	Nov 29, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699 001</u>	Apr 03, 2012
<u>AP</u>	! HOSPIRA	<u>5MG/ML</u>	<u>A075239 001</u>	Nov 29, 1999
<u>AP</u>	!	<u>5MG/ML</u>	<u>A075240 001</u>	Nov 29, 1999
<u>AP</u>	SAGENT AGILA LLC	<u>5MG/ML</u>	<u>A079134 001</u>	Feb 03, 2010
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/ML</u>	<u>A075303 001</u>	May 28, 1999

TABLET;ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	INNOGENIX	<u>100MG</u>	<u>A075215 001</u>	Jul 29, 1999
<u>AB</u>		<u>200MG</u>	<u>A075215 002</u>	Jul 29, 1999
<u>AB</u>		<u>300MG</u>	<u>A075215 003</u>	Jul 29, 1999
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787 003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908 001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908 002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908 003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113 001</u>	Aug 04, 1998
<u>AB</u>	!	<u>200MG</u>	<u>A075113 002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113 003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133 003</u>	Aug 03, 1998
<u>AB</u>	ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A207743 001</u>	Sep 19, 2017
<u>AB</u>		<u>200MG</u>	<u>A207743 002</u>	Sep 19, 2017
<u>AB</u>		<u>300MG</u>	<u>A207743 003</u>	Sep 19, 2017

TRANDATE

<u>AB</u>	CNTY LINE PHARMS	<u>100MG</u>	<u>N018716 001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716 002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716 003</u>	Aug 01, 1984

PRESCRIPTION DRUG PRODUCT LIST

LACOSAMIDE

SOLUTION;INTRAVENOUS

VIMPAT

+! UCB INC 200MG/20ML (10MG/ML) N022254 001 Oct 28, 2008

SOLUTION;ORAL

VIMPAT

+! UCB INC 10MG/ML N022255 001 Apr 20, 2010

TABLET;ORAL

VIMPAT

+ UCB INC 50MG N022253 001 Oct 28, 2008

+ 100MG N022253 002 Oct 28, 2008

+ 150MG N022253 003 Oct 28, 2008

+! 200MG N022253 004 Oct 28, 2008

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

! CUMBERLAND PHARMS 10GM/PACKET A074712 001 Dec 10, 1997

! 20GM/PACKET A074712 002 Dec 10, 1997

SOLUTION;ORAL

CONSTILAC**AA** ALRA 10GM/15ML A071054 001 Jul 26, 1988LACTULOSE**AA** ANI PHARMS 10GM/15ML A078430 001 Nov 28, 2007**AA** FRESENIUS KABI 10GM/15ML A090503 001 Jan 25, 2012**AA** ! HI TECH PHARMA 10GM/15ML A074076 001 Jul 03, 1995**AA** PHARM ASSOC 10GM/15ML A074623 001 Jul 30, 1996**AA** VINTAGE PHARMS 10GM/15ML A075993 001 Jul 26, 2001**AA** VISTAPHARM 10GM/15ML A074138 001 Sep 30, 1992**AA** WEST-WARD PHARMS 10GM/15ML A073591 001 May 29, 1992**AA** INT**AA** WOCKHARDT BIO AG 10GM/15ML A074602 001 Nov 14, 1996

SOLUTION;ORAL, RECTAL

CHOLAC**AA** ALRA 10GM/15ML A071331 001 Jul 26, 1988ENULOSE**AA** ! ACTAVIS MID 10GM/15ML A071548 001 Aug 15, 1988

ATLANTIC

GENERLAC**AA** WOCKHARDT BIO AG 10GM/15ML A074603 001 Oct 31, 1996LACTULOSE**AA** ANI PHARMS 10GM/15ML A090426 001 Nov 21, 2008**AA** BIO-PHARM INC 10GM/15ML A203762 001 Mar 27, 2015**AA** FRESENIUS KABI 10GM/15ML A090502 001 Jan 25, 2012**AA** HI TECH PHARMA 10GM/15ML A074077 001 Jul 03, 1995LAMIVUDINE

SOLUTION;ORAL

EPIVIR**AA** +! VIIV HLTHCARE 10MG/ML N020596 001 Nov 17, 1995LAMIVUDINE**AA** AUROBINDO PHARMA 10MG/ML A077695 001 Nov 21, 2016

LTD

AA SILARX PHARMS INC 10MG/ML A203564 001 Oct 31, 2014

EPIVIR-HBV

+! GLAXOSMITHKLINE 5MG/ML N021004 001 Dec 08, 1998

TABLET;ORAL

EPIVIR**AB** + VIIV HLTHCARE 150MG N020564 001 Nov 17, 1995**AB** +! 300MG N020564 003 Jun 24, 2002EPIVIR-HBV**AB** +! GLAXOSMITHKLINE 100MG N021003 001 Dec 08, 1998LAMIVUDINE**AB** APOTEX 150MG A091606 001 Dec 02, 2011**AB** 300MG A091606 002 Dec 02, 2011**AB** APOTEX INC 100MG A202941 001 Jan 02, 2014**AB** APPCO PHARMA LLC 150MG A206974 001 Nov 21, 2016**AB** 300MG A206974 002 Nov 21, 2016**AB** AUROBINDO PHARMA 150MG A077464 001 Nov 21, 2016

LTD

AB 150MG A202032 001 Nov 17, 2011**AB** 300MG A077464 002 Nov 21, 2016**AB** 300MG A202032 002 Nov 17, 2011**AB** CIPLA LTD 150MG A077221 001 Mar 03, 2017

PRESCRIPTION DRUG PRODUCT LIST

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

<u>AB</u>		<u>300MG</u>	<u>A077221</u>	<u>002</u>	Mar 03, 2017
<u>AB</u>	ECI PHARMS LLC	<u>150MG</u>	<u>A203586</u>	<u>001</u>	Nov 21, 2016
<u>AB</u>	HETERO LABS LTD V	<u>100MG</u>	<u>A203260</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>		<u>150MG</u>	<u>A203277</u>	<u>001</u>	Jan 06, 2014
<u>AB</u>		<u>300MG</u>	<u>A203277</u>	<u>002</u>	Jan 06, 2014
<u>AB</u>	LUPIN LTD	<u>150MG</u>	<u>A205217</u>	<u>001</u>	Dec 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A205217</u>	<u>002</u>	Dec 18, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A204002</u>	<u>001</u>	Dec 31, 2014
<u>AB</u>		<u>150MG</u>	<u>A204528</u>	<u>001</u>	Mar 04, 2016
<u>AB</u>		<u>300MG</u>	<u>A204528</u>	<u>002</u>	Mar 04, 2016

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

<u>AB</u>	+!	VIIV HLTHCARE	<u>150MG;300MG</u>	<u>N020857</u>	<u>001</u>	Sep 26, 1997
-----------	----	---------------	--------------------	----------------	------------	--------------

LAMIVUDINE AND ZIDOVUDINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG;300MG</u>	<u>A077558</u>	<u>001</u>	May 05, 2017
<u>AB</u>		<u>150MG;300MG</u>	<u>A202418</u>	<u>001</u>	May 15, 2012
<u>AB</u>	HETERO LABS LTD III	<u>150MG;300MG</u>	<u>A079124</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>	HETERO LABS LTD V	<u>150MG;300MG</u>	<u>A203259</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	LUPIN LTD	<u>150MG;300MG</u>	<u>A090246</u>	<u>001</u>	May 15, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>150MG;300MG</u>	<u>A204005</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>150MG;300MG</u>	<u>A079128</u>	<u>001</u>	May 13, 2015
<u>AB</u>	TEVA PHARMS	<u>150MG;300MG</u>	<u>A079081</u>	<u>001</u>	May 25, 2011
<u>BX</u>	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

<u>AB</u>	+!	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>	+		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>	+		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>	+		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994

LAMOTRIGINE

<u>AB</u>	ALEMbic PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420 002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420 003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420 004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525 002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525 003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525 004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388 001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388 002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388 003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388 004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947 002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947 003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947 004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170 001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170 002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170 003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170 004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633 003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633 004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633 005</u>	Jan 27, 2009
		50MG	A077633 002	Jan 27, 2009
		250MG	A077633 006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764 004</u>	Sep 08, 2000
<u>AB</u>	+		<u>5MG</u>	<u>N020764 001</u>	Aug 24, 1998
<u>AB</u>	+	!	<u>25MG</u>	<u>N020764 002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168 001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168 002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401 002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401 003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK PHARMS LTD	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420 001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420 002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+	!	<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>	+	!	<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>	+		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>	+		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013
<u>AB</u>		<u>50MG</u>	<u>A202383 002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383 003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383 004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383 005</u>	Jun 19, 2013
<u>AB</u>	HANDA PHARMS LLC	<u>25MG</u>	<u>A202887 001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887 002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887 003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887 004</u>	Jun 17, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791 001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791 002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791 003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791 004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791 005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791 006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370 001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370 002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370 003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370 004</u>	Dec 23, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498 001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498 002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498 003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498 004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498 005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251 001</u>	May 08, 2009
<u>AB</u>	+	!	<u>50MG</u>	<u>N022251 002</u>	May 08, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022251 003</u>	May 08, 2009
<u>AB</u>	+		<u>200MG</u>	<u>N022251 004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>		IMPAX LABS INC	<u>25MG</u>	<u>A200828 001</u>	Jul 15, 2013
<u>AB</u>			<u>50MG</u>	<u>A200828 002</u>	Jul 15, 2013
<u>AB</u>			<u>100MG</u>	<u>A200828 003</u>	Jul 15, 2013
<u>AB</u>			<u>200MG</u>	<u>A200828 004</u>	Jul 15, 2013
<u>AB</u>		PAR PHARM	<u>25MG</u>	<u>A204158 001</u>	Oct 27, 2015
<u>AB</u>			<u>50MG</u>	<u>A204158 002</u>	Oct 27, 2015
<u>AB</u>			<u>100MG</u>	<u>A204158 003</u>	Oct 27, 2015
<u>AB</u>			<u>200MG</u>	<u>A204158 004</u>	Oct 27, 2015
<u>AB</u>		SCIEGEN PHARMS INC	<u>25MG</u>	<u>A206382 001</u>	Jun 17, 2016
<u>AB</u>			<u>50MG</u>	<u>A206382 002</u>	Jun 17, 2016
<u>AB</u>			<u>100MG</u>	<u>A206382 003</u>	Jun 17, 2016
<u>AB</u>			<u>200MG</u>	<u>A206382 004</u>	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074 001	Aug 30, 2007
+	!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074 002	Aug 30, 2007
+	!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074 003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>		AJANTA PHARMA LTD	<u>15MG</u>	<u>A203957 001</u>	Oct 14, 2016
<u>AB</u>			<u>30MG</u>	<u>A203957 002</u>	Oct 14, 2016
<u>AB</u>		DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269 001</u>	Oct 15, 2010
<u>AB</u>			<u>30MG</u>	<u>A091269 002</u>	Oct 15, 2010
<u>AB</u>		INVENTIA HLTHCARE	<u>15MG</u>	<u>A205868 001</u>	Aug 30, 2017
<u>AB</u>			<u>30MG</u>	<u>A205868 002</u>	Aug 30, 2017
<u>AB</u>		KREMERS URBAN PHARMS	<u>15MG</u>	<u>A207156 001</u>	Sep 28, 2017
<u>AB</u>			<u>30MG</u>	<u>A207156 002</u>	Sep 28, 2017
<u>AB</u>		LABS LICONSA	<u>15MG</u>	<u>A203203 001</u>	Jul 25, 2016
<u>AB</u>			<u>30MG</u>	<u>A203203 002</u>	Jul 25, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>15MG</u>	<u>A090763 001</u>	Nov 10, 2009
<u>AB</u>			<u>30MG</u>	<u>A090763 002</u>	Nov 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921 001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921 002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331 001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331 002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A202637 001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509 001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255 001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255 002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176 001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176 002</u>	Sep 14, 2012
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366 001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366 002</u>	Aug 19, 2013

LANSOPRAZOLE

<u>AB</u>	KRKA TOVARNA ZDRAVIL	<u>15MG</u>	<u>A091212 001</u>	Sep 16, 2013
<u>AB</u>		<u>30MG</u>	<u>A091212 002</u>	Sep 16, 2013

PREVACID

<u>AB</u>	+ TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406 001</u>	May 10, 1995
<u>AB</u>	+!	<u>30MG</u>	<u>N020406 002</u>	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

<u>AB</u>	TEVA PHARMS USA	<u>15MG</u>	<u>A208784 001</u>	Sep 21, 2017
<u>AB</u>		<u>30MG</u>	<u>A208784 002</u>	Sep 21, 2017

PREVACID

<u>AB</u>	+ TAKEDA PHARMS USA	<u>15MG</u>	<u>N021428 001</u>	Aug 30, 2002
<u>AB</u>	+!	<u>30MG</u>	<u>N021428 002</u>	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

	+ SHIRE DEV LLC	EQ 750MG BASE	N204734 001	Sep 24, 2014
	+!	EQ 1GM BASE	N204734 002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

<u>AB</u>	+ SHIRE LLC	<u>EQ 500MG BASE</u>	<u>N021468 002</u>	Oct 26, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>N021468 003</u>	Nov 23, 2005
<u>AB</u>	+!	<u>EQ 1GM BASE</u>	<u>N021468 004</u>	Nov 23, 2005

LANTHANUM CARBONATE

<u>AB</u>	NATCO PHARMA LTD	<u>EQ 500MG BASE</u>	<u>A090978 001</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090978 002</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090978 003</u>	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

	+! NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059 001	Mar 13, 2007
--	----------------------------	---------------	-------------	--------------

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887 001</u>	Jul 19, 2011
<u>AT</u>	AMRING PHARMS	<u>0.005%</u>	<u>A200925 001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006 001</u>	Mar 22, 2011
<u>AT</u>	DR REDDYS LABS LTD	<u>0.005%</u>	<u>A202077 001</u>	Feb 11, 2013
<u>AT</u>	FDC LTD	<u>0.005%</u>	<u>A202442 001</u>	Apr 22, 2016
<u>AT</u>	MYLAN	<u>0.005%</u>	<u>A201786 001</u>	Mar 22, 2011
<u>AT</u>	SANDOZ INC	<u>0.005%</u>	<u>A091449 001</u>	Mar 22, 2011

XALATAN

<u>AT</u>	+! PHARMACIA AND UPJOHN	<u>0.005%</u>	<u>N020597 001</u>	Jun 05, 1996
-----------	----------------------------	---------------	--------------------	--------------

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC

VYZULTA

	+! BAUSCH AND LOMB	0.024%	N207795 001	Nov 02, 2017
--	--------------------	--------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEDIPASVIR; SOFOSBUVIR

TABLET; ORAL

HARVONI

+! GILEAD SCIENCES INC 90MG; 400MG N205834 001 Oct 10, 2014

LEFLUNOMIDE

TABLET; ORAL

ARAVA**AB** + SANOFI AVENTIS US **10MG** **N020905 001** Sep 10, 1998**AB** +! **20MG** **N020905 002** Sep 10, 1998**LEFLUNOMIDE****AB** ALEMBIC PHARMS LTD **10MG** **A091369 001** Nov 21, 2011**AB** **20MG** **A091369 002** Nov 21, 2011**AB** APOTEX INC **10MG** **A077090 001** Sep 13, 2005**AB** **20MG** **A077090 002** Sep 13, 2005**AB** BARR **10MG** **A077083 001** Sep 13, 2005**AB** **20MG** **A077083 002** Sep 13, 2005**AB** HERITAGE PHARMS INC **10MG** **A077086 001** Sep 13, 2005**AB** **20MG** **A077086 002** Sep 13, 2005**AB** TEVA PHARMS **10MG** **A077084 001** Sep 13, 2005**AB** **20MG** **A077084 002** Sep 13, 2005

ARAVA

+! SANOFI AVENTIS US 100MG N020905 003 Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

+ CELGENE 2.5MG N021880 005 Dec 21, 2011

+ 5MG N021880 001 Dec 27, 2005

+ 10MG N021880 002 Dec 27, 2005

+ 15MG N021880 003 Jun 29, 2006

+ 20MG N021880 006 Jun 05, 2013

+! 25MG N021880 004 Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

+ EISAI INC EQ 4MG BASE N206947 001 Feb 13, 2015

+! EQ 10MG BASE N206947 002 Feb 13, 2015

LESINURAD

TABLET; ORAL

ZURAMPIC

+! IRONWOOD PHARMS INC 200MG N207988 001 Dec 22, 2015

LETERMOVIR

SOLUTION; IV (INFUSION)

PREVMIS

+! MERCK SHARP DOHME 240MG/12ML (20MG/ML) N209940 001 Nov 08, 2017

+! 480MG/24ML (20MG/ML) N209940 002 Nov 08, 2017

TABLET; ORAL

PREVMIS

+ MERCK SHARP DOHME 240MG N209939 001 Nov 08, 2017

+! 480MG N209939 002 Nov 08, 2017

LETROZOLE

TABLET; ORAL

FEMARA**AB** +! NOVARTIS PHARMS **2.5MG** **N020726 001** Jul 25, 1997**LETROZOLE****AB** ACCORD HLTHCARE **2.5MG** **A090934 001** Jun 03, 2011**AB** APOTEX INC **2.5MG** **A091303 001** Apr 19, 2012**AB** DR REDDYS LABS LTD **2.5MG** **A091191 001** Jun 03, 2011**AB** FRESENIUS KABI **2.5MG** **A090491 001** Jun 03, 2011

ONCOL

AB HIKMA PHARMS **2.5MG** **A203796 001** Jun 03, 2016**AB** INDICUS PHARMA **2.5MG** **A201804 001** Jun 03, 2011**AB** JIANGSU HENGRUI MED **2.5MG** **A202716 001** May 16, 2013**AB** MYLAN **2.5MG** **A078190 001** Dec 24, 2008**AB** NATCO PHARMA LTD **2.5MG** **A200161 001** Jun 03, 2011**AB** TEVA PHARMS **2.5MG** **A090289 001** Jun 03, 2011**AB** VINTAGE PHARMS LLC **2.5MG** **A090789 001** Jun 03, 2011**AB** WEST-WARD PHARMS **2.5MG** **A090838 001** Jun 03, 2011

INT

PRESCRIPTION DRUG PRODUCT LIST

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+	!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017
---	---	-------------------------	-----------------------------	---------	-----	--------------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>		TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	!		<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>LEUCOVORIN CALCIUM PRESERVATIVE FREE</u>						
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A040286</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>		MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A203800</u>	<u>001</u>	May 19, 2017
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A203800</u>	<u>002</u>	May 19, 2017
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A203800</u>	<u>003</u>	May 19, 2017
<u>AP</u>		SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 100MG BASE/VIAL</u>	<u>A200753</u>	<u>002</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A200753</u>	<u>003</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A200855</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A209110</u>	<u>001</u>	Oct 26, 2017
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>	!		<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
	!		EQ 10MG BASE/ML	A040347	001	Apr 25, 2000

TABLET;ORAL

LEUCOVORIN CALCIUM

<u>AB</u>		BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		WEST-WARD PHARMS INT	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	!		<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
			EQ 10MG BASE	A072734	001	Feb 22, 1993
			EQ 15MG BASE	A072735	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	!	SANDOZ	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>		TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000
LUPRON DEPOT						
	+	!	ABEVIE ENDOCRINE INC	3.75MG	N020011	002 Oct 26, 1995
	+		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+		30MG/VIAL	N020517	002	May 30, 1997
	+		45MG/VIAL	N020517	003	Jun 17, 2011
LUPRON DEPOT-PED						
	+	!	ABEVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002 Apr 16, 1993
	+		11.25MG/VIAL	N020263	005	Jan 21, 1994
	+		11.25MG/VIAL	N020263	007	Aug 15, 2011
	+		15MG/VIAL	N020263	006	Jan 21, 1994
	+		30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+	!	TOLMAR THERAP	7.5MG/VIAL	N021343	001 Jan 23, 2002
	+		22.5MG/VIAL	N021379	001	Jul 24, 2002
	+		30MG/VIAL	N021488	001	Feb 13, 2003
	+		45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

	+		ABEVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001 Dec 14, 2012
	+	!		11.25MG/VIAL,N/A;N/A,5MG	N203696	002 Dec 14, 2012

PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	AUROBINDO PHARMA LTD	<u>EQ 0.25% BASE</u>	<u>A207628 001</u>	Jan 31, 2017
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A207625 001</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207625 002</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207625 003</u>	Dec 30, 2016
<u>AN</u>	CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171 002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171 003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171 001</u>	Dec 13, 2013
<u>AN</u>	IMPAX LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008
<u>AN</u>	MYLAN SPECIALITY LP	<u>EQ 0.0103% BASE</u>	<u>A077800 001</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800 002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800 003</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.0103% BASE</u>	<u>A203653 001</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A203653 002</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A203653 003</u>	Mar 22, 2016
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013

XOPENEX

<u>AN</u>	+! OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+!	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+!	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999
<u>AN</u>	+!	<u>EQ 0.25% BASE</u>	<u>N020837 004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+! SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+! UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872 001</u>	Jul 31, 2006
-----------	------------	-----------------------------	--------------------	--------------

LEVETIRACETAM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A204312 001</u>	Feb 01, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813 001</u>	May 26, 2010
<u>AP</u>		<u>500MG/5ML (100MG/ML)</u>	<u>A090876 001</u>	Aug 13, 2015
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981 001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/5ML (100MG/ML)</u>	<u>A202869 001</u>	Apr 06, 2012
<u>AP</u>	JUBILANT GENERICS	<u>500MG/5ML (100MG/ML)</u>	<u>A206838 001</u>	Jun 02, 2016
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143 001</u>	Jan 31, 2012
<u>AP</u>	MYLAN LABS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A203308 001</u>	Sep 16, 2016
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627 001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754 001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485 001</u>	Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/100ML (5MG/ML)</u>	<u>A207160 001</u>	Jan 04, 2017
<u>AP</u>		<u>1000MG/100ML (10MG/ML)</u>	<u>A207160 002</u>	Jan 04, 2017
<u>AP</u>		<u>1500MG/100ML (15MG/ML)</u>	<u>A207160 003</u>	Jan 04, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/100ML (5MG/ML)</u>	<u>A206880 001</u>	Oct 25, 2017
<u>AP</u>		<u>1000MG/100ML (10MG/ML)</u>	<u>A206880 002</u>	Oct 25, 2017
<u>AP</u>		<u>1500MG/100ML (15MG/ML)</u>	<u>A206880 003</u>	Oct 25, 2017
<u>AP</u>	+! HQ SPECIALITY PHARMA	<u>500MG/100ML (5MG/ML)</u>	<u>N202543 001</u>	Nov 09, 2011
<u>AP</u>	+!	<u>1000MG/100ML (10MG/ML)</u>	<u>N202543 002</u>	Nov 09, 2011
<u>AP</u>	+!	<u>1500MG/100ML (15MG/ML)</u>	<u>N202543 003</u>	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+! UCB INC	<u>100MG/ML</u>	<u>N021505 001</u>	Jul 15, 2003
-----------	------------	-----------------	--------------------	--------------

LEVETIRACETAM

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976 001</u>	Jan 15, 2009
<u>AA</u>	ALLIED PHARMA INC	<u>100MG/ML</u>	<u>A078582 001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992 001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARMA	<u>100MG/ML</u>	<u>A079063 001</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

LTD

<u>AA</u>	BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>	HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052</u>	<u>001</u>	Feb 28, 2013
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601</u>	<u>001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893</u>	<u>001</u>	Oct 17, 2011
<u>AA</u>	ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067</u>	<u>001</u>	May 09, 2013
<u>AA</u>	PHARM ASSOC	<u>100MG/ML</u>	<u>A201157</u>	<u>001</u>	Jun 04, 2015
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT BIO AG	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET;ORAL

KEPPRA

<u>AB</u>	+	UCB INC	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>	+		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>	+		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	+	!	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>		ACCORD HLTHCARE	<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>			<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>			<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>			<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>		ACI HEALTHCARE LTD	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		ACIC PHARMS	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>			<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>			<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>			<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		AJANTA PHARMA	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>			<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>			<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>			<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>			<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>			<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>			<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>			<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>			<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>			<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		HETERO LABS LTD III	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>			<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>			<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>			<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>			<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>			<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>			<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>		ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A078526 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484 001</u>	Aug 05, 2010
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106 001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106 002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106 003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106 004</u>	Feb 10, 2009
<u>AB</u>	SECAN PHARMS	<u>500MG</u>	<u>A205102 004</u>	Dec 16, 2015
<u>AB</u>		<u>1GM</u>	<u>A205102 003</u>	Dec 16, 2015
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960 004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960 003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960 002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960 001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101 004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858 004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A077319 001</u>	Mar 20, 2009
<u>AB</u>		<u>250MG</u>	<u>A091491 001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A077319 002</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A091491 002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A077319 003</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A091491 003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491 004</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042 004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918 001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918 002</u>	Apr 29, 2009

ROWEEPRA

<u>AB</u>	LOTUS PHARM CO LTD	<u>250MG</u>	<u>A090906 002</u>	Oct 31, 2016
<u>AB</u>		<u>500MG</u>	<u>A090906 001</u>	Nov 05, 2010
<u>AB</u>		<u>750MG</u>	<u>A090906 003</u>	Oct 31, 2016
<u>AB</u>		<u>1GM</u>	<u>A090906 004</u>	Oct 31, 2016

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	+ UCB INC	<u>500MG</u>	<u>N022285 001</u>	Sep 12, 2008
<u>AB</u>	+!	<u>750MG</u>	<u>N022285 002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557 002</u>	Sep 12, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093 002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360 001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360 002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261 002</u>	Sep 12, 2011
<u>AB</u>	DEXCEL PHARMA	<u>500MG</u>	<u>A202167 001</u>	Sep 04, 2015
<u>AB</u>		<u>750MG</u>	<u>A202167 002</u>	Sep 04, 2015
<u>AB</u>	ECI PHARMS LLC	<u>500MG</u>	<u>A204754 001</u>	Aug 26, 2016
<u>AB</u>		<u>750MG</u>	<u>A204754 002</u>	Aug 26, 2016
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>500MG</u>	<u>A204511 001</u>	Feb 23, 2016
<u>AB</u>		<u>750MG</u>	<u>A204511 002</u>	Feb 23, 2016
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A202095 002</u>	Jun 06, 2016
<u>AB</u>		<u>750MG</u>	<u>A202095 001</u>	Jun 06, 2016
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399 002</u>	Sep 12, 2011
<u>AB</u>	PHARMADAX INC	<u>500MG</u>	<u>A201464 001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464 002</u>	May 25, 2012
<u>AB</u>	PHARMTAK INC	<u>500MG</u>	<u>A207175 001</u>	Sep 28, 2017
<u>AB</u>		<u>750MG</u>	<u>A207175 002</u>	Sep 28, 2017
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A202533 001</u>	Jul 20, 2012
<u>AB</u>		<u>500MG</u>	<u>A203468 001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A202533 002</u>	Jul 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A203468</u>	<u>002</u>	May 21, 2015
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARM INDUSTRIES	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VIRTUS PHARMS	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
	APOTEX INC	1GM	A202958	001	Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015
+		500MG	N207958	002	Jul 31, 2015
+		750MG	N207958	003	Jul 31, 2015
+	!	1GM	N207958	004	Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+	ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+		<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	SANDOZ INC	<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

<u>AP</u>	+	LEADIANT BIOSCI INC	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	---	---------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>		LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>		WEST-WARD PHARMS INT	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001

SOLUTION;ORAL

CARNITOR

<u>AA</u>	+	LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	---	---------------------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	+	LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	---	---------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AA</u>		HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>		LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET;ORAL

CARNITOR

<u>AB</u>	+	LEADIANT BIOSCI INC	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	---	---------------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>		RISING PHARMS INC	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	--	-------------------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>		APOTEX INC	<u>2.5MG/5ML</u>	<u>A202915</u>	<u>001</u>	Aug 21, 2014
<u>AA</u>		L PERRIGO CO	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>		SILARX PHARMS INC	<u>2.5MG/5ML</u>	<u>A204599</u>	<u>001</u>	May 15, 2017
<u>AA</u>		TARO PHARM INDS	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

XYZAL

<u>AA</u>	+	SANOFI-AVENTIS US	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008
-----------	---	-------------------	------------------	----------------	------------	--------------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>		ALLIED PHARMA INC	<u>5MG</u>	<u>A204323</u>	<u>001</u>	Dec 20, 2016
<u>AB</u>		APOTEX INC	<u>5MG</u>	<u>A203027</u>	<u>001</u>	Feb 13, 2015
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>		GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A205564</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013
	INDIA				
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203646</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A201653</u>	<u>001</u>	Jun 26, 2015
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+!	SANOFI-AVENTIS US	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007
-----------	----	-------------------	------------	----------------	------------	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

<u>AP</u>	+!	JANSSEN PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>001</u>	Dec 20, 1996
<u>AP</u>	+!		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>004</u>	Dec 20, 1996

LEVOFLOXACIN

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436</u>	<u>001</u>	Jun 05, 2013
<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>		SAGENT AGILA LLC	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>001</u>	Jun 20, 2011
<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>002</u>	Jun 20, 2011
<u>AP</u>		ZYDUS PHARMS USA INC	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A205968</u>	<u>001</u>	Jun 01, 2017
<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A205968</u>	<u>002</u>	Jun 01, 2017

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	!	ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011
<u>AP</u>	!		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011
<u>AP</u>	!		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A206919</u>	<u>001</u>	Feb 10, 2016
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A206919</u>	<u>002</u>	Feb 10, 2016
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A206919</u>	<u>003</u>	Feb 10, 2016
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>001</u>	Aug 08, 2013
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>002</u>	Aug 08, 2013
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>003</u>	Aug 08, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>001</u>	Jun 19, 2013
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>002</u>	Jun 19, 2013
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>003</u>	Jun 19, 2013
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011
<u>AP</u>		HOSPIRA INC	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>001</u>	Sep 03, 2015
<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>002</u>	Sep 03, 2015
<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>003</u>	Sep 03, 2015

SOLUTION; ORAL

LEVOFLOXACIN

! HI TECH PHARMA

250MG/10ML

A091678 001 Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>		MYLAN LABS LTD	<u>0.5%</u>	<u>A204899</u>	<u>001</u>	Dec 08, 2017
<u>AT</u>	!	RISING PHARMS INC	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>		WATSON LABS TEVA	<u>0.5%</u>	<u>A076826</u>	<u>001</u>	Feb 10, 2011

TABLET; ORAL

LEVAQUIN

<u>AB</u>	+	JANSSEN PHARMS	<u>250MG</u>	<u>N020634</u>	<u>001</u>	Dec 20, 1996
<u>AB</u>	+		<u>500MG</u>	<u>N020634</u>	<u>002</u>	Dec 20, 1996
<u>AB</u>	+!		<u>750MG</u>	<u>N020634</u>	<u>003</u>	Sep 08, 2000

LEVOFLOXACIN

<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A090787</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>			<u>500MG</u>	<u>A090787</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>			<u>750MG</u>	<u>A090787</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043</u>	<u>001</u>	Jun 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>		<u>500MG</u>	<u>A201043</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	HETERO LABS LTD V	<u>250MG</u>	<u>A202801</u>	<u>001</u>	Jan 08, 2015
<u>AB</u>		<u>500MG</u>	<u>A202801</u>	<u>002</u>	Jan 08, 2015
<u>AB</u>		<u>750MG</u>	<u>A202801</u>	<u>003</u>	Jan 08, 2015
<u>AB</u>	JUBILANT GENERICS	<u>250MG</u>	<u>A203613</u>	<u>001</u>	Jun 19, 2015
<u>AB</u>		<u>500MG</u>	<u>A203613</u>	<u>002</u>	Jun 19, 2015
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839</u>	<u>001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839</u>	<u>002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839</u>	<u>003</u>	Mar 22, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A090367</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652</u>	<u>001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652</u>	<u>002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652</u>	<u>003</u>	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

<u>AP</u>	<u>+</u> !	SPECTRUM PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>N020140</u>	<u>001</u>	Mar 07, 2008
-----------	------------	-----------------	--------------------------	----------------	------------	--------------

LEVOLEUCOVORIN CALCIUM

<u>AP</u>		ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206516</u>	<u>001</u>	Feb 13, 2017
<u>AP</u>		AMNEAL PHARMS CO	<u>EQ 50MG BASE/VIAL</u>	<u>A207547</u>	<u>001</u>	Feb 13, 2017
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A206263</u>	<u>001</u>	Jun 16, 2016
	<u>+</u> !	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

<u>AP</u>		AMNEAL PHARMS CO	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A207548</u>	<u>001</u>	Sep 08, 2017
<u>AP</u>		MYLAN TEORANTA	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203576</u>	<u>001</u>	Oct 20, 2015
<u>AP</u>			<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A203576</u>	<u>002</u>	Oct 20, 2015
<u>AP</u>		SANDOZ INC	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203563</u>	<u>001</u>	Mar 09, 2015
<u>AP</u>	<u>!</u>		<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A203563</u>	<u>002</u>	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

<u>+</u>	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013
<u>+</u>		EQ 40MG BASE	N204168	002	Jul 25, 2013
<u>+</u>		EQ 80MG BASE	N204168	003	Jul 25, 2013
<u>+</u> !		EQ 120MG BASE	N204168	004	Jul 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

! DEPROCO

0.05MG/ML;2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

+! BAYER HLTHCARE

19.5MG

N208224 001 Sep 16, 2016

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015

MIRENA

+! BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+! BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

TABLET; ORAL

LEVONORGESTREL**AB** LOTUS PHARM CO LTD**0.75MG****A202684 001** Sep 02, 2016**AB** MYLAN LABS LTD**0.75MG****A202740 001** Sep 02, 2016**AB** ! PERRIGO R AND D**0.75MG****A090740 001** Dec 30, 2010LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

! SENTYNL THERAPS INC

2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

+ INSTITUT

0.013MG

N021924 013 Aug 01, 2007

BIOCHIMIQUE

+

0.025MG

N021924 002 Oct 13, 2006

+

0.05MG

N021924 003 Oct 13, 2006

+

0.075MG

N021924 004 Oct 13, 2006

+

0.088MG

N021924 010 Oct 02, 2009

+

0.1MG

N021924 005 Oct 13, 2006

+

0.112MG

N021924 008 Oct 02, 2009

+

0.125MG

N021924 006 Oct 13, 2006

+

0.137MG

N021924 009 Oct 02, 2009

+!

0.15MG

N021924 007 Oct 13, 2006

+

0.175MG

N021924 011 Apr 25, 2017

+

0.200MG

N021924 012 Apr 25, 2017

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM**AP** FERA PHARMS LLC**100MCG/VIAL****A206163 001** Jun 29, 2016**AP****500MCG/VIAL****A206163 002** Jun 29, 2016**AP** +! FRESENIUS KABI USA**100MCG/VIAL****N202231 001** Jun 24, 2011**AP** +!**200MCG/VIAL****N202231 002** Jun 24, 2011**AP** +!**500MCG/VIAL****N202231 003** Jun 24, 2011**AP** PAR STERILE**200MCG/VIAL****A205366 001** Dec 07, 2015

PRODUCTS

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

SYNTHROID**-->** + ABBVIE**--> AB1, AB2****0.025MG**

N021402 001 Jul 24, 2002

--> +**--> AB1, AB2****0.05MG**

N021402 002 Jul 24, 2002

--> +**--> AB1, AB2****0.075MG**

N021402 003 Jul 24, 2002

--> +**--> AB1, AB2****0.088MG**

N021402 004 Jul 24, 2002

--> +**--> AB1, AB2****0.1MG**

N021402 005 Jul 24, 2002

--> +**--> AB1, AB2****0.112MG**

N021402 006 Jul 24, 2002

--> +**--> AB1, AB2****0.125MG**

N021402 007 Jul 24, 2002

--> +**--> AB1, AB2****0.137MG**

N021402 008 Jul 24, 2002

--> +**--> AB1, AB2****0.15MG**

N021402 009 Jul 24, 2002

--> +**--> AB1, AB2****0.175MG**

N021402 010 Jul 24, 2002

--> +**--> AB1, AB2****0.2MG**

N021402 012 Jul 24, 2002

--> +!**--> AB1, AB2****0.3MG**

N021402 011 Jul 24, 2002

LEVO-T**-->** + CEDIPROF INC**--> AB1, AB2, AB3** **0.025MG**

N021342 001 Mar 01, 2002

--> +**--> AB1, AB2, AB3** **0.05MG**

N021342 002 Mar 01, 2002

--> +**--> AB1, AB2, AB3** **0.075MG**

N021342 003 Mar 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021342	004	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021342	005	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021342	006	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021342	007	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021342	012	Dec	08,	2003
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342	008	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342	009	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342	010	Mar	01,	2002
-->	+	-->	<u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342	011	Mar	01,	2002

UNITHROID

-->	+	STEVENS J	-->	<u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210	001	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210	002	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210	003	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210	004	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210	005	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210	006	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210	007	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210	012	Feb	08,	2008
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210	008	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210	009	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210	010	Aug	21,	2000
-->	+		-->	<u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210	011	Aug	21,	2000

LEVOTHYROXINE SODIUM

-->		MYLAN	-->		<u>0.025MG</u>	A076187	001	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.05MG</u>	A076187	002	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.075MG</u>	A076187	003	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.088MG</u>	A076187	004	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.1MG</u>	A076187	005	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.112MG</u>	A076187	006	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.125MG</u>	A076187	007	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.137MG</u>	A076187	012	Dec	13,	2006
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.15MG</u>	A076187	008	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.175MG</u>	A076187	009	Jun	05,	2002
-->			-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.2MG</u>	A076187	010	Jun	05,	2002
-->	!		-->	<u>AB1,AB2,AB3,AB4</u>	<u>0.3MG</u>	A076187	011	Jun	05,	2002

LEVOXYL

-->	+	KING PHARMS	-->	<u>AB1,AB3</u>	<u>0.025MG</u>	N021301	001	May	25,	2001
-->	+		-->	<u>AB1,AB3</u>	<u>0.05MG</u>	N021301	002	May	25,	2001
-->	+		-->	<u>AB1,AB3</u>	<u>0.075MG</u>	N021301	003	May	25,	2001
-->	+		-->	<u>AB1,AB3</u>	<u>0.088MG</u>	N021301	004	May	25,	2001
-->	+		-->	<u>AB1,AB3</u>	<u>0.1MG</u>	N021301	005	May	25,	2001
-->	+		-->	<u>AB1,AB3</u>	<u>0.112MG</u>	N021301	006	May	25,	2001

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOXYL

--> +	--> <u>AB1, AB3</u>	<u>0.125MG</u>	N021301 007	May 25, 2001
--> +	--> <u>AB1, AB3</u>	<u>0.137MG</u>	N021301 008	May 25, 2001
--> +	--> <u>AB1, AB3</u>	<u>0.15MG</u>	N021301 009	May 25, 2001
--> +	--> <u>AB1, AB3</u>	<u>0.175MG</u>	N021301 010	May 25, 2001
--> +!	--> <u>AB1, AB3</u>	<u>0.2MG</u>	N021301 011	May 25, 2001

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	ALKEM LABS LTD	<u>5%</u>	<u>A207810 001</u>	Mar 10, 2017
<u>AT</u>	AMNEAL PHARMS	<u>5%</u>	<u>A206297 001</u>	Aug 07, 2015
<u>AT</u>	! FOUGERA PHARMS INC	<u>5%</u>	<u>A080198 001</u>	
<u>AT</u>	GLENMARK PHARMS LTD	<u>5%</u>	<u>A206498 001</u>	Sep 09, 2016
<u>AT</u>	RICONPHARMA LLC	<u>5%</u>	<u>A208604 001</u>	Sep 20, 2017
<u>AT</u>	SEPTODONT INC	<u>5%</u>	<u>A040911 001</u>	May 23, 2011
<u>AT</u>	TARO	<u>5%</u>	<u>A086724 001</u>	
<u>AT</u>	TELIGENT PHARMA INC	<u>5%</u>	<u>A205318 001</u>	Feb 01, 2016
<u>AT</u>	VITRUVIAS THERAP	<u>5%</u>	<u>A208822 001</u>	Sep 25, 2017

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675 001</u>	Aug 23, 2012
<u>AB</u>	MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346 001</u>	Aug 07, 2015

LIDODERM

<u>AB</u>	+! TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612 001</u>	Mar 19, 1999
-----------	-----------------------	-----------	--------------------	--------------

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+!	AKORN	3.5%	N022221 001	Oct 07, 2008
----	-------	------	-------------	--------------

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A207182 001</u>	Oct 30, 2017
<u>AP</u>		<u>2%</u>	<u>A207182 002</u>	Oct 30, 2017
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328 001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158 001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329 001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078 001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158 002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294 001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158 003</u>	
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173 001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173 002</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850 001</u>	
<u>AP</u>	LUITPOLD PHARMS INC	<u>1%</u>	<u>A091564 001</u>	Aug 14, 2015

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830 002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLHCARE	<u>200MG/100ML</u>	<u>N018461 002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830 003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLHCARE	<u>400MG/100ML</u>	<u>N018461 003</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830 004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLHCARE	<u>800MG/100ML</u>	<u>N018461 004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586 001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325 001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299 001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327 001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040 001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082 001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040 002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082 002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A080404 002</u>	
<u>AP</u>		<u>2%</u>	<u>A080404 003</u>	
<u>AP</u>		<u>2%</u>	<u>N017584 001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584 002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
<u>AP</u>		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

XYLOCAINE

<u>AP</u>	+!	FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>
<u>AP</u>	+!		<u>1%</u>	<u>N006488</u>	<u>007</u>
<u>AP</u>	+!		<u>1.5%</u>	<u>N006488</u>	<u>010</u>
<u>AP</u>	+!		<u>2%</u>	<u>N006488</u>	<u>002</u>

XYLOCAINE 4% PRESERVATIVE FREE

<u>AP</u>	+!	FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>001</u>
-----------	----	--------------------	-----------	----------------	------------

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	+!	FRESENIUS KABI USA	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988
<u>AP</u>	+!		<u>2%</u>	<u>N016801</u>	<u>001</u>	
<u>AP</u>	+!		<u>4%</u>	<u>N016801</u>	<u>002</u>	
<u>AP</u>	+!		<u>20%</u>	<u>N016801</u>	<u>004</u>	

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
! HOSPIRA 5%

A083914 001

JELLY; TOPICAL

GLYDO

<u>AT</u>	SAGENT PHARMS	<u>2%</u>	<u>A201094</u>	<u>001</u>	Apr 28, 2014
-----------	---------------	-----------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003
<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	
<u>AT</u>	WATSON LABS INC	<u>2%</u>	<u>A040837</u>	<u>001</u>	Mar 23, 2011

XYLOCAINE

<u>AT</u>	+!	OAK PHARMS	<u>2%</u>	<u>N008816</u>	<u>001</u>
-----------	----	------------	-----------	----------------	------------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995
<u>AT</u>	WOCKHARDT BIO AG	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>	!	VINTAGE	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007
-----------	---	---------	-----------	----------------	------------	--------------

LIDOCAINE VISCOUS

<u>AT</u>	WEST-WARD PHARMS	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985
-----------	------------------	-----------	----------------	------------	--------------

INT

SOLUTION; TOPICAL

LARYNG-O-JET KIT

<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364</u>	<u>001</u>	
-----------	-----------------	-----------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	TELIGENT PHARMA INC	<u>4%</u>	<u>A204494</u>	<u>001</u>	Mar 12, 2014
<u>AT</u>	VINTAGE	<u>4%</u>	<u>A040710</u>	<u>001</u>	Feb 27, 2007
<u>AT</u>	WEST-WARD PHARMS	<u>4%</u>	<u>A088803</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>	INT				
<u>AT</u>	WOCKHARDT BIO AG	<u>4%</u>	<u>A087881</u>	<u>001</u>	Nov 18, 1982

LTA II KIT

<u>AT</u>	HOSPIRA	<u>4%</u>	<u>A080409</u>	<u>001</u>	
-----------	---------	-----------	----------------	------------	--

XYLOCAINE 4% PRESERVATIVE FREE

<u>AT</u>	+!	FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>002</u>
-----------	----	--------------------	-----------	----------------	------------

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

<u>AB</u>	+!	ACTAVIS LABS UT INC	<u>2.5%;2.5%</u>	<u>N019941</u>	<u>001</u>	Dec 30, 1992
-----------	----	---------------------	------------------	----------------	------------	--------------

LIDOCAINE AND PRILOCAINE

<u>AB</u>		FOUGERA PHARMS	<u>2.5%;2.5%</u>	<u>A076453</u>	<u>001</u>	Aug 18, 2003
<u>AB</u>		HI TECH PHARMA	<u>2.5%;2.5%</u>	<u>A076290</u>	<u>001</u>	Sep 25, 2003
<u>AB</u>		TOLMAR	<u>2.5%;2.5%</u>	<u>A076320</u>	<u>001</u>	Aug 27, 2003

GEL; PERIODONTAL

ORAQIX

+! DENTSPLY PHARM 2.5%;2.5%

N021451 001 Dec 19, 2003

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+! TARO PHARMS 7%;7% N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+! GALEN SPECIALTY 70MG;70MG N021623 001 Jun 23, 2005

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+! SHIRE DEV LLC 5% N208073 001 Jul 11, 2016

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+ FOREST LABS LLC 72MCG N202811 003 Jan 25, 2017

+ 145MCG N202811 001 Aug 30, 2012

+! 290MCG N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+! BOEHRINGER 5MG N201280 001 May 02, 2011

INGELHEIM

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

+ BOEHRINGER 2.5MG;500MG N201281 001 Jan 30, 2012

INGELHEIM

+ 2.5MG;850MG N201281 002 Jan 30, 2012

+! 2.5MG;1GM N201281 003 Jan 30, 2012

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

+ BOEHRINGER 2.5MG;1GM N208026 001 May 27, 2016

INGELHEIM

+! 5MG;1GM N208026 002 May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN**AP** +! PHARMACIA AND EQ 300MG BASE/ML **N050317 001**
UPJOHNLINCOMYCIN**AP** X-GEN PHARMS INC EQ 300MG BASE/ML **A201746 001** Jun 04, 2015LINDANE

LOTION; TOPICAL

LINDANE**AT** OLTA PHARMS 1% **A087313 001****AT** ! WOCKHARDT 1% **A088190 001** Aug 16, 1984

SHAMPOO; TOPICAL

LINDANE**AT** OLTA PHARMS 1% **A087266 001****AT** ! WOCKHARDT BIO AG 1% **A088191 001** Sep 18, 1984LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID**AB** WEST-WARD PHARMS 100MG/5ML **A200068 001** Jun 03, 2015
INTZYVOX**AB** +! PHARMACIA AND 100MG/5ML **N021132 001** Apr 18, 2000
UPJOHN

SOLUTION; IV (INFUSION)

LINEZOLID**AP** AUROBINDO PHARMA 600MG/300ML (2MG/ML) **A206917 001** Aug 04, 2016
LTD**AP** FRESENIUS KABI USA 600MG/300ML (2MG/ML) **A204764 001** Mar 15, 2016**AP** HOSPIRA INC 600MG/300ML (2MG/ML) **A205442 001** Jul 07, 2015**AP** HQ SPCLT PHARMA 200MG/100ML (2MG/ML) **A207001 001** Jul 07, 2017**AP** 600MG/300ML (2MG/ML) **A207001 002** Jul 07, 2017**AP** MYLAN LABS LTD 200MG/100ML (2MG/ML) **A205154 001** Dec 06, 2017**AP** 600MG/300ML (2MG/ML) **A205154 002** Dec 06, 2017**AP** NANG KUANG PHARM CO 200MG/100ML (2MG/ML) **A207354 001** Dec 20, 2016**AP** 600MG/300ML (2MG/ML) **A207354 002** Dec 20, 2016

PRESCRIPTION DRUG PRODUCT LIST

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

<u>AP</u>	SAGENT PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A204696 001</u>	Mar 02, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A204696 002</u>	Mar 02, 2017
<u>AP</u>	SANDOZ INC	<u>200MG/100ML (2MG/ML)</u>	<u>A200904 001</u>	Jul 16, 2015
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A200904 002</u>	Jul 16, 2015
<u>AP</u>	TEVA PHARMS	<u>600MG/300ML (2MG/ML)</u>	<u>A200222 001</u>	Jun 27, 2012

ZYVOX

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>200MG/100ML (2MG/ML)</u>	<u>N021131 001</u>	Apr 18, 2000
<u>AP</u>	+!	<u>600MG/300ML (2MG/ML)</u>	<u>N021131 003</u>	Apr 18, 2000
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+! HOSPIRA INC	600MG/300ML (2MG/ML)	N206473 001	Jun 18, 2015
	ZYVOX			
	+ PHARMACIA AND UPJOHN	400MG/200ML (2MG/ML)	N021131 002	Apr 18, 2000

TABLET;ORAL

LINEZOLID

<u>AB</u>	ALEMBIC PHARMS LTD	<u>600MG</u>	<u>A205233 001</u>	Dec 21, 2015
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A205517 001</u>	Dec 21, 2015
<u>AB</u>	AMNEAL PHARMS	<u>600MG</u>	<u>A204536 001</u>	Dec 21, 2015
<u>AB</u>	GATE PHARMS	<u>600MG</u>	<u>A091210 001</u>	Feb 05, 2016
<u>AB</u>	GLENMARK PHARMS	<u>600MG</u>	<u>A078987 001</u>	Dec 21, 2015
<u>AB</u>	HETERO LABS LTD V	<u>600MG</u>	<u>A204239 001</u>	Dec 21, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A078845 001</u>	Dec 21, 2015
<u>AB</u>	NOVEL LABS INC	<u>600MG</u>	<u>A207526 001</u>	Aug 22, 2016
<u>AB</u>	TEVA PHARMS USA	<u>600MG</u>	<u>A078061 001</u>	May 18, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A206097 001</u>	Feb 22, 2017

ZYVOX

<u>AB</u>	+! PHARMACIA AND UPJOHN	<u>600MG</u>	<u>N021130 002</u>	Apr 18, 2000
-----------	----------------------------	--------------	--------------------	--------------

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	X GEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923 001</u>	Aug 17, 2005
<u>AP</u>	+! PAR STERILE PRODUCTS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105 001</u>	Dec 31, 1991

TABLET;ORAL

CYTOMEL

<u>AB</u>	+ KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379 001</u>	
<u>AB</u>	+	<u>EQ 0.025MG BASE</u>	<u>N010379 002</u>	
<u>AB</u>	+!	<u>EQ 0.05MG BASE</u>	<u>N010379 003</u>	

LIOTHYRONINE SODIUM

<u>AB</u>	MAYNE PHARMA INC	<u>EQ 0.005MG BASE</u>	<u>A090097 001</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097 002</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097 003</u>	Mar 20, 2009
<u>AB</u>	MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326 001</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090326 002</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090326 003</u>	Jul 14, 2009
<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295 001</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295 002</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A200295 003</u>	Nov 29, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 0.005MG BASE</u>	<u>A091382 001</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A091382 002</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A091382 003</u>	Apr 20, 2016

LIOTRIX (T4;T3)

TABLET;ORAL

	THYROLAR-0.25			
	+ FOREST LABS	0.0125MG;0.0031MG	N016807 001	
	THYROLAR-0.5			
	+ FOREST LABS	0.025MG;0.0063MG	N016807 005	
	THYROLAR-1			
	+ FOREST LABS	0.05MG;0.0125MG	N016807 004	
	THYROLAR-2			
	+ FOREST LABS	0.1MG;0.025MG	N016807 002	
	THYROLAR-3			
	+! FOREST LABS	0.15MG;0.0375MG	N016807 003	

PRESCRIPTION DRUG PRODUCT LIST

LIRAGLUTIDE RECOMBINANT

SOLUTION;SUBCUTANEOUS

SAXENDA

+! NOVO NORDISK INC 18MG/3ML (6MG/ML) N206321 001 Dec 23, 2014

VICTOZA

+! NOVO NORDISK INC 18MG/3ML (6MG/ML) N022341 001 Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

VYVANSE

+ SHIRE DEVELOPMENT 10MG N021977 007 Oct 30, 2014

+ 20MG N021977 004 Dec 10, 2007

+ 30MG N021977 001 Feb 23, 2007

+ 40MG N021977 005 Dec 10, 2007

+ 50MG N021977 002 Feb 23, 2007

+ 60MG N021977 006 Dec 10, 2007

+! 70MG N021977 003 Feb 23, 2007

TABLET, CHEWABLE;ORAL

VYVANSE

+ SHIRE DEV LLC 10MG N208510 001 Jan 28, 2017

+ 20MG N208510 002 Jan 28, 2017

+ 30MG N208510 003 Jan 28, 2017

+ 40MG N208510 004 Jan 28, 2017

+ 50MG N208510 005 Jan 28, 2017

+! 60MG N208510 006 Jan 28, 2017

LISINAPRIL

SOLUTION;ORAL

QBRELIS

+! SILVERGATE PHARMS 1MG/ML N208401 001 Jul 29, 2016

TABLET;ORAL

LISINAPRIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554</u>	<u>001</u>	Jul 30, 2013
<u>AB</u>		<u>5MG</u>	<u>A202554</u>	<u>002</u>	Jul 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A202554</u>	<u>003</u>	Jul 30, 2013
<u>AB</u>		<u>20MG</u>	<u>A202554</u>	<u>004</u>	Jul 30, 2013
<u>AB</u>		<u>30MG</u>	<u>A202554</u>	<u>005</u>	Jul 30, 2013
<u>AB</u>		<u>40MG</u>	<u>A202554</u>	<u>006</u>	Jul 30, 2013
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A076102</u>	<u>001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102</u>	<u>002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102</u>	<u>003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102</u>	<u>004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102</u>	<u>005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102</u>	<u>006</u>	Sep 30, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622</u>	<u>001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622</u>	<u>002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622</u>	<u>003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622</u>	<u>004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622</u>	<u>005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622</u>	<u>006</u>	Feb 22, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508</u>	<u>003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508</u>	<u>004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508</u>	<u>005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508</u>	<u>006</u>	Oct 29, 2013
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075752</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<u>AB</u>		<u>40MG</u>	<u>A077321 006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071 006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A075743 001</u>	Jul 01, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076180 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743 002</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743 003</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743 004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164 001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743 005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164 002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743 006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994 006</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A075944 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944 006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944 005</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059 006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402 001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402 002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402 003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402 004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402 005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402 006</u>	Apr 19, 2007
<u>PRINIVIL</u>				
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558 001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558 002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558 003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558 004</u>	Oct 25, 1988
<u>ZESTRIL</u>				
<u>AB</u>	+ ALVOGEN MALTA	<u>2.5MG</u>	<u>N019777 005</u>	Apr 29, 1993
<u>AB</u>	+	<u>5MG</u>	<u>N019777 001</u>	May 19, 1988
<u>AB</u>	+	<u>10MG</u>	<u>N019777 002</u>	May 19, 1988
<u>AB</u>	+	<u>20MG</u>	<u>N019777 003</u>	May 19, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N019777 006</u>	Jan 20, 1999
<u>AB</u>	+!	<u>40MG</u>	<u>N019777 004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159 001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159 002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159 003</u>	Jan 12, 2009
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139 001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139 002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139 003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702 001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702 002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702 003</u>	Sep 25, 2009
<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A076243 002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243 001</u>	Jun 27, 2002

PRESCRIPTION DRUG PRODUCT LIST

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		600MG	A078763 001	Apr 15, 2008
AB	+	WEST-WARD PHARMS INT	150MG	N017812 002 Jan 28, 1987
AB	+		300MG	N017812 001
AB	+		600MG	N017812 003 Jan 28, 1987

TABLET;ORAL

LITHIUM CARBONATE

AB		SUN PHARM INDS INC	300MG	A091027 001 Jun 24, 2010
AB	+	WEST-WARD PHARMS INT	300MG	N018558 001 Jan 29, 1982

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC PHARMS LTD	300MG	A204445 001 Jun 10, 2015
AB		GLENMARK GENERICS	450MG	A091616 001 Feb 14, 2011
AB		GLENMARK PHARMS INC	300MG	A091544 001 Dec 27, 2010
AB		HERITAGE PHARMA	300MG	A205532 001 Sep 29, 2016
AB		MYLAN PHARMS INC	300MG	A202288 001 Jun 29, 2012
AB			450MG	A202219 001 Aug 08, 2012
AB		UNIQUE PHARM LABS	300MG	A204779 001 Jul 27, 2015
AB			450MG	A205663 001 Jun 05, 2017
AB		WEST-WARD PHARMS INT	300MG	A076832 001 Oct 28, 2004
AB	!		450MG	A076691 001 Jan 05, 2004

LITHOBID

AB	+	ANI PHARMS INC	300MG	N018027 001
-----------	---	----------------	--------------	--------------------

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421 001
AA		WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML	A070755 001 May 21, 1986

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

+	!	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471 001 Jul 27, 2016
+	!		0.3MG/3ML (0.1MG/ML)	N208471 002 Jul 27, 2016

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

+	!	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191 001 Sep 23, 1993
---	---	-------------------------	--------------	--------------------------

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+		AEGERION	EQ 5MG BASE	N203858 001 Dec 21, 2012
+			EQ 10MG BASE	N203858 002 Dec 21, 2012
+			EQ 20MG BASE	N203858 003 Dec 21, 2012
+			EQ 30MG BASE	N203858 004 Apr 23, 2015
+			EQ 40MG BASE	N203858 005 Apr 23, 2015
+	!		EQ 60MG BASE	N203858 006 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+		CORDEN PHARMA	5MG	N017588 004 Dec 19, 2014
+			10MG	N017588 001
+			40MG	N017588 002
+	!		100MG	N017588 003

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

AB	!	MYLAN	2MG	A072741 001 Sep 18, 1991
AB		TEVA	2MG	A073192 001 Apr 30, 1992

PRESCRIPTION DRUG PRODUCT LIST

LOPINAVIR; RITONAVIR

SOLUTION; ORAL

KALETRA

<u>AA</u>	<u>+</u> !	ABBVIE	<u>80MG/ML; 20MG/ML</u>	<u>N021251</u>	<u>001</u>	Sep 15, 2000
-----------	------------	--------	-------------------------	----------------	------------	--------------

LOPINAVIR AND RITONAVIR

<u>AA</u>		SILARX PHARMS INC	<u>80MG/ML; 20MG/ML</u>	<u>A207407</u>	<u>001</u>	Dec 27, 2016
-----------	--	-------------------	-------------------------	----------------	------------	--------------

TABLET; ORAL

KALETRA

<u>+</u>		ABBVIE	100MG; 25MG	N021906	002	Nov 09, 2007
----------	--	--------	-------------	---------	-----	--------------

<u>+</u> !			200MG; 50MG	N021906	001	Oct 28, 2005
------------	--	--	-------------	---------	-----	--------------

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

<u>AA</u>		AMNEAL PHARMS	<u>2MG/ML</u>	<u>A091383</u>	<u>001</u>	Dec 23, 2009
-----------	--	---------------	---------------	----------------	------------	--------------

<u>AA</u>		HI-TECH PHARMA CO	<u>2MG/ML</u>	<u>A200169</u>	<u>001</u>	Jan 30, 2012
-----------	--	-------------------	---------------	----------------	------------	--------------

<u>AA</u>		LUPIN LTD	<u>2MG/ML</u>	<u>A091407</u>	<u>001</u>	Feb 19, 2013
-----------	--	-----------	---------------	----------------	------------	--------------

<u>AA</u>		PHARM ASSOC	<u>2MG/ML</u>	<u>A090260</u>	<u>001</u>	Jun 15, 2010
-----------	--	-------------	---------------	----------------	------------	--------------

<u>AA</u>		SAPTALIS PHARMS	<u>2MG/ML</u>	<u>A079244</u>	<u>001</u>	Apr 28, 2009
-----------	--	-----------------	---------------	----------------	------------	--------------

LORAZEPAM INTENSOL

<u>AA</u>	<u>!</u>	WEST-WARD PHARMS	<u>2MG/ML</u>	<u>A072755</u>	<u>001</u>	Jun 28, 1991
-----------	----------	------------------	---------------	----------------	------------	--------------

INT

INJECTABLE; INJECTION

ATIVAN

<u>AP</u>	<u>+</u> !	WEST-WARD PHARMS	<u>2MG/ML</u>	<u>N018140</u>	<u>001</u>	
-----------	------------	------------------	---------------	----------------	------------	--

INT

<u>AP</u>	<u>+</u> !		<u>4MG/ML</u>	<u>N018140</u>	<u>002</u>	
-----------	------------	--	---------------	----------------	------------	--

LORAZEPAM

<u>AP</u>		AKORN	<u>2MG/ML</u>	<u>A075025</u>	<u>001</u>	Jul 23, 1998
-----------	--	-------	---------------	----------------	------------	--------------

<u>AP</u>		HOSPIRA	<u>2MG/ML</u>	<u>A074243</u>	<u>001</u>	Apr 12, 1994
-----------	--	---------	---------------	----------------	------------	--------------

<u>AP</u>			<u>2MG/ML</u>	<u>A074282</u>	<u>001</u>	May 27, 1994
-----------	--	--	---------------	----------------	------------	--------------

<u>AP</u>			<u>4MG/ML</u>	<u>A074243</u>	<u>002</u>	Apr 12, 1994
-----------	--	--	---------------	----------------	------------	--------------

<u>AP</u>			<u>4MG/ML</u>	<u>A074282</u>	<u>002</u>	May 27, 1994
-----------	--	--	---------------	----------------	------------	--------------

<u>AP</u>		INTL MEDICATION SYS	<u>2MG/ML</u>	<u>A076150</u>	<u>001</u>	Nov 15, 2004
-----------	--	---------------------	---------------	----------------	------------	--------------

LORAZEPAM PRESERVATIVE FREE

<u>AP</u>		BEDFORD LABS	<u>2MG/ML</u>	<u>A077074</u>	<u>001</u>	Jul 13, 2005
-----------	--	--------------	---------------	----------------	------------	--------------

<u>AP</u>			<u>4MG/ML</u>	<u>A077074</u>	<u>002</u>	Jul 13, 2005
-----------	--	--	---------------	----------------	------------	--------------

TABLET; ORAL

ATIVAN

<u>AB</u>	<u>+</u>	VALEANT INTL	<u>0.5MG</u>	<u>N017794</u>	<u>001</u>	
-----------	----------	--------------	--------------	----------------	------------	--

<u>AB</u>	<u>+</u>		<u>1MG</u>	<u>N017794</u>	<u>002</u>	
-----------	----------	--	------------	----------------	------------	--

<u>AB</u>	<u>+</u> !		<u>2MG</u>	<u>N017794</u>	<u>003</u>	
-----------	------------	--	------------	----------------	------------	--

LORAZEPAM

<u>AB</u>		AMNEAL PHARMS	<u>0.5MG</u>	<u>A078826</u>	<u>001</u>	Jun 23, 2010
-----------	--	---------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A078826</u>	<u>002</u>	Jun 23, 2010
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A078826</u>	<u>003</u>	Jun 23, 2010
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		ANI PHARMS INC	<u>0.5MG</u>	<u>A077396</u>	<u>001</u>	Dec 13, 2006
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A077396</u>	<u>002</u>	Dec 13, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A077396</u>	<u>003</u>	Dec 13, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		AUROLIFE PHARMA LLC	<u>0.5MG</u>	<u>A203572</u>	<u>001</u>	Dec 22, 2017
-----------	--	---------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A203572</u>	<u>002</u>	Dec 22, 2017
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A203572</u>	<u>003</u>	Dec 22, 2017
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		LEADING PHARMA LLC	<u>0.5MG</u>	<u>A078203</u>	<u>001</u>	Jul 30, 2007
-----------	--	--------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A078203</u>	<u>002</u>	Jul 30, 2007
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A078203</u>	<u>003</u>	Jul 30, 2007
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>0.5MG</u>	<u>A071589</u>	<u>001</u>	Oct 13, 1987
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.5MG</u>	<u>A077657</u>	<u>001</u>	Mar 16, 2006
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A071590</u>	<u>001</u>	Oct 13, 1987
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A077657</u>	<u>002</u>	Mar 16, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A077657</u>	<u>003</u>	Mar 16, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A071141</u>	<u>002</u>	Apr 21, 1987
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A071141</u>	<u>003</u>	Apr 21, 1987
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A071141</u>	<u>001</u>	Apr 21, 1987
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A076045</u>	<u>001</u>	Aug 29, 2001
-----------	--	--------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A076045</u>	<u>002</u>	Aug 29, 2001
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A076045</u>	<u>003</u>	Aug 29, 2001
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991
-----------	--	--	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+! EISAI INC 10MG N022529 001 Jun 27, 2012

TABLET, EXTENDED RELEASE; ORAL

BELVIQ XR

+! EISAI INC 20MG N208524 001 Jul 15, 2016

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	+	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>	+		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+!		<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>			<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>			<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>		HETERO LABS LTD V	<u>25MG</u>	<u>A203835</u>	<u>001</u>	Aug 12, 2015
<u>AB</u>			<u>50MG</u>	<u>A203835</u>	<u>002</u>	Aug 12, 2015
<u>AB</u>			<u>100MG</u>	<u>A203835</u>	<u>003</u>	Aug 12, 2015
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>			<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>			<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>		LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>			<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>			<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>			<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>			<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>		TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		UNICHEM LABS LTD	<u>25MG</u>	<u>A203030</u>	<u>001</u>	Oct 14, 2015
<u>AB</u>			<u>50MG</u>	<u>A203030</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>			<u>100MG</u>	<u>A203030</u>	<u>003</u>	Oct 14, 2015
<u>AB</u>		UPSHER-SMITH LABS	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		VIVA HLTHCARE	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>			<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>			<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>		VIVIMED GLOBAL	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		WEST-WARD PHARMS INT	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ZYDUS PHARMS USA INC	25MG	A078243 001	Oct 06, 2010
AB		50MG	A078243 002	Oct 06, 2010
AB		100MG	A078243 003	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+! BAUSCH AND LOMB INC 0.5% N202872 001 Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+! BAUSCH AND LOMB 0.5% N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+! BAUSCH AND LOMB 0.2% N020803 001 Mar 09, 1998

LOTEMAX

+! BAUSCH AND LOMB 0.5% N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+! BAUSCH AND LOMB 0.5%;0.3% N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	ACTAVIS ELIZABETH	10MG	A075828 001	Dec 17, 2001
AB		20MG	A075828 002	Dec 17, 2001
AB		40MG	A075828 003	Dec 17, 2001
AB	APOTEX INC	10MG	A077748 001	Feb 28, 2007
AB		20MG	A077748 002	Feb 28, 2007
AB		40MG	A077748 003	Feb 28, 2007
AB	CARLSBAD	10MG	A075991 001	Jun 05, 2002
AB		20MG	A075991 002	Jun 05, 2002
AB	!	40MG	A075991 003	Jun 05, 2002
AB	LUPIN	10MG	A078296 001	Mar 14, 2008
AB		20MG	A078296 002	Nov 01, 2007
AB		40MG	A078296 003	Nov 01, 2007
AB	MYLAN	10MG	A075451 001	Dec 17, 2001
AB		20MG	A075451 002	Dec 17, 2001
AB		40MG	A075451 003	Dec 17, 2001
AB	SANDOZ	10MG	A075300 001	Dec 17, 2001
AB		10MG	A075636 001	Dec 17, 2001
AB		20MG	A075300 002	Dec 17, 2001
AB		20MG	A075636 002	Dec 17, 2001
AB		40MG	A075300 003	Dec 17, 2001
AB		40MG	A075636 003	Dec 17, 2001
AB	SUN PHARM INDUSTRIES	10MG	A077520 001	Apr 14, 2006
AB		20MG	A077520 002	Apr 14, 2006
AB		40MG	A077520 003	Apr 14, 2006
AB	TEVA	10MG	A075551 003	Dec 17, 2001
AB		20MG	A075551 002	Dec 17, 2001
AB		40MG	A075551 001	Dec 17, 2001

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

+ COVIS PHARMA BV 20MG N021316 002 Jun 26, 2002

+ 40MG N021316 003 Jun 26, 2002

+! 60MG N021316 004 Jun 26, 2002

LOXAPINE

POWDER; INHALATION

ADASUVE

+! GALEN UK 10MG N022549 001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868 001	Aug 04, 2005
AB		EQ 10MG BASE	A076868 002	Aug 04, 2005
AB		EQ 25MG BASE	A076868 003	Aug 04, 2005
AB		EQ 50MG BASE	A076868 004	Aug 04, 2005

PRESCRIPTION DRUG PRODUCT LIST

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

<u>AB</u>	LANNETT HOLDINGS INC	<u>EQ 5MG BASE</u>	<u>A090695 001</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090695 002</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A090695 003</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695 004</u>	Sep 26, 2011
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762 001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762 002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762 003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762 004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205 001</u>	Jun 15, 1988
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A072206 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062 001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

+	SUCAMPO PHARMA LLC	8MCG	N021908 002	Apr 29, 2008
+	!	24MCG	N021908 001	Jan 31, 2006

LULICONAZOLE

CREAM;TOPICAL

LUZU

+	!	MEDICIS	1%	N204153 001	Nov 14, 2013
---	---	---------	----	-------------	--------------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

+	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011
+	!	40MG	N200603 001	Oct 28, 2010
+		60MG	N200603 005	Jul 12, 2013
+		80MG	N200603 002	Oct 28, 2010
+		120MG	N200603 004	Apr 26, 2012

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+	!	AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598 001	Dec 21, 2017
---	---	------------------	--------------------	-------------	--------------

MACITENTAN

TABLET;ORAL

OPSUMIT

+	!	ACTELION PHARMS LTD	10MG	N204410 001	Oct 18, 2013
---	---	---------------------	------	-------------	--------------

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

+	!	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763 001
---	---	---------------------	-----------------	-------------

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

<u>AT</u>	NOVAST LABS LTD	<u>5%</u>	<u>A206716 001</u>	Jul 31, 2017		
<u>AT</u>	PAR FORM	<u>5%</u>	<u>A201511 001</u>	Feb 12, 2013		
<u>AT</u>	+	!	MYLAN INSTITUTIONAL	<u>5%</u>	<u>N019832 003</u>	Jun 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696 001	Sep 29, 1989
---	---	---------	---	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378 001</u>	
<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378 002</u>	Nov 22, 1982
	ISOLYTE S IN PLASTIC CONTAINER			
	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711 001	Sep 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG	N017586	001	
	/100ML; 502MG/100ML			

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG	N019024	001	Jun 08, 1984
	/100ML; 500MG/100ML			

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG	N017637	002	Jul 08, 1982
	/100ML; 502MG/100ML			

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+! DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910	001	Jul 26, 2006
------------------	---	---------	-----	--------------

NORMOCARB HF 35

+! DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910	002	Jul 26, 2006
------------------	---	---------	-----	--------------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1GM/100ML</u>	<u>A206486</u>	<u>001</u>	Mar 07, 2016
<u>AP</u>	+! HOSPIRA	<u>1GM/100ML</u>	<u>N020488</u>	<u>001</u>	Jul 11, 1995
<u>AP</u>	HQ SPCLT PHARMA	<u>1GM/100ML</u>	<u>A207349</u>	<u>001</u>	Mar 02, 2016

MAGNESIUM SULFATE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>4GM/100ML (40MG/ML)</u>	<u>A206485</u>	<u>001</u>	Mar 15, 2016
<u>AP</u>		<u>4GM/50ML (80MG/ML)</u>	<u>A206485</u>	<u>002</u>	Mar 15, 2016
<u>AP</u>		<u>2GM/50ML (40MG/ML)</u>	<u>A206485</u>	<u>003</u>	Mar 15, 2016
<u>AP</u>		<u>20GM/500ML (40MG/ML)</u>	<u>A206485</u>	<u>004</u>	Mar 15, 2016
<u>AP</u>		<u>40GM/1000ML (40MG/ML)</u>	<u>A206485</u>	<u>005</u>	Mar 15, 2016
<u>AP</u>	+ HOSPIRA	<u>2GM/50ML (40MG/ML)</u>	<u>N020309</u>	<u>003</u>	Jan 26, 2007
<u>AP</u>	+!	<u>4GM/100ML (40MG/ML)</u>	<u>N020309</u>	<u>001</u>	Jun 24, 1994
<u>AP</u>	+!	<u>4GM/50ML (80MG/ML)</u>	<u>N020309</u>	<u>002</u>	Jun 24, 1994
<u>AP</u>	+	<u>20GM/500ML (40MG/ML)</u>	<u>N020309</u>	<u>004</u>	Jan 18, 1995
<u>AP</u>	+	<u>40GM/1000ML (40MG/ML)</u>	<u>N020309</u>	<u>005</u>	Jan 18, 1995
<u>AP</u>	HQ SPCLT PHARMA	<u>2GM/50ML (40MG/ML)</u>	<u>A207350</u>	<u>001</u>	Dec 06, 2017
<u>AP</u>		<u>4GM/100ML (40MG/ML)</u>	<u>A207350</u>	<u>002</u>	Dec 06, 2017
<u>AP</u>		<u>4GM/50ML (80MG/ML)</u>	<u>A207350</u>	<u>003</u>	Dec 06, 2017
<u>AP</u>		<u>20GM/500ML (40MG/ML)</u>	<u>A207350</u>	<u>004</u>	Dec 06, 2017
<u>AP</u>		<u>40GM/1000ML (40MG/ML)</u>	<u>A207350</u>	<u>005</u>	Dec 06, 2017

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+! HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995
------------	-----------	---------	-----	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

<u>AP</u>	EXELA PHARMA SCS	<u>5GM/10ML (500MG/ML)</u>	<u>A206039</u>	<u>001</u>	Dec 18, 2014
	LLC				
<u>AP</u>	+! FRESENIUS KABI USA	<u>5GM/10ML (500MG/ML)</u>	<u>N019316</u>	<u>001</u>	Sep 08, 1986
<u>AP</u>	! HOSPIRA	<u>5GM/10ML (500MG/ML)</u>	<u>A075151</u>	<u>001</u>	Apr 25, 2000
	+! FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016
	+! HOSPIRA INC	25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016
		10GM/20ML (500MG/ML)	A202411	001	May 14, 2015

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+! FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986
-----------------------	--------------------	---------	-----	--------------

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018508</u>	<u>001</u>	Feb 19, 1982
-----------	-----------------	--	----------------	------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018336</u>	<u>001</u>	
-----------	-----------------	--	----------------	------------	--

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

+! GATOR PHARMS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N204553	001	Dec 27, 2016
-----------------	-----------------------------------	---------	-----	--------------

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

<u>AA</u>	NOVEL LABS INC	<u>1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT</u>	<u>A202511</u>	<u>001</u>	Feb 23, 2017
-----------	----------------	--	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SUPREP BOWEL PREP KIT

AA	+ !	BRAINTREE LABS	<u>1.6GM/BOT;3.13GM/BOT;17.5GM/BOT</u>	<u>N022372 001</u>	Aug 05, 2010
-----------	------------	----------------	---	---------------------------	--------------

MALATHION

LOTION;TOPICAL

MALATHION

AT		SUVEN LIFE	<u>0.5%</u>	<u>A091559 001</u>	May 23, 2012
-----------	--	------------	--------------------	---------------------------	--------------

OVIDE

AT	+ !	TARO PHARM	<u>0.5%</u>	<u>N018613 001</u>	Aug 02, 1982
-----------	------------	------------	--------------------	---------------------------	--------------

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	<u>10GM/100ML</u>	<u>N020006 002</u>	Jul 26, 1993
-----------	--	---------	--------------------------	---------------------------	--------------

AP		ICU MEDICAL INC	<u>10GM/100ML</u>	<u>N019603 002</u>	Jan 08, 1987
-----------	--	-----------------	--------------------------	---------------------------	--------------

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	<u>15GM/100ML</u>	<u>N020006 003</u>	Jul 26, 1993
-----------	--	---------	--------------------------	---------------------------	--------------

AP		ICU MEDICAL INC	<u>15GM/100ML</u>	<u>N019603 003</u>	Jan 08, 1990
-----------	--	-----------------	--------------------------	---------------------------	--------------

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	<u>20GM/100ML</u>	<u>N020006 004</u>	Jul 26, 1993
-----------	--	---------	--------------------------	---------------------------	--------------

AP		ICU MEDICAL INC	<u>20GM/100ML</u>	<u>N019603 004</u>	Jan 08, 1990
-----------	--	-----------------	--------------------------	---------------------------	--------------

MANNITOL 25%

AP		FRESENIUS KABI USA	<u>12.5GM/50ML</u>	<u>A080677 001</u>	
-----------	--	--------------------	---------------------------	---------------------------	--

AP		HOSPIRA	<u>12.5GM/50ML</u>	<u>N016269 006</u>	Aug 25, 1994
-----------	--	---------	---------------------------	---------------------------	--------------

AP		INTL MEDICATION	<u>12.5GM/50ML</u>	<u>A083051 001</u>	
-----------	--	-----------------	---------------------------	---------------------------	--

AP		LUITPOLD	<u>12.5GM/50ML</u>	<u>A087409 001</u>	Jan 21, 1982
-----------	--	----------	---------------------------	---------------------------	--------------

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	<u>5GM/100ML</u>	<u>N020006 001</u>	Jul 26, 1993
-----------	--	---------	-------------------------	---------------------------	--------------

AP		ICU MEDICAL INC	<u>5GM/100ML</u>	<u>N019603 001</u>	Jan 08, 1987
-----------	--	-----------------	-------------------------	---------------------------	--------------

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684 002</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684 006</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 15% IN WATER

AP		BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684 004</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684 008</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 20% IN WATER

AP		BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684 003</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684 007</u>	
-----------	--	-----------------	--------------------------	---------------------------	--

OSMITROL 5% IN WATER

AP		BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684 001</u>	
-----------	--	-----------------	-------------------------	---------------------------	--

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684 005</u>	
-----------	--	-----------------	-------------------------	---------------------------	--

SOLUTION;IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N016772 002

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC

540MG/100ML;2.7GM/100ML

N018316 001

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN

25MG

A072285 002 Oct 03, 1988

!

50MG

A072285 001 Oct 03, 1988

75MG

A072285 003 Oct 03, 1988

MARAVIROC

SOLUTION;ORAL

SELZENTRY

+

VIIV HLTHCARE

20MG/ML

N208984 001 Nov 04, 2016

TABLET;ORAL

SELZENTRY

+

VIIV HLTHCARE

25MG

N022128 003 Nov 04, 2016

PRESCRIPTION DRUG PRODUCT LIST

MARAVIROC

TABLET; ORAL

SELZENTRY

+	75MG	N022128 004	Nov 04, 2016
+	150MG	N022128 001	Aug 06, 2007
+	300MG	N022128 002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

!	IMPAX LABS INC	100MG	A073580 001	Jan 04, 1995
+	JANSSEN PHARMS	500MG	N208398 001	Oct 19, 2016

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

!	NEXGEN PHARMA	2.5MG	A204054 001	Mar 19, 2013
---	---------------	-------	-------------	--------------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005
---	-----------	--------------------	-------------	--------------

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+	ACTELION PHARMS LTD	EQ 0.016% BASE	N202317 001	Aug 23, 2013
---	---------------------	----------------	-------------	--------------

INJECTABLE; INJECTION

MUSTARGEN

+	RECORDATI RARE	10MG/VIAL	N006695 001	
---	----------------	-----------	-------------	--

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451 001</u>	Feb 23, 2011
<u>AA</u>		<u>25MG</u>	<u>A201451 002</u>	Feb 23, 2011
<u>AA</u>	EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294 001</u>	Apr 13, 2012
<u>AA</u>		<u>25MG</u>	<u>A200294 002</u>	Apr 13, 2012
<u>AA</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659 001</u>	Jun 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A040659 002</u>	Jun 04, 2010
<u>AA</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A202640 001</u>	Sep 17, 2012
<u>AA</u>		<u>25MG</u>	<u>A202640 002</u>	Sep 17, 2012
<u>AA</u>	PAR PHARM	<u>12.5MG</u>	<u>A087127 001</u>	
<u>AA</u>		<u>25MG</u>	<u>A087128 001</u>	
<u>AA</u>	SANDOZ	<u>12.5MG</u>	<u>A084843 002</u>	May 22, 1989
<u>AA</u>		<u>25MG</u>	<u>A084092 003</u>	May 22, 1989

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

	EQ 50MG BASE	A071081 002	Sep 03, 1986
!	EQ 100MG BASE	A071081 001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246 001</u>	Oct 29, 1992
-----------	---	----------------------	-----------------	--------------------	--------------

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	AMPHASTAR PHARMS INC	<u>150MG/ML</u>	<u>A077235 001</u>	Nov 28, 2017
-----------	----------------------	-----------------	--------------------	--------------

<u>AB</u>		<u>150MG/ML</u>	<u>A077334 001</u>	Nov 28, 2017
<u>AB</u>	TEVA PHARMS USA	<u>150MG/ML</u>	<u>A076553 001</u>	Jul 28, 2004

DEPO-PROVERA

+	PHARMACIA AND UPJOHN	400MG/ML	N012541 003	
---	----------------------	----------	-------------	--

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583 001	Dec 17, 2004
---	----------------------	--------------	-------------	--------------

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	BARR	<u>2.5MG</u>	<u>A040159 001</u>	Aug 09, 1996
<u>AB</u>		<u>5MG</u>	<u>A040159 002</u>	Aug 09, 1996
<u>AB</u>		<u>10MG</u>	<u>A040159 003</u>	Aug 09, 1996

PRESCRIPTION DRUG PRODUCT LIST

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>	+		<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+	!	<u>10MG</u>	<u>N011839</u>	<u>004</u>	

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>		BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>		LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>		VINTAGE PHARMS LLC	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014
<u>AB</u>		VIVA HLTHCARE	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010

PONSTEL

<u>AB</u>	+	!	SHIONOGI INC	<u>250MG</u>	<u>N015034</u>	<u>003</u>
-----------	---	---	--------------	--------------	----------------	------------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	!	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>		WEST-WARD PHARMS INT	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

<u>AB</u>	+	!	ENDO PHARMS INC	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	---	---	-----------------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>		BRECKENRIDGE PHARM	<u>125MG/ML</u>	<u>A204688</u>	<u>001</u>	Dec 01, 2017
<u>AB</u>		HI-TECH PHARMACAL	<u>40MG/ML</u>	<u>A203960</u>	<u>001</u>	Jun 09, 2017
<u>AB</u>		PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>		TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>		TWI PHARMS INC	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>	!	WEST-WARD PHARMS INT	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		WOCKHARDT BIO AG	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>		BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>			<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	!		<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>		WEST-WARD PHARMS INT	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>			<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

CAPSULE; ORAL

VIVLODEX

	+	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015
	+	!	10MG	N207233	002	Oct 22, 2015

TABLET; ORAL

MELOXICAM

<u>AB</u>		APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>			<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>		AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>			<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>		BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>			<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>		GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>			<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102 001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102 002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936 001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936 002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927 001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927 002</u>	Dec 20, 2006
<u>AB</u>	YUNG SHIN PHARM	<u>7.5MG</u>	<u>A077918 001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918 002</u>	Dec 07, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921 001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921 002</u>	Jul 19, 2006
<u>MOBIC</u>				
<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938 001</u>	Apr 13, 2000
<u>AB</u>	+!	<u>15MG</u>	<u>N020938 002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

<u>AB</u>	+! APOTEX INC	<u>2MG</u>	<u>N014691 002</u>	
-----------	---------------	------------	--------------------	--

MELPHALAN

<u>AB</u>	ALVOGEN MALTA	<u>2MG</u>	<u>A207809 001</u>	Mar 22, 2017
-----------	---------------	------------	--------------------	--------------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

<u>AP</u>	ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206018 001</u>	Dec 19, 2016
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A203655 001</u>	Dec 08, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A203393 001</u>	Dec 22, 2017
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270 001</u>	Jun 09, 2009
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A204773 001</u>	Aug 22, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A201379 001</u>	Feb 28, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A090303 001</u>	Oct 28, 2010

POWDER; IV (INFUSION)

EVOMELA

	+! SPECTRUM PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>N207155 001</u>	Mar 10, 2016
--	--------------------	--------------------------	--------------------	--------------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>7MG</u>	<u>A205825 001</u>	Oct 12, 2016
<u>AB</u>		<u>14MG</u>	<u>A205825 002</u>	Oct 12, 2016
<u>AB</u>		<u>21MG</u>	<u>A205825 003</u>	Oct 12, 2016
<u>AB</u>		<u>28MG</u>	<u>A205825 004</u>	Oct 12, 2016
<u>AB</u>	ANCHEN PHARMS	<u>7MG</u>	<u>A205784 001</u>	Jun 09, 2017
<u>AB</u>		<u>14MG</u>	<u>A205784 002</u>	Jun 09, 2017
<u>AB</u>		<u>21MG</u>	<u>A205784 003</u>	Jun 09, 2017
<u>AB</u>		<u>28MG</u>	<u>A205784 004</u>	Jun 09, 2017
<u>AB</u>	APOTEX INC	<u>7MG</u>	<u>A206135 001</u>	Nov 22, 2016
<u>AB</u>		<u>14MG</u>	<u>A206135 002</u>	Nov 22, 2016
<u>AB</u>		<u>21MG</u>	<u>A206135 003</u>	Nov 22, 2016
<u>AB</u>		<u>28MG</u>	<u>A206135 004</u>	Nov 22, 2016
<u>AB</u>	LUPIN LTD	<u>7MG</u>	<u>A206028 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206028 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206028 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206028 004</u>	Sep 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>7MG</u>	<u>A206032 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206032 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206032 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206032 004</u>	Sep 28, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>7MG</u>	<u>A205905 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A205905 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A205905 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A205905 004</u>	Sep 28, 2016
<u>AB</u>	ZYDUS PHARMS USA INC	<u>7MG</u>	<u>A203293 001</u>	Aug 03, 2017
<u>AB</u>		<u>14MG</u>	<u>A203293 002</u>	Aug 03, 2017
<u>AB</u>		<u>21MG</u>	<u>A203293 003</u>	Aug 03, 2017
<u>AB</u>		<u>28MG</u>	<u>A203293 004</u>	Aug 03, 2017

PRESCRIPTION DRUG PRODUCT LIST

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

<u>AB</u>	+	FOREST LABS LLC	<u>7MG</u>	<u>N022525</u>	<u>001</u>	Jun 21, 2010
<u>AB</u>	+		<u>14MG</u>	<u>N022525</u>	<u>002</u>	Jun 21, 2010
<u>AB</u>	+		<u>21MG</u>	<u>N022525</u>	<u>003</u>	Jun 21, 2010
<u>AB</u>	+		<u>28MG</u>	<u>N022525</u>	<u>004</u>	Jun 21, 2010

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>		BIO-PHARM INC	<u>2MG/ML</u>	<u>A205446</u>	<u>001</u>	Dec 07, 2015
<u>AA</u>		MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790</u>	<u>001</u>	Oct 13, 2015
<u>AA</u>		SILARX PHARMS INC	<u>2MG/ML</u>	<u>A204033</u>	<u>001</u>	Oct 13, 2015

NAMENDA

<u>AA</u>	+	FOREST LABS LLC	<u>2MG/ML</u>	<u>N021627</u>	<u>001</u>	Apr 18, 2005
-----------	---	-----------------	---------------	----------------	------------	--------------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>			<u>10MG</u>	<u>A206528</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>		ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A200891</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A200891</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A090041</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>			<u>10MG</u>	<u>A090041</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A203175</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048</u>	<u>001</u>	Apr 14, 2010
<u>AB</u>			<u>10MG</u>	<u>A090048</u>	<u>002</u>	Apr 14, 2010
<u>AB</u>		JUBILANT GENERICS	<u>5MG</u>	<u>A091585</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A091585</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		LUPIN LTD	<u>5MG</u>	<u>A090051</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>			<u>10MG</u>	<u>A090051</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A202840</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A079225</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>			<u>10MG</u>	<u>A079225</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>		PURACAP PHARM LLC	<u>5MG</u>	<u>A206855</u>	<u>001</u>	Nov 17, 2015
<u>AB</u>			<u>10MG</u>	<u>A206855</u>	<u>002</u>	Nov 17, 2015
<u>AB</u>		SILARX PHARMS INC	<u>5MG</u>	<u>A207236</u>	<u>001</u>	Nov 10, 2016
<u>AB</u>			<u>10MG</u>	<u>A207236</u>	<u>002</u>	Nov 10, 2016
<u>AB</u>		STRIDES PHARMA	<u>5MG</u>	<u>A202350</u>	<u>001</u>	May 23, 2017
<u>AB</u>			<u>10MG</u>	<u>A202350</u>	<u>002</u>	May 23, 2017
<u>AB</u>		SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090058</u>	<u>001</u>	May 05, 2010
<u>AB</u>			<u>10MG</u>	<u>A090058</u>	<u>002</u>	May 05, 2010
<u>AB</u>		TEVA PHARMS	<u>5MG</u>	<u>A090052</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>			<u>10MG</u>	<u>A090052</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		TORRENT PHARMS LTD	<u>5MG</u>	<u>A200155</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A200155</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		UNICHEM LABS LTD	<u>5MG</u>	<u>A200022</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A200022</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		UPSHER-SMITH LABS	<u>5MG</u>	<u>A090043</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>			<u>10MG</u>	<u>A090043</u>	<u>002</u>	Jul 31, 2015
<u>AB</u>		WOCKHARDT LTD	<u>5MG</u>	<u>A090073</u>	<u>001</u>	Sep 04, 2015
<u>AB</u>			<u>10MG</u>	<u>A090073</u>	<u>002</u>	Sep 04, 2015
<u>AB</u>		ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090961</u>	<u>001</u>	Jul 10, 2017
<u>AB</u>			<u>10MG</u>	<u>A090961</u>	<u>002</u>	Jul 10, 2017

NAMENDA

<u>AB</u>	+	FOREST LABS LLC	<u>5MG</u>	<u>N021487</u>	<u>001</u>	Oct 16, 2003
<u>AB</u>	+		<u>10MG</u>	<u>N021487</u>	<u>002</u>	Oct 16, 2003

MENOTROPINS (FSH;LH)

INJECTABLE;SUBCUTANEOUS

MENOPUR

+	!	FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004
---	---	---------	-----------------------	---------	-----	--------------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

<u>AP</u>	+	!	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>
<u>AP</u>	+	!		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>
<u>AP</u>	+	!		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>
<u>AP</u>	+	!		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>

PRESCRIPTION DRUG PRODUCT LIST

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

<u>AP</u>	WEST-WARD PHARMS INT	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>	
<u>AP</u>		<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>	
<u>AP</u>		<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>	
<u>AP</u>		<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>	
<u>AP</u>		<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>	
<u>AP</u>		<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	! ICU MEDICAL INC	<u>10MG/ML</u>	<u>A088432</u>	<u>001</u>	Aug 16, 1984
<u>AP</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A081002</u>	<u>001</u>	Jul 30, 1993

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

! WEST-WARD PHARMS
INT

A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	+! US PHARM HOLDINGS	<u>50MG</u>	<u>N005010</u>	<u>001</u>	
<u>AA</u>	+!	<u>100MG</u>	<u>N005010</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AA</u>	BARR	<u>50MG</u>	<u>A088639</u>	<u>001</u>	Jul 02, 1984
<u>AA</u>		<u>100MG</u>	<u>A088640</u>	<u>001</u>	Sep 19, 1984
<u>AA</u>	EPIC PHARMA	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>		<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>	MIKART	<u>50MG</u>	<u>A040893</u>	<u>001</u>	Jun 24, 2009
<u>AA</u>		<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>	SPECGX LLC	<u>50MG</u>	<u>A040352</u>	<u>001</u>	Jun 13, 2000
<u>AA</u>		<u>100MG</u>	<u>A040352</u>	<u>002</u>	Jun 13, 2000
<u>AA</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
<u>AA</u>	WEST-WARD PHARMS INT	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
	MIKART	75MG	A040893	002	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+! HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+!	<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+!	<u>2%</u>	<u>N012250</u>	<u>002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	! SEPTODONT INC	<u>3%</u>	<u>A080925</u>	<u>001</u>	
-----------	-----------------	-----------	----------------	------------	--

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
-----------	-------------	-----------	----------------	------------	--------------

POLOCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	! DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984
-----------	-----------	-----------	----------------	------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>		<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>	INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>		<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	! WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	!	<u>400MG</u>	<u>A083308</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

+! NOVA LABS LTD 20MG/ML

N205919 001 Apr 28, 2014

TABLET; ORAL

MERCAPTOPYRINE**AB** DR REDDYS LABS SA **50MG****A040461 001** Feb 11, 2004**AB** MYLAN **50MG****A040594 001** Jul 01, 2005**AB** ! WEST-WARD PHARMS **50MG****A040528 001** Feb 13, 2004

INT

PURINETHOL**AB** + STASON PHARMS **50MG****N009053 002**MEROPEM

INJECTABLE; INJECTION

MEROPEM**AP** ACS DOBFAR **500MG/VIAL****A091404 001** Oct 26, 2011**AP** **1GM/VIAL****A091404 002** Oct 26, 2011**AP** AMNEAL PHARMS **500MG/VIAL****A205883 001** Apr 12, 2016**AP** **1GM/VIAL****A205883 002** Apr 12, 2016**AP** AUROBINDO PHARMA **500MG/VIAL****A205835 001** Mar 27, 2017

LTD

AP **1GM/VIAL****A205835 002** Mar 27, 2017**AP** DAEWOONG PHARM CO **500MG/VIAL****A204854 001** Dec 18, 2015**AP** **1GM/VIAL****A204854 002** Dec 18, 2015**AP** GLAND PHARMA LTD **500MG/VIAL****A206141 001** Jun 08, 2016**AP** **1GM/VIAL****A206141 002** Jun 08, 2016**AP** HOSPIRA INC **500MG/VIAL****A090940 001** Jun 22, 2010**AP** **1GM/VIAL****A090940 002** Jun 22, 2010**AP** PAR STERILE **500MG/VIAL****A204139 001** Jun 09, 2016

PRODUCTS

AP **1GM/VIAL****A204139 002** Jun 09, 2016**AP** SAVIOR LIFETEC CORP **500MG/VIAL****A206086 001** Apr 19, 2016**AP** **1GM/VIAL****A206086 002** Apr 19, 2016MERREM**AP** +! PFIZER **500MG/VIAL****N050706 003** Jun 21, 1996**AP** +! **1GM/VIAL****N050706 001** Jun 21, 1996

POWDER; IV (INFUSION)

MEROPEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC 500MG/VIAL

N202106 001 Apr 30, 2015

1GM/VIAL

N202106 002 Apr 30, 2015

MEROPEM; VABORBACTAM

POWDER; IV (INFUSION)

VABOMERE

+! REMPEX PHARMS 1GM/VIAL; 1GM/VIAL

N209776 001 Aug 29, 2017

MEDCNS

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+! APIL 400MG

N204412 001 Feb 01, 2013

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+! VALEANT PHARMS INTL 375MG

N022301 001 Oct 31, 2008

PENTASA

+ SHIRE 250MG

N020049 001 May 10, 1993

+! 500MG

N020049 002 Jul 08, 2004

ENEMA; RECTAL

MESALAMINE**AB** G AND W LABS INC **4GM/60ML****A076841 001** Sep 30, 2004**AB** PERRIGO ISRAEL **4GM/60ML****A076751 001** Sep 17, 2004ROWASA**AB** +! MYLAN SPECIALITY LP **4GM/60ML****N019618 001** Dec 24, 1987SFROWASA**AB** + MYLAN SPECIALITY LP **4GM/60ML****N019618 002** Jun 20, 2008

SUPPOSITORY; RECTAL

CANASA**AB** +! FOREST LABS LLC **1GM****N021252 002** Nov 05, 2004MESALAMINE**AB** MYLAN PHARMS INC **1GM****A204354 001** Nov 24, 2015

TABLET, DELAYED RELEASE; ORAL

ASACOL HD**AB** +! APIL **800MG****N021830 001** May 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

MESALAMINE

TABLET, DELAYED RELEASE;ORAL

LIALDA

AB	+ !	SHIRE	1.2GM	N022000	001	Jan 16, 2007
-----------	------------	-------	--------------	----------------	------------	--------------

MESALAMINE

AB		ZYDUS PHARMS USA INC	800MG	A203286	001	Jul 21, 2017
-----------	--	-------------------------	--------------	----------------	------------	--------------

AB			1.2GM	A091640	001	Jun 05, 2017
-----------	--	--	--------------	----------------	------------	--------------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP		FRESENIUS KABI USA	100MG/ML	A075811	001	Apr 26, 2001
-----------	--	--------------------	-----------------	----------------	------------	--------------

AP		GLAND PHARMA LTD	100MG/ML	A206992	001	Dec 18, 2017
-----------	--	------------------	-----------------	----------------	------------	--------------

AP		MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012
-----------	--	---------------------	-----------------	----------------	------------	--------------

AP		SAGENT PHARMS	100MG/ML	A090913	001	Apr 13, 2010
-----------	--	---------------	-----------------	----------------	------------	--------------

AP		TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001
-----------	--	-----------------	-----------------	----------------	------------	--------------

AP		WEST-WARD PHARMS INT	100MG/ML	A075739	001	Jan 09, 2004
-----------	--	-------------------------	-----------------	----------------	------------	--------------

MESNEX

AP	+ !	BAXTER HLTHCARE	100MG/ML	N019884	001	Dec 30, 1988
-----------	------------	-----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

MESNEX

+ !		BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002
------------	--	-----------------	-------	---------	-----	--------------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ !		ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001	
------------	--	---------------------	-------------	---------	-----	--

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

!		SILARX	10MG/5ML	A073632	001	Jul 22, 1992
----------	--	--------	----------	---------	-----	--------------

TABLET; ORAL

METAPROTERENOL SULFATE

		PAR PHARM	10MG	A072024	001	Jun 28, 1988
--	--	-----------	------	---------	-----	--------------

!			20MG	A072025	001	Jun 28, 1988
----------	--	--	------	---------	-----	--------------

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

!		FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	
----------	--	--------------------	-----------------	---------	-----	--

METAXALONE

TABLET; ORAL

METAXALONE

AB		ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017
-----------	--	---------------------	--------------	----------------	------------	--------------

AB		AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013
-----------	--	---------------	--------------	----------------	------------	--------------

AB		LANNETT HOLDINGS INC	800MG	A204770	001	Nov 22, 2016
-----------	--	-------------------------	--------------	----------------	------------	--------------

AB		SANDOZ	800MG	A040445	001	Mar 31, 2010
-----------	--	--------	--------------	----------------	------------	--------------

AB		SCIEGEN PHARMS INC	800MG	A207466	001	Aug 31, 2017
-----------	--	--------------------	--------------	----------------	------------	--------------

SKELAXIN

AB	+ !	KING PHARMS	800MG	N013217	003	Aug 30, 2002
-----------	------------	-------------	--------------	----------------	------------	--------------

METAXALONE

		COREPHARMA	400MG	A040486	001	Feb 27, 2015
--	--	------------	-------	---------	-----	--------------

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ !		SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003
------------	--	--------------------	-----------	---------	-----	--------------

TABLET; ORAL

GLUCOPHAGE

AB	+	BRISTOL MYERS SQUIBB	500MG	N020357	001	Mar 03, 1995
-----------	----------	-------------------------	--------------	----------------	------------	--------------

AB	+		850MG	N020357	002	Mar 03, 1995
-----------	----------	--	--------------	----------------	------------	--------------

AB	+ !		1GM	N020357	005	Nov 05, 1998
-----------	------------	--	------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

AB		ALKEM	500MG	A091184	001	Nov 01, 2010
-----------	--	-------	--------------	----------------	------------	--------------

AB			850MG	A091184	002	Nov 01, 2010
-----------	--	--	--------------	----------------	------------	--------------

AB			1GM	A091184	003	Nov 01, 2010
-----------	--	--	------------	----------------	------------	--------------

AB		AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006
-----------	--	------------------	--------------	----------------	------------	--------------

AB			850MG	A077880	002	Jun 05, 2006
-----------	--	--	--------------	----------------	------------	--------------

AB			1GM	A077880	003	Jun 05, 2006
-----------	--	--	------------	----------------	------------	--------------

AB		APOTEX	500MG	A075984	001	Apr 23, 2002
-----------	--	--------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>500MG</u>	<u>A090666 001</u>	Dec 07, 2011
<u>AB</u>		<u>850MG</u>	<u>A075984 002</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A090666 002</u>	Dec 07, 2011
<u>AB</u>		<u>1GM</u>	<u>A075984 003</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A090666 003</u>	Dec 07, 2011
<u>AB</u>	ATLAS PHARMS LLC	<u>500MG</u>	<u>A076033 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033 003</u>	Jan 24, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095 001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095 002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095 003</u>	Jan 14, 2005
<u>AB</u>	CHARTWELL LIFE SCI	<u>500MG</u>	<u>A075972 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972 003</u>	Jan 24, 2002
<u>AB</u>	CSPC OUYI PHARM CO	<u>500MG</u>	<u>A205096 001</u>	Jul 11, 2016
<u>AB</u>		<u>850MG</u>	<u>A205096 002</u>	Jul 11, 2016
<u>AB</u>		<u>1GM</u>	<u>A205096 003</u>	Jul 11, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787 001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787 002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787 003</u>	Aug 23, 2006
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170 001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170 002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170 003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564 001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564 002</u>	Apr 22, 2010
<u>AB</u>		<u>1GM</u>	<u>A090564 003</u>	Apr 22, 2010
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148 001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148 002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148 003</u>	Nov 25, 2008
<u>AB</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A205330 001</u>	Oct 31, 2017
<u>AB</u>		<u>850MG</u>	<u>A205330 002</u>	Oct 31, 2017
<u>AB</u>		<u>1GM</u>	<u>A205330 003</u>	Oct 31, 2017
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888 001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888 002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888 003</u>	Mar 12, 2012
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973 001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075976 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973 002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973 003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976 003</u>	Jan 24, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853 001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853 002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853 003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965 001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965 002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985 002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965 003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985 003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769 001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769 002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769 003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967 001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967 002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967 003</u>	Jan 29, 2002
<u>AB</u>	SUN PHARM INDUSTRIES	<u>500MG</u>	<u>A076038 001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038 002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038 003</u>	Feb 21, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978 002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978 003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711 001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711 002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711 003</u>	Jan 24, 2007
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686 001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686 002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686 003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064 001</u>	Apr 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG</u>	<u>A077064 002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064 003</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972 005	Jan 24, 2002
		750MG	A075972 004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+!	BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202 004</u>	Apr 11, 2003
-----------	----	-------------------------	--------------	--------------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869 001</u>	Apr 12, 2005
<u>AB</u>		AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596 002</u>	Jan 03, 2008
<u>AB</u>		APOTEX	<u>750MG</u>	<u>A076706 002</u>	Dec 29, 2005
<u>AB</u>		AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118 002</u>	Jul 20, 2012
<u>AB</u>		BARR	<u>750MG</u>	<u>A076863 001</u>	Oct 14, 2004
<u>AB</u>		BEXIMCO PHARMS USA	<u>750MG</u>	<u>A207427 002</u>	Dec 13, 2016
<u>AB</u>		CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321 002</u>	Apr 17, 2008
<u>AB</u>		INTELLIPHARMACEUTIC S	<u>750MG</u>	<u>A202306 002</u>	Feb 23, 2017
<u>AB</u>		MACLEODS PHARMS LTD	<u>750MG</u>	<u>A206955 002</u>	Dec 07, 2016
<u>AB</u>		MARKSANS PHARMA	<u>750MG</u>	<u>A090295 002</u>	Apr 29, 2016
<u>AB</u>		NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756 002</u>	Dec 12, 2011
<u>AB</u>		SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336 002</u>	Feb 09, 2006
<u>AB</u>		TEVA	<u>750MG</u>	<u>A076864 001</u>	Apr 12, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078 001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	+	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202 001</u>	Oct 13, 2000
------------	---	-------------------------	--------------	--------------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB1</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172 001</u>	Jun 16, 2004
<u>AB1</u>		AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596 001</u>	Jan 03, 2008
<u>AB1</u>		APOTEX	<u>500MG</u>	<u>A076706 001</u>	Dec 14, 2004
<u>AB1</u>		AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118 001</u>	Jul 20, 2012
<u>AB1</u>		BEXIMCO PHARMS USA	<u>500MG</u>	<u>A207427 001</u>	Dec 13, 2016
<u>AB1</u>		CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321 001</u>	Apr 17, 2008
<u>AB1</u>		INTELLIPHARMACEUTIC S	<u>500MG</u>	<u>A202306 001</u>	Feb 23, 2017
<u>AB1</u>		INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991 001</u>	Jan 18, 2012
<u>AB1</u>		MACLEODS PHARMS LTD	<u>500MG</u>	<u>A206955 001</u>	Dec 07, 2016
<u>AB1</u>		MARKSANS PHARMA	<u>500MG</u>	<u>A090295 001</u>	Apr 29, 2016
<u>AB1</u>		NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756 001</u>	Jul 26, 2006
<u>AB1</u>		SANDOZ	<u>500MG</u>	<u>A076873 001</u>	Dec 14, 2004
<u>AB1</u>		SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336 001</u>	Feb 09, 2006
<u>AB1</u>		TEVA	<u>500MG</u>	<u>A076269 001</u>	Jun 18, 2004
<u>AB1</u>		TORRENT PHARMS LTD	<u>500MG</u>	<u>A090014 001</u>	Dec 30, 2009
<u>AB1</u>		ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060 001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	+	ANDRX LABS LLC	<u>500MG</u>	<u>N021574 001</u>	Apr 27, 2004
<u>AB2</u>	+!		<u>1GM</u>	<u>N021574 002</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>		LUPIN LTD	<u>500MG</u>	<u>A090692 001</u>	Jun 29, 2011
<u>AB2</u>			<u>1GM</u>	<u>A090692 002</u>	Jun 29, 2011
<u>AB2</u>		MYLAN PHARMS INC	<u>500MG</u>	<u>A200690 001</u>	Aug 01, 2012
<u>AB2</u>			<u>1GM</u>	<u>A200690 002</u>	Aug 01, 2012
<u>AB2</u>		NOSTRUM LABS INC	<u>500MG</u>	<u>A203832 001</u>	Dec 26, 2017
<u>AB2</u>			<u>1GM</u>	<u>A203832 002</u>	Dec 26, 2017

GLUMETZA

<u>AB3</u>	+	SANTARUS INC	<u>500MG</u>	<u>N021748 001</u>	Jun 03, 2005
<u>AB3</u>	+!		<u>1GM</u>	<u>N021748 002</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A203755 001</u>	Aug 01, 2016
<u>AB3</u>			<u>1GM</u>	<u>A203755 002</u>	Aug 01, 2016
<u>AB3</u>		LUPIN LTD	<u>500MG</u>	<u>A091664 001</u>	Jul 19, 2013
<u>AB3</u>			<u>1GM</u>	<u>A091664 002</u>	Jul 19, 2013
<u>AB3</u>		SUN PHARMA GLOBAL	<u>500MG</u>	<u>A202917 001</u>	Aug 01, 2016
<u>AB3</u>			<u>1GM</u>	<u>A202917 002</u>	Aug 01, 2016

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

AB	+	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842 001</u>	Aug 29, 2005
AB	+	!	<u>850MG;EQ 15MG BASE</u>	<u>N021842 002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823 001</u>	Feb 13, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A200823 002</u>	Feb 13, 2013
AB	MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802 001</u>	Nov 05, 2015
AB		<u>850MG;EQ 15MG BASE</u>	<u>A204802 002</u>	Nov 05, 2015
AB	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406 001</u>	Feb 25, 2011
AB		<u>850MG;EQ 15MG BASE</u>	<u>A090406 002</u>	Feb 25, 2011
AB	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273 001</u>	Apr 16, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A091273 002</u>	Apr 16, 2013
AB	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155 001</u>	Mar 10, 2014
AB		<u>850MG;EQ 15MG BASE</u>	<u>A091155 002</u>	Mar 10, 2014
AB	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001 001</u>	Feb 13, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A202001 002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009
+	!	1GM;EQ 30MG BASE	N022024 002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

	LUPIN LTD	500MG;1MG	A200624 001	Jul 15, 2015
!		500MG;2MG	A200624 002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337 001	May 07, 2014
		500MG;EQ 1MG BASE	A077337 005	May 19, 2017
		500MG;EQ 4MG BASE	A077337 002	May 07, 2014
!		1GM;EQ 4MG BASE	A077337 004	May 07, 2014
		1GM;EQ 2MG BASE	A077337 003	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010
+	!	1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007
+	!	1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012
+	!	1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+	METHAPHARM	100MG/VIAL	N019193 001	Oct 31, 1986
---	------------	------------	-------------	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM	<u>10MG/ML</u>	<u>A040088 001</u>	Nov 30, 1994
AA	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A040180 001</u>	Apr 30, 1998

METHADONE HYDROCHLORIDE INTENSOL

AA	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A089897 001</u>	Sep 06, 1988
-----------	----------------------	----------------	--------------------	--------------

METHADOSE

AA	+	SPECGX LLC	<u>10MG/ML</u>	<u>N017116 002</u>
-----------	---	------------	----------------	--------------------

PRESCRIPTION DRUG PRODUCT LIST

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A208306</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	+! MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>N021624</u>	<u>001</u>	

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	VISTAPHARM	<u>5MG/5ML</u>	<u>A090707</u>	<u>001</u>	Jun 30, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A090707</u>	<u>002</u>	Jun 30, 2010
<u>AA</u>	! WEST-WARD PHARMS	<u>5MG/5ML</u>	<u>A087393</u>	<u>001</u>	
	INT				
<u>AA</u>	!	<u>10MG/5ML</u>	<u>A087997</u>	<u>001</u>	Aug 30, 1982

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+! WEST-WARD PHARMS	<u>5MG</u>	<u>N006134</u>	<u>002</u>	
	INT				
<u>AA</u>	+!	<u>10MG</u>	<u>N006134</u>	<u>010</u>	

METHADONE HYDROCHLORIDE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502</u>	<u>001</u>	Aug 31, 2015
<u>AA</u>		<u>10MG</u>	<u>A203502</u>	<u>002</u>	Aug 31, 2015
<u>AA</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090065</u>	<u>001</u>	Aug 18, 2015
<u>AA</u>		<u>10MG</u>	<u>A090065</u>	<u>002</u>	Aug 18, 2015
<u>AA</u>	SANDOZ	<u>10MG</u>	<u>A040241</u>	<u>002</u>	May 29, 1998
<u>AA</u>	SPECGX LLC	<u>5MG</u>	<u>A040517</u>	<u>001</u>	Apr 27, 2004
<u>AA</u>		<u>10MG</u>	<u>A040517</u>	<u>002</u>	Apr 27, 2004
<u>AA</u>	THE PHARMANETWORK	<u>10MG</u>	<u>A090635</u>	<u>001</u>	Nov 25, 2009

METHADOSE

<u>AA</u>	SPECGX LLC	<u>5MG</u>	<u>A040050</u>	<u>001</u>	Apr 15, 1993
<u>AA</u>		<u>10MG</u>	<u>A040050</u>	<u>002</u>	Apr 15, 1993

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	SANDOZ	<u>40MG</u>	<u>A075082</u>	<u>001</u>	Mar 25, 1998
<u>AA</u>	SPECGX LLC	<u>40MG</u>	<u>A077142</u>	<u>001</u>	Jul 12, 2005
<u>AA</u>	+! WEST-WARD PHARMS	<u>40MG</u>	<u>N017058</u>	<u>001</u>	
	INT				

METHADOSE

<u>AA</u>	SPECGX LLC	<u>40MG</u>	<u>A074184</u>	<u>001</u>	Apr 29, 1993
-----------	------------	-------------	----------------	------------	--------------

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

<u>AA</u>	+! RECORDATI RARE	<u>5MG</u>	<u>N005378</u>	<u>002</u>	
-----------	-------------------	------------	----------------	------------	--

METHAMPHETAMINE HYDROCHLORIDE

<u>AA</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091189</u>	<u>001</u>	Apr 21, 2010
<u>AA</u>	WEST-WARD PHARMS	<u>5MG</u>	<u>A203846</u>	<u>001</u>	Nov 17, 2015
	INT				

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	!	<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+! US PHARM HOLDINGS	<u>1GM</u>	<u>N017681</u>	<u>001</u>	
-----------	----------------------	------------	----------------	------------	--

METHENAMINE HIPPURATE

<u>AB</u>	AUROBINDO PHARMA	<u>1GM</u>	<u>A205661</u>	<u>001</u>	Jul 05, 2016
	LTD				
<u>AB</u>	IMPAX LABS INC	<u>1GM</u>	<u>A076411</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>	UREX	<u>1GM</u>	<u>N016151</u>	<u>001</u>	
	CNTY LINE PHARMS				

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>	ECI PHARMS LLC	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007

PRESCRIPTION DRUG PRODUCT LIST

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>	MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>AB</u>	!	<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>AB</u>	RISING PHARMS INC	<u>5MG</u>	<u>A202068</u>	<u>001</u>	Mar 07, 2012
<u>AB</u>		<u>10MG</u>	<u>A202068</u>	<u>002</u>	Mar 07, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>AB</u>		<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A040870</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>10MG</u>	<u>A040870</u>	<u>002</u>	Sep 25, 2007

TAPAZOLE

<u>AB</u>	KING PHARMS LLC	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>		<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A206128</u>	<u>001</u>	May 27, 2016
<u>AP</u>	LUITPOLD PHARMS INC	<u>1GM/10ML (100MG/ML)</u>	<u>A207496</u>	<u>001</u>	Jun 22, 2017
<u>AP</u>	MONTEREY PHARMS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A205354</u>	<u>001</u>	Oct 27, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404</u>	<u>001</u>	Dec 05, 2014
<u>AP</u>	NAVINTA LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A206071</u>	<u>001</u>	Nov 24, 2017
<u>AP</u>	RENAISSANCE SSA LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A208116</u>	<u>001</u>	Jan 19, 2017
<u>AP</u>	SAGENT PHARMS	<u>1GM/10ML (100MG/ML)</u>	<u>A205404</u>	<u>001</u>	Jul 18, 2017
<u>AP</u>	SOMERSET THERAPS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A207522</u>	<u>001</u>	Jul 31, 2017

ROBAXIN

<u>AP</u>	! WEST-WARD PHARMS INT	<u>1GM/10ML (100MG/ML)</u>	<u>N011790</u>	<u>001</u>	
-----------	------------------------	----------------------------	----------------	------------	--

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	ATLAS PHARMS LLC	<u>500MG</u>	<u>A203550</u>	<u>001</u>	Feb 08, 2017
<u>AA</u>		<u>750MG</u>	<u>A203550</u>	<u>002</u>	Feb 08, 2017
<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011
<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011
<u>AA</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A208507</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>750MG</u>	<u>A208507</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	HIKMA INTL PHARMS	<u>500MG</u>	<u>A085159</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A085123</u>	<u>001</u>	
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A086988</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084276</u>	<u>002</u>	

ROBAXIN

<u>AA</u>	! AUXILIUM PHARMS LLC	<u>500MG</u>	<u>N011011</u>	<u>004</u>	
-----------	-----------------------	--------------	----------------	------------	--

ROBAXIN-750

<u>AA</u>	! AUXILIUM PHARMS LLC	<u>750MG</u>	<u>N011011</u>	<u>006</u>	
-----------	-----------------------	--------------	----------------	------------	--

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	! PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	
+	!	2.5GM/VIAL	N011559	002	

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

+	! ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
+	!	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
+	!	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
+	!	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
+	!	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
+	!	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
+	!	25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013

RASUVO

+	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
+		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
+		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
+		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
+		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
+		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
+		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
+		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 25MG BASE/ML</u>	<u>A040265</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999

METHOTREXATE SODIUM

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	!	ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>002</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>003</u>	Feb 27, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>004</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		SANDOZ INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986

METHOTREXATE SODIUM

!		WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
---	--	-------------------------	-------------------------------------	---------	-----	--------------

METHOTREXATE SODIUM PRESERVATIVE FREE

!		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
---	--	-------------------------	------------------	---------	-----	--------------

SOLUTION; ORAL

XATMEP

+	!	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017
---	---	-------------------	------------------	---------	-----	--------------

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>		AMNEAL PHARMS	<u>EQ 2.5MG BASE</u>	<u>A210040</u>	<u>001</u>	Dec 22, 2017
<u>AB</u>		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u>		SUN PHARMA GLOBAL	<u>EQ 2.5MG BASE</u>	<u>A201749</u>	<u>001</u>	May 21, 2015
<u>AB</u>		WEST-WARD PHARMS INT	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 2.5MG BASE</u>	<u>A207812</u>	<u>001</u>	Jan 13, 2017
		TREXALL				
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

<u>AB</u>		ACTAVIS INC	<u>10MG</u>	<u>A202603</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>		STRIDES PHARMA	<u>10MG</u>	<u>A202687</u>	<u>001</u>	Jun 05, 2014

OXSORALEN-ULTRA

<u>AB</u>	+	DOW PHARM	<u>10MG</u>	<u>N019600</u>	<u>001</u>	Oct 30, 1986
-----------	---	-----------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METHOXSALLEN

INJECTABLE; INJECTION

UVADEX

+! MALLINCKRODT HOSP 0.02MG/ML N020969 001 Feb 25, 1999

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012
AA		5MG	A200602 002	Sep 24, 2012
AA	BRECKENRIDGE PHARM	2.5MG	A040642 001	Dec 06, 2011
AA		5MG	A040642 002	Dec 06, 2011
AA	! VINTAGE PHARMS	2.5MG	A040624 001	Dec 28, 2006
AA	!	5MG	A040624 002	Dec 28, 2006

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+ PARKE DAVIS 150MG N010596 007

+! 300MG N010596 008

METHYLCLOTHIAZIDE

TABLET; ORAL

METHYLCLOTHIAZIDE

! MYLAN PHARMS INC 5MG A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB	ACCORD HLTHCARE	250MG	A070084 001	Oct 15, 1985
AB		500MG	A070085 001	Oct 15, 1985
AB	IVAX SUB TEVA PHARMS	250MG	A070098 001	Feb 20, 1986
AB		500MG	A070343 001	Feb 20, 1986
AB	MYLAN	250MG	A070076 002	Apr 18, 1985
AB	!	500MG	A070076 001	Apr 18, 1985
AB	WATSON LABS	500MG	A070625 001	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

! LUITPOLD 50MG/ML A071279 001 Oct 02, 1987

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+! PROVEPHARM SAS 50MG/10ML (5MG/ML) N204630 001 Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+! EDISON THERAPS LLC	0.2MG/ML	N006035 004	
-----------	-----------------------	-----------------	--------------------	--

METHYLERGONOVINE MALEATE

AP	BRECKENRIDGE PHARM	0.2MG/ML	A040889 001	Sep 13, 2010
AP	LUITPOLD	0.2MG/ML	A090193 001	Nov 24, 2008

TABLET; ORAL

METHYLERGONOVINE MALEATE

! NOVEL LABS INC 0.2MG A091577 001 May 02, 2011

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

+! SALIX PHARMS 8MG/0.4ML (8MG/0.4ML) N021964 002 Sep 27, 2010

+! 12MG/0.6ML (12MG/0.6ML) N021964 001 Apr 24, 2008

+! 12MG/0.6ML (12MG/0.6ML) N021964 003 Sep 27, 2010

TABLET; ORAL

RELISTOR

+! SALIX PHARMS INC 150MG N208271 001 Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

+ NOVEN PHARMS INC 10MG/9HR (1.1MG/HR) N021514 001 Apr 06, 2006

+ 15MG/9HR (1.6MG/HR) N021514 002 Apr 06, 2006

+ 20MG/9HR (2.2MG/HR) N021514 003 Apr 06, 2006

+! 30MG/9HR (3.3MG/HR) N021514 004 Apr 06, 2006

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
+		17.3MG	N205489	002	Jun 19, 2017
+		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	BARR LABS INC	10MG	A079031	004	Oct 15, 2014
AB1		20MG	A079031	001	Jul 13, 2012
AB1		30MG	A079031	002	Jul 13, 2012
AB1		40MG	A079031	003	Jul 13, 2012
AB1	MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011
AB1		30MG	A078458	002	Dec 01, 2011
AB1		40MG	A078458	003	Dec 01, 2011

RITALIN LA

AB1	+	NOVARTIS	10MG	N021284	004	Apr 10, 2004
AB1	+		20MG	N021284	001	Jun 05, 2002
AB1	+		30MG	N021284	002	Jun 05, 2002
AB1	+		40MG	N021284	003	Jun 05, 2002

METADATE CD

AB2	+	UCB INC	10MG	N021259	003	May 27, 2003
AB2	+		20MG	N021259	001	Apr 03, 2001
AB2	+		30MG	N021259	002	Jun 19, 2003
AB2	+		40MG	N021259	004	Feb 19, 2006
AB2	+		50MG	N021259	005	Feb 19, 2006
AB2	+		60MG	N021259	006	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016
AB2		20MG	A205105	002	Jul 28, 2016
AB2		30MG	A205105	003	Jul 28, 2016
AB2		40MG	A205105	004	Jul 28, 2016
AB2		50MG	A205105	005	Jul 28, 2016
AB2		60MG	A205105	006	Jul 28, 2016
AB2	SPECGX LLC	10MG	A203583	001	Sep 29, 2015
AB2		20MG	A203583	002	Sep 29, 2015
AB2		30MG	A203583	003	Sep 29, 2015
AB2		40MG	A203583	004	Sep 29, 2015
AB2		50MG	A203583	005	Sep 29, 2015
AB2		60MG	A203583	006	Sep 29, 2015
AB2	TEVA PHARMS	10MG	A077707	001	Jul 19, 2012
AB2		20MG	A077707	002	Jul 19, 2012
AB2		30MG	A077707	003	Jul 19, 2012
AB2		40MG	A078873	001	Jul 19, 2012
AB2		50MG	A078873	002	Jul 19, 2012
AB2		60MG	A078873	003	Jul 19, 2012

APTENSIO XR

+	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015
+		15MG	N205831	002	Apr 17, 2015
+		20MG	N205831	003	Apr 17, 2015
+		30MG	N205831	004	Apr 17, 2015
+		40MG	N205831	005	Apr 17, 2015
+		50MG	N205831	006	Apr 17, 2015
+		60MG	N205831	007	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

! MAYNE PHARMA 60MG A078458 004 Jun 23, 2016

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+! NEXTWAVE PHARMS 5MG/ML N202100 001 Sep 27, 2012

SOLUTION;ORAL

METHYLIN

AA	+	SPECGX LLC	5MG/5ML	N021419	001	Dec 19, 2002
AA	+		10MG/5ML	N021419	002	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

AA	ABHAI LLC	5MG/5ML	A207485	001	Nov 18, 2016
AA		10MG/5ML	A207485	002	Nov 18, 2016
AA	BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013
AA		10MG/5ML	A201466	002	Nov 12, 2013
AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015
AA		10MG/5ML	A204602	002	Aug 14, 2015
AA	TRIS PHARMA INC	5MG/5ML	A091601	001	Jul 23, 2010

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		<u>10MG/5ML</u>	<u>A091601 002</u>	Jul 23, 2010
-----------	--	-----------------	--------------------	--------------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>5MG</u>	<u>A206932 001</u>	May 11, 2017
<u>AB</u>		<u>10MG</u>	<u>A206932 002</u>	May 11, 2017
<u>AB</u>		<u>20MG</u>	<u>A206932 003</u>	May 11, 2017
<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A040220 001</u>	Aug 29, 1997
<u>AB</u>		<u>10MG</u>	<u>A040220 002</u>	Aug 29, 1997
<u>AB</u>		<u>20MG</u>	<u>A040220 003</u>	Aug 29, 1997
<u>AB</u>	ASCENT PHARMS INC	<u>5MG</u>	<u>A207416 001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A207416 002</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A207416 003</u>	Sep 22, 2015
<u>AB</u>	BRECKENRIDGE PHARM	<u>5MG</u>	<u>A207587 001</u>	Mar 03, 2017
<u>AB</u>		<u>10MG</u>	<u>A207587 002</u>	Mar 03, 2017
<u>AB</u>		<u>20MG</u>	<u>A207587 003</u>	Mar 03, 2017
<u>AB</u>	CNTY LINE PHARMS	<u>5MG</u>	<u>A206840 001</u>	Sep 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A206840 002</u>	Sep 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A206840 003</u>	Sep 15, 2016
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A091159 001</u>	Mar 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A091159 002</u>	Mar 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A091159 003</u>	Mar 12, 2014
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A207884 001</u>	Nov 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A207884 002</u>	Nov 13, 2015
<u>AB</u>		<u>20MG</u>	<u>A207884 003</u>	Nov 13, 2015
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A040300 001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300 002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300 003</u>	Nov 27, 1998
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090710 001</u>	Mar 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A090710 002</u>	Mar 15, 2012
<u>AB</u>		<u>20MG</u>	<u>A090710 003</u>	Mar 15, 2012
<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429 001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085799 001</u>	
<u>AB</u>		<u>20MG</u>	<u>A086428 001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A202892 001</u>	Sep 23, 2014
<u>AB</u>		<u>10MG</u>	<u>A202892 002</u>	Sep 23, 2014
<u>AB</u>		<u>20MG</u>	<u>A202892 003</u>	Sep 23, 2014
<u>RITALIN</u>				
<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N010187 003</u>
<u>AB</u>	+		<u>10MG</u>	<u>N010187 006</u>
<u>AB</u>	+	!	<u>20MG</u>	<u>N010187 010</u>

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>2.5MG</u>	<u>A210354 001</u>	Dec 29, 2017
<u>AB</u>		<u>5MG</u>	<u>A210354 002</u>	Dec 29, 2017
<u>AB</u>		<u>10MG</u>	<u>A210354 003</u>	Dec 29, 2017
<u>AB</u>	BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A204954 001</u>	Jan 26, 2017
<u>AB</u>		<u>5MG</u>	<u>A204954 002</u>	Jan 26, 2017
<u>AB</u>		<u>10MG</u>	<u>A204954 003</u>	Jan 26, 2017
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204115 001</u>	Feb 25, 2015
<u>AB</u>		<u>5MG</u>	<u>A204115 002</u>	Feb 25, 2015
<u>AB</u>	!	<u>10MG</u>	<u>A204115 003</u>	Feb 25, 2015
<u>AB</u>	TEDOR PHARMA INC	<u>2.5MG</u>	<u>A205756 001</u>	Nov 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A205756 002</u>	Nov 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A205756 003</u>	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

<u>AB</u>	+	JANSSEN PHARMS	<u>18MG</u>	<u>N021121 001</u>	Aug 01, 2000
<u>AB</u>	+		<u>27MG</u>	<u>N021121 004</u>	Apr 01, 2002
<u>AB</u>	+		<u>36MG</u>	<u>N021121 002</u>	Aug 01, 2000
<u>AB</u>	+	!	<u>54MG</u>	<u>N021121 003</u>	Dec 08, 2000

METADATE ER

<u>AB</u>	!	UCB INC	<u>20MG</u>	<u>A089601 001</u>	Jun 01, 1988
-----------	---	---------	-------------	--------------------	--------------

METHYLIN ER

<u>AB</u>		SPECGX LLC	<u>10MG</u>	<u>A075629 001</u>	May 09, 2000
<u>AB</u>			<u>20MG</u>	<u>A075629 002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI LLC	<u>10MG</u>	<u>A207488 001</u>	Jun 09, 2015
<u>AB</u>		<u>20MG</u>	<u>A207488 002</u>	Jun 09, 2015
<u>AB</u>	CNTY LINE PHARMS	<u>10MG</u>	<u>A204772 001</u>	Feb 29, 2016

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>20MG</u>	<u>A204772 002</u>	Feb 29, 2016
<u>AB</u>	COREPHARMA	<u>18MG</u>	<u>A208607 001</u>	Jul 14, 2017
<u>AB</u>		<u>27MG</u>	<u>A208607 002</u>	Jul 14, 2017
<u>AB</u>		<u>36MG</u>	<u>A208607 003</u>	Jul 14, 2017
<u>AB</u>		<u>54MG</u>	<u>A208607 004</u>	Jul 14, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>18MG</u>	<u>A206726 001</u>	Oct 21, 2016
<u>AB</u>		<u>27MG</u>	<u>A206726 002</u>	Oct 21, 2016
<u>AB</u>		<u>36MG</u>	<u>A206726 003</u>	Oct 21, 2016
<u>AB</u>		<u>54MG</u>	<u>A206726 004</u>	Oct 21, 2016
<u>AB</u>	OSMOTICA	<u>18MG</u>	<u>A205327 001</u>	Jul 28, 2017
<u>AB</u>		<u>27MG</u>	<u>A205327 002</u>	Jul 28, 2017
<u>AB</u>		<u>36MG</u>	<u>A205327 003</u>	Jul 28, 2017
<u>AB</u>		<u>54MG</u>	<u>A205327 004</u>	Jul 28, 2017

RITALIN-SR

<u>AB</u>	+ NOVARTIS	<u>20MG</u>	<u>N018029 001</u>	Mar 30, 1982
<u>METHYLPHENIDATE HYDROCHLORIDE</u>				
BX	KREMERS URBAN PHARMS	18MG	A091695 001	Jul 09, 2013
BX		27MG	A091695 002	Jul 09, 2013
BX		36MG	A091695 003	Sep 23, 2013
BX		54MG	A091695 004	Sep 23, 2013
BX	SPECGX LLC	27MG	A202608 001	Dec 28, 2012
BX		36MG	A202608 002	Dec 28, 2012
BX		54MG	A202608 003	Dec 28, 2012
	OSMOTICA	72MG	A205327 005	Jul 28, 2017
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL				
<u>QUILLICHEW ER</u>				
	+ PFIZER INC	20MG	N207960 001	Dec 04, 2015
		30MG	N207960 002	Dec 04, 2015
	+!	40MG	N207960 003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>4MG</u>	<u>N011153 001</u>	
<u>AB</u>		<u>8MG</u>	<u>N011153 004</u>	
<u>AB</u>		<u>16MG</u>	<u>N011153 003</u>	
<u>AB</u>	+!	<u>32MG</u>	<u>N011153 006</u>	

METHYLPREDNISOLONE

<u>AB</u>	DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497 001</u>	Feb 21, 1984
<u>AB</u>	JUBILANT CADISTA	<u>4MG</u>	<u>A040189 001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189 002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189 003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189 004</u>	Jul 20, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194 001</u>	Oct 31, 1997
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183 001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232 001</u>	Oct 16, 1997
MEDROL				
	+ PHARMACIA AND UPJOHN	2MG	N011153 002	

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	+! PHARMACIA AND UPJOHN	<u>40MG/ML</u>	<u>N011757 001</u>	
<u>AB</u>	+!	<u>80MG/ML</u>	<u>N011757 004</u>	

METHYLPREDNISOLONE ACETATE

<u>AB</u>	SANDOZ INC	<u>40MG/ML</u>	<u>A040719 001</u>	Jan 29, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A040794 001</u>	Mar 05, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040719 002</u>	Jan 29, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040794 002</u>	Mar 05, 2009
<u>AB</u>	TEVA PHARMS USA	<u>40MG/ML</u>	<u>A040557 001</u>	Feb 23, 2005
<u>AB</u>		<u>40MG/ML</u>	<u>A040620 001</u>	Oct 27, 2006
<u>AB</u>		<u>80MG/ML</u>	<u>A040557 002</u>	Feb 23, 2005
<u>AB</u>		<u>80MG/ML</u>	<u>A040620 002</u>	Oct 27, 2006
DEPO-MEDROL				
	+! PHARMACIA AND UPJOHN	20MG/ML	N011757 002	

PRESCRIPTION DRUG PRODUCT LIST

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

<u>AP</u>	HOSPIRA	<u>EQ 40MG BASE/VIAL</u>	<u>A040664 001</u>	Dec 20, 2005
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040665 001</u>	Dec 20, 2005

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 40MG BASE/VIAL</u>	<u>A207549 001</u>	Nov 09, 2016
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A207549 002</u>	Nov 09, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A207667 001</u>	Dec 15, 2015
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A207667 002</u>	Dec 15, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A207667 003</u>	Dec 15, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A207667 004</u>	Dec 15, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040583 001</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040583 002</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040612 001</u>	Aug 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A202691 001</u>	Feb 16, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202691 002</u>	Feb 16, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>A040888 001</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040888 002</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040888 003</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040888 004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888 005</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856 003</u>	
<u>AP</u>	+!	<u>EQ 125MG BASE/VIAL</u>	<u>N011856 004</u>	
<u>AP</u>	+!	<u>EQ 500MG BASE/VIAL</u>	<u>N011856 005</u>	
<u>AP</u>	+!	<u>EQ 1GM BASE/VIAL</u>	<u>N011856 006</u>	
<u>AP</u>	+!	<u>EQ 2GM BASE/VIAL</u>	<u>N011856 007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A204851 001</u>	Sep 21, 2015
	<u>TESTRED</u>			
<u>AB</u>	! VALEANT PHARM INTL	<u>10MG</u>	<u>A083976 001</u>	
	TABLET; ORAL			
	ANDROID 25			
BP	VALEANT PHARM INTL	25MG	A087147 001	
	METHYLTESTOSTERONE			
BP	IMPAX LABS	10MG	A080767 002	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>	SANDOZ INC	<u>0.3%</u>	<u>A075720 001</u>	Aug 06, 2001
	<u>OPTIPRANOLOL</u>			
<u>AT</u>	+! BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907 001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204756 001</u>	Dec 20, 2013
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>			
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A091392 001</u>	Apr 19, 2013
<u>AP</u>	! HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118 001</u>	Jan 17, 1991
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A073135 001</u>	Nov 27, 1991

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402 001</u>	Jun 25, 1993
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744 001</u>	May 28, 1991
<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051 001</u>	Jan 26, 2001
<u>AA</u>	! WOCKHARDT BIO AG	<u>EQ 5MG BASE/5ML</u>	<u>A074703 001</u>	Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>EQ 5MG BASE</u>	<u>A071250 002</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250 001</u>	Feb 03, 1988
<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807 001</u>	Jun 12, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807 002</u>	Jun 12, 2008
<u>AB</u>	PAR PHARM INC	<u>EQ 10MG BASE</u>	<u>A070581 001</u>	Oct 17, 1985
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801 001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184 001</u>	Jul 29, 1985
<u>AB</u>	VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878 001</u>	Aug 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		EQ 10MG BASE	A077878 002	Aug 28, 2006
-----------	--	---------------------	--------------------	--------------

REGLAN

AB	+	ANI PHARMS	EQ 5MG BASE	N017854 002	May 05, 1987
-----------	---	------------	--------------------	--------------------	--------------

AB	+	!	EQ 10MG BASE	N017854 001	
-----------	---	---	---------------------	--------------------	--

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		NOVEL LABS INC	EQ 5MG BASE	A202191 001	Aug 15, 2014
-----------	--	----------------	--------------------	--------------------	--------------

METZOZOLV ODT

AB	+	SALIX PHARMS	EQ 5MG BASE	N022246 001	Sep 04, 2009
-----------	---	--------------	--------------------	--------------------	--------------

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 10MG BASE	A202191 002	Aug 15, 2014
--	--	----------------	---------------------	--------------------	--------------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB		MYLAN	2.5MG	A076698 001	Dec 23, 2003
-----------	--	-------	--------------	--------------------	--------------

AB			5MG	A076698 002	Oct 19, 2004
-----------	--	--	------------	--------------------	--------------

AB			10MG	A076698 003	Oct 19, 2004
-----------	--	--	-------------	--------------------	--------------

AB		SANDOZ	2.5MG	A076732 001	Dec 19, 2003
-----------	--	--------	--------------	--------------------	--------------

AB			5MG	A076466 001	Dec 19, 2003
-----------	--	--	------------	--------------------	--------------

AB			10MG	A076466 002	Dec 19, 2003
-----------	--	--	-------------	--------------------	--------------

ZAROXOLYN

AB	+	UCB INC	2.5MG	N017386 001	
-----------	---	---------	--------------	--------------------	--

AB	+	!	5MG	N017386 002	
-----------	---	---	------------	--------------------	--

AB	+	!	10MG	N017386 003	
-----------	---	---	-------------	--------------------	--

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161 001	Nov 25, 2016
-----------	--	-------------------	-------------------------	--------------------	--------------

AB			EQ 50MG TARTRATE	A204161 002	Nov 25, 2016
-----------	--	--	-------------------------	--------------------	--------------

AB			EQ 100MG TARTRATE	A204161 003	Nov 25, 2016
-----------	--	--	--------------------------	--------------------	--------------

AB			EQ 200MG TARTRATE	A204161 004	Nov 25, 2016
-----------	--	--	--------------------------	--------------------	--------------

AB		ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A077118 001	Aug 03, 2009
-----------	--	---------------------	-------------------------	--------------------	--------------

AB			EQ 50MG TARTRATE	A076862 001	Aug 03, 2009
-----------	--	--	-------------------------	--------------------	--------------

AB			EQ 100MG TARTRATE	A077298 001	Apr 15, 2010
-----------	--	--	--------------------------	--------------------	--------------

AB			EQ 200MG TARTRATE	A077298 002	Apr 15, 2010
-----------	--	--	--------------------------	--------------------	--------------

AB		DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012
-----------	--	--------------------	-------------------------	--------------------	--------------

AB			EQ 50MG TARTRATE	A090617 002	Aug 01, 2012
-----------	--	--	-------------------------	--------------------	--------------

AB		MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033 001	Dec 15, 2011
-----------	--	------------------	-------------------------	--------------------	--------------

AB			EQ 50MG TARTRATE	A202033 002	Dec 15, 2011
-----------	--	--	-------------------------	--------------------	--------------

AB			EQ 100MG TARTRATE	A202033 003	Dec 15, 2011
-----------	--	--	--------------------------	--------------------	--------------

AB			EQ 200MG TARTRATE	A202033 004	Dec 15, 2011
-----------	--	--	--------------------------	--------------------	--------------

AB		REDDYS	EQ 100MG TARTRATE	A078889 001	Aug 15, 2012
-----------	--	--------	--------------------------	--------------------	--------------

AB			EQ 200MG TARTRATE	A078889 002	Aug 15, 2012
-----------	--	--	--------------------------	--------------------	--------------

AB		WOCKHARDT	EQ 25MG TARTRATE	A090615 001	Jul 22, 2010
-----------	--	-----------	-------------------------	--------------------	--------------

AB			EQ 50MG TARTRATE	A090615 002	Jul 22, 2010
-----------	--	--	-------------------------	--------------------	--------------

AB			EQ 100MG TARTRATE	A090615 003	Jul 22, 2010
-----------	--	--	--------------------------	--------------------	--------------

AB			EQ 200MG TARTRATE	A090615 004	Jul 22, 2010
-----------	--	--	--------------------------	--------------------	--------------

TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962 004	Feb 05, 2001
-----------	---	---------------	-------------------------	--------------------	--------------

AB	+	!	EQ 50MG TARTRATE	N019962 001	Jan 10, 1992
-----------	---	---	-------------------------	--------------------	--------------

AB	+		EQ 100MG TARTRATE	N019962 002	Jan 10, 1992
-----------	---	--	--------------------------	--------------------	--------------

AB	+	!	EQ 200MG TARTRATE	N019962 003	Jan 10, 1992
-----------	---	---	--------------------------	--------------------	--------------

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

AP	+	NOVARTIS	1MG/ML	N018704 001	Mar 30, 1984
-----------	---	----------	---------------	--------------------	--------------

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	1MG/ML	A078950 001	Apr 29, 2013
-----------	--	----------------------	---------------	--------------------	--------------

AP		FRESENIUS KABI USA	1MG/ML	A091045 001	Oct 25, 2010
-----------	--	--------------------	---------------	--------------------	--------------

AP		GLAND PHARMA LTD	1MG/ML	A204205 001	Aug 27, 2014
-----------	--	------------------	---------------	--------------------	--------------

AP		HIKMA FARMACEUTICA	1MG/ML	A077761 001	May 30, 2007
-----------	--	--------------------	---------------	--------------------	--------------

AP		HOSPIRA	1MG/ML	A074133 001	Dec 21, 1993
-----------	--	---------	---------------	--------------------	--------------

AP			1MG/ML	A075160 001	Jul 06, 1998
-----------	--	--	---------------	--------------------	--------------

AP			1MG/ML	A078085 001	Apr 29, 2008
-----------	--	--	---------------	--------------------	--------------

AP		LUITPOLD	1MG/ML	A090386 001	Sep 30, 2009
-----------	--	----------	---------------	--------------------	--------------

AP			1MG/ML	A091307 001	Dec 29, 2010
-----------	--	--	---------------	--------------------	--------------

AP		SAGENT STRIDES	1MG/ML	A090317 001	Apr 19, 2010
-----------	--	----------------	---------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

<u>AP</u>	SANDOZ INC	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007
<u>AP</u>	WEST-WARD PHARMS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003

INT

TABLET; ORAL

LOPRESSOR

<u>AB</u>	+	US PHARMS HOLDINGS	<u>50MG</u>	<u>N017963</u>	<u>001</u>
		I			

<u>AB</u>	+		<u>100MG</u>	<u>N017963</u>	<u>002</u>
-----------	---	--	--------------	----------------	------------

METOPROLOL TARTRATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871</u>	<u>001</u>	May 28, 2013
<u>AB</u>			<u>50MG</u>	<u>A202871</u>	<u>002</u>	May 28, 2013
<u>AB</u>			<u>100MG</u>	<u>A202871</u>	<u>003</u>	May 28, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>			<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>			<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>			<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>			<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>			<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	!		<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>		RUBICON RES PVT LTD	<u>25MG</u>	<u>A200981</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>			<u>50MG</u>	<u>A200981</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>			<u>100MG</u>	<u>A200981</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>		SUN PHARM INDS INC	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>			<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>			<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		SUN PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
		INDUSTRIES				
<u>AB</u>			<u>50MG</u>	<u>A073654</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>			<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>			<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994
<u>AB</u>			<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994
		MYLAN	37.5MG	A076704	004	Mar 18, 2015
			75MG	A076704	005	Mar 18, 2015

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995
-----------	---	---------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995
-----------	---	------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004
<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007

NORITATE

+	!	VALEANT PHARMS	1%	N020743	001	Sep 26, 1997
		NORTH				

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u>	Nov 22, 1988
<u>AB</u>	+		<u>1%</u>	<u>N021789</u>	<u>001</u>	Jun 30, 2005

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018</u>	<u>001</u>	Jun 06, 2006
<u>AB</u>		G AND W LABS INC	<u>0.75%</u>	<u>A078178</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		TARO PHARM	<u>1%</u>	<u>A204651</u>	<u>001</u>	Mar 14, 2017
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547</u>	<u>001</u>	Jul 13, 2006
<u>AB</u>			<u>1%</u>	<u>A090903</u>	<u>001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	MEDICIS	<u>0.75%</u>	<u>N020208</u>	<u>001</u>	Aug 17, 1992
-----------	---	---------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264</u>	<u>001</u>	Oct 31, 2006
-----------	--	--------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

GEL;VAGINAL

VANDAZOLE

BX	TEVA PHARMS	0.75%	N021806 001	May 20, 2005
	NUVESSA			
	+! CHEMO RESEARCH SL	1.3%	N205223 001	Mar 24, 2014

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657 001</u>	
-----------	--------------------	--------------------	---------------------------	--

METRO I.V. IN PLASTIC CONTAINER

AP	+! B BRAUN	<u>500MG/100ML</u>	<u>N018900 001</u>	Sep 29, 1983
-----------	------------	--------------------	---------------------------	--------------

METRONIDAZOLE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>A078084 001</u>	Mar 31, 2008
-----------	-----------------	--------------------	---------------------------	--------------

CORP

AP	+! HOSPIRA	<u>500MG/100ML</u>	<u>N018890 002</u>	Nov 18, 1983
-----------	------------	--------------------	---------------------------	--------------

AP	MYLAN LABS LTD	<u>500MG/100ML</u>	<u>A205531 001</u>	May 09, 2017
-----------	----------------	--------------------	---------------------------	--------------

LOTION;TOPICAL

METROLOTION

AB	+! GALDERMA LABS LP	<u>0.75%</u>	<u>N020901 001</u>	Nov 24, 1998
-----------	---------------------	--------------	---------------------------	--------------

METRONIDAZOLE

AB	FOUGERA PHARMS	<u>0.75%</u>	<u>A077197 001</u>	May 24, 2006
-----------	----------------	--------------	---------------------------	--------------

TABLET;ORAL

FLAGYL

AB	+ GD SEARLE LLC	<u>250MG</u>	<u>N012623 001</u>	
-----------	-----------------	--------------	---------------------------	--

AB	+!	<u>500MG</u>	<u>N012623 003</u>	
-----------	----	--------------	---------------------------	--

METRONIDAZOLE

AB	ALEMbic PHARMS LTD	<u>250MG</u>	<u>A079067 001</u>	Mar 13, 2009
-----------	--------------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A079067 002</u>	Mar 13, 2009
-----------	--	--------------	---------------------------	--------------

AB	APPCO PHARMA LLC	<u>250MG</u>	<u>A205245 001</u>	Sep 23, 2015
-----------	------------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A205245 002</u>	Sep 23, 2015
-----------	--	--------------	---------------------------	--------------

AB	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A203974 001</u>	May 29, 2015
-----------	----------------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A203974 002</u>	May 29, 2015
-----------	--	--------------	---------------------------	--------------

AB	CADILA PHARMS LTD	<u>250MG</u>	<u>A209794 001</u>	Dec 12, 2017
-----------	-------------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A209794 002</u>	Dec 12, 2017
-----------	--	--------------	---------------------------	--------------

AB	FLAMINGO PHARMS	<u>250MG</u>	<u>A207309 001</u>	May 16, 2016
-----------	-----------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A207309 002</u>	May 16, 2016
-----------	--	--------------	---------------------------	--------------

AB	INNOGENIX	<u>250MG</u>	<u>A070772 001</u>	Jul 16, 1986
-----------	-----------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A070772 002</u>	Jul 16, 1986
-----------	--	--------------	---------------------------	--------------

AB	LUPIN LTD	<u>250MG</u>	<u>A209096 001</u>	Sep 12, 2017
-----------	-----------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A209096 002</u>	Sep 12, 2017
-----------	--	--------------	---------------------------	--------------

AB	ORIT LABS LLC	<u>250MG</u>	<u>A208681 001</u>	Jun 20, 2017
-----------	---------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A208681 002</u>	Jun 20, 2017
-----------	--	--------------	---------------------------	--------------

AB	PLIVA	<u>500MG</u>	<u>A070033 001</u>	Dec 06, 1984
-----------	-------	--------------	---------------------------	--------------

AB	STRIDES PHARMA	<u>250MG</u>	<u>A208162 001</u>	May 25, 2016
-----------	----------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A208162 002</u>	May 25, 2016
-----------	--	--------------	---------------------------	--------------

AB	TEVA PHARMS USA	<u>250MG</u>	<u>A070027 001</u>	Nov 06, 1984
-----------	-----------------	--------------	---------------------------	--------------

AB	UNICHEM LABS LTD	<u>250MG</u>	<u>A203458 001</u>	Jan 22, 2014
-----------	------------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A203458 002</u>	Jan 22, 2014
-----------	--	--------------	---------------------------	--------------

AB	VIVIMED GLOBAL	<u>250MG</u>	<u>A070040 001</u>	Jan 29, 1985
-----------	----------------	--------------	---------------------------	--------------

AB		<u>500MG</u>	<u>A070039 001</u>	Jan 29, 1985
-----------	--	--------------	---------------------------	--------------

AB	WATSON LABS	<u>250MG</u>	<u>A070035 001</u>	Dec 20, 1984
-----------	-------------	--------------	---------------------------	--------------

AB	WATSON LABS INC	<u>500MG</u>	<u>A070044 001</u>	Feb 08, 1985
-----------	-----------------	--------------	---------------------------	--------------

AB	ZYDUS PHARMS USA	<u>250MG</u>	<u>A206560 001</u>	Nov 16, 2016
-----------	------------------	--------------	---------------------------	--------------

AB	INC	<u>500MG</u>	<u>A206560 002</u>	Nov 16, 2016
-----------	-----	--------------	---------------------------	--------------

TABLET, EXTENDED RELEASE;ORAL

FLAGYL ER

AB	+! GD SEARLE LLC	<u>750MG</u>	<u>N020868 001</u>	Nov 26, 1997
-----------	------------------	--------------	---------------------------	--------------

METRONIDAZOLE

AB	ALEMbic PHARMS LTD	<u>750MG</u>	<u>A090222 001</u>	May 05, 2010
-----------	--------------------	--------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

TEVA	150MG	A074377 001	May 16, 1995
	200MG	A074377 002	May 16, 1995
!	250MG	A074377 003	May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+! ASTELLAS	EQ 50MG BASE/VIAL	N021506 002	Mar 16, 2005
+!	EQ 100MG BASE/VIAL	N021506 003	Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+! MIDATECH PHARMA US	50MG	N022404 001	Apr 16, 2010
-----------------------	------	-------------	--------------

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

<u>AB</u> ACTAVIS PHARMA	<u>200MG</u>	<u>A073508 001</u>	Nov 19, 1993
--------------------------	--------------	--------------------	--------------

MONISTAT 3

<u>AB</u> +! MEDTECH PRODUCTS	<u>200MG</u>	<u>N018888 001</u>	Aug 15, 1984
-------------------------------	--------------	--------------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+! MYLAN PHARMS INC	0.25%; 81.35%; 15%	N021026 001	Feb 16, 2006
---------------------	--------------------	-------------	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u> AKORN INC	<u>EQ 1MG BASE/ML</u>	<u>A075494 001</u>	Jun 30, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075481 001</u>	Jun 30, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075494 002</u>	Jun 30, 2000
<u>AP</u> FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154 002</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075154 001</u>	Jun 20, 2000
<u>AP</u> GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696 001</u>	Feb 29, 2012
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A090850 001</u>	Jan 25, 2012
<u>AP</u> ! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293 001</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 1MG BASE/ML</u>	<u>A075856 001</u>	Jun 13, 2002
<u>AP</u> !	<u>EQ 5MG BASE/ML</u>	<u>A075293 002</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075856 002</u>	Jun 13, 2002
<u>AP</u> WEST-WARD PHARMS INT	<u>EQ 1MG BASE/ML</u>	<u>A075243 001</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 1MG BASE/ML</u>	<u>A075247 002</u>	Jun 23, 2000
<u>AP</u>	<u>EQ 1MG BASE/ML</u>	<u>A075324 001</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 1MG BASE/ML</u>	<u>A075421 002</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075243 002</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075247 001</u>	Jun 23, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075324 002</u>	Jun 20, 2000
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A075421 001</u>	Jun 20, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u> FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A203460 001</u>	Aug 22, 2014
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A203460 002</u>	Aug 22, 2014
<u>AP</u> ! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857 001</u>	Jul 22, 2002
<u>AP</u> !	<u>EQ 5MG BASE/ML</u>	<u>A075857 002</u>	Jul 22, 2002
<u>AP</u> SAGENT AGILA LLC	<u>EQ 1MG BASE/ML</u>	<u>A090315 001</u>	Nov 29, 2010
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A090315 002</u>	Nov 29, 2010

MIDAZOLAM HYDROCHLORIDE

<u>AP</u> SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316 001</u>	May 04, 2011
<u>AP</u>	<u>EQ 5MG BASE/ML</u>	<u>A090316 002</u>	May 04, 2011

MIDAZOLAM HYDROCHLORIDE

FRESENIUS KABI USA

EQ 5MG BASE/ML	A208878 001	Mar 28, 2017
----------------	-------------	--------------

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u> HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u> PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005
<u>AA</u> ! WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002

PRESCRIPTION DRUG PRODUCT LIST

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	IMPAX PHARMS	2.5MG	A076449 001	May 27, 2004
AB		5MG	A076449 002	May 27, 2004
AB		10MG	A076449 003	Dec 16, 2005
AB	MYLAN PHARMS INC	2.5MG	A076577 001	Sep 10, 2003
AB	!	5MG	A076577 002	Sep 10, 2003
AB		10MG	A076577 003	Sep 10, 2003
AB	SANDOZ	2.5MG	A076514 001	Sep 11, 2003
AB		5MG	A076514 002	Sep 11, 2003
AB		10MG	A076514 003	Jul 02, 2004

ORVATEN

AB	UPSHER-SMITH LABS	2.5MG	A076725 001	Nov 03, 2004
AB		5MG	A076725 002	Nov 03, 2004
AB		10MG	A076725 003	Nov 03, 2004

MIDODRINE HYDROCHLORIDE

BX	APOTEX INC	2.5MG	A077746 001	Sep 12, 2006
BX		5MG	A077746 002	Sep 12, 2006
BX		10MG	A077746 003	Sep 12, 2006

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+	NOVARTIS PHARMS CORP	25MG	N207997 001	Apr 28, 2017
---	----------------------	------	-------------	--------------

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012
---	----------------	-------	-------------	--------------

MIFEPREX

+	DANCO LABS LLC	200MG	N020687 001	Sep 28, 2000
---	----------------	-------	-------------	--------------

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682 001	Dec 18, 1996
AB	+		50MG	N020682 002	Dec 18, 1996
AB	+		100MG	N020682 003	Dec 18, 1996

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965 001	Feb 24, 2015
AB		50MG	A203965 002	Feb 24, 2015
AB		100MG	A203965 003	Feb 24, 2015

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+	ACTELION PHARMS LTD	100MG	N021348 001	Jul 31, 2003
---	---------------------	-------	-------------	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB	AMNEAL PHARMS	12.5MG	A205081 001	Apr 22, 2016
AB		25MG	A205081 002	Apr 22, 2016
AB		50MG	A205081 003	Apr 22, 2016
AB		100MG	A205081 004	Apr 22, 2016

SAVELLA

AB	+	ALLERGAN SALES LLC	12.5MG	N022256 001	Jan 14, 2009
AB	+		25MG	N022256 002	Jan 14, 2009
AB	+		50MG	N022256 003	Jan 14, 2009
AB	+		100MG	N022256 004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	FRESENIUS KABI USA	EQ 1MG BASE/ML	A075936 001	May 28, 2002	
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190 001	Oct 31, 2006	
AP	!	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966 001	Dec 03, 2010
AP	HOSPIRA INC	EQ 1MG BASE/ML	A203280 001	Sep 03, 2014	
AP	INTL MEDICATED	EQ 1MG BASE/ML	A076013 001	Aug 02, 2002	
AP	WEST-WARD PHARMS	EQ 1MG BASE/ML	A075530 001	May 28, 2002	
AP	INT	EQ 1MG BASE/ML	A075660 001	May 28, 2002	

PRESCRIPTION DRUG PRODUCT LIST

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	RENAISSANCE SSA LLC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151 002</u>	Jul 20, 2005
-----------	---------------------	--	--------------------	--------------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	!	BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 001</u>	May 28, 2002
<u>AP</u>	!		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 002</u>	May 28, 2002
<u>AP</u>		HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 001</u>	May 28, 2002
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 002</u>	May 28, 2002
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 001</u>	May 21, 2008
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 002</u>	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 001</u>	Jan 21, 2010
<u>AP</u>			<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

+! KNIGHT THERAPS

50MG

N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>		CNTY LINE PHARMS	<u>EQ 50MG BASE</u>	<u>A063067 003</u>	Aug 14, 1990
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A063067 002</u>	Sep 15, 1999
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A063067 001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	+	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649 001</u>	May 31, 1990
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050649 002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470 001</u>	Mar 11, 2008
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065470 002</u>	Mar 11, 2008
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065470 003</u>	Mar 11, 2008
<u>AB</u>		IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005 001</u>	Mar 23, 1999
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065005 003</u>	Apr 18, 2001
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065005 002</u>	Mar 23, 1999
<u>AB</u>		SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867 001</u>	May 13, 2013
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090867 002</u>	May 13, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090867 003</u>	May 13, 2013
<u>AB</u>		TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065062 001</u>	Nov 30, 2000
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065062 002</u>	Nov 30, 2000
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065062 003</u>	Nov 30, 2000
<u>AB</u>		WATSON LABS	<u>EQ 75MG BASE</u>	<u>A063065 002</u>	Jun 10, 1999
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A063065 001</u>	Dec 30, 1991
<u>AB</u>		WATSON LABS TEVA	<u>EQ 50MG BASE</u>	<u>A063181 001</u>	Dec 30, 1991
<u>AB</u>		ZYDUS WORLDWIDE	<u>EQ 50MG BASE</u>	<u>A063011 001</u>	Mar 02, 1992
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A063009 002</u>	Aug 12, 2003
<u>AB</u>	!		<u>EQ 100MG BASE</u>	<u>A063009 001</u>	Mar 02, 1992

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

		SUN PHARM INDS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012
			EQ 90MG BASE	N201922 003	Jul 11, 2012
			EQ 135MG BASE	N201922 005	Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

+! REMPEX PHARMS INC

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+! ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436 001</u>	Dec 26, 2007
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065436 002</u>	Dec 26, 2007
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065436 003</u>	Dec 26, 2007
<u>AB</u>		PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131 001</u>	Apr 16, 2003
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065131 002</u>	Apr 16, 2003
<u>AB</u>	!		<u>EQ 100MG BASE</u>	<u>A065131 003</u>	Apr 16, 2003
<u>AB</u>		SUN PHARM INDUSTRIES	<u>EQ 50MG BASE</u>	<u>A090217 001</u>	Jan 29, 2016
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090217 002</u>	Jan 29, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090217 003</u>	Jan 29, 2016
<u>AB</u>		TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065156 001</u>	Jan 06, 2004
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065156 002</u>	Jan 06, 2004

PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004
-----------	--	----------------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 45MG BASE</u>	<u>A204453</u>	<u>001</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204453</u>	<u>002</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A204453</u>	<u>003</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204453</u>	<u>004</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204453</u>	<u>005</u>	Sep 28, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202261</u>	<u>006</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A202261</u>	<u>007</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261</u>	<u>005</u>	Nov 19, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>	!	<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394</u>	<u>001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394</u>	<u>004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394</u>	<u>005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394</u>	<u>007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118</u>	<u>001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118</u>	<u>004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118</u>	<u>005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118</u>	<u>006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118</u>	<u>008</u>	Sep 25, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 45MG BASE</u>	<u>A203553</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203553</u>	<u>004</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A203553</u>	<u>005</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203553</u>	<u>006</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A203553</u>	<u>008</u>	Nov 16, 2017

SOLODYN

<u>AB</u>	+ MEDICIS	<u>EQ 80MG BASE</u>	<u>N050808</u>	<u>007</u>	Aug 27, 2010
<u>AB</u>	+ MINOLIRA	<u>EQ 105MG BASE</u>	<u>N050808</u>	<u>006</u>	Aug 27, 2010
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017
		EQ 135MG BASE	N209269	002	May 08, 2017
	SOLODYN				
	+ MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010
	+	EQ 65MG BASE	N050808	004	Jul 23, 2009
	+!	EQ 115MG BASE	N050808	005	Jul 23, 2009

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u>	!	<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+!	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013
----	--------------------	---------------------	---------	-----	--------------

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012
+!		50MG	N202611	002	Jun 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666 001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666 002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666 003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921 001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921 002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921 003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921 004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122 003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541 004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541 001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541 002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541 003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119 001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119 002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119 003</u>	Jun 19, 2003
<u>AB</u>	UPSHER-SMITH LABS	<u>15MG</u>	<u>A076219 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219 003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312 003</u>	Jun 19, 2003
<u>REMERON</u>				
<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N020415 001</u>	Jun 14, 1996
<u>AB</u>	+	<u>30MG</u>	<u>N020415 002</u>	Jun 14, 1996
<u>AB</u>	+	<u>45MG</u>	<u>N020415 003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076307 001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307 002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307 003</u>	Feb 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376 002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376 003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376 004</u>	Feb 28, 2006
<u>AB</u>	IMPAX LABS INC	<u>15MG</u>	<u>A076901 001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901 002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901 003</u>	Jun 28, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A205798 001</u>	Jun 01, 2017
<u>AB</u>		<u>30MG</u>	<u>A205798 002</u>	Jun 01, 2017
<u>AB</u>		<u>45MG</u>	<u>A205798 003</u>	Jun 01, 2017
<u>REMERON SOLTAB</u>				
<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N021208 001</u>	Jan 12, 2001
<u>AB</u>	+	<u>30MG</u>	<u>N021208 002</u>	Jan 12, 2001
<u>AB</u>	+	<u>45MG</u>	<u>N021208 003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	+ GD SEARLE LLC	<u>0.1MG</u>	<u>N019268 003</u>	Sep 21, 1990
<u>AB</u>	+!	<u>0.2MG</u>	<u>N019268 001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095 001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095 002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667 001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667 002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+!	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012
----	---------------	------------	-------------	--------------

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	! ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144 001</u>	Apr 30, 1998
<u>AP</u>	!	<u>20MG/VIAL</u>	<u>A064144 002</u>	Apr 30, 1998
<u>AP</u>	!	<u>40MG/VIAL</u>	<u>A064144 003</u>	Aug 11, 2009
<u>AP</u>	MYLAN LABS LTD	<u>5MG/VIAL</u>	<u>A202670 001</u>	Oct 13, 2017
<u>AP</u>		<u>20MG/VIAL</u>	<u>A202670 002</u>	Oct 13, 2017

PRESCRIPTION DRUG PRODUCT LIST

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>		<u>40MG/VIAL</u>	<u>A203386 001</u>	Oct 13, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A064117 001</u>	Apr 19, 1995
<u>AP</u>		<u>5MG/VIAL</u>	<u>A064180 001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117 002</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180 002</u>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+! BRISTOL MYERS
SQUIBB

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496 003</u>	Apr 11, 2006
<u>AP</u>	! HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871 001</u>	Apr 11, 2006
<u>AP</u>	!	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871 002</u>	Apr 11, 2006
<u>AP</u>	!	<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871 003</u>	Apr 11, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980 001</u>	Apr 13, 2009
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980 002</u>	Apr 13, 2009
<u>AP</u>	MYLAN LABS LTD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A201014 001</u>	Dec 11, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356 003</u>	Apr 11, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611 003</u>	Apr 11, 2006

MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS

MIVACRON

+ ABBVIE
+!EQ 10MG BASE/5ML (EQ 2MG BASE/ML)
EQ 20MG BASE/10ML (EQ 2MG BASE/ML)N020098 004 Jan 22, 1992
N020098 005 Jan 22, 1992MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>	ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A202700 001</u>	Oct 18, 2012
<u>AB</u>		<u>200MG</u>	<u>A202700 002</u>	Oct 18, 2012
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077667 001</u>	Feb 03, 2014
<u>AB</u>		<u>200MG</u>	<u>A077667 002</u>	Feb 03, 2014
<u>AB</u>	APPCO PHARMA LLC	<u>100MG</u>	<u>A207196 001</u>	Aug 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A207196 002</u>	Aug 16, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566 001</u>	Sep 27, 2012
<u>AB</u>		<u>200MG</u>	<u>A202566 002</u>	Sep 27, 2012
<u>AB</u>	HIKMA PHARMS	<u>100MG</u>	<u>A090543 001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A090543 002</u>	Sep 26, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076594 001</u>	Jul 16, 2012
<u>AB</u>		<u>200MG</u>	<u>A076594 002</u>	Jul 16, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>100MG</u>	<u>A078963 001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A078963 002</u>	Sep 26, 2012
<u>AB</u>	WATSON LABS INC	<u>100MG</u>	<u>A076715 001</u>	Nov 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A076715 002</u>	Nov 01, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A209966 001</u>	Sep 14, 2017
<u>AB</u>		<u>200MG</u>	<u>A209966 002</u>	Sep 14, 2017
	<u>PROVIGIL</u>			
<u>AB</u>	+ CEPHALON	<u>100MG</u>	<u>N020717 001</u>	Dec 24, 1998
<u>AB</u>	+!	<u>200MG</u>	<u>N020717 002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454 001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454 002</u>	Jun 02, 2008
<u>AB</u>	CHARTWELL RX	<u>7.5MG</u>	<u>A077536 001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536 002</u>	Nov 30, 2006

PRESCRIPTION DRUG PRODUCT LIST

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

AB	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416 001</u>	Mar 30, 2010
AB		<u>15MG</u>	<u>A090416 002</u>	Mar 30, 2010
AB	TEVA	<u>7.5MG</u>	<u>A076204 001</u>	May 08, 2003
AB	!	<u>15MG</u>	<u>A076204 002</u>	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A090453 001 Mar 20, 2015

10MG

A090453 002 Mar 20, 2015

!

25MG

A090453 003 Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

+ MERCK SHARP DOHME

0.10MG/INH

N205641 001 Apr 25, 2014

+!

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

ELOCON

AB	+! MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625 002</u>	Apr 19, 2013
-----------	----------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

AB	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171 001</u>	Apr 08, 2005
AB	G AND W LABS	<u>0.1%</u>	<u>A077447 001</u>	May 22, 2006
AB	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541 001</u>	May 28, 2008
AB	TARO	<u>0.1%</u>	<u>A076679 001</u>	Dec 21, 2004
AB	TOLMAR	<u>0.1%</u>	<u>A076591 001</u>	Apr 18, 2007

IMPLANT; IMPLANTATION

SINUVA

+ INTERSECT ENT INC

1.35MG

N209310 001 Dec 08, 2017

LOTION; TOPICAL

ELOCON

AB	+! MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796 001</u>	Mar 30, 1989
-----------	----------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

AB	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919 001</u>	Nov 29, 2007
AB	G AND W LABS	<u>0.1%</u>	<u>A077678 001</u>	Nov 21, 2007
AB	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506 001</u>	Aug 09, 2010
AB	PERRIGO ISRAEL	<u>0.1%</u>	<u>A077180 001</u>	Apr 06, 2005
AB	TARO	<u>0.1%</u>	<u>A076788 001</u>	Mar 15, 2006
AB	TOLMAR	<u>0.1%</u>	<u>A076499 001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

AB	+! MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543 001</u>	Apr 30, 1987
-----------	----------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

AB	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061 001</u>	Mar 28, 2005
AB	G AND W LABS	<u>0.1%</u>	<u>A077401 001</u>	Jun 20, 2006
AB	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571 001</u>	May 28, 2008
AB	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067 001</u>	Mar 18, 2002
AB	TOLMAR	<u>0.1%</u>	<u>A076481 001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

+ MERCK SHARP DOHME

0.11MG/INH

N021067 002 Feb 01, 2008

+!

0.22MG/INH

N021067 001 Mar 30, 2005

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB	AMNEAL PHARMS	<u>EQ 0.05MG BASE/SPRAY</u>	<u>A207989 001</u>	Apr 03, 2017
AB	APOTEX INC	<u>EQ 0.05MG BASE/SPRAY</u>	<u>A091161 001</u>	Mar 22, 2016

NASONEX

AB	+! MERCK SHARP DOHME	<u>EQ 0.05MG BASE/SPRAY</u>	<u>N020762 001</u>	Oct 01, 1997
-----------	----------------------	-----------------------------	--------------------	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB	AJANTA PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A203438 001</u>	Jul 31, 2015
AB	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906 001</u>	Sep 17, 2012
AB	MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776 001</u>	Dec 18, 2012
AB	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955 001</u>	Aug 03, 2012

SINGULAIR

AB	+! MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409 001</u>	Jul 26, 2002
-----------	----------	---------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717 001</u>	Sep 21, 2012
<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A203432 001</u>	Jul 31, 2015
<u>AB</u>	AMNEAL PHARMS	<u>EQ 10MG BASE</u>	<u>A204604 001</u>	Sep 04, 2015
<u>AB</u>	ANBISON LAB CO LTD	<u>EQ 10MG BASE</u>	<u>A205683 001</u>	Jan 12, 2016
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294 001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468 001</u>	Aug 03, 2012
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A207463 001</u>	Oct 28, 2016
<u>AB</u>	CSPC OUYI PHARM CO	<u>EQ 10MG BASE</u>	<u>A209012 001</u>	Apr 24, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582 001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926 001</u>	Aug 03, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843 001</u>	Sep 10, 2014
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 10MG BASE</u>	<u>A201522 001</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366 001</u>	Sep 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103 001</u>	Aug 03, 2012
<u>AB</u>	PERRIGO R AND D	<u>EQ 10MG BASE</u>	<u>A206112 001</u>	Apr 26, 2017
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889 001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605 001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515 001</u>	Aug 03, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 10MG BASE</u>	<u>A204290 001</u>	Oct 08, 2015
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859 001</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576 001</u>	Aug 03, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 10MG BASE</u>	<u>A090655 001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	<u>+</u> ! MSD MERCK CO	<u>EQ 10MG BASE</u>	<u>N020829 002</u>	Feb 20, 1998
-----------	-------------------------	---------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A203328 001</u>	Jul 31, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203328 002</u>	Jul 31, 2015
<u>AB</u>	ANBISON LAB CO LTD	<u>EQ 4MG BASE</u>	<u>A205695 001</u>	Nov 05, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205695 002</u>	Nov 05, 2015
<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508 002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096 002</u>	Aug 03, 2012
<u>AB</u>	CSPC OUYI PHARM CO	<u>EQ 4MG BASE</u>	<u>A209011 001</u>	Apr 18, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A209011 002</u>	Apr 18, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581 001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581 002</u>	Aug 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 4MG BASE</u>	<u>A204093 001</u>	May 22, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204093 002</u>	May 22, 2015
<u>AB</u>	JUBILANT GENERICS	<u>EQ 4MG BASE</u>	<u>A203795 001</u>	Feb 27, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203795 002</u>	Feb 27, 2015
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 4MG BASE</u>	<u>A200405 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A203582 001</u>	Mar 12, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203582 002</u>	Mar 12, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142 002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037 001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037 002</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588 002</u>	Aug 03, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 4MG BASE</u>	<u>A091128 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128 002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	<u>+</u> MSD MERCK CO	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000
<u>AB</u>	<u>+</u> ! MSD MERCK CO	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB</u>	+	ALLERGAN SALES LLC	<u>10MG</u>	<u>N020616</u>	<u>008</u>	Apr 20, 2007
<u>AB</u>	+		<u>20MG</u>	<u>N020616</u>	<u>001</u>	Jul 03, 1996
<u>AB</u>	+		<u>30MG</u>	<u>N020616</u>	<u>004</u>	Mar 09, 2001
<u>AB</u>	+		<u>40MG</u>	<u>N020616</u>	<u>009</u>	Jul 09, 2012
<u>AB</u>	+		<u>50MG</u>	<u>N020616</u>	<u>002</u>	Jul 03, 1996
<u>AB</u>	+		<u>60MG</u>	<u>N020616</u>	<u>005</u>	Mar 09, 2001
<u>AB</u>	+		<u>70MG</u>	<u>N020616</u>	<u>010</u>	Jul 09, 2012
<u>AB</u>	+		<u>80MG</u>	<u>N020616</u>	<u>006</u>	Oct 27, 2006
<u>AB</u>	+		<u>100MG</u>	<u>N020616</u>	<u>003</u>	Jul 03, 1996

MORPHINE SULFATE

<u>AB</u>		IMPAX LABS INC	<u>20MG</u>	<u>A200411</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>			<u>30MG</u>	<u>A200411</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>			<u>50MG</u>	<u>A200411</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>			<u>60MG</u>	<u>A200411</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>			<u>80MG</u>	<u>A200411</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>			<u>100MG</u>	<u>A200411</u>	<u>006</u>	Apr 12, 2016
<u>AB</u>		PAR PHARM INC	<u>20MG</u>	<u>A200812</u>	<u>001</u>	Nov 10, 2011
<u>AB</u>			<u>30MG</u>	<u>A200812</u>	<u>002</u>	Nov 10, 2011
<u>AB</u>			<u>50MG</u>	<u>A200812</u>	<u>003</u>	Nov 10, 2011
<u>AB</u>			<u>60MG</u>	<u>A200812</u>	<u>004</u>	Nov 10, 2011
<u>AB</u>			<u>80MG</u>	<u>A200812</u>	<u>005</u>	Nov 10, 2011
<u>AB</u>			<u>100MG</u>	<u>A200812</u>	<u>006</u>	Nov 10, 2011
<u>AB</u>		TEVA PHARMS USA	<u>20MG</u>	<u>A202718</u>	<u>001</u>	Dec 29, 2014
<u>AB</u>			<u>30MG</u>	<u>A202718</u>	<u>002</u>	Dec 29, 2014
<u>AB</u>			<u>40MG</u>	<u>A202718</u>	<u>007</u>	Jun 03, 2015
<u>AB</u>			<u>50MG</u>	<u>A202718</u>	<u>003</u>	Dec 29, 2014
<u>AB</u>			<u>60MG</u>	<u>A202718</u>	<u>004</u>	Dec 29, 2014
<u>AB</u>			<u>70MG</u>	<u>A202718</u>	<u>008</u>	Jun 03, 2015
<u>AB</u>			<u>80MG</u>	<u>A202718</u>	<u>005</u>	Dec 29, 2014
<u>AB</u>			<u>100MG</u>	<u>A202718</u>	<u>006</u>	Dec 29, 2014
<u>AB</u>		UPSHER-SMITH LABS	<u>10MG</u>	<u>A202104</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>			<u>20MG</u>	<u>A202104</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>			<u>30MG</u>	<u>A202104</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>			<u>50MG</u>	<u>A202104</u>	<u>004</u>	Jun 03, 2013
<u>AB</u>			<u>60MG</u>	<u>A202104</u>	<u>005</u>	Jun 03, 2013
<u>AB</u>			<u>80MG</u>	<u>A202104</u>	<u>006</u>	Jun 03, 2013
<u>AB</u>			<u>100MG</u>	<u>A202104</u>	<u>007</u>	Jun 03, 2013

KADIAN

	+	ALLERGAN SALES LLC	130MG	N020616	011	Jul 09, 2012
	+		150MG	N020616	012	Jul 09, 2012
	+		200MG	N020616	007	Feb 27, 2007

MORPHINE SULFATE

		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>		FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+		<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984

MORPHINE SULFATE

<u>AP</u>		EUROHLTH INTL SARL	<u>4MG/ML</u>	<u>A205758</u>	<u>001</u>	May 21, 2015
<u>AP</u>			<u>8MG/ML</u>	<u>A205758</u>	<u>002</u>	May 21, 2015
<u>AP</u>			<u>10MG/ML</u>	<u>A205758</u>	<u>003</u>	May 21, 2015
<u>AP</u>		HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>			<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+	HOSPIRA INC	<u>4MG/ML</u>	<u>N202515</u>	<u>002</u>	Nov 14, 2011
<u>AP</u>	+		<u>8MG/ML</u>	<u>N202515</u>	<u>003</u>	Nov 14, 2011
<u>AP</u>	+		<u>10MG/ML</u>	<u>N202515</u>	<u>004</u>	Nov 14, 2011
<u>AP</u>	+	ICU MEDICAL INC	<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

INJECTABLE; INJECTION

INFUMORPH

+	!	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991
+	!		25MG/ML	N018565	004	Jul 19, 1991

MORPHINE SULFATE

+	!	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
+	!	ICU MEDICAL INC	5MG/ML	N019916	002	Oct 27, 2006
+	!	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

+	!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
+	!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
+	!		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
+	!		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
+	!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>		HI-TECH PHARMACAL	<u>100MG/5ML</u>	<u>A208809</u>	<u>001</u>	Jul 06, 2017
<u>AA</u>		NOSTRUM LABS INC	<u>10MG/5ML</u>	<u>A201011</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>			<u>20MG/5ML</u>	<u>A201011</u>	<u>002</u>	Feb 05, 2014
<u>AA</u>			<u>100MG/5ML</u>	<u>A204053</u>	<u>001</u>	Oct 06, 2016
<u>AA</u>		PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>		PHARM ASSOC	<u>100MG/5ML</u>	<u>A206573</u>	<u>001</u>	Nov 14, 2016
<u>AA</u>		RHODES PHARMS	<u>10MG/5ML</u>	<u>A206308</u>	<u>001</u>	Jun 22, 2017
<u>AA</u>			<u>20MG/5ML</u>	<u>A206420</u>	<u>001</u>	Jul 12, 2016
<u>AA</u>			<u>100MG/5ML</u>	<u>A206308</u>	<u>002</u>	Jun 22, 2017
<u>AA</u>		SPECGX LLC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>		TRIS PHARMA INC	<u>10MG/5ML</u>	<u>A203518</u>	<u>001</u>	May 12, 2015
<u>AA</u>			<u>20MG/5ML</u>	<u>A203519</u>	<u>001</u>	May 18, 2016
<u>AA</u>			<u>100MG/5ML</u>	<u>A203518</u>	<u>002</u>	May 12, 2015
<u>AA</u>		VINTAGE PHARMS LLC	<u>10MG/5ML</u>	<u>A202309</u>	<u>001</u>	Nov 25, 2015
<u>AA</u>			<u>20MG/5ML</u>	<u>A202310</u>	<u>001</u>	Oct 30, 2015
<u>AA</u>		VISTAPHARM	<u>10MG/5ML</u>	<u>A201947</u>	<u>001</u>	Jan 05, 2012
<u>AA</u>			<u>20MG/5ML</u>	<u>A201947</u>	<u>002</u>	Jan 05, 2012
<u>AA</u>	+	WEST-WARD PHARMS INT	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>	+		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+		<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
		LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011

TABLET; ORAL

MORPHINE SULFATE

+		WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008
+	!		30MG	N022207	002	Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>15MG</u>	<u>A203849</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>			<u>30MG</u>	<u>A203849</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>			<u>60MG</u>	<u>A203849</u>	<u>003</u>	Apr 06, 2015
<u>AB</u>			<u>100MG</u>	<u>A203849</u>	<u>004</u>	Apr 06, 2015
<u>AB</u>			<u>200MG</u>	<u>A203849</u>	<u>005</u>	Apr 06, 2015
<u>AB</u>		DAVA PHARMS INC	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>		EPIC PHARMA LLC	<u>15MG</u>	<u>A091357</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>			<u>30MG</u>	<u>A091357</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>			<u>60MG</u>	<u>A091357</u>	<u>003</u>	Jun 23, 2016
<u>AB</u>			<u>100MG</u>	<u>A091357</u>	<u>004</u>	Jun 23, 2016
<u>AB</u>			<u>200MG</u>	<u>A091357</u>	<u>005</u>	Jun 23, 2016
<u>AB</u>		MAYNE PHARMA INC	<u>15MG</u>	<u>A205386</u>	<u>001</u>	Oct 28, 2016
<u>AB</u>			<u>30MG</u>	<u>A205386</u>	<u>002</u>	Oct 28, 2016
<u>AB</u>			<u>60MG</u>	<u>A205386</u>	<u>003</u>	Oct 28, 2016
<u>AB</u>			<u>100MG</u>	<u>A205386</u>	<u>004</u>	Oct 28, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>15MG</u>	<u>A200824</u>	<u>001</u>	Oct 18, 2011
<u>AB</u>			<u>30MG</u>	<u>A200824</u>	<u>002</u>	Oct 18, 2011
<u>AB</u>			<u>60MG</u>	<u>A200824</u>	<u>003</u>	Oct 18, 2011
<u>AB</u>			<u>100MG</u>	<u>A200824</u>	<u>004</u>	Oct 18, 2011
<u>AB</u>			<u>200MG</u>	<u>A200824</u>	<u>005</u>	Oct 18, 2011
<u>AB</u>		NESHER PHARMS	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>			<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>			<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>		<u>100MG</u>	<u>A077855 001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855 002</u>	Sep 27, 2007
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A203602 001</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A203602 002</u>	Dec 16, 2015
<u>AB</u>		<u>60MG</u>	<u>A203602 003</u>	Dec 16, 2015
<u>AB</u>		<u>100MG</u>	<u>A203602 004</u>	Dec 16, 2015
<u>AB</u>		<u>200MG</u>	<u>A203602 005</u>	Dec 16, 2015
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862 001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862 002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862 003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769 001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769 002</u>	Jul 02, 1998
<u>AB</u>	SPECGX LLC	<u>15MG</u>	<u>A076412 001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412 002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412 003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438 001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438 002</u>	Jul 03, 2003
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761 001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761 002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761 003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761 004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761 005</u>	May 11, 2012
<u>AB</u>	SUN PHARM INDUSTRIES	<u>15MG</u>	<u>A205634 001</u>	Aug 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A205634 002</u>	Aug 25, 2016
<u>AB</u>		<u>60MG</u>	<u>A205634 003</u>	Aug 25, 2016
<u>AB</u>		<u>100MG</u>	<u>A205634 004</u>	Aug 25, 2016
<u>AB</u>		<u>200MG</u>	<u>A205634 005</u>	Aug 25, 2016
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295 001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295 002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295 003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295 004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295 005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	+	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516 003</u>	Sep 12, 1989
<u>AB</u>	+		<u>30MG</u>	<u>N019516 001</u>	May 29, 1987
<u>AB</u>	+		<u>60MG</u>	<u>N019516 002</u>	Apr 08, 1988
<u>AB</u>	+		<u>100MG</u>	<u>N019516 004</u>	Jan 16, 1990
<u>AB</u>	+		<u>200MG</u>	<u>N019516 005</u>	Nov 08, 1993
		ARYMO ER			
	+	EGALET	15MG	N208603 001	Jan 09, 2017
	+		30MG	N208603 002	Jan 09, 2017
	+		60MG	N208603 003	Jan 09, 2017
		MORPHABOND ER			
	+	DAIICHI SANKYO INC	15MG	N206544 001	Oct 02, 2015
	+		30MG	N206544 002	Oct 02, 2015
	+		60MG	N206544 003	Oct 02, 2015
	+		100MG	N206544 004	Oct 02, 2015

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

+	ALPHARMA PHARMS	20MG; 0.8MG	N022321 001	Aug 13, 2009
+		30MG; 1.2MG	N022321 002	Aug 13, 2009
+		50MG; 2MG	N022321 003	Aug 13, 2009
+		60MG; 2.4MG	N022321 004	Aug 13, 2009
+		80MG; 3.2MG	N022321 005	Aug 13, 2009
+		100MG; 4MG	N022321 006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572 001	Apr 03, 2015
!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833 001	May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<u>AT1</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A202916 001</u>	Nov 09, 2017
<u>AT1</u>	APOTEX INC	<u>EQ 0.5% BASE</u>	<u>A090080 001</u>	Jun 30, 2017
<u>AT1</u>	AUROBINDO PHARMA LTD	<u>EQ 0.5% BASE</u>	<u>A206242 001</u>	Oct 04, 2017

PRESCRIPTION DRUG PRODUCT LIST

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1	LUPIN LTD	EQ 0.5% BASE	A202867 001	Sep 04, 2014
AT1	WATSON LABS INC	EQ 0.5% BASE	A202525 001	Mar 06, 2015

VIGAMOX

AT1	+ ! NOVARTIS PHARMS CORP	EQ 0.5% BASE	N021598 001	Apr 15, 2003
------------	---------------------------------	---------------------	--------------------	--------------

MOXEZA

AT2	+ ! NOVARTIS PHARMS CORP	EQ 0.5% BASE	N022428 001	Nov 19, 2010
------------	---------------------------------	---------------------	--------------------	--------------

MOXIFLOXACIN HYDROCHLORIDE

AT2	LUPIN LTD	EQ 0.5% BASE	A204079 001	May 28, 2015
------------	-----------	---------------------	--------------------	--------------

TABLET;ORAL

AVELOX

AB	+ ! BAYER HLTHCARE	EQ 400MG BASE	N021085 001	Dec 10, 1999
-----------	---------------------------	----------------------	--------------------	--------------

MOXIFLOXACIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632 001	Mar 04, 2014
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348 001	Jan 14, 2016
AB	DR REDDYS LABS LTD	EQ 400MG BASE	A076938 001	Mar 04, 2014
AB	MSN LABS PVT LTD	EQ 400MG BASE	A208682 001	Sep 22, 2017
AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635 001	Aug 31, 2015
AB	NOVEL LABS INC	EQ 400MG BASE	A207285 001	Feb 13, 2017
AB	TEVA PHARMS USA	EQ 400MG BASE	A077437 001	Feb 18, 2014
AB	TORRENT PHARMS LTD	EQ 400MG BASE	A200160 001	Apr 03, 2014

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005
AB	GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011
AB	! PERRIGO NEW YORK	2%	A065123 001	Nov 07, 2003
AB	TARO	2%	A065170 001	Sep 23, 2005
AB	TEVA	2%	A065085 001	Nov 07, 2003

CENTANY

BX	PERRIGO NEW YORK	2%	N050788 001	Dec 04, 2002
-----------	------------------	-----------	--------------------	--------------

MUPIROCIN CALCIUM

CREAM;TOPICAL

BACTROBAN

AB	+ ! GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997
-----------	----------------------------	-------------------	--------------------	--------------

MUPIROCIN

AB	GLENMARK PHARMS INC	EQ 2% BASE	A201587 001	Jan 24, 2013
-----------	---------------------	-------------------	--------------------	--------------

OINTMENT;NASAL

BACTROBAN

+ !	GLAXOSMITHKLINE	EQ 2% BASE	N050703 001	Sep 18, 1995
------------	-----------------	-------------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

AB	+ ! ROCHE PALO	250MG	N050722 001	May 03, 1995
-----------	-----------------------	--------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	250MG	A090253 001	May 04, 2009
AB	ALKEM LABS LTD	250MG	A200197 001	Jun 13, 2013
AB	APOTEX CORP	250MG	A090419 001	Apr 22, 2009
AB	MYLAN	250MG	A065520 001	May 04, 2009
AB	SANDOZ	250MG	A065379 001	Oct 15, 2008
AB	STRIDES PHARMA	250MG	A090055 001	Jun 10, 2010
AB	TEVA PHARMS	250MG	A065491 001	May 06, 2009
AB	VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009
AB	WEST-WARD PHARMS INT	250MG	A065410 001	Jul 29, 2008
AB	ZHEJIANG HISUN PHARM	250MG	A204077 001	Nov 13, 2017

SUSPENSION;ORAL

CELLCEPT

AB	+ ! ROCHE PALO	200MG/ML	N050759 001	Oct 01, 1998
-----------	-----------------------	-----------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

AB	ALKEM LABS LTD	200MG/ML	A203005 001	Nov 14, 2014
-----------	----------------	-----------------	--------------------	--------------

TABLET;ORAL

CELLCEPT

AB	+ ! ROCHE PALO	500MG	N050723 001	Jun 19, 1997
-----------	-----------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLATE MOFETIL

TABLET; ORAL

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A065416</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A091249</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A090499</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A065521</u>	<u>001</u>	May 04, 2009
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065451</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES PHARMA	<u>500MG</u>	<u>A090456</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A065457</u>	<u>001</u>	May 04, 2009
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A090606</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>	WEST-WARD PHARMS INT	<u>500MG</u>	<u>A065413</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ZHEJIANG HISUN PHARM	<u>500MG</u>	<u>A204076</u>	<u>001</u>	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

<u>AP</u>	<u>+</u> !	ROCHE PALO	<u>500MG/VIAL</u>	<u>N050758</u>	<u>001</u>	Aug 12, 1998
-----------	------------	------------	-------------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>500MG/VIAL</u>	<u>A204043</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A203859</u>	<u>001</u>	Mar 31, 2017
<u>AP</u>		PAR STERILE PRODUCTS	<u>500MG/VIAL</u>	<u>A203575</u>	<u>001</u>	Oct 28, 2016
<u>AP</u>		ZYDUS PHARMS USA INC	<u>500MG/VIAL</u>	<u>A204473</u>	<u>001</u>	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

<u>AB</u>		ACCORD HLTHCARE	<u>180MG</u>	<u>A202555</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>			<u>360MG</u>	<u>A202555</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>		APOTEX INC	<u>180MG</u>	<u>A091558</u>	<u>001</u>	Aug 21, 2012
<u>AB</u>			<u>360MG</u>	<u>A091558</u>	<u>002</u>	Aug 19, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>180MG</u>	<u>A091248</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>			<u>360MG</u>	<u>A091248</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>		TEVA PHARMS USA	<u>180MG</u>	<u>A202720</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>			<u>360MG</u>	<u>A202720</u>	<u>002</u>	Oct 30, 2014
		<u>MYFORTIC</u>				
<u>AB</u>	<u>+</u>	NOVARTIS	<u>180MG</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
<u>AB</u>	<u>+</u> !		<u>360MG</u>	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

	<u>+</u> !	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985
--	------------	---------------------	-----	---------	-----	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>		APOTEX INC	<u>500MG</u>	<u>A090427</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>			<u>750MG</u>	<u>A090427</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		CHARTWELL MOLECULES	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>			<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		IMPAX LABS INC	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	<u>!</u>		<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001
<u>AB</u>		INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>			<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>500MG</u>	<u>A090516</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>			<u>750MG</u>	<u>A090516</u>	<u>002</u>	Jul 12, 2010
<u>AB</u>		SANDOZ	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>			<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>			<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	<u>+</u>	US WORLDMEDS LLC	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>	<u>+</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	<u>+</u> !		<u>80MG</u>	<u>N018063</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

NADOLOL

TABLET; ORAL

NADOLOL

<u>AB</u>	AMNEAL PHARMS CO	<u>20MG</u>	<u>A208832</u>	<u>001</u>	Jun 02, 2017
<u>AB</u>		<u>40MG</u>	<u>A208832</u>	<u>002</u>	Jun 02, 2017
<u>AB</u>		<u>80MG</u>	<u>A208832</u>	<u>003</u>	Jun 02, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A201893</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>		<u>80MG</u>	<u>A201893</u>	<u>002</u>	Sep 16, 2015
<u>AB</u>	INVAGEN PHARMS	<u>20MG</u>	<u>A203455</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>		<u>40MG</u>	<u>A203455</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>		<u>80MG</u>	<u>A203455</u>	<u>003</u>	Dec 18, 2015
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	LUPIN LTD	<u>20MG</u>	<u>A209309</u>	<u>001</u>	Oct 05, 2017
<u>AB</u>		<u>40MG</u>	<u>A209309</u>	<u>002</u>	Oct 05, 2017
<u>AB</u>		<u>80MG</u>	<u>A209309</u>	<u>003</u>	Oct 05, 2017
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>	ZYDUS PHARMS USA INC	<u>20MG</u>	<u>A207761</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>		<u>40MG</u>	<u>A207761</u>	<u>002</u>	Jul 28, 2017
<u>AB</u>		<u>80MG</u>	<u>A207761</u>	<u>003</u>	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+! GD SEARLE LLC EQ 0.2MG BASE/SPRAY N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200002</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200002</u>	<u>002</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A062527</u>	<u>004</u>	Aug 02, 1984
NALLPEN IN PLASTIC CONTAINER					
	+! BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!	EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TARO	<u>1%</u>	<u>A205975</u>	<u>001</u>	Sep 08, 2016
<u>AB</u>		<u>2%</u>	<u>A206901</u>	<u>001</u>	Jan 06, 2016
<u>AB</u>	TOLMAR	<u>2%</u>	<u>A206960</u>	<u>001</u>	Apr 10, 2017
<u>NAFTIN</u>					
<u>AB</u>	+! SEBELA IRELAND LTD	<u>1%</u>	<u>N019599</u>	<u>001</u>	Feb 29, 1988
<u>AB</u>	+!	<u>2%</u>	<u>N019599</u>	<u>002</u>	Jan 13, 2012

GEL; TOPICAL

NAFTIN

+! SEBELA IRELAND LTD 1% N019356 001 Jun 18, 1990
+! 2% N204286 001 Jun 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

AP	!	HOSPIRA	10MG/ML	A070914 001	Feb 03, 1989
AP	!		10MG/ML	A070915 001	Feb 03, 1989
AP	!		20MG/ML	A070916 001	Feb 03, 1989
AP	!		20MG/ML	A070918 001	Feb 03, 1989

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+	!	SHIONOGI INC	EQ 0.2MG BASE	N208854 001	Mar 23, 2017
---	---	--------------	---------------	-------------	--------------

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+		ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760 001	Sep 16, 2014
+	!		EQ 25MG BASE	N204760 002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

AP		WEST-WARD PHARMS INT	0.4MG/ML	A070299 001	Sep 24, 1986
-----------	--	-------------------------	-----------------	--------------------	--------------

NALOXONE HYDROCHLORIDE

AP		AKORN	0.4MG/ML	A208871 001	Feb 28, 2017
AP			0.4MG/ML	A208872 001	Mar 14, 2017
AP	!	HOSPIRA	0.4MG/ML	A070172 001	Sep 24, 1986
AP	!		0.4MG/ML	A070254 001	Jan 07, 1987
AP	!		0.4MG/ML	A070256 001	Jan 07, 1987
AP	!		0.4MG/ML	A070257 001	Jan 07, 1987
AP		INTL MEDICATION	0.4MG/ML	A070639 001	Sep 24, 1986
AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997 001	Mar 06, 2014
AP			0.4MG/ML	A205014 001	Jun 29, 2016
AP		SOMERSET THERAPS LLC	0.4MG/ML	A207633 001	Aug 08, 2017
AP			0.4MG/ML	A207634 001	Jul 26, 2017
	!	INTL MEDICATION	1MG/ML	A072076 001	Mar 24, 1988

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

	+	!	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862 001	Oct 19, 2016
--	---	---	-----------	-----------------------	-------------	--------------

SPRAY, METERED; NASAL

			NARCAN			
	+		ADAPT	2MG/SPRAY	N208411 002	Jan 24, 2017
	+	!		4MG/SPRAY	N208411 001	Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		GAVIS PHARMS	EQ 0.5MG BASE; EQ 50MG BASE	A075735 001	Jul 11, 2001
AB		SUN PHARM INDS LTD	EQ 0.5MG BASE; EQ 50MG BASE	A075523 001	Mar 17, 2000
AB	!	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	A074736 001	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+	!	ALKERMES	380MG/VIAL	N021897 001	Apr 13, 2006
---	---	----------	------------	-------------	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	50MG	A091205 001	Aug 17, 2011
AB		APOTEX INC	50MG	A207905 001	Jul 21, 2017
AB		BARR	50MG	A074918 001	May 08, 1998
AB		ELITE LABS	50MG	A075274 001	May 26, 1999
AB	!	SPECGX LLC	50MG	A076264 002	Mar 22, 2002
AB		SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012
		SPECGX LLC	25MG	A076264 001	Mar 22, 2002
			100MG	A076264 003	Mar 22, 2002

PRESCRIPTION DRUG PRODUCT LIST

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

! LUITPOLD PHARMS INC 200MG/ML

A091252 001 Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

! AKORN INC 0.1%

A083590 001

NAPROXEN

SUSPENSION; ORAL

NAPROSYN**AB** +! ATNAHS PHARMA US **25MG/ML****N018965 001** Mar 23, 1987NAPROXEN**AB** WEST-WARD PHARMS **25MG/ML****A074190 001** Mar 30, 1994

INT

TABLET; ORAL

NAPROSYN**AB** + ATNAHS PHARMA US **250MG****N017581 002****AB** + **375MG****N017581 003****AB** +! **500MG****N017581 004** Apr 15, 1982NAPROXEN**AB** AMNEAL PHARMS NY **250MG****A075927 001** Dec 18, 2001**AB** **375MG****A075927 002** Dec 18, 2001**AB** **500MG****A075927 003** Dec 18, 2001**AB** AUROBINDO PHARMA **250MG****A200429 001** Nov 08, 2011

LTD

AB **375MG****A200429 002** Nov 08, 2011**AB** **500MG****A200429 003** Nov 08, 2011**AB** GLENMARK GENERICS **250MG****A078250 001** Mar 28, 2007**AB** **375MG****A078250 002** Mar 28, 2007**AB** **500MG****A078250 003** Mar 28, 2007**AB** INVAGEN PHARMS **250MG****A091305 001** Aug 24, 2011**AB** **375MG****A091305 002** Aug 24, 2011**AB** **500MG****A091305 003** Aug 24, 2011**AB** MARKSANS PHARMA **250MG****A091416 001** Feb 14, 2011**AB** **375MG****A091416 002** Feb 14, 2011**AB** **500MG****A091416 003** Feb 14, 2011**AB** MYLAN **250MG****A074121 001** Dec 21, 1993**AB** **375MG****A074121 002** Dec 21, 1993**AB** **500MG****A074121 003** Dec 21, 1993**AB** PERRIGO R AND D **250MG****A077339 001** Apr 27, 2005**AB** **375MG****A077339 002** Apr 27, 2005**AB** **500MG****A077339 003** Apr 27, 2005**AB** TEVA **250MG****A074201 001** Dec 21, 1993**AB** **375MG****A074201 002** Dec 21, 1993**AB** **500MG****A074201 003** Dec 21, 1993**AB** ZYDUS PHARMS USA **250MG****A078620 001** Jun 07, 2007**AB** **375MG****A078620 002** Jun 07, 2007**AB** **500MG****A078620 003** Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN**AB** +! ATNAHS PHARMA US **375MG****N020067 002** Oct 14, 1994**AB** +! **500MG****N020067 003** Oct 14, 1994NAPROXEN**AB** INVAGEN PHARMS **375MG****A091432 001** Sep 19, 2011**AB** **500MG****A091432 002** Sep 19, 2011**AB** PLIVA **375MG****A075337 001** May 26, 1999**AB** **500MG****A075337 002** May 26, 1999**AB** TEVA **375MG****A075227 001** Jun 30, 1998**AB** **500MG****A075227 002** Jun 30, 1998NAPROXEN SODIUM

TABLET; ORAL

ANAPROX**AB** + ATNAHS PHARMA US **EQ 250MG BASE****N018164 001**ANAPROX DS**AB** +! ATNAHS PHARMA US **EQ 500MG BASE****N018164 003** Sep 30, 1987NAPROXEN SODIUM**AB** AMNEAL PHARMS NY **EQ 250MG BASE****A078432 001** Apr 25, 2007**AB** **EQ 500MG BASE****A078432 002** Apr 25, 2007**AB** AUROBINDO PHARMA **EQ 250MG BASE****A200629 001** Oct 31, 2011

LTD

PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629 002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486 001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486 002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 250MG BASE</u>	<u>A078314 001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314 002</u>	Apr 27, 2007
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198 001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198 002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

<u>AB</u>	+	ALVOGEN MALTA	<u>EQ 375MG BASE</u>	<u>N020353 001</u>	Jan 05, 1996
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N020353 002</u>	Jan 05, 1996
<u>AB</u>	+	!	<u>EQ 750MG BASE</u>	<u>N020353 003</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416 002</u>	Apr 23, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075416 001</u>	Aug 27, 2002
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075416 003</u>	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926 002	May 14, 2015
+	!	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763 002</u>	Feb 10, 1998
<u>AB</u>	+	!	<u>EQ 2.5MG BASE</u>	<u>N020763 001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373 001</u>	Apr 22, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091373 002</u>	Apr 22, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502 001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431 001</u>	May 31, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A202431 002</u>	May 31, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441 001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441 002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326 001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326 002</u>	Jul 08, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288 002</u>	Jul 07, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552 001</u>	Feb 14, 2011
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751 002</u>	Jul 07, 2010
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 1MG BASE</u>	<u>A090381 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381 002</u>	Jul 07, 2010

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	NOVARTIS PHARMS CORP	5%	N050514 001	
---	-------------------------	----	-------------	--

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	ALVOGEN MALTA	<u>60MG</u>	<u>A205055 001</u>	Dec 11, 2015	
<u>AB</u>		<u>120MG</u>	<u>A205055 002</u>	Dec 11, 2015	
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009	
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009	
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009	
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009	
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011	
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011	
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A205248 001</u>	Jul 06, 2016	
<u>AB</u>		<u>120MG</u>	<u>A205248 002</u>	Jul 06, 2016	
	<u>STARLIX</u>				
<u>AB</u>	+	NOVARTIS	<u>60MG</u>	<u>N021204 001</u>	Dec 22, 2000
<u>AB</u>	+	!	<u>120MG</u>	<u>N021204 002</u>	Dec 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

+	FOREST LABS	EQ 2.5MG BASE	N021742 002	Dec 17, 2007
+		EQ 5MG BASE	N021742 003	Dec 17, 2007
+		EQ 10MG BASE	N021742 004	Dec 17, 2007
+	!	EQ 20MG BASE	N021742 005	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

+	FOREST LABS LLC	EQ 5MG BASE; 80MG	N206302 001	Jun 03, 2016
---	-----------------	-------------------	-------------	--------------

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIIL

AT	+	ALLERGAN	2%	N021009 001	Dec 08, 1999
-----------	---	----------	-----------	--------------------	--------------

NEDOCROMIL SODIUM

AT		AKORN	2%	A090638 001	Aug 22, 2012
-----------	--	-------	-----------	--------------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	TEVA	50MG	A076037 001	Sep 16, 2003
		100MG	A076037 002	Sep 16, 2003
		150MG	A076037 003	Sep 16, 2003
		200MG	A076037 004	Sep 16, 2003
!		250MG	A076037 005	Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877 001	Oct 28, 2005
---	----------------------	---------------------	-------------	--------------

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+	AGOURON PHARMS	EQ 250MG BASE	N020779 001	Mar 14, 1997
+	!	EQ 625MG BASE	N021503 001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA		BRECKENRIDGE PHARM	500MG	A065468 001	Mar 29, 2010
AA		LANNETT HOLDINGS INC	500MG	A204435 001	Jun 10, 2016
AA	!	TEVA	500MG	A060304 001	
AA		X GEN PHARMS	500MG	A065220 001	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664 001	Apr 08, 1986
AT		X GEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106 001	Jan 31, 2006
AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108 001	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A060707 001	
-----------	---	----------------	--	--------------------	--

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078 001	May 31, 2013
AP	+	!	10MG/10ML (1MG/ML)	N204078 002	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933 001	Sep 25, 2017
AP			10MG/10ML (1MG/ML)	A209933 002	Sep 25, 2017
AP		EUROHLTH INTL SARL	5MG/10ML (0.5MG/ML)	A207042 001	Dec 28, 2015
AP			10MG/10ML (1MG/ML)	A207042 002	Dec 28, 2015
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405 001	Apr 26, 2017
AP			10MG/10ML (1MG/ML)	A208405 002	Apr 26, 2017
		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629 001	Jan 08, 2015
			10MG/10ML (1MG/ML)	N203629 002	Jan 08, 2015

PRESCRIPTION DRUG PRODUCT LIST

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

+	!	NOVARTIS PHARMS CORP	0.3%	N203491	001	Oct 16, 2012
---	---	-------------------------	------	---------	-----	--------------

NEVANAC

+	!	NOVARTIS PHARMS CORP	0.1%	N021862	001	Aug 19, 2005
---	---	-------------------------	------	---------	-----	--------------

NERATINIB MALEATE

TABLET;ORAL

NERLYNX

+	!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017
---	---	--------------	--------------	---------	-----	--------------

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS

NATRECOR

+	!	SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001
---	---	-----------	------------	---------	-----	--------------

NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

+	!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017
---	---	------------------	---------------	---------	-----	--------------

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL

AKYNZEO

+	!	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014
---	---	------------------	---------------------	---------	-----	--------------

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE

AA		AUROBINDO	50MG/5ML	A077702	001	May 22, 2012
-----------	--	-----------	-----------------	----------------	------------	--------------

AA		CIPLA LTD	50MG/5ML	A207684	001	Aug 03, 2017
-----------	--	-----------	-----------------	----------------	------------	--------------

VIRAMUNE

AA	+	!	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998
-----------	---	---	-------------------------	-----------------	----------------	------------	--------------

TABLET;ORAL

NEVIRAPINE

AB		APOTEX INC	200MG	A203021	001	May 22, 2012
-----------	--	------------	--------------	----------------	------------	--------------

AB		AUROBINDO	200MG	A077521	001	May 22, 2012
-----------	--	-----------	--------------	----------------	------------	--------------

AB		CIPLA	200MG	A077956	001	May 22, 2012
-----------	--	-------	--------------	----------------	------------	--------------

AB		HETERO LABS LTD III	200MG	A078584	001	May 22, 2012
-----------	--	---------------------	--------------	----------------	------------	--------------

AB		MICRO LABS LTD	200MG	A203080	001	May 22, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

AB		MYLAN LABS	200MG	A078864	001	May 22, 2012
-----------	--	------------	--------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	200MG	A202523	001	May 22, 2012
-----------	--	------------------	--------------	----------------	------------	--------------

AB		PRINSTON INC	200MG	A078644	001	May 22, 2012
-----------	--	--------------	--------------	----------------	------------	--------------

AB		STRIDES PHARMA	200MG	A078195	001	May 22, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

AB		TECH ORGANIZED	200MG	A203176	001	May 22, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

VIRAMUNE

AB	+	!	BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996
-----------	---	---	-------------------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB		ALVOGEN MALTA	100MG	A204621	002	Nov 09, 2015
-----------	--	---------------	--------------	----------------	------------	--------------

AB			400MG	A204621	001	Jul 10, 2015
-----------	--	--	--------------	----------------	------------	--------------

AB		APOTEX INC	400MG	A205258	001	Apr 03, 2014
-----------	--	------------	--------------	----------------	------------	--------------

AB		AUROBINDO PHARMA LTD	100MG	A208616	001	Nov 23, 2016
-----------	--	-------------------------	--------------	----------------	------------	--------------

AB			400MG	A207698	001	Feb 28, 2017
-----------	--	--	--------------	----------------	------------	--------------

AB		CIPLA LTD	400MG	A206448	001	Oct 15, 2015
-----------	--	-----------	--------------	----------------	------------	--------------

AB		MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017
-----------	--	---------------------	--------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	100MG	A206271	001	Nov 09, 2015
-----------	--	------------------	--------------	----------------	------------	--------------

AB			400MG	A205651	001	Oct 27, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB		SANDOZ INC	400MG	A203411	001	Apr 03, 2014
-----------	--	------------	--------------	----------------	------------	--------------

AB		TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017
-----------	--	----------------	--------------	----------------	------------	--------------

AB			400MG	A207467	002	Jul 31, 2017
-----------	--	--	--------------	----------------	------------	--------------

VIRAMUNE XR

AB	+	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012
-----------	---	-------------------------	--------------	----------------	------------	--------------

AB	+	!		400MG	N201152	001	Mar 25, 2011
-----------	---	---	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NIACIN

TABLET; ORAL

NIACIN

AA	WOCKHARDT	500MG	A081134 001	Apr 28, 1992
-----------	-----------	--------------	--------------------	--------------

NIACOR

AA	!	AVONDALE PHARMS	500MG	A040378 001	May 03, 2000
-----------	---	-----------------	--------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	AMNEAL PHARMS	500MG	A203578 001	Jul 24, 2015
AB		750MG	A204178 001	Dec 11, 2015
AB		1GM	A203578 002	Jul 24, 2015
AB	BARR	500MG	A076378 001	Apr 26, 2005
AB		750MG	A076378 002	Apr 26, 2005
AB		1GM	A076250 001	Apr 14, 2005
AB	LANNETT CO INC	500MG	A203899 001	Jun 16, 2017
AB		1GM	A203899 002	Jun 16, 2017
AB	LUPIN LTD	500MG	A090860 001	Mar 20, 2014
AB		750MG	A090892 001	Mar 20, 2014
AB		1GM	A090446 001	Mar 20, 2014
AB	SUN PHARMA GLOBAL	500MG	A200484 001	Apr 23, 2014
AB		750MG	A201273 001	Apr 23, 2014
AB		1GM	A200484 002	Apr 23, 2014

NIASPAN

AB	+	ABEVIE	500MG	N020381 002	Jul 28, 1997
AB	+	!	750MG	N020381 003	Jul 28, 1997
AB	+	!	1GM	N020381 004	Jul 28, 1997

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS INC	20MG	A074439 001	Dec 10, 1996
AB		20MG	A074540 001	Oct 28, 1996
AB		30MG	A074439 002	Dec 10, 1996
AB		30MG	A074540 002	Oct 28, 1996
AB	EPIC PHARMA	20MG	A074928 001	Mar 19, 1998
AB		30MG	A074928 002	Mar 19, 1998
AB	MYLAN	20MG	A074642 001	Jul 18, 1996
AB	!	30MG	A074642 002	Jul 18, 1996

INJECTABLE; INJECTION

CARDENE

AP	+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734 001	Jan 30, 1992
-----------	---	----------------	-----------------------------	--------------------	--------------

NICARDIPINE HYDROCHLORIDE

AP	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276 001	Jul 24, 2008
AP	LUITPOLD PHARMS INC	25MG/10ML (2.5MG/ML)	A090534 001	Nov 17, 2009
AP	MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664 001	Nov 17, 2009
AP	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125 001	Nov 17, 2009
AP	SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405 001	Nov 17, 2009
AP	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714 001	Dec 28, 2009
AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671 001	Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734 004	Nov 07, 2008
---	----------------	-----------------------	-------------	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734 003	Jul 31, 2008
---	----------------	-----------------------	-------------	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734 002	Jul 31, 2008
---	----------------	-----------------------	-------------	--------------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734 005	Nov 07, 2008
---	----------------	-----------------------	-------------	--------------

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA	20MG/200ML (0.1MG/ML)	N022276 002	Apr 07, 2016
--------------	-----------------------	-------------	--------------

SCIENCE

40MG/200ML (0.2MG/ML)	N022276 003	Apr 07, 2016
-----------------------	-------------	--------------

NICOTINE

INHALANT; ORAL

NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714 001	May 02, 1997
---	-------------------------	---------------	-------------	--------------

SPRAY, METERED; NASAL

NICOTROL

+	PFIZER INC	0.5MG/SPRAY	N020385 001	Mar 22, 1996
---	------------	-------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579 001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556 001</u>	Sep 20, 1990
<u>AB</u>	HERITAGE PHARMA	<u>10MG</u>	<u>A202644 001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644 002</u>	Apr 25, 2013
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781 001</u>	Jul 30, 1993
<u>AB</u>	VALIDUS PHARMS	<u>10MG</u>	<u>A073250 001</u>	Oct 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A074045 001</u>	Apr 30, 1992

PROCARDIA

<u>AB</u>	+! PFIZER	<u>10MG</u>	<u>N018482 001</u>	
-----------	-----------	-------------	--------------------	--

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	+ ALVOGEN	<u>30MG</u>	<u>N020198 001</u>	Apr 21, 1993
<u>AB1</u>	+!	<u>60MG</u>	<u>N020198 002</u>	Apr 21, 1993
<u>AB1</u>	+!	<u>90MG</u>	<u>N020198 003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>60MG</u>	<u>A075659 001</u>	Oct 26, 2001
<u>AB1</u>	WATSON LABS TEVA	<u>30MG</u>	<u>A075128 001</u>	Mar 10, 2000

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071 001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071 002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071 003</u>	Dec 03, 2010
<u>AB1</u>	NOVAST LABS LTD	<u>30MG</u>	<u>A202987 001</u>	Aug 25, 2016
<u>AB1</u>		<u>60MG</u>	<u>A202987 002</u>	Aug 25, 2016
<u>AB1</u>		<u>90MG</u>	<u>A202987 003</u>	Aug 25, 2016
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899 001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899 002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899 003</u>	May 25, 2012
<u>AB1</u>	VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075269 001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269 002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070 001</u>	Aug 16, 2002
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649 001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649 002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649 003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM US	<u>30MG</u>	<u>A077127 001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127 002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410 001</u>	Oct 03, 2007
<u>AB2</u>	TWI PHARMS INC	<u>30MG</u>	<u>A203126 001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126 002</u>	Apr 03, 2014
<u>AB2</u>		<u>90MG</u>	<u>A203126 003</u>	Apr 03, 2014
<u>AB2</u>	VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075289 002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289 001</u>	Sep 27, 2000
<u>AB2</u>	ZYDUS PHARMS USA INC	<u>30MG</u>	<u>A210012 001</u>	Dec 19, 2017
<u>AB2</u>		<u>60MG</u>	<u>A210012 002</u>	Dec 19, 2017
<u>AB2</u>		<u>90MG</u>	<u>A210012 003</u>	Dec 19, 2017

PROCARDIA XL

<u>AB2</u>	+ PFIZER	<u>30MG</u>	<u>N019684 001</u>	Sep 06, 1989
<u>AB2</u>	+!	<u>60MG</u>	<u>N019684 002</u>	Sep 06, 1989
<u>AB2</u>	+!	<u>90MG</u>	<u>N019684 003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 150MG BASE	N022068 002	Jun 17, 2010
+	!	EQ 200MG BASE	N022068 001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

<u>AB</u>	+! CONCORDIA PHARMS INC	<u>150MG</u>	<u>N020169 002</u>	Apr 30, 1999
-----------	----------------------------	--------------	--------------------	--------------

NILUTAMIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A207631 001</u>	Jul 15, 2016
-----------	----------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	!	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008
AB		HERITAGE PHARMS INC	30MG	A077811	001	May 02, 2007
AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015
AB		SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007
AB		THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

+	!	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013
---	---	------------------	-----------	---------	-----	--------------

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

+		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
---	--	-------------------------	---------------	---------	-----	--------------

+	!		EQ 150MG BASE	N205832	002	Oct 15, 2014
---	---	--	---------------	---------	-----	--------------

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	!	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017
---	---	------------	---------------	---------	-----	--------------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011
AB			17MG	A091001	002	Jan 26, 2011
AB			34MG	A091001	004	Jan 26, 2011

SULAR

AB	+	!	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008
AB	+	!		17MG	N020356	007	Jan 02, 2008
AB	+	!		34MG	N020356	005	Jan 02, 2008

NISOLDIPINE

		MYLAN	20MG	A079051	001	Jul 25, 2008
			25.5MG	A091001	003	Jan 26, 2011
	!		30MG	A079051	002	Jul 25, 2008
	!		40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION;ORAL

ALINIA

+	!	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002
---	---	--------	-----------	---------	-----	--------------

TABLET;ORAL

ALINIA

+	!	ROMARK	500MG	N021497	001	Jul 21, 2004
---	---	--------	-------	---------	-----	--------------

NITISINONE

CAPSULE;ORAL

ORFADIN

+		SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002
+			5MG	N021232	002	Jan 18, 2002
+			10MG	N021232	003	Jan 18, 2002
+	!		20MG	N021232	004	Jun 13, 2016

SUSPENSION;ORAL

ORFADIN

+	!	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016
---	---	----------------	--------	---------	-----	--------------

TABLET;ORAL

NITYR

+		CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017
+			5MG	N209449	002	Jul 26, 2017
+	!		10MG	N209449	003	Jul 26, 2017

NITRIC OXIDE

GAS;INHALATION

INOMAX

+	!	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999
---	---	-------------------	--------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+!	CASPER PHARMA LLC	25MG/5ML	<u>N009175</u>	<u>001</u>	
-----------	-----------	-------------------	-----------------	-----------------------	-------------------	--

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	<u>A205180</u>	<u>001</u>	May 03, 2016
AB		AMNEAL PHARMS	25MG/5ML	<u>A201679</u>	<u>001</u>	May 11, 2011
AB		NOSTRUM LABS INC	25MG/5ML	<u>A201355</u>	<u>001</u>	Aug 14, 2013
AB		NOVEL LABS INC	25MG/5ML	<u>A201693</u>	<u>001</u>	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	+	ALVOGEN MALTA	25MG	<u>N016620</u>	<u>003</u>	
AB	+		50MG	<u>N016620</u>	<u>001</u>	
AB	+!		100MG	<u>N016620</u>	<u>002</u>	

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	25MG	<u>A091095</u>	<u>001</u>	Jun 18, 2015
AB			50MG	<u>A091095</u>	<u>002</u>	Jun 18, 2015
AB			100MG	<u>A091095</u>	<u>003</u>	Jun 18, 2015
AB		IMPAX LABS INC	50MG	<u>A073671</u>	<u>001</u>	Jan 28, 1993
AB			100MG	<u>A073652</u>	<u>001</u>	Jan 28, 1993
AB		MYLAN	50MG	<u>A074967</u>	<u>001</u>	Jul 09, 1997
AB			100MG	<u>A077025</u>	<u>001</u>	Aug 18, 2004
AB		SUN PHARM INDUSTRIES	25MG	<u>A201722</u>	<u>001</u>	Feb 16, 2016
AB			50MG	<u>A201722</u>	<u>002</u>	Feb 16, 2016
AB			100MG	<u>A201722</u>	<u>003</u>	Feb 16, 2016
AB		ZYDUS PHARMS USA INC	50MG	<u>A205005</u>	<u>001</u>	Dec 12, 2017
AB			100MG	<u>A205005</u>	<u>002</u>	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+!	ALVOGEN MALTA	75MG; 25MG	<u>N020064</u>	<u>001</u>	Dec 24, 1991
-----------	-----------	---------------	-------------------	-----------------------	-------------------	--------------

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	75MG; 25MG	<u>A207372</u>	<u>001</u>	May 15, 2017
AB		MYLAN	75MG; 25MG	<u>A076648</u>	<u>001</u>	Mar 22, 2004
AB		SANDOZ	75MG; 25MG	<u>A077066</u>	<u>001</u>	Apr 05, 2005
AB		WATSON LABS INC	75MG; 25MG	<u>A202250</u>	<u>001</u>	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+!	MIST PHARMS LLC	0.4MG/SPRAY	<u>N021780</u>	<u>001</u>	Nov 02, 2006
-----------	-----------------	-------------	-----------------------	-------------------	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1		MEDICIS	0.4MG/HR	<u>A089773</u>	<u>001</u>	Aug 30, 1996
AB1		VALEANT PHARMS	0.1MG/HR	<u>A089771</u>	<u>001</u>	Aug 30, 1996
AB1			0.6MG/HR	<u>A089774</u>	<u>001</u>	Aug 30, 1996
AB1		VALEANT PHARMS NORTH	0.2MG/HR	<u>A089772</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

AB1	+!	USPHARMA	0.1MG/HR	<u>N020145</u>	<u>001</u>	Apr 04, 1995
AB1	+!		0.2MG/HR	<u>N020145</u>	<u>002</u>	Apr 04, 1995
AB1	+!		0.4MG/HR	<u>N020145</u>	<u>004</u>	Apr 04, 1995
AB1	+!		0.6MG/HR	<u>N020145</u>	<u>005</u>	Apr 04, 1995

NITROGLYCERIN

AB2		HERCON PHARM	0.2MG/HR	<u>A089884</u>	<u>001</u>	Oct 30, 1998
AB2			0.4MG/HR	<u>A089885</u>	<u>001</u>	Oct 30, 1998
AB2			0.6MG/HR	<u>A089886</u>	<u>001</u>	Oct 30, 1998
AB2	!	MYLAN TECHNOLOGIES	0.2MG/HR	<u>A074559</u>	<u>003</u>	Aug 30, 1996
AB2	!		0.4MG/HR	<u>A074559</u>	<u>002</u>	Aug 30, 1996
AB2	!		0.6MG/HR	<u>A074559</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

+!	USPHARMA	0.3MG/HR	<u>N020145</u>	<u>003</u>	Apr 04, 1995
+!		0.8MG/HR	<u>N020145</u>	<u>006</u>	Apr 04, 1995

NITROGLYCERIN

!	MYLAN TECHNOLOGIES	0.1MG/HR	<u>A074559</u>	<u>004</u>	Feb 06, 1998
----------	--------------------	----------	-----------------------	-------------------	--------------

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	+!	BAXTER HLTHCARE	10MG/100ML	<u>N019970</u>	<u>001</u>	Dec 29, 1989
AP	+!		20MG/100ML	<u>N019970</u>	<u>002</u>	Dec 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	+ !		40MG/100ML	N019970 003	Dec 29, 1989
AP		HOSPIRA	10MG/100ML	A071846 001	Aug 31, 1990
AP			20MG/100ML	A071847 001	Aug 31, 1990
AP			40MG/100ML	A071848 001	Aug 31, 1990

NITROGLYCERIN

! LUITPOLD

5MG/ML

A072034 001 May 24, 1988

OINTMENT; INTRA-ANAL

RECTIV

+! FOREST LABS INC

0.4%

N021359 001 Jun 21, 2011

OINTMENT; TRANSDERMAL

NITROGLYCERIN

! FOUGERA PHARMS INC

2%

A087355 001 Jul 08, 1988

POWDER; SUBLINGUAL

GONITRO

+! POHL BOSKAMP

0.4MG/PACKET

N208424 001 Jun 08, 2016

SPRAY, METERED; SUBLINGUAL

NITROGLYCERIN

AB		PERRIGO ISRAEL	0.4MG/SPRAY	A091496 001	Sep 20, 2013
-----------	--	----------------	--------------------	--------------------	--------------

NITROLINGUAL PUMPSPRAY

AB	+ !	POHL BOSKAMP	0.4MG/SPRAY	N018705 002	Jan 10, 1997
-----------	------------	--------------	--------------------	--------------------	--------------

TABLET; SUBLINGUAL

NITROGLYCERIN

AB		ACTAVIS LABS FL INC	0.3MG	A203693 001	Oct 16, 2017
AB			0.4MG	A203693 002	Oct 16, 2017
AB			0.6MG	A203693 003	Oct 16, 2017
AB		DR REDDYS LABS INC	0.3MG	A208191 001	Aug 26, 2016
AB			0.4MG	A208191 002	Aug 26, 2016
AB			0.6MG	A208191 003	Aug 26, 2016
AB		GLENMARK PHARMS LTD	0.3MG	A206391 001	Sep 19, 2017
AB			0.4MG	A206391 002	Sep 19, 2017
AB			0.6MG	A206391 003	Sep 19, 2017

NITROSTAT

AB	+	PFIZER PHARMS	0.3MG	N021134 001	May 01, 2000
AB	+		0.4MG	N021134 002	May 01, 2000
AB	+ !		0.6MG	N021134 003	May 01, 2000

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB		ANI PHARMS INC	150MG	A075668 001	Sep 12, 2002
AB			300MG	A075668 002	Sep 12, 2002
AB		DR REDDYS LABS LTD	150MG	A077314 001	Sep 15, 2005
AB			300MG	A077314 002	Sep 15, 2005
AB		GLENMARK GENERICS	150MG	A090618 001	Jul 15, 2011
AB			300MG	A090618 002	Jul 15, 2011
AB		MYLAN PHARMS INC	150MG	A075806 001	Jul 05, 2002
AB	!		300MG	A075806 002	Jul 05, 2002
AB		SANDOZ	150MG	A076178 001	Jul 05, 2002
AB			300MG	A076178 002	Jul 05, 2002
AB		WATSON LABS	150MG	A075616 001	Jul 09, 2002
AB			300MG	A075616 002	Jul 09, 2002

SOLUTION; ORAL

NIZATIDINE

! AMNEAL PHARMS

15MG/ML

A090576 001 Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP	+ !	HOSPIRA	EQ 1MG BASE/ML	N007513 001	
-----------	------------	---------	-----------------------	--------------------	--

NOREPINEPHRINE BITARTRATE

AP		BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012
AP		TEVA PHARMS USA	EQ 1MG BASE/ML	A040455 001	Mar 03, 2003
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462 001	Oct 31, 2003

PRESCRIPTION DRUG PRODUCT LIST

NORETHINDRONE

TABLET; ORAL-28

CAMILA

AB1	MAYNE PHARMA	0.35MG	A076177 001	Oct 21, 2002
------------	--------------	---------------	--------------------	--------------

HEATHER

AB1	GLENMARK GENERICS	0.35MG	A090454 001	Apr 23, 2010
------------	-------------------	---------------	--------------------	--------------

INCASSIA

AB1	AUROBINDO PHARMA LTD	0.35MG	A207304 001	Sep 23, 2016
------------	----------------------	---------------	--------------------	--------------

NOR-QD

AB1	+! APIL	0.35MG	N017060 001	
------------	---------	---------------	--------------------	--

NORETHINDRONE

AB1	ACCORD HLTHCARE	0.35MG	A206807 001	Dec 13, 2016
------------	-----------------	---------------	--------------------	--------------

AB1	AMNEAL PHARMS	0.35MG	A202260 001	Aug 01, 2013
------------	---------------	---------------	--------------------	--------------

AB1	LUPIN LTD	0.35MG	A091325 001	Sep 19, 2011
------------	-----------	---------------	--------------------	--------------

AB1	MYLAN LABS LTD	0.35MG	A201483 001	Jun 24, 2013
------------	----------------	---------------	--------------------	--------------

AB1	NOVAST LABS LTD	0.35MG	A202014 001	Sep 13, 2013
------------	-----------------	---------------	--------------------	--------------

ERRIN

AB2	MAYNE PHARMA	0.35MG	A076225 001	Oct 21, 2002
------------	--------------	---------------	--------------------	--------------

JENCYCLA

AB2	LUPIN LTD	0.35MG	A091323 001	Mar 28, 2013
------------	-----------	---------------	--------------------	--------------

MICRONOR

AB2	+! JANSSEN PHARMS	0.35MG	N016954 001	
------------	-------------------	---------------	--------------------	--

NORETHINDRONE

AB2	GLENMARK GENERICS	0.35MG	A091209 001	Jul 22, 2010
------------	-------------------	---------------	--------------------	--------------

AB2	MYLAN LABS LTD	0.35MG	A200980 001	Jun 12, 2013
------------	----------------	---------------	--------------------	--------------

AB2	NOVAST LABS	0.35MG	A200961 001	Sep 13, 2013
------------	-------------	---------------	--------------------	--------------

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB	+! DURAMED RES	5MG	N018405 001	Apr 21, 1982
-----------	----------------	------------	--------------------	--------------

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012
-----------	---------------	------------	--------------------	--------------

AB	AUROBINDO PHARMA LTD	5MG	A204236 001	Jan 08, 2016
-----------	----------------------	------------	--------------------	--------------

AB	BARR	5MG	A075951 001	May 25, 2001
-----------	------	------------	--------------------	--------------

AB	GLENMARK GENERICS	5MG	A091090 001	Jul 21, 2010
-----------	-------------------	------------	--------------------	--------------

AB	MYLAN LABS LTD	5MG	A205278 001	Nov 10, 2016
-----------	----------------	------------	--------------------	--------------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB	MAYNE PHARMA	EQ 10MG BASE	A073553 001	Mar 30, 1992
-----------	--------------	---------------------	--------------------	--------------

AB		EQ 25MG BASE	A073554 001	Mar 30, 1992
-----------	--	---------------------	--------------------	--------------

AB		EQ 50MG BASE	A073555 001	Mar 30, 1992
-----------	--	---------------------	--------------------	--------------

AB		EQ 75MG BASE	A073556 001	Mar 30, 1992
-----------	--	---------------------	--------------------	--------------

AB	TARO PHARM	EQ 10MG BASE	A075520 004	May 08, 2000
-----------	------------	---------------------	--------------------	--------------

AB		EQ 25MG BASE	A075520 003	May 08, 2000
-----------	--	---------------------	--------------------	--------------

AB		EQ 50MG BASE	A075520 001	May 08, 2000
-----------	--	---------------------	--------------------	--------------

AB		EQ 75MG BASE	A075520 002	May 08, 2000
-----------	--	---------------------	--------------------	--------------

AB	TEVA	EQ 10MG BASE	A074132 001	Mar 27, 1995
-----------	------	---------------------	--------------------	--------------

AB		EQ 25MG BASE	A074132 002	Mar 27, 1995
-----------	--	---------------------	--------------------	--------------

AB		EQ 50MG BASE	A074132 003	Mar 27, 1995
-----------	--	---------------------	--------------------	--------------

AB		EQ 75MG BASE	A074132 004	Mar 27, 1995
-----------	--	---------------------	--------------------	--------------

PAMELOR

AB	+ SPECGX LLC	EQ 10MG BASE	N018013 001	
-----------	--------------	---------------------	--------------------	--

AB	+	EQ 25MG BASE	N018013 002	
-----------	---	---------------------	--------------------	--

AB	+	EQ 50MG BASE	N018013 004	
-----------	---	---------------------	--------------------	--

AB	+!	EQ 75MG BASE	N018013 003	
-----------	----	---------------------	--------------------	--

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	! PHARM ASSOC	EQ 10MG BASE/5ML	A075606 001	Aug 28, 2000
-----------	---------------	-------------------------	--------------------	--------------

AA	TARO	EQ 10MG BASE/5ML	A077965 001	Jun 20, 2006
-----------	------	-------------------------	--------------------	--------------

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

+	BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531 001	Dec 23, 2016
---	-------------	----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN

CREAM; TOPICAL

NYSTATIN

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949 001</u>	Jun 13, 1988
<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM</u>	<u>A207733 001</u>	Sep 26, 2017
<u>AT</u>	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129 001</u>	
<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM</u>	<u>A061966 001</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225 001</u>	
<u>AT</u>	! TARO	<u>100,000 UNITS/GM</u>	<u>A064022 001</u>	Jan 29, 1993
<u>AT</u>	VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315 001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840 001</u>	Nov 13, 1987
<u>AT</u>	! FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124 002</u>	Sep 23, 1982
<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM</u>	<u>A209114 001</u>	Oct 06, 2017
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472 001</u>	Feb 13, 1984

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138 001</u>	Jul 23, 2004
<u>AT</u>	LYNE	<u>100,000 UNITS/GM</u>	<u>A208838 001</u>	May 30, 2017
<u>AT</u>	! MAYNE PHARMA INC	<u>100,000 UNITS/GM</u>	<u>A065203 001</u>	Jul 15, 2004
<u>AT</u>	NESHER PHARMS	<u>100,000 UNITS/GM</u>	<u>A208581 001</u>	Jun 08, 2017
<u>AT</u>	UPSHER-SMITH LABS	<u>100,000 UNITS/GM</u>	<u>A065183 001</u>	May 03, 2005
<u>AT</u>	X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175 001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>	PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118 001</u>	Aug 16, 1996
-----------	-------------	-------------------------	--------------------	--------------

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/ML</u>	<u>A062517 001</u>	Jun 07, 1984
<u>AA</u>	G AND W LABS INC	<u>100,000 UNITS/ML</u>	<u>A062349 001</u>	Jul 14, 1982
<u>AA</u>	HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042 001</u>	Feb 28, 1994
<u>AA</u>	PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621 001</u>	Jan 07, 2016
<u>AA</u>	TARO PHARM	<u>100,000 UNITS/ML</u>	<u>A062876 001</u>	Feb 29, 1988
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148 001</u>	Jun 28, 2005
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142 001</u>	Jun 25, 1998
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422 001</u>	Mar 07, 2011
<u>AA</u>	! WOCKHARDT BIO AG	<u>100,000 UNITS/ML</u>	<u>A062512 001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474 001</u>	Dec 22, 1983
<u>AA</u>	SUN PHARM INDUSTRIES	<u>500,000 UNITS</u>	<u>A062838 001</u>	Dec 22, 1988
<u>AA</u>	! TEVA	<u>500,000 UNITS</u>	<u>A062506 001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

!	ODYSSEY PHARMS	100,000 UNITS	A062615 001	Oct 17, 1985
---	----------------	---------------	-------------	--------------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062367 001</u>	May 28, 1985
-----------	------------------	-------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207730 001</u>	Dec 26, 2017
<u>AT</u>	DR REDDYS LABS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208326 001</u>	Oct 26, 2016
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599 001</u>	Oct 08, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208136 001</u>	Oct 24, 2016
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208479 001</u>	Aug 14, 2017
<u>AT</u>	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364 001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062733 001</u>	Mar 06, 1987
-----------	------------------	-------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207217 001</u>	Aug 04, 2017
<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207731 001</u>	Dec 26, 2017
<u>AT</u>	DR REDDYS LABS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207741 001</u>	Jan 31, 2017
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602 001</u>	Oct 09, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208300 001</u>	Jun 23, 2016
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207380 001</u>	Dec 20, 2016
<u>AT</u>	RICONPHARMA LLC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A206785 001</u>	Dec 29, 2016
<u>AT</u>	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305 001</u>	Mar 29, 1993
<u>AT</u>	TELIGENT PHARMA INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208287 001</u>	Dec 30, 2016

PRESCRIPTION DRUG PRODUCT LIST

OBETICHOLIC ACID

TABLET; ORAL

OCALIVA

+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
+	!	10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198</u>	<u>001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198</u>	<u>002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198</u>	<u>003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834</u>	<u>003</u>	Nov 12, 2013
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005

SANDOSTATIN

<u>AP</u>	+! NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+!	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991
	SANDOSTATIN LAR				
+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
+	!	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+! ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
-----------	-------------	-------------	----------------	------------	--------------

OFLOXACIN

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>	ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692</u>	<u>001</u>	Apr 29, 2013
<u>AT</u>	ALVOGEN	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004
<u>AT</u>	SANDOZ INC	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

OFLOXACIN

<u>AT</u>	ALVOGEN	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>	! BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	SANDOZ INC	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008

PRESCRIPTION DRUG PRODUCT LIST

OFLOXACIN

TABLET; ORAL

OFLOXACIN

<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A091656 001</u>	Sep 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A091656 002</u>	Sep 18, 2014
<u>AB</u>		<u>400MG</u>	<u>A091656 003</u>	Sep 18, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098 001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098 002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098 003</u>	Feb 10, 2006
<u>AB</u>	LARKEN LABS	<u>400MG</u>	<u>A076093 003</u>	Sep 02, 2003
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182 001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182 002</u>	Sep 02, 2003
<u>AB</u>	!	<u>400MG</u>	<u>A076182 003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>	LUITPOLD	<u>10MG/VIAL</u>	<u>A201741 001</u>	Mar 20, 2012
<u>AP</u>	SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588 001</u>	Oct 24, 2011
<u>ZYPREXA</u>				
<u>AP</u>	+!	<u>10MG/VIAL</u>	<u>N021253 001</u>	Mar 29, 2004

TABLET; ORAL

OLANZAPINE

<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A202295 001</u>	Oct 20, 2015
<u>AB</u>		<u>5MG</u>	<u>A202295 002</u>	Oct 20, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A202295 003</u>	Oct 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A202295 004</u>	Oct 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A202295 005</u>	Oct 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A202295 006</u>	Oct 20, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A090798 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A090798 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A090798 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A090798 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A090798 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A090798 006</u>	Apr 23, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202050 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050 006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133 001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133 002</u>	Oct 24, 2011
<u>AB</u>	HIKMA PHARMS	<u>2.5MG</u>	<u>A204866 001</u>	Jun 16, 2017
<u>AB</u>		<u>5MG</u>	<u>A204866 002</u>	Jun 16, 2017
<u>AB</u>		<u>7.5MG</u>	<u>A204866 003</u>	Jun 16, 2017
<u>AB</u>		<u>10MG</u>	<u>A204866 004</u>	Jun 16, 2017
<u>AB</u>		<u>15MG</u>	<u>A204866 005</u>	Jun 16, 2017
<u>AB</u>		<u>20MG</u>	<u>A204866 006</u>	Jun 16, 2017
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203333 001</u>	Mar 15, 2016
<u>AB</u>		<u>5MG</u>	<u>A203333 002</u>	Mar 15, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A203333 003</u>	Mar 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A203333 004</u>	Mar 15, 2016
<u>AB</u>		<u>15MG</u>	<u>A203333 005</u>	Mar 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A203333 006</u>	Mar 15, 2016
<u>AB</u>	IVAX PHARMS INC	<u>20MG</u>	<u>A077301 001</u>	Apr 29, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862 001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862 002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862 003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862 004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862 005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862 006</u>	Aug 15, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287 006</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>	QILU PHARM CO LTD	<u>2.5MG</u>	<u>A204319 001</u>	Jan 27, 2016
<u>AB</u>		<u>5MG</u>	<u>A204319 002</u>	Jan 27, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A204319 003</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A204319 004</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A204319 005</u>	Jan 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A204319 006</u>	Jan 27, 2016
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038 006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000 001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000 002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000 003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000 004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000 005</u>	Oct 24, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A091434 001</u>	Apr 23, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG</u>	<u>A091434 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434 006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	+ LILLY	<u>2.5MG</u>	<u>N020592 001</u>	Sep 30, 1996
<u>AB</u>	+!	<u>5MG</u>	<u>N020592 002</u>	Sep 30, 1996
<u>AB</u>	+	<u>7.5MG</u>	<u>N020592 003</u>	Sep 30, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020592 004</u>	Sep 30, 1996
<u>AB</u>	+	<u>15MG</u>	<u>N020592 005</u>	Sep 09, 1997
<u>AB</u>	+	<u>20MG</u>	<u>N020592 006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A204320 001</u>	May 30, 2017
<u>AB</u>		<u>10MG</u>	<u>A204320 002</u>	May 30, 2017
<u>AB</u>		<u>15MG</u>	<u>A204320 003</u>	May 30, 2017
<u>AB</u>		<u>20MG</u>	<u>A204320 004</u>	May 30, 2017
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265 004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708 001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708 002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708 003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708 004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243 001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243 002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243 003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243 004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534 004</u>	Oct 24, 2011
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A203456 001</u>	Mar 16, 2016
<u>AB</u>		<u>10MG</u>	<u>A203456 002</u>	Mar 16, 2016
<u>AB</u>		<u>15MG</u>	<u>A203456 003</u>	Mar 16, 2016
<u>AB</u>		<u>20MG</u>	<u>A203456 004</u>	Mar 16, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221 001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221 002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221 003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221 004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044 001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044 002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044 003</u>	Feb 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A203044 004</u>	Feb 20, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202285 001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285 002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285 003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285 004</u>	May 12, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A202937 001</u>	Mar 02, 2015

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>10MG</u>	<u>A202937 002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937 003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937 004</u>	Mar 02, 2015
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109 004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881 001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881 002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881 003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881 004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415 001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415 002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415 003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415 004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>				
<u>AB</u>	+! LILLY	<u>5MG</u>	<u>N021086 001</u>	Apr 06, 2000
<u>AB</u>	+	<u>10MG</u>	<u>N021086 002</u>	Apr 06, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N021086 003</u>	Apr 06, 2000
<u>AB</u>	+	<u>20MG</u>	<u>N021086 004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173 001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173 002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173 003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162 001	Dec 19, 2014
----	--------------------	------	-------------	--------------

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558 001	Aug 17, 2017
+!		150MG	N208558 002	Aug 17, 2017

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

<u>AB</u>	+	DAIICHI SANKYO	<u>5MG</u>	<u>N021286 001</u>	Apr 25, 2002
<u>AB</u>	+		<u>20MG</u>	<u>N021286 003</u>	Apr 25, 2002
<u>AB</u>	+!		<u>40MG</u>	<u>N021286 004</u>	Apr 25, 2002

OLMESARTAN MEDOXOMIL

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A207662 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A207662 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A207662 003</u>	Apr 24, 2017
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A203012 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A203012 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A203012 003</u>	Apr 24, 2017
<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A206763 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A206763 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A206763 003</u>	Apr 24, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A204798 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A204798 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A204798 003</u>	Apr 24, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>5MG</u>	<u>A203281 001</u>	May 25, 2017
<u>AB</u>		<u>20MG</u>	<u>A203281 002</u>	May 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A203281 003</u>	May 25, 2017
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A205482 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A205482 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A205482 003</u>	Apr 24, 2017
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A206631 001</u>	Apr 27, 2017
<u>AB</u>		<u>20MG</u>	<u>A206631 002</u>	Apr 27, 2017
<u>AB</u>		<u>40MG</u>	<u>A206631 003</u>	Apr 27, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A204814 001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A204814 002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A204814 003</u>	Apr 24, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A078276 001</u>	Oct 26, 2016
<u>AB</u>		<u>20MG</u>	<u>A078276 002</u>	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB		40MG	A078276 003	Oct 26, 2016
AB	TEVA PHARMS USA	5MG	A091079 001	Apr 24, 2017
AB		20MG	A091079 002	Apr 24, 2017
AB		40MG	A091079 003	Apr 24, 2017
AB	TORRENT PHARMS LTD	5MG	A202375 001	Apr 24, 2017
AB		20MG	A202375 002	Apr 24, 2017
AB		40MG	A202375 003	Apr 24, 2017
AB	ZYDUS PHARMS USA INC	5MG	A205192 001	Apr 24, 2017
AB		20MG	A205192 002	Apr 24, 2017
AB		40MG	A205192 003	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108 001	Jul 31, 2014
---	-------------------------	----------------------	-------------	--------------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH; EQ 0.0025MG BASE/INH	N206756 001	May 21, 2015
---	-------------------------	---	-------------	--------------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	AKORN	EQ 0.2% BASE	A204723 001	Dec 05, 2017
AT	AKORN INC	EQ 0.1% BASE	A204532 001	Jan 10, 2017
AT	APOTEX INC	EQ 0.1% BASE	A078350 001	Dec 07, 2015
AT		EQ 0.2% BASE	A090918 001	Dec 05, 2017
AT	AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812 001	Dec 18, 2015
AT	BARR LABS INC	EQ 0.2% BASE	A090848 001	Jul 13, 2015
AT	CIPLA LTD	EQ 0.1% BASE	A206046 001	Jul 26, 2017
AT		EQ 0.2% BASE	A206087 001	Dec 05, 2017
AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306 001	Dec 07, 2015
AT	USV NORTH AMERICA	EQ 0.1% BASE	A203152 001	Dec 07, 2015
AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810 001	Jun 28, 2017
AT	ZAMBON SPA	EQ 0.1% BASE	A204706 001	Dec 07, 2015

PATADAY

AT	+	NOVARTIS PHARMS CORP	EQ 0.2% BASE	N021545 001	Dec 22, 2004
-----------	---	-------------------------	---------------------	--------------------	--------------

PATANOL

AT	+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020688 001	Dec 18, 1996
-----------	---	-------------------------	---------------------	--------------------	--------------

PAZEO

+	NOVARTIS PHARMS CORP	EQ 0.7% BASE	N206276 001	Jan 30, 2015
---	-------------------------	--------------	-------------	--------------

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	APOTEX INC	0.665MG/SPRAY	A091572 001	Oct 08, 2014
AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853 001	Jan 31, 2017

PATANASE

AB	+	NOVARTIS PHARMS CORP	0.665MG/SPRAY	N021861 001	Apr 15, 2008
-----------	---	-------------------------	----------------------	--------------------	--------------

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+	MYLAN SPECIALITY LP	250MG	N019715 001	Jul 31, 1990
---	---------------------	-------	-------------	--------------

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+	TEVA PHARMS INTL	3.5MG/VIAL	N203585 001	Oct 26, 2012
---	------------------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL

TECHNIVIE

+! ABBVIE INC

12.5MG; 75MG; 50MG

N207931 001 Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZAAB +! SMITHKLINE BEECHAM1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSN021654 001 Nov 10, 2004OMEGA-3-ACID ETHYL ESTERSAB AMNEAL PHARMS1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA204940 001 Nov 27, 2015AB APOTEX INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA090973 001 Sep 30, 2014AB PAR PHARM INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091018 001 Jun 24, 2014AB STRIDES PHARMA1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA203893 001 Sep 19, 2017AB TEVA PHARMS USA1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091028 001 Apr 07, 2014OMEGA-3-CARBOXYLIC ACIDS

CAPSULE; ORAL

EPANOVA

+! ASTRAZENECA PHARMS

1GM CONTAINS AT LEAST 850MG OF
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLEAB ACTAVIS LABS FL INC10MGA075347 001 May 30, 2008AB20MGA075347 002 May 30, 2008AB40MGA075347 003 May 30, 2008AB APOTEX10MGA076048 001 Oct 22, 2007AB20MGA076048 002 Oct 22, 2007AB40MGA076048 003 Jan 21, 2009AB AUROBINDO PHARMA
LTD10MGA203270 001 Aug 19, 2015AB20MGA203270 002 Aug 19, 2015AB40MGA203270 003 Aug 19, 2015AB BRECKENRIDGE PHARM10MGA203481 001 Jul 03, 2017AB20MGA203481 002 Jul 03, 2017AB40MGA203481 003 Jul 03, 2017AB DR REDDYS LABS LTD10MGA075576 003 Oct 22, 2007AB10MGA078490 002 Mar 16, 2009AB20MGA075576 002 Oct 22, 2007AB20MGA078490 003 Mar 16, 2009AB40MGA075576 001 Jan 21, 2009AB40MGA078490 001 Apr 17, 2009AB GLENMARK GENERICS10MGA091672 001 Oct 31, 2014AB20MGA091672 002 Oct 31, 2014AB40MGA091672 003 Oct 31, 2014AB IMPAX LABS10MGA075785 001 Oct 22, 2007AB20MGA075785 002 Oct 22, 2007AB40MGA075785 003 Jan 21, 2009AB10MGA075410 001 Nov 01, 2002AB KREMERS URBAN
PHARMS20MGA075410 002 Nov 01, 2002AB40MGA075410 003 Jan 23, 2009AB40MGA202384 001 Aug 25, 2015AB LUPIN LTD40MGA075876 001 May 29, 2003AB10MGA075876 002 May 29, 2003AB20MGA075876 003 Jan 21, 2009AB40MGA075757 001 Jan 28, 2003AB SANDOZ10MGA075757 002 Jan 28, 2003AB20MGA076515 001 Jan 21, 2009AB !40MGA204661 001 Jun 13, 2017AB !20MGA204661 002 Jun 13, 2017AB TEVA PHARMS USA10MGA091352 001 Nov 19, 2012AB20MGA091352 002 Nov 19, 2012AB40MGA091352 003 Nov 19, 2012AB ZYDUS PHARMS USA
INC10MGA091352 001 Nov 19, 2012AB20MGA091352 002 Nov 19, 2012AB40MGA091352 003 Nov 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRIOLOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG;1.1GM</u>	<u>A204228</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204228</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>20MG;1.1GM</u>	<u>A204922</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204922</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG;1.1GM</u>	<u>A204068</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204068</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966</u>	<u>001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966</u>	<u>002</u>	May 25, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>20MG;1.1GM</u>	<u>A207476</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A207476</u>	<u>002</u>	Dec 06, 2016

ZEGERID

<u>AB</u>	+	SANTARUS INC	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+	!	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>001</u>	Jul 27, 2016
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>002</u>	Jul 27, 2016
<u>AB</u>	PAR PHARM	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>002</u>	Apr 19, 2013

ZEGERID

<u>AB</u>	+	SANTARUS INC	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>001</u>	Jun 15, 2004
<u>AB</u>	+	!	<u>40MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>002</u>	Dec 21, 2004

ONDANSETRON

FILM; ORAL

ZUPLENZ

+	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010
+	!	8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602</u>	<u>002</u>	Feb 24, 2011
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810</u>	<u>002</u>	Jun 25, 2007

ZOFRAN ODT

<u>AB</u>	+	NOVARTIS PHARMS CORP	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	!	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846</u>	<u>001</u>	Jul 13, 2015	
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599</u>	<u>001</u>	Dec 21, 2012	
<u>AP</u>	!	BAXTER HLTHCARE CORP	<u>EQ 2MG BASE/ML</u>	<u>A078288</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424</u>	<u>001</u>	Apr 16, 2010	
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006	
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009	
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090648</u>	<u>001</u>	Jun 15, 2012	
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006	
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006	

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840 001</u>	Jan 19, 2007
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079039 001</u>	Nov 18, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A204906 001</u>	Jul 31, 2017
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 2MG BASE/ML</u>	<u>A203711 001</u>	Sep 08, 2014
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077430 001</u>	Jun 27, 2007
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876 001</u>	Nov 22, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A076967 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077365 001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577 001</u>	Dec 26, 2006
<u>ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE</u>				
<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206845 001</u>	Mar 10, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600 001</u>	Dec 21, 2012
<u>AP</u>	! BAXTER HLTHCARE CORP	<u>EQ 2MG BASE/ML</u>	<u>A078287 001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945 001</u>	Jan 03, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A202253 001</u>	Jul 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780 001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548 001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032 001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077551 001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173 001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759 001</u>	Nov 22, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A077011 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077541 001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716 001</u>	Dec 26, 2006

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483 001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127 001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776 001</u>	Nov 28, 2007
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342 001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009 001</u>	Nov 30, 2007
<u>AA</u>	WEST-WARD PHARMS INT	<u>EQ 4MG BASE/5ML</u>	<u>A076960 001</u>	Dec 26, 2006

ZOFRAN

<u>AA</u>	+! NOVARTIS PHARMS CORP	<u>EQ 4MG BASE/5ML</u>	<u>N020605 001</u>	Jan 24, 1997
-----------	----------------------------	------------------------	--------------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306 002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539 001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539 002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539 003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183 003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183 002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183 001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535 003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761 001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761 002</u>	Jan 23, 2014
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930 004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851 002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112 003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517 003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050 002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252 002</u>	Jun 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB		EQ 24MG BASE	A076252 003	Jun 25, 2007
	ZOFRAN			
AB	+ NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103 001	Dec 31, 1992
AB	+	EQ 8MG BASE	N020103 002	Dec 31, 1992
AB	+!	EQ 24MG BASE	N020103 003	Aug 27, 1999
	ONDANSETRON HYDROCHLORIDE DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

+!	THE MEDICINES CO	EQ 400MG BASE/VIAL	N206334 001	Aug 06, 2014
----	------------------	--------------------	-------------	--------------

ORLISTAT

CAPSULE; ORAL

XENICAL

+!	CHEPLAPHARM	120MG	N020766 001	Apr 23, 1999
----	-------------	-------	-------------	--------------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	!	AKORN	30MG/ML	A040484 001	May 24, 2006
AP		SAGENT PHARMS	30MG/ML	A090585 001	Aug 30, 2011
AP		WATSON LABS	30MG/ML	A084779 001	Mar 15, 1982
AP		WEST-WARD PHARMS INT	30MG/ML	A040463 001	Mar 04, 2003

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB		GAVIS PHARMS	100MG	A040284 001	Jun 19, 1998
AB		IMPAX PHARMS	100MG	A040368 001	Jun 23, 2000
AB		INVAGEN PHARMS	100MG	A091158 001	Jul 27, 2012
AB	!	SANDOZ	100MG	A040327 001	Feb 15, 2000
AB		TEDOR PHARMA INC	100MG	A040249 001	Jan 29, 1999

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	EQ 30MG BASE	A209093 001	May 17, 2017
AB			EQ 45MG BASE	A209093 002	May 17, 2017
AB			EQ 75MG BASE	A209093 003	May 17, 2017
AB		LUPIN ATLANTIS	EQ 30MG BASE	A208348 001	Jan 09, 2018
AB			EQ 45MG BASE	A208348 002	Jan 09, 2018
AB			EQ 75MG BASE	A208348 003	Jan 09, 2018
AB		MACLEODS PHARMS LTD	EQ 30MG BASE	A207211 001	Sep 14, 2017
AB			EQ 45MG BASE	A207211 002	Sep 14, 2017
AB			EQ 75MG BASE	A207211 003	Sep 14, 2017
AB		NATCO PHARMA LTD	EQ 30MG BASE	A202595 001	Aug 03, 2016
AB			EQ 45MG BASE	A202595 002	Aug 03, 2016
AB			EQ 75MG BASE	A202595 003	Aug 03, 2016
AB		NESHER PHARMS	EQ 30MG BASE	A208578 001	Feb 24, 2017
AB			EQ 45MG BASE	A208578 002	Feb 24, 2017
AB			EQ 75MG BASE	A208578 003	Feb 24, 2017

TAMIFLU

AB	+	ROCHE	EQ 30MG BASE	N021087 003	Jul 02, 2007
AB	+		EQ 45MG BASE	N021087 002	Jul 02, 2007
AB	+!		EQ 75MG BASE	N021087 001	Oct 27, 1999

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB		ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823 001	Oct 31, 2017
AB		NESHER PHARMS	EQ 6MG BASE/ML	A209113 001	Sep 14, 2017

TAMIFLU

AB	+!	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011
-----------	----	-------	-----------------------	--------------------	--------------

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

+	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065 001	Nov 13, 2015
+!		EQ 80MG BASE	N208065 002	Nov 13, 2015

PRESCRIPTION DRUG PRODUCT LIST

OSPENIFENE

TABLET; ORAL

OSPHENA

+! DUCHESNAY

60MG

N203505 001 Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539 001</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201539 002</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201538 001</u>	Jan 18, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A203950 001</u>	Dec 11, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203950 002</u>	Dec 11, 2015
<u>AP</u>	RENAISSANCE SSA LLC	<u>EQ 1GM BASE/VIAL</u>	<u>A206681 001</u>	Sep 11, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A206681 002</u>	Sep 11, 2017
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206760 001</u>	Oct 26, 2017
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246 001</u>	Mar 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091246 002</u>	Mar 30, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091245 001</u>	Mar 30, 2012
<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061490 003</u>	
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A061490 004</u>	
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A061490 006</u>	May 09, 1991
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 1GM BASE/VIAL</u>	<u>A207147 001</u>	Jul 31, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A207147 002</u>	Jul 31, 2017
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A207148 001</u>	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 20MG BASE/ML

N050640 001 Oct 26, 1989

+!

EQ 40MG BASE/ML

N050640 002 Oct 26, 1989

POWDER; INTRAVENOUS

OXACILLIN SODIUM

<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062737 001</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062737 002</u>	Dec 23, 1986

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u>	+! SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759 001</u>	Jan 31, 2005
<u>AP</u>	+!	<u>100MG/20ML (5MG/ML)</u>	<u>N021759 002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>50MG/10ML (5MG/ML)</u>	<u>A207474 001</u>	Mar 21, 2017
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207474 002</u>	Mar 21, 2017
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A207474 003</u>	Mar 21, 2017
<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803 001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078803 002</u>	Aug 08, 2012
<u>AP</u>	CIPLA LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A208523 001</u>	Feb 10, 2017
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A208523 002</u>	Feb 10, 2017
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/10ML (5MG/ML)</u>	<u>A078811 001</u>	Jun 10, 2010
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078811 002</u>	Jun 10, 2010
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078810 001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078810 002</u>	Aug 07, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A078819 001</u>	Jun 02, 2010
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A090030 001</u>	Jan 31, 2017
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078819 002</u>	Jun 02, 2010
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A090030 002</u>	Jan 31, 2017
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A090030 003</u>	Jan 31, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A207325 001</u>	Feb 10, 2017
<u>AP</u>		<u>50MG/VIAL</u>	<u>A207385 001</u>	May 23, 2017
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207325 002</u>	Feb 10, 2017
<u>AP</u>		<u>100MG/VIAL</u>	<u>A207385 002</u>	May 23, 2017
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A207325 003</u>	Oct 18, 2017
<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815 001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815 002</u>	Sep 30, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009
<u>AP</u>	JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014
<u>AP</u>	LUITPOLD PHARMS INC	<u>50MG/10ML (5MG/ML)</u>	<u>A204378 001</u>	May 12, 2017
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204378 002</u>	May 12, 2017
<u>AP</u>	MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200979 001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A200979 002</u>	Aug 08, 2012

PRESCRIPTION DRUG PRODUCT LIST

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A091358 003</u>	Nov 14, 2017
<u>AP</u>	QILU PHARM CO LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A204368 001</u>	Jun 07, 2016
<u>AP</u>		<u>50MG/VIAL</u>	<u>A204616 001</u>	May 11, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204368 002</u>	Jun 07, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204616 002</u>	May 11, 2016
<u>AP</u>	!	<u>200MG/40ML (5MG/ML)</u>	<u>A204368 003</u>	Jun 07, 2016
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817 001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817 002</u>	Jan 24, 2011
<u>AP</u>	SANJA PHARMS CO	<u>50MG/10ML (5MG/ML)</u>	<u>A205529 001</u>	Sep 06, 2017
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A205529 002</u>	Sep 06, 2017
<u>AP</u>	!	<u>50MG/VIAL</u>	<u>A078818 001</u>	Aug 07, 2009
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A202922 001</u>	Apr 08, 2014
<u>AP</u>	!	<u>100MG/VIAL</u>	<u>A078818 002</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A202922 002</u>	Apr 08, 2014
<u>AP</u>	+!	<u>50MG/10ML (5MG/ML)</u>	<u>N022160 001</u>	Aug 07, 2009
<u>AP</u>	+!	<u>100MG/20ML (5MG/ML)</u>	<u>N022160 002</u>	Aug 07, 2009

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	+	GEMINI LABS LLC	<u>2.5MG</u>	<u>N013718 001</u>	
<u>AB</u>	+!		<u>10MG</u>	<u>N013718 002</u>	Nov 05, 2001

OXANDROLONE

<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A077827 001</u>	Jun 22, 2007
<u>AB</u>			<u>10MG</u>	<u>A077827 002</u>	Jun 22, 2007
<u>AB</u>		UPSHER-SMITH LABS	<u>2.5MG</u>	<u>A076761 001</u>	Dec 01, 2006
<u>AB</u>			<u>10MG</u>	<u>A078033 001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+!	GD SEARLE	<u>600MG</u>	<u>N018841 004</u>	Oct 29, 1992
-----------	----	-----------	--------------	--------------------	--------------

OXAPROZIN

<u>AB</u>		AMNEAL PHARMS CO	<u>600MG</u>	<u>A208633 001</u>	May 04, 2017
<u>AB</u>		APOTEX INC	<u>600MG</u>	<u>A075987 001</u>	Sep 02, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855 001</u>	Jan 31, 2001
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846 001</u>	May 13, 2002
<u>AB</u>		SANDOZ	<u>600MG</u>	<u>A075845 001</u>	Jan 31, 2001
<u>AB</u>		SUN PHARM INDS INC	<u>600MG</u>	<u>A075844 001</u>	Jan 03, 2002
<u>AB</u>		TEVA	<u>600MG</u>	<u>A075849 001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072253 002</u>	Apr 14, 1988
<u>AB</u>			<u>15MG</u>	<u>A072253 003</u>	Apr 14, 1988
<u>AB</u>	!		<u>30MG</u>	<u>A072253 001</u>	Apr 14, 1988
<u>AB</u>		SANDOZ	<u>10MG</u>	<u>A071813 001</u>	Apr 19, 1988
<u>AB</u>			<u>15MG</u>	<u>A071756 001</u>	Apr 19, 1988
<u>AB</u>			<u>30MG</u>	<u>A071814 001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>		AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961 001</u>	Sep 17, 2012
<u>AB</u>		SUN PHARM INDS LTD	<u>300MG/5ML</u>	<u>A078734 001</u>	Jun 26, 2009
<u>AB</u>		WEST-WARD PHARMS INT	<u>300MG/5ML</u>	<u>A201193 001</u>	Oct 03, 2012

TRILEPTAL

<u>AB</u>	+!	NOVARTIS	<u>300MG/5ML</u>	<u>N021285 001</u>	May 25, 2001
-----------	----	----------	------------------	--------------------	--------------

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		ANI PHARMS INC	<u>150MG</u>	<u>A078005 001</u>	Dec 11, 2007
<u>AB</u>			<u>300MG</u>	<u>A078005 002</u>	Dec 11, 2007
<u>AB</u>			<u>600MG</u>	<u>A078005 003</u>	Dec 11, 2007
<u>AB</u>		APOTEX INC	<u>150MG</u>	<u>A077747 001</u>	Apr 09, 2008
<u>AB</u>			<u>300MG</u>	<u>A077747 002</u>	Apr 09, 2008
<u>AB</u>			<u>600MG</u>	<u>A077747 003</u>	Apr 09, 2008
<u>AB</u>		BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069 001</u>	Jan 11, 2008
<u>AB</u>			<u>300MG</u>	<u>A078069 002</u>	Jan 11, 2008
<u>AB</u>			<u>600MG</u>	<u>A078069 003</u>	Jan 11, 2008

PRESCRIPTION DRUG PRODUCT LIST

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

<u>AB</u>	GLENMARK PHARMS LTD	<u>150MG</u>	<u>A077802 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802 003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794 003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801 001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801 002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801 003</u>	Nov 15, 2007
<u>AB</u>	WEST-WARD PHARMS INT	<u>150MG</u>	<u>A077795 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795 003</u>	Oct 09, 2007

TRILEPTAL

<u>AB</u>	+ NOVARTIS	<u>150MG</u>	<u>N021014 001</u>	Jan 14, 2000
<u>AB</u>	+	<u>300MG</u>	<u>N021014 002</u>	Jan 14, 2000
<u>AB</u>	+!	<u>600MG</u>	<u>N021014 003</u>	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

+	SUPERMUS PHARMS	150MG	N202810 001	Oct 19, 2012
+		300MG	N202810 002	Oct 19, 2012
+	!	600MG	N202810 003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

<u>AB</u>	TARO	<u>EQ 1% BASE</u>	<u>A205076 001</u>	Mar 07, 2016	
<u>AB</u>	+!	<u>FOUGERA PHARMS</u>	<u>EQ 1% BASE</u>	<u>N019828 001</u>	Dec 30, 1988
	LOTION;TOPICAL				
	OXISTAT				
	+!	FOUGERA PHARMS	EQ 1% BASE	N020209 001	Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

!	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983
---	---------------------	-------	-------------	--------------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

<u>AB</u>	BARR LABS DIV TEVA	<u>3.9MG/24HR</u>	<u>A090526 001</u>	Mar 04, 2014	
<u>AB</u>	+!	ALLERGAN SALES LLC	<u>3.9MG/24HR</u>	<u>N021351 002</u>	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+	ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204 001	Jan 27, 2009
---	--------------------	--------------------	-------------	--------------

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137 001</u>	Dec 18, 1998
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520 001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682 001</u>	Dec 28, 2004
<u>AA</u>	! WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A074868 001</u>	Feb 12, 1997

TABLET;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	ABHAI LLC	<u>5MG</u>	<u>A209335 001</u>	Dec 22, 2017
<u>AB</u>	APPCO PHARMA LLC	<u>5MG</u>	<u>A209025 001</u>	Dec 21, 2017
<u>AB</u>	NOVITIUM PHARMA	<u>5MG</u>	<u>A209823 001</u>	Oct 23, 2017
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655 001</u>	Nov 14, 1988
<u>AB</u>	UPSHER-SMITH LABS	<u>5MG</u>	<u>A074625 001</u>	Jul 31, 1996
<u>AB</u>	! VINTAGE PHARMS	<u>5MG</u>	<u>A075079 001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

<u>AB</u>	+ JANSSEN PHARMS	<u>5MG</u>	<u>N020897 001</u>	Dec 16, 1998
<u>AB</u>	+	<u>10MG</u>	<u>N020897 002</u>	Dec 16, 1998
<u>AB</u>	+!	<u>15MG</u>	<u>N020897 003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A207138 001</u>	Feb 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A207138 002</u>	Feb 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A207138 003</u>	Feb 29, 2016

PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A204010</u>	<u>001</u>	Nov 23, 2015
<u>AB</u>		<u>10MG</u>	<u>A204010</u>	<u>002</u>	Nov 23, 2015
<u>AB</u>		<u>15MG</u>	<u>A204010</u>	<u>003</u>	Nov 23, 2015
<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644</u>	<u>002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM US	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009
<u>AB</u>	UNIQUE PHARM LABS	<u>5MG</u>	<u>A206121</u>	<u>001</u>	May 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206121</u>	<u>002</u>	May 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206121</u>	<u>003</u>	May 27, 2016
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A202332</u>	<u>001</u>	Jun 26, 2017
<u>AB</u>		<u>10MG</u>	<u>A202332</u>	<u>002</u>	Jun 26, 2017
<u>AB</u>		<u>15MG</u>	<u>A202332</u>	<u>003</u>	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+	!	36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>5MG</u>	<u>A205177</u>	<u>001</u>	Mar 31, 2016		
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773</u>	<u>001</u>	Aug 17, 2015		
<u>AB</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A203823</u>	<u>001</u>	Aug 01, 2014		
<u>AB</u>	+	!	LEHIGH VALLEY	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012		
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752</u>	<u>001</u>	Aug 24, 2015		

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ABHAI LLC	<u>5MG/5ML</u>	<u>A208593</u>	<u>001</u>	Jul 21, 2017		
<u>AA</u>		<u>100MG/5ML</u>	<u>A208593</u>	<u>002</u>	Jul 21, 2017		
<u>AA</u>	ANI PHARMS INC	<u>5MG/5ML</u>	<u>A204979</u>	<u>001</u>	Jun 01, 2015		
<u>AA</u>		<u>100MG/5ML</u>	<u>A203447</u>	<u>001</u>	Aug 30, 2017		
<u>AA</u>	ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A209021</u>	<u>001</u>	Nov 09, 2017		
<u>AA</u>		<u>100MG/5ML</u>	<u>A209021</u>	<u>002</u>	Nov 09, 2017		
<u>AA</u>	HI-TECH PHARMACAL	<u>5MG/5ML</u>	<u>A208817</u>	<u>001</u>	Aug 10, 2017		
<u>AA</u>		<u>100MG/5ML</u>	<u>A208795</u>	<u>001</u>	Aug 07, 2017		
<u>AA</u>	LANNETT HOLDINGS INC	<u>100MG/5ML</u>	<u>A204085</u>	<u>001</u>	Sep 09, 2014		
<u>AA</u>	+	!	LEHIGH VALLEY	<u>5MG/5ML</u>	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+	!		<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	MAYNE PHARMA INC	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014		
<u>AA</u>	NOVEL LABS INC	<u>100MG/5ML</u>	<u>A204603</u>	<u>001</u>	Apr 29, 2015		
<u>AA</u>	PHARM ASSOC	<u>100MG/5ML</u>	<u>A206822</u>	<u>001</u>	Aug 15, 2017		
<u>AA</u>	+	!	VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012		
<u>AA</u>	WES PHARMA INC	<u>5MG/5ML</u>	<u>A207511</u>	<u>001</u>	Nov 23, 2016		
<u>AA</u>		<u>100MG/5ML</u>	<u>A209897</u>	<u>001</u>	Sep 06, 2017		
<u>AA</u>	WEST-WARD PHARMS INT	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013		
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208</u>	<u>001</u>	Jul 12, 2013		
<u>AA</u>	WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A206456</u>	<u>001</u>	Jun 16, 2015		

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A076636</u>	<u>003</u>	Apr 07, 2015
<u>AB</u>		<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN MALTA	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	ASCENT PHARMS INC	<u>15MG</u>	<u>A207418</u>	<u>001</u>	Aug 07, 2017
<u>AB</u>		<u>30MG</u>	<u>A207418</u>	<u>002</u>	Aug 07, 2017
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A202662</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A202662</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A202662</u>	<u>004</u>	Sep 22, 2015
<u>AB</u>	KEN LIFESCIENCE	<u>5MG</u>	<u>A207119</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A207119</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A207119</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A207119</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A207119</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>10MG</u>	<u>A091313</u>	<u>004</u>	Apr 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>20MG</u>	<u>A091313</u>	<u>005</u>	Apr 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204021</u>	<u>001</u>	Jun 12, 2017
<u>AB</u>		<u>10MG</u>	<u>A204021</u>	<u>002</u>	Jun 12, 2017
<u>AB</u>		<u>15MG</u>	<u>A204021</u>	<u>003</u>	Jun 12, 2017
<u>AB</u>		<u>20MG</u>	<u>A204021</u>	<u>004</u>	Jun 12, 2017
<u>AB</u>		<u>30MG</u>	<u>A204021</u>	<u>005</u>	Jun 12, 2017
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>10MG</u>	<u>A077712</u>	<u>004</u>	Apr 13, 2015
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077712</u>	<u>005</u>	Apr 13, 2015
<u>AB</u>		<u>30MG</u>	<u>A077712</u>	<u>002</u>	Jan 31, 2007

ROXICODONE

<u>AB</u>	+	SPECGX LLC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	!	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>	+		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

OXAYDO

	EGALET US INC	5MG	N202080	001	Jun 17, 2011
		7.5MG	N202080	002	Jun 17, 2011

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXYBOND

DAIICHI SANKYO INC	5MG	N209777	001	Apr 20, 2017
	15MG	N209777	002	Apr 20, 2017
	30MG	N209777	003	Apr 20, 2017

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
+		15MG	N022272	002	Apr 05, 2010
+		20MG	N022272	003	Apr 05, 2010
+		30MG	N022272	004	Apr 05, 2010
+		40MG	N022272	005	Apr 05, 2010
+		60MG	N022272	006	Apr 05, 2010
+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL

RHOFADÉ

+	ALLERGAN INC	1%	N208552	001	Jan 18, 2017
---	--------------	----	---------	-----	--------------

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED; NASAL

KOVANAZE

+	ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016
---	------------	------------------------	---------	-----	--------------

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+	MYLAN SPECIALITY LP	50MG	N016848	001	
---	---------------------	------	---------	-----	--

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OPANA

<u>AB</u>	+	ENDO PHARMS	<u>5MG</u>	<u>N021611</u>	<u>001</u>	Jun 22, 2006
<u>AB</u>	+		<u>10MG</u>	<u>N021611</u>	<u>002</u>	Jun 22, 2006

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A204459</u>	<u>001</u>	Apr 26, 2016
<u>AB</u>			<u>10MG</u>	<u>A204459</u>	<u>002</u>	Apr 26, 2016
<u>AB</u>		AVANTHI INC	<u>5MG</u>	<u>A203601</u>	<u>001</u>	Jan 30, 2013
<u>AB</u>			<u>10MG</u>	<u>A203601</u>	<u>002</u>	Jan 30, 2013
<u>AB</u>		EPIC PHARMA LLC	<u>5MG</u>	<u>A201187</u>	<u>001</u>	Dec 15, 2014
<u>AB</u>			<u>10MG</u>	<u>A201187</u>	<u>002</u>	Dec 15, 2014
<u>AB</u>		SPECGX LLC	<u>5MG</u>	<u>A202321</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>			<u>10MG</u>	<u>A202321</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>		TEVA	<u>5MG</u>	<u>A091443</u>	<u>002</u>	Feb 15, 2011
<u>AB</u>			<u>10MG</u>	<u>A091443</u>	<u>001</u>	Feb 15, 2011
<u>AB</u>		WEST-WARD PHARMS INT	<u>5MG</u>	<u>A090964</u>	<u>001</u>	Sep 27, 2010
<u>AB</u>			<u>10MG</u>	<u>A090964</u>	<u>002</u>	Sep 27, 2010

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>5MG</u>	<u>A079046</u>	<u>003</u>	Jul 11, 2013
<u>AB</u>			<u>7.5MG</u>	<u>A079046</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>			<u>10MG</u>	<u>A079046</u>	<u>004</u>	Jul 11, 2013
<u>AB</u>			<u>15MG</u>	<u>A079046</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>			<u>20MG</u>	<u>A079046</u>	<u>005</u>	Jul 11, 2013
<u>AB</u>			<u>30MG</u>	<u>A079046</u>	<u>006</u>	Jul 11, 2013
<u>AB</u>			<u>40MG</u>	<u>A079046</u>	<u>007</u>	Jul 11, 2013
<u>AB</u>		IMPAX LABS	<u>5MG</u>	<u>A079087</u>	<u>001</u>	Jun 14, 2010
<u>AB</u>			<u>7.5MG</u>	<u>A079087</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>			<u>10MG</u>	<u>A079087</u>	<u>003</u>	Jun 14, 2010
<u>AB</u>			<u>15MG</u>	<u>A079087</u>	<u>004</u>	Dec 21, 2010
<u>AB</u>			<u>20MG</u>	<u>A079087</u>	<u>005</u>	Jun 14, 2010
<u>AB</u>			<u>30MG</u>	<u>A079087</u>	<u>006</u>	Jul 22, 2010
<u>AB</u>			<u>40MG</u>	<u>A079087</u>	<u>007</u>	Jun 14, 2010
<u>AB</u>		SPECGX LLC	<u>5MG</u>	<u>A202946</u>	<u>001</u>	Jun 27, 2014
<u>AB</u>			<u>7.5MG</u>	<u>A202946</u>	<u>002</u>	Jun 27, 2014
<u>AB</u>			<u>10MG</u>	<u>A202946</u>	<u>003</u>	Jun 27, 2014
<u>AB</u>			<u>15MG</u>	<u>A202946</u>	<u>004</u>	Jun 27, 2014
<u>AB</u>			<u>20MG</u>	<u>A202946</u>	<u>005</u>	Jun 27, 2014
<u>AB</u>			<u>30MG</u>	<u>A202946</u>	<u>006</u>	Jun 27, 2014
<u>AB</u>			<u>40MG</u>	<u>A202946</u>	<u>007</u>	Jun 27, 2014
<u>AB</u>		SUN PHARM INDS LTD	<u>5MG</u>	<u>A203506</u>	<u>001</u>	Apr 24, 2015
<u>AB</u>			<u>7.5MG</u>	<u>A203506</u>	<u>002</u>	Apr 24, 2015

PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

<u>AB</u>	+	JANSSEN PHARMS	<u>1.5MG</u>	<u>N021999 006</u>	Aug 26, 2008
<u>AB</u>	+		<u>3MG</u>	<u>N021999 001</u>	Dec 19, 2006
<u>AB</u>	+		<u>6MG</u>	<u>N021999 002</u>	Dec 19, 2006
<u>AB</u>	+		<u>9MG</u>	<u>N021999 003</u>	Dec 19, 2006

PALIPERIDONE

<u>AB</u>		ACTAVIS LABS FL INC	<u>1.5MG</u>	<u>A202645 001</u>	Aug 03, 2015
<u>AB</u>			<u>3MG</u>	<u>A202645 002</u>	Aug 03, 2015
<u>AB</u>			<u>6MG</u>	<u>A202645 003</u>	Aug 03, 2015
<u>AB</u>			<u>9MG</u>	<u>A202645 004</u>	Aug 03, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>1.5MG</u>	<u>A203802 001</u>	Sep 24, 2015
<u>AB</u>			<u>3MG</u>	<u>A203802 002</u>	Sep 24, 2015
<u>AB</u>			<u>6MG</u>	<u>A203802 003</u>	Sep 24, 2015
<u>AB</u>			<u>9MG</u>	<u>A203802 004</u>	Sep 24, 2015

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009
+		156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946 001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946 002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946 003	May 18, 2015
+		819MG/2.625ML (312MG/ML)	N207946 004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

ALOXI

<u>AP</u>	+	HELFINN HLTHCARE	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 002</u>	Feb 29, 2008
<u>AP</u>	+		<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 001</u>	Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>A201533 001</u>	Apr 21, 2016
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A201533 002</u>	Apr 21, 2016
<u>AP</u>		SANDOZ INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A202521 001</u>	Oct 13, 2015

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

		EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963 001	Aug 22, 2016
+		FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109 001	Nov 21, 2017

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>		AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433 001</u>	Nov 26, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077433 003</u>	Nov 26, 2008
<u>AP</u>		FRESENIUS KABI USA	<u>30MG/VIAL</u>	<u>A075773 001</u>	May 06, 2002
<u>AP</u>			<u>30MG/10ML (3MG/ML)</u>	<u>A076207 001</u>	May 17, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075773 002</u>	May 06, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076207 002</u>	May 17, 2002
<u>AP</u>	!	HOSPIRA	<u>30MG/10ML (3MG/ML)</u>	<u>A075841 001</u>	Jun 27, 2002
<u>AP</u>	!		<u>60MG/10ML (6MG/ML)</u>	<u>A075841 002</u>	Jun 27, 2002
<u>AP</u>	!		<u>90MG/10ML (9MG/ML)</u>	<u>A075841 003</u>	Jun 27, 2002
<u>AP</u>		LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942 001</u>	Jul 25, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078942 002</u>	Jul 25, 2008
<u>AP</u>		MYLAN LABS LTD	<u>30MG/10ML (3MG/ML)</u>	<u>A078520 001</u>	Oct 31, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078520 002</u>	Oct 31, 2008
<u>AP</u>		PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156 001</u>	Aug 19, 2008
<u>AP</u>			<u>60MG/10ML (6MG/ML)</u>	<u>A078156 002</u>	Aug 19, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078156 003</u>	Aug 19, 2008
<u>AP</u>		SAGENT PHARMS	<u>30MG/10ML (3MG/ML)</u>	<u>A078373 001</u>	Dec 23, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078373 002</u>	Dec 23, 2008
<u>AP</u>		SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703 001</u>	Dec 24, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077703 002</u>	Dec 24, 2008
<u>AP</u>		TEVA PHARMS USA	<u>30MG/10ML (3MG/ML)</u>	<u>A076153 001</u>	Mar 27, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076153 002</u>	Mar 27, 2002
<u>AP</u>		WEST-WARD PHARMS INT	<u>30MG/VIAL</u>	<u>A075290 001</u>	Apr 30, 2001

PRESCRIPTION DRUG PRODUCT LIST

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	+		<u>30MG/10ML (3MG/ML)</u>	<u>N021113 001</u>	Mar 04, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075290 003</u>	Apr 30, 2001
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>N021113 002</u>	Mar 04, 2002
		AREVA PHARMS	60MG/VIAL	A077433 002	Nov 26, 2008

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

+	ABEVIE	60,000USP UNITS; 12,000USP UNITS; 38,000USP UNITS	N020725 002	Apr 30, 2009
+		15,000USP UNITS; 3,000USP UNITS; 9,500USP UNITS	N020725 004	Jul 12, 2011
+		30,000USP UNITS; 6,000USP UNITS; 19,000USP UNITS	N020725 001	Apr 30, 2009
+		180,000USP UNITS; 36,000USP UNITS; 114,000USP UNITS	N020725 005	Mar 14, 2013
+	!	120,000USP UNITS; 24,000USP UNITS; 76,000USP UNITS	N020725 003	Apr 30, 2009

PANCREAZE

+	JANSSEN PHARMS	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523 005	Mar 07, 2014
+		17,500USP/ UNITS; 4,200USP/ UNITS; 10,000USP/ UNITS	N022523 001	Apr 12, 2010
+		43,750USP/ UNITS; 10,500USP/ UNITS; 25,000USP/ UNITS	N022523 002	Apr 12, 2010
+	!	61,000USP/ UNITS; 21,000USP/ UNITS; 37,000USP/ UNITS	N022523 003	Apr 12, 2010
+		70,000USP/ UNITS; 16,800USP/ UNITS; 40,000USP/ UNITS	N022523 004	Apr 12, 2010

PERTZYE

+	DIGESTIVE CARE INC	30,250USP UNITS; 8,000USP UNITS; 28,750USP UNITS	N022175 001	May 17, 2012
+	!	60,500USP UNITS; 16,000USP UNITS; 57,500USP UNITS	N022175 002	May 17, 2012
+		15,125USP UNITS; 4,000USP UNITS; 14,375USP UNITS	N022175 003	Oct 06, 2016
+		90,750USP UNITS; 24,000USP UNITS; 86,250USP UNITS	N022175 004	Jul 13, 2017

ULTRESA

+	FOREST LABS INC	27,600USP UNITS; 13,800USP UNITS; 27,600USP UNITS	N022222 001	Mar 01, 2012
+		41,400USP UNITS; 20,700USP UNITS; 41,400USP UNITS	N022222 002	Mar 01, 2012
+	!	46,000USP UNITS; 23,000USP UNITS; 46,000USP UNITS	N022222 003	Mar 01, 2012

ZENPEP

+	FOREST LABS INC	168,000USP UNITS; 40,000USP UNITS; 126,000USP UNITS	N022210 007	Mar 25, 2014
+		14,000USP UNITS; 3,000USP UNITS; 10,000USP UNITS	N022210 005	Jun 15, 2011
+		24,000USP UNITS; 5,000USP UNITS; 17,000USP UNITS	N022210 001	Aug 27, 2009
+		42,000USP UNITS; 10,000USP UNITS; 32,000USP UNITS	N022210 002	Aug 27, 2009
+		63,000USP UNITS; 15,000USP UNITS; 47,000USP UNITS	N022210 003	Aug 27, 2009
+		84,000USP UNITS; 20,000USP UNITS; 63,000USP UNITS	N022210 004	Aug 27, 2009
+	!	105,000USP UNITS; 25,000USP UNITS; 79,000USP UNITS	N022210 006	Jul 13, 2011

TABLET; ORAL

VIOKACE

+	FOREST LABS INC	39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS	N022542 001	Mar 01, 2012
+	!	78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS	N022542 002	Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A072320 001</u>	Jan 19, 1989
<u>AP</u>	!	TEVA PHARMS USA	<u>1MG/ML</u>	<u>A072759 001</u>	Jul 31, 1990
	!		2MG/ML	A072760 001	Jul 31, 1990

PRESCRIPTION DRUG PRODUCT LIST

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

+	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353 001	Feb 23, 2015
+		EQ 15MG BASE	N205353 002	Feb 23, 2015
+	!	EQ 20MG BASE	N205353 003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+	!	WYETH PHARMS INC	EQ 40MG BASE	N022020 001	Nov 14, 2007
---	---	------------------	--------------	-------------	--------------

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AKORN INC	<u>EQ 40MG BASE/VIAL</u>	<u>A079197 001</u>	Nov 08, 2012
AP	AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A205675 001</u>	Mar 30, 2016
AP	SANDOZ INC	<u>EQ 40MG BASE/VIAL</u>	<u>A090296 001</u>	Jul 14, 2015

PROTONIX IV

AP	+	!	WYETH PHARMS INC	<u>EQ 40MG BASE/VIAL</u>	<u>N020988 001</u>	Mar 22, 2001
-----------	---	---	------------------	---------------------------------	---------------------------	--------------

POWDER;IV (INFUSION)

PANTOPRAZOLE SODIUM

		EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL	N209463 001	Jun 30, 2017
--	--	-------------------------	-------------------	-------------	--------------

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797 001</u>	Feb 07, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A090797 002</u>	Feb 07, 2011		
AB	AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A205119 001</u>	Jan 26, 2016		
AB		<u>EQ 40MG BASE</u>	<u>A205119 002</u>	Jan 26, 2016		
AB	APOTEX INC	<u>EQ 20MG BASE</u>	<u>A090807 001</u>	May 02, 2012		
AB		<u>EQ 40MG BASE</u>	<u>A090807 002</u>	May 02, 2012		
AB	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038 001</u>	Sep 28, 2012		
AB		<u>EQ 40MG BASE</u>	<u>A202038 002</u>	Sep 28, 2012		
AB	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619 001</u>	Jan 19, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A077619 002</u>	Jan 19, 2011		
AB	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882 001</u>	Sep 10, 2014		
AB		<u>EQ 40MG BASE</u>	<u>A202882 002</u>	Sep 10, 2014		
AB	JUBILANT GENERICS	<u>EQ 20MG BASE</u>	<u>A090901 001</u>	Aug 30, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A090901 002</u>	Aug 30, 2011		
AB	KREMERS URBAN PHARMS	<u>EQ 20MG BASE</u>	<u>A078281 001</u>	Jan 20, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A078281 002</u>	Jan 20, 2011		
AB	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A200821 001</u>	Feb 16, 2012		
AB		<u>EQ 40MG BASE</u>	<u>A200821 002</u>	Feb 16, 2012		
AB	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970 001</u>	Jan 19, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A090970 002</u>	Jan 19, 2011		
AB	ORCHID HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202052 001</u>	Dec 02, 2014		
AB		<u>EQ 40MG BASE</u>	<u>A202052 002</u>	Dec 02, 2014		
AB	PERRIGO R AND D	<u>EQ 20MG BASE</u>	<u>A203024 001</u>	May 07, 2014		
AB	SUN PHARM INDS LTD	<u>EQ 20MG BASE</u>	<u>A200794 001</u>	May 02, 2012		
AB		<u>EQ 40MG BASE</u>	<u>A200794 002</u>	May 02, 2012		
AB	TEVA	<u>EQ 20MG BASE</u>	<u>A077056 001</u>	Aug 02, 2007		
AB		<u>EQ 40MG BASE</u>	<u>A077056 002</u>	Aug 02, 2007		
AB	TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074 001</u>	Jan 19, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A090074 002</u>	Jan 19, 2011		
AB	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A091231 001</u>	Jan 19, 2011		
AB		<u>EQ 40MG BASE</u>	<u>A091231 002</u>	Jan 19, 2011		
<u>PROTONIX</u>						
AB	+	!	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
AB	+	!		<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	AMNEAL PHARMS	<u>1MCG</u>	<u>A204327 001</u>	Jan 13, 2016
AB		<u>2MCG</u>	<u>A204327 002</u>	Jan 13, 2016
AB		<u>4MCG</u>	<u>A204327 003</u>	Jan 13, 2016
AB	AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672 001</u>	Jan 14, 2016
AB		<u>2MCG</u>	<u>A207672 002</u>	Jan 14, 2016
AB		<u>4MCG</u>	<u>A207672 003</u>	Jan 14, 2016
AB	BIONPHARMA INC	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
AB		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014

PRESCRIPTION DRUG PRODUCT LIST

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	ECI PHARMS LLC	<u>1MCG</u>	<u>A206710 001</u>	Feb 24, 2016
<u>AB</u>		<u>2MCG</u>	<u>A206710 002</u>	Feb 24, 2016
<u>AB</u>		<u>4MCG</u>	<u>A206710 003</u>	Feb 24, 2016
<u>AB</u>	MARKSANS PHARMA	<u>1MCG</u>	<u>A204948 001</u>	Oct 07, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204948 002</u>	Oct 07, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204948 003</u>	Oct 07, 2016
<u>AB</u>	RISING PHARMS INC	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>	!	<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013

ZEMPLAR

<u>AB</u>	+ ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>	+	<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>	ACCORD HLTHCARE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N207174 001</u>	Feb 04, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N207174 002</u>	Feb 04, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N207174 003</u>	Feb 04, 2016
<u>AP</u>	AKORN	<u>0.005MG/ML (0.005MG/ML)</u>	<u>A207692 001</u>	Oct 16, 2017
<u>AP</u>	AMNEAL PHARMS CO	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A206699 001</u>	Mar 09, 2017
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A206699 002</u>	Mar 09, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A206699 003</u>	Mar 09, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A204910 001</u>	Aug 17, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A204910 002</u>	Aug 17, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A204910 003</u>	Aug 17, 2016
<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	MYLAN LABS LTD	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A203897 001</u>	Nov 02, 2017
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A203897 002</u>	Nov 02, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A203897 003</u>	Nov 02, 2017
<u>AP</u>	SANDOZ INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011

ZEMPLAR

<u>AP</u>	+! ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+!	<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+!	<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007
<u>AA</u>	!	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

	+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710 001	Jun 25, 1997
--	----	---------------------	------------------	-------------	--------------

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205528 001</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205528 002</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A205528 003</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205528 004</u>	Nov 27, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	OXFORD PHARMS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A078194 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194 003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194 004</u>	Jun 29, 2007
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 12.5MG BASE</u>	<u>A204744 001</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204744 002</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204744 003</u>	Jun 10, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 12.5MG BASE</u>	<u>A204134 001</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204134 002</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204134 003</u>	Jan 20, 2017
<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011

PAXIL CR

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

<u>AB</u>	+	SEBELA IRELAND LTD	<u>EQ 7.5MG BASE</u>	<u>N204516 001</u>	Jun 28, 2013
-----------	---	--------------------	----------------------	--------------------	--------------

PAROXETINE MESYLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 7.5MG BASE</u>	<u>A207139 001</u>	Jun 20, 2017
<u>AB</u>	PRINSTON INC	<u>EQ 7.5MG BASE</u>	<u>A207188 001</u>	Aug 18, 2017

TABLET; ORAL

PEXEVA

+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299 001	Jul 03, 2003
+		EQ 20MG BASE	N021299 002	Jul 03, 2003
+		EQ 30MG BASE	N021299 003	Jul 03, 2003
+		EQ 40MG BASE	N021299 004	Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

+	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677 001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677 002	Dec 14, 2012
+		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677 003	Dec 14, 2012

PRESCRIPTION DRUG PRODUCT LIST

PASIREOTIDE PAMOATE

POWDER; INTRAMUSCULAR

SIGNIFOR LAR

+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255 001	Dec 15, 2014
+		EQ 40MG BASE/VIAL	N203255 002	Dec 15, 2014
+		EQ 60MG BASE/VIAL	N203255 003	Dec 15, 2014

PATIROMER SORBITE X CALCIUM

POWDER; ORAL

VELTASSA

+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739 001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739 002	Oct 21, 2015
+		EQ 25.2GM BASE/PACKET	N205739 003	Oct 21, 2015

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465 001	Oct 19, 2009
---	-------------------------	---------------	-------------	--------------

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+	SIGMA TAU	250 UNITS/ML	N019818 001	Mar 21, 1990
---	-----------	--------------	-------------	--------------

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004
---	--------------------	----------------------	-------------	--------------

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+	PHARMACIA AND UPJOHN	10MG/VIAL	N021106 001	Mar 25, 2003
+		15MG/VIAL	N021106 002	Mar 25, 2003
+		20MG/VIAL	N021106 003	Mar 25, 2003
+		25MG/VIAL	N021106 004	Jul 31, 2014
+		30MG/VIAL	N021106 005	Jul 31, 2014

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+	LILLY	EQ 100MG BASE/VIAL	N021462 002	Sep 07, 2007
+		EQ 500MG BASE/VIAL	N021462 001	Feb 04, 2004

PENCICLOVIR

CREAM; TOPICAL

DENA VIR

+	MYLAN PHARMS INC	1%	N020629 001	Sep 24, 1996
---	------------------	----	-------------	--------------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+	ATON	250MG	N019853 001	
---	------	-------	-------------	--

TABLET; ORAL

DEPEN

+	MYLAN SPECIALITY LP	250MG	N019854 001	
---	---------------------	-------	-------------	--

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC	+	KING PHARMS LLC	600,000 UNITS/ML	N050141 001
----	---	-----------------	------------------	-------------

PERMAPEN

BC		CASPER PHARMA LLC	600,000 UNITS/ML	A060014 001
----	--	-------------------	------------------	-------------

BICILLIN L-A

+	KING PHARMS LLC	300,000 UNITS/ML	N050141 003	
---	-----------------	------------------	-------------	--

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+	KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML	N050138 002	
---	-----------------	------------------------------------	-------------	--

+		300,000 UNITS/ML; 300,000 UNITS/ML	N050138 001	
---	--	------------------------------------	-------------	--

BICILLIN C-R 900/300

+	KING PHARMS LLC	900,000 UNITS/2ML; 300,000 UNITS/2ML	N050138 003	
---	-----------------	--------------------------------------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u>	HANFORD GC	<u>5,000,000 UNITS/VIAL</u>	<u>A065149 002</u>	Jul 23, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065149 003</u>	Jul 23, 2009
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>5,000,000 UNITS/VIAL</u>	<u>A065448 001</u>	Aug 18, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065448 002</u>	Aug 18, 2009
<u>AP</u>	SANDOZ	<u>5,000,000 UNITS/VIAL</u>	<u>A065079 002</u>	Aug 30, 2002
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065079 003</u>	Aug 30, 2002

PFIZERPEN

<u>AP</u>	! PFIZER	<u>5,000,000 UNITS/VIAL</u>	<u>A060657 002</u>	
<u>AP</u>	!	<u>20,000,000 UNITS/VIAL</u>	<u>A060657 003</u>	
	PENICILLIN G POTASSIUM HANFORD GC	1,000,000 UNITS/VIAL	A065149 001	Jul 23, 2009
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER			
	+! BAXTER HLTHCARE	20,000 UNITS/ML	N050638 001	Jun 25, 1990
	+!	40,000 UNITS/ML	N050638 002	Jun 25, 1990
	+!	60,000 UNITS/ML	N050638 003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

!	KING PHARMS LLC	300,000 UNITS/ML	A060101 002	
!		600,000 UNITS/ML	A060101 001	

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

!	SANDOZ	5,000,000 UNITS/VIAL	A065068 001	Feb 26, 2001
---	--------	----------------------	-------------	--------------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

<u>AA</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062981 001</u>	Feb 10, 1989
<u>AA</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062981 002</u>	Feb 10, 1989
	<u>PENICILLIN-VK</u>			
<u>AA</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A060456 001</u>	
<u>AA</u>	!	<u>EQ 250MG BASE/5ML</u>	<u>A060456 002</u>	

TABLET; ORAL

PENICILLIN V POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A065435 001</u>	Apr 29, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065435 002</u>	Apr 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062936 001</u>	Nov 25, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062935 001</u>	Nov 23, 1988
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE</u>	<u>A090549 001</u>	Oct 11, 2013
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090549 002</u>	Oct 11, 2013
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064071 001</u>	Nov 30, 1995
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A064071 002</u>	Nov 30, 1995
	<u>PENICILLIN-VK</u>			
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A060711 002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A060711 003</u>	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+!	FRESENIUS KABI USA	300MG/VIAL	N019887 001	Jun 15, 1989
----	--------------------	------------	-------------	--------------

INJECTABLE; INJECTION

PENTAM

<u>AP</u>	+! FRESENIUS KABI USA	<u>300MG/VIAL</u>	<u>N019264 001</u>	Oct 16, 1984
	<u>PENTAMIDINE ISETHIONATE</u>			
<u>AP</u>	SETON PHARMS	<u>300MG/VIAL</u>	<u>A206666 001</u>	Sep 28, 2017

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+!	HOSPIRA	EQ 30MG BASE/ML	N016194 001	
----	---------	-----------------	-------------	--

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+!	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004
----	--------------------	------------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+! HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM**AP** ! OAK PHARMS **50MG/ML** **A083246 001**PENTOBARBITAL SODIUM**AP** CUSTOPHARM INC **50MG/ML** **A203619 001** Nov 13, 2017**AP** RENAISSANCE SSA LLC **50MG/ML** **A206677 001** Nov 27, 2017**AP** SAGENT PHARMS **50MG/ML** **A206404 001** May 23, 2016PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+! JANSSEN PHARMS 100MG N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT**AP** +! HOSPIRA INC **10MG/VIAL** **N020122 001** Oct 11, 1991PENTOSTATIN**AP** MYLAN INSTITUTIONAL **10MG/VIAL** **A203554 001** Sep 19, 2014**AP** WEST-WARD PHARMS **10MG/VIAL** **A077841 001** Aug 07, 2007

INT

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE**AB** ! APOTEX **400MG** **A075191 001** Jun 09, 1999**AB** MYLAN **400MG** **A074425 001** Jul 08, 1997**AB** VALEANT PHARMS **400MG** **A075028 001** Jul 20, 1998PENTOXIL**AB** UPSHER-SMITH LABS **400MG** **A074962 001** Mar 31, 1999PERAMIVIR

SOLUTION; IV (INFUSION)

RAPIVAB

+! BIOCRYST 200MG/20ML (10MG/ML) N206426 001 Dec 19, 2014

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+! EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016

TABLET; ORAL

FYCOMPA

+ EISAI INC 2MG N202834 001 Oct 22, 2012

+ 4MG N202834 002 Oct 22, 2012

+ 6MG N202834 003 Oct 22, 2012

+ 8MG N202834 004 Oct 22, 2012

+ 10MG N202834 005 Oct 22, 2012

+! 12MG N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+! LANTHEUS MEDCL 6.52MG/ML N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE**AB** ANI PHARMS INC **2MG** **A078138 001** Nov 10, 2009**AB** **4MG** **A078138 002** Nov 10, 2009**AB** **8MG** **A078138 003** Nov 10, 2009**AB** APOTEX **2MG** **A090463 001** Aug 30, 2010**AB** **4MG** **A090463 002** Aug 30, 2010**AB** **8MG** **A090463 003** Aug 30, 2010**AB** ! AUROBINDO PHARMA **2MG** **A079070 001** Nov 10, 2009**AB** ! **4MG** **A079070 002** Nov 10, 2009**AB** ! **8MG** **A079070 003** Nov 10, 2009**AB** WEST-WARD PHARMS **2MG** **A090072 001** Nov 10, 2009

INT

AB **4MG** **A090072 002** Nov 10, 2009**AB** **8MG** **A090072 003** Nov 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+ !	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989
-----------	------------	------------------	-----------	----------------	------------	--------------

PERMETHRIN

AB		ACTAVIS LABS	5%	A074806	001	Jan 23, 1998
AB		PERRIGO NEW YORK	5%	A076369	001	Apr 21, 2003

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB		MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017
AB			4MG	A206691	002	Apr 14, 2017
AB			8MG	A206691	003	Apr 14, 2017
AB			16MG	A206691	004	Apr 14, 2017
AB		SANDOZ	2MG	A089685	002	Dec 08, 1988
AB			4MG	A089685	003	Dec 08, 1988
AB			8MG	A089685	001	Dec 08, 1988
AB	!		16MG	A089685	004	Dec 08, 1988
AB		VINTAGE PHARMS	2MG	A040226	001	Dec 31, 1998
AB			4MG	A040226	002	Dec 31, 1998
AB			8MG	A040226	003	Dec 31, 1998
AB			16MG	A040226	004	Dec 31, 1998
AB		WATSON LABS INC	2MG	A207582	001	Oct 17, 2016
AB			4MG	A207582	002	Oct 17, 2016
AB			8MG	A207582	003	Oct 17, 2016
AB			16MG	A207582	004	Oct 17, 2016
AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015
AB			4MG	A205973	002	Dec 17, 2015
AB			8MG	A205973	003	Dec 17, 2015
AB			16MG	A205973	004	Dec 17, 2015

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+ !	SANDOZ	105MG	N018074	001	
------------	--------	-------	----------------	------------	--

TABLET; ORAL

BONTRIL PDM

AA	!	VALEANT	35MG	A085272	001	
-----------	----------	---------	-------------	----------------	------------	--

PHENDIMETRAZINE TARTRATE

AA		ELITE LABS INC	35MG	A040762	001	Jan 28, 2008
AA			35MG	A203600	001	Dec 27, 2017
AA		KVK TECH	35MG	A091042	001	Aug 31, 2010
AA		MIKART	35MG	A089452	001	Oct 30, 1991
AA		SANDOZ	35MG	A085588	001	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

AB	+ !	PARKE DAVIS	EQ 15MG BASE	N011909	002	
-----------	------------	-------------	---------------------	----------------	------------	--

PHENELZINE SULFATE

AB		NOVEL LABS INC	EQ 15MG BASE	A200181	001	Dec 08, 2010
-----------	--	----------------	---------------------	----------------	------------	--------------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+ !	CONCORDIA PHARMS INC	10MG	N008708	001	
-----------	------------	----------------------	-------------	----------------	------------	--

PHENOXYBENZAMINE HYDROCHLORIDE

AB		PAR PHARM INC	10MG	A204522	001	Jan 24, 2017
AB		WEST-WARD PHARMS INT	10MG	A201050	001	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

AA	!	TEVA	37.5MG	A088023	001	Aug 02, 1983
-----------	----------	------	---------------	----------------	------------	--------------

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	15MG	A204318	001	Nov 09, 2016
AA			30MG	A204318	002	Nov 09, 2016
AA		BARR	15MG	A090591	001	Mar 18, 2010
AA			30MG	A090591	002	Mar 18, 2010
AA		ELITE LABS	15MG	A202248	001	Sep 28, 2012
AA			30MG	A202248	002	Sep 28, 2012
AA		ELITE LABS INC	37.5MG	A040228	001	Jun 19, 1997

PRESCRIPTION DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	INVAGEN PHARMS	<u>15MG</u>	<u>A202858</u>	<u>001</u>	Feb 14, 2014
<u>AA</u>		<u>30MG</u>	<u>A202858</u>	<u>002</u>	Feb 14, 2014
<u>AA</u>		<u>30MG</u>	<u>A204414</u>	<u>001</u>	May 05, 2014
<u>AA</u>		<u>37.5MG</u>	<u>A202846</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>	KEN LIFESCIENCE	<u>15MG</u>	<u>A205019</u>	<u>001</u>	Dec 05, 2014
<u>AA</u>		<u>30MG</u>	<u>A205019</u>	<u>002</u>	Dec 05, 2014
<u>AA</u>		<u>37.5MG</u>	<u>A205017</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>		<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		<u>30MG</u>	<u>A091359</u>	<u>001</u>	Jul 16, 2010
<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>	!	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
<u>AA</u>	!	<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	!	<u>30MG</u>	<u>A087190</u>	<u>001</u>	
<u>AA</u>	SUN PHARM INDUSTRIES	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003

TABLET; ORAL

ADIPEX-P

<u>AA</u>	!	TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
-----------	---	------	---------------	----------------	------------	--

LOMAIRA

<u>AA</u>	!	AVANTHI INC	<u>8MG</u>	<u>A203495</u>	<u>001</u>	Sep 12, 2016
-----------	---	-------------	------------	----------------	------------	--------------

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068</u>	<u>001</u>	Aug 06, 2014
<u>AA</u>	BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
<u>AA</u>	ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	ELITE LABS INC	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30, 1997
<u>AA</u>	INGENUS PHARMS NJ	<u>37.5MG</u>	<u>A091451</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>	INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>	KEN LIFESCIENCE	<u>37.5MG</u>	<u>A205008</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>	KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>	KVK TECH INC	<u>8MG</u>	<u>A203436</u>	<u>001</u>	Mar 17, 2017
<u>AA</u>	LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>	POLYGEN PHARMS	<u>37.5MG</u>	<u>A206342</u>	<u>001</u>	Nov 18, 2016
<u>AA</u>	PRINSTON INC	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002
<u>AA</u>	SUN PHARM INDS INC	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
<u>AA</u>	SUN PHARM INDUSTRIES	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

PHENTERMINE HYDROCHLORIDE

	ZYDUS PHARMS USA	15MG	A204663	001	Jun 28, 2017
	INC	30MG	A204663	002	Jun 28, 2017
		37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

+	VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
+		EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
+		EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
+	!	EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<u>AP</u>	PRECISION DOSE INC	<u>5MG/VIAL</u>	<u>A207686</u>	<u>001</u>	Jul 14, 2017	
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A040235</u>	<u>001</u>	Mar 11, 1998
	ORAVERSE					
+	!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PRESCRIPTION DRUG PRODUCT LIST

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

+	!	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012
---	---	----------------------	-------------------	---------	-----	--------------

VAZCULEP

+		AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014
+			50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014
+	!		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

+	!	AKORN INC	2.5%	N207926	001	Jan 15, 2015
+	!		10%	N207926	002	Jan 15, 2015
+	!	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
+	!		10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		HI-TECH PHARMACAL	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040675</u>	<u>001</u>	Dec 23, 2014
AA		VINTAGE	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040654</u>	<u>001</u>	Dec 07, 2006
<u>PROMETH VC PLAIN</u>						
AA		! G AND W LABS INC	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A088761</u>	<u>001</u>	Nov 08, 1984
<u>PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE</u>						
AA		AMNEAL PHARMS	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040902</u>	<u>001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB		+	!	PARKE DAVIS	<u>125MG/5ML</u>	<u>N008762</u>	<u>001</u>	
<u>PHENYTOIN</u>								
AB				TARO	<u>125MG/5ML</u>	<u>A040521</u>	<u>001</u>	Mar 08, 2004
AB				VISTAPHARM	<u>125MG/5ML</u>	<u>A040342</u>	<u>001</u>	Jan 31, 2001
AB					<u>125MG/5ML</u>	<u>A040610</u>	<u>001</u>	Aug 18, 2005
AB				WOCKHARDT EU OPERATN	<u>125MG/5ML</u>	<u>A040420</u>	<u>001</u>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

AB		!		PFIZER	<u>50MG</u>	<u>A084427</u>	<u>001</u>	
<u>PHENYTOIN</u>								
AB				EPIC PHARMA LLC	<u>50MG</u>	<u>A040884</u>	<u>001</u>	Nov 28, 2014
AB				MYLAN PHARMS INC	<u>50MG</u>	<u>A200691</u>	<u>001</u>	Dec 26, 2012
AB				TARO	<u>50MG</u>	<u>A200565</u>	<u>001</u>	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

AB		!		PARKE-DAVIS	<u>100MG EXTENDED</u>	<u>A084349</u>	<u>002</u>	
<u>EXTENDED PHENYTOIN SODIUM</u>								
AB				AMNEAL PHARMS NY	<u>100MG EXTENDED</u>	<u>A040765</u>	<u>001</u>	Nov 12, 2008
AB				MYLAN	<u>100MG EXTENDED</u>	<u>A040298</u>	<u>001</u>	Dec 28, 1998
AB				SUN PHARM INDS	<u>200MG EXTENDED</u>	<u>A040731</u>	<u>001</u>	Jun 30, 2008
AB					<u>300MG EXTENDED</u>	<u>A040731</u>	<u>002</u>	Jun 30, 2008
AB				SUN PHARM INDS (IN)	<u>100MG EXTENDED</u>	<u>A040621</u>	<u>001</u>	Dec 11, 2006
AB				TARO	<u>100MG EXTENDED</u>	<u>A040684</u>	<u>001</u>	Sep 05, 2006

PHENYTEK

AB				MYLAN	<u>200MG EXTENDED</u>	<u>A040298</u>	<u>002</u>	Dec 06, 2001
AB				!	<u>300MG EXTENDED</u>	<u>A040298</u>	<u>003</u>	Dec 06, 2001

PHENYTOIN SODIUM

AB				AUROBINDO PHARMA LTD	<u>100MG EXTENDED</u>	<u>A204309</u>	<u>001</u>	Jun 10, 2015
-----------	--	--	--	----------------------	-----------------------	-----------------------	-------------------	--------------

DILANTIN

!		PARKE-DAVIS	<u>30MG EXTENDED</u>	A084349	001	
---	--	-------------	----------------------	---------	-----	--

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP				ACELLA PHARMS LLC	<u>50MG/ML</u>	<u>A040573</u>	<u>001</u>	Sep 13, 2006
AP				LUITPOLD	<u>50MG/ML</u>	<u>A040781</u>	<u>001</u>	Dec 04, 2007
AP				! WEST-WARD PHARMS INT	<u>50MG/ML</u>	<u>A084307</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	!	INTL MEDICATION	1MG/0.5ML	A083722	001		
		VITAMIN K1					
BP	!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983	
	!		10MG/ML	A087955	001	Jul 25, 1983	
		MEPHYTON					
	+	VALEANT PHARMS	5MG	N010104	003		

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

<u>AT</u>	+	NOVARTIS PHARMS CORP	<u>1%</u>	<u>N200890</u>	<u>001</u>	Jun 22, 2010	
<u>AT</u>	+		<u>2%</u>	<u>N200890</u>	<u>002</u>	Jun 22, 2010	
<u>AT</u>	+		<u>4%</u>	<u>N200890</u>	<u>003</u>	Jun 22, 2010	
		<u>PILOCARPINE HYDROCHLORIDE</u>					
<u>AT</u>		AKORN INC	<u>1%</u>	<u>A204398</u>	<u>001</u>	Sep 27, 2017	
<u>AT</u>			<u>2%</u>	<u>A204398</u>	<u>002</u>	Sep 27, 2017	
<u>AT</u>			<u>4%</u>	<u>A204398</u>	<u>003</u>	Sep 27, 2017	

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

<u>AB</u>		IMPAX LABS	<u>5MG</u>	<u>A077248</u>	<u>001</u>	Mar 31, 2006	
<u>AB</u>			<u>7.5MG</u>	<u>A077248</u>	<u>002</u>	Mar 31, 2006	
<u>AB</u>		INNOGENIX	<u>5MG</u>	<u>A076963</u>	<u>001</u>	Dec 22, 2004	
<u>AB</u>			<u>7.5MG</u>	<u>A076963</u>	<u>002</u>	Feb 27, 2007	
<u>AB</u>		LANNETT	<u>5MG</u>	<u>A077220</u>	<u>001</u>	Oct 14, 2005	
<u>AB</u>			<u>7.5MG</u>	<u>A077220</u>	<u>002</u>	May 06, 2009	
<u>AB</u>		PERRIGO PHARMA INTL	<u>5MG</u>	<u>A076746</u>	<u>001</u>	Nov 16, 2004	
		<u>SALAGEN</u>					
<u>AB</u>	+	EISAI INC	<u>5MG</u>	<u>N020237</u>	<u>001</u>	Mar 22, 1994	
<u>AB</u>	+		<u>7.5MG</u>	<u>N020237</u>	<u>002</u>	Apr 18, 2003	

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

	+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	
--	---	-------------------	--------------	---------	-----	--------------	--

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

	+	VALEANT BERMUDA	1%	N021302	001	Dec 13, 2001	
--	---	-----------------	----	---------	-----	--------------	--

PIMOZIDE

TABLET; ORAL

ORAP

<u>AB</u>	+	TEVA	<u>1MG</u>	<u>N017473</u>	<u>003</u>	Aug 27, 1997	
<u>AB</u>	+		<u>2MG</u>	<u>N017473</u>	<u>001</u>	Jul 31, 1984	

PIMOZIDE

<u>AB</u>		PAR PHARM	<u>1MG</u>	<u>A204521</u>	<u>001</u>	Sep 28, 2015	
<u>AB</u>			<u>2MG</u>	<u>A204521</u>	<u>002</u>	Sep 28, 2015	

PINDOLOL

TABLET; ORAL

PINDOLOL

<u>AB</u>		IDT AUSTRALIA LTD	<u>5MG</u>	<u>A073608</u>	<u>001</u>	Mar 29, 1993	
<u>AB</u>			<u>10MG</u>	<u>A073609</u>	<u>001</u>	Mar 29, 1993	
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A074019</u>	<u>001</u>	Sep 03, 1992	
<u>AB</u>	!		<u>10MG</u>	<u>A074019</u>	<u>002</u>	Sep 03, 1992	
<u>AB</u>		NOSTRUM LABS INC	<u>5MG</u>	<u>A205415</u>	<u>001</u>	Jan 13, 2016	
<u>AB</u>			<u>10MG</u>	<u>A205415</u>	<u>002</u>	Jan 13, 2016	
<u>AB</u>		SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A074063</u>	<u>001</u>	Jan 27, 1994	
<u>AB</u>			<u>10MG</u>	<u>A074063</u>	<u>002</u>	Jan 27, 1994	
<u>AB</u>		ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A209866</u>	<u>001</u>	Aug 18, 2017	
<u>AB</u>			<u>10MG</u>	<u>A209866</u>	<u>002</u>	Aug 18, 2017	

PRESCRIPTION DRUG PRODUCT LIST

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

<u>AB</u>	+	TAKEDA PHARMS USA	<u>EQ 15MG BASE</u>	<u>N021073 001</u>	Jul 15, 1999
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N021073 002</u>	Jul 15, 1999
<u>AB</u>	+		<u>EQ 45MG BASE</u>	<u>N021073 003</u>	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 15MG BASE</u>	<u>A200044 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A200044 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A200044 003</u>	Feb 13, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 15MG BASE</u>	<u>A200268 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A200268 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A200268 003</u>	Feb 13, 2013
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 15MG BASE</u>	<u>A078472 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078472 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078472 003</u>	Feb 13, 2013
<u>AB</u>		CIPLA LTD	<u>EQ 15MG BASE</u>	<u>A076798 001</u>	Oct 26, 2012
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076798 002</u>	Oct 26, 2012
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A076798 003</u>	Oct 26, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 15MG BASE</u>	<u>A078383 001</u>	Mar 12, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078383 002</u>	Mar 12, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078383 003</u>	Mar 12, 2013
<u>AB</u>		LUPIN LTD	<u>EQ 15MG BASE</u>	<u>A204133 001</u>	Apr 07, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204133 002</u>	Apr 07, 2014
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A204133 003</u>	Apr 07, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467 001</u>	Feb 06, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202467 002</u>	Feb 06, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A202467 003</u>	Feb 06, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801 001</u>	Aug 17, 2012
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076801 002</u>	Aug 17, 2012
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A076801 003</u>	Aug 17, 2012
<u>AB</u>		PURACAP PHARM LLC	<u>EQ 15MG BASE</u>	<u>A206738 001</u>	Oct 06, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A206738 002</u>	Oct 06, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A206738 003</u>	Oct 06, 2017
<u>AB</u>		SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078670 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078670 003</u>	Feb 13, 2013
<u>AB</u>		TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210 001</u>	Jan 10, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A077210 002</u>	Jan 10, 2014
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A077210 003</u>	Jan 10, 2014
<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A091298 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A091298 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A091298 003</u>	Feb 13, 2013
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456 001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202456 002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A202456 003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

!		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003
!			EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003
!			EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003
!			EQ 40GM BASE/VIAL	A065157 001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>		APOLLO PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A207847 001</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A207847 002</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207848 002</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A207847 003</u>	Jan 13, 2017
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498 001</u>	May 23, 2011
<u>AP</u>			<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498 002</u>	May 23, 2011
<u>AP</u>			<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498 003</u>	May 23, 2011
<u>AP</u>		HOSPIRA INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386 001</u>	Sep 15, 2009
<u>AP</u>			<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386 002</u>	Sep 15, 2009
<u>AP</u>			<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386 003</u>	Sep 15, 2009
<u>AP</u>			<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446 001</u>	Sep 15, 2009
<u>AP</u>		ISTITUTO BIO ITA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523 001</u>	May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

SPA

<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523 002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523 003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498 001</u>	May 31, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458 001</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458 002</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458 003</u>	Aug 15, 2014
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362 003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363 003</u>	Oct 21, 2010
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A207146 001</u>	Mar 17, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A206996 001</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A206996 002</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A206996 003</u>	Mar 22, 2017

ZOSYN

<u>AP</u>	+!	WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684 001</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684 002</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684 003</u>	Oct 22, 1993
<u>AP</u>	+!		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684 004</u>	Oct 22, 1993
		ZOSYN IN PLASTIC CONTAINER			
	+!	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001	Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002	Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003	Feb 24, 1998

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

SANDOZ INC

EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL A203557 001 Oct 29, 2014

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+! GENENTECH INC 267MG N022535 001 Oct 15, 2014

TABLET; ORAL

ESBRIET

+ GENENTECH INC 267MG N208780 001 Jan 11, 2017

+! 801MG N208780 003 Jan 11, 2017

PIROXICAM

CAPSULE; ORAL

FELDENE

<u>AB</u>	+	PFIZER	<u>10MG</u>	<u>N018147 002</u>	Apr 06, 1982
<u>AB</u>	+!		<u>20MG</u>	<u>N018147 003</u>	Apr 06, 1982

PIROXICAM

<u>AB</u>		FLAMINGO PHARMS	<u>10MG</u>	<u>A207938 001</u>	Sep 09, 2016
<u>AB</u>			<u>20MG</u>	<u>A207938 002</u>	Sep 09, 2016
<u>AB</u>		HIKMA PHARMS	<u>10MG</u>	<u>A209256 001</u>	Aug 11, 2017
<u>AB</u>			<u>20MG</u>	<u>A209256 002</u>	Aug 11, 2017
<u>AB</u>	+	MICRO LABS	<u>10MG</u>	<u>A206152 001</u>	Dec 29, 2017
<u>AB</u>	+		<u>20MG</u>	<u>A206152 002</u>	Dec 29, 2017
<u>AB</u>		MYLAN IRELAND LTD	<u>10MG</u>	<u>A074116 001</u>	Jun 15, 1993
<u>AB</u>			<u>20MG</u>	<u>A074118 001</u>	Jun 15, 1993
<u>AB</u>		PII	<u>10MG</u>	<u>A206136 001</u>	Jun 20, 2017
<u>AB</u>			<u>20MG</u>	<u>A206136 002</u>	Jun 20, 2017
<u>AB</u>		SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A073536 002</u>	Jan 23, 2008
<u>AB</u>			<u>20MG</u>	<u>A073536 001</u>	Mar 12, 1993
<u>AB</u>		TEVA	<u>10MG</u>	<u>A074131 001</u>	Dec 11, 1992
<u>AB</u>			<u>20MG</u>	<u>A074131 002</u>	Dec 11, 1992
<u>AB</u>		UNICHEM LABS LTD	<u>10MG</u>	<u>A208340 001</u>	Apr 13, 2017
<u>AB</u>			<u>20MG</u>	<u>A208340 002</u>	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

<u>AB</u>	+	KOWA CO	<u>EQ 1MG BASE</u>	<u>N022363 001</u>	Aug 03, 2009
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N022363 002</u>	Aug 03, 2009
<u>AB</u>	+!		<u>EQ 4MG BASE</u>	<u>N022363 003</u>	Aug 03, 2009

PITAVASTATIN CALCIUM

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 1MG BASE</u>	<u>A206015 001</u>	Dec 20, 2016
-----------	--	------------------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

LTD

<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A206015 002</u>	Dec 20, 2016
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A206015 003</u>	Dec 20, 2016
<u>AB</u>	ORIENT PHARMA CO LTD	<u>EQ 1MG BASE</u>	<u>A205932 001</u>	Feb 03, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205932 002</u>	Feb 03, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205932 003</u>	Feb 03, 2017
<u>AB</u>	SAWAI USA	<u>EQ 1MG BASE</u>	<u>A205955 001</u>	Feb 03, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205955 002</u>	Feb 03, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205955 003</u>	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379 001	Jul 14, 2017
+		EQ 2MG BASE	N208379 002	Jul 14, 2017
+	!	EQ 4MG BASE	N208379 003	Jul 14, 2017

PLECANATIDE

TABLET;ORAL

TRULANCE

+	!	SYNERGY PHARMS	3MG	N208745 001	Jan 19, 2017
---	---	----------------	-----	-------------	--------------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

+	!	GENZYME	24MG/1.2ML (20MG/ML)	N022311 001	Dec 15, 2008
---	---	---------	----------------------	-------------	--------------

PODOFILOX

GEL;TOPICAL

CONDYLOX

+	!	ALLERGAN SALES LLC	0.5%	N020529 001	Mar 13, 1997
---	---	--------------------	------	-------------	--------------

SOLUTION;TOPICAL

CONDYLOX

<u>AT</u>	+	!	ALLERGAN SALES LLC	<u>0.5%</u>	<u>N019795 001</u>	Dec 13, 1990
<u>AT</u>	+	!	PADDOCK LLC	<u>0.5%</u>	<u>A075600 001</u>	Jan 29, 2002

POLIDOCANOL

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

VARITHENA

+	!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098 002	Dec 21, 2017
---	---	-----------	-------------------------	-------------	--------------

SOLUTION;INTRAVENOUS

ASCLERA

+		CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201 001	Mar 30, 2010
---	--	-------------------------	-------------------	-------------	--------------

+	!		20MG/2ML (10MG/ML)	N021201 002	Mar 30, 2010
---	---	--	--------------------	-------------	--------------

VARITHENA

+	!	PROVENSIS	180MG/18ML (10MG/ML)	N205098 001	Nov 25, 2013
---	---	-----------	----------------------	-------------	--------------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

<u>AA</u>		KREMERS URBAN PHARMS	<u>17GM/SCOOPFUL</u>	<u>A076652 001</u>	Jul 02, 2004
<u>AA</u>		BRECKENRIDGE PHARM	<u>17GM/SCOOPFUL</u>	<u>A077736 001</u>	May 26, 2006
<u>AA</u>		NEXGEN PHARMA INC	<u>17GM/SCOOPFUL</u>	<u>A077706 001</u>	Sep 27, 2006
<u>AA</u>		PADDOCK LLC	<u>17GM/SCOOPFUL</u>	<u>A077893 001</u>	May 26, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKS

<u>AA</u>		PADDOCK LLC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A079232 001</u>	Feb 25, 2010
-----------	--	-------------	---	--------------------	--------------

NULYTELY

<u>AA</u>	+	!	BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>N019797 001</u>	Apr 22, 1991
-----------	---	---	-----------	---	--------------------	--------------

NULYTELY-FLAVORED

<u>AA</u>	+	!	BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>N019797 002</u>	Nov 18, 1994
-----------	---	---	-----------	---	--------------------	--------------

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

<u>AA</u>		NOVEL LABS INC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2</u>	<u>A090019 001</u>	May 27, 2009
-----------	--	----------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

		<u>GM/BOT</u>			
<u>AA</u>	STRIDES PHARMA	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A204559 001</u>	Apr 13, 2015	
		<u>BOT</u>			
		<u>PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE</u>			
<u>AA</u>	BRECKENRIDGE PHARM	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A202060 001</u>	Mar 08, 2017	
		<u>BOT</u>			
		<u>TRILYTE</u>			
<u>AA</u>	MYLAN PHARMS INC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A076491 001</u>	Feb 05, 2004	
		<u>BOT</u>			

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

<u>AA</u>	MYLAN SPECIALITY LP	<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>N018983 012</u>	Oct 08, 1998	
		<u>GOLYTELY</u>			
<u>AA</u>	+! BRAINTREE	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>N019011 001</u>	Jul 13, 1984	
		<u>PEG 3350 AND ELECTROLYTES</u>			
<u>AA</u>	NOVEL LABS INC	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>A090231 001</u>	Jun 01, 2009	
<u>AA</u>		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>A090186 001</u>	Jun 01, 2009	
		<u>GOLYTELY</u>			
	+! BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011 002	Jun 02, 1992	

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

<u>AP</u>	SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A090110 001</u>	Jun 29, 2011	
		<u>POLYMYXIN B SULFATE</u>			
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A206589 001</u>	Apr 04, 2016	
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A065372 001</u>	Jan 10, 2008	
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A207322 001</u>	Apr 14, 2016	
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A060716 001</u>		
<u>AP</u>	X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A063000 001</u>	Sep 30, 1994	
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A202766 001</u>	Jan 15, 2014	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

<u>AT</u>	+! ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>N050567 001</u>	Oct 20, 1988	
		<u>TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE</u>			
<u>AT</u>	AKORN INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A065006 001</u>	Dec 17, 1998	
<u>AT</u>	BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064120 001</u>	Feb 14, 1997	
<u>AT</u>	SANDOZ INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064211 001</u>	Apr 13, 1998	

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

	+ CELGENE	1MG	N204026 001	Feb 08, 2013	
		2MG	N204026 002	Feb 08, 2013	
		3MG	N204026 003	Feb 08, 2013	
	+!	4MG	N204026 004	Feb 08, 2013	

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	+ ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012	
		EQ 30MG BASE	N203469 003	Apr 23, 2015	
	+!	EQ 45MG BASE	N203469 002	Dec 14, 2012	

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+! CHIESI USA INC	80MG/ML	N020744 001	Nov 18, 1999	
--	-------------------	---------	-------------	--------------	--

PRESCRIPTION DRUG PRODUCT LIST

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

CONCORDIA LABS INC 75MG/VIAL

N020451 001 Dec 27, 1995

POSACONAZOLE

SOLUTION; IV (INFUSION)

NOXAFIL

+! MERCK SHARP DOHME 300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014

SUSPENSION; ORAL

NOXAFIL

+! SCHERING 40MG/ML

N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

+! MERCK SHARP DOHME 100MG

N205053 001 Nov 25, 2013

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE**AP** EXELA PHARMA SCS **2MEQ/ML****A206203 001** Dec 29, 2015

LLC

AP +! HOSPIRA **2MEQ/ML****N018896 001** Jul 20, 1984POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON**AB** UPSHER-SMITH LABS **8MEQ****A203106 001** Jul 10, 2015**AB** **10MEQ****A203106 002** Jul 10, 2015MICRO-K**AB** + NESHER PHARMS **8MEQ****N018238 001**MICRO-K 10**AB** + NESHER PHARMS **10MEQ****N018238 002** May 14, 1984POTASSIUM CHLORIDE**AB** ACTAVIS LABS FL INC **8MEQ****A077419 001** Jun 02, 2008**AB** ! **10MEQ****A077419 002** Jun 02, 2008**AB** ADARE PHARMS INC **8MEQ****A208864 001** Mar 17, 2017**AB** **10MEQ****A208864 002** Mar 17, 2017**AB** AMNEAL PHARMS **10MEQ****A202128 001** Feb 22, 2013**AB** ANCHEN PHARMS **8MEQ****A202886 001** Dec 26, 2013**AB** **10MEQ****A202886 002** Dec 26, 2013**AB** GLENMARK PHARMS LTD **10MEQ****A202868 001** Jan 19, 2016**AB** KREMERS URBAN **8MEQ****A204210 001** Mar 28, 2016

PHARMS

AB **10MEQ****A204210 002** Mar 28, 2016**AB** LUPIN LTD **8MEQ****A203002 001** Dec 18, 2015**AB** **10MEQ****A203002 002** Dec 18, 2015**AB** NOVEL LABS INC **8MEQ****A204828 001** Aug 16, 2016**AB** **10MEQ****A204828 002** Aug 16, 2016**AB** PADDOCK LLC **8MEQ****A200185 001** May 18, 2011**AB** **10MEQ****A200185 002** May 18, 2011**AB** PII **8MEQ****A205549 001** Dec 08, 2015**AB** **10MEQ****A205549 002** Dec 08, 2015**AB** TRIS PHARMA INC **8MEQ****A201944 001** Mar 04, 2016**AB** **10MEQ****A201944 002** Mar 04, 2016

FOR SOLUTION; ORAL

KLOR-CON**AA** UPSHER-SMITH LABS **20MEQ****A209662 001** Oct 23, 2017POTASSIUM CHLORIDE**AA** +! PHARMA RES SOFTWARE **20MEQ****N208019 001** Aug 19, 2015

INJECTABLE; INJECTION

POTASSIUM CHLORIDE**AP** B BRAUN **2MEQ/ML****A085870 001****AP** FRESENIUS KABI USA **2MEQ/ML****A080225 001****AP** ! HOSPIRA **2MEQ/ML****A080205 001**POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER**AP** +! BAXTER HLTHCARE **14.9MG/ML****N019904 001** Dec 26, 1989**AP** +! **746MG/100ML****N019904 005** Dec 17, 1990**AP** + ICU MEDICAL INC **14.9MG/ML****N020161 005** Nov 30, 1992**AP** + **745MG/100ML****N020161 001** Nov 30, 1992POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER**AP** +! BAXTER HLTHCARE **29.8MG/ML****N019904 002** Dec 26, 1989**AP** +! **1.49GM/100ML****N019904 006** Dec 17, 1990**AP** +! ICU MEDICAL INC **29.8MG/ML****N020161 006** Aug 11, 1998**AP** + **1.49GM/100ML****N020161 002** Nov 30, 1992

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

<u>AP</u>	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>2.24GM/100ML</u>	<u>N019904</u>	<u>003</u>	Dec 26, 1989
<u>AP</u>	<u>+!</u>	<u>ICU MEDICAL INC</u>	<u>2.24GM/100ML</u>	<u>N020161</u>	<u>003</u>	Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>2.98GM/100ML</u>	<u>N019904</u>	<u>004</u>	Dec 26, 1989
<u>AP</u>	<u>+!</u>	<u>ICU MEDICAL INC</u>	<u>2.98GM/100ML</u>	<u>N020161</u>	<u>004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>2MEQ/ML</u>	<u>A088901</u>	<u>001</u>	Jan 25, 1985
<u>AP</u>			<u>2MEQ/ML</u>	<u>A088908</u>	<u>001</u>	Jan 25, 1985

POTASSIUM CHLORIDE

! FRESENIUS KABI USA 3MEQ/ML

A080225 003

SOLUTION; ORAL

POTASSIUM CHLORIDE

+ GENUS LIFESCIENCES 20MEQ/15ML

N206814 001 Dec 22, 2014

+! 40MEQ/15ML

N206814 002 Dec 22, 2014

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10

<u>AB1</u>		<u>UPSHER-SMITH LABS</u>	<u>10MEQ</u>	<u>A074726</u>	<u>002</u>	Aug 09, 2000
------------	--	--------------------------	--------------	----------------	------------	--------------

KLOR-CON M20

<u>AB1</u>	<u>!</u>	<u>UPSHER-SMITH LABS</u>	<u>20MEQ</u>	<u>A074726</u>	<u>001</u>	Nov 20, 1998
------------	----------	--------------------------	--------------	----------------	------------	--------------

POTASSIUM CHLORIDE

<u>AB1</u>		<u>ACTAVIS LABS FL INC</u>	<u>10MEQ</u>	<u>A075604</u>	<u>001</u>	Apr 10, 2002
------------	--	----------------------------	--------------	----------------	------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A075604</u>	<u>002</u>	Apr 10, 2002
------------	--	--	--------------	----------------	------------	--------------

<u>AB1</u>		<u>ADARE PHARMS INC</u>	<u>20MEQ</u>	<u>A076368</u>	<u>001</u>	Aug 18, 2004
------------	--	-------------------------	--------------	----------------	------------	--------------

<u>AB1</u>		<u>GLENMARK PHARMS LTD</u>	<u>10MEQ</u>	<u>A203562</u>	<u>001</u>	Jul 26, 2016
------------	--	----------------------------	--------------	----------------	------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A203562</u>	<u>002</u>	Jul 26, 2016
------------	--	--	--------------	----------------	------------	--------------

<u>AB1</u>		<u>NOVEL LABS INC</u>	<u>10MEQ</u>	<u>A206347</u>	<u>001</u>	Jan 21, 2016
------------	--	-----------------------	--------------	----------------	------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A206347</u>	<u>002</u>	Jan 21, 2016
------------	--	--	--------------	----------------	------------	--------------

KLOR-CON

<u>AB2</u>	<u>+</u>	<u>UPSHER-SMITH LABS</u>	<u>8MEQ</u>	<u>N019123</u>	<u>001</u>	Apr 17, 1986
------------	----------	--------------------------	-------------	----------------	------------	--------------

<u>AB2</u>	<u>+!</u>		<u>10MEQ</u>	<u>N019123</u>	<u>002</u>	Apr 17, 1986
------------	-----------	--	--------------	----------------	------------	--------------

POTASSIUM CHLORIDE

<u>AB2</u>		<u>MYLAN PHARMS INC</u>	<u>8MEQ</u>	<u>A204662</u>	<u>001</u>	Aug 21, 2014
------------	--	-------------------------	-------------	----------------	------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A204662</u>	<u>002</u>	Aug 21, 2014
------------	--	--	--------------	----------------	------------	--------------

<u>AB2</u>		<u>NOVEL LABS INC</u>	<u>8MEQ</u>	<u>A206759</u>	<u>001</u>	Aug 09, 2016
------------	--	-----------------------	-------------	----------------	------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A206759</u>	<u>002</u>	Aug 09, 2016
------------	--	--	--------------	----------------	------------	--------------

<u>AB2</u>		<u>PADDOCK LLC</u>	<u>8MEQ</u>	<u>A205993</u>	<u>001</u>	Nov 05, 2015
------------	--	--------------------	-------------	----------------	------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A205993</u>	<u>002</u>	Nov 05, 2015
------------	--	--	--------------	----------------	------------	--------------

<u>AB2</u>		<u>SIGMAPHARM LABS LLC</u>	<u>8MEQ</u>	<u>A207528</u>	<u>001</u>	Aug 19, 2016
------------	--	----------------------------	-------------	----------------	------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A207528</u>	<u>002</u>	Aug 19, 2016
------------	--	--	--------------	----------------	------------	--------------

K-TAB

BC	<u>+</u>	<u>ABEVIE</u>	<u>8MEQ</u>	<u>N018279</u>	<u>002</u>	Aug 01, 1988
----	----------	---------------	-------------	----------------	------------	--------------

BC	<u>+</u>		<u>10MEQ</u>	<u>N018279</u>	<u>001</u>	
----	----------	--	--------------	----------------	------------	--

BC	<u>+!</u>		<u>20MEQ</u>	<u>N018279</u>	<u>003</u>	Nov 25, 2013
----	-----------	--	--------------	----------------	------------	--------------

KLOR-CON M15

UPSHER-SMITH LABS 15MEQ

A074726 003 Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>		<u>ICU MEDICAL INC</u>	<u>149MG/100ML; 450MG/100ML</u>	<u>A078446</u>	<u>001</u>	Sep 10, 2008
-----------	--	------------------------	---------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>150MG/100ML; 450MG/100ML</u>	<u>N017648</u>	<u>005</u>	Nov 26, 2002
-----------	-----------	------------------------	---------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		<u>B BRAUN</u>	<u>150MG/100ML; 900MG/100ML</u>	<u>N019708</u>	<u>004</u>	Sep 29, 1989
-----------	--	----------------	---------------------------------	----------------	------------	--------------

<u>AP</u>	<u>+</u>	<u>BAXTER HLTHCARE</u>	<u>150MG/100ML; 900MG/100ML</u>	<u>N017648</u>	<u>001</u>	
-----------	----------	------------------------	---------------------------------	----------------	------------	--

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	<u>+</u>	<u>BAXTER HLTHCARE</u>	<u>300MG/100ML; 900MG/100ML</u>	<u>N017648</u>	<u>002</u>	
-----------	----------	------------------------	---------------------------------	----------------	------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		<u>ICU MEDICAL INC</u>	<u>149MG/100ML; 900MG/100ML</u>	<u>N019686</u>	<u>001</u>	Oct 17, 1988
-----------	--	------------------------	---------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		<u>ICU MEDICAL INC</u>	<u>298MG/100ML; 900MG/100ML</u>	<u>N019686</u>	<u>002</u>	Oct 17, 1988
-----------	--	------------------------	---------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%

+ BAXTER HLTHCARE 224MG/100ML; 900MG/100ML

N017648 003

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

<u>AB</u>	COREPHARMA	<u>5MEO</u>	<u>A077440 001</u>	Jun 09, 2006
<u>AB</u>		<u>10MEO</u>	<u>A077440 002</u>	Jun 09, 2006
<u>AB</u>	STRIDES PHARMA	<u>5MEO</u>	<u>A206813 001</u>	Sep 11, 2017
<u>AB</u>		<u>10MEO</u>	<u>A206813 002</u>	Sep 11, 2017
<u>AB</u>		<u>15MEO</u>	<u>A206813 003</u>	Sep 11, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MEO</u>	<u>A203546 001</u>	Aug 06, 2014
<u>AB</u>		<u>10MEO</u>	<u>A203546 002</u>	Aug 06, 2014
<u>AB</u>		<u>15MEO</u>	<u>A203546 003</u>	Aug 06, 2014
<u>UROCIIT-K</u>				
<u>AB</u>	+ MISSION PHARMA	<u>5MEO</u>	<u>N019071 001</u>	Aug 30, 1985
<u>AB</u>	+ "	<u>10MEO</u>	<u>N019071 002</u>	Aug 31, 1992
<u>AB</u>	+!	<u>15MEO</u>	<u>N019071 003</u>	Dec 30, 2009

POVIDONE-IODINESOLUTION/DROPS;OPHTHALMIC
BETADINE

+! ALCON PHARMS LTD 5% N018634 001 Dec 17, 1986

PRALATREXATESOLUTION;INTRAVENOUS
FOLOTYN+ ALLOS 20MG/ML (20MG/ML) N022468 001 Sep 24, 2009
+! 40MG/2ML (20MG/ML) N022468 002 Sep 24, 2009PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE

+! MERIDIAN MEDCL 300MG/ML N018986 001 Apr 26, 1983
TECHN

PROTOPAM CHLORIDE

+! BAXTER HLTHCARE 1GM/VIAL N014134 001
CORPPRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667 001</u>	Jul 01, 1997
<u>AB</u>	+!	<u>0.25MG</u>	<u>N020667 002</u>	Jul 01, 1997
<u>AB</u>	+ "	<u>0.5MG</u>	<u>N020667 006</u>	Feb 12, 1998
<u>AB</u>	+ "	<u>0.75MG</u>	<u>N020667 007</u>	Jul 30, 2007
<u>AB</u>	+ "	<u>1MG</u>	<u>N020667 003</u>	Jul 01, 1997
<u>AB</u>	+ "	<u>1.5MG</u>	<u>N020667 005</u>	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.125MG</u>	<u>A078894 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894 005</u>	Oct 08, 2010
<u>AB</u>	APOTEX INC	<u>0.125MG</u>	<u>A090151 001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151 002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151 003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151 006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151 004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151 005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633 001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633 002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633 003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633 004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633 005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633 006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724 001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724 002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724 003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724 004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724 005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450 004</u>	Oct 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>1.5MG</u>	<u>A091450 005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090781 006</u>	Sep 11, 2015
<u>AB</u>		<u>1MG</u>	<u>A090781 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781 005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164 001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164 002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164 003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164 004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164 005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764 001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854 005</u>	Oct 08, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A091683 001</u>	Mar 27, 2013
<u>AB</u>		<u>0.25MG</u>	<u>A091683 002</u>	Mar 27, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091683 003</u>	Mar 27, 2013
<u>AB</u>		<u>0.75MG</u>	<u>A091683 004</u>	Mar 27, 2013
<u>AB</u>		<u>1MG</u>	<u>A091683 005</u>	Mar 27, 2013
<u>AB</u>		<u>1.5MG</u>	<u>A091683 006</u>	Mar 27, 2013
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090241 006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865 006</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920 003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920 005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421 001</u>	Feb 19, 2010
<u>AB</u>	+		<u>0.75MG</u>	<u>N022421 002</u>	Feb 19, 2010
<u>AB</u>	+		<u>1.5MG</u>	<u>N022421 003</u>	Feb 19, 2010
<u>AB</u>	+		<u>2.25MG</u>	<u>N022421 006</u>	Jun 17, 2011
<u>AB</u>	+		<u>3MG</u>	<u>N022421 004</u>	Feb 19, 2010
<u>AB</u>	+		<u>3.75MG</u>	<u>N022421 007</u>	Jun 17, 2011
<u>AB</u>	+		<u>4.5MG</u>	<u>N022421 005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.375MG</u>	<u>A201963 001</u>	Apr 21, 2016
<u>AB</u>			<u>0.75MG</u>	<u>A201963 002</u>	Apr 21, 2016
<u>AB</u>			<u>1.5MG</u>	<u>A201963 003</u>	Apr 21, 2016
<u>AB</u>			<u>2.25MG</u>	<u>A203615 001</u>	Oct 14, 2016
<u>AB</u>			<u>3MG</u>	<u>A201963 004</u>	Apr 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>3.75MG</u>	<u>A203615</u>	<u>002</u>	Jan 03, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A201963</u>	<u>005</u>	Apr 21, 2016
<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206</u>	<u>001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206</u>	<u>002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206</u>	<u>003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206</u>	<u>004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206</u>	<u>005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206</u>	<u>006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206</u>	<u>007</u>	Feb 06, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>0.375MG</u>	<u>A203354</u>	<u>001</u>	Aug 07, 2015
<u>AB</u>		<u>0.75MG</u>	<u>A203354</u>	<u>002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354</u>	<u>003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354</u>	<u>004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354</u>	<u>005</u>	Aug 07, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.375MG</u>	<u>A206156</u>	<u>001</u>	Jun 24, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A206156</u>	<u>002</u>	Jun 24, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A206156</u>	<u>003</u>	Jun 24, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A206156</u>	<u>004</u>	Jun 24, 2016
<u>AB</u>		<u>3MG</u>	<u>A206156</u>	<u>005</u>	Jun 24, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A206156</u>	<u>007</u>	Jan 23, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A206156</u>	<u>006</u>	Jun 24, 2016
<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353</u>	<u>001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353</u>	<u>002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353</u>	<u>003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353</u>	<u>004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353</u>	<u>005</u>	Dec 04, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.375MG</u>	<u>A202891</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		<u>0.75MG</u>	<u>A202891</u>	<u>002</u>	Dec 12, 2017
<u>AB</u>		<u>1.5MG</u>	<u>A202891</u>	<u>003</u>	Dec 12, 2017
<u>AB</u>		<u>2.25MG</u>	<u>A202891</u>	<u>004</u>	Dec 12, 2017
<u>AB</u>		<u>3MG</u>	<u>A202891</u>	<u>005</u>	Dec 12, 2017
<u>AB</u>		<u>3.75MG</u>	<u>A202891</u>	<u>006</u>	Dec 12, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A202891</u>	<u>007</u>	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+ ASTRAZENECA AB

+!

EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)

EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)

N021332 002 Sep 25, 2007

N021332 003 Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+! AMAG PHARMS INC

6.5MG

N208470 001 Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENTAB + ELI LILLY AND COAB +!EQ 5MG BASEEQ 10MG BASEN022307 001 Jul 10, 2009N022307 002 Jul 10, 2009PRASUGRELAB AUROBINDO PHARMA
LTDABAB LIBERTY PHARMA INCABAB MYLAN PHARMS INCABAB PANACEA BIOTEC LTDABEQ 5MG BASEEQ 10MG BASEEQ 5MG BASEEQ 10MG BASEEQ 5MG BASEEQ 10MG BASEEQ 5MG BASEEQ 10MG BASEA205888 001 Oct 16, 2017A205888 002 Oct 16, 2017A205790 001 Oct 16, 2017A205790 002 Oct 16, 2017A205927 001 Jul 12, 2017A205927 002 Jul 12, 2017A205897 001 Oct 16, 2017A205897 002 Oct 16, 2017PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOLAB + BRISTOL MYERS
SQUIBBAB +AB +!20MG40MG80MGN019898 003 Oct 31, 1991N019898 004 Mar 22, 1993N019898 008 Dec 18, 2001PRAVASTATIN SODIUMAB ACCORD HLTHCAREAB10MG20MGA207068 001 Nov 17, 2016A207068 002 Nov 17, 2016

PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>40MG</u>	<u>A207068</u>	<u>003</u>	Nov 17, 2016
<u>AB</u>		<u>80MG</u>	<u>A207068</u>	<u>004</u>	Nov 17, 2016
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A203367</u>	<u>001</u>	Feb 02, 2017
<u>AB</u>		<u>20MG</u>	<u>A203367</u>	<u>002</u>	Feb 02, 2017
<u>AB</u>		<u>40MG</u>	<u>A203367</u>	<u>003</u>	Feb 02, 2017
<u>AB</u>		<u>80MG</u>	<u>A203367</u>	<u>004</u>	Feb 02, 2017
<u>AB</u>	CIPLA LTD	<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077904</u>	<u>004</u>	Mar 22, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187</u>	<u>001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187</u>	<u>002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187</u>	<u>003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187</u>	<u>004</u>	May 27, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076397</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

<u>AB</u>	+	BAYER HLTHCARE	<u>600MG</u>	<u>N018714</u>	<u>001</u>	Dec 29, 1982
<u>AB</u>		PAR PHARM INC	<u>600MG</u>	<u>A208820</u>	<u>001</u>	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	+	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>	+		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989
<u>AB</u>		TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071745</u>	<u>002</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A071745</u>	<u>003</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT**AB** +! VALEANT BERMUDA **0.1%** **N020279 001** Oct 29, 1993PREDNICARBATE**AB** FOUGERA PHARMS **0.1%** **A077287 001** Sep 19, 2006

OINTMENT; TOPICAL

DERMATOP**AB** +! VALEANT PHARMS **0.1%** **N019568 001** Sep 23, 1991

NORTH

PREDNICARBATE**AB** FOUGERA PHARMS **0.1%** **A077236 001** Mar 09, 2007PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE**AA** ! HI TECH PHARMA CO **15MG/5ML** **A040401 001** Feb 27, 2003**AA** PHARM ASSOC **15MG/5ML** **A040399 001** Mar 05, 2003**AA** VINTAGE **15MG/5ML** **A040775 001** Sep 21, 2007**AA** VISTAPHARM **15MG/5ML** **A040323 001** May 13, 1999**AA** WOCKHARDT BIO AG **15MG/5ML** **A040313 001** Sep 10, 2003PRELONE**AA** TEVA **15MG/5ML** **A089081 001** Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

! WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED**AB** NOVARTIS PHARMS **1%** **N017469 001**

CORP

PRED FORTE**AB** +! ALLERGAN **1%** **N017011 001**

PRED MILD

+! ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

! ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+! ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED**AA** +! SETON PHARM **EQ 5MG BASE/5ML** **N019157 001** May 28, 1986PREDNISOLONE SODIUM PHOSPHATE**AA** CHARTWELL RX **EQ 5MG BASE/5ML** **A075988 001** May 25, 2004**AA** EDENBRIDGE PHARMS **EQ 10MG BASE/5ML** **A203559 001** Dec 20, 2016**AA** **EQ 20MG BASE/5ML** **A203559 002** Dec 20, 2016**AA** HI TECH PHARMA **EQ 5MG BASE/5ML** **A075183 001** Mar 26, 2003**AA** ! PHARM ASSOC **EQ 10MG BASE/5ML** **A078465 001** Mar 07, 2008**AA** **EQ 15MG BASE/5ML** **A076913 001** Apr 25, 2005**AA** ! **EQ 20MG BASE/5ML** **A078988 001** Jun 09, 2008**AA** VINTAGE **EQ 15MG BASE/5ML** **A079010 001** May 26, 2009**AA** ! WOCKHARDT **EQ 15MG BASE/5ML** **A076895 001** Oct 04, 2004**AA** WOCKHARDT BIO AG **EQ 5MG BASE/5ML** **A075099 001** Jun 28, 2002

! MISSION PHARMA

EQ 25MG BASE/5ML

A091396 001 Sep 13, 2010

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT**AB** + CONCORDIA PHARMS **EQ 10MG BASE** **N021959 001** Jun 01, 2006

INC

AB + **EQ 15MG BASE** **N021959 002** Jun 01, 2006**AB** +! **EQ 30MG BASE** **N021959 003** Jun 01, 2006PREDNISOLONE SODIUM PHOSPHATE**AB** MYLAN PHARMS INC **EQ 10MG BASE** **A202179 001** Apr 10, 2013**AB** **EQ 15MG BASE** **A202179 002** Apr 10, 2013**AB** **EQ 30MG BASE** **A202179 003** Apr 10, 2013

PRESCRIPTION DRUG PRODUCT LIST

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449 001	Dec 29, 1995
AT		SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630 001	May 27, 1993

PREDNISONE

SOLUTION;ORAL

PREDNISONE

!	WEST-WARD PHARMS	5MG/5ML	A088703 001	Nov 08, 1984
---	------------------	---------	-------------	--------------

INT

PREDNISONE INTENSOL

!	WEST-WARD PHARMS	5MG/ML	A088810 001	Feb 20, 1985
---	------------------	--------	-------------	--------------

INT

TABLET;ORAL

PREDNISONE

AB		HIKMA PHARMS	2.5MG	A040538 001	Jan 08, 2004
AB			50MG	A088465 001	Jun 01, 1984
AB		JUBILANT CADISTA	1MG	A040611 001	Jun 06, 2005
AB			5MG	A040362 002	Aug 29, 2001
AB			10MG	A040362 001	Aug 29, 2001
AB			20MG	A040362 003	Jun 29, 2005
AB		MUTUAL PHARM	5MG	A089245 001	Dec 04, 1985
AB		MYLAN PHARMS INC	5MG	A080292 001	
AB			10MG	A088832 001	Dec 04, 1985
AB			20MG	A083677 001	
AB		SUN PHARM	10MG	A089246 001	Dec 04, 1985
		INDUSTRIES			
AB			20MG	A089247 001	Dec 04, 1985
AB		VINTAGE PHARMS	1MG	A040584 001	Dec 21, 2004
AB			2.5MG	A040581 001	Dec 21, 2004
AB			5MG	A040256 001	Jul 12, 2002
AB			10MG	A040256 002	Jul 12, 2002
AB			20MG	A040392 001	Feb 12, 2003
AB		WATSON LABS	5MG	A080356 001	
AB			10MG	A085162 001	
AB			20MG	A085161 001	
AB	!	WEST-WARD PHARMS	1MG	A087800 001	Apr 22, 1982
		INT			
AB	!		2.5MG	A087801 001	Apr 22, 1982
AB	!		5MG	A080352 001	
AB	!		10MG	A084122 001	
AB	!		20MG	A087342 001	
AB	!		50MG	A084283 001	

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

AB		ACTAVIS LABS FL INC	1MG	A204867 001	Apr 25, 2017
AB			2MG	A204867 002	Apr 25, 2017
AB			5MG	A204867 003	Apr 25, 2017

RAYOS

AB	+	HORIZON PHARMA	1MG	N202020 001	Jul 26, 2012
AB	+		2MG	N202020 002	Jul 26, 2012
AB	+		5MG	N202020 003	Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICA

+	PF PRISM CV	25MG	N021446 001	Dec 30, 2004
+		50MG	N021446 002	Dec 30, 2004
+		75MG	N021446 003	Dec 30, 2004
+		100MG	N021446 004	Dec 30, 2004
+		150MG	N021446 005	Dec 30, 2004
+		200MG	N021446 006	Dec 30, 2004
+		225MG	N021446 007	Dec 30, 2004
+	!	300MG	N021446 008	Dec 30, 2004

SOLUTION;ORAL

LYRICA

+	PF PRISM CV	20MG/ML	N022488 001	Jan 04, 2010
---	-------------	---------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

+	PFIZER INC	82.5MG	N209501 001	Oct 11, 2017
+		165MG	N209501 002	Oct 11, 2017
+	!	330MG	N209501 003	Oct 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

! SEPTODONT INC 4%

A079235 001 Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE**AB** +! SANOFI AVENTIS US **EQ 15MG BASE****N008316 001**PRIMAQUINE PHOSPHATE**AB** ALVOGEN INC **EQ 15MG BASE****A203924 001** Feb 03, 2014**AB** BAYSHORE PHARMS LLC **EQ 15MG BASE****A204476 001** Feb 25, 2014**AB** INGENUS PHARMS NJ **EQ 15MG BASE****A206043 001** Jun 23, 2016PRIMIDONE

TABLET; ORAL

MYSOLINE**AB** +! VALEANT **50MG****N009170 003****AB** + **250MG****N009170 002**PRIMIDONE**AB** AMNEAL PHARM **50MG****A040866 001** Apr 23, 2008**AB** **250MG****A040866 002** Apr 23, 2008**AB** ANDA REPOSITORY **50MG****A040626 001** Sep 29, 2005**AB** **250MG****A040626 002** Sep 29, 2005**AB** HIKMA INTL PHARMS **250MG****A040667 002** Jul 27, 2006**AB** LANNETT **50MG****A084903 002** May 24, 2001**AB** **250MG****A084903 001****AB** VINTAGE PHARMS **50MG****A040586 001** Feb 24, 2005**AB** **250MG****A040586 002** Feb 24, 2005**AB** WATSON LABS **250MG****A083551 001**PROBENECID

TABLET; ORAL

PROBALAN**AB** LANNETT **500MG****A080966 001**PROBENECID**AB** ! MYLAN **500MG****A084211 002****AB** WATSON LABS TEVA **500MG****A084442 004** Mar 29, 1983PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE**AP** ! HOSPIRA **100MG/ML****A089069 001** Feb 12, 1986**AP** INTL MEDICATION **100MG/ML****A088636 001** Jul 31, 1984**AP** NEXUS PHARMS **100MG/ML****A206332 001** Oct 13, 2017**AP** **500MG/ML****A206332 002** Oct 13, 2017

! HOSPIRA 500MG/ML

A089070 001 Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+! LEADIANT BIOSCI INC EQ 50MG BASE

N016785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO**AB** PADDOCK LLC **25MG****A040246 001** Jun 28, 2000PROCHLORPERAZINE**AB** ! G AND W LABS **25MG****A040058 001** Nov 24, 1993PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE**AP** ! EMCURE PHARMS LTD **EQ 5MG BASE/ML****A204147 001** Oct 15, 2013**AP** WEST-WARD PHARMS **EQ 5MG BASE/ML****A089903 001** Aug 29, 1989

INT

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE**AB** MYLAN **EQ 5MG BASE****A040185 002** Oct 28, 1996**AB** **EQ 10MG BASE****A040185 001** Oct 28, 1996**AB** SANDOZ **EQ 5MG BASE****A040101 001** Jul 19, 1996**AB** ! **EQ 10MG BASE****A040101 002** Jul 19, 1996**AB** TEVA PHARMS **EQ 5MG BASE****A040120 001** Jul 11, 1996**AB** **EQ 10MG BASE****A040120 002** Jul 11, 1996

PRESCRIPTION DRUG PRODUCT LIST

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	AMNEAL PHARMS NY	100MG	A207724 001	Sep 07, 2017
AB		200MG	A207724 002	Sep 07, 2017
AB	BIONPHARMA INC	100MG	A200900 001	Aug 16, 2013
AB		200MG	A200900 002	Aug 16, 2013
AB	DR REDDYS LABS INC	100MG	A208801 001	Feb 28, 2017
AB		200MG	A208801 002	Feb 28, 2017
AB	SANDOZ INC	100MG	A205229 001	Oct 20, 2017
AB		200MG	A205229 002	Oct 20, 2017
AB	SOFGEN PHARMS	100MG	A200456 001	Sep 28, 2012
AB		200MG	A200456 002	Sep 28, 2012
AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012
AB		200MG	A202121 002	Feb 29, 2012

PROMETRIUM

AB	+ VIRTUS PHARMS	100MG	N019781 001	May 14, 1998
AB	+!	200MG	N019781 002	Oct 15, 1999

GEL; VAGINAL

CRINONE

	+!	ALLERGAN SALES LLC	4%	N020701 001	Jul 31, 1997
	+!		8%	N020701 002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

AO	+!	ACTAVIS LABS UT INC	50MG/ML	N017362 002	
AO		FRESENIUS KABI USA	50MG/ML	A075906 001	Apr 25, 2001
AO		HIKMA FARMACEUTICA	50MG/ML	A091033 001	Oct 28, 2010
AO		LUITPOLD	50MG/ML	A090845 001	Jun 22, 2009

INSERT; VAGINAL

ENDOMETRIN

	+!	FERRING	100MG	N022057 001	Jun 21, 2007
--	----	---------	-------	-------------	--------------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	!	WEST-WARD PHARMS	25MG/ML	A083312 001	
		INT			
AP	!		50MG/ML	A083312 002	
AP		X-GEN PHARMS	25MG/ML	A040737 001	Apr 24, 2008
AP			50MG/ML	A040737 002	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		G AND W LABS	12.5MG	A040428 002	Mar 31, 2003
AB	!		25MG	A040428 001	Feb 05, 2002
AB		PERRIGO NEW YORK	12.5MG	A040500 001	Jun 30, 2003
AB			25MG	A040500 002	Jun 30, 2003
AB		TARO	12.5MG	A040603 001	Oct 26, 2006
AB			25MG	A040603 002	Oct 26, 2006
AB		WATSON LABS INC	12.5MG	A040479 001	Jun 24, 2003
AB			25MG	A040479 002	Jun 24, 2003

PROMETHEGAN

	!	G AND W LABS	50MG	A087165 001	Aug 14, 1987
--	---	--------------	------	-------------	--------------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	6.25MG/5ML	A040882 001	Dec 30, 2009
AA		HI TECH PHARMA	6.25MG/5ML	A040026 001	Sep 25, 1998
AA		NOSTRUM LABS INC	6.25MG/5ML	A040891 001	Mar 13, 2009
AA		TARO	6.25MG/5ML	A040718 001	Apr 04, 2007
AA		TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012
AA		VINTAGE	6.25MG/5ML	A040643 001	Apr 26, 2006

PROMETHAZINE PLAIN

AA	!	WOCKHARDT BIO AG	6.25MG/5ML	A087953 001	Nov 15, 1982
-----------	---	------------------	-------------------	--------------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	12.5MG	A091179 001	Dec 13, 2010
AB			25MG	A091179 002	Dec 13, 2010
AB			50MG	A091179 003	Dec 13, 2010
AB		HERITAGE PHARMA	12.5MG	A040673 001	Mar 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040712</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	STRIDES PHARMA	<u>12.5MG</u>	<u>A209177</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A209177</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>		<u>50MG</u>	<u>A209177</u>	<u>003</u>	Jun 30, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005
<u>AB</u>	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
		25MG	A040791	003	Feb 12, 2008

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	GLENMARK PHARMS LTD	<u>225MG</u>	<u>A205268</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>		<u>325MG</u>	<u>A205268</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>		<u>425MG</u>	<u>A205268</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>225MG</u>	<u>A203803</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>		<u>325MG</u>	<u>A203803</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>		<u>425MG</u>	<u>A203803</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
<u>AB</u>	WATSON LABS INC	<u>225MG</u>	<u>A202688</u>	<u>001</u>	Aug 24, 2015
<u>AB</u>		<u>325MG</u>	<u>A202688</u>	<u>002</u>	Aug 24, 2015
<u>AB</u>		<u>425MG</u>	<u>A202688</u>	<u>003</u>	Aug 24, 2015
	<u>RYTHMOL SR</u>				
<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>	+	<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202445</u>	<u>001</u>	May 11, 2016
<u>AB</u>		<u>225MG</u>	<u>A202445</u>	<u>002</u>	May 11, 2016
<u>AB</u>		<u>300MG</u>	<u>A202445</u>	<u>003</u>	May 11, 2016
<u>AB</u>	SUN PHARM INDUSTRIES	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000
	<u>RYTHMOL</u>				
<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151</u>	<u>001</u>	Nov 27, 1989
<u>AB</u>	+	<u>225MG</u>	<u>N019151</u>	<u>003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151</u>	<u>002</u>	Nov 27, 1989

PRESCRIPTION DRUG PRODUCT LIST

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

! WEST-WARD PHARMS 15MG

A080927 002

INT

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE**AT** ! NOVARTIS PHARMS 0.5%**A080027 001**

CORP

PROPARACAINE HYDROCHLORIDE**AT** AKORN INC 0.5%**A040277 001** Mar 16, 2000**AT** BAUSCH AND LOMB 0.5%**A040074 001** Sep 29, 1995PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN**AB** +! FRESENIUS KABI USA 10MG/ML**N019627 002** Jun 11, 1996PROPOFOL**AB** HOSPIRA 10MG/ML**A077908 001** Mar 17, 2006**AB** SAGENT PHARMS 10MG/ML**A075102 001** Jan 04, 1999**AB** WATSON LABS INC 10MG/ML**A205307 001** Dec 22, 2015PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA**AB** + ANI PHARMS INC 60MG**N018553 004** Mar 18, 1987**AB** + 80MG**N018553 002** Apr 19, 1983**AB** + 120MG**N018553 003** Apr 19, 1983**AB** +! 160MG**N018553 001** Apr 19, 1983PROPRANOLOL HYDROCHLORIDE**AB** ACTAVIS ELIZABETH 60MG**A078494 001** Aug 10, 2007**AB** 80MG**A078494 002** Aug 10, 2007**AB** 120MG**A078494 003** Aug 10, 2007**AB** 160MG**A078494 004** Aug 10, 2007**AB** MYLAN 60MG**A078022 001** Feb 15, 2007**AB** 80MG**A078022 002** Feb 15, 2007**AB** 120MG**A078022 003** Feb 15, 2007**AB** 160MG**A078022 004** Feb 15, 2007**AB** NORTEC DEV ASSOC 60MG**A078065 001** Jan 26, 2007**AB** 80MG**A078065 002** Jan 26, 2007**AB** 120MG**A078065 003** Jan 26, 2007**AB** 160MG**A078065 004** Jan 26, 2007**AB** RP SCHERER 60MG**A078703 001** Jul 15, 2011**AB** 80MG**A078703 002** Jul 15, 2011**AB** 120MG**A078703 003** Jul 15, 2011**AB** 160MG**A078703 004** Jul 15, 2011**AB** ZYDUS PHARMS USA 60MG**A090321 001** Mar 25, 2011**AB** 80MG**A090321 002** Mar 25, 2011**AB** 120MG**A090321 003** Mar 25, 2011**AB** 160MG**A090321 004** Mar 25, 2011

INNOPRAN XL

BX ANI PHARMS INC 80MG

N021438 001 Mar 12, 2003

BX 120MG

N021438 002 Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE**AP** ATHENEX INC 1MG/ML**A075792 001** Aug 29, 2000**AP** +! BAXTER HLTHCARE 1MG/ML**N016419 001**

CORP

AP FRESENIUS KABI USA 1MG/ML**A075826 001** Aug 31, 2001**AP** HIKMA FARMACEUTICA 1MG/ML**A077760 001** Jan 31, 2008

SOLUTION; ORAL

HEMANGEOL

+! PIERRE FABRE DERMA 4.28MG/ML

N205410 001 Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

! WEST-WARD PHARMS 20MG/5ML

A070979 001 May 15, 1987

INT

! 40MG/5ML

A070690 001 May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE**AB** IMPAX LABS INC 10MG**A071972 001** Apr 06, 1988**AB** 20MG**A071973 001** Apr 06, 1988**AB** 40MG**A071974 001** Apr 06, 1988

PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>60MG</u>	<u>A071975 001</u>	Apr 06, 1988
<u>AB</u>	!	<u>80MG</u>	<u>A071976 001</u>	Apr 06, 1988
<u>AB</u>	IPCA LABS LTD	<u>10MG</u>	<u>A078955 001</u>	Jun 02, 2008
<u>AB</u>		<u>20MG</u>	<u>A078955 002</u>	Jun 02, 2008
<u>AB</u>		<u>40MG</u>	<u>A078955 003</u>	Jun 02, 2008
<u>AB</u>		<u>60MG</u>	<u>A078955 004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955 005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213 002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213 003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213 001</u>	Nov 19, 1985
<u>AB</u>		<u>60MG</u>	<u>A070213 005</u>	Apr 08, 2011
<u>AB</u>		<u>80MG</u>	<u>A070213 004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213 001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213 002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213 003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213 004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213 005</u>	Jan 10, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070221 002</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070221 003</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070219 001</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070221 004</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070221 005</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221 001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175 001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176 001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177 001</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A070178 001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172 001	
BD	+! DAVA PHARMS INC	50MG	N006188 001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

!	FRESENIUS KABI USA	10MG/ML	A089454 001	Apr 07, 1987
---	--------------------	---------	-------------	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220 001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220 002</u>	Nov 19, 2012
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462 001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462 002</u>	May 03, 2010
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A078913 001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913 002</u>	Sep 16, 2008
	<u>VIVACTIL</u>			
<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644 001</u>	Aug 24, 1995
<u>AB</u>	!	<u>10MG</u>	<u>A073645 001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	AKORN	<u>500MG</u>	<u>A081319 001</u>	Jun 30, 1992
<u>AB</u>	! DAVA PHARMS INC	<u>500MG</u>	<u>A080157 001</u>	

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+! VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830 001</u>	
-----------	-----------------------	---------------	--------------------	--

REGONOL

<u>AP</u>	SANDOZ INC	<u>5MG/ML</u>	<u>N017398 001</u>	
-----------	------------	---------------	--------------------	--

SYRUP; ORAL

MESTINON

+	VALEANT PHARMS	60MG/5ML	N015193 001	
---	----------------	----------	-------------	--

TABLET; ORAL

MESTINON

<u>AB</u>	+! VALEANT PHARMS LLC	<u>60MG</u>	<u>N009829 002</u>	
-----------	-----------------------	-------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

<u>AB</u>	IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>	Apr 24, 2003
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A205650</u>	<u>001</u>	Jun 22, 2015

TABLET, EXTENDED RELEASE; ORAL

MESTINON

<u>AB</u>	+!	VALEANT PHARMS LLC	<u>180MG</u>	<u>N011665</u>	<u>001</u>
-----------	----	--------------------	--------------	----------------	------------

PYRIDOSTIGMINE BROMIDE

<u>AB</u>	ALVOGEN MALTA	<u>180MG</u>	<u>A204737</u>	<u>001</u>	Jun 26, 2015
<u>AB</u>	IMPAX LABS INC	<u>180MG</u>	<u>A203184</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>	KINEDEXE UK	<u>180MG</u>	<u>A205464</u>	<u>001</u>	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

<u>AP</u>	!	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080618</u>	<u>001</u>
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A204879</u>	<u>001</u>

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+!	VYERA PHARMS LLC	25MG	N008578	001
----	------------------	------	---------	-----

QUAZEPAM

TABLET; ORAL

DORAL

+!	CUTIS HEALTH LLC	15MG	N018708	001	Dec 27, 1985
----	------------------	------	---------	-----	--------------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203390</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203390</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203390</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203390</u>	<u>004</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203390</u>	<u>005</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203390</u>	<u>006</u>	Oct 28, 2014
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504</u>	<u>001</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201504</u>	<u>002</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201504</u>	<u>003</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201504</u>	<u>004</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201504</u>	<u>005</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201504</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201504</u>	<u>007</u>	Feb 12, 2013
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150</u>	<u>001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109</u>	<u>001</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203359 001</u>	May 17, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203359 002</u>	May 17, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203359 003</u>	May 17, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203359 004</u>	May 17, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203359 005</u>	May 17, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203359 006</u>	May 17, 2016
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A202674 001</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202674 002</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202674 003</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202674 004</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202674 005</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202674 006</u>	Mar 08, 2016
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 25MG BASE</u>	<u>A090120 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012

SEROQUEL

<u>AB</u>	+!	ASTRAZENECA PHARMS	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+!		<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>	+		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 50MG BASE</u>	<u>A206252 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090681 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090681 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090681 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090681 004</u>	Nov 01, 2016
<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A090757 001</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090757 002</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090757 003</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090757 004</u>	Dec 01, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE</u>	<u>A207655 001</u>	Nov 29, 2017

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A207655 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A207655 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A207655 004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207655 005</u>	Nov 29, 2017
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>EQ 50MG BASE</u>	<u>A202939 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A202939 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202939 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202939 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202939 005</u>	May 09, 2017
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204203 001</u>	May 17, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A204203 002</u>	May 17, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204203 003</u>	May 17, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204203 004</u>	May 17, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204203 005</u>	May 17, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A204253 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204253 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204253 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204253 004</u>	Nov 29, 2017
<u>AB</u>	NOVAST LABS LTD	<u>EQ 50MG BASE</u>	<u>A208947 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208947 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A208947 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A208947 004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208947 005</u>	Nov 29, 2017
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A090482 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090482 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090482 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090482 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090482 005</u>	May 09, 2017
<u>AB</u>	PHARMADAX INC	<u>EQ 50MG BASE</u>	<u>A206260 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A206260 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A206260 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206260 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A206260 005</u>	May 09, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A209635 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209635 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209635 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A209635 004</u>	Nov 29, 2017
<u>SEROQUEL XR</u>				
<u>AB</u>	+	ASTRAZENECA	<u>EQ 50MG BASE</u>	<u>N022047 001</u> May 17, 2007
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N022047 005</u> Aug 11, 2008
<u>AB</u>	+	!	<u>EQ 200MG BASE</u>	<u>N022047 002</u> May 17, 2007
<u>AB</u>	+		<u>EQ 300MG BASE</u>	<u>N022047 003</u> May 17, 2007
<u>AB</u>	+		<u>EQ 400MG BASE</u>	<u>N022047 004</u> May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

<u>AB</u>	+	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885 001</u> Nov 19, 1991
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N019885 002</u> Nov 19, 1991
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N019885 003</u> Nov 19, 1991
<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N019885 004</u> Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725 003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725 004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457 004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	PRINSTON INC	EQ 5MG BASE	A205823 001	Sep 15, 2016
AB		EQ 10MG BASE	A205823 002	Sep 15, 2016
AB		EQ 20MG BASE	A205823 003	Sep 15, 2016
AB		EQ 40MG BASE	A205823 004	Sep 15, 2016
AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607 001	Dec 15, 2004
AB		EQ 10MG BASE	A076607 002	Dec 15, 2004
AB		EQ 20MG BASE	A076607 003	Dec 15, 2004
AB		EQ 40MG BASE	A076607 004	Dec 15, 2004
AB	TEVA	EQ 5MG BASE	A075504 001	Aug 24, 2007
AB		EQ 10MG BASE	A075504 002	Aug 24, 2007
AB		EQ 20MG BASE	A075504 003	Aug 24, 2007
AB		EQ 40MG BASE	A075504 004	Aug 24, 2007

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	! SUN PHARM INDUSTRIES	324MG	A089338 001	Feb 11, 1987
-----------	------------------------	-------	-------------	--------------

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

AB	SANDOZ	200MG	A088072 002	
AB		300MG	A088072 001	Sep 26, 1983
AB	SUN PHARM INDUSTRIES	200MG	A081030 001	Apr 14, 1989
AB		300MG	A081031 001	Apr 14, 1989
AB	! WATSON LABS	200MG	A083288 001	
AB	!	300MG	A085583 001	

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

! G AND W LABS INC

300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+! SUN PHARM INDUSTRIES	324MG	N021799 001	Aug 12, 2005
-----------	-------------------------	--------------	--------------------	--------------

QUININE SULFATE

AB	AMNEAL PHARMS	324MG	A203729 001	Jul 15, 2015
AB	LUPIN LTD	324MG	A203112 001	Apr 24, 2015
AB	MYLAN PHARMS INC	324MG	A202581 001	Dec 14, 2012
AB	RICONPHARMA LLC	324MG	A204372 001	Jul 22, 2015
AB	TEVA PHARMS	324MG	A091661 001	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

+ AVADEL PHARMS

5MG

N204736 001 Mar 26, 2013

+!

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

AB	+! EISAI INC	20MG	N020973 002	Aug 19, 1999
-----------	--------------	-------------	--------------------	--------------

RABEPRAZOLE SODIUM

AB	AMNEAL PHARMS	20MG	A204179 001	Jul 31, 2015
AB	AUROBINDO PHARMA LTD	20MG	A205761 001	Feb 17, 2017
AB	BRECKENRIDGE PHARM	20MG	A204237 001	Nov 18, 2015
AB	DR REDDYS LABS LTD	20MG	A076824 001	Nov 08, 2013
AB	KREMERS URBAN PHARMS	20MG	A090678 001	Nov 08, 2013
AB	LUPIN LTD	20MG	A078964 001	Nov 08, 2013
AB	MYLAN PHARMS INC	20MG	A076885 001	Nov 08, 2013
AB	TEVA PHARMS USA	20MG	A076822 001	Nov 08, 2013
AB	TORRENT PHARMS LTD	20MG	A202376 001	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+! BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

PRESCRIPTION DRUG PRODUCT LIST

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

<u>AB</u>	<u>+</u> !	LILLY	<u>60MG</u>	<u>N020815</u>	<u>001</u>	Dec 09, 1997
<u>RALOXIFENE HYDROCHLORIDE</u>						
<u>AB</u>		AMNEAL PHARMS	<u>60MG</u>	<u>A208206</u>	<u>001</u>	Apr 08, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>60MG</u>	<u>A204310</u>	<u>001</u>	Aug 28, 2015
<u>AB</u>		GLENMARK PHARMS LTD	<u>60MG</u>	<u>A204491</u>	<u>001</u>	Mar 22, 2016
<u>AB</u>		INVAGEN PHARMS	<u>60MG</u>	<u>A090842</u>	<u>001</u>	Sep 24, 2014
<u>AB</u>		SCIEGEN PHARMS INC	<u>60MG</u>	<u>A206384</u>	<u>001</u>	Oct 12, 2016
<u>AB</u>		TEVA PHARMS USA	<u>60MG</u>	<u>A078193</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>		WATSON LABS INC	<u>60MG</u>	<u>A200825</u>	<u>001</u>	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

<u>+</u> !	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013
------------	-------------------	----------------------	---------	-----	--------------

TABLET; ORAL

ISENTRESS

<u>+</u> !	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007
------------	-------------------	---------------	---------	-----	--------------

ISENTRESS HD

<u>+</u>	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017
----------	-------------------	---------------	---------	-----	--------------

TABLET, CHEWABLE; ORAL

ISENTRESS

<u>+</u>	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
----------	-------------------	--------------	---------	-----	--------------

<u>+</u> !		EQ 100MG BASE	N203045	002	Dec 21, 2011
------------	--	---------------	---------	-----	--------------

RAMELTEON

TABLET; ORAL

RAMELTEON

<u>AB</u>		ACTAVIS LABS FL INC	<u>8MG</u>	<u>A091610</u>	<u>001</u>	Aug 19, 2015
<u>AB</u>		DR REDDYS LABS INTL	<u>8MG</u>	<u>A091693</u>	<u>001</u>	Jul 26, 2013
<u>ROZEREM</u>						
<u>AB</u>	<u>+</u> !	TAKEDA PHARMS USA	<u>8MG</u>	<u>N021782</u>	<u>001</u>	Jul 22, 2005

RAMIPRIL

CAPSULE; ORAL

ALTACE

<u>AB</u>	<u>+</u>	KING PHARMS LLC	<u>1.25MG</u>	<u>N019901</u>	<u>001</u>	Jan 28, 1991
<u>AB</u>	<u>+</u>		<u>2.5MG</u>	<u>N019901</u>	<u>002</u>	Jan 28, 1991
<u>AB</u>	<u>+</u>		<u>5MG</u>	<u>N019901</u>	<u>003</u>	Jan 28, 1991
<u>AB</u>	<u>+</u> !		<u>10MG</u>	<u>N019901</u>	<u>004</u>	Jan 28, 1991

RAMIPRIL

<u>AB</u>		ACCORD HLTHCARE	<u>1.25MG</u>	<u>A202392</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>			<u>2.5MG</u>	<u>A202392</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>			<u>5MG</u>	<u>A202392</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>			<u>10MG</u>	<u>A202392</u>	<u>004</u>	Apr 15, 2014
<u>AB</u>		APOTEX	<u>1.25MG</u>	<u>A079116</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A079116</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>			<u>5MG</u>	<u>A079116</u>	<u>003</u>	Jun 20, 2008
<u>AB</u>			<u>10MG</u>	<u>A079116</u>	<u>004</u>	Jun 20, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>1.25MG</u>	<u>A091604</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>			<u>2.5MG</u>	<u>A091604</u>	<u>002</u>	Jun 08, 2011
<u>AB</u>			<u>5MG</u>	<u>A091604</u>	<u>003</u>	Jun 08, 2011
<u>AB</u>			<u>10MG</u>	<u>A091604</u>	<u>004</u>	Jun 08, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>1.25MG</u>	<u>A078191</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078191</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		INVAGEN PHARMS	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>			<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>			<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>		TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005

PRESCRIPTION DRUG PRODUCT LIST

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

<u>AB</u>		<u>2.5MG</u>	<u>A076549 002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549 003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549 004</u>	Oct 24, 2005
<u>AB</u>	WEST-WARD PHARMS INT	<u>1.25MG</u>	<u>A077900 001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900 002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900 003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900 004</u>	Jun 18, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832 001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832 002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832 003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832 004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

APOTEX INC

!

	1.25MG	A091069 001	Dec 02, 2015
	2.5MG	A091069 002	Dec 02, 2015
	5MG	A091069 003	Dec 02, 2015
	10MG	A091069 004	Dec 02, 2015

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742 001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742 002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655 001</u>	Oct 22, 1997
<u>AB</u>	!	<u>EQ 300MG BASE</u>	<u>A074655 002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	MYLAN LABS LTD	<u>EQ 25MG BASE/ML</u>	<u>A079076 001</u>	Jun 09, 2016
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 25MG BASE/ML</u>	<u>A074777 001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458 001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>EQ 25MG BASE/ML</u>	<u>A091534 001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+! TELIGENT	<u>EQ 25MG BASE/ML</u>	<u>N019090 001</u>	Oct 19, 1984
-----------	-------------	------------------------	--------------------	--------------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124 001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312 001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 15MG BASE/ML</u>	<u>A090623 001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102 001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684 001</u>	Aug 27, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078 001</u>	Mar 22, 2011
<u>AA</u>	NOSTRUM LABS INC	<u>EQ 15MG BASE/ML</u>	<u>A091091 001</u>	Sep 20, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405 001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288 001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476 001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054 001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890 001</u>	Jul 01, 2010

ZANTAC

<u>AA</u>	+! GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675 001</u>	Dec 30, 1988
-----------	------------------	------------------------	--------------------	--------------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	ACIC PHARMS	<u>EQ 150MG BASE</u>	<u>A203694 001</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203694 002</u>	Nov 30, 2017
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824 001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824 002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165 001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165 002</u>	Sep 30, 1998
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999

PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	STRIDES PHARMA	<u>EQ 150MG BASE</u>	<u>A205512 001</u>	Aug 22, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A205512 002</u>	Aug 22, 2016
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488 001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488 002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT LTD	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998

ZANTAC 150

<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703 001</u>	Jun 09, 1983
-----------	-----------------	----------------------	--------------------	--------------

ZANTAC 300

<u>AB</u>	+! GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703 002</u>	Dec 09, 1985
-----------	------------------	----------------------	--------------------	--------------

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

	+ GILEAD	500MG	N021526 002	Jan 27, 2006
	+!	1GM	N021526 001	Feb 12, 2007

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	+ TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+!	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006

RASAGILINE MESYLATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A201889 001</u>	Oct 30, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201889 002</u>	Oct 30, 2017
<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950 001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950 002</u>	Sep 12, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 0.5MG BASE</u>	<u>A201971 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201971 002</u>	May 15, 2017
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A201970 001</u>	Mar 15, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201970 002</u>	Mar 15, 2016
<u>AB</u>	WATSON LABS INC	<u>EQ 0.5MG BASE</u>	<u>A201823 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201823 002</u>	Jul 01, 2013

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

	+! ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161 001	Apr 10, 2008
--	-------------	-----------------------	-------------	--------------

REGORAFENIB

TABLET; ORAL

STIVARGA

	+! BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012
--	-------------------	------	-------------	--------------

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

	+ MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996
	+	EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996
	+!	EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

<u>AB</u>	+ GEMINI LABS LLC	<u>0.5MG</u>	<u>N020741 001</u>	Dec 22, 1997
<u>AB</u>	+	<u>1MG</u>	<u>N020741 002</u>	Dec 22, 1997
<u>AB</u>	+!	<u>2MG</u>	<u>N020741 003</u>	Dec 22, 1997

REPAGLINIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u>	Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A203820 003</u>	Jan 22, 2014
<u>AB</u>	BOSCOGEN	<u>0.5MG</u>	<u>A091517 001</u>	Apr 24, 2015
<u>AB</u>		<u>1MG</u>	<u>A091517 002</u>	Apr 24, 2015
<u>AB</u>		<u>2MG</u>	<u>A091517 003</u>	Apr 24, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252 001</u>	Aug 23, 2013
<u>AB</u>		<u>1MG</u>	<u>A090252 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090252 003</u>	Jan 22, 2014

PRESCRIPTION DRUG PRODUCT LIST

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189 001</u>	Jul 17, 2013
<u>AB</u>		<u>1MG</u>	<u>A201189 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A201189 003</u>	Jan 22, 2014
<u>AB</u>	SANDOZ INC	<u>0.5MG</u>	<u>A078555 001</u>	Nov 22, 2013
<u>AB</u>		<u>1MG</u>	<u>A078555 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A078555 003</u>	Jan 22, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>1MG</u>	<u>A077571 002</u>	Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571 003</u>	Jul 11, 2013

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+! AQUA PHARMS LLC 1% N022055 001 Apr 12, 2007

RIBAVIRIN

CAPSULE; ORAL

REBETOLAB +! MERCK SHARP DOHME 200MG N020903 002 Jul 25, 2001RIBASPHEREAB KADMON PHARMS LLC 200MG A076203 001 Apr 06, 2004RIBAVARINAB AUROBINDO PHARMA 200MG A079117 001 Sep 17, 2009RIBAVIRINAB SANDOZ 200MG A076192 001 Apr 06, 2004AB TEVA 200MG A076277 001 Oct 04, 2004AB ZYDUS PHARMS USA 200MG A077224 001 Oct 28, 2005

FOR SOLUTION; INHALATION

RIBAVIRINAN NAVINTA LLC 6GM/VIAL A207366 001 Oct 06, 2016VIRAZOLEAN +! VALEANT PHARM INTL 6GM/VIAL N018859 001 Dec 31, 1985

SOLUTION; ORAL

REBETOL

+! SCHERING 40MG/ML N021546 001 Jul 29, 2003

TABLET; ORAL

COPEGUSAB ROCHE 200MG N021511 001 Dec 03, 2002RIBAVIRINAB AUROBINDO PHARMA 200MG A079111 001 Sep 17, 2009AB KADMON PHARMS LLC 200MG A077456 001 Dec 05, 2005AB 400MG A077456 002 Dec 05, 2005AB ! 600MG A077456 003 Dec 05, 2005AB SANDOZ 200MG A077743 001 Oct 03, 2006AB SANDOZ INC 200MG A202546 001 Aug 12, 2014AB 400MG A202546 002 Aug 12, 2014AB 500MG A202546 003 Aug 12, 2014AB 600MG A202546 004 Aug 12, 2014AB TEVA 200MG A077053 001 Dec 05, 2005AB ZYDUS PHARMS USA 200MG A077094 001 Dec 05, 2005AB 400MG A077094 002 Mar 16, 2007AB 500MG A077094 004 Apr 18, 2008AB 600MG A077094 003 Mar 16, 2007RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

+! NOVARTIS PHARMS CORP EQ 200MG BASE N209092 001 Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+! AVEDRO INC 0.146% N203324 001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+! AVEDRO INC 0.146% N203324 002 Apr 15, 2016

PRESCRIPTION DRUG PRODUCT LIST

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

AB	+ !	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992
-----------	------------	-------------------------	--------------	----------------	------------	--------------

RIFABUTIN

AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014
-----------	--	-----------	--------------	----------------	------------	--------------

RIFAMPIN

CAPSULE; ORAL

RIFADIN

AB		SANOFI AVENTIS US	150MG	A062303	001	
-----------	--	-------------------	--------------	----------------	------------	--

AB	+ !		300MG	N050420	001	
-----------	------------	--	--------------	----------------	------------	--

RIFAMPIN

AB		AKORN	150MG	A065028	001	Mar 14, 2001
-----------	--	-------	--------------	----------------	------------	--------------

AB			300MG	A065028	002	Mar 14, 2001
-----------	--	--	--------------	----------------	------------	--------------

AB		LANNETT	150MG	A065390	001	Mar 28, 2008
-----------	--	---------	--------------	----------------	------------	--------------

AB			300MG	A065390	002	Mar 28, 2008
-----------	--	--	--------------	----------------	------------	--------------

AB		LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013
-----------	--	--------------	--------------	----------------	------------	--------------

AB			300MG	A090034	002	Aug 21, 2013
-----------	--	--	--------------	----------------	------------	--------------

AB		SANDOZ	150MG	A064150	002	Jan 02, 1998
-----------	--	--------	--------------	----------------	------------	--------------

AB			300MG	A064150	001	May 28, 1997
-----------	--	--	--------------	----------------	------------	--------------

RIMACTANE

AB		OXFORD PHARMS	300MG	N050429	001	
-----------	--	---------------	--------------	----------------	------------	--

INJECTABLE; INJECTION

RIFADIN

AP	+ !	SANOFI AVENTIS US	600MG/VIAL	N050627	001	May 25, 1989
-----------	------------	-------------------	-------------------	----------------	------------	--------------

RIFAMPIN

AP		AKORN	600MG/VIAL	A065502	001	Sep 21, 2010
-----------	--	-------	-------------------	----------------	------------	--------------

AP		EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014
-----------	--	-------------------	-------------------	----------------	------------	--------------

AP		FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014
-----------	--	--------------------	-------------------	----------------	------------	--------------

AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016
-----------	--	--------------	-------------------	----------------	------------	--------------

AP		MYLAN LABS LTD	600MG/VIAL	A065421	001	May 22, 2008
-----------	--	----------------	-------------------	----------------	------------	--------------

AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016
-----------	--	--------------------	-------------------	----------------	------------	--------------

AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999
-----------	--	-------------------------	-------------------	----------------	------------	--------------

RIFAPENTINE

TABLET; ORAL

PRIFTIN

	+ !	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
--	------------	-------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+ !	SALIX PHARMS	200MG	N021361	001	May 25, 2004
--	------------	--------------	-------	---------	-----	--------------

	+ !		550MG	N022554	001	Mar 24, 2010
--	------------	--	-------	---------	-----	--------------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

	+ !	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011
--	------------	---------------	--------------	---------	-----	--------------

RILUZOLE

TABLET; ORAL

RILUTEK

AB	+ !	COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995
-----------	------------	-----------------	-------------	----------------	------------	--------------

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016
-----------	--	----------------	-------------	----------------	------------	--------------

AB		APOTEX CORP	50MG	A091300	001	Jun 18, 2013
-----------	--	-------------	-------------	----------------	------------	--------------

AB		GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013
-----------	--	---------------------	-------------	----------------	------------	--------------

AB		IMPAX LABS	50MG	A076173	001	Jan 29, 2003
-----------	--	------------	-------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013
-----------	--	------------------	-------------	----------------	------------	--------------

AB		SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013
-----------	--	--------------------	-------------	----------------	------------	--------------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

AB	+ !	SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993
-----------	------------	--------------------	--------------	----------------	------------	--------------

RIMANTADINE HYDROCHLORIDE

AB		IMPAX LABS	100MG	A076132	001	Aug 30, 2002
-----------	--	------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

RIOCIGUAT

TABLET; ORAL

ADEMPAS

+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
+		1MG	N204819	002	Oct 08, 2013
+		1.5MG	N204819	003	Oct 08, 2013
+		2MG	N204819	004	Oct 08, 2013
+		2.5MG	N204819	005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	+	APIL	5MG	N020835	002	Apr 14, 2000
AB	+		30MG	N020835	001	Mar 27, 1998
AB	+	!	35MG	N020835	003	May 25, 2002
AB	+	!	150MG	N020835	005	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	35MG	A090877	001	Nov 30, 2015
AB			75MG	A090877	002	Jun 10, 2014
AB			150MG	A090877	003	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	5MG	A200296	001	Nov 30, 2015
AB			30MG	A200296	002	Nov 30, 2015
AB			35MG	A200296	003	Nov 30, 2015
AB			150MG	A206768	001	Oct 21, 2016
AB		MACLEODS PHARMS LTD	5MG	A203533	001	Dec 09, 2015
AB			30MG	A203533	002	Dec 09, 2015
AB			35MG	A203533	003	Nov 29, 2016
AB		MYLAN PHARMS INC	5MG	A200477	001	Nov 30, 2015
AB			30MG	A200477	002	Nov 30, 2015
AB			35MG	A200477	003	Nov 30, 2015
AB			75MG	A200477	004	Jun 10, 2014
AB			150MG	A200477	005	Jun 10, 2014
AB		SUN PHARMA GLOBAL	5MG	A090886	001	Nov 30, 2015
AB			30MG	A090886	002	Nov 30, 2015
AB			35MG	A090886	003	Nov 30, 2015
AB			75MG	A090886	004	Jun 10, 2014
AB			150MG	A090886	005	Jun 10, 2014
AB		TEVA PHARMS USA	5MG	A077132	001	Oct 05, 2007
AB			30MG	A077132	002	Oct 05, 2007
AB			35MG	A077132	003	Oct 05, 2007
AB			150MG	A079215	001	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010
-----------	---	------	-------------	----------------	------------	--------------

RISEDRONATE SODIUM

AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015
-----------	--	-----------------	-------------	----------------	------------	--------------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
+	!	25MG/VIAL	N021346	001	Oct 29, 2003
+		37.5MG/VIAL	N021346	002	Oct 29, 2003
+		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996
-----------	---	----------------	---------------	----------------	------------	--------------

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011
AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009
AA		APOTEX INC	1MG/ML	A077719	001	Jul 29, 2009
AA		BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009
AA		LIFESTAR PHARMA	1MG/ML	A078452	001	Sep 04, 2009
AA		PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010
AA		TARO	1MG/ML	A090347	001	Feb 07, 2011
AA		TRIS PHARMA INC	1MG/ML	A079059	001	Dec 12, 2012
AA		VINTAGE	1MG/ML	A079158	001	Dec 03, 2010
AA		WEST-WARD PHARMS INT	1MG/ML	A076904	001	Jul 29, 2009

TABLET; ORAL

RISPERDAL

AB	+	JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999
AB	+		0.5MG	N020272	007	Jan 27, 1999

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERDAL

AB	+!	1MG	N020272 001	Dec 29, 1993
AB	+	2MG	N020272 002	Dec 29, 1993
AB	+	3MG	N020272 003	Dec 29, 1993
AB	+	4MG	N020272 004	Dec 29, 1993

RISPERIDONE

AB	AJANTA PHARMA LTD	0.25MG	A201003 001	Aug 24, 2011
AB		0.5MG	A201003 002	Aug 24, 2011
AB		1MG	A201003 003	Aug 24, 2011
AB		2MG	A201003 004	Aug 24, 2011
AB		3MG	A201003 005	Aug 24, 2011
AB		4MG	A201003 006	Aug 24, 2011
AB	APOTEX INC	0.25MG	A077953 001	Sep 15, 2008
AB		0.5MG	A077953 002	Sep 15, 2008
AB		1MG	A077953 003	Sep 15, 2008
AB		2MG	A077953 004	Sep 15, 2008
AB		3MG	A077953 005	Sep 15, 2008
AB		4MG	A077953 006	Sep 15, 2008
AB	AUROBINDO PHARMA	0.25MG	A078269 001	Oct 08, 2008
AB		0.5MG	A078269 002	Oct 08, 2008
AB		1MG	A078269 003	Oct 08, 2008
AB		2MG	A078269 004	Oct 08, 2008
AB		3MG	A078269 005	Oct 08, 2008
AB		4MG	A078269 006	Oct 08, 2008
AB	CIPLA	0.25MG	A077543 001	May 18, 2011
AB		0.5MG	A077543 002	May 18, 2011
AB		1MG	A077543 003	May 18, 2011
AB		2MG	A077543 004	May 18, 2011
AB		3MG	A077543 005	May 18, 2011
AB		4MG	A077543 006	May 18, 2011
AB	DR REDDYS LABS LTD	0.25MG	A076879 001	Oct 24, 2008
AB		0.5MG	A076879 002	Oct 24, 2008
AB		1MG	A076879 003	Oct 24, 2008
AB		2MG	A076879 004	Oct 24, 2008
AB		3MG	A076879 005	Oct 24, 2008
AB		4MG	A076879 006	Oct 24, 2008
AB	MYLAN	0.25MG	A076288 001	Sep 15, 2008
AB		0.5MG	A076288 002	Sep 15, 2008
AB		1MG	A076288 003	Sep 15, 2008
AB		2MG	A076288 004	Sep 15, 2008
AB		3MG	A076288 005	Sep 15, 2008
AB		4MG	A076288 006	Sep 15, 2008
AB	OXFORD PHARMS	0.25MG	A078071 001	Jun 17, 2009
AB		0.5MG	A078071 002	Jun 17, 2009
AB		1MG	A078071 003	Jun 17, 2009
AB		2MG	A078071 004	Jun 17, 2009
AB		3MG	A078071 005	Jun 17, 2009
AB		4MG	A078071 006	Jun 17, 2009
AB	PLIVA HRVATSKA DOO	0.25MG	A077769 001	Oct 16, 2008
AB		0.5MG	A077769 002	Oct 16, 2008
AB		1MG	A077769 003	Oct 16, 2008
AB		2MG	A077769 004	Oct 16, 2008
AB		3MG	A077769 005	Oct 16, 2008
AB		4MG	A077769 006	Oct 16, 2008
AB	PRINSTON INC	0.25MG	A077493 001	Nov 29, 2011
AB		0.25MG	A078707 001	Dec 29, 2008
AB		0.5MG	A077493 002	Nov 29, 2011
AB		0.5MG	A078707 002	Dec 29, 2008
AB		1MG	A077493 003	Nov 29, 2011
AB		1MG	A078707 003	Dec 29, 2008
AB		2MG	A077493 004	Nov 29, 2011
AB		2MG	A078707 004	Dec 29, 2008
AB		3MG	A077493 005	Nov 29, 2011
AB		3MG	A078707 005	Dec 29, 2008
AB		4MG	A077493 006	Nov 29, 2011
AB		4MG	A078707 006	Dec 29, 2008
AB	SANDOZ	0.25MG	A078528 001	Oct 16, 2009
AB		0.5MG	A078528 002	Oct 16, 2009
AB		1MG	A078528 003	Oct 16, 2009
AB		2MG	A078528 004	Oct 16, 2009

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>0.25MG</u>	<u>A078036</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078036</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		<u>1MG</u>	<u>A078036</u>	<u>003</u>	Mar 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A078036</u>	<u>004</u>	Mar 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A078036</u>	<u>005</u>	Mar 10, 2014
<u>AB</u>		<u>4MG</u>	<u>A078036</u>	<u>006</u>	Mar 10, 2014
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	+	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+		<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>	+		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	+		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>		<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

<u>AB</u>		<u>2MG</u>	<u>A077542 003</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A078464 003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464 004</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078474 001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078464 005</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078474 002</u>	Aug 06, 2010
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908 001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908 002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908 003</u>	Mar 12, 2012
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516 001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516 003</u>	May 01, 2009
	PAR PHARM	0.25MG	A077494 001	Apr 30, 2009

RITONAVIR

CAPSULE;ORAL

NORVIR

+! ABBVIE

100MG

N020945 001 Jun 29, 1999

POWDER;ORAL

NORVIR

+! ABBVIE INC

100MG/PACKET

N209512 001 Jun 07, 2017

SOLUTION;ORAL

NORVIR

+! ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIRAB +! ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB WEST-WARD PHARMS
INT100MGA202573 001 Jan 15, 2015RIVAROXABAN

TABLET;ORAL

XARELTO

+ JANSSEN PHARMS

10MG

N022406 001 Jul 01, 2011

+

15MG

N022406 002 Nov 04, 2011

+!

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELONAB + NOVARTIS4.6MG/24HRN022083 001 Jul 06, 2007AB +!9.5MG/24HRN022083 002 Jul 06, 2007AB +13.3MG/24HRN022083 005 Aug 31, 2012RIVASTIGMINEAB ALVOGEN MALTA4.6MG/24HRA204403 001 Sep 03, 2015AB9.5MG/24HRA204403 002 Sep 03, 2015AB13.3MG/24HRA204403 003 Aug 31, 2015RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELONAB +! NOVARTISEQ 1.5MG BASEN020823 003 Apr 21, 2000AB +EQ 3MG BASEN020823 004 Apr 21, 2000AB +EQ 4.5MG BASEN020823 005 Apr 21, 2000AB +!EQ 6MG BASEN020823 006 Apr 21, 2000RIVASTIGMINE TARTRATEAB AJANTA PHARMA LTDEQ 1.5MG BASEA207797 001 Sep 28, 2017ABEQ 3MG BASEA207797 002 Sep 28, 2017ABEQ 4.5MG BASEA207797 003 Sep 28, 2017ABEQ 6MG BASEA207797 004 Sep 28, 2017AB ALEMBIC PHARMS LTDEQ 1.5MG BASEA091689 001 Jun 12, 2012ABEQ 3MG BASEA091689 002 Jun 12, 2012ABEQ 4.5MG BASEA091689 003 Jun 12, 2012ABEQ 6MG BASEA091689 004 Jun 12, 2012AB APOTEX INCEQ 1.5MG BASEA091072 001 May 16, 2013ABEQ 3MG BASEA091072 002 May 16, 2013ABEQ 4.5MG BASEA091072 003 May 16, 2013ABEQ 6MG BASEA091072 004 May 16, 2013AB AUROBINDO PHARMA
LTDEQ 1.5MG BASEA204572 001 Mar 25, 2016ABEQ 3MG BASEA204572 002 Mar 25, 2016ABEQ 4.5MG BASEA204572 003 Mar 25, 2016

PRESCRIPTION DRUG PRODUCT LIST

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A204572 004</u>	Mar 25, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203844 001</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203844 002</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203844 003</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203844 004</u>	Feb 13, 2017
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130 001</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077130 002</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130 003</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077130 004</u>	Oct 31, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148 001</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203148 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203148 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203148 004</u>	Aug 22, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1.5MG BASE</u>	<u>A090879 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090879 002</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A090879 003</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090879 004</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 1.5MG BASE</u>	<u>A077131 001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131 002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131 003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131 004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129 003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129 004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

<u>AB</u>	+	MERCK	<u>EQ 5MG BASE</u>	<u>N020864 001</u>	Jun 29, 1998
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N020864 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A203269 001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203269 002</u>	Feb 18, 2016
<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202244 002</u>	Dec 31, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490 002</u>	Dec 31, 2012
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A077526 001</u>	Mar 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077526 002</u>	Mar 26, 2013
<u>AB</u>	ECI PHARMS LLC	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090 001</u>	Nov 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204090 002</u>	Nov 26, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967 002</u>	Dec 31, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204339 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252 001</u>	Dec 31, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203252 002</u>	Dec 31, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147 001</u>	Feb 11, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203147 002</u>	Feb 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482 002</u>	Dec 31, 2012
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A207836 001</u>	Mar 07, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207836 002</u>	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	+	MERCK	<u>EQ 5MG BASE</u>	<u>N020865 001</u>	Jun 29, 1998
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477 002</u>	Jul 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203334 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203334 002</u>	Oct 16, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 5MG BASE</u>	<u>A204722 001</u>	Jan 11, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204722 002</u>	Jan 11, 2017
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739 002</u>	Jul 01, 2013
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A207835 001</u>	Mar 07, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207835 002</u>	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A206206 001</u>	Apr 12, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A206206 002</u>	Apr 12, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651 001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651 002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519 002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199 002</u>	Nov 26, 2008
<u>AP</u>	SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A091458 001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458 002</u>	Jul 28, 2010
<u>AP</u>	! SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A079195 001</u>	Dec 05, 2008
<u>AP</u>	!	<u>100MG/10ML (10MG/ML)</u>	<u>A079195 002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115 001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115 002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717 002</u>	Nov 26, 2008
<u>AP</u>	WEST WARD PHARM CORP	<u>50MG/5ML (10MG/ML)</u>	<u>A204679 001</u>	Feb 28, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A204679 002</u>	Feb 28, 2017

ROFLUMILAST

TABLET;ORAL

DALIRESP

+! ASTRAZENECA PHARMS

500MCG

N022522 001 Feb 28, 2011

ROLAPITANT HYDROCHLORIDE

EMULSION;IV (INFUSION)

VARUBI

+! TESARO INC

EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)

N208399 001 Oct 25, 2017

TABLET;ORAL

VARUBI

+! TESARO INC

EQ 90MG BASE

N206500 001 Sep 01, 2015

ROMIDEPSIN

POWDER;IV (INFUSION)

ISTODAX

+! CELGENE

10MG/VIAL

N022393 001 Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

<u>AB</u>	+! GLAXOSMITHKLINE LLC	<u>EQ 0.25MG BASE</u>	<u>N020658 001</u>	Sep 19, 1997
<u>AB</u>	+	<u>EQ 0.5MG BASE</u>	<u>N020658 002</u>	Sep 19, 1997
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N020658 003</u>	Sep 19, 1997
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N020658 004</u>	Sep 19, 1997
<u>AB</u>	+	<u>EQ 3MG BASE</u>	<u>N020658 006</u>	Jan 27, 1999
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N020658 007</u>	Jan 27, 1999
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020658 005</u>	Sep 19, 1997

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A204022 001</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A204022 002</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A204022 003</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A204022 004</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204022 005</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A204022 006</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204022 007</u>	Feb 28, 2017
<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429 001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429 002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429 003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429 004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429 005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429 006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429 007</u>	Mar 24, 2010
<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>	G AND W LABS INC	<u>EQ 0.25MG BASE</u>	<u>A077460 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460 007</u>	May 19, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 0.25MG BASE</u>	<u>A077852 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852 007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050 006</u>	May 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050 007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411 001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411 002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411 003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411 004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411 005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411 006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411 007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	+!	GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008 001</u>	Jun 13, 2008
<u>AB</u>	+		<u>EQ 4MG BASE</u>	<u>N022008 003</u>	Jun 13, 2008
<u>AB</u>	+		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>N022008 004</u>	Jun 13, 2008
<u>AB</u>	+		<u>EQ 12MG BASE</u>	<u>N022008 005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869 001</u>	May 17, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090869 002</u>	May 17, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A090869 003</u>	May 17, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090869 004</u>	May 17, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090869 005</u>	May 17, 2012
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A202786 001</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A202786 002</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A202786 003</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A202786 004</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A202786 005</u>	Apr 22, 2013
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201576 002</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201576 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201576 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201576 005</u>	Jun 06, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462 001</u>	Oct 15, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A200462 003</u>	Oct 15, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A200462 004</u>	Oct 15, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A200462 005</u>	Oct 15, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A200462 006</u>	Oct 15, 2012
<u>AB</u>		SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201047 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201047 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201047 005</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201047 006</u>	Jun 06, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A200431 002</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A200431 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A200431 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A200431 005</u>	Jun 06, 2012
<u>AB</u>		WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395 001</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A091395 002</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091395 003</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A091395 004</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A091395 005</u>	Aug 27, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/10ML (2MG/ML)</u>	<u>N020533 001</u>	May 01, 1998
<u>AP</u>	+		<u>40MG/20ML (2MG/ML)</u>	<u>N020533 002</u>	Sep 24, 1996
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N020533 003</u>	May 01, 1998
<u>AP</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N020533 005</u>	Sep 24, 1996
<u>AP</u>	+		<u>150MG/20ML (7.5MG/ML)</u>	<u>N020533 004</u>	Sep 24, 1996
<u>AP</u>	+		<u>150MG/30ML (5MG/ML)</u>	<u>N020533 008</u>	Sep 24, 1996
<u>AP</u>	+		<u>200MG/100ML (2MG/ML)</u>	<u>N020533 006</u>	Sep 24, 1996
<u>AP</u>	+!		<u>200MG/20ML (10MG/ML)</u>	<u>N020533 011</u>	Sep 24, 1996

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>150MG/30ML (5MG/ML)</u>	<u>A203955 001</u>	Apr 11, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>40MG/20ML (2MG/ML)</u>	<u>A205612 001</u>	Jul 13, 2016
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A205612 003</u>	Jul 13, 2016
<u>AP</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A205612 006</u>	Jul 13, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A205612 004</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A205612 005</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A205612 002</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A205612 007</u>	Jul 13, 2016
<u>AP</u>	HOSPIRA	<u>20MG/10ML (2MG/ML)</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A090194 005</u>	Sep 23, 2014
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090194 006</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>150MG/30ML (5MG/ML)</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SAGENT STRIDES	<u>40MG/20ML (2MG/ML)</u>	<u>A090318 001</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090318 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090318 004</u>	Sep 23, 2014
	NAROPIN			
	+ FRESenius KABI USA	400MG/200ML (2MG/ML)	N020533 007	Sep 24, 1996
	+	500MG/100ML (5MG/ML)	N020533 009	Jan 04, 2011
	+	1GM/200ML (5MG/ML)	N020533 010	Jan 04, 2011

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

<u>AB</u>	+ SB PHARMCO	<u>EQ 2MG BASE</u>	<u>N021071 002</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N021071 003</u>	May 25, 1999
<u>AB</u>	+!	<u>EQ 8MG BASE</u>	<u>N021071 004</u>	May 25, 1999

ROSIGLITAZONE MALEATE

<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747 001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747 002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747 003</u>	Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

<u>AB</u>	+ IPR	<u>5MG</u>	<u>N021366 002</u>	Aug 12, 2003
<u>AB</u>	+	<u>10MG</u>	<u>N021366 003</u>	Aug 12, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021366 004</u>	Aug 12, 2003
<u>AB</u>	+!	<u>40MG</u>	<u>N021366 005</u>	Aug 12, 2003

ROSUVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A206434 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A206434 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A206434 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A206434 004</u>	Oct 31, 2016
<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A206465 001</u>	Mar 21, 2017
<u>AB</u>		<u>10MG</u>	<u>A206465 002</u>	Mar 21, 2017
<u>AB</u>		<u>20MG</u>	<u>A206465 003</u>	Mar 21, 2017
<u>AB</u>		<u>40MG</u>	<u>A206465 004</u>	Mar 21, 2017
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A079145 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079145 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079145 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079145 004</u>	Jul 19, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A079170 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079170 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079170 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079170 004</u>	Jul 19, 2016
<u>AB</u>	BIOCON LTD	<u>5MG</u>	<u>A207752 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207752 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207752 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207752 004</u>	Oct 31, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>5MG</u>	<u>A207453 001</u>	Nov 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A207453 002</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A207453 003</u>	Nov 23, 2016
<u>AB</u>		<u>40MG</u>	<u>A207453 004</u>	Nov 23, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>5MG</u>	<u>A207408 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207408 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207408 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207408 004</u>	Oct 31, 2016
<u>AB</u>	GLENMARK PHARMS	<u>5MG</u>	<u>A079172 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079172 002</u>	Jul 19, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

<u>AB</u>		<u>20MG</u>	<u>A079172</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079172</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A207616</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207616</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207616</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207616</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A207062</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207062</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207062</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207062</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A205587</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		<u>10MG</u>	<u>A205587</u>	<u>002</u>	Jul 31, 2017
<u>AB</u>		<u>20MG</u>	<u>A205587</u>	<u>003</u>	Jul 31, 2017
<u>AB</u>		<u>40MG</u>	<u>A205587</u>	<u>004</u>	Jul 31, 2017
<u>AB</u>	MSN LABS PVT LTD	<u>5MG</u>	<u>A208898</u>	<u>001</u>	Nov 22, 2017
<u>AB</u>		<u>10MG</u>	<u>A208898</u>	<u>002</u>	Nov 22, 2017
<u>AB</u>		<u>20MG</u>	<u>A208898</u>	<u>003</u>	Nov 22, 2017
<u>AB</u>		<u>40MG</u>	<u>A208898</u>	<u>004</u>	Nov 22, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A079161</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079161</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079161</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079161</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A079168</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079168</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079168</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079168</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A079171</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079171</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079171</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079171</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A079169</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079169</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079169</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079169</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A079166</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079166</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079166</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079166</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG</u>	<u>A201619</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A201619</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A201619</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A201619</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A079167</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A079167</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A079167</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A079167</u>	<u>004</u>	Apr 29, 2016

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+	!	2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

SOLUTION; INTRAVENOUS

RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016

PRESCRIPTION DRUG PRODUCT LIST

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115 001	Dec 19, 2016
+		EQ 250MG BASE	N209115 003	May 01, 2017
+	!	EQ 300MG BASE	N209115 002	Dec 19, 2016

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011
---	-----------	---------	-------------	--------------

TABLET; ORAL

BANZEL

AB	+	EISAI INC	200MG	N021911 002	Nov 14, 2008
AB	+	!	400MG	N021911 003	Nov 14, 2008

RUFINAMIDE

AB		GLENMARK PHARMS LTD	200MG	A205075 001	May 16, 2016
AB			400MG	A205075 002	May 16, 2016
AB		MYLAN PHARMS INC	200MG	A205095 001	May 16, 2016
AB			400MG	A205095 002	May 16, 2016
AB		WEST-WARD PHARMS INT	200MG	A204988 001	May 16, 2016
AB			400MG	A204988 002	May 16, 2016

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

+	INCYTE CORP	EQ 5MG BASE	N202192 001	Nov 16, 2011
+		EQ 10MG BASE	N202192 002	Nov 16, 2011
+		EQ 15MG BASE	N202192 003	Nov 16, 2011
+		EQ 20MG BASE	N202192 004	Nov 16, 2011
+	!	EQ 25MG BASE	N202192 005	Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+	QOL MEDCL	8,500 IU/ML	N020772 001	Apr 09, 1998
---	-----------	-------------	-------------	--------------

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620 001	Jul 07, 2015
+		49MG; 51MG	N207620 002	Jul 07, 2015
+	!	97MG; 103MG	N207620 003	Jul 07, 2015

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+	US WORLDMEDS LLC	50MG	N207145 001	Mar 21, 2017
+	!	100MG	N207145 002	Mar 21, 2017

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692 001	Sep 19, 1997
---	-----------------	--------------------	-------------	--------------

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+	LANTHEUS MEDICAL	50mCi/ML	N020570 001	Mar 28, 1997
---	------------------	----------	-------------	--------------

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+	BIOMARIN PHARM	100MG/PACKET	N205065 001	Dec 19, 2013
+		500MG/PACKET	N205065 002	Oct 27, 2015

TABLET; ORAL

KUVAN

+	BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007
---	----------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+! HOFFMANN LA ROCHE EQ 200MG BASE N020628 001 Dec 06, 1995

TABLET; ORAL

INVIRASE

+! HOFFMANN-LA ROCHE EQ 500MG BASE N021785 001 Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

+ ASTRAZENECA AB EQ 2.5MG BASE N022350 001 Jul 31, 2009

+! EQ 5MG BASE N022350 002 Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE**AB** PERRIGO PHARMS CO **1MG/72HR****A078830 001** Jan 30, 2015TRANSDERM SCOP**AB** +! GLAXOSMITHKLINE CON **1MG/72HR****N017874 001**SECNIDAZOLE

GRANULE; ORAL

SOLOSEC

+! LUPIN 2GM/PACKET N209363 001 Sep 15, 2017

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

! VALEANT PHARMS 50MG A086101 001 Oct 03, 1983

NORTH

! 100MG A086101 002 Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+! CHIRHOCLIN 16MCG/VIAL N021256 001 Apr 09, 2004

+ 40MCG/VIAL N021256 002 Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+! SOMERSET 6MG/24HR N021336 001 Feb 27, 2006

+ 9MG/24HR N021336 002 Feb 27, 2006

+ 12MG/24HR N021336 003 Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL**AB** +! SOMERSET **5MG****N020647 001** May 15, 1996SELEGILINE HYDROCHLORIDE**AB** APOTEX **5MG****A075321 001** Dec 04, 1998**AB** DAVA PHARMS INC **5MG****A075352 001** Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDE**AB** ! APOTEX INC **5MG****A074871 001** Jun 06, 1997**AB** BOSCOGEN **5MG****A074912 001** Apr 30, 1998**AB** MYLAN **5MG****A074866 001** Nov 26, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+! VALEANT PHARM INTL 1.25MG N021479 001 Jun 14, 2006

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE**AT** PERRIGO NEW YORK **2.5%****A089996 001** Jan 10, 1991**AT** WOCKHARDT BIO AG **2.5%****A088228 001** Sep 01, 1983SELSUN**AT** +! CHATTEM **2.5%****N007936 001**SELEXIPAG

TABLET; ORAL

UPTRAVI

+ ACTELION PHARMS LTD 0.2MG N207947 001 Dec 21, 2015

+ 0.4MG N207947 002 Dec 21, 2015

+ 0.6MG N207947 003 Dec 21, 2015

+ 0.8MG N207947 004 Dec 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

SELEXIPAG

TABLET; ORAL

UPTRA VI

+	1MG	N207947 005	Dec 21, 2015
+	1.2MG	N207947 006	Dec 21, 2015
+	1.4MG	N207947 007	Dec 21, 2015
+	1.6MG	N207947 008	Dec 21, 2015

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

OZEMPIC

+	NOVO NORDISK INC	2MG/1.5ML (1.34MG/ML)	N209637 001	Dec 05, 2017
---	------------------	-----------------------	-------------	--------------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385 001	Dec 10, 2003
---	--------------------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARMA	<u>EQ 20MG BASE/ML</u>	<u>A078861 001</u>	Oct 31, 2008
-----------	------------------	------------------------	--------------------	--------------

ZOLOFT

<u>AA</u>	+	PFIZER	<u>EQ 20MG BASE/ML</u>	<u>N020990 001</u>	Dec 07, 1999
-----------	---	--------	------------------------	--------------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202825 001</u>	Nov 07, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202825 002</u>	Nov 07, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202825 003</u>	Nov 07, 2014
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A076882 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076882 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076882 003</u>	Feb 06, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A077206 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077206 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077206 003</u>	Feb 06, 2007
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677 001</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078677 002</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078677 003</u>	Mar 04, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397 003</u>	Feb 06, 2007
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670 003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626 001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626 002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626 003</u>	Jan 31, 2008
<u>AB</u>	OXFORD PHARMS	<u>EQ 25MG BASE</u>	<u>A078175 001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175 002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175 003</u>	Jul 21, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A077977 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977 003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465 001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465 002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465 003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765 003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403 003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106 003</u>	Feb 06, 2007

ZOLOFT

<u>AB</u>	+	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839 005</u>	Mar 06, 1996
-----------	---	--------	---------------------	--------------------	--------------

<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N019839 001</u>	Dec 30, 1991
-----------	---	--	---------------------	--------------------	--------------

<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N019839 002</u>	Dec 30, 1991
-----------	---	--	----------------------	--------------------	--------------

SERTRALINE HYDROCHLORIDE

SUN PHARM INDS LTD

EQ 150MG BASE	A077977 004	Feb 06, 2007
---------------	-------------	--------------

EQ 200MG BASE	A077977 005	Feb 06, 2007
---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

<u>AB</u>	<u>+</u>	GENZYME	<u>800MG/PACKET</u>	<u>N022318</u>	<u>001</u>	Aug 12, 2009
<u>AB</u>	<u>+</u>	!	<u>2.4GM/PACKET</u>	<u>N022318</u>	<u>002</u>	Feb 18, 2009

SEVELAMER CARBONATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>800MG/PACKET</u>	<u>A207624</u>	<u>001</u>	Jun 13, 2017
<u>AB</u>			<u>2.4GM/PACKET</u>	<u>A207624</u>	<u>002</u>	Jun 13, 2017

TABLET;ORAL

RENVELA

<u>AB</u>	<u>+</u>	GENZYME	<u>800MG</u>	<u>N022127</u>	<u>001</u>	Oct 19, 2007
-----------	----------	---------	--------------	----------------	------------	--------------

SEVELAMER CARBONATE

<u>AB</u>		AMNEAL PHARMS CO	<u>800MG</u>	<u>A207288</u>	<u>001</u>	Nov 28, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>800MG</u>	<u>A207179</u>	<u>001</u>	Jul 17, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>800MG</u>	<u>A206094</u>	<u>001</u>	Sep 29, 2017
<u>AB</u>		IMPAX LABS INC	<u>800MG</u>	<u>A090975</u>	<u>001</u>	Oct 23, 2017
<u>AB</u>		INVAGEN PHARMS	<u>800MG</u>	<u>A203860</u>	<u>001</u>	Oct 26, 2017

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

<u>+</u>	GENZYME	400MG	N021179	001	Jul 12, 2000
<u>+</u>	!	800MG	N021179	002	Jul 12, 2000

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

<u>AN</u>		BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>		HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
<u>AN</u>		SHANGHAI HENGRUI	<u>100%</u>	<u>A203793</u>	<u>001</u>	Nov 03, 2015

SOJOURN

<u>AN</u>		PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007
-----------	--	------------------	-------------	----------------	------------	--------------

ULTANE

<u>AN</u>	<u>+</u>	ABBVIE	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995
-----------	----------	--------	-------------	----------------	------------	--------------

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

<u>+</u>	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012
----------	--------	-----------------	---------	-----	--------------

SOLUTION;INTRAVENOUS

REVATIO

<u>AP</u>	<u>+</u>	PFIZER	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>N022473</u>	<u>001</u>	Nov 18, 2009
-----------	----------	--------	---	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>A203988</u>	<u>001</u>	Apr 01, 2015
-----------	--	----------------------	---	----------------	------------	--------------

TABLET;ORAL

REVATIO

<u>AB</u>	<u>+</u>	PFIZER	<u>EQ 20MG BASE</u>	<u>N021845</u>	<u>001</u>	Jun 03, 2005
-----------	----------	--------	---------------------	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AB</u>		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A202025</u>	<u>001</u>	Feb 28, 2013
<u>AB</u>		APOTEX CORP	<u>EQ 20MG BASE</u>	<u>A091379</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A203963</u>	<u>001</u>	Nov 18, 2015
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A202598</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>		HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A203623</u>	<u>001</u>	Nov 26, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203814</u>	<u>001</u>	Dec 17, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150</u>	<u>001</u>	Nov 09, 2012
<u>AB</u>		RUBICON RES PVT LTD	<u>EQ 20MG BASE</u>	<u>A204883</u>	<u>001</u>	Jun 20, 2016
<u>AB</u>		TEVA	<u>EQ 25MG BASE</u>	<u>A077342</u>	<u>001</u>	Mar 09, 2016
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077342</u>	<u>002</u>	Mar 09, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077342</u>	<u>003</u>	Mar 09, 2016
<u>AB</u>		TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380</u>	<u>001</u>	Jan 07, 2013
<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503</u>	<u>001</u>	Nov 06, 2012

VIAGRA

<u>AB</u>	<u>+</u>	PFIZER INC	<u>EQ 25MG BASE</u>	<u>N020895</u>	<u>001</u>	Mar 27, 1998
<u>AB</u>	<u>+</u>		<u>EQ 50MG BASE</u>	<u>N020895</u>	<u>002</u>	Mar 27, 1998
<u>AB</u>	<u>+</u>	!	<u>EQ 100MG BASE</u>	<u>N020895</u>	<u>003</u>	Mar 27, 1998

PRESCRIPTION DRUG PRODUCT LIST

SILODOSIN

CAPSULE;ORAL

RAPAFLO

<u>AB</u>	+	ALLERGAN SALES LLC	<u>4MG</u>	<u>N022206</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>	+		<u>8MG</u>	<u>N022206</u>	<u>002</u>	Oct 08, 2008

SILODOSIN

<u>AB</u>		SANDOZ INC	<u>4MG</u>	<u>A204726</u>	<u>001</u>	Mar 31, 2017
<u>AB</u>			<u>8MG</u>	<u>A204726</u>	<u>002</u>	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

<u>AB</u>	+	KING PHARMS LLC	<u>1%</u>	<u>N017381</u>	<u>001</u>	
-----------	---	-----------------	-----------	----------------	------------	--

SSD

<u>AB</u>		DR REDDYS LA	<u>1%</u>	<u>N018578</u>	<u>001</u>	Feb 25, 1982
-----------	--	--------------	-----------	----------------	------------	--------------

THERMAZENE

<u>AB</u>		THEPHARMANETWORK LLC	<u>1%</u>	<u>N018810</u>	<u>001</u>	Dec 23, 1985
-----------	--	----------------------	-----------	----------------	------------	--------------

SSD AF

BX		DR REDDYS LA	<u>1%</u>	<u>N018578</u>	<u>003</u>	Jul 11, 1990
----	--	--------------	-----------	----------------	------------	--------------

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+	!	JANSSEN PRODS	EQ 150MG BASE	<u>N205123</u>	<u>001</u>	Nov 22, 2013
---	---	---------------	---------------	----------------	------------	--------------

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+		TCG FLUENT PHARMA	20MG/5ML	<u>N206679</u>	<u>001</u>	Apr 21, 2016
---	--	-------------------	----------	----------------	------------	--------------

+	!		40MG/5ML	<u>N206679</u>	<u>002</u>	Apr 21, 2016
---	---	--	----------	----------------	------------	--------------

TABLET;ORAL

SIMVASTATIN

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A078155</u>	<u>005</u>	Apr 05, 2013
-----------	--	-----------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
-----------	--	------------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		BIOCON LIMITED	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
-----------	--	----------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		DR REDDYS LABS INC	<u>5MG</u>	<u>A077752</u>	<u>005</u>	Jan 23, 2008
-----------	--	--------------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
-----------	--	---------------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		HISUN PHARM HANGZHOU	<u>10MG</u>	<u>A206557</u>	<u>001</u>	Nov 13, 2017
-----------	--	-------------------------	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A206557</u>	<u>002</u>	Nov 13, 2017
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A206557</u>	<u>003</u>	Nov 13, 2017
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A206557</u>	<u>004</u>	Nov 13, 2017
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
-----------	--	-------------------------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
-----------	--	-------	------------	----------------	------------	--------------

<u>AB</u>			<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>			<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
-----------	--	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A078735 001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735 002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735 003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735 004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735 005</u>	Aug 30, 2010
<u>AB</u>	VIVA HLTHCARE	<u>5MG</u>	<u>A090383 001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383 002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383 003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383 004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383 005</u>	Sep 16, 2011
<u>AB</u>	WATSON LABS TEVA	<u>5MG</u>	<u>A076685 001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685 002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685 003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685 004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685 005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837 001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837 002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837 003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837 004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837 005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	+ MSD MERCK CO	<u>5MG</u>	<u>N019766 001</u>	Dec 23, 1991
<u>AB</u>	+	<u>10MG</u>	<u>N019766 002</u>	Dec 23, 1991
<u>AB</u>	+	<u>20MG</u>	<u>N019766 003</u>	Dec 23, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019766 004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766 005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+! BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+! MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+! PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	+ PF PRISM CV	<u>0.5MG</u>	<u>N021110 004</u>	Jan 25, 2010
<u>AB</u>	+	<u>1MG</u>	<u>N021110 001</u>	Aug 25, 2000
<u>AB</u>	+	<u>2MG</u>	<u>N021110 002</u>	Aug 22, 2002

SIROLIMUS

<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A201578 001</u>	Oct 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A201578 002</u>	Oct 27, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A201676 003</u>	Jan 08, 2014

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

+ MERCK SHARP DOHME

EQ 25MG BASE

N021995 001 Oct 16, 2006

+

EQ 50MG BASE

N021995 002 Oct 16, 2006

+!

EQ 100MG BASE

N021995 003 Oct 16, 2006

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

+! FRESenius KABI USA

4MEQ/ML

A206687 001 Oct 30, 2017

+! HOSPIRA

2MEQ/ML

N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

<u>AP</u>	+! MEDICIS	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>N020645 001</u>	Feb 17, 2005
-----------	------------	------------------------------------	--------------------	--------------

SODIUM PHENYLACETATE AND SODIUM BENZOATE

<u>AP</u>	AILEX PHARMS LLC	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>A207096 001</u>	Feb 24, 2016
<u>AP</u>	MAIA PHARMS INC	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>A208521 001</u>	May 08, 2017
<u>AP</u>	NAVINTA LLC	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>A205880 001</u>	Aug 04, 2016

PRESCRIPTION DRUG PRODUCT LIST

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

<u>AP</u>	!	HOSPIRA	<u>0.9MEQ/ML</u>	<u>A077394 001</u>	Nov 09, 2005
<u>AP</u>	!		<u>1MEQ/ML</u>	<u>A077394 002</u>	Nov 09, 2005
<u>AP</u>		HOSPIRA INC	<u>0.9MEQ/ML</u>	<u>A202494 001</u>	Mar 06, 2017
<u>AP</u>			<u>1MEQ/ML</u>	<u>A202432 001</u>	Sep 26, 2017
<u>AP</u>			<u>1MEQ/ML</u>	<u>A202494 002</u>	Mar 06, 2017
<u>AP</u>		INTL MEDICATION SYS	<u>1MEQ/ML</u>	<u>A203449 001</u>	Sep 19, 2017
		HOSPIRA INC	0.5MEQ/ML	A202679 001	Mar 07, 2017
			0.5MEQ/ML	A202981 001	Mar 04, 2016
			1MEQ/ML	A202495 001	Mar 06, 2017

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088911 001</u>	Feb 07, 1985
<u>AP</u>	+	HOSPIRA	<u>9MG/ML</u>	<u>N018800 001</u>	Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>450MG/100ML</u>	<u>N019635 001</u>	Mar 09, 1988
<u>AP</u>		BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N018016 001</u>	
<u>AP</u>		HOSPIRA	<u>450MG/100ML</u>	<u>N019759 001</u>	Jun 08, 1988
<u>AP</u>	+	ICU MEDICAL INC	<u>450MG/100ML</u>	<u>N018090 001</u>	

SODIUM CHLORIDE 0.9%

<u>AP</u>		SPECTRA MDCL DEVICES	<u>9MG/ML</u>	<u>A206171 001</u>	Jul 21, 2017
<u>AP</u>		WEST-WARD PHARMS INT	<u>9MG/ML</u>	<u>A201850 001</u>	Jan 20, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>900MG/100ML</u>	<u>N017464 001</u>	
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019635 002</u>	Mar 09, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N016677 004</u>	Oct 30, 1985
<u>AP</u>	+		<u>9MG/ML</u>	<u>N020178 002</u>	Dec 07, 1992
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N016677 001</u>	
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N020178 001</u>	Dec 07, 1992
<u>AP</u>	!	FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088912 001</u>	Jan 10, 1985
<u>AP</u>			<u>900MG/100ML</u>	<u>A207310 001</u>	Sep 19, 2017
<u>AP</u>		FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177 001</u>	Apr 12, 2007
<u>AP</u>		HAEMONETICS	<u>900MG/100ML</u>	<u>A076316 001</u>	Oct 27, 2004
<u>AP</u>	+	HOSPIRA	<u>9MG/ML</u>	<u>N018803 001</u>	Oct 29, 1982
<u>AP</u>	+		<u>9MG/ML</u>	<u>N019217 001</u>	Jul 13, 1984
<u>AP</u>	+		<u>9MG/ML</u>	<u>N019465 002</u>	Jul 15, 1985
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019465 001</u>	Jul 15, 1985
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019480 001</u>	Sep 17, 1985
<u>AP</u>	+	ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N016366 001</u>	
<u>AP</u>		JUBILANT HOLLISTRSTR LABORATORIOS GRIFOLS	<u>9MG/ML</u>	<u>A203352 001</u>	May 18, 2016
<u>AP</u>			<u>900MG/100ML</u>	<u>A207956 001</u>	May 25, 2017
<u>AP</u>	!	TARO	<u>9MG/ML</u>	<u>A077407 001</u>	Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>3GM/100ML</u>	<u>N019635 003</u>	Mar 09, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>3GM/100ML</u>	<u>N019022 001</u>	Nov 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>5GM/100ML</u>	<u>N019635 004</u>	Mar 09, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N019022 002</u>	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+	B BRAUN	900MG/10ML	N019635 005	Aug 11, 2016
		MEDEFIL INC	90MG/10ML (9MG/ML)	N202832 006	Jan 06, 2012

SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	9MG/ML	A201833 001	Sep 24, 2013
--	--	-------------------------	--------	-------------	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569 001	Jul 27, 2006
	+		1012.5MG/125ML (9MG/ML)	N021569 002	Jul 27, 2006

SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	2.5MEQ/ML	N018897 001	Jul 20, 1984
--	---	---------	-----------	-------------	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>900MG/100ML</u>	<u>N016733 001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427 001</u>	
<u>AT</u>			<u>900MG/100ML</u>	<u>N017867 001</u>	
<u>AT</u>		ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N017514 001</u>	
<u>AT</u>			<u>900MG/100ML</u>	<u>N018314 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

SODIUM CHLORIDE

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT**AB** +! SANOFI AVENTIS US **62.5MG/5ML** **N020955 001** Feb 18, 1999SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE**AB** WEST-WARD PHARMS **62.5MG/5ML** **A078215 001** Mar 31, 2011
INTSODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18**AP** 3D IMAGING DRUG **10-200mCi/ML** **A203777 001** Oct 19, 2015**AP** BIOMEDCL RES FDN **10-200mCi/ML** **A204351 001** Jan 09, 2015**AP** CARDINAL HEALTH 414 **10-200mCi/ML** **A203780 001** Jul 30, 2015**AP** ESSENTIAL ISOTOPIES **10-200mCi/ML** **A204541 001** Oct 29, 2014**AP** GLOBAL ISOTOPIES LLC **10-200mCi/ML** **A204464 001** Oct 21, 2014**AP** HOT SHOTS NM LLC **10-200mCi/ML** **A204530 001** Jul 29, 2015**AP** ! HOUSTON CYCLOTRON **10-200mCi/ML** **A203544 001** Dec 26, 2012**AP** JUBILANT DRAXIMAGE **10-200mCi/ML** **A203968 001** Oct 23, 2015**AP** KREITCHMAN PET CTR **10-200mCi/ML** **A203936 001** May 19, 2016**AP** MIDWEST MEDCL **10-200mCi/ML** **A204440 001** Nov 17, 2015**AP** MIPS CRF **10-200mCi/ML** **A204517 001** Jul 21, 2015**AP** NCM USA BRONX LLC **10-200mCi/ML** **A204513 001** Nov 28, 2014**AP** PETNET **10-200mCi/ML** **A203890 001** Sep 28, 2015**AP** PRECISION NUCLEAR **10-200mCi/ML** **A204542 001** Feb 27, 2015**AP** SHERTECH LABS LLC **10-200mCi/ML** **A204315 001** Sep 22, 2014**AP** SPECTRON MRC LLC **10-200mCi/ML** **A203912 001** Apr 22, 2015**AP** UCSF RODIOPHARM **10-200mCi/ML** **A204437 001** Mar 13, 2014**AP** UNIV TX MD ANDERSON **10-200mCi/ML** **A203247 001** Dec 23, 2013**AP** UNIV UTAH CYCLOTRON **10-200mCi/ML** **A204497 001** Apr 20, 2015**AP** ZEVACOR PHARMA INC **10-200mCi/ML** **A203592 001** Aug 18, 2015

! M CPRF 10-91.5mCi/ML A203605 001 Jun 28, 2013

THE FEINSTEIN INST 20-600mCi/ML A204328 001 Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123**AA** +! CARDINAL HEALTH 418 **100uCi** **N018671 001** May 27, 1982**AA** +! **200uCi** **N018671 002** May 27, 1982**AA** MALLINKRODT NUCLEAR **100uCi** **A071909 001** Feb 28, 1989**AA** **200uCi** **A071910 001** Feb 28, 1989SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ JUBILANT DRAXIMAGE 0.009-0.1mCi N021305 006 May 19, 2005

+! MALLINKRODT NUCLEAR 0.8-100mCi N016517 001

SOLUTION; ORAL

HICON

+! JUBILANT DRAXIMAGE 250-1000mCi N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+! MALLINKRODT NUCLEAR 3.5-150mCi/VIAL N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

+! HOSPIRA 5MEQ/ML N018947 001 Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+! HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODETE

+! HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML N201444 001 Jan 14, 2011
(250MG/ML)

PRESCRIPTION DRUG PRODUCT LIST

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

AP	!	HOSPIRA	25MG/ML	A071961 001	Aug 01, 1988
-----------	----------	---------	----------------	--------------------	--------------

SODIUM NITROPRUSSIDE

AP		AKORN	25MG/ML	A208635 001	May 04, 2017
-----------	--	-------	----------------	--------------------	--------------

AP		AMNEAL PHARMS CO	25MG/ML	A209493 001	Nov 07, 2017
-----------	--	------------------	----------------	--------------------	--------------

AP		AMPHASTAR PHARMS	25MG/ML	A209832 001	Dec 18, 2017
-----------	--	------------------	----------------	--------------------	--------------

AP		INC			
-----------	--	-----	--	--	--

AP		MICRO LABS	25MG/ML	A209352 001	Dec 08, 2017
-----------	--	------------	----------------	--------------------	--------------

AP		NAMIGEN LLC	25MG/ML	A207426 001	Dec 08, 2016
-----------	--	-------------	----------------	--------------------	--------------

AP		NEXUS PHARMS	25MG/ML	A207499 001	May 25, 2017
-----------	--	--------------	----------------	--------------------	--------------

SOLUTION; IV (INFUSION)

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+	!	EXELA PHARMA SCS	10MG/50ML (0.2MG/ML)	N209387 002	Dec 07, 2017
---	---	------------------	----------------------	-------------	--------------

		LLC			
--	--	-----	--	--	--

+	!		50MG/100ML (0.5MG/ML)	N209387 001	Mar 08, 2017
---	---	--	-----------------------	-------------	--------------

SODIUM OXYBATE

SOLUTION; ORAL

SODIUM OXYBATE

AA		WEST-WARD PHARMS	500MG/ML	A202090 001	Jan 17, 2017
-----------	--	------------------	-----------------	--------------------	--------------

INT

XYREM

AA	+	!	JAZZ PHARMS	500MG/ML	N021196 001	Jul 17, 2002
-----------	----------	----------	-------------	-----------------	--------------------	--------------

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+	!	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573 001	Apr 30, 1996
-----------	----------	----------	--------------------	------------------------	--------------------	--------------

SODIUM PHENYLBUTYRATE

AB			PAR PHARM	3GM/TEASPOONFUL	A203918 001	Jun 15, 2016
-----------	--	--	-----------	------------------------	--------------------	--------------

AB			SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819 001	Mar 22, 2013
-----------	--	--	---------------------	------------------------	--------------------	--------------

TABLET; ORAL

BUPHENYL

AB	+	!	HORIZON PHARMA INC	500MG	N020572 001	May 13, 1996
-----------	----------	----------	--------------------	--------------	--------------------	--------------

SODIUM PHENYLBUTYRATE

AB			ALVOGEN MALTA	500MG	A090910 001	Nov 18, 2011
-----------	--	--	---------------	--------------	--------------------	--------------

AB			PAR PHARM	500MG	A204395 001	Apr 15, 2016
-----------	--	--	-----------	--------------	--------------------	--------------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+	!	SALIX PHARMS	0.398GM;1.102GM	N021892 001	Mar 16, 2006
---	---	--------------	-----------------	-------------	--------------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+	!	HOSPIRA	142MG/ML;276MG/ML	N018892 001	May 10, 1983
---	---	---------	-------------------	-------------	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

AA	!	KVK TECH	454GM/BOT	A040905 001	Mar 30, 2009
-----------	----------	----------	------------------	--------------------	--------------

KIONEX

AA		PADDOCK LLC	454GM/BOT	A040029 001	Feb 06, 1998
-----------	--	-------------	------------------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

AA		AILEX PHARMS LLC	454GM/BOT	A206815 001	Feb 18, 2016
-----------	--	------------------	------------------	--------------------	--------------

AA		BELCHER PHARMS LLC	454GM/BOT	A205727 001	Feb 23, 2016
-----------	--	--------------------	------------------	--------------------	--------------

AA		CMP PHARMA INC	454GM/BOT	A089910 001	Jan 19, 1989
-----------	--	----------------	------------------	--------------------	--------------

AA		ECI PHARMS LLC	453.6GM/BOT	A090313 001	Dec 21, 2011
-----------	--	----------------	--------------------	--------------------	--------------

AA		EPIC PHARMA LLC	453.6GM/BOT	A202333 001	Mar 19, 2014
-----------	--	-----------------	--------------------	--------------------	--------------

AA		NUVO PHARM INC	454GM/BOT	A204071 001	Nov 28, 2014
-----------	--	----------------	------------------	--------------------	--------------

KALEXATE

		KVK TECH	15GM/BOT	A040905 002	Apr 03, 2015
--	--	----------	----------	-------------	--------------

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARM INC	15GM/BOT	A204071 002	Nov 28, 2014
--	--	----------------	----------	-------------	--------------

SUSPENSION; ORAL, RECTAL

KIONEX

AA		PADDOCK LLC	15GM/60ML	A040028 001	Sep 17, 2007
-----------	--	-------------	------------------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LLC	15GM/60ML	A090590 001	May 13, 2011
-----------	--	-------------	------------------	--------------------	--------------

AA		WEST-WARD PHARMS	15GM/60ML	A089049 001	Nov 17, 1986
-----------	--	------------------	------------------	--------------------	--------------

INT

PRESCRIPTION DRUG PRODUCT LIST

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SPS

AA	!	CMP PHARMA INC	15GM/60ML	A087859 001	Dec 08, 1982
-----------	---	----------------	------------------	--------------------	--------------

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

!	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)		A040541 001	Nov 12, 2004
---	---------------------	--------------------	--	-------------	--------------

!		60MG/2ML (30MG/ML)		A040541 002	Nov 12, 2004
---	--	--------------------	--	-------------	--------------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)		N203923 001	Feb 14, 2012
---	-------------	------------------------	--	-------------	--------------

SOFOBUVIR

TABLET; ORAL

SOVALDI

+	GILEAD SCIENCES INC	400MG		N204671 001	Dec 06, 2013
---	---------------------	-------	--	-------------	--------------

SOFOBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG; 100MG		N208341 001	Jun 28, 2016
---	---------------------	--------------	--	-------------	--------------

SOFOBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL

VOSEVI

+	GILEAD SCIENCES INC	400MG; 100MG; 100MG		N209195 001	Jul 18, 2017
---	---------------------	---------------------	--	-------------	--------------

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB		TEVA PHARMS USA	5MG	A091464 001	Apr 02, 2014
-----------	--	-----------------	------------	--------------------	--------------

AB			10MG	A091464 002	Apr 02, 2014
-----------	--	--	-------------	--------------------	--------------

VESICARE

AB	+	ASTELLAS	5MG	N021518 001	Nov 19, 2004
-----------	---	----------	------------	--------------------	--------------

AB	+	!	10MG	N021518 002	Nov 19, 2004
-----------	---	---	-------------	--------------------	--------------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280 006	Aug 24, 1995
----	---	----------------------	------------	-------------	--------------

GENOTROPIN PRESERVATIVE FREE

BX	+	PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280 004	Aug 24, 1995
----	---	----------------------	------------	-------------	--------------

HUMATROPE

BX	+	LILLY	5MG/VIAL	N019640 004	Mar 08, 1987
----	---	-------	----------	-------------	--------------

BX	+		6MG/VIAL	N019640 005	Feb 04, 1999
----	---	--	----------	-------------	--------------

NORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010
----	--	------------------	-----------	-------------	--------------

BX			10MG/1.5ML	N021148 009	Mar 01, 2010
----	--	--	------------	-------------	--------------

OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426 002	May 30, 2006
----	--	--------	------------	-------------	--------------

BX			5MG/1.5ML	N021426 003	Jan 16, 2008
----	--	--	-----------	-------------	--------------

BX			5.8MG/VIAL	N021426 001	May 30, 2006
----	--	--	------------	-------------	--------------

BX			10MG/1.5ML	N021426 004	Aug 25, 2008
----	--	--	------------	-------------	--------------

SAIZEN

BX	+	EMD SERONO	5MG/VIAL	N019764 002	Oct 08, 1996
----	---	------------	----------	-------------	--------------

SEROSTIM

BX		EMD SERONO	5MG/VIAL	N020604 002	Aug 23, 1996
----	--	------------	----------	-------------	--------------

BX			6MG/VIAL	N020604 001	Aug 23, 1996
----	--	--	----------	-------------	--------------

VALTROPIN

BX		LG CHEM LTD	5MG/VIAL	N021905 001	Apr 19, 2007
----	--	-------------	----------	-------------	--------------

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774 002	Jan 04, 2002
----	---	---------	----------	-------------	--------------

GENOTROPIN

+	PHARMACIA AND UPJOHN	13.8MG/VIAL		N020280 007	Oct 23, 1996
---	----------------------	-------------	--	-------------	--------------

GENOTROPIN PRESERVATIVE FREE

+	PHARMACIA AND UPJOHN	0.2MG/VIAL		N020280 001	Jan 27, 1998
---	----------------------	------------	--	-------------	--------------

+		0.4MG/VIAL		N020280 002	Jan 27, 1998
---	--	------------	--	-------------	--------------

+		0.6MG/VIAL		N020280 003	Jan 27, 1998
---	--	------------	--	-------------	--------------

+		0.8MG/VIAL		N020280 005	Jan 27, 1998
---	--	------------	--	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN PRESERVATIVE FREE

+		1MG/VIAL	N020280	008	Jan 27, 1998
+		1.2MG/VIAL	N020280	009	Jan 27, 1998
+		1.4MG/VIAL	N020280	010	Jan 27, 1998
+		1.6MG/VIAL	N020280	011	Jan 27, 1998
+		1.8MG/VIAL	N020280	012	Jan 27, 1998
+	!	2MG/VIAL	N020280	013	Jan 27, 1998

HUMATROPE

+	!	LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
+	!		24MG/VIAL	N019640	007	Feb 04, 1999

NORDITROPIN FLEXPRO

NOVO NORDISK INC

		15MG/1.5ML	N021148	010	Mar 01, 2010
		30MG/3ML	N021148	011	Jan 23, 2015

NUTROPIN AQ NUSPIN

+	!	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
+	!		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
+	!		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008

NUTROPIN AQ PEN

+	!	GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
+	!		20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008

SAIZEN

+	!	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
---	---	------------	------------	---------	-----	--------------

SEROSTIM

EMD SERONO

		4MG/VIAL	N020604	003	Jul 25, 1997
--	--	----------	---------	-----	--------------

ZOMACTON

+		FERRING	10MG/VIAL	N019774	003	Mar 07, 2012
---	--	---------	-----------	---------	-----	--------------

ZORBTIVE

+	!	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003
---	---	------------	------------	---------	-----	--------------

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+	!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015
---	---	-------------------	---------------	---------	-----	--------------

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+	!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005
---	---	----------------	---------------	---------	-----	--------------

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE

		3GM/100ML	N017863	001	
--	--	-----------	---------	-----	--

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN

		3.3GM/100ML	N016741	001	
--	--	-------------	---------	-----	--

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+	!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009
---	---	----------------------	----------------------	---------	-----	--------------

SOLUTION; ORAL

SOTYLIZE

+	!	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014
---	---	------------------	-----------------	---------	-----	--------------

TABLET; ORAL

BETAPACE

AB1	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992
AB1	+		120MG	N019865	005	Apr 20, 1994
AB1	+	!	160MG	N019865	002	Oct 30, 1992
AB1	+		240MG	N019865	003	Oct 30, 1992

SORINE

AB1		UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001
AB1			120MG	A075500	004	Apr 27, 2001
AB1			160MG	A075500	002	Apr 27, 2001
AB1			240MG	A075500	003	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB1		APOTEX INC	80MG	A076140	001	Sep 26, 2002
AB1			120MG	A076140	002	Sep 26, 2002
AB1			160MG	A076140	003	Sep 26, 2002
AB1			240MG	A076140	004	Sep 26, 2002
AB1		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016
AB1			120MG	A207428	002	Oct 21, 2016
AB1			160MG	A207428	003	Oct 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB1</u>	TEVA	<u>80MG</u>	<u>A075429 001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075429 002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075429 003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075429 004</u>	May 01, 2000
<u>AB1</u>	UPSHER-SMITH LABS	<u>80MG</u>	<u>A075366 001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075366 002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075366 003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075366 004</u>	May 01, 2000
<u>AB1</u>	VINTAGE PHARMS	<u>80MG</u>	<u>A075563 001</u>	Nov 07, 2003
<u>AB1</u>		<u>120MG</u>	<u>A075563 002</u>	Nov 07, 2003
<u>AB1</u>		<u>160MG</u>	<u>A075563 003</u>	Nov 07, 2003
<u>AB1</u>		<u>240MG</u>	<u>A075563 004</u>	Nov 07, 2003

BETAPACE AF

<u>AB2</u>	+	COVIS PHARMA BV	<u>80MG</u>	<u>N021151 001</u>	Feb 22, 2000
<u>AB2</u>	+		<u>120MG</u>	<u>N021151 002</u>	Feb 22, 2000
<u>AB2</u>	+	!	<u>160MG</u>	<u>N021151 003</u>	Feb 22, 2000

SOTALOL HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214 001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214 002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214 003</u>	Aug 27, 2003
<u>AB2</u>	EPIC PHARMA INC	<u>80MG</u>	<u>A077070 001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070 002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070 003</u>	Nov 04, 2005
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616 001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616 002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616 003</u>	Feb 07, 2007

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+	FRESENIUS	<u>10%</u>	<u>N017643 001</u>	
-----------	---	-----------	------------	--------------------	--

INTRALIPID 20%

<u>AP</u>	+	FRESENIUS	<u>20%</u>	<u>N018449 001</u>	
<u>AP</u>	+	!	<u>20%</u>	<u>N020248 001</u>	Aug 07, 1996

NUTRILIPID 10%

<u>AP</u>	+	B BRAUN	<u>10%</u>	<u>N019531 001</u>	May 28, 1993
-----------	---	---------	------------	--------------------	--------------

NUTRILIPID 20%

<u>AP</u>	+	B BRAUN	<u>20%</u>	<u>N019531 002</u>	May 28, 1993
-----------	---	---------	------------	--------------------	--------------

INTRALIPID 30%

	+	FRESENIUS	<u>30%</u>	<u>N019942 001</u>	Dec 30, 1993
--	---	-----------	------------	--------------------	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO LLC	<u>0.9%</u>	<u>N022408 001</u>	Jan 18, 2011
--	---	-------------	-------------	--------------------	--------------

SPIRONOLACTONE

SUSPENSION; ORAL

CAROSPIR

	+	CMP DEV LLC	<u>25MG/5ML</u>	<u>N209478 001</u>	Aug 04, 2017
--	---	-------------	-----------------	--------------------	--------------

TABLET; ORAL

ALDACTONE

<u>AB</u>	+	GD SEARLE LLC	<u>25MG</u>	<u>N012151 009</u>	Dec 30, 1983
<u>AB</u>	+		<u>50MG</u>	<u>N012151 008</u>	Dec 30, 1982
<u>AB</u>	+	!	<u>100MG</u>	<u>N012151 010</u>	Dec 30, 1983

SPIRONOLACTONE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A203512 001</u>	Sep 19, 2016
<u>AB</u>		<u>50MG</u>	<u>A203512 002</u>	Sep 19, 2016
<u>AB</u>		<u>100MG</u>	<u>A203512 003</u>	Sep 19, 2016
<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353 003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353 001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353 002</u>	Jul 29, 1999
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426 001</u>	Jul 02, 2010
<u>AB</u>		<u>50MG</u>	<u>A091426 002</u>	Jul 02, 2010
<u>AB</u>		<u>100MG</u>	<u>A091426 003</u>	Jul 02, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A202187 001</u>	Mar 06, 2014
<u>AB</u>		<u>50MG</u>	<u>A202187 002</u>	Mar 06, 2014
<u>AB</u>		<u>100MG</u>	<u>A202187 003</u>	Mar 06, 2014
<u>AB</u>	JUBILANT GENERICS	<u>25MG</u>	<u>A203253 001</u>	Apr 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203253 002</u>	Apr 23, 2014

PRESCRIPTION DRUG PRODUCT LIST

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

<u>AB</u>		<u>100MG</u>	<u>A203253 003</u>	Apr 23, 2014
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424 001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424 002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424 003</u>	Aug 20, 2001
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809 001</u>	
<u>AB</u>	SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A089424 001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424 003</u>	Aug 11, 1999
<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750 001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750 002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750 003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672 003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672 004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672 001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672 002</u>	Dec 29, 2008
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A078957 001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957 002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957 003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957 004</u>	Dec 29, 2008
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A079069 001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A079069 002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069 003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069 004</u>	Dec 29, 2008

ZERIT

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412 002</u>	Jun 24, 1994
<u>AB</u>	+	<u>20MG</u>	<u>N020412 003</u>	Jun 24, 1994
<u>AB</u>	+	<u>30MG</u>	<u>N020412 004</u>	Jun 24, 1994
<u>AB</u>	+!	<u>40MG</u>	<u>N020412 005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030 001</u>	Mar 20, 2009
-----------	-----------	---------------	--------------------	--------------

ZERIT

<u>AA</u>	+! BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413 001</u>	Sep 06, 1996
-----------	----------------------------	---------------	--------------------	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+! HOSPIRA	<u>100%</u>	<u>N018802 001</u>	Oct 27, 1982
-----------	------------	-------------	--------------------	--------------

STERILE WATER FOR INJECTION

<u>AP</u>	FRESENIUS KABI USA	<u>100%</u>	<u>A209689 001</u>	Nov 24, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>100%</u>	<u>A206369 001</u>	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>100%</u>	<u>N019633 001</u>	Feb 29, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>100%</u>	<u>N018632 001</u>	Jun 30, 1982
<u>AP</u>	+!	<u>100%</u>	<u>N018632 002</u>	Apr 19, 1988
<u>AP</u>	FRESENIUS KABI USA	<u>100%</u>	<u>A088400 001</u>	Jan 16, 1984
<u>AP</u>	+! HOSPIRA	<u>100%</u>	<u>N018801 001</u>	Oct 27, 1982
<u>AP</u>	+! ICU MEDICAL INC	<u>100%</u>	<u>N018233 001</u>	
<u>AP</u>	+!	<u>100%</u>	<u>N019869 001</u>	Dec 26, 1989
<u>AP</u>	TARO	<u>100%</u>	<u>A077393 001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017428 001</u>	
-----------	-----------------	-------------	--------------------	--

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>100%</u>	<u>N016734 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017866 001</u>	
<u>AT</u>	ICU MEDICAL INC	<u>100%</u>	<u>N017513 001</u>	
<u>AT</u>		<u>100%</u>	<u>N018313 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

! X GEN PHARMS

EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+! TEVA PHARMS USA

1GM/VIAL

N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON**AP** +! GE HEALTHCARE1mCi/ML**N020134 001** Jun 18, 1993STRONTIUM CHLORIDE SR-89**AP** BIO NUCLEONICS1mCi/ML**A075941 001** Jan 06, 2003SUCCIMER

CAPSULE; ORAL

CHEMET

+! RECORDATI RARE

100MG

N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE**AP** +! SANDOZ INC20MG/ML**N008453 002**QUELICIN**AP** +! HOSPIRA20MG/ML**N008845 006**QUELICIN PRESERVATIVE FREE**AP** +! HOSPIRA20MG/ML**N008845 001**SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+! FOREST LABS INC

1GM/10ML

N019183 001 Dec 16, 1993

TABLET; ORAL

CARAFATE**AB** +! FOREST LABS INC1GM**N018333 001**SUCRALFATE**AB** MYLAN IRELAND LTD1GM**A074415 001** Jun 08, 1998**AB** TEVA1GM**A070848 001** Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+! VIFOR FRESENIUS

500MG

N205109 001 Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE**AP** +! AKORNEQ 0.05MG BASE/ML**N019050 001** May 04, 1984SUFENTANIL CITRATE**AP** HOSPIRAEQ 0.05MG BASE/ML**A074534 001** Dec 11, 1996**AP** WEST-WARD PHARMSEQ 0.05MG BASE/ML**A074413 001** Dec 15, 1995

INT

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

+ ORGANON SUB MERCK

EQ 200MG BASE/2ML (EQ 100MG BASE/ML)

N022225 002 Dec 15, 2015

+!

EQ 500MG BASE/5ML (EQ 100MG BASE/ML)

N022225 001 Dec 15, 2015

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+! SUN PHARM INDS INC

1%

N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+! SUN PHARM INDS INC

1%

N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON**AB** +! VALEANT PHARMS10%**N019931 001** Dec 23, 1996

NORTH

SULFACETAMIDE SODIUM**AB** FOUGERA PHARMS10%**A077015 001** Nov 17, 2006**AB** PERRIGO CO10%**A078649 001** Mar 23, 2009

PRESCRIPTION DRUG PRODUCT LIST

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

TENNESSEE

AB TARO **10%** **A078668 001** May 20, 2009

OINTMENT; OPHTHALMIC

SULFACETAMIDE SODIUM

! PERRIGO CO 10%

A080029 001

TENNESSEE

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10**AT** ! ALLERGAN **10%** **A080028 001**SULFACETAMIDE SODIUM**AT** AKORN **10%** **A040215 001** May 25, 1999**AT** BAUSCH AND LOMB **10%** **A040066 001** Dec 28, 1994**AT** SANDOZ INC **10%** **A089560 001** Oct 18, 1988SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

! SANDOZ 500MG

A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AP** MYLAN LABS LTD **80MG/ML; 16MG/ML** **A206607 001** Aug 30, 2017**AP** ! TEVA PHARMS USA **80MG/ML; 16MG/ML** **A073303 001** Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AUROBINDO PHARMA **200MG/5ML; 40MG/5ML** **A091348 001** Jun 08, 2010**AB** ! HI TECH PHARMA **200MG/5ML; 40MG/5ML** **A074650 001** Dec 29, 1997**AB** VINTAGE **200MG/5ML; 40MG/5ML** **A077785 001** Jan 24, 2007SULFATRIM PEDIATRIC**AB** STI PHARMA LLC **200MG/5ML; 40MG/5ML** **N018615 001** Jan 07, 1983

TABLET; ORAL

BACTRIM**AB** + SUN PHARM **400MG; 80MG** **N017377 001**

INDUSTRIES

BACTRIM DS**AB** +! SUN PHARM **800MG; 160MG** **N017377 002**

INDUSTRIES

SEPTRA**AB** MONARCH PHARMS **400MG; 80MG** **N017376 001**SEPTRA DS**AB** MONARCH PHARMS **800MG; 160MG** **N017376 002**SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AMNEAL PHARMS NY **400MG; 80MG** **A076899 001** Jan 27, 2005**AB** **800MG; 160MG** **A076899 002** Jan 27, 2005**AB** AUROBINDO PHARMA **400MG; 80MG** **A090624 001** Feb 16, 2010**AB** **800MG; 160MG** **A090624 002** Feb 16, 2010**AB** CHARTWELL MOLECULES **400MG; 80MG** **A078060 002** Jan 25, 2007**AB** **800MG; 160MG** **A078060 001** Jan 25, 2007**AB** GLENMARK GENERICS **400MG; 80MG** **A090828 002** Dec 22, 2010**AB** **800MG; 160MG** **A090828 001** Dec 22, 2010**AB** SUN PHARM **800MG; 160MG** **A071017 001** Aug 25, 1986

INDUSTRIES

AB VISTA PHARMS **400MG; 80MG** **A076817 001** Oct 07, 2005**AB** **800MG; 160MG** **A076817 002** Oct 07, 2005SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH**AB** TEVA **800MG; 160MG** **A070037 001** Jun 02, 1987SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH**AB** TEVA PHARMS **400MG; 80MG** **A070030 001** Jun 02, 1987

SULFAMETHOXAZOLE AND TRIMETHOPRIM

SUN PHARM 400MG; 80MG

A071017 002 Aug 25, 1986

INDUSTRIES

SULFANILAMIDE

CREAM; VAGINAL

AVC

+! MYLAN SPECIALITY LP 15%

N006530 003 Jan 27, 1987

PRESCRIPTION DRUG PRODUCT LIST

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

! PHARMACIA AND 250MG/5ML A086983 001
UPJOHN

TABLET; ORAL

AZULFIDINE**AB** +! PHARMACIA AND 500MG N007073 001
UPJOHNSULFASALAZINE**AB** VINTAGE PHARMS 500MG A040349 001 Jan 11, 2002**AB** WATSON LABS 500MG A085828 001

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS**AB** +! PHARMACIA AND 500MG N007073 002 Apr 06, 1983
UPJOHNSULFASALAZINE**AB** VINTAGE PHARMS 500MG A075339 001 Jan 11, 2002SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+! BRACCO 60.7MG/25MG N203684 001 Oct 15, 2014

SULINDAC

TABLET; ORAL

SULINDAC**AB** EPIC PHARMA 150MG A072710 001 Mar 25, 1991**AB** 200MG A072711 001 Mar 25, 1991**AB** EPIC PHARMA LLC 150MG A073262 002 Sep 06, 1991**AB** 200MG A073262 001 Sep 06, 1991**AB** MYLAN 150MG A073039 002 Jun 22, 1993**AB** 200MG A073039 001 Jun 22, 1993**AB** SUN PHARM 150MG A072050 001 Apr 17, 1991
INDUSTRIES**AB** 200MG A072051 001 Apr 17, 1991**AB** WATSON LABS 150MG A071891 001 Apr 03, 1990**AB** ! 200MG A071795 001 Apr 03, 1990SUMATRIPTAN

SPRAY; NASAL

IMITREX**AB** +! GLAXOSMITHKLINE 5MG/SPRAY N020626 001 Aug 26, 1997**AB** +! 20MG/SPRAY N020626 003 Aug 26, 1997SUMATRIPTAN**AB** LANNETT CO INC 5MG/SPRAY A204841 001 Feb 19, 2016**AB** 20MG/SPRAY A204841 002 Feb 19, 2016SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE**AB** +! GLAXOSMITHKLINE EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N020080 002 Feb 01, 2006**AB** +! EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N020080 003 Dec 23, 1996SUMATRIPTAN SUCCINATE**AB** ANTARES PHARMA INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078319 001 Dec 10, 2015**AB** EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078319 002 Dec 10, 2015**AB** DR REDDYS LABS INC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090495 001 Jan 29, 2014**AB** SUN PHARMA GLOBAL EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090358 001 Jun 21, 2011IMITREX**AP** +! GLAXOSMITHKLINE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N020080 001 Dec 28, 1992SUMATRIPTAN SUCCINATE**AP** AUROBINDO PHARMA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A202758 001 Apr 23, 2013
LTD**AP** FRESENIUS KABI USA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079242 001 Mar 02, 2009**AP** HIKMA FARMACEUTICA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A200183 001 Sep 16, 2013**AP** INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090310 001 Aug 11, 2010**AP** MYLAN LABS LTD EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A203322 001 Apr 14, 2014**AP** PAR PHARM EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077332 001 Oct 09, 2009**AP** PAR STERILE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077871 001 Jul 09, 2009
PRODUCTS**AP** SAGENT AGILA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090641 001 Jul 28, 2010**AP** SAGENT AGILA LLC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090314 001 Jun 10, 2010**AP** TEVA PHARMS USA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077907 001 Feb 06, 2009**AP** WEST-WARD PHARMS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009
INT**AP** WOCKHARDT EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078593 001 Feb 06, 2009

PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMAVEL DOSEPRO

BX	+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013
BX	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009

POWDER; INHALATION

ONZETRA XSAIL

	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016
--	---	---------------	--------------	---------	-----	--------------

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016
--	--	--------------------	---------------------------------------	---------	-----	--------------

TABLET; ORAL

IMITREX

AB	+	GLAXOSMITHKLINE	EQ 25MG BASE	N020132	002	Jun 01, 1995
AB	+		EQ 50MG BASE	N020132	003	Jun 01, 1995
AB	+		EQ 100MG BASE	N020132	001	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	EQ 25MG BASE	A200263	001	Jun 19, 2012
AB			EQ 50MG BASE	A200263	002	Jun 19, 2012
AB			EQ 100MG BASE	A200263	003	Jun 19, 2012
AB		AUROBINDO PHARMA	EQ 25MG BASE	A078327	001	Aug 10, 2009
AB			EQ 50MG BASE	A078327	002	Aug 10, 2009
AB			EQ 100MG BASE	A078327	003	Aug 10, 2009
AB		DR REDDYS LABS INC	EQ 25MG BASE	A076847	001	Aug 10, 2009
AB			EQ 50MG BASE	A076847	002	Aug 10, 2009
AB			EQ 100MG BASE	A076847	003	Aug 10, 2009
AB		MYLAN	EQ 25MG BASE	A077744	001	Aug 10, 2009
AB			EQ 50MG BASE	A077744	002	Aug 10, 2009
AB			EQ 100MG BASE	A077744	003	Aug 10, 2009
AB		ORCHID HLTHCARE	EQ 25MG BASE	A078284	001	Aug 10, 2009
AB			EQ 50MG BASE	A078284	002	Aug 10, 2009
AB			EQ 100MG BASE	A078284	003	Aug 10, 2009
AB		SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009
AB			EQ 50MG BASE	A078295	002	Aug 10, 2009
AB			EQ 100MG BASE	A078295	003	Aug 10, 2009
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009
AB			EQ 50MG BASE	A076554	002	Aug 10, 2009
AB			EQ 100MG BASE	A076572	001	Feb 09, 2009
AB		WATSON LABS	EQ 25MG BASE	A076933	001	Aug 10, 2009
AB			EQ 50MG BASE	A076933	002	Aug 10, 2009
AB			EQ 100MG BASE	A076933	003	Aug 10, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

	+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006
	+		EQ 25MG BASE	N021938	002	Jan 26, 2006
	+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009
	+		EQ 50MG BASE	N021938	003	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

	+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
	+		10MG	N204569	002	Aug 13, 2014
	+		15MG	N204569	003	Aug 13, 2014
	+		20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

AB	+	ASTELLAS	EQ 0.5MG BASE	N050708	003	Aug 24, 1998
AB	+		EQ 1MG BASE	N050708	001	Apr 08, 1994
AB	+		EQ 5MG BASE	N050708	002	Apr 08, 1994

TACROLIMUS

AB		ACCORD HLTHCARE	EQ 0.5MG BASE	A091195	001	Aug 31, 2011
AB			EQ 1MG BASE	A091195	002	Aug 31, 2011
AB			EQ 5MG BASE	A091195	003	Aug 31, 2011
AB		BELCHER PHARMS LLC	EQ 0.5MG BASE	A206651	001	Nov 30, 2017
AB			EQ 1MG BASE	A206651	002	Nov 30, 2017
AB			EQ 5MG BASE	A206651	003	Nov 30, 2017
AB		DR REDDYS LABS LTD	EQ 0.5MG BASE	A090509	001	May 12, 2010
AB			EQ 1MG BASE	A090509	002	May 12, 2010
AB			EQ 5MG BASE	A090509	003	May 12, 2010

PRESCRIPTION DRUG PRODUCT LIST

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
AB		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
AB		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
AB	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
AB		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
AB		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
AB	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
AB		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
AB		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
AB	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
AB		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
AB		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096 001	Jul 19, 2013
+		EQ 1MG BASE	N204096 002	Jul 19, 2013
+	!	EQ 5MG BASE	N204096 003	Jul 19, 2013

INJECTABLE; INJECTION

PROGRAF

AP	+	ASTELLAS	<u>EQ 5MG BASE/ML</u>	<u>N050709 001</u>	Apr 08, 1994
-----------	---	----------	------------------------------	---------------------------	--------------

TACROLIMUS

AP		HOSPIRA INC	<u>EQ 5MG BASE/ML</u>	<u>A203900 001</u>	Aug 25, 2017
-----------	--	-------------	------------------------------	---------------------------	--------------

OINTMENT; TOPICAL

PROTOPIC

AB	+	LEO PHARMA AS	<u>0.03%</u>	<u>N050777 001</u>	Dec 08, 2000
AB	+	!	<u>0.1%</u>	<u>N050777 002</u>	Dec 08, 2000

TACROLIMUS

AB		FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744 001</u>	Sep 09, 2014
AB			<u>0.1%</u>	<u>A200744 002</u>	Sep 09, 2014

TABLET, EXTENDED RELEASE; ORAL

ENVARUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406 001	Jul 10, 2015
+		EQ 1MG BASE	N206406 002	Jul 10, 2015
+	!	EQ 4MG BASE	N206406 003	Jul 10, 2015

TADALAFIL

TABLET; ORAL

ADCIRCA

+	ELI LILLY CO	20MG	N022332 001	May 22, 2009
---	--------------	------	-------------	--------------

CIALIS

+	LILLY	2.5MG	N021368 004	Jan 07, 2008
+		5MG	N021368 001	Nov 21, 2003
+		10MG	N021368 002	Nov 21, 2003
+	!	20MG	N021368 003	Nov 21, 2003

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	OAK PHARMS INC	0.0015%	N202514 001	Feb 10, 2012
---	----------------	---------	-------------	--------------

TALC

AEROSOL, METERED; INTRAPLEURAL

SCLEROSOL

+	LYMOL MEDCL	400MG/SPRAY	N020587 001	Dec 24, 1997
---	-------------	-------------	-------------	--------------

POWDER; INTRAPLEURAL

STERITALC

+	NOVATECH SA	2GM/VIAL	N205555 001	May 01, 2017
+		3GM/VIAL	N205555 002	May 01, 2017
+	!	4GM/VIAL	N205555 003	May 01, 2017

TALC

+	LYMOL MEDCL	5GM/BOT	N021388 001	Dec 15, 2003
---	-------------	---------	-------------	--------------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012
---	--------	----------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 10MG BASE</u>	<u>A070929 001</u>	Feb 20, 2003
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A070929 002</u>	Feb 20, 2003
<u>AB</u>		APOTEX	<u>EQ 10MG BASE</u>	<u>A090878 001</u>	Sep 23, 2011
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A090878 002</u>	Sep 23, 2011
<u>AB</u>		MAYNE PHARMA	<u>EQ 10MG BASE</u>	<u>A075797 001</u>	Feb 20, 2003
<u>AB</u>	!		<u>EQ 20MG BASE</u>	<u>A075797 002</u>	Feb 20, 2003
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A074732 002</u>	Feb 20, 2003
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A074732 001</u>	Feb 20, 2003
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 10MG BASE</u>	<u>A206694 001</u>	Oct 27, 2017
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A206694 002</u>	Oct 27, 2017

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.4MG</u>	<u>N020579 001</u>	Apr 15, 1997
-----------	---	-------------------------	--------------	--------------------	--------------

TAMSULOSIN HYDROCHLORIDE

<u>AB</u>		ANCHEN PHARMS	<u>0.4MG</u>	<u>A202010 001</u>	Jan 04, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.4MG</u>	<u>A202433 001</u>	Apr 30, 2013
<u>AB</u>		IMPAX LABS	<u>0.4MG</u>	<u>A090377 001</u>	Mar 02, 2010
<u>AB</u>		MACLEODS PHARMS LTD	<u>0.4MG</u>	<u>A204645 001</u>	Jan 20, 2017
<u>AB</u>		MYLAN	<u>0.4MG</u>	<u>A090408 001</u>	Apr 27, 2010
<u>AB</u>		SANDOZ	<u>0.4MG</u>	<u>A078015 001</u>	Apr 27, 2010
<u>AB</u>		SUN PHARM INDS LTD	<u>0.4MG</u>	<u>A090931 001</u>	Jul 15, 2010
<u>AB</u>		SYNTHON PHARMS	<u>0.4MG</u>	<u>A078801 001</u>	Apr 27, 2010
<u>AB</u>		TEVA PHARMS	<u>0.4MG</u>	<u>A077630 001</u>	Apr 27, 2010
<u>AB</u>		WOCKHARDT	<u>0.4MG</u>	<u>A078938 001</u>	Apr 27, 2010
<u>AB</u>		ZYDUS PHARMS USA INC	<u>0.4MG</u>	<u>A078225 001</u>	Apr 27, 2010

TAMSULOSIN HYDROCHLORIDE

<u>AB</u>		ALKEM LABS LTD	<u>0.4MG</u>	<u>A207405 001</u>	Aug 11, 2017
-----------	--	----------------	--------------	--------------------	--------------

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+! DEPOMED INC EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TABLET;ORAL

NUCYNTA

+ DEPOMED INC EQ 50MG BASE

N022304 001 Nov 20, 2008

+ EQ 75MG BASE

N022304 002 Nov 20, 2008

+! EQ 100MG BASE

N022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

+ DEPOMED INC EQ 50MG BASE

N200533 001 Aug 25, 2011

+ EQ 100MG BASE

N200533 002 Aug 25, 2011

+ EQ 150MG BASE

N200533 003 Aug 25, 2011

+ EQ 200MG BASE

N200533 004 Aug 25, 2011

+! EQ 250MG BASE

N200533 005 Aug 25, 2011

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

+! VANDA PHARMS INC 20MG

N205677 001 Jan 31, 2014

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

+! ANACOR PHARMS INC 5%

N204427 001 Jul 07, 2014

TAZAROTENE

AEROSOL, FOAM;TOPICAL

FABIOR

+! MAYNE PHARMA 0.1%

N202428 001 May 11, 2012

CREAM;TOPICAL

AVAGE

<u>AB</u>	+	ALLERGAN	<u>0.1%</u>	<u>N021184 003</u>	Sep 30, 2002
-----------	---	----------	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TAZAROTENE

CREAM; TOPICAL

TAZAROTENE

AB	G AND W LABS INC	0.1%	A208662 001	Dec 22, 2017
AB	TARO	0.1%	A208258 001	Apr 03, 2017

TAZORAC

AB	+! ALLERGAN	0.1%	N021184 002	Sep 29, 2000
	+!	0.05%	N021184 001	Sep 29, 2000

GEL; TOPICAL

TAZORAC

	+! ALLERGAN	0.05%	N020600 001	Jun 13, 1997
	+!	0.1%	N020600 002	Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS	+! JUBILANT DRAXIMAGE	N/A	N017776 001	
----	-----------------------	-----	-------------	--

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	+! DRAXIMAGE	N/A	N017881 001	Dec 30, 1987
----	--------------	-----	-------------	--------------

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

	+! LANTHEUS MEDCL	N/A	N020256 001	Nov 23, 1994
--	-------------------	-----	-------------	--------------

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

	PHARMALUCENCE	N/A	N018467 001	Mar 16, 1982
--	---------------	-----	-------------	--------------

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

	+! GE HEALTHCARE	N/A	N019829 001	Dec 30, 1988
--	------------------	-----	-------------	--------------

POWDER; INTRAVENOUS

DRAX EXAMETAZIME

	JUBILANT DRAXIMAGE	N/A	N208870 001	Aug 17, 2017
--	--------------------	-----	-------------	--------------

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC

AP	+! BRACCO	N/A	N018963 001	Jan 21, 1987
-----------	-----------	------------	--------------------	--------------

TECHNETIUM TC-99M MEBROFENIN

AP	PHARMALUCENCE	N/A	A078242 001	Jan 29, 2008
-----------	---------------	------------	--------------------	--------------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

	+! JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004
--	-----------------------	-----	-------------	--------------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP

AP	PHARMALUCENCE	N/A	N018124 001	
-----------	---------------	------------	--------------------	--

MDP-BRACCO

AP	CARDINAL HEALTH 414	N/A	N018107 001	
-----------	---------------------	------------	--------------------	--

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3

	+! MALLINKRODT NUCLEAR	N/A	N019882 001	Jun 15, 1990
--	------------------------	-----	-------------	--------------

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

	+! MALLINKRODT NUCLEAR	N/A	N018321 001	
--	------------------------	-----	-------------	--

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

DTPA

	+! DRAXIMAGE	N/A	N018511 001	Dec 29, 1989
--	--------------	-----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

AP	PHARMALUCENCE	N/A	N019039 001	Jun 30, 1987
-----------	---------------	------------	--------------------	--------------

TECHNESCAN PYP KIT

AP	MALLINKRODT NUCLEAR	N/A	N017538 001	
-----------	---------------------	------------	--------------------	--

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

+	MALLINKRODT NUCLEAR	N/A	N019981 001	Jun 10, 1991
---	---------------------	------------	--------------------	--------------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

AP	+	LANTHEUS MEDCL	N/A	N019785 001	Dec 21, 1990
-----------	---	----------------	------------	--------------------	--------------

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	A078809 001	Apr 28, 2009
-----------	---------------------	------------	--------------------	--------------

AP	JUBILANT DRAXIMAGE	N/A	A078806 001	Apr 29, 2009
-----------	--------------------	------------	--------------------	--------------

AP	PHARMALUCENCE	10-30mCi	A079157 001	Jul 10, 2009
-----------	---------------	-----------------	--------------------	--------------

TECHNETIUM TC-99M SESTAMIBI

AP	MALLINKRODT NUCLEAR	N/A	A078098 001	Sep 22, 2008
-----------	---------------------	------------	--------------------	--------------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771 002	Feb 12, 2014
---	----------------	-------------------	--------------------	--------------

ULTRA-TECHNEKOW FM

+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243 003	Feb 18, 2014
---	---------------------	-------------------	--------------------	--------------

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693 002	Dec 13, 2013
---	---------------	----------------------	--------------------	--------------

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+	PHARMALUCENCE	N/A	N017858 001	
---	---------------	------------	--------------------	--

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUEW 30ML

+	GE HEALTHCARE	N/A	N020372 002	Jul 07, 2005
---	---------------	------------	--------------------	--------------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+	CARDINAL HEALTH 414	N/A	N202207 001	Mar 13, 2013
---	---------------------	------------	--------------------	--------------

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+	CUBIST PHARMS LLC	200MG/VIAL	N205436 001	Jun 20, 2014
---	-------------------	------------	--------------------	--------------

TABLET; ORAL

SIVEXTRO

+	CUBIST PHARMS LLC	200MG	N205435 001	Jun 20, 2014
---	-------------------	-------	--------------------	--------------

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+	NPS PHARMS INC	5MG/VIAL	N203441 001	Dec 21, 2012
---	----------------	----------	--------------------	--------------

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

+	THERAVANCE BIOPHARMA	EQ 750MG BASE/VIAL	N022110 002	Sep 11, 2009
---	-------------------------	--------------------	--------------------	--------------

TELMISARTAN

TABLET; ORAL

MICARDIS

AB	+	BOEHRINGER INGELHEIM	20MG	N020850 003	Apr 04, 2000
-----------	---	-------------------------	-------------	--------------------	--------------

AB	+		40MG	N020850 001	Nov 10, 1998
-----------	---	--	-------------	--------------------	--------------

AB	+		80MG	N020850 002	Nov 10, 1998
-----------	---	--	-------------	--------------------	--------------

TELMISARTAN

AB	ALEMBIC PHARMS LTD	20MG	A202130 001	Jul 07, 2014
-----------	--------------------	-------------	--------------------	--------------

AB		40MG	A202130 002	Jul 07, 2014
-----------	--	-------------	--------------------	--------------

AB		80MG	A202130 003	Jul 07, 2014
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TELMISARTAN

TABLET; ORAL

TELMISARTAN

<u>AB</u>	AMNEAL PHARMS	<u>20MG</u>	<u>A204415 001</u>	Sep 08, 2015
<u>AB</u>		<u>40MG</u>	<u>A204415 002</u>	Sep 08, 2015
<u>AB</u>		<u>80MG</u>	<u>A204415 003</u>	Sep 08, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206511 001</u>	Sep 03, 2015
<u>AB</u>		<u>40MG</u>	<u>A206511 002</u>	Sep 03, 2015
<u>AB</u>		<u>80MG</u>	<u>A206511 003</u>	Sep 03, 2015
<u>AB</u>	CADILA PHARMS LTD	<u>20MG</u>	<u>A208605 001</u>	Jul 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A208605 002</u>	Jul 25, 2017
<u>AB</u>		<u>80MG</u>	<u>A208605 003</u>	Jul 25, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>20MG</u>	<u>A090032 001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A090032 002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A090032 003</u>	Jul 07, 2014
<u>AB</u>	HETERO LABS LTD V	<u>20MG</u>	<u>A205901 001</u>	Apr 22, 2016
<u>AB</u>		<u>40MG</u>	<u>A205901 002</u>	Apr 22, 2016
<u>AB</u>		<u>80MG</u>	<u>A205901 003</u>	Apr 22, 2016
<u>AB</u>	INVENTIA HLTHCARE	<u>20MG</u>	<u>A205150 001</u>	Oct 30, 2015
<u>AB</u>		<u>40MG</u>	<u>A205150 002</u>	Oct 30, 2015
<u>AB</u>		<u>80MG</u>	<u>A205150 003</u>	Oct 30, 2015
<u>AB</u>	JUBILANT GENERICS	<u>20MG</u>	<u>A204164 001</u>	Aug 22, 2016
<u>AB</u>		<u>40MG</u>	<u>A204164 002</u>	Aug 22, 2016
<u>AB</u>		<u>80MG</u>	<u>A204164 003</u>	Aug 22, 2016
<u>AB</u>	MICRO LABS	<u>20MG</u>	<u>A207016 001</u>	Oct 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A207016 002</u>	Oct 03, 2017
<u>AB</u>		<u>80MG</u>	<u>A207016 003</u>	Oct 03, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>20MG</u>	<u>A202397 001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A202397 002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A202397 003</u>	Jul 07, 2014
<u>AB</u>	PRINSTON INC	<u>20MG</u>	<u>A207882 001</u>	May 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A207882 002</u>	May 03, 2017
<u>AB</u>		<u>80MG</u>	<u>A207882 003</u>	May 03, 2017
<u>AB</u>	SANDOZ INC	<u>20MG</u>	<u>A203867 001</u>	Nov 03, 2014
<u>AB</u>		<u>40MG</u>	<u>A203867 002</u>	Nov 03, 2014
<u>AB</u>		<u>80MG</u>	<u>A203867 003</u>	Nov 03, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>20MG</u>	<u>A203171 001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A203171 002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A203171 003</u>	Jul 07, 2014
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A078710 001</u>	Jan 08, 2014
<u>AB</u>		<u>40MG</u>	<u>A078710 002</u>	Jan 08, 2014
<u>AB</u>		<u>80MG</u>	<u>A078710 003</u>	Jan 08, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>20MG</u>	<u>A203325 001</u>	Aug 26, 2014
<u>AB</u>		<u>40MG</u>	<u>A203325 002</u>	Aug 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A203325 003</u>	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET; ORAL

XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE N208794 001 Feb 28, 2017

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	+ SPECGX LLC	<u>7.5MG</u>	<u>N018163 003</u>	Oct 25, 1991
<u>AB</u>	+	<u>15MG</u>	<u>N018163 001</u>	
<u>AB</u>	+	<u>22.5MG</u>	<u>N018163 004</u>	Nov 02, 2004
<u>AB</u>	+!	<u>30MG</u>	<u>N018163 002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071620 002</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620 001</u>	Aug 07, 1987
<u>AB</u>	AMNEAL PHARMS	<u>7.5MG</u>	<u>A203482 001</u>	May 23, 2016
<u>AB</u>		<u>15MG</u>	<u>A203482 002</u>	May 23, 2016
<u>AB</u>		<u>22.5MG</u>	<u>A203482 003</u>	May 23, 2016
<u>AB</u>		<u>30MG</u>	<u>A203482 004</u>	May 23, 2016
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A070920 002</u>	May 21, 2010
<u>AB</u>		<u>15MG</u>	<u>A070920 004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920 003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920 001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>7.5MG</u>	<u>A071457 002</u>	Jun 22, 2012
<u>AB</u>		<u>15MG</u>	<u>A071456 001</u>	Apr 21, 1987
<u>AB</u>		<u>22.5MG</u>	<u>A071457 003</u>	Jun 22, 2012

PRESCRIPTION DRUG PRODUCT LIST

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

<u>AB</u>		<u>30MG</u>	<u>A071457</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	PRINSTON INC	<u>7.5MG</u>	<u>A201781</u>	<u>001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781</u>	<u>002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781</u>	<u>003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781</u>	<u>004</u>	Jun 04, 2015
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>7.5MG</u>	<u>A078581</u>	<u>001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175</u>	<u>002</u>	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029</u>	<u>001</u>	Aug 11, 1999
<u>AB</u>	+		<u>20MG</u>	<u>N021029</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>	+		<u>100MG</u>	<u>N021029</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	+		<u>140MG</u>	<u>N021029</u>	<u>005</u>	Oct 19, 2006
<u>AB</u>	+		<u>180MG</u>	<u>N021029</u>	<u>006</u>	Oct 19, 2006
<u>AB</u>	+		<u>250MG</u>	<u>N021029</u>	<u>004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A201528</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>			<u>20MG</u>	<u>A201528</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>			<u>100MG</u>	<u>A201528</u>	<u>003</u>	Feb 27, 2017
<u>AB</u>			<u>140MG</u>	<u>A201528</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>			<u>180MG</u>	<u>A201528</u>	<u>005</u>	Feb 27, 2017
<u>AB</u>			<u>250MG</u>	<u>A201528</u>	<u>006</u>	Feb 27, 2017
<u>AB</u>		AMERIGEN PHARMS LTD	<u>5MG</u>	<u>A203490</u>	<u>001</u>	Jul 13, 2016
<u>AB</u>			<u>20MG</u>	<u>A203490</u>	<u>002</u>	Jul 13, 2016
<u>AB</u>			<u>100MG</u>	<u>A203490</u>	<u>003</u>	Jul 13, 2016
<u>AB</u>			<u>140MG</u>	<u>A203490</u>	<u>004</u>	Jul 13, 2016
<u>AB</u>			<u>180MG</u>	<u>A203490</u>	<u>005</u>	Jul 13, 2016
<u>AB</u>			<u>250MG</u>	<u>A203490</u>	<u>006</u>	Jul 13, 2016
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A203691</u>	<u>001</u>	May 08, 2015
<u>AB</u>			<u>20MG</u>	<u>A203691</u>	<u>002</u>	May 08, 2015
<u>AB</u>			<u>100MG</u>	<u>A203691</u>	<u>003</u>	May 08, 2015
<u>AB</u>			<u>140MG</u>	<u>A203691</u>	<u>004</u>	May 08, 2015
<u>AB</u>			<u>180MG</u>	<u>A203691</u>	<u>005</u>	May 08, 2015
<u>AB</u>			<u>250MG</u>	<u>A203691</u>	<u>006</u>	May 08, 2015
<u>AB</u>		BARR	<u>5MG</u>	<u>A078879</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>			<u>20MG</u>	<u>A078879</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>			<u>100MG</u>	<u>A078879</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>			<u>140MG</u>	<u>A078879</u>	<u>005</u>	Mar 01, 2010
<u>AB</u>			<u>180MG</u>	<u>A078879</u>	<u>006</u>	Mar 01, 2010
<u>AB</u>			<u>250MG</u>	<u>A078879</u>	<u>004</u>	Mar 01, 2010
<u>AB</u>		CHEMI SPA	<u>5MG</u>	<u>A204639</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>			<u>20MG</u>	<u>A204639</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>			<u>100MG</u>	<u>A204639</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>			<u>140MG</u>	<u>A204639</u>	<u>004</u>	Nov 23, 2016
<u>AB</u>			<u>180MG</u>	<u>A204639</u>	<u>005</u>	Nov 23, 2016
<u>AB</u>			<u>250MG</u>	<u>A204639</u>	<u>006</u>	Nov 23, 2016
<u>AB</u>		DEVA HOLDING AS	<u>5MG</u>	<u>A207658</u>	<u>001</u>	Apr 26, 2017
<u>AB</u>			<u>20MG</u>	<u>A207658</u>	<u>002</u>	Apr 26, 2017
<u>AB</u>			<u>100MG</u>	<u>A207658</u>	<u>003</u>	Apr 26, 2017
<u>AB</u>			<u>140MG</u>	<u>A207658</u>	<u>004</u>	Apr 26, 2017
<u>AB</u>			<u>180MG</u>	<u>A207658</u>	<u>005</u>	Apr 26, 2017
<u>AB</u>			<u>250MG</u>	<u>A207658</u>	<u>006</u>	Apr 26, 2017
<u>AB</u>		IDT AUSTRALIA LTD	<u>5MG</u>	<u>A206413</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>			<u>20MG</u>	<u>A206413</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>			<u>100MG</u>	<u>A206413</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>			<u>140MG</u>	<u>A206413</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>			<u>180MG</u>	<u>A206413</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>			<u>250MG</u>	<u>A206413</u>	<u>006</u>	Apr 12, 2016
<u>AB</u>		KREMERS URBAN PHARMS	<u>5MG</u>	<u>A203898</u>	<u>001</u>	Feb 10, 2016
<u>AB</u>			<u>20MG</u>	<u>A203898</u>	<u>002</u>	Feb 10, 2016
<u>AB</u>			<u>100MG</u>	<u>A203898</u>	<u>003</u>	Feb 10, 2016
<u>AB</u>			<u>140MG</u>	<u>A203898</u>	<u>004</u>	Feb 10, 2016
<u>AB</u>			<u>180MG</u>	<u>A203898</u>	<u>005</u>	Feb 10, 2016
<u>AB</u>			<u>250MG</u>	<u>A203898</u>	<u>006</u>	Feb 10, 2016

PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	MYLAN PHARMS INC	5MG	A205227 001	Jun 29, 2016
AB		20MG	A205227 002	Jun 29, 2016
AB		100MG	A205227 003	Jun 29, 2016
AB		140MG	A205227 004	Jun 29, 2016
AB		180MG	A205227 005	Jun 29, 2016
AB		250MG	A205227 006	Jun 29, 2016
AB	RISING PHARMS INC	5MG	A206309 001	Apr 27, 2016
AB		20MG	A206309 002	Apr 27, 2016
AB		100MG	A206309 003	Apr 27, 2016
AB		140MG	A206309 004	Apr 27, 2016
AB		180MG	A206309 005	Apr 27, 2016
AB		250MG	A206309 006	Apr 27, 2016
AB	SUN PHARMA GLOBAL	5MG	A201742 001	Feb 12, 2014
AB		20MG	A201742 002	Feb 12, 2014
AB		100MG	A201742 003	Feb 12, 2014
AB		140MG	A201742 004	Feb 12, 2014
AB		180MG	A201742 005	Feb 12, 2014
AB		250MG	A201742 006	Feb 12, 2014
AB	WATSON LABS TEVA	5MG	A203959 001	Apr 18, 2017
AB		20MG	A203959 002	Apr 18, 2017
AB		100MG	A203959 003	Apr 18, 2017
AB		140MG	A203959 004	Apr 18, 2017
AB		250MG	A203959 005	Apr 18, 2017
AB	ZYDUS PHARMS USA INC	5MG	A206750 001	Jul 31, 2017
AB		20MG	A206750 002	Jul 31, 2017
AB		100MG	A206750 003	Jul 31, 2017
AB		140MG	A206750 004	Jul 31, 2017
AB		180MG	A206750 005	Jul 31, 2017
AB		250MG	A206750 006	Jul 31, 2017

POWDER; INTRAVENOUS

TEMODAR

+! MERCK SHARP DOHME 100MG/VIAL N022277 001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+! PF PRISM CV 25MG/ML (25MG/ML) N022088 001 May 30, 2007

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

VEMLIDY

+! GILEAD SCIENCES INC EQ 25MG BASE N208464 001 Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+! GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	300MG	A091612 001	Mar 18, 2015
AB	+! GILEAD SCIENCES INC	300MG	N021356 001	Oct 26, 2001
	+	150MG	N021356 002	Jan 18, 2012
	+	200MG	N021356 003	Jan 18, 2012
	+	250MG	N021356 004	Jan 18, 2012

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	APOTEX	EQ 1MG BASE	A075498 001	Apr 12, 2001
AB		EQ 2MG BASE	A075498 002	Apr 12, 2001
AB		EQ 5MG BASE	A075498 003	Apr 12, 2001
AB		EQ 10MG BASE	A075498 004	Apr 12, 2001
AB	IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075614 002	Jan 30, 2001
AB		EQ 2MG BASE	A075614 001	Jan 30, 2001
AB		EQ 5MG BASE	A075614 003	Jan 30, 2001
AB		EQ 10MG BASE	A075614 004	Jan 30, 2001
AB	JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004
AB		EQ 2MG BASE	A075317 002	Dec 20, 2004
AB		EQ 5MG BASE	A075317 003	Dec 20, 2004

PRESCRIPTION DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB		EQ 10MG BASE	A075317 004	Dec 20, 2004
AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140 002	Feb 11, 2000
AB		EQ 2MG BASE	A075140 003	Feb 11, 2000
AB		EQ 5MG BASE	A075140 001	Feb 11, 2000
AB		EQ 10MG BASE	A075140 004	Feb 11, 2000
AB	SANDOZ	EQ 1MG BASE	A074823 001	Mar 30, 1998
AB	!	EQ 2MG BASE	A074823 002	Mar 30, 1998
AB		EQ 5MG BASE	A074823 003	Mar 30, 1998
AB		EQ 10MG BASE	A074823 004	Mar 30, 1998

TERBINAFFINE HYDROCHLORIDE

TABLET; ORAL

LAMISIL

AB	+!	NOVARTIS	EQ 250MG BASE	N020539 001	May 10, 1996
-----------	----	----------	----------------------	--------------------	--------------

TERBINAFFINE HYDROCHLORIDE

AB		APOTEX	EQ 250MG BASE	A078199 001	Jul 02, 2007
AB		AUROBINDO PHARMA	EQ 250MG BASE	A078297 001	Jul 02, 2007
AB		BRECKENRIDGE PHARM	EQ 250MG BASE	A077714 001	Jun 04, 2010
AB		CIPLA LTD	EQ 250MG BASE	A077137 001	Jul 02, 2007
AB		DR REDDYS LABS INC	EQ 250MG BASE	A076390 001	Jul 02, 2007
AB		GLENMARK GENERICS	EQ 250MG BASE	A078157 001	Jul 02, 2007
AB		HARRIS PHARM	EQ 250MG BASE	A077919 001	Jul 02, 2007
AB		INVAGEN PHARMS	EQ 250MG BASE	A077533 001	Jul 02, 2007
AB		ORCHID HLTHCARE	EQ 250MG BASE	A078163 001	Jul 02, 2007
AB		TEVA	EQ 250MG BASE	A076377 001	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP		AKORN	1MG/ML	A078151 001	Jan 07, 2008
AP	!	ATHENEX INC	1MG/ML	A076770 001	Apr 23, 2004
AP		FRESENIUS KABI USA	1MG/ML	A076887 001	May 26, 2004
AP		HIKMA FARMACEUTICA	1MG/ML	A078630 001	May 20, 2009
AP		UNITED BIOMEDCL	1MG/ML	A200122 001	Nov 08, 2013

TABLET; ORAL

TERBUTALINE SULFATE

AB		IMPAX LABS	2.5MG	A075877 001	Jun 26, 2001
AB			5MG	A075877 002	Jun 26, 2001
AB		LANNETT	2.5MG	A077152 001	Mar 25, 2005
AB	!		5MG	A077152 002	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 7

AB	+!	JANSSSEN PHARMS	0.4%	N019579 001	Dec 31, 1987
-----------	----	-----------------	-------------	--------------------	--------------

TERCONAZOLE

AB		FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005
AB		TARO	0.4%	A076043 001	Jan 19, 2005
BX	+!	NYCOMED US	0.8%	N021735 001	Oct 01, 2004
BX	!	TARO	0.8%	A075953 001	Apr 06, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

AB	+!	JANSSSEN PHARMS	80MG	N019641 001	May 24, 1988
-----------	----	-----------------	-------------	--------------------	--------------

TERCONAZOLE

AB		PERRIGO NEW YORK	80MG	A077149 001	Mar 17, 2006
AB		TARO	80MG	A077553 001	Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

	+	SANOFI AVENTIS US	7MG	N202992 001	Sep 12, 2012
	+	!	14MG	N202992 002	Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

	+	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318 002	Jun 25, 2008
--	---	-------	--------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+! THERATECHNOLOGIES EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+! ALLERGAN SALES LLC 2MG/24HR

N020489 003 Oct 20, 2011

+! 4MG/24HR

N020489 004 Oct 20, 2011

GEL; TRANSDERMAL

ANDROGELAB1 + ABBVIE25MG/2.5GM PACKETN021015 001 Feb 28, 2000AB1 +!50MG/5GM PACKETN021015 002 Feb 28, 2000TESTOSTERONEAB1 ACTAVIS LABS UT INC25MG/2.5GM PACKETA076737 001 Jan 27, 2006AB1 50MG/5GM PACKETA076737 002 Jan 27, 2006AB1 PAR PHARM25MG/2.5GM PACKETA076744 001 May 23, 2007AB1 50MG/5GM PACKETA076744 002 May 23, 2007AB1 PERRIGO ISRAEL25MG/2.5GM PACKETN203098 002 Jan 31, 2013AB1 50MG/5GM PACKETN203098 003 Jan 31, 2013ANDROGELAB2 + ABBVIE1.62% (20.25MG/1.25GM PACKET)N022309 002 Sep 07, 2012AB2 +!1.62% (40.5MG/2.5GM PACKET)N022309 003 Sep 07, 2012TESTIMAB2 +! AUXILIUM PHARMS LLC50MG/5GM PACKETN021454 001 Oct 31, 2002TESTOSTERONEAB2 ACTAVIS LABS UT INC50MG/5GM PACKETA091073 001 Sep 18, 2017AB2 PERRIGO UK FINCO1.62% (20.25MG/1.25GM PACKET)A205781 001 Jul 12, 2017AB2 1.62% (40.5MG/2.5GM PACKET)A205781 002 Jul 12, 2017VOGELXOAB2 UPSHER-SMITH LABS50MG/5GM PACKETN204399 002 Jun 04, 2014

TESTOSTERONE

BX ANI PHARMS INC 25MG/2.5GM PACKET

N202763 001 Feb 14, 2012

BX 50MG/5GM PACKET

N202763 002 Feb 14, 2012

GEL, METERED; NASAL

NATESTO

AYTU BIOSCIENCE INC 5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014

GEL, METERED; TRANSDERMAL

ANDROGELAB +! ABBVIE1.62% (20.25MG/1.25GM ACTUATION)N022309 001 Apr 29, 2011AB +!12.5MG/1.25GM ACTUATIONN021015 003 Sep 26, 2003FORTESTAAB +! ENDO PHARMS10MG/0.5GM ACTUATIONN021463 001 Dec 29, 2010TESTOSTERONEAB ACTAVIS LABS UT INC10MG/0.5GM ACTUATIONA204571 001 Aug 05, 2015AB 12.5MG/1.25GM ACTUATIONA076737 003 Mar 09, 2015AB PERRIGO ISRAEL12.5MG/1.25GM ACTUATIONN203098 001 Jan 31, 2013AB 1.62% (20.25MG/1.25GM ACTUATION)A204268 001 Aug 04, 2015VOGELXO

BX UPSHER-SMITH LABS

12.5MG/1.25GM ACTUATION

N204399 003 Jun 04, 2014

PELLET; IMPLANTATION

TESTOPEL

! AUXILIUM PHARMS INC 75MG

A080911 001

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONEAT ACTAVIS LABS UT INC30MG/1.5ML ACTUATIONA205328 001 Aug 07, 2017AT LUPIN LTD30MG/1.5ML ACTUATIONA208061 001 Oct 23, 2017AT ! PERRIGO ISRAEL30MG/1.5ML ACTUATIONA204255 001 Feb 28, 2017

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+! AUXILIUM PHARMS LLC 30MG

N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONEAO ! PHARMACIA AND100MG/MLA085635 002

UPJOHN

AO !200MG/MLA085635 003TESTOSTERONE CYPIONATEAO HIKMA FARMACEUTICA200MG/MLA091244 001 May 01, 2012AO LUITPOLD PHARMS INC200MG/MLA207742 001 Jun 16, 2017AO MYLAN INSTITUTIONAL200MG/MLA040652 001 Dec 11, 2006AO PADDOCK LLC200MG/MLA040530 001 Jan 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

<u>AO</u>	SANDOZ INC	<u>100MG/ML</u>	<u>A040615 001</u>	Aug 10, 2006
<u>AO</u>		<u>200MG/ML</u>	<u>A040615 002</u>	Aug 10, 2006
<u>AO</u>	SUN PHARM INDS LTD	<u>100MG/ML</u>	<u>A201720 001</u>	Jun 03, 2013
<u>AO</u>		<u>200MG/ML</u>	<u>A201720 002</u>	Jun 03, 2013
<u>AO</u>	WATSON PHARMS INC	<u>200MG/ML</u>	<u>A086030 001</u>	
<u>AO</u>	WEST-WARD PHARMS INT	<u>100MG/ML</u>	<u>A090387 001</u>	Jul 15, 2010
<u>AO</u>		<u>200MG/ML</u>	<u>A090387 002</u>	Jul 15, 2010

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

<u>AO</u>	+! ENDO PHARMS	<u>200MG/ML</u>	<u>N009165 003</u>	
-----------	----------------	-----------------	--------------------	--

TESTOSTERONE ENANTHATE

<u>AO</u>	HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120 001</u>	Sep 18, 2012
<u>AO</u>	MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040647 001</u>	Oct 05, 2009
<u>AO</u>	PADDOCK LLC	<u>200MG/ML</u>	<u>A040575 001</u>	Jun 14, 2006
<u>AO</u>	WATSON PHARMS INC	<u>200MG/ML</u>	<u>A085598 001</u>	

TESTOSTERONE UNDECANOATE

INJECTABLE; INTRAMUSCULAR

AVEED

+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219 001	Mar 05, 2014
----	-----------------	----------------------	-------------	--------------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>25MG</u>	<u>A206686 001</u>	Jul 07, 2017
<u>AB</u>	APICORE US	<u>12.5MG</u>	<u>A207682 001</u>	Jan 31, 2017
<u>AB</u>		<u>25MG</u>	<u>A207682 002</u>	Jan 31, 2017
<u>AB</u>	BIONPHARMA INC	<u>12.5MG</u>	<u>A208826 001</u>	Dec 18, 2017
<u>AB</u>		<u>25MG</u>	<u>A208826 002</u>	Dec 18, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG</u>	<u>A209284 001</u>	Jan 08, 2018
<u>AB</u>		<u>25MG</u>	<u>A209284 002</u>	Jan 08, 2018
<u>AB</u>	HETERO LABS LTD V	<u>12.5MG</u>	<u>A204574 001</u>	Feb 03, 2016
<u>AB</u>		<u>25MG</u>	<u>A204574 002</u>	Feb 03, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>12.5MG</u>	<u>A206129 001</u>	Aug 17, 2015
<u>AB</u>		<u>25MG</u>	<u>A206129 002</u>	Aug 17, 2015
	<u>XENAZINE</u>			
<u>AB</u>	+ VALEANT PHARMS NORTH	<u>12.5MG</u>	<u>N021894 001</u>	Aug 15, 2008
<u>AB</u>	+!	<u>25MG</u>	<u>N021894 002</u>	Aug 15, 2008

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+!	NOVARTIS PHARMS CORP	0.5%	N208135 001	Feb 29, 2016
----	-------------------------	------	-------------	--------------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

<u>AB</u>	+ HERITAGE PHARMA	<u>250MG</u>	<u>N050278 003</u>	
<u>AB</u>	+!	<u>500MG</u>	<u>N050278 001</u>	

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>	CHARTWELL TETRA	<u>250MG</u>	<u>A062752 001</u>	Aug 12, 1988
<u>AB</u>		<u>500MG</u>	<u>A062752 002</u>	Aug 12, 1988
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A061837 001</u>	
<u>AB</u>		<u>500MG</u>	<u>A061837 002</u>	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

!	FOUGERA PHARMS	0.05%	A086576 002	
		0.1%	A086576 001	

SPRAY; NASAL

TYZINE

!	FOUGERA PHARMS	0.1%	A086576 003	
---	----------------	------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

THALIDOMIDE

CAPSULE; ORAL

THALOMID

+	CELGENE	50MG	N020785 001	Jul 16, 1998
+		100MG	N020785 002	Jan 17, 2003
+		150MG	N020785 004	Jan 10, 2007
+	!	200MG	N020785 003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110 002</u>	Feb 27, 1996
AP	+	LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806 001</u>	
AP	+	MALLINKRODT NUCLEAR	<u>1mCi/ML</u>	<u>N018150 001</u>	

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

AP	+	LANTHEUS MEDCL	<u>2mCi/ML</u>	<u>N017806 002</u>	Oct 09, 1998
-----------	---	----------------	----------------	---------------------------	--------------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

		ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983
!		AUXILIUM PHARMS INC	400MG	A081034 001	Feb 28, 1992
		AUXILIUM PHARMS LLC	200MG	A087943 001	Aug 22, 1983
			300MG	A087944 001	Aug 22, 1983

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>40MG/100ML</u>	<u>N019826 001</u>	Aug 14, 1992
-----------	---	---------	-------------------	---------------------------	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>160MG/100ML</u>	<u>N019826 003</u>	Aug 14, 1992
-----------	---	---------	--------------------	---------------------------	--------------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>320MG/100ML</u>	<u>N019826 006</u>	Aug 14, 1992
-----------	---	---------	--------------------	---------------------------	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA INC	<u>40MG/100ML</u>	<u>N019211 001</u>	Dec 14, 1984
-----------	---	-------------	-------------------	---------------------------	--------------

AP	+		<u>160MG/100ML</u>	<u>N019211 003</u>	Dec 14, 1984
-----------	---	--	--------------------	---------------------------	--------------

AP	+		<u>320MG/100ML</u>	<u>N019211 006</u>	Jan 20, 1988
-----------	---	--	--------------------	---------------------------	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	80MG/100ML	N019826 002	Aug 14, 1992
---	---------	------------	-------------	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA INC	4MG/ML	N019211 007	Dec 14, 1984
---	-------------	--------	-------------	--------------

SOLUTION; ORAL

THEOPHYLLINE

AA	!	SILARX	<u>80MG/15ML</u>	<u>A091156 001</u>	Apr 13, 2011
-----------	---	--------	------------------	---------------------------	--------------

AA		TRIS PHARMA INC	<u>80MG/15ML</u>	<u>A091586 001</u>	Jun 15, 2012
-----------	--	-----------------	------------------	---------------------------	--------------

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

AA	!	NOSTRUM LABS INC	<u>80MG/15ML</u>	<u>A085186 001</u>	
-----------	---	------------------	------------------	---------------------------	--

THEOPHYLLINE

AA		PHARM ASSOC	<u>80MG/15ML</u>	<u>A206344 001</u>	Dec 16, 2016
-----------	--	-------------	------------------	---------------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB		ALEMBIC PHARMS LTD	<u>300MG</u>	<u>A090430 001</u>	Oct 27, 2010
-----------	--	--------------------	--------------	---------------------------	--------------

AB		GLENMARK GENERICS	<u>400MG</u>	<u>A090355 001</u>	Jul 13, 2010
-----------	--	-------------------	--------------	---------------------------	--------------

AB			<u>600MG</u>	<u>A090355 002</u>	Jul 13, 2010
-----------	--	--	--------------	---------------------------	--------------

AB		MYLAN IRELAND LTD	<u>400MG</u>	<u>A040560 003</u>	Apr 21, 2006
-----------	--	-------------------	--------------	---------------------------	--------------

AB	!		<u>600MG</u>	<u>A040560 002</u>	Apr 21, 2006
-----------	---	--	--------------	---------------------------	--------------

AB	!	PLIVA	<u>100MG</u>	<u>A089807 001</u>	Apr 30, 1990
-----------	---	-------	--------------	---------------------------	--------------

AB	!		<u>200MG</u>	<u>A089808 001</u>	Apr 30, 1990
-----------	---	--	--------------	---------------------------	--------------

AB			<u>300MG</u>	<u>A089763 001</u>	Apr 30, 1990
-----------	--	--	--------------	---------------------------	--------------

AB		RHODES PHARMS	<u>400MG</u>	<u>A087571 001</u>	Sep 01, 1982
-----------	--	---------------	--------------	---------------------------	--------------

AB			<u>600MG</u>	<u>A040086 001</u>	Apr 15, 1996
-----------	--	--	--------------	---------------------------	--------------

THEOCHRON

		NOSTRUM PHARMS LLC	100MG	A087400 003	Feb 21, 1985
--	--	--------------------	-------	-------------	--------------

			200MG	A087400 004	Feb 21, 1985
--	--	--	-------	-------------	--------------

THEOPHYLLINE

!	ALEMBIC PHARMS LTD	450MG	A090430 002	Oct 27, 2010
---	--------------------	-------	-------------	--------------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	!	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556 001</u>	
-----------	---	--------------------	-----------------	---------------------------	--

AP		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623 001</u>	Jun 25, 2012
-----------	--	---------------------	-----------------	---------------------------	--------------

AP		SAGENT PHARMS	<u>100MG/ML</u>	<u>A206106 001</u>	Dec 01, 2017
-----------	--	---------------	-----------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+! ASPEN GLOBAL INC 40MG N012429 001

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A088004 002</u>	Mar 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A088004 003</u>	Mar 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A088004 004</u>	Mar 15, 1983
<u>AB</u>	!	<u>100MG</u>	<u>A088004 001</u>	Nov 18, 1983
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A089953 004</u>	Aug 01, 1986
<u>AB</u>		<u>25MG</u>	<u>A089953 003</u>	Aug 01, 1986
<u>AB</u>		<u>50MG</u>	<u>A089953 002</u>	Aug 01, 1986
<u>AB</u>		<u>100MG</u>	<u>A089953 001</u>	Oct 07, 1988

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

! WEST-WARD PHARMS 15MG/VIAL A075547 001 Apr 02, 2001

INT

POWDER; IV (INFUSION)

TEPADINA

+! ADIENNE SA 15MG/VIAL N208264 001 Jan 26, 2017

+! 100MG/VIAL N208264 002 Jan 26, 2017

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

MYLAN

1MG A071093 002 Jun 23, 1987

2MG A071093 003 Jun 23, 1987

! 5MG A071093 004 Jun 23, 1987

10MG A071093 001 Jun 23, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+! GENZYME 1.1MG/VIAL N020898 001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

<u>AB</u>	+	CEPHALON	<u>2MG</u>	<u>N020646 005</u>	Apr 16, 1999
<u>AB</u>	+!		<u>4MG</u>	<u>N020646 001</u>	Sep 30, 1997
<u>AB</u>	+		<u>12MG</u>	<u>N020646 002</u>	Sep 30, 1997
<u>AB</u>	+		<u>16MG</u>	<u>N020646 003</u>	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS CO	<u>2MG</u>	<u>A208181 001</u>	Dec 08, 2017
<u>AB</u>		<u>4MG</u>	<u>A208181 002</u>	Dec 08, 2017
<u>AB</u>		<u>12MG</u>	<u>A208181 003</u>	Dec 08, 2017
<u>AB</u>		<u>16MG</u>	<u>A208181 004</u>	Dec 08, 2017
<u>AB</u>	SUN PHARM INDS	<u>2MG</u>	<u>A077555 001</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A077555 002</u>	Nov 04, 2011
<u>AB</u>	WILSHIRE PHARMS INC	<u>2MG</u>	<u>A206857 001</u>	Oct 13, 2017
<u>AB</u>		<u>4MG</u>	<u>A206857 002</u>	Oct 13, 2017
<u>AB</u>		<u>12MG</u>	<u>A206857 003</u>	Oct 13, 2017
<u>AB</u>		<u>16MG</u>	<u>A206857 004</u>	Oct 13, 2017

TICAGRELOR

TABLET; ORAL

BRILINTA

+ ASTRAZENECA PHARMS 60MG N022433 002 Sep 03, 2015

+! 90MG N022433 001 Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089 001</u>	Jul 01, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>250MG</u>	<u>A075526 001</u>	Sep 26, 2002
<u>AB</u>	!	TEVA	<u>A075149 001</u>	Aug 20, 1999

PRESCRIPTION DRUG PRODUCT LIST

TIGECYCLINE

POWDER; IV (INFUSION)

TIGECYCLINE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N205645</u>	<u>001</u>	Dec 01, 2016
<u>AP</u>	SANDOZ INC	<u>50MG/VIAL</u>	<u>A091620</u>	<u>001</u>	May 27, 2015

TYGACIL

<u>AP</u>	+! PF PRISM CV	<u>50MG/VIAL</u>	<u>N021821</u>	<u>001</u>	Jun 15, 2005
-----------	----------------	------------------	----------------	------------	--------------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

<u>AT</u>	+! OAK PHARMS INC	<u>EQ 0.25% BASE</u>	<u>N020439</u>	<u>001</u>	Mar 31, 1995
<u>AT</u>	+!	<u>EQ 0.5% BASE</u>	<u>N020439</u>	<u>002</u>	Mar 31, 1995

TIMOLOL

<u>AT</u>	AKORN	<u>EQ 0.25% BASE</u>	<u>A205309</u>	<u>001</u>	Sep 30, 2016
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A205309</u>	<u>002</u>	Sep 30, 2016

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AB</u>	SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
<u>AB</u>		<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998

TIMOPTIC-XE

<u>AB</u>	+! VALEANT PHARMS LLC	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
<u>AB</u>	+!	<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
<u>AT</u>	PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	! SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>A074261</u>	<u>001</u>	Apr 28, 1995
<u>AT</u>	WOCKHARDT	<u>EQ 0.25% BASE</u>	<u>A078771</u>	<u>001</u>	Sep 28, 2009
<u>AT1</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A074466</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>		<u>EQ 0.5% BASE</u>	<u>A074516</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A074776</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	FDC LTD	<u>EQ 0.5% BASE</u>	<u>A077259</u>	<u>002</u>	Apr 30, 2008
<u>AT1</u>	HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A075163</u>	<u>001</u>	Sep 10, 2002
<u>AT1</u>	PACIFIC PHARMA	<u>EQ 0.5% BASE</u>	<u>A074747</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	! SANDOZ INC	<u>EQ 0.5% BASE</u>	<u>A074262</u>	<u>001</u>	Apr 28, 1995
<u>AT1</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078771</u>	<u>002</u>	Sep 28, 2009

ISTALOL

<u>AT2</u>	+! BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>N021516</u>	<u>001</u>	Jun 04, 2004
------------	--------------------	---------------------	----------------	------------	--------------

TIMOLOL MALEATE

<u>AT2</u>	APOTEX INC	<u>EQ 0.5% BASE</u>	<u>A204936</u>	<u>001</u>	Apr 17, 2015
	TIMOPTIC IN OCUDOSE				
	+! ATON	<u>EQ 0.25% BASE</u>	<u>N019463</u>	<u>001</u>	Nov 05, 1986
	+!	<u>EQ 0.5% BASE</u>	<u>N019463</u>	<u>002</u>	Nov 05, 1986

TABLET; ORAL

TIMOLOL MALEATE

MYLAN

5MG

A072668 002 Jun 08, 1990

10MG

A072668 003 Jun 08, 1990

!

20MG

A072668 001 Jun 08, 1990TINIDAZOLE

TABLET; ORAL

TINDAMAX

<u>AB</u>	+ MISSION PHARMA	<u>250MG</u>	<u>N021618</u>	<u>001</u>	May 17, 2004
<u>AB</u>	+!	<u>500MG</u>	<u>N021618</u>	<u>002</u>	May 17, 2004

TINIDAZOLE

<u>AB</u>	EDENBRIDGE PHARMS	<u>250MG</u>	<u>A203808</u>	<u>001</u>	Aug 04, 2015
<u>AB</u>		<u>500MG</u>	<u>A203808</u>	<u>002</u>	Aug 04, 2015
<u>AB</u>	NOVEL LABS INC	<u>250MG</u>	<u>A202044</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202044</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>	UNIQUE PHARM LABS	<u>250MG</u>	<u>A202489</u>	<u>001</u>	Oct 09, 2013
<u>AB</u>		<u>500MG</u>	<u>A202489</u>	<u>002</u>	Oct 09, 2013
<u>AB</u>	WEST-WARD PHARMS	<u>250MG</u>	<u>A201172</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>	INT	<u>500MG</u>	<u>A201172</u>	<u>002</u>	Apr 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

TIOPRONIN

TABLET; ORAL

THIOLA

+! MISSION PHARMA 100MG N019569 001 Aug 11, 1988

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+! BOEHRINGER EQ 0.018MG BASE/INH N021395 001 Jan 30, 2004

INGELHEIM

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+ BOEHRINGER EQ 0.00125MG BASE/INH N021936 002 Sep 15, 2015

INGELHEIM

+! EQ 0.0025MG BASE/INH N021936 001 Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

LONSURF

+ TAIHO ONCOLOGY EQ 6.14MG BASE;15MG N207981 001 Sep 22, 2015

+! EQ 8.19MG BASE;20MG N207981 002 Sep 22, 2015

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+! BOEHRINGER 250MG N021814 001 Jun 22, 2005

INGELHEIM

SOLUTION; ORAL

APTIVUS

+! BOEHRINGER 100MG/ML N022292 001 Jun 23, 2008

INGELHEIM

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

+ MEDICURE EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) N020913 002 May 17, 2002

+! EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) N020913 003 Apr 20, 2000

SOLUTION; INJECTION

AGGRASTAT

+! MEDICURE EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) N020912 002 Aug 31, 2016

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 2MG BASE</u>	<u>A078868 001</u>	Feb 03, 2012
AB		<u>EQ 4MG BASE</u>	<u>A078868 002</u>	Feb 03, 2012
AB		<u>EQ 6MG BASE</u>	<u>A078868 003</u>	Feb 03, 2012
AB	JUBILANT GENERICS	<u>EQ 2MG BASE</u>	<u>A209605 001</u>	Aug 04, 2017
AB		<u>EQ 4MG BASE</u>	<u>A209605 002</u>	Aug 04, 2017
AB		<u>EQ 6MG BASE</u>	<u>A209605 003</u>	Aug 04, 2017
AB	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A091502 001</u>	Nov 09, 2012
AB		<u>EQ 4MG BASE</u>	<u>A091502 002</u>	Nov 09, 2012
AB		<u>EQ 6MG BASE</u>	<u>A091502 003</u>	Nov 09, 2012
AB	PAR PHARM INC	<u>EQ 2MG BASE</u>	<u>A207199 001</u>	Mar 14, 2017
AB		<u>EQ 4MG BASE</u>	<u>A207199 002</u>	Mar 14, 2017
AB		<u>EQ 6MG BASE</u>	<u>A207199 003</u>	Mar 14, 2017
AB	ZYDUS PHARMS USA INC	<u>EQ 2MG BASE</u>	<u>A208622 001</u>	Mar 03, 2017
AB		<u>EQ 4MG BASE</u>	<u>A208622 002</u>	Mar 03, 2017
AB		<u>EQ 6MG BASE</u>	<u>A208622 003</u>	Mar 03, 2017

ZANAFLEX

AB	+ COVIS PHARMA BV	<u>EQ 2MG BASE</u>	<u>N021447 001</u>	Aug 29, 2002
AB	+	<u>EQ 4MG BASE</u>	<u>N021447 002</u>	Aug 29, 2002
AB	+!	<u>EQ 6MG BASE</u>	<u>N021447 003</u>	Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX	<u>EQ 2MG BASE</u>	<u>A076533 001</u>	Jan 16, 2004
AB		<u>EQ 4MG BASE</u>	<u>A076533 002</u>	Jan 16, 2004
AB	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286 001</u>	Jul 03, 2002
AB		<u>EQ 4MG BASE</u>	<u>A076286 002</u>	Jul 03, 2002
AB	EPIC PHARMA LLC	<u>EQ 2MG BASE</u>	<u>A076347 001</u>	Oct 11, 2002
AB		<u>EQ 4MG BASE</u>	<u>A076347 002</u>	Oct 11, 2002
AB	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354 001</u>	Mar 28, 2003
AB		<u>EQ 4MG BASE</u>	<u>A076354 002</u>	Mar 28, 2003
AB	OXFORD PHARMS	<u>EQ 2MG BASE</u>	<u>A076281 001</u>	Oct 20, 2003

PRESCRIPTION DRUG PRODUCT LIST

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281 002</u>	Oct 20, 2003
<u>AB</u>	PAR PHARM INC	<u>EQ 2MG BASE</u>	<u>A207170 001</u>	Jan 26, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A207170 002</u>	Jan 26, 2017
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A076280 001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280 002</u>	Jun 27, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2MG BASE</u>	<u>A076416 001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416 002</u>	Sep 29, 2003
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076284 001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284 002</u>	Jul 03, 2002
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283 002</u>	Nov 28, 2012
<u>ZANAFLEX</u>				
<u>AB</u>	+! COVIS PHARMA BV	<u>EQ 4MG BASE</u>	<u>N020397 001</u>	Nov 27, 1996

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+! NOVARTIS PHARMS
CORP

N050555 001

POWDER; INHALATION

TOBI PODHALER

+! NOVARTIS

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

KITABIS PAK

<u>AN</u>	PULMOFLOW INC	<u>300MG/5ML</u>	<u>N205433 001</u>	Dec 02, 2014
-----------	---------------	------------------	--------------------	--------------

TOBI

<u>AN</u>	+! NOVARTIS PHARMS	<u>300MG/5ML</u>	<u>N050753 001</u>	Dec 22, 1997
-----------	--------------------	------------------	--------------------	--------------

TOBRAMYCIN

<u>AN</u>	AKORN INC	<u>300MG/5ML</u>	<u>A201422 001</u>	May 28, 2014
-----------	-----------	------------------	--------------------	--------------

<u>AN</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A205501 001</u>	Jul 13, 2015
-----------	---------------	------------------	--------------------	--------------

<u>AN</u>	LUPIN ATLANTIS	<u>300MG/5ML</u>	<u>A208964 001</u>	Mar 22, 2017
-----------	----------------	------------------	--------------------	--------------

<u>AN</u>	MYLAN PHARMS INC	<u>300MG/5ML</u>	<u>A209554 001</u>	Oct 13, 2017
-----------	------------------	------------------	--------------------	--------------

<u>AN</u>	TEVA PHARMS USA	<u>300MG/5ML</u>	<u>A091589 001</u>	Oct 10, 2013
-----------	-----------------	------------------	--------------------	--------------

BETHKIS

+! CHIESI USA INC

N201820 001 Oct 12, 2012

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096 001</u>	Jan 31, 1996
-----------	-------	-------------	--------------------	--------------

TOBRAMYCIN

<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052 001</u>	Nov 29, 1993
-----------	-----------------	-------------	--------------------	--------------

<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A065026 001</u>	Sep 11, 2001
-----------	-------------	-------------	--------------------	--------------

<u>AT</u>	SOMERSET THERAPS LLC	<u>0.3%</u>	<u>A207444 001</u>	Jun 28, 2017
-----------	-------------------------	-------------	--------------------	--------------

TOBREX

<u>AT</u>	+! NOVARTIS PHARMS CORP	<u>0.3%</u>	<u>N050541 001</u>	
-----------	----------------------------	-------------	--------------------	--

<u>AT</u>	SANDOZ INC	<u>0.3%</u>	<u>A062535 001</u>	Dec 13, 1984
-----------	------------	-------------	--------------------	--------------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	AKORN	<u>EQ 40MG BASE/ML</u>	<u>A205179 001</u>	Sep 16, 2014
-----------	-------	------------------------	--------------------	--------------

<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 40MG BASE/ML</u>	<u>A206965 001</u>	Jul 01, 2016
-----------	-------------------------	------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A065122 001</u>	Nov 29, 2002
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>	!	<u>EQ 40MG BASE/ML</u>	<u>A065122 002</u>	Nov 29, 2002
-----------	---	------------------------	--------------------	--------------

<u>AP</u>	!	<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789 001</u>	Jul 13, 2004
-----------	---	---------------------------	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063112 001</u>	Apr 30, 1991
-----------	---------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111 001</u>	Apr 30, 1991
-----------	--	------------------------	--------------------	--------------

<u>AP</u>	MYLAN LABS LTD	<u>EQ 40MG BASE/ML</u>	<u>A065407 001</u>	Mar 11, 2008
-----------	----------------	------------------------	--------------------	--------------

<u>AP</u>	TEVA PHARMS USA	<u>EQ 40MG BASE/ML</u>	<u>A063100 001</u>	Jan 30, 1992
-----------	-----------------	------------------------	--------------------	--------------

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 40MG BASE/ML</u>	<u>A063117 001</u>	Apr 26, 1991
-----------	-------------------------	------------------------	--------------------	--------------

<u>AP</u>	!	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013 001</u>	Aug 17, 2001
-----------	---	---------------------------	--------------------	--------------

<u>AP</u>	XELLIA PHARMS APS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A205685 001</u>	Sep 16, 2014
-----------	-------------------	---------------------------	--------------------	--------------

TOBRAMYCIN SULFATE (PHARMACY BULK)

!	FRESENIUS KABI USA	<u>EQ 40MG BASE/ML</u>	<u>A065120 001</u>	Nov 29, 2002
---	--------------------	------------------------	--------------------	--------------

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

!	HOSPIRA	<u>EQ 1.2MG BASE/ML</u>	<u>A063081 003</u>	Jul 31, 1990
---	---------	-------------------------	--------------------	--------------

!		<u>EQ 1.6MG BASE/ML</u>	<u>A063081 006</u>	Jun 02, 1993
---	--	-------------------------	--------------------	--------------

!		<u>EQ 80MG BASE/100ML</u>	<u>A063081 001</u>	Jul 31, 1990
---	--	---------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+! PF PRISM CV EQ 5MG BASE

N203214 001 Nov 06, 2012

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

+! PFIZER INC EQ 11MG BASE

N208246 001 Feb 23, 2016

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

MYLAN PHARMS INC 250MG

A070259 001 Jan 02, 1986

! 500MG

A070259 003 Mar 17, 1986

TOLBUTAMIDE

TABLET;ORAL

TOLBUTAMIDE

! MYLAN PHARMS INC 500MG

A086445 001

TOLCAPONE

TABLET;ORAL

TASMAR**AB** +! VALEANT PHARMS LLC **100MG****N020697 001** Jan 29, 1998TOLCAPONE**AB** PAR PHARM INC **100MG****A204584 001** Mar 26, 2015TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM**AB** MYLAN **EQ 400MG BASE****A073393 001** May 27, 1993**AB** ! TEVA **EQ 400MG BASE****A073290 001** Nov 27, 1991

TABLET;ORAL

TOLMETIN SODIUM

! MYLAN EQ 600MG BASE

A074473 001 Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA**AB** + PHARMACIA AND **2MG****N021228 001** Dec 22, 2000

UPJOHN

AB +! **4MG****N021228 002** Dec 22, 2000TOLTERODINE TARTRATE**AB** HETERO LABS LTD III **2MG****A206419 001** Dec 12, 2017**AB** **4MG****A206419 002** Dec 12, 2017**AB** MYLAN PHARMS INC **2MG****A201486 001** Oct 31, 2013**AB** **4MG****A201486 002** Oct 31, 2013**AB** TEVA PHARMS USA **2MG****A079141 001** Nov 22, 2016**AB** **4MG****A079141 002** Nov 22, 2016**AB** TORRENT PHARMS LTD **2MG****A203016 001** Aug 11, 2015**AB** **4MG****A203016 002** Aug 11, 2015

TABLET;ORAL

DETROL**AB** + PHARMACIA AND **1MG****N020771 001** Mar 25, 1998

UPJOHN

AB +! **2MG****N020771 002** Mar 25, 1998TOLTERODINE TARTRATE**AB** APOTEX CORP **1MG****A200164 001** Sep 25, 2012**AB** **2MG****A200164 002** Sep 25, 2012**AB** IVAX SUB TEVA **1MG****A077006 001** Feb 23, 2015

PHARMS

AB **2MG****A077006 002** Feb 23, 2015**AB** MACLEODS PHARMS LTD **1MG****A203409 001** Aug 31, 2015**AB** **2MG****A203409 002** Aug 31, 2015**AB** MYLAN PHARMS INC **1MG****A202641 001** Nov 27, 2012**AB** **2MG****A202641 002** Nov 27, 2012TOLVAPTAN

TABLET;ORAL

SAMSCA

+ OTSUKA AMERICA 15MG

N022275 001 May 19, 2009

PHARM

+! 30MG

N022275 002 May 19, 2009

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998
<u>AB</u>	+	!	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>		TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>			<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>		WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009
<u>AB</u>			<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>			<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

<u>AB</u>		ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A207382</u>	<u>001</u>	Nov 24, 2017
<u>AB</u>			<u>50MG</u>	<u>A207382</u>	<u>002</u>	Nov 24, 2017
<u>AB</u>			<u>100MG</u>	<u>A207382</u>	<u>003</u>	Nov 24, 2017

TROKENDI XR

<u>AB</u>	+	SUPERNUS PHARMS	<u>25MG</u>	<u>N201635</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>	+		<u>50MG</u>	<u>N201635</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>	+		<u>100MG</u>	<u>N201635</u>	<u>003</u>	Aug 16, 2013

QUDEXY XR

	+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014
	+		50MG	N205122	002	Mar 11, 2014
	+		100MG	N205122	003	Mar 11, 2014
	+		150MG	N205122	004	Mar 11, 2014
	+	!	200MG	N205122	005	Mar 11, 2014

TROKENDI XR

	+	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013
--	---	-----------------	-------	---------	-----	--------------

TABLET; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996
<u>AB</u>	+		<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996
<u>AB</u>	+	!	<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996
<u>AB</u>	+		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>		ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		LUPIN	<u>25MG</u>	<u>A078410</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>			<u>50MG</u>	<u>A078410</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>			<u>100MG</u>	<u>A078410</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>			<u>200MG</u>	<u>A078410</u>	<u>004</u>	Sep 11, 2013
<u>AB</u>		SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		SUN PHARMA GLOBAL	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317 004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153 004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162 004</u>	Feb 19, 2013
<u>AB</u>	UPSHER-SMITH LABS	<u>25MG</u>	<u>A078499 001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499 002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499 003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499 004</u>	Jan 07, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235 004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

+	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981 001	Oct 11, 2007
+	!	EQ 1MG BASE	N020981 002	Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTIN

<u>AP</u>	+	!	NOVARTIS PHARMS CORP	<u>EQ 4MG BASE/VIAL</u>	<u>N020671 001</u>	May 28, 1996
-----------	---	---	-------------------------	-------------------------	--------------------	--------------

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351 001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620 001</u>	Dec 02, 2010
<u>AP</u>	CIPLA LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091199 001</u>	Dec 01, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191 001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089 001</u>	Nov 29, 2010
<u>AP</u>	HONG KONG	<u>EQ 4MG BASE/VIAL</u>	<u>A201166 001</u>	Aug 08, 2012
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542 001</u>	Aug 28, 2012
<u>AP</u>	NOVAST LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A206962 001</u>	Nov 30, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284 001</u>	Jan 26, 2011

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204406 002</u>	Jul 06, 2017		
<u>AP</u>	+	!	HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582 001</u>	Feb 02, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A206074 001</u>	Nov 24, 2017		
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453 001</u>	Dec 20, 2012		
	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406 001	Jul 06, 2017		

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	!	KYOWA KIRIN	EQ 60MG BASE	N020497 001	May 29, 1997
---	---	-------------	--------------	-------------	--------------

TORSEMIDE

TABLET; ORAL

DEMADEX

<u>AB</u>	+	MYLAN SPECIALITY LP	<u>5MG</u>	<u>N020136 001</u>	Aug 23, 1993
<u>AB</u>	+		<u>10MG</u>	<u>N020136 002</u>	Aug 23, 1993
<u>AB</u>	+	!	<u>20MG</u>	<u>N020136 003</u>	Aug 23, 1993
<u>AB</u>	+		<u>100MG</u>	<u>N020136 004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894 001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894 002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894 003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894 004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249 001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249 002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249 003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249 004</u>	Oct 17, 2007

PRESCRIPTION DRUG PRODUCT LIST

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005

TRABECTEDIN

POWDER; IV (INFUSION)

YONDELIS

+! JANSSEN PRODS 1MG/VIAL N207953 001 Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
+		150MG	N022370	004	Aug 01, 2011
+		200MG	N022370	002	May 07, 2010
+		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACI HEALTHCARE LTD	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A205702</u>	<u>001</u>	Sep 25, 2015
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SPECGX LLC	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	SUN PHARM INDUSTRIES	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+!	JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	----	----------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A204421</u>	<u>001</u>	Oct 20, 2015
<u>AB1</u>		<u>200MG</u>	<u>A204421</u>	<u>002</u>	Oct 20, 2015
<u>AB1</u>		<u>300MG</u>	<u>A204421</u>	<u>003</u>	Oct 20, 2015
<u>AB1</u>	! LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A205257</u>	<u>001</u>	Dec 22, 2015
<u>AB1</u>		<u>200MG</u>	<u>A205257</u>	<u>002</u>	Dec 22, 2015
<u>AB1</u>		<u>300MG</u>	<u>A205257</u>	<u>003</u>	Dec 22, 2015
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>		<u>200MG</u>	<u>A078783 002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783 003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384 001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384 002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384 003</u>	Dec 07, 2011
<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609 001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609 002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609 003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491 001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491 002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491 003</u>	Jun 27, 2012
<u>AB2</u>	! SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607 001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607 002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607 003</u>	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+	NOVARTIS PHARMS	EQ 0.5MG	N204114 001	May 29, 2013
	CORP			
+	!	EQ 2MG	N204114 003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

MAVIK

<u>AB</u>	+	ABBVIE	<u>1MG</u>	<u>N020528 001</u>	Apr 26, 1996
<u>AB</u>	+		<u>2MG</u>	<u>N020528 002</u>	Apr 26, 1996
<u>AB</u>	+	!	<u>4MG</u>	<u>N020528 003</u>	Apr 26, 1996

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438 003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508 003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508 001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508 002</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522 003</u>	Jun 12, 2007
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489 001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489 002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489 003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805 003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

<u>AB</u>	+	ABBVIE	<u>1MG;240MG</u>	<u>N020591 003</u>	Oct 22, 1996
<u>AB</u>	+		<u>2MG;180MG</u>	<u>N020591 001</u>	Oct 22, 1996
<u>AB</u>	+		<u>2MG;240MG</u>	<u>N020591 004</u>	Oct 22, 1996
<u>AB</u>	+	!	<u>4MG;240MG</u>	<u>N020591 002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135 004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135 001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135 002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135 003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281 001</u>	Dec 30, 1986
-----------	---	----------------------	-----------------	--------------------	--------------

TRANEXAMIC ACID

<u>AP</u>	ACIC FINE CHEMS	<u>100MG/ML</u>	<u>A202436 001</u>	Feb 11, 2014
<u>AP</u>	AKORN	<u>100MG/ML</u>	<u>A202373 001</u>	Nov 17, 2011
<u>AP</u>		<u>100MG/ML</u>	<u>A206594 001</u>	Sep 28, 2017
<u>AP</u>		<u>100MG/ML</u>	<u>A206634 001</u>	Jun 09, 2016
<u>AP</u>	AMNEAL PHARMS CO	<u>100MG/ML</u>	<u>A208840 001</u>	Feb 28, 2017
<u>AP</u>	AUROBINDO PHARMA LTD	<u>100MG/ML</u>	<u>A205035 001</u>	Jan 14, 2016
<u>AP</u>	EMCURE PHARMS LTD	<u>100MG/ML</u>	<u>A203521 001</u>	Aug 12, 2014

PRESCRIPTION DRUG PRODUCT LIST

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

<u>AP</u>	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596</u>	<u>001</u>	Mar 02, 2012
<u>AP</u>	GLAND PHARMA LTD	<u>100MG/ML</u>	<u>A207239</u>	<u>001</u>	Feb 13, 2017
<u>AP</u>	LUITPOLD	<u>100MG/ML</u>	<u>A201885</u>	<u>001</u>	Aug 10, 2011
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657</u>	<u>001</u>	Nov 03, 2011
<u>AP</u>	VIRTUS PHARMS	<u>100MG/ML</u>	<u>A202755</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>	VIVA HLTHCARE	<u>100MG/ML</u>	<u>A206713</u>	<u>001</u>	Jun 27, 2017
<u>AP</u>	X-GEN PHARMS INC	<u>100MG/ML</u>	<u>A201580</u>	<u>001</u>	Jun 14, 2013
<u>AP</u>	ZYDUS PHARMS USA INC	<u>100MG/ML</u>	<u>A205228</u>	<u>001</u>	Jul 17, 2017

TABLET; ORAL

LYSTEDA

<u>AB</u>	<u>+</u> ! FERRING PHARMS INC	<u>650MG</u>	<u>N022430</u>	<u>001</u>	Nov 13, 2009
-----------	-------------------------------	--------------	----------------	------------	--------------

TRANEXAMIC ACID

<u>AB</u>	ACTAVIS LABS FL INC	<u>650MG</u>	<u>A202093</u>	<u>001</u>	Dec 27, 2012
<u>AB</u>	APOTEX INC	<u>650MG</u>	<u>A202286</u>	<u>001</u>	Jan 27, 2014
<u>AB</u>	MYLAN	<u>650MG</u>	<u>A205133</u>	<u>001</u>	Sep 21, 2015

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	<u>+</u> ! CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985
-----------	------------------------------------	---------------------	----------------	------------	--------------

TRANLYCYPROMINE SULFATE

<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006
-----------	-----------	---------------------	----------------	------------	--------------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

<u>AT</u>	<u>+</u> ! NOVARTIS PHARMS CORP	<u>0.004%</u>	<u>N021994</u>	<u>001</u>	Sep 21, 2006
-----------	------------------------------------	---------------	----------------	------------	--------------

TRAVOPROST

<u>AT</u>	APOTEX INC	<u>0.004%</u>	<u>A203431</u>	<u>001</u>	Jul 10, 2015
<u>AT</u>	MYLAN PHARMS INC	<u>0.004%</u>	<u>A205050</u>	<u>001</u>	Jul 07, 2017
	! PAR PHARM	0.004%	A091340	001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A206923</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>		<u>100MG</u>	<u>A206923</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>		<u>150MG</u>	<u>A206923</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>		<u>300MG</u>	<u>A206923</u>	<u>004</u>	Sep 08, 2017
<u>AB</u>	ALVOGEN	<u>50MG</u>	<u>A071636</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>		<u>100MG</u>	<u>A071514</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>	! APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>		<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993
<u>AB</u>		<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993
<u>AB</u>		<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995
<u>AB</u>	TEVA PHARMS USA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>		<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A202180</u>	<u>001</u>	Nov 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A202180</u>	<u>002</u>	Nov 27, 2013
<u>AB</u>		<u>150MG</u>	<u>A202180</u>	<u>003</u>	Nov 27, 2013
<u>AB</u>		<u>300MG</u>	<u>A202180</u>	<u>004</u>	Nov 27, 2013
<u>AB</u>	VINTAGE	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>		<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A205253</u>	<u>001</u>	Oct 10, 2017
<u>AB</u>		<u>100MG</u>	<u>A205253</u>	<u>002</u>	Oct 10, 2017
<u>AB</u>		<u>150MG</u>	<u>A205253</u>	<u>003</u>	Oct 10, 2017
<u>AB</u>		<u>300MG</u>	<u>A205253</u>	<u>004</u>	Oct 10, 2017

PRESCRIPTION DRUG PRODUCT LIST

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	+	UNITED THERAP	<u>1MG/ML</u>	<u>N021272</u>	<u>001</u>	May 21, 2002
AP	+		<u>2.5MG/ML</u>	<u>N021272</u>	<u>002</u>	May 21, 2002
AP	+		<u>5MG/ML</u>	<u>N021272</u>	<u>003</u>	May 21, 2002
AP	+		<u>10MG/ML</u>	<u>N021272</u>	<u>004</u>	May 21, 2002

TREPROSTINIL

AP		SANDOZ INC	<u>1MG/ML</u>	<u>A203649</u>	<u>001</u>	Nov 30, 2017
AP			<u>2.5MG/ML</u>	<u>A203649</u>	<u>002</u>	Nov 30, 2017
AP			<u>5MG/ML</u>	<u>A203649</u>	<u>003</u>	Nov 30, 2017
AP			<u>10MG/ML</u>	<u>A203649</u>	<u>004</u>	Nov 30, 2017
SOLUTION; INHALATION						
TYVASO						
	+	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

	+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
	+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
	+		EQ 1MG BASE	N203496	003	Dec 20, 2013
	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
	+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB		ANCHEN PHARMS	<u>10MG</u>	<u>A201687</u>	<u>001</u>	Oct 24, 2012
AB	!	BARR LABS INC	<u>10MG</u>	<u>A077684</u>	<u>001</u>	Jun 22, 2007
AB		GLENMARK PHARMS LTD	<u>10MG</u>	<u>A208279</u>	<u>001</u>	Dec 23, 2016

CREAM; TOPICAL

AVITA

AB		MYLAN PHARMS INC	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997
-----------	--	------------------	---------------	-----------------------	-------------------	--------------

RETIN-A

AB	+	VALEANT BERMUDA	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988
AB	+	VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N017340</u>	<u>001</u>	

TRETINOIN

AB		PERRIGO PHARMA INTL	<u>0.025%</u>	<u>A075264</u>	<u>001</u>	Dec 24, 1998
AB			<u>0.1%</u>	<u>A075213</u>	<u>001</u>	Dec 24, 1998

RETIN-A

AB1	+	VALEANT BERMUDA	<u>0.05%</u>	<u>N017522</u>	<u>001</u>	
------------	---	-----------------	--------------	-----------------------	-------------------	--

TRETINOIN

AB1		PERRIGO PHARMA INTL	<u>0.05%</u>	<u>A075265</u>	<u>001</u>	Dec 24, 1998
------------	--	---------------------	--------------	-----------------------	-------------------	--------------

RENOVA

AB2	+	VALEANT PHARMS NORTH	<u>0.05%</u>	<u>N019963</u>	<u>001</u>	Dec 29, 1995
------------	---	-------------------------	--------------	-----------------------	-------------------	--------------

TRETINOIN

AB2		ZO SKIN HEALTH	<u>0.05%</u>	<u>A076498</u>	<u>001</u>	Sep 15, 2005
RENOVA						
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

GEL; TOPICAL

ATRALIN

AB	+	DOW PHARM	<u>0.05%</u>	<u>N022070</u>	<u>001</u>	Jul 26, 2007
-----------	---	-----------	--------------	-----------------------	-------------------	--------------

RETIN-A

AB	+	VALEANT INTL	<u>0.01%</u>	<u>N017955</u>	<u>001</u>	
AB	+		<u>0.025%</u>	<u>N017579</u>	<u>002</u>	

RETIN-A MICRO

AB	+	VALEANT INTL	<u>0.04%</u>	<u>N020475</u>	<u>002</u>	May 10, 2002
AB	+		<u>0.1%</u>	<u>N020475</u>	<u>001</u>	Feb 07, 1997

TRETINOIN

AB		MYLAN PHARMS INC	<u>0.04%</u>	<u>A202567</u>	<u>001</u>	Jul 17, 2013
AB			<u>0.05%</u>	<u>A207955</u>	<u>001</u>	Aug 13, 2015
AB			<u>0.1%</u>	<u>A202026</u>	<u>001</u>	Jul 17, 2013
AB		PERRIGO PHARMA INTL	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
AB			<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000

AVITA

BT		MYLAN	0.025%	N020400	001	Jan 29, 1998
----	--	-------	--------	---------	-----	--------------

RETIN-A-MICRO

	+	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017
	+		0.08%	N020475	003	Jan 28, 2014

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ALKEM LABS LTD	<u>0.025%</u>	<u>A207651 001</u>	Dec 26, 2017
<u>AT</u>		<u>0.1%</u>	<u>A207651 002</u>	Dec 26, 2017
<u>AT</u>		<u>0.5%</u>	<u>A207651 003</u>	Dec 26, 2017
<u>AT</u>	! FOUGERA PHARMS	<u>0.025%</u>	<u>A085692 001</u>	
<u>AT</u>	!	<u>0.1%</u>	<u>A085692 003</u>	
<u>AT</u>	!	<u>0.5%</u>	<u>A085692 002</u>	
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089797 001</u>	May 31, 1991
<u>AT</u>		<u>0.1%</u>	<u>A089798 001</u>	May 31, 1991
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A207117 001</u>	Aug 05, 2016
<u>AT</u>	LUPIN ATLANTIS	<u>0.025%</u>	<u>A208763 001</u>	Feb 01, 2017
<u>AT</u>		<u>0.1%</u>	<u>A208763 002</u>	Feb 01, 2017
<u>AT</u>		<u>0.5%</u>	<u>A208763 003</u>	Feb 01, 2017
<u>AT</u>	+ MYLAN PHARMS INC	<u>0.025%</u>	<u>N011601 003</u>	
<u>AT</u>	+	<u>0.1%</u>	<u>N011601 006</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415 001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A086414 001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086413 001</u>	
<u>AT</u>	TARO	<u>0.1%</u>	<u>A040039 001</u>	Nov 26, 1997
<u>AT</u>	TELIGENT PHARMA INC	<u>0.1%</u>	<u>A208848 001</u>	Sep 18, 2017
<u>AT</u>	VINTAGE	<u>0.025%</u>	<u>A040671 001</u>	Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671 002</u>	Jun 09, 2006

TRIDERM

<u>AT</u>	CROWN LABS	<u>0.025%</u>	<u>A088042 002</u>	Mar 25, 2015
<u>AT</u>		<u>0.1%</u>	<u>A088042 001</u>	Mar 19, 1984
<u>AT</u>		<u>0.5%</u>	<u>A088042 003</u>	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+! FLEXION THERAPS INC 32MG/VIAL

N208845 001 Oct 06, 2017

INJECTABLE; INJECTION

KENALOG-40

<u>AP</u>	+! APOTHECON	<u>40MG/ML</u>	<u>N014901 001</u>	
-----------	--------------	----------------	--------------------	--

TRIAMCINOLONE ACETONIDE

<u>AP</u>	AMNEAL PHARMS CO	<u>40MG/ML</u>	<u>A207550 001</u>	Dec 11, 2017
-----------	------------------	----------------	--------------------	--------------

KENALOG-10

+ APOTHECON 10MG/ML

N012041 001

INJECTABLE; INTRAVITREAL

TRIESENCE

+! NOVARTIS PHARMS CORP 40MG/ML (40MG/ML)

N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.025%</u>	<u>A202374 001</u>	May 08, 2013
<u>AT</u>		<u>0.1%</u>	<u>A202374 002</u>	May 08, 2013
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A040467 001</u>	Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467 002</u>	Apr 21, 2003
<u>AT</u>	G AND W LABS INC	<u>0.1%</u>	<u>A089129 001</u>	Aug 14, 1986
<u>AT</u>	TELIGENT PHARMA INC	<u>0.025%</u>	<u>A204608 001</u>	Jul 07, 2016
<u>AT</u>		<u>0.1%</u>	<u>A204606 001</u>	Jul 07, 2016
<u>AT</u>	VINTAGE	<u>0.1%</u>	<u>A040672 002</u>	Dec 13, 2006
<u>AT</u>	! WOCKHARDT BIO AG	<u>0.025%</u>	<u>A088450 001</u>	Apr 01, 1985
<u>AT</u>	!	<u>0.1%</u>	<u>A088451 001</u>	Apr 03, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A085691 001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A085691 003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A085691 002</u>	
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089795 001</u>	Dec 23, 1988
<u>AT</u>		<u>0.1%</u>	<u>A089796 001</u>	Dec 23, 1988
<u>AT</u>	G AND W LABS INC	<u>0.5%</u>	<u>A208925 001</u>	Oct 06, 2017
<u>AT</u>	GLENMARK PHARMS	<u>0.1%</u>	<u>A208320 001</u>	Aug 22, 2017
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.5%</u>	<u>A206379 001</u>	Jul 22, 2016
<u>AT</u>	! PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356 001</u>	
<u>AT</u>	!	<u>0.1%</u>	<u>A087357 001</u>	
<u>AT</u>	!	<u>0.5%</u>	<u>A087385 001</u>	
<u>AT</u>	TARO	<u>0.1%</u>	<u>A040037 001</u>	Sep 30, 1994
<u>AT</u>	TELIGENT PHARMA INC	<u>0.1%</u>	<u>A205373 001</u>	May 13, 2016
<u>AT</u>		<u>0.5%</u>	<u>A208590 001</u>	Mar 03, 2017

TRIAMCINOLONE ACETONIDE IN ABSORBASE

! CMP PHARMA INC 0.05%

A089595 001 Mar 23, 1995

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	AKORN	<u>0.1%</u>	<u>A206312</u>	<u>001</u>	Aug 11, 2016
AT	G AND W LABS INC	<u>0.1%</u>	<u>A205592</u>	<u>001</u>	Jan 12, 2017
AT	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u>	Jul 01, 2010
AT	! TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

AT	+! RANBAXY LABS LTD	<u>0.147MG/GM</u>	<u>N012104</u>	<u>001</u>	
-----------	---------------------	-------------------	----------------	------------	--

TRIAMCINOLONE ACETONIDE

AT	AKORN	<u>0.147MG/GM</u>	<u>A207094</u>	<u>001</u>	Dec 07, 2016
AT	PERRIGO UK FINCO	<u>0.147MG/GM</u>	<u>A205782</u>	<u>001</u>	Apr 13, 2015
AT	RICONPHARMA LLC	<u>0.147MG/GM</u>	<u>A206786</u>	<u>001</u>	Sep 08, 2017

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+!	SANDOZ INC	5MG/ML	N016466	001	
+!		20MG/ML	N016466	002	

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

+	CONCORDIA PHARMS INC	50MG	N013174	001	
+!		100MG	N013174	002	

TRIAZOLAM

TABLET; ORAL

HALCION

AB	+ PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
AB	+!	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982

TRIAZOLAM

AB	MYLAN PHARMS INC	<u>0.125MG</u>	<u>A074031</u>	<u>001</u>	Mar 25, 1994
AB		<u>0.25MG</u>	<u>A074031</u>	<u>002</u>	Mar 25, 1994
AB	WEST-WARD PHARMS INT	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
AB		<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

+!	ATON	250MG	N019194	001	Nov 08, 1985
----	------	-------	---------	-----	--------------

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB	MYLAN	<u>EQ 1MG BASE</u>	<u>A040209</u>	<u>001</u>	Jul 07, 1997
AB		<u>EQ 2MG BASE</u>	<u>A040209</u>	<u>002</u>	Jul 07, 1997
AB		<u>EQ 5MG BASE</u>	<u>A040209</u>	<u>003</u>	Jul 07, 1997
AB	!	<u>EQ 10MG BASE</u>	<u>A040209</u>	<u>004</u>	Jul 07, 1997
AB	SANDOZ	<u>EQ 1MG BASE</u>	<u>A085785</u>	<u>001</u>	
AB		<u>EQ 2MG BASE</u>	<u>A085786</u>	<u>001</u>	
AB		<u>EQ 5MG BASE</u>	<u>A085789</u>	<u>001</u>	
AB		<u>EQ 10MG BASE</u>	<u>A085788</u>	<u>001</u>	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT	HI-TECH PHARMACAL	<u>1%</u>	<u>A205438</u>	<u>001</u>	Jul 28, 2017
AT	SANDOZ INC	<u>1%</u>	<u>A074311</u>	<u>001</u>	Oct 06, 1995
AT	+! MONARCH PHARMS	<u>1%</u>	<u>N018299</u>	<u>001</u>	

TRIHExYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHExYPHENIDYL HYDROCHLORIDE

AA	MIKART	<u>2MG/5ML</u>	<u>A040251</u>	<u>001</u>	Sep 27, 1999
AA	! PHARM ASSOC	<u>2MG/5ML</u>	<u>A040177</u>	<u>001</u>	Apr 17, 1997

TABLET; ORAL

TRIHExYPHENIDYL HYDROCHLORIDE

AA	NATCO PHARMA LTD	<u>2MG</u>	<u>A091630</u>	<u>001</u>	Nov 17, 2010
AA		<u>5MG</u>	<u>A091630</u>	<u>002</u>	Nov 17, 2010
AA	VINTAGE PHARMS LLC	<u>2MG</u>	<u>A040254</u>	<u>001</u>	Dec 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA			5MG	A040254 002	Dec 24, 1998
AA	!	WATSON LABS	2MG	A084363 001	
AA	!		5MG	A084364 001	

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+	!	ABBVIE	150MG	N005856 009	
---	---	--------	-------	-------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB	+	!	KING PHARMS LLC	300MG	N017531 006	Dec 13, 2001
-----------	---	---	-----------------	--------------	--------------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB			GAVIS PHARMS	300MG	A076546 001	Aug 20, 2003
-----------	--	--	--------------	--------------	--------------------	--------------

AB			SUN PHARM INDUSTRIES	300MG	A076570 001	Aug 28, 2003
-----------	--	--	----------------------	--------------	--------------------	--------------

INJECTABLE; INJECTION

TIGAN

AP	+	!	PAR STERILE PRODUCTS	100MG/ML	N017530 001	
-----------	---	---	----------------------	-----------------	--------------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP			LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011
-----------	--	--	----------	-----------------	--------------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP			LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011
-----------	--	--	----------	-----------------	--------------------	--------------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	+	!	MAYNE PHARMA	100MG	N018679 001	Jul 30, 1982
-----------	---	---	--------------	--------------	--------------------	--------------

AB			NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011
-----------	--	--	----------------	--------------	--------------------	--------------

AB			WATSON LABS	100MG	A070049 001	Jun 06, 1985
-----------	--	--	-------------	--------------	--------------------	--------------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	!	ALLEGIS	EQ 50MG BASE/5ML	N074973 001	Jan 24, 2000
---	---	---------	------------------	-------------	--------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB	+		ODYSSEY PHARMS	EQ 25MG BASE	N016792 001	
-----------	---	--	----------------	---------------------	--------------------	--

AB	+	!		EQ 50MG BASE	N016792 002	
-----------	---	---	--	---------------------	--------------------	--

AB	+			EQ 100MG BASE	N016792 003	Sep 15, 1982
-----------	---	--	--	----------------------	--------------------	--------------

TRIMIPRAMINE MALEATE

AB			CROSSMEDIKA SA	EQ 25MG BASE	A208127 001	Apr 15, 2016
-----------	--	--	----------------	---------------------	--------------------	--------------

AB				EQ 50MG BASE	A208127 002	Apr 15, 2016
-----------	--	--	--	---------------------	--------------------	--------------

AB				EQ 100MG BASE	A208127 003	Apr 15, 2016
-----------	--	--	--	----------------------	--------------------	--------------

AB			ELITE LABS INC	EQ 25MG BASE	A077361 001	Aug 02, 2006
-----------	--	--	----------------	---------------------	--------------------	--------------

AB				EQ 50MG BASE	A077361 002	Aug 02, 2006
-----------	--	--	--	---------------------	--------------------	--------------

AB				EQ 100MG BASE	A077361 003	Aug 02, 2006
-----------	--	--	--	----------------------	--------------------	--------------

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

TRIPTODUR KIT

+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956 001	Jun 29, 2017
---	---	------------------	---------------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	!	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715 001	Jun 15, 2000
---	---	--------------------	---------------------	-------------	--------------

+	!		EQ 11.25MG BASE/VIAL	N021288 001	Jun 29, 2001
---	---	--	----------------------	-------------	--------------

+	!		EQ 22.5MG BASE/VIAL	N022437 001	Mar 10, 2010
---	---	--	---------------------	-------------	--------------

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	!	HOSPIRA	3.6GM/100ML	N013025 002	
---	---	---------	-------------	-------------	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

AT	!		NOVARTIS PHARMS CORP	1%	A084306 001	
-----------	---	--	----------------------	-----------	--------------------	--

AT	!		SANDOZ INC	0.5%	A084305 001	
-----------	---	--	------------	-------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICACYL

AT	AKORN	0.5%	A040314 001	Sep 29, 2000
AT		1%	A040315 001	Sep 29, 2000

TROPICAMIDE

AT	BAUSCH AND LOMB	0.5%	A040067 001	Jul 27, 1994
AT		1%	A040064 001	Jul 27, 1994

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

AB	!	ACTAVIS LABS FL INC	60MG	A091289 001	Oct 12, 2012
AB		PADDOCK LLC	60MG	A201291 001	May 24, 2013

TABLET;ORAL

TROSPIUM CHLORIDE

AB		APOTEX	20MG	A091513 001	Dec 06, 2011
AB	!	GLENMARK GENERICS	20MG	A091575 001	Aug 13, 2010
AB		HERITAGE PHARMS INC	20MG	A204945 001	Aug 30, 2016
AB		INVAGEN PHARMS	20MG	A091688 001	Aug 23, 2016
AB		PADDOCK LLC	20MG	A091573 001	Nov 17, 2010

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

+	!	DORC	0.15%	N022278 001	Feb 20, 2009
---	---	------	-------	-------------	--------------

VISIONBLUE

+	!	DORC	0.06%	N021670 001	Dec 16, 2004
---	---	------	-------	-------------	--------------

ULIPRISTAL ACETATE

TABLET;ORAL

ELLA

AB	+	!	LAB HRA PHARMA	30MG	N022474 001	Aug 13, 2010
-----------	---	---	----------------	-------------	--------------------	--------------

LOGILTA

AB		TEVA PHARMS USA	30MG	A207952 001	Feb 13, 2017
-----------	--	-----------------	-------------	--------------------	--------------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+	!	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382 001	Apr 30, 2014
---	---	-------------------	---------------------	-------------	--------------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+	!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975 001	Dec 18, 2013
---	---	-----------------	--	-------------	--------------

UREA, C-14

CAPSULE;ORAL

PYTEST

+	!	AVENT	1uCi	N020617 001	May 09, 1997
---	---	-------	------	-------------	--------------

PYTEST KIT

+	!	AVENT	1uCi	N020617 002	May 09, 1997
---	---	-------	------	-------------	--------------

URIDINE TRIACETATE

GRANULE;ORAL

VISTOGARD

+	!	WELLSTAT THERAP	10GM/PACKET	N208159 001	Dec 11, 2015
---	---	-----------------	-------------	-------------	--------------

XURIDEN

+	!	WELLSTAT THERAP	2GM/PACKET	N208169 001	Sep 04, 2015
---	---	-----------------	------------	-------------	--------------

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+	!	FERRING	75 IU/VIAL	N021289 001	May 06, 2002
---	---	---------	------------	-------------	--------------

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	+	!	ALLERGAN SALES LLC	300MG	N019594 002	Dec 31, 1987
-----------	---	---	--------------------	--------------	--------------------	--------------

URSODIOL

AB		EPIC PHARMA	300MG	A075517 001	Mar 14, 2000
AB		LANNETT	300MG	A079082 001	Dec 15, 2008
AB		MYLAN	300MG	A090530 001	Feb 17, 2010
AB		TEVA PHARMS	300MG	A075592 001	May 25, 2000

PRESCRIPTION DRUG PRODUCT LIST

URSODIOL

TABLET; ORAL

URSO 250

<u>AB</u>	<u>+</u>	FOREST LABS INC	<u>250MG</u>	<u>N020675</u>	<u>001</u>	Dec 10, 1997
-----------	----------	-----------------	--------------	----------------	------------	--------------

URSO FORTE

<u>AB</u>	<u>+</u>	FOREST LABS INC	<u>500MG</u>	<u>N020675</u>	<u>002</u>	Jul 21, 2004
-----------	----------	-----------------	--------------	----------------	------------	--------------

URSODIOL

<u>AB</u>		GLENMARK GENERICS	<u>250MG</u>	<u>A090801</u>	<u>001</u>	Jul 12, 2011
-----------	--	-------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A090801</u>	<u>002</u>	Jul 12, 2011
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		IMPAX LABS INC	<u>250MG</u>	<u>A200826</u>	<u>001</u>	Dec 23, 2011
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A200826</u>	<u>002</u>	Dec 23, 2011
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		PAR PHARM	<u>250MG</u>	<u>A202540</u>	<u>001</u>	Feb 14, 2013
-----------	--	-----------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A202540</u>	<u>002</u>	Feb 14, 2013
-----------	--	--	--------------	----------------	------------	--------------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>		APOTEX INC	<u>EQ 500MG BASE</u>	<u>A090500</u>	<u>001</u>	Apr 04, 2014
-----------	--	------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A090500</u>	<u>002</u>	Apr 04, 2014
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A090682</u>	<u>001</u>	May 24, 2010
-----------	--	------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A090682</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		CIPLA LTD	<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
-----------	--	-----------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 500MG BASE</u>	<u>A079012</u>	<u>001</u>	May 24, 2010
-----------	--	--------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A079012</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		HETERO LABS LTD V	<u>EQ 500MG BASE</u>	<u>A203047</u>	<u>001</u>	Apr 08, 2015
-----------	--	-------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A203047</u>	<u>002</u>	Apr 08, 2015
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		JUBILANT GENERICS	<u>EQ 500MG BASE</u>	<u>A201506</u>	<u>001</u>	Apr 03, 2012
-----------	--	-------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A201506</u>	<u>002</u>	Apr 03, 2012
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518</u>	<u>001</u>	May 24, 2010
-----------	--	------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A078518</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
-----------	--	--------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A077478</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 500MG BASE</u>	<u>A076588</u>	<u>001</u>	Jan 31, 2007
-----------	--	--------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A076588</u>	<u>002</u>	Jan 31, 2007
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A077655</u>	<u>001</u>	May 24, 2010
-----------	--	-------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A077655</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS INC	<u>EQ 500MG BASE</u>	<u>A090370</u>	<u>001</u>	Mar 16, 2011
-----------	--	-----------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A090370</u>	<u>002</u>	Mar 16, 2011
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		WEST-WARD PHARMS	<u>EQ 500MG BASE</u>	<u>A078656</u>	<u>001</u>	May 24, 2010
-----------	--	------------------	----------------------	----------------	------------	--------------

<u>AB</u>		INT				
-----------	--	-----	--	--	--	--

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A078656</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		WOCKHARDT	<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010
-----------	--	-----------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 500MG BASE</u>	<u>A079137</u>	<u>001</u>	Dec 29, 2017
-----------	--	------------------	----------------------	----------------	------------	--------------

<u>AB</u>		INC				
-----------	--	-----	--	--	--	--

<u>AB</u>			<u>EQ 1GM BASE</u>	<u>A079137</u>	<u>002</u>	Dec 29, 2017
-----------	--	--	--------------------	----------------	------------	--------------

VALTREX

<u>AB</u>	<u>+</u>	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487</u>	<u>001</u>	Jun 23, 1995
-----------	----------	-----------------	----------------------	----------------	------------	--------------

<u>AB</u>	<u>+</u>		<u>EQ 1GM BASE</u>	<u>N020487</u>	<u>002</u>	Jun 23, 1995
-----------	----------	--	--------------------	----------------	------------	--------------

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

<u>+</u>	NEUROCRINE	40MG	<u>N209241</u>	<u>001</u>	Apr 11, 2017
----------	------------	------	----------------	------------	--------------

<u>+</u>		80MG	<u>N209241</u>	<u>002</u>	Oct 04, 2017
----------	--	------	----------------	------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

<u>AB</u>	<u>+</u>	HOFFMANN LA ROCHE	<u>50MG/ML</u>	<u>N022257</u>	<u>001</u>	Aug 28, 2009
-----------	----------	-------------------	----------------	----------------	------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>50MG/ML</u>	<u>A205220</u>	<u>001</u>	Jul 18, 2016
-----------	--	---------------------	----------------	----------------	------------	--------------

TABLET; ORAL

VALCYTE

<u>AB</u>	<u>+</u>	HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304</u>	<u>001</u>	Mar 29, 2001
-----------	----------	-------------------	----------------------	----------------	------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 450MG BASE</u>	<u>A204750</u>	<u>001</u>	Mar 31, 2016
-----------	--	------------------	----------------------	----------------	------------	--------------

<u>AB</u>		LTD				
-----------	--	-----	--	--	--	--

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511</u>	<u>001</u>	Nov 04, 2014
-----------	--	--------------------	----------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 450MG BASE</u>	<u>A206876</u>	<u>001</u>	Dec 12, 2017
-----------	--	--	----------------------	----------------	------------	--------------

<u>AB</u>		ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790</u>	<u>001</u>	Nov 04, 2014
-----------	--	-----------------	----------------------	----------------	------------	--------------

<u>AB</u>		HETERO LABS LTD V	<u>EQ 450MG BASE</u>	<u>A205166</u>	<u>001</u>	Mar 18, 2016
-----------	--	-------------------	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPAICON

<u>AP</u>	<u>+</u> !	ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593</u>	<u>001</u>	Dec 30, 1996
-----------	------------	--------	-------------------------	----------------	------------	--------------

VALPROATE SODIUM

<u>AP</u>		ATHENEX INC	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	<u>+</u> !	ABBVIE	<u>250MG</u>	<u>N018081</u>	<u>001</u>	
-----------	------------	--------	--------------	----------------	------------	--

VALPROIC ACID

<u>AB</u>		BIONPHARMA INC	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037</u>	<u>001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

<u>AA</u>	<u>+</u> !	ABBVIE	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	
-----------	------------	--------	------------------	----------------	------------	--

VALPROIC ACID

<u>AA</u>		ANI PHARMS INC	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992
<u>AA</u>		ECI PHARMS LLC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>		VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006
<u>AA</u>		VISTAPHARM	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>		WOCKHARDT BIO AG	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

<u>+</u> !	ENDO PHARM	<u>40MG/ML</u>	<u>N020892</u>	<u>001</u>	Sep 25, 1998
------------	------------	----------------	----------------	------------	--------------

VALSARTAN

SOLUTION; ORAL

PREXXARTAN

<u>+</u> !	CARMEL BIOSCIENCES	<u>20MG/5ML</u>	<u>N209139</u>	<u>001</u>	Dec 19, 2017
<u>+</u> !		<u>80MG/20ML</u>	<u>N209139</u>	<u>002</u>	Dec 19, 2017

TABLET; ORAL

DIOVAN

<u>AB</u>	<u>+</u>	NOVARTIS	<u>40MG</u>	<u>N021283</u>	<u>004</u>	Aug 14, 2002
<u>AB</u>	<u>+</u>		<u>80MG</u>	<u>N021283</u>	<u>001</u>	Jul 18, 2001
<u>AB</u>	<u>+</u>		<u>160MG</u>	<u>N021283</u>	<u>002</u>	Jul 18, 2001
<u>AB</u>	<u>+</u> !		<u>320MG</u>	<u>N021283</u>	<u>003</u>	Jul 18, 2001

VALSARTAN

<u>AB</u>		ALEMBIC PHARMS LTD	<u>40MG</u>	<u>A091367</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A091367</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A091367</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A091367</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		AMNEAL PHARMS	<u>40MG</u>	<u>A204011</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>			<u>80MG</u>	<u>A204011</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>			<u>160MG</u>	<u>A204011</u>	<u>003</u>	Jan 11, 2016
<u>AB</u>			<u>320MG</u>	<u>A204011</u>	<u>004</u>	Jan 11, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A202223</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A202223</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A202223</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A202223</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		HETERO LABS LTD V	<u>40MG</u>	<u>A203311</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A203311</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A203311</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A203311</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		IVAX PHARMS	<u>40MG</u>	<u>A077530</u>	<u>001</u>	Jan 04, 2016
<u>AB</u>			<u>80MG</u>	<u>A077530</u>	<u>002</u>	Jan 04, 2016
<u>AB</u>			<u>160MG</u>	<u>A077530</u>	<u>003</u>	Jan 04, 2016
<u>AB</u>			<u>320MG</u>	<u>A077530</u>	<u>004</u>	Jan 04, 2016
<u>AB</u>		JUBILANT GENERICS	<u>40MG</u>	<u>A203536</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A203536</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A203536</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>			<u>320MG</u>	<u>A203536</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>		LUPIN LTD	<u>40MG</u>	<u>A201677</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>			<u>80MG</u>	<u>A201677</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>			<u>160MG</u>	<u>A201677</u>	<u>003</u>	Jan 05, 2015

PRESCRIPTION DRUG PRODUCT LIST

VALSARTAN

TABLET; ORAL

VALSARTAN

<u>AB</u>		<u>320MG</u>	<u>A201677 004</u>	Jan 05, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>40MG</u>	<u>A202696 001</u>	Sep 16, 2016
<u>AB</u>		<u>80MG</u>	<u>A202696 002</u>	Sep 16, 2016
<u>AB</u>		<u>160MG</u>	<u>A202696 003</u>	Sep 16, 2016
<u>AB</u>		<u>320MG</u>	<u>A202696 004</u>	Sep 16, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>40MG</u>	<u>A090866 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090866 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090866 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090866 004</u>	Jan 05, 2015
<u>AB</u>	OHM LABS INC	<u>40MG</u>	<u>A077492 001</u>	Jun 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A077492 002</u>	Jun 26, 2014
<u>AB</u>		<u>160MG</u>	<u>A077492 003</u>	Jun 26, 2014
<u>AB</u>		<u>320MG</u>	<u>A077492 004</u>	Jun 26, 2014
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A204821 001</u>	Jun 09, 2015
<u>AB</u>		<u>80MG</u>	<u>A204821 002</u>	Jun 09, 2015
<u>AB</u>		<u>160MG</u>	<u>A204821 003</u>	Jun 09, 2015
<u>AB</u>		<u>320MG</u>	<u>A204821 004</u>	Jun 09, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>40MG</u>	<u>A202728 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A202728 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A202728 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A202728 004</u>	Jan 05, 2015
<u>AB</u>	WATSON LABS INC	<u>40MG</u>	<u>A090642 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090642 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090642 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090642 004</u>	Jan 05, 2015

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>	+	ANI PHARMS INC	<u>EQ 125MG BASE</u>	<u>N050606 001</u>	Apr 15, 1986
<u>AB</u>	+	!	<u>EQ 250MG BASE</u>	<u>N050606 002</u>	Apr 15, 1986

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		AKORN	<u>EQ 125MG BASE</u>	<u>A065478 001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065478 002</u>	Apr 09, 2012
<u>AB</u>		FRESENIUS KABI USA	<u>EQ 125MG BASE</u>	<u>A065453 001</u>	Jun 18, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065453 002</u>	Jun 18, 2012
<u>AB</u>		LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439 001</u>	Jan 28, 2015
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A090439 002</u>	Jan 28, 2015
<u>AB</u>		STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490 001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065490 002</u>	Apr 09, 2012
<u>AB</u>		WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510 001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065510 002</u>	Apr 09, 2012

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205780 001</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205780 002</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A205779 001</u>	Mar 29, 2016
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A205779 002</u>	Mar 29, 2016
<u>AP</u>		CFT PHARMS LLC	<u>EQ 5GM BASE/VIAL</u>	<u>A204125 001</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A204125 002</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A204107 001</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A204107 002</u>	Dec 28, 2015
<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202275 001</u>	Oct 31, 2013
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A202275 002</u>	Oct 31, 2013
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A202464 001</u>	Oct 09, 2013
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A202274 001</u>	Oct 31, 2013
<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663 001</u>	Mar 17, 1987
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062663 005</u>	Aug 17, 2016
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062663 002</u>	Jul 31, 1987
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A062663 003</u>	Jun 03, 1988
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A062663 004</u>	Nov 28, 1997
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205694 001</u>	Jan 21, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205694 002</u>	Jan 21, 2016
<u>AP</u>	!	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911 001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A062931 001</u>	Oct 29, 1992
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062912 002</u>	Jan 07, 2009
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062933 002</u>	May 27, 2009
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062912 001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062933 001</u>	Oct 29, 1992

PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A063076 001</u>	Dec 21, 1990
<u>AP</u>		HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455 001</u>	Apr 29, 2009
<u>AP</u>		MUSTAFA NEVZAT ILAC	<u>EQ 500MG BASE/VIAL</u>	<u>A065401 001</u>	Jun 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065401 002</u>	Jun 30, 2008
<u>AP</u>		MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397 001</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065397 002</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A065432 001</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091469 001</u>	Jul 01, 2011
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091554 001</u>	Sep 19, 2011
<u>AP</u>		SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837 001</u>	Aug 10, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A200837 002</u>	Sep 02, 2014
<u>AP</u>		SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250 001</u>	Apr 27, 2010
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A090250 002</u>	Apr 27, 2010
<u>AP</u>		SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048 001</u>	Aug 10, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A201048 002</u>	Aug 10, 2012
<u>AP</u>		XELLIA PHARMS APS	<u>EQ 500MG BASE/VIAL</u>	<u>A091377 001</u>	Sep 09, 2015
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A091377 002</u>	Sep 09, 2015
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A206243 001</u>	Dec 23, 2015
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A206243 002</u>	Dec 23, 2015
		VANCOVIN HYDROCHLORIDE IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671 001	Apr 29, 1993
	+		EQ 750MG BASE/150ML	N050671 002	Dec 20, 2010
		POWDER; IV (INFUSION)			
		VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER			
		SAMSON MEDCL	EQ 100GM BASE	A091532 001	Jan 06, 2016

VANDETANIB

TABLET; ORAL

CAPRELSA

+	GENZYME CORP	100MG	N022405 001	Apr 06, 2011
+	!	300MG	N022405 002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

+	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003
+		5MG	N021400 001	Aug 19, 2003
+		10MG	N021400 002	Aug 19, 2003
+	!	20MG	N021400 004	Aug 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

+	BAYER HLTHCARE	10MG	N200179 001	Jun 17, 2010
---	----------------	------	-------------	--------------

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

+	PFIZER INC	EQ 0.5MG BASE	N021928 001	May 10, 2006
+	!	EQ 1MG BASE	N021928 002	May 10, 2006

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485 001	Apr 17, 2014
+	!	200UNITS/10ML (20UNITS/ML)	N204485 002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>		GLAND PHARMA LTD	<u>10MG/VIAL</u>	<u>A205390 001</u>	May 26, 2016
<u>AP</u>			<u>20MG/VIAL</u>	<u>A205390 002</u>	May 26, 2016
<u>AP</u>		HOSPIRA	<u>10MG/VIAL</u>	<u>A075164 001</u>	Oct 21, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A075164 002</u>	Oct 21, 1999
<u>AP</u>		MYLAN LABS LTD	<u>10MG/VIAL</u>	<u>A090243 001</u>	May 11, 2010
<u>AP</u>			<u>20MG/VIAL</u>	<u>A090243 002</u>	May 11, 2010
<u>AP</u>		SAGENT PHARMS	<u>10MG/VIAL</u>	<u>A078274 001</u>	Dec 29, 2008
<u>AP</u>			<u>20MG/VIAL</u>	<u>A078274 002</u>	Dec 29, 2008
<u>AP</u>	!	SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001 001</u>	Jun 17, 2009
<u>AP</u>	!		<u>20MG/VIAL</u>	<u>A079001 002</u>	Jun 17, 2009
<u>AP</u>		TEVA PHARMS USA	<u>10MG/VIAL</u>	<u>A074688 001</u>	Aug 25, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A074688 002</u>	Aug 25, 1999
<u>AP</u>		WEST-WARD PHARMS	<u>10MG/VIAL</u>	<u>A075549 001</u>	Jun 13, 2000

PRESCRIPTION DRUG PRODUCT LIST

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

INT

AP		20MG/VIAL	A075549 002	Jun 13, 2000
-----------	--	------------------	--------------------	--------------

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575 001	Feb 26, 2010
--	---------------------	----------------	-------------	--------------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+	!	HOFFMANN LA ROCHE	240MG	N202429 001	Aug 17, 2011
---	---	-------------------	-------	-------------	--------------

VENETOCLAX

TABLET; ORAL

VENCLEXTA

+		ABBVIE INC	10MG	N208573 001	Apr 11, 2016
---	--	------------	------	-------------	--------------

+			50MG	N208573 002	Apr 11, 2016
---	--	--	------	-------------	--------------

+	!		100MG	N208573 003	Apr 11, 2016
---	---	--	-------	-------------	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

AB	+	WYETH PHARMS INC	EQ 37.5MG BASE	N020699 001	Oct 20, 1997
-----------	---	------------------	-----------------------	--------------------	--------------

AB	+		EQ 75MG BASE	N020699 002	Oct 20, 1997
-----------	---	--	---------------------	--------------------	--------------

AB	+	!	EQ 150MG BASE	N020699 004	Oct 20, 1997
-----------	---	---	----------------------	--------------------	--------------

VENLAFAXINE HYDROCHLORIDE

AB		ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012
-----------	--	---------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A078087 002	Mar 16, 2012
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A078087 003	Mar 16, 2012
-----------	--	--	----------------------	--------------------	--------------

AB		AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011
-----------	--	----------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A200834 002	Apr 14, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A200834 003	Apr 14, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011
-----------	--	--------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A078421 002	May 06, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A078421 003	May 06, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889 001	Oct 05, 2017
-----------	--	---------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A204889 002	Oct 05, 2017
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A204889 003	Oct 05, 2017
-----------	--	--	----------------------	--------------------	--------------

AB		ORCHID HLTHCARE	EQ 37.5MG BASE	A091123 001	Jul 11, 2011
-----------	--	-----------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A091123 002	Jul 11, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A091123 003	Jul 11, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		TEVA	EQ 37.5MG BASE	A076565 001	Jun 28, 2010
-----------	--	------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A076565 002	Jun 28, 2010
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A076565 003	Jun 28, 2010
-----------	--	--	----------------------	--------------------	--------------

AB		TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011
-----------	--	--------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A090899 002	Jun 01, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A090899 003	Jun 01, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071 001	Apr 15, 2011
-----------	--	----------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A090071 002	Apr 15, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A090071 003	Apr 15, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011
-----------	--	-----------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A078865 002	Apr 14, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A078865 003	Apr 14, 2011
-----------	--	--	----------------------	--------------------	--------------

AB		ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011
-----------	--	----------------------	-----------------------	--------------------	--------------

AB			EQ 75MG BASE	A090174 002	Apr 14, 2011
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 150MG BASE	A090174 003	Apr 14, 2011
-----------	--	--	----------------------	--------------------	--------------

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ALEMIC PHARMS LTD	EQ 25MG BASE	A078932 001	Dec 14, 2010
-----------	--	-------------------	---------------------	--------------------	--------------

AB			EQ 37.5MG BASE	A078932 002	Dec 14, 2010
-----------	--	--	-----------------------	--------------------	--------------

AB			EQ 50MG BASE	A078932 003	Dec 14, 2010
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 75MG BASE	A078932 004	Dec 14, 2010
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 100MG BASE	A078932 005	Dec 14, 2010
-----------	--	--	----------------------	--------------------	--------------

AB		AMNEAL PHARMS	EQ 25MG BASE	A079098 001	May 11, 2010
-----------	--	---------------	---------------------	--------------------	--------------

AB			EQ 37.5MG BASE	A079098 002	May 11, 2010
-----------	--	--	-----------------------	--------------------	--------------

AB			EQ 50MG BASE	A079098 003	May 11, 2010
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 75MG BASE	A079098 004	May 11, 2010
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 100MG BASE	A079098 005	May 11, 2010
-----------	--	--	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	PRINSTON INC	<u>EQ 25MG BASE</u>	<u>A090027 001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027 002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027 003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027 004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027 005</u>	Aug 04, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>	!	<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036 003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036 004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036 005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	NOSTRUM LABS INC	<u>EQ 150MG BASE</u>	<u>A205468 002</u>	Mar 24, 2017
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A205468 003</u>	Mar 24, 2017
<u>AB</u>	+ OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+!	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 225MG BASE</u>	<u>N022104 004</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306 001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306 002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306 003</u>	Aug 09, 2007
	<u>VERELAN</u>			
<u>AB</u>	+ RECRO GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>	+	<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>	+	<u>240MG</u>	<u>N019614 002</u>	May 29, 1990

PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN PM

<u>AB</u>	+	RECRO GAINESVILLE	<u>100MG</u>	<u>N020943</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>	+		<u>200MG</u>	<u>N020943</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	+	!	<u>300MG</u>	<u>N020943</u>	<u>003</u>	Nov 25, 1998

VERELAN

+	!	RECRO GAINESVILLE	360MG	N019614	004	May 10, 1996
---	---	-------------------	-------	---------	-----	--------------

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>		EXELA PHARMA SCS LLC	<u>5MG/2ML (2.5MG/ML)</u>	<u>N018925</u>	<u>001</u>	Mar 30, 1984
<u>AP</u>	!	HOSPIRA	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
<u>AP</u>	!		<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998
<u>AP</u>	!		<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
<u>AP</u>	!		<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737</u>	<u>002</u>	May 06, 1987

TABLET;ORAL

CALAN

<u>AB</u>	+	GD SEARLE LLC	<u>80MG</u>	<u>N018817</u>	<u>001</u>	Sep 10, 1984
<u>AB</u>	+	!	<u>120MG</u>	<u>N018817</u>	<u>002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>		HERITAGE PHARMS INC	<u>40MG</u>	<u>A071881</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>			<u>80MG</u>	<u>A071881</u>	<u>003</u>	Apr 05, 1988
<u>AB</u>			<u>120MG</u>	<u>A071881</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		MYLAN	<u>80MG</u>	<u>A071483</u>	<u>002</u>	Feb 15, 1989
<u>AB</u>			<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>		WATSON LABS	<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>			<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>			<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

<u>AB</u>	+	!	PFIZER	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
<u>AB</u>	+	!		<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>		APOTEX CORP	<u>120MG</u>	<u>A200878</u>	<u>001</u>	Apr 20, 2012
<u>AB</u>			<u>180MG</u>	<u>A200878</u>	<u>002</u>	Apr 20, 2012
<u>AB</u>			<u>240MG</u>	<u>A200878</u>	<u>003</u>	Apr 20, 2012
<u>AB</u>		CADILA PHARMS LTD	<u>180MG</u>	<u>A206173</u>	<u>001</u>	May 05, 2017
<u>AB</u>			<u>240MG</u>	<u>A206173</u>	<u>002</u>	May 05, 2017
<u>AB</u>		GLENMARK GENERICS	<u>120MG</u>	<u>A090700</u>	<u>001</u>	Aug 03, 2011
<u>AB</u>	!		<u>180MG</u>	<u>A090700</u>	<u>002</u>	Aug 03, 2011
<u>AB</u>			<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
<u>AB</u>			<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
<u>AB</u>			<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997
<u>AB</u>			<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997
<u>AB</u>			<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996
<u>AB</u>		PAR PHARM	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
<u>AB</u>			<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
<u>AB</u>		SUN PHARM INDS INC	<u>120MG</u>	<u>A090529</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>			<u>180MG</u>	<u>A090529</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>			<u>240MG</u>	<u>A090529</u>	<u>003</u>	Dec 30, 2011

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+	!	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000
---	---	--------------------	-----------	---------	-----	--------------

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

<u>AA</u>	+	!	LUNDBECK PHARMS LLC	<u>500MG/PACKET</u>	<u>N022006</u>	<u>001</u>	Aug 21, 2009
-----------	---	---	---------------------	---------------------	----------------	------------	--------------

VIGABATRIN

<u>AA</u>		PAR PHARM INC	<u>500MG/PACKET</u>	<u>A208218</u>	<u>001</u>	Apr 27, 2017
-----------	--	---------------	---------------------	----------------	------------	--------------

TABLET;ORAL

SABRIL

+	!	LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009
---	---	---------------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	!	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011
+			20MG	N022567	002	Jan 21, 2011
+			40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

!		FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
!		WEST-WARD PHARMS	10MG/VIAL	A089395	001	Apr 09, 1987

INT

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988
AP		TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+	!	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012
---	---	--------------	------------------	---------	-----	--------------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP	+	PIERRE FABRE	EQ 10MG BASE/ML	N020388	001	Dec 23, 1994
-----------	---	--------------	------------------------	----------------	------------	--------------

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009
AP		DR REDDYS LABS LTD	EQ 10MG BASE/ML	A202017	001	Sep 12, 2013
AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849	001	Apr 18, 2005
AP		HOSPIRA	EQ 10MG BASE/ML	A076827	001	Jun 02, 2005
AP		JIANGSU HANSON	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012
		PHARM				
AP		TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003
AP		WEST-WARD PHARMS	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003
		INT				
AP			EQ 10MG BASE/ML	A076461	001	Dec 11, 2003

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	!	GENENTECH	150MG	N203388	001	Jan 30, 2012
---	---	-----------	-------	---------	-----	--------------

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+	!	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	
---	---	---------	-------------------------	---------	-----	--

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+	!	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014
---	---	---------------	----------------	---------	-----	--------------

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+	PF PRISM CV	200MG/5ML	N021630	001	Dec 19, 2003
-----------	---	-------------	------------------	----------------	------------	--------------

VORICONAZOLE

AB		AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016
AB		MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013
AB		NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002
-----------	---	-------------	-------------------	----------------	------------	--------------

VORICONAZOLE

AP		ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016
AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012

POWDER; IV (INFUSION)

VORICONAZOLE

		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017
--	--	-------------------	------------	---------	-----	--------------

TABLET; ORAL

VFEND

AB	+	PF PRISM CV	50MG	N021266	001	May 24, 2002
AB	+		200MG	N021266	002	May 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

<u>AB</u>	AJANTA PHARMA LTD	<u>50MG</u>	<u>A206181</u>	<u>001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206181</u>	<u>002</u>	May 24, 2016
<u>AB</u>	AKORN	<u>50MG</u>	<u>A207049</u>	<u>001</u>	Sep 07, 2016
<u>AB</u>		<u>200MG</u>	<u>A207049</u>	<u>002</u>	Sep 07, 2016
<u>AB</u>	APPCO PHARMA LLC	<u>50MG</u>	<u>A206762</u>	<u>001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206762</u>	<u>002</u>	May 24, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206837</u>	<u>001</u>	Jan 22, 2016
<u>AB</u>		<u>200MG</u>	<u>A206837</u>	<u>002</u>	Jan 22, 2016
<u>AB</u>	GLENMARK PHARMS LTD	<u>50MG</u>	<u>A203503</u>	<u>001</u>	Sep 02, 2015
<u>AB</u>		<u>200MG</u>	<u>A203503</u>	<u>002</u>	Sep 02, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A090547</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>200MG</u>	<u>A090547</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>	NOVEL LABS INC	<u>50MG</u>	<u>A207371</u>	<u>001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A207371</u>	<u>002</u>	May 24, 2016
<u>AB</u>	PRINSTON INC	<u>50MG</u>	<u>A206654</u>	<u>001</u>	Aug 08, 2016
<u>AB</u>		<u>200MG</u>	<u>A206654</u>	<u>002</u>	Aug 08, 2016
<u>AB</u>	SANDOZ INC	<u>50MG</u>	<u>A200265</u>	<u>001</u>	Dec 12, 2011
<u>AB</u>		<u>200MG</u>	<u>A200265</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	TEVA PHARMS	<u>50MG</u>	<u>A091658</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>		<u>200MG</u>	<u>A091658</u>	<u>002</u>	Apr 06, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A206747</u>	<u>001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206747</u>	<u>002</u>	May 24, 2016

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+! MERCK

100MG

N021991 001 Oct 06, 2006

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+ TAKEDA PHARMS USA

EQ 5MG BASE

N204447 001 Sep 30, 2013

+

EQ 10MG BASE

N204447 002 Sep 30, 2013

+!

EQ 20MG BASE

N204447 004 Sep 30, 2013

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218</u>	<u>022</u>	Mar 01, 1990
<u>AB</u>	+	<u>2MG</u>	<u>N009218</u>	<u>013</u>	
<u>AB</u>	+	<u>2.5MG</u>	<u>N009218</u>	<u>018</u>	
<u>AB</u>	+	<u>3MG</u>	<u>N009218</u>	<u>025</u>	Nov 18, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N009218</u>	<u>023</u>	Aug 24, 1993
<u>AB</u>	+	<u>5MG</u>	<u>N009218</u>	<u>007</u>	
<u>AB</u>	+	<u>6MG</u>	<u>N009218</u>	<u>026</u>	Nov 18, 1996
<u>AB</u>	+	<u>7.5MG</u>	<u>N009218</u>	<u>016</u>	
<u>AB</u>	+!	<u>10MG</u>	<u>N009218</u>	<u>005</u>	

JANTOVEN

<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416</u>	<u>001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416</u>	<u>002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416</u>	<u>003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416</u>	<u>004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>1MG</u>	<u>A202202</u>	<u>001</u>	Mar 04, 2013
<u>AB</u>		<u>2MG</u>	<u>A202202</u>	<u>002</u>	Mar 04, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A202202</u>	<u>003</u>	Mar 04, 2013
<u>AB</u>		<u>3MG</u>	<u>A202202</u>	<u>004</u>	Mar 04, 2013
<u>AB</u>		<u>4MG</u>	<u>A202202</u>	<u>005</u>	Mar 04, 2013
<u>AB</u>		<u>5MG</u>	<u>A202202</u>	<u>006</u>	Mar 04, 2013
<u>AB</u>		<u>6MG</u>	<u>A202202</u>	<u>007</u>	Mar 04, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A202202</u>	<u>008</u>	Mar 04, 2013
<u>AB</u>		<u>10MG</u>	<u>A202202</u>	<u>009</u>	Mar 04, 2013
<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997

PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>2MG</u>	<u>A040145 002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145 003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145 008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145 004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145 005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145 009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145 006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145 007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935 001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935 002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935 003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935 004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935 005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935 006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935 007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935 008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935 009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104 001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104 002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104 003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104 004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104 005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104 006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104 007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104 008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104 009</u>	Jun 27, 2013
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616 009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616 001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616 002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616 003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616 004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616 005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616 006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616 007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616 008</u>	Jul 05, 2006
<u>AB</u>	TARO PHARM	<u>1MG</u>	<u>A040301 002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301 003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301 004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301 005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301 006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301 007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301 008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301 009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301 001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663 001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663 002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663 003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663 004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663 005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663 006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663 007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663 008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663 009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

	LANTHEUS MEDCL	10mCi/VIAL	N017284 001	
		20mCi/VIAL	N017284 002	
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327 001	Mar 09, 1982
		20mCi/VIAL	N018327 002	Mar 09, 1982

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	+	PAR PHARM INC	<u>10MG</u>	<u>N020547 003</u>	Sep 17, 1999
<u>AB</u>	+	!	<u>20MG</u>	<u>N020547 001</u>	Sep 26, 1996
<u>ZAFIRLUKAST</u>					
<u>AB</u>		DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372 001</u>	Nov 18, 2010
<u>AB</u>			<u>20MG</u>	<u>A090372 002</u>	Nov 18, 2010

PRESCRIPTION DRUG PRODUCT LIST

ZALEPLON

CAPSULE; ORAL

SONATA

AB	+	PFIZER	5MG	N020859 001	Aug 13, 1999
AB	+	!	10MG	N020859 002	Aug 13, 1999

ZALEPLON

AB		AUROBINDO PHARMA	5MG	A078829 001	Jun 06, 2008
AB			10MG	A078829 002	Jun 06, 2008
AB		CIPLA LTD	5MG	A077505 001	Jun 20, 2008
AB			10MG	A077505 002	Jun 20, 2008
AB		HIKMA PHARMS	5MG	A078147 001	Nov 25, 2008
AB			10MG	A078147 002	Nov 25, 2008
AB		ORCHID HLTHCARE	5MG	A090374 001	Sep 17, 2009
AB			10MG	A090374 002	Sep 17, 2009
AB		TEVA PHARMS	5MG	A077239 001	Jun 06, 2008
AB			10MG	A077239 002	Jun 06, 2008
AB		UNICHEM	5MG	A078989 001	Jun 06, 2008
AB			10MG	A078989 002	Jun 06, 2008
AB		WEST-WARD PHARMS INT	5MG	A077237 001	Jun 06, 2008
AB			10MG	A077237 002	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+	!	GLAXOSMITHKLINE	5MG	N021036 001	Jul 26, 1999
----------	---	-----------------	------------	--------------------	--------------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	!	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004
+	!		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004
+	!		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+	!	VIIV HLTHCARE	100MG	N019655 001	Mar 19, 1987
-----------	----------	---	---------------	--------------	--------------------	--------------

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	100MG	A078128 001	Mar 27, 2006
AB		CIPLA LTD	100MG	A078349 001	May 23, 2007

INJECTABLE; INJECTION

RETROVIR

AP	+	!	VIIV HLTHCARE	10MG/ML	N019951 001	Feb 02, 1990
-----------	----------	---	---------------	----------------	--------------------	--------------

ZIDOVUDINE

AP			LUITPOLD	10MG/ML	A091457 001	May 06, 2010
-----------	--	--	----------	----------------	--------------------	--------------

SYRUP; ORAL

RETROVIR

AA	+	!	VIIV HLTHCARE	50MG/5ML	N019910 001	Sep 28, 1989
-----------	----------	---	---------------	-----------------	--------------------	--------------

ZIDOVUDINE

AA			AUROBINDO	50MG/5ML	A077268 001	Sep 19, 2005
AA			CIPLA LTD	50MG/5ML	A077981 001	Jun 26, 2008

TABLET; ORAL

ZIDOVUDINE

AB			AUROBINDO	300MG	A077267 001	Sep 19, 2005
AB			CIPLA	300MG	A090561 001	Oct 27, 2010
AB	!		HETERO LABS LTD III	300MG	A090092 001	Apr 25, 2008
AB			MYLAN PHARMS INC	300MG	A078922 001	Feb 14, 2008
AB			WEST-WARD PHARMS INT	300MG	A076844 001	Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

+	!	CHIESI USA INC	600MG	N020471 003	Dec 09, 1996
----------	---	----------------	--------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

AB			RISING PHARMS INC	600MG	A204929 001	Mar 17, 2017
-----------	--	--	-------------------	--------------	--------------------	--------------

ZYFLO CR

AB	+	!	CHIESI USA INC	600MG	N022052 001	May 30, 2007
-----------	----------	---	----------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ZINC ACETATE

CAPSULE; ORAL

GALZIN

+ TEVA

EQ 25MG ZINC

N020458 001 Jan 28, 1997

+!

EQ 50MG ZINC

N020458 002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA

EQ 1MG ZINC/ML

N018959 001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODONAB +! PFIZEREQ 20MG BASEN020825 001 Feb 05, 2001AB +EQ 40MG BASEN020825 002 Feb 05, 2001AB +EQ 60MG BASEN020825 003 Feb 05, 2001AB +EQ 80MG BASEN020825 004 Feb 05, 2001ZIPRASIDONE HYDROCHLORIDEAB APOTEX INCEQ 20MG BASEA077561 001 Mar 02, 2012ABEQ 40MG BASEA077561 002 Mar 02, 2012ABEQ 60MG BASEA077561 003 Mar 02, 2012ABEQ 80MG BASEA077561 004 Mar 02, 2012AB AUROBINDO PHARMA LTDEQ 20MG BASEA204117 001 Dec 27, 2016ABEQ 40MG BASEA204117 002 Dec 27, 2016ABEQ 60MG BASEA204117 003 Dec 27, 2016ABEQ 80MG BASEA204117 004 Dec 27, 2016AB DR REDDYS LABS INCEQ 20MG BASEA077565 001 Mar 02, 2012ABEQ 40MG BASEA077565 002 Mar 02, 2012ABEQ 60MG BASEA077565 003 Mar 02, 2012ABEQ 80MG BASEA077565 004 Mar 02, 2012AB LUPIN PHARMSEQ 20MG BASEA077560 001 Mar 02, 2012ABEQ 40MG BASEA077560 002 Mar 02, 2012ABEQ 60MG BASEA077560 003 Mar 02, 2012ABEQ 80MG BASEA077560 004 Mar 02, 2012AB MACLEODS PHARMS LTDEQ 20MG BASEA204375 001 Feb 17, 2017ABEQ 40MG BASEA204375 002 Feb 17, 2017ABEQ 60MG BASEA204375 003 Feb 17, 2017ABEQ 80MG BASEA204375 004 Feb 17, 2017AB MYLAN PHARMS INCEQ 20MG BASEA202395 001 Oct 10, 2013ABEQ 40MG BASEA202395 002 Oct 10, 2013ABEQ 60MG BASEA202395 003 Oct 10, 2013ABEQ 80MG BASEA202395 004 Oct 10, 2013AB SANDOZ INCEQ 20MG BASEA077562 001 Jun 01, 2012ABEQ 40MG BASEA077562 002 Jun 01, 2012ABEQ 60MG BASEA077562 003 Jun 01, 2012ABEQ 80MG BASEA077562 004 Jun 01, 2012AB WOCKHARDT LTDEQ 20MG BASEA090348 001 Sep 05, 2012ABEQ 40MG BASEA090348 002 Sep 05, 2012ABEQ 60MG BASEA090348 003 Sep 05, 2012ABEQ 80MG BASEA090348 004 Sep 05, 2012AB ZYDUS PHARMS USA INCEQ 20MG BASEA208988 001 Aug 22, 2017ABEQ 40MG BASEA208988 002 Aug 22, 2017ABEQ 60MG BASEA208988 003 Aug 22, 2017ABEQ 80MG BASEA208988 004 Aug 22, 2017ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+! PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLASTAP +! NOVARTISEQ 5MG BASE/100MLN021817 001 Apr 16, 2007ZOLEDRONIC ACIDAP ACCORD HLTHCAREEQ 4MG BASE/5MLA205279 001 Nov 28, 2016AP ACS DOBFAR INFO SAEQ 4MG BASE/100MLN203231 001 Aug 02, 2013APEQ 5MG BASE/100MLA202828 001 Sep 23, 2013AP ACTAVIS INCEQ 4MG BASE/5MLA202472 001 Mar 04, 2013APEQ 5MG BASE/100MLA200918 001 Aug 21, 2014APEQ 4MG BASE/5MLA202548 001 May 22, 2014AP APOTEX INCEQ 5MG BASE/100MLA204367 001 Dec 24, 2015

PRESCRIPTION DRUG PRODUCT LIST

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A207751 001</u>	Sep 26, 2016
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209125 001</u>	Dec 08, 2017
<u>AP</u>	BPI LABS LLC	<u>EQ 4MG BASE/5ML</u>	<u>A207341 001</u>	Dec 29, 2017
<u>AP</u>	BRECKENRIDGE PHARM	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
<u>AP</u>	CIPLA LTD	<u>EQ 4MG BASE/100ML</u>	<u>A210174 001</u>	Oct 27, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363 001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783 001</u>	Mar 12, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801 001</u>	Mar 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/5ML</u>	<u>A091516 001</u>	Apr 23, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930 001</u>	Aug 05, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A204217 001</u>	Aug 18, 2016
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182 001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 4MG BASE/5ML</u>	<u>A090621 001</u>	Mar 19, 2015
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A203841 001</u>	Feb 14, 2017
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A205254 001</u>	Oct 27, 2017
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091493 001</u>	Nov 24, 2014
<u>AP</u>	! SUN PHARMA GLOBAL	<u>EQ 4MG BASE/VIAL</u>	<u>A090018 001</u>	Mar 04, 2013
<u>AP</u>	USV NORTH AMERICA	<u>EQ 4MG BASE/5ML</u>	<u>A202923 001</u>	Sep 04, 2014

ZOMETA

<u>AP</u>	+! NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223 002</u>	Mar 07, 2003
<u>AP</u>	+!	<u>EQ 4MG BASE/100ML</u>	<u>N021223 003</u>	Jun 17, 2011

SOLUTION; IV (INFUSION)

ZOLEDRONIC ACID

	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016 001	Dec 28, 2015
--	-------------	---------------------------------------	-------------	--------------

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

	+ ASTRAZENECA	2.5MG/SPRAY	N021450 003	Sep 16, 2013
	+!	5MG/SPRAY	N021450 004	Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A204041 001</u>	May 20, 2016
<u>AB</u>		<u>5MG</u>	<u>A204041 002</u>	May 20, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204232 001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A204232 002</u>	Sep 30, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078 002</u>	May 14, 2013
<u>AB</u>	APPCO PHARMA LLC	<u>2.5MG</u>	<u>A206973 001</u>	Jun 30, 2017
<u>AB</u>		<u>5MG</u>	<u>A206973 002</u>	Jun 30, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A207021 001</u>	May 11, 2016
<u>AB</u>		<u>5MG</u>	<u>A207021 002</u>	May 11, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779 002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284 001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284 002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279 001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279 002</u>	Nov 20, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A203772 001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A203772 002</u>	Sep 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186 002</u>	May 14, 2013
<u>AB</u>	PLD ACQUISITIONS LLC	<u>2.5MG</u>	<u>A207867 001</u>	Feb 27, 2017
<u>AB</u>		<u>5MG</u>	<u>A207867 002</u>	Feb 27, 2017
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090861 001</u>	Mar 04, 2014
<u>AB</u>		<u>5MG</u>	<u>A090861 002</u>	Mar 04, 2014
	<u>ZOMIG</u>			
<u>AB</u>	+ IPR	<u>2.5MG</u>	<u>N020768 001</u>	Nov 25, 1997
<u>AB</u>	+!	<u>5MG</u>	<u>N020768 002</u>	Nov 25, 1997
	TABLET, ORALLY DISINTEGRATING; ORAL			
	<u>ZOLMITRIPTAN</u>			
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A205074 001</u>	Dec 01, 2016

PRESCRIPTION DRUG PRODUCT LIST

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

<u>AB</u>		<u>5MG</u>	<u>A205074</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202476</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202476</u>	<u>002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560</u>	<u>002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A204336</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>		<u>5MG</u>	<u>A204336</u>	<u>002</u>	Oct 22, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890</u>	<u>001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890</u>	<u>002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	+	ASTRAZENECA	<u>2.5MG</u>	<u>N021231</u>	<u>001</u>	Feb 13, 2001
<u>AB</u>	+	!	<u>5MG</u>	<u>N021231</u>	<u>002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+	!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008
---	---	--------------	-----------	---------	-----	--------------

TABLET;ORAL

AMBIEN

<u>AB</u>	+	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992
<u>AB</u>	+	!	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>		ACME LABS	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>			<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>		CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>			<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>		INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>			<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		SANDOZ INC	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		SUN PHARM INDS LTD	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>			<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>		VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>			<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>		WOCKHARDT	<u>5MG</u>	<u>A078426</u>	<u>001</u>	May 15, 2007
<u>AB</u>			<u>10MG</u>	<u>A078426</u>	<u>002</u>	May 15, 2007
<u>AB</u>		YUNG SHIN PHARM	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>			<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

<u>AB</u>	+	MYLAN SPECIALITY LP	<u>5MG</u>	<u>N021997</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>	+	!	<u>10MG</u>	<u>N021997</u>	<u>002</u>	Mar 13, 2009

INTERMEZZO

<u>AB</u>	+	PURDUE PHARMA	<u>1.75MG</u>	<u>N022328</u>	<u>001</u>	Nov 23, 2011
<u>AB</u>	+	!	<u>3.5MG</u>	<u>N022328</u>	<u>002</u>	Nov 23, 2011

ZOLPIDEM TARTRATE

<u>AB</u>		DR REDDYS LABS INC	<u>1.75MG</u>	<u>A204503</u>	<u>001</u>	Nov 18, 2016
<u>AB</u>			<u>3.5MG</u>	<u>A204503</u>	<u>002</u>	Nov 18, 2016
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A202657</u>	<u>001</u>	Aug 08, 2016
<u>AB</u>			<u>10MG</u>	<u>A202657</u>	<u>002</u>	Aug 08, 2016
<u>AB</u>		NOVEL LABS INC	<u>1.75MG</u>	<u>A204299</u>	<u>001</u>	Jun 03, 2015
<u>AB</u>			<u>3.5MG</u>	<u>A204299</u>	<u>002</u>	Jun 03, 2015
<u>AB</u>		PAR FORM	<u>5MG</u>	<u>A201509</u>	<u>001</u>	Aug 01, 2016
<u>AB</u>			<u>10MG</u>	<u>A201509</u>	<u>002</u>	Aug 01, 2016
<u>AB</u>		PAR PHARM INC	<u>1.75MG</u>	<u>A204229</u>	<u>001</u>	Sep 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET;SUBLINGUAL

ZOLPIDEM TARTRATE

<u>AB</u>		<u>3.5MG</u>	<u>A204229 002</u>	Sep 11, 2017
TABLET, EXTENDED RELEASE;ORAL				

AMBIEN CR

<u>AB</u>	+	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774 002</u>	Sep 02, 2005
<u>AB</u>	+	!	<u>12.5MG</u>	<u>N021774 001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179 002</u>	Oct 13, 2010
<u>AB</u>			<u>12.5MG</u>	<u>A078179 001</u>	Jun 06, 2011
<u>AB</u>		ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153 001</u>	Mar 25, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A090153 002</u>	Mar 25, 2013
<u>AB</u>		ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148 002</u>	Apr 14, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A078148 001</u>	Dec 03, 2010
<u>AB</u>		APOTEX INC	<u>6.25MG</u>	<u>A200266 001</u>	Sep 10, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A200266 002</u>	Sep 10, 2013
<u>AB</u>		LUPIN LTD	<u>6.25MG</u>	<u>A078970 001</u>	Sep 11, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A078970 002</u>	Sep 11, 2013
<u>AB</u>		SANDOZ	<u>6.25MG</u>	<u>A090107 001</u>	Jul 01, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A090107 002</u>	Jul 01, 2011
<u>AB</u>		SUN PHARMA GLOBAL	<u>6.25MG</u>	<u>A204170 001</u>	Jan 24, 2017
<u>AB</u>			<u>12.5MG</u>	<u>A204170 002</u>	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	+	SUNOVION PHARMS INC	<u>25MG</u>	<u>N020789 003</u>	Aug 22, 2003
<u>AB</u>	+		<u>50MG</u>	<u>N020789 002</u>	Aug 22, 2003
<u>AB</u>	+	!	<u>100MG</u>	<u>N020789 001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>		APOTEX INC	<u>25MG</u>	<u>A077642 001</u>	Dec 22, 2005
<u>AB</u>			<u>50MG</u>	<u>A077642 002</u>	Dec 22, 2005
<u>AB</u>			<u>100MG</u>	<u>A077642 003</u>	Dec 22, 2005
<u>AB</u>		BIONPHARMA INC	<u>25MG</u>	<u>A077813 001</u>	Aug 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077813 002</u>	Aug 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077813 003</u>	Aug 16, 2006
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077651 001</u>	Jan 30, 2006
<u>AB</u>			<u>50MG</u>	<u>A077651 002</u>	Jan 30, 2006
<u>AB</u>			<u>100MG</u>	<u>A077651 003</u>	Jan 30, 2006
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A077869 001</u>	May 31, 2006
<u>AB</u>			<u>50MG</u>	<u>A077869 002</u>	May 31, 2006
<u>AB</u>			<u>100MG</u>	<u>A077869 003</u>	May 31, 2006
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A077637 001</u>	Dec 22, 2005
<u>AB</u>			<u>50MG</u>	<u>A077637 002</u>	Dec 22, 2005
<u>AB</u>			<u>100MG</u>	<u>A077637 003</u>	Dec 22, 2005
<u>AB</u>		SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634 001</u>	Mar 17, 2006
<u>AB</u>			<u>50MG</u>	<u>A077634 002</u>	Mar 17, 2006
<u>AB</u>			<u>100MG</u>	<u>A077634 003</u>	Mar 17, 2006
<u>AB</u>		WOCKHARDT	<u>25MG</u>	<u>A077636 003</u>	Jul 27, 2006
<u>AB</u>			<u>50MG</u>	<u>A077636 002</u>	Jul 27, 2006
<u>AB</u>			<u>100MG</u>	<u>A077636 001</u>	Dec 22, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625 001</u>	Oct 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077625 002</u>	Oct 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077625 003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

G AND W LABS	120MG	N018060	001	
	325MG	A072344	001	Mar 27, 1992
	325MG	N018060	003	Dec 18, 1986
	650MG	A072237	001	Mar 27, 1992
	650MG	N018060	002	

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
	650MG	A070608	001	Dec 01, 1986
+ TARO PHARMS NORTH	120MG	N018337	003	Sep 12, 1983
+	325MG	N018337	002	
+!	650MG	N018337	001	

INFANTS' FEVERALL

+ TARO PHARMS NORTH	80MG	N018337	004	Aug 26, 1992
---------------------	------	---------	-----	--------------

NEOPAP

POLYMEDICA	120MG	N016401	001	
------------	-------	---------	-----	--

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

AUROBINDO PHARMA LTD	650MG	A207229	001	Nov 09, 2016
OHM LABS	650MG	A076200	001	Mar 19, 2002
PERRIGO	650MG	A075077	001	Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011

TYLENOL

+! J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994
+!	650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001
---------	------------------	---------	-----	--------------

EXCEDRIN (MIGRAINE)

+! GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998
-------------------------	------------------	---------	-----	--------------

ADAPALENE

GEL;TOPICAL

DIFFERIN

+! GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016
---------------------	------	---------	-----	--------------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD

+! 3M	61%;1%	N021074	001	Jun 07, 2001
-------	--------	---------	-----	--------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

+ SANOFI AVENTIS US	80MG;20MG	N018685	001	Dec 09, 1983
+!	160MG;40MG	N018685	002	Dec 09, 1983

ASPIRIN

CAPSULE;ORAL

ASPIRIN

+! PLX PHARMA	325MG	N203697	001	Jan 14, 2013
---------------	-------	---------	-----	--------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM;TOPICAL

ANTHELIOS SX

+! LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
---------------	-----------	---------	-----	--------------

CAPITAL SOLEIL 15

+! LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006
---------------	-----------	---------	-----	--------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM;TOPICAL

ANTHELIOS 20

+! LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
---------------	--------------	---------	-----	--------------

ANTHELIOS 40

+! LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
---------------	--------------	---------	-----	--------------

+!	2%;3%;10%;5%	N022009	002	Oct 29, 2009
----	--------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+! STAND HOMEOPATH 5% N020532 001 Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

LUMIFY

+! BAUSCH AND LOMB INC 0.025% N208144 001 Dec 22, 2017

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015

RHINOCORT ALLERGY

+! ASTRAZENECA PHARMS 0.032MG/SPRAY N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO 1% A205181 001 Nov 16, 2017

LOTRIMIN ULTRA

+! BAYER HEALTHCARE 1% N021307 001 Dec 07, 2001

LLC

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG A077355 001 Feb 06, 2008

800MG;10MG;165MG A204782 001 Aug 29, 2016

PEPCID COMPLETE

+! J AND J CONSUMER 800MG;10MG;165MG N020958 001 Oct 16, 2000

INC

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG A207235 001 Aug 12, 2016

+ BIONPHARMA INC 5MG N022429 001 Jul 23, 2009

+! 10MG N022429 004 Jul 23, 2009

STRIDES PHARMA 10MG A205291 001 Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

+ BIONPHARMA INC 5MG N022429 003 Jul 23, 2009

+! 10MG N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ALLIED PHARMA INC 5MG/5ML A091327 001 Oct 17, 2011

AMNEAL PHARMS 5MG/5ML A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 002 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 002 Mar 30, 2009

PERRIGO R AND D 5MG/5ML A204226 001 Sep 09, 2013

5MG/5ML A090254 002 Apr 09, 2008

SILARX 5MG/5ML A091130 001 Apr 22, 2011

TARO 5MG/5ML A090182 002 Apr 22, 2008

5MG/5ML A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ALLIED PHARMA INC 5MG/5ML A091327 002 Oct 17, 2011

AMNEAL PHARMS 5MG/5ML A090765 001 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 001 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 001 Mar 30, 2009

PERRIGO R AND D 5MG/5ML A090254 001 Apr 09, 2008

SILARX 5MG/5ML A091130 002 Apr 22, 2011

TARO 5MG/5ML A090182 001 Apr 22, 2008

5MG/5ML A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+! J AND J CONSUMER 5MG/5ML N022155 002 Nov 16, 2007

INC

CHILDREN'S ZYRTEC HIVES RELIEF

+! J AND J CONSUMER 5MG/5ML N022155 001 Nov 16, 2007

INC

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG A078780 001 Jan 21, 2010

10MG A078780 004 Jan 21, 2010

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
	10MG	A090760	003	Aug 05, 2015
CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
GRANULES INDIA LTD	10MG	A209274	001	Dec 22, 2017
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
JUBILANT CADISTA	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
JUBILANT CADISTA	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
	10MG	A090760	004	Aug 05, 2015
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

ZYRTEC ALLERGY

+	J AND J CONSUMER INC	5MG	N019835 003	Nov 16, 2007
---	-------------------------	-----	-------------	--------------

+	!	10MG	N019835 004	Nov 16, 2007
---	---	------	-------------	--------------

ZYRTEC HIVES RELIEF

+	J AND J CONSUMER INC	5MG	N019835 005	Nov 16, 2007
---	-------------------------	-----	-------------	--------------

+	!	10MG	N019835 006	Nov 16, 2007
---	---	------	-------------	--------------

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS	5MG	A091116 001	Feb 19, 2015
-------------------	-----	-------------	--------------

	10MG	A091116 002	Feb 19, 2015
--	------	-------------	--------------

NOVEL LABS INC	5MG	A206793 001	Mar 08, 2016
----------------	-----	-------------	--------------

	10MG	A206793 002	Mar 08, 2016
--	------	-------------	--------------

SANDOZ	5MG	A078692 001	Feb 14, 2008
--------	-----	-------------	--------------

!	10MG	A078692 002	Feb 14, 2008
---	------	-------------	--------------

SUN PHARMA GLOBAL	5MG	A090142 001	Aug 30, 2011
-------------------	-----	-------------	--------------

	10MG	A090142 002	Aug 30, 2011
--	------	-------------	--------------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS	5MG	A091116 003	Feb 19, 2015
-------------------	-----	-------------	--------------

	10MG	A091116 004	Feb 19, 2015
--	------	-------------	--------------

SUN PHARMA GLOBAL	5MG	A090142 003	Aug 30, 2011
-------------------	-----	-------------	--------------

	10MG	A090142 004	Aug 30, 2011
--	------	-------------	--------------

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PERRIGO R AND D	10MG	A205490 001	Sep 02, 2015
-----------------	------	-------------	--------------

ZYRTEC ALLERGY

+	J AND J CONSUMER INC	10MG	N022578 001	Sep 03, 2010
---	-------------------------	------	-------------	--------------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA	5MG;120MG	A077170 001	Feb 25, 2008
---------------	-----------	-------------	--------------

PHARMS

SANDOZ	5MG;120MG	A077991 001	Mar 05, 2008
--------	-----------	-------------	--------------

SUN PHARM INDS LTD	5MG;120MG	A090922 001	Sep 28, 2012
--------------------	-----------	-------------	--------------

ZYRTEC-D 12 HOUR

+	J AND J CONSUMER INC	5MG;120MG	N021150 002	Nov 09, 2007
---	-------------------------	-----------	-------------	--------------

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+	XTRTRIUM	4%	N019127 001	Dec 24, 1984
---	----------	----	-------------	--------------

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+	SAGE PRODS	2%	N021669 001	Apr 25, 2005
---	------------	----	-------------	--------------

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO	4%	A071419 001	Dec 17, 1987
--------	----	-------------	--------------

CHG SCRUB

ECOLAB	4%	N019258 002	Jul 22, 1986
--------	----	-------------	--------------

CIDA-STAT

ECOLAB	2%	N019258 001	Jul 22, 1986
--------	----	-------------	--------------

DYNA-HEX

BAJAJ MEDICAL LLC	0.75%	N020111 001	Sep 11, 1997
-------------------	-------	-------------	--------------

EXIDINE

+	XTRTRIUM	2%	N019422 001	Dec 17, 1985
---	----------	----	-------------	--------------

	4%	N019125 001	Dec 24, 1984
--	----	-------------	--------------

HIBICLENS

+	MOLNLYCKE HLTH	4%	N017768 001
---	----------------	----	-------------

HIBISTAT

+	MOLNLYCKE HLTH	0.5%	N018300 001
---	----------------	------	-------------

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN	4%	N019822 001	Mar 31, 1989
---------	----	-------------	--------------

CHLORHEXIDINE GLUCONATE

!	BECTON DICKINSON	4%	A072525 001	Oct 24, 1989
---	------------------	----	-------------	--------------

OTC DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
----	---------------------	----------------	---------	-----	--------------

CHLORAPREP WITH TINT

+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
----	---------------------	-----------------	---------	-----	--------------

CHLORAPREP SINGLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005
----	---------------------	-----------------	---------	-----	--------------

CHLORAPREP TRIPLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
----	---------------------	-----------------	---------	-----	--------------

PREVANTICS MAXI SWABSTICK

+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
----	------------	-------------------	---------	-----	--------------

PREVANTICS SWAB

+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
----	------------	-----------------	---------	-----	--------------

PREVANTICS SWABSTICK

+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005
----	------------	-------------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+!	BAYER HEALTHCARE LLC	12MG	N007638	002	
----	-------------------------	------	---------	-----	--

CHLORPHENIRAMINE MALEATE

	AVANTHI INC	12MG	A040829	001	May 13, 2009
--	-------------	------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+!	PFIZER	4MG;200MG;10MG	N022113	001	Dec 21, 2011
----	--------	----------------	---------	-----	--------------

ADVIL MULTI-SYMPTOM COLD & FLU

+!	PFIZER	4MG;200MG;10MG	N022113	002	Apr 28, 2017
----	--------	----------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+!	PFIZER	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
----	--------	----------------------------	---------	-----	--------------

TABLET; ORAL

ADVIL ALLERGY SINUS

+!	PFIZER	2MG;200MG;30MG	N021441	001	Dec 19, 2002
----	--------	----------------	---------	-----	--------------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998
--	--------	-------	---------	-----	--------------

		200MG	A074948	002	Jul 26, 2002
--	--	-------	---------	-----	--------------

	IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
--	-------------------------	-------	---------	-----	--------------

	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998
--	--------------	-------	---------	-----	--------------

TAGAMET HB

+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996
----	------------------	-------	---------	-----	--------------

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995
--	--------------	--------	---------	-----	--------------

	SANDOZ	1.34MG	A073458	001	Oct 31, 1993
--	--------	--------	---------	-----	--------------

TAVIST-1

+!	GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992
----	-------------------------	--------	---------	-----	--------------

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

!	ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993
---	-------------------------	----	---------	-----	--------------

	TARO	1%	A072641	001	Dec 04, 1995
--	------	----	---------	-----	--------------

OTC DRUG PRODUCT LIST

CLOTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

BAYER HEALTHCARE 1%
LLC

N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2%

N021143 001 Apr 12, 2000

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE 1%,100MG
LLC

N020389 002 Jun 23, 1994

TABLET;VAGINAL

MYCELEX-7

BAYER HEALTHCARE 100MG
LLC

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

! BAUSCH AND LOMB 5.2MG/SPRAY
PERRIGO 5.2MG/SPRAY

A075702 001 Jul 03, 2001

A075427 001 Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

! AVANTHI INC 6MG;120MG

A078648 001 Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL 30MG;600MG
60MG;1.2GM

A091070 001 Aug 31, 2015

A091070 002 Aug 31, 2015

AUROBINDO PHARMA 30MG;600MG
LTD

A206941 001 Mar 17, 2017

60MG;1.2GM

A206941 002 Mar 17, 2017

MUCINEX DM

+ RECKITT BENCKISER 30MG;600MG

N021620 002 Apr 29, 2004

+! 60MG;1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+! RECKITT BENCKISER EQ 30MG HBR/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

AMNEAL PHARMS LLC EQ 30MG HBR/5ML

A203133 001 Jul 28, 2017

TRIS PHARMA INC EQ 30MG HBR/5ML

A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+! PFIZER 38MG;200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG;200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+! PFIZER 25MG;EQ 200MG FREE ACID AND POTASSIUM
SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND POTASSIUM
SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM
SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+! BAYER HLTHCARE 25MG;220MG

N205352 001 Jan 17, 2014

DOCOSANOL

CREAM;TOPICAL

ABREVA

+! GLAXOSMITHKLINE 10%

N020941 001 Jul 25, 2000

OTC DRUG PRODUCT LIST

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

LNK	25MG	A040564	001	Aug 27, 2004
PERRIGO	25MG	A040167	001	Sep 18, 1996

UNISOM

+! CHATTEM	25MG	N018066	001	
------------	------	---------	-----	--

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017
----------------------	--------------	---------	-----	--------------

PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017
-----------------	--------------	---------	-----	--------------

NEXIUM 24HR

+! ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014
-------------------	--------------	---------	-----	--------------

TABLET, DELAYED RELEASE;ORAL

NEXIUM 24HR

+! ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015
-------------------	--------------	---------	-----	--------------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016
----------------------	------	---------	-----	--------------

	20MG	A206531	002	Apr 26, 2016
--	------	---------	-----	--------------

DR REDDYS LABS LTD	10MG	A075758	001	Aug 17, 2001
--------------------	------	---------	-----	--------------

	20MG	A077367	001	Sep 25, 2006
--	------	---------	-----	--------------

IVAX SUB TEVA PHARMS	10MG	A075512	001	Jul 26, 2001
----------------------	------	---------	-----	--------------

MYLAN	10MG	A075674	001	Dec 21, 2001
-------	------	---------	-----	--------------

PERRIGO	10MG	A075400	001	Mar 18, 2005
---------	------	---------	-----	--------------

PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
-----------------	------	---------	-----	--------------

SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009
--------------------	------	---------	-----	--------------

	20MG	A090283	002	Nov 17, 2009
--	------	---------	-----	--------------

TEVA	10MG	A075312	001	May 31, 2001
------	------	---------	-----	--------------

WOCKHARDT	10MG	A077146	001	Mar 07, 2005
-----------	------	---------	-----	--------------

	20MG	A090837	001	Aug 04, 2010
--	------	---------	-----	--------------

PEPCID AC

+ J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995
------------------------	------	---------	-----	--------------

+!	20MG	N020325	002	Sep 23, 2003
----	------	---------	-----	--------------

PEPCID AC

J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999
----------------------	------	---------	-----	--------------

TABLET, CHEWABLE;ORAL

FAMOTIDINE

PERRIGO	10MG	A075715	001	Aug 22, 2003
---------	------	---------	-----	--------------

PEPCID AC

+! J AND J CONSUMER INC	20MG	N020801	002	Dec 17, 2007
-------------------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+! SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011
----------------------	----------	---------	-----	--------------

CHILDREN'S ALLEGRA HIVES

+! SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011
----------------------	----------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	30MG/5ML	A203330	001	Nov 18, 2014
----------------------	----------	---------	-----	--------------

TARO PHARM	30MG/5ML	A208123	001	Nov 09, 2017
------------	----------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC	30MG/5ML	A203330	002	Nov 18, 2014
----------------------	----------	---------	-----	--------------

TARO PHARM	30MG/5ML	A208123	002	Nov 09, 2017
------------	----------	---------	-----	--------------

TABLET;ORAL

ALLEGRA ALLERGY

+ SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
---------------------	------	---------	-----	--------------

+!	180MG	N020872	010	Jan 24, 2011
----	-------	---------	-----	--------------

ALLEGRA HIVES

+ SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011
---------------------	------	---------	-----	--------------

+!	180MG	N020872	009	Jan 24, 2011
----	-------	---------	-----	--------------

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011
---------------------	------	---------	-----	--------------

OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011
---	-------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014
DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
MYLAN	30MG	A077081	004	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
TEVA	30MG	A076447	004	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
MYLAN	30MG	A077081	005	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
TEVA	30MG	A076447	005	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
	180MG	A202039	003	Nov 19, 2014
DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
	180MG	A076502	008	Apr 12, 2011
HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
	180MG	A204097	003	Aug 19, 2016
MYLAN	60MG	A077081	006	Jul 21, 2011
	180MG	A077081	008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
	180MG	A204507	003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
	180MG	A204507	005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
	180MG	A076447	009	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	!	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
---	---	-------------------	------	---------	-----	--------------

CHILDREN'S ALLEGRA HIVES

+	!	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011
---	---	-------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
--------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013
--------------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	!	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
---	---	-------------------	------------	---------	-----	--------------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	!	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
---	---	-------------------	-------------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROLIFE PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017
DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
	180MG;240MG	A079043	002	Jun 22, 2011
SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015

OTC DRUG PRODUCT LIST

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016
+	CONS				

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+	GLAXOSMITHKLINE	0.05MG/SPRAY	N205434	001	Jul 23, 2014
+	CONS				

FLUTICASONE PROPIONATE

APOTEX INC

0.05MG/SPRAY

A208150 001 Feb 29, 2016

WEST-WARD PHARMS

0.05MG/SPRAY

A207957 001 May 26, 2016

INT

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL 1.2GM

A091009 002 Sep 03, 2015

GUARDIAN PHARMS 600MG

A209215 001 Sep 06, 2017

1.2GM

A209215 002 Sep 06, 2017

PERRIGO R AND D 600MG

A078912 001 Nov 23, 2011

MUCINEX

+ RECKITT BENCKISER 600MG

N021282 001 Jul 12, 2002

+! 1.2GM

N021282 002 Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG

A091071 001 May 27, 2015

1.2GM;120MG

A091071 002 May 27, 2015

DR REDDYS LABS LTD 600MG;60MG

A208369 001 Dec 29, 2017

1.2GM;120MG

A208369 002 Dec 29, 2017

MUCINEX D

+ RECKITT BENCKISER 600MG;60MG

N021585 001 Jun 22, 2004

+! 1.2GM;120MG

N021585 002 Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+! PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+! PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

ASCENT PHARMS INC EQ 200MG FREE ACID AND POTASSIUM SALT

A206999 001 Dec 21, 2017

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

HUMANWELL PURACAP EQ 200MG FREE ACID AND POTASSIUM SALT

A206568 001 Jun 21, 2016

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

P AND L DEV LLC EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A203599 001 Sep 07, 2016

MIDOL LIQUID GELS

+! BIONPHARMA INC 200MG

N021472 001 Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

PFIZER 100MG/5ML

N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER 100MG/5ML

N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML

A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+! J AND J CONSUMER 100MG/5ML

N020516 001 Jun 16, 1995

INC

IBUPROFEN

ACTAVIS MID 100MG/5ML

A074916 001 Apr 30, 1999

ATLANTIC

ARISE PHARMS 100MG/5ML

A200457 001 Aug 18, 2011

TARO 100MG/5ML

A209207 001 Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+! J AND J CONSUMER 40MG/ML

N020603 001 Jun 10, 1996

INC

OTC DRUG PRODUCT LIST

IBUPROFEN

SUSPENSION/DROPS;ORAL

IBUPROFEN

L FERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009

PEDIATRIC ADVIL

+! PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998
-----------	-------------	---------	-----	--------------

TABLET;ORAL

ADVIL

PFIZER	200MG	N018989	001	May 18, 1984
--------	-------	---------	-----	--------------

IBU-TAB 200

ALRA	200MG	A071057	001	Aug 11, 1988
------	-------	---------	-----	--------------

IBUPROFEN

AIPING PHARM INC	200MG	A207095	001	May 05, 2017
------------------	-------	---------	-----	--------------

AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
---------------	-------	---------	-----	--------------

AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
------------------	-------	---------	-----	--------------

	200MG	A072199	001	May 23, 1988
--	-------	---------	-----	--------------

AUROBINDO PHARMA	200MG	A208865	001	Nov 08, 2017
------------------	-------	---------	-----	--------------

LTD

AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
--------------	-------	---------	-----	--------------

CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987
--------------------	-------	---------	-----	--------------

	200MG	A072299	001	Jul 01, 1988
--	-------	---------	-----	--------------

DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
--------------	-------	---------	-----	--------------

DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001
--------------------	-------	---------	-----	--------------

GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
----------------	-------	---------	-----	--------------

GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
--------------------	-------	---------	-----	--------------

LNK	100MG	A076741	001	Jun 17, 2004
-----	-------	---------	-----	--------------

	200MG	A075010	001	Mar 01, 1999
--	-------	---------	-----	--------------

	200MG	A075139	001	Mar 01, 1999
--	-------	---------	-----	--------------

MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
-----------------	-------	---------	-----	--------------

	200MG	A091239	001	Feb 01, 2011
--	-------	---------	-----	--------------

MCNEIL	200MG	A073019	001	Mar 30, 1994
--------	-------	---------	-----	--------------

MERRO PHARM	200MG	A070985	001	Oct 02, 1987
-------------	-------	---------	-----	--------------

OHM	200MG	A071163	001	Jul 15, 1986
-----	-------	---------	-----	--------------

PAR PHARM	200MG	A070481	001	Sep 24, 1986
-----------	-------	---------	-----	--------------

PERRIGO	200MG	A072096	001	Dec 08, 1987
---------	-------	---------	-----	--------------

	200MG	A075995	001	Mar 14, 2002
--	-------	---------	-----	--------------

PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
-----------------	-------	---------	-----	--------------

STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
----------------	-------	---------	-----	--------------

	200MG	A091355	001	Apr 04, 2011
--	-------	---------	-----	--------------

	200MG	A207052	001	May 30, 2017
--	-------	---------	-----	--------------

VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
----------------	-------	---------	-----	--------------

	200MG	A071639	001	Feb 02, 1988
--	-------	---------	-----	--------------

IBUPROHM

OHM LABS	200MG	A071214	001	Dec 01, 1986
----------	-------	---------	-----	--------------

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020267	002	Dec 13, 1996
--------	-------	---------	-----	--------------

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO	100MG	A075367	001	Apr 22, 1999
--------------	-------	---------	-----	--------------

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER	100MG	N020602	001	Jun 10, 1996
------------------	-------	---------	-----	--------------

INC

MOTRIN IB

+! J AND J CONSUMER	200MG	N019012	003	Dec 17, 1990
---------------------	-------	---------	-----	--------------

INC

PROFEN

CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
--------------------	-------	---------	-----	--------------

TAB-PROFEN

PERRIGO	200MG	A072095	001	Dec 08, 1987
---------	-------	---------	-----	--------------

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

PFIZER	50MG	N020944	001	Dec 18, 1998
--------	------	---------	-----	--------------

CHILDREN'S MOTRIN

+ J AND J CONSUMER	50MG	N020601	001	Nov 15, 1996
--------------------	------	---------	-----	--------------

INC

IBUPROFEN

PERRIGO	50MG	A076359	001	Jan 16, 2004
---------	------	---------	-----	--------------

	100MG	A076359	002	Jan 16, 2004
--	-------	---------	-----	--------------

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020944	002	Dec 18, 1998
--------	-------	---------	-----	--------------

JUNIOR STRENGTH MOTRIN

+! J AND J CONSUMER	100MG	N020601	003	Nov 15, 1996
---------------------	-------	---------	-----	--------------

INC

OTC DRUG PRODUCT LIST

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+	!	PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803 001	Jun 12, 2012
---	---	-------------------------	---------------	-------------	--------------

IBUPROFEN SODIUM

		PERRIGO R AND D	EQ 200MG BASE	A206581 001	Aug 03, 2015
--	--	-----------------	---------------	-------------	--------------

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF

+	!	PFIZER	200MG;10MG	N022565 001	May 27, 2010
---	---	--------	------------	-------------	--------------

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

		PERRIGO R AND D	200MG;10MG	A203200 001	Jul 03, 2014
--	--	-----------------	------------	-------------	--------------

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

ADVIL COLD AND SINUS

+	!	PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374 001	May 30, 2002
---	---	--------	---	-------------	--------------

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

		AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235 001	Dec 01, 2017
--	--	-------------------------	---	-------------	--------------

SUSPENSION;ORAL

CHILDREN'S ADVIL COLD

		PFIZER	100MG/5ML;15MG/5ML	N021373 001	Apr 18, 2002
--	--	--------	--------------------	-------------	--------------

CHILDREN'S MOTRIN COLD

+	!	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128 001	Aug 01, 2000
---	---	-------------------------	--------------------	-------------	--------------

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

		PERRIGO	100MG/5ML;15MG/5ML	A076478 001	Nov 05, 2003
--	--	---------	--------------------	-------------	--------------

TABLET;ORAL

ADVIL COLD AND SINUS

+	!	PFIZER	200MG;30MG	N019771 001	Sep 19, 1989
---	---	--------	------------	-------------	--------------

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

		DR REDDYS LABS LTD	200MG;30MG	A077628 001	Aug 14, 2006
--	--	--------------------	------------	-------------	--------------

IBUPROHM COLD AND SINUS

		OHM LABS	200MG;30MG	A074567 001	Apr 17, 2001
--	--	----------	------------	-------------	--------------

SINE-AID IB

		J AND J CONSUMER INC	200MG;30MG	N019899 001	Dec 31, 1992
--	--	-------------------------	------------	-------------	--------------

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN R PEN

+	!	LILLY	100 UNITS/ML	N018780 005	Aug 06, 1998
---	---	-------	--------------	-------------	--------------

NOVOLIN R

+	!	NOVO NORDISK INC	100 UNITS/ML	N019938 001	Jun 25, 1991
---	---	------------------	--------------	-------------	--------------

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN R

+	!	LILLY	100 UNITS/ML	N018780 001	Oct 28, 1982
---	---	-------	--------------	-------------	--------------

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN 70/30

+	!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717 001	Apr 25, 1989
---	---	-------	-------------------------	-------------	--------------

HUMULIN 70/30 PEN

+	!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717 002	Aug 06, 1998
---	---	-------	-------------------------	-------------	--------------

NOVOLIN 70/30

+	!	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991 001	Jun 25, 1991
---	---	------------------	-------------------------	-------------	--------------

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN N

+	!	LILLY	100 UNITS/ML	N018781 001	Oct 28, 1982
---	---	-------	--------------	-------------	--------------

NOVOLIN N

+	!	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991
---	---	------------------	--------------	-------------	--------------

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

+	!	3M	EQ 0.7% IODINE;74% (6ML)	N021586 001	Sep 29, 2006
---	---	----	--------------------------	-------------	--------------

+	!		EQ 0.7% IODINE;74% (26ML)	N021586 002	Sep 29, 2006
---	---	--	---------------------------	-------------	--------------

OTC DRUG PRODUCT LIST

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+! JOHNSON AND JOHNSON 1%

N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+! BAUSCH AND LOMB EQ 0.025% BASE

N021996 001 Dec 01, 2006

+ EQ 0.035% BASE

N021996 002 Feb 11, 2015

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE

A077958 001 Jul 26, 2007

! ALCON PHARMS LTD EQ 0.025% BASE

A077200 001 Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG

A202194 001 May 18, 2012

KREMERS URBAN 15MG

A207157 001 Sep 29, 2017

PHARMS

MYLAN PHARMS INC 15MG

A203187 001 Jun 01, 2016

NATCO PHARMA LTD 15MG

A203306 001 Jan 13, 2016

PERRIGO R AND D 15MG

A202319 001 May 18, 2012

WOCKHARDT LTD 15MG

A202727 001 May 18, 2012

PREVACID 24 HR

+! GLAXOSMITHKLINE 15MG

N022327 001 May 18, 2009

CONS

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

LANSOPRAZOLE

DEXCEL PHARMA 15MG

N208025 001 Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML)

N209090 001 Jan 31, 2017

TABLET; ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG

N209089 001 Jan 31, 2017

LEVONORGESTREL

TABLET; ORAL

ATHENTIA NEXT

AUROBINDO PHARMA 1.5MG

A206867 001 Dec 08, 2015

LTD

FALLBACK SOLO

LUPIN LTD 1.5MG

A201446 001 Jun 19, 2014

HER STYLE

NOVAST LABS LTD 1.5MG

A207976 001 Mar 11, 2016

LEVONORGESTREL

FDN CONSUMER 1.5MG

A200670 001 Jul 12, 2012

GLENMARK PHARMS LTD 1.5MG

A207044 001 Mar 25, 2016

LOTUS PHARM CO LTD 0.75MG

A202684 001 Sep 02, 2016

MYLAN LABS LTD 0.75MG

A202740 001 Sep 02, 2016

1.5MG

A202739 001 Oct 31, 2014

NOVEL LABS INC 1.5MG

A202508 001 Feb 22, 2013

OC PHARMA 1.5MG

A202380 001 May 29, 2015

! PERRIGO R AND D 0.75MG

A090740 001 Dec 30, 2010

1.5MG

A202334 001 Aug 20, 2014

RECKITT BENCKISER 1.5MG

A202246 001 Jun 05, 2015

OPCICON ONE-STEP

SUN PHARM INDS LTD 1.5MG

A202635 001 Sep 11, 2014

PLAN B ONE-STEP

+! FDN CONSUMER 1.5MG

N021998 001 Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

+ BIONPHARMA INC 1MG

N021855 001 Aug 04, 2005

+! 2MG

N021855 002 Aug 04, 2005

SOLUTION; ORAL

IMODIUM A-D

+! J AND J CONSUMER 1MG/5ML

N019487 001 Mar 01, 1988

INC

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC 1MG/5ML

A073079 001 Apr 30, 1992

HI TECH PHARMA 1MG/5ML

A074352 001 Nov 17, 1995

OTC DRUG PRODUCT LIST

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
-----------------	-----------	---------	-----	--------------

TABLET;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
-------------------------	-----	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
----------------------	-----	---------	-----	--------------

L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
--------------	-----	---------	-----	--------------

LNK	2MG	A076497	001	Jun 10, 2003
-----	-----	---------	-----	--------------

OHM LABS	2MG	A074091	001	Dec 10, 1992
----------	-----	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPOM RELIEF

+! J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006
--------------------	-----------	---------	-----	--------------

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002
-----------	-----------	---------	-----	--------------

LORATADINE

CAPSULE;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
-------------------------	------	---------	-----	--------------

LORATADINE

MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
-----------------	------	---------	-----	--------------

SUSPENSION;ORAL

LORATADINE

+! TARO	1MG/ML	N021734	001	Oct 04, 2005
---------	--------	---------	-----	--------------

SYRUP;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
-------------------------	--------	---------	-----	--------------

LORATADINE

PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
---------	--------	---------	-----	--------------

SILARX	1MG/ML	A077421	001	Jun 29, 2006
--------	--------	---------	-----	--------------

TARO	1MG/ML	A076805	001	Aug 20, 2004
------	--------	---------	-----	--------------

TARO PHARM	1MG/ML	A201865	001	Jul 31, 2015
------------	--------	---------	-----	--------------

TEVA	1MG/ML	A075505	001	Nov 07, 2003
------	--------	---------	-----	--------------

WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004
------------------	--------	---------	-----	--------------

TABLET;ORAL

CLARITIN

+! BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
-------------------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF

+! BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
-------------------------	------	---------	-----	--------------

LORATADINE

APOTEX INC	10MG	A076471	001	Feb 14, 2006
------------	------	---------	-----	--------------

MYLAN	10MG	A075790	001	Nov 07, 2008
-------	------	---------	-----	--------------

	10MG	A076154	001	Aug 20, 2003
--	------	---------	-----	--------------

	10MG	A078447	001	Aug 12, 2011
--	------	---------	-----	--------------

PERRIGO	10MG	A076301	001	Jun 25, 2004
---------	------	---------	-----	--------------

SANDOZ	10MG	A075209	001	Jan 21, 2003
--------	------	---------	-----	--------------

SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
--------------------	------	---------	-----	--------------

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+! BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
-------------------------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

PFIZER 10MG N021375 001 Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+! BAYER HEALTHCARE 10MG N020704 003 Nov 19, 2003
LLC

CLARITIN REDITABS

+! BAYER HEALTHCARE 5MG N021993 001 Dec 12, 2006
LLC

+! 10MG N020704 002 Nov 27, 2002

LORATADINE

ACTAVIS LABS FL INC 10MG A075990 001 Nov 03, 2003

PERRIGO PHARMA INTL 10MG A076011 001 Sep 29, 2003

PFIZER 10MG A075822 001 Feb 10, 2003

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+! BAYER HEALTHCARE 5MG;120MG N019670 002 Nov 27, 2002
LLC

CLARITIN-D 24 HOUR

+! BAYER HEALTHCARE 10MG;240MG N020470 002 Nov 27, 2002
LLC

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC 10MG;240MG A075706 001 Feb 21, 2003

PERRIGO PHARMA INTL 5MG;120MG A076050 001 Jan 30, 2003

10MG;240MG A075989 001 Mar 04, 2004

SUN PHARM INDS LTD 10MG;240MG A076557 001 Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+! HISAMITSU PHARM CO 3%;10% N022029 001 Feb 20, 2008

+ 3%;10% N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%,4% A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,4% N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+! MEDTECH PRODUCTS 2%,4% N021261 001 Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3

TARO 4% A076773 001 Mar 02, 2005

MICONAZOLE 7

ACTAVIS MID 2% A074164 001 Mar 29, 1996

ATLANTIC

MICONAZOLE NITRATE

G AND W LABS INC 2% A074366 001 Feb 22, 1996

PERRIGO 2% A074760 001 May 15, 1997

PERRIGO R AND D 4% A091366 001 Jan 15, 2010

TARO 2% A074444 001 Jan 13, 1997

MONISTAT 3

+! MEDTECH PRODUCTS 4% N020827 001 Mar 30, 1998

MONISTAT 7

+! MEDTECH PRODUCTS 2% N017450 002 Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID 2%,200MG A074926 001 Apr 16, 1999

ATLANTIC

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 2%,100MG A076585 001 Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM A079114 001 Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 2%,200MG A075329 001 Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM N021308 001 Jun 29, 2001

MONISTAT 3 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,200MG N020670 002 Apr 16, 1996

OTC DRUG PRODUCT LIST

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 7 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,100MG N020288 002 Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA 100MG A073507 001 Nov 19, 1993

G AND W LABS 100MG A074414 001 Apr 30, 1997

! PERRIGO 100MG A074395 001 Mar 20, 1997

MONISTAT 7

+! MEDTECH PRODUCTS 100MG N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+! JOHNSON AND JOHNSON 5% N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5% A091344 001 Apr 28, 2011

MINOXIDIL (FOR MEN)

WATSON LABS INC 5% A208092 001 Feb 17, 2017

MINOXIDIL (FOR WOMEN)

WATSON LABS INC 5% A208092 002 Jul 27, 2017

WOMEN'S ROGAINE

+! JOHNSON AND JOHNSON 5% N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID 2% A074588 001 Apr 05, 1996

ATLANTIC

HI TECH PHARMA 2% A074731 001 Dec 24, 1996

L PERRIGO CO 2% A075357 001 Jul 30, 1999

WOCKHARDT BIO AG 2% A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2% A074731 002 May 11, 2005

L PERRIGO CO 2% A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID 5% A075518 001 Nov 17, 2000

ATLANTIC

AVACOR PRODS 5% A075619 001 Nov 17, 2000

PERRIGO 5% A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5% A075737 001 Mar 15, 2002

WOCKHARDT BIO AG 5% A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+! JOHNSON AND JOHNSON 2% N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+! JOHNSON AND JOHNSON 2% N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+! JOHNSON AND JOHNSON 5% N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2% A078176 001 Nov 09, 2007

5% A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3% A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315% A078208 001 Sep 27, 2010

NAPHCN-A

+! ALCON 0.025%;0.3% N020226 001 Jun 08, 1994

OPCON-A

+! BAUSCH AND LOMB 0.02675%;0.315% N020065 001 Jun 08, 1994

VISINE-A

+! JOHNSON AND JOHNSON 0.025%;0.3% N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+! BIONPHARMA INC EQ 200MG BASE N021920 001 Feb 17, 2006

TABLET;ORAL

ALEVE

+! BAYER EQ 200MG BASE N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE A079096 001 Dec 16, 2008

AUROBINDO PHARMA EQ 200MG BASE A205497 001 Mar 18, 2016

LTD

OTC DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+! BAYER	200MG;120MG	N021076	001	Nov 29, 1999
----------	-------------	---------	-----	--------------

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+	14MG/24HR	N020076	005	Nov 12, 1999
+!	21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
+	14MG/24HR	N020165	005	Aug 02, 1996
+!	21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+	EQ 2MG BASE	N018612	004	Sep 25, 2000
+!	EQ 4MG BASE	N020066	002	Feb 09, 1996
+	EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+	EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

ACTAVIS LABS NY INC	EQ 2MG BASE	A074507	001	Mar 15, 1999
	EQ 2MG BASE	A076569	001	Jul 29, 2004
	EQ 2MG BASE	A078699	001	Dec 29, 2008
	EQ 2MG BASE	A079216	001	Jul 08, 2009
	EQ 2MG BASE	A204794	001	May 10, 2016
	EQ 4MG BASE	A074707	001	Mar 19, 1999
	EQ 4MG BASE	A076568	002	Jul 29, 2004
	EQ 4MG BASE	A078697	001	Dec 29, 2008
	EQ 4MG BASE	A079038	001	Jul 08, 2009
	EQ 4MG BASE	A079219	001	Jul 08, 2009
	EQ 4MG BASE	A204833	001	Feb 26, 2016
L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
	EQ 2MG BASE	A076776	001	Sep 16, 2004
	EQ 2MG BASE	A076777	001	Sep 16, 2004
	EQ 4MG BASE	A076778	001	Sep 16, 2004
	EQ 4MG BASE	A076779	001	Sep 16, 2004
	EQ 4MG BASE	A076789	001	Sep 16, 2004
PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
	EQ 2MG BASE	A078547	001	May 24, 2007
	EQ 2MG BASE	A078967	001	Apr 23, 2008
	EQ 2MG BASE	A091349	001	Jul 20, 2011
	EQ 2MG BASE	A206394	001	Dec 15, 2016
	EQ 4MG BASE	A078326	001	Oct 30, 2006
	EQ 4MG BASE	A078546	001	May 24, 2007
	EQ 4MG BASE	A078968	001	Apr 23, 2008
	EQ 4MG BASE	A091354	001	Jul 20, 2011
	EQ 4MG BASE	A206393	001	Dec 15, 2016
WATSON LABS	EQ 2MG BASE	A079044	001	Jul 08, 2009

OTC DRUG PRODUCT LIST

NICOTINE POLACRILEXGUM, CHEWING;BUCCAL
THRIVE

NOVARTIS	EQ 2MG BASE	A077658 001	Jun 19, 2007
	EQ 4MG BASE	A077656 001	Jun 19, 2007

TROCHE/LOZENGE;ORAL
COMMIT

+ GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330 001	Oct 31, 2002
---------------------------	-------------	-------------	--------------

+!	EQ 4MG BASE	N021330 002	Oct 31, 2002
----	-------------	-------------	--------------

NICORETTE

+ GLAXOSMITHKLINE CONS	EQ 2MG BASE	N022360 001	May 18, 2009
---------------------------	-------------	-------------	--------------

+!	EQ 4MG BASE	N022360 002	May 18, 2009
----	-------------	-------------	--------------

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	A077007 001	Jan 31, 2006
	EQ 2MG BASE	A090711 001	Jul 10, 2009
	EQ 2MG BASE	A090821 001	Jul 10, 2009
	EQ 2MG BASE	A203690 001	Oct 09, 2012
	EQ 4MG BASE	A077007 002	Jan 31, 2006
	EQ 4MG BASE	A090711 002	Jul 10, 2009
	EQ 4MG BASE	A090821 002	Jul 10, 2009
	EQ 4MG BASE	A203690 002	Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+! PFIZER	75MG	N020555 001	May 09, 1996
-----------	------	-------------	--------------

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+! MAYER LABS INC	1GM	N018683 001	Apr 01, 1983
-------------------	-----	-------------	--------------

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+! DEXCEL PHARMA	20MG	N022032 001	Dec 04, 2007
------------------	------	-------------	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+ DEXCEL PHARMA	20MG	N209400 001	Jul 05, 2017
-----------------	------	-------------	--------------

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

! DR REDDYS LABS LTD	EQ 20MG BASE	A078878 001	Jun 05, 2009
----------------------	--------------	-------------	--------------

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D	EQ 20MG BASE	A204152 001	Jul 30, 2015
-----------------	--------------	-------------	--------------

PRILOSEC OTC

+! ASTRAZENECA PHARMS	EQ 20MG BASE	N021229 001	Jun 20, 2003
-----------------------	--------------	-------------	--------------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ACTAVIS ELIZABETH	20MG;1.1GM	A204137 001	Jul 15, 2016
-------------------	------------	-------------	--------------

AUROLIFE PHARMA LLC	20MG;1.1GM	A204923 001	Nov 07, 2016
---------------------	------------	-------------	--------------

PAR PHARM	20MG;1.1GM	A201946 001	Jul 15, 2016
-----------	------------	-------------	--------------

PERRIGO R AND D	20MG;1.1GM	A201361 001	Jul 15, 2016
-----------------	------------	-------------	--------------

ZEGERID OTC

+! BAYER HEALTHCARE LLC	20MG;1.1GM	N022281 001	Dec 01, 2009
----------------------------	------------	-------------	--------------

FOR SUSPENSION;ORAL

ZEGERID OTC

+! BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283 001	Jun 17, 2013
----------------------------	---------------------------	-------------	--------------

ORLISTAT

CAPSULE;ORAL

ALLI

+! GLAXOSMITHKLINE CONS	60MG	N021887 001	Feb 07, 2007
----------------------------	------	-------------	--------------

OTC DRUG PRODUCT LIST

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+! ALLERGAN SALES LLC 3.9MG/24HR N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

+! JOHNSON AND JOHNSON 0.025% N019407 001 Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+! MEDTECH PRODUCTS 1% N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID

1%

A075014 001 Mar 28, 2000

ATLANTIC

PERRIGO NEW YORK

1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

KREMERS URBAN

17GM/PACKET

A090600 001 Oct 06, 2009

PHARMS

17GM/SCOOPFUL

A090600 002 Oct 06, 2009

MIRALAX

+! BAYER HEALTHCARE

17GM/SCOOPFUL

N022015 001 Oct 06, 2006

LLC

POLYETHYLENE GLYCOL 3350

AILEX PHARMS LLC

17GM/SCOOPFUL

A202071 001 Dec 28, 2012

ANI PHARMS INC

17GM/SCOOPFUL

A202850 001 Dec 15, 2015

MYLAN

17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009

NEXGEN PHARMA

17GM/SCOOPFUL

A090812 001 Oct 07, 2009

NOVEL LABS INC

17GM/SCOOPFUL

A091077 001 Oct 06, 2009

NUVO PHARM INC

17GM/SCOOPFUL

A206105 001 Oct 28, 2016

PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013

PERRIGO R AND D

17GM/PACKET

A090685 001 Oct 06, 2009

17GM/SCOOPFUL

A090685 002 Oct 06, 2009

STRIDES PHARMA

17GM/SCOOPFUL

A203928 001 Aug 24, 2016

17GM/PACKET

A203928 002 Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL

65MG/ML

A206211 001 Mar 24, 2016

CO

THYROSHIELD

! ARCO PHARMS LLC

65MG/ML

A077218 001 Jan 12, 2005

TABLET;ORAL

IOSAT

+ ANBEX

65MG

N018664 002 May 12, 2011

+!

130MG

N018664 001 Oct 14, 1982

THYROSAFE

! RECIP

65MG

A076350 001 Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+! ALLEGIANCE HLTHCARE 1%

N019522 001 Mar 31, 1989

SPONGE;TOPICAL

E-Z SCRUB 201

+! BECTON DICKINSON

20%

N019240 001 Nov 29, 1985

E-Z SCRUB 241

+! BECTON DICKINSON

10%

N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA

120MG

A209008 001 Jun 09, 2017

LTD

L PERRIGO CO

120MG

A075153 001 Feb 26, 1999

SUN PHARM INDS LTD

120MG

A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

! MCNEIL CONS

120MG

A073585 001 Oct 31, 1991

OTC DRUG PRODUCT LIST

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SUDAFED 24 HOUR

+	!	J AND J CONSUMER	240MG	N020021	002	Dec 15, 1992
		INC				

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+	!	SCHERING PLOUGH	120MG	N018191	001	
---	---	-----------------	-------	---------	-----	--

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+	!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011
---	---	----------------	-------	---------	-----	--------------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 75MG BASE

A075167 001 May 04, 2000

EQ 150MG BASE

A200172 001 May 31, 2012

AUROBINDO PHARMA

EQ 75MG BASE

A207579 001 Nov 13, 2017

LTD

EQ 150MG BASE

A207578 001 Nov 13, 2017

DR REDDYS LABS LTD

EQ 75MG BASE

A075294 001 Mar 28, 2000

EQ 150MG BASE

A078192 001 Aug 31, 2007

IVAX SUB TEVA

EQ 75MG BASE

A075296 001 Jan 14, 2000

PHARMS

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000

PERRIGO

EQ 75MG BASE

A076195 001 Aug 30, 2002

PERRIGO R AND D

EQ 150MG BASE

A091429 001 May 11, 2011

EQ 150MG BASE

A091429 002 May 11, 2011

STRIDES PHARMA

EQ 75MG BASE

A201745 001 Feb 29, 2012

EQ 150MG BASE

A200536 001 Jun 28, 2011

WOCKHARDT

EQ 75MG BASE

A076760 001 Feb 24, 2006

ZANTAC 150

+	!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004
---	---	-----------	---------------	---------	-----	--------------

+			EQ 150MG BASE	N021698	002	Mar 13, 2007
---	--	--	---------------	---------	-----	--------------

ZANTAC 75

+		SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995
---	--	-----------	--------------	---------	-----	--------------

SODIUM CHLORIDE

AEROSOL, METERED;INHALATION

BRONCHO SALINE

+	!	BLAIREX	0.9%	N019912	001	Sep 03, 1992
---	---	---------	------	---------	-----	--------------

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+	!	COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997
---	---	-------------------	------------	---------	-----	--------------

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+	!	NOVARTIS	1%	N021958	001	Jul 24, 2006
---	---	----------	----	---------	-----	--------------

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+	!	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999
---	---	-----------------	----	---------	-----	--------------

TERBINAFINE HYDROCHLORIDE

TARO

1%

A077511 001 Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+	!	NOVARTIS	1%	N021124	001	Mar 17, 2000
---	---	----------	----	---------	-----	--------------

SPRAY;TOPICAL

LAMISIL AT

+	!	NOVARTIS	1%	N021124	002	Mar 17, 2000
---	---	----------	----	---------	-----	--------------

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

		PERRIGO	6.5%	A075915	001	Nov 21, 2001
--	--	---------	------	---------	-----	--------------

VAGISTAT-1

+	!	COMBE	6.5%	N020676	001	Feb 11, 1997
---	---	-------	------	---------	-----	--------------

OTC DRUG PRODUCT LISTTRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+! SANOFI AVENTIS US

0.055MG/SPRAY

N020468 002 Oct 11, 2013

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL

0.055MG/SPRAY

A078104 002 Nov 14, 2014

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

N760305

Jun 30, 1978

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS

A710497

Nov 06, 1987

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL
SYSTEMS, INC

N160767

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

HAEMONETICS

MANUFACTURING INC

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

0.042GM/100ML;0.276GM/100ML;

N820915

Oct 19, 1984

MANUFACTURING INC

0.410GM/100ML;0.30GM/100ML;

1.10GM/100ML;0.588GM/100ML

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983
-------------	---	---------	--------------

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
----------------------------	--	---------	--------------

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003
-----------------------------	--	---------	--------------

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION
(CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016
------------	--	---------	--------------

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984
---------	--	---------	--------------

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992
-------------	----------------------	---------	--------------

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992
-------------	------------------------	---------	--------------

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999
-------------	-----------	---------	--------------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML A740193 Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N890105 Apr 04, 1991

NONE

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML A740592 Nov 12, 1998

MEDICINES INC

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL A110013 Jan 09, 2015

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML N070012 Dec 27, 2007

DEUTSCHLAND GMBH

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINERSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

HAEMONETICS CORP N90067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP N110059 Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTIONSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,
DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATESTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 Dec 09, 2009
1.53G/500ML; 0.465G/500ML

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ABARELIXINJECTABLE; INTRAMUSCULAR
PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL

N021320 001 Nov 25, 2003

ACAMPROSATE CALCIUMTABLET, DELAYED RELEASE; ORAL
CAMPRAL

+ FOREST LABS 333MG **

N021431 001 Jul 29, 2004

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE
WATSON LABS

EQ 200MG BASE

A074007 001 Oct 18, 1995

EQ 400MG BASE

A074007 002 Oct 18, 1995

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML

N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG

A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG

A073106 001 Feb 27, 1995

325MG

A073107 001 Feb 27, 1995

650MG

A073108 001 Feb 27, 1995

ACINO PRODS 120MG

A071010 001 May 12, 1987

650MG

A071011 001 May 12, 1987

TYLENOL

J AND J CONSUMER INC 120MG

N017756 002

650MG

N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG

A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG

A081095 001 Oct 26, 1990

150MG; 180MG; 30MG

A081096 001 Oct 26, 1990

150MG; 180MG; 60MG

A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG

A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG

A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG

A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG

A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG

A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT 650MG; 50MG

A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT 650MG; 50MG

A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG

A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG

A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG

A087550 001 Oct 19, 1984

BUTAPAP

MIKART 650MG; 50MG

A089988 001 Oct 26, 1992

PHRENILIN

VALEANT 325MG; 50MG **

A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND 650MG; 50MG

A088944 001 Oct 17, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG; 50MG; 40MG A088743 001 Jul 18, 1985

325MG; 50MG; 40MG A088765 001 Mar 27, 1985

325MG; 50MG; 40MG A089067 001 Apr 19, 1985

HIKMA PHARMS 500MG; 50MG; 40MG A040261 001 Oct 28, 1998

MALLINCKRODT 325MG; 50MG; 40MG A088758 001 Mar 27, 1985

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG; 50MG; 40MG ** A088825 001 Dec 05, 1984

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A040085 001 Mar 28, 1996

FEMCET

MALLINCKRODT 325MG; 50MG; 40MG A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG; 50MG; 40MG A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT 325MG; 50MG; 40MG A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE 325MG; 50MG; 40MG A040390 001 Jul 23, 2001

500MG; 50MG; 40MG A040394 001 Jul 23, 2001

GILBERT LABS 325MG; 50MG; 40MG A087629 001 Nov 13, 1984

HIKMA PHARMS 500MG; 50MG; 40MG A040336 001 Aug 18, 1999

MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003

MIRROR PHARMS LLC 500MG; 50MG; 40MG A040883 001 Dec 23, 2008

NOVAST LABS LTD 325MG; 50MG; 40MG A040864 001 Dec 01, 2008

SUN PHARM INDUSTRIES 325MG; 50MG; 40MG A040601 001 Jul 29, 2005

VINTAGE PHARMS 500MG; 50MG; 40MG A040513 001 Aug 25, 2003

WATSON LABS 325MG; 50MG; 40MG A089536 001 Feb 16, 1988

500MG; 50MG; 40MG A040267 001 Jul 30, 1998

ESGIC

FOREST PHARMS 325MG; 50MG; 40MG A089660 001 Dec 23, 1988

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG; 50MG; 40MG; 30MG A076528 001 Aug 21, 2003

HIKMA INTL PHARMS 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART 356.4MG; 30MG; 16MG A040109 001 Aug 26, 1997

WRASER PHARMS LLC 356.4MG; 30MG; 16MG A040688 001 Apr 03, 2007

DHC PLUS

PHARM RES ASSOC 356.4MG; 30MG; 16MG A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS 356.4MG; 30MG; 16MG A089166 001 May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC 712.8MG; 60MG; 32MG A040701 001 Apr 03, 2007

MIKART 712.8MG; 60MG; 32MG A040316 001 Apr 28, 1999

WEST-WARD PHARM CORP 712.8MG; 60MG; 32MG A040637 001 Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS 500MG; EQ 0.25MG BASE; 30MG N021082 001 Mar 01, 2001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG;15MG	A088537	001	Jun 04, 1984
	300MG;30MG	A088324	001	Dec 29, 1983
	300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3				
ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4				
ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3				
SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3				
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4				
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
ALLIED PHARMA INC	120MG/5ML;12MG/5ML	A086366	001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	

SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452	001	Aug 01, 2002
	300MG;60MG	A040459	001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
ANDA REPOSITORY	300MG;15MG	A089673	002	Feb 10, 1988
	300MG;30MG	A089673	003	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG **	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;30MG	A085794	001	
	300MG;60MG	A087653	001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A081249	001	Jul 16, 1992
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	
PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
	325MG;15MG **	A085056	002	
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG;15MG	A085055	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

SCHERING PLOUGH 500MG;3MG;60MG N019453 001 May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS 500MG;5MG A088898 001 Mar 27, 1985

ALLAY

IVAX PHARMS 500MG;5MG A089907 001 Jan 13, 1989

BANCAP HC

FOREST PHARMS 500MG;5MG A087961 001 Mar 17, 1983

CO-GESIC

CENT PHARMS 500MG;5MG A089360 001 Mar 02, 1988

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT 500MG;5MG A088956 001 Jul 19, 1985

500MG;5MG A089006 001 Aug 09, 1985

MIKART 500MG;5MG A081067 001 Nov 30, 1989

500MG;5MG A081068 001 Nov 30, 1989

500MG;5MG A081069 001 Nov 30, 1989

500MG;5MG A081070 001 Nov 30, 1989

500MG;5MG A089008 001 Feb 21, 1986

LORCET-HD

MALLINCKRODT 500MG;5MG A087336 001 Jul 08, 1982

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001

MALLINCKRODT INC 500MG/15ML;10MG/15ML A040508 001 Aug 29, 2003

MIKART 500MG/15ML;5MG/15ML A081226 001 Oct 27, 1992

500MG/15ML;5MG/15ML A089557 001 Apr 29, 1992

500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992

NESHER PHARMS 500MG/15ML;7.5MG/15ML A040366 001 Jan 23, 2002

PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998

VINTAGE PHARMS 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003

ZYFREL

CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML A090468 001 Apr 14, 2016

TABLET;ORAL

ANEXSIA

MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987

750MG;10MG A040468 001 Oct 31, 2002

ANEXSIA 7.5/650

MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987

CO-GESIC

UCB INC 500MG;5MG A087757 001 May 03, 1982

DURADYNE DHC

FOREST PHARMS 500MG;5MG A087809 001 Mar 17, 1983

HY-PHEN

ASCHER 500MG;5MG A087677 001 May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE 325MG;5MG A040478 001 Nov 08, 2002

325MG;7.5MG A040464 001 Oct 23, 2002

325MG;10MG A040464 002 Oct 23, 2002

500MG;5MG A040477 001 Nov 06, 2002

500MG;7.5MG A040490 001 May 21, 2003

500MG;10MG A040473 001 Nov 06, 2002

650MG;7.5MG A040474 001 Jan 02, 2003

650MG;10MG A040476 001 Oct 23, 2002

750MG;7.5MG A040469 001 Oct 25, 2002

AMNEAL PHARMS NY 500MG;5MG A040729 001 Aug 25, 2006

500MG;7.5MG A040748 001 Aug 25, 2006

500MG;10MG A040813 001 Feb 23, 2007

650MG;7.5MG A040754 001 Aug 25, 2006

650MG;10MG A040757 001 Aug 25, 2006

750MG;7.5MG A040769 001 Aug 28, 2006

APIL 500MG;10MG A040148 002 Feb 14, 1997

BARR 500MG;2.5MG A040307 001 Jul 26, 2000

500MG;5MG A040308 001 Jul 26, 2000

500MG;5MG A088577 001 Dec 21, 1984

500MG;7.5MG A040307 002 Jul 26, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX				
ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX				
JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984

SOLUTION; ORAL

ROXICET

WEST-WARD PHARMS INT	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986
----------------------	-------------------	---------	-----	--------------

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
	325MG;7.5MG	A040800	001	Apr 03, 2012
	325MG;10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
	650MG;10MG	A040789	002	Nov 27, 2007
BARR	325MG;5MG	A087406	001	
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
	650MG;10MG	A040550	002	Jun 30, 2004
MAYNE PHARMA INC	500MG;7.5MG	A090177	005	Oct 20, 2008
	650MG;10MG	A090177	006	Oct 20, 2008
MIKART	400MG;2.5MG	A040679	001	May 16, 2006
	400MG;5MG	A040687	001	Apr 27, 2006
	400MG;7.5MG	A040698	001	Apr 27, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN				
	400MG;10MG	A040692	001	Apr 27, 2006
	500MG;10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000
	650MG;10MG	A040371	002	Dec 29, 2000
PERCOCET				
VINTAGE PHARMS LLC	325MG;5MG	A085106	002	
	500MG;7.5MG	A040341	001	Jul 26, 1999
	650MG;10MG	A040341	002	Jul 26, 1999
ROXICET 5/500				
ROXANE	500MG;5MG	A089775	001	Jan 12, 1989
TABLET, EXTENDED RELEASE; ORAL				
XARTEMIS XR				
+	MALLINCKRODT INC	325MG;7.5MG	N204031	001
				Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX				
ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000
TALACEN				
SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET				
AAIPHARMA LLC	325MG;32.5MG	N016844	001	
DOLENE AP-65				
LEDERLE	650MG;65MG	A085100	001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG;65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500				
XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
DARVOCET-N 100				
XANODYNE PHARM	650MG;100MG	N017122	002	
DARVOCET-N 50				
XANODYNE PHARM	325MG;50MG	N017122	001	
PROPACET 100				
TEVA	650MG;100MG	A070107	001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985
	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

CSPC OUYI PHARM CO	325MG;37.5MG	A076914	001	Jul 26, 2006
--------------------	--------------	---------	-----	--------------

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
SUN PHARM INDUSTRIES	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	
	250MG	A088882	001	Oct 22, 1985
DIAMOX				
+ TEVA BRANDED PHARM	125MG **	N008943	001	
+	250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
DIAMOX				
+ TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	
ACETIC ACID				
KV PHARM	2%	A085493	001	
ORLEX				
WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994
BOROFAIR				
PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985
DOMEBORO				
BAYER PHARMS	2%;0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON

BAYER PHARMS	2%;0.05%	N017914	001	
--------------	----------	---------	-----	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492	001	
----------	-------	---------	-----	--

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ORLEX HC

WARNER CHILCOTT

2%;1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC

NEO-CORT-DOME

BAYER PHARMS

2%;1%;EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

ANI PHARMS INC

250MG

A070869 001 Feb 09, 1987

500MG

A070870 001 Feb 09, 1987

USL PHARMA

250MG

A070753 001 Nov 03, 1986

500MG

A070754 001 Nov 03, 1986

WATSON LABS TEVA

250MG

A071893 001 Nov 25, 1987

500MG

A071894 001 Nov 25, 1987

DYMELOR

LILLY

250MG

N013378 002

500MG

N013378 001

ACETOPHENAZINE MALEATE

TABLET;ORAL

TINDAL

SCHERING

20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION;INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53%

N009008 001

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA

10%

A071364 001 May 01, 1989

20%

A071365 001 May 01, 1989

ROXANE

10%

A072323 001 Apr 30, 1992

10%

A072621 001 Sep 30, 1992

20%

A072324 001 Apr 30, 1992

20%

A072622 001 Sep 30, 1992

MUCOMYST

+ APOTHECON

10% **

N013601 002

+

20% **

N013601 001

MUCOSIL-10

DEY

10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY

20%

A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION;INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%;0.05%

N017366 001

ACETYLDIGITOXIN

TABLET;ORAL

ACYLANID

NOVARTIS

0.1MG

N009436 001

ACITRETIN

CAPSULE;ORAL

ACITRETIN

MYLAN PHARMS INC

17.5MG

A203707 001 Sep 10, 2015

22.5MG

A203707 002 Sep 10, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING

2MG/GM

N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG

A074906 001 Aug 26, 1997

CHARTWELL MOLECULES

200MG

A074872 001 Apr 22, 1997

HERITAGE PHARMS INC

200MG

A074889 001 Oct 31, 1997

IVAX SUB TEVA PHARMS

200MG

A074674 001 Apr 22, 1997

LEK PHARM

200MG

A074750 001 Apr 22, 1997

MYLAN

200MG

A074727 001 Apr 22, 1997

200MG

A074977 001 Apr 13, 1998

RANBAXY

200MG

A074975 001 Sep 30, 1998

ROXANE

200MG

A074570 002 Apr 22, 1997

TEVA

200MG

A074828 001 Apr 22, 1997

TEVA PHARMS

200MG

A074914 001 Nov 26, 1997

WATSON LABS

200MG

A075101 001 Apr 15, 1998

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

400MG

A074870 001 Jun 05, 1997

800MG

A074870 002 Jun 05, 1997

CHARTWELL MOLECULES

400MG

A074834 001 Apr 24, 1997

800MG

A074834 002 Apr 24, 1997

IVAX SUB TEVA PHARMS

400MG

A074836 001 Apr 22, 1997

800MG

A074836 002 Apr 22, 1997

LEK PHARM

400MG

A074658 001 Apr 22, 1997

800MG

A074658 002 Apr 22, 1997

MYLAN

400MG

A074976 001 Apr 13, 1998

800MG

A074976 002 Apr 13, 1998

SUN PHARM INDS LTD

400MG

A074980 001 Sep 30, 1998

800MG

A074980 002 Sep 30, 1998

TEVA

200MG **

A074556 001 Apr 22, 1997

TEVA PHARMS

400MG

A075021 001 Mar 18, 1998

800MG

A075021 002 Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE

EQ 50MG BASE/ML

A075114 001 Jul 26, 1999

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A074885 001 Dec 19, 1997

EQ 1GM BASE/VIAL

A074885 002 Dec 19, 1997

ACYCLOVIR SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A074897 001 Feb 27, 1998

EQ 1GM BASE/VIAL

A074897 002 Feb 27, 1998

ATHENEX INC

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997

EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A074913 001 Oct 15, 1997

EQ 1GM BASE/VIAL

A074913 002 Oct 15, 1997

HOSPIRA

EQ 25MG BASE/ML

A074720 001 Apr 22, 1997

EQ 50MG BASE/ML

A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

MYLAN LABS LTD

EQ 500MG BASE/VIAL

A203927 001 Mar 29, 2017

EQ 1GM BASE/VIAL

A203927 002 Mar 29, 2017

TEVA PARENTERAL

EQ 50MG BASE/ML

A075627 001 Mar 28, 2001

EQ 500MG BASE/VIAL

A074969 001 Aug 26, 1997

EQ 1GM BASE/VIAL

A074969 002 Aug 26, 1997

ZOVIRAX

+ GLAXOSMITHKLINE

EQ 250MG BASE/VIAL **

N018603 003 Aug 30, 1983

+

EQ 500MG BASE/VIAL **

N018603 001 Oct 22, 1982

+

EQ 1GM BASE/VIAL **

N018603 002 Jun 29, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ADAPALENESOLUTION; TOPICAL
DIFFERIN

+ GALDERMA LABS LP 0.1% ** N020338 001 May 31, 1996

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

TEVA PHARMS USA 3MG/ML A076564 001 Jun 16, 2004

3MG/ML A078676 001 Jul 31, 2008

WEST-WARD PHARMS INT 3MG/ML A076501 001 Jun 16, 2004

WOCKHARDT 3MG/ML A090220 001 Jul 20, 2009

SOLUTION; IV (INFUSION)

ADENOSCAN

+ ASTELLAS 60MG/20ML (3MG/ML) ** N020059 001 May 18, 1995

+ 90MG/30ML (3MG/ML) ** N020059 002 May 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER EQ 200MG BASE/VIAL N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL N020760 002 Dec 18, 1997

ALBENDAZOLE

TABLET, CHEWABLE; ORAL

ALBENZA

AMEDRA PHARMS LLC 200MG N207844 001 Jun 11, 2015

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX 100uCi/VIAL N017835 001

250uCi/VIAL N017835 002

500uCi/VIAL N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS 2.5uCi/AMP N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT 6.67uCi/ML N017844 003

10uCi/ML N017844 001

100uCi/ML N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX 2mCi/VIAL N017837 003

5uCi/AMP N017837 004

20uCi/AMP N017837 005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS 0.09MG/INH A072273 001 Aug 14, 1996

GENPHARM 0.09MG/INH A073045 001 Aug 19, 1997

IVAX SUB TEVA PHARMS 0.09MG/INH A073272 001 Dec 28, 1995

PLIVA 0.09MG/INH A074072 001 Aug 01, 1996

PROVENTIL

SCHERING 0.09MG/INH N017559 001

VENTOLIN

GLAXOSMITHKLINE 0.09MG/INH N018473 001

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE EQ 0.2MG BASE N019489 001 May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC EQ 0.083% BASE A073533 001 Sep 26, 1995

APOTEX INC EQ 0.021% BASE A078623 001 Apr 05, 2010

EQ 0.042% BASE A078623 002 Apr 05, 2010

EQ 0.083% BASE A075717 001 Feb 02, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987
SYRUP; ORAL				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987
TABLET; ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
FOSUN PHARMA	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072152	001	Dec 05, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 2MG BASE	A072764	001	Aug 28, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991
PROVENTIL				
+ SCHERING	EQ 2MG BASE **	N017853	001	May 07, 1982
+	EQ 4MG BASE **	N017853	002	May 07, 1982
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986
	EQ 4MG BASE	N019112	002	Jul 10, 1986
TABLET, EXTENDED RELEASE; ORAL				
PROVENTIL				
SCHERING	EQ 4MG BASE	N019383	001	Jul 13, 1987
VOLMAX				
MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992
	EQ 8MG BASE	N019604	001	Dec 23, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE; IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATION
COMBIVENT

BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;0.018MG/INH N020291 001 Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC EQ 0.083% BASE;0.017% A077117 001 Dec 31, 2007

SANDOZ INC EQ 0.083% BASE;0.017% A076867 001 Dec 21, 2006

DUONEB

+ MYLAN SPECIALITY LP EQ 0.083% BASE;0.017% ** N020950 001 Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

+ FOUGERA PHARMS 0.05% ** N018707 001 Dec 14, 1982

OINTMENT; TOPICAL

ACLOVATE

+ FOUGERA PHARMS 0.05% ** N018702 001 Dec 14, 1982

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES 5ML/100ML A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 10% AND DEXTROSE 5%

B BRAUN 10ML/100ML; 5GM/100ML N004589 006

ALCOHOL 5% AND DEXTROSE 5%

B BRAUN 5ML/100ML; 5GM/100ML N004589 004

ALCOHOL 5% IN D5-W

HOSPIRA 5ML/100ML; 5GM/100ML A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE 5ML/100ML; 5GM/100ML A083256 001

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+ MERCK EQ 70MG BASE/75ML ** N021575 001 Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN EQ 35MG BASE A078638 001 Aug 04, 2008

EQ 70MG BASE A078638 002 Aug 04, 2008

TEVA PHARMS EQ 35MG BASE A076184 002 Aug 04, 2008

EQ 70MG BASE A076184 001 Feb 06, 2008

UPSHER-SMITH LABS EQ 5MG BASE A075871 001 Apr 22, 2009

EQ 10MG BASE A075871 002 Apr 22, 2009

EQ 35MG BASE A075871 004 Apr 22, 2009

EQ 40MG BASE A075871 003 Apr 22, 2009

EQ 70MG BASE A075871 005 Apr 22, 2009

FOSAMAX

+ MERCK AND CO INC EQ 5MG BASE ** N020560 003 Apr 25, 1997

+ EQ 10MG BASE ** N020560 001 Sep 29, 1995

+ EQ 35MG BASE ** N020560 004 Oct 20, 2000

+ EQ 40MG BASE ** N020560 002 Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME 10 UNITS/ML N020057 004 May 08, 1992

80 UNITS/ML N020057 003 Apr 05, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545 001	Aug 26, 2010
	EQ 150MG BASE;EQ 10MG BASE	N022545 002	Aug 26, 2010
	EQ 300MG BASE;EQ 5MG BASE	N022545 003	Aug 26, 2010
	EQ 300MG BASE;EQ 10MG BASE	N022545 004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045 001	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045 002	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045 003	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045 004	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045 005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS	EQ 150MG BASE;160MG	N022217 001	Sep 16, 2009
	EQ 300MG BASE;320MG	N022217 002	Sep 16, 2009

ALKAVERVIR

TABLET; ORAL

VERILOID

3M	2MG	N007336 002	
	3MG	N007336 003	

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM	100MG	A070466 001	Dec 24, 1985
	300MG	A070467 001	Dec 24, 1985
PURACAP PHARM	100MG	A070150 001	Dec 10, 1985
	300MG	A070147 001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
	300MG	A070580 001	Apr 14, 1986
SANDOZ	100MG	A070268 001	Dec 31, 1985
	300MG	A070269 001	Dec 31, 1985
SUPERPHARM	100MG	A070950 001	Nov 30, 1988
	300MG	A070951 001	Nov 30, 1988
WATSON LABS	100MG	N018241 001	Nov 16, 1984
	100MG	N018785 001	Sep 28, 1984
	300MG	N018241 002	Nov 16, 1984
	300MG	N018785 002	Sep 28, 1984
LOPURIN			
ABBOTT	100MG	N018297 001	
	300MG	N018297 002	

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
--------	-----------	-------------	--------------

TABLET; ORAL

ALPRAZOLAM

ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
	0.5MG	A074085 002	Feb 16, 1994
	1MG	A074085 003	Feb 16, 1994
	2MG	A074085 004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
	0.5MG	A074294 002	Jul 29, 1994
	1MG	A074294 003	Jul 29, 1994
	2MG	A074294 004	Jul 29, 1994
MYLAN PHARMS INC	0.25MG	A074046 001	Oct 19, 1993
	0.5MG	A074046 002	Oct 19, 1993
	1MG	A074046 003	Oct 19, 1993
	2MG	A074046 004	May 07, 1997
ROXANE	0.25MG	A074199 001	Oct 19, 1993
	0.5MG	A074199 002	Oct 19, 1993
	1MG	A074199 003	Oct 19, 1993
WATSON LABS	0.25MG	A074456 001	Aug 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

0.25MG	A074479 001	Jan 21, 1997
0.5MG	A074456 002	Aug 31, 1995
0.5MG	A074479 002	Jan 21, 1997
1MG	A074456 003	Aug 31, 1995
1MG	A074479 003	Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

ACTAVIS LABS FL INC	0.5MG	A077198 001	May 13, 2010
	1MG	A077198 002	May 13, 2010
	2MG	A077198 003	May 13, 2010
	3MG	A077198 004	May 13, 2010
ANI PHARMS INC	0.5MG	A077979 001	Feb 28, 2007
	1MG	A077979 002	Feb 28, 2007
	2MG	A077979 003	Feb 28, 2007
	3MG	A077979 004	Feb 28, 2007
IMPAX LABS	0.5MG	A077968 004	May 24, 2007
	1MG	A077968 003	May 24, 2007
	2MG	A077968 002	May 24, 2007
	3MG	A077968 001	May 24, 2007
IMPAX LABS INC	0.5MG	A077996 001	Jan 31, 2007
	1MG	A077996 002	Jan 31, 2007
	2MG	A077996 003	Jan 31, 2007
	3MG	A077996 004	Jan 31, 2007
MYLAN	0.5MG	A077391 002	Jan 26, 2006
	1MG	A077391 003	Jan 26, 2006
	2MG	A077391 004	Jan 26, 2006
	3MG	A077391 001	Jan 26, 2006
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006
	1MG	A077777 002	Jun 30, 2006
	2MG	A077777 003	Jun 30, 2006
	3MG	A077777 004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007
	1MG	A078442 002	Oct 15, 2007
	2MG	A078442 003	Oct 15, 2007
	3MG	A078442 004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

+	UCB INC	0.25MG **	N021726 001	Jan 19, 2005
+		0.5MG **	N021726 002	Jan 19, 2005
+		1MG **	N021726 003	Jan 19, 2005
+		2MG **	N021726 004	Jan 19, 2005

ALPROSTADILINJECTABLE; INJECTION
CAVERJECT

PFIZER	0.005MG/ML	N020755 001	Oct 31, 1997
	0.01MG/ML	N020755 002	Oct 01, 1997
	0.02MG/ML	N020755 003	Oct 01, 1997

EDEX

AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649 001	Jun 12, 1997
---------------------	--------------	-------------	--------------

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS	2MG	N009215 001	
----------	-----	-------------	--

RAUWILOID

3M	2MG	N008867 001	
----	-----	-------------	--

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

ALUMINIUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX	80MG; 20MG	A089449 001	Nov 27, 1987
FOAMCOAT			
GUARDIAN DRUG	80MG; 20MG	A071793 001	Sep 04, 1987
FOAMICON			
NOVARTIS	80MG; 20MG	A072687 001	Jun 28, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A077659 001 Feb 23, 2006

WATSON LABS

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

+ ENDO PHARMS

100MG **

N016020 001

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

G AND W LABS INC

50MG/5ML

A072655 001 Oct 30, 1990

SILARX

50MG/5ML

A076352 001 Sep 10, 2004

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

VINTAGE

50MG/5ML

A077992 001 Dec 12, 2006

SYMMETREL

+ ENDO PHARMS

50MG/5ML **

N016023 002

TABLET; ORAL

SYMMETREL

+ ENDO PHARMS

100MG **

N018101 001

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US

10MG

N010155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+ ASTELLAS

0.025%

N018116 001

+

0.1%

N018116 002

LOTION; TOPICAL

CYCLOCORT

+ ASTELLAS

0.1%

N019729 001 Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

+ ASTELLAS

0.1%

N018498 001

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE

250MG/VIAL

N050565 001 Dec 21, 1984

500MG/VIAL

N050565 002 Dec 21, 1984

1GM/VIAL

N050565 003 Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN HLTHCARE

375MG/VIAL

N020221 002 Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT

EQ 250MG BASE/ML

A063265 001 Nov 30, 1994

EQ 250MG BASE/ML

A063266 001 Oct 31, 1994

HOSPIRA

EQ 50MG BASE/ML

A063263 001 Nov 30, 1994

EQ 50MG BASE/ML

A063350 001 Jul 30, 1993

EQ 62.5MG BASE/ML

A063283 001 Oct 31, 1994

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994

EQ 250MG BASE/ML

A063350 002 Jul 30, 1993

EQ 250MG BASE/ML

A064098 001 Jun 26, 1995

EQ 250MG BASE/ML

A064099 001 Jun 20, 1995

IGI LABS INC

EQ 50MG BASE/ML

A063167 001 Dec 14, 1995

EQ 250MG BASE/ML

A063169 001 Dec 14, 1995

TEVA PHARMS USA

EQ 50MG BASE/ML

A064045 001 Sep 28, 1993

WEST-WARD PHARMS INT

EQ 50MG BASE/ML

A063274 001 May 18, 1992

EQ 250MG BASE/ML

A063275 001 May 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 500MG BASE/100ML

A064146 001 Apr 02, 1997

AMIKIN

APOTHECON

EQ 50MG BASE/ML

A062311 001

EQ 50MG BASE/ML

A062562 001 Sep 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN

+	EQ 50MG BASE/ML **	N050495 001	
	EQ 250MG BASE/ML	A062311 002	
	EQ 250MG BASE/ML	A062562 002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495 002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	APOTHECON EQ 5MG BASE/ML	N050618 002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618 001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	FOSUN PHARMA EQ 5MG ANHYDROUS; 50MG	A073357 001	Nov 27, 1991
	TEVA EQ 5MG ANHYDROUS; 50MG	A070795 001	Apr 17, 1988
	WATSON LABS EQ 5MG ANHYDROUS; 50MG	A073334 001	Jul 19, 1991
HYDRO-RIDE			
	PAR PHARM EQ 5MG ANHYDROUS; 50MG	A070347 001	Dec 25, 1990
MODURETIC 5-50			
+	MERCK EQ 5MG ANHYDROUS; 50MG **	N018201 001	

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

	HOSPIRA 5.2% (5.2GM/100ML)	N018901 001	Apr 06, 1984
AMINOSYN 3.5% IN PLASTIC CONTAINER			
	ABBOTT 3.5% (3.5GM/100ML)	N018804 001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875 001	Aug 08, 1984
AMINOSYN II 3.5%			
	ICU MEDICAL INC 3.5% (3.5GM/100ML)	N019438 001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER			
	ABBOTT 3.5% (3.5GM/100ML)	N019491 001	Oct 10, 1986
AMINOSYN II 5%			
	ICU MEDICAL INC 5% (5GM/100ML)	N019438 002	Apr 03, 1986
AMINOSYN-HBC 7% IN PLASTIC CONTAINER			
	ABBOTT 7% (7GM/100ML)	N019400 001	Jul 23, 1986
BRANCHAMIN 4%			
	BAXTER HLTHCARE 4% (4GM/100ML)	N018678 001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE 4% (4GM/100ML)	N018684 001	Sep 28, 1984
FREAMINE 8.5%			
	B BRAUN 8.5% (8.5GM/100ML)	N016822 001	
FREAMINE II 8.5%			
	B BRAUN 8.5% (8.5GM/100ML)	N016822 002	
HEPATASOL 8%			
	BAXTER HLTHCARE 8% (8GM/100ML)	A020360 001	Apr 04, 1996
NEOPHAM 6.4%			
	HOSPIRA 6.4% (6.4GM/100ML)	N018792 001	Jan 17, 1984
NOVAMINE 11.4%			
	HOSPIRA INC 11.4% (11.4GM/100ML)	N017957 003	Aug 09, 1982
NOVAMINE 15%			
	HOSPIRA INC 15% (75GM/500ML)	N017957 004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER			
	BAXTER HLTHCARE 15% (15GM/100ML)	N020107 001	Feb 05, 1993
NOVAMINE 8.5%			
	HOSPIRA INC 8.5% (8.5GM/100ML)	N017957 002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES			
	BAXTER HLTHCARE 6.5% (6.5GM/100ML)	N017493 007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES			
	BAXTER HLTHCARE 10% (10GM/100ML)	N017493 006	
TRAVASOL 5.5% W/O ELECTROLYTES			
	BAXTER HLTHCARE 5.5% (5.5GM/100ML)	N017493 004	
TRAVASOL 8.5% W/O ELECTROLYTES			
	BAXTER HLTHCARE 8.5% (8.5GM/100ML)	N017493 005	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 001	Sep 12, 1988	
HOSPIRA INC				
	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 001	Nov 07, 1988	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 002	Sep 12, 1988	
HOSPIRA INC				
	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 002	Nov 07, 1988	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 004	Sep 12, 1988	
HOSPIRA INC				
	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683 003	Nov 07, 1988	
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714 003	Sep 12, 1988	
HOSPIRA INC				
	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683 004	Nov 07, 1988	

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118 001	Oct 11, 1984	
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120 001	Oct 11, 1984	
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119 001	Oct 11, 1984	
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505 002	Nov 07, 1986	
	3.5%;25GM/100ML	N019713 006	Sep 09, 1988	
HOSPIRA	3.5%;25GM/100ML	N019681 001	Nov 01, 1988	
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506 001	Nov 07, 1986	
	3.5%;5GM/100ML	N019713 002	Sep 09, 1988	
HOSPIRA	3.5%;5GM/100ML	N019681 002	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713 001	Sep 09, 1988	
HOSPIRA	4.25%;10GM/100ML	N019681 004	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713 004	Sep 09, 1988	
HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986	
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988	
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988	
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986	
	5%;25GM/100ML	N019713 003	Sep 09, 1988	
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988	
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712 002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682 003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 001	Dec 16, 1986
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712 001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 004	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 005	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 001	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 007	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 008	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147 009	Oct 23, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE 4.25%; 25GM/100ML; 51MG/100ML; 261MG/100ML N020147 010 Oct 23, 1995
; 297MG/100ML; 77MG/100ML

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 4.25%; 5GM/100ML; 51MG/100ML; 261MG/100ML; N020147 006 Oct 23, 1995
297MG/100ML; 77MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; N018804 002 May 15, 1984
234MG/100ML3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; N018875 002 Aug 08, 1984
234MG/100MLAMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC 3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML N017789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT 3.5%; 32MG/100ML; 128MG/100ML; 222MG/100ML N019493 001 Oct 16, 1986
; 49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA INC 8%; 61MG/100ML; 211MG/100ML; 56MG/100ML; 38 N017957 001
8MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC 7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 4 N019437 006 Apr 03, 1986
10MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC 3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; N019437 007 Apr 03, 1986
49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML N020177 001 Oct 23, 1995
; 35MG/100ML

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE 3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML N017493 003
; 35MG/100ML

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 5.5%; 102MG/100ML; 522MG/100ML; 431MG/100 N020173 001 Oct 27, 1995
L; 224MG/100ML

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE 5.5%; 102MG/100ML; 522MG/100ML; 431MG/100 N017493 001
L; 224MG/100ML

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 8.5%; 102MG/100ML; 522MG/100ML; 594MG/100 N020173 002 Oct 27, 1995
L; 154MG/100ML

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE 8.5%; 102MG/100ML; 522MG/100ML; 594MG/100 N017493 002
L; 154MG/100MLAMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

+ CLOVER PHARMS 250MG/ML ** N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM 250MG/ML A070522 001 Jun 17, 1986

BAXTER HLTHCARE 250MG/ML N018590 001 Oct 29, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK

20%

N005619 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001 Jul 23, 1982

INTL MEDICATION

25MG/ML

A087209 001 Feb 01, 1982

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

LYPHOMED

25MG/ML

A087431 001

PHARMA SERVE NY

25MG/ML

A087387 001 Jun 03, 1983

25MG/ML

A087392 001 Dec 15, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001 May 30, 1985

25MG/ML

A088749 001 May 30, 1985

TEVA PARENTERAL

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABS

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

AMINOPHYLLINE

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

BARR	100MG	A088297 001	Aug 19, 1983
	200MG	A088298 001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182 001	Mar 31, 1983
	200MG	A088183 001	Mar 31, 1983
HALSEY	100MG	A084674 001	
HIKMA INTL PHARMS	100MG	A084540 001	
	200MG	A085003 001	
IDT AUSTRALIA LTD	100MG	A085261 003	
	100MG	A085262 002	
	200MG	A085261 002	
IMPAX LABS	100MG	A084574 001	
	200MG	A084576 001	
KV PHARM	100MG	A085284 001	
	200MG	A085289 001	
LANNETT	100MG	A084588 001	
	200MG	A084588 002	
PAL PAK	100MG	A084533 001	
PANRAY	100MG	A084552 001	
	200MG	A084552 002	
PUREPAC PHARM	100MG	A084699 001	
	200MG	A085333 001	
ROXANE	100MG	A087500 001	Feb 09, 1982
	200MG	A087501 001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563 001	
VANGARD	100MG	A088314 001	Oct 03, 1983
	200MG	A088319 001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409 001	
	200MG	A085410 001	
WATSON LABS	100MG	A085567 001	
	200MG	A085564 001	

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS	100MG	A084577 001	
	200MG	A084575 001	
TABLICAPS	100MG	A084632 002	
VALE	100MG	A084531 001	
	200MG	A084530 001	

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC	225MG	A086760 001	
-----------------	-------	-------------	--

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947 001	
----------------	------------	-------------	--

SODIUM AMINOSALICYLATE

HEXCEL	100%	A080097 001	
--------	------	-------------	--

TABLET; ORAL

PARASAL SODIUM

PANRAY	500MG	N006811 006	
	1GM	N006811 011	

SODIUM P.A.S.

LANNETT	500MG	A080138 002	
---------	-------	-------------	--

TEEBACIN

CONSOLIDATED MIDLAND	500MG	N007320 002	
----------------------	-------	-------------	--

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC	846MG;112MG	A080059 002	
---------------------	-------------	-------------	--

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY	500MG	N006811 001	
	1GM	N006811 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD	50MG/ML	A076018	001	Oct 15, 2002
BEDFORD LABS	50MG/ML	A076299	001	Oct 24, 2002
BEN VENUE	50MG/ML	A076088	001	Oct 15, 2002
HOSPIRA	50MG/ML	A076108	001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML	N021594	001	Feb 04, 2004
PAR STERILE PRODUCTS	50MG/ML	A076394	001	Apr 25, 2003
TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003

CORDARONE

+ WYETH PHARMS INC 50MG/ML ** N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

MYLAN	200MG	A075188	001	Feb 24, 1999
TEVA	200MG	A074895	001	Apr 16, 1999

CORDARONE

+ WYETH PHARMS INC 200MG ** N018972 001 Dec 24, 1985

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE 40MG/ML A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML A085594 001

ELAVIL

ASTRAZENECA 10MG/ML N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB	10MG	A086454	001	
	25MG	A086454	002	
	50MG	A086454	003	
	75MG	A086454	004	
	100MG	A086454	005	

AMITRIL

WARNER CHILCOTT	10MG	A083939	001	
	25MG	A083937	001	
	50MG	A083938	002	
	75MG	A084957	001	
	100MG	A085093	001	
	150MG	A086295	001	

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP	25MG	A088672	001	Nov 20, 1984
	50MG	A088673	001	Nov 20, 1984
	75MG	A088674	001	Nov 20, 1984
	100MG	A088675	001	Nov 20, 1984
ANI PHARMS INC	10MG	A085031	002	
	25MG	A085031	001	
	50MG	A085031	003	
	75MG	A085031	004	
COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
	10MG	A089399	002	Jul 14, 1987
	25MG	A040816	001	Jun 27, 2008
	25MG	A089399	001	Jul 14, 1987
	50MG	A040816	003	Jun 27, 2008
	50MG	A089399	003	Jul 14, 1987
	75MG	A040816	004	Jun 27, 2008
	75MG	A089399	004	Jul 14, 1987
	100MG	A040816	005	Jun 27, 2008
	100MG	A089399	005	Jul 14, 1987
	150MG	A040816	006	Jun 27, 2008
	150MG	A089399	006	Jul 14, 1987
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

TEVA	10MG	A086610	001	
	25MG	A086859	001	
	50MG	A086857	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
+ ASTRAZENECA	10MG **	N012703	001	
+	25MG **	N012703	003	
+	50MG **	N012703	004	
+	75MG **	N012703	005	
+	100MG **	N012703	006	
+	150MG **	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
LIMBITROL				
+ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949	001	
LIMBITROL DS				
+ HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

SCHERING 10MG; 2MG ** N014713 007

ETRAFON 2-25

SCHERING 25MG; 2MG ** N014713 004

ETRAFON-A

SCHERING 10MG; 4MG ** N014713 002

ETRAFON-FORTE

SCHERING 25MG; 4MG ** N014713 006

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 10MG; 2MG A070935 001 Sep 11, 1986

10MG; 4MG A070937 001 Sep 11, 1986

25MG; 2MG A070936 001 Sep 11, 1986

25MG; 4MG A070938 001 Sep 11, 1986

50MG; 4MG A070939 001 Sep 12, 1986

PAR PHARM

10MG; 2MG A070565 001 Sep 11, 1986

10MG; 4MG A070620 001 Sep 11, 1986

25MG; 2MG A070621 001 Sep 11, 1986

25MG; 4MG A070595 001 Sep 11, 1986

50MG; 4MG A070574 001 Sep 11, 1986

SANDOZ

10MG; 2MG A071062 001 Nov 27, 1987

10MG; 4MG A071862 001 Dec 21, 1987

25MG; 2MG A071063 001 Nov 27, 1987

25MG; 4MG A071064 001 Nov 27, 1987

50MG; 4MG A071863 001 Dec 21, 1987

SUN PHARM INDUSTRIES

10MG; 2MG A071077 001 Nov 12, 1986

10MG; 4MG A071078 001 Nov 12, 1986

25MG; 2MG A070297 001 Nov 12, 1986

25MG; 4MG A071079 001 Nov 12, 1986

WATSON LABS

10MG; 2MG A070373 001 Aug 25, 1986

10MG; 2MG A072539 001 Feb 15, 1989

10MG; 2MG A073007 001 Oct 17, 1991

10MG; 4MG A070375 001 Aug 25, 1986

10MG; 4MG A072540 001 Feb 15, 1989

10MG; 4MG A073009 001 Oct 17, 1991

25MG; 2MG A070374 001 Aug 25, 1986

25MG; 2MG A072541 001 Feb 15, 1989

25MG; 2MG A073008 001 Oct 17, 1991

25MG; 4MG A070376 001 Aug 25, 1986

25MG; 4MG A072134 001 Feb 15, 1989

25MG; 4MG A073010 001 Oct 17, 1991

50MG; 4MG A070377 001 Nov 04, 1986

50MG; 4MG A071558 001 Mar 02, 1987

50MG; 4MG A072135 001 Feb 15, 1989

TRIAVIL 2-10

NEW RIVER 10MG; 2MG ** N014715 004

TRIAVIL 2-25

NEW RIVER 25MG; 2MG ** N014715 002

TRIAVIL 4-10

NEW RIVER 10MG; 4MG ** N014715 003

TRIAVIL 4-25

NEW RIVER 25MG; 4MG ** N014715 005

TRIAVIL 4-50

NEW RIVER 50MG; 4MG ** N014715 006

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU 5% N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU 2MG N021727 001 Sep 29, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

FOSUN PHARMA	EQ 2.5MG BASE	A076859 001	Sep 10, 2007
	EQ 5MG BASE	A076859 002	Sep 10, 2007
	EQ 10MG BASE	A076859 003	Sep 10, 2007
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007
	EQ 5MG BASE	A077333 002	Jul 17, 2007
	EQ 10MG BASE	A077333 003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362 001	Jul 09, 2007
	EQ 5MG BASE	A077362 002	Jul 09, 2007
	EQ 10MG BASE	A077362 003	Jul 09, 2007
MYLAN PHARMS INC	EQ 2.5MG BASE	A078224 001	Feb 27, 2008
	EQ 5MG BASE	A078224 002	Feb 27, 2008
	EQ 10MG BASE	A078224 003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007
	EQ 5MG BASE	A078131 002	Sep 04, 2007
	EQ 10MG BASE	A078131 003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900 001	Jul 23, 2015
	EQ 5MG BASE	A204900 002	Jul 23, 2015
	EQ 10MG BASE	A204900 003	Jul 23, 2015
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081 001	Jan 31, 2008
	EQ 5MG BASE	A078081 002	Jan 31, 2008
	EQ 10MG BASE	A078081 003	Jan 31, 2008
SYNTHON PHARMS	EQ 2.5MG BASE	A077080 001	Jun 27, 2007
	EQ 5MG BASE	A077080 002	Jun 27, 2007
	EQ 10MG BASE	A077080 003	Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026 001	Sep 27, 2007
	EQ 5MG BASE	N022026 002	Sep 27, 2007
	EQ 10MG BASE	N022026 003	Sep 27, 2007

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015
--------------------	----------------	-------------	--------------

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130 001	
GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE			
MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%			
B BRAUN	40MEQ/100ML	A085734 001	

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

RANBAXY	EQ 12% BASE **	N020508 001	Aug 29, 1996
---------	----------------	-------------	--------------

LOTION; TOPICAL

LAC-HYDRIN

+ RANBAXY	EQ 12% BASE **	N019155 001	Apr 24, 1985
-----------	----------------	-------------	--------------

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441 001	
-------------	---------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXAPINE

TABLET; ORAL

AMOXAPINE

UPSHER-SMITH LABS	25MG	A072943 001	Jun 28, 1991
	50MG	A072944 001	Jun 28, 1991
	100MG	A072878 001	Jun 28, 1991
	150MG	A072879 001	Jun 28, 1991
WATSON PHARMS TEVA	25MG	A072418 001	May 11, 1989
	50MG	A072419 001	May 11, 1989
	100MG	A072420 001	May 11, 1989
	150MG	A072421 001	May 11, 1989
ASENDIN			
LEDERLE	25MG	N018021 001	
	50MG	N018021 002	
	100MG	N018021 003	
	150MG	N018021 004	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL	250MG	A062528 001	Aug 07, 1985
	500MG	A062528 002	Aug 07, 1985
MYLAN	250MG	A062067 001	
	500MG	A062067 002	
SUN PHARM INDS LTD	250MG	A065016 001	Apr 08, 1999
	500MG	A065016 002	Apr 08, 1999
TEVA	250MG	A062853 001	Dec 22, 1987
	250MG	A063030 001	Feb 28, 1989
	500MG	A062854 001	Dec 22, 1987
	500MG	A063031 001	Feb 28, 1989

AMOXIL

+	GLAXOSMITHKLINE	250MG **	N050459 001
+		500MG **	N050459 002

TRIMOX

APOTHECON	250MG	A061885 001	
	250MG	A062098 001	
	250MG	A062152 001	
	250MG	A063099 001	Mar 20, 1992
	500MG	A061885 002	
	500MG	A062098 002	
	500MG	A062152 002	
	500MG	A063099 002	Mar 20, 1992

UTIMOX

PARKE DAVIS	250MG	A062107 001	
	500MG	A062107 002	

WYMOX

WYETH AYERST	250MG	A062120 001	
	500MG	A062120 002	

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS	125MG/5ML	A062059 001	
	250MG/5ML	A062059 002	
MYLAN	125MG/5ML	A062090 001	
	250MG/5ML	A062090 002	
SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002
	400MG/5ML	A065113 002	Nov 29, 2002
TEVA	125MG/5ML	A062946 001	Nov 01, 1988
	250MG/5ML	A063001 001	Jan 06, 1989

AMOXIL

+	DR REDDYS LABS INC	200MG/5ML **	N050760 001	Apr 15, 1999
+		400MG/5ML **	N050760 002	Apr 15, 1999
+	GLAXOSMITHKLINE	50MG/ML **	N050460 005	
+		125MG/5ML **	N050460 001	
+		250MG/5ML **	N050460 002	

LAROTID

+	GLAXOSMITHKLINE	50MG/ML **	N050460 006	
---	-----------------	------------	-------------	--

POLYMOX

APOTHECON	125MG/5ML	A061851 001	
	125MG/5ML	A062323 001	
	250MG/5ML	A061851 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLINFOR SUSPENSION;ORAL
POLYMOX

	250MG/5ML	A062323 002	
TRIMOX			
APOTHECON	50MG/ML	A061886 001	
	125MG/5ML	A061886 002	
	125MG/5ML	A062099 001	
	125MG/5ML	A062154 001	
	125MG/5ML	A062885 001	Mar 08, 1988
	250MG/5ML	A061886 003	
	250MG/5ML	A062099 002	
	250MG/5ML	A062154 002	
	250MG/5ML	A062885 002	Mar 08, 1988
UTIMOX			
PARKE DAVIS	125MG/5ML	A062127 001	
	250MG/5ML	A062127 002	
WYMOX			
WYETH AYERST	125MG/5ML	A062131 001	
	250MG/5ML	A062131 002	

TABLET;ORAL

AMOXICILLIN

DAVA PHARMS INC	875MG	A065344 001	Jan 15, 2009
SUN PHARM INDS LTD	500MG	A065059 001	Nov 24, 2000
	875MG	A065059 002	Nov 24, 2000

AMOXIL

+ DR REDDYS LABS INC	500MG **	N050754 002	Jul 10, 1998
+	875MG **	N050754 001	Jul 10, 1998

TABLET, CHEWABLE;ORAL

AMOXICILLIN

APOTHECON	125MG	A064131 001	May 06, 1996
	250MG	A064131 002	May 06, 1996
DAVA PHARMS INC	125MG	A064139 001	Jan 29, 1996
	250MG	A064139 002	Jan 29, 1996
SUN PHARM INDS LTD	125MG	A065021 001	Dec 23, 1999
	200MG	A065060 001	Nov 29, 2000
	250MG	A065021 002	Dec 23, 1999
	400MG	A065060 002	Nov 29, 2000
TEVA	125MG	A064031 001	Dec 19, 1996
	250MG	A064031 002	Dec 19, 1996

AMOXIL

+ DR REDDYS LABS INC	125MG **	N050542 002	
	200MG	N050761 001	Apr 15, 1999
+	250MG **	N050542 001	
	400MG	N050761 002	Apr 15, 1999

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007
	400MG	A065324 002	Jan 17, 2007

DISPERMOX

RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003
	400MG	A065080 001	Aug 11, 2003
	600MG	A065159 001	Dec 04, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132 001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132 002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207 002	Jan 30, 2007

AUGMENTIN '200'

+ DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725 001	May 31, 1996
----------------------	------------------------------	-------------	--------------

AUGMENTIN '400'

+ DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725 002	May 31, 1996
----------------------	----------------------------	-------------	--------------

AUGMENTIN ES-600

+ DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755 001	Jun 22, 2001
----------------------	------------------------------	-------------	--------------

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002
AUGMENTIN '250'				
+ DR REDDYS LABS INC	250MG;EQ 125MG BASE **	N050564	001	Aug 06, 1984
AUGMENTIN '500'				
+ DR REDDYS LABS INC	500MG;EQ 125MG BASE **	N050564	002	Aug 06, 1984
TABLET, CHEWABLE; ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003
	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003
AUGMENTIN '125'				
+ DR REDDYS LABS INC	125MG;EQ 31.25MG BASE **	N050597	001	Jul 22, 1985
AUGMENTIN '200'				
+ DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
AUGMENTIN '250'				
+ DR REDDYS LABS INC	250MG;EQ 62.5MG BASE **	N050597	002	Jul 22, 1985
AUGMENTIN '400'				
+ DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG **	A083564	001
2.5MG;2.5MG;2.5MG;2.5MG **	A083564	002
3.75MG;3.75MG;3.75MG;3.75MG **	A083564	003
5MG;5MG;5MG;5MG **	A083564	004

TABLET; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG	A083563	004
2.5MG;2.5MG;2.5MG;2.5MG	A083563	003
3.75MG;3.75MG;3.75MG;3.75MG	A083563	002
5MG;5MG;5MG;5MG	A083563	001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

+ TEVA WOMENS

2.5MG;2.5MG;2.5MG;2.5MG **

N011522 007 Feb 13, 1996

ADDERALL 12.5

+ TEVA WOMENS

3.125MG;3.125MG;3.125MG;3.125MG **

N011522 012 Aug 31, 2000

ADDERALL 15

+ TEVA WOMENS

3.75MG;3.75MG;3.75MG;3.75MG **

N011522 013 Aug 31, 2000

ADDERALL 20

+ TEVA WOMENS

5MG;5MG;5MG;5MG **

N011522 008 Feb 13, 1996

ADDERALL 30

+ TEVA WOMENS

7.5MG;7.5MG;7.5MG;7.5MG **

N011522 010 May 12, 1997

ADDERALL 5

+ TEVA WOMENS

1.25MG;1.25MG;1.25MG;1.25MG **

N011522 009 May 12, 1997

ADDERALL 7.5

+ TEVA WOMENS

1.875MG;1.875MG;1.875MG;1.875MG **

N011522 011 Aug 31, 2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS

1.25MG;1.25MG;1.25MG;1.25MG

A040472 001 Sep 30, 2003

2.5MG;2.5MG;2.5MG;2.5MG

A040472 002 Sep 30, 2003

5MG;5MG;5MG;5MG

A040472 003 Sep 30, 2003

7.5MG;7.5MG;7.5MG;7.5MG

A040472 004 Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC

EQ 6.25MG BASE;EQ 6.25MG BASE

N010093 007

BIPHETAMINE 20

UCB INC

EQ 10MG BASE;EQ 10MG BASE

N010093 003

BIPHETAMINE 7.5

UCB INC

EQ 3.75MG BASE;EQ 3.75MG BASE

N010093 009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001 Aug 31, 1984

10MG

A083901 002 Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001 Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001 Apr 13, 1987

TEVA PARENTERAL

50MG/VIAL

A064062 001 Mar 31, 1995

FUNGIZONE

APOTHECON

50MG/VIAL

A060517 001

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996

100MG/VIAL

N050729 002 Nov 22, 1996

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 125MG BASE/VIAL

A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003 Feb 05, 1988

EQ 1GM BASE/VIAL

A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005 Feb 05, 1988

CONSOLIDATED PHARM

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

HANFORD GC

EQ 125MG BASE/VIAL

A062772 005 Apr 15, 1993

EQ 500MG BASE/VIAL

A062772 008 Apr 15, 1993

EQ 1GM BASE/VIAL

A062772 002 Apr 15, 1993

EQ 2GM BASE/VIAL

A062772 004 Apr 15, 1993

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003 Jan 09, 1987

LILLY

EQ 500MG BASE/VIAL

A062565 001 Apr 04, 1985

EQ 1GM BASE/VIAL

A062565 002 Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003 Jun 24, 1986

WATSON LABS INC

EQ 125MG BASE/VIAL

A062816 001 Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002 Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003 Oct 24, 1988

EQ 1GM BASE/VIAL

A062816 004 Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005 Oct 24, 1988

EQ 10GM BASE/VIAL

A062994 001 Sep 15, 1988

WEST-WARD PHARMS INT

EQ 125MG BASE/VIAL

A062692 001 Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002 Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003 Jun 24, 1986

EQ 1GM BASE/VIAL

A062692 004 Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005 Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006 Jun 24, 1986

OMNIPEN-N

WYETH AYERST

EQ 125MG BASE/VIAL

A060626 001

EQ 125MG BASE/VIAL

A062718 001 Dec 16, 1986

EQ 250MG BASE/VIAL

A060626 002

EQ 250MG BASE/VIAL

A062718 002 Dec 16, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

EQ 500MG BASE/VIAL	A060626	003	
EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
EQ 1GM BASE/VIAL	A060626	004	
EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
EQ 2GM BASE/VIAL	A060626	005	
EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986

PENBRITIN-S

+ WYETH AYERST

EQ 125MG BASE/VIAL **	N050072	001	
EQ 250MG BASE/VIAL **	N050072	002	
EQ 500MG BASE/VIAL **	N050072	003	
EQ 1GM BASE/VIAL **	N050072	004	
EQ 2GM BASE/VIAL **	N050072	005	
EQ 4GM BASE/VIAL **	N050072	006	

POLYCILLIN-N

BRISTOL

EQ 125MG BASE/VIAL **	N050309	001	
EQ 250MG BASE/VIAL **	N050309	002	
EQ 500MG BASE/VIAL **	N050309	003	
EQ 1GM BASE/VIAL **	N050309	004	
EQ 2GM BASE/VIAL **	N050309	005	

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 125MG BASE/VIAL	A060677	001	
EQ 250MG BASE/VIAL	A060677	002	
EQ 500MG BASE/VIAL	A060677	003	
EQ 1GM BASE/VIAL	A060677	004	
EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986
EQ 2GM BASE/VIAL	A060677	005	
EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
EQ 10GM BASE/VIAL	A060677	006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
---------------------------------------	---------	-----	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE	A062041	001	
EQ 500MG BASE	A062041	002	

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE	A061602	001	
---------------	---------	-----	--

EQ 500MG BASE	A061602	002	
---------------	---------	-----	--

IVAX SUB TEVA PHARMS

EQ 250MG BASE	A060765	001	
---------------	---------	-----	--

EQ 500MG BASE	A060765	002	
---------------	---------	-----	--

LEDERLE

EQ 250MG BASE	A062208	001	
---------------	---------	-----	--

EQ 500MG BASE	A062208	002	
---------------	---------	-----	--

MYLAN

EQ 250MG BASE	A061755	001	
---------------	---------	-----	--

EQ 500MG BASE	A061755	002	
---------------	---------	-----	--

PUREPAC PHARM

EQ 250MG BASE	A061853	001	
---------------	---------	-----	--

EQ 500MG BASE	A061853	002	
---------------	---------	-----	--

TEVA

EQ 250MG BASE	A061502	001	
---------------	---------	-----	--

EQ 500MG BASE	A061502	002	
---------------	---------	-----	--

VITARINE

EQ 250MG BASE	A061387	001	
---------------	---------	-----	--

EQ 500MG BASE	A061387	003	
---------------	---------	-----	--

OMNIPEN (AMPICILLIN)

WYETH AYERST

250MG	A060624	001	
-------	---------	-----	--

500MG	A060624	002	
-------	---------	-----	--

PENBRITIN

WYETH AYERST

EQ 250MG BASE	A060908	001	
---------------	---------	-----	--

EQ 500MG BASE	A060908	002	
---------------	---------	-----	--

PFIZERPEN-A

PFIZER

EQ 250MG BASE	A062050	001	
---------------	---------	-----	--

EQ 500MG BASE	A062050	002	
---------------	---------	-----	--

POLYCILLIN

BRISTOL

EQ 250MG BASE	N050310	001	
---------------	---------	-----	--

EQ 500MG BASE	N050310	002	
---------------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PRINCIPEN

APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE	A062157 002	
	EQ 250MG BASE	N050056 001	

PRINCIPEN '500'

APOTHECON	EQ 500MG BASE	A062157 001	
	EQ 500MG BASE	N050056 002	

TOTACILLIN

GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
	EQ 250MG BASE	A062212 001	
	EQ 500MG BASE	A060060 002	
	EQ 500MG BASE	A062212 002	

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
	EQ 250MG BASE/5ML	A062030 002	

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601 001	
	EQ 250MG BASE/5ML	A061601 002	
MYLAN	EQ 125MG BASE/5ML	A061829 002	
	EQ 250MG BASE/5ML	A061829 001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001	
	EQ 250MG BASE/5ML	A061980 002	
TEVA	EQ 125MG BASE/5ML	A061370 001	
	EQ 250MG BASE/5ML	A061370 002	

OMNIPEN (AMPICILLIN)

WYETH AYERST	100MG/ML	A060625 001	
	125MG/5ML	A060625 002	
	250MG/5ML	A060625 003	
	500MG/5ML	A060625 004	

PENBRITIN

WYETH AYERST	EQ 100MG BASE/ML	N050019 001	
	EQ 125MG BASE/5ML	N050019 002	
	EQ 250MG BASE/5ML	N050019 003	

PFIZERPEN-A

PFIZER	EQ 125MG BASE/5ML	A062049 001	
	EQ 250MG BASE/5ML	A062049 002	

POLYCILLIN

APOTHECON	EQ 125MG BASE/5ML	A062297 001	
	EQ 250MG BASE/5ML	A062297 002	
BRISTOL	EQ 100MG BASE/ML	N050308 004	
	EQ 125MG BASE/5ML	N050308 001	
	EQ 250MG BASE/5ML	N050308 002	
	EQ 500MG BASE/5ML	N050308 003	

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	A061394 001	
	EQ 125MG BASE/5ML	A061394 002	
	EQ 250MG BASE/5ML	A061394 003	

PRINCIPEN '125'

APOTHECON	EQ 125MG BASE/5ML	A060127 002	
	EQ 125MG BASE/5ML	A062151 001	

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE/5ML	A060127 001	
	EQ 250MG BASE/5ML	A062151 002	

TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001	
	EQ 125MG BASE/5ML	A062223 001	
	EQ 250MG BASE/5ML	A060666 002	
	EQ 250MG BASE/5ML	A062223 002	

TABLET, CHEWABLE; ORAL

POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093 001	
---------	---------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE;111MG

A062150 001

EQ 389MG BASE;111MG

N050488 001

FOR SUSPENSION; ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT;1GM/BOT

A061898 001

BRISTOL

EQ 3.5GM BASE/BOT;1GM/BOT

N050457 001

PROBAMPACIN

G AND W LABS INC

EQ 3.5GM BASE/BOT;1GM/BOT

A061741 001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE

50MG

N021007 001 Apr 15, 1999

150MG

N021007 002 Apr 15, 1999

SOLUTION; ORAL

AGENERASE

+ GLAXOSMITHKLINE

15MG/ML **

N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

+ SHIRE LLC

EQ 1MG BASE **

N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 0.5MG BASE

A076811 001 Apr 18, 2005

EQ 0.5MG BASE

A077613 001 Jun 27, 2006

EQ 1MG BASE

A076811 002 Apr 18, 2005

EQ 1MG BASE

A077613 002 Jun 27, 2006

ROXANE

EQ 0.5MG BASE

A076489 001 Apr 18, 2005

EQ 1MG BASE

A076489 002 Apr 18, 2005

UPSHER-SMITH LABS

EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

KREMERS URBAN PHARMS

1MG

A091331 001 Jan 05, 2011

SANDOZ

1MG

A079007 001 Jun 28, 2010

SUN PHARM INDS LTD

1MG

A091177 001 Jul 15, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

WATSON LABS TEVA

1MG

A078984 001 Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE;INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE;INJECTION

NORMIFLO

+ PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **

N020227 002 May 23, 1997

+

10,000 UNITS/0.5ML **

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION;IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIPIRAZOLE

INJECTABLE;INTRAMUSCULAR

ABILIFY

OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION;ORAL

ABILIFY

+ OTSUKA

1MG/ML **

N021713 001 Dec 10, 2004

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

OTSUKA

10MG **

N021729 002 Jun 07, 2006

15MG **

N021729 003 Jun 07, 2006

+

20MG **

N021729 004 Jun 07, 2006

+

30MG **

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

NUVIGIL

+ CEPHALON

100MG **

N021875 002 Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

BEROCCA PN

ROCHE

50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;

N006071 003 Oct 10, 1985

100

IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2

N018440 002 Aug 08, 1985

0

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

M.V.I.-12 ADULT

HOSPIRA

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2

N008809 004 Aug 08, 1985

0

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

+

20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;

N008809 006 Sep 09, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 20 IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT PHARMA INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001MG/VIAL; 400 IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VIAL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ 2, 300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

NOVEL LABS INC

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

MEASURIN

BAYER

650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS

650MG; 50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC

325MG; 50MG; 40MG

A078149 001 Jun 13, 2007

WATSON LABS

325MG; 50MG; 40MG

A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH

325MG; 50MG; 40MG

A086710 002 Aug 23, 1983

HALSEY

325MG; 50MG; 40MG

A089448 001 Dec 01, 1986

IVAX PHARMS

325MG; 50MG; 40MG

A085441 002 Oct 31, 1984

PURACAP PHARM

325MG; 50MG; 40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS

325MG; 50MG; 40MG

A088972 001 Jun 18, 1985

SANDOZ

325MG; 50MG; 40MG

A086398 002 Apr 06, 1984

WATSON LABS

325MG; 50MG; 40MG

A086237 002 Mar 23, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORINAL

+ ALLERGAN SALES LLC 325MG; 50MG; 40MG ** N017534 003 Apr 16, 1986

LANORINAL

LANNETT 325MG; 50MG; 40MG A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC 325MG; 50MG; 40MG; 30MG A075351 001 Mar 05, 1999

WATSON LABS 325MG; 50MG; 40MG; 30MG A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ 385MG; 30MG; 25MG A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ 770MG; 60MG; 50MG A074817 002 Nov 27, 1996

NORGESIC

+ MEDICIS 385MG; 30MG; 25MG ** N013416 003 Oct 27, 1982

NORGESIC FORTE

+ MEDICIS 770MG; 60MG; 50MG ** N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J 385MG; 30MG; 25MG A074988 001 Apr 30, 1999

770MG; 60MG; 50MG A074988 002 Apr 30, 1999

ORPHENGESIC

PRINSTON INC 385MG; 30MG; 25MG A075141 001 May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC 770MG; 60MG; 50MG A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA 389MG; 32.4MG; 65MG A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM 389MG; 32.4MG; 32MG N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM 389MG; 32.4MG; 65MG N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS 389MG; 32.4MG; 65MG A083077 002 Dec 07, 1984

SANDOZ 389MG; 32.4MG; 65MG A080044 002 Sep 16, 1983

TEVA 389MG; 32.4MG; 65MG A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG; 32.4MG; 65MG A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS 389MG; 32.4MG; 65MG A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS 325MG; 200MG A088809 001 Oct 03, 1985

SOMA COMPOUND

MEDA PHARMS 325MG; 200MG ** N012365 005 Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

OXFORD PHARMS 325MG; 200MG; 16MG A040283 001 Dec 29, 1998

SOMA COMPOUND W/ CODEINE

MEDA PHARMS 325MG; 200MG; 16MG ** N012366 002 Jul 11, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG; 5MG ** A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG; 5MG A086333 001 Sep 14, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

SUN PHARM INDUSTRIES	325MG;200MG	N011702 003	Dec 29, 1983
MEPRO-ASPIRIN			
SANDOZ	325MG;200MG	A089127 001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN			
PAR PHARM	325MG;200MG	A089126 001	Aug 19, 1986
MICRAININ			
MEDPOINTE PHARM HLC	325MG;200MG	A084978 001	
Q-GESIC			
QUANTUM PHARMICS	325MG;200MG	A088740 001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG;400MG	A087211 001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193 001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657 001	Nov 04, 1988
ROBAXISAL			
ROBINS AH	325MG;400MG	N012281 001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464 001	Jul 01, 1982
OXYCODONE AND ASPIRIN			
SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260 001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794 001	May 26, 1982
WATSON LABS	325MG;4.5MG;0.38MG	A040255 001	Feb 27, 1998
OXYCODONE AND ASPIRIN (HALF-STRENGTH)			
ROXANE	325MG;2.25MG;0.19MG	A087742 001	Jun 04, 1982
PERCODAN			
ENDO PHARMS	325MG;4.5MG;0.38MG **	N007337 006	
PERCODAN-DEMI			
ENDO PHARMS	325MG;2.25MG;0.19MG **	N007337 005	
ROXIPRIN			
ROXANE	325MG;4.5MG;0.38MG	A087743 001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

+ SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891 001	
---------------------	-------------------------	-------------	--

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387 006	Jun 24, 2003
----------------------	--------------------	-------------	--------------

TABLET, TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387 001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387 002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387 003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387 004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387 005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG;65MG	N010996 005	
----------------	------------	-------------	--

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016829 001	
---------------	-------------	-------------	--

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016863 001	
---------------	-------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

+ BRISTOL MYERS SQUIBB EQ 100MG BASE ** N021567 001 Jun 20, 2003

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

+ ASTRAZENECA 0.5MG/ML ** N019058 001 Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907 001	Jul 30, 2004
	50MG	A076907 002	Jul 30, 2004
	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
DAVA PHARMS INC	25MG	A074099 001	Apr 28, 1992
MYLAN	25MG	A074126 003	Aug 26, 1998
	50MG	A074126 001	Mar 23, 1994
	100MG	A074126 002	Mar 23, 1994
NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
	50MG	A078254 002	Sep 25, 2009
	100MG	A078254 003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SANDOZ	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404 001	May 14, 1998
	100MG; 25MG	A074404 002	May 14, 1998
PLIVA	50MG; 25MG	A074107 001	Sep 24, 1997
	100MG; 25MG	A074107 002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010
	25MG	A079017 002	Sep 17, 2010
	40MG	A079017 003	Sep 17, 2010
	60MG	A079017 004	Sep 17, 2010
	80MG	A079017 005	Sep 17, 2010
	100MG	A079017 006	Sep 17, 2010

STRATTERA

LILLY 5MG N021411 001 Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012
	EQ 20MG BASE	A078773 002	May 29, 2012
	EQ 40MG BASE	A078773 003	May 29, 2012
	EQ 80MG BASE	A078773 004	May 29, 2012

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

+	MERCK SHARP DOHME	EQ 10MG BASE;10MG **	N200153	001	May 03, 2013
+		EQ 20MG BASE;10MG **	N200153	002	May 03, 2013
+		EQ 40MG BASE;10MG **	N200153	003	May 03, 2013
+		EQ 80MG BASE;10MG **	N200153	004	May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

+	GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992
---	---------------------	----------	---------	-----	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

	BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
		10MG/ML	A074740	001	Mar 28, 1997
	TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
	WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
	ATRACURIUM BESYLATE PRESERVATIVE FREE				
	BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
		10MG/ML	A074639	001	Mar 25, 1997
		10MG/ML	A074741	001	Mar 28, 1997
	WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
	TRACRIUM				
+	HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
	TRACRIUM PRESERVATIVE FREE				
+	HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
--	--------	----------------------	---------	-----	--------------

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

	US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
--	---------	--------------------	---------	-----	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001	
--	--------------------	---------------	---------	-----	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

	SCHERER RP	0.025MG;2.5MG	A086440	001	
--	------------	---------------	---------	-----	--

SOLUTION; ORAL

COLONOID

	MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
--	---------------------	-----------------------	---------	-----	--

LOMANATE

	ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
--	--------------------	-----------------------	---------	-----	--

LOMOTIL

	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	
--	---------------	-----------------------	---------	-----	--

TABLET; ORAL

COLONOID

	MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
--	---------------------	---------------	---------	-----	--

DI-ATRO

	MD PHARM	0.025MG;2.5MG	A085266	001	
--	----------	---------------	---------	-----	--

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
	ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
	HEATHER	0.025MG;2.5MG	A086798	001	
	HIKMA PHARMS	0.025MG;2.5MG	A087765	001	Mar 15, 1982
	INWOOD LABS	0.025MG;2.5MG	A085509	001	
	KV PHARM	0.025MG;2.5MG	A085659	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

LEDERLE	0.025MG;2.5MG	A086950	001	
PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
SANDOZ	0.025MG;2.5MG	A086173	001	
SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876	001	
LO-TROL				
VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOGEN				
SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LONOX				
SANDOZ	0.025MG;2.5MG	A085311	002	
LOW-QUEL				
HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002
---------	-----------------------	---------	-----	--------------

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992
---	----------------------	------------	---------	-----	--------------

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING	1MG	N017601	001	
----------	-----	---------	-----	--

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982
----------	-----------	---------	-----	--------------

AZATHIOPRINE

TABLET; ORAL

IMURAN

+	SEBELA IRELAND LTD	25MG **	N016324	002
---	--------------------	---------	---------	-----

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

+	CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391	001
---	-------------------	-----------------------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPTIVAR

+ MYLAN SPECIALITY LP 0.05%

N021127 001 May 22, 2000

SPRAY, METERED;NASAL

ASTEPRO

MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE;ORAL

ZITHROMAX

+ PFIZER EQ 250MG BASE **

N050670 001 Nov 01, 1991

FOR SUSPENSION;ORAL

AZITHROMYCIN

SANDOZ EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE;INJECTION

AZITHROMYCIN

CSPC OUYI PHARM CO EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

TABLET;ORAL

AZITHROMYCIN

MYLAN EQ 250MG BASE

A065365 001 May 30, 2007

EQ 500MG BASE

A065366 001 May 30, 2007

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET;ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER EQ 1GM BASE,N/A;N/A,EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE;INJECTION

AZLIN

BAYER PHARMS EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE;INJECTION

AZACTAM

BRISTOL MYERS SQUIBB 500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB 10MG/ML

N050632 003 May 24, 1989

AZTREONAM

WEST-WARD PHARMS INT 1GM/VIAL

A065286 001 Mar 23, 2011

2GM/VIAL

A065286 002 Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION;ORAL

SPECTROBID

PFIZER 125MG/5ML

N050556 001 Mar 23, 1982

TABLET;ORAL

SPECTROBID

PFIZER 400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

PFIZER 50,000 UNITS/VIAL

A060282 001

OINTMENT;OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN 500 UNITS/GM

A060734 001

BACITRACIN

LILLY 500 UNITS/GM

A060687 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT;TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER;FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

+ CASPER PHARMA LLC

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **

N050416 002

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT;TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062167 001

NEO-POLYICIN

DOW PHARM

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060647 001

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM;10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM **

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731	002
--------	--	---------	-----

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048	001
----------------------	---	---------	-----

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598	001	Sep 22, 1986
-------	-----------------------------	---------	-----	--------------

BACLOFEN

TABLET;ORAL

BACLOFEN

MYLAN	10MG	A077181	001	Jul 29, 2005
TEVA	10MG	A073043	001	Feb 27, 1992
	20MG	A073044	001	Feb 27, 1992
USL PHARMA	10MG	A071260	001	May 06, 1988
	20MG	A071261	001	May 06, 1988
WATSON LABS	10MG	A072824	001	Sep 18, 1991
	10MG	A073092	001	Jan 28, 1994
	10MG	A074698	001	Aug 20, 1996
	20MG	A072825	001	Sep 18, 1991
	20MG	A073093	001	Jan 28, 1994
	20MG	A074698	002	Aug 20, 1996

Lioresal

+ NOVARTIS

10MG **

N017851 001

+

+ NOVARTIS

20MG **

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

UCB INC	10MG	N021589	001	Oct 30, 2003
	20MG	N021589	002	Oct 30, 2003

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-CAT DRY

+ BRACCO

40% (9GM/POUCH)

N208036 003 Jan 03, 2017

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

BECLOVENT

GLAXOSMITHKLINE	0.042MG/INH	N018153	001
-----------------	-------------	---------	-----

VANCERIL

SCHERING	0.042MG/INH	N017573	001
----------	-------------	---------	-----

VANCERIL DOUBLE STRENGTH

SCHERING	0.084MG/INH	N020486	001	Dec 24, 1996
----------	-------------	---------	-----	--------------

AEROSOL, METERED;NASAL

BECONASE

GLAXOSMITHKLINE	0.042MG/INH	N018584	001
-----------------	-------------	---------	-----

VANCENASE

SCHERING	0.042MG/INH	N018521	001
----------	-------------	---------	-----

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

VANCENASE AQ

SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987
----------	-------------------------	---------	-----	--------------

	EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996
--	-------------------------	---------	-----	--------------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004
---------------------	-----	---------	-----	--------------

	10MG	A076267	002	Feb 11, 2004
--	------	---------	-----	--------------

	20MG	A076267	003	Feb 11, 2004
--	------	---------	-----	--------------

	40MG	A076267	004	Feb 11, 2004
--	------	---------	-----	--------------

GENPHARM	5MG	A076476	001	Feb 11, 2004
----------	-----	---------	-----	--------------

	10MG	A076476	002	Feb 11, 2004
--	------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC 5MG;6.25MG

A076342 001 Feb 11, 2004

10MG;12.5MG

A076342 002 Feb 11, 2004

20MG;12.5MG

A076342 003 Feb 11, 2004

20MG;25MG

A076342 004 Feb 11, 2004

IVAX SUB TEVA PHARMS 5MG;6.25MG

A076348 001 Feb 11, 2004

10MG;12.5MG

A076348 002 Feb 11, 2004

20MG;12.5MG

A076348 003 Feb 11, 2004

20MG;25MG

A076348 004 Feb 11, 2004

MYLAN PHARMS INC 5MG;6.25MG

A076612 001 Feb 11, 2004

10MG;12.5MG

A076612 002 Feb 11, 2004

20MG;12.5MG

A076612 003 Feb 11, 2004

20MG;25MG

A076612 004 Feb 11, 2004

SUN PHARM INDS LTD 5MG;6.25MG

A077483 001 Sep 08, 2005

10MG;12.5MG

A077483 002 Sep 08, 2005

20MG;12.5MG

A077483 003 Sep 08, 2005

20MG;25MG

A077483 004 Sep 08, 2005

LOTENSIN HCT

+ US PHARMS HOLDINGS I 5MG;6.25MG

N020033 001 May 19, 1992

BENDROFLUMETHIAZIDE

TABLET;ORAL

NATURETIN-10

APOTHECON 10MG

N012164 003

NATURETIN-2.5

APOTHECON 2.5MG

N012164 001

NATURETIN-5

APOTHECON 5MG

N012164 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

MYLAN 5MG;40MG

A078688 001 Feb 15, 2008

5MG;80MG

A078688 002 Feb 15, 2008

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND 0.4%

A084149 001

BENTIROMIDE

SOLUTION;ORAL

CHYMEX

SAVAGE LABS 500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE;ORAL

BENZONATATE

NESHER PHARMS 100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

TESSALON

+ PFIZER 200MG **

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

VALEANT BERMUDA 5%;EQ 1% BASE

N050756 002 Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

EPIC PHARMA LLC 50MG

A040714 001 Oct 29, 2007

IMPAX LABS 50MG

A040845 001 Nov 18, 2008

DIDREX

+ PHARMACIA AND UPJOHN 25MG **

N012427 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX

+

50MG **

N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

ANDA REPOSITORY

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

LANNETT HOLDINGS INC

0.5MG **

A088877 001 Apr 11, 1985

1MG **

A088894 001 Apr 11, 1985

2MG **

A088895 001 Apr 11, 1985

OXFORD PHARMS

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

+ MERCK

0.5MG **

N009193 004

+

1MG **

N009193 003

+

2MG **

N009193 002

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING

EQ 0.1% BASE

N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS

EQ 0.05% BASE

A071085 001 Feb 03, 1987

G AND W LABS INC

EQ 0.05% BASE

A071882 001 Jun 06, 1988

PHARMADERM

EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO

EQ 0.05% BASE

A072276 001 Aug 24, 1988

EQ 0.05% BASE

A074272 001 Sep 30, 1994

DIPROSONE

+ SCHERING

EQ 0.05% BASE **

N017781 001

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM

EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA

EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017691 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML A085738 001

CELESTONE

+ SCHERING EQ 3MG BASE/ML ** N017561 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070485 001 May 29, 1987

TARO EQ 0.1% BASE A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE N016322 002

EQ 0.1% BASE N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE N018863 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC EQ 0.5% BASE A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG N019507 001 Oct 27, 1989

20MG N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US 5MG;12.5MG N019807 001 Oct 30, 1992

10MG;12.5MG N019807 002 Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; Pilocarpine Hydrochloride

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON EQ 0.25% BASE;1.75% N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY 50MG/ML N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

+ ODYSSEY PHARMS 5MG/ML ** N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE 5MG A040492 001 Jul 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	10MG	A040483 001	Jul 27, 2004
	25MG	A040485 001	Jul 27, 2004
	50MG	A040509 001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552 001	Oct 28, 2004
	10MG	A040553 001	Oct 28, 2004
	25MG	A040554 001	Oct 28, 2004
	50MG	A040551 001	Oct 28, 2004
ASCOT	10MG	A088288 001	Jun 08, 1983
	25MG	A088289 001	Jun 08, 1983
IMPAX LABS	5MG	A040721 001	Nov 01, 2006
	10MG	A040721 002	Nov 01, 2006
	25MG	A040721 003	Nov 01, 2016
	50MG	A040721 004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689 001	
LANNETT	5MG	A084702 001	
	10MG	A084712 001	
	25MG	A084074 001	
SANDOZ	5MG	A084353 001	
	10MG	A084378 001	
	10MG	A084379 001	
	25MG	A084383 001	
	25MG	A084384 001	
SUN PHARM INDS INC	5MG	A040897 001	Apr 22, 2009
	10MG	A040897 002	Apr 22, 2009
	25MG	A040897 003	Apr 22, 2009
	50MG	A040897 004	Apr 22, 2009
WATSON LABS	5MG	A084402 001	
	5MG	A085230 002	
	5MG	A085841 001	
	10MG	A084408 001	
	10MG	A085228 001	
	10MG	A085842 001	
	25MG	A084441 001	
	25MG	A085229 001	
	25MG	A085839 001	
	50MG	A087397 001	
	50MG	A087444 001	
MYOTONACHOL			
GLENWOOD	5MG	A084188 001	
	10MG	A084188 003	
	25MG	A084188 004	
URECHOLINE			
+	ODYSSEY PHARMS	5MG **	N006536 003
+		10MG **	N006536 002
+		25MG **	N006536 004
+		50MG **	N006536 005

BETHANIDINE SULFATE

TABLET;ORAL

TENATHAN

ROBINS AH

10MG	N017675 001
25MG	N017675 002

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

KUDCO IRELAND

ROXANE

SYNTHON PHARMS

50MG	A077995 001	Jul 06, 2009
50MG	A078285 001	Mar 24, 2011
50MG	A077973 001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

+ ALLERGAN

0.03% **	N021275 001	Mar 16, 2001
----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

ABBVIE

2MG

N012003 001

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE

5MG/ML

N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+ BRAINTREE

5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM
; N/A, 5.6GM **

N021551 003 Jul 16, 2010

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+ CASPER PHARMA LLC

262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 5
00MG **

N050719 001 Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

ANDA REPOSITORY

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

ZEBETA

TEVA WOMENS

5MG **

N019982 002 Jul 31, 1992

10MG **

N019982 001 Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG; 6.25MG

A075672 001 Sep 25, 2000

5MG; 6.25MG

A075672 002 Sep 25, 2000

10MG; 6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG; 6.25MG

A075642 002 Dec 27, 2000

5MG; 6.25MG

A075642 001 Dec 27, 2000

10MG; 6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG

A075632 001 Sep 27, 2000

5MG; 6.25MG

A075632 002 Sep 27, 2000

10MG; 6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG; 6.25MG

A075527 001 Sep 25, 2000

5MG; 6.25MG

A075527 003 Sep 25, 2000

10MG; 6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG; 6.25MG

A075686 001 Jan 19, 2001

5MG; 6.25MG

A075686 002 Jan 19, 2001

10MG; 6.25MG

A075686 003 Jan 19, 2001

WATSON LABS TEVA

2.5MG; 6.25MG

A075469 001 Sep 25, 2000

5MG; 6.25MG

A075469 002 Sep 25, 2000

10MG; 6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

+ BRISTOL MYERS SQUIBB

EQ 15 UNITS BASE/VIAL **

N050443 001

+

EQ 30 UNITS BASE/VIAL **

N050443 002 Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007

TEVA PARENTERAL

EQ 15 UNITS BASE/VIAL

A064084 001 Jun 01, 1996

EQ 30 UNITS BASE/VIAL

A064084 002 Jun 01, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011
-------------------	-------	---------	-----	--------------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
EUROHLTH INTL SARL	50MG/ML	A070546	001	May 14, 1986
+ HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
	200MG/100ML	N019121	002	Apr 29, 1986
	400MG/100ML	N019121	003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986

BRETYLOL

HOSPIRA	50MG/ML	N017954	001	
---------	---------	---------	-----	--

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

+ ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997

BRIMONIDINE TARTRATE

TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
-----------------	------	---------	-----	--------------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
-----------------------	------------------	---------	-----	--------------

BROMFENAC SODIUM

COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
----------------	---------------	---------	-----	--------------

XIBROM

+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005
-----------------------	------------------	---------	-----	--------------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
-----------	-------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984	001	
-------------	------	---------	-----	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS	12.5MG/5ML; 10MG/5ML	N009319	006	Jan 10, 1984
-------------	----------------------	---------	-----	--------------

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML; 10MG/5ML	A088343	001	Aug 15, 1984
--------------------	----------------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML; 10MG/5ML	A088626	001	Oct 12, 1984
-----------	----------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	
--------------	---------	---------	-----	--

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
UPSHER-SMITH LABS	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	
------------	-----	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A088722	001	Mar 07, 1985
--------------------	-----------------------------	---------	-----	--------------

BROMFED-DM

WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A089681	001	Dec 22, 1988
-----------	-----------------------------	---------	-----	--------------

DIMETANE-DX

+ ROBINS AH	2MG/5ML; 10MG/5ML; 30MG/5ML **	N019279	001	Aug 24, 1984
-------------	--------------------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG; 240MG	N019672	001	Mar 29, 1996
------	-------------	---------	-----	--------------

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS	50MG	N010911	006	
---------------	------	---------	-----	--

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
-------------	-------------	---------	-----	--------------

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997

BUMEX

+ VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983
------------------	--------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA 0.75%

A070587 001 Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA 0.075%

N019978 001 Sep 03, 1992

0.114%

N019978 002 Sep 03, 1992

0.23%

N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED 0.25%

A076012 001 Jan 09, 2002

0.5%

A076012 002 Jan 09, 2002

0.75%

A076012 003 Jan 09, 2002

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA 0.25%; 0.005MG/ML

A071166 001 Jun 16, 1988

0.5%; 0.005MG/ML

A071169 001 Jun 16, 1988

0.75%; 0.005MG/ML

A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)

N021496 001 May 23, 2003

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

+ INDIVIOR INC EQ 2MG BASE **

N020732 002 Oct 08, 2002

+ EQ 8MG BASE **

N020732 003 Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

+ INDIVIOR INC EQ 2MG BASE; EQ 0.5MG BASE **

N020733 001 Oct 08, 2002

+ EQ 8MG BASE; EQ 2MG BASE

N020733 002 Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ 75MG

A075613 002 Oct 10, 2000

100MG

A075613 001 Oct 10, 2000

TEVA 75MG

A075310 001 Nov 29, 1999

100MG

A075310 002 Nov 29, 1999

WELLBUTRIN

+ GLAXOSMITHKLINE 50MG **

N018644 001 Dec 30, 1985

+ 75MG **

N018644 002 Dec 30, 1985

+ 100MG **

N018644 003 Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC 300MG

A077715 002 Jun 13, 2007

IMPAX LABS 300MG

A077415 002 Dec 15, 2006

SANDOZ 100MG

A076845 001 Jul 14, 2005

150MG

A076834 001 Jul 14, 2005

150MG

A076845 002 Jul 14, 2005

WOCKHARDT LTD 100MG

A201331 001 Aug 30, 2012

150MG

A201331 002 Aug 30, 2012

200MG

A201331 003 Aug 30, 2012

WELLBUTRIN SR

GLAXOSMITHKLINE 50MG

N020358 001 Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE 100MG

N020711 002 May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB 5MG

N021190 001 Dec 20, 2000

7.5MG

N021190 002 Dec 20, 2000

10MG

N021190 003 Dec 20, 2000

15MG

N021190 004 Dec 20, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

+	BRISTOL MYERS SQUIBB	5MG **	N018731 001	Sep 29, 1986
+		10MG **	N018731 002	Sep 29, 1986
+		15MG **	N018731 003	Apr 22, 1996
+		30MG **	N018731 004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

APOTEX

		5MG	A075521 001	Apr 05, 2002
		10MG	A075521 002	Apr 05, 2002
		15MG	A075521 003	Apr 05, 2002

EGIS

		5MG	A075119 001	Mar 14, 2002
		10MG	A075119 002	Mar 14, 2002
		15MG	A075119 003	Jan 23, 2003

IVAX SUB TEVA PHARMS

		5MG **	A075385 001	Mar 01, 2002
		10MG **	A075385 002	Mar 01, 2002
		15MG **	A075385 003	Mar 01, 2002

MYLAN

		5MG	A075467 001	Feb 28, 2002
		10MG	A075467 003	Feb 28, 2002
		15MG	A075467 004	Feb 28, 2002

NESHER PHARMS

		5MG	A075572 001	Feb 27, 2002
		10MG	A075572 002	Feb 27, 2002
		15MG	A075572 003	Feb 27, 2002

OXFORD PHARMS

		5MG	A075388 001	May 09, 2002
		10MG	A075388 002	May 09, 2002
		15MG	A075388 003	May 09, 2002

SANDOZ

		5MG	A075413 001	Mar 19, 2002
		10MG	A075413 002	Mar 19, 2002
		15MG	A075413 003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

	MEDPOINTE PHARM HLC	15MG	A085381 001	
		30MG	A085381 002	
		50MG	A085381 003	
		100MG	A085381 004	

ELIXIR; ORAL

BUTABARB

	ALPHARMA US PHARMS	30MG/5ML	A085873 001	
--	--------------------	----------	-------------	--

BUTABARBITAL SODIUM

	WOCKHARDT	30MG/5ML	A085383 001	
--	-----------	----------	-------------	--

BUTALAN

	LANNETT	33.3MG/5ML	A085880 001	
--	---------	------------	-------------	--

BUTISOL SODIUM

	MEDA PHARMS	30MG/5ML	A085380 001	
--	-------------	----------	-------------	--

SARISOL

	HALSEY	30MG/5ML	A084723 001	
--	--------	----------	-------------	--

TABLET; ORAL

BUTABARBITAL

	BUNDY	30MG	A085550 001	
--	-------	------	-------------	--

BUTABARBITAL SODIUM

	SANDOZ	15MG	A084292 003	Feb 09, 1982
--	--------	------	-------------	--------------

		15MG	A085938 001	
--	--	------	-------------	--

		30MG	A084272 002	
--	--	------	-------------	--

		30MG	A085934 001	
--	--	------	-------------	--

	SOLVAY	16.2MG	A083606 001	
--	--------	--------	-------------	--

		32.4MG	A083898 001	
--	--	--------	-------------	--

		48.6MG	A083897 001	
--	--	--------	-------------	--

		97.2MG	A083896 001	
--	--	--------	-------------	--

	TEVA	15MG	A088632 001	May 18, 1985
--	------	------	-------------	--------------

		30MG	A088631 001	May 01, 1985
--	--	------	-------------	--------------

	WATSON LABS	15MG	A085764 001	
--	-------------	------	-------------	--

		30MG	A085772 001	
--	--	------	-------------	--

	WHITEWORTH TOWN PLSN	15MG	A083325 002	
--	----------------------	------	-------------	--

		30MG	A083337 001	
--	--	------	-------------	--

BUTISOL SODIUM

	MYLAN SPECIALITY LP	15MG	N000793 002	
--	---------------------	------	-------------	--

		50MG	N000793 003	
--	--	------	-------------	--

		100MG	N000793 005	
--	--	-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUTABARBITAL SODIUM

TABLET; ORAL

SARISOL NO. 1				
HALSEY	15MG		A084719	001
SARISOL NO. 2				
HALSEY	30MG		A084719	002
SODIUM BUTABARBITAL				
HIKMA PHARMS	15MG		A085418	001
	30MG		A085432	001
IVAX SUB TEVA PHARMS	15MG		A083484	001
	30MG		A084040	001
LANNETT	15MG		A085849	001
	30MG		A085866	001
	100MG		A085881	001
MARSHALL PHARMA	16.2MG		A083524	001
	32.4MG		A083858	001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN	1%		N021408	001	Oct 17, 2002
-------	----	--	---------	-----	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

PERRIGO PHARMA INTL	2%		N019881	001	Feb 07, 1997
---------------------	----	--	---------	-----	--------------

FEMSTAT

ROCHE PALO	2%		N019215	001	Nov 25, 1985
------------	----	--	---------	-----	--------------

FEMSTAT 3

+ BAYER	2%		N020421	001	Dec 21, 1995
---------	----	--	---------	-----	--------------

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO	100MG		N019359	001	Nov 25, 1985
------------	-------	--	---------	-----	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

BAXTER HLTHCARE CORP	2MG/ML		A075697	001	Oct 23, 2001
----------------------	--------	--	---------	-----	--------------

HIKMA FARMACEUTICA	2MG/ML		A078247	001	Apr 29, 2009
--------------------	--------	--	---------	-----	--------------

HOSPIRA	1MG/ML		A075342	001	Nov 04, 1999
---------	--------	--	---------	-----	--------------

	1MG/ML		A075559	001	Mar 20, 2000
--	--------	--	---------	-----	--------------

	2MG/ML		A075342	002	Nov 04, 1999
--	--------	--	---------	-----	--------------

	2MG/ML		A075559	002	Mar 20, 2000
--	--------	--	---------	-----	--------------

BUTORPHANOL TARTRATE PRESERVATIVE FREE

BAXTER HLTHCARE CORP	1MG/ML		A075695	001	Oct 23, 2001
----------------------	--------	--	---------	-----	--------------

	2MG/ML		A075695	002	Oct 23, 2001
--	--------	--	---------	-----	--------------

HOSPIRA	1MG/ML		A074620	001	Jan 22, 1997
---------	--------	--	---------	-----	--------------

	1MG/ML		A075170	001	Sep 28, 1998
--	--------	--	---------	-----	--------------

	2MG/ML		A074620	002	Jan 22, 1997
--	--------	--	---------	-----	--------------

	2MG/ML		A075170	002	Sep 28, 1998
--	--------	--	---------	-----	--------------

STADOL

APOTHECON	2MG/ML	**		N017857	004
-----------	--------	----	--	---------	-----

STADOL PRESERVATIVE FREE

APOTHECON	1MG/ML	**		N017857	001
-----------	--------	----	--	---------	-----

	2MG/ML	**		N017857	002
--	--------	----	--	---------	-----

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	**		N019890	001	Dec 12, 1991
----------------------	-----------	----	--	---------	-----	--------------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

IMPAX LABS INC	0.5MG		A077843	001	Jul 03, 2007
----------------	-------	--	---------	-----	--------------

DOSTINEX

+ PHARMACIA AND UPJOHN	0.5MG	**		N020664	001	Dec 23, 1996
------------------------	-------	----	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

CAFERGOT

+ NOVARTIS

100MG;2MG **

N009000 002

TABLET;ORAL

CAFERGOT

NOVARTIS

100MG;1MG

N006620 001

WIGRAINE

ORGANON USA INC

100MG;1MG

A086562 001

CALCIFEDIOL

CAPSULE;ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT;TOPICAL

DOVONEX

+ LEO PHARMA AS

0.005% **

N020273 001 Dec 29, 1993

SOLUTION;TOPICAL

DOVONEX

+ LEO PHARM

0.005% **

N020611 001 Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE;INJECTION

CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCIMAR

SANOFI AVENTIS US

200 IU/ML

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

SPRAY, METERED;NASAL

MIACALCIN

+ MYLAN IRELAND LTD

200 IU/SPRAY

N020313 002 Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

UPSHER-SMITH LABS

200 IU/SPRAY

N021406 001 Aug 12, 2005

CALCITRIOL

INJECTABLE;INJECTION

CALCIJEX

+ ABBVIE

0.001MG/ML **

N018874 001 Sep 25, 1986

+

0.002MG/ML **

N018874 002 Sep 25, 1986

CALCITRIOL

AKORN

0.002MG/ML

A078066 002 Jan 29, 2008

FRESENIUS KABI USA

0.001MG/ML

A075836 001 Dec 31, 2002

0.002MG/ML

A075836 002 Dec 31, 2002

FRESENIUS MEDCL

0.001MG/ML

A075766 001 Feb 20, 2003

0.002MG/ML

A075766 002 Feb 20, 2003

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

LUITPOLD

0.001MG/ML

A075746 001 Sep 26, 2003

0.002MG/ML

A075746 002 Sep 26, 2003

ROCKWELL MEDCL

0.001MG/ML

A076206 001 Sep 17, 2003

SAGENT PHARMS

0.001MG/ML

A077102 001 Feb 08, 2006

TEVA PARENTERAL

0.001MG/ML

A075823 001 Mar 31, 2003

0.002MG/ML

A075823 002 Mar 31, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL 333.5MG
667MGN021160 001 Apr 02, 2001
N021160 002 Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

WEST-WARD PHARMS INT 667MG

A077693 001 Jan 30, 2008

PHOSLO

+ FRESENIUS MEDCL 667MG **

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT EQ 500MG BASE, N/A; N/A, 35MG **

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

N021703 012 Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 005 Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 008 Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 007 Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP 3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 009 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

ALCON PHARMS LTD 0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML;
0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML

N022193 001 Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML

N019864 001 Jun 10, 1993

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML

N018271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML

N019867 001 Dec 20, 1993

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML

N018269 002 Jan 17, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001		
-----------------	--	---------	-----	--	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807	001	Aug 26, 1983	
	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807	003	Aug 26, 1983	

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807	002	Aug 26, 1983	
	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807	004	Aug 26, 1983	

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	006	Jan 29, 1986	
---------	---	---------	-----	--------------	--

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	001		
---------	---	---------	-----	--	--

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	003		
---------	--	---------	-----	--	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		
-----------------	---	---------	-----	--	--

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		
-----------------	---	---------	-----	--	--

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	
-----------------	---	---------	-----	--------------	--

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		
-----------------	--	---------	-----	--	--

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	
-----------------	---	---------	-----	--------------	--

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	
-----------------	---	---------	-----	--------------	--

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	
-----------------	---	---------	-----	--------------	--

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982	
-----------------	--	---------	-----	--------------	--

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986	
	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	002		

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983	
---------	--	---------	-----	--------------	--

	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	008	Jan 29, 1986	
--	--	---------	-----	--------------	--

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986	
	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	004		

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994	
-----------	---	---------	-----	--------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS 18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML A020374 002 Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS 18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML A020374 003 Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS 18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML A020374 004 Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;380MG/1 00ML;600MG/100ML N018258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML N018254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML N018256 001

BAXTER HLTHCARE 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML N016695 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 4MG/100ML;4GM/100ML;6MG/100ML;120MG/100 ML;62MG/100ML N019634 002 Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML N017510 001

MILES 20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML N018499 001

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML N019685 005 Oct 17, 1988

20MG/100ML;5GM/100ML;179MG/100ML;600MG/ 100ML;310MG/100ML N019685 006 Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML N019685 007 Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML N019685 003 Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML N019685 001 Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;538MG/100ML;44 8MG/100ML N019395 001 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML;538MG/100ML;44 8MG/100ML N019395 002 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML;538MG/100ML;4 48MG/100ML N019395 003 Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT 16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML; 16.1MG/ML N019399 001 Jun 16, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018899 001	Oct 31, 1983
	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019718 001	Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438 001	
-----------------	--	-------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018725 001	Nov 29, 1982
---------	--	-------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N018721 001	Nov 09, 1982
---------	-------------------------------------	-------------	--------------

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML; 30MG/100ML; 860MG/100ML	N018462 001	
--------	-------------------------------------	-------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019485 001	Oct 24, 1985
B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018023 001	
MILES	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018417 001	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933 001	Aug 29, 1989
-----------------	--	-------------	--------------

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
	EQ 90MG CALCIUM/5ML	A083159 001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470 001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML	N016847 001	
---------------	--	-------------	--

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML; 140.1MG/ML; 461.8MG/ML	N017506 001	
---------------	-----------------------------------	-------------	--

CANDICIDIN

OINTMENT; VAGINAL

VANOVID

SANOFI AVENTIS US	0.6MG/GM	A061596 001	
-------------------	----------	-------------	--

TABLET; VAGINAL

VANOVID

SANOFI AVENTIS US	3MG	A061613 001	
-------------------	-----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRIL

TABLET; ORAL

CAPOTEN

+	PAR PHARM	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995

CAPTOPRIL

APOTEX

		12.5MG	A074737 001	Oct 28, 1998
		25MG	A074737 002	Oct 28, 1998
		50MG	A074737 003	Oct 28, 1998
		100MG	A074737 004	Oct 28, 1998

APOTHECON

		12.5MG	A074472 001	Mar 31, 1995
		25MG	A074472 002	Mar 31, 1995
		50MG	A074472 003	Mar 31, 1995
		100MG	A074472 004	Mar 31, 1995

BOSCOGEN

		12.5MG	A074677 004	May 30, 1997
		25MG	A074677 002	May 30, 1997
		50MG	A074677 001	May 30, 1997
		100MG	A074677 003	May 30, 1997

DAVA PHARMS INC

		12.5MG	A074423 001	Feb 13, 1996
		25MG	A074423 002	Feb 13, 1996
		50MG	A074423 003	Feb 13, 1996
		100MG	A074423 004	Feb 13, 1996

EGIS PHARMS

		12.5MG	A074748 004	May 29, 1997
		25MG	A074748 002	May 29, 1997
		50MG	A074748 001	May 29, 1997
		100MG	A074748 003	May 29, 1997

FOSUN PHARMA

		12.5MG	A074363 001	Nov 09, 1995
		25MG	A074363 002	Nov 09, 1995
		50MG	A074363 003	Nov 09, 1995
		100MG	A074363 004	Nov 09, 1995

G AND W LABS INC

		12.5MG	A074433 001	Feb 13, 1996
		12.5MG	A074462 001	Feb 13, 1996
		12.5MG	A074483 001	Feb 13, 1996
		12.5MG	A074590 004	Aug 30, 1996
		25MG	A074433 002	Feb 13, 1996
		25MG	A074462 002	Feb 13, 1996
		25MG	A074483 002	Feb 13, 1996
		25MG	A074590 002	Aug 30, 1996
		50MG	A074433 003	Feb 13, 1996
		50MG	A074462 003	Feb 13, 1996
		50MG	A074483 003	Feb 13, 1996
		50MG	A074590 001	Aug 30, 1996
		100MG	A074433 004	Feb 13, 1996
		100MG	A074462 004	Feb 13, 1996
		100MG	A074483 004	Feb 13, 1996
		100MG	A074590 003	Aug 30, 1996

PAR PHARM

		12.5MG	A074493 001	Feb 13, 1996
		25MG	A074493 002	Feb 13, 1996
		50MG	A074493 003	Feb 13, 1996
		100MG	A074493 004	Feb 13, 1996

PUREPAC PHARM

		12.5MG	A074640 001	Mar 31, 1997
		25MG	A074640 002	Mar 31, 1997
		50MG	A074640 003	Mar 31, 1997
		100MG	A074640 004	Mar 31, 1997

SANDOZ

		12.5MG	A074481 001	Feb 13, 1996
		12.5MG	A074519 001	Feb 13, 1996
		25MG	A074481 002	Feb 13, 1996
		25MG	A074519 002	Feb 13, 1996
		50MG	A074481 003	Feb 13, 1996
		50MG	A074519 003	Feb 13, 1996
		100MG	A074481 004	Feb 13, 1996
		100MG	A074519 004	Feb 13, 1996

VINTAGE PHARMS LLC

		12.5MG	A074418 001	Feb 13, 1996
		25MG	A074418 002	Feb 13, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRILTABLET; ORAL
CAPTOPRIL

	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
WATSON LABS	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15			
+ APOTHECON	25MG;15MG **	N018709 001	Oct 12, 1984
CAPOZIDE 25/25			
+ APOTHECON	25MG;25MG **	N018709 002	Oct 12, 1984
CAPOZIDE 50/15			
+ APOTHECON	50MG;15MG **	N018709 004	Oct 12, 1984
CAPOZIDE 50/25			
+ APOTHECON	50MG;25MG **	N018709 003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998
	25MG;25MG	A075055 002	Jun 18, 1998
	50MG;15MG	A075055 004	Jun 18, 1998
	50MG;25MG	A075055 003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG	A074788 001	Dec 29, 1997
	25MG;25MG	A074788 002	Dec 29, 1997
	50MG;15MG	A074788 004	Dec 29, 1997
	50MG;25MG	A074788 003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832 001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL			
PHARMAFAIR	0.01%	A070292 001	May 21, 1986
CARBASTAT			
NOVARTIS	0.01%	A073677 001	Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE			
TARO	100MG/5ML	A075875 001	Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE			
ACTAVIS ELIZABETH	200MG	A071696 001	Nov 09, 1987
INWOOD LABS	200MG	A070231 001	Aug 14, 1986
PLIVA	200MG	A071479 001	Jul 24, 1987
USL PHARMA	200MG	A070300 001	May 15, 1986
WARNER CHILCOTT	200MG	A070429 001	Jan 02, 1987
TERIL			
TARO	200MG	A076525 001	Sep 26, 2003
CARBAMAZEPINE			
JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN			
ROERIG	EQ 1GM BASE/VIAL	N050306 001	
	EQ 2GM BASE/VIAL	N050306 004	
	EQ 5GM BASE/VIAL	N050306 002	
	EQ 10GM BASE/VIAL	N050306 006	
	EQ 30GM BASE/VIAL	N050306 007	
PYOPEN			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001	
	EQ 2GM BASE/VIAL	N050298 002	
	EQ 5GM BASE/VIAL	N050298 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBENICILLIN DISODIUMINJECTABLE; INJECTION
PYOPENEQ 10GM BASE/VIAL N050298 006
EQ 20GM BASE/VIAL N050298 007CARBENICILLIN INDANYL SODIUMTABLET; ORAL
GEOCILLIN

PFIZER EQ 382MG BASE N050435 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

IDT AUSTRALIA LTD	10MG;100MG	A073587 002	Jun 29, 1995
	25MG;100MG	A073587 001	Jun 29, 1995
	25MG;250MG	A073587 003	Jun 29, 1995
SCS	10MG;100MG	A074080 001	Mar 25, 1994
	25MG;100MG	A074080 002	Mar 25, 1994
	25MG;250MG	A074080 003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381 001	Sep 28, 1993
	25MG;100MG	A073382 001	Sep 28, 1993
	25MG;250MG	A073383 001	Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM 50MG;200MG A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY	10MG;100MG	A076643 001	Jun 10, 2005
	25MG;100MG	A076643 002	Jun 10, 2005
	25MG;250MG	A076643 003	Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010
	25MG;100MG	A090631 002	Jun 08, 2010
	25MG;250MG	A090631 003	Jun 08, 2010

PARCOPA

UCB INC	10MG;100MG **	A076699 001	Aug 27, 2004
	25MG;100MG **	A076699 002	Aug 27, 2004
	25MG;250MG **	A076699 003	Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

+ MCNEIL 4MG/5ML ** N008955 001

TABLET; ORAL

CLISTIN

+ ORTHO MCNEIL PHARM 4MG ** N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006
	150MG/VIAL	A077383 002	Jan 27, 2006
	450MG/VIAL	A077383 003	Jan 27, 2006
FRESENIUS KABI USA	50MG/VIAL	A076235 001	Oct 14, 2004
	150MG/VIAL	A076235 002	Oct 14, 2004
	450MG/VIAL	A076235 003	Oct 14, 2004
HOSPIRA	50MG/VIAL	A076473 001	Oct 27, 2004
	150MG/VIAL	A076473 002	Oct 27, 2004
	450MG/VIAL	A076473 003	Oct 27, 2004
MYLAN LABS LTD	50MG/VIAL	A091510 001	May 29, 2012
	150MG/VIAL	A091510 002	May 29, 2012
	450MG/VIAL	A091510 003	May 29, 2012
PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004
	150MG/VIAL	A076602 002	Nov 16, 2004
	450MG/VIAL	A076602 003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005
	150MG/VIAL	A076959 002	Mar 18, 2005
	450MG/VIAL	A076959 003	Mar 18, 2005
WATSON LABS TEVA	50MG/VIAL	A076162 001	Oct 14, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	150MG/VIAL	A076162 002	Oct 14, 2004
	450MG/VIAL	A076162 003	Oct 14, 2004
WEST-WARD PHARMS INT	50MG/VIAL	A076099 001	Oct 14, 2004
	150MG/VIAL	A076099 002	Oct 14, 2004
	450MG/VIAL	A076099 003	Oct 14, 2004
PARAPLATIN			
+	CORDEN PHARMA	50MG/VIAL **	N019880 001
+		150MG/VIAL **	N019880 002
+		450MG/VIAL **	N019880 003

INJECTABLE; IV (INFUSION)

CARBOPLATIN

ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012
	150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012
	450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012
	600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012
FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389 001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389 002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389 003	Mar 30, 2007
PARAPLATIN			
+	CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452 001
+		150MG/15ML (10MG/ML) **	N020452 002
+		450MG/45ML (10MG/ML) **	N020452 003
+		600MG/60ML (10MG/ML) **	N020452 004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MYLAN SPECIALITY LP	250MG	N011792 003	
---------------------	-------	-------------	--

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421 001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397 001	Sep 21, 2000
OXFORD PHARMS	350MG	A040188 001	Mar 07, 1997
PIONEER PHARMS	350MG	A089390 001	Oct 13, 1988
SANDOZ	350MG	A081025 001	Apr 13, 1989
	350MG	A089566 001	Aug 30, 1988
SUN PHARM INDS LTD	350MG	A040755 001	Feb 27, 2007
WATSON LABS	350MG	A040152 001	Dec 03, 1996
	350MG	A085433 001	
WATSON LABS TEVA	350MG	A086179 001	
RELA			
SCHERING	350MG	N012155 001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173 001	
--------------	---------	-------------	--

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768 001	
	25MG	N012768 002	
	50MG	N012768 004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550 002	Dec 31, 1987
	150MG	N018550 003	Dec 31, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC

1%

A076097 001 Feb 06, 2002

OCUPRESS

+ NOVARTIS

1%

N019972 001 May 23, 1990

TABLET;ORAL

CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET;ORAL

CARVEDILOL

HIKMA

3.125MG

A077887 001 Sep 07, 2007

6.25MG

A077887 002 Sep 07, 2007

12.5MG

A077887 003 Sep 07, 2007

25MG

A077887 004 Sep 07, 2007

PLIVA HRVATSKA DOO

3.125MG

A078240 001 Oct 30, 2007

6.25MG

A078240 002 Oct 30, 2007

12.5MG

A078240 003 Oct 30, 2007

25MG

A078240 004 Oct 30, 2007

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

CEFACLOR

CAPSULE;ORAL

CECLOR

+ LILLY

EQ 250MG BASE **

N050521 001

+

EQ 500MG BASE **

N050521 002

CEFACLOR

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

WATSON LABS INC

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

FOR SUSPENSION;ORAL

CECLOR

+ LILLY

EQ 125MG BASE/5ML **

N050522 001

+

EQ 250MG BASE/5ML **

N050522 002

CEFACLOR

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

WATSON LABS INC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFACTOR

FOR SUSPENSION;ORAL

CEFACTOR

EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD

EQ 125MG BASE	A065092	001	Dec 22, 2003
EQ 187MG BASE	A065092	002	Dec 22, 2003
EQ 250MG BASE	A065092	003	Dec 22, 2003
EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY

EQ 375MG BASE	N050673	001	Jun 28, 1996
EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFACTOR

WORLD GEN

EQ 500MG BASE	A065057	001	Jan 05, 2001
---------------	---------	-----	--------------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS

EQ 500MG BASE	A062766	001	Mar 03, 1987
---------------	---------	-----	--------------

PUREPAC PHARM

EQ 500MG BASE	A063017	001	Jan 05, 1989
---------------	---------	-----	--------------

RANBAXY LABS LTD

EQ 500MG BASE	A065015	001	Jun 22, 1999
---------------	---------	-----	--------------

SANDOZ

EQ 500MG BASE	A062291	001	
---------------	---------	-----	--

TEVA

EQ 500MG BASE	A062695	001	Feb 10, 1989
---------------	---------	-----	--------------

DURICEF

WARNER CHILCOTT

EQ 250MG BASE	N050512	002	
---------------	---------	-----	--

+

EQ 500MG BASE **	N050512	001	
------------------	---------	-----	--

ULTRACEF

BRISTOL

EQ 500MG BASE	A062378	001	Mar 16, 1982
---------------	---------	-----	--------------

FOR SUSPENSION;ORAL

CEFADROXIL

ANI PHARMS INC

EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006
-------------------	---------	-----	--------------

APOTHECON

EQ 125MG BASE/5ML	A062334	001	
-------------------	---------	-----	--

EQ 250MG BASE/5ML	A062334	002	
-------------------	---------	-----	--

EQ 500MG BASE/5ML	A062334	003	
-------------------	---------	-----	--

SUN PHARM INDS LTD

EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003
-------------------	---------	-----	--------------

DURICEF

+

WARNER CHILCOTT

EQ 125MG BASE/5ML **	N050527	002	
----------------------	---------	-----	--

+

EQ 250MG BASE/5ML **	N050527	003	
----------------------	---------	-----	--

+

EQ 500MG BASE/5ML **	N050527	001	
----------------------	---------	-----	--

ULTRACEF

BRISTOL

EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
-------------------	---------	-----	--------------

EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
-------------------	---------	-----	--------------

EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982
-------------------	---------	-----	--------------

TABLET;ORAL

CEFADROXIL

RANBAXY

EQ 1GM BASE	A065018	001	Apr 23, 1999
-------------	---------	-----	--------------

DURICEF

+

WARNER CHILCOTT

EQ 1GM BASE **	N050528	001	
----------------	---------	-----	--

ULTRACEF

APOTHECON

EQ 1GM BASE	A062390	001	Jun 10, 1982
-------------	---------	-----	--------------

BRISTOL

EQ 1GM BASE	A062408	001	Aug 31, 1982
-------------	---------	-----	--------------

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION

MANDOL

LILLY

EQ 500MG BASE/VIAL	N050504	001	
--------------------	---------	-----	--

EQ 1GM BASE/VIAL	A062560	001	Sep 10, 1985
------------------	---------	-----	--------------

EQ 1GM BASE/VIAL	N050504	002	
------------------	---------	-----	--

EQ 2GM BASE/VIAL	A062560	002	Sep 10, 1985
------------------	---------	-----	--------------

EQ 2GM BASE/VIAL	N050504	003	
------------------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFAMANDOLE NAFATEINJECTABLE; INJECTION
MANDOL

EQ 10GM BASE/VIAL N050504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
---------	--------------------	-------------	--------------

CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008

BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988

CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009

FACTA FARMA	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991
	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991
	EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991

FRESENIUS KABI USA	EQ 20GM BASE/VIAL	A063209 002	Apr 30, 1999
	EQ 500MG BASE/VIAL **	A064169 001	Aug 14, 1998
	EQ 1GM BASE/VIAL **	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998

GLAXOSMITHKLINE	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
-----------------	-------------------	-------------	--------------

STERI PHARMA	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
--------------	------------------	-------------	--------------

TEVA PHARMS	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989

WATSON LABS INC	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989

WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989

WEST-WARD PHARMS INT	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988

WEST-WARD PHARMS INT	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988

WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807 006	Jan 12, 1988
----------------------	--------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
----------------------	------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
----------------------	------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
----------------------	-------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
----------------------	-------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
----------------------	--------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
----------------------	--------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
----------------------	------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
----------------------	------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
----------------------	-------------------	-------------	--------------

WEST-WARD PHARMS INT	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
----------------------	-------------------	-------------	--------------

KEFZOL

ACS DOBFAR	EQ 250MG BASE/VIAL	A061773 001	
	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987

LILLY	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFDINIR

CAPSULE; ORAL

OMNICEF

+ ABBVIE

300MG **

N050739 001 Dec 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

+ ABBVIE

125MG/5ML **

N050749 001 Dec 04, 1997

+

250MG/5ML **

N050749 002 Jul 29, 2004

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG

N021222 001 Aug 29, 2001

400MG

N021222 002 Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+ LEDERLE

100MG/5ML **

N050622 001 Apr 28, 1989

TABLET; ORAL

SUPRAX

+ LEDERLE

200MG **

N050621 001 Apr 28, 1989

+

400MG **

N050621 002 Apr 28, 1989

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

+ PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL **

N050637 001 Dec 11, 1989

+

EQ 2GM BASE/VIAL **

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

+ PHARMACIA AND UPJOHN

EQ 20MG BASE/ML **

N050683 001 Dec 29, 1992

+

EQ 40MG BASE/ML **

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

EQ 40MG BASE/ML

N050613 001 Jul 23, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM				
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
CLAFORAN				
SANOVI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
	EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

TELIGENT	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER				
TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988
--------	------------------	---------	-----	--------------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
	EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
	EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
	EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
MEFOXIN				
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+	EQ 1GM BASE/VIAL **	N050517	001	
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+	EQ 2GM BASE/VIAL **	N050517	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

+		EQ 10GM BASE/VIAL **	N050517	003	
	MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
	MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST

	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD

	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
	EQ 100MG BASE/5ML	A065082	002	May 31, 2002

VANTIN

+ PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML **

+

EQ 100MG BASE/5ML **

TABLET; ORAL

BANAN

SANKYO

	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD

	EQ 100MG BASE	A065083	001	Aug 20, 2003
	EQ 200MG BASE	A065083	002	Aug 20, 2003

VANTIN

+ PHARMACIA AND UPJOHN

EQ 100MG BASE **

+

EQ 200MG BASE **

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

	125MG/5ML	A065202	001	Jun 30, 2006
	250MG/5ML	A065202	002	Jun 30, 2006

CEFZIL

+ CORDEN PHARMA

125MG/5ML

+

250MG/5ML

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD

	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006

CEFZIL

+ CORDEN PHARMA

250MG

+

500MG

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD

	500MG/VIAL	A065481	001	May 28, 2010
	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE

	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE

	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTAZIDIMEINJECTABLE; INJECTION
PENTACEF

2GM/VIAL	A063322	002	Nov 07, 1995
2GM/VIAL	A064006	002	Mar 31, 1992
6GM/VIAL	A064008	001	Mar 31, 1992
10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY

1GM/VIAL	A062655	001	Nov 20, 1985
2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY

1GM/VIAL	A062739	001	Jul 10, 1986
2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

TELIGENT

EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
-----------------	---------	-----	--------------

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

PERNIX THERAP

EQ 400MG BASE	N050685	002	Dec 20, 1995
---------------	---------	-----	--------------

FOR SUSPENSION; ORAL

CEDAX

+ PERNIX THERAP

EQ 90MG BASE/5ML **	N050686	001	Dec 20, 1995
---------------------	---------	-----	--------------

+

EQ 180MG BASE/5ML **	N050686	002	Dec 20, 1995
----------------------	---------	-----	--------------

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS

EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AGILA SPECLTS

EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
-------------------	---------	-----	--------------

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
-------------------	---------	-----	--------------

FACTA FARMA

EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007
-------------------	---------	-----	--------------

FRESENIUS KABI USA

EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006
-------------------	---------	-----	--------------

HOSPIRA INC

EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005
------------------	---------	-----	--------------

EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012
------------------	---------	-----	--------------

EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005
------------------	---------	-----	--------------

EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012
------------------	---------	-----	--------------

TEVA

EQ 10GM BASE/VIAL	A065274	001	May 01, 2006
-------------------	---------	-----	--------------

ROCEPHIN

HOFFMANN LA ROCHE

EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
--------------------	---------	-----	--------------

EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
--------------------	---------	-----	--------------

EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993
--------------------	---------	-----	--------------

EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
------------------	---------	-----	--------------

EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993
------------------	---------	-----	--------------

EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
------------------	---------	-----	--------------

+

EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
-------------------	---------	-----	--------------

ROCHE

EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
--------------------	---------	-----	--------------

EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
--------------------	---------	-----	--------------

EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007

ROCEPHIN

+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
+		EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
+		EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
+		EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFUROXIME AXETIL

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SANDOZ	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFUROXIME SODIUM

INJECTABLE; INJECTION

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
-------	--------------------	-------------	--------------

ZINACEF IN PLASTIC CONTAINER

TELIGENT	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
----------	-----------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986
------------	--------------------	-------------	--------------

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986
-------	--------------------	-------------	--------------

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986
-------	--------------------	-------------	--------------

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988
	EQ 500MG BASE	A063063 002	Sep 29, 1989
	EQ 500MG BASE	A063186 002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773 001	Jun 26, 1987
	EQ 500MG BASE	A062775 001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118 001	
	EQ 500MG BASE	A062118 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	
	EQ 500MG BASE	A061969 002	
PUREPAC PHARM	EQ 250MG BASE	A062809 001	Apr 22, 1987
	EQ 500MG BASE	A062809 002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870 001	Mar 17, 1988
	EQ 500MG BASE	A062869 001	Mar 17, 1988
SUN PHARM INDS LTD	EQ 250MG BASE	A065007 001	Sep 16, 1999
	EQ 500MG BASE	A065007 002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988

KEFLEX

+ PRAGMA PHARMS LLC	EQ 333MG BASE **	N050405 004	May 12, 2006
---------------------	------------------	-------------	--------------

FOR SUSPENSION; ORAL

CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **	A062117 001	
	EQ 125MG BASE/5ML **	A062117 002	
	EQ 250MG BASE/5ML **	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987

KEFLEX

+ PRAGMA PHARMS LLC	EQ 100MG BASE/ML **	N050406 003	
+	EQ 125MG BASE/5ML **	N050406 001	
+	EQ 250MG BASE/5ML **	N050406 002	

TABLET;ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988

KEFLET

LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE;ORAL

KAFOCIN

LILLY	250MG	N050219 001	
-------	-------	-------------	--

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730 002	Mar 05, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 002	Jan 31, 1984
KEFLIN			
LILLY	EQ 1GM BASE/VIAL	N050482 001	
	EQ 2GM BASE/VIAL	N050482 002	
	EQ 4GM BASE/VIAL	N050482 003	
	EQ 20GM BASE/VIAL	N050482 007	
KEFLIN IN PLASTIC CONTAINER			
LILLY	EQ 1GM BASE/VIAL	A062549 001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549 002	Sep 10, 1985
SEFFIN			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435 001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435 002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435 003	Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	A062961 001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446 005	
	EQ 1GM BASE/VIAL	A061769 001	
	EQ 1GM BASE/VIAL	A062724 001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961 002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446 001	
	EQ 2GM BASE/VIAL	A061769 002	
	EQ 2GM BASE/VIAL	A062724 002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961 003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446 002	
	EQ 4GM BASE/VIAL	A061769 003	
	EQ 4GM BASE/VIAL	A062961 004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446 003	
	EQ 20GM BASE/VIAL	N050446 004	
CEPHAPIRIN SODIUM			
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723 001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723 002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723 003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723 005	Nov 17, 1986
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859 001	
	500MG	A061859 002	
CEPHRADINE			
BARR	250MG	A062850 001	Apr 22, 1988
	500MG	A062851 001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762 001	Mar 06, 1987
	500MG	A062762 002	Mar 06, 1987
TEVA	250MG	A062683 001	Jan 09, 1987
	500MG	A062683 002	Jan 09, 1987
VITARINE	250MG	A062813 001	Feb 25, 1988
	500MG	A062813 002	Feb 25, 1988
VELOSEF			
APOTHECON	250MG	A061764 001	
	500MG	A061764 002	
VELOSEF '250'			
ERSANA	250MG	N050548 001	
VELOSEF '500'			
ERSANA	500MG	N050548 002	
FOR SUSPENSION; ORAL			
ANSPOR			
GLAXOSMITHKLINE	125MG/5ML	A061866 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHRADINE

FOR SUSPENSION; ORAL

ANSPOR

250MG/5ML

A061866 002

CEPHRADINE

BARR

125MG/5ML

A062858 001 May 19, 1988

250MG/5ML

A062859 001 May 19, 1988

TEVA

125MG/5ML

A062693 001 Jan 09, 1987

250MG/5ML

A062693 002 Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML

A061763 001

VELOSEF '250'

APOTHECON

250MG/5ML

A061763 002

INJECTABLE; INJECTION

VELOSEF

APOTHECON

250MG/VIAL

A061976 001

500MG/VIAL

A061976 002

1GM/VIAL

A061976 004

2GM/VIAL

A061976 003

4GM/VIAL

A061976 005

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB 1GM

N050530 001

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

0.8MG

N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 5MG/5ML

A078617 001 Feb 02, 2010

APOTEX INC 5MG/5ML

A078412 001 Jun 18, 2008

AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009

RANBAXY LABS LTD 5MG/5ML

A077472 001 Jun 18, 2008

WOCKHARDT 5MG/5ML

A078757 001 Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 002 May 09, 2008

APOTEX INC 5MG/5ML

A090188 002 Apr 22, 2008

CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 002 Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 001 May 09, 2008

APOTEX INC 5MG/5ML

A090188 001 Apr 22, 2008

CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 001 Apr 24, 2008

ZYRTEC

J AND J CONSUMER INC 5MG/5ML **

N020346 001 Sep 27, 1996

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH 5MG

A078615 003 Dec 28, 2007

10MG

A078615 004 Dec 28, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG

A077631 004 Jan 11, 2008

10MG

A077631 003 Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG

A077631 001 Jan 11, 2008

10MG

A077631 002 Jan 11, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG **

N021621 003 Nov 16, 2007

+ 10MG **

N021621 004 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG **

N021621 005 Nov 16, 2007

+ 10MG **

N021621 006 Nov 16, 2007

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CHENODIOL

TABLET;ORAL

CHENIX

+ LEADIANT BIOSCI INC 250MG **

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL

ULO

3M 25MG/5ML

N012126 001

CHLORAMPHENICOL

CREAM;TOPICAL

CHLOROMYCETIN

PARKE DAVIS 1%

N050183 001

FOR SOLUTION;OPHTHALMIC

CHLOROMYCETIN

PARKEDALE 25MG/VIAL

N050143 001

INJECTABLE;INJECTION

CHLOROMYCETIN

PARKE DAVIS 250MG/ML

N050153 001

OINTMENT;OPHTHALMIC

CHLORAMPHENICOL

ALTANA 1%

A060133 001

CHLOROFAIR

PHARMAFAIR 1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1%

A061187 001

ECONOCHLOR

ALCON 1%

A061648 001

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL

AKORN 0.5%

A062042 001

ALCON 0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5%

N050091 001

ECONOCHLOR

ALCON 0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE 0.5%

A061220 001

OPTOMYCIN

OPTOPICS 0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN

PARKEDALE 0.5%

N050205 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

+ PARKEDALE EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL

A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS 10MG/GM; 666 UNITS/GM; 1 UNITS/GM

N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCIN

PARKE DAVIS 1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN 1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL 30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL 5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT 5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE 5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT 5MG

A087525 001 Jan 07, 1982

10MG

A087524 001 Jan 07, 1982

25MG

A087512 001 Jan 07, 1982

FERRANTE 5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY 5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

IMPAX LABS 5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS 5MG

A083741 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A083742	001	
	25MG	A083570	001	
LEDERLE	5MG	A086892	001	
	5MG	A087234	001	
	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
UPSHER-SMITH LABS	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
USL PHARMA	5MG	A084644	001	
	10MG	A084623	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	
INJECTABLE; INJECTION				
LIBRIUM				
VALEANT PHARMS LLC	100MG/AMP	N012301	001	
<u>CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED</u>				
TABLET; ORAL				
MENRIUM 10-4				
ROCHE	10MG; 0.4MG	N014740	006	
MENRIUM 5-2				
ROCHE	5MG; 0.2MG	N014740	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 5-4

ROCHE

5MG;0.4MG

N014740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

APOTEX INC

0.12%

A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTTRIUM

2.5%

N019421 001 Dec 17, 1985

MICRODERM

J AND J

4%

A072255 001 Apr 15, 1991

PREVACARE R

J AND J

0.5%

A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL

4%

A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

+ MOLNLYCKE HLTH

4% **

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

PHARMASEAL SCRUB CARE

CAREFUSION 2200

4%

N019793 001 Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US

EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

+ SANOFI AVENTIS US

EQ 300MG BASE

N006002 001

CHLOROQUINE PHOSPHATE

IMPAX LABS

EQ 150MG BASE

A080880 001

EQ 300MG BASE

A040516 001 Aug 29, 2003

MD PHARM

EQ 150MG BASE

A087228 001

PUREPAC PHARM

EQ 150MG BASE

A080886 001

TEVA

EQ 150MG BASE

A087504 001 Jan 13, 1982

WATSON LABS

EQ 150MG BASE

A087979 001 Dec 21, 1982

EQ 300MG BASE

A088030 001 Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US

EQ 300MG BASE;EQ 45MG BASE

N014860 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569	001	
HIKMA INTL PHARMS	250MG	A086028	001	Jul 14, 1982
	500MG	A087736	001	Jul 14, 1982
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
+ OAK PHARMS AKORN	250MG **	N011145	004	
+	500MG **	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK	150MG;250MG	N016016	001	
-------	-------------	---------	-----	--

ALDOCLOR-250

MERCK	250MG;250MG	N016016	002	
-------	-------------	---------	-----	--

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM	150MG;250MG	A070783	001	Nov 06, 1987
	250MG;250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS	250MG;0.125MG	A088557	001	Dec 22, 1983
	500MG;0.125MG	A088365	001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	250MG;0.125MG	A084853	001	
	500MG;0.125MG	A088151	001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN	250MG;0.125MG	A087744	001	May 06, 1982
	500MG;0.125MG	A087745	001	May 06, 1982

DIUPRES-250

MERCK	250MG;0.125MG	N011635	003	Aug 26, 1987
-------	---------------	---------	-----	--------------

DIUPRES-500

MERCK	500MG;0.125MG	N011635	006	Aug 26, 1987
-------	---------------	---------	-----	--------------

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS	12MG	A084652	001	
-------------------	------	---------	-----	--

TACE

SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	

CHLOROXYLINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB	2%	N017594	001	
-----------------	----	---------	-----	--

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PAMLAB LLC	400MG	N014217	002	
------------	-------	---------	-----	--

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
---------------------	------	---------	-----	--------------

TELDRIN

GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH	10MG/ML	N008826	001
	100MG/ML	N008794	001

CHLORPHENIRAMINE MALEATE

BEL MAR	10MG/ML	A080821	001
ELKINS SINN	10MG/ML	A080797	001
WATSON LABS	10MG/ML	A083593	001
	10MG/ML	A086096	001
	100MG/ML	A086095	001

PYRIDAMAL 100

BEL MAR	100MG/ML	A083733	001
---------	----------	---------	-----

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING	2MG/5ML	N006921	006
----------	---------	---------	-----

CHLORPHENIRAMINE MALEATE

PHARM ASSOC	2MG/5ML	A087520	001 Feb 10, 1982
-------------	---------	---------	------------------

TABLET; ORAL

ANTAGONATE

BAYER PHARMS	4MG	A083381	001
--------------	-----	---------	-----

CHLOR-TRIMETON

SCHERING	4MG	N006921	002
----------	-----	---------	-----

CHLORPHENIRAMINE MALEATE

ANABOLIC	4MG	A083078	001
AUROLIFE PHARMA LLC	4MG	A080961	001
BELL PHARMA	4MG	A083062	001
ELKINS SINN	4MG	A080938	001
IMPAX LABS	4MG	A080809	001
IVAX SUB TEVA PHARMS	4MG	A080779	001
KV PHARM	4MG	A087164	001
LEDERLE	4MG	A086941	001
NEWTRON PHARMS	4MG	A086519	001
PANRAY	4MG	A083243	001
PHARMAVITE	4MG	A085104	001
PHARMERAL	4MG	A083753	001
PIONEER PHARMS	4MG	A088556	001 Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001
PVT FORM	4MG	A080786	001
ROXANE	4MG	A080626	001
SUN PHARM INDUSTRIES	4MG	A080700	001
VITARINE	4MG	A085837	001
WATSON LABS	4MG	A080696	001
	4MG	A080791	001
	4MG	A085139	001
WEST WARD	4MG	A083787	001

KLOROMIN

HALSEY	4MG	A083629	001
--------	-----	---------	-----

PHENETRON

LANNETT	4MG	A080846	001
---------	-----	---------	-----

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

BAYER HEALTHCARE LLC	8MG	N007638	001
----------------------	-----	---------	-----

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002 Nov 18, 1994
------	------	---------	------------------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

SPRIASO LLC	8MG; 54.3MG	N206323	001 Jun 22, 2015
-------------	-------------	---------	------------------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001 Jan 27, 2015
-----------------	------------------	---------	------------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

TRIS PHARMA INC 4MG/5ML;5MG/5ML;60MG/5ML A203838 001 Nov 26, 2014

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

COLD CAPSULE IV

GRAHAM DM 12MG;75MG N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG;75MG N018794 001 Apr 23, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIAMINIC-12

NOVARTIS 12MG;75MG N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA 12MG;120MG N018935 001 Apr 15, 1985

ISOCLOR

FISONS 8MG;120MG N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG;120MG N019428 001 Aug 02, 1988

GRAHAM DM 8MG;120MG N018844 001 Mar 20, 1985

12MG;120MG N018843 001 Mar 18, 1985

KV PHARM 12MG;120MG A071455 001 Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC 8MG;120MG N018397 001

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

CHLORPHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PRE-SATE

PARKE DAVIS EQ 65MG BASE N014696 001

CHLORPROMAZINE

SUPPOSITORY;RECTAL

THORAZINE

+ GLAXOSMITHKLINE 25MG ** N009149 024

+ 100MG ** N009149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

THORAZINE

GLAXOSMITHKLINE 30MG N011120 016

75MG N011120 017

150MG N011120 018

200MG N011120 019

300MG N011120 020

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 100MG/ML A086863 001

PHARM ASSOC 30MG/ML A040231 001 Dec 30, 1999

100MG/ML A040224 001 Jan 26, 1999

WOCKHARDT 30MG/ML A087032 001 Jul 08, 1982

100MG/ML A087053 001

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

CYCLE PHARMS LTD 30MG/ML A088157 001 Apr 27, 1983

100MG/ML A088158 001 Apr 27, 1983

SONAZINE

SANDOZ 30MG/ML A080983 004

100MG/ML A080983 005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THORAZINE

+	GLAXOSMITHKLINE	30MG/ML **	N009149	032
+		100MG/ML **	N009149	043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	ABRAXIS PHARM	25MG/ML	A084911	001	
	MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
	WATSON LABS	25MG/ML	A080365	001	
		25MG/ML	A085591	001	
	WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

+	GLAXOSMITHKLINE	25MG/ML **	N009149	011
---	-----------------	------------	---------	-----

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	ALPHARMA US PHARMS	10MG/5ML	A086712	001
--	--------------------	----------	---------	-----

SONAZINE

	SANDOZ	10MG/5ML	A083040	001
--	--------	----------	---------	-----

THORAZINE

+	GLAXOSMITHKLINE	10MG/5ML **	N009149	022
---	-----------------	-------------	---------	-----

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	ABBOTT	10MG	A084414	001	
		25MG	A084415	001	
		50MG	A084411	001	
		100MG	A084412	001	
		200MG	A084413	001	
	CYCLE PHARMS LTD	10MG	A085331	001	
		25MG	A085331	002	
		50MG	A085331	003	
		100MG	A085331	004	
		200MG	A085331	005	
	IVAX SUB TEVA PHARMS	10MG	A083549	001	
		25MG	A083549	002	
		50MG	A083549	003	
		100MG	A083574	001	
		200MG	A083575	001	
	KV PHARM	10MG	A085750	002	Jan 04, 1982
		25MG	A085751	001	
		50MG	A085484	001	
		100MG	A085752	001	
		200MG	A085748	002	Jan 04, 1982
	LEDERLE	10MG	A084803	001	
		25MG	A084801	001	
		50MG	A084800	001	
		100MG	A084789	001	
		200MG	A084802	001	
	PUREPAC PHARM	10MG	A080403	004	
		25MG	A080403	001	
		50MG	A080403	002	
		100MG	A080403	003	
		200MG	A080403	005	
	PVT FORM	25MG	A080340	001	
		50MG	A080340	002	
		200MG	A080340	003	
	SANDOZ	10MG **	A080439	001	
		25MG **	A080439	002	
		50MG **	A080439	003	
		100MG **	A080439	004	
		200MG **	A080439	005	
	VANGARD	10MG	A088038	001	Aug 16, 1982
		25MG	A087645	001	
		50MG	A087646	001	
	WATSON LABS	10MG	A085959	001	
		25MG	A085956	001	
		50MG	A085960	001	
		100MG	A085957	001	
		200MG	A085958	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A089446 001	Nov 17, 1986
	250MG	A087353 001	
	250MG	A088813 001	Oct 19, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A089447 001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852 001	Sep 26, 1984
	250MG	A088826 001	Sep 26, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149 002	
-------	-----------	-------------	--

INJECTABLE; INJECTION

TARACTAN

ROCHE	12.5MG/ML	N012487 001	
-------	-----------	-------------	--

TABLET; ORAL

TARACTAN

ROCHE	10MG	N012486 005	
	25MG	N012486 004	
	50MG	N012486 003	
	100MG	N012486 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC

AUREOMYCIN

LEDERLE

1%

N050404 001

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

ABBOTT

25MG

A087364 001

50MG

A087384 001

ASCOT

25MG

A087698 001 Oct 20, 1982

50MG

A087699 001 Oct 20, 1982

BARR LABS INC

25MG

A088902 001 Sep 19, 1985

50MG

A088903 001 Sep 19, 1985

DAVA PHARMS INC

25MG

A087451 001

50MG

A087450 001

G AND W LABS INC

50MG

A088651 001 May 30, 1985

IVAX PHARMS

25MG

A087555 001

25MG

A088164 001 Jan 09, 1984

50MG

A087176 001

50MG

A087947 001 Feb 27, 1984

KV PHARM

25MG

A087311 001

50MG

A087312 001

MUTUAL PHARM

25MG

A087292 001

25MG

A089738 001 Sep 19, 1988

50MG

A087293 001

50MG

A089739 001 Sep 19, 1988

PIONEER PHARMS

50MG

A089591 001 Jul 21, 1988

PUREPAC PHARM

25MG

A088139 001 Jul 16, 1986

50MG

A088140 001 Aug 11, 1983

SANDOZ

25MG

A087380 001

50MG

A087118 001

50MG

A087381 001

SUPERPHARM

25MG

A087473 001 Feb 09, 1983

50MG

A087247 001 Feb 09, 1983

USL PHARMA

25MG

A089051 001 Jun 01, 1987

50MG

A089052 001 Jun 01, 1987

VANGARD

25MG

A088012 001 Jul 14, 1982

50MG

A088073 001 Mar 25, 1983

WARNER CHILCOTT

25MG

A087515 001 Jan 24, 1983

50MG

A087516 001 Feb 09, 1983

WATSON LABS

25MG

A087050 001

25MG

A087100 001

25MG

A087296 001

25MG

A087706 001

50MG

A087029 001

50MG

A087082 001

50MG

A087521 001

50MG

A087689 001

HYGROTON

+ SANOFI AVENTIS US

25MG **

N012283 004

+

50MG **

N012283 003

THALITONE

CASPER PHARMA LLC

15MG **

N019574 001 Dec 20, 1988

25MG

N019574 002 Feb 12, 1992

MONARCH PHARMS

25MG

A088051 001 Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM

15MG;0.1MG

A071179 001 Dec 16, 1987

15MG;0.2MG

A071178 001 Dec 16, 1987

15MG;0.3MG

A071142 001 Dec 16, 1987

COMBIPRES

+ BOEHRINGER INGELHEIM

15MG;0.1MG **

N017503 001

+

15MG;0.2MG **

N017503 002

+

15MG;0.3MG **

N017503 003 Apr 10, 1984

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS

25MG;100MG

N019451 001 Dec 31, 1987

25MG;200MG

N019451 002 Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US

25MG;0.125MG

N015103 002

REGROTON

SANOFI AVENTIS US

50MG;0.25MG

N015103 001

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH

250MG

A088928 001 May 08, 1987

500MG

A040113 001 Sep 29, 1995

AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988

500MG

A089853 001 May 04, 1988

OHM LABS

250MG

A081298 001 Dec 29, 1993

500MG

A081299 001 Dec 29, 1993

PAR PHARM

250MG

A087981 001 Sep 20, 1983

PIONEER PHARMS

250MG

A089592 001 Jan 06, 1989

500MG

A089948 001 Jan 06, 1989

SUN PHARM INDUSTRIES

500MG

A089970 001 Sep 27, 1990

WATSON LABS

250MG

A086901 001

250MG

A086948 001 Aug 09, 1982

500MG

A040137 001 Aug 09, 1996

500MG

A081019 001 Jul 29, 1991

500MG

A081040 001 Aug 22, 1989

PARAFLEX

+ ORTHO MCNEIL PHARM

250MG **

N011300 003

PARAFON FORTE DSC

+ JANSSEN R AND D

500MG **

N011529 002 Jun 15, 1987

STRIFON FORTE DSC

FERNDALE LABS

500MG

A081008 001 Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS

EQ 4GM RESIN/BAR

A071621 001 May 26, 1988

EQ 4GM RESIN/BAR

A071739 001 May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

ANI PHARMS INC

EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996

IVAX SUB TEVA PHARMS

EQ 4GM RESIN/PACKET

A074771 001 Jul 09, 1997

EQ 4GM RESIN/SCOOPFUL

A074771 002 Jul 09, 1997

TEVA

EQ 4GM RESIN/PACKET

A074347 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074347 002 May 28, 1998

CHOLESTYRAMINE LIGHT

TEVA

EQ 4GM RESIN/PACKET

A074348 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074348 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

LOCHOLEST

SANDOZ

EQ 4GM RESIN/PACKET

A074561 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074561 002 Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ

EQ 4GM RESIN/PACKET

A074562 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074562 002 Aug 15, 1996

QUESTRAN

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N016640 001

+

EQ 4GM RESIN/SCOOPFUL **

N016640 003

QUESTRAN LIGHT

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N019669 001 Dec 05, 1988

+

EQ 4GM RESIN/SCOOPFUL **

N019669 003 Dec 05, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHOLESTYRAMINETABLET; ORAL
QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403 002	Dec 27, 1999
	EQ 1GM RESIN	A073403 001	Apr 28, 1994

CHORIOGONADOTROPIN ALFAINJECTABLE; INJECTION
OVIDREL

EMD SERONO	0.25MG/VIAL	N021149 001	Sep 20, 2000
------------	-------------	-------------	--------------

CHROMIC CHLORIDEINJECTABLE; INJECTION
CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271 001	May 05, 1987
---------------	------------------------	-------------	--------------

CHROMIC PHOSPHATE P-32INJECTABLE; INJECTION
PHOSPHOCOL P32

MALLINKRODT NUCLEAR	5mCi/ML	N017084 001	
---------------------	---------	-------------	--

CHYMOPAPAININJECTABLE; INJECTION
CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663 002	Aug 21, 1984
+	10,000 UNITS/VIAL **	N018663 001	Nov 10, 1982
DISCASE			
ABBOTT	12,500 UNITS/VIAL	N018625 001	Jan 18, 1984

CHYMOTRYPSINFOR SOLUTION; OPHTHALMIC
ALPHA CHYMAR

SOLA BARNES HIND	750 UNITS/VIAL	N011837 001	
CATARASE			
CIBA	300 UNITS/VIAL	N016938 001	
NOVARTIS	150 UNITS/VIAL	N018121 001	
ZOLYSE			
ALCON	750 UNITS/VIAL	N011903 001	

CICLOPIROXSOLUTION; TOPICAL
CICLOPIROX

MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007
TEVA PHARMS	8%	A078079 001	Sep 18, 2007

CIDOFOVIRINJECTABLE; INJECTION
VISTIDE

+	GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638 001	Jun 26, 1996
---	---------------------	--------------------	-------------	--------------

CILASTATIN SODIUM; IMPENEMINJECTABLE; INJECTION
PRIMAXIN

MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756 001	Jan 08, 1987
	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756 002	Jan 08, 1987

POWDER; INTRAMUSCULAR
PRIMAXIN

MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630 001	Dec 14, 1990
	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630 002	Dec 14, 1990

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028 002	Nov 26, 2004
EPIC PHARMA LLC	50MG	A077150 001	Mar 11, 2005
	100MG	A077022 001	Nov 23, 2004
FRONTIDA BIOPHARM	50MG	A077208 002	Mar 29, 2006
	100MG	A077208 001	Mar 29, 2006
IVAX SUB TEVA PHARMS	100MG	A077020 002	Mar 01, 2005
MYLAN	50MG	A077323 002	Apr 20, 2006
	100MG	A077323 001	Apr 20, 2006
MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004
	100MG	A077019 002	Nov 23, 2004
PLIVA HRVATSKA DOO	50MG	A077898 001	Oct 29, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CILOSTAZOLTABLET;ORAL
CILOSTAZOL

	100MG	A077898 002	Oct 29, 2007
PLETAL			
+ OTSUKA	50MG **	N020863 001	Jan 15, 1999
+	100MG **	N020863 002	Jan 15, 1999

CIMETIDINESUSPENSION;ORAL
TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951 001	Jul 09, 1999
-----------------	------------	-------------	--------------

TABLET;ORAL
CIMETIDINE

CHARTWELL MOLECULES	200MG	A074281 001	May 17, 1994
	300MG	A074281 002	May 17, 1994
	400MG	A074281 003	May 17, 1994
	800MG	A074329 001	May 17, 1994
CONTRACT PHARMACAL	200MG	A074961 001	Jun 19, 1998
	200MG	A074963 001	Jun 19, 1998
CYCLE PHARMS LTD	300MG	A074361 001	Dec 23, 1994
	400MG	A074361 002	Dec 23, 1994
	800MG	A074371 001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340 001	Jun 23, 1995
	400MG	A074340 002	Jun 23, 1995
	800MG	A074339 001	Jun 23, 1995
FOSUN PHARMA	200MG	A074100 001	Jan 31, 1995
	300MG	A074100 002	Jan 31, 1995
	400MG	A074100 003	Jan 31, 1995
	800MG	A074100 004	Jan 31, 1995
IVAX SUB TEVA PHARMS	200MG	A074401 001	May 30, 1995
	200MG	A074424 001	Jul 28, 1995
	300MG	A074401 002	May 30, 1995
	300MG	A074424 002	Jul 28, 1995
	400MG	A074401 003	May 30, 1995
	400MG	A074424 003	Jul 28, 1995
	800MG	A074402 001	May 30, 1995
	800MG	A074424 004	Jul 28, 1995
PERRIGO	100MG	A074972 001	Jun 19, 1998
PLIVA	200MG	A074568 001	Feb 27, 1997
	300MG	A074568 002	Feb 27, 1997
	400MG	A074568 003	Feb 27, 1997
SANDOZ INC	100MG	A075122 001	Jun 19, 1998
	200MG	A074250 001	Jun 29, 1995
	200MG	A075122 002	Jun 19, 1998
	300MG	A074250 002	Jun 29, 1995
	400MG	A074250 003	Jun 29, 1995
	800MG	A074250 004	Jun 29, 1995
TEVA	200MG	A074365 001	Feb 28, 1995
	300MG	A074365 002	Feb 28, 1995
	400MG	A074365 003	Feb 28, 1995
	800MG	A074365 004	Feb 28, 1995
UPSHER-SMITH LABS	200MG	A074506 001	Jan 24, 1996
	300MG	A074506 002	Jan 24, 1996
	400MG	A074506 003	Jan 24, 1996
	800MG	A074506 004	Jan 24, 1996
WATSON LABS INC	200MG	A074349 001	Aug 30, 1996
	300MG	A074349 002	Aug 30, 1996
	400MG	A074349 003	Aug 30, 1996
	800MG	A074316 001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425 001	Jul 29, 1999
TAGAMET			
GLAXOSMITHKLINE	200MG **	N017920 002	
	300MG **	N017920 003	
	400MG **	N017920 004	Dec 14, 1983
	800MG **	N017920 005	Apr 30, 1986
TAGAMET HB			
+ MEDTECH PRODUCTS	100MG **	N020238 001	Jun 19, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	
-----------------	----------------------	---------	-----	--

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434	001	Oct 31, 1985
-------------------	-------------------	---------	-----	--------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924	001	
-----------------	----------------------	---------	-----	--

CINOXACIN

CAPSULE; ORAL

CINOXACIN

LILLY	250MG	N018067	001	
	500MG	N018067	002	
CINOXACIN				
TEVA	250MG	A073005	001	Feb 28, 1992
	500MG	A073006	001	Feb 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

+ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990
+ BAYER HLTHCARE	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990
+ BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003	Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990
+ BAYER HLTHCARE	400MG/200ML	N019857	002	Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990
--------------	-------------	---------	-----	--------------

CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
--------------------	-------------	---------	-----	--------------

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
	400MG/200ML	A077888	002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
	400MG/200ML	A078114	002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

400MG/200ML

A077138 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AMRING PHARMS

EQ 0.3% BASE

A078598 001 Jan 16, 2008

APOTEX INC

EQ 0.3% BASE

A075928 001 Jun 09, 2004

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR

EQ 250MG BASE

A074124 001 Jun 09, 2004

EQ 500MG BASE

A074124 002 Jun 09, 2004

EQ 750MG BASE

A074124 003 Jun 09, 2004

IDT AUSTRALIA LTD

EQ 100MG BASE

A075939 001 Mar 03, 2005

EQ 250MG BASE

A075939 002 Jun 09, 2004

EQ 500MG BASE

A075939 003 Jun 09, 2004

EQ 750MG BASE

A075939 004 Jun 09, 2004

MYLAN

EQ 250MG BASE

A075685 002 Jun 09, 2004

EQ 500MG BASE

A075685 003 Jun 09, 2004

EQ 750MG BASE

A075685 001 Jun 09, 2004

NOSTRUM LABS

EQ 250MG BASE

A076138 001 Jun 09, 2004

EQ 500MG BASE

A076138 002 Jun 09, 2004

EQ 750MG BASE

A076138 003 Jun 09, 2004

PLIVA

EQ 100MG BASE

A076426 001 Jun 15, 2005

EQ 250MG BASE

A076426 002 Jun 15, 2005

EQ 500MG BASE

A076426 003 Jun 15, 2005

EQ 750MG BASE

A076426 004 Jun 15, 2005

SANDOZ

EQ 250MG BASE

A076593 002 Jun 09, 2004

EQ 500MG BASE

A076593 003 Jun 09, 2004

EQ 750MG BASE

A076593 004 Jun 09, 2004

TEVA

EQ 250MG BASE

A076136 001 Jun 09, 2004

EQ 500MG BASE

A076136 002 Jun 09, 2004

EQ 750MG BASE

A076136 003 Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE

212.6MG;EQ 287.5MG BASE **

N021473 001 Dec 13, 2002

425.2MG;EQ 574.9MG BASE **

N021473 002 Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

ACTAVIS LABS FL INC

212.6MG;EQ 287.5MG BASE

A077417 001 Nov 30, 2010

425.2MG;EQ 574.9MG BASE

A077809 001 Nov 30, 2010

DR REDDYS LABS LTD

212.6MG;EQ 287.5MG BASE

A077701 002 Oct 31, 2007

SANDOZ

212.6MG;EQ 287.5MG BASE

A078712 001 Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS

EQ 1MG BASE/ML

N020398 001 Sep 15, 1995

TABLET; ORAL

PROPULSID

JANSSEN PHARMS

EQ 10MG BASE

N020210 001 Jul 29, 1993

EQ 20MG BASE

N020210 002 Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA

EQ 20MG BASE

N020767 001 Nov 07, 1997

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD

10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

TEVA PHARMS USA

1MG/ML

A074814 001 May 16, 2000

PLATINOL

+

HQ SPCLT PHARMA

10MG/VIAL

N018057 001

+

50MG/VIAL

N018057 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CISPLATIN

INJECTABLE; INJECTION

PLATINOL-AQ

+ HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION; ORAL

CELEXA

+ FOREST LABS

EQ 10MG BASE/5ML **

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

APOTEX INC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET; ORAL

CELEXA

FOREST LABS

EQ 60MG BASE

N020822 004 Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH

EQ 10MG BASE

A077033 001 Oct 28, 2004

EQ 20MG BASE

A077033 002 Oct 28, 2004

EQ 40MG BASE

A077033 003 Oct 28, 2004

EPIC PHARMA LLC

EQ 10MG BASE

A077036 001 Oct 28, 2004

EQ 20MG BASE

A077036 002 Oct 28, 2004

EQ 40MG BASE

A077036 003 Oct 28, 2004

MYLAN

EQ 10MG BASE

A077039 001 Feb 03, 2005

EQ 20MG BASE

A077039 002 Feb 03, 2005

EQ 40MG BASE

A077039 003 Feb 03, 2005

MYLAN PHARMS INC

EQ 10MG BASE

A077037 001 Nov 05, 2004

EQ 20MG BASE

A077037 002 Nov 05, 2004

EQ 40MG BASE

A077037 003 Nov 05, 2004

NATCO PHARMA LTD

EQ 20MG BASE

A077141 002 Apr 10, 2008

EQ 40MG BASE

A077141 001 Apr 10, 2008

ROXANE

EQ 10MG BASE

A077041 001 Nov 23, 2004

EQ 20MG BASE

A077041 002 Nov 23, 2004

EQ 40MG BASE

A077041 003 Nov 23, 2004

SANDOZ

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

SUN PHARM INDUSTRIES

EQ 10MG BASE

A077052 001 Jul 03, 2006

EQ 20MG BASE

A077052 002 Jul 03, 2006

EQ 40MG BASE

A077052 003 Jul 03, 2006

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TEVA PHARMS

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 40MG BASE

A077213 003 Mar 31, 2006

WATSON LABS

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 40MG BASE

A077034 003 Jun 30, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018904 001 May 27, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

+ JANSSEN PHARMS 1MG/ML ** N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE 187MG/5ML N050698 003 Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS 250MG A065137 001 May 31, 2005

500MG A065137 002 May 31, 2005

MYLAN 250MG A065195 001 Mar 11, 2005

500MG A065195 002 Mar 11, 2005

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

+ ABBVIE 500MG ** N050775 001 Mar 03, 2000

CLARITHROMYCIN

IDT AUSTRALIA LTD 500MG A065250 001 Aug 25, 2005

RANBAXY 1GM A065210 001 Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

GLAXOSMITHKLINE EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL A062691 001 Dec 19, 1986

EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL N050590 001 Apr 01, 1985

EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL N050590 002 Apr 01, 1985

EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL N050590 003 Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE EQ 100MG BASE/100ML; EQ 3GM BASE/100ML N050658 001 Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML A074075 001 Oct 31, 1993

APOTEX INC EQ 0.5MG BASE/5ML A075703 001 Nov 27, 2000

SILARX EQ 0.5MG BASE/5ML A074884 001 Dec 17, 1997

TEVA PHARMS EQ 0.5MG BASE/5ML A073095 001 Apr 21, 1992

TAVIST

+ NOVARTIS EQ 0.5MG BASE/5ML ** N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

ANI PHARMS INC 1.34MG A073282 001 Jan 31, 1992

1.34MG A073282 002 Dec 03, 1992

SANDOZ 2.68MG A073459 001 Oct 31, 1993

TAVIST

NOVARTIS 2.68MG N017661 001

TAVIST-1

NOVARTIS 1.34MG N017661 002

1.34MG N017661 003 Aug 21, 1992

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE 2.5MG N010355 001

5MG N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE A061809 001

EQ 150MG BASE A061809 002

CLINDAMYCIN HYDROCHLORIDE

MYLAN PHARMS INC EQ 75MG BASE A091225 001 May 31, 2011

EQ 150MG BASE A091225 002 May 31, 2011

EQ 300MG BASE A091225 003 May 31, 2011

TEVA EQ 75MG BASE A063027 001 Sep 20, 1989

WATSON LABS EQ 75MG BASE A063082 001 Jul 31, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE/5ML ** A061827 001

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 2% BASE N050680 001 Aug 11, 1992

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN EQ 150MG BASE/ML A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM EQ 150MG BASE/ML A062747 001 Jun 03, 1988

BEDFORD EQ 150MG BASE/ML A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB EQ 150MG BASE/ML A062908 001 Feb 01, 1989

IGI LABS INC EQ 150MG BASE/ML A062928 001 Feb 13, 1989

LOCH EQ 150MG BASE/ML A062905 001 May 09, 1988

MARSAM PHARMS LLC EQ 150MG BASE/ML A062913 001 Oct 20, 1988

SOLOPAK EQ 150MG BASE/ML A062819 001 Mar 15, 1988

EQ 150MG BASE/ML A062852 001 Mar 17, 1988

TEVA PARENTERAL EQ 150MG BASE/ML A063041 001 Dec 29, 1989

EQ 150MG BASE/ML A063282 001 May 29, 1992

WATSON LABS EQ 150MG BASE/ML A062900 001 Jun 08, 1988

EQ 150MG BASE/ML A063079 001 Mar 05, 1990

WEST-WARD PHARMS INT EQ 150MG BASE/ML A062806 001 Oct 15, 1987

EQ 150MG BASE/ML A062953 001 Apr 21, 1988

EQ 150MG BASE/ML A063068 001 Aug 28, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM EQ 12MG BASE/ML N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE EQ 6MG BASE/ML A065027 001 Jun 29, 2001

EQ 12MG BASE/ML A065027 002 Jun 29, 2001

EQ 18MG BASE/ML A065027 003 Jun 29, 2001

BAXTER HLTHCARE EQ 6MG BASE/ML N050648 001 Dec 29, 1989

EQ 12MG BASE/ML N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML N050648 003 Dec 29, 1989

SOLUTION;TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN EQ 1% BASE A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC EQ 1% BASE A062944 001 Jan 11, 1989

NOVAST LABS LTD EQ 1% BASE A064108 001 Sep 27, 1996

VINTAGE PHARMS EQ 1% BASE A062930 001 Jun 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL

NYSTAFORM

BAYER PHARMS 10MG/GM;100,000 UNITS/GM N050235 001

CLOBAZAM

TABLET;ORAL

ONFI

LUNDBECK PHARMS LLC 5MG N202067 001 Oct 21, 2011

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

TEVA PHARMS USA 0.05% A074087 001 Feb 16, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

NOVAST LABS LTD 0.05% A075733 001 Aug 22, 2001

TEMOVATE

+ FOUGERA PHARMS 0.05% ** N019322 001 Dec 27, 1985

TEMOVATE E

+ FOUGERA PHARMS 0.05% ** N020340 001 Jun 17, 1994

GEL;TOPICAL

TEMOVATE

+ FOUGERA PHARMS 0.05% ** N020337 001 Apr 29, 1994

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC 0.05% A074128 001 Aug 03, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

TEMOVATE

+ FOUGERA PHARMS 0.05% ** N019323 001 Dec 27, 1985

SOLUTION; TOPICAL

TEMOVATE

+ FOUGERA PHARMS 0.05% ** N019966 001 Feb 22, 1990

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG N019500 002 Dec 15, 1986

100MG N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX

50MG

A072196 001 Dec 20, 1988

SEROPHENE

EMD SERONO

50MG

N018361 001 Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

TEVA

25MG

A074849 001 Apr 04, 1997

50MG

A074849 002 Apr 04, 1997

75MG

A074849 003 Apr 04, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

APOTEX INC

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

MYLAN PHARMS INC

0.5MG

A074940 001 Oct 30, 1997

1MG

A074940 002 Oct 30, 1997

2MG

A074940 003 Oct 30, 1997

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

+ ROCHE

0.125MG **

N020813 001 Dec 23, 1997

+

0.25MG **

N020813 002 Dec 23, 1997

+

0.5MG **

N020813 003 Dec 23, 1997

+

1MG **

N020813 004 Dec 23, 1997

+

2MG **

N020813 005 Dec 23, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.17MG BASE N022500 001 Dec 03, 2009

EQ 0.26MG BASE N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP 0.1MG A070881 001 Jul 08, 1986

0.2MG A070882 001 Jul 08, 1986

0.3MG A070883 001 Jul 08, 1986

AUROLIFE PHARMA LLC 0.1MG A070887 001 Aug 31, 1988

0.2MG A070886 001 Aug 31, 1988

0.3MG A071294 001 Aug 31, 1988

CHARTWELL MOLECULES 0.3MG A071785 001 Apr 05, 1988

DURAMED PHARMS BARR 0.1MG A071103 001 Aug 14, 1986

0.2MG A071102 001 Aug 14, 1986

0.3MG A071101 001 Aug 14, 1986

INTERPHARM 0.1MG A071252 001 Oct 01, 1986

0.2MG A071253 001 Oct 01, 1986

0.3MG A071254 001 Oct 01, 1986

PAR PHARM 0.1MG A070461 001 Jul 08, 1986

0.2MG A070460 001 Jul 08, 1986

0.3MG A070459 001 Jul 08, 1986

TEVA 0.1MG A070747 001 Jul 08, 1986

0.2MG A070702 001 Jul 08, 1986

0.3MG A070659 001 Jul 08, 1986

WARNER CHILCOTT 0.1MG A072138 001 Jun 13, 1988

0.2MG A072139 001 Jun 13, 1988

0.3MG A072140 001 Jun 13, 1988

WATSON LABS 0.1MG A070395 001 Mar 23, 1987

0.1MG A070965 001 Jul 08, 1986

0.2MG A070396 001 Mar 23, 1987

0.2MG A070964 001 Jul 08, 1986

0.3MG A070397 001 Mar 23, 1987

0.3MG A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH 0.2MG A202792 002 May 15, 2015

0.2MG A203320 002 May 15, 2015

ANCHEN PHARMS 0.1MG A202983 001 Apr 02, 2014

0.2MG A202983 002 Apr 02, 2014

CLONIDINE HYDROCHLORIDE

ANCHEN PHARMS 0.2MG A202984 002 Sep 30, 2013

JENLOGA

+ CONCORDIA PHARMS INC 0.1MG ** N022331 001 Sep 30, 2009

+ 0.2MG ** N022331 002 May 25, 2010

KAPVAY

+ CONCORDIA PHARMS INC 0.2MG ** N022331 004 Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA EQ 75MG BASE A090307 001 May 28, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE 3.75MG A071777 001 Jul 14, 1987

7.5MG A071778 001 Jul 14, 1987

15MG A071779 001 Jul 14, 1987

AM THERAP 3.75MG A071429 001 Jun 23, 1987

7.5MG A071430 001 Jun 23, 1987

15MG A071431 001 Jun 23, 1987

AUROLIFE PHARMA LLC 15MG A072112 001 Aug 26, 1988

DAVA PHARMS INC 3.75MG A071742 001 Dec 14, 1987

7.5MG A071743 001 Dec 14, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
RECORDATI RARE	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
	7.5MG	A076911	002	Sep 29, 2004
	15MG	A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988
TRANXENE				
RECORDATI RARE	3.75MG	N017105	006	
TRANXENE SD				
RECORDATI RARE	11.25MG	N017105	005	
	22.5MG	N017105	004	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOTRIMAZOLE

CREAM;TOPICAL

LOTRIMIN

SCHERING PLOUGH 1% N017619 001

MYCELEX

BAYER HEALTHCARE LLC 1% N018183 001

CREAM;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 1% N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 2% N020574 001 Nov 24, 1998

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,200MG N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,100MG N020289 002 Apr 26, 1993

LOTION;TOPICAL

LOTRIMIN

SCHERING 1% N018813 001 Feb 17, 1984

SOLUTION;TOPICAL

LOTRIMIN

+ SCHERING PLOUGH 1% N017613 001

MYCELEX

+ BAYER HLTHCARE 1% ** N018181 001

TABLET;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG N020525 001 Jul 29, 1996

GYNIX

TEVA PHARMS 100MG A073249 001 Feb 13, 1998

MYCELEX-G

BAYER PHARMS 500MG N019069 001 Apr 19, 1985

TROCHE/LOZENGE;ORAL

MYCELEX

+ BAYER HLTHCARE 10MG ** N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL

CLOXACILLIN SODIUM

APOTHECON EQ 250MG BASE A061452 001

EQ 500MG BASE A061452 002

TEVA EQ 250MG BASE A062240 001

EQ 500MG BASE A062240 002

CLOXAPEN

GLAXOSMITHKLINE EQ 250MG BASE A061806 001

EQ 250MG BASE A062233 001

EQ 500MG BASE A061806 002

EQ 500MG BASE A062233 002

FOR SOLUTION;ORAL

CLOXACILLIN SODIUM

TEVA EQ 125MG BASE/5ML A062268 001

EQ 125MG BASE/5ML A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON EQ 125MG BASE/5ML A061453 001

EQ 125MG BASE/5ML N050192 001

CLOZAPINE

TABLET;ORAL

CLOZAPINE

PAR PHARM 25MG A075162 001 Apr 26, 2005

100MG A075162 002 Apr 26, 2005

SANDOZ 25MG A074546 001 Aug 30, 1996

100MG A074546 002 Aug 30, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

JAZZ PHARMS III 50MG N021590 003 Jun 03, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-57 KIT

BRACCO

N/A;N/A;N/A;N/A

N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-60 KIT

BRACCO

N/A;N/A;N/A;N/A

N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

+ ANI PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML **

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML;5MG/5ML;6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML;5MG/5ML;6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML;5MG/5ML;6.25MG/5ML

A088896 001 Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

+ ANI PHARMS

10MG/5ML;6.25MG/5ML **

N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY

10MG/5ML;6.25MG/5ML

A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC

10MG/5ML;6.25MG/5ML

A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI

10MG/5ML;6.25MG/5ML

A088814 001 Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE

10MG/5ML;30MG/5ML;1.25MG/5ML

N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI

10MG/5ML;30MG/5ML;1.25MG/5ML

A089018 001 Jul 23, 1986

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

WOCKHARDT

10MG/5ML;30MG/5ML;1.25MG/5ML

A088833 001 Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

WEST-WARD PHARMS INT 30MG/5ML

N202245 001 Jun 30, 2011

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

+ MERCK

0.5MG;500MG **

N012383 001

PROBEN-C

WATSON LABS

0.5MG;500MG

A085552 001

PROBENECID AND COLCHICINE

ANI PHARMS INC

0.5MG;500MG

A083734 001

BEECHAM

0.5MG;500MG

A084321 001

IMPAX LABS

0.5MG;500MG

A083720 002

SANDOZ

0.5MG;500MG

A086130 001

PROBENECID W/ COLCHICINE

LEDERLE

0.5MG;500MG

A086954 001

WATSON LABS

0.5MG;500MG

A083221 001

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL

DAIICHI SANKYO

375MG

N021141 001 May 26, 2000

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

PARKE DAVIS

EQ 25MG BASE/5ML

N050355 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

CUMBERLAND PHARMS 20MG/4ML (5MG/ML) N021697 001 Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7

GD SEARLE LLC 89MG N017408 001

TATUM-T

GD SEARLE LLC 120MG N018205 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE 25 UNITS/VIAL N008317 002

40 UNITS/VIAL N008317 004

ACTHAR

SANOFI AVENTIS US 25 UNITS/VIAL N007504 002

40 UNITS/VIAL N007504 003

CORTICOTROPIN

ORGANICS LAGRANGE 40 UNITS/ML N010831 001

80 UNITS/ML N010831 002

WATSON LABS 40 UNITS/VIAL A088772 001 Nov 21, 1984

H.P. ACTHAR GEL

MALLINCKRODT ARD 40 UNITS/ML N008372 006

PURIFIED CORTROPHIN GEL

ANI PHARMS INC 40 UNITS/ML N008975 001

80 UNITS/ML N008975 002

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ANI PHARMS INC 40 UNITS/ML N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN 25MG/ML N008126 002

WATSON LABS 25MG/ML A083147 003

25MG/ML A085677 001

50MG/ML A083147 004

50MG/ML A085677 002

CORTONE

MERCK 25MG/ML N007110 002

50MG/ML N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR 25MG A083471 001

ELKINS SINN 25MG A080836 001

EVERYLIFE 25MG A084246 001

HEATHER 25MG A085736 001

IMPAX LABS 25MG N009458 001

INWOOD LABS 25MG A080731 001

IVAX SUB TEVA PHARMS 25MG A080630 001

25MG A083536 001

LANNETT 25MG A080694 001

PANRAY 5MG N008284 002

25MG N008284 001

PHARMACIA AND UPJOHN 5MG N008126 003

10MG N008126 004

25MG N008126 001

PUREPAC PHARM 25MG A080493 001

VITARINE 25MG A080333 001

WATSON LABS 25MG A085884 001

WHITEWORTH TOWN PLSN 25MG A080341 001

CORTONE

+ MERCK 25MG ** N007750 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ INC

0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PHARMS LLC

0.8MG/INH

N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

+ SANOFI AVENTIS US

20MG **

N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC

100MG

N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS

100MG/5ML

A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

10MG/ML

A075067 001 Jul 19, 1999

APOTEX INC

10MG/ML

A075333 001 Apr 30, 2002

BAUSCH AND LOMB

10MG/ML

A075585 001 Dec 21, 2000

PHARMASCIENCE INC

10MG/ML

A075437 001 Apr 21, 2000

ROXANE

10MG/ML

A075175 001 Sep 30, 1999

WATSON LABS

10MG/ML

A076469 001 Jun 17, 2005

INTAL

+ KING PHARMS LLC

10MG/ML **

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROLOM

BAUSCH AND LOMB

4%

A074443 001 Jan 30, 1995

CROMOLYN SODIUM

APOTEX INC

4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS

4%

A075088 001 Apr 27, 1999

OPTICROM

+ ALLERGAN

4% **

N018155 001 Oct 03, 1984

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

+ BLACKSMITH BRANDS

5.2MG/SPRAY **

N020463 001 Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

ABRAXIS PHARM

EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

BETALIN 12

LILLY

0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS

0.1MG/ML

A083013 001

1MG/ML

A083064 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

ABRAXIS PHARM	0.03MG/ML	A080510 003	
	0.1MG/ML	A080510 001	
	1MG/ML	A080510 002	
AKORN	1MG/ML	A087969 001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689 001	
	0.1MG/ML	A080689 002	
	1MG/ML	A080689 003	
FRESENIUS KABI USA	0.1MG/ML	A080557 002	
LUITPOLD	0.03MG/ML	A080668 001	
LYPHOMED	1MG/ML	A083075 001	
MYLAN INSTITUTIONAL	1MG/ML	A040451 001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564 001	
SOLOPAK	1MG/ML	A087551 001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085 002	
WATSON LABS	0.1MG/ML	A080573 002	
	0.1MG/ML	A083120 001	
	1MG/ML	A080573 001	
	1MG/ML	A083120 002	
WYETH AYERST	0.1MG/ML	A080554 001	
	1MG/ML	A080554 002	
DODEX			
ACCORD HLTHCARE	1MG/ML	A083022 001	
REDISOL			
MERCK	1MG/ML	N006668 010	
RUBIVITE			
BEL MAR	0.03MG/ML	N010791 004	
	0.05MG/ML	N010791 001	
	0.1MG/ML	N010791 002	
	0.12MG/ML	N010791 005	
	1MG/ML	N010791 003	
RUBRAMIN PC			
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
+	1MG/ML **	N006799 004	
+	1MG/ML **	N006799 010	Apr 28, 1988
RUVITE			
SAVAGE LABS	1MG/ML	A080570 002	
VI-TWEL			
BAYER HLTHCARE	1MG/ML	N007012 002	
SPRAY, METERED; NASAL			
CALOMIST			
PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007
TABLET; ORAL			
CYANOCOBALAMIN			
WEST WARD	1MG	A084264 001	

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO 0.5-1uCi N016089 002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO 0.5-1uCi N016090 002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE N/A; N/A; N/A N017406 001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT 0.1MG; 0.5uCi; 60MG N016635 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM

0.5MG/ML; 2.3MG/ML; 1MG/ML

N011208 001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST

125MG/5ML

N050508 001

250MG/5ML

N050508 002

500MG/5ML

N050508 003

TABLET; ORAL

CYCLACILLIN

TEVA

250MG

A062895 001 Aug 04, 1988

500MG

A062895 002 Aug 04, 1988

CYCLAPEN-W

WYETH AYERST

250MG

N050509 001

500MG

N050509 002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE

50MG/ML

N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

TWI PHARMS INC

15MG

A091281 001 Jan 31, 2013

30MG

A091281 002 Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ

10MG

A073683 001 Feb 26, 1993

UPSHER-SMITH LABS

5MG

A072854 002 Feb 03, 2006

10MG

A072854 001 Nov 19, 1991

WATSON LABS

10MG

A073143 001 Nov 27, 1991

10MG

A074436 001 Nov 30, 1994

FLEXERIL

+ JANSSEN RES AND DEV

5MG **

N017821 001

+

10MG **

N017821 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN

1%

A085555 001

AKPENTOLATE

AKORN

2%

A040165 001 Jan 13, 1997

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD

1%

A089162 001 Jan 24, 1991

SOLA BARNES HIND

1%

A084150 001

1%

A084863 001

PENTOLAIR

PHARMAFAIR

0.5%

A088643 001 Feb 09, 1987

1%

A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE

100MG/VIAL

A088371 001 Jul 03, 1986

200MG/VIAL

A088372 001 Jul 03, 1986

500MG/VIAL

A088373 001 Jul 03, 1986

1GM/VIAL

A088374 001 Sep 24, 1986

CYTOXAN

+ BAXTER HLTHCARE

100MG/VIAL **

N012142 001

+

200MG/VIAL **

N012142 002

CYTOXAN (LYOPHILIZED)

+ BAXTER HLTHCARE

500MG/VIAL

N012142 003

+

500MG/VIAL **

N012142 008 Jan 04, 1984

+

1GM/VIAL

N012142 004 Aug 30, 1982

+

1GM/VIAL **

N012142 010 Sep 24, 1985

+

2GM/VIAL

N012142 005 Aug 30, 1982

+

2GM/VIAL **

N012142 009 Dec 10, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

LYOPHILIZED CYTOXAN

+ BAXTER HLTHCARE	100MG/VIAL **	N012142 006	Dec 05, 1985
+ BAXTER HLTHCARE	200MG/VIAL **	N012142 007	Dec 10, 1985

NEOSAR

BEDFORD	100MG/VIAL	A087442 001	Feb 16, 1982
	200MG/VIAL	A087442 002	Feb 16, 1982
	500MG/VIAL	A087442 003	Feb 16, 1982
	1GM/VIAL	A087442 004	Jul 08, 1983
	2GM/VIAL	A087442 005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015 001	Apr 29, 1993
	200MG/VIAL	A040015 002	Apr 29, 1993
	500MG/VIAL	A040015 003	Apr 29, 1993
	1GM/VIAL	A040015 004	Apr 29, 1993
	2GM/VIAL	A040015 005	Apr 29, 1993

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE	25MG	A040032 001	Aug 17, 1999
	50MG	A040032 002	Aug 17, 1999

CYTOXAN

+ BAXTER HLTHCARE	25MG **	N012141 002	
+ BAXTER HLTHCARE	50MG **	N012141 001	

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

+ NOVARTIS	50MG **	N050715 003	Jul 14, 1995
------------	---------	-------------	--------------

SOLUTION; ORAL

CYCLOSPORINE

APOTEX INC	100MG/ML	A065167 001	Jan 05, 2005
------------	----------	-------------	--------------

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY	2MG	N013157 002	
-------	-----	-------------	--

FLUIDIL

PHARMACIA AND UPJOHN	2MG	N018173 001	
----------------------	-----	-------------	--

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY	1.25MG	N008951 001	
	2.5MG	N008951 002	

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	2MG/5ML **	A086833 001	
HALSEY	2MG/5ML	A089199 001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001 001	Nov 04, 1982
NASKA	2MG/5ML	A089021 001	Dec 21, 1987

PERIACTIN

+ MERCK	2MG/5ML **	N013220 002	
---------	------------	-------------	--

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP	4MG	A088798 001	Feb 15, 1985
ASCOT	4MG	A087685 001	Oct 25, 1982
CHARTWELL RX	4MG	A088212 001	May 26, 1983
DURAMED PHARMS BARR	4MG	A088232 001	Oct 25, 1983
HALSEY	4MG	A089057 001	Jul 03, 1986
KV PHARM	4MG	A086737 001	
MD PHARM	4MG	A087566 001	Nov 10, 1982
MYLAN	4MG	A086678 001	
PIONEER PHARMS	4MG	A087839 001	Feb 08, 1984
PLIVA	4MG	A088205 001	Jul 26, 1983
SANDOZ	4MG	A086808 001	
SUPERPHARM	4MG	A087405 001	
VITARINE	4MG	A087284 001	
WATSON LABS	4MG	A085245 001	
	4MG	A086165 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

4MG

A086580 001

PERIACTIN

+ MERCK

4MG **

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

+ HOSPIRA

7.25% **

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

+ TEVA PARENTERAL

100MG/VIAL **

N016793 001

+

500MG/VIAL **

N016793 002

+

1GM/VIAL **

N016793 003 Dec 21, 1987

+

2GM/VIAL **

N016793 004 Dec 21, 1987

CYTOSAR-U

TEVA PHARMS USA

100MG/VIAL

A075206 001 Dec 30, 1998

500MG/VIAL

A075206 002 Dec 30, 1998

1GM/VIAL

A075206 004 Dec 30, 1998

2GM/VIAL

A075206 003 Dec 30, 1998

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL

A070962 001 Aug 28, 1986

200MG/VIAL

A070990 001 Aug 28, 1986

DTIC-DOME

+ BAYER HLTHCARE

100MG/VIAL

N017575 001

+

200MG/VIAL

N017575 002

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

WEST-WARD PHARMS INT

0.5MG/VIAL

A090304 001 Mar 16, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL

N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

+ FERA PHARMS

0.5% **

N019849 001 Dec 31, 1990

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DAPTOMYCIN

POWDER; IV (INFUSION)

CUBICIN

CUBIST PHARMS LLC

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 300MG BASE **

N021976 001 Jun 23, 2006

+

EQ 400MG BASE **

N021976 003 Oct 21, 2008

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

WATSON LABS

500MG/VIAL

A076806 001 Mar 31, 2006

2GM/VIAL

A076806 002 Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET; ORAL

DECLOMYCIN

COREPHARMA

75MG

N050261 001

150MG

N050261 002

300MG

N050261 003

DEMECLOCYCLINE HYDROCHLORIDE

IMPAX LABS

150MG

A065094 001 Mar 22, 2004

300MG

A065094 002 Mar 22, 2004

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE

0.125MG; 25MG

N012148 001

ORETICYL 50

ABBVIE

0.125MG; 50MG

N012148 003

ORETICYL FORTE

ABBVIE

0.25MG; 25MG

N012148 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESERPIDINE; METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT 0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT 0.5MG; 5MG

N012775 002

METHYLCLOTHIAZIDE AND DESERPIDINE

WATSON LABS 0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US 25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC 100MG

A071803 001 May 29, 1997

USL PHARMA 25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS 0.2MG/ML

N009282 002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC 0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD 0.004MG/ML

A074575 001 Feb 18, 2000

HOSPIRA 0.004MG/ML

A075220 001 Aug 28, 2000

TEVA PHARMS USA 0.004MG/ML

A074888 001 Oct 15, 1997

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD 0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING 0.01%

N019776 001 Dec 26, 1990

SPRAY, METERED; NASAL

DDAVP

+ FERRING PHARMS INC 0.01MG/SPRAY **

N017922 002 Feb 06, 1989

STIMATE

FERRING PHARMS INC 0.15MG/SPRAY

N020355 001 Mar 07, 1994

TABLET; ORAL

DESMOPRESSIN ACETATE

FERRING 0.1MG

N021795 001 May 08, 2008

0.2MG

N021795 002 May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC 0.15MG; 0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR 0.15MG; 0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS 0.15MG; 0.03MG

N020301 001 Dec 14, 1992

TABLET; ORAL-28

MIRCETTE

+ TEVA BRANDED PHARM 0.15MG, N/A; 0.02MG, 0.01MG **

N020713 001 Apr 22, 1998

ORTHO-CEPT

JANSSEN PHARMS 0.15MG; 0.03MG

N020301 002 Dec 14, 1992

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

+ TARO 0.25% **

N017856 001

TOPICORT LP

+ TARO 0.05% **

N018309 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESOXIMETASONE

GEL; TOPICAL			
TOPICORT			
+ TARO	0.05% **	N018586 001	Mar 29, 1982
OINTMENT; TOPICAL			
DESOXIMETASONE			
ALTANA	0.25%	A073440 001	Apr 01, 1998
TOPICORT			
+ TARO	0.25% **	N018763 001	Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION			
DOCA			
ORGANON USA INC	5MG/ML	N001104 001	
PELLET; IMPLANTATION			
PERCORTEN			
NOVARTIS	125MG	N005151 001	

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION			
PERCORTEN			
NOVARTIS	25MG/ML	N008822 001	

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL			
DESVENLAFAXINE			
TEVA PHARMS USA	EQ 50MG BASE	N205208 001	Oct 11, 2013
	EQ 100MG BASE	N205208 002	Oct 11, 2013

DEXAMETHASONE

AEROSOL; TOPICAL			
AEROSEB-DEX			
ALLERGAN HERBERT	0.01% **	A083296 002	
DECASPRAY			
+ MERCK	0.04% **	N012731 002	
ELIXIR; ORAL			
DECADRON			
MERCK	0.5MG/5ML	N012376 002	
DEXAMETHASONE			
ALPHARMA US PHARMS	0.5MG/5ML	A088997 001	Oct 10, 1986
HEXADROL			
ORGANON USA INC	0.5MG/5ML	N012674 001	
GEL; TOPICAL			
DECADERM			
MERCK	0.1%	N013538 001	
SUSPENSION/DROPS; OPHTHALMIC			
DEXAMETHASONE			
WATSON LABS	0.1%	A089170 001	May 09, 1989
TABLET; ORAL			
DECADRON			
+ MERCK	0.25MG **	N011664 004	
	0.5MG **	N011664 001	
	0.75MG **	N011664 002	
	1.5MG **	N011664 003	
	4MG **	N011664 005	
	6MG **	N011664 006	Jul 30, 1982
DEXAMETHASONE			
IDT AUSTRALIA LTD	0.75MG	A080399 001	
IMPAX LABS	0.75MG	A085376 001	
PAR PHARM	0.25MG	A088149 001	Apr 28, 1983
PHOENIX LABS NY	0.75MG	A083806 001	
PVT FORM	0.75MG	A083420 001	
ROXANE	0.25MG	A084614 001	
SUN PHARM INDUSTRIES	0.25MG	A084013 001	
	0.25MG	A084764 001	
	0.5MG	A084084 001	
	0.5MG	A084766 001	
	0.75MG	A084081 001	
	0.75MG	A084765 001	
	1.5MG	A084086 001	
	1.5MG	A084763 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

UPSHER SMITH	0.75MG	A087534	001
	1.5MG	A087533	001
WATSON LABS	0.25MG	A085455	001
	0.5MG	A085458	001
	0.75MG	A080968	001
	0.75MG	A084457	001
	0.75MG	A085818	001
	1.5MG	A085456	001
	1.5MG	A085840	001
WHITEWORTH TOWN PLSN	0.75MG	A084327	001
DEXONE 0.5			
SOLVAY	0.5MG	A084991	001
DEXONE 0.75			
SOLVAY	0.75MG	A084993	001
DEXONE 1.5			
SOLVAY	1.5MG	A084990	001
DEXONE 4			
SOLVAY	4MG	A084992	001
HEXADROL			
ASPEN GLOBAL INC	0.5MG	N012675	004
	0.75MG	N012675	007
	1.5MG	N012675	009
	4MG	N012675	010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

+ MERCK	EQ 8MG BASE/ML **	N016675	001
---------	-------------------	---------	-----

DEXAMETHASONE ACETATE

WATSON LABS	EQ 8MG BASE/ML	A084315	001
-------------	----------------	---------	-----

WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001 May 24, 1982
------------------	-----------------	---------	------------------

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242	001
---------	------------------------	---------	-----

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413	001
---------	------------------------	---------	-----

CREAM; TOPICAL

DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011983	002
-------	-------------------	---------	-----

INJECTABLE; INJECTION

DECADRON

+ MERCK	EQ 4MG PHOSPHATE/ML **	N012071	002
---------	------------------------	---------	-----

+ MERCK	EQ 24MG PHOSPHATE/ML **	N012071	004
---------	-------------------------	---------	-----

DEXACEN-4

CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342	001
-------------	---------------------	---------	-----

DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001 Jan 25, 1984
---------------	---------------------	---------	------------------

FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469	001 Jan 25, 1984
--------------------	----------------------	---------	------------------

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493	001
-------	---------------------	---------	-----

BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001
---------	---------------------	---------	-----

DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001
-----------	---------------------	---------	-----

INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001 Feb 17, 1984
-----------------	----------------------	---------	------------------

LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065	001
----------	---------------------	---------	-----

TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001 Aug 31, 1990
-----------------	---------------------	---------	------------------

TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126	001 Aug 31, 1990
-----------------	----------------------	---------	------------------

WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001
-------------	---------------------	---------	-----

WATSON LABS	EQ 4MG PHOSPHATE/ML	A084355	001
-------------	---------------------	---------	-----

WATSON LABS	EQ 4MG PHOSPHATE/ML	A089169	001 Apr 09, 1986
-------------	---------------------	---------	------------------

WATSON LABS	EQ 10MG PHOSPHATE/ML	A087668	001 Jul 01, 1982
-------------	----------------------	---------	------------------

WATSON LABS	EQ 24MG PHOSPHATE/ML	A085606	001
-------------	----------------------	---------	-----

WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001
--------------	---------------------	---------	-----

HEXADROL

+ ORGANON USA INC	EQ 4MG PHOSPHATE/ML **	N014694	002
-------------------	------------------------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HEXADROL

+

EQ 10MG PHOSPHATE/ML **

N014694 003

EQ 20MG PHOSPHATE/ML

N014694 004

OINTMENT; OPHTHALMIC

DECADRON

MERCCK

EQ 0.05% PHOSPHATE

N011977 001

DEXAIR

PHARMAFAIR

EQ 0.05% PHOSPHATE

A088071 001 Dec 28, 1982

MAXIDEX

ALCON

EQ 0.05% PHOSPHATE

A083342 001

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR

EQ 0.1% PHOSPHATE

A088433 001 Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND

EQ 0.1% PHOSPHATE

A084170 001

EQ 0.1% PHOSPHATE

A084173 001

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

MERCCK

EQ 0.1% PHOSPHATE

N011984 001

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 0.1% PHOSPHATE

A084855 001

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

MERCCK

EQ 4MG PHOSPHATE/ML; 10MG/ML

N013334 002

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEODECADRON

MERCCK

EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM

N050324 001

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

MERCCK

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

N050322 001

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A064055 001 Oct 30, 1995

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A062714 001 Jul 21, 1986

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A062539 001 Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062566 001 Feb 22, 1985

DEXASPORIN

PHARMAFAIR

0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062411 001 May 16, 1983

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062544 001 Oct 29, 1984

DEXASPORIN

PHARMAFAIR

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062428 001 May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL

DISOMER

SCHERING

2MG/5ML

N011814 002

TABLET; ORAL

DISOMER

SCHERING

2MG

N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL

DISOPHROL

SCHERING

2MG; 60MG

N012394 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM 6MG;120MG

A089116 001 Jan 22, 1987

DISOBROM

SANDOZ 6MG;120MG

A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH 6MG;120MG

N013483 004 Sep 13, 1982

DRIXORAL

+ SCHERING PLOUGH 6MG;120MG **

N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS 6MG;120MG

A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLARAMINE

SCHERING 2MG/5ML

A086837 001 Jul 19, 1982

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC 2MG

A088682 001 Jan 17, 1986

POLARAMINE

SCHERING 2MG

A086835 001

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

+ TAKEDA PHARMS USA 30MG

N208056 001 Jan 26, 2016

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX

TEVA 15MG

A085355 001

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

ABLE 5MG

A076814 001 Aug 25, 2004

10MG

A076814 002 Aug 25, 2004

15MG

A076814 003 Aug 25, 2004

ELIXIR;ORAL

DEXEDRINE

GLAXOSMITHKLINE 5MG/5ML **

A083902 001

TABLET;ORAL

DEXAMPEX

TEVA 5MG

A083735 001

10MG

A083735 002

DEXEDRINE

GLAXOSMITHKLINE 5MG

A084935 001

DEXTROAMPHETAMINE SULFATE

EPIC PHARMA LLC 5MG

A090652 001 Mar 07, 2014

10MG

A090652 002 Mar 07, 2014

HALSEY 10MG

A083930 001

IDT AUSTRALIA LTD 5MG

A085370 001

LANNETT 5MG

A083903 001

10MG

A083903 003

15MG

A085652 001

MAST MM 5MG

A086521 001

NESHER PHARMS 5MG

A040365 001 Oct 31, 2002

10MG

A040367 001 Oct 31, 2002

PUREPAC PHARM 5MG

A084125 001

SANDOZ 10MG

A085371 001

VINTAGE PHARMS LLC 5MG

A040299 001 May 13, 1999

VITARINE 5MG

A084986 001

10MG

A085892 001

DEXTROSTAT

SHIRE 5MG **

A084051 001

10MG **

A084051 002

FERNDEX

FERNDALE LABS 5MG

A084001 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY 15MG/5ML; 6.25MG/5ML A088913 001 Mar 02, 1987

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AMNEAL PHARMS 15MG/5ML; 6.25MG/5ML A090575 001 Feb 08, 2011

+ ANI PHARMS 15MG/5ML; 6.25MG/5ML ** N011265 002 Apr 02, 1984

TRIS PHARMA INC 15MG/5ML; 6.25MG/5ML A091687 001 Jun 28, 2012

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML N018046 001

MILES 10GM/100ML N018504 001

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 2.5GM/100ML N018358 001

2.5GM/100ML N019626 001 Feb 02, 1988

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT 38.5GM/100ML N018923 001 Sep 19, 1984

DEXTROSE 5% IN PLASTIC CONTAINER

DHL 5GM/100ML N019971 001 Sep 28, 1995

DEXTROSE 50% IN PLASTIC CONTAINER

ICU MEDICAL INC 50GM/100ML N019894 001 Dec 26, 1989

DEXTROSE 60%

B BRAUN 60GM/100ML N017995 002 Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN 60GM/100ML N017995 001

BAXTER HLTHCARE 60GM/100ML N020047 002 Jul 02, 1991

HOSPIRA 60GM/100ML N019346 001 Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN 7.7GM/100ML N019626 003 Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML N019025 001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML N019515 001 May 08, 1986

L

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML N019844 001 Jun 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML N018273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML N019843 001 Aug 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML N018274 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML N017451 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 37MG/100ML	N019699 001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 75MG/100ML	N018744 001	Nov 09, 1982
	5GM/100ML; 75MG/100ML	N019699 002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 110MG/100ML	N019699 003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML	N018744 002	Nov 09, 1982
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML	N018744 003	Nov 09, 1982
	5GM/100ML; 220MG/100ML	N019699 005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML	N018744 004	Nov 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG /100ML; 207MG/100ML	N019514 001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG /100ML; 91MG/100ML	N019870 001	Jun 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG /100ML; 91MG/100ML	N018270 001	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG /100ML; 220MG/100ML	N018840 001	Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%			
B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268 014	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%			
B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268 010	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268 001	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;200MG/100ML	N018386	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;450MG/100ML	N018229	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;900MG/100ML	N018047	001
BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N018030	005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;200MG/100ML	N018030	004
MILES	5GM/100ML;200MG/100ML	N018399	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;225MG/100ML	N019482	001 Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;300MG/100ML	N019486	001 Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030	003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484	001 Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030	002
MILES	5GM/100ML;450MG/100ML	N018400	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483	001 Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026	001
MILES	5GM/100ML;900MG/100ML	N018500	001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN			
ABBVIE	1MG	N012302	005
	2MG	N012302	002
	4MG	N012302	004
	6MG	N012302	006

DEZOCINE

INJECTABLE; INJECTION

DALGAN			
ASTRAZENECA	5MG/ML	N019082	001 Dec 29, 1989
	10MG/ML	N019082	002 Dec 29, 1989
	15MG/ML	N019082	003 Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282			
BAYER HLTHCARE	60%	A087726	001 Sep 23, 1982
CARDIOGRAFIN			
BRACCO	85%	N011620	002
DIATRIZOATE MEGLUMINE			
BRACCO	76%	N010040	017
HYPAAQUE			
GE HEALTHCARE	30%	N016403	002
	60%	N016403	001
RENO-60			
BRACCO	60%	N010040	016
RENO-DIP			
BRACCO	30%	N010040	012
UROVIST MEGLUMINE DIU/CT			
BAYER HLTHCARE	30%	A087739	001 Sep 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIATRIZOATE MEGLUMINE

SOLUTION; URETERAL

RENO-30

BRACCO 30%

N010040 021

UROVIST CYSTO

BAYER HLTHCARE 30%

A087729 001 Sep 23, 1982

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE 30%

A087731 001 Sep 23, 1982

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE 30%

N016403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE 52%;8%

A087724 001 Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE 66%;10%

A087723 001 Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION 52%;8%

A088166 001 Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE 66%;10%

A086505 001

HYPAQUE-M, 75%

GE HEALTHCARE 50%;25%

N010220 003

HYPAQUE-M, 90%

GE HEALTHCARE 60%;30%

N010220 002

MD-60

MALLINCKRODT 52%;8%

A087074 001

MD-76

MALLINCKRODT 66%;10%

A087073 001

MD-76R

+ LIEBEL-FLARSHEIM 66%;10%

N019292 001 Sep 29, 1989

RENOCAL-76

BRACCO 66%;10%

A089347 001 Jun 01, 1988

RENOGRAFIN-60

BRACCO 52%;8%

N010040 006

RENOVIST

BRACCO 34.3%;35%

N010040 020

RENOVIST II

BRACCO 28.5%;29.1%

N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10%

A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100%

N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT 50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50%

A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20%

N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE 15MG

N018179 001

GEL; RECTAL

DIASTAT

+ VALEANT PHARMS NORTH 5MG/ML (5MG/ML) **

N020648 002 Jul 29, 1997

+ 10MG/2ML (5MG/ML) **

N020648 003 Jul 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIAZEPAM

GEL;RECTAL

DIASTAT

+

15MG/3ML (5MG/ML) **

N020648 004 Jul 29, 1997

+

20MG/4ML (5MG/ML) **

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM

5MG/ML

A070662 001 Jun 25, 1986

HOSPIRA

5MG/ML

A071584 001 Oct 13, 1987

MARSAM PHARMS LLC

5MG/ML

A072371 001 Jan 29, 1993

PARENTA PHARMS

5MG/ML

A076815 001 Apr 15, 2004

US ARMY

5MG/ML **

N020124 001 Dec 05, 1990

WARNER CHILCOTT

5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS

5MG/ML

A070296 001 Feb 12, 1986

5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

WATSON LABS INC

5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

WEST-WARD PHARMS INT

5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A070313 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

DIZAC

PHARMACIA AND UPJOHN

5MG/ML **

N019287 001 Jun 18, 1993

VALIUM

+ ROCHE

5MG/ML **

N016087 001

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH

2MG

A070781 001 Mar 19, 1986

5MG

A070706 001 Mar 19, 1986

10MG

A070707 001 Mar 19, 1986

DAVA PHARMS INC

10MG

A070228 001 Sep 26, 1985

DURAMED PHARMS BARR

2MG

A070894 001 Aug 27, 1986

5MG

A070895 001 Aug 27, 1986

10MG

A070896 001 Aug 27, 1986

FERNDALE LABS

2MG

A070903 001 Apr 01, 1987

5MG

A070904 001 Apr 01, 1987

10MG

A070905 001 Apr 01, 1987

HALSEY

2MG

A070987 001 Aug 15, 1986

5MG

A070996 001 Aug 15, 1986

10MG

A070956 001 Aug 15, 1986

IVAX SUB TEVA PHARMS

2MG

A070360 001 Sep 04, 1985

5MG

A070361 001 Sep 04, 1985

10MG

A070362 001 Sep 04, 1985

MARTEC USA LLC

10MG

A072402 001 Apr 25, 1989

PIONEER PHARMS

2MG

A070787 001 Aug 02, 1988

5MG

A070788 001 Aug 02, 1988

10MG

A070776 001 Aug 02, 1988

ROXANE

2MG

A070356 001 Jun 17, 1986

5MG

A070357 001 Jun 17, 1986

10MG

A070358 001 Jun 17, 1986

TEVA PHARMS

5MG

A070153 001 Nov 01, 1985

UPSHER-SMITH LABS

2MG

A070302 001 Dec 20, 1985

5MG

A070303 001 Dec 20, 1985

10MG

A070304 001 Dec 20, 1985

VIRTUS PHARMS

2MG

A070462 001 Feb 25, 1986

5MG

A070463 001 Feb 25, 1986

10MG

A070464 001 Feb 25, 1986

WARNER CHILCOTT

2MG

A070209 001 Sep 04, 1985

5MG

A070210 001 Sep 04, 1985

10MG

A070222 001 Sep 04, 1985

WATSON LABS

2MG

A070456 001 Nov 01, 1985

5MG

A070457 001 Nov 01, 1985

10MG

A070458 001 Nov 01, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIAZEPAM

TABLET; ORAL

Q-PAM

QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425	001	
	100MG	N017425	002	

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCALINE

NOVARTIS	2.5MG/ML	N006203	001	
----------	----------	---------	-----	--

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

+ STRONGBRIDGE US	50MG **	N011366	001	
-------------------	---------	---------	-----	--

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

+ NOVARTIS	25MG **	N020142	001	Nov 24, 1993
	50MG **	N020142	002	Nov 24, 1993

DICLOFENAC POTASSIUM

SANDOZ	50MG	A075582	001	Feb 23, 2001
SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION; TOPICAL

PENNSAID

+ NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009
-------------------	---------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC	0.1%	A077600	001	Nov 13, 2008
FALCON PHARMS	0.1%	N020809	001	May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997

VOLTAREN

+ NOVARTIS	25MG **	N019201	001	Jul 28, 1988
	50MG **	N019201	002	Jul 28, 1988
	75MG **	N019201	003	Jul 28, 1988

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
-------------------	-------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE;ORAL

VOLTAREN-XR

+ NOVARTIS

100MG **

N020254 001 Mar 08, 1996

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION;ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE;ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET;ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS

10MG

A040204 001 Feb 28, 1997

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

SUN PHARM INDUSTRIES

10MG

A084505 001 Oct 21, 1986

WATSON LABS

10MG

A083179 001 Feb 12, 1986

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP;ORAL

BENTYL

+ APTALIS PHARMA US

10MG/5ML **

N007961 002 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS

20MG

A040161 001 Oct 01, 1996

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

SUN PHARM INDUSTRIES

20MG

A084600 001 Jul 29, 1985

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

MYLAN PHARMS INC

125MG

A090788 001 Apr 08, 2010

200MG

A090788 002 Apr 08, 2010

250MG

A090788 003 Apr 08, 2010

400MG

A090788 004 Apr 08, 2010

FOR SOLUTION;ORAL

DIDANOSINE

AUROBINDO PHARMA

10MG/ML

A078112 001 Mar 08, 2007

VIDEX

BRISTOL MYERS SQUIBB

100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIRIDANOSINE

TABLET, CHEWABLE;ORAL

VIDEX

+	BRISTOL MYERS SQUIBB	25MG **	N020154 002	Oct 09, 1991
+		50MG **	N020154 003	Oct 09, 1991
+		100MG **	N020154 004	Oct 09, 1991
+		150MG **	N020154 005	Oct 09, 1991
+		200MG **	N020154 006	Oct 28, 1999

TABLET, FOR SUSPENSION;ORAL

DIRIDANOSINE

AUROBINDO	100MG	A077275 001	Aug 14, 2012
	150MG	A077275 002	Aug 14, 2012
	200MG	A077275 003	Aug 14, 2012

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM	0.01%	N006110 005	
--------------------	-------	-------------	--

DV

SANOFI AVENTIS US	0.01%	A083518 001	
-------------------	-------	-------------	--

ESTRAGUARD

SOLVAY	0.01%	A084436 001	
--------	-------	-------------	--

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US	0.7MG	A083517 001	
-------------------	-------	-------------	--

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE	50MG	N006459 001	
---------	------	-------------	--

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

CHARTWELL RX	25MG	A088267 001	Aug 25, 1983
	25MG	A088268 001	Aug 25, 1983
EPIC PHARMA LLC	25MG	A040828 001	Nov 05, 2008
SANDOZ	25MG	A085916 001	
TEVA	25MG	A088642 001	Sep 20, 1984
UCB INC	25MG	A085544 001	
WATSON LABS	25MG	A085741 001	

TENUATE

SANOFI AVENTIS US	25MG	N017668 001	
-------------------	------	-------------	--

TEPANIL

3M	25MG	N011673 001	
----	------	-------------	--

TABLET, EXTENDED RELEASE;ORAL

TENUATE

SANOFI AVENTIS US	75MG	N017669 001	
-------------------	------	-------------	--

TEPANIL TEN-TAB

3M	75MG	N017956 001	
----	------	-------------	--

DIETHYLSTILBESTROL

INJECTABLE;INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003	
	0.5MG/ML	N004056 004	
	1MG/ML	N004056 005	
	5MG/ML	N004056 006	

SUPPOSITORY;VAGINAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004040 001	
	0.5MG	N004040 002	

STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056 001	
	0.5MG	N004056 002	

TABLET;ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004041 002	
	0.5MG	N004041 003	
	1MG	N004041 004	
	5MG	N004041 005	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIETHYLSTILBESTROL

TABLET; ORAL

STILBESTROL

TABLICAPS	0.5MG	A083004	001
	1MG	A083002	001
	5MG	A083006	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	007
	0.25MG	N004056	017
	0.5MG	N004056	008
	1MG	N004056	009
	5MG	N004056	010

TABLET, DELAYED RELEASE; ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004039	002
	0.25MG	N004039	005
	0.5MG	N004039	003
	1MG	N004039	004
	5MG	N004039	006

STILBESTROL

TABLICAPS	0.5MG	A083003	001
	1MG	A083005	001
	5MG	A083007	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	011
	0.5MG	N004056	012
	1MG	N004056	013
	5MG	N004056	014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010	001
--------------	-----------	---------	-----

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS	50MG	N010010	002
--------------	------	---------	-----

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS	0.05%	A075187	001	Mar 30, 1998
----------------	-------	---------	-----	--------------

FLORONE

PHARMACIA AND UPJOHN	0.05% **	N017741	001
----------------------	----------	---------	-----

FLORONE E

PHARMACIA AND UPJOHN	0.05%	N019259	001	Aug 28, 1985
----------------------	-------	---------	-----	--------------

PSORCON

+ TARO PHARMS NORTH	0.05% **	N020205	001	Nov 20, 1992
---------------------	----------	---------	-----	--------------

OINTMENT; TOPICAL

PSORCON

+ PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985
------------------------	-------	---------	-----	--------------

PSORCON E

PHARMACIA AND UPJOHN	0.05%	N017994	001
----------------------	-------	---------	-----

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

ALLIED PHARMA INC	250MG	A073562	001	Nov 27, 1992
	500MG	A073563	001	Nov 27, 1992
IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996
PUREPAC PHARM	250MG	A074285	001	May 07, 1996
	500MG	A074285	002	May 07, 1996
TEVA	250MG	A073679	001	Jul 31, 1992
WATSON LABS	250MG	A074400	001	Jul 17, 1997
	500MG	A074400	002	Jul 17, 1997

DOLOBID

+ MERCK	250MG **	N018445	001	Apr 19, 1982
---------	----------	---------	-----	--------------

+	500MG **	N018445	002	Apr 19, 1982
---	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

LANOXIN

CONCORDIA PHARMS INC

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML

N018885 001 Nov 30, 1984

0.5MG/0.7ML; 5,000

N018885 002 Nov 30, 1984

UNITS/0.7ML; 7.46MG/0.7ML

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

+ BIOVAIL

60MG **

N019471 001 Jan 23, 1989

+

90MG **

N019471 002 Jan 23, 1989

+

120MG **

N019471 003 Jan 23, 1989

+

180MG **

N019471 004 Jan 23, 1989

DILACOR XR

+ ALLERGAN SALES LLC

120MG **

N020092 001 May 29, 1992

+

180MG **

N020092 002 May 29, 1992

+

240MG **

N020092 003 May 29, 1992

DILT-CD

APOTEX

120MG

A076151 001 May 20, 2004

180MG

A076151 002 May 20, 2004

240MG

A076151 003 May 20, 2004

300MG

A076151 004 May 20, 2004

DILTIAZEM HYDROCHLORIDE

ACTAVIS LABS FL INC

120MG

A074852 001 Oct 10, 1997

180MG

A074852 002 Oct 10, 1997

240MG

A074852 003 Oct 10, 1997

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

NESHER PHARMS

120MG

A076563 002 Sep 12, 2006

180MG

A076563 003 Sep 12, 2006

240MG

A076563 004 Sep 12, 2006

300MG

A076563 005 Sep 12, 2006

360MG

A076563 006 Sep 12, 2006

420MG

A076563 001 Sep 12, 2006

TEVA

60MG

A074079 001 Nov 30, 1993

90MG

A074079 002 Nov 30, 1993

120MG

A074079 003 Nov 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **	N020027	001	Oct 24, 1991
+	25MG/VIAL **	N020027	003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML	A075375	001	Sep 30, 1999
TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL; 5MG	N020507	001	Oct 04, 1996
---------	-------------------	---------	-----	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001
WATSON LABS	50MG/ML	A083531	001
WATSON LABS TEVA	50MG/ML	A080615	001
WYETH AYERST	50MG/ML	A084316	001

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001
------	------------	---------	-----

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001
NEXGEN PHARMA INC	50MG	A085985	001
WATSON LABS	50MG	A085166	001

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

VESSELON SPV LLC	0.92MG/VIAL; 0.092MG/VIAL	N021191	001	May 31, 2002
------------------	---------------------------	---------	-----	--------------

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434	001
----------------------	----------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING 100MG N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS 25MG N005845 007

50MG N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA 25MG A080519 004

50MG A080519 003

ANABOLIC 50MG A083275 001

ELKINS SINN 25MG A085701 001

50MG A085701 002

HALSEY 50MG A087914 001 Jun 04, 1984

HEATHER 25MG A084524 001

50MG A083953 001

HIKMA INTL PHARMS 50MG A083567 001

IMPAX LABS 25MG A080807 001

50MG A080807 002

IVAX SUB TEVA PHARMS 25MG A080762 001

50MG A080762 002

LANNETT 25MG A080868 001

50MG A080868 002

LEDERLE 25MG A086874 001

50MG A086875 001

LNK 25MG A087977 001 Jan 27, 1983

50MG A087978 001 Jan 27, 1983

MK LABS 25MG A083087 001

50MG A083087 002

MUTUAL PHARM 25MG A084506 001

NEWTRON PHARMS 25MG A086543 001

50MG A086544 001

NEXGEN PHARMA INC 25MG A083634 001

PERRIGO 25MG A083061 001

50MG A083061 002

PIONEER PHARMS 25MG A089101 001 Dec 20, 1985

50MG A088880 001 Dec 20, 1985

PUREPAC PHARM 25MG A085156 001

50MG A085150 001

PVT FORM 25MG A083027 001

50MG A083027 002

ROXANE 50MG A080635 001

SANDOZ 25MG A080832 001

25MG A080845 002

50MG A080832 002

50MG A080845 001

SUN PHARM INDUSTRIES 25MG A089488 001 Jan 02, 1987

50MG A089489 001 Jan 02, 1987

SUPERPHARM 25MG A089040 001 May 15, 1985

50MG A089041 001 May 15, 1985

TEVA 25MG A085874 001

50MG A085874 002

VALEANT PHARM INTL 25MG A080596 001

50MG A080592 001

VANGARD 25MG A088034 001 Oct 27, 1982

50MG A087630 001

WATSON LABS 25MG A080728 001

25MG A083797 001

25MG A085138 001

50MG A080727 001

50MG A083797 002

50MG A085083 001

WHITEWORTH TOWN PLSN 25MG A083441 001

50MG A080800 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

BELIX

HALSEY 12.5MG/5ML A086586 001 Oct 03, 1983

BENADRYL

MCNEIL CONS 12.5MG/5ML N005845 004

DIBENIL

CENCI 12.5MG/5ML A088304 001 Dec 16, 1983

DIPHEN

USL PHARMA 12.5MG/5ML A084640 001

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY 12.5MG/5ML A083674 001

CENCI 12.5MG/5ML A087941 001 Dec 17, 1982

KV PHARM 12.5MG/5ML A085621 001

LANNETT 12.5MG/5ML A080939 002

LEDERLE 12.5MG/5ML A086937 001

MK LABS 12.5MG/5ML A083088 002

NASKA 12.5MG/5ML A088680 001 May 31, 1985

PERRIGO 12.5MG/5ML A083063 001

PUREPAC PHARM 12.5MG/5ML A083237 001 Jan 25, 1982

PVT FORM 12.5MG/5ML A085287 001

ROXANE 12.5MG/5ML A080643 001

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A080763 002

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS 10MG/ML N006146 001

+ 50MG/ML ** N006146 002

BENADRYL PRESERVATIVE FREE

+ MCNEIL CONS 50MG/ML ** N009486 001

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR 10MG/ML A080822 001

EUROHLTH INTL SARL 50MG/ML A083183 001

LYPHOMED 10MG/ML A087066 001

WATSON LABS 10MG/ML A083533 001

WATSON LABS TEVA 10MG/ML A080873 001

50MG/ML A080873 002

WYETH AYERST 50MG/ML A080577 001

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM 50MG/ML A080586 002

INTL MEDICATION 50MG/ML A084094 001

WATSON LABS TEVA 50MG/ML A080873 003

SYRUP; ORAL

ANTITUSSIVE

PERRIGO 12.5MG/5ML A071292 001 Apr 10, 1987

BELDIN

HALSEY 12.5MG/5ML A089179 001 Jun 05, 1986

BENYLIN

PARKE DAVIS 12.5MG/5ML N006514 004

DIPHEN

MORTON GROVE 12.5MG/5ML A070118 001 Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS 12.5MG/5ML A070497 001 Apr 25, 1989

CUMBERLAND SWAN 12.5MG/5ML A073611 001 Aug 20, 1992

HI TECH PHARMA 12.5MG/5ML A072416 001 Sep 28, 1990

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A070205 001 Jan 28, 1986

SILPHEN

SILARX 12.5MG/5ML A072646 001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT 12.5MG/5ML A070524 001 Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS 12.5MG/5ML; 30MG/5ML N019014 001 Jun 11, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE EQ 25MG BASE N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE 5MG N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AKORN 0.1% A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1% A074188 001 May 19, 1995

FALCON PHARMS 0.1% A073636 001 Jun 30, 1994

PROPINE

ALLERGAN 0.1% N018239 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

HOSPIRA 5MG/ML A074601 001 Dec 19, 1997

MYLAN LABS LTD 5MG/ML A075769 001 Nov 27, 2002

TEVA PHARMS USA 5MG/ML A074952 001 Nov 26, 1997

IV PERSANTINE

+ BOEHRINGER INGELHEIM 5MG/ML ** N019817 001 Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

GLENMARK GENERICS 25MG A088999 001 Feb 05, 1991

50MG A089000 001 Feb 05, 1991

75MG A089001 001 Feb 05, 1991

IDT AUSTRALIA LTD 25MG A086944 002 Apr 16, 1991

50MG A086944 001 Feb 25, 1992

75MG A086944 003 Feb 25, 1992

LANNETT 25MG A040898 001 Apr 23, 2008

50MG A040898 002 Apr 23, 2008

75MG A040898 003 Apr 23, 2008

OXFORD PHARMS 25MG A040542 001 Apr 21, 2006

50MG A040542 002 Apr 21, 2006

75MG A040542 003 Apr 21, 2006

PUREPAC PHARM 25MG A089425 001 Jul 12, 1990

50MG A089426 001 Jul 12, 1990

75MG A089427 001 Jul 12, 1990

WATSON LABS 50MG A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS 250MG N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AUROLIFE PHARMA LLC EQ 100MG BASE A070470 001 Dec 10, 1985

EQ 150MG BASE A070471 001 Dec 10, 1985

INTERPHARM EQ 100MG BASE A071190 001 Jan 15, 1987

EQ 150MG BASE A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS EQ 100MG BASE A070186 001 Nov 18, 1985

EQ 150MG BASE A070187 001 Nov 18, 1985

MYLAN EQ 100MG BASE A070138 001 Jun 14, 1985

EQ 150MG BASE A070139 001 Jun 14, 1985

SUN PHARM INDUSTRIES EQ 100MG BASE A070351 001 Dec 17, 1985

EQ 150MG BASE A070352 001 Dec 17, 1985

SUPERPHARM EQ 100MG BASE A070940 001 Feb 09, 1987

EQ 150MG BASE A070941 001 Feb 09, 1987

WATSON LABS EQ 100MG BASE A070240 001 Feb 02, 1986

EQ 150MG BASE A070241 001 Feb 02, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS

EQ 150MG BASE

A071200 001 Dec 15, 1987

DISULFIRAM

TABLET;ORAL

ANTABUSE

+ TEVA WOMENS

250MG **

N007883 003

+

500MG **

N007883 002

DISULFIRAM

PAR PHARM

250MG

A088792 001 Aug 14, 1984

500MG

A088793 001 Aug 14, 1984

WATSON LABS

250MG

A086889 001

250MG

A087973 001 Aug 05, 1983

500MG

A087974 001 Aug 05, 1983

WATSON LABS TEVA

500MG

A086890 001

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT

EQ 250MG BASE

N019794 001 Jul 11, 1990

EQ 500MG BASE

N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

MYLAN

EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008

EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008

EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

G AND W LABS INC

EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE

EQ 12.5MG BASE/ML

A074381 001 Sep 26, 1996

HOSPIRA

EQ 1.25GM BASE/100ML

A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML

A074545 001 Jun 25, 1998

TELGENT PHARMA INC

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995

TEVA PARENTERAL

EQ 12.5MG BASE/ML

A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML

A074279 001 Feb 18, 1998

EQ 12.5MG BASE/ML

A074995 001 Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993

DOBUTREX

+ LILLY

EQ 12.5MG BASE/ML

N017820 002

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ

+ SUN PHARMA GLOBAL

20MG/VIAL

N022534 001 May 03, 2011

+

80MG/VIAL

N022534 002 May 03, 2011

DOCETAXEL

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012

+ HOSPIRA INC

120MG/6ML (20MG/ML)

N022234 006 Jun 23, 2016

PFIZER LABS

20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014

80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014

130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014

200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014

TAXOTERE

+ SANOFI AVENTIS US

40MG/ML **

N020449 001 May 14, 1996

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

+ US PHARM HOLDINGS

12.5MG/0.625ML (20MG/ML)

N020624 002 Sep 11, 1997

+

100MG/5ML (20MG/ML)

N020624 001 Sep 11, 1997

500MG/25ML (20MG/ML)

N020624 003 Dec 11, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOLASETRON MESYLATE

TABLET; ORAL

ANZEMET

+	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
-----------	---------	---------	-----	--------------

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
	10MG	A201335	002	Aug 29, 2011
HIKMA PHARMS	5MG	A090247	001	May 31, 2011
	10MG	A090247	002	May 31, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
	10MG	A077975	001	Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

+	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
+		500MG/VIAL	N022106	001	Oct 12, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC EQ 2% BASE A078395 001 Oct 28, 2008

ZAMBON SPA EQ 2% BASE A091034 001 Dec 04, 2013

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC EQ 2% BASE;EQ 0.5% BASE A078201 001 Oct 28, 2008

LANNETT HOLDINGS INC EQ 2% BASE;EQ 0.5% BASE A201998 001 Dec 17, 2014

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE EQ 1MG BASE/ML N019946 001 Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS 20MG/ML A073529 001 Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH EQ 1MG BASE A075574 001 Oct 18, 2000

EQ 2MG BASE A075574 002 Oct 18, 2000

EQ 4MG BASE A075574 003 Oct 18, 2000

EQ 8MG BASE A075574 004 Oct 18, 2000

FOSUN PHARMA EQ 1MG BASE A075646 001 Oct 18, 2000

EQ 2MG BASE A075646 002 Oct 18, 2000

EQ 4MG BASE A075646 003 Oct 18, 2000

EQ 8MG BASE A075646 004 Oct 18, 2000

GENPHARM EQ 1MG BASE A075466 001 Oct 18, 2000

EQ 2MG BASE A075466 002 Oct 18, 2000

EQ 4MG BASE A075466 003 Oct 18, 2000

EQ 8MG BASE A075466 004 Oct 18, 2000

IDT AUSTRALIA LTD EQ 1MG BASE A075432 001 Oct 18, 2000

EQ 2MG BASE A075432 002 Oct 18, 2000

EQ 4MG BASE A075432 003 Oct 18, 2000

EQ 8MG BASE A075432 004 Oct 18, 2000

IVAX SUB TEVA PHARMS EQ 1MG BASE A075453 001 Oct 18, 2000

EQ 2MG BASE A075453 002 Oct 18, 2000

EQ 4MG BASE A075453 003 Oct 18, 2000

EQ 8MG BASE A075453 004 Oct 18, 2000

NESHER PHARMS EQ 1MG BASE A075609 001 Oct 18, 2000

EQ 2MG BASE A075609 002 Oct 18, 2000

EQ 4MG BASE A075609 003 Oct 18, 2000

EQ 8MG BASE A075609 004 Oct 18, 2000

TEVA EQ 1MG BASE A075353 001 Jan 12, 2001

EQ 2MG BASE A075353 002 Jan 12, 2001

EQ 4MG BASE A075353 003 Jan 12, 2001

EQ 8MG BASE A075353 004 Jan 12, 2001

WATSON LABS INC EQ 1MG BASE A075426 001 Oct 18, 2000

EQ 2MG BASE A075426 002 Oct 18, 2000

EQ 4MG BASE A075426 003 Oct 18, 2000

EQ 8MG BASE A075426 004 Oct 18, 2000

DOXEPIIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIIN HYDROCHLORIDE

DAVA PHARMS INC EQ 10MG BASE A071685 001 Jan 05, 1988

EQ 25MG BASE A071686 001 Jan 05, 1988

EQ 50MG BASE A071673 001 Jan 05, 1988

EQ 75MG BASE A071674 001 Jan 05, 1988

EQ 100MG BASE A071675 001 Jan 05, 1988

EQ 150MG BASE A071676 001 Jan 05, 1988

NEW RIVER EQ 10MG BASE N016987 001

EQ 25MG BASE N016987 002

EQ 50MG BASE N016987 003

EQ 75MG BASE N016987 006

EQ 100MG BASE N016987 004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

	EQ 150MG BASE	N016987 007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987
	EQ 25MG BASE	A071437 001	Nov 09, 1987
	EQ 50MG BASE	A071595 001	Nov 09, 1987
	EQ 75MG BASE	A071608 001	Nov 09, 1987
	EQ 100MG BASE	A071422 001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987 001	Mar 29, 1991
SINEQUAN			
+ PFIZER	EQ 10MG BASE **	N016798 003	
+	EQ 25MG BASE **	N016798 001	
+	EQ 50MG BASE **	N016798 002	
+	EQ 75MG BASE **	N016798 006	
+	EQ 100MG BASE **	N016798 005	
+	EQ 150MG BASE **	N016798 007	

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC	EQ 10MG BASE/ML	A075924 001	Jan 15, 2004
SINEQUAN			
+ PFIZER	EQ 10MG BASE/ML **	N017516 001	

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

MYLAN PHARMS INC	EQ 3MG BASE	A202337 001	Jan 20, 2016
	EQ 6MG BASE	A202337 002	Jan 20, 2016

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN	2MG/ML	A063165 001	Jan 30, 1991
	200MG/100ML	A063165 002	Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

PHARMACIA AND UPJOHN	10MG/VIAL	N050467 001	
	20MG/VIAL	N050467 003	May 20, 1985
	50MG/VIAL	N050467 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

	150MG/VIAL	N050467 004	Jul 22, 1987
SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012
RUBEX			
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926 001	Apr 13, 1989
	50MG/VIAL	A062926 002	Apr 13, 1989
	100MG/VIAL	A062926 003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	A065055 004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000
	EQ 100MG BASE	A065032 002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041 001	Apr 28, 2000
	EQ 100MG BASE	A065041 002	Apr 28, 2000
FOR SUSPENSION; ORAL			
DOXYCHEL			
RACHELLE	EQ 25MG BASE/5ML	A061720 001	
TABLET; ORAL			
DOXYCYCLINE			
SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006
	EQ 75MG BASE	A065353 002	Nov 27, 2006
	EQ 100MG BASE	A065353 003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471 001	Apr 17, 2009
	EQ 75MG BASE	A065471 002	Apr 17, 2009
	EQ 100MG BASE	A065471 003	Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497 001	Aug 23, 1984
	EQ 100MG BASE	A062497 002	Jun 15, 1984
DOXYCYCLINE HYCLATE			
HALSEY	EQ 50MG BASE	A062119 002	May 24, 1985
	EQ 100MG BASE	A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463 001	Dec 07, 1983
	EQ 100MG BASE	A062463 002	Dec 07, 1983
INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988
	EQ 100MG BASE	A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418 001	Jan 28, 1983
	EQ 100MG BASE	A062418 002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984
	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	
PERIOSTAT			
+ COLLAGENEX	EQ 20MG BASE **	N050744 001	Sep 30, 1998
VIBRAMYCIN			
+ PFIZER	EQ 50MG BASE **	N050007 001	
CAPSULE, COATED PELLETS; ORAL			
DOXYCYCLINE HYCLATE			
PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
CAPSULE, DELAYED RELEASE; ORAL			
DORYX			
+ MAYNE PHARMA INTL	EQ 75MG BASE	N050582 002	Aug 13, 2001
+ WARNER CHILCOTT	EQ 100MG BASE	N050582 001	Jul 22, 1985
	EQ 100MG BASE	A062653 001	Oct 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005

EQ 100MG BASE

A065281 002 Dec 21, 2005

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE

EQ 100MG BASE/VIAL

A061953 001

DOXYCYCLINE

WEST-WARD PHARMS INT

EQ 100MG BASE/VIAL

A062450 001 Oct 27, 1983

EQ 200MG BASE/VIAL

A062450 002 Oct 27, 1983

EQ 200MG BASE/VIAL

A062569 002 Mar 09, 1988

DOXYCYCLINE HYCLATE

WEST-WARD PHARMS INT

EQ 100MG BASE/VIAL

A062992 001 Feb 16, 1989

EQ 200MG BASE/VIAL

A062992 002 Feb 16, 1989

VIBRAMYCIN

+ PFIZER

EQ 100MG BASE/VIAL **

N050442 002

+

EQ 200MG BASE/VIAL **

N050442 001

TABLET; ORAL

DOXY-LEMMON

TEVA

EQ 100MG BASE

A062581 001 Mar 15, 1985

DOXYCYCLINE HYCLATE

EPIC PHARMA LLC

EQ 20MG BASE

A065182 001 May 13, 2005

HEATHER

EQ 100MG BASE

A062462 001 May 11, 1983

INTERPHARM

EQ 100MG BASE

A062764 001 Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE

A062391 001 Sep 30, 1982

SUPERPHARM

EQ 100MG BASE

A062494 001 Feb 20, 1985

VINTAGE PHARMS

EQ 100MG BASE

A062538 001 Apr 07, 1986

WARNER CHILCOTT

EQ 100MG BASE

A062593 001 Aug 28, 1985

WATSON LABS

EQ 50MG BASE

A062392 001 Mar 31, 1983

EQ 100MG BASE

A062392 002 Mar 31, 1983

PERIOSTAT

+ GALDERMA LABS LP

EQ 20MG BASE **

N050783 001 Feb 02, 2001

VIBRA-TABS

+ PFIZER

EQ 100MG BASE **

N050533 001

TABLET, DELAYED RELEASE; ORAL

DORYX MPC

+ MAYNE PHARMA

EQ 60MG BASE

N050795 007 May 20, 2016

DOXYCYCLINE HYCLATE

IMPAX LABS INC

EQ 75MG BASE

A090505 001 Dec 28, 2010

EQ 100MG BASE

A090505 002 Dec 28, 2010

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG

N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG

N006412 015

25MG

N006412 014

DOXY-SLEEP-AID

PAR PHARM

25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG

A088900 002 Feb 12, 1988

QUANTUM PHARMICS

25MG

A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG;10MG **

N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DRONABINOL

CAPSULE; ORAL

DRONABINOL

INSYS THERAP	2.5MG	A078501 001	Aug 19, 2011
	5MG	A078501 002	Aug 19, 2011
	10MG	A078501 003	Aug 19, 2011

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992 001	Nov 17, 1986
	2.5MG/ML	A070993 001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018 001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645 001	Apr 07, 1988
	2.5MG/ML	A072272 001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019 001	Oct 19, 1988
	2.5MG/ML	A072020 001	Oct 19, 1988
	2.5MG/ML	A072021 001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335 001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750 001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754 001	Sep 06, 1988
	2.5MG/ML	A071755 001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520 001	Nov 27, 1991
	2.5MG/ML	A073521 001	Nov 27, 1991
	2.5MG/ML	A073523 001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028 001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982 001	May 04, 1988
INNOVAR			
AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049 001	

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

+	ASTRAZENECA	0.5% **	N009925 002
+		1% **	N009925 001

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY	5MG **	N017388 001
	10MG **	N017388 002

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA	160MG/15ML	N007794 003
------	------------	-------------

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA	250MG/ML	N009088 001
------	----------	-------------

TABLET; ORAL

DILOR

SAVAGE LABS	200MG	A084514 001
-------------	-------	-------------

DILOR-400

SAVAGE LABS	400MG	A084751 001
-------------	-------	-------------

LUFYLLIN

MYLAN SPECIALITY LP	200MG	A084566 001
---------------------	-------	-------------

	400MG	A084566 002
--	-------	-------------

NEOTHYLLINE

TEVA	200MG	N007794 001
------	-------	-------------

	400MG	N007794 002
--	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ECHOTHIOPHATE IODIDEFOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

WYETH PHARMS INC	0.03%	N011963	002
	0.06%	N011963	004
	0.25%	N011963	003

EDETATE CALCIUM DISODIUM

TABLET;ORAL

CALCIUM DISODIUM VERSENATE
MEDICIS

500MG	N008922	002
-------	---------	-----

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA	10MG/ML
WATSON LABS	10MG/ML

A040131	001	Feb 24, 1998
A040044	001	Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS	10MG/ML
-------------	---------

A040043	001	Mar 20, 1996
---------	-----	--------------

REVERSOL

ORGANON USA INC	10MG/ML
-----------------	---------

A089624	001	May 13, 1988
---------	-----	--------------

TENSILON

+ TELIGENT	10MG/ML **
------------	------------

N007959	001
---------	-----

TENSILON PRESERVATIVE FREE

+ TELIGENT	10MG/ML **
------------	------------

N007959	002
---------	-----

EFAVIRENZ

CAPSULE;ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB	100MG **
------------------------	----------

N020972	002	Sep 17, 1998
---------	-----	--------------

TABLET;ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB	300MG **
------------------------	----------

N021360	001	Feb 01, 2002
---------	-----	--------------

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US	200MG/ML
-------------------	----------

N019879	002	Nov 28, 1990
---------	-----	--------------

ELVITEGRAVIR

TABLET;ORAL

VITEKTA

+ GILEAD SCIENCES INC	85MG
-----------------------	------

N203093	001	Sep 24, 2014
---------	-----	--------------

+	150MG
---	-------

N203093	002	Sep 24, 2014
---------	-----	--------------

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

APOTHECON	2.5MG
-----------	-------

A075583	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075583	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075583	003	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075583	004	Aug 22, 2000
---------	-----	--------------

IVAX SUB TEVA PHARMS	2.5MG
----------------------	-------

A075482	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075482	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075482	003	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075482	004	Aug 22, 2000
---------	-----	--------------

KRKA DD NOVO MESTO	2.5MG
--------------------	-------

A075370	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075370	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075369	001	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075369	002	Aug 22, 2000
---------	-----	--------------

MYLAN	2.5MG
-------	-------

A075472	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075472	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075472	003	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075472	004	Aug 22, 2000
---------	-----	--------------

SANDOZ	2.5MG
--------	-------

A075048	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075048	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075048	003	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075048	004	Aug 22, 2000
---------	-----	--------------

SANDOZ INC	2.5MG
------------	-------

A075621	001	Aug 22, 2000
---------	-----	--------------

	5MG
--	-----

A075621	002	Aug 22, 2000
---------	-----	--------------

	10MG
--	------

A075621	003	Aug 22, 2000
---------	-----	--------------

	20MG
--	------

A075621	004	Aug 22, 2000
---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

SUN PHARM INDS LTD	2.5MG	A075556 001	Aug 22, 2000
	5MG	A075556 002	Aug 22, 2000
	10MG	A075556 003	Aug 22, 2000
	20MG	A075556 004	Aug 22, 2000
WATSON LABS	2.5MG	A075501 001	Aug 22, 2000
	5MG	A075501 002	Aug 22, 2000
	10MG	A075501 003	Aug 22, 2000
	20MG	A075501 004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668 002	Oct 28, 1998
	5MG; 5MG	N020668 001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736 001	Mar 25, 2003
	10MG; 25MG	A075736 002	Mar 25, 2003
UPSHER-SMITH LABS	5MG; 12.5MG	A076116 001	Sep 19, 2001
	10MG; 25MG	A076116 002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000
VASOTEC + BIOVAIL LABS INTL	1.25MG/ML	N019309 001	Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803 001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396 001	Jul 29, 1994
ETHRANE			
BAXTER HLTHCARE	99.9%	N017087 001	

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US	200MG	N019616 004	Dec 31, 1991
	400MG	N019616 005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

+ SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164 006	Jun 02, 2000
---------------------	--------------------------	-------------	--------------

ENTACAPONE

TABLET; ORAL

ENTACAPONE

MYLAN PHARMS INC	200MG	A202394 001	May 13, 2013
------------------	-------	-------------	--------------

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING	0.25MG/INH	N016803 001	
EPINEPHRINE			
ARMSTRONG PHARMS	0.2MG/INH	A087907 001	May 23, 1984
PRIMATENE MIST			
WYETH CONS	0.2MG/INH	N016126 001	

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

FOREST LABS	1.5MG/AMP	N007942 003	Feb 05, 1999
	5MG/ML	N007942 001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430 004	Aug 03, 1995
---------------------	-----------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR

EPIPEN E Z PEN

MYLAN SPECIALITY LP 0.3MG/DELIVERY

N019430 003 Aug 03, 1995

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.15

IMPAX LABS INC EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004

TWINJECT 0.3

IMPAX LABS INC EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS 0.3MG/INH

N016126 002

MEDIHALER-EPI

3M 0.3MG/INH

N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 1% **

N017751 006

+ 0.005MG/ML; 1.5% **

N017751 007

+ DENTSPLY PHARM 0.005MG/ML; 1.5% **

N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA 0.005MG/ML; 4%

N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 0.5% **

N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE 0.01MG/ML; 2%

A084720 001

0.02MG/ML; 2%

A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

BELMORA LLC 0.01MG/ML; 2%

A080504 004 Oct 19, 1983

0.02MG/ML; 2%

A080504 005 Oct 19, 1983

HOSPIRA 0.005MG/ML; 1%

A089649 001 Jun 21, 1988

0.005MG/ML; 1.5%

A089650 001 Jun 21, 1988

WEST-WARD PHARMS INT 0.01MG/ML; 1%

A080406 001

0.01MG/ML; 2%

A080406 002

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT 0.01MG/ML; 1%

A083154 001

BEL MAR 0.01MG/ML; 1%

A080820 001

0.01MG/ML; 2%

A080757 001

DELL LABS 0.01MG/ML; 1%

A083389 001

0.01MG/ML; 2%

A083390 001

INTL MEDICATION 0.01MG/ML; 1%

A086402 001

WATSON LABS 0.01MG/ML; 1%

A080377 003

0.01MG/ML; 1%

A085463 001

0.01MG/ML; 2%

A080377 004

LIDOCATON

PHARMATON 0.01MG/ML; 2%

A084729 001 Aug 17, 1983

0.02MG/ML; 2%

A084728 001 Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM 0.01MG/ML; 2%

N021381 001

0.02MG/ML; 2%

N021381 002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA 0.005MG/ML; 1%

N010418 006

0.005MG/ML; 1.5%

N010418 010

0.005MG/ML; 2%

N010418 008

FRESENIUS KABI USA 0.01MG/ML; 2%

N006488 003

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS 1.05MG/PATCH; 100MG/PATCH

N021504 001 May 06, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED

0.01MG/ML; 2%

N020530 001 Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI

0.01MG/ML; 2%

N021486 001 Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR

0.02MG/ML; 1%

A080758 001

0.02MG/ML; 2%

A080759 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

EBEWE PHARMA

50MG/25ML (2MG/ML)

A065339 001 Dec 22, 2009

200MG/100ML (2MG/ML)

A065339 002 Dec 22, 2009

HOSPIRA

50MG/25ML (2MG/ML)

A065343 002 Apr 19, 2007

MUSTAFA NEVSAT

50MG/25ML (2MG/ML)

A090266 001 Apr 15, 2011

200MG/100ML (2MG/ML)

A090266 002 Apr 15, 2011

MYLAN INSTITUTIONAL

50MG/25ML (2MG/ML)

A065371 001 Nov 28, 2007

200MG/100ML (2MG/ML)

A065371 002 Nov 28, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE

EQ 300MG BASE

N020738 004 Dec 22, 1997

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE

600MG; 12.5MG

N021268 001 Nov 01, 2001

600MG; 25MG

N021268 002 Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

TEVA PHARMS USA

75MG/100ML

A091555 001 Jun 05, 2015

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES	1MG	A087244 001	Aug 16, 1982
GERIMAL			
WATSON LABS	1MG	A088207 001	Mar 22, 1984
HYDERGINE			
NOVARTIS	0.5MG	N017993 003	
+	1MG	N017993 001	
TABLET; SUBLINGUAL			
ALKERGOT			
SANDOZ	0.5MG	A085153 001	
	1MG	A087417 001	
CIRCANOL			
3M	0.5MG	A084868 001	
	1MG	A085809 001	
DEAPRIL-ST			
BRISTOL MYERS SQUIBB	1MG	A085020 002	
ERGOLOID MESYLATES			
KV PHARM	0.5MG	A085899 001	
	0.5MG	A086265 001	
	1MG	A085900 001	
	1MG	A086264 001	
LEDERLE	0.5MG	A086984 001	
	1MG	A086985 001	
SUN PHARM INDUSTRIES	0.5MG	A087407 001	
	1MG	A087552 001	
SUPERPHARM	0.5MG	A089233 001	Sep 23, 1986
	1MG	A089234 001	Sep 23, 1986
VANGARD	0.5MG	A088013 001	Sep 20, 1982
	1MG	A088014 001	Sep 20, 1982
WATSON LABS	0.5MG	A084930 001	
	0.5MG	A087233 001	
	1MG	A085177 001	
	1MG	A087183 001	
GERIMAL			
WATSON LABS	0.5MG	A086189 001	
	1MG	A086188 001	
HYDERGINE			
NOVARTIS	0.5MG	N009087 002	
	1MG	N009087 001	
HYDROGENATED ERGOT ALKALOIDS			
IVAX PHARMS	0.5MG	A087186 001	
	1MG	A087185 001	

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE			
3M	0.36MG/INH	N012102 001	
TABLET; SUBLINGUAL			
ERGOSTAT			
WATSON LABS INC	2MG	A088337 001	Jun 08, 1984
WIGRETTES			
ORGANON USA INC	2MG	A086750 001	Jul 29, 1982

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE			
MYLAN PHARMS INC	EQ 25MG BASE	A091002 001	Jun 11, 2014
	EQ 100MG BASE	A091002 002	Jun 11, 2014
	EQ 150MG BASE	A091002 003	Jun 11, 2014
TEVA PHARMS USA	EQ 100MG BASE	A091059 002	Aug 28, 2015
	EQ 150MG BASE	A091059 003	Aug 28, 2015

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC			
PARKE DAVIS	250MG	A062546 001	Jul 25, 1985
	250MG	A062618 001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG	A062338 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC 125					
PARKE DAVIS	125MG		A062648	001	Oct 24, 1985
ERYC SPRINKLES					
HOSPIRA	125MG		N050593	001	Jul 22, 1985
ERYTHROMYCIN					
BARR	250MG		A063098	001	May 04, 1989
GEL;TOPICAL					
E-GLADES					
MYLAN PHARMS INC	2%		A065009	001	Mar 18, 2002
EMGEL					
ALTANA	2%		A063107	001	Aug 23, 1991
LOTION;TOPICAL					
E-SOLVE 2					
SYOSSET	2%		A062467	001	Jul 03, 1985
OINTMENT;OPHTHALMIC					
ERYTHROMYCIN					
PHARMADERM	5MG/GM		A062446	001	Sep 26, 1983
PHARMAFAIR	5MG/GM		A062481	001	Apr 05, 1984
ILOTYCIN					
DISTA	0.5%		N050368	001	
OINTMENT;TOPICAL					
AKNE-MYCIN					
+ DOW PHARM	2%		N050584	001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING					
ERYTHROMYCIN					
PADDOCK LLC	100%		N050610	001	Nov 07, 1986
SOLUTION;TOPICAL					
A/T/S					
TARO	2%		A062405	001	Nov 18, 1982
C-SOLVE-2					
FOUGERA PHARMS	2%		A062468	001	Jul 03, 1985
ERYDERM					
ARBOR PHARMS INC	2%		A062290	001	
ERYMAX					
MERZ PHARMS	2%		A062508	002	Jul 11, 1985
ERYTHRA-DERM					
SAPTALIS PHARMS	2%		A062687	001	Feb 05, 1988
ERYTHRO-STATIN					
HI TECH PHARMA	2%		A064101	001	Oct 22, 1996
ERYTHROMYCIN					
ALPHARMA US PHARMS	1.5%		A062328	001	Apr 19, 1982
	2%		A062326	001	Apr 19, 1982
	2%		A062327	001	Apr 19, 1982
	2%		A062342	001	Feb 25, 1982
	2%		A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%		A064039	001	Jan 27, 1994
FOUGERA PHARMS	2%		A064187	001	Sep 30, 1997
LILLY	2%		N050532	001	
PHARMAFAIR	1.5%		A062485	001	Jul 11, 1984
	2%		A062616	001	Jul 25, 1985
RENAISSANCE PHARMA	2%		A064127	001	Feb 14, 1997
SANSAC					
DOW PHARM	2%		A062522	001	Jan 24, 1985
STATICIN					
+ WESTWOOD SQUIBB	1.5% **		N050526	001	
T-STAT					
WESTWOOD SQUIBB	2% **		A062436	001	Mar 09, 1983
SWAB;TOPICAL					
C-SOLVE-2					
IVAX SUB TEVA PHARMS	2%		A062751	001	Jul 30, 1993
ERYCETTE					
+ JOHNSON AND JOHNSON	2% **		N050594	001	Feb 15, 1985
ERYTHROMYCIN					
FOUGERA PHARMS	2%		A065320	001	Jul 25, 2006
MYLAN PHARMS INC	2%		A064128	001	Jul 03, 1996
T-STAT					
WESTWOOD SQUIBB	2%		A062748	001	Jul 23, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN

TABLET, DELAYED RELEASE;ORAL

E-BASE

BARR	333MG	A063028 001	May 15, 1990
	333MG	A063086 001	May 15, 1990
	500MG	A062999 001	Nov 25, 1988

E-MYCIN

ARBOR PHARMS INC	250MG	A060272 001	
	333MG	A060272 002	

ILOTYCIN

DISTA	250MG	A061910 001	
-------	-------	-------------	--

R-P MYCIN

SOLVAY	250MG	A061659 001	
--------	-------	-------------	--

ROBIMYCIN

ROBINS AH	250MG	A061633 001	
-----------	-------	-------------	--

ERYTHROMYCIN ESTOLATE

CAPSULE;ORAL

ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162 001	
	EQ 250MG BASE	A062162 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237 001	
WATSON LABS	EQ 250MG BASE	A062087 001	

ILOSONE

LILLY	EQ 125MG BASE	A061897 001	
	EQ 250MG BASE	A061897 002	

FOR SUSPENSION;ORAL

ILOSONE

DISTA	EQ 125MG BASE/5ML	A061893 001	
-------	-------------------	-------------	--

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
G AND W LABS INC	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982

ILOSONE

LILLY	EQ 125MG BASE/5ML	A061894 001	
	EQ 125MG BASE/5ML	N050010 001	
	EQ 250MG BASE/5ML	A061894 002	
	EQ 250MG BASE/5ML	N050010 002	

SUSPENSION/DROPS;ORAL

ILOSONE

LILLY	EQ 100MG BASE/ML	A061894 003	
-------	------------------	-------------	--

TABLET;ORAL

ILOSONE

LILLY	EQ 500MG BASE	A061896 001	
-------	---------------	-------------	--

TABLET, CHEWABLE;ORAL

ILOSONE

DISTA	EQ 125MG BASE	A061895 001	
	EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989
-------	-------------------------------------	-------------	--------------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

ANI PHARMS INC	EQ 200MG BASE/5ML	A062055 001	
----------------	-------------------	-------------	--

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
-----------	-------------------	-------------	--

SUSPENSION;ORAL

E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
	EQ 400MG BASE/5ML	A062198 002	

E.E.S. 200

ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001	
------------------	----------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION;ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML **

A061639 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML

A062200 001

EQ 400MG BASE/5ML

A062200 002

DISTA EQ 200MG BASE/5ML

A062177 001

EQ 400MG BASE/5ML

A062177 002

NASKA EQ 400MG BASE/5ML

A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML

A062231 001

EQ 400MG BASE/5ML

A062231 002

PHARMAFAIR EQ 200MG BASE/5ML

A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML

A062558 001 Mar 15, 1985

PEDIAMYCIN

ARBOR PHARMS LLC EQ 200MG BASE/5ML

A062304 001

PEDIAMYCIN 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML

A062304 002

WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML

A062123 002

EQ 400MG BASE/5ML

A062123 001

SUSPENSION/DROPS;ORAL

PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML

A062305 002

TABLET;ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE

A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE

A062256 001

MYLAN EQ 400MG BASE

A062847 001 Sep 14, 1988

TABLET, CHEWABLE;ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE

N050297 002

ERYPED

ARBOR PHARMS INC EQ 200MG BASE

N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE

A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

BARR EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062759 001 May 20, 1988

ERYZOLE

ALRA EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE;INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL

N050370 001

EQ 500MG BASE/VIAL

N050370 002

EQ 1GM BASE/VIAL

N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL

A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL

A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL

N050182 002

EQ 1GM BASE/VIAL

N050182 003

EQ 1GM BASE/VIAL

N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL

A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL

A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL

A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL

A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL

A062993 001 May 09, 1989

EQ 1GM BASE/VIAL

A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL

A063253 001 Jul 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

EQ 1GM BASE/VIAL

A063253 002 Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL

EQ 250MG BASE

A061304 001

EQ 250MG BASE

A061887 001

ERYPAR

PARKE DAVIS

EQ 250MG BASE

A062032 001

EQ 500MG BASE

A062032 002

WARNER CHILCOTT

EQ 250MG BASE

A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC

EQ 125MG BASE

A060359 002

EQ 500MG BASE

A060359 003

ERYTHROMYCIN STEARATE

ANI PHARMS INC

EQ 250MG BASE

A061461 001

EQ 250MG BASE

A061591 001

EQ 500MG BASE

A061461 002

EQ 500MG BASE

A063179 001 May 15, 1990

LEDERLE

EQ 250MG BASE

A062089 001

EQ 500MG BASE

A062089 002

MYLAN

EQ 250MG BASE

A061505 001

EQ 500MG BASE

A061505 002

PUREPAC PHARM

EQ 250MG BASE

A061743 001

WATSON LABS

EQ 250MG BASE

A062121 002

EQ 500MG BASE

A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB

EQ 250MG BASE

A061605 001

ETHRIL 500

BRISTOL MYERS SQUIBB

EQ 500MG BASE

A061605 002

PFIZER-E

PFIZER

EQ 250MG BASE

A061791 001

EQ 500MG BASE

A061791 002

WYAMYCIN S

WYETH AYERST

EQ 250MG BASE

A061675 001

EQ 500MG BASE

A061675 002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC

EQ 5MG BASE

A077660 001 Jul 31, 2007

EQ 10MG BASE

A077660 002 Jul 31, 2007

EQ 20MG BASE

A077660 003 Jul 31, 2007

TABLET; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015

EQ 10MG BASE

A077550 002 May 14, 2015

EQ 20MG BASE

A077550 003 May 14, 2015

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE

10MG/ML

N019386 003 Aug 15, 1988

20MG/ML

N019386 007 May 28, 2003

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AUROBINDO PHARMA LTD

EQ 20MG BASE/VIAL

A204657 001 Aug 10, 2016

MYLAN LABS LTD

EQ 20MG BASE/VIAL

A202686 001 May 17, 2017

SUN PHARMA GLOBAL

EQ 20MG BASE/VIAL

A200882 001 Mar 18, 2013

NEXIUM IV

+ ASTRAZENECA PHARMS

EQ 20MG BASE/VIAL

N021689 001 Mar 31, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+ R2 PHARMA LLC 24.65MG N202342 001 Aug 06, 2013

ESTAZOLAM

TABLET;ORAL

PROSOM

+ ABBOTT 1MG ** N019080 001 Dec 26, 1990

+ 2MG ** N019080 002 Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE 0.025MG/24HR N020847 001 Aug 04, 1998

0.0375MG/24HR N020847 002 Aug 04, 1998

0.05MG/24HR N020847 003 Aug 04, 1998

0.075MG/24HR N020847 004 Aug 04, 1998

0.1MG/24HR N020847 005 Aug 04, 1998

ESTRADERM

+ NOVARTIS 0.05MG/24HR N019081 002 Sep 10, 1986

+ 0.1MG/24HR N019081 003 Sep 10, 1986

ESTRADIOL

ORTHO MCNEIL PHARM 0.05MG/24HR N021048 001 Sep 20, 1999

0.075MG/24HR N021048 002 Sep 20, 1999

0.1MG/24HR N021048 003 Sep 20, 1999

FEMPATCH

PARKE DAVIS 0.025MG/24HR N020417 001 Dec 03, 1996

VIVELLE

NOVARTIS 0.025MG/24HR N020323 005 Aug 16, 2000

0.0375MG/24HR N020323 001 Oct 28, 1994

0.05MG/24HR N020323 002 Oct 28, 1994

0.075MG/24HR N020323 003 Oct 28, 1994

0.1MG/24HR N020323 004 Oct 28, 1994

GEL;TOPICAL

ESTROGEL

ASCEND THERAPS US 0.06% N021166 001 Feb 09, 2004

TABLET;ORAL

ESTRACE

BRISTOL MYERS SQUIBB 0.5MG A081295 001 Jun 30, 1993

1MG A084499 001

2MG A084500 001

ESTRADIOL

LANNETT HOLDINGS INC 0.5MG A040138 001 Jan 30, 1998

1MG A040138 002 Jan 30, 1998

2MG A040138 003 Jan 30, 1998

USL PHARMA 0.5MG A040297 001 Apr 17, 2002

1MG A040297 002 Apr 17, 2002

2MG A040297 003 Apr 17, 2002

GYNODIOL

DURAMED PHARMS BARR 0.5MG A040212 001 Dec 29, 1997

1MG A040212 002 Dec 29, 1997

1.5MG A040212 003 Dec 29, 1997

2MG A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC 0.5MG A040312 001 Nov 19, 1999

1MG A040312 002 Nov 19, 1999

2MG A040312 003 Nov 19, 1999

TABLET;VAGINAL

VAGIFEM

+ NOVO NORDISK INC 25MCG ** N020908 001 Mar 26, 1999

ESTRADIOL ACETATE

TABLET;ORAL

FEMTRACE

+ APIL 0.45MG N021633 001 Aug 20, 2004

+ 0.9MG N021633 002 Aug 20, 2004

+ 1.8MG N021633 003 Aug 20, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001
	3MG/ML	A085470	002

ESTRADIOL CYPIONATE

WATSON LABS	5MG/ML	A085620	001
-------------	--------	---------	-----

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000
----------------------	-----------------------	---------	-----	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML; 50MG/ML	N017968	001
----------------------	-----------------	---------	-----

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML; 50MG/ML	A085603	001	Mar 13, 1986
-------------	-----------------	---------	-----	--------------

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007
------------	---------	---------	-----	--------------

	20MG/ML	A040628	002	Oct 04, 2007
--	---------	---------	-----	--------------

	40MG/ML	A040628	003	Oct 04, 2007
--	---------	---------	-----	--------------

WATSON LABS	10MG/ML	A083546	001
-------------	---------	---------	-----

	40MG/ML	A083714	001
--	---------	---------	-----

WATSON LABS INC	20MG/ML	A083547	001
-----------------	---------	---------	-----

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS	8MG/ML; 180MG/ML	A086423	001
-------------	------------------	---------	-----

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS	4MG/ML; 90MG/ML	A085865	001
-------------	-----------------	---------	-----

	8MG/ML; 180MG/ML	A085860	001
--	------------------	---------	-----

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+	TEVA WOMENS	1MG, 1MG; N/A, 0.09MG **	N021040	001	Oct 22, 1999
---	-------------	--------------------------	---------	-----	--------------

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC	2.5MG	N004782	002
------------------	-------	---------	-----

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008
-------------	------------	---------	-----	--------------

TABLET; ORAL

CENESTIN

+	TEVA BRANDED PHARM	0.3MG **	N020992	001	Jun 21, 2002
---	--------------------	----------	---------	-----	--------------

+		0.45MG **	N020992	005	Feb 05, 2004
---	--	-----------	---------	-----	--------------

+		0.625MG **	N020992	002	Mar 24, 1999
---	--	------------	---------	-----	--------------

+		0.9MG **	N020992	003	Mar 24, 1999
---	--	----------	---------	-----	--------------

+		1.25MG **	N020992	004	Mar 13, 2000
---	--	-----------	---------	-----	--------------

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004
--------------------	-------	---------	-----	--------------

	0.45MG	N021443	002	Dec 20, 2004
--	--------	---------	-----	--------------

	0.625MG **	N021443	003	May 10, 2004
--	------------	---------	-----	--------------

	0.9MG	N021443	005	Apr 27, 2007
--	-------	---------	-----	--------------

	1.25MG **	N021443	004	May 10, 2004
--	-----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)			
WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)			
WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994

ESTROGENS, CONJUGATED; Meprobamate

TABLET; ORAL

MILPREM-200			
MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002	
MILPREM-400			
MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001	
PMB 200			
WYETH AYERST	0.45MG;200MG	N010971 005	
PMB 400			
WYETH AYERST	0.45MG;400MG	N010971 003	

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN			
BRISTOL MYERS SQUIBB	0.3MG	A083266 001	
	0.625MG	A083266 002	
	1.25MG	A083266 003	
	2.5MG	A083266 004	
ESTERIFIED ESTROGENS			
PVT FORM	0.625MG	A083414 001	
	1.25MG	A083765 001	
	2.5MG	A085907 001	
SANDOZ	1.25MG	A085302 001	
ESTRATAB			
SOLVAY	0.3MG	A086715 001	
	0.625MG	A083209 001	
	1.25MG	A083856 001	
	2.5MG	A083857 001	
EVEX			
ROCHE PALO	0.625MG	A084215 001	
	1.25MG	A083376 002	
FEMOGEN			
PVT FORM	0.625MG	A085076 001	
	1.25MG	A085008 001	
	2.5MG	A085007 001	

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE			
WYETH AYERST	2MG/ML	A083488 001	
ESTRONE			
WATSON LABS	2MG/ML	A083397 001	
WATSON LABS TEVA	5MG/ML	A085239 001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
WATSON LABS	2MG/ML	A085237 001	Nov 23, 1982
THEELIN			
PARKEDEALE	1MG/ML	N003977 001	
	2MG/ML	N003977 002	
	5MG/ML	N003977 003	

ESTROPIPATE

CREAM; VAGINAL

OGEN			
PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001	

TABLET; ORAL

ESTROPIPATE			
BARR	0.75MG	A040135 001	Nov 27, 1996
	1.5MG	A040135 002	Nov 27, 1996
	3MG	A040135 003	Nov 27, 1996
DURAMED PHARMS BARR	0.75MG	A040296 001	Nov 01, 1999
	1.5MG	A040296 002	Nov 01, 1999
	3MG	A040296 003	Nov 01, 1999
MYLAN	3MG	A040359 003	Aug 26, 1999
WATSON LABS	0.75MG	A081213 001	Sep 23, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

	1.5MG	A081214 001	Sep 23, 1993
	6MG	A081216 001	Sep 23, 1993
WATSON LABS TEVA	3MG	A081215 001	Sep 23, 1993
OGEN .625			
PHARMACIA AND UPJOHN	0.75MG	A083220 001	
OGEN 1.25			
PHARMACIA AND UPJOHN	1.5MG	A083220 002	
OGEN 2.5			
PHARMACIA AND UPJOHN	3MG	A083220 003	
ORTHO-EST			
SUN PHARM INDS INC	0.75MG	A089567 001	Feb 27, 1991
	1.5MG	A089582 001	Jul 17, 1991

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011
	2MG	A091165 002	Jul 14, 2011
	3MG	A091165 003	Jul 14, 2011

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

ATON	50MG	N016092 002	
------	------	-------------	--

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

MYAMBUTOL

STI PHARMA LLC	200MG	N016320 002	
	500MG	N016320 004	

ETHCHLORVYNOL

CAPSULE;ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463 001	
	200MG	A084463 002	
	500MG	A084463 003	
	750MG	A084463 004	

PLACIDYL

ABBVIE	100MG	N010021 004	
	200MG	N010021 007	
	500MG	N010021 002	
	750MG	N010021 010	

ETHINAMATE

CAPSULE;ORAL

VALMID

DISTA	500MG	N009750 001	
-------	-------	-------------	--

ETHINYL ESTRADIOL

TABLET;ORAL

ESTINYL

SCHERING	0.02MG	N005292 001	
	0.05MG	N005292 002	
	0.5MG	N005292 003	

FEMINONE

PHARMACIA AND UPJOHN	0.05MG	N016649 001	
----------------------	--------	-------------	--

LYNORAL

ORGANON USA INC	0.01MG	N005490 003	
	0.05MG	N005490 002	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC	0.035MG;1MG **	N018168 001	
---------------	----------------	-------------	--

DEMULEN 1/50-21

GD SEARLE LLC	0.05MG;1MG	N016927 001	
---------------	------------	-------------	--

ZOVIA 1/35E-21

WATSON PHARMS TEVA	0.035MG;1MG	A072720 001	Dec 30, 1991
--------------------	-------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21			
ZOVIA 1/50E-21			
WATSON LABS	0.05MG;1MG	A072722 001	Dec 30, 1991
TABLET;ORAL-28			
DEMULEN 1/35-28			
GD SEARLE LLC	0.035MG;1MG **	N018160 001	
DEMULEN 1/50-28			
GD SEARLE LLC	0.05MG;1MG **	N016936 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28			
NORQUEST FE			
GD SEARLE LLC	0.035MG;75MG;1MG	N018926 001	Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28			
NORLESTRIN FE 1/50			
PARKE DAVIS	0.05MG;75MG;1MG	N016766 001	
NORLESTRIN FE 2.5/50			
PARKE DAVIS	0.05MG;75MG;2.5MG	N016854 001	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL			
LYBREL			
+ WYETH PHARMS INC	0.02MG;0.09MG **	N021864 001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT			
TEVA BRANDED PHARM	0.05MG;0.25MG	N020946 001	Sep 01, 1998
TABLET;ORAL-21			
ALESSE			
+ WYETH PHARMS	0.02MG;0.1MG **	N020683 001	Mar 27, 1997
AVIANE-21			
DURAMED PHARMS BARR	0.02MG;0.1MG	A075796 002	Apr 30, 2001
ENPRESSE-21			
DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809 001	Jul 16, 2001
LESSINA-21			
BARR	0.02MG;0.1MG	A075803 001	Mar 20, 2002
LEVLITE			
+ BAYER HLTHCARE	0.02MG;0.1MG **	N020860 001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL			
BARR	0.02MG;0.1MG	A075862 001	Apr 29, 2003
LEVORA 0.15/30-21			
WATSON LABS	0.03MG;0.15MG	A073592 001	Dec 13, 1993
NORDETTE-21			
TEVA BRANDED PHARM	0.03MG;0.15MG	N018668 001	May 10, 1982
PORTIA-21			
BARR	0.03MG;0.15MG	A075866 001	May 23, 2002
TRIPHASIL-21			
+ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192 001	Nov 01, 1984
TRIVORA-21			
MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538 001	Dec 18, 1997
TABLET;ORAL-28			
ALESSE			
+ WYETH PHARMS	0.02MG;0.1MG **	N020683 002	Mar 27, 1997
LEVLITE			
+ BAYER HLTHCARE	0.02MG;0.1MG **	N020860 002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL			
BARR	0.02MG;0.1MG	A075862 002	Apr 29, 2003
NORDETTE-28			
+ TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782 001	Jul 21, 1982
TRIPHASIL-28			
+ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190 001	Nov 01, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+ JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR ** N021180 001 Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR 0.035MG;0.4MG A076198 001 Apr 22, 2004

BREVICON 21-DAY

ALLERGAN SALES LLC 0.035MG;0.5MG N017566 001

GENCEPT 10/11-21

BARR 0.035MG,0.035MG;0.5MG,1MG A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM 0.035MG;0.5MG N017488 001

N.E.E. 1/35 21

LPI 0.035MG;1MG A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM 0.035MG;1MG A071545 001 Feb 09, 1989

NORETHIN 1/35E-21

WATSON PHARMS TEVA 0.035MG;1MG A071480 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG;0.4MG A078379 001 Feb 23, 2010

0.035MG;0.5MG A070684 001 Jan 29, 1987

WATSON PHARMS TEVA 0.035MG;1MG A070685 001 Jan 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991

NORTREL 0.5/35-21

BARR 0.035MG;0.5MG A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM 0.035MG;1MG N017489 002

ORTHO-NOVUM 10/11-21

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG ** N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG N019004 001 Apr 04, 1984

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 001 Apr 04, 1984

OVCON-35

+ WARNER CHILCOTT 0.035MG;0.4MG ** N018127 001

OVCON-50

WARNER CHILCOTT 0.05MG;1MG N018128 001

TRI-NORINYL 21-DAY

MAYNE PHARMA 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG N018977 001 Apr 13, 1984

TABLET; ORAL-28

GENCEPT 10/11-28

BARR 0.035MG,0.035MG;0.5MG,1MG A072697 001 Feb 28, 1992

N.E.E. 1/35 28

LPI 0.035MG;1MG A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM 0.035MG;1MG A071546 001 Feb 09, 1989

NORETHIN 1/35E-28

WATSON LABS 0.035MG;1MG A071481 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A200486 001 Dec 28, 2015

0.035MG;0.5MG A200488 001 Oct 21, 2015

0.035MG;1MG A200489 001 Oct 21, 2015

WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A076393 001 Feb 04, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071042 001 Sep 24, 1991

ORTHO-NOVUM 10/11-28

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG N019004 002 Apr 04, 1984

OVCON-35

+ WARNER CHILCOTT LLC 0.035MG;0.4MG ** N017716 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
OVCON-50
WARNER CHILCOTT LLC 0.05MG; 1MG N017576 001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
FEMHRT
+ APIL 0.005MG; 1MG ** N021065 002 Oct 15, 1999
TABLET; ORAL-21
ESTROSTEP 21
+ APIL 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG ** N020130 001 Oct 09, 1996
NORLESTRIN 21 1/50
PARKE DAVIS 0.05MG; 1MG N016749 001
NORLESTRIN 21 2.5/50
PARKE DAVIS 0.05MG; 2.5MG N016852 001
TABLET; ORAL-28
NORLESTRIN 28 1/50
PARKE DAVIS 0.05MG; 1MG N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21
ORTHO CYCLEN-21
JANSSEN PHARMS 0.035MG; 0.25MG N019653 001 Dec 29, 1989
ORTHO TRI-CYCLEN
JANSSEN PHARMS 0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG N019697 002 Jul 03, 1992
TABLET; ORAL-28
NORGESTIMATE AND ETHINYL ESTRADIOL
WATSON LABS 0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG A090479 001 Mar 09, 2011
0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG A076626 001 Aug 17, 2006
0.035MG; 0.25MG A076627 001 Aug 17, 2006

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
LO/OVRAL
PELAGIUS 0.03MG; 0.3MG N017612 001
LOW-OGESTREL-21
MAYNE PHARMA 0.03MG; 0.3MG A075288 001 Jul 28, 1999
OGESTREL 0.5/50-21
WATSON LABS 0.05MG; 0.5MG A075406 001 Dec 15, 1999
OVRAL
WYETH PHARMS 0.05MG; 0.5MG N016672 001
TABLET; ORAL-28
LO/OVRAL-28
WYETH PHARMS 0.03MG; 0.3MG ** N017802 001
NORGESTREL AND ETHINYL ESTRADIOL
MYLAN LABS LTD 0.03MG; 0.3MG A201828 001 Jun 21, 2016
0.05MG; 0.5MG A202875 001 May 08, 2017
OVRAL-28
WYETH PHARMS 0.05MG; 0.5MG N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL
PARSIDOL
PARKE DAVIS 10MG N009078 003
50MG N009078 006
100MG N009078 008

ETHOTOIN

TABLET; ORAL
PEGANONE
RECORDATI RARE 500MG N010841 003

ETHOXZOLAMIDE

TABLET; ORAL
CARDRASE
PHARMACIA AND UPJOHN 62.5MG N011047 002
125MG N011047 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHOXZOLAMIDE

TABLET; ORAL

ETHAMIDE

ALLERGAN

125MG

N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC

2MG/5ML

N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC

2MG

N014005 002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC

1MG; 0.1MG

N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC

1MG; 0.1MG

N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC

1MG; 0.1MG

N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA

0.5% **

N017751 003

+

1% **

N017751 005

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

TABLET; ORAL

DIDRONEL

+ APIL

200MG

N017831 001

+

400MG

N017831 002

ETODOLAC

CAPSULE; ORAL

ETODOLAC

ANI PHARMS INC

200MG

A074899 001 Jul 08, 1997

300MG

A074899 002 Jul 08, 1997

CHARTWELL MOLECULES

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

ECI PHARMS LLC

300MG

A074929 001 Jan 30, 1998

IDT AUSTRALIA LTD

200MG

A074840 001 Aug 29, 1997

300MG

A074840 002 Aug 29, 1997

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074942 001 Sep 30, 1997

300MG

A074942 002 Sep 30, 1997

WATSON LABS

200MG

A074844 001 Dec 23, 1997

300MG

A074844 002 Dec 23, 1997

LODINE

+ WYETH PHARMS INC

200MG **

N018922 002 Jan 31, 1991

+

300MG

N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

CHARTWELL MOLECULES

400MG

A074841 001 Jun 27, 1997

ECI PHARMS LLC

400MG

A074927 001 Oct 30, 1997

IVAX SUB TEVA PHARMS

400MG

A074883 001 Feb 28, 1997

500MG

A074883 002 Nov 20, 1998

MYLAN

400MG

A075012 001 Sep 30, 1998

500MG

A075012 002 Sep 30, 1998

MYLAN PHARMS INC

400MG

A075104 001 Feb 06, 1998

500MG

A075104 002 Nov 20, 1998

OXFORD PHARMS

400MG

A074819 001 Feb 28, 1997

500MG

A074819 002 Apr 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETODOLAC

TABLET; ORAL

ETODOLAC

RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
	500MG	A075226 002	Nov 24, 1998
SANDOZ	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
TEVA	400MG	A074847 001	Apr 23, 1999
	500MG	A074847 002	Apr 23, 1999
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

LODINE

+ WYETH PHARMS INC	400MG **	N018922 004	Jul 29, 1993
+	500MG **	N018922 005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
IDT AUSTRALIA LTD	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG **	N020584 001	Oct 25, 1996
	500MG **	N020584 003	Jan 20, 1998
+	600MG **	N020584 002	Oct 25, 1996

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006
-----------------	--------------	-------------	--------------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

+ DAVA PHARMS INC	50MG	N019557 001	Dec 30, 1986
+	100MG	N019557 002	Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA	20MG/ML	A074320 001	Aug 30, 1995
	20MG/ML	A074351 001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML	A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510 001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML	A074284 001	Feb 10, 1994
WATSON LABS	20MG/ML	A074228 001	Oct 15, 1996
WATSON LABS INC	20MG/ML	A074968 001	Jan 09, 1998

TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166 001	Feb 27, 1995
-----------------	---------	-------------	--------------

VEPESID

+ CORDEN PHARMA	20MG/ML **	N018768 001	Nov 10, 1983
-----------------	------------	-------------	--------------

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906 002	Feb 27, 1998

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE	10MG	N019369 001	Sep 30, 1986
	25MG	N019369 002	Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS	0.5% **	N008041 001	
-------------	---------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EZOGABINE

TABLET; ORAL

POTIGA

+	GLAXOSMITHKLINE	50MG	N022345 001	Jun 10, 2011
+		200MG	N022345 002	Jun 10, 2011
+		300MG	N022345 003	Jun 10, 2011
+		400MG	N022345 004	Jun 10, 2011

FAMCICLOVIR

TABLET; ORAL

FAMVIR

+	NOVARTIS	125MG	N020363 003	Dec 11, 1995
+		250MG	N020363 001	Apr 26, 1996
+		500MG	N020363 002	Jun 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

	APOTEX INC	10MG/ML	A075942 001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707 001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075705 001	Apr 16, 2001
		10MG/ML	A075870 001	Nov 23, 2001
		10MG/ML	A075905 001	Nov 23, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075799 001	Apr 30, 2002
	FAMOTIDINE PRESERVATIVE FREE			
	APOTEX INC	10MG/ML	A076324 001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708 001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075669 001	Apr 16, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075789 001	Apr 30, 2002
	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)			
	APOTEX INC	10MG/ML	A076322 001	Nov 27, 2002
	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER			
	ABBVIE	0.4MG/ML	A075729 001	Dec 17, 2001
	PEPCID			
+	MERCK	10MG/ML **	N019510 001	Nov 04, 1986
	PEPCID PRESERVATIVE FREE			
+	MERCK	10MG/ML **	N019510 004	Nov 04, 1986
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER			
+	MERCK SHARP DOHME	0.4MG/ML **	N020249 001	Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

	ACTAVIS ELIZABETH	20MG	A075650 001	Sep 14, 2001
		40MG	A075650 002	Sep 14, 2001
	APOTEX	10MG	A075610 001	Mar 12, 2002
	MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001
		40MG	A075457 002	Apr 18, 2001
	SANDOZ	10MG	A076101 001	Oct 21, 2002
		20MG	A075302 001	Apr 16, 2001
		20MG	A075607 001	May 10, 2001
		20MG	A075793 001	Apr 16, 2001
		40MG	A075302 002	Apr 16, 2001
		40MG	A075607 002	May 10, 2001
		40MG	A075793 002	Apr 16, 2001
	SUN PHARM INDUSTRIES	20MG	A075639 002	Dec 12, 2001
		40MG	A075639 001	Dec 12, 2001
	WATSON LABS	10MG	A075404 001	Nov 28, 2001
		20MG	A075062 002	Apr 16, 2001
		40MG	A075062 001	Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

+	J AND J CONSUMER INC	10MG **	N020801 001	Sep 24, 1998
---	----------------------	---------	-------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	UCB INC	20MG	N021712 001	Sep 24, 2004
		40MG	N021712 002	Sep 24, 2004

PEPCID RPD

	MERCK	20MG	N020752 001	May 28, 1998
		40MG	N020752 002	May 28, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012
	5MG	A091484 002	Aug 15, 2012
	10MG	A091484 003	Aug 15, 2012

PLENDIL

+ ASTRAZENECA	2.5MG **	N019834 004	Sep 22, 1994
+	5MG **	N019834 001	Jul 25, 1991
+	10MG **	N019834 002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695 002	Nov 30, 2004
----------------	------	-------------	--------------

LIPIDIL

ABBVIE	100MG	N019304 001	Dec 31, 1993
--------	-------	-------------	--------------

LIPOFEN

CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006
-------------------	-------	-------------	--------------

TRICOR (MICRONIZED)

+ ABBVIE	67MG **	N019304 002	Feb 09, 1998
+	134MG **	N019304 003	Jun 30, 1999
+	200MG **	N019304 004	Jun 30, 1999

TABLET;ORAL

FENOFIBRATE

MYLAN	107MG	A076520 002	Dec 29, 2005
-------	-------	-------------	--------------

TRICOR

+ ABBVIE INC	54MG **	N021203 001	Sep 04, 2001
+	160MG **	N021203 003	Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG	50MG	N021350 001	May 07, 2005
---------------	------	-------------	--------------

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
	EQ 300MG BASE	A072308 001	Aug 22, 1988
AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394 001	Oct 17, 1988
	EQ 300MG BASE	A072395 001	Oct 17, 1988
HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
	EQ 300MG BASE	A072356 001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
	EQ 300MG BASE	A072438 001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
	EQ 300MG BASE	A071738 001	Aug 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
	EQ 300MG BASE	A072472 001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
	EQ 200MG BASE	A072981 001	Aug 19, 1991
	EQ 300MG BASE	A072293 001	Aug 17, 1988
	EQ 300MG BASE	A072982 001	Aug 19, 1991

NALFON

XSPIRE PHARMA	EQ 300MG BASE	N017604 002	
---------------	---------------	-------------	--

TABLET;ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274 001	May 02, 1988
AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396 001	Oct 17, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429 001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902 001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

WATSON LABS

EQ 600MG BASE

A072165 001 Aug 17, 1988

EQ 600MG BASE

A072602 001 Oct 11, 1988

WATSON LABS TEVA

EQ 600MG BASE

A072407 001 Aug 17, 1988

NALFON

DISTA

EQ 600MG BASE

N017710 001

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

NOVEN

100MCG/HR

A077775 004 Oct 16, 2009

FENTANYL-25

NOVEN

25MCG/HR

A077775 001 Oct 16, 2009

FENTANYL-50

NOVEN

50MCG/HR

A077775 002 Oct 16, 2009

FENTANYL-75

NOVEN

75MCG/HR

A077775 003 Oct 16, 2009

FENTANYL CITRATE

FILM; BUCCAL

ONSOLIS

BDSI

EQ 0.2MG BASE

N022266 001 Jul 16, 2009

EQ 0.4MG BASE

N022266 002 Jul 16, 2009

EQ 0.6MG BASE

N022266 003 Jul 16, 2009

EQ 0.8MG BASE

N022266 004 Jul 16, 2009

EQ 1.2MG BASE

N022266 005 Jul 16, 2009

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

TABLET; BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS

EQ 0.1MG BASE

A079075 001 Jan 07, 2011

EQ 0.2MG BASE

A079075 002 Jan 07, 2011

EQ 0.4MG BASE

A079075 003 Jan 07, 2011

EQ 0.6MG BASE

A079075 004 Jan 07, 2011

EQ 0.8MG BASE

A079075 005 Jan 07, 2011

FENTORA

+ CEPHALON

EQ 0.3MG BASE **

N021947 006 Mar 02, 2007

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG; 0.33MG

N006012 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC EQ 11.2MG IRON/ML N020416 001 Aug 30, 1996

FERUMOXSIIL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC EQ 0.175MG IRON/ML N020410 001 Dec 06, 1996

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

ALKEM LABS LTD 4MG A204827 001 Dec 10, 2015
8MG A204827 002 Dec 10, 2015FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US 60MG ** N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR 60MG A076169 001 Jul 13, 2005

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

BARR 60MG; 120MG A076236 001 Apr 14, 2005

IMPAX PHARMS 60MG; 120MG A076298 001 Nov 12, 2010

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE 154uCi/VIAL N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT 140uCi/ML N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS 5MG A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

IMPAX PHARMS 100MG A076234 001 Aug 28, 2003

URISPAS

ORTHO MCNEIL JANSSEN 100MG N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC 50MG A079164 001 Jul 09, 2009

100MG A079164 002 Jul 09, 2009

150MG A079164 003 Jul 09, 2009

IDT AUSTRALIA LTD 50MG A076030 001 Oct 28, 2002

100MG A076030 002 Oct 28, 2002

150MG A076030 003 Oct 28, 2002

TAMBOCOR

CNTY LINE PHARMS 200MG N018830 002 Oct 31, 1985

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML) N202008 001 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

+ HOSPIRA 500MG/VIAL ** N016929 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

SUN PHARM INDS LTD	50MG/5ML	A076332 001	Jul 29, 2004
	200MG/5ML	A076332 002	Jul 29, 2004
TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006
	200MG/5ML	A076918 002	Dec 18, 2006

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950 003	Sep 29, 1992
+ PFIZER	400MG/200ML (2MG/ML)	N019950 005	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER	200MG/100ML (2MG/ML)	N019950 001	Jan 29, 1990
+ PFIZER	400MG/200ML (2MG/ML)	N019950 006	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950 002	Jan 29, 1990
+ PFIZER	400MG/200ML (2MG/ML)	N019950 004	Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653 002	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	200MG/100ML (2MG/ML)	A076617 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617 002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005
TEVA PHARMS	200MG/100ML (2MG/ML)	A076837 001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837 002	Jan 13, 2005

TABLET;ORAL

FLUCONAZOLE

GEDEON RICHTER USA	50MG	A076432 001	Jul 29, 2004
	100MG	A076432 002	Jul 29, 2004
	150MG	A076432 003	Jul 29, 2004
	200MG	A076432 004	Jul 29, 2004
IDT AUSTRALIA LTD	50MG	A076086 001	Jul 29, 2004
	100MG	A076086 002	Jul 29, 2004
	150MG	A076086 003	Jul 29, 2004
	200MG	A076086 004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042 001	Jul 29, 2004
	100MG	A076042 002	Jul 29, 2004
	150MG	A076042 003	Jul 29, 2004
	200MG	A076042 004	Jul 29, 2004
PLIVA	50MG	A076424 001	Jul 29, 2004
	100MG	A076424 002	Jul 29, 2004
	150MG	A076424 003	Jul 29, 2004
	200MG	A076424 004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004
	100MG	A076386 002	Jul 29, 2004
	150MG	A076386 003	Jul 29, 2004
	200MG	A076386 004	Jul 29, 2004
ROXANE	50MG	A076213 001	Jul 29, 2004
	100MG	A076213 002	Jul 29, 2004
	150MG	A076213 003	Jul 29, 2004
	200MG	A076213 004	Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARA

+ GENZYME CORP	50MG/VIAL **	N020038 001	Apr 18, 1991
----------------	--------------	-------------	--------------

TABLET;ORAL

OFORTA

SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008
-------------------	------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

+ DOWNSTATE CLINCL

4-40mCi/ML **

N020306 001 Aug 19, 1994

+

4-90mCi/ML **

N020306 002 Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

WEILL MEDCL COLL

10-100mCi/ML **

N021768 001 Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

+ CASPER PHARMA LLC

0.1MG **

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

BAXTER HLTHCARE CORP 0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004

TEVA PHARMS USA 0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

ROMAZICON

+ HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) **

N020073 001 Dec 20, 1991

+

0.5MG/5ML (0.1MG/ML) **

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

FLUONID

ALLERGAN HERBERT 0.025% A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS 0.025% A088172 001 Mar 09, 1983

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.01% A087159 001 Jun 16, 1982

BAUSCH AND LOMB 0.01% A040059 001 Dec 20, 1993

MORTON GROVE 0.01% A088312 001 Jan 27, 1984

PHARMADERM 0.01% A088048 001 Dec 16, 1982

PHARMAFAIR 0.01% A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT 0.01% A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS 0.01% A088171 001 Mar 09, 1983

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK 0.05% A071790 001 Jul 13, 1988

LIDEX

+ CNTY LINE PHARMS 0.05% N016908 002

LIDEX-E

+ CNTY LINE PHARMS 0.05% N016908 003

SOLUTION; TOPICAL

FLUOCINONIDE

TARO 0.05% A072857 001 Aug 02, 1989

TEVA PHARMS 0.05% A072522 001 Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

+ NOVARTIS 25% ** N017869 001

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN 0.025% N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS 0.1% A070185 001 Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

ALCON 0.1%; 0.3% N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN 0.1%; 10% N019525 001 Sep 29, 1989

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN 50MG/ML A081222 001 Jun 28, 1991

50MG/ML N017959 001

TEVA PARENTERAL 50MG/ML A040023 001 Oct 18, 1991

50MG/ML A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC 50MG/ML A088929 001 Mar 04, 1986

ABRAXIS PHARM 50MG/ML A089152 001 Mar 21, 1986

50MG/ML A089428 001 Jan 12, 1987

50MG/ML A089519 001 Mar 12, 1987

BEDFORD 50MG/ML A089508 001 Jan 26, 1988

EBEWE PHARMA 500MG/10ML (50MG/ML) A040772 001 Aug 11, 2008

FRESENIUS KABI USA 50MG/ML A040291 001 Mar 24, 1999

50MG/ML A040379 001 Nov 15, 2000

MARCHAR 50MG/ML A087791 001 Jan 18, 1983

SANDOZ 2.5GM/50ML (50MG/ML) A091299 001 May 02, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+	500MG/10ML (50MG/ML) **	N012209	001	
+	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC

1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ANI PHARMS INC

EQ 10MG BASE

A076287 001 May 20, 2008

EQ 20MG BASE

A076287 002 May 20, 2008

BARR

EQ 40MG BASE

A076251 001 May 18, 2005

CARLSBAD

EQ 10MG BASE

A076022 001 Jan 30, 2002

EQ 20MG BASE

A076022 002 Jan 30, 2002

CR DOUBLE CRANE

EQ 10MG BASE

A076165 001 Feb 01, 2002

EQ 20MG BASE

A076165 002 Feb 01, 2002

MYLAN

EQ 10MG BASE

A075207 001 Jan 30, 2002

EQ 20MG BASE

A075207 002 Jan 30, 2002

EQ 40MG BASE

A075207 003 May 25, 2007

MYLAN PHARMS INC

EQ 10MG BASE

A075577 001 Jan 29, 2002

EQ 20MG BASE

A075577 002 Jan 29, 2002

PAR PHARM

EQ 10MG BASE

A076922 001 Dec 16, 2004

EQ 20MG BASE

A076922 002 Dec 16, 2004

SANDOZ

EQ 10MG BASE

A075807 001 Jan 29, 2002

EQ 10MG BASE

A077469 001 Nov 17, 2008

EQ 20MG BASE

A075807 002 Jan 29, 2002

EQ 20MG BASE

A077469 002 Nov 17, 2008

WOCKHARDT LTD

EQ 10MG BASE

A078143 001 Jan 16, 2008

EQ 20MG BASE

A078143 002 Jan 16, 2008

EQ 40MG BASE

A078143 003 Jan 16, 2008

PROZAC

ELI LILLY AND CO

EQ 60MG BASE

N018936 004 Jun 15, 1999

SARAFEM

+ ELI LILLY AND CO

EQ 10MG BASE **

N018936 007 Jul 06, 2000

+

EQ 20MG BASE **

N018936 008 Jul 06, 2000

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 20MG BASE/5ML

A075690 001 Jan 31, 2002

APOTEX INC

EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002

HI TECH PHARMA

EQ 20MG BASE/5ML

A075525 001 Jun 27, 2002

LANNETT

EQ 20MG BASE/5ML

A076458 001 May 14, 2004

PROZAC

+ LILLY

EQ 20MG BASE/5ML **

N020101 001 Apr 24, 1991

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR

EQ 10MG BASE

A075810 001 Feb 01, 2002

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075865 001 Feb 28, 2002

EQ 40MG BASE

A075865 003 Aug 30, 2004

SANDOZ

EQ 10MG BASE

A076024 001 Jan 29, 2002

PROZAC

+ LILLY

EQ 10MG BASE **

N020974 001 Mar 09, 1999

+

EQ 20MG BASE **

N020974 002 Mar 09, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL 10MG

A087196 001

FLUOXYMESTERONE

VALEANT PHARM INTL 10MG

A088221 001 May 05, 1983

WATSON LABS 2MG

A088260 001 Dec 06, 1983

5MG

A088265 001 Dec 06, 1983

10MG

A088309 001 Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN 2MG

N010611 002

5MG

N010611 006

10MG

N010611 010

ORA-TESTRYL

BRISTOL MYERS SQUIBB 2MG

N011359 001

5MG

N011359 002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA 25MG/ML

A074966 001 Apr 16, 1998

MYLAN LABS LTD 25MG/ML

A075918 001 Aug 17, 2001

TEVA PARENTERAL 25MG/ML

A074795 001 Sep 10, 1996

PROLIXIN DECANOATE

+ BRISTOL MYERS SQUIBB 25MG/ML **

N016727 001

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON 25MG/ML

N016110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC 5MG/ML

A073058 001 Aug 30, 1991

PERMITIL

SCHERING 5MG/ML

N016008 001

PROLIXIN

APOTHECON 5MG/ML

A070533 001 Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC 2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

+ APOTHECON 2.5MG/5ML **

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON 2.5MG/ML

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS 1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING 0.25MG

N012034 001

2.5MG

N012034 004

5MG

N012034 005

10MG

N012034 006

PROLIXIN

+ APOTHECON 1MG

N011751 004

+ 2.5MG

N011751 001

+ 5MG

N011751 003

+ 10MG

N011751 002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING 1MG

N012419 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN 1.5MG

N012259 002

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

+ AQUA PHARMS 0.025% **

N012806 004

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL 15MG **

N016721 001

+ 30MG **

N016721 002

FLURAZEPAM HYDROCHLORIDE

AUROLIFE PHARMA LLC 15MG

A071717 002 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

HALSEY 15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

HIKMA INTL PHARMS 15MG

A071107 001 Dec 08, 1986

HIKMA PHARMS 30MG

A071108 001 Dec 08, 1986

PAR PHARM 15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM 15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SUN PHARM INDUSTRIES 15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

SUPERPHARM 15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA 15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT 15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

WATSON LABS 15MG

A071205 001 Nov 25, 1986

15MG

A072368 001 Mar 30, 1989

30MG

A071068 001 Nov 25, 1986

30MG

A072369 001 Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

ANSAID

PHARMACIA AND UPJOHN 50MG

N018766 002 Oct 31, 1988

100MG

N018766 003 Oct 31, 1988

FLURBIPROFEN

AUROLIFE PHARMA LLC 50MG

A074448 001 Jul 28, 1995

100MG

A074448 002 Jul 28, 1995

IVAX SUB TEVA PHARMS 50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

PLIVA 50MG

A074647 001 Apr 01, 1997

100MG

A074647 002 Apr 01, 1997

TEVA 50MG

A074405 002 May 24, 1995

100MG

A074405 001 May 24, 1995

THERAGEN 100MG

A074560 002 May 16, 1997

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

+ SCHERING

125MG

N018554 001 Jan 27, 1989

FLUTAMIDE

FOSUN PHARMA

125MG

A075818 001 Sep 18, 2001

MYLAN

125MG

A076224 001 May 09, 2003

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020548 001 Mar 27, 1996

0.11MG/INH

N020548 002 Mar 27, 1996

0.22MG/INH

N020548 003 Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

+ FOUGERA PHARMS

0.05% **

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

SPRAY, METERED; NASAL

FLONASE

+ GLAXOSMITHKLINE

0.05MG/SPRAY **

N020121 001 Oct 19, 1994

FLUVASTATIN SODIUM

CAPSULE; ORAL

LESCOL

+ NOVARTIS

EQ 20MG BASE

N020261 001 Dec 31, 1993

+

EQ 40MG BASE

N020261 002 Dec 31, 1993

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

+ JAZZ PHARMS

100MG

N022033 001 Feb 28, 2008

+

150MG

N022033 002 Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

ANI PHARMS INC

25MG

A075898 001 Mar 12, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075898 003 Mar 12, 2001

ECI PHARMS LLC

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

MYLAN

50MG

A075950 001 Oct 15, 2001

100MG

A075950 002 Oct 15, 2001

SUN PHARM INDUSTRIES

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

UPSHER-SMITH LABS

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

WATSON LABS

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

LUVOX

+ SOLVAY

25MG **

N020243 001 Dec 05, 1994

+

50MG **

N020243 002 Dec 05, 1994

+

100MG **

N020243 003 Dec 05, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

+

150MG **

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

WYETH PHARMS INC

5MG/ML

N005897 008

TABLET; ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

CONTRACT PHARMACAL

1MG

A085061 001

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

IMPAX LABS

1MG

A080686 001

IVAX SUB TEVA PHARMS

1MG

A083000 001

JUBILANT CADISTA

1MG

A040514 001 Jun 14, 2005

LANNETT

1MG

A080816 001

LILLY

1MG

N006135 003

MK LABS

1MG

A083526 001

NEXGEN PHARMA INC

1MG

A084915 001

PHARMERAL

1MG

A084158 001

PIONEER PHARMS

1MG

A088949 001 Sep 13, 1985

PUREPAC PHARM

1MG

A080784 001

SANDOZ

1MG

A084472 001

SUN PHARM INDUSTRIES

1MG

A040582 001 Jul 18, 2005

TABLICAPS

1MG

A083133 002

UDL

1MG

A088199 001 Mar 29, 1983

USL PHARMA

1MG

A087828 001 May 13, 1982

VALEANT PHARM INTL

1MG

A080903 001

VANGARD

1MG

A088730 001 Mar 23, 1984

VINTAGE PHARMS

1MG

A086296 001

WATSON LABS

1MG

A083141 001

1MG

A085141 002

WHITEWORTH TOWN PLSN

1MG

A080691 002

FOLICET

MISSION PHARMA

1MG

A087438 001

FOLVITE

WYETH PHARMS INC

1MG

N005897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC

75 IU/VIAL

N020582 001 Sep 29, 1997

150 IU/VIAL

N020582 002 Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

150 IU/0.18ML

N021211 003 Feb 11, 2004

150 IU/0.5ML

N021273 002 Aug 26, 2005

GONAL-F

EMD SERONO

37.5 IU/VIAL

N020378 003 May 25, 2000

37.5 IU/VIAL

N021765 001 Mar 25, 2004

75 IU/VIAL

N020378 001 Sep 29, 1997

150 IU/VIAL

N020378 002 Sep 29, 1997

150 IU/VIAL

N021765 003 Mar 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML)

A079033 001 Apr 07, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS

6.6MG/ML

N020961 001 Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ NOVARTIS

0.012MG/INH

N020831 001 Feb 16, 2001

FORADIL CERTIHALER

NOVARTIS

0.0085MG/INH

N021592 001 Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+ MERCK AND CO INC

EQ 115MG BASE/VIAL **

N022023 001 Jan 25, 2008

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

HOSPIRA

2.4GM/100ML

A077174 001 May 31, 2005

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

ACTAVIS LABS FL INC

10MG

A076620 001 Oct 15, 2004

20MG

A076620 002 Oct 15, 2004

40MG

A076620 003 Oct 15, 2004

RANBAXY LABS LTD

10MG

A076580 001 Apr 23, 2004

20MG

A076580 002 Apr 23, 2004

40MG

A076580 003 Apr 23, 2004

UPSHER-SMITH LABS

10MG

A076188 001 Oct 08, 2004

20MG

A076188 002 Oct 08, 2004

40MG

A076188 003 Oct 08, 2004

WATSON LABS

10MG

A076987 001 Dec 23, 2004

10MG

A077531 001 Aug 31, 2006

20MG

A076987 002 Dec 23, 2004

20MG

A077531 002 Aug 31, 2006

40MG

A076987 003 Dec 23, 2004

40MG

A077531 003 Aug 31, 2006

MONOPRIL

+ BRISTOL MYERS SQUIBB

10MG **

N019915 002 May 16, 1991

+ BRISTOL MYERS SQUIBB

20MG **

N019915 003 May 16, 1991

+ BRISTOL MYERS SQUIBB

40MG **

N019915 004 Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC

10MG; 12.5MG

A076608 001 Dec 03, 2004

20MG; 12.5MG

A076608 002 Dec 03, 2004

MYLAN

10MG; 12.5MG

A077705 001 Aug 14, 2006

20MG; 12.5MG

A077705 002 Aug 14, 2006

SUN PHARM INDS LTD

10MG; 12.5MG

A076739 001 Dec 17, 2004

20MG; 12.5MG

A076739 002 Dec 17, 2004

TEVA

10MG; 12.5MG

A076945 001 Jul 05, 2006

20MG; 12.5MG

A076945 002 Jul 05, 2006

WATSON LABS

10MG; 12.5MG

A077144 001 Aug 16, 2005

20MG; 12.5MG

A077144 002 Aug 16, 2005

MONOPRIL-HCT

+ BRISTOL MYERS SQUIBB

10MG; 12.5MG **

N020286 002 Nov 30, 1994

+ BRISTOL MYERS SQUIBB

20MG; 12.5MG **

N020286 001 Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML

A078126 001 Aug 06, 2007

HOSPIRA

EQ 50MG PHENYTOIN NA/ML

A078158 001 Aug 06, 2007

TEVA PHARMS USA

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOSPROPOFOL DISODIUMSOLUTION; INTRAVENOUS
LUSEDRA

EISAI INC 1050MG/30ML (35MG/ML) N022244 001 Dec 12, 2008

FURAZOLIDONESUSPENSION; ORAL
FUROXONE

SHIRE 50MG/15ML N011323 002

TABLET; ORAL
FUROXONE

SHIRE 100MG N011270 002

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

ABRAXIS PHARM 10MG/ML N018507 001 Jul 30, 1982

10MG/ML N019036 001 Aug 13, 1984

ACCORD HLTHCARE 10MG/ML A070017 001 Dec 15, 1986

ASTRAZENECA 10MG/ML A070014 001 Sep 09, 1985

HOSPIRA 10MG/ML A070578 001 Jul 08, 1987

10MG/ML A072080 001 Aug 13, 1991

10MG/ML A074337 001 Oct 31, 1994

IGI LABS INC 10MG/ML A070095 001 Sep 09, 1985

10MG/ML A070096 001 Sep 09, 1985

INTL MEDICATION 10MG/ML N018025 001

+ LUITPOLD 10MG/ML ** N018579 001 Nov 30, 1983

MARSAM PHARMS LLC 10MG/ML A074017 001 Jun 30, 1994

SMITH AND NEPHEW 10MG/ML A070023 001 Feb 05, 1986

10MG/ML A070078 001 Feb 05, 1986

WARNER CHILCOTT 10MG/ML N018420 001 Feb 26, 1982

WATSON LABS 10MG/ML A070019 001 Sep 22, 1986

10MG/ML A070604 001 Jan 02, 1987

WEST-WARD PHARMS INT 10MG/ML A071439 001 Sep 14, 1990

10MG/ML N018267 001

WYETH AYERST 10MG/ML N018670 001 Jul 20, 1982

LASIX

+ SANOFI AVENTIS US 10MG/ML ** N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US 10MG/ML N017688 001

TABLET; ORAL

FUROSEMIDE

DAVA PHARMS INC 20MG N018415 001 Jul 27, 1982

40MG N018415 002 Jul 27, 1982

80MG N018415 003 Nov 26, 1984

INTL MEDICATION 20MG N018753 001 Feb 28, 1984

40MG N018753 002 Feb 28, 1984

KALAPHARM 20MG N018868 001 Jun 28, 1983

40MG N018868 002 Jun 28, 1983

SANDOZ 40MG N018750 002 Jul 30, 1984

SUN PHARM INDS INC 20MG A091258 001 Apr 01, 2014

40MG A091258 002 Apr 01, 2014

40MG N018790 001 Nov 29, 1983

SUN PHARM INDUSTRIES 20MG A091258 003 Apr 01, 2014

80MG A070043 001 Sep 26, 1985

80MG A070100 001 Jan 26, 1988

SUPERPHARM 20MG N018370 002 Jun 26, 1984

40MG N018370 001 Feb 10, 1983

WARNER CHILCOTT 20MG N018419 001 Jan 31, 1983

40MG N018419 002 Jan 31, 1983

80MG N018419 003 Nov 13, 1984

WATSON LABS 20MG A070412 001 Feb 26, 1986

20MG A071379 001 Jan 02, 1987

20MG N018369 001 May 14, 1982

40MG A070413 001 Feb 26, 1986

40MG A070450 001 Nov 22, 1985

40MG N018369 002 May 14, 1982

80MG A071594 001 Feb 09, 1988

WATSON LABS TEVA 20MG A070449 001 Nov 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FUROSEMIDETABLET; ORAL
FUROSEMIDE

80MG A070528 001 Jan 07, 1986

GABAPENTINCAPSULE; ORAL
GABAPENTIN

CSPC OUYI PHARM CO	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
HIKMA	100MG	A078150 001	Sep 25, 2007
	300MG	A078150 002	Sep 25, 2007
	400MG	A078150 003	Sep 25, 2007
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
	300MG	A076606 002	Oct 07, 2005
	400MG	A076606 003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDEINJECTABLE; INJECTION
OMNISCAN

GE HEALTHCARE 14.35GM/50ML (287MG/ML) N022066 001 Sep 05, 2007

GADOFOSVESET TRISODIUMSOLUTION; INTRAVENOUS
ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

IMPAX LABS	EQ 8MG BASE	A078484 001	May 27, 2009
	EQ 16MG BASE	A078484 002	May 27, 2009
	EQ 24MG BASE	A078484 003	May 27, 2009

SOLUTION; ORAL

RAZADYNE

JANSSEN PHARMS 4MG/ML ** N021224 001 Jun 22, 2001

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
MYLAN	EQ 4MG BASE	A077603 001	Aug 28, 2008
	EQ 8MG BASE	A077603 002	Aug 28, 2008
	EQ 12MG BASE	A077603 003	Aug 28, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001
	100MG/ML	N007842 002

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001
---------------	---------	-------------

NEOSCAN

GE HEALTHCARE	2mCi/ML	N017655 001
---------------	---------	-------------

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE	25MG/ML **	N019961 002	Jan 17, 1991
-------------------	------------	-------------	--------------

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

+ ROCHE PALO

250MG **

N020460 001

Dec 22, 1994

+ GANCICLOVIR

500MG **

N020460 002

Dec 12, 1997

GANCICLOVIR

RANBAXY LABS LTD

250MG

A076457 001

Jun 27, 2003

500MG

A076457 002

Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB

4.5MG

N020569 001

Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

WEST-WARD PHARMS INT EQ 500MG BASE/VIAL

A076222 001

Jul 16, 2003

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001

Aug 19, 2011

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001

May 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

SAGENT PHARMS

EQ 200MG BASE/VIAL

A091597 001

May 07, 2013

EQ 1GM BASE/VIAL

A091597 002

May 07, 2013

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001

Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001

Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET; ORAL

GEMFIBROZIL

FOSUN PHARMA

600MG

A074615 001

Sep 29, 1995

MYLAN

600MG

A074452 001

Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001

Aug 31, 1994

WATSON LABS

600MG

A074156 001

Oct 24, 1994

600MG

A074442 001

Apr 28, 1995

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001

May 17, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING EQ 0.1% BASE ** A060462 001

GENTAFAIR

PHARMAFAIR EQ 0.1% BASE A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS EQ 0.1% BASE A062471 001 Sep 27, 1983

FOUGERA PHARMS INC EQ 0.1% BASE A062531 001 Jul 05, 1984

PHARMADERM EQ 1MG BASE/GM A062530 001 Jul 05, 1984

TARO EQ 0.1% BASE A062427 001 May 26, 1983

INJECTABLE; INJECTION

APOGEN

KING PHARMS EQ 10MG BASE/ML A062289 001

EQ 40MG BASE/ML A062289 002

BRISTAGEN

BRISTOL EQ 40MG BASE/ML A062288 001

GARAMYCIN

SCHERING EQ 1MG BASE/ML ** A061716 002

EQ 10MG BASE/ML ** A061739 001

EQ 40MG BASE/ML ** A061716 001

GENTAFAIR

PHARMAFAIR EQ 40MG BASE/ML A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION EQ 1MG BASE/ML A062325 003 Jun 23, 1982

EQ 40MG BASE/ML A062325 001

EQ 100MG BASE/100ML A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML A062413 004 Aug 11, 1983

EQ 2MG BASE/ML A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML A062413 007 Aug 11, 1983

EQ 80MG BASE/100ML A062413 008 Aug 11, 1983

EQ 90MG BASE/100ML A062413 009 Aug 11, 1983

EQ 100MG BASE/100ML A062413 010 Aug 11, 1983

FRESENIUS KABI USA EQ 10MG BASE/ML A062356 001 Mar 04, 1982

EQ 40MG BASE/ML A062356 002 Mar 04, 1982

KALAPHARM EQ 40MG BASE/ML A062354 001 Apr 05, 1982

PHARM SPEC EQ 40MG BASE/ML A062340 001 Mar 28, 1983

SOLOPAK EQ 10MG BASE/ML A062507 001 Jun 06, 1985

EQ 40MG BASE/ML A062507 002 Jun 06, 1985

TEVA PARENTERAL EQ 10MG BASE/ML A063149 001 Nov 21, 1991

EQ 40MG BASE/ML A063106 002 Nov 21, 1991

WATSON LABS EQ 10MG BASE/ML A062318 002

EQ 40MG BASE/ML A062318 001

WEST-WARD PHARMS INT EQ 10MG BASE/ML A062251 002

EQ 40MG BASE/ML A062251 001

WYETH AYERST EQ 10MG BASE/ML A062264 001

EQ 40MG BASE/ML A062264 002

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

EQ 0.8MG BASE/ML A062814 001 Aug 28, 1987

EQ 1.2MG BASE/ML A062814 002 Aug 28, 1987

EQ 1.4MG BASE/ML A062814 003 Aug 28, 1987

EQ 1.6MG BASE/ML A062814 004 Aug 28, 1987

EQ 1.8MG BASE/ML A062814 005 Aug 28, 1987

EQ 2MG BASE/ML A062814 006 Aug 28, 1987

EQ 2.4MG BASE/ML A062814 007 Aug 28, 1987

EQ 40MG BASE/100ML A062814 008 Aug 28, 1987

EQ 60MG BASE/100ML A062814 009 Aug 28, 1987

EQ 70MG BASE/100ML A062814 010 Aug 28, 1987

EQ 80MG BASE/100ML A062814 011 Aug 28, 1987

EQ 90MG BASE/100ML A062814 012 Aug 28, 1987

EQ 100MG BASE/100ML A062814 013 Aug 28, 1987

EQ 120MG BASE/100ML A062814 014 Aug 28, 1987

BAXTER HLTHCARE EQ 0.8MG BASE/ML A062373 001 Sep 07, 1982

EQ 2.4MG BASE/ML A062373 010 Sep 07, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	EQ 40MG BASE/100ML	A062373 003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373 004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588 001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414 002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588 002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588 003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414 004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588 004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414 005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588 005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414 006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588 006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414 007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588 007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588 008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414 009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588 009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588 010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248 001	
	EQ 40MG BASE/ML	A062248 002	

INJECTABLE; INTRATHECAL

GARAMYCIN

+ SCHERING	EQ 2MG BASE/ML **	N050505 001	
------------	-------------------	-------------	--

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425 001	
----------	--------------	-------------	--

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501 001	Jul 26, 1984
----------	--------------	-------------	--------------

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443 001	May 26, 1983
------------	----------------	-------------	--------------

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE **	A060463 001	
----------	-----------------	-------------	--

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444 001	May 26, 1983
------------	--------------	-------------	--------------

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496 001	Mar 14, 1984
--------------------	--------------	-------------	--------------

G AND W LABS INC	EQ 0.1% BASE	A064054 001	Apr 29, 1994
------------------	--------------	-------------	--------------

PHARMADERM	EQ 0.1% BASE	A062534 001	Oct 10, 1984
------------	--------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

+ SCHERING	EQ 0.3% BASE **	N050039 002	
------------	-----------------	-------------	--

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480 001	Mar 30, 1984
----------	--------------	-------------	--------------

GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440 001	May 03, 1983
------------	--------------	-------------	--------------

GENTAMICIN SULFATE

ALCON PHARMS LTD	EQ 0.3% BASE	A062523 001	Nov 25, 1985
------------------	--------------	-------------	--------------

PACO	EQ 3MG BASE/ML	A062932 001	Nov 07, 1988
------	----------------	-------------	--------------

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513 001	
-------------	------	-------------	--

TAMPON; VAGINAL

GENAPAX

KEY PHARMS	5MG	A085017 001	
------------	-----	-------------	--

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA	20MG/VIAL	N020622 001	Dec 20, 1996
-----------------	-----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

ACTAVIS LABS FL INC	1MG	A076995 001	Apr 27, 2010
	2MG	A076995 002	Apr 27, 2010
	4MG	A076995 003	Apr 27, 2010
EPIC PHARMA LLC	1MG	A077274 001	Oct 06, 2005
	2MG	A077274 002	Oct 06, 2005
	4MG	A077274 003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952 001	Aug 01, 2013
	2MG	A078952 002	Aug 01, 2013
	4MG	A078952 003	Aug 01, 2013
MYLAN	1MG	A077486 001	Feb 10, 2006
	2MG	A077486 002	Feb 10, 2006
	4MG	A077486 003	Feb 10, 2006
RANBAXY	3MG	A077366 001	Oct 06, 2005
	6MG	A077366 002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005
	2MG	A076875 002	Oct 06, 2005
	4MG	A076875 003	Oct 06, 2005
	8MG	A076875 004	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+	SB PHARMCO	1MG; 4MG **	N021700 001	Nov 23, 2005
+		2MG; 4MG **	N021700 002	Nov 23, 2005
+		2MG; 8MG **	N021700 004	Mar 30, 2007
+		4MG; 4MG **	N021700 003	Nov 23, 2005
+		4MG; 8MG **	N021700 005	Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

ANI PHARMS INC	5MG	A074387 001	Mar 04, 1996
	10MG	A074387 002	Mar 04, 1996
BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
MYLAN	5MG	A074438 001	Jun 20, 1995
	10MG	A074438 002	Jun 20, 1995
SANDOZ	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994
GLUCOTROL			
PFIZER	2.5MG	N017783 003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

+	BRISTOL MYERS SQUIBB	2.5MG; 250MG **	N021460 001	Oct 21, 2002
+		2.5MG; 500MG **	N021460 002	Oct 21, 2002
+		5MG; 500MG **	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	EQ 1MG BASE/VIAL **	N012122 001
+		EQ 10MG BASE/VIAL **	N012122 002

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

SANOFI AVENTIS US	500MG	N009519 008
-------------------	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLUTETHIMIDE

TABLET; ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519 002
	500MG	N009519 005

GLUTETHIMIDE

HALSEY	250MG	A089458 001	Oct 10, 1986
	500MG	A089459 001	Oct 10, 1986
LANNETT	250MG	A083475 001	
	500MG	A085571 001	
UCB INC	500MG	A085171 001	
UPSHER-SMITH LABS	500MG	A083234 002	
VITARINE	500MG	A087297 001	
WATSON LABS	500MG	A084362 001	
	500MG	A085763 001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
	3MG	A075947 002	Nov 14, 2002
	6MG	A075947 003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

FOSUN PHARMA	1.5MG	A075174 001	Jun 22, 1998
	3MG	A075174 002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
	3MG	N020055 002	Apr 17, 1992
	6MG	N020055 003	Mar 08, 2000

GLYNASE

+ PHARMACIA AND UPJOHN	4.5MG **	N020051 003	Sep 24, 1993
------------------------	----------	-------------	--------------

MICRONASE

+ PHARMACIA AND UPJOHN	1.25MG **	N017498 001	May 01, 1984
	2.5MG	N017498 002	May 01, 1984
+	5MG **	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

+ BRISTOL MYERS SQUIBB	1.25MG; 250MG **	N021178 001	Jul 31, 2000
+	2.5MG; 500MG	N021178 002	Jul 31, 2000
+	5MG; 500MG	N021178 003	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

IMPAX LABS INC	1.25MG; 250MG	A076731 001	Nov 19, 2004
	2.5MG; 500MG	A076731 002	Nov 19, 2004
	5MG; 500MG	A076731 003	Nov 19, 2004
TEVA	1.25MG; 250MG	A076821 001	Jan 27, 2005
	2.5MG; 500MG	A076821 002	Jan 27, 2005
	5MG; 500MG	A076821 003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983

ROBINUL

ROBINS AH	0.2MG/ML	N014764 001	
+ WEST-WARD PHARMS INT	0.2MG/ML **	N017558 001	

TABLET; ORAL

GLYCOPYRROLATE

EPIC PHARMA LLC	1MG	A040568 001	Dec 22, 2004
	2MG	A040568 002	Dec 22, 2004
HIKMA INTL PHARMS	1MG	A040836 001	Mar 05, 2009
	2MG	A040836 002	Mar 05, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
----------------------	-------------------	---------	-----	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427	001	
-----------	--	---------	-----	--

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788	001	Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383	001	Aug 31, 1982
------------	--	---------	-----	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007
-----------------	---------------------------------	---------	-----	--------------

KYTRIL

+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239	003	Sep 17, 2004
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239	004	Mar 11, 1994
+		EQ 3MG BASE/ML **	N020239	001	Dec 29, 1993
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239	002	Mar 11, 1994

SOLUTION; ORAL

GRANISOL

PEDIATRAX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008
-----------	------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

KYTRIL

+ ROCHE

EQ 2MG BASE/10ML **

N021238 001 Jun 27, 2001

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

BARR

EQ 1MG BASE

A078221 001 Dec 31, 2007

EPIC PHARMA LLC

EQ 1MG BASE

A078260 001 Dec 31, 2007

KYTRIL

+ ROCHE

EQ 1MG BASE **

N020305 001 Mar 16, 1995

+

EQ 2MG BASE **

N020305 002 Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL

RAXAR

OTSUKA

EQ 200MG BASE

N020695 001 Nov 06, 1997

EQ 400MG BASE

N020695 002 May 14, 1998

EQ 600MG BASE

N020695 003 May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL

GRISACTIN

WYETH AYERST

125MG

N050051 002

250MG

N050051 001

SUSPENSION;ORAL

GRIFULVIN V

+ JOHNSON AND JOHNSON

125MG/5ML **

N050448 001

TABLET;ORAL

FULVICIN-U/F

CHARTWELL RX

250MG

A060569 002

500MG

A060569 001

GRIFULVIN V

J AND J

125MG

A060618 001

250MG

A060618 002

500MG

A060618 003

VALEANT LUXEMBOURG

125MG

A062279 001

250MG **

A062279 002

GRISACTIN

WYETH AYERST

500MG

A060212 001

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

125MG/5ML **

A062483 001 Jan 26, 1984

TABLET;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

500MG

A062279 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

CHARTWELL RX

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

CHARTWELL RX

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

CHARTWELL RX

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON

+ SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

ANI PHARMS INC EQ 4MG BASE A074267 001 Jun 01, 1994

EQ 8MG BASE A074267 002 Jun 01, 1994

SANDOZ EQ 4MG BASE A074517 001 Sep 30, 1998

EQ 8MG BASE A074517 002 Sep 30, 1998

WATSON LABS EQ 4MG BASE A074025 001 Feb 28, 1994

EQ 8MG BASE A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST EQ 4MG BASE N018587 001 Sep 07, 1982

EQ 8MG BASE N018587 002 Sep 07, 1982

EQ 16MG BASE N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

PHARMACIA AND UPJOHN 10MG N018104 001 Dec 29, 1982

25MG N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS EQ 10MG SULFATE A086113 001 Mar 26, 1985

EQ 25MG SULFATE A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS EQ 10MG SULFATE N012329 001

EQ 25MG SULFATE N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS 10MG; 25MG N013553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS EQ 1MG BASE A074762 001 Jun 25, 1997

EQ 2MG BASE A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA EQ 3MG BASE N019032 003 Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC EQ 1MG BASE A202238 001 Oct 20, 2015

EQ 2MG BASE A202238 002 Oct 20, 2015

EQ 3MG BASE A202238 003 Oct 20, 2015

EQ 4MG BASE A202238 004 Oct 20, 2015

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING 20MG N017736 003

40MG N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB 0.025% N017818 001

HALOG-E

SUN PHARM INDS INC 0.1% N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB 0.025% N018125 001

SOLUTION; TOPICAL

HALOG

SUN PHARM INDS INC 0.1% N017823 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

+ ORTHO MCNEIL

0.5MG **

N015921 001

+

1MG **

N015921 002

+

2MG **

N015921 003

+

5MG **

N015921 004

+

10MG **

N015921 005

+

20MG **

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

ANDA REPOSITORY

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

10MG

A071173 001 Jan 07, 1988

20MG

A071177 001 Jan 07, 1988

CYCLE PHARMS LTD

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

2MG

A071130 001 Feb 17, 1987

5MG

A071131 001 Feb 17, 1987

10MG

A071132 001 May 12, 1987

20MG

A071133 001 May 12, 1987

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

PAR PHARM

20MG

A071328 001 Jul 20, 1987

PUREPAC PHARM

0.5MG

A071071 001 Nov 03, 1986

1MG

A071072 001 Nov 03, 1986

2MG

A071073 001 Nov 03, 1986

5MG

A071074 001 Nov 03, 1986

10MG

A071075 001 Aug 04, 1987

20MG

A071076 001 Aug 04, 1987

QUANTUM PHARMICS

0.5MG

A071255 001 Feb 17, 1987

1MG

A071269 001 Feb 17, 1987

2MG

A071256 001 Feb 17, 1987

5MG

A071257 001 Feb 17, 1987

ROYCE LABS

0.5MG

A071722 001 Dec 24, 1987

1MG

A071723 001 Dec 24, 1987

2MG

A071724 001 Dec 24, 1987

5MG

A071725 001 Dec 24, 1987

10MG

A072121 001 Dec 24, 1987

20MG

A072122 001 Dec 24, 1987

SCS

0.5MG

A070720 001 Jun 10, 1986

1MG

A070721 001 Jun 10, 1986

2MG

A070722 001 Jun 10, 1986

5MG

A070723 001 Jun 10, 1986

10MG

A070724 001 Jun 10, 1986

20MG

A070725 001 Sep 24, 1986

VINTAGE

0.5MG

A071235 002 Nov 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	1MG	A071235 003	Nov 03, 1986
	2MG	A071235 001	Nov 03, 1986
	5MG	A071235 004	Nov 03, 1986
	10MG	A071235 005	Jul 20, 1987
WATSON LABS	0.5MG	A070981 001	Mar 06, 1987
	0.5MG	A071571 001	Jun 03, 1988
	1MG	A070982 001	Mar 06, 1987
	1MG	A071572 001	Jun 03, 1988
	2MG	A070983 001	Mar 06, 1987
	2MG	A071573 001	Jun 03, 1988
	5MG	A070984 001	Mar 06, 1987
	5MG	A071374 001	Jun 03, 1988
	10MG	A071375 001	Jun 03, 1988
	10MG	A072113 001	Aug 27, 1991
	20MG	A071376 001	Jun 03, 1988
	20MG	A072353 001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176 001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176 002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463 001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463 002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922 001	
HALOPERIDOL			
ALPHARMA	EQ 2MG BASE/ML	A070318 001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710 001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726 001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015 001	Aug 25, 1987
HALOPERIDOL INTENSOL			
CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045 001	Apr 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993
SANDOZ INC	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995
----------------------	----------------	-------------	--------------

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942 001	
-----------------	----	-------------	--

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943 001	
-----------------	----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST 99.99% N011338 001

HALOTHANE

BH 99.99% A084977 001

HALOCARBON 99.99% A080810 001

HOSPIRA 99.99% A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US 25,000 UNITS/ML N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA 100 UNITS/ML N005264 010

INTL MEDICATION 10 UNITS/ML A086357 001

500 UNITS/ML A086357 002

LUITPOLD 10 UNITS/ML A089063 001

100 UNITS/ML A089064 001 Oct 09, 1985

PARKE DAVIS 10 UNITS/ML N017346 006

SMITH AND NEPHEW 10 UNITS/ML A087904 001

10 UNITS/ML A087958 001 Apr 20, 1983

10 UNITS/ML A088458 001 Jul 26, 1984

10 UNITS/ML A088580 001 Oct 25, 1984

100 UNITS/ML A087906 001 Apr 20, 1983

100 UNITS/ML A087959 001 Apr 20, 1983

100 UNITS/ML A088460 001 Jul 26, 1984

100 UNITS/ML A088581 001 Oct 25, 1984

SOLOPAK 10 UNITS/ML A087903 001 Apr 20, 1983

10 UNITS/ML A088457 001 Oct 25, 1984

100 UNITS/ML A087905 001 Apr 20, 1983

100 UNITS/ML A088459 001 Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM 1,000 UNITS/ML N017033 001

1,000 UNITS/ML N017979 001

5,000 UNITS/ML N017979 003

10,000 UNITS/ML N017979 002

AKORN 1,000 UNITS/ML N017486 001

5,000 UNITS/ML N017486 002

10,000 UNITS/ML N017486 003

20,000 UNITS/ML N017486 004

40,000 UNITS/ML N017486 005

CHAMBERLIN PARENTERL 1,000 UNITS/ML N017130 001

5,000 UNITS/ML N017130 002

10,000 UNITS/ML N017130 003

20,000 UNITS/ML N017130 004

DELL LABS 1,000 UNITS/ML N017540 001

5,000 UNITS/ML N017540 002

10,000 UNITS/ML N017540 003

20,000 UNITS/ML N017540 004

40,000 UNITS/ML N017540 005

FRESENIUS KABI USA 1,000 UNITS/ML N017651 005

5,000 UNITS/ML N017029 002

10,000 UNITS/ML N017651 003

20,000 UNITS/ML N017651 008

HOSPIRA 2,500 UNITS/ML A088099 001 Apr 28, 1983

10,000 UNITS/ML A040095 001 Jul 26, 1996

LILLY 1,000 UNITS/ML N005521 001

10,000 UNITS/ML N005521 002

20,000 UNITS/ML N005521 004

LUITPOLD 1,000 UNITS/ML A087452 001 Oct 31, 1983

ORGANON USA INC 1,000 UNITS/ML N000552 008

5,000 UNITS/ML N000552 009

10,000 UNITS/ML N000552 010

PARKE DAVIS 1,000 UNITS/ML N017346 001

5,000 UNITS/ML N017346 002

7,500 UNITS/ML N017346 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
WATSON LABS INC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001	
	2,500 UNITS/ML	N017007	007	
	5,000 UNITS/ML	N017007	002	
	5,000 UNITS/0.5ML	N017007	010	
	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
	7,500 UNITS/ML	N017007	003	
	10,000 UNITS/ML	N017007	004	
	15,000 UNITS/ML	N017007	005	
	20,000 UNITS/ML	N017007	006	
HEPARIN SODIUM 1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	
SODIUM HEPARIN				
ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HETACILLIN

FOR SUSPENSION;ORAL

VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML
EQ 112.5MG AMPICIL/5ML
EQ 112.5MG AMPICIL/ML
EQ 225MG AMPICIL/5MLA061398 001
N050060 001
N050060 003
A061398 002HETACILLIN POTASSIUM

CAPSULE;ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL
EQ 450MG AMPICILA061396 001
A061396 002HEXACHLOROPHENE

AEROSOL;TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION;TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N006882 001

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP;TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION;TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE;TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE;INJECTION

MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML

N009789 003

HEXOCYLIUM METHYLSULFATE

TABLET;ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION;TOPICAL

CYCLAINE

MERCK

5%

N008472 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HISTAMINE PHOSPHATEINJECTABLE; INJECTION
HISTAMINE PHOSPHATE
LILLYEQ 0.1MG BASE/ML N000734 003
EQ 0.2MG BASE/ML N000734 002
EQ 1MG BASE/ML N000734 001HISTRELIN ACETATEINJECTABLE; INJECTION
SUPPRELIN
SHIREEQ 0.2MG BASE/ML N019836 001 Dec 24, 1991
EQ 0.5MG BASE/ML N019836 002 Dec 24, 1991
EQ 1MG BASE/ML N019836 003 Dec 24, 1991HOMATROPINE METHYLBROMIDETABLET; ORAL
HOMAPIN-10

MISSION PHARMA 10MG A086308 001

HOMAPIN-5

MISSION PHARMA 5MG A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA 3MG A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

+ ENDO PHARMS 1.5MG/5ML; 5MG/5ML ** N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML; 5MG/5ML A040285 001 Jul 19, 1999

HYDRODANE

HALSEY 1.5MG/5ML; 5MG/5ML A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH 1.5MG; 5MG A040295 001 Dec 01, 2000

HYCODAN

+ ENDO PHARMS 1.5MG; 5MG ** N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC 150 UNITS/ML N021716 001 Oct 25, 2005

VITRASE

BAUSCH AND LOMB 6,200 UNITS/VIAL N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE 150 UNITS/ML ** N006343 002

150 UNITS/VIAL ** N006343 006

1,500 UNITS/VIAL ** N006343 005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

+ NOVARTIS 20MG/ML ** N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM 20MG/ML A089532 001 Aug 11, 1987

SMITH AND NEPHEW 20MG/ML A088518 001 Apr 20, 1984

SOLOPAK 20MG/ML A088517 001 Aug 22, 1985

TEVA PARENTERAL 20MG/ML A040373 001 Feb 23, 2000

TABLET; ORAL

APRESOLINE

+ NOVARTIS 10MG ** N008303 004

+ 25MG ** N008303 001

+ 50MG ** N008303 002

+ 100MG ** N008303 005

DRALZINE

TEVA 25MG A084301 001

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH 25MG A088560 001 Oct 04, 1984

50MG A088649 001 Oct 18, 1984

ACTAVIS GRP PTC 10MG A091679 001 Mar 04, 2013

25MG A091679 002 Mar 04, 2013

50MG A091679 003 Mar 04, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	100MG	A091679	004	Mar 04, 2013
ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986
	25MG	A089258	001	May 05, 1986
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
MYLAN	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER-SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001	
	50MG; 50MG	A084810	001	
	100MG; 50MG	A084811	001	
HYDRA-ZIDE				
PAR PHARM	100MG; 50MG	A088961	001	Oct 21, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;25MG	A087608	001	Feb 08, 1982
	50MG;50MG	A087213	001	Feb 08, 1982
	100MG;50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200	001	Feb 09, 1987
	50MG;50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457	001	Mar 04, 1982
	50MG;50MG	A085446	001	Mar 04, 1982
	100MG;50MG	A085440	001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG;50MG	A088358	001	Apr 10, 1984
-------------	------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG;25MG	A088356	001	Apr 10, 1984
-------------	-----------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG;50MG	A088357	001	Apr 10, 1984
-------------	-----------	---------	-----	--------------

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG;15MG	N012026	002	
----------	-----------	---------	-----	--

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG;15MG	A085827	001	
-------------	-----------	---------	-----	--

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG;15MG	A085373	001	
-------------	-----------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	
--------------	-----------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	
----------------------	-----------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN	25MG;15MG;0.1MG	A087085	001	
-------	-----------------	---------	-----	--

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	25MG;15MG;0.1MG	A085771	001	
-------------	-----------------	---------	-----	--

HYDRAP-ES

SANDOZ	25MG;15MG;0.1MG	A084876	001	
--------	-----------------	---------	-----	--

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS	25MG;15MG;0.1MG	A083770	001	
-------------	-----------------	---------	-----	--

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001	
----------------------	-----------------	---------	-----	--

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;15MG;0.1MG	A088376	001	Oct 28, 1983
--------	-----------------	---------	-----	--------------

SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984
----------------------	-----------------	---------	-----	--------------

WATSON LABS	25MG;15MG;0.1MG	A085549	001	
-------------	-----------------	---------	-----	--

	25MG;15MG;0.1MG	A087556	001	
--	-----------------	---------	-----	--

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE	25MG;15MG;0.1MG	A087709	001	May 13, 1982
---------	-----------------	---------	-----	--------------

SER-A-GEN

SOLVAY	25MG;15MG;0.1MG	A087210	001	
--------	-----------------	---------	-----	--

SER-AP-ES

NOVARTIS	25MG;15MG;0.1MG	N012193	005	
----------	-----------------	---------	-----	--

UNIPRES

SOLVAY	25MG;15MG;0.1MG	A085893	001	
--------	-----------------	---------	-----	--

	25MG;15MG;0.1MG	A086298	001	
--	-----------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ	25MG;0.1MG	A084617	001	
--------	------------	---------	-----	--

SERPASIL-APRESOLINE

NOVARTIS	25MG;0.1MG	N009296	004	
----------	------------	---------	-----	--

	50MG;0.2MG	N009296	002	
--	------------	---------	-----	--

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
-------------------	--------	---------	-----	--------------

LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012
----------------------	--------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
ROXANE	50MG/5ML	A088587	001	Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE	100MG/ML	A088588	001	Jul 02, 1984
--------	----------	---------	-----	--------------

TABLET; ORAL

ESIDRIX

NOVARTIS	25MG	N011793	005	
	50MG	N011793	008	
	100MG	N011793	009	

HYDRO-D

HALSEY	25MG	A086504	001	
	50MG	A083891	002	

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	
	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	50MG	A083965	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
FOSUN PHARMA	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	50MG	A087587 001	May 03, 1982
WATSON LABS	25MG	A081189 001	Jan 24, 1992
	25MG	A083458 001	
	25MG	A085232 002	
	50MG	A083456 001	
	50MG	A085233 001	
	50MG	A086087 001	
	50MG	A086594 001	
	100MG	A081190 001	Jan 24, 1992
	100MG	A085099 001	
	100MG	A087002 001	
WATSON LABS TEVA	50MG	A083232 001	
WEST WARD	25MG	A084899 001	
WHITEWORTH TOWN PLSN	25MG	A083809 002	
	50MG	A083809 001	
	100MG	A085347 001	
HYDRODIURIL			
+ MERCK	25MG **	N011835 003	
+	50MG **	N011835 006	
+	100MG **	N011835 007	
ORETIC			
ABBVIE	25MG	N011971 001	
	50MG	N011971 002	
ZIDE			
SOLVAY	50MG	A083925 001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

+	SANOFI AVENTIS US	12.5MG; 75MG **	N020758 001	Sep 30, 1997
+		25MG; 300MG **	N020758 004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE				
TEVA	25MG; 300MG	A077369 003	Mar 30, 2012	
WATSON LABS INC	12.5MG; 150MG	A091539 001	Oct 22, 2012	
	12.5MG; 300MG	A091539 002	Oct 22, 2012	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG; 100MG	N019046 001	Apr 06, 1987	
	25MG; 200MG	N019046 002	Apr 06, 1987	
	25MG; 300MG	N019046 003	Apr 06, 1987	
	25MG; 400MG	N019046 004	Apr 06, 1987	
TRANDATE HCT				
GLAXOSMITHKLINE	25MG; 100MG	N019174 001	Apr 10, 1987	
	25MG; 200MG	N019174 002	Apr 10, 1987	
	25MG; 300MG	N019174 003	Apr 10, 1987	
	25MG; 400MG	N019174 004	Apr 10, 1987	

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG; 10MG	A075926 001	Jul 01, 2002	
	12.5MG; 20MG	A075926 002	Jul 01, 2002	
	25MG; 20MG	A075926 003	Jul 01, 2002	
TEVA	12.5MG; 10MG	A075869 001	Jul 01, 2002	
	12.5MG; 20MG	A075869 002	Jul 01, 2002	
	25MG; 20MG	A075869 003	Jul 01, 2002	
PRINZIDE				
+ MERCK	12.5MG; 10MG **	N019778 003	Nov 18, 1993	
+	12.5MG; 20MG **	N019778 001	Feb 16, 1989	
+	25MG; 20MG **	N019778 002	Feb 16, 1989	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS	12.5MG; 50MG	A200180 001	Jan 12, 2011
	12.5MG; 100MG	A200180 002	Jan 12, 2011
	25MG; 100MG	A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG; 250MG	N013402 001	
-------	-------------	-------------	--

ALDORIL 25

MERCK	25MG; 250MG	N013402 002	
-------	-------------	-------------	--

ALDORIL D30

MERCK	30MG; 500MG	N013402 003	
-------	-------------	-------------	--

ALDORIL D50

MERCK	50MG; 500MG	N013402 004	
-------	-------------	-------------	--

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC	15MG; 250MG	A072507 001	Jun 02, 1989
-----------------	-------------	-------------	--------------

	25MG; 250MG	A072508 001	Jun 02, 1989
--	-------------	-------------	--------------

	30MG; 500MG	A072509 001	Jun 02, 1989
--	-------------	-------------	--------------

	50MG; 500MG	A072510 001	Jun 02, 1989
--	-------------	-------------	--------------

FOSUN PHARMA	15MG; 250MG	A070182 001	Jan 15, 1986
--------------	-------------	-------------	--------------

	25MG; 250MG	A070183 001	Jan 15, 1986
--	-------------	-------------	--------------

	30MG; 500MG	A070543 001	Jan 15, 1986
--	-------------	-------------	--------------

IVAX SUB TEVA PHARMS	15MG; 250MG	A071458 001	Mar 08, 1988
----------------------	-------------	-------------	--------------

	25MG; 250MG	A071459 001	Mar 08, 1988
--	-------------	-------------	--------------

	30MG; 500MG	A071460 001	Mar 08, 1988
--	-------------	-------------	--------------

	50MG; 500MG	A071461 001	Mar 08, 1988
--	-------------	-------------	--------------

PAR PHARM	15MG; 250MG	A070616 001	Feb 02, 1987
-----------	-------------	-------------	--------------

	25MG; 250MG	A070612 001	Feb 02, 1987
--	-------------	-------------	--------------

	30MG; 500MG	A070613 001	Feb 02, 1987
--	-------------	-------------	--------------

	50MG; 500MG	A070614 001	Feb 02, 1987
--	-------------	-------------	--------------

PARKE DAVIS	15MG; 250MG	A071897 001	Nov 23, 1987
-------------	-------------	-------------	--------------

	25MG; 250MG	A071898 001	Nov 23, 1987
--	-------------	-------------	--------------

	30MG; 500MG	A071899 001	Nov 23, 1987
--	-------------	-------------	--------------

	50MG; 500MG	A071900 001	Nov 23, 1987
--	-------------	-------------	--------------

PUREPAC PHARM	15MG; 250MG	A070853 001	Oct 08, 1986
---------------	-------------	-------------	--------------

	25MG; 250MG	A070688 001	Apr 24, 1986
--	-------------	-------------	--------------

	30MG; 500MG	A070854 001	Oct 08, 1986
--	-------------	-------------	--------------

	50MG; 500MG	A070689 001	Apr 24, 1986
--	-------------	-------------	--------------

SANDOZ	15MG; 250MG	A070829 001	Mar 09, 1987
--------	-------------	-------------	--------------

	25MG; 250MG	A070830 001	Mar 09, 1987
--	-------------	-------------	--------------

	50MG; 500MG	A070544 001	Jan 15, 1986
--	-------------	-------------	--------------

TEVA	15MG; 250MG	A071819 001	Apr 08, 1988
------	-------------	-------------	--------------

	25MG; 250MG	A071820 001	Apr 08, 1988
--	-------------	-------------	--------------

	30MG; 500MG	A071821 001	Apr 08, 1988
--	-------------	-------------	--------------

	50MG; 500MG	A071822 001	Apr 08, 1988
--	-------------	-------------	--------------

WATSON LABS	15MG; 250MG	A070365 001	Mar 19, 1986
-------------	-------------	-------------	--------------

	15MG; 250MG	A070958 001	Feb 06, 1989
--	-------------	-------------	--------------

	15MG; 250MG	A071920 001	Aug 29, 1988
--	-------------	-------------	--------------

	25MG; 250MG	A070366 001	Apr 16, 1986
--	-------------	-------------	--------------

	25MG; 250MG	A070959 001	Jan 19, 1989
--	-------------	-------------	--------------

	25MG; 250MG	A071921 001	Aug 29, 1988
--	-------------	-------------	--------------

	30MG; 500MG	A070367 001	Mar 19, 1986
--	-------------	-------------	--------------

	30MG; 500MG	A071069 001	Jan 19, 1989
--	-------------	-------------	--------------

	30MG; 500MG	A071922 001	Aug 29, 1988
--	-------------	-------------	--------------

	50MG; 500MG	A070368 001	Apr 16, 1986
--	-------------	-------------	--------------

	50MG; 500MG	A070960 001	Feb 06, 1989
--	-------------	-------------	--------------

	50MG; 500MG	A071923 001	Aug 29, 1988
--	-------------	-------------	--------------

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

+ US PHARMS HOLDINGS I	50MG; 100MG **	N018303 003	Dec 31, 1984
------------------------	----------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	12.5MG; 7.5MG	A090096 001	Sep 25, 2008
	12.5MG; 15MG	A090096 002	Sep 25, 2008
	25MG; 15MG	A090096 003	Sep 25, 2008

UNIRETIC

UCB INC	12.5MG; 7.5MG **	N020729 001	Jun 27, 1997
	12.5MG; 15MG **	N020729 003	Feb 14, 2002
	25MG; 15MG **	N020729 002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS	25MG; 5MG	N018872 001	Jul 22, 1987
	25MG; 10MG	N018872 002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG; 120MG	N019059 002	Jul 03, 1985
--------------	-------------	-------------	--------------

INDERIDE LA 160/50

WYETH AYERST	50MG; 160MG	N019059 003	Jul 03, 1985
--------------	-------------	-------------	--------------

INDERIDE LA 80/50

WYETH AYERST	50MG; 80MG	N019059 001	Jul 03, 1985
--------------	------------	-------------	--------------

TABLET; ORAL

INDERIDE-40/25

+ WYETH PHARMS INC	25MG; 40MG **	N018031 001	
--------------------	---------------	-------------	--

INDERIDE-80/25

+ WYETH PHARMS INC	25MG; 80MG **	N018031 002	
--------------------	---------------	-------------	--

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR	25MG; 40MG	A071126 001	Mar 02, 1987
---------------------	------------	-------------	--------------

	25MG; 80MG	A071127 001	Mar 02, 1987
--	------------	-------------	--------------

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	25MG; 40MG	A070851 001	May 15, 1986
-------------------	------------	-------------	--------------

	25MG; 80MG	A070852 001	May 15, 1986
--	------------	-------------	--------------

ANI PHARMS INC	25MG; 40MG	A070704 001	Oct 01, 1986
----------------	------------	-------------	--------------

	25MG; 80MG	A070705 001	Oct 01, 1986
--	------------	-------------	--------------

FOSUN PHARMA	25MG; 40MG	A071060 001	Aug 26, 1987
--------------	------------	-------------	--------------

	25MG; 80MG	A071061 001	Aug 26, 1987
--	------------	-------------	--------------

IVAX SUB TEVA PHARMS	25MG; 40MG	A071552 001	Dec 01, 1988
----------------------	------------	-------------	--------------

	25MG; 80MG	A071553 001	Dec 01, 1988
--	------------	-------------	--------------

WARNER CHILCOTT	25MG; 40MG	A071771 001	Jan 26, 1988
-----------------	------------	-------------	--------------

	25MG; 80MG	A071772 001	Jan 26, 1988
--	------------	-------------	--------------

WATSON LABS	25MG; 40MG	A070301 001	Apr 18, 1986
-------------	------------	-------------	--------------

	25MG; 40MG	A071498 001	Dec 18, 1991
--	------------	-------------	--------------

	25MG; 80MG	A070305 001	Apr 18, 1986
--	------------	-------------	--------------

	25MG; 80MG	A071501 001	Dec 18, 1991
--	------------	-------------	--------------

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SUN PHARM INDS LTD	12.5MG; EQ 10MG BASE	A078211 001	Mar 04, 2009
--------------------	----------------------	-------------	--------------

	12.5MG; EQ 20MG BASE	A078211 002	Mar 04, 2009
--	----------------------	-------------	--------------

	25MG; EQ 20MG BASE	A078211 003	Mar 04, 2009
--	--------------------	-------------	--------------

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG; 0.125MG	A085338 001	
----------------------	---------------	-------------	--

HYDRO-RESERP

ABC HOLDING	50MG; 0.125MG	A084714 002	Jun 29, 1982
-------------	---------------	-------------	--------------

HYDRO-SERP "25"

SANDOZ	25MG; 0.125MG	A084827 001	
--------	---------------	-------------	--

HYDRO-SERP "50"

SANDOZ	50MG; 0.125MG	A085213 001	
--------	---------------	-------------	--

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS	25MG; 0.1MG	A083572 001	
----------------------	-------------	-------------	--

	25MG; 0.125MG	A083571 001	
--	---------------	-------------	--

	50MG; 0.1MG	A083568 001	
--	-------------	-------------	--

	50MG; 0.125MG	A083573 001	
--	---------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	
HYDROPRES 25				
MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50				
MERCK	50MG;0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
FOSUN PHARMA	25MG;25MG	A086881	001	
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398	001	
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	
	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG;10MG	N018061	001	
-------	-----------	---------	-----	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC	25MG;50MG	N016042	002	
---------------------	-----------	---------	-----	--

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	25MG;37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

ACTAVIS LABS FL INC 5MG;200MG

A077454 001 Jun 23, 2010

VICOPROFEN

+ ABBVIE 7.5MG;200MG

N020716 001 Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL

CODAMINE

ALPHARMA US PHARMS 5MG/5ML;25MG/5ML

A075103 001 Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

TRIS PHARMA INC 5MG/5ML;60MG/5ML

A203839 001 Oct 28, 2014

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL

MAGNACORT

PFIZER 0.5%

N010554 001

HYDROCORTISONE

AEROSOL;TOPICAL

AEROSEB-HC

ALLERGAN HERBERT 0.5%

A085805 001

CREAM;TOPICAL

CORT-DOME

BAYER PHARMS 0.5%
1%

N009585 003

N009585 001

DERMACORT

MONARCH PHARMS 1%

A083011 002

ELDECORT

VALEANT PHARM INTL 1%
2.5%

A080459 001

A084055 001

FLEXICORT

WESTWOOD SQUIBB 0.5%
1%
2.5%

A087136 003 Apr 08, 1982

A087136 002 Apr 08, 1982

A087136 001 Apr 08, 1982

H-CORT

PHARM ASSOC 0.5%

A086823 001

HC #1

BAYER PHARMS 0.5%

A080438 001

HC #4

BAYER PHARMS 1%

A080438 002

HC (HYDROCORTISONE)

C AND M PHARMA 0.5%
1%

A080482 003

A080482 004

HI-COR

C AND M PHARMA 2.5%

A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS 2.5%

A089754 001 Feb 01, 1989

ALTANA 0.5%

A080848 002

1%

A080848 003

AMBIX 1%

A086080 001

2.5%

A086271 001

EVERYLIFE 0.5%

A080452 001

1%

A080452 002

G AND W LABS 1%

A084059 001

INGRAM PHARM 0.5%

A080456 002

1%

A080456 003

IVAX PHARMS 1%

A085733 001

NASKA 1%

A089706 001 Mar 10, 1988

PERRIGO NEW YORK 0.5%

A084970 002

1%

A085026 001

PHARMADERM 1%

A088845 001 Feb 27, 1986

2.5%

A089413 001 Dec 16, 1986

PHARMAFAIR 1%

A087838 001 Jul 28, 1982

STIEFEL 1%

A086170 001

SYOSSET 0.5%

A085527 001

TARO 0.5%

A086154 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

	1%	A086155 001	
TEVA	0.5%	A080400 002	
	1%	A080400 003	
	1%	A085191 001	
	2.5%	A080400 004	
TOPIDERM	1%	A089273 001	Feb 17, 1989
USL PHARMA	1%	A088027 001	Sep 27, 1983
	2.5%	A088029 001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496 002	
HYTONE			
VALEANT INTL	1%	A080472 003	
	2.5%	A080472 004	
NOGENIC HC			
IVAX PHARMS	1%	A087427 001	Apr 04, 1988
NUTRACORT			
DOW PHARM	0.5%	A080442 002	
	1%	A080442 003	
PENECORT			
ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
PROCTOCORT			
MONARCH PHARMS	1%	A083011 001	
SYNACORT			
MEDICIS	0.5%	A087459 001	
	1%	A087458 001	
	2.5%	A087457 001	
GEL;TOPICAL			
NUTRACORT			
HEALTHPOINT	1%	A084698 001	
PENECORT			
ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
INJECTABLE; INJECTION			
CORTEF			
PHARMACIA AND UPJOHN	50MG/ML	N009864 001	
LOTION;TOPICAL			
ACTICORT			
BAKER NORTON	1%	A086535 001	
ALA-CORT			
CROWN LABS	1%	A083201 001	
BALNEOL-HC			
SOLVAY	1%	A088041 001	Dec 03, 1982
BETA-HC			
BETA DERMAC	1%	A089495 001	Jan 25, 1988
CETACORT			
DOW PHARM	0.5%	A080426 002	
	1%	A080426 001	
CORT-DOME			
BAYER PHARMS	0.5%	N009895 003	
	1%	N009895 001	
DERMACORT			
SOLVAY	0.5%	A084573 002	
	1%	A086462 001	
EPICORT			
BLULINE	0.5%	A083219 002	
GLYCORT			
HERAN	1%	A087489 001	Oct 03, 1983
H-CORT			
PHARM ASSOC	0.5%	A086824 001	
HYDROCORTISONE			
ALPHARMA US PHARMS	0.5%	A087317 001	Jun 07, 1982
	1%	A087315 001	Jun 07, 1982
MERICON	0.5%	A085282 001	
	1%	A085282 002	Feb 26, 1987
NASKA	1%	A089705 001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662 001	
	1%	A085663 001	
TARO	1%	A089024 001	Feb 12, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

LOTION; TOPICAL

HYTONE

VALEANT INTL	1%	A080473 003	
	2.5%	A080473 004	Nov 30, 1982

NUTRACORT

DOW PHARM	0.5%	A080443 002	
	1%	A080443 003	
	2.5%	A087644 001	Aug 24, 1982

STIE-CORT

PERRIGO CO	1%	A089066 001	Nov 25, 1985
------------	----	-------------	--------------

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL	1%	N009176 001	
	2.5%	N009176 002	

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080481 001	
	1%	A080481 002	

HYDROCORTISONE

ALTANA	0.5%	A080489 002	
	1%	A080489 003	
AMBIX	1%	A086079 001	
	2.5%	A086272 001	
NASKA	1%	A089704 001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969 003	
	1%	A085028 001	
PHARMADERM	1%	A088842 001	Feb 09, 1987
TARO	0.5%	A086256 001	
	2.5%	A040310 001	Dec 29, 2000
USL PHARMA	1%	A088061 001	Sep 27, 1983
	2.5%	A088039 001	Sep 27, 1983

HYTONE

DERMIK LABS	1%	A080474 003	
	2.5%	A080474 004	

PENECORT

ALLERGAN HERBERT	2.5%	A088217 001	Jun 06, 1984
------------------	------	-------------	--------------

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH	100%	A087834 001	Mar 29, 1982
-------	------	-------------	--------------

HYDRO-RX

X GEN PHARMS	100%	A085982 001	
--------------	------	-------------	--

HYDROCORTISONE

PADDOCK LLC	100%	A088082 001	Apr 08, 1983
-------------	------	-------------	--------------

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT	1%	A088214 001	Jun 06, 1984
------------------	----	-------------	--------------

TEXACORT

MISSION PHARMA	1%	A080425 001	
----------------	----	-------------	--

TABLET; ORAL

CORTRIL

PFIZER	10MG	N009127 005	
	20MG	N009127 003	

HYDROCORTISONE

BARR	20MG	A083999 001	
ELKINS SINN	20MG	A080624 001	
FERRANTE	10MG	A080568 001	
	20MG	A080568 002	
IMPAX LABS	20MG	A080781 001	
INWOOD LABS	20MG	A080732 001	
LANNETT	20MG	A085070 001	
NEXGEN PHARMA INC	20MG	A083140 001	
PANRAY	10MG	N009659 001	
	20MG	N009659 002	
PARKE DAVIS	20MG	A084243 001	
PUREPAC PHARM	10MG	A084247 003	Aug 31, 1982
	20MG	A080395 001	
	20MG	A084247 002	
ROXANE	10MG	A088539 001	Mar 21, 1984
SANDOZ	20MG	A080642 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

WATSON LABS	20MG	A080355	001
WHITEWORTH TOWN PLSN	10MG	A080344	001
	20MG	A080344	002

HYDROCORTONE

MERCK	10MG	N008506	007
	20MG	N008506	011

TABLET; VAGINAL

CORTRIL

PFIPHARMECS	10MG	N009796	001
-------------	------	---------	-----

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992
------	----	---------	-----	--------------

HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
FERNDAL LABS	2.5%	A040259	001	Jul 29, 1999
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

MICORT-HC

SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002
--------------------	----	---------	-----	--------------

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002
----------------------	---------	---------	-----

CORTRIL

PFIZER	25MG/ML	N009164	001
--------	---------	---------	-----

HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001
	50MG/ML	N009637	002
BEL MAR	25MG/ML	A083739	001
	50MG/ML	A083739	002
WATSON LABS	25MG/ML	A083128	001
	25MG/ML	A083759	001
	50MG/ML	A083759	002
	50MG/ML	A085214	001

HYDROCORTONE

MERCK	25MG/ML	N008228	001
	50MG/ML	N008228	004

LOTION; TOPICAL

DRICORT

INGRAM PHARM	0.5%	A086207	001
--------------	------	---------	-----

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828	001
-------------	------	---------	-----

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK	1.5%	N009018	003
-------	------	---------	-----

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002
+	2.5% **	N008917	001

PASTE; TOPICAL

ORABASE HCA

COLGATE	0.5%	A083205	001
---------	------	---------	-----

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS	100%	A085981	001
--------------	------	---------	-----

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
	2.5%;EQ 3.5MG BASE/GM	A061049	002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
----------------------	-----------------------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEO-CORTEF

1.5%;EQ 3.5MG BASE/GM

A060610 002

OINTMENT;TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM

A060751 001

1%;EQ 3.5MG BASE/GM

A060751 002

2.5%;EQ 3.5MG BASE/GM

A060751 003

SUSPENSION/DROPS;OPHTHALMIC

COR-OTICIN

AKORN

1.5%;EQ 3.5MG BASE/ML

A060188 001

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/ML

A060612 002

1.5%;EQ 3.5MG BASE/ML

A060612 001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC

TERRA-CORTRIL

PFIZER

1.5%;EQ 5MG BASE/ML

A061016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

VINTAGE PHARMS 1%;1%

A089440 001 May 17, 1988

LOTION;TOPICAL

PRAMOSONE

FERNDALE LABS

0.5%;1%

A083213 002

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

CARMOL HC

FOUGERA PHARMS

1%;10%

A080505 001

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001 Jan 07, 1983

OINTMENT;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001 Jul 03, 1984

SOLUTION;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001 Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL

CORTEF

PHARMACIA AND UPJOHN EQ 10MG BASE/5ML

N009900 001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HYDROCORTONE

MERCK

EQ 50MG BASE/ML

N012052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL

A085928 001

EQ 100MG BASE/VIAL

A089577 001 Apr 11, 1989

EQ 250MG BASE/VIAL

A089578 001 Apr 11, 1989

EQ 500MG BASE/VIAL

A089579 001 Apr 11, 1989

EQ 1GM BASE/VIAL

A089580 001 Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL

A040666 001 Apr 06, 2006

EQ 100MG BASE/VIAL

A085929 001

EQ 250MG BASE/VIAL

A085930 001

EQ 500MG BASE/VIAL

A085931 001

EQ 1GM BASE/VIAL

A085932 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001 Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001 Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001 Jun 08, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

	EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
	EQ 250MG BASE/VIAL	A087567 001	
	EQ 500MG BASE/VIAL	A087568 001	
	EQ 1GM BASE/VIAL	A087569 001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
	EQ 100MG BASE/VIAL	A084738 001	
	EQ 250MG BASE/VIAL	A084737 001	
	EQ 500MG BASE/VIAL	A084747 001	
	EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

G AND W LABS INC	0.2%	A074489 001	Aug 12, 1998
WESTCORT			
+ RANBAXY LABS LTD	0.2% **	N017950 001	
OINTMENT; TOPICAL			
HYDROCORTISONE VALERATE			
FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
WESTCORT			
+ RANBAXY	0.2% **	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982
OTOCORT			
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	
SUSPENSION/DROPS; OPHTHALMIC			
CORTISPORIN			
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985
SUSPENSION/DROPS; OTIC			
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
OTICAIR			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982
OTOBIONE			
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
OTOCORT			
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985
PEDIOTIC			
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
PYOCIDIN			
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

ACHROMYCIN

LEDERLE	1.5%;1%	N050272 001	
---------	---------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

BIOGLAN 1%;10% A086008 001

CALMURID HC

PHARMACIA AND UPJOHN 1%;10% A083947 001

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST 50MG A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM 50MG A088850 001 May 31, 1985

WATSON LABS 50MG A088031 001 Apr 06, 1983

50MG A088528 001 Aug 15, 1984

SALURON

+ SHIRE LLC 50MG N011949 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA 50MG;0.125MG A088195 001 Oct 26, 1983

WATSON LABS 25MG;0.125MG A088127 001 Mar 22, 1983

50MG;0.125MG A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS 50MG;0.125MG A088932 001 Jan 11, 1985

PAR PHARM 50MG;0.125MG A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE 50MG;0.125MG N012359 003

SALUTENSIN-DEMI

SHIRE 25MG;0.125MG N012359 004

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP 12MG N021044 001 Sep 24, 2004

16MG N021044 002 Sep 24, 2004

24MG N021044 003 Sep 24, 2004

32MG N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

DILAUDID-HP

FRESENIUS KABI USA 250MG/VIAL N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

HOSPIRA 10MG/ML A074598 001 Jun 19, 1997

WATSON LABS 10MG/ML A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS 2MG A077311 001 Nov 09, 2005

4MG A077311 002 Nov 09, 2005

8MG A077311 003 Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK 1MG/ML A080778 001

CYANOKIT

SERB SA 2.5GM/VIAL (5GM/KIT) N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM 1MG/ML A084921 001

WATSON LABS 1MG/ML A085528 001

HYDROXOMIN

BEL MAR 1MG/ML A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS 1% N000004 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

+	BRISTOL MYERS SQUIBB	125MG/ML	**	N010347	004
+		125MG/ML	**	N016911	001
+		250MG/ML	**	N010347	002
+		250MG/ML	**	N016911	002

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

ALLERGAN SALES LLC

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW

25MG/ML

A087592 001

SOLOPAK

25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS

25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A085779 001

50MG/ML

A087274 002

WYETH AYERST

25MG/ML

A086258 001

50MG/ML

A086258 002

ORGATRAK

ORGANON USA INC

25MG/ML

A087014 001

50MG/ML

A087014 002

VISTARIL

+ PFIZER

25MG/ML **

N011111 001

+

50MG/ML **

N011111 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

ATARAX

ROERIG 10MG/5ML ** N010485 001

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS 10MG/5ML A088785 001 Feb 03, 1988

KV PHARM 10MG/5ML A087730 001 Jul 01, 1982

STI PHARMA LLC 10MG/5ML A086880 001

TABLET;ORAL

ATARAX

PFIZER 10MG ** N010392 001

25MG ** N010392 004

50MG ** N010392 006

100MG ** N010392 005

HYDROXYZINE HYDROCHLORIDE

ABLE 10MG A040559 001 Jul 22, 2004

25MG A040562 001 Jul 22, 2004

50MG A040563 001 Jul 22, 2004

ACTAVIS ELIZABETH 10MG A089071 001 Jul 22, 1986

25MG A089072 001 Jul 22, 1986

50MG A089073 001 Jul 22, 1986

AUROLIFE PHARMA LLC 10MG A087871 002 Dec 20, 1982

25MG A087871 003 Dec 20, 1982

50MG A087871 001 Dec 20, 1982

HALSEY 10MG A089366 001 May 02, 1988

25MG A089117 001 May 02, 1988

50MG A089396 001 May 02, 1988

IVAX PHARMS 10MG A087216 001

25MG A087410 001

50MG A087411 001

KV PHARM 10MG A087819 001 Jun 23, 1982

25MG A087820 001 Jun 23, 1982

50MG A087821 001 Jun 23, 1982

100MG A087822 001 Jun 23, 1982

MUTUAL PHARM 10MG A088409 001 Nov 15, 1983

25MG A087857 001 Apr 18, 1983

50MG A087860 001 Apr 18, 1983

PLIVA 100MG A081054 001 Sep 25, 1995

PUREPAC PHARM 10MG A088120 001 Sep 25, 1984

25MG A088121 001 Sep 25, 1984

50MG A088122 001 Sep 25, 1984

QUANTUM PHARMICS 10MG A088540 001 Oct 22, 1985

25MG A088551 001 Oct 22, 1985

50MG A088529 001 Oct 22, 1985

SANDOZ 10MG A087246 002

25MG A085247 001

50MG A087245 001

SUN PHARM INDS INC 10MG A040899 001 Jun 10, 2008

25MG A040899 002 Jun 10, 2008

50MG A040899 003 Jun 10, 2008

SUN PHARM INDUSTRIES 10MG A089381 001 May 19, 1986

25MG A089382 001 May 19, 1986

50MG A089383 001 May 19, 1986

100MG A087862 001 Apr 18, 1983

SUPERPHARM 10MG A088794 001 Dec 05, 1984

25MG A088795 001 Dec 05, 1984

50MG A088796 001 Dec 05, 1984

USL PHARMA 10MG A089121 001 Mar 20, 1986

25MG A089122 001 Mar 20, 1986

50MG A089123 001 Mar 20, 1986

VINTAGE 10MG A087602 001 Jan 22, 1982

25MG A087603 001 Jan 22, 1982

50MG A087604 001 Jan 22, 1982

WATSON LABS 10MG A081149 001 Mar 18, 1994

10MG A086827 001

10MG A088348 001 Sep 15, 1983

25MG A081150 001 Mar 18, 1994

25MG A086829 001

25MG A088349 001 Sep 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

50MG	A081151	001	Mar 18, 1994
50MG	A086836	001	
50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA

EQ 25MG HCL A088713 001 Mar 04, 1985

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR

EQ 25MG HCL A088593 001 Feb 29, 1984

EQ 50MG HCL A088594 001 Feb 29, 1984

EQ 100MG HCL A088595 001 Feb 29, 1984

IVAX SUB TEVA PHARMS

EQ 25MG HCL A087761 001 Mar 05, 1982

EQ 50MG HCL A087760 001 Mar 05, 1982

PAR PHARM

EQ 25MG HCL A087656 001 Jun 11, 1982

EQ 25MG HCL A089145 001 Mar 17, 1986

EQ 50MG HCL A087657 001 Jun 11, 1982

EQ 50MG HCL A089146 001 Mar 17, 1986

EQ 100MG HCL A087658 001 Jun 11, 1982

SANDOZ

EQ 25MG HCL A081127 001 Jun 28, 1991

EQ 50MG HCL A081128 001 Jun 28, 1991

EQ 100MG HCL A081129 001 Jun 28, 1991

SUPERPHARM

EQ 25MG HCL A089031 001 Jan 02, 1987

EQ 50MG HCL A089032 001 Jan 02, 1987

EQ 100MG HCL A089033 001 Jan 02, 1987

VANGARD

EQ 25MG HCL A088392 001 Sep 19, 1983

EQ 50MG HCL A088393 001 Sep 19, 1983

WATSON LABS

EQ 25MG HYDROCHLORIDE A081165 001 Jul 31, 1991

EQ 25MG HCL A086698 001

EQ 25MG HCL A086840 001 Jul 01, 1982

EQ 50MG HCL A086695 001

EQ 50MG HCL A086705 001 Jul 01, 1982

EQ 50MG HCL A087767 001 Aug 16, 1982

EQ 100MG HCL A086697 001

EQ 100MG HCL A086728 001 Oct 05, 1982

EQ 100MG HCL A087790 001 Aug 16, 1982

VISTARIL

PFIZER

EQ 100MG HCL ** N011459 006

SUSPENSION; ORAL

VISTARIL

PFIZER

EQ 25MG HCL/5ML N011795 001

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

+ HOFFMANN LA ROCHE

EQ 2.5MG BASE ** N021455 001 May 16, 2003

IBANDRONATE SODIUM

MYLAN PHARMS INC

EQ 150MG BASE A078995 001 Mar 19, 2012

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

CONTRACT PHARMACAL

200MG A074782 001 Jul 06, 1998

MIDOL

BAYER

200MG ** A070626 001 Sep 02, 1987

200MG ** A071002 001 Sep 02, 1987

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS

400MG/4ML (100MG/ML) N022348 001 Jun 11, 2009

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS

100MG/5ML N019833 002 Sep 19, 1989

IBU

ABBOTT

100MG/5ML N019784 001 Dec 18, 1989

MOTRIN

+ MCNEIL CONSUMER

100MG/5ML ** N019842 001 Sep 19, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

SUSPENSION/DROPS;ORAL

MOTRIN

MCNEIL	40MG/ML	N020476	001	May 25, 1995
--------	---------	---------	-----	--------------

TABLET;ORAL

ACHES-N-PAIN

LEDERLE	200MG	A071065	001	May 28, 1987
---------	-------	---------	-----	--------------

CAP-PROFEN

PERRIGO	200MG	A072097	001	Dec 08, 1987
---------	-------	---------	-----	--------------

IBU

BASF	400MG	A070083	001	Feb 22, 1985
------	-------	---------	-----	--------------

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA	800MG	A071965	001	Aug 11, 1988
------	-------	---------	-----	--------------

IBUPRIN

PLIVA	200MG	A071773	001	Jul 16, 1987
-------	-------	---------	-----	--------------

IBUPROFEN

ABBOTT	600MG	A070556	001	Jun 14, 1985
--------	-------	---------	-----	--------------

800MG

A071264 001 Jul 25, 1986

ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987
----------------	-------	---------	-----	--------------

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986
---------------------	-------	---------	-----	--------------

400MG

A070736 003 Jun 12, 1986

600MG

A070736 001 Jun 12, 1986

800MG

A071938 001 Jan 14, 1988

CONTRACT PHARMACAL	200MG	A071735	001	Sep 10, 1987
--------------------	-------	---------	-----	--------------

200MG

A073691 001 Feb 25, 1994

200MG

A074931 001 Jul 20, 1998

HALSEY	200MG	A071027	001	Sep 29, 1987
--------	-------	---------	-----	--------------

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
----------------------	-------	---------	-----	--------------

200MG

A072040 001 Apr 29, 1988

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
----------------------	-------	---------	-----	--------------

LEDERLE	400MG	A070629	001	Sep 19, 1986
---------	-------	---------	-----	--------------

600MG

A070630 001 Sep 19, 1986

LEINER	300MG	A071266	001	Oct 15, 1986
--------	-------	---------	-----	--------------

MCNEIL	600MG	A070476	001	Jun 16, 1986
--------	-------	---------	-----	--------------

MYLAN	200MG	A071870	001	May 05, 1988
-------	-------	---------	-----	--------------

600MG

A070057 001 Sep 24, 1985

800MG

A071999 001 Dec 03, 1987

MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985
------------------	-------	---------	-----	--------------

NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
--------------------	-------	---------	-----	--------------

600MG

A078132 002 Sep 10, 2007

800MG

A078132 003 Sep 10, 2007

OHM LABS	400MG	A070818	001	Dec 26, 1985
----------	-------	---------	-----	--------------

PAR PHARM	200MG	A071575	001	May 08, 1987
-----------	-------	---------	-----	--------------

300MG

A070328 001 Aug 06, 1985

400MG

A070329 001 Aug 06, 1985

600MG

A070330 001 Aug 06, 1985

800MG

A070986 001 Jul 25, 1986

PERRIGO	200MG	A072098	001	Dec 08, 1987
---------	-------	---------	-----	--------------

PLIVA	400MG	A071666	001	Jun 18, 1987
-------	-------	---------	-----	--------------

600MG

A071667 001 Jun 18, 1987

800MG

A071668 001 Jun 18, 1987

PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
---------------	-------	---------	-----	--------------

200MG

A071664 001 Feb 03, 1987

300MG

A071123 001 Sep 19, 1986

400MG

A071124 001 Sep 19, 1986

600MG

A071125 001 Sep 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	800MG		A071964	001	Feb 01, 1988
SANDOZ	200MG		A070733	001	Sep 19, 1986
	200MG		A071807	001	Feb 25, 1988
	200MG		A074525	001	Dec 15, 1995
	200MG		A074533	001	Dec 15, 1995
	400MG		A072064	001	Jan 14, 1988
	600MG		A072065	001	Jan 14, 1988
	800MG		A072169	001	Dec 11, 1987
SUN PHARM INDUSTRIES	200MG		A070493	001	Dec 24, 1985
	200MG		A070908	001	Sep 26, 1986
	200MG		A071462	001	Oct 02, 1986
	400MG		A070079	001	Jul 24, 1985
	600MG		A070080	001	Jul 24, 1985
	800MG		A071448	001	Feb 18, 1987
SUPERPHARM	600MG		A070709	001	Apr 25, 1986
TEVA	200MG		A073141	001	May 29, 1992
	400MG		A073343	001	Jun 30, 1992
	600MG		A073344	001	Jun 30, 1992
	800MG		A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG		A072249	001	Jan 10, 1989
	300MG		A071230	001	Oct 22, 1986
	400MG		A071231	001	Oct 22, 1986
	600MG		A071232	001	Oct 22, 1986
	800MG		A072004	001	Nov 18, 1987
WATSON LABS	200MG		A070435	001	Mar 05, 1986
	200MG		A071765	001	Sep 04, 1987
	200MG		A071905	001	Mar 08, 1988
	300MG		A071338	001	Dec 01, 1986
	400MG		A070038	001	Sep 06, 1985
	400MG		A070436	001	Aug 21, 1985
	600MG		A070041	001	Sep 06, 1985
	600MG		A070437	001	Aug 21, 1985
	800MG		A071547	001	Jul 02, 1987
	800MG		A071911	001	Oct 13, 1987
IBUPROHM					
OHM LABS	400MG		A070469	001	Aug 29, 1985
MEDIPREN					
MCNEIL	200MG		A070475	001	Feb 06, 1986
	200MG		A071215	001	Jun 26, 1986
MIDOL					
BAYER	200MG		A070591	001	Sep 02, 1987
	200MG		A071001	001	Sep 02, 1987
MOTRIN					
+	MCNEIL CONSUMER	300MG **	N017463	003	
+		400MG **	N017463	002	
+		600MG **	N017463	004	
+		800MG **	N017463	005	May 22, 1985
	MCNEIL PED	100MG	N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN					
J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000
NUPRIN					
BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
	200MG		A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984
	200MG		N019012	002	Jul 29, 1987
RUFEN					
BASF	600MG		N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL					
MOTRIN					
MCNEIL PED	50MG		N020135	001	Nov 16, 1994
	100MG		N020135	002	Nov 16, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS 400MG;5MG **

N021378 001 Nov 26, 2004

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

WATSON LABS 400MG;5MG

A078394 001 Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG;30MG

A075588 001 Apr 08, 2002

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN 5MG/VIAL

N050661 002 Sep 27, 1990

10MG/VIAL

N050661 001 Sep 27, 1990

20MG/VIAL

N050661 003 Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ 1MG/ML

A091293 001 Mar 29, 2011

TEVA PARENTERAL 5MG/VIAL

A065037 003 May 01, 2002

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE 0.5%

N015868 001

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+ ALCON 0.1%

N014169 001

HERPLEX

ALLERGAN 0.1%

N013935 002

STOXIL

GLAXOSMITHKLINE 0.1%

N013934 001

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE 1GM/VIAL;100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL;100MG/ML

N019763 004 Oct 10, 1992

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

TEVA PHARMS USA 1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)

A075874 001 Feb 26, 2002

3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)

A075874 002 Feb 26, 2002

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

+ NOVARTIS EQ 50MG BASE **

N021335 001 May 10, 2001

+ EQ 100MG BASE **

N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS 25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS 12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE 10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

OXFORD PHARMS 50MG

A040751 001 Feb 28, 2008

PAR PHARM 10MG

A089422 001 Jul 14, 1987

25MG

A089497 001 Jul 14, 1987

ROXANE 10MG

A083799 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

	25MG	A083799	002	
	50MG	A083799	003	
SANDOZ	10MG	A085200	001	
	25MG	A084869	002	
	50MG	A085133	001	
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982
	25MG	A087619	001	Feb 09, 1982
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

MYLAN PHARMS INC	EQ 75MG HCL	A202338	001	Jun 28, 2013
	EQ 100MG HCL	A202338	002	Jun 28, 2013
	EQ 125MG HCL	A202338	003	Jun 28, 2013
	EQ 150MG HCL	A202338	004	Jun 28, 2013
TOFRANIL-PM				
+	SPECGX LLC	EQ 75MG HCL **	N017090	001
+		EQ 100MG HCL **	N017090	004
+		EQ 125MG HCL **	N017090	003
+		EQ 150MG HCL **	N017090	002

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR				
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

ANI PHARMS INC	1.25MG	A074498	002	Feb 12, 1998
	2.5MG	A074498	001	Oct 31, 1996
FOSUN PHARMA	1.25MG	A074594	001	May 23, 1996
	2.5MG	A074594	002	May 23, 1996
MYLAN PHARMS INC	1.25MG	A075105	001	Jul 23, 1998
	2.5MG	A075105	002	Jul 23, 1998
TEVA	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074665	002	Apr 04, 1997
WATSON LABS	1.25MG	A074585	001	Sep 26, 1996
	2.5MG	A074585	002	Sep 26, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDAPAMIDE

TABLET; ORAL

LOZOL

+	SANOFI AVENTIS US	1.25MG **	N018538 002	Apr 29, 1993
+		2.5MG **	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

	LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
		EQ 75MG BASE	N019693 002	Dec 29, 1989
		EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
		EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

	AKORN	10MG/VIAL	N011525 003	
		40MG/VIAL	N011525 004	
		50MG/VIAL	N011525 002	

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

	TEVA	25MG	A070266 001	Nov 07, 1985
		50MG	A070267 001	Nov 07, 1985

INDOCIN

+	IROKO PHARMS LLC	25MG **	N016059 001	
+		50MG **	N016059 002	

INDOMETHACIN

	ABLE	25MG	A076666 001	Dec 17, 2003
		50MG	A076666 002	Dec 17, 2003
	CHARTWELL MOLECULES	25MG	N018829 002	Aug 06, 1984
		50MG	A070651 001	Mar 05, 1986
		50MG	N018829 001	Aug 06, 1984
	CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
		50MG	A070354 001	Jun 18, 1985
	DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
		50MG	A070327 001	Oct 18, 1985
	HALSEY	25MG	A070782 001	Jun 03, 1987
		50MG	A070635 001	Jun 03, 1987
	IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
		50MG	N018730 002	May 04, 1984
	MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
		50MG	A070068 001	Oct 03, 1986
	MYLAN	50MG	N018858 002	Apr 20, 1984
	PARKE DAVIS	25MG	N018806 001	Nov 23, 1984
		50MG	N018806 002	Nov 23, 1984
	PIONEER PHARMS	25MG	A070813 001	Aug 11, 1986
		50MG	A070592 001	Aug 11, 1986
	PLIVA	25MG	A071148 001	Mar 18, 1987
		50MG	A071149 001	Mar 18, 1987
	SUN PHARM INDUSTRIES	25MG	A070900 002	Feb 09, 1987
		50MG	A070900 001	Feb 09, 1987
	SUPERPHARM	25MG	A070487 001	Oct 10, 1986
		50MG	A070488 001	Oct 10, 1986
	TEVA	25MG	A071342 001	Apr 18, 1988
		50MG	A071343 001	Apr 18, 1988
	WATSON LABS	25MG	A070529 001	Oct 18, 1985
		25MG	A070784 001	Aug 20, 1986
		25MG	A072996 001	Jul 31, 1991
		25MG	N018690 001	Jul 31, 1984
		50MG	A070530 001	Oct 18, 1985
		50MG	A070785 001	Aug 20, 1986
		50MG	A071635 001	May 18, 1987
		50MG	A072997 001	Jul 31, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

50MG

N018690 002 Jul 31, 1984

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+ IROKO PHARMS

75MG **

N018185 001 Feb 23, 1982

INDOMETHACIN

ABLE

75MG

A076114 001 Feb 06, 2002

INWOOD LABS

75MG

A072410 001 Mar 15, 1989

WATSON LABS INC

75MG

A202572 001 Dec 09, 2013

SUPPOSITORY;RECTAL

INDOCIN

+ IROKO PHARMS

50MG **

N017814 001 Aug 13, 1984

SUSPENSION;ORAL

INDOMETHACIN

CYCLE PHARMS LTD

25MG/5ML

A071412 001 Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC

50 UNITS/ML;50 UNITS/ML

N021810 001 Aug 26, 2008

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC

210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 002 Nov 01, 2001

210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 003 Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG INNOLET

NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N020986 004 Apr 23, 2004

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN

NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N021536 002 Jun 16, 2005

LEVEMIR INNOLET

NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N021536 003 Jun 16, 2005

LEVEMIR PENFILL

NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N021536 004 Jun 16, 2005

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG MIX 50/50 PEN

LILLY

50 UNITS/ML;50 UNITS/ML

N021018 003 Dec 22, 1999

HUMALOG MIX 75/25 PEN

LILLY

75 UNITS/ML;25 UNITS/ML

N021017 003 Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG PEN

LILLY

100 UNITS/ML

N020563 002 Aug 06, 1998

INSULIN PORK

INJECTABLE;INJECTION

ILETIN I

LILLY

500 UNITS/ML

N017931 001

INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017926 001

REGULAR INSULIN

NOVO NORDISK INC

100 UNITS/ML

N017926 003

INSULIN PURIFIED BEEF

INJECTABLE;INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

Iletin II

LILLY 500 UNITS/ML N018344 002

REGULAR Iletin II (PORK)

LILLY 100 UNITS/ML N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC 100 UNITS/ML N018381 001

VELOSULIN

NOVO NORDISK INC 100 UNITS/ML N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY 100 UNITS/ML N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC 100 UNITS/ML N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER 1MG/INH N021868 001 Jan 27, 2006

3MG/INH N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY 50 UNITS/ML; 50 UNITS/ML N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC 100 UNITS/ML N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC 100 UNITS/ML N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS 30 UNITS/ML; 70 UNITS/ML N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC 40 UNITS/ML N017929 001

100 UNITS/ML N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH Iletin I (BEEF-PORK)

LILLY 40 UNITS/ML N017936 001

100 UNITS/ML N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH Iletin II

LILLY 100 UNITS/ML N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC 100 UNITS/ML N018194 001

NPH Iletin II (PORK)

LILLY 100 UNITS/ML N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC 100 UNITS/ML N018623 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC 100 UNITS/ML

N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML

N019065 001 Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY 40 UNITS/ML
100 UNITS/ML

N017932 001

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY 100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB 40 UNITS/ML
100 UNITS/ML

N017928 001

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY 100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC 40 UNITS/ML
100 UNITS/ML

N017998 001

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC 100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY 40 UNITS/ML
100 UNITS/ML

N019571 001 Jun 10, 1987

N019571 002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC 100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY 100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC 100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC 100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML

N018347 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY

100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX

100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE

10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE

2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT

750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO

65%

N017902 001

RENOVUE-DIP

BRACCO

24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO

10.3%

N009321 007

+

52%

N009321 003

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO

20%

N009321 001

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE

55%

N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IODOXAMATE MEGLUMINEINJECTABLE; INJECTION
CHOLOVUE

BRACCO	9.9%	N018077 001
	40.3%	N018076 001

IOFETAMINE HYDROCHLORIDE I-123INJECTABLE; INJECTION
SPECTAMINE

IMP	1mCi/ML	N019432 001 Dec 24, 1987
-----	---------	--------------------------

IOHEXOLINJECTABLE; INJECTION
OMNIPAQUE 210

GE HEALTHCARE	45.3%	N018956 006 Jun 30, 1989
---------------	-------	--------------------------

SOLUTION; URETHRAL
OMNIPAQUE 70

GE HEALTHCARE	15.1%	N018956 007 Jun 01, 1994
---------------	-------	--------------------------

IOPAMIDOLINJECTABLE; INJECTION
IOPAMIDOL

BAXTER HLTHCARE	41%	A074629 001 Nov 06, 1996
	51%	A074629 004 Mar 31, 1998
	61%	A074629 002 Nov 06, 1996
	76%	A074629 003 Nov 06, 1996
HOSPIRA	61%	A074734 001 Dec 10, 1996
	76%	A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING	41%	A074881 001 Jul 28, 2000
HOSPIRA	41%	A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA	41%	A074636 001 Dec 30, 1997
---------	-----	--------------------------

IOPAMIDOL-250

COOK IMAGING	51%	A074881 002 Jul 28, 2000
FRESENIUS KABI USA	51%	A074679 001 Apr 02, 1997
HOSPIRA	51%	A074898 002 Dec 30, 1997
	51%	A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA	51%	A074636 002 Dec 30, 1997
---------	-----	--------------------------

IOPAMIDOL-300

ABBVIE	61%	A074638 001 Apr 30, 1997
COOK IMAGING	61%	A074881 003 Jul 28, 2000
FRESENIUS KABI USA	61%	A074679 002 Apr 02, 1997
HOSPIRA	61%	A074898 003 Dec 30, 1997
	61%	A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636 003 Dec 30, 1997
	61%	A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881 004 Jul 28, 2000
FRESENIUS KABI USA	76%	A074679 003 Apr 02, 1997
HOSPIRA	76%	A074898 004 Dec 30, 1997
	76%	A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636 004 Dec 30, 1997
---------	-----	--------------------------

ISOVUE-128

BRACCO	26%	N018735 005 Oct 21, 1986
--------	-----	--------------------------

ISOVUE-200

BRACCO	41%	N020327 001 Oct 12, 1994
--------	-----	--------------------------

IOPANOIC ACIDTABLET; ORAL
TELEPAQUE

GE HEALTHCARE	500MG	N008032 001
---------------	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON

100%

N005319 001

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST 150

+ BAYER HLTHCARE

31.2%

N020220 004 May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+ BAYER HLTHCARE

62.3%

N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT

52%;26%

N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT

80%

N013319 001

CONRAY 325

MALLINCKRODT

54.3%

N017685 001

CONRAY 400

MALLINCKRODT

66.8%

N014295 001

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE

40.6%

N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE

51.3%

N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

LIEBEL-FLARSHEIM

34%

N019710 003 Dec 30, 1988

OPTIRAY 240

LIEBEL-FLARSHEIM

51%

N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

GUERBET

39.3%;19.6%

N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET

62%

N020316 001 Dec 21, 1995

OXILAN-350

GUERBET

73%

N020316 002 Dec 21, 1995

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO

3GM/PACKET

N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE

500MG

A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO

500MG

N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

+ BOEHRINGER INGELHEIM

0.02% **

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC

0.02%

A075111 001 Apr 22, 1999

APOTEX INC

0.02%

A075441 001 Mar 28, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001
MYLAN SPECIALITY LP	0.02%	A074755	001	Jan 10, 1997
PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001
ROXANE	0.02%	A075867	001	Jul 22, 2002
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003
	0.042MG/SPRAY	A076155	001	Apr 18, 2003

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
-------------------	-----------------	---------	-----	--

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON	1%	A086711	001	
BRONKOSOL				
SANOFI AVENTIS US	0.25%	N012339	009	
	1%	N012339	008	

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982
	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

INTL MEDICATION

0.077%

A086651 001

0.08%

A086651 002

0.1%

A086651 003

0.143%

A086651 004

0.167%

A086651 005

0.2%

A086651 006

0.25%

A086651 007

1%

A086651 008

PARKE DAVIS 0.5%

A085997 001

1%

A085889 001

ROXANE 0.1%

A087396 001

0.125%

A087025 001

0.167%

A088226 001 Sep 16, 1983

0.2%

A087324 001

0.25%

A088275 001 Jun 03, 1983

1%

A086899 001

ISOETHARINE HYDROCHLORIDE S/F

DEY 0.08%

A089817 001 Nov 22, 1988

0.1%

A089818 001 Nov 22, 1988

0.17%

A089819 001 Nov 22, 1988

0.25%

A089820 001 Nov 22, 1988

1%

A089252 001 Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US 0.34MG/INH

N012339 007

ISOETHARINE MESYLATE

ALPHARMA US PHARMS 0.34MG/INH

A087858 001 Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

WATSON LABS INC 99.9%

A074393 001 May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK 0.025%

N010656 001

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ 100MG/ML **

N008662 001

RIMIFON

ROCHE 25MG/ML

N008420 002

100MG/ML

N008420 003

SYRUP; ORAL

ISONIAZID

MIKART 50MG/5ML

A081118 001 Jul 21, 1997

LANIAZID

LANNETT 50MG/5ML

A089243 001 Feb 03, 1986

RIMIFON

ROCHE 50MG/5ML

N008420 001

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM 300MG

A080330 002

HYZYD

MEDPOINTE PHARM HLC 100MG

A080134 003

300MG

A080134 004

INH

NOVARTIS 300MG

A080935 001

ISONIAZID

DURAMED PHARMS BARR 100MG

A088231 001 Mar 17, 1983

300MG

A088119 001 Mar 17, 1983

HALSEY 50MG

A083632 001

HIKMA INTL PHARMS 100MG

A080212 001

300MG

A087425 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISONIAZID

TABLET; ORAL

ISONIAZID

IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MK LABS	100MG	A080941	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
SUN PHARM INDUSTRIES	100MG	A080136	001	
	300MG	A083633	001	
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID				
LANNETT	50MG	A080140	001	
	100MG	A080140	002	
NYDRAZID				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG; 300MG	A065221	001	Jul 29, 2005
-------------------	--------------	---------	-----	--------------

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	
-----------------	-------------	---------	-----	--

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004	
----	------------	---------	-----	--

ALPHARMA US PHARMS	0.12MG/INH	A085904	001	
--------------------	------------	---------	-----	--

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001	
-------------------	-------------	---------	-----	--

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001	
--------	-------	---------	-----	--

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001	
---------------	----------	---------	-----	--

BAXTER HLTHCARE	0.2MG/ML	A083486	001	
-----------------	----------	---------	-----	--

HOSPIRA	0.02MG/ML	A083283	001	
---------	-----------	---------	-----	--

	0.2MG/ML	A083346	001	
--	----------	---------	-----	--

INTL MEDICATION	0.2MG/ML	A083724	001	
-----------------	----------	---------	-----	--

SOLUTION; INHALATION

AEROLONE

LILLY	0.25%	N007245	001	
-------	-------	---------	-----	--

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
--------------	--------	---------	-----	--------------

	0.062%	A087936	001	Nov 18, 1982
--	--------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

ISOPROTERENOL HYDROCHLORIDE

DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002	
	1%	N006327	003	

VAPO-ISO

FISONS	0.5%	N016813	001	
--------	------	---------	-----	--

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US	10MG	N006328	001	
	15MG	N006328	002	

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001	
----	------------------------	---------	-----	--

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M	0.08MG/INH	N010375	003	
----	------------	---------	-----	--

POWDER; INHALATION

NORISODRINE

ABBVIE	10%	N006905	003	
	25%	N006905	002	

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON	100GM/220ML	N017063	001	
-------	-------------	---------	-----	--

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

TABLET; ORAL

ISORDIL

+ VALEANT PHARMS NORTH	10MG **	N012093	002	Jul 29, 1988
	20MG **	N012093	006	Jul 29, 1988
	30MG **	N012093	005	Jul 29, 1988

ISOSORBIDE DINITRATE

SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986
SUPERPHARM	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988

SORBITRATE

ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996
	20MG	A086405	002	Aug 21, 1990
	30MG	A088124	001	Aug 21, 1990
	40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

+ BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
	5MG **	N012940	003	Jul 29, 1988
	10MG **	N012940	005	Jul 29, 1988

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
	5MG	A086055	001	Nov 02, 1987
SANDOZ	2.5MG	A086225	001	Feb 19, 1988
	5MG	A086222	001	Feb 19, 1988
SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

5MG	A086168	001	Sep 18, 1986
10MG	A087545	001	Sep 18, 1986
2.5MG **	A086033	001	Feb 26, 1988
5MG **	A086031	001	Sep 29, 1987

SORBITRATE

ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
	5MG	N016191	001	Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
	10MG	N016776	003	Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST	40MG	N012882	001	Jul 29, 1988
--------------	------	---------	-----	--------------

ISOSORBIDE DINITRATE

IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008
----------------	------	---------	-----	--------------

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA	20MG	N019091	001	Dec 30, 1991
----------------	------	---------	-----	--------------

TABLET, EXTENDED RELEASE;ORAL

IMDUR

+	SCHERING PLOUGH	30MG **	N020225	001	Aug 12, 1993
+		60MG **	N020225	002	Aug 12, 1993
+		120MG **	N020225	003	Mar 30, 1995

ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998
	60MG	A075306	002	Dec 31, 1998
ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998
IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
	60MG	A075448	001	Jun 19, 2000
	120MG	A075448	003	Aug 07, 2001
SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION

LYMPHAZURIN

+	COVIDIEN	1% **	N018310	001
---	----------	-------	---------	-----

ISOTRETINOIN

CAPSULE;ORAL

ACCUTANE

+	HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
+		20MG **	N018662	004	Mar 28, 1983
+		40MG **	N018662	003	May 07, 1982

SOTRET

SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
	20MG	A076041	002	Dec 24, 2002
	30MG	A076503	001	Jun 20, 2003
	40MG	A076041	003	Dec 24, 2002

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

+	SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
+		5MG	N019546	002	Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

+	GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
+		10MG **	N020336	002	Jun 01, 1994

ISRADIPINE

MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015
	10MG	A201067	002	Nov 27, 2015

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

SOLUTION; ORAL

ITRACONAZOLE

AMNEAL PHARMS

10MG/ML

A205573 001 Oct 30, 2015

IVERMECTIN

TABLET; ORAL

STROMEKTOL

MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

WEST-WARD PHARMS INT

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

EQ 1GM BASE/3ML

A062324 003

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

INTL MEDICATION

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

LOCH

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

PHARMAFAIR

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

SOLOPAK

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

EQ 1GM BASE/3ML

A062170 003

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

+

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

APOTEX

200MG

A075912 001 Jan 10, 2002

PLIVA

200MG

A075362 001 Jun 15, 1999

SUN PHARM INDUSTRIES

200MG

A075314 001 Jun 15, 1999

TEVA

200MG

A074971 001 Jun 15, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOCONAZOLE

TABLET; ORAL

NIZORAL

+ JANSSEN PHARMS 200MG ** N018533 001

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AUROLIFE PHARMA LLC 50MG A074024 001 Dec 29, 1995

75MG A074024 002 Dec 29, 1995

TEVA 25MG A073515 001 Dec 22, 1992

ORUDIS

+ WYETH AYERST 25MG ** N018754 001 Jul 31, 1987

+ 50MG ** N018754 002 Jan 09, 1986

+ 75MG ** N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ALKERMES GAINESVILLE 200MG A074879 001 Dec 10, 1997

ORUVAIL

+ WYETH PHARMS INC 100MG ** N019816 003 Feb 08, 1995

+ 150MG ** N019816 002 Feb 08, 1995

+ 200MG ** N019816 001 Sep 24, 1993

FILM; ORAL

NEXCEDE

NOVARTIS 12.5MG N022470 001 Nov 25, 2009

TABLET; ORAL

ACTRON

BAYER 12.5MG N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO 12.5MG A075364 001 Feb 07, 2002

ORUDIS KT

+ WYETH CONS 12.5MG ** N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

APOTEX INC 30MG/ML A075626 001 Jul 24, 2001

30MG/ML A077201 001 Oct 14, 2005

APOTHECON 15MG/ML A075348 001 Nov 28, 2000

30MG/ML A075348 002 Nov 28, 2000

BAXTER HLTHCARE CORP 15MG/ML A075631 002 Jun 29, 2001

30MG/ML A075631 001 Jun 29, 2001

BEDFORD 15MG/ML A075230 002 Oct 25, 1999

30MG/ML A075230 001 Oct 25, 1999

GLAND PHARMA LTD 15MG/ML A076722 001 Jul 27, 2004

30MG/ML A076722 002 Jul 27, 2004

HOSPIRA 15MG/ML A074801 001 Jun 05, 1997

30MG/ML A074801 002 Jun 05, 1997

LUITPOLD 15MG/ML A078145 001 Jan 14, 2008

30MG/ML A078145 002 Jan 14, 2008

MYLAN LABS LTD 15MG/ML A078299 001 Jul 16, 2007

15MG/ML A201155 001 Aug 04, 2014

30MG/ML A078299 002 Jul 16, 2007

30MG/ML A201155 002 Aug 04, 2014

SANDOZ INC 15MG/ML A076271 001 Oct 06, 2004

SUN PHARMA GLOBAL 15MG/ML A078737 001 Oct 06, 2008

30MG/ML A078737 002 Oct 06, 2008

WEST-WARD PHARMS INT 15MG/ML ** A075222 001 Apr 26, 1999

15MG/ML A075299 001 Nov 03, 1999

15MG/ML A075772 001 Jul 21, 2004

30MG/ML ** A075222 002 Apr 26, 1999

30MG/ML ** A075228 001 Apr 26, 1999

30MG/ML A075299 002 Nov 03, 1999

30MG/ML A075772 002 Jul 21, 2004

30MG/ML A077943 001 Mar 27, 2007

TORADOL

+ ROCHE PALO 15MG/ML ** N019698 001 Nov 30, 1989

+ 30MG/ML ** N019698 002 Nov 30, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOROLAC TROMETHAMINESOLUTION/DROPS;OPHTHALMIC
ACULAR PRESERVATIVE FREE

ALLERGAN 0.5% N020811 001 Nov 03, 1997

KETOROLAC TROMETHAMINE

AKORN 0.45% A203376 001 Feb 10, 2014

TABLET;ORAL

KETOROLAC TROMETHAMINE

CYCLE PHARMS LTD 10MG A074790 001 Jun 26, 1997

WATSON LABS 10MG A074955 001 Sep 19, 1997

TORADOL

+ ROCHE PALO 10MG ** N019645 001 Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

APOTEX INC EQ 0.025% BASE A077354 001 May 09, 2006

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE ** N021066 002 Oct 19, 2006

KRYPTON, KR-81M

GAS;INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE N/A N018088 001

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

APOTHECON 5MG/ML A075355 001 Nov 29, 1999

BAXTER HLTHCARE CORP 5MG/ML A076051 001 Jul 05, 2002

HOSPIRA 5MG/ML A075242 001 Sep 30, 1999

NORMODYNE

SCHERING 5MG/ML N018686 001 Aug 01, 1984

TRANDATE

+ SEBELA IRELAND LTD 5MG/ML ** N019425 001 Dec 31, 1985

TABLET;ORAL

LABETALOL HYDROCHLORIDE

APOTHECON 100MG A075223 001 Nov 20, 1998

200MG A075223 002 Nov 20, 1998

300MG A075223 003 Nov 20, 1998

TEVA 100MG A074989 001 Sep 30, 1998

200MG A074989 002 Sep 30, 1998

300MG A074989 003 Sep 30, 1998

NORMODYNE

+ SCHERING 100MG ** N018687 001 Aug 31, 1987

+ 200MG ** N018687 002 Aug 01, 1984

+ 300MG ** N018687 003 Aug 01, 1984

+ 400MG ** N018687 004 Aug 01, 1984

TRANDATE

+ CNTY LINE PHARMS 400MG ** N018716 004 Aug 01, 1984

LACTULOSE

SOLUTION;ORAL

CHRONULAC

+ SANOFI AVENTIS US 10GM/15ML ** N017884 001

CONSTULOSE

ACTAVIS MID ATLANTIC 10GM/15ML A070288 001 Aug 15, 1988

DUPHALAC

SOLVAY 10GM/15ML A072372 001 Mar 22, 1989

EVALOSE

TEVA PHARMS 10GM/15ML A073497 001 May 28, 1993

LACTULOSE

APOTEX INC 10GM/15ML A075911 001 Feb 21, 2002

MORTON GROVE 10GM/15ML A071841 001 Sep 22, 1988

PACO 10GM/15ML A073160 001 Aug 25, 1992

LAXILOSE

NOSTRUM LABS 10GM/15ML A073686 001 May 28, 1993

SOLUTION;ORAL, RECTAL

ACILAC

NOSTRUM LABS 10GM/15ML A073685 001 May 28, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LACTULOSE

SOLUTION;ORAL, RECTAL

CEPHULAC

+ SANOFI AVENTIS US 10GM/15ML **

N017657 001

GENERLAC

MORTON GROVE 10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS 10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

APOTEX INC 10GM/15ML

A076645 001 Jul 28, 2003

PACO 10GM/15ML

A072029 001 Aug 25, 1992

ROXANE 10GM/15ML

A073590 001 May 29, 1992

SOLVAY 10GM/15ML

N017906 001

PORTALAC

SOLVAY 10GM/15ML

A072374 001 Mar 22, 1989

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL

DUTREBIS

MERCK SHARP DOHME 150MG;EQ 300MG BASE

N206510 001 Feb 06, 2015

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

+ GLAXOSMITHKLINE LLC 50MG **

N020241 006 Dec 27, 1994

+ 250MG **

N020241 004 Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA 25MG

A078669 001 Apr 08, 2011

100MG

A078669 002 Apr 08, 2011

150MG

A078669 003 Apr 08, 2011

200MG

A078669 004 Apr 08, 2011

HIKMA PHARMS 25MG

A078134 001 Apr 19, 2011

100MG

A078134 002 Apr 19, 2011

150MG

A078134 003 Apr 19, 2011

200MG

A078134 004 Apr 19, 2011

MYLAN 25MG

A077428 001 Jan 27, 2009

100MG

A077428 002 Jan 27, 2009

150MG

A077428 003 Jan 27, 2009

200MG

A077428 004 Jan 27, 2009

MYLAN LABS LTD 25MG

A078443 001 Feb 11, 2009

100MG

A078443 002 Feb 11, 2009

150MG

A078443 003 Feb 11, 2009

200MG

A078443 004 Feb 11, 2009

PHARMASCIENCE INC 25MG

A078310 001 Feb 04, 2009

100MG

A078310 002 Feb 04, 2009

150MG

A078310 003 Feb 04, 2009

200MG

A078310 004 Feb 04, 2009

ROXANE 25MG

A077392 001 Jan 27, 2009

100MG

A077392 002 Jan 27, 2009

150MG

A077392 003 Jan 27, 2009

200MG

A077392 004 Jan 27, 2009

SANDOZ 25MG

A078645 001 Jan 27, 2009

100MG

A078645 002 Jan 27, 2009

150MG

A078645 003 Jan 27, 2009

200MG

A078645 004 Jan 27, 2009

WOCKHARDT 25MG

A078982 001 Jan 27, 2009

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC 100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

MYLAN 5MG

A076630 001 Jan 22, 2009

25MG

A076630 002 Jan 22, 2009

SANDOZ 5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA	15MG/PACKET	N021281 001	May 03, 2001
	30MG/PACKET	N021281 002	May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

+ TAKEDA PHARMS NA	30MG/VIAL **	N021566 001	May 27, 2004
--------------------	--------------	-------------	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

ANI PHARMS INC	15MG	A078730 001	Oct 15, 2010
	30MG	A078730 002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507 002	Nov 14, 2003
--------------------	-----------------------	-------------	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507 003	Nov 14, 2003
------------------	--------------------	-------------	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507 004	Nov 14, 2003
------------------	--------------------	-------------	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004
-----------	---------------	-------------	--------------

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%	N011914 001	
-------------------	-----------	-------------	--

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%	A077697 001	Mar 22, 2011
------------	--------	-------------	--------------

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

SANDOZ	10MG	A077085 001	Sep 13, 2005
	10MG	A077087 001	Sep 13, 2005
	20MG	A077085 002	Sep 13, 2005
	20MG	A077087 002	Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION

REFLUDAN

BAYER HLTHCARE	50MG/VIAL	N020807 001	Mar 06, 1998
----------------	-----------	-------------	--------------

LETROZOLE

TABLET;ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG	A090292 001	Jul 13, 2011
IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011
KREMERS URBAN PHARMS	2.5MG	A091098 001	Jun 03, 2011
LANNETT HOLDINGS INC	2.5MG	A202048 001	Oct 29, 2014
SUN PHARM INDS LTD	2.5MG	A091466 001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107 003	Jan 30, 1987
---------	-------------------	-------------	--------------

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352 001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353 001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939 001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480 001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224 001	Jun 03, 1994
+ HOSPIRA	EQ 3MG BASE/ML **	N008107 001	
+	EQ 50MG BASE/VIAL **	N008107 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

+		EQ 100MG BASE/VIAL **	N008107 004	May 23, 1988
+		EQ 350MG BASE/VIAL **	N008107 005	Apr 05, 1989
	PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262 001	Dec 15, 1999
	PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628 001	Apr 17, 1997
		EQ 100MG BASE/VIAL	A089915 001	Apr 17, 1997
	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993
	LEUCOVORIN CALCIUM PRESERVATIVE FREE			
	HOSPIRA	EQ 10MG BASE/ML **	A040147 001	Jun 25, 1997
	LUITPOLD	EQ 50MG BASE/VIAL	A040338 001	Jan 31, 2001
	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332 001	Jun 28, 1999
	WELLCOVORIN			
	GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439 001	Oct 19, 1982
		EQ 25MG BASE/VIAL	A089833 001	Jan 23, 1989
		EQ 50MG BASE/VIAL	A089465 001	Jan 23, 1989
		EQ 100MG BASE/VIAL	A089834 001	Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

	EPIC PHARMA LLC	EQ 5MG BASE	A074544 001	Aug 28, 1997
		EQ 25MG BASE	A074544 002	Aug 28, 1997
	IDT AUSTRALIA LTD	EQ 15MG BASE	A075327 001	Mar 24, 1999
	PAR PHARM	EQ 5MG BASE	A071600 001	Oct 14, 1987
		EQ 25MG BASE	A071598 001	Oct 14, 1987
	PHARMACHEMIE	EQ 5MG BASE	A073099 001	Mar 28, 1997
		EQ 25MG BASE	A073101 001	Mar 28, 1997
	XANODYNE PHARM	EQ 5MG BASE	N018459 001	Jan 30, 1986
		EQ 10MG BASE	A071962 001	Nov 19, 1987
		EQ 15MG BASE	A071104 001	Mar 04, 1987

WELLCOVORIN

+	GLAXOSMITHKLINE	EQ 5MG BASE **	N018342 001	Jul 08, 1983
+		EQ 25MG BASE **	N018342 002	Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

	ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088 001	Mar 03, 2000
--	----------------------	--------------	-------------	--------------

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

	GENZYME	1MG/0.2ML	A075721 001	Nov 29, 2001
	LUPRON			
	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010 001	Apr 09, 1985
	LUPRON DEPOT			
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011 001	Oct 22, 1990
	LUPRON DEPOT-PED			
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL **	N020263 003	Apr 16, 1993
+		7.5MG/VIAL, 7.5MG/VIAL **	N020263 004	Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

	ROCHE	1MG/ML	N010423 001	
--	-------	--------	-------------	--

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

	JANSSEN PHARMA	EQ 50MG BASE	N020035 001	Jun 18, 1990
--	----------------	--------------	-------------	--------------

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

	APOTEX INC	100MG/ML	A090187 001	Aug 05, 2011
--	------------	----------	-------------	--------------

TABLET; ORAL

LEVETIRACETAM

	ACTAVIS LABS FL INC	250MG	A077408 001	Mar 02, 2009
		500MG	A077408 002	Mar 02, 2009
		750MG	A077408 003	Mar 02, 2009
	MYLAN	250MG	A078731 001	Feb 10, 2009
		500MG	A078731 002	Feb 10, 2009
		750MG	A078731 003	Feb 10, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	1GM	A078731 004	Feb 10, 2009
SANDOZ	1GM	A077324 004	Jan 15, 2009
	250MG	A077324 001	Jan 15, 2009
	500MG	A077324 002	Jan 15, 2009
	750MG	A077324 003	Jan 15, 2009
WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
	500MG	A078797 003	Jan 15, 2009
	750MG	A078797 004	Jan 15, 2009
	1GM	A078797 001	Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

MYLAN PHARMS INC	500MG	A200475 001	Dec 19, 2011
	750MG	A200475 002	Dec 19, 2011
	1GM	A200475 003	Dec 07, 2015
SANDOZ	500MG	A091668 001	Nov 01, 2012
	750MG	A091668 002	Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000
------------------	--------------	-------------	--------------

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

ALCON LABS INC	0.25%	A074851 001	Oct 28, 1996
APOTEX INC	0.25%	A075473 001	Aug 03, 2000
	0.5%	A075475 001	Aug 03, 2000
BAUSCH AND LOMB	0.25%	A074307 001	Mar 04, 1994

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997 001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997 002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997 003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
----------	---------------	-------------	--------------

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
-----------------	----------	-------------	--------------

SOLUTION; ORAL

CARNITOR

LEADIANT BIOSCI INC	1GM/10ML	N018948 002	Apr 27, 1988
---------------------	----------	-------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ	5MG	A090486 001	Mar 26, 2013
--------	-----	-------------	--------------

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL	100MG	N016948 003	
	250MG	N016948 001	
	500MG	N016948 002	

DOPAR

SHIRE	100MG	N016913 003	
	250MG	N016913 001	
	500MG	N016913 002	

LARODOPA

ROCHE	100MG	N016912 002	
	250MG	N016912 001	
	500MG	N016912 006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVODOPA

TABLET; ORAL

DOPAR

SHIRE	250MG	N016913 004
	500MG	N016913 005

LARODOPA

ROCHE	100MG	N016912 005
	250MG	N016912 003
	500MG	N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996

LEVOFLOXACIN

AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011
HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015

SOLUTION; ORAL

LEVAQUIN

+	JANSSEN PHARMS	250MG/10ML	N021721 001	Oct 21, 2004
---	----------------	------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

IQUIX

+	SANTEN	1.5% **	N021571 001	Mar 01, 2004
---	--------	---------	-------------	--------------

LEVOFLOXACIN

APOTEX INC	0.5%	A078282 001	Dec 20, 2010
------------	------	-------------	--------------

QUIXIN

+	SANTEN	0.5% **	N021199 001	Aug 18, 2000
---	--------	---------	-------------	--------------

TABLET; ORAL

LEVOFLOXACIN

MYLAN	250MG	A076276 001	Jun 20, 2011
	500MG	A076276 002	Jun 20, 2011
	750MG	A077097 001	Jun 20, 2011
WATSON LABS INC	250MG	A201484 001	Nov 22, 2013
	500MG	A201484 002	Nov 22, 2013
	750MG	A201484 003	Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 29, 2011
		**		
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140 003	Apr 29, 2011

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX	20MG/ML	N015865 001
---------	---------	-------------

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

+	ROXANE	10MG/ML **	N020315 001	Jul 09, 1993
---	--------	------------	-------------	--------------

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY	0.05MG/ML; 2%	A085010 001
--------	---------------	-------------

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK	0.05MG/ML; 2%	N012125 002
---------------	---------------	-------------

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SEPTODONT INC	0.05MG/ML; 2%	A084697 001
---------------	---------------	-------------

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

BELMORA LLC	0.05MG/ML; 2%	A084850 002	Oct 21, 1983
-------------	---------------	-------------	--------------

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM	0.05MG/ML; 2%	A089517 001	Apr 14, 1988
----------------	---------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK 0.05MG/ML; 2%; 0.4% N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE

+ POPULATION COUNCIL 75MG/IMPLANT ** N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC 75MG/IMPLANT N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL 36MG/IMPLANT N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC 36MG/IMPLANT N020088 001 Dec 10, 1990

TABLET; ORAL

LEVONORGESTREL

FDN CONSUMER 0.75MG ** A078665 001 Aug 28, 2009

LUPIN LTD 0.75MG A091328 001 Jan 23, 2013

WATSON LABS 0.75MG A078666 001 Jun 24, 2009

PLAN B

+ FDN CONSUMER 0.75MG ** N021045 001 Jul 28, 1999

+ 0.75MG ** N021045 002 Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY EQ 50MG BASE N012928 006

EQ 100MG BASE N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY EQ 50MG BASE/5ML N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL 2MG/ML N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

+ VALEANT PHARM INTL 2MG ** N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM

SOLUTION; ORAL

TIROSINT-SOL

+ INSTITUT BIOCHIMIQUE 13MCG/ML N206977 001 Dec 15, 2016

+ 25MCG/ML N206977 002 Dec 15, 2016

+ 50MCG/ML N206977 003 Dec 15, 2016

+ 75MCG/ML N206977 004 Dec 15, 2016

+ 88MCG/ML N206977 005 Dec 15, 2016

+ 100MCG/ML N206977 006 Dec 15, 2016

+ 112MCG/ML N206977 007 Dec 15, 2016

+ 125MCG/ML N206977 008 Dec 15, 2016

+ 137MCG/ML N206977 009 Dec 15, 2016

+ 150MCG/ML N206977 010 Dec 15, 2016

+ 175MCG/ML N206977 011 Dec 15, 2016

+ 200MCG/ML N206977 012 Dec 15, 2016

TABLET; ORAL

LEVOLET

GENUS LIFESCIENCES 0.025MG N021137 001 Jun 06, 2003

0.05MG N021137 002 Jun 06, 2003

0.075MG N021137 003 Jun 06, 2003

0.088MG N021137 004 Jun 06, 2003

0.1MG N021137 005 Jun 06, 2003

0.112MG N021137 006 Jun 06, 2003

0.125MG N021137 007 Jun 06, 2003

0.137MG N021137 008 Jun 06, 2003

0.15MG N021137 009 Jun 06, 2003

0.175MG N021137 010 Jun 06, 2003

0.2MG N021137 011 Jun 06, 2003

0.3MG N021137 012 Jun 06, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOTHYROXINE SODIUM

MERCCK KGAA

0.025MG
0.05MG
0.075MG
0.088MG
0.1MG
0.112MG
0.125MG
0.15MG
0.175MG
0.2MG
0.3MGA076752 001 Jun 16, 2005
A076752 002 Jun 16, 2005
A076752 003 Jun 16, 2005
A076752 004 Jun 16, 2005
A076752 005 Jun 16, 2005
A076752 006 Jun 16, 2005
A076752 007 Jun 16, 2005
A076752 008 Jun 16, 2005
A076752 009 Jun 16, 2005
A076752 010 Jun 16, 2005
A076752 011 Jun 16, 2005

LEVOXYL

+ KING PHARMS

0.3MG **

N021301 012 May 25, 2001

NOVOTHYROX

MERCCK KGAA

0.025MG
0.05MG
0.075MG
0.088MG
0.1MG
0.112MG
0.125MG
0.137MG
0.15MG
0.175MG
0.2MG
0.3MGN021292 001 May 31, 2002
N021292 002 May 31, 2002
N021292 003 May 31, 2002
N021292 004 May 31, 2002
N021292 005 May 31, 2002
N021292 006 May 31, 2002
N021292 007 May 31, 2002
N021292 008 May 31, 2002
N021292 009 May 31, 2002
N021292 010 May 31, 2002
N021292 011 May 31, 2002
N021292 012 May 31, 2002

THYRO-TABS

+ LLOYD

0.025MG **
0.05MG **
0.075MG **
0.088MG **
0.1MG **
0.112MG **
0.125MG **
0.137MG **
0.15MG **
0.175MG **
0.2MG **
0.3MG **N021116 001 Oct 24, 2002
N021116 002 Oct 24, 2002
N021116 003 Oct 24, 2002
N021116 010 Oct 24, 2002
N021116 004 Oct 24, 2002
N021116 011 Oct 24, 2002
N021116 005 Oct 24, 2002
N021116 012 Dec 07, 2004
N021116 006 Oct 24, 2002
N021116 007 Oct 24, 2002
N021116 008 Oct 24, 2002
N021116 009 Oct 24, 2002LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%
5%
5%A084944 001
A084946 001
A084947 001

LIDOCAINE

BELMORA LLC

5%

A080210 001

XYLOCAINE

+ ASTRAZENECA

5% **

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%

N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG

N013077 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE 2% A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT 10% A087980 001 Feb 02, 1983

20% A089362 001 May 25, 1988

ABRAXIS PHARM 1% A080420 001

1% A086761 001

1.5% A080420 005

2% A080420 002

2% A080420 004

2% A086761 002

2% N017508 001

4% N017508 002

20% N017508 004

AKORN 1% A085037 001

2% A085037 002

BEL MAR 1% A080710 001

2% A080760 001

BELMORA LLC 2% A080504 001

DELL LABS 1% A083387 001

2% A083388 001

ELKINS SINN 0.5% A085131 001

4% A084626 001

GD SEARLE LLC 1% A083135 001

2% A083135 002

HOSPIRA 1% A040013 001 Jun 23, 1995

1.5% A088330 001 May 17, 1984

2% A088331 001 May 17, 1984

INTL MEDICATION 1% N017701 002

2% N017701 001

1GM/VIAL N018543 001

2GM/VIAL N018543 002

LUITPOLD 2% A083198 001

LYPHOMED 1% A080390 001

2% A080390 002

MILES 1% A080414 001

2% A080414 002

MYLAN LABS LTD 0.5% A091056 001 Dec 08, 2010

0.5% A091058 001 Sep 30, 2010

1% A091056 002 Dec 08, 2010

1% A091058 002 Sep 30, 2010

2% A202242 001 Apr 11, 2014

WATSON LABS 1% A080377 001

1% A083627 001

2% A080377 002

2% A083627 002

WEST-WARD PHARMS INT 1% A080407 001

2% A080407 002

WYETH AYERST 1% A083083 001

2% A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 100MG/100ML N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 200MG/100ML N018967 001 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA 200MG/100ML A083158 005

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 200MG/100ML N018954 001 Jul 09, 1985

HOSPIRA 200MG/100ML N018388 001

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 400MG/100ML N018967 002 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%

HOSPIRA 400MG/100ML A083158 006

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 400MG/100ML N018388 002

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 800MG/100ML N018967 003 Mar 30, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	800MG/100ML	N018388 003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326 001	Jul 31, 1984
	10%	A088367 001	Jul 31, 1984
	20%	A088368 001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
INTL MEDICATION	4%	N017702 002	
MYLAN LABS LTD	2%	A090665 001	Sep 27, 2010
WEST-WARD PHARMS INT	1%	A084625 001	
	2%	A084625 002	
LIDOCATON			
PHARMATON	2%	A084727 001	Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549 001	
XYLOCAINE			
ASTRAZENECA	1%	N010418 005	
	1.5%	N010418 009	
	2%	N010418 007	
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380 001	
XYLOCAINE PRESERVATIVE FREE			
FRESENIUS KABI USA	10%	N016801 003	
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297 001	
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496 002	Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BIONPHARMA INC	2%	A080429 001	
LIDOCAINE HYDROCHLORIDE			
G AND W LABS INC	2%	A081318 001	Apr 29, 1993
SOLUTION; ORAL			
LIDOCAINE HYDROCHLORIDE VISCOUS			
ACTAVIS MID ATLANTIC	2%	A086578 001	
INTL MEDICATION	2%	A086389 001	Feb 02, 1982
XYLOCAINE VISCOUS			
FRESENIUS KABI USA	2% **	N009470 001	
SOLUTION; TOPICAL			
LARYNGOTRACHEAL ANESTHESIA KIT			
KENDALL IL	4%	A087931 001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE			
PACO	4%	A089688 001	Jun 30, 1989
LTA II KIT			
HOSPIRA	4%	A088542 001	Jul 31, 1984
PEDIATRIC LTA KIT			
ABBOTT	2%	A088572 001	Jul 31, 1984
HOSPIRA	2%	A085995 001	

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER	2%; 50MG/ML	A060567 001	
	2%; 125MG/ML	A060567 002	

LIDOCAINE; PRILUCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA	2.5%; 2.5%	N020962 001	Feb 04, 1998
-------------	------------	-------------	--------------

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
	EQ 500MG BASE	N050316 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS

EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN 400MG **

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.25MG;0.0625MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LISINAPRIL

TABLET;ORAL

PRINIVIL

MERCCK

2.5MG

N019558 006 Jan 28, 1994

LITHIUM CARBONATE

CAPSULE;ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET;ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG

A078715 001 Dec 28, 2010

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE;ORAL

ESKALITH CR

JDS PHARMS

450MG **

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

HIKMA INTL PHARMS

450MG

A076490 001 Jun 17, 2003

LITHIUM CITRATE

SYRUP;ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

J AND J CONSUMER INC

2MG **

N017690 001

2MG **

N017694 001

LOPERAMIDE HYDROCHLORIDE

FOSUN PHARMA

2MG

A072993 001 Aug 28, 1992

ROXANE

2MG

A073080 001 Nov 27, 1991

TEVA

2MG

A073122 001 Aug 30, 1991

SOLUTION;ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

CONTRACT PHARMACAL

2MG

A073254 001 Jul 30, 1993

PERRIGO

2MG

A074194 001 Oct 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LOPERAMIDE HYDROCHLORIDETABLET, CHEWABLE;ORAL
IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONETABLET, CHEWABLE;ORAL
IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996

LOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

ABBVIE 133.3MG;33.3MG

N021226 001 Sep 15, 2000

LORACARBEF

CAPSULE;ORAL

LORABID

KING PHARMS 200MG
400MG

N050668 001 Dec 31, 1991

N050668 002 Apr 05, 1996

FOR SUSPENSION;ORAL

LORABID

KING PHARMS 100MG/5ML
200MG/5ML

N050667 001 Dec 31, 1991

N050667 002 Dec 31, 1991

LORATADINE

SYRUP;ORAL

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 1MG/ML **

N020641 003 Nov 19, 2003

LORATADINE

APOTEX INC 1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD 1MG/ML

A076529 001 Aug 20, 2004

TABLET;ORAL

LORATADINE

PERRIGO 10MG

N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC 5MG;120MG

A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN 2MG/ML

A074974 001 Jul 23, 1998

BEDFORD 2MG/ML

A077076 001 Jul 13, 2005

4MG/ML

A077076 002 Jul 13, 2005

DAVA PHARMS INC 2MG/ML

A074793 001 Mar 16, 2000

4MG/ML

A074793 002 Mar 16, 2000

HOSPIRA 2MG/ML

A074280 001 May 27, 1994

2MG/ML

A074300 001 Apr 12, 1994

4MG/ML

A074280 002 May 27, 1994

4MG/ML

A074300 003 Mar 19, 1997

SAGENT AGILA LLC 2MG/ML

A200217 001 Apr 04, 2017

2MG/ML

A200542 001 Apr 28, 2017

4MG/ML

A200217 002 Apr 04, 2017

4MG/ML

A200542 002 Apr 28, 2017

WATSON LABS 2MG/ML

A074276 001 Apr 15, 1994

4MG/ML

A074276 002 Apr 15, 1994

WATSON LABS INC 1MG/0.5ML

A074551 003 Sep 12, 1996

2MG/ML

A074535 001 Sep 12, 1996

2MG/ML

A074551 001 Sep 12, 1996

4MG/ML

A074535 002 Sep 12, 1996

4MG/ML

A074551 002 Sep 12, 1996

WEST-WARD PHARMS INT 2MG/ML

A074496 001 Sep 28, 1998

4MG/ML

A074496 002 Sep 28, 1998

SOLUTION;ORAL

LORAZEPAM

ROXANE 0.5MG/5ML

A074648 001 Mar 18, 1997

TABLET;ORAL

LORAZ

QUANTUM PHARMICS 0.5MG

A070200 001 Aug 09, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LORAZEPAM

TABLET; ORAL

LORAZ

1MG	A070201	001	Aug 09, 1985
2MG	A070202	001	Aug 09, 1985

LORAZEPAM

AM THERAP

0.5MG	A070727	001	Mar 07, 1986
1MG	A070728	001	Mar 07, 1986
2MG	A070729	001	Mar 07, 1986

ANDA REPOSITORY

0.5MG	A072553	001	Mar 29, 1991
1MG	A072554	001	Mar 29, 1991
2MG	A072555	001	Mar 29, 1991

HALSEY

0.5MG	A071434	001	Sep 01, 1987
1MG	A071435	001	Sep 01, 1987
2MG	A071436	001	Sep 01, 1987

MUTUAL PHARM

0.5MG	A070472	001	Dec 10, 1985
1MG	A070473	001	Dec 10, 1985
2MG	A070474	001	Dec 10, 1985

MYLAN

2MG	A071591	001	Oct 13, 1987
-----	---------	-----	--------------

PAR PHARM

0.5MG	A070675	001	Dec 01, 1986
1MG	A070676	001	Dec 01, 1986
2MG	A070677	001	Dec 01, 1986

SANDOZ

0.5MG	A071193	001	Apr 15, 1988
1MG	A071194	001	Apr 15, 1988
2MG	A071195	001	Apr 15, 1988

SUPERPHARM

0.5MG	A071245	001	Feb 09, 1987
1MG	A071246	001	Feb 09, 1987
2MG	A071247	001	Feb 09, 1987

USL PHARMA

1MG	A070539	001	Dec 22, 1986
2MG	A070540	001	Dec 22, 1986

WARNER CHILCOTT

1MG	A071038	001	Jan 12, 1988
2MG	A071039	001	Jan 12, 1988

WATSON LABS

0.5MG	A071086	001	Mar 23, 1987
0.5MG	A071117	001	Jul 24, 1986
1MG	A071087	001	Mar 23, 1987
1MG	A071118	001	Jul 24, 1986
2MG	A071088	001	Mar 23, 1987
2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS

0.5%	N020841	001	Mar 09, 1998
------	---------	-----	--------------

LOVASTATIN

TABLET; ORAL

LOVASTATIN

MYLAN

10MG	A075935	001	Dec 17, 2001
20MG	A075935	002	Dec 17, 2001
40MG	A075935	003	Dec 17, 2001

MEVACOR

+ MERCK

10MG **	N019643	002	Mar 28, 1991
---------	---------	-----	--------------

+

20MG **	N019643	003	Aug 31, 1987
---------	---------	-----	--------------

+

40MG **	N019643	004	Dec 14, 1988
---------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

COVIS PHARMA BV

10MG	N021316	001	Jun 26, 2002
------	---------	-----	--------------

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

ACTAVIS LABS UT INC

EQ 25MG BASE/ML	N017658	001	
-----------------	---------	-----	--

INJECTABLE; INJECTION

LOXITANE IM

ACTAVIS LABS UT INC

EQ 50MG BASE/ML	N018039	001	
-----------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

+	ACTAVIS LABS UT INC	EQ 5MG BASE **	N017525 001
+		EQ 10MG BASE **	N017525 002
+		EQ 25MG BASE **	N017525 003
+		EQ 50MG BASE **	N017525 004

TABLET; ORAL

LOXITANE

+	ACTAVIS LABS UT INC	EQ 10MG BASE **	N017525 006
+		EQ 25MG BASE **	N017525 007
+		EQ 50MG BASE **	N017525 008

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

WINDTREE THERAP	8.5ML	N021746 001	Mar 06, 2012
-----------------	-------	-------------	--------------

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004
------------	------------	-------------	--------------

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS	0.185MG/ML	N016755 001	
----------	------------	-------------	--

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047 001	Jun 15, 1984
-----------------	--------------------------------------	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	N019006 001	Apr 04, 1984
---------	---	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018252 001	
---------	---	-------------	--

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N018406 001	
-------------	---	-------------	--

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N018406 002	Jul 08, 1982
-------------	---	-------------	--------------

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N019326 001	Jan 25, 1985
-----------------	---	-------------	--------------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001	Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001	Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002	Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM **	N203595 001	Jan 18, 2013
---	----------------	--	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC 0.5%

A078743 001 Mar 06, 2009

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

IC TARGETS 37.9MG/ML

N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO 3.49MG/GM

N020686 001 Dec 19, 1997

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM EQ 0.1MG MANGANESE/ML

N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

B BRAUN 10GM/100ML

N016080 002

HOSPIRA 10GM/100ML

N016269 002

MILES 10GM/100ML

N016472 002

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN 10GM/100ML

N016080 006

MANNITOL 15%

B BRAUN 15GM/100ML

N016080 003

HOSPIRA 15GM/100ML

N016269 003

MILES 15GM/100ML

N016472 005

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN 15GM/100ML

N016080 005

MANNITOL 20%

B BRAUN 20GM/100ML

N014738 001

20GM/100ML

N016080 004

HOSPIRA 20GM/100ML

N016269 004

MILES 20GM/100ML

N016472 004

MANNITOL 25%

ABRAXIS PHARM 12.5GM/50ML

A086754 001

HOSPIRA 12.5GM/50ML

N016269 005

IGI LABS INC 12.5GM/50ML

A089239 001 May 06, 1987

12.5GM/50ML

A089240 001 May 06, 1987

MERCK 12.5GM/50ML

N005620 001

WATSON LABS 12.5GM/50ML

A087460 001 Jun 27, 1983

MANNITOL 5%

B BRAUN 5GM/100ML

N016080 001

HOSPIRA 5GM/100ML

N016269 001

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN 5GM/100ML

N016080 007

POWDER; INHALATION

ARIDOL KIT

PHARMAXIS LTD N/A, 5MG, 10MG, 20MG, 40MG

N022368 001 Oct 05, 2010

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN 5GM/100ML

N016704 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA 540MG/100ML; 2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA 540MG/100ML; 2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS 25MG

N017543 001

50MG

N017543 002

75MG

N017543 003 Sep 30, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129 001	Jan 14, 1988
	50MG	A072130 001	Jan 14, 1988
	75MG	A072131 001	Jan 14, 1988
WATSON LABS	25MG	A071943 001	Dec 30, 1987
	50MG	A071944 001	Dec 30, 1987
	75MG	A071945 001	Dec 30, 1987
	75MG	A072164 001	Jun 01, 1988
WATSON LABS TEVA	25MG	A072162 001	Jun 01, 1988
	50MG	A072163 001	Jun 01, 1988

MASOPROCOL

CREAM;TOPICAL

ACTINEX

UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992
--------------------	-----	-------------	--------------

MAZINDOL

TABLET;ORAL

MAZANOR

WYETH AYERST	1MG	N017980 002	
	2MG	N017980 001	

SANOREX

+ NOVARTIS	1MG **	N017247 001	
+	2MG **	N017247 002	

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+ JANSSEN PHARMS	100MG **	N017481 001	
------------------	----------	-------------	--

MEBUTAMATE

TABLET;ORAL

DORMATE

MEDPOINTE PHARM HLC	600MG	N017374 001	
---------------------	-------	-------------	--

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

INVERSINE

+ TARGACEPT	2.5MG **	N010251 001	
-------------	----------	-------------	--

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE;SUBCUTANEOUS

IPLEX

INSMED	36MG/0.6ML	N021884 001	Dec 12, 2005
--------	------------	-------------	--------------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

ANTIVERT

CASPER PHARMA LLC	12.5MG	N010721 006	
	25MG	N010721 004	
	50MG	N010721 001	Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253 001	
	25MG	A085252 001	
AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
ANABOLIC	25MG	A085891 001	
ANI PHARMS INC	12.5MG	A084975 001	
	25MG	A084657 001	
BUNDY	12.5MG	A084382 001	
	25MG	A084872 001	
IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
KV PHARM	12.5MG	A085524 001	
	25MG	A085523 001	
MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012
PAR PHARM	50MG	A089674 001	Mar 31, 1988
PLIVA	12.5MG	A088732 001	Dec 11, 1985
	25MG	A088734 001	Dec 11, 1985
RISING PHARMS INC	12.5MG	A040179 001	Jan 30, 1997
	25MG	A040179 002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
	25MG	A089114 001	Aug 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

UDL	12.5MG	A088256 001	Jun 13, 1983
	25MG	A088257 001	Jun 13, 1983
VANGARD	12.5MG	A087877 001	Apr 20, 1982
	25MG	A087620 001	Jan 04, 1982
WATSON LABS	12.5MG	A085195 001	
	12.5MG	A085269 001	
	25MG	A085740 001	

TABLET, CHEWABLE; ORAL

ANTIVERT

CASPER PHARMA LLC	25MG	N010721 005	
MECLIZINE HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	25MG	A084976 001	
NEXGEN PHARMA INC	25MG	A086392 001	
PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518 001	
---------------------	----	-------------	--

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
	EQ 100MG BASE	A071381 001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
	EQ 100MG BASE	A071363 001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
	EQ 100MG BASE	A072809 001	Mar 20, 1989
PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
	EQ 100MG BASE	A072078 001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710 001	Jun 15, 1988
	EQ 100MG BASE	A071684 001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400 001	Nov 25, 1986
	EQ 50MG BASE	A071468 001	Apr 15, 1987
	EQ 50MG BASE	A071640 001	Aug 11, 1987
	EQ 100MG BASE	A070401 001	Nov 25, 1986
	EQ 100MG BASE	A071641 001	Aug 11, 1987
WATSON LABS TEVA	EQ 100MG BASE	A071469 001	Apr 15, 1987

MECLOMEN

PARKE DAVIS	EQ 50MG BASE	N018006 001	
	EQ 100MG BASE	N018006 002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+ PHARMACIA AND UPJOHN	100MG/ML **	N012541 002	
------------------------	-------------	-------------	--

MEDROXYPROGESTERONE ACETATE

SANDOZ INC	150MG/ML	A078711 001	May 20, 2009
TEVA PHARMS USA	150MG/ML	A076552 001	Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS	10MG	A083242 001	
---------------	------	-------------	--

CURRETAB

SOLVAY	10MG	A085686 001	
--------	------	-------------	--

CYCRIN

ESI	2.5MG	A081239 001	Oct 30, 1992
	5MG	A081240 001	Oct 30, 1992
	10MG	A089386 001	Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR	2.5MG	A040311 001	Dec 01, 1999
	5MG	A040311 002	Dec 01, 1999
	10MG	A040311 003	Dec 01, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

USL PHARMA

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

+ ROCHE

250MG **

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA INTL PHARMS

250MG

A077699 001 Apr 21, 2010

SANDOZ

250MG

A076175 001 Feb 20, 2002

US ARMY WALTER REED

250MG **

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB

40MG/ML

N020264 001 Sep 10, 1993

MEGESTROL ACETATE

APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB

20MG **

N016979 001

+

40MG **

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM

7.5MG/5ML

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAM

ANDA REPOSITORY

7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

IMPAX LABS INC

7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

MYLAN

7.5MG

A077934 001 Jul 20, 2006

15MG

A077934 002 Jul 20, 2006

ROXANE

7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

SUN PHARM INDS INC

7.5MG

A077937 001 Jul 19, 2006

15MG

A077937 002 Jul 19, 2006

YABAO PHARM

7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+ APOTEX INC

EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL

EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

ORCHID HLTHCARE

5MG

A090044 001 Mar 12, 2012

10MG

A090044 002 Mar 12, 2012

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY

10MG/ML

N005725 001

SYNKAYVITE

ROCHE

5MG/ML

N003718 004

10MG/ML

N003718 006

37.5MG/ML

N003718 008

TABLET; ORAL

SYNKAYVITE

ROCHE

5MG

N003718 010

MENADIONE

TABLET; ORAL

MENADIONE

LILLY

5MG

N002139 003

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC

75 IU/VIAL; 75 IU/VIAL

N020328 001 Sep 01, 1994

150 IU/VIAL; 150 IU/VIAL

N020328 002 Sep 01, 1994

MENOTROPINS

FERRING

75 IU/VIAL; 75 IU/VIAL

A073598 001 Jan 30, 1997

150 IU/VIAL; 150 IU/VIAL

A073599 001 Jan 30, 1997

PERGONAL

SERONO

75 IU/AMP; 75 IU/AMP

N017646 001

150 IU/AMP; 150 IU/AMP

N017646 002 May 20, 1985

REPRONEX

FERRING

150 IU/VIAL; 150 IU/VIAL

N021047 002 Aug 27, 1999

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

FERRING

75 IU/VIAL; 75 IU/VIAL

N021047 001 Aug 27, 1999

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US

25MG/5ML

N010679 004

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US

25MG

N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

US PHARM HOLDINGS

25MG/ML

N005010 007

50MG/ML

N005010 002

75MG/ML

N005010 009

100MG/ML

N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML

A080388 001

50MG/ML

A080385 001

50MG/ML

A080387 001

75MG/ML

A080389 001

100MG/ML

A080386 001

BAXTER HLTHCARE

25MG/ML

A088279 001 Jun 15, 1984

50MG/ML

A088280 001 Jun 15, 1984

75MG/ML

A088281 001 Jun 15, 1984

100MG/ML

A088282 001 Jun 15, 1984

IGI LABS INC

25MG/ML

A089781 001 Mar 31, 1989

50MG/ML

A089782 001 Mar 31, 1989

50MG/ML

A089783 001 Mar 31, 1989

50MG/ML

A089784 001 Mar 31, 1989

75MG/ML

A089785 001 Mar 31, 1989

100MG/ML

A089786 001 Mar 31, 1989

100MG/ML

A089787 001 Mar 31, 1989

100MG/ML

A089788 001 Mar 31, 1989

INTL MEDICATION

10MG/ML

A086332 001

PARKE DAVIS

50MG/ML

A080364 002

75MG/ML

A080364 003

100MG/ML

A080364 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

WATSON LABS

50MG/ML

A073444 001 Mar 17, 1992

100MG/ML

A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML

A040305 001 Mar 10, 1999

INTL MEDICATION

10MG/ML

A081309 001 Aug 30, 1993

SPECGX LLC

10MG/ML

A040163 001 May 12, 1997

WATSON LABS

10MG/ML

A073443 001 Mar 17, 1992

SYRUP; ORAL

DEMEROL

US PHARM HOLDINGS

50MG/5ML **

N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG

A040318 001 Oct 05, 1999

100MG

A040318 002 Oct 05, 1999

SUN PHARM INDUSTRIES

50MG

A080448 001

100MG

A080448 002

WATSON LABS

50MG

A040186 001 Jun 30, 1997

100MG

A040186 002 Jun 30, 1997

WYETH AYERST

50MG

A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

WEST-WARD PHARMS INT 25MG/ML; 25MG/ML

N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP EQ 15MG BASE/ML

N008248 002

EQ 30MG BASE/ML

N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

+ NOVARTIS

100MG **

N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY

3%

A084777 002 Apr 18, 1982

CARBOCAINE

+ EASTMAN KODAK

3% **

N012125 003

MEPIVACAINE HYDROCHLORIDE

BELMORA LLC

3%

A083559 001

INTL MEDICATION SYS

1%

A087509 001 Oct 05, 1982

WATSON LABS

1%

A088769 001 Nov 20, 1984

2%

A088770 001 Nov 20, 1984

POLOCAINE

DENTSPLY PHARM

3%

A088653 001 Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING

4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST

400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC

200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDALE LABS

400MG

A084030 001

BAMATE

ALRA

200MG

A080380 001

400MG

A080380 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPROBAMATE

TABLET; ORAL

EQUANIL

WYETH AYERST	200MG	N010028	005
	400MG	N010028	004

MEPRIAM

TEVA	400MG	N016069	001
------	-------	---------	-----

MEPROBAMATE

AUROLIFE PHARMA LLC	400MG	A080655	001
---------------------	-------	---------	-----

BARR	600MG	A084230	001
------	-------	---------	-----

ELKINS SINN	200MG	N015426	002
-------------	-------	---------	-----

	400MG	N015426	001
--	-------	---------	-----

HEATHER	400MG	N016928	003
---------	-------	---------	-----

	600MG	A084329	001
--	-------	---------	-----

IMPAX LABS	200MG	N014322	002
------------	-------	---------	-----

	400MG	N014322	001
--	-------	---------	-----

IVAX SUB TEVA PHARMS	200MG	N015438	001
----------------------	-------	---------	-----

	400MG	N015438	002
--	-------	---------	-----

	600MG	A084181	001
--	-------	---------	-----

IVC INDS	400MG	A084153	001
----------	-------	---------	-----

LANNETT	200MG	N014882	002
---------	-------	---------	-----

	400MG	N014882	001
--	-------	---------	-----

LEDERLE	400MG	A086299	001
---------	-------	---------	-----

LEE KM	400MG	A089538	001
--------	-------	---------	-----

Nov 25, 1987

MALLARD	400MG	N015072	002
---------	-------	---------	-----

MK LABS	200MG	N014368	004
---------	-------	---------	-----

	400MG	N014368	002
--	-------	---------	-----

MYLAN	400MG	A083618	001
-------	-------	---------	-----

NEXGEN PHARMA INC	200MG	A084220	001
-------------------	-------	---------	-----

	400MG	A084589	001
--	-------	---------	-----

PARKE DAVIS	200MG	A084744	001
-------------	-------	---------	-----

	400MG	A084744	002
--	-------	---------	-----

PERRIGO	200MG	A084546	001
---------	-------	---------	-----

	400MG	A084547	001
--	-------	---------	-----

PHARMAVITE	400MG	A084438	001
------------	-------	---------	-----

PUREPAC PHARM	200MG	A084804	001
---------------	-------	---------	-----

	400MG	A084804	002
--	-------	---------	-----

PVT FORM	400MG	N014601	001
----------	-------	---------	-----

ROXANE	600MG	A084332	001
--------	-------	---------	-----

SANDOZ	200MG	N014547	002
--------	-------	---------	-----

	400MG	N014547	001
--	-------	---------	-----

SCHERER LABS	400MG	A083343	001
--------------	-------	---------	-----

SOLVAY	200MG	A084435	001
--------	-------	---------	-----

STANLABS PHARM	200MG	N014474	002
----------------	-------	---------	-----

	400MG	N014474	004
--	-------	---------	-----

SUN PHARM INDUSTRIES	200MG	A080699	001
----------------------	-------	---------	-----

	400MG	A080699	002
--	-------	---------	-----

TABLICAPS	400MG	A083494	001
-----------	-------	---------	-----

TARO	200MG	A200998	001
------	-------	---------	-----

May 23, 2011

	400MG	A200998	002
--	-------	---------	-----

May 23, 2011

USL PHARMA	200MG	A087825	001
------------	-------	---------	-----

Mar 18, 1982

	400MG	A087826	001
--	-------	---------	-----

Mar 18, 1982

VALEANT PHARM INTL	200MG	N015139	006
--------------------	-------	---------	-----

	400MG	N015139	005
--	-------	---------	-----

VANGARD	400MG	A088011	001
---------	-------	---------	-----

Jul 14, 1982

WATSON LABS	200MG	A085720	001
-------------	-------	---------	-----

	400MG	A085721	001
--	-------	---------	-----

	600MG	A084274	001
--	-------	---------	-----

	600MG	A085719	001
--	-------	---------	-----

WEST WARD	200MG	N015417	003
-----------	-------	---------	-----

	400MG	N015417	002
--	-------	---------	-----

WHITEWORTH TOWN PLSN	200MG	A083830	001
----------------------	-------	---------	-----

	400MG	A083442	001
--	-------	---------	-----

MILTOWN

+	MEDPOINTE PHARM HLC	200MG	**	N009698	004
---	---------------------	-------	----	---------	-----

+		400MG	**	N009698	002
---	--	-------	----	---------	-----

		600MG		A083919	001
--	--	-------	--	---------	-----

NEURAMATE

HALSEY	200MG	N014359	002
--------	-------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPROBAMATETABLET; ORAL
NEURAMATE

400MG N014359 001

TRANMEP

SOLVAY

400MG A084369 001

400MG N016249 001

MEQUINOL; TRETINOINSOLUTION; TOPICAL
SOLAGE

AQUA PHARMS

2%; 0.01%

N020922 001 Dec 10, 1999

MEROPENEMINJECTABLE; INJECTION
MEROPENEM

SANDOZ

500MG/VIAL

A091201 001 Mar 29, 2011

1GM/VIAL

A091201 002 Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS

100MG/ML; 50MG/ML

A084875 001

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

FOREST LABS LLC

500MG

N021252 001 Jan 05, 2001

ROWASA

+ MEDA PHARMS

500MG **

N019919 001 Dec 18, 1990

TABLET, DELAYED RELEASE; ORAL

ASACOL

APIL

400MG

N019651 001 Jan 31, 1992

MESNA

INJECTABLE; INTRAVENOUS

MESNA

MYLAN LABS LTD

100MG/ML

A203364 001 Jul 18, 2014

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016997 001

INJECTABLE; INJECTION

SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS

EQ 10MG BASE

N016774 001

EQ 25MG BASE

N016774 002

EQ 50MG BASE

N016774 003

EQ 100MG BASE

N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

ACTAVIS LABS UT INC

0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS

0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

ACTAVIS LABS UT INC

0.05MG; 1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC

0.08MG; 1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM

0.05MG; 1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM

0.08MG; 1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM

0.06MG; 10MG

N012728 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM 0.1MG; 2MG N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS 0.05MG; 1MG A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC 0.08MG; 1MG N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN 0.05MG; 1MG N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG; 1MG N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC 0.075MG; 5MG N010976 008

0.15MG; 9.85MG N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG; 5MG N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG; 2.5MG N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC 0.1MG; 2.5MG N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.65MG/INH N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.4% N018761 002 Oct 10, 1986

0.6% N018761 001 Jun 30, 1983

5% N017659 001

METAPROTERENOL SULFATE

APOTEX INC

0.4% A075402 001 Feb 28, 2001

0.6% A075403 001 Feb 28, 2001

ASTRAZENECA 0.4% A071275 001 Jul 27, 1988

0.6% A071018 001 Jul 27, 1988

DEY 0.33% A071806 001 Aug 05, 1988

0.5% A071805 001 Aug 05, 1988

5% A070805 001 Aug 17, 1987

MYLAN SPECIALITY LP 0.4% A071786 001 Aug 05, 1988

0.6% A070804 001 Aug 17, 1987

NEPHRON 0.4% A071855 001 Jul 14, 1988

0.6% A071726 001 Jul 14, 1988

WOCKHARDT 0.4% A075586 001 May 30, 2002

0.6% A075586 002 May 30, 2002

5% A072190 001 Jun 07, 1988

PROMETA

MURO

5% A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG/5ML N017571 001

METAPROTERENOL SULFATE

APOTEX INC

10MG/5ML A075235 001 Jan 27, 2000

G AND W LABS INC 10MG/5ML A072761 001 Feb 27, 1992

10MG/5ML A073034 001 Aug 30, 1991

MORTON GROVE 10MG/5ML A071656 001 Oct 13, 1987

WOCKHARDT 10MG/5ML A074702 001 Mar 24, 1997

PROMETA

MURO

10MG/5ML A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG N015874 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METAPROTERENOL SULFATE

TABLET; ORAL

ALUPENT

	20MG	N015874 001	
METAPROTERENOL SULFATE			
AM THERAP	10MG	A072054 001	Jun 23, 1988
	20MG	A072055 001	Jun 23, 1988
TEVA	10MG	A072519 001	Mar 30, 1990
	20MG	A072520 001	Mar 30, 1990
USL PHARMA	10MG	A071013 001	Jan 25, 1988
	20MG	A071014 001	Jan 25, 1988
WATSON LABS	10MG	A073013 001	Jan 31, 1991
	20MG	A072795 001	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

+ MERCK	EQ 10MG BASE/ML **	N009509 002	Dec 22, 1987
METARAMINOL BITARTRATE			
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431 001	
ELKINS SINN	EQ 10MG BASE/ML	A083363 001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418 001	
	EQ 20MG BASE/ML	A086418 002	

METAXALONE

TABLET; ORAL

METAXALONE

EPIC PHARMA LLC	640MG	N022503 001	Jun 01, 2015
SKELAXIN			
+ KING PHARMS	400MG **	N013217 001	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

+ BRISTOL MYERS SQUIBB	625MG **	N020357 003	Nov 05, 1998
+ BRISTOL MYERS SQUIBB	750MG **	N020357 004	Nov 05, 1998
METFORMIN HYDROCHLORIDE			
BARR	500MG	A075971 001	Jan 25, 2002
	850MG	A075971 002	Jan 25, 2002
	1GM	A075971 003	Jan 25, 2002
IPCA LABS LTD	500MG	A078422 001	Aug 06, 2007
	850MG	A078422 002	Aug 06, 2007
	1GM	A078422 003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975 001	Jan 24, 2002
	625MG	A075975 004	Jan 24, 2002
	750MG	A075975 005	Jan 24, 2002
	850MG	A075975 002	Jan 24, 2002
	1GM	A075975 003	Jan 24, 2002
MYLAN PHARMS INC	500MG	A075969 001	Jan 29, 2002
	850MG	A075969 002	Jan 29, 2002
	1GM	A075969 003	Jan 29, 2002
TEVA	500MG	A076328 001	Dec 16, 2002
	850MG	A076328 002	Dec 16, 2002
	1GM	A076328 003	Dec 16, 2002
WATSON LABS	500MG	A075979 001	Jan 24, 2002
	850MG	A075979 002	Jan 24, 2002
	1GM	A075979 003	Jan 24, 2002
WATSON LABS FLORIDA	500MG	A075961 001	Jan 25, 2002
	850MG	A075961 002	Jan 25, 2002
	1GM	A075961 003	Jan 25, 2002
TABLET, EXTENDED RELEASE; ORAL			
METFORMIN HYDROCHLORIDE			
ACTAVIS ELIZABETH	500MG	A076450 001	Oct 01, 2004
	750MG	A076878 001	Apr 13, 2005
BARR	500MG	A076496 001	Nov 25, 2005
IMPAX LABS	500MG	A076249 001	Jul 30, 2004
	750MG	A076985 001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003
MYLAN	500MG	A076650 001	Sep 13, 2005
	750MG	A077113 001	Sep 08, 2005
RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

	750MG	A077211 001	Jun 29, 2005
SANDOZ	500MG	A076223 001	Dec 14, 2004
SUN PHARM INDUSTRIES	500MG	A077124 001	Dec 21, 2005
TORRENT PHARMS LTD	750MG	A079226 001	Feb 18, 2010
WATSON LABS INC	500MG	A076818 001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

+ NOVO NORDISK INC	500MG;1MG	N022386 001	Jun 23, 2008
+	500MG;2MG	N022386 002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

+ SB PHARMCO	500MG;EQ 1MG BASE **	N021410 001	Oct 10, 2002
+	500MG;EQ 2MG BASE **	N021410 002	Oct 10, 2002
+	500MG;EQ 4MG BASE **	N021410 003	Oct 10, 2002
+	1GM;EQ 2MG BASE **	N021410 004	Aug 25, 2003
+	1GM;EQ 4MG BASE **	N021410 005	Aug 25, 2003

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+ METHAPHARM	1600MG/VIAL	N019193 002	Aug 29, 2016
--------------	-------------	-------------	--------------

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641 001	
	EQ 280MG BASE	A060641 002	

SYRUP;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641 003	
---------------------	------------------	-------------	--

METHADONE HYDROCHLORIDE

POWDER;FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT INC	50GM/BOT	N006383 002	
	100GM/BOT	N006383 003	
	500GM/BOT	N006383 004	

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

WEST-WARD PHARMS INT	10MG/30ML	N006134 004	
----------------------	-----------	-------------	--

TABLET;ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108 001	Mar 08, 1983
	10MG	A088109 001	Mar 08, 1983
	40MG	A074081 001	Apr 28, 1995
SANDOZ	5MG	A040241 001	May 29, 1998

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ	2.5MG	N017108 001	
--------	-------	-------------	--

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ	5MG	N017108 002	
	10MG	N017108 003	
	40MG	N017108 004	

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA	10MG	A083889 001	
------	------	-------------	--

METHAMPHETAMINE HYDROCHLORIDE

ABLE	5MG	A040529 001	Feb 25, 2004
REXAR	5MG	A084931 001	
	10MG	A084931 002	
TEVA	5MG	A086359 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHAMPHETAMINE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
DESOXYN

RECORDATI RARE	5MG	N005378 004
	10MG	N005378 003
	15MG	N005378 005

METHANTHELINE BROMIDE

TABLET;ORAL

BANTHINE

SHIRE	50MG	N007390 001
-------	------	-------------

METHARBITAL

TABLET;ORAL

GEMONIL

ABBVIE	100MG	N008322 001
--------	-------	-------------

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

APPLIED ANAL	25MG	A040011 001	Jul 17, 1997
	50MG	A040011 002	Jul 17, 1997
SANDOZ	25MG	A040102 001	Aug 28, 1996
	50MG	A040102 002	Aug 28, 1996

NEPTAZANE

+ LEDERLE 25MG **

N011721 002 Nov 25, 1991

+ 50MG **

N011721 001

METHDILAZINE

TABLET, CHEWABLE;ORAL

TACARYL

WESTWOOD SQUIBB	3.6MG	N011950 009
-----------------	-------	-------------

METHDILAZINE HYDROCHLORIDE

SYRUP;ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	4MG/5ML	A087122 001
--------------------	---------	-------------

TACARYL

WESTWOOD SQUIBB	4MG/5ML	N011950 007
-----------------	---------	-------------

TABLET;ORAL

TACARYL

WESTWOOD SQUIBB	8MG	N011950 006
-----------------	-----	-------------

METHICILLIN SODIUM

INJECTABLE;INJECTION

STAPHCILLIN

APOTHECON	EQ 900MG BASE/VIAL	A061449 001
	EQ 900MG BASE/VIAL	N050117 001
	EQ 3.6GM BASE/VIAL	A061449 002
	EQ 3.6GM BASE/VIAL	N050117 002
	EQ 5.4GM BASE/VIAL	A061449 003
	EQ 5.4GM BASE/VIAL	N050117 003

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

ECI PHARMS LLC	15MG	A040619 003	Jul 12, 2005
----------------	------	-------------	--------------

	20MG	A040547 004	Feb 18, 2005
--	------	-------------	--------------

MYLAN	20MG	A040350 003	Jun 07, 2001
-------	------	-------------	--------------

TAPAZOLE

+ KING PHARMS 5MG ** N007517 002

+ 10MG ** N007517 004

METHIXENE HYDROCHLORIDE

TABLET;ORAL

TREST

NOVARTIS	1MG	N013420 001
----------	-----	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC	100MG/ML	A089849 001	Dec 27, 1991
WATSON LABS	100MG/ML	A086459 001	

TABLET; ORAL

DELAXIN

FERNDALE LABS	500MG	A085454 001	
---------------	-------	-------------	--

FORBAXIN

FOREST LABS	750MG	A085136 001	
-------------	-------	-------------	--

METHOCARBAMOL

ABLE	500MG	A040413 001	Mar 17, 2003
	750MG	A040413 002	Mar 17, 2003
AM THERAP	500MG	A089417 001	Feb 11, 1987
	750MG	A089418 001	Feb 11, 1987
ASCOT	500MG	A087660 001	Oct 27, 1982
	750MG	A087661 001	Oct 27, 1982
CLONMEL HLTHCARE	500MG	A085961 001	
	750MG	A085963 001	
HEATHER	500MG	A084675 001	
	750MG	A084924 001	
IMPAX LABS	500MG	A084927 001	
	750MG	A084928 001	
INWOOD LABS	500MG	A085137 001	
IVAX SUB TEVA PHARMS	500MG	A084648 001	
	750MG	A084649 001	
KV PHARM	500MG	A085660 001	
	750MG	A085658 001	
LANNETT HOLDINGS INC	500MG	A084756 002	Mar 31, 2003
	750MG	A084756 001	
MYLAN	500MG	A084259 001	
	750MG	A084323 001	
NYLOS	750MG	A085033 001	
PIONEER PHARMS	500MG	A088731 001	Dec 13, 1985
	750MG	A089082 001	Dec 13, 1985
PURACAP PHARM	500MG	A084231 002	
	750MG	A084471 001	
PUREPAC PHARM	500MG	A085718 001	
	750MG	A085718 002	
ROXANE	500MG	A088646 001	Feb 29, 1984
	750MG	A088647 001	Feb 29, 1984
SANDOZ	500MG	A084616 001	
	500MG	A087283 001	
	750MG	A084615 001	
	750MG	A087282 001	
SOLVAY	500MG	A084448 001	
	750MG	A084449 001	
SUN PHARM INDUSTRIES	500MG	A084488 001	
	750MG	A084486 001	
SUPERPHARM	500MG	A087589 001	Jan 22, 1982
	750MG	A087590 001	Jan 22, 1982
TABLICAPS	500MG	A084846 001	
UPSHER SMITH	500MG	A087453 001	
	750MG	A087454 001	
WATSON LABS	500MG	A083605 001	
	500MG	A085180 001	
	750MG	A083605 002	
	750MG	A085192 001	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559 004	Dec 21, 2012
	5GM/VIAL	N011559 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

+	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
---	--------------------	---------------------------	---------	-----	--------------

OTREXUP PFS

+	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017

RASUVO

+	MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
---	------------------	-------------------------------	---------	-----	--------------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ	25MG BASE/ML	A089161	001	Mar 10, 1987
EQ	50MG BASE/VIAL	A089354	001	Jul 17, 1987
EQ	100MG BASE/VIAL	A089355	001	Jul 17, 1987
EQ	250MG BASE/VIAL	A089356	001	Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ	25MG BASE/VIAL	A087695	001	Apr 08, 1983
EQ	50MG BASE/VIAL	A087695	002	Apr 08, 1983
EQ	100MG BASE/VIAL	A087695	003	Apr 08, 1983
EQ	250MG BASE/VIAL	A088954	001	Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ	25MG BASE/ML	A081242	001	Aug 23, 1991
EQ	25MG BASE/ML	A089180	001	Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ	25MG BASE/ML	N011719	007	Mar 31, 1982
----	--------------	---------	-----	--------------

METHOTREXATE PRESERVATIVE FREE

HOSPIRA

EQ	20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
----	---------------------------------	---------	-----	--------------

+

EQ	500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
----	--------------------------------------	---------	-----	--------------

EQ	2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
----	------------------------------------	---------	-----	--------------

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ	2.5MG BASE/ML	A089323	001	Jun 13, 1986
EQ	20MG BASE/VIAL	A088935	001	Oct 11, 1985
EQ	25MG BASE/ML	A089263	001	Jun 13, 1986
EQ	25MG BASE/ML	A089322	001	Jun 13, 1986
EQ	50MG BASE/VIAL	A088936	001	Oct 11, 1985
EQ	100MG BASE/VIAL	A088937	001	Oct 11, 1985

HOSPIRA

EQ	2.5MG BASE/ML	N011719	004	
EQ	20MG BASE/VIAL	N011719	001	
EQ	25MG BASE/ML	N011719	005	
EQ	50MG BASE/VIAL	N011719	003	
EQ	100MG BASE/VIAL	N011719	006	

NORBROOK

EQ	25MG BASE/ML	A088648	001	May 09, 1986
----	--------------	---------	-----	--------------

PHARMACHEMIE USA

EQ	25MG BASE/ML	A089158	001	Jul 08, 1988
----	--------------	---------	-----	--------------

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ	1GM BASE/VIAL	N011719	009	Apr 07, 1988
----	---------------	---------	-----	--------------

MEXATE

BRISTOL

EQ	20MG BASE/VIAL	A086358	001	
EQ	50MG BASE/VIAL	A086358	002	
EQ	100MG BASE/VIAL	A086358	003	
EQ	250MG BASE/VIAL	A086358	004	

MEXATE-AQ

BRISTOL MYERS

EQ	25MG BASE/ML	A088760	001	Feb 14, 1985
----	--------------	---------	-----	--------------

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ	25MG BASE/ML	A089887	001	Apr 14, 1989
----	--------------	---------	-----	--------------

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ	2.5MG BASE	A040233	001	Jun 17, 1999
----	------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772	002
	20MG/ML	N006772	001

METHOXSALEN

CAPSULE; ORAL

8-MOP

+ VALEANT PHARM INTL	10MG	N009048	001
----------------------	------	---------	-----

METHOXSALEN

IDT AUSTRALIA LTD	10MG	A087781	001 Jun 08, 1982
-------------------	------	---------	------------------

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL	1%	N009048	002
----------------------	----	---------	-----

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970	001
----------	-------	---------	-----

PAMINE

FOUGERA PHARMS	2.5MG **	N008848	001
----------------	----------	---------	-----

PAMINE FORTE

FOUGERA PHARMS	5MG **	N008848	002 Mar 25, 2003
----------------	--------	---------	------------------

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364	001
---------------------	-----	---------	-----

ENDURON

+ ABBVIE	2.5MG **	N012524	001
----------	----------	---------	-----

+	5MG **	N012524	004
---	--------	---------	-----

METHYCLOTHIAZIDE

FOSUN PHARMA	2.5MG	A089835	001 Aug 18, 1988
--------------	-------	---------	------------------

	5MG	A089837	001 Aug 18, 1988
--	-----	---------	------------------

IVAX PHARMS	2.5MG	A087913	001 Jun 03, 1982
-------------	-------	---------	------------------

	5MG	A087786	001 May 18, 1982
--	-----	---------	------------------

MYLAN	2.5MG	A087671	001 Aug 17, 1982
-------	-------	---------	------------------

PAR PHARM	2.5MG	A089135	001 Feb 12, 1986
-----------	-------	---------	------------------

	5MG	A089136	001 Feb 12, 1986
--	-----	---------	------------------

USL PHARMA	5MG	A088745	001 Mar 21, 1985
------------	-----	---------	------------------

WATSON LABS	2.5MG	A085487	001 Mar 11, 1982
-------------	-------	---------	------------------

	2.5MG	A088750	001 Sep 06, 1984
--	-------	---------	------------------

	5MG	A085476	001 Mar 11, 1982
--	-----	---------	------------------

	5MG	A088724	001 Sep 06, 1984
--	-----	---------	------------------

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG; 25MG	N016047	001
--------	-----------	---------	-----

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG; 0.1MG	N012708	005
---------------------	--------------	---------	-----

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP	EQ 16.8% BASE	N021415	001 Jul 27, 2004
------------------	---------------	---------	------------------

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001
-------	-----------	---------	-----

TABLET; ORAL

ALDOMET

+ MERCK	125MG **	N013400	003
---------	----------	---------	-----

+	250MG **	N013400	001
---	----------	---------	-----

+	500MG **	N013400	002
---	----------	---------	-----

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003 Oct 15, 1985
-----------------	-------	---------	------------------

DURAMED PHARMS BARR	250MG	A071006	001 Dec 16, 1986
---------------------	-------	---------	------------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLDOPATABLET; ORAL
METHYLDOPA

	500MG	A071009	001	Dec 16, 1986
FOSUN PHARMA	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

+ MERCK

50MG/ML **

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM

50MG/ML

A070652 001 Jun 03, 1986

BAXTER HLTHCARE

50MG/ML

A070291 001 Jul 01, 1986

HOSPIRA

50MG/ML

A070691 001 Jun 19, 1987

50MG/ML

A070698 001 Jun 15, 1987

50MG/ML

A070699 001 Jun 15, 1987

50MG/ML

A070849 001 Jun 19, 1987

MARSAM PHARMS LLC

50MG/ML

A071812 001 Dec 22, 1987

SMITH AND NEPHEW

50MG/ML

A070841 001 Jan 02, 1987

TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

+ EDISON THERAPS LLC

0.2MG **

N006035 003

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RITALIN LA

+ NOVARTIS

60MG **

N021284 005 Oct 27, 2014

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE

5MG

A040404 001 Mar 29, 2001

10MG

A040404 002 Mar 29, 2001

20MG

A040404 003 Mar 29, 2001

ACTAVIS ELIZABETH

5MG

A040321 001 Feb 05, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

10MG	A040321	002	Feb 05, 2002
20MG	A040321	003	Feb 05, 2002

TABLET, CHEWABLE; ORAL

METHYLIN

+ SPECGX LLC	2.5MG **	N021475	001	Apr 15, 2003
+	5MG **	N021475	002	Apr 15, 2003
+	10MG **	N021475	003	Apr 15, 2003

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG	A040306	001	Oct 20, 1999
---------	------	---------	-----	--------------

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032	001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001
WATSON LABS	20MG	A040410	001	Feb 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153	005	
----------------------	------	---------	-----	--

METHYLPREDNISOLONE

HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
----------------------	----------	---------	-----	--

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

	EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987
HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008
	EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008
METHYLPREDNISOLONE			
ELKINS SINN	EQ 125MG BASE/VIAL	A086906 002	
	EQ 500MG BASE/VIAL	A086906 003	
	EQ 1GM BASE/VIAL	A086906 004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535 001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535 002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE			
ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676 001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143 001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677 001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144 001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678 001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186 001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187 001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679 001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188 001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189 001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906 001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812 001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813 001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851 001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852 001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267 001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268 001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953 001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030 001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523 001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524 001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN 0.1%;EQ 3.5MG BASE/GM A060645 001

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967 001	
VIRILON			
STAR PHARMS FL	10MG	A087750 001	Nov 24, 1982
TABLET; BUCCAL			
ANDROID 5			
VALEANT PHARM INTL	5MG	A087222 001	
ORETON			
SCHERING	10MG	A080281 001	
TABLET; BUCCAL, SUBLINGUAL			
METANDREN			
NOVARTIS	5MG	N003240 004	
	10MG	N003240 001	
	10MG	N003240 005	
	25MG	N003240 003	
METHYLTESTOSTERONE			
IMPAX LABS	10MG	A084287 001	
LILLY	10MG	A080256 001	
	25MG	A080256 002	
PUREPAC PHARM	10MG	A080308 001	
	10MG	A080475 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLTESTOSTERONETABLET;BUCCAL, SUBLINGUAL
METHYLTESTOSTERONE

10MG	A080475 002
25MG	A080475 003
PVT FORM	A083836 001
TABLICAPS	A085125 001
USL PHARMA	A080271 001

TABLET;ORAL

ANDROID 10

VALEANT PHARMS NORTH 10MG A086450 001

METHYLTESTOSTERONE

IMPAX LABS 25MG A084310 001

INWOOD LABS 10MG A080839 001

25MG A080973 001

KV PHARM 10MG A084312 001

LANNETT 10MG A087092 001 Nov 05, 1982

25MG A087111 001 Jan 27, 1983

PARKE DAVIS 10MG A084244 001

25MG A084241 001

PUREPAC PHARM 10MG A080309 001

25MG A080310 001

PVT FORM 5MG A080214 001

10MG A080214 002

25MG A080214 003

TABLICAPS 10MG A080313 001

25MG A085270 001

WATSON LABS 10MG A080933 001

25MG A080931 001

WEST WARD 10MG A084331 001

25MG A084331 002

25MG A084642 001

ORETON METHYL

SCHERING 10MG N003158 001

25MG N003158 002

METHYPRYLON

CAPSULE;ORAL

NOLUDAR

ROCHE 300MG N009660 008

ELIXIR;ORAL

NOLUDAR

ROCHE 50MG/5ML N009660 007

TABLET;ORAL

NOLUDAR

ROCHE 50MG N009660 002

200MG N009660 004

METHYSERGIDE MALEATE

TABLET;ORAL

SANSERT

NOVARTIS 2MG N012516 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE;ORAL

METOCLOPRAMIDE INTENSOL

ROXANE EQ 10MG BASE/ML A072995 001 Jan 30, 1992

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD EQ 5MG BASE/ML A072155 001 Mar 30, 1992

EQ 5MG BASE/ML A072244 001 Mar 30, 1992

EQ 5MG BASE/ML A072247 001 May 18, 1992

HOSPIRA EQ 5MG BASE/ML A070505 001 Jun 23, 1989

EQ 5MG BASE/ML A070506 001 Jun 22, 1989

EQ 5MG BASE/ML A070847 001 Nov 07, 1988

EQ 5MG BASE/ML A071291 001 Mar 03, 1989

EQ 5MG BASE/ML A071990 001 Jan 18, 1989

EQ 5MG BASE/ML A073117 001 Jan 17, 1991

EQ 5MG BASE/ML A074147 001 Aug 02, 1996

LYPHOMED EQ 10MG BASE/2ML A070293 001 Jan 24, 1986

NORBROOK EQ 10MG BASE/2ML A070892 001 Aug 26, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

REGLAN

WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001	
	EQ 10MG BASE/ML	N017862	004	May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993

REGLAN

+ ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
-------------	--------------------	---------	-----	--------------

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
------------------	--------------	---------	-----	--------------

MAXOLON

KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
-------------	--------------	---------	-----	--------------

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
FOSUN PHARMA	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A072215	001	Jan 30, 1990
	EQ 10MG BASE	A074478	002	Oct 05, 1995
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
	EQ 10MG BASE	A078374	002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 10MG BASE	A070850	001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
	EQ 10MG BASE	A071536	001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

+ SALIX PHARMS	EQ 10MG BASE **	N022246	002	Sep 04, 2009
----------------	-----------------	---------	-----	--------------

REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632	003	
-------	--------	---------	-----	--

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	

METOLAZONE

ROXANE	10MG	A076482	002	Apr 29, 2004
TEVA	2.5MG	A076600	001	Jan 06, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOLAZONETABLET; ORAL
METOLAZONE

	5MG	A076833	001	Mar 01, 2004
	10MG	A075543	003	Dec 24, 2003
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
UCB INC	0.5MG	N019532	001	Oct 30, 1987

METOPROLOL FUMARATETABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008

METOPROLOL TARTRATEINJECTABLE; INJECTION
METOPROLOL TARTRATE

WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
-------------	--------	---------	-----	--------------

TABLET; ORAL
METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
FOSUN PHARMA	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PRINSTON INC	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994

METRIZAMIDEINJECTABLE; INJECTION
AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003
------	-------	---------	-----	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353	002	
--------	-------------	---------	-----	--

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
---------	-------------	---------	-----	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE

500MG/100ML

A070170 001 Apr 01, 1986

WEST-WARD PHARMS INT 500MG/100ML

N018907 001 Mar 30, 1984

TABLET; ORAL

METROMIDOL

LABS AF

250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE

250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

CHARTWELL MOLECULES

250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

HALSEY

250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS

250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK

250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM

250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

SANDOZ

250MG

N018620 001 Mar 04, 1982

250MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

SUPERPHARM

250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

WATSON LABS

250MG

N018599 001 Sep 17, 1982

250MG

N018764 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

500MG

N018764 002 Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM

250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS

250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE

750MG

A076462 001 Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL **

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

IDT AUSTRALIA LTD

150MG

A074450 001 May 16, 1996

200MG

A074450 002 May 16, 1996

250MG

A074450 003 May 16, 1996

WATSON LABS

150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

MEXITIL

BOEHRINGER INGELHEIM

150MG

N018873 002 Dec 30, 1985

200MG

N018873 003 Dec 30, 1985

250MG

N018873 004 Dec 30, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333 001	
	EQ 1GM BASE/VIAL	A062372 005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549 001	
	EQ 2GM BASE/VIAL	A062333 002	
	EQ 2GM BASE/VIAL	A062372 001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549 002	
	EQ 3GM BASE/VIAL	A062333 003	
	EQ 3GM BASE/VIAL	A062372 002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697 001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549 003	
	EQ 4GM BASE/VIAL	A062333 004	
	EQ 4GM BASE/VIAL	A062372 003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697 002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549 004	
	EQ 20GM BASE/VIAL	A062372 004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549 005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040 001	
----------------	---------	-------------	--

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017494 001	
----------------	----	-------------	--

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136 001	Jan 04, 1995
TEVA PHARMS	2%	A074030 001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%, 100MG	A074586 001	Jul 17, 1997
----------------------	-----------	-------------	--------------

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017739 001	
----------------	----	-------------	--

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592 001	Oct 27, 1989
----------------	-------	-------------	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTHECON	EQ 1MG BASE/ML	A075620 001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620 002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641 001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637 001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637 002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249 001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455 001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396 001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396 002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484 001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409 001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263 001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144 001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144 002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020 001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020 002	Jul 16, 2004
WOCKHARDT	EQ 1MG BASE/ML	A078141 001	May 30, 2008
	EQ 1MG BASE/ML	A078511 001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141 002	May 30, 2008
	EQ 5MG BASE/ML	A078511 002	Nov 10, 2008
VERSED			
+ HLR	EQ 1MG BASE/ML **	N018654 002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654 001	Dec 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077115 001 Sep 09, 2005

SUN PHARM INDS LTD

EQ 2MG BASE/ML

A076058 001 Mar 15, 2002

VERSED

+ ROCHE

EQ 2MG BASE/ML **

N020942 001 Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

+ SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

+

5MG

N019815 002 Sep 06, 1996

+

10MG

N019815 003 Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

WINDLAS HLTHCARE

12.5MG

A205071 001 Jan 27, 2016

25MG

A205071 002 Jan 27, 2016

50MG

A205071 003 Jan 27, 2016

100MG

A205071 004 Jan 27, 2016

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 1MG BASE/ML

A076427 001 Sep 21, 2004

HOSPIRA

EQ 1MG BASE/ML

A075830 001 May 28, 2002

EQ 1MG BASE/ML

A075884 001 May 28, 2002

MYLAN INSTITUTIONAL

EQ 1MG BASE/ML

A076428 001 Jun 16, 2003

WEST-WARD PHARMS INT

EQ 1MG BASE/ML

A075852 001 May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A076414 001 Aug 18, 2004

BAXTER HLTHCARE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A076259 001 Aug 08, 2002

RENAISSANCE SSA LLC

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A077151 001 Jul 20, 2005

WEST-WARD PHARMS INT

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A075510 001 May 28, 2002

PRIMACOR

+ SANOFI AVENTIS US

EQ 1MG BASE/ML **

N019436 001 Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ SANOFI AVENTIS US

EQ 10MG BASE/100ML **

N020343 001 Aug 09, 1994

+ EQ 15MG BASE/100ML **

N020343 002 Aug 09, 1994

+ EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

N020343 003 Aug 09, 1994

+

EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)

N020343 004 Aug 09, 1994

+

**

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

+ PRECISION DERMAT

EQ 75MG BASE **

N050649 003 Feb 12, 2001

TRIAx PHARMS

EQ 50MG BASE

N050315 002

EQ 100MG BASE

N050315 001

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

SUN PHARM INDS LTD

EQ 67.5MG BASE

N201922 002 Jul 11, 2012

EQ 112.5MG BASE

N201922 004 Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE

EQ 100MG BASE/VIAL

A062139 001

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT

EQ 50MG BASE/5ML

N050445 001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

+ TRIAX PHARMS

EQ 50MG BASE **

N050451 003 Aug 10, 1982

+

EQ 100MG BASE **

N050451 002 Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

BARR LABS INC

EQ 45MG BASE

A065485 001 Mar 17, 2009

EQ 65MG BASE

A065485 004 May 18, 2012

EQ 80MG BASE

A065485 007 Apr 26, 2017

EQ 90MG BASE

A065485 002 Mar 17, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

	EQ 105MG BASE	A065485 008	Apr 26, 2017
	EQ 115MG BASE	A065485 005	May 18, 2012
	EQ 135MG BASE	A065485 003	Mar 17, 2009
IMPAX LABS INC	EQ 45MG BASE	A090024 001	Feb 03, 2009
	EQ 90MG BASE	A090024 002	Feb 03, 2009
	EQ 135MG BASE	A090024 003	Feb 03, 2009
LUPIN LTD	EQ 55MG BASE	A091424 002	Nov 30, 2011
MYLAN PHARMS INC	EQ 45MG BASE	A090911 001	Jul 20, 2010
	EQ 80MG BASE	A203443 002	Aug 22, 2014
	EQ 90MG BASE	A090911 002	Jul 20, 2010
	EQ 105MG BASE	A203443 003	Aug 22, 2014
	EQ 135MG BASE	A090911 003	Jul 20, 2010
SOLODYN			
+ MEDICIS	EQ 45MG BASE **	N050808 001	May 08, 2006
+	EQ 90MG BASE **	N050808 002	May 08, 2006
+	EQ 135MG BASE **	N050808 003	May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924 001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643 001	Apr 09, 1996
COPLY PHARM	2%	A074500 001	May 23, 1996
SIGHT PHARMS	2%	A074743 002	Oct 18, 1996
TEVA	2%	A074589 001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)			
APOTEX INC	2%	A074924 002	Apr 29, 1998
SIGHT PHARMS	2%	A074743 001	Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)			
APOTEX INC	5%	A075839 001	Oct 01, 2001

TABLET;ORAL

LONITEN

+ PHARMACIA AND UPJOHN	2.5MG **	N018154 001	
+	10MG **	N018154 003	

MINODYL

QUANTUM PHARMICS	2.5MG	A072153 001	Jul 13, 1988
	10MG	A071534 001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799 001	Nov 10, 1987
	10MG	A071796 001	Nov 10, 1987
USL PHARMA	2.5MG	A071537 001	Dec 16, 1988

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241 001	Jun 25, 2003
	15MG	A076308 001	Jun 20, 2003
	30MG	A076241 002	Jun 25, 2003
	30MG	A076308 002	Jun 20, 2003
	45MG	A076241 003	Jun 25, 2003
	45MG	A076308 003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336 001	Jun 20, 2003
	30MG	A076336 002	Jun 20, 2003
	45MG	A076336 003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244 001	Dec 22, 2003
	30MG	A076244 002	Dec 22, 2003
	45MG	A076244 003	Dec 22, 2003
MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003
	30MG	A076176 002	Jun 19, 2003
	45MG	A076176 003	Jun 19, 2003
ROXANE	15MG	A076270 001	Jun 19, 2003
	30MG	A076270 002	Jun 19, 2003
	45MG	A076270 003	Jun 19, 2003
UPSHER-SMITH LABS	15MG	A076189 001	Jun 19, 2003
	30MG	A076189 002	Jun 19, 2003
	45MG	A076189 003	Jun 19, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MIRTAZAPINETABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689 001	Aug 31, 2005
	15MG	A077959 001	Feb 14, 2011
	30MG	A076689 002	Aug 31, 2005
	30MG	A077959 002	Feb 14, 2011
	45MG	A076689 003	Aug 31, 2005
	45MG	A077959 003	Feb 14, 2011

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106 001	Nov 29, 1995
MITOZYTREX			
+ SUPERGEN	5MG/VIAL **	N050763 001	Nov 14, 2002
MUTAMYCIN			
+ BRISTOL	5MG/VIAL	N050450 001	
+	20MG/VIAL	N050450 002	
BRISTOL MYERS	5MG/VIAL	A062336 001	
	20MG/VIAL	A062336 002	
	40MG/VIAL	A062336 003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008
NOVANTRONE			
EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987
+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297 002	Dec 23, 1987
+	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297 003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992

MIVACURIUM CHLORIDE

MYLAN LABS LTD
SOLUTION; INTRAVENOUS

MIVACRON			
+ ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098 001	Jan 22, 1992

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIVASC

UCB INC	7.5MG **	N020312 001	Apr 19, 1995
	15MG **	N020312 002	Apr 19, 1995

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

+ ENDO PHARMS	5MG **	N017111 001	
+	10MG **	N017111 002	
+	25MG **	N017111 003	

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS	20MG/ML	N017938 001	
-------------	---------	-------------	--

TABLET; ORAL

MOBAN

+ ENDO PHARMS	5MG **	N017111 004	
+	10MG **	N017111 005	
+	25MG **	N017111 006	
+	50MG **	N017111 007	
+	100MG **	N017111 008	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOMETASONE FUROATE

CREAM;TOPICAL

ELOCON

MERCCK SHARP DOHME 0.1%

N019625 001 May 06, 1987

OINTMENT;TOPICAL

MOMETASONE FUROATE

TARO 0.1%

A076624 001 Dec 03, 2004

MONOBENZONE

CREAM;TOPICAL

BENOQUIN

VALEANT PHARM INTL 20%

N008173 003

MONOCTANOIN

LIQUID;PERFUSION, BILIARY

MOCTANIN

ETHITEK 100%

N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDE

TABLET;ORAL

ETHMOZINE

SHIRE 200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

KING PHARMS LLC 30MG

N021260 001 Mar 20, 2002

45MG

N021260 005 Dec 18, 2008

60MG

N021260 002 Mar 20, 2002

75MG

N021260 006 Dec 18, 2008

90MG

N021260 003 Mar 20, 2002

120MG

N021260 004 Mar 20, 2002

INJECTABLE;INJECTION

MORPHINE SULFATE

+

HOSPIRA INC 15MG/ML

N202515 005 Nov 14, 2011

ICU MEDICAL INC 0.5MG/ML

N019917 001 Oct 30, 1992

SPECGX LLC 1MG/ML

N020631 001 Jul 03, 1996

2MG/ML

N020631 002 Jul 03, 1996

WATSON LABS 0.5MG/ML

A073373 001 Sep 30, 1991

0.5MG/ML

A073375 001 Sep 30, 1991

1MG/ML

A073374 001 Sep 30, 1991

1MG/ML

A073376 001 Sep 30, 1991

INJECTABLE, LIPOSOMAL;EPIDURAL

DEPODUR

PACIRA PHARMS INC 10MG/ML (10MG/ML)

N021671 001 May 18, 2004

15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004

20MG/2ML (10MG/ML)

N021671 003 May 18, 2004

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

WATSON LABS 100MG

A075656 001 Jan 30, 2001

ORAMORPH SR

XANODYNE PHARMS INC 15MG

N019977 004 Nov 23, 1994

30MG

N019977 001 Aug 15, 1991

60MG

N019977 002 Aug 15, 1991

100MG

N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE;INJECTION

MOXAM

LILLY EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 400MG/250ML (1.6MG/ML) N021277 001 Nov 30, 2001

MUPIROCIIN

OINTMENT;TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE 2% ** N050591 001 Dec 31, 1987

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD 250MG A091315 001 Oct 27, 2011

JUBILANT CADISTA 250MG A090762 001 Dec 15, 2014

ZYDUS PHARMS USA INC 250MG A065433 001 May 04, 2009

TABLET;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD 500MG A090464 001 Sep 13, 2010

JUBILANT CADISTA 500MG A090661 001 Dec 15, 2014

ZYDUS PHARMS USA INC 500MG A065477 001 May 04, 2009

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLBY PHARM 750MG A075179 001 Jun 06, 2000

OXFORD PHARMS 500MG A079093 001 Feb 27, 2009

750MG A079093 002 Feb 27, 2009

SANDOZ 500MG A075590 001 Feb 25, 2002

750MG A075590 002 Feb 25, 2002

SCIEGEN PHARMS INC 500MG A078420 001 Sep 24, 2008

750MG A078420 002 Sep 24, 2008

RELAFEN

+ SMITHKLINE BEECHAM 500MG ** N019583 001 Dec 24, 1991

+ 750MG ** N019583 002 Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

US WORLDMEDS LLC 120MG N018063 003

160MG N018063 004

NADOLOL

IVAX SUB TEVA PHARMS 120MG A074255 002 Jan 24, 1996

160MG A074255 003 Jan 24, 1996

TEVA PHARMS 80MG A074368 001 Aug 31, 1994

120MG A074368 002 Aug 31, 1994

160MG A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE N050111 001

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE/5ML N050199 001

INJECTABLE;INJECTION

NAFCILLIN SODIUM

APOTHECON EQ 500MG BASE/VIAL A061984 001

EQ 1GM BASE/VIAL A061984 002

EQ 2GM BASE/VIAL A061984 003

EQ 4GM BASE/VIAL A061984 005

SANDOZ EQ 500MG BASE/VIAL A062527 001 Aug 02, 1984

WATSON LABS INC EQ 500MG BASE/VIAL A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL A063008 001 Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE EQ 500MG BASE/VIAL A061999 001

EQ 1GM BASE/VIAL A061999 002

EQ 1GM BASE/VIAL A062755 001 Dec 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAFCILLIN SODIUMINJECTABLE; INJECTION
NALLPEN

EQ 2GM BASE/VIAL	A061999	003	
EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
EQ 10GM BASE/VIAL	A061999	004	

UNIPEN

WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320	001	
	EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320	003	
+	EQ 4GM BASE/VIAL **	N050320	004	
+	EQ 10GM BASE/VIAL **	N050320	005	
+	EQ 20GM BASE/VIAL **	N050320	006	

UNIPEN IN PLASTIC CONTAINER

+	WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002
---	--------------	---------------------	---------	-----

TABLET; ORAL

UNIPEN

WYETH AYERST	EQ 500MG BASE	N050462	001	
--------------	---------------	---------	-----	--

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
BARR	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989

NUBAIN

+	PAR PHARM INC	10MG/ML **	N018024	001
+		20MG/ML **	N018024	002
				May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US	250MG/5ML	N017430	001	
-------------------	-----------	---------	-----	--

TABLET; ORAL

NALIDIXIC ACID

SUN PHARM INDUSTRIES	250MG	A070270	001	Jun 29, 1988
	500MG	A070271	001	Jun 29, 1988
	1GM	A070272	001	Jun 29, 1988
WATSON LABS	250MG	A071936	001	Jun 29, 1988
	500MG	A072061	001	Jun 29, 1988
	1GM	A071919	001	Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US	250MG	N014214	002	
	500MG	N014214	004	
	1GM	N014214	005	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML **	N020459	001
+		EQ 1MG BASE/ML **	N020459	002
				Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

	0.4MG/ML	A070190 001	Sep 24, 1986
	0.4MG/ML	A070191 001	Sep 24, 1986
NALOXONE HYDROCHLORIDE			
ABRAXIS PHARM	0.02MG/ML	A070648 001	Nov 17, 1986
	0.02MG/ML	A070661 001	Nov 17, 1986
	0.4MG/ML	A070649 001	Nov 17, 1986
	1MG/ML	A071604 001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081 001	Apr 11, 1989
EUROHLTH INTL SARI	0.02MG/ML	A071272 001	May 24, 1988
	1MG/ML	A071273 001	May 24, 1988
	1MG/ML	A071274 001	May 24, 1988
	1MG/ML	A071287 001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171 001	Sep 24, 1986
	0.02MG/ML	A070252 001	Jan 16, 1987
	0.02MG/ML	A070253 001	Jan 16, 1987
	0.4MG/ML	A070255 001	Jan 07, 1987
IGI LABS INC	0.02MG/ML	A072082 001	Apr 11, 1989
	0.02MG/ML	A072083 001	Apr 11, 1989
	0.02MG/ML	A072084 001	Apr 11, 1989
	0.02MG/ML	A072085 001	Apr 11, 1989
	0.4MG/ML	A072086 001	Apr 11, 1989
	0.4MG/ML	A072087 001	Apr 11, 1989
	0.4MG/ML	A072088 001	Apr 11, 1989
	0.4MG/ML	A072089 001	Apr 11, 1989
	0.4MG/ML	A072090 001	Apr 11, 1989
	1MG/ML	A072091 001	Apr 11, 1989
	1MG/ML	A072092 001	Apr 11, 1989
	1MG/ML	A072093 001	Apr 11, 1989
INTL MEDICATION	0.4MG/ML	A070417 001	Sep 24, 1986
	1MG/ML	A072115 001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811 001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671 001	Nov 17, 1987
	0.4MG/ML	A071681 001	Nov 17, 1987
	0.4MG/ML	A071682 001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672 001	Nov 17, 1987
	0.4MG/ML	A071683 001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339 001	Nov 18, 1987
NARCAN			
+	ADAPT	0.02MG/ML **	N016636 002
+		0.4MG/ML **	N016636 001
+		1MG/ML **	N016636 003
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083 001
		1MG/ML	A071084 001
		1MG/ML	A071311 001
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS			
EVZIO			
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787 001
Apr 03, 2014			

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

+	PURDUE PHARMA LP	5MG; 10MG	N205777 001	Jul 23, 2014
+		10MG; 20MG	N205777 002	Jul 23, 2014
+		20MG; 40MG	N205777 003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

	SANOFT AVENTIS US	EQ 0.5MG BASE; EQ 50MG BASE **	N018733 001	Dec 16, 1982
--	-------------------	--------------------------------	-------------	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

	SANDOZ	50MG	A075434 001	Mar 08, 2000
REVIA				
	TEVA WOMENS	50MG	N018932 001	Nov 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROXYCA ER

PFIZER INC	1.2MG;10MG	N207621 001	Aug 19, 2016
	2.4MG;20MG	N207621 002	Aug 19, 2016
	3.6MG;30MG	N207621 003	Aug 19, 2016
	4.8MG;40MG	N207621 004	Aug 19, 2016
	7.2MG;60MG	N207621 005	Aug 19, 2016
	9.6MG;80MG	N207621 006	Aug 19, 2016

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ASPEN GLOBAL INC	50MG/ML	N013132 001	Jun 12, 1986
	100MG/ML	N013132 002	Jun 12, 1986
+	200MG/ML **	N013132 003	Jun 12, 1986
NANDROLONE DECANOATE			
ABRAXIS PHARM	100MG/ML	A088290 001	Oct 03, 1983
	200MG/ML	A088317 001	Oct 14, 1983
AKORN	100MG/ML	A087519 001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385 001	Jan 13, 1984
	50MG/ML	A087598 001	Oct 06, 1983
	50MG/ML	A088554 001	Feb 10, 1986
	100MG/ML	A086598 001	Jan 13, 1984
	100MG/ML	A087599 001	Oct 06, 1983
	200MG/ML	A088128 001	Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC	25MG/ML	N011891 001	
	50MG/ML	N011891 002	
NANDROLONE PHENPROPIONATE			
WATSON LABS	25MG/ML	A086386 001	Jun 17, 1983
	50MG/ML	A087488 001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

ALLERGAN	0.1% **	A080248 001	
NAFAZAIR			
BAUSCH AND LOMB	0.1%	A040073 001	May 25, 1994
PHARMAFAIR	0.1%	A088101 001	Apr 15, 1983
NAPHCN FORTE			
ALCON	0.1%	A080229 001	
OPCON			
BAUSCH AND LOMB	0.1%	A087506 001	
VASOCON			
NOVARTIS	0.1%	A080235 002	Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

CHARTWELL MOLECULES	250MG	A074410 001	Apr 28, 1995
	375MG	A074410 002	Apr 28, 1995
	500MG	A074410 003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105 001	Dec 21, 1993
	375MG	A074105 002	Dec 21, 1993
	500MG	A074105 003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110 001	Oct 30, 1992
	375MG	A074110 002	Oct 30, 1992
	500MG	A074110 003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494 001	Jan 14, 2004
	375MG	A076494 002	Jan 14, 2004
	500MG	A076494 003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111 001	Feb 28, 1995
	375MG	A074111 002	Feb 28, 1995
	500MG	A074111 003	Feb 28, 1995
PLIVA	250MG	A074182 001	Jun 27, 1996
	375MG	A074182 002	Jun 27, 1996
	500MG	A074182 003	Jun 27, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPROXEN

TABLET; ORAL

NAPROXEN

PUREPAC PHARM	250MG	A074263 001	Dec 21, 1993
	375MG	A074263 002	Dec 21, 1993
	500MG	A074263 003	Dec 21, 1993
ROXANE	250MG	A074211 001	Feb 28, 1994
	375MG	A074211 002	Feb 28, 1994
	500MG	A074211 003	Feb 28, 1994
SANDOZ	250MG	A074140 001	Dec 21, 1993
	375MG	A074140 002	Dec 21, 1993
	500MG	A074140 003	Dec 21, 1993
TEVA	250MG	A074129 001	Dec 21, 1993
	250MG	A074216 001	Apr 11, 1996
	375MG	A074129 002	Dec 21, 1993
	375MG	A074216 002	Apr 11, 1996
	500MG	A074129 003	Dec 21, 1993
	500MG	A074216 003	Apr 11, 1996
TEVA PHARMS	250MG	A074207 001	Dec 21, 1993
	375MG	A074207 002	Dec 21, 1993
	500MG	A074207 003	Dec 21, 1993
WATSON LABS	250MG	A074457 001	May 31, 1995
	375MG	A074457 002	May 31, 1995
	500MG	A074457 003	May 31, 1995
WATSON LABS TEVA	250MG	A074163 001	Feb 10, 1995
	375MG	A074163 002	Feb 10, 1995
	500MG	A074163 003	Feb 10, 1995

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998
	500MG	A074936 002	Feb 24, 1998
MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001
	500MG	A075390 002	Apr 19, 2001
SANDOZ	375MG	A075061 001	Feb 18, 1998
	500MG	A075061 002	Feb 18, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
CONTRACT PHARMACAL HAMILTON PHARMS	EQ 200MG BASE	A074789 001	Feb 27, 1997
	EQ 250MG BASE	A074106 001	Aug 31, 1993
HIKMA	EQ 500MG BASE	A074106 002	Aug 31, 1993
	EQ 250MG BASE	A074480 002	Feb 18, 1998
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A074480 001	May 14, 1996
	EQ 250MG BASE	A074230 001	Mar 14, 1995
MYLAN	EQ 500MG BASE	A074230 002	Mar 14, 1995
	EQ 250MG BASE	A074367 001	Aug 31, 1994
PLIVA	EQ 500MG BASE	A074367 002	Aug 31, 1994
	EQ 250MG BASE	A074242 001	Jun 20, 1996
PUREPAC PHARM	EQ 500MG BASE	A074242 002	Jun 20, 1996
	EQ 250MG BASE	A074319 001	Mar 20, 1995
ROXANE	EQ 500MG BASE	A074319 002	Mar 20, 1995
	EQ 250MG BASE	A074257 001	Dec 21, 1993
SANDOZ	EQ 500MG BASE	A074257 002	Dec 21, 1993
	EQ 200MG BASE	A074646 001	Jan 13, 1997
	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741 001	Jun 24, 2015
	EQ 5MG BASE	A203741 002	Jun 24, 2015
	EQ 10MG BASE	A203741 003	Jun 24, 2015
	EQ 20MG BASE	A203741 004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659 001	Apr 16, 2015
	EQ 5MG BASE	A203659 002	Apr 16, 2015
	EQ 10MG BASE	A203659 003	Apr 16, 2015
	EQ 20MG BASE	A203659 004	Apr 16, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821 001	May 25, 2017
	EQ 5MG BASE	A203821 002	May 25, 2017
	EQ 10MG BASE	A203821 003	May 25, 2017
	EQ 20MG BASE	A203821 004	May 25, 2017
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828 001	Jul 29, 2015
	EQ 5MG BASE	A203828 002	Jul 29, 2015
	EQ 10MG BASE	A203828 003	Jul 29, 2015
	EQ 20MG BASE	A203828 004	Jul 29, 2015
WATSON LABS INC	EQ 2.5MG BASE	A203683 001	Nov 27, 2015
	EQ 5MG BASE	A203683 002	Nov 27, 2015
	EQ 10MG BASE	A203683 003	Nov 27, 2015
	EQ 20MG BASE	A203683 004	Nov 27, 2015

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS LLC	1.75MG/INH	N019660 001	Dec 30, 1992
-----------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
	100MG	A076309 002	Sep 16, 2003
	150MG	A076309 003	Sep 16, 2003
	200MG	A076309 004	Sep 16, 2003
	250MG	A076309 005	Sep 16, 2003
IDT AUSTRALIA LTD	50MG	A076072 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
+	BRISTOL MYERS SQUIBB 50MG **	N020152 001	Dec 22, 1994
+	100MG **	N020152 002	Dec 22, 1994
+	150MG **	N020152 003	Dec 22, 1994
+	200MG **	N020152 004	Dec 22, 1994
+	250MG **	N020152 005	Dec 22, 1994
+	300MG **	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
----------------	-----------------------	-------------	--------------

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS	100%	A061579 001	
--------------	------	-------------	--

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
----------------------	--------------------	-------------	--

NEO-FRADIN

X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002
--------------	--------------------	-------------	--------------

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
----------------------	---------------	-------------	--

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475 001	
--------	---------------	-------------	--

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365 001	
----------------------	-------	-------------	--

LANNETT	500MG	A060607 001	
---------	-------	-------------	--

LILLY	500MG	A060385 001	
-------	-------	-------------	--

ROXANE	500MG	A062173 001	
--------	-------	-------------	--

SANDOZ	500MG	A061586 001	
--------	-------	-------------	--

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985
-----------------	----------------------------------	-------------	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	
-------	----------------------------------	-------------	--

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
-------	----------------------------------	-------------	--------------

	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	
--	----------------------------------	-------------	--

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	
----------	------------------------------------	-------------	--

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
----------------------	------------------------	-------------	--

	EQ 3.5MG BASE/GM;0.5%	A061039 001	
--	-----------------------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	
----------------------	------------------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCCK

EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTRES A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062600 001 Jul 21, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTRES A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062608 001 May 23, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062607 001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING

EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

NIACIN

CAPSULE;ORAL

WAMPOCAP

MEDPOINTE PHARM HLC

500MG

N011073 003

TABLET;ORAL

NIACIN

EVERYLIFE

500MG

A083203 001

HALSEY

500MG

A083453 001

HIKMA PHARMS

500MG

A083718 001

IMPAX LABS

500MG

A083115 001

IVAX SUB TEVA PHARMS

500MG

A083180 001

MK LABS

500MG

A083525 001

PUREPAC PHARM

500MG

A083271 001

SANDOZ

500MG

A083306 001

TABLICAPS

500MG

A084237 001

WATSON LABS

500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

NICOLAR

SANOFI AVENTIS US

500MG

A083823 001

TABLET, EXTENDED RELEASE;ORAL

NIASPAN

ABBVIE

375MG

N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE

375MG;500MG;750MG

N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL

TPN

INTL MINERALS

15MG/5ML;3.75MG/5ML;600MG/5ML

N008378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

CHIESI USA INC

20MG **

N019488 001 Dec 21, 1988

30MG **

N019488 002 Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

WATSON LABS

20MG

A074670 001 Oct 28, 1996

30MG

A074670 002 Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

+

CHIESI USA INC

30MG **

N020005 001 Feb 21, 1992

+

45MG **

N020005 002 Feb 21, 1992

+

60MG **

N020005 003 Feb 21, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NICLOSAMIDE

TABLET, CHEWABLE;ORAL

NICLOCIDE

BAYER PHARMS

500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTROL

MCNEIL CONS

15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA

11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS

EQ 2MG BASE

A076880 001 Feb 18, 2009

EQ 4MG BASE

A077850 001 Feb 18, 2009

NIFEDIPINE

CAPSULE;ORAL

ADALAT

BAYER PHARMS

10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ

10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA

10MG

A072651 001 Feb 19, 1992

PROCARDIA

+ PFIZER

20MG **

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

MARTEC USA LLC

90MG

A075414 003 Mar 23, 2004

MYLAN

30MG

A075108 001 Dec 17, 1999

MYLAN LABS LTD

30MG

A090602 001 Sep 13, 2010

60MG

A090602 002 Sep 13, 2010

90MG

A090602 003 Sep 13, 2010

NILUTAMIDE

TABLET;ORAL

NILANDRON

CONCORDIA PHARMS INC 50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE;ORAL

NIMOTOP

+ BAYER PHARMS

30MG **

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

+ COVIS PHARMA BV

10MG **

N020356 001 Feb 02, 1995

+

20MG **

N020356 002 Feb 02, 1995

+

25.5MG **

N020356 006 Jan 02, 2008

+

30MG **

N020356 003 Feb 02, 1995

+

40MG **

N020356 004 Feb 02, 1995

NITRIC OXIDE

GAS;INHALATION

INOMAX

+ MALLINCKRODT HOSP

100PPM **

N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

100MG

A084326 002

TABLET;ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROFURANTOIN

TABLET; ORAL

FURALAN

	100MG	A080017	002
NITROFURANTOIN			
ELKINS SINN	50MG	A080003	001
	100MG	A080003	002
IVAX SUB TEVA PHARMS	50MG	A080078	002
	100MG	A080078	001
SANDOZ	50MG	A080043	001
	100MG	A080043	002
WATSON LABS	50MG	A080447	001
	50MG	A085797	001
	100MG	A080447	002
	100MG	A085796	001
WHITEWORTH TOWN PLSN	100MG	A084085	002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001
--------------------	--------------------	---------	-----

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

MYLAN	100MG	A074967	002	Jul 09, 1997
SANDOZ	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005
------------------	-----------	---------	-----	--------------

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE	0.2%	A083789	001
-------	------	---------	-----

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL	0.2%	N017343	001
----------------	------	---------	-----

OINTMENT; TOPICAL

FURACIN

SHIRE	0.2%	N005795	001
-------	------	---------	-----

NITROFURAZONE

AMBIX	0.2%	A086077	001
LANNETT	0.2%	A084393	001
PERRIGO NEW YORK	0.2%	A084968	001
TARO	0.2%	A086156	001
WENDT	0.2%	A086766	001

POWDER; TOPICAL

FURACIN

SHIRE	0.2%	A083791	001
-------	------	---------	-----

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001
WENDT	0.2%	A087081	001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
--------------	-------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

KREMERS URBAN PHARMS	0.2MG/HR	A075115 001	Aug 10, 2004
	0.4MG/HR	A075115 002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992 004	Nov 12, 1999
	0.2MG/HR	A074992 003	Nov 12, 1999
	0.4MG/HR	A074992 002	Nov 12, 1999
	0.6MG/HR	A074992 001	Nov 12, 1999

TRANSDERM-NITRO

+	NOVARTIS	0.1MG/HR **	N020144 001	Feb 27, 1996
+		0.2MG/HR **	N020144 002	Feb 27, 1996
+		0.4MG/HR **	N020144 003	Feb 27, 1996
+		0.6MG/HR **	N020144 004	Feb 27, 1996
+		0.8MG/HR **	N020144 005	Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP	5MG/ML	N018672 002	Aug 30, 1983
--------------	--------	-------------	--------------

NITRO-BID

SANOFI AVENTIS US	5MG/ML	N018621 001	Jan 05, 1982
	10MG/ML	A071159 001	Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077 001	Dec 13, 1985	
	5MG/ML	A071203 001	May 08, 1987	
+	HOSPIRA	5MG/ML **	N018531 001	
	INTL MEDICATION	5MG/ML	A070026 001	Sep 10, 1985
	LUITPOLD	5MG/ML	A071492 001	May 24, 1988
	SMITH AND NEPHEW	5MG/ML	A070633 001	Jun 19, 1986
	5MG/ML	A070634 001	Jun 19, 1986	

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083 001	Oct 26, 1994
---------	----------	-------------	--------------

NITROL

RORER	0.8MG/ML	N018774 001	Jan 19, 1983
-------	----------	-------------	--------------

NITRONAL

POHL BOSKAMP	1MG/ML	N018672 001	Aug 30, 1983
--------------	--------	-------------	--------------

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588 001	
	5MG/ML	A070863 001	Jan 08, 1987
	5MG/ML	N018588 002	Dec 23, 1983
	10MG/ML	A070871 001	Jan 08, 1987
	10MG/ML	A070872 001	Jan 08, 1987

TRIDIL

HOSPIRA	0.5MG/ML	N018537 002	Jun 16, 1983
	5MG/ML	N018537 001	

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988
	300MG	N019508 002	Apr 12, 1988

NIZATIDINE

ANI PHARMS INC	150MG	A075461 001	Jul 08, 2002
	300MG	A075461 002	Jul 08, 2002
APOTEX INC	150MG	A076383 001	Jan 23, 2003
	300MG	A076383 002	Jan 23, 2003
MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002
	300MG	A075934 002	Jul 09, 2002

SOLUTION; ORAL

AXID

+	BRAINTREE	15MG/ML **	N021494 001	May 25, 2004
---	-----------	------------	-------------	--------------

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS	12.5%	N014349 002	
----------------	-------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM

EQ 1MG BASE/ML

A040522 001 Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK

EQ 0.033MG BASE/ML; 2%; 0.4%

N008592 003

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS

5MG

N010895 002

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

TABLET; ORAL

NOROXIN

+ MERCK

400MG **

N019384 002 Oct 31, 1986

NORGESTREL

TABLET; ORAL

OPILL

+ LABORATOIRE HRA

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

AUROLIFE PHARMA LLC

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074835 004 Jun 30, 1997

IDT AUSTRALIA LTD

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 75MG BASE

A074054 004 Dec 31, 1992

MYLAN

EQ 10MG BASE

A074234 001 Jul 26, 1993

EQ 25MG BASE

A074234 002 Jul 26, 1993

EQ 50MG BASE

A074234 003 Jul 26, 1993

EQ 75MG BASE

A074234 004 Jul 26, 1993

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

SOLUTION; ORAL

AVENTYL

+ RANBAXY

EQ 10MG BASE/5ML **

N014685 001

PAMELOR

SPECGX LLC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NYSTATIN

CREAM; TOPICAL				
NYSTATIN				
TARO	100,000 UNITS/GM	A062457	001	Jul 28, 1983
LOTION; TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233	001	
OINTMENT; TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060571	001	
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731	001	Sep 22, 1986
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444	001	
PASTILLE; ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987
POWDER; ORAL				
BARSTATIN 100				
BARLAN	100%	A062489	001	Apr 27, 1988
NILSTAT				
+ DAVA PHARMS INC	100% **	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK LLC	100%	A062613	001	Nov 26, 1985
POWDER; TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060578	001	
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006
SUPPOSITORY; VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478	001	
SUSPENSION; ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001	
NILSTAT				
+ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001	
NYSTATIN				
ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
G AND W LABS INC	100,000 UNITS/ML	A062776	001	Dec 17, 1987
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET; ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET; VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NYSTATIN

TABLET;VAGINAL

NYSTATIN

TEVA	100,000 UNITS	A062502 001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176 001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCO-TRIA CET II

TEVA	100,000 UNITS/GM;0.1%	A061954 002	Sep 20, 1985
------	-----------------------	-------------	--------------

MYCOLOG-II

DEL COR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576 002	May 01, 1985
MYLAN PHARMS INC	100,000 UNITS/GM;0.1% **	A062606 001	May 15, 1985

MYTRES F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597 001	Oct 08, 1985
-------------	-----------------------	-------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010 001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186 002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657 001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347 001	Mar 30, 1987

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596 001	Oct 08, 1985
------------	-----------------------	-------------	--------------

OINTMENT;TOPICAL

MYCO-TRIA CET II

TEVA	100,000 UNITS/GM;0.1%	A062045 002	Nov 26, 1985
------	-----------------------	-------------	--------------

MYCOLOG-II

MYLAN PHARMS INC	100,000 UNITS/GM;0.1% **	A060572 001	Jun 28, 1985
------------------	--------------------------	-------------	--------------

MYTRES F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601 001	Oct 09, 1985
-------------	-----------------------	-------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280 002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656 001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603 001	Oct 09, 1985
------------	-----------------------	-------------	--------------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329 001	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077329 002	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077330 001	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077329 003	Mar 04, 2008
	EQ 1MG BASE/ML	A077331 001	Mar 04, 2008
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011
	EQ 1MG BASE/ML	A090986 002	May 11, 2011

OCTREOTIDE ACETATE PRESERVATIVE FREE

WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985 002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985 003	May 11, 2011

OFLOXACIN

INJECTABLE;INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087 002	Mar 31, 1992
	40MG/ML	N020087 003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087 001	Mar 31, 1992
--------------------	-------------	-------------	--------------

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087 004	Mar 31, 1992
	400MG/100ML	N020087 005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762 001	Jan 16, 2002
---------	---------	-------------	--------------

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

APOTEX INC	0.3%	A076513 001	May 14, 2004
SANDOZ	0.3%	A076848 001	Nov 25, 2008

SOLUTION/DROPS;OTIC

FLOXIN OTIC

+	DAIICHI	0.3% **	N020799 001	Dec 16, 1997
---	---------	---------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OFLOXACIN

TABLET; ORAL

FLOXIN

JANSSEN PHARMS	200MG **	N019735 001	Dec 28, 1990
	300MG **	N019735 002	Dec 28, 1990
	400MG **	N019735 003	Dec 28, 1990

OFLOXACIN

LARKEN LABS	200MG	A076093 001	Sep 02, 2003
	300MG	A076093 002	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003
	300MG	A076220 002	Sep 02, 2003
	400MG	A076220 003	Sep 02, 2003

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AJANTA PHARMA LTD	2.5MG	A206711 001	Aug 30, 2016
	5MG	A206711 002	Aug 30, 2016
	7.5MG	A206711 003	Aug 30, 2016
	10MG	A206711 004	Aug 30, 2016
	15MG	A206711 005	Aug 30, 2016
	20MG	A206711 006	Aug 30, 2016
MYLAN PHARMS INC	2.5MG	A076866 001	Apr 23, 2012
	5MG	A076866 002	Apr 23, 2012
	7.5MG	A076866 003	Apr 23, 2012
	10MG	A076866 004	Apr 23, 2012
	15MG	A076866 005	Apr 23, 2012
	20MG	A076866 006	Apr 23, 2012

OLIVE OIL; SOYBEAN OIL

INJECTABLE; INJECTION

CLINOLIPID 20%

+ BAXTER HLTHCARE CORP	16%(160GM/1000ML); 4% (40GM/1000ML)	N204508 001	Oct 03, 2013
------------------------	-------------------------------------	-------------	--------------

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

+ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977 001	Apr 23, 2014
------------	--	-------------	--------------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

+ ASTRAZENECA PHARMS	10MG **	N019810 003	Oct 05, 1995
+	20MG **	N019810 001	Sep 14, 1989
+	40MG **	N019810 002	Jan 15, 1998

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

CHARTWELL MOLECULES	4MG	A076506 001	Dec 26, 2006
	8MG	A076506 002	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006
NESHER PHARMS	4MG	A077717 001	Jun 25, 2007
	8MG	A077717 002	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
	EQ 2MG BASE/ML	A090883 001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
MYLAN LABS LTD	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007
SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172 001	Dec 26, 2006
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER			
HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006
MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008

ZOFRAN

+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML **	N020007	001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER				
+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403	001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE				
+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML **	N020007	003	Dec 10, 1993

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007
	EQ 8MG BASE	A077303	002	Jun 25, 2007
	EQ 24MG BASE	A077303	004	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007
	EQ 8MG BASE	A077545	002	Sep 06, 2007
	EQ 24MG BASE	A077545	003	Sep 06, 2007
TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
	EQ 8MG BASE	A077729	002	Mar 28, 2011
	EQ 24MG BASE	A077729	003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

TELIGENT	30MG/ML	N013055	001	
----------	---------	---------	-----	--

ORPHENADRINE CITRATE

WATSON LABS	30MG/ML	A087062	001	
-------------	---------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

+ MEDICIS	100MG	N012157	001	
-----------	-------	---------	-----	--

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M	50MG	N010653	001	
----	------	---------	-----	--

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
-------	-----------------	---------	-----	--------------

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	

OXACILLIN SODIUM

ANI PHARMS INC	EQ 250MG BASE	A062222	001	
	EQ 500MG BASE	A062222	002	
APOTHECON	EQ 250MG BASE	A061450	002	
	EQ 500MG BASE	A061450	001	

PROSTAPHLIN

APOTHECON	EQ 500MG BASE	N050118	002	
-----------	---------------	---------	-----	--

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321	001	
-----------------	-------------------	---------	-----	--

OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE/5ML	A061457	001	
TEVA	EQ 250MG BASE/5ML	A062252	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXACILLIN SODIUM

FOR SOLUTION; ORAL

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL **

A061334 009 Mar 26, 1982

EQ 1GM BASE/VIAL **

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL **

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL **

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL **

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL **

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL **

A061334 010

OXACILLIN SODIUM

+ APOTHECON

EQ 250MG BASE/VIAL **

N050195 001

+

EQ 500MG BASE/VIAL **

N050195 002

+

EQ 1GM BASE/VIAL **

N050195 003

+

EQ 2GM BASE/VIAL **

N050195 004

+

EQ 4GM BASE/VIAL **

N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

MYLAN LABS LTD

EQ 1GM BASE/VIAL

A091486 001 Aug 25, 2014

EQ 2GM BASE/VIAL

A091486 002 Aug 25, 2014

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

WATSON LABS INC

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

+ SANOFI AVENTIS US

50MG/VIAL **

N021492 001 Aug 09, 2002

+

100MG/VIAL **

N021492 002 Aug 09, 2002

+

200MG/40ML (5MG/ML) **

N021759 003 Nov 17, 2006

OXALIPLATIN

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

SANDOZ INC

50MG/10ML (5MG/ML)

A078812 001 Aug 07, 2009

100MG/20ML (5MG/ML)

A078812 002 Aug 07, 2009

OXAMNIOUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXAPROZIN

TABLET;ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET;ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002
-----------	-------	---------	-----	--------------

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
ANDA REPOSITORY	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG **	N015539	002	
	15MG **	N015539	004	
	30MG **	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET;ORAL

OXAZEPAM

PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG **	N015539	008	
--------------------	---------	---------	-----	--

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010
	300MG	A090239	002	Jan 25, 2010
	600MG	A090239	003	Jan 25, 2010

OXPRENOLOL HYDROCHLORIDE

CAPSULE;ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION;ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
-------------	-----------	---------	-----	--------------

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
--------------	-----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXTRIPHYLLINE

SYRUP;ORAL

CHOLEDYL

PARKE DAVIS 50MG/5ML

N009268 011

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE 50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE;ORAL

CHOLEDYL

PARKE DAVIS 100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS 100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

WARNER CHILCOTT LLC 600MG

A086742 001

OXYBUTYNIN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+ ALLERGAN SALES LLC 3%

N202513 001 Dec 07, 2011

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

DITROPAN

+ ORTHO MCNEIL JANSSEN 5MG/5ML **

N018211 001

OXYBUTYNIN CHLORIDE

APOTEX INC 5MG/5ML

A074997 001 Oct 15, 1997

MIKART 5MG/5ML

A075039 001 Jan 29, 1999

TABLET;ORAL

DITROPAN

+ JANSSEN PHARMS 5MG **

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS 5MG

A072296 001 Dec 08, 1988

USL PHARMA 5MG

A070746 001 Mar 10, 1988

WATSON LABS 5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROXICODONE

ROXANE 10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC 0.025%

N018471 001 May 30, 1986

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

OPANA

+ ENDO PHARMS 1MG/ML

N011707 002

1.5MG/ML

N011707 001

SUPPOSITORY;RECTAL

NUMORPHAN

ENDO PHARMS 5MG

N011738 004

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

ENDO PHARMS 5MG **

N021610 001 Jun 22, 2006

+ 5MG

N201655 001 Dec 09, 2011

+ 7.5MG **

N021610 005 Feb 29, 2008

+ 7.5MG

N201655 002 Dec 09, 2011

+ 10MG **

N021610 002 Jun 22, 2006

+ 10MG

N201655 003 Dec 09, 2011

+ 15MG **

N021610 006 Feb 29, 2008

+ 15MG

N201655 004 Dec 09, 2011

+ 20MG **

N021610 003 Jun 22, 2006

+ 20MG

N201655 005 Dec 09, 2011

+ 30MG **

N021610 007 Feb 29, 2008

+ 30MG

N201655 006 Dec 09, 2011

+ 40MG **

N021610 004 Jun 22, 2006

+ 40MG

N201655 007 Dec 09, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

PAR PHARM	5MG	A200792 001	Oct 24, 2014
	7.5MG	A200792 002	Oct 24, 2014
	10MG	A200792 003	Oct 24, 2014
	15MG	A200792 004	Oct 24, 2014
	20MG	A200792 005	Oct 24, 2014
	30MG	A200792 006	Oct 24, 2014
	40MG	A200792 007	Oct 24, 2014

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS	100MG	A088399 001	Sep 17, 1984
TANDEARIL			
NOVARTIS	100MG	N012542 004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON

PFIZER	10MG	N011612 001	
--------	------	-------------	--

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL

NOVARTIS	5MG	N008492 002	
----------	-----	-------------	--

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN

PFIZER	250MG	N050287 001	
--------	-------	-------------	--

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL

TERRAMYCIN

PFIZER	EQ 125MG BASE/5ML	A060595 001	
--------	-------------------	-------------	--

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

OXY-KESSO-TETRA

FERRANTE	EQ 250MG BASE	A060179 001	
----------	---------------	-------------	--

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS	EQ 250MG BASE	A060770 001	
IMPAX LABS	EQ 250MG BASE	A060760 001	
PROTER	EQ 250MG BASE	A060869 001	
PUREPAC PHARM	EQ 250MG BASE	A060634 001	

TERRAMYCIN

PFIZER	EQ 125MG BASE	N050286 001	
	EQ 250MG BASE	N050286 002	

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER	EQ 250MG BASE/VIAL	A060586 001	
	EQ 500MG BASE/VIAL	A060586 002	

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841 001	
--------	--------------------------------	-------------	--

TABLET;VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001	
--------	-----------------------------	-------------	--

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008
	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

+ ABBOTT	1USP UNITS/100ML **	N019185 004	Mar 29, 1985
----------	---------------------	-------------	--------------

+ ABBOTT	2USP UNITS/100ML **	N019185 003	Mar 29, 1985
----------	---------------------	-------------	--------------

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

+ ABBOTT	2USP UNITS/100ML **	N019185 002	Mar 29, 1985
----------	---------------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

+ ABBOTT 1USP UNITS/100ML ** N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS 10USP UNITS/ML N018245 001

SOLUTION; NASAL

SYNTOCINON

RTRX 40USP UNITS/ML N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE 6MG/ML A075436 001 Nov 12, 2004

HOSPIRA 6MG/ML A076233 001 Aug 01, 2002

MYLAN 6MG/ML A075278 001 Jan 25, 2002

PLIVA LACHEMA 6MG/ML A077413 001 Mar 12, 2008

TEVA PHARMS USA 6MG/ML A075297 001 Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

+ JANSSEN PHARMS 12MG ** N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

+ HELSINN HLTHCARE EQ 0.5MG BASE ** N022233 001 Aug 22, 2008

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML) N203050 001 Mar 01, 2016

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) N203050 002 Mar 01, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

+ NOVARTIS 30MG/VIAL ** N020036 001 Oct 31, 1991

60MG/VIAL N020036 003 May 06, 1993

90MG/VIAL N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN 30MG/VIAL A075594 001 May 06, 2002

90MG/VIAL A075594 002 May 06, 2002

MN PHARMS 30MG/VIAL A078300 001 Mar 10, 2009

90MG/VIAL A078300 002 Mar 10, 2009

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC 30,000USP UNITS; 8,000USP
UNITS; 30,000USP UNITS N020580 001 Dec 09, 1996PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN 1MG/ML A072058 001 Mar 23, 1988

2MG/ML A072059 001 Mar 23, 1988

2MG/ML A072060 001 Mar 23, 1988

HOSPIRA 2MG/ML A072321 001 Jan 19, 1989

IGI LABS INC 1MG/ML A072210 001 Mar 31, 1988

2MG/ML A072211 001 Mar 31, 1988

2MG/ML A072212 001 Mar 31, 1988

2MG/ML A072213 001 Mar 31, 1988

PAVULON

+ ORGANON USA INC 1MG/ML N017015 002

+ 2MG/ML N017015 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

SUN PHARM INDS LTD	EQ 20MG BASE	A077058 001	Sep 10, 2007
	EQ 40MG BASE	A077058 002	Sep 10, 2007

PARAMETHADIONE

CAPSULE;ORAL

PARADIONE

ABBVIE	150MG	N006800 003	
	300MG	N006800 001	

SOLUTION;ORAL

PARADIONE

ABBVIE	300MG/ML	N006800 002	
--------	----------	-------------	--

PARAMETHASONE ACETATE

TABLET;ORAL

HALDRONE

LILLY	1MG	N012772 005	
	2MG	N012772 006	

PARGYLINE HYDROCHLORIDE

TABLET;ORAL

EUTONYL

ABBOTT	10MG	N013448 002	
	25MG	N013448 003	
	50MG	N013448 004	

PARICALCITOL

CAPSULE;ORAL

ZEMPLAR

+ ABBVIE	4MCG **	N021606 003	May 26, 2005
----------	---------	-------------	--------------

PAROMOMYCIN SULFATE

CAPSULE;ORAL

HUMATIN

KING PFIZER	EQ 250MG BASE	A062310 001	
PARKEDALE	EQ 250MG BASE	A060521 001	

SYRUP;ORAL

HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522 001	
-------------	-------------------	-------------	--

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

+ APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885 001	Oct 09, 1998
+	EQ 20MG BASE **	N020885 002	Oct 09, 1998
+	EQ 30MG BASE **	N020885 003	Oct 09, 1998
+	EQ 40MG BASE **	N020885 004	Oct 09, 1998

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006
------------	------------------	-------------	--------------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004
	EQ 20MG BASE	A075716 002	Mar 08, 2004
	EQ 30MG BASE	A075716 003	Mar 08, 2004
	EQ 40MG BASE	A075716 004	Mar 08, 2004
ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007
	EQ 20MG BASE	A078026 002	Jun 29, 2007
	EQ 30MG BASE	A078026 003	Jun 29, 2007
	EQ 40MG BASE	A078026 004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007
	EQ 20MG BASE	A077082 002	Jun 29, 2007
	EQ 30MG BASE	A077082 003	Jun 29, 2007
	EQ 40MG BASE	A077082 004	Jun 29, 2007
UPSHER-SMITH LABS	EQ 10MG BASE	A075566 001	Mar 08, 2004
	EQ 20MG BASE	A075566 002	Mar 08, 2004
	EQ 30MG BASE	A075566 003	Mar 08, 2004
	EQ 40MG BASE	A075566 004	Mar 08, 2004

PAXIL

APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031 004	Dec 29, 1992
---------------------	--------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

NOVARTIS PHARMS CORP EQ 400MG BASE

N022465 002 Oct 19, 2009

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA EQ 10MG BASE/ML (EQ 10MG BASE/ML)

N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)

N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)

N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)

N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)

N202799 005 Mar 27, 2012

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)

N202799 006 Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN 0.1%

N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT 18.75MG

N016832 001

37.5MG

N016832 002

75MG

N016832 003

PEMOLINE

ACTAVIS ELIZABETH 18.75MG

A075595 001 Feb 28, 2000

37.5MG

A075595 002 Feb 28, 2000

75MG

A075595 003 Feb 28, 2000

MALLINCKRODT 18.75MG

A075726 003 Mar 30, 2001

37.5MG

A075726 002 Mar 30, 2001

75MG

A075726 001 Mar 30, 2001

SANDOZ 18.75MG

A075286 001 Dec 27, 1999

37.5MG

A075286 002 Jun 30, 1999

75MG

A075286 003 Jun 30, 1999

TEVA PHARMS 18.75MG

A075030 003 Feb 22, 2000

37.5MG

A075030 001 Jan 29, 1999

75MG

A075030 002 Jan 29, 1999

VINTAGE PHARMS 18.75MG

A075328 001 Apr 19, 2000

37.5MG

A075328 002 Apr 19, 2000

75MG

A075328 003 Apr 19, 2000

WATSON LABS 18.75MG

A075287 001 Jun 13, 2001

37.5MG

A075287 002 Sep 18, 2000

75MG

A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT 37.5MG

N017703 001

PEMOLINE

ACTAVIS ELIZABETH 37.5MG

A075678 001 Jul 26, 2000

TEVA PHARMS 37.5MG

A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

+ AUXILIUM PHARMS LLC 10MG **

N018976 001 Dec 30, 1987

+ 20MG **

N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON 125MG

N019853 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

SUSPENSION; ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET; ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL **

A065079 001

Aug 30, 2002

WATSON LABS INC

1,000,000 UNITS/VIAL

A062991 001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991 002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991 003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991 004

Sep 13, 1988

PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL **

A060657 001

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

800,000 UNITS

A060781 004

PUREPAC PHARM

200,000 UNITS

A061588 001

250,000 UNITS

A061588 002

400,000 UNITS

A061588 003

TEVA

200,000 UNITS

A060306 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G POTASSIUM

TABLET; ORAL

PENICILLIN G POTASSIUM

	250,000 UNITS	A060306 002
	400,000 UNITS	A060306 003
	500,000 UNITS	A060306 004
WYETH AYERST	200,000 UNITS	A060413 001
	250,000 UNITS	A060413 002
	400,000 UNITS	A060413 003
PENTIDS '200'		
APOTHECON	200,000 UNITS	A062155 001
PENTIDS '250'		
APOTHECON	250,000 UNITS	A062155 002
PENTIDS '400'		
APOTHECON	400,000 UNITS	A060392 004
	400,000 UNITS	A062155 003
PENTIDS '800'		
APOTHECON	800,000 UNITS	A060392 005
	800,000 UNITS	A062155 004
PFIZERPEN G		
PFIZER	50,000 UNITS	A060075 001
	100,000 UNITS	A060075 002
	200,000 UNITS	A060075 003
	250,000 UNITS	A060075 004
	400,000 UNITS	A060075 005
	800,000 UNITS	A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001
PENICILLIN G PROCAINE		
CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
	600,000 UNITS/1.2ML	A060800 002
PARKE DAVIS	300,000 UNITS/ML	A062029 001
PFIZER	300,000 UNITS/VIAL	A060099 001
	1,500,000 UNITS/VIAL	A060099 002
PFIZERPEN-AS		
PFIZER	300,000 UNITS/ML	A060286 001
	600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
COPANOS	5,000,000 UNITS/VIAL	A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS		
PENICILLIN G SODIUM		
WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002 001
-------	-------------	-------------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001
	EQ 250MG BASE/5ML	A062270 002
BETAPEN-VK		
APOTHECON	EQ 125MG BASE/5ML	A061149 001
	EQ 250MG BASE/5ML	A061149 002
LEDERCILLIN VK		
LEDERLE	EQ 125MG BASE/5ML	A060136 001
	EQ 250MG BASE/5ML	A060136 002
PEN-VEE K		
WYETH AYERST	EQ 125MG BASE/5ML	A060007 001
	EQ 250MG BASE/5ML	A060007 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENAPAR-VK		
PARKE DAVIS	EQ 125MG BASE/5ML	A062002 001
	EQ 250MG BASE/5ML	A062002 002
PENICILLIN V POTASSIUM		
AM ANTIBIOTICS		
	EQ 125MG BASE/5ML	A061529 001
	EQ 250MG BASE/5ML	A061529 002
MYLAN	EQ 125MG BASE/5ML	A061624 002
	EQ 250MG BASE/5ML	A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061758 001
	EQ 250MG BASE/5ML	A061758 002
PFIZERPEN VK		
PFIZER	EQ 125MG BASE/5ML	A061815 001
	EQ 250MG BASE/5ML	A061815 002
V-CILLIN K		
LILLY	EQ 125MG BASE/5ML	A060004 001
	EQ 250MG BASE/5ML	A060004 002
VEETIDS		
APOTHECON		
	EQ 125MG BASE/5ML	A061410 001
	EQ 250MG BASE/5ML	A061410 002
VEETIDS '125'		
APOTHECON		
	EQ 125MG BASE/5ML	A061206 001
	EQ 125MG BASE/5ML	A062153 001
VEETIDS '250'		
APOTHECON		
	EQ 250MG BASE/5ML	A061206 002
	EQ 250MG BASE/5ML	A062153 002
TABLET;ORAL		
BEEPEN-VK		
GLAXOSMITHKLINE		
	EQ 250MG BASE	A062273 001
	EQ 500MG BASE	A062273 002
BETAPEN-VK		
BRISTOL		
	EQ 250MG BASE	A061150 001
	EQ 500MG BASE	A061150 002
LEDERCILLIN VK		
LEDERLE		
	EQ 250MG BASE	A060134 001
	EQ 500MG BASE	A060134 002
PEN-VEE K		
WYETH AYERST		
	EQ 125MG BASE	A060006 001
	EQ 250MG BASE	A060006 002
	EQ 500MG BASE	A060006 003
PENAPAR-VK		
PARKE DAVIS		
	EQ 250MG BASE	A062001 001
	EQ 500MG BASE	A062001 002
PENICILLIN V POTASSIUM		
AM ANTIBIOTICS		
	EQ 250MG BASE	A061528 001
	EQ 500MG BASE	A061528 002
IVAX SUB TEVA PHARMS		
	EQ 125MG BASE	A060518 001
	EQ 250MG BASE	A060518 002
	EQ 500MG BASE	A060518 003
MYLAN	EQ 250MG BASE	A061530 001
	EQ 500MG BASE	A061530 002
PUREPAC PHARM	EQ 125MG BASE	A061571 001
	EQ 250MG BASE	A061571 002
	EQ 500MG BASE	A061571 003
PFIZERPEN VK		
PFIZER		
	EQ 250MG BASE	A061836 001
	EQ 500MG BASE	A061836 002
UTICILLIN VK		
PHARMACIA AND UPJOHN		
	EQ 250MG BASE	A061651 001
	EQ 500MG BASE	A061651 002
V-CILLIN K		
LILLY		
	EQ 125MG BASE **	A060003 001
	EQ 250MG BASE **	A060003 002
	EQ 500MG BASE **	A060003 003
VEETIDS		
APOTHECON		
	EQ 250MG BASE	A061411 001
	EQ 500MG BASE	A061411 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

TABLET; ORAL

VEETIDS '250'

APOTHECON

EQ 250MG BASE

A061164 001

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

+ WYETH AYERST

0.25MG/ML **

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA

600MG/VIAL

N019887 002 Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001 Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001 Jun 30, 1992

WATSON LABS

300MG/VIAL

A074303 001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

PENTOBARBITAL SODIUM

LANNETT

50MG

A085937 001

100MG

A085915 001

VITARINE

100MG

A083284 001

WHITEWORTH TOWN PLSN

100MG

A083338 001

SODIUM PENTOBARBITAL

ANABOLIC

100MG

A084590 001

ELKINS SINN

100MG

A083368 001

EVERYLIFE

100MG

A083259 001

HALSEY

100MG

A084677 001

IVAX SUB TEVA PHARMS

50MG

A083461 001

100MG

A083461 002

PARKE DAVIS

100MG

A084156 001

PERRIGO

100MG

A084560 001

PUREPAC PHARM

100MG

A083301 001

VALEANT PHARM INTL

100MG

A083264 001

WATSON LABS

100MG

A085791 001

WYETH AYERST

100MG

A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN

50MG/ML

A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST

50MG/ML

A083261 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENTOBARBITAL SODIUMSUPPOSITORY;RECTAL
NEMBUTAL

OAK PHARMS	30MG	A083247 001	Jan 25, 1982
	60MG	A083247 002	Jan 25, 1982
	120MG	A083247 003	Jan 25, 1982
	200MG	A083247 004	Jan 25, 1982

TABLET;ORAL

PENTOBARBITAL SODIUM

VITARINE	100MG	A083285 001	
----------	-------	-------------	--

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC	100MG	A084238 001	
-------------------	-------	-------------	--

PENTOLINIUM TARTRATE

INJECTABLE;INJECTION

ANSOLYSEN

WYETH AYERST	10MG/ML	N009372 001	
--------------	---------	-------------	--

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH	400MG	A074878 001	Jul 09, 1997
HERITAGE PHARMS INC	400MG	A074877 001	Jul 08, 1997
IMPAX LABS	400MG	A075093 001	Aug 10, 1999
PLIVA	400MG	A074874 001	May 25, 1999
TEVA	400MG	A075199 001	Sep 03, 1999
WATSON LABS	400MG	A075107 001	Sep 04, 1998

TRENENTAL

+ US PHARM HOLDINGS	400MG **	N018631 001	Aug 30, 1984
---------------------	----------	-------------	--------------

PERFLUBRON

LIQUID;ORAL

IMAGENT

ALLIANCE PHARM	100%	N020091 001	Aug 13, 1993
----------------	------	-------------	--------------

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE;TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY	50%;50%	N021084 001	Feb 17, 2000
---------	---------	-------------	--------------

PERGOLIDE MESYLATE

TABLET;ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094 001	Sep 04, 2003
	EQ 0.25MG BASE	A076094 002	Sep 04, 2003
	EQ 1MG BASE	A076094 003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061 001	Nov 27, 2002
	EQ 0.25MG BASE	A076061 002	Nov 27, 2002
	EQ 1MG BASE	A076061 003	Nov 27, 2002

PERMAX

VALEANT PHARM INTL	EQ 0.05MG BASE	N019385 001	Dec 30, 1988
	EQ 0.25MG BASE	N019385 002	Dec 30, 1988
	EQ 1MG BASE	N019385 003	Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET;ORAL

ACEON

+ SYMPLMED PHARMS LLC	2MG	N020184 001	Dec 30, 1993
	4MG	N020184 002	Dec 30, 1993
	8MG	N020184 003	Dec 30, 1993

PERINDOPRIL ERBUMINE

LUPIN LTD	2MG	A078263 001	Jan 27, 2010
	4MG	A078263 002	Jan 27, 2010
	8MG	A078263 003	Jan 27, 2010

PERMETHRIN

LOTION;TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435 001	Mar 31, 1986
-----------------	----	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC

16MG/5ML

A040360 001 May 25, 2001

TRILAFON

SCHERING

16MG/5ML

N011557 001

INJECTABLE; INJECTION

TRILAFON

SCHERING

5MG/ML

N011213 002

SYRUP; ORAL

TRILAFON

SCHERING

2MG/5ML

N011294 002

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC

2MG

A089707 001 Sep 10, 1987

4MG

A089708 001 Sep 10, 1987

8MG

A089456 001 Sep 10, 1987

16MG

A089457 001 Sep 10, 1987

TRILAFON

+ SCHERING

2MG **

N010775 001

+

4MG **

N010775 002

+

8MG **

N010775 003

+

16MG **

N010775 004

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET; ORAL

PHENURONE

+ ABBVIE

500MG **

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

+ ROCHE

100MG; 500MG **

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE 200MG, N/A, N/A; N/A, 800MG, 160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

+ ROCHE

50MG; 500MG **

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
SANDOZ	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085497	001	
	35MG	A085830	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A086365	001
	35MG	A086370	001
SOLVAY	35MG	A083993	001
USL PHARMA	35MG	A083805	001
	35MG	A084398	001
	35MG	A084399	001
VITARINE	35MG	A085519	001
	35MG	A086005	001
	35MG	A086106	001
WATSON LABS	35MG	A085767	001
	35MG	A085768	001
	35MG	A085770	001
	35MG	A085773	001
PLEGINE			
WYETH AYERST	35MG **	N012248	001
STATOBEX			
TEVA	35MG	A086013	001
STATOBEX-G			
TEVA	35MG	A085095	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550	001
	35MG	A086551	001
	35MG	A086552	001
	35MG	A086553	001
	35MG	A086554	001

PHENINDIONE

TABLET;ORAL

HEDULIN

SANOFI AVENTIS US 50MG N008767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL

PRELUDIN

BOEHRINGER INGELHEIM 25MG N010460 005

TABLET, EXTENDED RELEASE;ORAL

PRELUDIN

BOEHRINGER INGELHEIM 50MG N011752 004

75MG N011752 003

PHENPROCOUMON

TABLET;ORAL

LIQUAMAR

ORGANON USA INC 3MG N011228 001

PHENSUXIMIDE

CAPSULE;ORAL

MILONTIN

PARKE DAVIS 500MG N008855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

FASTIN

GLAXOSMITHKLINE 30MG ** N017352 001

OBESTIN-30

FERNDAL LABS 30MG A087144 001

OBY-TRIM

SHIRE RICHWOOD 30MG A087764 001 Mar 18, 1982

ONA-MAST

MAST MM 30MG A086511 001

30MG A086516 001

PHENTERMINE HYDROCHLORIDE

ABC HOLDING 30MG A085411 001

ABLE 15MG A040497 001 Mar 13, 2003

30MG A040403 001 Aug 30, 2001

30MG A040427 001 Aug 30, 2001

CAMALL 15MG A086735 001

30MG A087226 001

CHARTWELL RX 18.75MG A088576 001 May 23, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
ELITE LABS INC	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
IVAX PHARMS	30MG	A086329	001	
MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
SUN PHARM INDUSTRIES	37.5MG	A040527	001	Oct 23, 2003
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
USL PHARMA	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET; ORAL				
ONA-MAST				
MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE				
ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
CHARTWELL RX	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	
WILPO				
+ SANDOZ	8MG **	N012737	001	
TABLET, ORALLY DISINTEGRATING; ORAL				
SUPRENZA				
CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011
	30MG	N202088	002	Jun 13, 2011
	37.5MG	N202088	003	Mar 27, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

IONAMIN

UCB INC

EQ 15MG BASE **

N011613 004

EQ 30MG BASE **

N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS

EQ 30MG BASE

A089120 001 Feb 04, 1988

PHENTERMINE RESIN COMPLEX

LANNETT HOLDINGS INC

EQ 15MG BASE

A040872 001 Jul 28, 2011

EQ 30MG BASE

A040872 002 Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

REGITINE

+ NOVARTIS

5MG/VIAL

N008278 003

PHENYL AMINOSALICYLATE

POWDER;ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

50%

N011695 002

TABLET;ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

500MG

N011695 003

PHENYLBUTAZONE

CAPSULE;ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087260 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 009

PHENYLBUTAZONE

IVAX PHARMS

100MG

A088218 001 Jun 24, 1983

SANDOZ

100MG

A087774 001 Jun 16, 1982

SUN PHARM INDUSTRIES

100MG

A088994 001 Dec 04, 1985

WATSON LABS

100MG

A087756 001 Dec 17, 1982

TABLET;ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087091 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 008

PHENYLBUTAZONE

SANDOZ

100MG

A084339 001

SUN PHARM INDUSTRIES

100MG

A088863 001 Dec 04, 1985

WATSON LABS

100MG

A086151 001

100MG

A087674 001 Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC

+ ANI PHARMS

5MG/5ML;6.25MG/5ML **

N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY

5MG/5ML;6.25MG/5ML

A088868 001 Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML;6.25MG/5ML

A088815 001 Nov 22, 1985

WOCKHARDT

5MG/5ML;6.25MG/5ML

A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%;0.1%

N007953 001

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001 Sep 25, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC

100MG EXTENDED

A040435 001 Jun 20, 2003

100MG EXTENDED

A089441 001 Dec 18, 1986

WOCKHARDT

30MG EXTENDED

A040759 001 Dec 18, 2007

WOCKHARDT USA

100MG EXTENDED

A040732 001 Jan 30, 2008

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

ANI PHARMS INC

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

PHENYTOIN SODIUM

FRESENIUS KABI USA

50MG/ML

A089003 001 May 31, 1985

HOSPIRA

50MG/ML

A089521 001 Mar 17, 1987

50MG/ML

A089744 001 Dec 18, 1987

MARSAM PHARMS LLC

50MG/ML

A089501 001 Oct 13, 1987

50MG/ML

A089779 001 Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001 Dec 19, 1984

50MG/ML

A088521 001 Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001 Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001 Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

+ TELIGENT

1MG/0.5ML **

N012223 002

+

10MG/ML **

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

AKORN

5MG

N017431 001

OCUSERT PILO-40

AKORN

11MG

N017548 001

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

ALCON

4%

N018796 001 Oct 01, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM

12.5MG

N019456 001 Dec 28, 1989

25MG

N019456 002 Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

G AND W LABS INC

5MG

A073661 001 Oct 31, 1993

5MG

A073687 001 Feb 26, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PINDOLOLTABLET; ORAL
PINDOLOL

	10MG	A073687 002	Feb 26, 1993
	10MG	A074123 002	Apr 17, 1997
MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992
	10MG	A074018 001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474 001	Oct 28, 1996
	10MG	A074474 002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125 001	Apr 28, 1993
	10MG	A074125 002	Apr 28, 1993
WATSON LABS	5MG	A074437 001	Feb 27, 1995
	10MG	A074437 002	Feb 27, 1995
VISKEN			
+ NOVARTIS	5MG **	N018285 001	Sep 03, 1982
+	10MG **	N018285 002	Sep 03, 1982

PIPECURONIUM BROMIDEINJECTABLE; INJECTION
ARDUAN

ORGANON USA INC	10MG/VIAL	N019638 001	Jun 26, 1990
-----------------	-----------	-------------	--------------

PIPERACETAZINETABLET; ORAL
QUIDE

DOW PHARM	10MG	N013615 001	
	25MG	N013615 002	

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
+	EQ 2GM BASE/VIAL **	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
+	EQ 3GM BASE/VIAL **	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
+	EQ 4GM BASE/VIAL **	N050545 004	
+	EQ 40GM BASE/VIAL **	N050545 006	Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL			
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE			
BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE			
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
LANNETT	EQ 500MG BASE/5ML	A080963 001	
LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL			
SOLVAY	EQ 500MG BASE/5ML	A080992 001	

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE			
IMPAX LABS	EQ 250MG BASE	A080874 001	

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000
----------------------	------------------	-------------	--------------

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT	10MG	N016245 001	
	25MG	N016245 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992
VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986

PIRFENIDONE

TABLET; ORAL

ESBRIET

+ GENENTECH INC	534MG	N208780	002	Jan 11, 2017
-----------------	-------	---------	-----	--------------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993
	20MG	A073651	002	Feb 26, 1993
EGIS	10MG	A074808	001	Jul 08, 1997
	20MG	A074808	002	Jul 08, 1997
IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
	20MG	A074148	002	Jun 03, 1996
MYLAN	10MG	A074043	001	Sep 22, 1992
	10MG	A074102	001	Jul 31, 1992
	20MG	A074043	002	Sep 22, 1992
	20MG	A074102	002	Jul 31, 1992
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995

PITAVASTATIN SODIUM

TABLET; ORAL

NIKITA

+ LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017
	EQ 2MG BASE	N209875	002	Aug 04, 2017
	EQ 4MG BASE	N209875	003	Aug 04, 2017

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	
--------	------------	---------	-----	--

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010
---------------------	------	---------	-----	--------------

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	
--------------	----------	---------	-----	--

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN	420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT	A090409	001	Apr 02, 2010
-------	---	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

CLENZ-LYTE

PADDOCK LLC

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A090769 001 Jun 07, 2010

SOLUTION;ORAL

OCL

HOSPIRA

6GM/100ML;75MG/100ML;168MG/100ML;146MG/
100ML;1.29GM/100ML

N019284 001 Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MYLAN SPECIALITY LP

120GM/PACKET;1.49GM/PACKET;3.36GM/PACKE
T;2.92GM/PACKET;11.36GM/PACKET

N018983 005 Oct 26, 1984

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PAC
KET;5.53GM/PACKET;21.5GM/PACKET

N018983 004 Oct 26, 1984

227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53G
M/BOT;21.5GM/BOT

N018983 010 Jan 31, 1989

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/
BOT;22.72GM/BOT

N018983 007 Jun 12, 1987

360GM/PACKET;4.47GM/PACKET;10.08GM/PACK
ET;8.76GM/PACKET;34.08GM/PACKET

N018983 006 Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP

227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53G
M/BOT;21.5GM/BOT

N018983 008 Nov 14, 1991

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/
BOT;22.72GM/BOT

N018983 009 Nov 14, 1991

PEG 3350 AND ELECTROLYTES

MYLAN

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A090928 001 Jan 28, 2010

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/
BOT;22.72GM/BOT

A090712 001 Feb 25, 2010

FOR SUSPENSION;ORAL

CO-LAV

VINTAGE PHARMS

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/
BOT;22.72GM/BOT

A073428 001 Jan 28, 1992

COLOVAGE

DYNAPHARM

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PAC
KET;5.53GM/PACKET;21.5GM/PACKET

A071320 001 Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A071278 001 Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A072319 001 Dec 23, 1988

GO-EVAC

VINTAGE PHARMS

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/
BOT;22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER;FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET;ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER	0.5MG;EQ 1MG BASE	N017986 001
	0.5MG;EQ 2MG BASE	N017986 002
	0.5MG;EQ 5MG BASE	N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER	2MG;0.25MG	N013636 001
--------	------------	-------------

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD	500MG	N009395 004
----------	-------	-------------

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL	100%	A080098 001
--------	------	-------------

TABLET; ORAL

PASKALIUM

GLENWOOD	1GM	N009395 003
----------	-----	-------------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
	10MEQ	A072427 001	Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
---------------	-------	-------------	--------------

TEVA	8MEQ	A073531 001	Apr 26, 1996
------	------	-------------	--------------

	10MEQ	A073532 001	Apr 26, 1996
--	-------	-------------	--------------

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM	20MEQ/PACKET	N019561 003	Aug 26, 1988
----------	--------------	-------------	--------------

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204 001	
	2MEQ/ML	A084290 001	
	2MEQ/ML	A086713 001	
	2MEQ/ML	A086714 001	
	2MEQ/ML	A087787 001	Apr 20, 1982
	2MEQ/ML	A087885 001	Feb 03, 1983
AKORN	2MEQ/ML	A088286 001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203 001	
	2MEQ/ML	A085499 001	
FRESENIUS KABI USA	2MEQ/ML	A087817 001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219 001	
	2MEQ/ML	A086219 002	
	2MEQ/ML	A086220 002	
	3MEQ/ML	A086219 003	
	3MEQ/ML	A086220 001	
	4MEQ/ML	A086219 004	
HOSPIRA	1MEQ/ML	A080205 003	
	1MEQ/ML	A083345 003	
	1.5MEQ/ML	A083345 001	
	2MEQ/ML	A083345 002	
	2.4MEQ/ML	A080205 004	
	3.2MEQ/ML	A080205 005	
INTL MEDICATION	2MEQ/ML	A083163 001	
LILLY	2MEQ/ML	N007865 002	
LUITPOLD	2MEQ/ML	A080221 001	
	2MEQ/ML	A080736 001	
	2MEQ/ML	A087584 001	
	2MEQ/ML	A087585 001	
MILES	1MEQ/ML	A080195 002	
	2MEQ/ML	A080195 001	
	3MEQ/ML	A080195 003	
	4MEQ/ML	A080195 004	
PHARMA SERVE NY	2MEQ/ML	A086297 001	
	2MEQ/ML	A087362 001	Mar 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

WATSON LABS

2MEQ/ML

A086208 001

2MEQ/ML

A089163 001 Mar 10, 1988

2MEQ/ML

A089421 001 Jan 02, 1987

3MEQ/ML

A086210 001

TABLET, EXTENDED RELEASE; ORAL

K+10

FUTURE PAK

10MEQ

A070999 001 Oct 22, 1987

K+8

FUTURE PAK

8MEQ

A070998 001 Jan 25, 1993

KAON CL

SAVAGE LABS

6.7MEQ

N017046 001

KAON CL-10

SAVAGE LABS

10MEQ

N017046 002

KLOTRIX

APOTHECON

10MEQ

N017850 001

POTASSIUM CHLORIDE

COPLEY PHARM

8MEQ

A070618 001 Sep 09, 1987

NESHER PHARMS

20MEQ

A076044 001 Apr 05, 2002

+ SCHERING

10MEQ **

N019439 002 Jun 13, 1986

+

20MEQ **

N019439 001 Jun 13, 1986

SLOW-K

NOVARTIS

8MEQ

N017476 002

TEN-K

NOVARTIS

10MEQ

N019381 001 Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

37MG/100ML; 900MG/100ML

N019708 001 Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

75MG/100ML; 900MG/100ML

N019708 002 Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

110MG/100ML; 900MG/100ML

N019708 003 Sep 29, 1989

POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

220MG/100ML; 900MG/100ML

N019708 005 Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

300MG/100ML; 900MG/100ML

N019708 006 Sep 29, 1989

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN

75MG/100ML; 900MG/100ML

N018722 001 Nov 09, 1982

BAXTER HLTHCARE

75MG/100ML; 900MG/100ML

N017648 004

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN

150MG/100ML; 900MG/100ML

N018722 002 Nov 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN

220MG/100ML; 900MG/100ML

N018722 003 Nov 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN

300MG/100ML; 900MG/100ML

N018722 004 Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA

370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL

N013025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

+ UT SW MEDCTR

10MEQ/PACKET **

N019647 002 Oct 13, 1988

+

20MEQ/PACKET **

N019647 001 Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML

N018551 001 Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDA PHARMS

130MG

N018307 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG

N017551 001

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS GRP PTC

0.125MG

A091254 001 Nov 30, 2010

0.25MG

A091254 002 Nov 30, 2010

0.5MG

A091254 003 Nov 30, 2010

0.75MG

A091254 004 Nov 30, 2010

1MG

A091254 005 Nov 30, 2010

1.5MG

A091254 006 Nov 30, 2010

SANDOZ

0.125MG

A090190 001 Jul 06, 2010

0.25MG

A090190 002 Jul 06, 2010

0.5MG

A090190 003 Jul 06, 2010

0.75MG

A090190 006 Oct 08, 2010

1MG

A090190 004 Jul 06, 2010

1.5MG

A090190 005 Jul 06, 2010

WATSON LABS

0.125MG

A078551 001 Oct 08, 2010

0.25MG

A078551 002 Oct 08, 2010

0.5MG

A078551 003 Oct 08, 2010

1MG

A078551 004 Oct 08, 2010

1.5MG

A078551 005 Oct 08, 2010

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB

EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)

N021332 001 Mar 16, 2005

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

+ BRISTOL MYERS SQUIBB

10MG **

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

MYLAN

10MG

A077013 001 Oct 23, 2006

20MG

A077013 002 Oct 23, 2006

40MG

A077013 003 Oct 23, 2006

80MG

A077013 004 Dec 28, 2007

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982

PRAZEPAM

USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS	10MG	N017415	001	
-------------	------	---------	-----	--

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
IDT AUSTRALIA LTD	EQ 1MG BASE	A072577	002	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072577	003	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING	0.5%	N010209	002	
----------	------	---------	-----	--

SYRUP; ORAL

PREDNISOLONE

APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005
	15MG/5ML	A040571	001	Aug 25, 2005
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998

PRELONE

MURO	5MG/5ML	A089654	001	Jan 17, 1989
------	---------	---------	-----	--------------

TABLET; ORAL

CORTALONE

HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	

DELTA-CORTEF

PHARMACIA AND UPJOHN	5MG	N009987	004	
----------------------	-----	---------	-----	--

FERNISOLONE-P

FERNDAL LABS	5MG	A083941	001	
--------------	-----	---------	-----	--

PREDNISOLONE

AUROLIFE PHARMA LLC	5MG	A084773	001	
BARR	5MG	A084426	002	
BUNDY	5MG	A083675	001	
CHARTWELL RX	5MG	A084542	001	
ELKINS SINN	5MG	A080625	001	
EVERYLIFE	1MG	A084439	001	
	2.5MG	A084439	002	
	5MG	A084439	003	
FERRANTE	2.5MG	A080562	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	5MG	A080562	002	
HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	
LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
ROXANE	5MG	A080327	002	
SANDOZ	5MG	A080339	001	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255	002	
PREDNISOLONE ACETATE				
AKORN	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	
CENT PHARMS	25MG/ML	A084717	001	
	50MG/ML	A084717	002	
WATSON LABS	25MG/ML	A083398	001	
	25MG/ML	A083654	001	
	40MG/ML	A083767	001	
	50MG/ML	A083764	001	
	50MG/ML	A085781	001	
STERANE				
PFIZER	25MG/ML	N011446	001	

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON	0.125%	N017468	001	
-------	--------	---------	-----	--

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON	0.25%;10%	A087771	001	Aug 06, 1993
METIMYD				
SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
VASOCIDIN				
NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION;OPHTHALMIC

ISOPTO CETAPRED

ALCON 0.25%;10% A087547 001

SUSPENSION/DROPS;OPHTHALMIC

METIMYD

SCHERING 0.5%;10% N010210 001

PREDAMIDE

AKORN 0.5%;10% A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR 0.2%;10% A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB 0.5%;10% A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCCK EQ 20MG PHOSPHATE/ML N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS EQ 20MG PHOSPHATE/ML A080517 001

OINTMENT;OPHTHALMIC, OTIC

HYDELTRASOL

MERCCK EQ 0.25% PHOSPHATE N011028 001

SOLUTION;ORAL

ORAPRED

CONCORDIA PHARMS INC EQ 15MG BASE/5ML ** A075117 001 Dec 14, 2000

PREDNISOLONE SODIUM PHOSPHATE

AMNEAL PHARMS EQ 15MG BASE/5ML A078345 001 Mar 10, 2009

MEDICIS PHARMS EQ 15MG BASE/5ML A075250 001 Jul 12, 2002

NESHER PHARMS EQ 5MG BASE/5ML A076982 001 May 24, 2005

EQ 15MG BASE/5ML A076988 001 May 24, 2005

PHARM ASSOC EQ 5MG BASE/5ML A076123 001 Dec 23, 2002

VINTAGE PHARMS EQ 5MG BASE/5ML A078416 001 Oct 31, 2007

WE PHARMS EQ 5MG BASE/5ML A075181 001 Dec 23, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

NOVARTIS EQ 0.9% PHOSPHATE A080751 002

INFLAMASE MILD

NOVARTIS EQ 0.11% PHOSPHATE A080751 001

METRETON

SCHERING EQ 0.5% PHOSPHATE A083834 001

PREDAIR

PHARMAFAIR EQ 0.11% PHOSPHATE A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR EQ 0.9% PHOSPHATE A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN EQ 0.11% PHOSPHATE A083358 001

EQ 0.9% PHOSPHATE A083358 002

ALCON PHARMS LTD EQ 0.11% PHOSPHATE A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE A081044 001 Oct 24, 1991

BAUSCH AND LOMB EQ 0.11% PHOSPHATE A040065 001 Jul 29, 1994

SOLA BARNES HIND EQ 0.11% PHOSPHATE A084171 001

EQ 0.9% PHOSPHATE A084168 001

EQ 0.9% PHOSPHATE A084169 001

EQ 0.9% PHOSPHATE A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULSTER

AKORN EQ 0.23% PHOSPHATE;10% A074511 001 Jul 30, 1996

VASOCIDIN

+ NOVARTIS EQ 0.23% PHOSPHATE;10% ** N018988 001 Aug 26, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISON

SOLUTION; ORAL

PREDNISON

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP; ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET; ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

+ PHARMACIA AND UPJOHN

2.5MG **

N009986 005

+

PHARMACIA AND UPJOHN

5MG **

N009986 002

+

PHARMACIA AND UPJOHN

10MG **

N009986 006

+

PHARMACIA AND UPJOHN

20MG **

N009986 007

+

PHARMACIA AND UPJOHN

50MG **

N009986 008

FERNISON

FERNDAL LABS

5MG

A083364 001

METICORTEN

+ SCHERING

1MG **

N009766 002

+

SCHERING

5MG **

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISON

AM THERAP

5MG

A089387 001 Nov 06, 1986

10MG

A089388 001 Nov 06, 1986

20MG

A089389 001 Nov 06, 1986

AMNEAL PHARMS NY

5MG

A089597 001 Oct 05, 1987

10MG

A089598 001 Oct 05, 1987

20MG

A089599 001 Oct 05, 1987

AUROLIFE PHARMA LLC

5MG

A084774 001

10MG

A089983 001 Jan 12, 1989

20MG

A085813 001

50MG

A089984 001 Jan 12, 1989

BUNDY

5MG

A083676 001

CHARTWELL RX

5MG

A083059 001

CONTRACT PHARMACAL

5MG

A080209 001

DURAMED PHARMS BARR

5MG

A088394 001 Oct 04, 1983

10MG

A088395 001 Oct 04, 1983

20MG

A088396 001 Oct 04, 1983

ELKINS SINN

5MG

A080491 001

20MG

A085811 001

EVERYLIFE

1MG

A084440 001

2.5MG

A084440 002

5MG

A084440 003

FERRANTE

2.5MG

A080563 001

5MG

A080563 002

HALSEY

5MG

A080300 001

HEATHER

5MG

A080320 001

10MG

A084341 001

20MG

A084417 001

20MG

A085543 001

50MG

A086946 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISON

TABLET; ORAL

PREDNISON

HIKMA PHARMS	1MG	A040890 001	Nov 01, 2010
IMPAX LABS	5MG	A080782 001	
INWOOD LABS	1MG	A080328 001	
	2.5MG	A080306 001	
	5MG	A080279 001	
IVAX SUB TEVA PHARMS	5MG	A080283 001	
	10MG	A084133 001	
	20MG	A084134 001	
KV PHARM	5MG	A084236 001	
LANNETT	5MG	A080514 001	
	20MG	A084275 001	
LEDERLE	5MG	A086968 001	
MARSHALL PHARMA	5MG	A080301 001	
MUTUAL PHARM	5MG	A080701 001	
	10MG	A086595 001	
	20MG	A084634 001	
NYLOS	5MG	A085115 001	
PANRAY	1MG	A080350 001	
	2.5MG	A080350 002	
	5MG	A080350 003	
PHARMAVITE	5MG	A084662 002	
PHOENIX LABS NY	5MG	A080321 001	
	20MG	A083807 001	
PUREPAC PHARM	5MG	A080353 001	
	10MG	A086062 001	
	20MG	A086061 001	
PVT FORM	20MG	A085151 001	
REXALL	5MG	A080232 001	
ROXANE	20MG	N017109 001	
	25MG	A087833 001	May 04, 1982
SANDOZ	5MG	A080336 002	
SCHERER LABS	5MG	A080371 001	
SPERTI	1MG	A080359 001	
	2.5MG	A080359 002	
	5MG	A080359 003	
SUN PHARM INDUSTRIES	50MG	A086596 001	
SUPERPHARM	5MG	A088865 001	Oct 25, 1984
	10MG	A088866 001	Oct 25, 1984
	20MG	A088867 001	Oct 25, 1984
TEVA	5MG	A080397 001	
UDL	5MG	A087984 001	Jan 18, 1983
	10MG	A087985 001	Jan 18, 1983
	20MG	A087986 001	Jan 18, 1983
UPSHER SMITH	5MG	A087471 001	
	20MG	A087470 001	
VALEANT PHARM INTL	5MG	A080237 001	
VANGARD	5MG	A087682 001	Jan 15, 1982
	20MG	A087701 001	Jan 15, 1982
VITARINE	5MG	A080334 001	
	5MG	A080506 001	
WATSON LABS	5MG	A085084 002	
	10MG	A087773 001	Jul 13, 1982
	20MG	A086813 001	
	50MG	A086867 001	
	50MG	A087772 001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913 001	
	5MG	A080343 001	
	10MG	A089028 001	Jul 24, 1986
	20MG	A084913 002	
SERVISONE			
LEDERLE	5MG	A080223 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

+	ASTRAZENECA	1% **	N014763	004
+		2% **	N014763	005
+		3% **	N014763	003

CITANEST PLAIN

+	ASTRAZENECA	4% **	N014763	007
---	-------------	-------	---------	-----

CITANEST PLAIN DENTAL

	DENTSPLY PHARM	4%	N021382	001
--	----------------	----	---------	-----

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

	NURO PHARMA	250MG/5ML	N010401	001
--	-------------	-----------	---------	-----

TABLET; ORAL

PRIMIDONE

	DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
		250MG	A040862	002	Oct 03, 2008
	HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
	IMPAX LABS	50MG	A040717	001	Feb 12, 2008
		250MG	A040717	002	Feb 12, 2008
	WATSON LABS	250MG	A085052	001	

PROBENECID

TABLET; ORAL

BENEMID

+	MERCK	500MG **	N007898	004
---	-------	----------	---------	-----

PROBENECID

	IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
	LEDERLE	500MG	A086917	001	
	WATSON LABS	500MG	A086150	002	Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

	SANOFI AVENTIS US	250MG	N017535	001	
		500MG	N017535	002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

	ASCOT	250MG	A087542	001	Jan 08, 1982
		375MG	A087697	001	Mar 01, 1983
		500MG	A087543	001	Jan 08, 1982
	IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986
		375MG	A089219	002	Jul 01, 1986
		500MG	A089219	003	Jul 01, 1986
	IVAX SUB TEVA PHARMS	250MG	A084604	001	
		375MG	A084595	001	
		500MG	A084606	001	
	LANNETT	250MG	A083693	001	
		500MG	A084696	001	
	LEDERLE	250MG	A086942	001	
		375MG	A086952	001	
		500MG	A086943	001	
	ROXANE	250MG	A088989	001	Apr 26, 1985
		500MG	A088990	001	Apr 26, 1985
	VANGARD	250MG	A087643	001	Jun 01, 1982
		500MG	A087875	001	Jun 01, 1982
	WATSON LABS	250MG	A083287	001	
		250MG	A083795	001	
		250MG	A085167	001	
		375MG	A084403	001	
		375MG	A087020	001	
		500MG	A084280	001	
		500MG	A084357	001	
		500MG	A087021	001	
	PROCAN				
	PARKE DAVIS	250MG	A085804	001	
		375MG	A087502	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAN

500MG A085079 001

PROCAPAN

PANRAY

250MG A083553 002

PRONESTYL

+ APOTHECON

250MG ** N007335 001

+

375MG ** N007335 004

+

500MG ** N007335 003

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML A089415 001 Nov 17, 1986

500MG/ML A089416 001 Nov 17, 1986

HOSPIRA

500MG/ML A089537 001 Aug 25, 1987

INTL MEDICATION

500MG/ML A088637 001 Jul 31, 1984

PHARMAFAIR

100MG/ML A088824 001 Nov 20, 1985

500MG/ML A088830 001 Nov 20, 1985

SMITH AND NEPHEW

100MG/ML A088530 001 Mar 04, 1985

500MG/ML A088531 001 Mar 04, 1985

SOLOPAK

500MG/ML A088532 001 Mar 04, 1985

WARNER CHILCOTT

100MG/ML A089528 001 May 03, 1988

500MG/ML A089529 001 May 03, 1988

WATSON LABS

100MG/ML A087079 001

500MG/ML A087080 001

WEST-WARD PHARMS INT

100MG/ML A089029 001 Apr 17, 1986

500MG/ML A089030 001 Apr 17, 1986

PRONESTYL

+ APOTHECON

100MG/ML ** N007335 002

+

500MG/ML ** N007335 005

TABLET; ORAL

PRONESTYL

APOTHECON

250MG N017371 001

375MG N017371 002

500MG N017371 003

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC

250MG A088958 001 Dec 02, 1985

500MG A088959 001 Dec 02, 1985

500MG A088974 001 Jul 22, 1985

750MG A089438 001 Mar 23, 1987

1GM A040111 001 Dec 13, 1996

IDT AUSTRALIA LTD

250MG A089369 001 Aug 14, 1987

500MG A089369 002 Jan 09, 1987

750MG A089369 003 Aug 14, 1987

INWOOD LABS

500MG A089840 001 Mar 06, 1989

SANDOZ

500MG A089284 001 Jun 23, 1986

WATSON LABS

250MG A088533 001 Dec 03, 1984

250MG A089026 001 Oct 22, 1985

500MG A088534 001 Dec 03, 1984

500MG A089027 001 Oct 22, 1985

750MG A088535 001 Nov 03, 1984

750MG A089042 001 Oct 22, 1985

1GM A089520 001 Jan 15, 1987

PROCAN SR

PARKE DAVIS

250MG A086468 001

PARKEDALE

500MG A086065 001

750MG A087510 001 Apr 01, 1982

1GM A088489 001 Jan 16, 1985

PROCANBID

KING PHARMS

500MG N020545 001 Jan 31, 1996

1GM N020545 002 Jan 31, 1996

PRONESTYL-SR

APOTHECON

500MG A087361 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003
	2%	A085362	004
	10%	A086797	001

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002
	1%	A080421	001
	2%	A080384	003
	2%	A080421	002
BEL MAR	1%	A080711	001
	2%	A080756	001
ELKINS SINN	1%	A083315	001
	2%	A083315	002
GD SEARLE LLC	1%	A086202	001
	2%	A086202	002
HOSPIRA	1%	A080416	001
	2%	A080416	002
MILES	1%	A080415	001
	2%	A080415	002
WATSON LABS	1%	A080658	001
	1%	A083535	001
	2%	A080658	002
	2%	A083535	002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL; 100MG/VIAL	N050276	001
	40MG/VIAL; 250MG/VIAL	N050276	003

TETRACYN

PFIZER	40MG/VIAL; 100MG/VIAL	A060285	002
	40MG/VIAL; 250MG/VIAL	A060285	003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY	100MG/ML; 50MG/ML	N008869	001
-------	-------------------	---------	-----

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE	2.5MG **	N011127	003
	5MG **	N011127	001
	25MG **	N011127	002

PROCHLORPERAZINE

ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001
-----------------	-----------------	---------	-----

PROCHLORPERAZINE

ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982
--------------------	-----------------	---------	-----	--------------

PROCHLORPERAZINE EDISYLATE

MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984
--------------	-----------------	---------	-----	--------------

INJECTABLE; INJECTION

COMPAZINE

+ GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742	002
-------------------	-------------------	---------	-----

PROCHLORPERAZINE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982
-----------------	----------------	---------	-----	--------------

PROCHLORPERAZINE EDISYLATE

ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004
HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

EQ 5MG BASE/ML	A089605 001	Jul 08, 1987
EQ 5MG BASE/ML	A089606 001	Jul 08, 1987
WEST-WARD PHARMS INT EQ 5MG BASE/ML	A089523 001	May 03, 1988
WYETH AYERST EQ 5MG BASE/ML	A086348 001	

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE	N011000 001	
EQ 10MG BASE	N021019 001	Oct 06, 1999
EQ 15MG BASE	N011000 002	
EQ 15MG BASE	N021019 002	Oct 06, 1999
EQ 30MG BASE	N011000 003	
EQ 75MG BASE	N011000 004	

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE **	N010571 001	
EQ 10MG BASE **	N010571 002	
EQ 25MG BASE **	N010571 003	

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE	A085580 001	
EQ 10MG BASE	A085178 001	
EQ 25MG BASE	A085579 001	

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE	A040207 001	May 01, 1997
EQ 5MG BASE	A089484 001	Jan 20, 1987
EQ 10MG BASE	A040207 002	May 01, 1997
EQ 10MG BASE	A089485 001	Jan 20, 1987
EQ 25MG BASE	A089486 001	Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE	A040162 001	Jan 20, 1998
EQ 10MG BASE	A040162 002	Jan 20, 1998

SANDOZ

EQ 25MG BASE A040101 003 Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG	N009818 005	
5MG	N009818 003	

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

VIRTUS PHARMS

300MG N019781 003 Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML	N009238 002	
50MG/ML	N009238 001	

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML	N010942 001	
100MG/ML	N010942 004	

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML	A084510 001	
50MG/ML	A084517 001	

SPARINE

BAXTER HLTHCARE CORP

25MG/ML N010349 008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

50MG/ML

N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG

N010348 006

25MG

N010348 001

50MG

N010348 002

100MG

N010348 003

200MG

N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML

N008857 002

50MG/ML

N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML

A084223 001

50MG/ML

A084222 001

AKORN

25MG/ML

A083955 002

50MG/ML

A083955 001

BEDFORD LABS

25MG/ML

A040524 001 Mar 17, 2004

50MG/ML

A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML

A040372 001 Jun 08, 2000

50MG/ML

A040372 002 Jun 08, 2000

50MG/ML

A083838 002

LUITPOLD

25MG/ML

A040515 001 Mar 19, 2003

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

50MG/ML

A089477 001 May 02, 1988

MYLAN INSTITUTIONAL

25MG/ML

A040471 001 Nov 21, 2002

SANDOZ

25MG/ML

A040593 001 Nov 08, 2006

50MG/ML

A040593 002 Nov 08, 2006

TEVA PHARMS USA

25MG/ML **

A040454 001 Aug 22, 2002

50MG/ML **

A040454 002 Aug 22, 2002

WATSON LABS

25MG/ML

A083532 001

25MG/ML

A084591 001

50MG/ML

A080629 002

50MG/ML

A083532 002

WOCKHARDT

25MG/ML

A040785 001 Sep 26, 2008

50MG/ML

A040785 002 Sep 26, 2008

ZIPAN-25

ALTANA

25MG/ML

A083997 001

ZIPAN-50

ALTANA

50MG/ML

A083997 002

SUPPOSITORY; RECTAL

PHENERGAN

+ MYLAN PHARMS INC

12.5MG **

N010926 002

+

25MG **

N010926 001

+

50MG **

N011689 001

PROMETHACON

POLYMEDICA

25MG

A084901 001

50MG

A084902 001

PROMETHAZINE HYDROCHLORIDE

ABLE

12.5MG

A040504 001 Apr 11, 2003

25MG

A040504 002 Apr 11, 2003

50MG

A040449 001 Feb 27, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA

25MG/5ML

A087996 001 Jan 18, 1983

PROMETH FORTIS

ALPHARMA US PHARMS

25MG/5ML

A084772 001

PROMETH PLAIN

ACTAVIS MID ATLANTIC

6.25MG/5ML

A085953 001

PROMETHAZINE

CENCI

6.25MG/5ML

A089013 001 Sep 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

KV PHARM

6.25MG/5ML

A085388 001

25MG/5ML

A085385 001

PHARM ASSOC

6.25MG/5ML

A087518 001

WHITEWORTH TOWN PLSN

6.25MG/5ML

A086395 001

PROMETHAZINE HYDROCHLORIDE PLAIN

+ ANI PHARMS

6.25MG/5ML **

N008381 004 Apr 18, 1984

+

25MG/5ML **

N008381 003

TABLET; ORAL

PHENERGAN

+ DELCOR ASSET CORP

12.5MG **

N007935 002

+

25MG **

N007935 003

+

50MG **

N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT

12.5MG

A084160 001

25MG

A084166 001

50MG

A084539 001

ABLE

12.5MG

A040558 001 Jul 01, 2004

25MG

A040558 002 Jul 01, 2004

50MG

A040558 003 Jul 01, 2004

IMPAX LABS

25MG

A084214 002 Jul 07, 1982

50MG

A040791 001 May 20, 2008

IVAX SUB TEVA PHARMS

12.5MG

A083604 001

25MG

A083603 001

50MG

A083613 001

LANNETT

12.5MG

A080949 001

25MG

A080949 002

50MG

A080949 003

MYLAN

12.5MG

A091054 001 Aug 30, 2011

25MG

A091054 002 Aug 30, 2011

50MG

A091054 003 Aug 30, 2011

PVT FORM

12.5MG

A083214 001

25MG

A083658 001

SANDOZ

12.5MG

A084176 002 May 22, 2009

12.5MG

A084233 001

25MG

A085146 001

50MG

A085146 002

SUN PHARM INDUSTRIES

12.5MG

A084555 001

25MG

A084554 001

50MG

A084557 001

TABLICAPS

12.5MG

A084080 001

25MG

A084027 001

TEVA

25MG

A089109 001 Sep 10, 1985

WATSON LABS

12.5MG

A083401 001

12.5MG

A083712 001

12.5MG

A085986 001

25MG

A083204 001

25MG

A085684 001

50MG

A083403 001

50MG

A085664 001

REMSSED

BRISTOL MYERS SQUIBB

25MG

A083176 002

50MG

A083176 001

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS

150MG

A076193 001 Feb 07, 2002

225MG

A076193 002 Feb 07, 2002

300MG

A076193 003 Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC

30MG/VIAL

N008843 001

TABLET; ORAL

PRO-BANTHINE

+ SHIRE

7.5MG **

N008732 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPANTHELINE BROMIDE

TABLET; ORAL

PRO-BANTHINE

+

15MG **

N008732 002

PROPANTHELINE BROMIDE

ASCOT

15MG

A087663 001

Oct 25, 1982

HEATHER

15MG

A085780 001

IMPAX LABS

15MG

A084541 002

MYLAN

15MG

A083706 001

PAR PHARM

15MG

A088377 001

Dec 08, 1983

PVT FORM

15MG

A080977 001

SANDOZ

15MG

A080928 001

TABLICAPS

15MG

A084428 001

WATSON LABS

15MG

A083029 002

15MG

A083151 001

WEST-WARD PHARMS INT

7.5MG

A080927 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR

0.5%

A088087 001

Jun 07, 1983

OPHTHAINE

+

APOTHECON

0.5% **

N008883 001

OPHTHETIC

+

ALLERGAN

0.5% **

N012583 001

PARACAINE

OPTOPICS

0.5%

A087681 001

Aug 05, 1982

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND

0.5%

A084144 001

0.5%

A084151 001

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS

N/A

N011657 001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

WEST-WARD PHARMS INT 20MG/ML

N012382 002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

FRESENIUS KABI USA 10MG/ML

N019627 001

Oct 02, 1989

PROPOFOL

TEVA PARENTERAL 10MG/ML

A075392 001

Sep 19, 2000

WEST-WARD PHARMS INT 10MG/ML

A074848 001

Apr 19, 2005

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM 32MG

N010997 001

65MG

N010997 003

DOLENE

HERITAGE PHARMS INC 65MG

A080530 001

KESSO-GESIC

MK LABS 65MG

A083544 001

PROPHENE 65

HALSEY 65MG

A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG

A083184 001

IMPAX LABS 65MG

A083317 001

IVAX SUB TEVA PHARMS 32MG

A083597 001

MUTUAL PHARM 65MG

A083186 001

MYLAN 32MG

A083528 001

65MG

A040569 001

Dec 16, 2004

65MG

A083299 001

NEXGEN PHARMA INC 65MG

A083185 001

PAR PHARM 65MG

A080269 001

PUREPAC PHARM 65MG

A083278 001

PVT FORM 32MG

A083464 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	
PROPOXYPHENE HYDROCHLORIDE	65			
WARNER CHILCOTT	65MG	A083786	001	

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET; ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989
UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009
	80MG	A078311	002	Mar 06, 2009
	120MG	A078311	003	Mar 06, 2009
	160MG	A078311	004	Mar 06, 2009

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST 10MG/ML N019536 001 Dec 12, 1986

TABLET; ORAL

INDERAL

+ WYETH PHARMS INC	10MG **	N016418	001	
	20MG **	N016418	003	
	40MG **	N016418	002	
	60MG **	N016418	009	Oct 18, 1982
	80MG **	N016418	004	
	90MG **	N016418	010	Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985
	20MG	A070320	001	Oct 22, 1985
	40MG	A070103	001	Oct 22, 1985
	60MG	A070321	001	Sep 24, 1986
	80MG	A070322	001	Aug 04, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988
DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985
	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
	90MG	A071496	001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
INTERPHARM	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A070663	001	Jun 13, 1986
	10MG	A071658	001	Jul 05, 1988
	20MG	A070664	001	Jun 13, 1986
	20MG	A071687	001	Jul 05, 1988
	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	80MG	A070442 001	Sep 15, 1986
WATSON LABS	10MG	A070140 001	Jul 30, 1985
	10MG	A070378 001	Mar 19, 1987
	20MG	A070141 001	Jul 30, 1985
	20MG	A070379 001	Mar 19, 1987
	40MG	A070142 001	Jul 30, 1985
	40MG	A070380 001	Mar 19, 1987
	60MG	A070143 001	Jan 15, 1987
	60MG	A070381 001	Mar 19, 1987
	60MG	A071098 001	Oct 06, 1986
	60MG	A071791 001	Jul 15, 1987
	80MG	A070144 001	Jul 30, 1985
	80MG	A070382 001	Mar 19, 1987
	80MG	A070551 001	Jul 10, 1986
	90MG	A071183 001	Oct 06, 1986
	90MG	A071792 001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548 001	Jul 10, 1986
	20MG	A070549 001	Apr 11, 1986
	40MG	A070550 001	Apr 11, 1986

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE 50% N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE 60% N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075 001	
ANABOLIC	50MG	A080285 001	
ANI PHARMS INC	50MG	A080215 001	
CHARTWELL RX	50MG	A084543 001	
HALSEY	50MG	A080015 001	
HIKMA INTL PHARMS	50MG	A080154 001	
IMPAX LABS	50MG	A080159 001	
LANNETT	50MG	A080016 001	
LILLY	50MG	N006213 001	
SUN PHARM INDUSTRIES	50MG	A083982 001	
TABLICAPS	50MG	A080840 001	
WATSON LABS	50MG	A080932 001	
	50MG	A085201 001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	LILLY	10MG/ML **	N006460 002	
	PHARMACIA AND UPJOHN	50MG/VIAL	N007413 001	
		250MG/VIAL	N007413 002	Aug 02, 1984
	WEST-WARD PHARMS INT	10MG/ML	A089474 001	Nov 05, 1986
		10MG/ML	A089475 001	Nov 05, 1986

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE 5% N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN 5% N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT 0.5MG/ML N017638 001

THYREL TRH

FERRING 0.5MG/ML N018087 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROTOKYLLOL HYDROCHLORIDETABLET; ORAL
VENTAIRE

SANOFI AVENTIS US 2MG A083459 001

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
VIVACTILTEVA WOMENS 5MG ** N016012 001
10MG ** N016012 002PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NOVAFEDSANOFI AVENTIS US 120MG N017603 001
SUDAFED 12 HOUR
+ GLAXOSMITHKLINE 120MG ** N017941 002PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
ACTIFEDGLAXOSMITHKLINE 120MG; 5MG N018996 001 Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
KV PHARM 120MG; 5MG A071798 001 Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI 30MG/5ML; 1.25MG/5ML A088344 001 Feb 09, 1984

HISTAFED

CENCI 30MG/5ML; 1.25MG/5ML A088283 001 Apr 20, 1984

MYFED

USL PHARMA 30MG/5ML; 1.25MG/5ML A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS 30MG/5ML; 1.25MG/5ML A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM 60MG; 2.5MG A088860 001 Jan 31, 1985

CORPHED

SANDOZ 60MG; 2.5MG A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ 60MG; 2.5MG A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS 60MG; 2.5MG A088515 001 Jan 09, 1985

TRIPHED

TEVA 60MG; 2.5MG A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS 60MG; 2.5MG A088318 002 Jan 13, 1984

WEST WARD 60MG; 2.5MG A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 60MG; 2.5MG A085273 001 Dec 12, 1984

SUPERPHARM 60MG; 2.5MG A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG; 5MG A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREXSUSPENSION, EXTENDED RELEASE; ORAL
PSEUDO-12

UCB INC EQ 60MG HCL/5ML N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC 30MG A040512 002 Jul 20, 2005

60MG A040512 001 Oct 08, 2003

IMPAX LABS INC 60MG A040457 001 Dec 26, 2002

SOLVAY 30MG A089572 001 Nov 27, 1990

US ARMY 30MG N020414 001 Feb 05, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

WATSON LABS

100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE

25MG; 500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET; ORAL

DORAL

CUTIS HEALTH LLC

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013

EQ 50MG BASE

A201762 002 Feb 27, 2013

EQ 100MG BASE

A201762 003 Feb 27, 2013

EQ 150MG BASE

A201762 004 Feb 27, 2013

EQ 200MG BASE

A201762 005 Feb 27, 2013

EQ 300MG BASE

A201762 006 Feb 27, 2013

EQ 400MG BASE

A201762 007 Feb 27, 2013

MYLAN PHARMS INC

EQ 25MG BASE

A090323 001 Mar 27, 2012

SEROQUEL

+

ASTRAZENECA PHARMS

EQ 150MG BASE **

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

ACTAVIS LABS FL INC

EQ 5MG BASE

A076049 001 Jan 14, 2005

EQ 10MG BASE

A076049 002 Jan 14, 2005

EQ 20MG BASE

A076049 003 Jan 14, 2005

EQ 40MG BASE

A076049 004 Jan 14, 2005

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

EQ 40MG BASE

A076240 004 Jan 26, 2006

FOSUN PHARMA

EQ 5MG BASE

A076803 001 Mar 02, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 40MG BASE	A076036 004	Jan 28, 2005
SUN PHARM INDS LTD	EQ 5MG BASE	A090800 001	Jun 18, 2009
	EQ 10MG BASE	A090800 002	Jun 18, 2009
	EQ 20MG BASE	A090800 003	Jun 18, 2009
	EQ 40MG BASE	A090800 004	Jun 18, 2009

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE	50MG	N013264 001	
---------	------	-------------	--

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE	50MG; 0.125MG	N013927 001	
---------	---------------	-------------	--

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET; ORAL

QUINACT

BAYER HLTHCARE	266MG	A085978 001	
	400MG	A086099 001	

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT	330MG	N017917 001	
-----------------	-------	-------------	--

QUINAGLUTE

BAYER HLTHCARE	324MG	N016647 001	
----------------	-------	-------------	--

QUINALAN

LANNETT	324MG	A088081 001	Feb 10, 1986
---------	-------	-------------	--------------

QUINATIME

WATSON LABS	324MG	A087448 001	
-------------	-------	-------------	--

QUINIDINE GLUCONATE

ASCOT	324MG	A088582 001	Jun 17, 1985
AUROLIFE PHARMA LLC	324MG	A089894 001	Dec 15, 1988
CYCLE PHARMS LTD	324MG	A088431 001	Jan 06, 1984
HALSEY	324MG	A089476 001	Apr 10, 1987
SUPERPHARM	324MG	A089164 001	Nov 21, 1985
WATSON LABS	324MG	A087785 001	Jan 24, 1983
	324MG	A087810 001	Sep 29, 1982

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642 002	
-----------------	-------	-------------	--

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY	200MG	A085296 001	
	300MG	A085297 001	

QUINIDINE SULFATE

LILLY	200MG	A085103 001	
-------	-------	-------------	--

TABLET; ORAL

CIN-QUIN

SOLVAY	100MG	A085299 001	
--------	-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINIDINE SULFATE

TABLET; ORAL

CIN-QUIN

	200MG	A084932	001	
	300MG	A085298	001	
QUINIDINE SULFATE				
BARR	200MG	A084177	001	
CONTRACT PHARMACAL	200MG	A083808	001	
CYCLE PHARMS LTD	200MG	A083640	001	
	300MG	A085632	001	
DAVA PHARMS INC	200MG	A087011	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA PHARMS	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUN PHARM INDUSTRIES	100MG	A081029	001	Apr 14, 1989
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	
QUINORA				
KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	
TABLET, EXTENDED RELEASE; ORAL				
QUINIDEX				
WYETH PHARMS INC	300MG	N012796	002	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

+ EISAI INC 10MG ** N020973 001 May 29, 2002

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
FOSUN PHARMA	1.25MG	A077514	001	Jun 18, 2008
	2.5MG	A077514	002	Jun 18, 2008
	5MG	A077514	003	Jun 18, 2008
	10MG	A077514	004	Jun 18, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAMIPRIL

TABLET;ORAL

ALTACE

+	KING PFIZER	1.25MG **	N022021	001	Feb 27, 2007
+		2.5MG **	N022021	002	Feb 27, 2007
+		5MG **	N022021	003	Feb 27, 2007
+		10MG **	N022021	004	Feb 27, 2007

RAMIPRIL

	MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011
		2.5MG	A090650	002	Jun 30, 2011
		5MG	A090650	003	Jun 30, 2011
		10MG	A090650	004	Jun 30, 2011
	ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
		2.5MG	A090697	002	Sep 24, 2009
		5MG	A090697	003	Sep 24, 2009
		10MG	A090697	004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

	GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
--	-----------------	-------	---------	-----	--------------

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

	MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000
		EQ 300MG BASE	A075564	002	Oct 27, 2000
	TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
		EQ 300MG BASE	A075557	002	Oct 31, 2003

ZANTAC 150

+	GLAXOSMITHKLINE	EQ 150MG BASE **	N020095	001	Mar 08, 1994
---	-----------------	------------------	---------	-----	--------------

ZANTAC 300

+	GLAXOSMITHKLINE	EQ 300MG BASE **	N020095	002	Mar 08, 1994
---	-----------------	------------------	---------	-----	--------------

GRANULE, EFFERVESCENT;ORAL

ZANTAC 150

	GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994
--	---------------	----------------------	---------	-----	--------------

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

	BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
--	---------	-----------------	---------	-----	--------------

ZANTAC IN PLASTIC CONTAINER

	TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
--	----------	----------------	---------	-----	--------------

		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986
--	--	--------------------	---------	-----	--------------

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
--	------------	-----------------	---------	-----	--------------

	RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
--	---------	-----------------	---------	-----	--------------

	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
--	-----------	-----------------	---------	-----	--------------

		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009
--	--	-----------------	---------	-----	--------------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
--	----------------------	---------------	---------	-----	--------------

		EQ 300MG BASE	A074662	002	Aug 29, 1997
--	--	---------------	---------	-----	--------------

	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
--	--------------------	--------------	---------	-----	--------------

	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997
--	-------	---------------	---------	-----	--------------

		EQ 150MG BASE	A074552	001	Jul 30, 1998
--	--	---------------	---------	-----	--------------

		EQ 300MG BASE	A074023	002	Aug 22, 1997
--	--	---------------	---------	-----	--------------

		EQ 300MG BASE	A074552	002	Jul 30, 1998
--	--	---------------	---------	-----	--------------

	RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
--	---------	--------------	---------	-----	--------------

		EQ 150MG BASE	A075000	001	Jan 30, 1998
--	--	---------------	---------	-----	--------------

		EQ 300MG BASE	A075000	002	Jan 30, 1998
--	--	---------------	---------	-----	--------------

	SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
--	--------	--------------	---------	-----	--------------

	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000
--	--------------------	--------------	---------	-----	--------------

		EQ 150MG BASE	A075439	001	Apr 19, 2000
--	--	---------------	---------	-----	--------------

		EQ 300MG BASE	A075439	002	Apr 19, 2000
--	--	---------------	---------	-----	--------------

	WATSON LABS	EQ 75MG BASE	A075212	001	Jan 14, 2000
--	-------------	--------------	---------	-----	--------------

		EQ 150MG BASE	A074864	001	Oct 20, 1997
--	--	---------------	---------	-----	--------------

		EQ 300MG BASE	A074864	002	Oct 20, 1997
--	--	---------------	---------	-----	--------------

	WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005
--	-----------------	---------------	---------	-----	--------------

		EQ 300MG BASE	A077426	002	Dec 19, 2005
--	--	---------------	---------	-----	--------------

	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008
--	-----------	--------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

EQ 150MG BASE	A078653	001	Nov 26, 2007
EQ 150MG BASE	A078701	001	Nov 12, 2009
EQ 300MG BASE	A078701	002	Dec 11, 2009

TABLET, EFFERVESCENT;ORAL

ZANTAC 150

GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994
---------------	---------------	---------	-----	--------------

ZANTAC 25

GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004
---------------	--------------	---------	-----	--------------

ZANTAC 75

+ SANOFI US	EQ 75MG BASE **	N020745	001	Feb 26, 1998
-------------	-----------------	---------	-----	--------------

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

LUPIN LTD	500MG	A201046	001	Jul 29, 2013
	1GM	A201046	002	Jul 29, 2013

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION

RAPLON

ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
	200MG/VIAL	N020984	002	Aug 18, 1999

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276	003
	50MG	N009276	005
	100MG	N009276	004

HYSERPIN

PHYS PRODS VA	50MG	N010581	001
---------------	------	---------	-----

KONGLUCOID

PANRAY	50MG	N009278	001
	100MG	N009278	002

RAUDIXIN

APOTHECON	50MG	N008842	001
	100MG	N008842	002

RAUSERPIN

FERNDALE LABS	50MG	N009926	002
	100MG	N009926	004

RAUVAL

PAL PAK	50MG	N009108	002
	100MG	N009108	004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477	001
	100MG	N009477	002

HALSEY	50MG	A080498	001
	100MG	A080498	002

IMPAX LABS	50MG	N009273	001
	100MG	N009273	002

IVAX SUB TEVA PHARMS	50MG	N011521	001
	100MG	N011521	002

PUREPAC PHARM	50MG	A080842	001
	100MG	A080842	002

PVT FORM	50MG	A080583	001
	100MG	A080583	002

SOLVAY	50MG	A080500	001
	100MG	A080500	002

TABLICAPS	50MG	A083867	001
	100MG	A083444	001

VALEANT PHARM INTL	50MG	N009668	001
	100MG	N009668	002

WATSON LABS	50MG	A080907	001
	100MG	A080914	001

WOLFINA

FOREST PHARMS	50MG	N009255	008
	100MG	N009255	006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET; ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE; INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET; ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

RAU-SED

BRISTOL MYERS SQUIBB

0.1MG

N009357 001

0.25MG

N009357 004

0.5MG

N009357 006

1MG

N009357 008

RESERPINE

BARR

0.25MG

A080721 002

BELL PHARMA

0.1MG

A083058 001

0.25MG

A083058 002

BUNDY

0.1MG

N009663 001

0.25MG

N009663 003

CYCLE PHARMS LTD

0.1MG

N009859 001

0.25MG

N009859 002

ELKINS SINN

0.1MG

A083145 001

0.25MG

A083145 002

EVERYLIFE

0.1MG

N010441 001

0.25MG

N010441 002

0.5MG

N010441 003

1MG

N010441 004

HALSEY

0.1MG

A080457 002

0.25MG

A080457 001

1MG

A080457 003

HIKMA INTL PHARMS

0.1MG

A080975 001

0.25MG

A080975 002

1MG

A080975 003

IMPAX LABS

0.1MG

N009627 001

0.25MG

N009627 002

IVAX SUB TEVA PHARMS

0.1MG

N011185 001

0.25MG

N011185 002

MARSHALL PHARMA

0.1MG

A080492 001

0.25MG

A080492 002

MK LABS

0.1MG

A080525 002

0.25MG

A080525 001

MYLAN

1MG

A084974 001

PHARMAVITE

0.25MG

A084663 001

PUREPAC PHARM

0.1MG

A080753 002

0.25MG

A080753 001

PVT FORM

0.1MG

A086117 001

0.25MG

A080582 001

0.25MG

A085775 001

1MG

A080582 002

REXALL

0.25MG

A080637 001

+ SANDOZ

0.1MG

N009838 001

+ SOLVAY

0.25MG

N009838 002

SOLVAY

0.25MG

A080446 001

TABLICAPS

0.25MG

A085207 001

TEVA

0.1MG

A089020 001 Mar 07, 1985

0.25MG

A089019 001 Mar 07, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINE

TABLET;ORAL

RESERPINE

VALEANT PHARM INTL	0.1MG	N009667 001
	0.25MG	N009667 002
WATSON LABS	0.1MG	A080679 001
	0.25MG	A080393 001
	0.25MG	A085401 001
	1MG	A080749 001
WHITEWORTH TOWN PLSN	0.1MG	A080723 001
	0.25MG	A080723 002
	1MG	A080723 003
SANDRIL		
LILLY	0.1MG	N009376 004
	0.25MG	N009376 001
SERPALAN		
LANNETT	0.1MG	N010124 001
	0.25MG	N010124 002
SERPANRAY		
PANRAY	0.1MG	N009391 001
	0.25MG	N009391 002
	1MG	N009391 004
SERPASIL		
NOVARTIS	0.1MG	N009115 001
	0.25MG	N009115 003
	1MG	N009115 004
SERPATE		
VALE	0.1MG	N009453 001
	0.25MG	N009453 002
SERPIVITE		
VITARINE	0.25MG	N009645 002

RESERPINE; TRICHLORMETHIAZIDE

TABLET;ORAL

METATENSIN #2

SANOFI AVENTIS US	0.1MG;2MG	N012972 001
METATENSIN #4		
SANOFI AVENTIS US	0.1MG;4MG	N012972 002
NAQUIVAL		
SCHERING	0.1MG;4MG	N012265 003
TRICHLORMETHIAZIDE W/ RESERPINE		
WATSON LABS	0.1MG;4MG	A085248 001

RIBAVIRIN

CAPSULE;ORAL

REBETOL

MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy**	N020903 001	Jun 03, 1998
-------------------	---	-------------	--------------

TABLET;ORAL

COPEGUS

ROCHE	400MG	N021511 002	Jun 21, 2005
-------	-------	-------------	--------------

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL

FLUMADINE

FOREST LABS	50MG/5ML	N019650 001	Sep 17, 1993
-------------	----------	-------------	--------------

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A076375 001	Jan 14, 2003
IMPAX LABS INC	100MG	A075916 001	Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

ALCON	1%	N020474 001	Dec 30, 1994
-------	----	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

+ APIL

75MG **

N020835 004 Apr 16, 2007

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

SILARX PHARMS INC

1MG/ML

A202386 001 Jan 12, 2015

WOCKHARDT

1MG/ML

A078744 001 Oct 08, 2009

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005 Dec 29, 1993

RISPERIDONE

JUBILANT CADISTA

0.25MG

A078828 001 Mar 23, 2009

0.5MG

A078828 002 Mar 23, 2009

1MG

A078828 003 Mar 23, 2009

2MG

A078828 004 Mar 23, 2009

3MG

A078828 005 Mar 23, 2009

4MG

A078828 006 Mar 23, 2009

RATIOPHARM

0.25MG

A077784 001 Jun 08, 2010

0.5MG

A077784 002 Jun 08, 2010

1MG

A077784 003 Jun 08, 2010

2MG

A077784 004 Jun 08, 2010

3MG

A077784 005 Jun 08, 2010

4MG

A077784 006 Jun 08, 2010

SYNTHON PHARMS

0.25MG

A078187 001 Oct 22, 2009

0.5MG

A078187 002 Oct 22, 2009

1MG

A078187 003 Oct 22, 2009

2MG

A078187 004 Oct 22, 2009

3MG

A078187 005 Oct 22, 2009

4MG

A078187 006 Oct 22, 2009

WATSON LABS

0.25MG

A077860 001 Dec 05, 2008

0.5MG

A077860 002 Dec 05, 2008

1MG

A077860 003 Dec 05, 2008

2MG

A077860 004 Dec 05, 2008

3MG

A077860 005 Dec 05, 2008

4MG

A077860 006 Dec 05, 2008

WEST WARD PHARMS

0.25MG

A078740 001 May 29, 2009

0.5MG

A078740 002 May 29, 2009

1MG

A078740 003 May 29, 2009

2MG

A078740 004 May 29, 2009

3MG

A078740 005 May 29, 2009

4MG

A078740 006 May 29, 2009

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

MYLAN PHARMS INC

0.25MG

A091537 006 Feb 12, 2013

0.5MG

A091537 001 Mar 30, 2011

1MG

A091537 002 Mar 30, 2011

2MG

A091537 003 Mar 30, 2011

3MG

A091537 004 Mar 30, 2011

4MG

A091537 005 Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM

10MG/ML

A071188 001 Jul 23, 1987

15MG/ML

A071189 001 Jul 23, 1987

HOSPIRA

10MG/ML

A071618 001 Feb 28, 1991

15MG/ML

A071619 001 Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001 Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001 Mar 01, 1996

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

NOVARTIS

EQ 2MG BASE/ML

N021025 001 Apr 21, 2000

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

+ ORGANON USA INC

50MG/5ML (10MG/ML) **

N020214 001 Mar 17, 1994

+

10MG/ML (10MG/ML) **

N020214 002 Mar 17, 1994

+

100MG/10ML (10MG/ML) **

N020214 003 Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001 May 20, 1999

25MG/5ML

N021052 002 May 20, 1999

TABLET; ORAL

VIOXX

MERCK

12.5MG

N021042 001 May 20, 1999

25MG

N021042 002 May 20, 1999

50MG

N021042 003 Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

EPIC PHARMA LLC

EQ 0.25MG BASE

A078230 001 May 20, 2008

EQ 0.5MG BASE

A078230 002 May 20, 2008

EQ 1MG BASE

A078230 003 May 20, 2008

EQ 2MG BASE

A078230 004 May 20, 2008

EQ 3MG BASE

A078230 005 May 20, 2008

EQ 4MG BASE

A078230 006 May 20, 2008

EQ 5MG BASE

A078230 007 May 20, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+ GLAXOSMITHKLINE LLC

EQ 3MG BASE **

N022008 002 Jun 13, 2008

ROPINIROLE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 3MG BASE

A200462 002 Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

FRESENIUS KABI USA

50MG/10ML (5MG/ML)

N020533 013 May 01, 1998

75MG/10ML (7.5MG/ML)

N020533 012 Sep 24, 1996

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL

N016224 001

1mCi/VIAL

N016224 002

2mCi/VIAL

N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML

N017318 001

RUFINAMIDE

TABLET; ORAL

BANZEL

+ EISAI INC

100MG **

N021911 001 Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

+ HOFFMANN LA ROCHE

200MG **

N020828 001 Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

100MG

A085903 001

PARKE DAVIS

100MG

A084762 001

PERRIGO

100MG

A084561 001

PUREPAC PHARM

100MG

A085867 001

VALEANT PHARM INTL

100MG

A085477 001

VITARINE

100MG

A085898 001

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

60MG

A086530 002

120MG

A086530 003

200MG

A086530 004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING

75CU/VIAL

N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFFLO

CHIRHOCLIN

16MCG/VIAL

N021136 001 Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

LANNETT HOLDINGS INC 5MG

A075145 001 Sep 15, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996
	5MG	A074641	001	Aug 02, 1996
G AND W LABS INC	5MG	A074537	001	Aug 02, 1996
	5MG	A074744	001	Jan 27, 1997
	5MG	A074756	001	Nov 25, 1998
SIEGFRIED	5MG	A074672	001	Apr 01, 1997
+ SOMERSET	5MG **	N019334	001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT	2.5%	A083892	001	
SELENIUM SULFIDE				
ACTAVIS MID ATLANTIC	2.5%	A084394	001	
G AND W LABS INC	2.5%	A086209	001	
IVAX PHARMS	2.5%	A085777	001	

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001	
MALLINCKRODT	100uCi/ML	N017098	001	
PHARMALUCENCE	500uCi/ML	N017322	001	
SETHOTOPE				
BRACCO	85-550uCi/ML	N017047	001	

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+ EMD SERONO	EQ 0.05MG BASE/AMP **	N019863	001	Dec 28, 1990
+ EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443	001	Sep 26, 1997
+	EQ 1MG BASE/VIAL **	N020443	002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006
RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007
	EQ 50MG BASE	A076881	002	Feb 06, 2007
	EQ 100MG BASE	A076881	003	Feb 06, 2007
ACTAVIS ELIZABETH	EQ 25MG BASE	A077345	001	Feb 06, 2007
	EQ 50MG BASE	A077345	002	Feb 06, 2007
	EQ 100MG BASE	A077345	003	Feb 06, 2007
ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007
	EQ 50MG BASE	A077818	002	Feb 06, 2007
	EQ 100MG BASE	A077818	003	Feb 06, 2007
CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007
	EQ 50MG BASE	A077162	002	Feb 06, 2007
	EQ 100MG BASE	A077162	003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
	EQ 50MG BASE	A077864	002	Aug 10, 2009
	EQ 100MG BASE	A077864	003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
	EQ 50MG BASE	A075719	001	Jun 30, 2006
	EQ 100MG BASE	A075719	002	Jun 30, 2006
MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007
	EQ 50MG BASE	A076671	002	Feb 06, 2007
	EQ 100MG BASE	A076671	003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
	EQ 50MG BASE	A076540	002	Mar 20, 2007
	EQ 100MG BASE	A076540	003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299	001	Feb 06, 2007
	EQ 50MG BASE	A077299	002	Feb 06, 2007
	EQ 100MG BASE	A077299	003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713	001	Feb 06, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	EQ 50MG BASE	A077713 002	Feb 06, 2007
	EQ 100MG BASE	A077713 003	Feb 06, 2007
SCIEGEN PHARMS INC	EQ 25MG BASE	A076442 001	Apr 30, 2007
	EQ 50MG BASE	A076442 002	Apr 30, 2007
	EQ 100MG BASE	A076442 003	Apr 30, 2007
SUN PHARM INDS (IN)	EQ 25MG BASE	A078108 001	Feb 06, 2007
	EQ 50MG BASE	A078108 002	Feb 06, 2007
	EQ 100MG BASE	A078108 003	Feb 06, 2007
WATSON LABS TEVA	EQ 25MG BASE	A077663 001	Feb 06, 2007
	EQ 50MG BASE	A077663 002	Feb 06, 2007
	EQ 100MG BASE	A077663 003	Feb 06, 2007
ZOLOFT			
+ PFIZER	EQ 150MG BASE **	N019839 003	Dec 30, 1991
+	EQ 200MG BASE **	N019839 004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL

RENAGEL

GENZYME	403MG	N020926 001	Oct 30, 1998
---------	-------	-------------	--------------

SIBUTRAMINE HYDROCHLORIDE

CAPSULE;ORAL

MERIDIA

ABBOTT	5MG	N020632 001	Nov 22, 1997
	10MG	N020632 002	Nov 22, 1997
	15MG	N020632 003	Nov 22, 1997

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

ACTAVIS GRP PTC	EQ 20MG BASE	A200149 001	Feb 25, 2013
-----------------	--------------	-------------	--------------

SILVER SULFADIAZINE

DRESSING;TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989
-----------------	----	-------------	--------------

SIMETHICONE-CELLULOSE

SUSPENSION;ORAL

SONORX

BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998
--------	----------	-------------	--------------

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

FOSUN PHARMA	5MG	A077766 001	Dec 20, 2006
	10MG	A077766 002	Dec 20, 2006
	20MG	A077766 003	Dec 20, 2006
	40MG	A077766 004	Dec 20, 2006
	80MG	A077766 005	Dec 20, 2006
MYLAN PHARMS INC	5MG	A090868 001	Jun 08, 2010
	10MG	A090868 002	Jun 08, 2010
	20MG	A090868 003	Jun 08, 2010
	40MG	A090868 004	Jun 08, 2010
	80MG	A090868 005	Jun 08, 2010
SUN PHARM INDS LTD	5MG	A076285 001	Dec 20, 2006
	10MG	A076285 002	Dec 20, 2006
	20MG	A076285 003	Dec 20, 2006
	40MG	A076285 004	Dec 20, 2006
	80MG	A076285 005	Jun 23, 2006
TABLET, ORALLY DISINTEGRATING;ORAL			
SIMVASTATIN			
SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
	20MG	N021961 002	Oct 09, 2007
	40MG	N021961 003	Oct 09, 2007
	80MG	N021961 004	Oct 09, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343 004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343 001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343 005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343 002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343 006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343 003	Oct 07, 2011

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+	PF PRISM CV	5MG **	N021110 003	Feb 23, 2004
---	-------------	--------	-------------	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

	B BRAUN	100MG/ML;100MG/ML	N019530 001	Dec 23, 1987
--	---------	-------------------	-------------	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

+	ABBOTT	0.9MEQ/ML **	N019443 001	Jun 03, 1986
+		1MEQ/ML **	N019443 002	Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985
--	------------------	-------------------	-------------	--------------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABRAXIS PHARM	9MG/ML	A088909 001	Feb 07, 1985
--	---------------	--------	-------------	--------------

SODIUM CHLORIDE

	ABBOTT	20GM/100ML	N017013 001	
--	--------	------------	-------------	--

	B BRAUN	20GM/100ML	N017038 001	
--	---------	------------	-------------	--

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	450MG/100ML	N018184 001	
--	---------	-------------	-------------	--

	MILES	450MG/100ML	N018503 001	
--	-------	-------------	-------------	--

SODIUM CHLORIDE 0.9%

	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832 002	Jan 06, 2012
--	-------------	-------------------	-------------	--------------

		22.5MG/2.5ML (9MG/ML)	N202832 003	Jan 06, 2012
--	--	-----------------------	-------------	--------------

		27MG/3ML (9MG/ML)	N202832 004	Jan 06, 2012
--	--	-------------------	-------------	--------------

		45MG/5ML (9MG/ML)	N202832 005	Jan 06, 2012
--	--	-------------------	-------------	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	9MG/ML	N019218 001	Jul 13, 1984
--	--------	--------	-------------	--------------

	MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001	Jan 06, 2012
--	-------------	-----------------	-------------	--------------

	MILES	900MG/100ML	N018502 001	
--	-------	-------------	-------------	--

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

+	ABRAXIS PHARM	234MG/ML **	N019329 001	Apr 22, 1987
---	---------------	-------------	-------------	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	450MG/100ML	N017864 001	
--	-----------------	-------------	-------------	--

		450MG/100ML	N018497 001	Feb 19, 1982
--	--	-------------	-------------	--------------

	HOSPIRA	450MG/100ML	N017670 001	
--	---------	-------------	-------------	--

		450MG/100ML	N018380 001	
--	--	-------------	-------------	--

SODIUM CHLORIDE IN PLASTIC CONTAINER

	MILES	900MG/100ML	N018247 001	
--	-------	-------------	-------------	--

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

	BRACCO	2mCi/VIAL	N013993 002	
--	--------	-----------	-------------	--

		200uCi/ML	N013993 001	
--	--	-----------	-------------	--

SODIUM CHROMATE CR 51

	MALLINKRODT NUCLEAR	100uCi/ML	N016708 001	
--	---------------------	-----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

+ GE HEALTHCARE

2mCi/ML **

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML **

N022494 001 Jan 26, 2011

SODIUM FLUORIDE F-18

UIHC PET IMAGING

10-200mCi/ML

A204462 001 Nov 17, 2015

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

JUBILANT DRAXIMAGE

100uCi

N017316 002

MALLINKRODT NUCLEAR

2-200mCi

N021305 004 Nov 18, 2004

0.8-100mCi

N016515 002

15-100uCi

N016517 002

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

BAXTER HLTHCARE

1.87GM/100ML

N016692 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N020004 001 Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

+

ABBVIE

50MG/VIAL **

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM

50MG/VIAL

A070031 001 Jan 17, 1985

+

BAXTER HLTHCARE

50MG/VIAL **

N018581 001 Jul 28, 1982

TEVA PARENTERAL

25MG/ML

A073465 001 Mar 30, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM PHOSPHATE P-32SOLUTION;INJECTION, ORAL
PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N010927 001
SODIUM PHOSPHATE P 32		
MALLINCKRODT	0.67mCi/ML	N011777 001
	1.5mCi/VIAL	N011777 002

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATETABLET;ORAL
VISICOL

SALIX PHARMS	0.398GM;1.102GM	N021097 001	Sep 21, 2000
--------------	-----------------	-------------	--------------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC	0.398GM;1.102GM	A079247 001	Dec 30, 2011
----------------	-----------------	-------------	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KAYEXALATE

+ CONCORDIA PHARMS INC	453.6GM/BOT	N011287 001
------------------------	-------------	-------------

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA	454GM/BOT	A040909 001	Dec 03, 2008
WOCKHARDT	453.6GM/BOT	A088786 001	Sep 11, 1984

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
ROXANE	15GM/60ML	A088453 001	Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE;INJECTION

SODIUM SUCCINATE

ELKINS SINN	30%	A080516 001
-------------	-----	-------------

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SOTRADECOL

+ ELKINS SINN	1% **	N005970 004
+	3% **	N005970 005

SODIUM THIOSULFATE

INJECTABLE;INJECTION

SODIUM THIOSULFATE

US ARMY	250MG/ML	N020166 001	Feb 14, 1992
---------	----------	-------------	--------------

SOMATREM

INJECTABLE;INJECTION

PROTROPIN

GENENTECH	5MG/VIAL	N019107 001	Oct 17, 1985
	10MG/VIAL	N019107 002	Oct 24, 1989

SOMATROPIN

INJECTABLE;INJECTION

ASELLACRIN 10

SERONO	10 IU/VIAL	N017726 001
--------	------------	-------------

ASELLACRIN 2

SERONO	2 IU/VIAL	N017726 002	Jul 21, 1983
--------	-----------	-------------	--------------

CRESCORMON

GENENTECH	4 IU/VIAL	N017992 001
-----------	-----------	-------------

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

ACCRETROPIN

EMERGENT	5MG/ML (5MG/ML)	N021538 001	Jan 23, 2008
----------	-----------------	-------------	--------------

BIO-TROPIN

FERRING	4.8MG/VIAL	N019774 001	May 25, 1995
---------	------------	-------------	--------------

HUMATROPE

LILLY	2MG/VIAL	N019640 001	Jun 23, 1987
-------	----------	-------------	--------------

NORDITROPIN

NOVO NORDISK INC	4MG/VIAL	N019721 001	May 08, 1995
	5MG/1.5ML	N021148 001	Jun 20, 2000
	8MG/VIAL	N019721 002	May 08, 1995
	10MG/1.5ML	N021148 002	Jun 20, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

	15MG/1.5ML	N021148 003	Jun 20, 2000
NORDITROPIN NORDIFLEX			
NOVO NORDISK INC	5MG/1.5ML	N021148 004	Oct 01, 2004
	10MG/1.5ML	N021148 005	Oct 01, 2004
	15MG/1.5ML	N021148 006	Oct 01, 2004
	30MG/3ML	N021148 007	Mar 10, 2009
NUTROPIN			
GENENTECH	5MG/VIAL	N020168 001	Nov 17, 1993
	10MG/VIAL	N020168 002	Nov 17, 1993
NUTROPIN AQ			
GENENTECH	10MG/2ML (5MG/ML)	N020522 001	Dec 29, 1995
NUTROPIN DEPOT			
GENENTECH	13.5MG/VIAL	N021075 001	Dec 22, 1999
	18MG/VIAL	N021075 002	Dec 22, 1999
	22.5MG/VIAL	N021075 003	Dec 22, 1999
SAIZEN			
EMD SERONO	4MG/VIAL	N019764 005	Jan 16, 2007
	6MG/VIAL	N019764 001	Oct 08, 1996
SEROSTIM			
EMD SERONO	8.8MG/VIAL	N020604 004	Sep 06, 2001
ZORBITIVE			
EMD SERONO	4MG/VIAL	N021597 001	Dec 01, 2003
	5MG/VIAL	N021597 002	Dec 01, 2003
	6MG/VIAL	N021597 003	Dec 01, 2003
INJECTABLE; SUBCUTANEOUS			
SEROSTIM LQ			
EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604 005	Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N018512 001	May 27, 1982
-----------------	-----------	-------------	--------------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

COVIS PHARMA BV	320MG	N019865 004	Oct 30, 1992
BETAPACE AF			
COVIS PHARMA BV	40MG	N021151 006	Apr 02, 2003
	60MG	N021151 007	Apr 02, 2003
	100MG	N021151 005	Mar 14, 2003

SOTALOL HYDROCHLORIDE

IMPAX PHARMS	80MG	A075663 001	Nov 07, 2000
	120MG	A075663 002	Nov 07, 2000
	160MG	A075663 003	Nov 07, 2000
	240MG	A075663 004	Nov 07, 2000
MYLAN	80MG	A075237 001	May 01, 2000
	80MG	A075725 001	Dec 19, 2000
	120MG	A075237 002	May 01, 2000
	120MG	A075725 002	Dec 19, 2000
	160MG	A075237 003	May 01, 2000
	160MG	A075725 003	Dec 19, 2000
	240MG	A075237 004	May 01, 2000
	240MG	A075725 004	Dec 19, 2000
SUN PHARM INDUSTRIES	80MG	A075515 001	Oct 15, 2001
	80MG	A076576 001	Apr 08, 2004
	120MG	A075515 004	Oct 15, 2001
	120MG	A076576 002	Apr 08, 2004
	160MG	A075515 002	Oct 15, 2001
	160MG	A076576 003	Apr 08, 2004
	240MG	A075515 003	Oct 15, 2001
TEVA	80MG	A076883 001	Jul 26, 2004
	120MG	A076883 002	Jul 26, 2004
	160MG	A076883 003	Jul 26, 2004
WATSON LABS	80MG	A075238 001	Jul 13, 2000
	120MG	A075238 002	Jul 13, 2000
	160MG	A075238 003	Jul 13, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

240MG

A075238 004 Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

HOSPIRA

10%

N018969 001 Sep 24, 1984

LIPOSYN III 20%

HOSPIRA

20%

N018970 001 Sep 25, 1984

LIPOSYN III 30%

HOSPIRA

30%

N020181 001 Jan 13, 1998

SOYACAL 10%

ALPHA THERA

10%

N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

STAVUDINE

MYLAN LABS LTD

30MG

A078775 001 Jan 05, 2009

40MG

A078775 002 Jan 05, 2009

ZERIT

BRISTOL MYERS SQUIBB 5MG

N020412 001 Jun 24, 1994

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

STAVUDINE

CAPSULE, EXTENDED RELEASE;ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG
	50MG
	75MG
	100MG

N021453	001	Dec 31, 2002
N021453	002	Dec 31, 2002
N021453	003	Dec 31, 2002
N021453	004	Dec 31, 2002

FOR SOLUTION;ORAL

STAVUDINE

AUROBINDO PHARMA 1MG/ML

A077774 001 Dec 29, 2008

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%
	100%

A089099	001	Dec 29, 1987
A089100	001	Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN 100%

N019077 001 Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES 100%

N018246 001

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML
LILLY	EQ 1GM BASE/VIAL
	EQ 1GM BASE/2ML
	EQ 5GM BASE/VIAL
PFIZER	EQ 1GM BASE/VIAL
	EQ 1GM BASE/2.5ML
	EQ 5GM BASE/VIAL

A060684	001
A060107	001
A060404	001
A060107	002
A060076	001
A060111	001
A060076	002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

SANDOZ INC	50MG/ML
	500MG/VIAL
	1GM/VIAL

N008453	003
N008453	001
N008453	004

QUELICIN PRESERVATIVE FREE

HOSPIRA	50MG/ML
	100MG/ML

N008845	002
N008845	004

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL
ORGANON USA INC	20MG/ML

A085400	001	Feb 04, 1982
A080997	001	

SUCOSTRIN

APOTHECON	20MG/ML
	100MG/ML

N008847	001
N008847	003

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

WATSON LABS EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

BLEPH-10

ALLERGAN 10%

A084015 001

CETAMIDE

ALCON 10%

A080021 001

SODIUM SULAMYD

+ SCHERING 10% **

N005963 002

SULFAIR 10

PHARMAFAIR 10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS;OPHTHALMIC

BLEPH-30

ALLERGAN 30%

A080028 002

ISOPTO CETAMIDE

ALCON 15%

A080020 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

OCUSULF-10

MIZA PHARMS USA 10% A080660 001

OCUSULF-30

MIZA PHARMS USA 30% A080660 002

SODIUM SULAMYD

+ SCHERING 10% ** N005963 001

+ 30% ** N005963 003

SODIUM SULFACETAMIDE

AKORN 10% A083021 001

15% A083021 002

30% A083021 003

SOLA BARNES HIND 10% A084143 001

10% A084145 001

30% A084146 001

30% A084147 001

SULF-10

NOVARTIS 10% A080025 001

SULF-15

NOVARTIS 15% A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS 15% A080024 001

SULFACETAMIDE SODIUM

AKORN 30% A040216 001 May 25, 1999

ALCON PHARMS LTD 30% A089068 001 May 05, 1987

PHARMAFAIR 10% A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR 10% A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR 30% A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR 15% A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB 10% A087818 001 Feb 03, 1983

SULFACYTINE

TABLET;ORAL

RENOQUID

GLENWOOD 250MG N017569 001

SULFADIAZINE

TABLET;ORAL

SULFADIAZINE

ABBVIE 300MG N004125 005

EVERYLIFE 500MG A080088 001

IMPAX LABS 500MG A080081 001

LANNETT 500MG A080084 001

LEDERLE 500MG N004054 001

LILLY 500MG N004122 002

SULFADIAZINE SODIUM

INJECTABLE;INJECTION

SULFADIAZINE SODIUM

LEDERLE 250MG/ML N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION;ORAL

SULFONAMIDES DUPLEX

LILLY 250MG/5ML;250MG/5ML N006317 007

SULFAMETER

TABLET;ORAL

SULLA

BAYER HLTHCARE 500MG N016000 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS 1GM A086012 001

PROKLAR

FOREST PHARMS 500MG A080273 001

THIOSULFIL

WYETH AYERST 250MG N008565 001

500MG N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE 500MG/5ML N013664 002

TABLET; ORAL

GANTANOL

ROCHE 500MG N012715 002

GANTANOL-DS

ROCHE 1GM N012715 003

SULFAMETHOXAZOLE

ASCOT 500MG A087662 001 Oct 20, 1982

AUROLIFE PHARMA LLC 500MG A085844 001

BARR 500MG A087189 001 Jul 25, 1983

HEATHER 500MG A086163 001

WATSON LABS 500MG A085053 001

1GM A086000 001

UROBAK

SHIONOGI 500MG A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

+ SUN PHARM INDS INC 80MG/ML; 16MG/ML ** N018374 001

SEPTRA

MONARCH PHARMS 80MG/ML; 16MG/ML N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM 80MG/ML; 16MG/ML A070223 001 Dec 29, 1987

BEDFORD 80MG/ML; 16MG/ML A072383 001 Apr 29, 1992

HOSPIRA 80MG/ML; 16MG/ML A073199 001 Sep 11, 1992

WATSON LABS 80MG/ML; 16MG/ML A071556 001 Dec 29, 1987

WEST-WARD PHARMS INT 80MG/ML; 16MG/ML A070627 001 Dec 29, 1987

80MG/ML; 16MG/ML A070628 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

SUN PHARM INDUSTRIES 200MG/5ML; 40MG/5ML ** N017560 001

BACTRIM PEDIATRIC

SUN PHARM INDUSTRIES 200MG/5ML; 40MG/5ML ** N017560 002

SEPTRA

MONARCH PHARMS 200MG/5ML; 40MG/5ML ** N017598 001

SEPTRA GRAPE

MONARCH PHARMS 200MG/5ML; 40MG/5ML ** N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS INC 200MG/5ML; 40MG/5ML A070028 001 Jun 02, 1987

200MG/5ML; 40MG/5ML ** A077612 001 Nov 13, 2006

TEVA 200MG/5ML; 40MG/5ML N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML N018812 002 Jun 10, 1983

SULFATRIM

STI PHARMA LLC 200MG/5ML; 40MG/5ML N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA 200MG/5ML; 40MG/5ML A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML; 40MG/5ML A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML; 40MG/5ML A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML A072398 001 May 23, 1988

NASKA 200MG/5ML; 40MG/5ML A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA 400MG; 80MG A070034 001 May 16, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

COTRIM D.S.

TEVA	800MG;160MG	A070048	001	Mar 18, 1985
SULFAMETHOPRIM				
NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985
SULFAMETHOPRIM-DS				
NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
HEATHER	400MG;80MG	N018946	001	Aug 10, 1984
	800MG;160MG	N018946	002	Aug 10, 1984
INTERPHARM	400MG;80MG	A071299	001	Oct 27, 1987
	800MG;160MG	A071300	001	Oct 27, 1987
MARTEC USA LLC	400MG;80MG	A072408	001	Dec 07, 1988
MUTUAL PHARM	400MG;80MG	A070006	001	Nov 14, 1984
PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
	800MG;160MG	A070216	001	Sep 10, 1985
ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
SANDOZ	400MG;80MG	A070889	001	Nov 13, 1986
	400MG;80MG	N018598	003	May 19, 1982
	800MG;160MG	A070890	001	Nov 13, 1986
TEVA	400MG;80MG	N018242	001	
	800MG;160MG	N018242	002	
USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985
	800MG;160MG	A070204	001	Nov 08, 1985
WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
	400MG;80MG	N018852	001	May 09, 1983
	800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
SANDOZ	800MG;160MG	N018598	004	May 19, 1982
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

G AND W LABS INC 15% A088718 001 Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

MYLAN SPECIALITY LP 1.05GM N006530 004 Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC 500MG/5ML N013093 001

TABLET; ORAL

SULFABID

PURDUE FREDERICK 500MG N013092 002

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY 500MG N000159 001

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN 250MG/5ML N018605 001

TABLET; ORAL

S.A.S.-500

SOLVAY 500MG A083450 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

HERITAGE PHARMS INC	500MG	A080197	001	
SANDOZ	500MG	A086184	001	
SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS	500MG	A088052	001	May 24, 1983
-------------	-------	---------	-----	--------------

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

+ NOVARTIS	200MG **	N011556	004	
------------	----------	---------	-----	--

SULFINPYRAZONE

BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985
VANGARD	200MG	A088666	001	Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS	100MG **	N011556	003	
----------	----------	---------	-----	--

SULFINPYRAZONE

BARR	100MG	A087665	001	Sep 17, 1982
IVAX PHARMS	100MG	A087769	001	Jun 01, 1982
PAR PHARM	100MG	A088933	001	Sep 06, 1985
WATSON LABS	100MG	A087667	001	May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE	500MG	N006525	001	
-------	-------	---------	-----	--

SOSOL

MK LABS	500MG	A080036	001	
---------	-------	---------	-----	--

SOXAZOLE

ALRA	500MG	A080366	001	
------	-------	---------	-----	--

SULFALAR

PARKE DAVIS	500MG	A084955	001	
-------------	-------	---------	-----	--

SULFISOXAZOLE

ANI PHARMS INC	500MG	A080142	001	
AUROLIFE PHARMA LLC	500MG	A085628	001	
BARR	500MG	A084031	001	
HEATHER	500MG	A080189	001	
IMPAX LABS	500MG	A080109	001	
LANNETT	500MG	A080085	001	
LEDERLE	500MG	A087649	001	
PHARMERAL	500MG	A084385	001	
PUREPAC PHARM	500MG	A080087	001	
ROXANE	500MG	A080082	001	
VALEANT PHARM INTL	500MG	A080268	002	
VITARINE	500MG	A087332	001	
WATSON LABS	500MG	A085534	001	
WEST WARD	500MG	A080379	001	

SULSOXIN

SOLVAY	500MG	A080040	001	
--------	-------	---------	-----	--

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182	009	
-------	-----------------	---------	-----	--

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182	004	
-------	-------------------	---------	-----	--

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182	002	
-------	-------------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE

EQ 400MG BASE/ML

N006917 001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N008414 002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND

EQ 4% BASE

A084148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE

165MG

N006044 003

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS

33.32%

N002918 001

SULINDAC

TABLET; ORAL

CLINORIL

+ MERCK

150MG **

N017911 001

+

200MG **

N017911 002

SULINDAC

ANI PHARMS INC

150MG

A072972 001 Feb 28, 1992

200MG

A072973 001 Feb 28, 1992

SANDOZ

150MG

A072712 001 Aug 30, 1991

200MG

A072713 001 Aug 30, 1991

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

MERIDIAN MEDCL

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022377 001 Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

SANDOZ INC

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

SYSTEM; IONTOPHORESIS

ZECURITY

+ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR

N202278 001 Jan 17, 2013

TABLET; ORAL

SUMATRIPTAN SUCCINATE

HIKMA PHARMS

EQ 25MG BASE

A078298 001 May 21, 2013

EQ 50MG BASE

A078298 002 May 21, 2013

EQ 100MG BASE

A078298 003 May 21, 2013

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

SANDOZ

EQ 25MG BASE

A076976 001 Aug 10, 2009

EQ 50MG BASE

A076976 002 Aug 10, 2009

EQ 100MG BASE

A076976 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT;TOPICAL

TRAVASE

+ ABBOTT

82,000 UNITS/GM **

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE;ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010

TALBUTAL

TABLET;ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET;ORAL

NOLVADEX

+ ASTRAZENECA

EQ 10MG BASE **

N017970 001

+

EQ 20MG BASE **

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC

EQ 10MG BASE

A076179 001 Feb 20, 2003

EQ 20MG BASE

A076179 002 Feb 20, 2003

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE;INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNESCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE;INJECTION

MICROLITE

PHARMALUCENCE

N/A

N018263 001 Mar 25, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

JUBILANT DRAXIMAGE N/A

N017714 001

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

+ GE HEALTHCARE 2-100mCi/ML **

N017471 001

+ MALLINCKRODT 10-60mCi/ML **

N017725 001

PHARMALUCENCE 12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO 0.22-2.22 CI/GENERATOR

N017339 001

SOLUTION; INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

MALLINCKRODT NUCLEAR 0.25-3 CI/GENERATOR

N017243 002

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE 830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE N/A

N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML

N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A

N017784 001

TESULOID

BRACCO N/A

N016923 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO

N/A

N019928 001 Dec 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

+ GE HEALTHCARE

N/A

N020372 001 Feb 09, 1996

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

US WORLDMEDS LLC

EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELAPREVIR

TABLET; ORAL

INCIVEK

VERTEX PHARMS

375MG

N201917 001 May 23, 2011

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

+ THERAVANCE BIOPHARMA

EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009

TABLET; ORAL

TYZEKA

+ NOVARTIS

600MG

N022011 001 Oct 25, 2006

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005

400MG

N021144 001 Apr 01, 2004

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001 Oct 15, 1985

30MG

A070547 001 Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR

15MG

A071708 001 Sep 29, 1988

30MG

A071709 001 Sep 29, 1988

SUN PHARM INDUSTRIES

15MG

A071174 001 Jul 10, 1986

30MG

A071175 001 Jul 10, 1986

USL PHARMA

15MG

A070489 001 Jul 07, 1986

30MG

A070490 001 Jul 07, 1986

WATSON LABS

15MG

A070383 001 Mar 23, 1987

15MG

A071446 001 May 21, 1993

30MG

A070384 001 Mar 23, 1987

30MG

A071447 001 May 21, 1993

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA

10MG/ML

N020119 001 Jul 14, 1992

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

+ ABBOTT

EQ 1MG BASE **

N020347 001 Dec 14, 1994

+

EQ 2MG BASE **

N020347 002 Dec 14, 1994

+

EQ 5MG BASE **

N020347 003 Dec 14, 1994

+

EQ 10MG BASE **

N020347 004 Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE

A075384 001 Dec 01, 2000

EQ 2MG BASE

A075384 002 Dec 01, 2000

EQ 5MG BASE

A075384 003 Dec 01, 2000

EQ 10MG BASE

A075384 004 Dec 01, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

RANBAXY LABS LTD

EQ 1MG BASE

A076021 001 Aug 22, 2002

EQ 2MG BASE

A076021 002 Aug 22, 2002

EQ 5MG BASE

A076021 003 Aug 22, 2002

EQ 10MG BASE

A076021 004 Aug 22, 2002

SANDOZ

EQ 1MG BASE

A075667 001 Jul 28, 2000

EQ 2MG BASE

A075667 002 Jul 28, 2000

EQ 5MG BASE

A075667 003 Jul 28, 2000

EQ 10MG BASE

A075667 004 Jul 28, 2000

TABLET; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE

N019057 001 Aug 07, 1987

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

EQ 10MG BASE

N019057 004 Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A074530 001 Apr 21, 2000

EQ 2MG BASE

A074530 002 Apr 21, 2000

EQ 5MG BASE

A074530 003 Apr 21, 2000

EQ 10MG BASE

A074530 004 Apr 21, 2000

SANDOZ

EQ 1MG BASE

A074315 001 Dec 31, 1998

EQ 1MG BASE

A074657 001 Apr 28, 2000

EQ 2MG BASE

A074315 002 Dec 31, 1998

EQ 2MG BASE

A074657 002 Apr 28, 2000

EQ 5MG BASE

A074315 003 Dec 31, 1998

EQ 5MG BASE

A074657 003 Apr 28, 2000

EQ 10MG BASE

A074315 004 Dec 31, 1998

EQ 10MG BASE

A074657 004 Apr 28, 2000

TEVA

EQ 1MG BASE

A074446 001 May 18, 2000

EQ 2MG BASE

A074446 002 May 18, 2000

EQ 5MG BASE

A074446 003 May 18, 2000

EQ 10MG BASE

A074446 004 May 18, 2000

TERBINAFFINE

GEL; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020846 001 Apr 29, 1998

TERBINAFFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS

1%

N020192 001 Dec 30, 1992

GRANULE; ORAL

LAMISIL

+ NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

SOLUTION; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020749 001 Oct 17, 1997

TABLET; ORAL

TERBINAFFINE HYDROCHLORIDE

GEDEON RICHTER USA

EQ 250MG BASE

A077065 001 Jul 02, 2007

MYLAN

EQ 250MG BASE

A077136 001 Jul 02, 2007

EQ 250MG BASE

A077195 001 Jul 02, 2007

ROXANE

EQ 250MG BASE

A077223 001 Jul 02, 2007

WOCKHARDT

EQ 250MG BASE

A078229 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS

0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US

0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

+ PHARMACARE

1MG/ML **

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

+ ANI PHARMS INC

2.5MG **

N017849 001

+

5MG **

N017849 002

BRICANYL

SANOFI AVENTIS US

2.5MG

N017618 001

5MG

N017618 002

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS

0.8%

N019964 001 Feb 21, 1991

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

THERATECHNOLOGIES

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG

N016118 001

250MG

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ALLERGAN SALES LLC

2.5MG/24HR

N020489 001 Sep 29, 1995

5MG/24HR

N020489 002 May 02, 1997

TESTODERM

ALZA

4MG/24HR

N019762 001 Oct 12, 1993

6MG/24HR

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA

5MG/24HR

N020791 001 Dec 18, 1997

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS

25MG/ML

A086420 001 May 10, 1983

50MG/ML

A086419 001 Aug 23, 1983

100MG/ML

A086417 001 Jul 07, 1983

SOLUTION, METERED; TRANSDERMAL

AXIRON

+ ELI LILLY AND CO

30MG/1.5ML ACTUATION

N022504 001 Nov 23, 2010

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN

50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS

100MG/ML

A084401 001

100MG/ML

A086029 001

200MG/ML

A084401 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARMS 200MG/ML N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS 100MG/ML A083667 001

100MG/ML A085599 001

200MG/ML A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR 25MG/ML A080741 001

50MG/ML A080742 001

100MG/ML A080743 001

ELKINS SINN 25MG/ML A080276 001

LILLY 50MG/ML A080254 002

WATSON LABS 25MG/ML A080188 001

25MG/ML A085490 001

50MG/ML A080188 002

50MG/ML A085490 002

100MG/ML A080188 003

100MG/ML A083595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL 250MG A061658 001

250MG A061888 001

500MG A061658 002

500MG A061888 002

CYCLOPAR

WARNER CHILCOTT 250MG A061725 001

250MG A062175 001

250MG A062332 001

500MG A061725 002

500MG A062332 002

PANMYCIN

PHARMACIA AND UPJOHN 250MG A060347 001

RETET

SOLVAY 250MG A061443 001

500MG A061443 002

ROBITET

WYETH AYERST 250MG A061734 001

500MG A061734 002

SUMYCIN

APOTHECON 100MG A060429 002

125MG A060429 004

250MG A060429 001

500MG A060429 003

TETRACHEL

ANGUS 250MG A060343 001

500MG A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT 250MG A061802 001

500MG A061802 002

ELKINS SINN 250MG A060059 001

FERRANTE 125MG A060173 001

250MG A060173 002

HEATHER 250MG A061148 001

500MG A061148 002

HIKMA PHARMS 250MG A060768 001

500MG A060768 002

IDT AUSTRALIA LTD 250MG A061471 001

IMPAX LABS 100MG A060469 002

250MG A060469 001

500MG A060469 003

IVAX SUB TEVA PHARMS 250MG A060704 001

500MG A060704 002

MAST MM 250MG A062085 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

MYLAN	250MG	A060783 001	
	500MG	A060783 002	
PUREPAC PHARM	250MG	A060290 001	
	500MG	A060290 002	
PVT FORM	250MG	A062686 001	Jul 24, 1986
	500MG	A062686 002	Jul 24, 1986
ROXANE	500MG	A061214 002	
SUN PHARM INDUSTRIES	250MG	A060736 001	
	500MG	A060736 002	
SUPERPHARM	250MG	A062540 001	Mar 21, 1985
	500MG	A062540 002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471 001	
	500MG	A060471 002	
WARNER CHILCOTT	250MG	A062300 001	
	500MG	A062300 002	
WATSON LABS	250MG	A062103 001	
	250MG	A062343 001	
	500MG	A062103 002	
	500MG	A062343 002	
WYETH AYERST	250MG	A061685 001	
	500MG	A061685 002	

TETRACYN

PFIPHARMECS	250MG	A060082 003	
	500MG	A060082 004	

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
---------------	--------------	-------------	--------------

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE	2.2MG/ML	N050493 001	
-------	----------	-------------	--

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	250MG/VIAL	N050273 002	
	500MG/VIAL	N050273 003	

TETRACYN

PFIZER	250MG/VIAL	A060096 001	
	500MG/VIAL	A060096 002	

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ	10MG/GM	N050266 001	
-------	---------	-------------	--

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE	125MG/5ML	N050263 002	
---------	-----------	-------------	--

SUMYCIN

PAR PHARM	125MG/5ML	A060400 001	
-----------	-----------	-------------	--

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633 001	
FERRANTE	125MG/5ML	A060174 001	
PROTER	125MG/5ML	A060446 001	
PUREPAC PHARM	125MG/5ML	A060291 001	

TETRACYN

PFIPHARMECS	125MG/5ML	A060095 001	
-------------	-----------	-------------	--

TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
----------------------	-----------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ	1%	N050268 001	
-------	----	-------------	--

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705 001	
	500MG	A061705 002	

SUMYCIN

PAR PHARM	50MG	A061147 003	
	100MG	A061147 002	
	250MG	A061147 001	
	500MG	A061147 004	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL	EQ 100MG HCL	A061653 001	
	EQ 250MG HCL	A061653 002	
	EQ 250MG HCL	A061889 002	
	EQ 250MG HCL	N050212 002	
	EQ 500MG HCL	A061653 003	
	EQ 500MG HCL	A061889 001	
	EQ 500MG HCL	N050212 003	

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548 001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569 001	Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

MALLINKRODT NUCLEAR	2mCi/ML	A077698 001	Nov 09, 2006
---------------------	---------	-------------	--------------

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US	100MG	A085264 001	
	200MG	A085264 002	

ELIXOPHYLLIN

FOREST LABS	100MG	A085545 001	Jul 31, 1984
	200MG	A083921 001	Jul 31, 1984

SOMOPHYLLIN-T

FISONS	100MG	A087155 001	Feb 25, 1985
	200MG	A087155 002	Feb 25, 1985
	250MG	A087155 003	Feb 25, 1985

THEOPHYLLINE

KV PHARM	100MG	A085263 001	
	200MG	A085263 002	
SCHERER RP	100MG	A084731 002	Nov 07, 1986
	200MG	A084731 001	Nov 07, 1986
	250MG	A084731 003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS	65MG	A085075 003	Nov 24, 1986
----------------	------	-------------	--------------

AEROLATE JR

FLEMING PHARMS	130MG	A085075 002	Nov 24, 1986
----------------	-------	-------------	--------------

AEROLATE SR

FLEMING PHARMS	260MG	A085075 001	Nov 24, 1986
----------------	-------	-------------	--------------

ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826 001	Jan 29, 1985
	250MG	A086826 002	Jan 29, 1985

SLO-BID

SANOFI AVENTIS US	50MG	A088269 001	Jan 31, 1985
	75MG	A089539 001	May 10, 1989
	100MG	A087892 001	Jan 31, 1985
	125MG	A089540 001	May 10, 1989
	200MG	A087893 001	Jan 31, 1985
	300MG	A087894 001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206 001	May 24, 1982
	125MG	A085203 001	May 24, 1982
	250MG	A085205 001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763 001	Feb 27, 1985
	100MG	A087194 001	
	200MG	A088382 001	Feb 27, 1985
	250MG	A087193 001	
	300MG	A088383 001	Feb 27, 1985

THEO-DUR

SCHERING	50MG	A088022 001	Sep 10, 1985
	75MG	A088015 001	Sep 10, 1985
	125MG	A088016 001	Sep 10, 1985
	200MG	A087995 001	Sep 10, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEOBID			
WHITBY	260MG	A085983 001	Mar 20, 1985
THEOBID JR.			
WHITBY	130MG	A087854 001	Mar 20, 1985
THEOCLEAR L.A.-130			
SCHWARZ PHARMA	130MG	A086569 001	May 27, 1982
THEOCLEAR L.A.-260			
SCHWARZ PHARMA	260MG	A086569 002	May 27, 1982
THEOPHYL-SR			
ORTHO MCNEIL PHARM	125MG	A086480 001	Feb 08, 1985
	250MG	A086471 001	Feb 08, 1985
THEOPHYLLINE			
CENT PHARMS			
	125MG	A088654 001	Feb 12, 1985
	250MG	A088689 001	Feb 12, 1985
HOSPIRA			
	100MG	A089976 001	Jan 04, 1995
	200MG	A089977 001	Jan 04, 1995
	300MG	A089932 001	Jan 04, 1995
INWOOD LABS			
	100MG	A040052 001	Feb 14, 1994
	125MG	A040052 002	Feb 14, 1994
	200MG	A040052 003	Feb 14, 1994
	300MG	A040052 004	Feb 14, 1994
SANDOZ	260MG	A087462 001	May 11, 1982
THEOPHYLLINE-SR			
SCHERER RP	300MG	A088255 001	Jun 12, 1986
THEOVENT			
SCHERING	125MG	A087010 001	Jan 31, 1985
	250MG	A087910 001	Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN			
CENCI	80MG/15ML	A088303 001	Jan 25, 1984
LANOPHYLLIN			
LANNETT	80MG/15ML	A084578 001	
THEOLIXIR			
PANRAY	80MG/15ML	A084559 001	
THEOPHYL-225			
ORTHO MCNEIL PHARM	112.5MG/15ML	A086485 001	
THEOPHYLLINE			
ALPHARMA US PHARMS	80MG/15ML	A089223 001	May 27, 1988
CENCI	80MG/15ML	A087679 001	Apr 15, 1982
CHARTWELL RX	80MG/15ML	A085952 001	
HALSEY	80MG/15ML	A085169 001	
PHARM ASSOC	80MG/15ML	A086720 001	
PRECISION DOSE	80MG/15ML	A085863 001	
ROXANE	80MG/15ML	A084739 001	
TARO	80MG/15ML	A089626 001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748 001	

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	40MG/100ML	N019083 001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	80MG/100ML	N019083 002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	160MG/100ML	N019083 003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N019212 001	Nov 07, 1984
	200MG/100ML	N019826 004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	4MG/ML	N019212 003	Nov 07, 1984
	400MG/100ML	N019212 002	Nov 07, 1984
	400MG/100ML	N019826 005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982
	40MG/100ML	N018649 001	Jul 26, 1982
	80MG/100ML	N018649 002	Jul 26, 1982
	160MG/100ML	N018649 003	Jul 26, 1982
	200MG/100ML	N018649 004	Jul 26, 1982
	320MG/100ML	N018649 006	Nov 13, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

400MG/100ML

N018649 005 Jul 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA INC

80MG/100ML

N019211 002 Dec 14, 1984

200MG/100ML

N019211 004 Dec 14, 1984

400MG/100ML

N019211 005 Dec 14, 1984

SOLUTION; ORAL

AEROLATE

FLEMING PHARMS

150MG/15ML

A089141 001 Dec 03, 1986

THEOLAIR

3M

80MG/15ML

A086107 001

THEOPHYLLINE

ROXANE

80MG/15ML

A087449 001 Sep 15, 1983

SUSPENSION; ORAL

ELIXICON

FOREST LABS

100MG/5ML

A085502 001

SYRUP; ORAL

ACCURBRON

SANOFI AVENTIS US

150MG/15ML

A088746 001 Nov 22, 1985

AQUAPHYLLIN

FERNDALE LABS

80MG/15ML

A087917 001 Jan 18, 1983

SLO-PHYLLIN

SANOFI AVENTIS US

80MG/15ML

A085187 001

THEOCLEAR-80

CENT PHARMS

80MG/15ML

A087095 001 Mar 01, 1982

THEOPHYLLINE

ALPHARMA US PHARMS

80MG/15ML

A086001 001

150MG/15ML

A086545 001

TABLET; ORAL

QUIBRON-T

MONARCH PHARMS

300MG

A088656 001 Aug 22, 1985

SLO-PHYLLIN

SANOFI AVENTIS US

100MG

A085202 001

200MG

A085204 001

THEOCLEAR-100

CENT PHARMS

100MG

A085353 002

THEOCLEAR-200

CENT PHARMS

200MG

A085353 001

THEOLAIR

MEDICIS

125MG

A086399 001

250MG

A086399 002

THEOPHYL-225

ORTHO MCNEIL PHARM

225MG

A084726 001

TABLET, CHEWABLE; ORAL

THEOPHYL

ORTHO MCNEIL PHARM

100MG

A086506 001 Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL

FOREST LABS

100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

LABID

WARNER CHILCOTT

250MG

A087225 001

QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOCHRON

NOSTRUM PHARMS LLC

300MG

A087400 002 Jan 11, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

TEVA PHARMS

450MG

A081236 001 Nov 09, 1992

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOPHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001 Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

HOSPIRA

100MG/ML

A040079 001 May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A080571 001

100MG/ML

A083534 001

200MG/ML

A080571 002

200MG/ML

A083534 002

WEST-WARD PHARMS INT

100MG/ML

A080575 001

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE;INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIETHYLPERAZINE MALEATE

SUPPOSITORY;RECTAL

TORECAN

NOVARTIS 10MG N013247 001

TABLET;ORAL

TORECAN

NOVARTIS 10MG N012753 001

THIOPENTAL SODIUM

SUSPENSION;RECTAL

PENTOTHAL

ABBOTT 400MG/GM N011679 001

THIORIDAZINE

SUSPENSION;ORAL

MELLARIL-S

NOVARTIS EQ 25MG HCL/5ML ** N017923 001

EQ 100MG HCL/5ML ** N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

MELLARIL

NOVARTIS 30MG/ML ** N011808 012

100MG/ML ** N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 100MG/ML A088229 001 Aug 23, 1983

ALPHARMA US PHARMS 30MG/ML A087766 001 Apr 26, 1983

ANI PHARMS INC 30MG/ML A089602 001 Nov 09, 1987

100MG/ML A089603 001 Nov 09, 1987

HI TECH PHARMA 30MG/ML A040125 001 Aug 16, 1996

100MG/ML A040126 001 Aug 16, 1996

PHARM ASSOC 30MG/ML A040187 001 Aug 28, 1997

100MG/ML A040213 001 May 29, 1998

SANDOZ 30MG/ML A088307 001 Nov 23, 1983

100MG/ML A088308 001 Nov 23, 1983

WOCKHARDT 30MG/ML A088258 001 Jul 25, 1983

100MG/ML A088227 001 Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE 30MG/ML A088941 001 Dec 16, 1985

100MG/ML A088942 001 Dec 16, 1985

TABLET;ORAL

MELLARIL

+ NOVARTIS 10MG ** N011808 003

+ 15MG ** N011808 016

+ 25MG ** N011808 006

+ 50MG ** N011808 011

+ 100MG ** N011808 009

+ 150MG ** N011808 017

+ 200MG ** N011808 015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC 10MG A088270 001 Apr 14, 1983

10MG A088493 001 May 17, 1985

15MG A088271 001 Apr 14, 1983

25MG A088272 001 Apr 14, 1983

50MG A088194 001 Apr 14, 1983

100MG A088273 001 Oct 03, 1983

100MG A088456 001 May 17, 1985

MUTUAL PHARM 10MG A088375 001 Nov 18, 1983

25MG A087264 001 Nov 18, 1983

50MG A088370 001 Nov 18, 1983

100MG A088379 001 Nov 16, 1983

MYLAN 10MG A088332 001 Jun 27, 1983

25MG A088333 001 Jun 27, 1983

50MG A088334 001 Jun 27, 1983

100MG A088335 001 Nov 18, 1983

PAR PHARM 10MG A088351 001 Dec 05, 1983

15MG A088352 001 Dec 05, 1983

25MG A088336 001 Dec 05, 1983

50MG A088322 001 Dec 05, 1983

100MG A088480 001 Dec 29, 1983

150MG A089764 001 Feb 09, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	200MG	A089765 001	Feb 09, 1988
ROXANE	10MG	A088663 001	Mar 15, 1984
	25MG	A088664 001	Mar 15, 1984
	50MG	A088665 001	Mar 15, 1984
	100MG	A089048 001	Feb 26, 1985
SANDOZ	10MG	A088131 001	Aug 30, 1983
	15MG	A088132 001	Aug 30, 1983
	25MG	A088133 001	Aug 30, 1983
	50MG	A088134 001	Aug 30, 1983
	100MG	A088135 001	Nov 20, 1984
	150MG	A088136 001	Sep 17, 1986
	200MG	A088137 001	Sep 17, 1986
SUN PHARM INDUSTRIES	15MG	A088461 001	Nov 18, 1983
	150MG	A088737 001	Sep 26, 1984
	200MG	A088738 001	Oct 16, 1984
SUPERPHARM	10MG	A089103 001	Jul 02, 1985
	25MG	A089104 001	Jul 02, 1985
	50MG	A089105 001	Jul 02, 1985
WATSON LABS	10MG	A088412 001	Sep 12, 1983
	10MG	A088476 001	Nov 08, 1983
	10MG	A088561 001	May 11, 1984
	15MG	A088345 001	Jul 28, 1983
	15MG	A088562 001	May 11, 1984
	25MG	A088296 001	Jul 28, 1983
	25MG	A088478 001	Nov 08, 1983
	25MG	A088755 001	Jul 24, 1984
	50MG	A088323 001	Jul 28, 1983
	50MG	A088479 001	Nov 08, 1983
	50MG	A088563 001	May 11, 1984
	100MG	A088284 001	Aug 25, 1983
	100MG	A088564 001	May 11, 1984
	100MG	A088736 001	Jul 24, 1984
	150MG	A088410 001	Mar 05, 1984
	150MG	A088869 001	Jun 28, 1985
	200MG	A088381 001	Mar 14, 1984
WATSON LABS TEVA	15MG	A088477 001	Nov 08, 1983
	25MG	A088567 001	May 11, 1984
	200MG	A088872 001	Apr 26, 1985
WEST WARD	10MG	A088658 001	Mar 26, 1984
	15MG	A088659 001	Mar 26, 1984
	25MG	A088660 001	Mar 26, 1984
	50MG	A088661 001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

+ IMMUNEX

15MG/VIAL **

N020058 001 Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL

A075698 001 Sep 20, 2001

IMMUNEX

15MG/VIAL

N011683 001

TEVA PARENTERAL

15MG/VIAL **

A075730 001 Apr 20, 2001

30MG/VIAL **

A075730 002 Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER

1MG **

N016584 001

2MG **

N016584 002

5MG **

N016584 003

10MG **

N016584 004

20MG **

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001 Aug 12, 1987

2MG

A071885 001 Aug 12, 1987

5MG

A071886 001 Aug 12, 1987

10MG

A071887 001 Aug 12, 1987

20MG

A072200 001 Dec 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

SANDOZ	1MG	A071529 002	Jun 24, 1987
	2MG	A071529 003	Jun 24, 1987
	5MG	A071529 001	Jun 24, 1987
	10MG	A071529 004	Jun 24, 1987
WATSON LABS	1MG	A070600 001	Jun 05, 1987
	2MG	A070601 001	Jun 05, 1987
	2MG	A071626 001	Jun 25, 1987
	5MG	A070602 001	Jun 05, 1987
	5MG	A071627 001	Jun 25, 1987
	10MG	A070603 001	Jun 05, 1987
	10MG	A071628 001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758 001	
THIOTHIXENE HYDROCHLORIDE			
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969 001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917 001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL			
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494 001	Jun 30, 1992
INJECTABLE; INJECTION			
NAVANE			
PFIZER	EQ 2MG BASE/ML	N016904 001	
	EQ 10MG BASE/VIAL	N016904 002	

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245 009	
	32MG	N002245 005	
	65MG	N002245 002	
	100MG	N002245 008	
	130MG	N002245 010	
	200MG	N002245 007	
	325MG	N002245 004	
THYROGLOBULIN			
IMPAX LABS	64.8MG	A080151 001	

THYTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US	10 IU/VIAL	N008682 001	
-------------------	------------	-------------	--

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646 006	Nov 29, 2005
	8MG	N020646 007	Nov 29, 2005
	10MG	N020646 008	Nov 29, 2005
	20MG	N020646 004	Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497 001	
	EQ 3GM BASE/VIAL	A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497 002	
	EQ 6GM BASE/VIAL	N050497 003	
	EQ 20GM BASE/VIAL	N050497 004	
	EQ 30GM BASE/VIAL	N050497 005	Apr 04, 1984

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979 001	Mar 24, 1993
	250MG	N019979 002	Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999
FOSUN PHARMA	250MG	A075318 001	Aug 20, 1999
	250MG	A075326 001	Aug 20, 1999
MYLAN	250MG	A075161 001	Sep 13, 1999
	250MG	A075316 001	Nov 02, 1999
WATSON LABS	250MG	A075309 001	Apr 26, 2000

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707 001	Mar 07, 1997
---------------------	------------------	-------------	--------------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TIMOPTIC

+ ATON	EQ 0.25% BASE **	N018086 001	
+	EQ 0.5% BASE **	N018086 002	

TABLET; ORAL

BLOCADREN

MERCK	5MG	N018017 001	
	10MG	N018017 002	
	20MG	N018017 004	

TIMOLOL MALEATE

FOSUN PHARMA	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989
QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	5MG	A072917 001	Jul 31, 1991
	10MG	A072270 001	Apr 11, 1989
	10MG	A072918 001	Jul 31, 1991
	20MG	A072271 001	Apr 11, 1989
	20MG	A072919 001	Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000
---------------	--------------	-------------	--------------

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983
--------	----	-------------	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 2MG BASE	A076283 001	Jul 12, 2002
	EQ 4MG BASE	A076283 002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371 001	Apr 09, 2003
	EQ 4MG BASE	A076371 002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321 001	Sep 30, 2004
	EQ 4MG BASE	A076321 002	Sep 30, 2004
MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003
	EQ 4MG BASE	A076282 002	Dec 16, 2003
ZANAFLEX			
+ COVIS PHARMA BV	EQ 2MG BASE **	N020397 002	Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
APOTEX INC	0.3%	A065087 001	Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008 004	
	EQ 10MG BASE/ML	A062707 001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477 005	
	EQ 40MG BASE/ML	A062008 001	
+	EQ 1.2GM BASE/VIAL **	N050519 001	

TOBRAMYCIN SULFATE

APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994
	EQ 40MG BASE/ML	A064021 002	May 31, 1994
	EQ 40MG BASE/ML	A064026 001	May 31, 1994
HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161 001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122 001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945 002	Aug 09, 1989
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991
TOBRAMYCIN SULFATE (PHARMACY BULK)			
HOSPIRA	EQ 40MG BASE/ML **	A063116 001	May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257 001	Nov 09, 1984
	600MG	N018257 002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162 001	Jan 14, 1986
	250MG	A070163 001	Jan 14, 1986
	500MG	A070164 001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165 001	Jan 10, 1986
	250MG	A070166 001	Jan 10, 1986
	500MG	A070167 001	Jan 10, 1986
FOSUN PHARMA	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986
G AND W LABS INC	100MG	N018894 001	Nov 02, 1984
	250MG	N018894 002	Nov 02, 1984
	500MG	N018894 003	Nov 02, 1984
INTERPHARM	250MG	A071270 001	Sep 23, 1986
	500MG	A071271 001	Sep 23, 1986
PAR PHARM	100MG	A070159 001	Jan 06, 1986
	250MG	A070160 001	Jan 06, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

	500MG		A070161	001	Jan 06, 1986
SANDOZ	100MG		A071633	001	Dec 09, 1987
SUN PHARM INDUSTRIES	100MG		A071357	001	Jul 16, 1987
	250MG		A071358	001	Jul 16, 1987
	500MG		A071359	001	Jul 16, 1987
SUPERPHARM	250MG		A070763	001	Jun 16, 1986
	500MG		A070764	001	Jun 16, 1986
USL PHARMA	100MG		A071355	001	Jan 11, 1988
	250MG		A070168	001	Apr 02, 1986
	500MG		A070169	001	Apr 02, 1986
WATSON LABS	100MG		A070242	001	Aug 01, 1986
	100MG		A070513	001	Jan 09, 1986
	250MG		A070243	001	Aug 01, 1986
	250MG		A070514	001	Jan 09, 1986
	500MG		A070244	001	Aug 01, 1986
	500MG		A070515	001	Jan 09, 1986
TOLINASE					
+ PHARMACIA AND UPJOHN	100MG **		N015500	002	
+	250MG **		N015500	004	
+	500MG **		N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS 25MG/ML N006403 005 Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG **		N010670	002	
	500MG **		N010670	001	

TOLBUTAMIDE

ALRA	500MG		A086141	001	
ASCOT	500MG		A087541	001	Mar 01, 1983
BARR	500MG		A087121	001	
DAVA PHARMS INC	500MG		A086926	001	
IVAX PHARMS	500MG		A087093	001	
PARKE DAVIS	500MG		A086047	001	
PUREPAC PHARM	500MG		A088950	001	Jun 17, 1985
SANDOZ	500MG		A086574	001	
	500MG		N012678	001	
SUPERPHARM	500MG		A088893	001	Nov 19, 1984
VANGARD	500MG		A087876	001	Apr 20, 1982
WATSON LABS	250MG		A089110	001	May 29, 1987
	500MG		A086109	001	
	500MG		A087318	001	
	500MG		A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN EQ 1GM BASE/VIAL N012095 001

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC 200MG N020697 002 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN EQ 400MG BASE N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 400MG BASE		A073308	001	Jan 24, 1992
IVAX SUB TEVA PHARMS	EQ 400MG BASE		A073392	001	Jan 24, 1992
SANDOZ	EQ 400MG BASE		A073462	001	Apr 30, 1992
SUN PHARM INDUSTRIES	EQ 400MG BASE		A073311	001	Nov 27, 1991
TEVA	EQ 400MG BASE		A073519	001	May 29, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLMETIN SODIUM

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH EQ 600MG BASE

A073527 001 Jun 30, 1992

G AND W LABS INC EQ 600MG BASE

A074399 001 Mar 28, 1996

EQ 600MG BASE

A074729 001 Feb 27, 1997

SANDOZ EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

SUN PHARM INDUSTRIES EQ 200MG BASE

A073310 001 Nov 27, 1991

TOLVAPTAN

TABLET; ORAL

SAMSCA

+ OTSUKA AMERICA PHARM 60MG **

N022275 003 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG

N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

MYLAN 15MG

A078418 001 Oct 14, 2009

25MG

A078418 002 Oct 14, 2009

SANDOZ 15MG

A079206 001 Oct 14, 2009

25MG

A079206 002 Oct 14, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS 300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA 25MG

A078637 001 Feb 27, 2013

50MG

A078637 002 Feb 27, 2013

100MG

A078637 003 Feb 27, 2013

200MG

A078637 004 Feb 27, 2013

BARR 25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

MYLAN 25MG

A076314 001 Mar 27, 2009

50MG

A076314 002 Mar 27, 2009

100MG

A076314 003 Mar 27, 2009

200MG

A076314 004 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE 25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

WATSON LABS 25MG

A077643 001 Mar 27, 2009

50MG

A077643 002 Mar 27, 2009

100MG

A077643 003 Mar 27, 2009

200MG

A077643 004 Mar 27, 2009

WOCKHARDT USA 25MG

A090353 001 Sep 01, 2010

50MG

A090353 002 Sep 01, 2010

100MG

A090353 003 Sep 01, 2010

200MG

A090353 004 Sep 01, 2010

TOPIRAMATE

HIKMA PHARMS 25MG

A091185 001 Nov 25, 2013

50MG

A091185 002 Nov 25, 2013

100MG

A091185 003 Nov 25, 2013

200MG

A091185 004 Nov 25, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199	001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199	002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199	003	Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

+	ROCHE	50MG/5ML (10MG/ML) **	N020137	002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137	001	Aug 23, 1993

TORSEMIDE

LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008

TABLET; ORAL

TORSEMIDE

SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008
	10MG	A078478	002	Feb 26, 2008
	20MG	A078478	003	Feb 26, 2008
	100MG	A078478	004	Feb 26, 2008

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
ASTA	50MG	A075974	001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
SANDOZ	50MG	A075968	001	Jun 25, 2002
WATSON LABS	50MG	A075962	001	Jun 24, 2002

ULTRAM

JANSSEN PHARMS	100MG	N020281	001	Mar 03, 1995
----------------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008

ULTRAM ER

+	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005
+		200MG	N021692	002	Sep 08, 2005
+		300MG	N021692	003	Sep 08, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

SHIONOGI INC	50MG	N021693	001	May 05, 2005
--------------	------	---------	-----	--------------

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

+	NOVARTIS PHARMS CORP	EQ 1MG	N204114	002	May 29, 2013
---	----------------------	--------	---------	-----	--------------

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

CIPLA	1MG	A077307	002	Jun 12, 2007
	2MG	A077307	001	Jun 12, 2007
	4MG	A077307	003	Jun 12, 2007
DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008
	2MG	A078493	002	Aug 25, 2008
	4MG	A078493	003	Aug 25, 2008
EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007
	2MG	A077256	002	Jun 12, 2007
	4MG	A077256	003	Jun 12, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

INVAGEN PHARMS	1MG	A078320 001	Jun 12, 2007
	2MG	A078320 002	Jun 12, 2007
	4MG	A078320 003	Jun 12, 2007
MYLAN	1MG	A078346 001	Apr 28, 2008
	2MG	A078346 002	Apr 28, 2008
	4MG	A078346 003	Apr 28, 2008

TRANEXAMIC ACID

TABLET;ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN	500MG	N019280 001	Dec 30, 1986
----------------------	-------	-------------	--------------

TRANEXAMIC ACID

AMERIGEN PHARMS LTD	650MG	A203256 001	Jul 25, 2016
---------------------	-------	-------------	--------------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ NOVARTIS PHARMS CORP	0.003% **	N204822 001	May 15, 2014
------------------------	-----------	-------------	--------------

TRAVATAN

+ ALCON PHARMS LTD	0.004% **	N021257 001	Mar 16, 2001
--------------------	-----------	-------------	--------------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

+ PRAGMA PHARMS LLC	50MG **	N018207 001	
---------------------	---------	-------------	--

	100MG **	N018207 002	
--	----------	-------------	--

	150MG **	N018207 003	Mar 25, 1985
--	----------	-------------	--------------

	300MG **	N018207 004	Nov 07, 1988
--	----------	-------------	--------------

TRAZODONE HYDROCHLORIDE

AM THERAP	50MG	A071139 001	Oct 29, 1986
-----------	------	-------------	--------------

	100MG	A071140 001	Oct 29, 1986
--	-------	-------------	--------------

AUROLIFE PHARMA LLC	50MG	A072484 001	Apr 30, 1990
---------------------	------	-------------	--------------

MYLAN	50MG	A071405 001	Feb 27, 1991
-------	------	-------------	--------------

	100MG	A071406 001	Feb 27, 1991
--	-------	-------------	--------------

MYLAN PHARMS INC	50MG	A090514 001	Jun 02, 2009
------------------	------	-------------	--------------

	100MG	A090514 002	Jun 02, 2009
--	-------	-------------	--------------

	150MG	A090514 003	Jun 02, 2009
--	-------	-------------	--------------

	300MG	A090514 004	Jun 02, 2009
--	-------	-------------	--------------

QUANTUM PHARMICS	100MG	A070921 001	Dec 01, 1986
------------------	-------	-------------	--------------

SANDOZ	100MG	A072483 001	Apr 30, 1990
--------	-------	-------------	--------------

TEVA	150MG	A074357 001	Apr 30, 1997
------	-------	-------------	--------------

USL PHARMA	50MG	A070491 001	Apr 29, 1987
------------	------	-------------	--------------

	100MG	A070492 001	Apr 29, 1987
--	-------	-------------	--------------

WATSON LABS	50MG	A070857 001	Oct 10, 1986
-------------	------	-------------	--------------

	50MG	A071112 001	Nov 17, 1986
--	------	-------------	--------------

	100MG	A070858 001	Oct 10, 1986
--	-------	-------------	--------------

	100MG	A071113 001	Nov 17, 1986
--	-------	-------------	--------------

TRIALODINE

QUANTUM PHARMICS	50MG	A070942 001	Dec 01, 1986
------------------	------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

+ ANGELINI PHARMA	150MG **	N022411 001	Feb 02, 2010
-------------------	----------	-------------	--------------

	300MG **	N022411 002	Feb 02, 2010
--	----------	-------------	--------------

TRETINOIN

CAPSULE;ORAL

VESANOID

+ CHEPLAPHARM	10MG **	N020438 001	Nov 22, 1995
---------------	---------	-------------	--------------

CREAM;TOPICAL

TRETINOIN

ALLERGAN SALES LLC	0.0375%	A090098 001	Mar 22, 2010
--------------------	---------	-------------	--------------

	0.075%	A202209 001	Oct 11, 2012
--	--------	-------------	--------------

SOLUTION;TOPICAL

RETIN-A

+ VALEANT INTL	0.05%	N016921 001	
----------------	-------	-------------	--

TRETINOIN

TEVA PHARMS	0.05%	A074873 001	Jun 19, 1998
-------------	-------	-------------	--------------

WOCKHARDT	0.05%	A075260 001	Jan 25, 1999
-----------	-------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRETINOIN

SWAB; TOPICAL

RETIN-A

VALEANT INTL 0.05% N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS	1MG	N011161 009
	2MG	N011161 004
	4MG	N011161 007
	8MG	N011161 011
	16MG	N011161 010

KENACORT

DELCOR ASSET CORP	1MG	N011283 003
	2MG	N011283 008
	4MG	N011283 006
	8MG	N011283 010

TRIAMCINOLONE

BARR	2MG	A084286 001
	2MG	A084318 001
	4MG	A084267 001
	4MG	A084319 001
	8MG	A084268 001
	8MG	A084320 001
IMPAX LABS	4MG	A084340 001
IVAX SUB TEVA PHARMS	4MG	A083750 001
MYLAN	2MG	A084406 001
PUREPAC PHARM	2MG	A084020 002
	4MG	A084020 003
ROXANE	2MG	A084708 001
	4MG	A084709 001
	8MG	A084707 001
SANDOZ	4MG	A085601 001
TEVA	4MG	A084775 001
WATSON LABS	4MG	A084270 001
	4MG	A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE 0.1MG/INH N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US 0.055MG/INH N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS	0.025%	A083017 003
	0.1%	A083016 004
	0.5%	A083015 002

ARISTOCORT A

ASTELLAS	0.025%	A083017 004
	0.025%	A088818 001 Oct 16, 1984
	0.1%	A083016 005
	0.1%	A088819 001 Oct 16, 1984
	0.5%	A083015 003
	0.5%	A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS	0.025%	A085539 001
	0.1%	A085539 002
	0.5%	A085539 003

KENALOG

DELCOR ASSET CORP 0.5% A083943 001

KENALOG-H

DELCOR ASSET CORP 0.1% A086240 001

TRIACET

TEVA	0.025%	A084908 001
	0.1%	A084908 002
	0.5%	A084908 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIACORT

SOLVAY 0.1% A087113 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC 0.1% A087798 001 Jun 04, 1982

ALPHARMA US PHARMS 0.025% A087797 001 Jun 07, 1982

AMBIX 0.025% A087932 001 May 09, 1983

MORTON GROVE 0.025% A088094 001 Sep 01, 1983

0.1% A088095 001 Sep 01, 1983

0.5% A088096 001 Sep 01, 1983

PHARMADERM 0.025% A087990 001 Jul 07, 1983

0.1% A087991 001 Jul 07, 1983

0.5% A087992 001 Jul 07, 1983

PHARMAFAIR 0.025% A087921 001 Aug 10, 1982

0.1% A087912 001 Aug 10, 1982

0.5% A087922 001 Aug 10, 1982

TARO 0.025% A040038 001 Oct 26, 1994

0.025% A086277 001

0.1% A086276 001

0.5% A086275 001

TOPIDERM 0.025% A089274 001 Feb 21, 1989

0.1% A089275 001 Feb 21, 1989

0.5% A089276 001 Feb 21, 1989

TRIATEX

IVAX PHARMS 0.025% A087430 001 Nov 01, 1988

0.1% A087429 001 Nov 01, 1988

0.5% A087428 001 Nov 01, 1988

TRYMEX

SAVAGE LABS 0.025% A088196 001 Mar 25, 1983

0.1% A088197 001 Mar 25, 1983

0.5% A088198 001 Mar 25, 1983

GEL;TOPICAL

ARISTOGEL

ASTELLAS 0.1% A083380 001

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL 3MG/ML N019503 001 Oct 16, 1987

SANDOZ INC 10MG/ML A090166 001 May 27, 2009

40MG/ML A090164 001 Jun 01, 2009

WATSON LABS 40MG/ML A085825 001

INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

+ ALLERGAN 8MG/0.1ML (8MG/0.1ML) ** N022220 001 Jun 16, 2008

LOTION;TOPICAL

KENALOG

DELCOR ASSET CORP 0.025% ** A084343 001

+ 0.025% ** N011602 003

0.1% ** A084343 002

+ 0.1% ** N011602 001

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.025% A087191 001 Sep 08, 1982

0.1% A087192 001 Sep 08, 1982

OINTMENT;TOPICAL

ARISTOCORT

ASTELLAS 0.1% A080750 004

0.5% ** A080745 002

ARISTOCORT A

ASTELLAS 0.1% A080750 003

0.1% A088780 001 Oct 01, 1984

0.5% ** A080745 003

0.5% A088781 001 Oct 05, 1984

FLUTEX

IVAX PHARMS 0.025% A087375 001 Nov 01, 1988

0.1% A087377 001 Nov 01, 1988

0.5% A087376 001 Nov 01, 1988

KENALOG

DELCOR ASSET CORP 0.5% ** A083944 001

+ MYLAN PHARMS INC 0.025% N011600 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

KENALOG

+

0.1%

N011600 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC 0.1%

A087799 001 Jun 07, 1982

ALPHARMA US PHARMS 0.5%

A089913 001 Dec 23, 1988

MORTON GROVE 0.025%

A088090 001 Sep 01, 1983

0.1%

A088091 001 Sep 01, 1983

0.5%

A088092 001 Sep 01, 1983

PHARMADERM 0.025%

A088692 001 Aug 02, 1984

0.1%

A088690 001 Aug 02, 1984

TARO 0.025%

A040040 001 Sep 30, 1994

0.025%

A040374 001 Jun 05, 2001

0.1%

A087902 001 Dec 27, 1982

0.5%

A040386 001 Jun 05, 2001

TRYMEX

SAVAGE LABS 0.025%

A088693 001 Aug 02, 1984

0.1%

A088691 001 Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

+

DELCO ASSET CORP 0.1% **

N012097 001

ORALONE

TARO 0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS 0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US 0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL 0.055MG/SPRAY

A078104 001 Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

FOSUN PHARMA 25MG/ML

N011685 003

+

40MG/ML **

N012802 001

TRIAMCINOLONE DIACETATE

AKORN 25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS 40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS 2MG/5ML

N011960 004

KENACORT

DELCO ASSET CORP EQ 4MG BASE/5ML

N012515 001

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN 0.5MG

N017892 002 Nov 15, 1982

TRIAZOLAM

WATSON LABS 0.125MG

A074445 001 Oct 20, 1995

0.25MG

A074445 002 Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US 2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING 2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT 4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM 4MG

A086259 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

CHARTWELL RX	4MG	A085568	001
IMPAX LABS	4MG	A083967	001
PAR PHARM	2MG	A087007	001
	4MG	A087005	001
SANDOZ	4MG	A086171	001
WATSON LABS	2MG	A083847	001
	2MG	A086458	001
	4MG	A083462	001
	4MG	A083855	001
	4MG	A085962	001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US	1.5GM/15ML	N016830	001
-------------------	------------	---------	-----

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US	750MG	N016809	002
-------------------	-------	---------	-----

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE	10MG/ML	N009729	001
---------	---------	---------	-----

TABLET; ORAL

PATHILON

LEDERLE	25MG	N009489	005
---------	------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

+ GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552	006
-------------------	--------------------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982
WOCKHARDT	EQ 10MG BASE/ML	A088143	001	Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

+ GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552	005
-------------------	-------------------	---------	-----

TABLET; ORAL

STELAZINE

+ GLAXOSMITHKLINE	EQ 1MG BASE **	N011552	001
	EQ 2MG BASE **	N011552	002
	EQ 5MG BASE **	N011552	003
	EQ 10MG BASE **	N011552	004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR	EQ 1MG BASE	A088967	001	Apr 23, 1985
	EQ 2MG BASE	A088968	001	Apr 23, 1985
	EQ 5MG BASE	A088969	001	Apr 23, 1985
	EQ 10MG BASE	A088970	001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
	EQ 2MG BASE	A087613	001	Nov 19, 1982
	EQ 5MG BASE	A087328	001	Nov 19, 1982
	EQ 10MG BASE	A087614	001	Nov 19, 1982
SANDOZ	EQ 1MG BASE	A040153	001	Oct 25, 1996
	EQ 2MG BASE	A040153	002	Oct 25, 1996
	EQ 5MG BASE	A040153	003	Oct 25, 1996
	EQ 10MG BASE	A040153	004	Oct 25, 1996
WATSON LABS	EQ 1MG BASE	A085975	001	Jun 23, 1988
	EQ 2MG BASE	A085976	001	Jun 23, 1988
	EQ 5MG BASE	A085973	001	Jun 23, 1988
	EQ 10MG BASE	A088710	001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON	EQ 50MG HCL/5ML	N011491	004
-----------	-----------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON	3MG/ML	N011325	005
	10MG/ML	N011325	004
	20MG/ML	N011325	001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB	10MG	N011123	001
	25MG	N011123	002
	50MG	N011123	003

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE	5MG	N006773	010
	5MG	N012947	001

ELIXIR; ORAL

ARTANE

LEDERLE	2MG/5ML	N006773	009
---------	---------	---------	-----

TRIHEXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES	2MG/5ML	A089514	001	Apr 07, 1989
----------------	---------	---------	-----	--------------

TABLET; ORAL

ARTANE

+ LEDERLE	2MG **	N006773	005
+	5MG **	N006773	003

TREMINE

SCHERING	2MG	A080381	001
	5MG	A080381	003

TRIHEXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS	2MG	A040337	002	Feb 16, 2000
	5MG	A040337	001	Feb 16, 2000
NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A040184	001	Feb 06, 1998
	2MG	A085117	001	
	5MG	A040184	002	Feb 06, 1998
	5MG	A085105	001	

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316	004
------------------	-------------	---------	-----

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003
------------------	-------------------	---------	-----

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001
------------------	---------------	---------	-----

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE	300MG	N005856	005
--------	-------	---------	-----

SOLUTION; ORAL

TRIDIONE

ABBVIE	200MG/5ML	N005856	002
--------	-----------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE	50MG/ML	N008983	001
-------	---------	---------	-----

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001
-------	-------	---------	-----

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982
-------	-------	---------	-----	--------------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995
---------	------------------	---------	-----	--------------

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL	5MG	N012697	001
--------------------	-----	---------	-----

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS	EQ 25MG HCL/5ML	N005914	004
----------	-----------------	---------	-----

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS	25MG	A083149	001
	50MG	N005914	002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC	50MG	A083037	001
BARR	50MG	A080744	001
HEATHER	50MG	A083989	001
IMPAX LABS	50MG	A080785	001
LANNETT	50MG	A083557	001
NYLOS	50MG	A085412	001
PARKE DAVIS	25MG	A083625	001
	50MG	A083626	001
WATSON LABS	50MG	A080713	001
	50MG	A080790	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPLENNAMINE HYDROCHLORIDE

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

3.7%; 2.86%; 3.42%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

3.7%; 2.86%; 3.42%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

3.7%; 2.86%; 3.42%

A087864 001 Sep 01, 1982

FOUGERA

3.7%; 2.86%; 3.42%

A086424 001

PERRIGO NEW YORK

3.7%; 2.86%; 3.42%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

3.7%; 2.86%; 3.42%

A087887 001 Jul 23, 1982

VAGILIA

G AND W LABS INC

3.7%; 2.86%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

184MG; 143.75MG; 172.5MG

N005794 002

TRIPLE SULFA

FOUGERA

184MG; 143.75MG; 172.5MG

A088463 001 Jan 03, 1985

PHARMADERM

184MG; 143.75MG; 172.5MG

A088462 001 Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIDIL

GLAXOSMITHKLINE

1.25MG/5ML

N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA

1.25MG/5ML

A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS

1.25MG/5ML

A085940 001

HALSEY

1.25MG/5ML

A088735 001 Jan 17, 1985

PHARM ASSOC

1.25MG/5ML

A087514 001 Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE

2.5MG

N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE

2.5MG

A085610 001

WATSON LABS

2.5MG

A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT

167MG/5ML; 167MG/5ML; 167MG/5ML

A080123 002

NEOTRIZINE

LILLY

167MG/5ML; 167MG/5ML; 167MG/5ML

N006317 012

SULFALOID

FOREST PHARMS

167MG/5ML; 167MG/5ML; 167MG/5ML

A080100 001

SULFOSE

WYETH AYERST

167MG/5ML; 167MG/5ML; 167MG/5ML

A080013 002

TERFONYL

BRISTOL MYERS SQUIBB

167MG/5ML; 167MG/5ML; 167MG/5ML

N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS

167MG/5ML; 167MG/5ML; 167MG/5ML

A080280 001

TRIPLE SULFAS

LEDERLE

167MG/5ML; 167MG/5ML; 167MG/5ML

N006920 003

TABLET; ORAL

NEOTRIZINE

LILLY

167MG; 167MG; 167MG

N006317 011

SULFA-TRIPLE #2

IMPAX LABS

167MG; 167MG; 167MG

A080079 001

SULFALOID

FOREST PHARMS

167MG; 167MG; 167MG

A080099 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET;ORAL

SULFOSE

WYETH AYERST	167MG;167MG;167MG	A080013	001
--------------	-------------------	---------	-----

TERFONYL

BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904	001
----------------------	-------------------	---------	-----

TRIPLE SULFA

PUREPAC PHARM	167MG;167MG;167MG	A080086	001
---------------	-------------------	---------	-----

TRIPLE SULFAS

LEDERLE	167MG;167MG;167MG	N006920	002
---------	-------------------	---------	-----

TRIPLE SULFOID

PAL PAK	167MG;167MG;167MG	A080094	001
---------	-------------------	---------	-----

TROGLITAZONE

TABLET;ORAL

PRELAY

SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997

REZULIN

PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC

CERUMENEX

PHARM RES ASSOC	10%	N011340	002
-----------------	-----	---------	-----

TROLEANDOMYCIN

CAPSULE;ORAL

TAO

PFIZER	EQ 250MG BASE	N050336	002
--------	---------------	---------	-----

SUSPENSION;ORAL

TAO

PFIZER	EQ 125MG BASE/5ML	N050332	001
--------	-------------------	---------	-----

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON	0.5% **	N012111	002
	1% **	N012111	004

MYDRIAFAIR

PHARMAFAIR	0.5%	A088274	001	Sep 16, 1983
	1%	A088230	001	Sep 16, 1983

TROPICAMIDE

WATSON LABS	AKORN	1%	A088447	001	Aug 28, 1985
	ALCON PHARMS LTD	1%	A089172	001	Dec 28, 1990
	MIZA PHARMS USA	0.5%	A087636	001	Jul 30, 1982
		1%	A087637	001	Aug 09, 1982
		0.5%	A089171	001	Dec 28, 1990

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

+ ALLERGAN	60MG **	N022103	001	Aug 03, 2007
------------	---------	---------	-----	--------------

TROSPIUM CHLORIDE

UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015
-------------------	------	---------	-----	--------------

TABLET;ORAL

SANCTURA

+ ALLERGAN	20MG **	N021595	001	May 28, 2004
------------	---------	---------	-----	--------------

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER	EQ 100MG BASE	N020759	001	Dec 18, 1997
	EQ 200MG BASE	N020759	002	Dec 18, 1997

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657	001
HOSPIRA	3MG/ML	N006095	001
LILLY	3MG/ML	N006325	001

TYROPANOATE SODIUM

CAPSULE; ORAL

BILOPAQUE

GE HEALTHCARE	750MG	N013731	001
---------------	-------	---------	-----

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+ SUCAMPO PHARMA LLC	0.15% **	N021214	001 Aug 03, 2000
----------------------	----------	---------	------------------

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

SHIRE	1MG	N012892	001
-------	-----	---------	-----

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA	40GM/VIAL	N017698	001
---------	-----------	---------	-----

UREAPHIL

HOSPIRA	40GM/VIAL	N012154	001
---------	-----------	---------	-----

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586	002 May 10, 2001
----------------	---------------	---------	------------------

HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092	001 Dec 17, 1999
---------------------	------------	---------	------------------

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586	001 Sep 17, 1996
----------------	------------	---------	------------------

PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900	001 Feb 04, 1999
-------------	------------	---------	------------------

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

METRODIN

SERONO	75 IU/AMP	N019415	002 Sep 18, 1986
	150 IU/AMP	N019415	003 Sep 18, 1986

INJECTABLE; SUBCUTANEOUS

FERTINEX

SERONO	75 IU/AMP	N019415	005 Aug 23, 1996
	150 IU/AMP	N019415	004 Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846	003
	9,000 IU/VIAL	N021846	002
	250,000 IU/VIAL	N021846	001

URSODIOL

CAPSULE; ORAL

ACTIGALL

ALLERGAN SALES LLC	150MG	N019594	001 Dec 31, 1987
--------------------	-------	---------	------------------

URSODIOL

IMPAX LABS INC	300MG	A077895	001 Jul 27, 2006
----------------	-------	---------	------------------

TABLET; ORAL

URSODIOL

TEVA PHARMS USA	250MG	A079184	001 May 13, 2009
	500MG	A079184	002 May 13, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

MYLAN

EQ 500MG BASE

A078070 001 May 24, 2010

EQ 1GM BASE

A078070 002 May 24, 2010

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

+ BIONPHARMA INC

125MG **

N022152 001 Jul 29, 2008

+

250MG **

N022152 002 Jul 29, 2008

+

500MG **

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/VIAL **

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL **

A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL **

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL **

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL **

A062812 003 Nov 17, 1987

VANCOLED

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL **

A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL **

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL **

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL **

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL **

A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

TEVA PHARMS USA

EQ 1GM BASE/VIAL

A201251 002 Dec 23, 2015

EQ 5GM BASE/VIAL

A201250 001 Dec 23, 2015

EQ 10GM BASE/VIAL

A201250 002 Dec 23, 2015

EQ 500MG BASE/VIAL

A201251 001 Dec 23, 2015

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

TEVA PHARMS

2.5MG

A091347 001 May 03, 2012

5MG

A091347 002 May 03, 2012

10MG

A091347 003 May 03, 2012

20MG

A091347 004 May 03, 2012

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

+ PARKE DAVIS

5PRESSOR UNITS/ML **

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

+ ORGANON USA INC

10MG/VIAL **

N018776 002 Apr 30, 1984

+

20MG/VIAL **

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

20MG/VIAL

A074334 002 Aug 31, 1995

WEST-WARD PHARMS INT

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC 200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

MYLAN

EQ 37.5MG BASE

A078789 001 Jun 01, 2011

EQ 75MG BASE

A078789 002 Jun 01, 2011

EQ 150MG BASE

A078789 003 Jun 01, 2011

TABLET; ORAL

EFFEXOR

+ WYETH PHARMS INC

EQ 12.5MG BASE **

N020151 001 Dec 28, 1993

+

EQ 25MG BASE **

N020151 002 Dec 28, 1993

+

EQ 37.5MG BASE **

N020151 006 Dec 28, 1993

+

EQ 50MG BASE **

N020151 003 Dec 28, 1993

+

EQ 75MG BASE **

N020151 004 Dec 28, 1993

+

EQ 100MG BASE **

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE

A078517 001 Jun 13, 2008

EQ 37.5MG BASE

A078517 002 Jun 13, 2008

EQ 50MG BASE

A078517 003 Jun 13, 2008

EQ 75MG BASE

A078517 004 Jun 13, 2008

EQ 100MG BASE

A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE

A077515 001 Jun 13, 2008

EQ 37.5MG BASE

A077515 002 Jun 13, 2008

EQ 50MG BASE

A077515 003 Jun 13, 2008

EQ 75MG BASE

A077515 004 Jun 13, 2008

EQ 100MG BASE

A077515 005 Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC

2.5MG/ML

N019038 001 Mar 30, 1984

ISOPTIN

+ MT ADAMS

2.5MG/ML **

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML

A070348 001 May 01, 1986

BEDFORD

2.5MG/ML

A072888 001 Jul 28, 1995

HOSPIRA

2.5MG/ML

A070577 001 Feb 02, 1987

2.5MG/ML

A070739 001 May 06, 1987

2.5MG/ML

A070740 001 May 06, 1987

INTL MEDICATION

2.5MG/ML

A070451 001 Dec 16, 1985

LUITPOLD

2.5MG/ML

A070225 001 Nov 12, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

	2.5MG/ML	A070617 001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993
	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC	40MG	N018817 003	Feb 23, 1988
	160MG	N018817 004	Feb 23, 1988

ISOPTIN

MT ADAMS	40MG	N018593 003	Nov 23, 1987
	80MG	N018593 001	Mar 08, 1982
	120MG	N018593 002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
FOSUN PHARMA	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	120MG	A070483 001	Sep 24, 1986
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SUN PHARM INDUSTRIES	80MG	A071489 002	Jan 13, 1988
	120MG	A071489 001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989
	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

+ PFIZER	180MG **	N019152 002	Dec 15, 1989
----------	----------	-------------	--------------

COVERA-HS

GD SEARLE LLC	180MG	N020552 001	Feb 26, 1996
	240MG	N020552 002	Feb 26, 1996

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996
-------	-------	-------------	--------------

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	
---------------------	-------------	-------------	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDEALE	EQ 187.4MG BASE/ML	N050523 001	
------------	--------------------	-------------	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDEALE	3%	N050486 001	
------------	----	-------------	--

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY	10MG/VIAL	N012665 001	
-------	-----------	-------------	--

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY	1MG/VIAL	N014103 001	
	1MG/ML	N014103 003	Mar 07, 1984
	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987
-----------------	--------	-------------	--------------

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988
----------------------	----------	-------------	--------------

VINCRIStINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002
	1MG/ML	A076401 001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988
	2MG/VIAL	A071560 001	Apr 11, 1988
	5MG/VIAL	A071561 001	Apr 11, 1988

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

EBEWE PHARMA	EQ 10MG BASE/ML	A078408 001	Feb 13, 2008
MYLAN LABS LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086 001	
	EQ 5GM BASE/VIAL	A061086 002	

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002	
	50,000USP UNITS	A083080 001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
CHASE CHEM	50,000 IU	A083351 001	
EVERYLIFE	50,000 IU	A083134 001	
IMPAX LABS	50,000USP UNITS	A080952 001	
WEST WARD	50,000USP UNITS	A080985 001	

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
-------------------	----------------------	-------------	--

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883 001	
-------	----------------------	-------------	--

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
--------------	----------------------	-------------	--

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
--------------	----------------------	-------------	--

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
	EQ 50,000 UNITS BASE	A083207 001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	
	EQ 50,000 UNITS BASE	A083114 001	
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001	
	EQ 50,000 UNITS BASE	A080955 001	
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001	
	EQ 50,000 UNITS BASE	A083190 001	
MK LABS	EQ 25,000 UNITS BASE	A083457 002	
	EQ 50,000 UNITS BASE	A083457 001	
WEST WARD	EQ 50,000 UNITS BASE	A080967 001	
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001	
VITAMIN A PALMITATE			
ARCUM	EQ 50,000 UNITS BASE	A083311 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A PALMITATE

	EQ 50,000 UNITS BASE	A083321 001
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001
	EQ 50,000 UNITS BASE	A083981 001

VITAMIN A SOLUBILIZED

TEVA

EQ 50,000 UNITS BASE A080921 001

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR

EQ 50,000 UNITS BASE/ML A080819 001

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+ TAKEDA PHARMS USA EQ 15MG BASE ** N204447 003 Sep 30, 2013

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC

2MG	N011771 007
5MG	N011771 004
10MG	N011771 005
25MG	N011771 006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
	50MG/VIAL	N009218 020	
	75MG/VIAL	N009218 012	

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC

5MG	N011771 003
10MG	N011771 002
25MG	N011771 001

PANWARFIN

ABBOTT

2MG	N017020 001
2.5MG	N017020 002
5MG	N017020 003
7.5MG	N017020 004
10MG	N017020 005

WARFARIN SODIUM

FOSUN PHARMA

1MG	A040196 001	Sep 30, 1997
2MG	A040196 002	Sep 30, 1997
2.5MG	A040196 003	Sep 30, 1997
3MG	A040196 008	Jul 26, 2000
4MG	A040196 004	Sep 30, 1997
5MG	A040196 005	Sep 30, 1997
6MG	A040196 009	Jul 26, 2000
7.5MG	A040196 006	Sep 30, 1997
10MG	A040196 007	Sep 30, 1997

MYLAN

1MG	A040415 001	Sep 27, 2004
2MG	A040415 002	Sep 27, 2004
2.5MG	A040415 003	Sep 29, 2004
3MG	A040415 004	Sep 27, 2004
4MG	A040415 005	Sep 27, 2004
5MG	A040415 006	Sep 27, 2004
6MG	A040415 007	Sep 27, 2004
7.5MG	A040415 008	Sep 27, 2004
10MG	A040415 009	Sep 27, 2004

USL PHARMA

2MG	A088719 001	Jun 27, 1985
2.5MG	A088720 001	Aug 06, 1985
5MG	A088721 001	Jul 02, 1985

WATSON LABS

2MG	A086123 001	Aug 17, 1982
2.5MG	A086120 001	Aug 17, 1982
5MG	A086119 001	Aug 17, 1982
7.5MG	A086118 001	Aug 17, 1982
10MG	A086122 001	Aug 17, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT

5mCi/VIAL

N018536 001 Oct 01, 1982

10mCi/VIAL

N018536 002 Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE

1 CI/AMP

N017256 002

10mCi/VIAL

N017687 002

20mCi/VIAL

N017687 003

GEN ELECTRIC

5-100 CI/CYLINDER

N017550 001

0.25-5 CI/AMP

N017550 003

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL

N017687 001

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP

N017256 001

LANTHEUS MEDCL

6.3mCi/ML

N017283 001

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP

N017262 002

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT

N017605 001

XYLOSE

LYNE

25GM/BOT

N018856 001 Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

MYLAN

5MG

A077238 001 Jun 06, 2008

10MG

A077238 002 Jun 06, 2008

UPSHER-SMITH LABS

5MG

A078095 001 Jun 06, 2008

5MG

A078706 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

10MG

A078706 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

+

300MG **

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

HEC PHARM USA INC

300MG

A202058 001 Oct 07, 2011

MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI USA INC

300MG

N020471 001 Dec 09, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

SUN PHARMA GLOBAL

EQ 4MG BASE/5ML

A202746 001 Mar 04, 2013

ZOMETA

+ NOVARTIS

EQ 4MG BASE/VIAL **

N021223 001 Aug 20, 2001

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

SUN PHARMA GLOBAL

2.5MG

A203476 001 Nov 13, 2014

5MG

A203476 002 Nov 13, 2014

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD

5MG

A077985 001 Apr 23, 2007

10MG

A077985 002 Apr 23, 2007

HIKMA

5MG

A078129 001 Apr 30, 2008

10MG

A078129 002 Apr 30, 2008

MYLAN PHARMS INC

5MG

A078016 001 Apr 23, 2007

10MG

A078016 002 Apr 23, 2007

SUN PHARM INDUSTRIES

5MG

A077288 001 Apr 23, 2007

10MG

A077288 002 Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001 Apr 23, 2007

10MG

A077540 002 Apr 23, 2007

VIVIMED GLOBAL

5MG

A076062 001 Apr 23, 2007

10MG

A076062 002 Apr 23, 2007

WATSON LABS

5MG

A077773 001 Apr 23, 2007

10MG

A077773 002 Apr 23, 2007

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

SYNTHON PHARMS

6.25MG

A078483 001 Apr 12, 2011

12.5MG

A078483 002 Jun 06, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007

10MG

N021412 002 Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

ANI PHARMS INC

25MG

A077639 001 Dec 22, 2005

25MG

A077641 003 Dec 22, 2005

50MG

A077639 002 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077639 003 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

DR REDDYS LABS LTD

25MG

A077645 002 Sep 29, 2006

50MG

A077645 003 Sep 29, 2006

100MG

A077645 001 Dec 22, 2005

EPIC PHARMA LLC

25MG

A077876 001 Feb 21, 2007

50MG

A077876 002 Feb 21, 2007

100MG

A077876 003 Feb 21, 2007

MYLAN PHARMS INC

25MG

A077647 001 Dec 22, 2005

50MG

A077647 002 Dec 22, 2005

100MG

A077647 003 Dec 22, 2005

ROXANE

25MG

A077648 001 Dec 22, 2005

50MG

A077648 002 Dec 22, 2005

100MG

A077648 003 Dec 22, 2005

SUN PHARM INDUSTRIES

25MG

A077635 001 Dec 22, 2005

50MG

A077635 002 Dec 22, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

	100MG	A077635 003	Dec 22, 2005
UPSHER-SMITH LABS	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005
WATSON LABS	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

** A **

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPIRAZOLE
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
ABILIFY MYCITE KIT, ARIPIPIRAZOLE
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTICLATE CAP, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE

APPENDIX A - PRODUCT NAME INDEX

** A **

ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIQUAT
ADENOCARD, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADMELOG, INSULIN LISPRO
ADMELOG SOLOSTAR, INSULIN LISPRO
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMP TOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOLX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKOAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTIPAK, BENZOYL PEROXIDE
AKTOB, TOBRAMYCIN
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

** A **

ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
ALKERAN, MELPHALAN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPIREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALUNBRIG, BRIGATINIB
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

** A **

AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX, NAPROXEN SODIUM
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE

APPENDIX A - PRODUCT NAME INDEX

** A **

ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ARISTADA, ARIPIPIRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARMONAIR RESPICLICK, FLUTICASONE PROPIONATE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ARYMO ER, MORPHINE SULFATE
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN, ASPIRIN (OTC)
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN

APPENDIX A - PRODUCT NAME INDEX

** A **

ATRIDOX, DOXYCYCLINE HYCLATE
 ATRIPLA, EFAVIRENZ
 ATROPEN, ATROPINE
 ATROPINE SULFATE, ATROPINE SULFATE
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
 ATROPINE SULFATE LIFESHIELD ABOJECT SYRINGE, ATROPINE SULFATE
 ATROVENT, IPRATROPIUM BROMIDE
 ATROVENT HFA, IPRATROPIUM BROMIDE
 AUBAGIO, TERIFLUNOMIDE
 AUGMENTIN '125', AMOXICILLIN
 AUGMENTIN '250', AMOXICILLIN
 AUGMENTIN '875', AMOXICILLIN
 AUGMENTIN XR, AMOXICILLIN
 AUROVELA 1.5/30, ETHINYL ESTRADIOL
 AUROVELA 1/20, ETHINYL ESTRADIOL
 AUROVELA 24 FE, ETHINYL ESTRADIOL
 AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
 AUROVELA FE 1/20, ETHINYL ESTRADIOL
 AURYXIA, FERRIC CITRATE
 AUSTEDO, DEUTETRABENAZINE
 AUVI-Q, EPINEPHRINE
 AVAGARD, ALCOHOL (OTC)
 AVAGE, TAZAROTENE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVANDIA, ROSIGLITAZONE MALEATE
 AVAPRO, IRBESARTAN
 AVC, SULFANILAMIDE
 AVEED, TESTOSTERONE UNDECANOATE
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 AVIANE-28, ETHINYL ESTRADIOL
 AVITA, TRETINOIN
 AVODART, DUTASTERIDE
 AVYCAZ, AVIBACTAM SODIUM
 AXERT, ALMOTRIPTAN MALATE
 AXID AR, NIZATIDINE (OTC)
 AXUMIN, FLUCICLOVINE F-18
 AYGESTIN, NORETHINDRONE ACETATE
 AYUNA, ETHINYL ESTRADIOL
 AZACITIDINE, AZACITIDINE
 AZACTAM, AZTREONAM
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM
 AZASAN, AZATHIOPRINE
 AZASITE, AZITHROMYCIN
 AZATHIOPRINE, AZATHIOPRINE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 AZELEX, AZELAIC ACID
 AZILECT, RASAGILINE MESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 AZOPT, BRINZOLAMIDE
 AZOR, AMLODIPINE BESYLATE
 AZTREONAM, AZTREONAM
 AZULFIDINE, SULFASALAZINE
 AZULFIDINE EN-TABS, SULFASALAZINE

** B **

BACIIM, BACITRACIN
 BACITRACIN, BACITRACIN
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
 BACLOFEN, BACLOFEN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM

APPENDIX A - PRODUCT NAME INDEX

** B **

BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BASAGLAR, INSULIN GLARGINE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE, BENZAEPRIIL HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENZAEPRIIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAFLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEVYXXA, BETRIXABAN
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BIAXIN, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE

APPENDIX A - PRODUCT NAME INDEX

** B **

BIVALIRUDIN, BIVALIRUDIN
 BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BLEPH-10, SULFACETAMIDE SODIUM
 BLEPHAMIDE, PREDNISOLONE ACETATE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
 BONIVA, IBANDRONATE SODIUM
 BONJESTA, DOXYLAMINE SUCCINATE
 BONTRIL PDM, PHENDIMETRAZINE TARTRATE
 BORTEZOMIB, BORTEZOMIB
 BOSULIF, BOSUTINIB MONOHYDRATE
 BRAVELLE, UROFOLLITROPIN
 BREO ELLIPTA, FLUTICASON FUROATE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVICON 28-DAY, ETHINYL ESTRADIOL
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
 BRIDION, SUGAMMADEX SODIUM
 BRIELLYN, ETHINYL ESTRADIOL
 BRILINTA, TICAGRELOR
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BRISDELLE, PAROXETINE MESYLATE
 BRIVIACT, BRIVARACETAM
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
 BROMSITE, BROMFENAC SODIUM
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)
 BROVANA, ARFORMOTEROL TARTRATE
 BSS, CALCIUM CHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 BUDESONIDE, BUDESONIDE
 BUMETANIDE, BUMETANIDE
 BUMEX, BUMETANIDE
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
 BUPHENYL, SODIUM PHENYLBUTYRATE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 BUSULFEX, BUSULFAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 BUTAPAP, ACETAMINOPHEN
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 BUTISOL SODIUM, BUTABARBITAL SODIUM

APPENDIX A - PRODUCT NAME INDEX

** B **

BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTRANS, BUPRENORPHINE
 BYDUREON, EXENATIDE SYNTHETIC
 BYDUREON BCISE, EXENATIDE
 BYDUREON PEN, EXENATIDE SYNTHETIC
 BYETTA, EXENATIDE SYNTHETIC
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 BYVALSON, NEBIVOLOL HYDROCHLORIDE

** C **

CABERGOLINE, CABERGOLINE
 CABOMETYX, CABOZANTINIB S-MALATE
 CADUET, AMLODIPINE BESYLATE
 CAFKIT, CAFFEINE CITRATE
 CAFERGOT, CAFFEINE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALAN, VERAPAMIL HYDROCHLORIDE
 CALAN SR, VERAPAMIL HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CALCIUM DISODIUM VERSENATE, EDTATE CALCIUM DISODIUM
 CALCIUM GLUCONATE, CALCIUM GLUCONATE
 CALDOLOR, IBUPROFEN
 CALQUENCE, ACALABRUTINIB
 CAMBIA, DICLOFENAC POTASSIUM
 CAMILA, NORETHINDRONE
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 CANASA, MESALAMINE
 CANCIDAS, CASPOFUNGIN ACETATE
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPASTAT SULFATE, CAPREOMYCIN SULFATE
 CAPECITABINE, CAPECITABINE
 CAPEX, FLUOCINOLONE ACETONIDE
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)
 CAPRELSA, VANDETANIB
 CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
 CAPTOPRIL, CAPTOPRIL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CARAC, FLUOROURACIL
 CARAFATE, SUCRALFATE
 CARBAGLU, CARGLUMIC ACID
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBATROL, CARBAMAZEPINE
 CARBIDOPA, CARBIDOPA
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CARDENE, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARDIZEM, DILTIAZEM HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNEXIV, CARBAMAZEPINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACTOR, CEFACTOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CERDELGA, ELIGLUSTAT TARTRATE

APPENDIX A - PRODUCT NAME INDEX

** C **

CEREBYX, FOSPHENYTOIN SODIUM
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 CEREZYME, IMIGLUCERASE
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CERVIDIL, DINOPROSTONE
 CESAMET, NABILONE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
 CETROTIDE, CETRORELIX
 CETYLEV, ACETYLCYSTEINE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHANTIX, VARENICLINE TARTRATE
 CHEMET, SUCCIMER
 CHENODIOL, CHENODIOL
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CHLORZOAZONE, CHLORZOAZONE
 CHOLAC, LACTULOSE
 CHOLBAM, CHOLIC ACID
 CHOLEDYL SA, OXTRIPHYLLINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CHOLINE C-11, CHOLINE C-11

APPENDIX A - PRODUCT NAME INDEX

** C **

CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX

** C **

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBEX, CLOBETASOL PROPIONATE
 CLODERM, CLOCORTOLONE PIVALATE
 CLOFARABINE, CLOFARABINE
 CLOLAR, CLOFARABINE
 CLOMID, CLOMIPHENE CITRATE
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE, CLONIDINE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
 CLORPRES, CHLOROTHALIDONE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOZAPINE, CLOZAPINE
 CLOZARIL, CLOZAPINE
 COARTEM, ARTEMETHER
 CODEINE SULFATE, CODEINE SULFATE
 COGENTIN, BENZTROPINE MESYLATE
 COL-PROBENECID, COLCHICINE
 COLAZAL, BALSALAZIDE DISODIUM
 COLCRYS, COLCHICINE
 COLESTID, COLESTIPOL HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 COLGATE TOTAL, SODIUM FLUORIDE (OTC)
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 COLOCORT, HYDROCORTISONE
 COLPREP KIT, MAGNESIUM SULFATE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 COLY-MYCIN S, COLISTIN SULFATE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 COMBIGAN, BRIMONIDINE TARTRATE
 COMBIPATCH, ESTRADIOL
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE

APPENDIX A - PRODUCT NAME INDEX

** C **

COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COUMADIN, WARFARIN SODIUM
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE)
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL

APPENDIX A - PRODUCT NAME INDEX**** C ****

CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYCLOSET, BROMOCRIPTINE MESYLATE
 CYCLOSPORINE, CYCLOSPORINE
 CYKLOKAPRON, TRANEXAMIC ACID
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 CYONANZ, ETHINYL ESTRADIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 CYSTADANE, BETAINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
 CYTARABINE, CYTARABINE
 CYTOMEL, LIOTHYRONINE SODIUM
 CYTOTEC, MISOPROSTOL
 CYTOVENE, GANCICLOVIR SODIUM

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 DACARBAZINE, DACARBAZINE
 DACOGEN, DECITABINE
 DACTINOMYCIN, DACTINOMYCIN
 DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DALIRESP, ROFLUMILAST
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DANTRIUM, DANTROLENE SODIUM
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DAPSONE, DAPSONE
 DAPTOMYCIN, DAPTOMYCIN
 DARAPRIM, PYRIMETHAMINE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
 DASATINIB, DASATINIB
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DATSCAN, IOFLUPANE I-123
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DAYPRO, OXAPROZIN
 DAYSEE, ETHINYL ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 DDAVP, DESMOPRESSIN ACETATE
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEFINITY, PERFLUTREN
 DEFITELIO, DEFIBROTIDE SODIUM
 DELATESTRYL, TESTOSTERONE ENANTHATE
 DELESTROGEN, ESTRADIOL VALERATE
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** D **

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 DELZICOL, MESALAMINE
 DEMADEX, TORSEMIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEMSER, METYROSINE
 DENAVIR, PENCICLOVIR
 DEPACON, VALPROATE SODIUM
 DEPAKENE, VALPROIC ACID
 DEPAKOTE, DIVALPROEX SODIUM
 DEPAKOTE ER, DIVALPROEX SODIUM
 DEPEN, PENICILLAMINE
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DEPOCYT, CYTARABINE
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMABET, BETAMETHASONE VALERATE
 DERMATOP, PREDNICARBATE
 DERMATOP E EMOLLIENT, PREDNICARBATE
 DERMOTIC, FLUOCINOLONE ACETONIDE
 DESCOVY, EMTRICITABINE
 DESFERAL, DEFEROXAMINE MESYLATE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESOGEN, DESOGESTREL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DESONATE, DESONIDE
 DESONIDE, DESONIDE
 DESOWEN, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 DESVENLAFAXINE, DESVENLAFAXINE
 DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DETROL, TOLTERODINE TARTRATE
 DETROL LA, TOLTERODINE TARTRATE
 DEXAMETHASONE, DEXAMETHASONE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXFERRUM, IRON DEXTRAN
 DEXILANT, DEXLANSOPRAZOLE
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

** D **

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50% , DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** D **

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM , DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DISULFIRAM , DISULFIRAM
DITROPAN XL, OXYBUTYNYN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** D **

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DUZALLO, ALLOPURINOL
DYANAVAL XR, AMPHETAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYLOJECT, DICLOFENAC SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

APPENDIX A - PRODUCT NAME INDEX

** E **

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCÉ, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** E **

ENSKYCE, DESOGESTREL
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 ENTACAPONE, ENTACAPONE
 ENTECAVIR, ENTECAVIR
 ENTEREG, ALVIMOPAN
 ENTOCORT EC, BUDESONIDE
 ENTRESTO, SACUBITRIL
 ENULOSE, LACTULOSE
 ENVARBUS XR, TACROLIMUS
 EOVIIST, GADOXETATE DISODIUM
 EPANED, ENALAPRIL MALEATE
 EPANED KIT, ENALAPRIL MALEATE
 EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
 EPCLUSA, SOFOSBUVIR
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPIDUO, ADAPALENE
 EPIDUO FORTE, ADAPALENE
 EPIFOAM, HYDROCORTISONE ACETATE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPINEPHRINE, EPINEPHRINE
 EPIPEN, EPINEPHRINE
 EPIPEN JR., EPINEPHRINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EPITOL, CARBAMAZEPINE
 EPIVIR, LAMIVUDINE
 EPIVIR-HBV, LAMIVUDINE
 EPLERENONE, EPLERENONE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 EPTIFIBATIDE, EPTIFIBATIDE
 EPZICOM, ABACAVIR SULFATE
 EQUETRO, CARBAMAZEPINE
 ERAXIS, ANIDULAFUNGIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 ERGOMAR, ERGOTAMINE TARTRATE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ERIVEDGE, VISMODEGIB
 ERRIN, NORETHINDRONE
 ERTACZO, SERTACONAZOLE NITRATE
 ERY-TAB, ERYTHROMYCIN
 ERYC, ERYTHROMYCIN
 ERYGEL, ERYTHROMYCIN
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN, ERYTHROMYCIN
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ESBRIET, PIRFENIDONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESKATA, HYDROGEN PEROXIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
 ESTARYLLA, ETHINYL ESTRADIOL
 ESTAZOLAM, ESTAZOLAM
 ESTRACE, ESTRADIOL
 ESTRADIOL, ESTRADIOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** E **

ESTRADIOL VALERATE, ESTRADIOL VALERATE
 ESTRASORB, ESTRADIOL HEMIHYDRATE
 ESTRING, ESTRADIOL
 ESTROGEL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ESTROSTEP FE, ETHINYL ESTRADIOL
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHAMOLIN, ETHANOLAMINE OLEATE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETHYOL, AMIFOSTINE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
 ETODOLAC, ETODOLAC
 ETOMIDATE, ETOMIDATE
 ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
 ETOPOSIDE, ETOPOSIDE
 EUCRISA, CRISABOROLE
 EURAX, CROTAMITON
 EVAMIST, ESTRADIOL
 EVEKEO, AMPHETAMINE SULFATE
 EVISTA, RALOXIFENE HYDROCHLORIDE
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EVOMELA, MELPHALAN HYDROCHLORIDE
 EVOTAZ, ATAZANAVIR SULFATE
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 EVZIO, NALOXONE HYDROCHLORIDE
 EXALGO, HYDROMORPHONE HYDROCHLORIDE
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 EXELDERM, SULCONAZOLE NITRATE
 EXELON, RIVASTIGMINE
 EXELON, RIVASTIGMINE TARTRATE
 EXEMESTANE, EXEMESTANE
 EXFORGE, AMLODIPINE BESYLATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
 EXJADE, DEFERASIROX
 EXONDYS 51, ETEPLIRSEN
 EXPAREL, BUPIVACAINE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 EXTRANEAL, ICODEXTRIN
 EZETIMIBE, EZETIMIBE
 EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE

** F **

FABIOR, TAZAROTENE
 FACTIVE, GEMIFLOXACIN MESYLATE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FALMINA, ETHINYL ESTRADIOL
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FANAPT, ILOPERIDONE
 FARESTON, TOREMIFENE CITRATE
 FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
 FARYDAK, PANOBINOSTAT LACTATE
 FASLODEX, FULVESTRANT
 FAYOSIM, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** F **

FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIASP, INSULIN ASPART
FIASP FLEXTOUCH, INSULIN ASPART
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRMAGON, DEGARELIX ACETATE
FLAGYL, METRONIDAZOLE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOWTUSS, GUAIFENESIN
FLOXURIDINE, FLOXURIDINE

APPENDIX A - PRODUCT NAME INDEX

** F **

FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULYZAQ, CROFELEMER
FURADANTIN, NITROFURANTOIN

APPENDIX A - PRODUCT NAME INDEX

** F **

FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

** G **

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR
GANCICLOVIR, GANCICLOVIR SODIUM
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD
GILOTRIF, AFATINIB DIMALEATE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** G **

GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 GLUCOTROL, GLIPIZIDE
 GLUCOTROL XL, GLIPIZIDE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 GLYBURIDE, GLYBURIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 GLYXAMBI, EMPAGLIFLOZIN
 GOCOVRI, AMANTADINE HYDROCHLORIDE
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONAL-F, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONITRO, NITROGLYCERIN
 GOPRELTO, COCAINE HYDROCHLORIDE
 GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUANABENZ ACETATE, GUANABENZ ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GYNAZOLE-1, BUTOCONAZOLE NITRATE

** H **

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HALAVEN, ERIBULIN MESYLATE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HARVONI, LEDIPASVIR
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HEMABATE, CARBOPROST TROMETHAMINE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

APPENDIX A - PRODUCT NAME INDEX

** H **

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
 HEPSERA, ADEFOVIR DIPIVOXIL
 HER STYLE, LEVONORGESTREL (OTC)
 HETLIOZ, TASIMELTEON
 HEXALEN, ALTRETAMINE
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 HYCOFENIX, GUAIFENESIN
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
 HYSINGLA, HYDROCODONE BITARTRATE
 HYZAAR, HYDROCHLOROTHIAZIDE

** I **

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBRANCE, PALBOCICLIB
 IBU-TAB, IBUPROFEN

APPENDIX A - PRODUCT NAME INDEX

** I **

IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROHM, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILOPERIDONE, ILOPERIDONE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSPRA, EPLERENONE

APPENDIX A - PRODUCT NAME INDEX

** I **

INTEGRILIN, EPTIFIBATIDE
 INTELENCE, ETRAVIRINE
 INTERMEZZO, ZOLPIDEM TARTRATE
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL
 INTRAROSA, PRASTERONE
 INTROVALE, ETHINYL ESTRADIOL
 INTUNIV, GUANFACINE HYDROCHLORIDE
 INVANZ, ERTAPENEM SODIUM
 INVEGA, PALIPERIDONE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVIRASE, SAQUINAVIR MESYLATE
 INVOKAMET, CANAGLIFLOZIN
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IONSYS, FENTANYL HYDROCHLORIDE
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE
 IOSAT, POTASSIUM IODIDE (OTC)
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IPRIVASK, DESIRUDIN RECOMBINANT
 IRBESARTAN, IRBESARTAN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRESSA, GEFITINIB
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISENTRESS, RALTEGRAVIR POTASSIUM
 ISENTRESS HD, RALTEGRAVIR POTASSIUM
 ISIBLOOM, DESOGESTREL
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISONIAZID, ISONIAZID
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 ISOPTO ATROPINE, ATROPINE SULFATE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 ISORDIL, ISOSORBIDE DINITRATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 ISOTRETINOIN, ISOTRETINOIN
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 ISRADIPINE, ISRADIPINE
 ISTALOL, TIMOLOL MALEATE
 ISTODAX, ROMIDEPSIN
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 IVERMECTIN, IVERMECTIN
 IVY BLOCK, BENTOQUATAM (OTC)
 IXEMPRA KIT, IXABEPILONE

** J **

JADENU, DEFERASIROX
 JADENU SPRINKLE, DEFERASIROX
 JAIMIESS, ETHINYL ESTRADIOL
 JAKAFI, RUXOLITINIB PHOSPHATE
 JALYN, DUTASTERIDE

APPENDIX A - PRODUCT NAME INDEX

** J **

JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE

** K **

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHEDEZLA, DESVENLAFAXINE
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** K **

KLOR-CON M20, POTASSIUM CHLORIDE
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 KORLYM, MIFEPRISTONE
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
 KURVELO, ETHINYL ESTRADIOL
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE
 KYBELLA, DEOXYCHOLIC ACID
 KYLEENA, LEVONORGESTREL
 KYNAMRO, MIPOMERSEN SODIUM
 KYPROLIS, CARFILZOMIB

** L **

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACRISERT, HYDROXYPROPYL CELLULOSE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTULOSE, LACTULOSE
 LAMICTAL, LAMOTRIGINE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL ODT, LAMOTRIGINE
 LAMICTAL XR, LAMOTRIGINE
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LAMISIL AT, TERBINAFINE (OTC)
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMIVUDINE, LAMIVUDINE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LANIAZID, ISONIAZID
 LANORINAL, ASPIRIN
 LANOXIN, DIGOXIN
 LANOXIN PEDIATRIC, DIGOXIN
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE , LANSOPRAZOLE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LANTHANUM CARBONATE, LANTHANUM CARBONATE
 LANTUS, INSULIN GLARGINE RECOMBINANT
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LAROTID, AMOXICILLIN
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 LASIX, FUROSEMIDE
 LASTACAFT, ALCAFTADINE
 LATANOPROST, LATANOPROST
 LATISSE, BIMATOPROST
 LATUDA, LURASIDONE HYDROCHLORIDE
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 LAZANDA, FENTANYL CITRATE
 LEFLUNOMIDE, LEFLUNOMIDE
 LENVIMA, LENVATINIB MESYLATE
 LERIBANE, ETHINYL ESTRADIOL
 LESCOL XL, FLUVASTATIN SODIUM
 LESSINA-28, ETHINYL ESTRADIOL
 LETAIRIS, AMBRISENTAN
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUKERAN, CHLORAMBUCIL
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** L **

LEVAQUIN, LEVOFLOXACIN
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
 LEVETIRACETAM, LEVETIRACETAM
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 LEVO-T, LEVOTHYROXINE SODIUM **
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LEVONEST, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LEVOXYL, LEVOTHYROXINE SODIUM **
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 LEXISCAN, REGADENOSON
 LEXIVA, FOSAMPRENAVIR CALCIUM
 LIALDA, MESALAMINE
 LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIDEX, FLUOCINONIDE
 LIDOCAINE, LIDOCAINE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDODERM, LIDOCAINE
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 LILETTA, LEVONORGESTREL
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 LINDANE, LINDANE
 LINEZOLID, LINEZOLID
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINZESS, LINACLOTIDE
 LIORESAL, BACLOFEN
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LIPIODOL, ETHIODIZED OIL
 LIPITOR, ATORVASTATIN CALCIUM
 LIPOFEN, FENOFIBRATE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LISINOPRIL, LISINOPRIL
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE

APPENDIX A - PRODUCT NAME INDEX

** L **

LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LO SIMPESE, ETHINYL ESTRADIOL
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGILIA, ULIPRISTAL ACETATE
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONHALA MAGNAIR KIT, GLYCOPYRROLATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPRDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN

APPENDIX A - PRODUCT NAME INDEX

** L **

LYRICA CR, PREGABALIN
 LYSODREN, MITOTANE
 LYSTEDA, TRANEXAMIC ACID

** M **

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MACRILEN, MACIMORELIN ACETATE
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 MACUGEN, PEGAPTANIB SODIUM
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MALARONE, ATOVAQUONE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALATHION, MALATHION
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 25%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARINOL, DRONABINOL
 MARLISSA, ETHINYL ESTRADIOL
 MARPLAN, ISOCARBOXAZID
 MARQIBO KIT, VINCRISTINE SULFATE
 MATULANE, PROCARBAZINE HYDROCHLORIDE
 MAVIK, TRANDOLAPRIL
 MAVYRET, GLECAPREVIR
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 MAXIDEX, DEXAMETHASONE
 MAXIPIME, CEFEPIME HYDROCHLORIDE
 MAXITROL, DEXAMETHASONE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MEDROL, METHYLPREDNISOLONE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFENAMIC ACID, MEFENAMIC ACID
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 MEGACE ES, MEGESTROL ACETATE
 MEGATOPE, ALBUMIN IODINATED I-131 SERUM
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 MELAMISA, DROSPIRENONE

APPENDIX A - PRODUCT NAME INDEX

** M **

MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH)
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

APPENDIX A - PRODUCT NAME INDEX

** M **

METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** M **

MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHABOND ER, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN

APPENDIX A - PRODUCT NAME INDEX

** M **

MYOVIEV 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYRBETRIQ, MIRABEGRON
 MYSOLINE, PRIMIDONE
 MYZILRA, ETHINYL ESTRADIOL

** N **

NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NAFACILLIN SODIUM, NAFACILLIN SODIUM
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFACILLIN SODIUM
 NALOXONE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NANDROLONE DECANOATE, NANDROLONE DECANOATE
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN, NAPROXEN
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARCAN, NALOXONE HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATESTO, TESTOSTERONE
 NATRECOR, NESIRITIDE RECOMBINANT
 NATROBA, SPINOSAD
 NAVALBINE, VINORELBINE TARTRATE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NEOPAP, ACETAMINOPHEN (OTC)
 NEOPROFEN, IBUPROFEN LYSINE
 NEORAL, CYCLOSPORINE
 NEOSPORIN, BACITRACIN ZINC
 NEOSPORIN, GRAMICIDIN
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE

APPENDIX A - PRODUCT NAME INDEX

** N **

NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETNOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCTIVA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE

APPENDIX A - PRODUCT NAME INDEX

** N **

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORITATE, METRONIDAZOLE
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
 NORTHERA, DROXIDOPA
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NORVASC, AMLODIPINE BESYLATE
 NORVIR, RITONAVIR
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOXAFIL, POSACONAZOLE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUPLAZID, PIMAVANSERIN TARTRATE
 NUTRESTORE, L-GLUTAMINE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
 NUVARING, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 NUVIGIL, ARMODAFINIL
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

** O **

OCALIVA, OBETICHOLIC ACID
 OCTOCAINE, EPINEPHRINE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUFEN, FLURBIPROFEN SODIUM

APPENDIX A - PRODUCT NAME INDEX

** O **

OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIRATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OLYSIO, SIMEPREVIR SODIUM
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIMARK, GADOVERSETAMIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAIN HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVerse, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE

APPENDIX A - PRODUCT NAME INDEX

** O **

ORFADIN, NITISINONE
 ORKAMBI, IVACAFTOR
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 ORSYTHIA, ETHINYL ESTRADIOL
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OSENI, ALOGLIPTIN BENZOATE
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 OSPHENA, OSPEMIFENE
 OTEZLA, APREMILAST
 OTICAIR, HYDROCORTISONE
 OTIPRIO, CIPROFLOXACIN
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
 OTREXUP, METHOTREXATE
 OVIDE, MALATHION
 OVIDREL, CHORIOGONADOTROPIN ALFA
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXANDRIN, OXANDROLONE
 OXANDROLONE, OXANDROLONE
 OXAPROZIN, OXAPROZIN
 OXAYDO, OXYCODONE HYDROCHLORIDE
 OXAZEPAM, OXAZEPAM
 OXCARBAZEPINE, OXCARBAZEPINE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 OXISTAT, OXICONAZOLE NITRATE
 OXSORALEN-ULTRA, METHOXSALLEN
 OXTELLAR XR, OXCARBAZEPINE
 OXYBUTYNYNIN, OXYBUTYNYNIN
 OXYBUTYNYNIN CHLORIDE, OXYBUTYNYNIN CHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNYNIN
 OXYTROL FOR WOMEN, OXYBUTYNYNIN (OTC)
 OZEMPIC, SEMAGLUTIDE
 OZURDEX, DEXAMETHASONE

** P **

PACERONE, AMIODARONE HYDROCHLORIDE
 PACITAXEL, PACLITAXEL
 PACLITAXEL, PACLITAXEL
 PALIPERIDONE, PALIPERIDONE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** P **

PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCREAZE, PANCRELIPASE (AMYLASE)
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN

APPENDIX A - PRODUCT NAME INDEX

** P **

PERPHENAZINE, PERPHENAZINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PERSANTINE, DIPYRIDAMOLE
 PERTZYE, PANCRELIPASE (AMYLASE)
 PEXEVA, PAROXETINE MESYLATE
 PFIZERPEN, PENICILLIN G POTASSIUM
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENELZINE SULFATE, PHENELZINE SULFATE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PHENYTOIN, PHENYTOIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHILITH, ETHINYL ESTRADIOL
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PHOTOFRIN, PORFIMER SODIUM
 PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PICATO, INGENOL MEBUTATE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIMOZIDE, PIMOZIDE
 PIMTREA, DESOGESTREL
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIPERACILLIN, PIPERACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PIROXICAM, PIROXICAM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 PITOCIN, OXYTOCIN
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLIAGLIS, LIDOCAINE
 PODOFILOX, PODOFILOX
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PORTIA-28, ETHINYL ESTRADIOL
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

** P **

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 POVIDONE IODINE, POVIDONE-IODINE (OTC)
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAMOSONE, HYDROCORTISONE ACETATE
 PRANDIN, REPAGLINIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVACHOL, PRAVASTATIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZIQUANTEL, PRAZIQUANTEL
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PRE-OP, HEXACHLOROPHENE
 PRE-OP II, HEXACHLOROPHENE
 PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PRECOSE, ACARBOSE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PREDNICARBATE, PREDNICARBATE
 PREDNISOLONE, PREDNISOLONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISONE, PREDNISONE
 PREDNISONE INTENSOL, PREDNISONE
 PREGNYL, GONADOTROPIN, CHORIONIC
 PRELONE, PREDNISOLONE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

** P **

PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PRESTALIA, AMLODIPINE BESYLATE
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREVYMIS, LETERMOVIR
PREXXARTAN, VALSARTAN
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM

APPENDIX A - PRODUCT NAME INDEX

** P **

PROMACTA, ELTROMBOPAG OLAMINE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 PROMETRIUM, PROGESTERONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 PROPECIA, FINASTERIDE
 PROPOFOL, PROPOFOL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PROSCAR, FINASTERIDE
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PROTONIX, PANTOPRAZOLE SODIUM
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
 PROTOPIC, TACROLIMUS
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 PROVAYBLUE, METHYLENE BLUE
 PROVENTIL-HFA, ALBUTEROL SULFATE
 PROVERA, MEDROXYPROGESTERONE ACETATE
 PROVIGIL, MODAFINIL
 PROVOCHOLINE, METHACHOLINE CHLORIDE
 PROZAC, FLUOXETINE HYDROCHLORIDE
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 PULMICORT FLEXHALER, BUDESONIDE
 PULMICORT RESPULES, BUDESONIDE
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 PUR-WASH, PURIFIED WATER (OTC)
 PURINETHOL, MERCAPTOPYRIMIDINE
 PURIXAN, MERCAPTOPYRIMIDINE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 PYTEST, UREA, C-14
 PYTEST KIT, UREA, C-14

** Q **

QBRELIS, LISINAPRIL
 QNASL, BECLOMETHASONE DIPROPIONATE
 QOLIANA, BRIMONIDINE TARTRATE
 QSYMIA, PHENTERMINE HYDROCHLORIDE
 QTERN, DAPAGLIFLOZIN PROPANEDIOL
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
 QUALAQUIN, QUININE SULFATE
 QUARTETTE, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** Q **

QUASENSE, ETHINYL ESTRADIOL
 QUDEXY XR, TOPIRAMATE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINARETIC, HYDROCHLOROTHIAZIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 QUININE SULFATE, QUININE SULFATE
 QUTENZA, CAPSAICIN
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 QVAR REDHALER, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RADICAVA, EDARAVONE
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMELTEON, RAMELTEON
 RAMIPRIL, RAMIPRIL
 RANEXA, RANOLAZINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RAPAFLO, SILODOSIN
 RAPAMUNE, SIROLIMUS
 RAPIVAB, PERAMIVIR
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RASUVO, METHOTREXATE
 RAVICTI, GLYCEROL PHENYL BUTYRATE
 RAYALDEE, CALCIFEDIOL
 RAYOS, PREDNISONE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 READI-CAT 2, BARIUM SULFATE
 READI-CAT 2 SMOOTHIES, BARIUM SULFATE
 REBETOL, RIBAVIRIN
 RECLAST, ZOLEDRONIC ACID
 RECTIV, NITROGLYCERIN
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 RELENZA, ZANAMIVIR
 RELISTOR, METHYLNALTREXONE BROMIDE
 RELPAX, ELETRIPTAN HYDROBROMIDE
 REMERON, MIRTAZAPINE
 REMERON SOLTAB, MIRTAZAPINE
 REMODULIN, TREPROSTINIL
 RENACIDIN, CITRIC ACID
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 RENOVA, TRETINOIN
 RENVELA, SEVELAMER CARBONATE
 REPAGLINIDE, REPAGLINIDE
 REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 REPRESXAIN, HYDROCODONE BITARTRATE
 REQUIP, ROPINIROLE HYDROCHLORIDE
 REQUIP XL, ROPINIROLE HYDROCHLORIDE
 RESCRIPTOR, DELAVIRDINE MESYLATE
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RESTASIS, CYCLOSPORINE

APPENDIX A - PRODUCT NAME INDEX

** R **

RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPIRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL DIMESYLATE
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROWEEPRA, LEVETIRACETAM
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXYBOND, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
RUBRACA, RUCAPARIB CAMSYLATE

APPENDIX A - PRODUCT NAME INDEX

** R **

RUBY-FILL, RUBIDIUM CHLORIDE RB-82
 RUFINAMIDE, RUFINAMIDE
 RYANODEX, DANTROLENE SODIUM
 RYDAPT, MIDOSTAURIN
 RYTARY, CARBIDOPA
 RYTHMOL, PROPAFENONE HYDROCHLORIDE
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 RYZODEG 70/30, INSULIN ASPART

** S **

SABRIL, VIGABATRIN
 SAFYRAL, DROSPIRENONE
 SAIZEN, SOMATROPIN RECOMBINANT
 SALAGEN, PILOCARPINE HYDROCHLORIDE
 SALONPAS, MENTHOL (OTC)
 SAMSCA, TOLVAPTAN
 SANCUSO, GRANISETRON
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SAPHRIS, ASENAPINE MALEATE
 SARAFEM, FLUOXETINE HYDROCHLORIDE
 SAVAYSA, EDOXABAN TOSYLATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 SCANDONEST L, LEVONORDEFIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL
 SCLEROSOL, TALC
 SCOPOLAMINE, SCOPOLAMINE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 SECONAL SODIUM, SECOBARBITAL SODIUM
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE
 SEEBRI, GLYCOPYRROLATE
 SEGLUOMET, ERTUGLIFLOZIN
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 SELSUN, SELENIUM SULFIDE
 SELZENTRY, MARAVIROC
 SEMPRES-D, ACRIVASTINE
 SENSIPAR, CINACALCET HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE
 SEPTRA, SULFAMETHOXAZOLE
 SEPTRA DS, SULFAMETHOXAZOLE
 SEREVENT, SALMETEROL XINAFOATE
 SERNIVO, BETAMETHASONE DIPROPIONATE
 SEROMYCIN, CYCLOSERINE
 SEROQUEL, QUETIAPINE FUMARATE
 SEROQUEL XR, QUETIAPINE FUMARATE
 SEROSTIM, SOMATROPIN RECOMBINANT
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SETLAKIN, ETHINYL ESTRADIOL
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SEVOFLURANE, SEVOFLURANE
 SFROWASA, MESALAMINE
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 SIGNIFOR LAR, PASIREOTIDE PAMOATE
 SIKLOS, HYDROXYUREA
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 SILODOSIN, SILODOSIN

APPENDIX A - PRODUCT NAME INDEX

** S **

SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE , MAGNESIUM SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** S **

SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD, SILVER SULFADIAZINE
SSD AF, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STELUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN

APPENDIX A - PRODUCT NAME INDEX

** S **

SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
 SUPPRELIN LA, HISTRELIN ACETATE
 SUPRANE, DESFLURANE
 SUPRAX, CEFIXIME
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
 SURMONTIL, TRIMIPRAMINE MALEATE
 SURVANTA, BERACTANT
 SUSTIVA, EFAVIRENZ
 SUSTOL, GRANISETRON
 SUTENT, SUNITINIB MALATE
 SYEDA, DROSPIRENONE
 SYMBICORT, BUDESONIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 SYMJEPI, EPINEPHRINE
 SYMLIN, PRAMLINTIDE ACETATE
 SYMPROIC, NALDEMEDINE TOSYLATE
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALGOS-DC, ASPIRIN
 SYNAREL, NAFARELIN ACETATE
 SYNDROS, DRONABINOL
 SYNERA, LIDOCAINE
 SYNERCID, DALFOPRISTIN
 SYNJARDY, EMPAGLIFLOZIN
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNRIPO, OMACETAXINE MEPESUCCINATE
 SYNTHROID, LEVOTHYROXINE SODIUM **
 SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

TAB-PROFEN, IBUPROFEN (OTC)
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TAFINLAR, DABRAFENIB MESYLATE
 TAGAMET HB, CIMETIDINE (OTC)
 TAGITOL V, BARIUM SULFATE
 TAGRISSO, OSIMERTINIB MESYLATE
 TALC, TALC
 TALWIN, PENTAZOCINE LACTATE
 TAMBOCOR, FLECAINIDE ACETATE
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE , TAMSULOSIN HYDROCHLORIDE
 TAPAZOLE, METHIMAZOLE
 TARCEVA, ERLOTINIB HYDROCHLORIDE
 TARGRETIN, BEXAROTENE
 TARKA, TRANDOLAPRIL
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
 TASMAR, TOLCAPONE
 TAVIST-1, CLEMASTINE FUMARATE (OTC)
 TAXOL, PACLITAXEL
 TAXOTERE, DOCETAXEL
 TAYTULLA, ETHINYL ESTRADIOL
 TAZAROTENE, TAZAROTENE
 TAZICEF, CEFTAZIDIME
 TAZORAC, TAZAROTENE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TECFIDERA, DIMETHYL FUMARATE
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

APPENDIX A - PRODUCT NAME INDEX

** T **

TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNIVIE, OMBITASVIR
 TEFLARO, CEFTAROLINE FOSAMIL
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TEKTURNA, ALISKIREN HEMIFUMARATE
 TEKTURNA HCT, ALISKIREN HEMIFUMARATE
 TELMISARTAN, TELMISARTAN
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TEMAZEPAM, TEMAZEPAM
 TEMODAR, TEMOZOLOMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TENEX, GUANFACINE HYDROCHLORIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 TENUATE, DIETHYLPROPION HYDROCHLORIDE
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 TEPADINA, THIOTEPA
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TERCONAZOLE, TERCONAZOLE
 TERIL, CARBAMAZEPINE
 TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
 TESSALON, BENZONATATE
 TESTIM, TESTOSTERONE
 TESTOPEL, TESTOSTERONE
 TESTOSTERONE, TESTOSTERONE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TESTRED, METHYLTESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TEVETEN, EPROSARTAN MESYLATE
 TEXACORT, HYDROCORTISONE
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 THALOMID, THALIDOMIDE
 THAM, TROMETHAMINE
 THEO-24, THEOPHYLLINE
 THEOCHRON, THEOPHYLLINE
 THEOPHYLLINE, THEOPHYLLINE
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THERMAZENE, SILVER SULFADIAZINE
 THEROXIDIL, MINOXIDIL (OTC)
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOGUANINE, THIOGUANINE
 THIOLA, TIOPRONIN
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 THIOTHIXENE, THIOTHIXENE
 THRIVE, NICOTINE POLACRILEX (OTC)
 THYROGEN, THYROTROPIN ALFA

APPENDIX A - PRODUCT NAME INDEX

** T **

THYROLAR-0.25, LIOTRIX (T4)
THYROLAR-0.5, LIOTRIX (T4)
THYROLAR-1, LIOTRIX (T4)
THYROLAR-2, LIOTRIX (T4)
THYROLAR-3, LIOTRIX (T4)
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIKOSYN, DOFETILIDE
TIMOLOL, TIMOLOL
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIVICAY, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBEX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM

APPENDIX A - PRODUCT NAME INDEX

** T **

TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVATAN Z, TRAVOPROST
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRECATOR, ETHIONAMIDE
 TRELEGY ELLIPTA, FLUTICASONE FUROATE
 TRELSTAR, TRIPTORELIN PAMOATE
 TREPROSTINIL, TREPROSTINIL
 TRESIBA, INSULIN DEGLUDEC
 TRETINOIN, TRETINOIN
 TREXALL, METHOTREXATE SODIUM
 TREXIMET, NAPROXEN SODIUM
 TREZIX, ACETAMINOPHEN
 TRI LO SPRINTEC, ETHINYL ESTRADIOL
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 TRI-MILI, ETHINYL ESTRADIOL
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 TRIACIN-C, CODEINE PHOSPHATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE IN ABSORBABLE, TRIAMCINOLONE ACETONIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIBENZOR, AMLODIPINE BESYLATE
 TRICOR, FENOFIBRATE
 TRIDERM, TRIAMCINOLONE ACETONIDE
 TRIDIONE, TRIMETHADIONE
 TRISENCE, TRIAMCINOLONE ACETONIDE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRIFLURIDINE, TRIFLURIDINE
 TRIGLIDE, FENOFIBRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRILEPTAL, OXCARBAZEPINE
 TRILIPIX, CHOLINE FENOFIBRATE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 TRIOSTAT, LIOTHYRONINE SODIUM
 TRIPTODUR KIT, TRIPTORELIN PAMOATE
 TRISENOX, ARSENIC TRIOXIDE
 TRIUMEQ, ABACAVIR SULFATE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 TRIVORA-28, ETHINYL ESTRADIOL
 TRIZIVIR, ABACAVIR SULFATE
 TROKENDI XR, TOPIRAMATE
 TROPHAMINE, AMINO ACIDS
 TROPHAMINE 10%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

** T **

TROPICACYL, TROPICAMIDE
 TROPICAMIDE, TROPICAMIDE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 TRULANCE, PLECANATIDE
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
 TRUVADA, EMTRICITABINE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
 TUSSIGON, HOMATROPINE METHYLBROMIDE
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
 TWYNSTA, AMLODIPINE BESYLATE
 TYBOST, COBICISTAT
 TYDEMY, DROSPIRENONE
 TYGACIL, TIGECYCLINE
 TYKERB, LAPATINIB DITOSYLATE
 TYLENOL, ACETAMINOPHEN (OTC)
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 TYMLOS, ABALOPARATIDE
 TYVASO, TREPROSTINIL
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

** U **

U-CORT, HYDROCORTISONE ACETATE
 UCERIS, BUDESONIDE
 ULESFIA, BENZYL ALCOHOL
 ULORIC, FEBUXOSTAT
 ULTACAN, ARTICAINA HYDROCHLORIDE
 ULTACAN FORTE, ARTICAINA HYDROCHLORIDE
 ULTANE, SEVOFLURANE
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 ULTRAVATE, HALOBETASOL PROPIONATE
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 240, IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 ULTRESA, PANCRELIPASE (AMYLASE)
 UNASYN, AMPICILLIN SODIUM
 UNISOM, DOXYLAMINE SUCCINATE (OTC)
 UNITHROID, LEVOTHYROXINE SODIUM **
 UPTRAVI, SELEXIPAG
 URECHOLINE, BETHANECHOL CHLORIDE
 UREX, METHENAMINE HIPPURATE
 UROCIT-K, POTASSIUM CITRATE
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 URSODIOL, URSODIOL
 UTIBRON, GLYCOPYRROLATE
 UVADEX, METHOXSALLEN

** V **

VABOMERE, MEROPENEM
 VAGIFEM, ESTRADIOL
 VAGISTAT-1, TIOCONAZOLE (OTC)
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALIUM, DIAZEPAM

APPENDIX A - PRODUCT NAME INDEX

** v **

VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VANTRELA ER, HYDROCODONE BITARTRATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARIBAR, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERMOX, MEBENDAZOLE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** V **

VIGABATRIN, VIGABATRIN
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIIBRYD, VILAZODONE HYDROCHLORIDE
 VIMOVO, ESOMEPRAZOLE MAGNESIUM
 VIMPAT, LACOSAMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE
 VIOKACE, PANCRELIPASE (AMYLASE)
 VIORELE, DESOGESTREL
 VIRACEPT, NELFINAVIR MESYLATE
 VIRAMUNE, NEVIRAPINE
 VIRAMUNE XR, NEVIRAPINE
 VIRAZOLE, RIBAVIRIN
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VIROPTIC, TRIFLURIDINE
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
 VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 VISIONBLUE, TRYPAN BLUE
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VISTARIL, HYDROXYZINE PAMOATE
 VISTOGARD, URIDINE TRIACETATE
 VISUDYNE, VERTEPORFIN
 VITAMIN D, ERGOCALCIFEROL
 VITAMIN K1, PHYTONADIONE
 VITRASE, HYALURONIDASE
 VITUZ, CHLORPHENIRAMINE MALEATE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
 VIVELLE-DOT, ESTRADIOL
 VIVITROL, NALTREXONE
 VIVLODEX, MELOXICAM
 VIZAMYL, FLUTEMETAMOL F-18
 VOGELXO, TESTOSTERONE
 VOLNEA, DESOGESTREL
 VOLTAREN, DICLOFENAC SODIUM
 VORICONAZOLE, VORICONAZOLE
 VOSEVI, SOFOSBUVIR
 VOSOL, ACETIC ACID, GLACIAL
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VPRIV, VELAGLUCERASE ALFA
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE
 VUSION, MICONAZOLE NITRATE
 VYFEMLA, ETHINYL ESTRADIOL
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE
 VYXEOS, CYTARABINE
 VYZULTA, LATANOPROSTENE BUNOD

** W **

WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WERA, ETHINYL ESTRADIOL
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

** X **

XADAGO, SAFINAMIDE MESYLATE
 XALATAN, LATANOPROST
 XALKORI, CRIZOTINIB
 XANAX, ALPRAZOLAM
 XANAX XR, ALPRAZOLAM

APPENDIX A - PRODUCT NAME INDEX

** X **

XARELTO, RIVAROXABAN
 XATMEP, METHOTREXATE SODIUM
 XELJANZ, TOFACITINIB CITRATE
 XELJANZ XR, TOFACITINIB CITRATE
 XELODA, CAPECITABINE
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENON XE 133, XENON XE-133
 XEPI, OZENOXACIN
 XERESE, ACYCLOVIR
 XERMELLO, TELOTRISTAT ETIPRATE
 XHANCE, FLUTICASONE PROPIONATE
 XIFAXAN, RIFAXIMIN
 XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL
 XIIDRA, LIFITEGRAST
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 XOLEGEL, KETOCONAZOLE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XTAMPZA ER, OXYCODONE
 XTANDI, ENZALUTAMIDE
 XTORO, FINAFLOXACIN
 XULANE, ETHINYL ESTRADIOL
 XULTOPHY 100/3.6, INSULIN DEGLUDEC
 XURIDEN, URIDINE TRIACETATE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYREM, SODIUM OXYBATE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

** Y **

YAELA, DROSPIRENONE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE
 YONDELIS, TRABECTEDIN
 YOSPRALA, ASPIRIN

** Z **

ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
 ZARONTIN, ETHOSUXIMIDE
 ZAROXOLYN, METOLAZONE
 ZAVESCA, MIGLUSTAT
 ZEGERID, OMEPRAZOLE
 ZEGERID OTC, OMEPRAZOLE (OTC)
 ZEJULA, NIRAPARIB TOSYLATE
 ZELAPAR, SELEGILINE HYDROCHLORIDE
 ZELBORAF, VEMURAFENIB
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZEMPLAR, PARICALCITOL
 ZENATANE, ISOTRETINOIN
 ZENPEP, PANCRELIPASE (AMYLASE)
 ZEPATIER, ELBASVIR
 ZERBAXA, CEFTOLOZANE SULFATE

APPENDIX A - PRODUCT NAME INDEX

** Z **

ZERIT, STAVUDINE
ZERVIAE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN RECOMBINANT
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUPLENZ, ONDANSETRON
ZURAMPIC, LESINURAD
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZYPREXA, OLANZAPINE

ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ZYPREXA ZYDIS, OLANZAPINE

ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

ZYTIGA, ABIRATERONE ACETATE

ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3D IMAGING DRUG**

- * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M DRUG DELIVERY

- * 3M DRUG DELIVERY SYSTEMS
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

**** A ******AAA USA INC**

- * ADVANCED ACCELERATOR APPLICATIONS USA INC
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ANDROGEL, TESTOSTERONE
BIAXIN, CLARITHROMYCIN
CREON, PANCRELIPASE (AMYLASE)
CYCLOSPORINE, CYCLOSPORINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
MIVACRON, MIVACURIUM CHLORIDE
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC

- * ABBVIE INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ABBVIE INC**

DUOPA, CARBIDOPA
 MAVYRET, GLECAPREVIR
 NORVIR, RITONAVIR
 TECHNIVIE, OMBITASVIR
 VENCLEXTA, VENETOCLAX
 VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
 VIEKIRA XR, DASABUVIR SODIUM

ABHAI INC*** ABHAI INC**

DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC*** ABHAI LLC**

HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

ABON PHARMS LLC*** ABON PHARMACEUTICALS LLC**

CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE*** ABRAXIS BIOSCIENCE LLC**

ABRAXANE, PACLITAXEL

ABRAXIS PHARM*** ABRAXIS PHARMACEUTICAL PRODUCTS**

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADIA PHARMS INC*** ACADIA PHARMACEUTICALS INC**

NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS*** ACCELRX LABS LLC**

CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE*** ACCORD HEALTHCARE INC**

ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BIVALIRUDIN, BIVALIRUDIN
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBOPLATIN, CARBOPLATIN
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 DECITABINE, DECITABINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ENTECAVIR, ENTECAVIR
 EPLERENONE, EPLERENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACCORD HEALTHCARE INC
 ETOPOSIDE, ETOPOSIDE
 FINASTERIDE, FINASTERIDE
 FLUOROURACIL, FLUOROURACIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL, LISINOPRIL
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLDOPA, METHYLDOPA
 MITOMYCIN, MITOMYCIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SPIRONOLACTONE, SPIRONOLACTONE
 TACROLIMUS, TACROLIMUS
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
- ACELLA PHARMS LLC**
- * ACELLA PHARMACEUTICALS LLC
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
- ACI HEALTHCARE LTD**
- * ACI HEALTHCARE LTD
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 LEVETIRACETAM, LEVETIRACETAM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- ACIC FINE CHEMS**
- * ACIC FINE CHEMICALS INC
 TRANEXAMIC ACID, TRANEXAMIC ACID
- ACIC PHARMS**
- * ACIC PHARMACEUTICALS INC
 LEVETIRACETAM, LEVETIRACETAM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ACLARIS THERAPS INC**

* ACLARIS THERAPEUTICS INC
ESKATA, HYDROGEN PEROXIDE

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
QUTENZA, CAPSAICIN

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAZONE, CEFTRIAZONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
KEFZOL, CEFAZOLIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR INFO SA

* ACS DOBFAR INFO SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS ELIZABETH LLC
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - PROPYLTHIOURACIL, PROPYLTHIOURACIL
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SPIRONOLACTONE, SPIRONOLACTONE
 - TEMAZEPAM, TEMAZEPAM
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - ALPRAZOLAM, ALPRAZOLAM
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - LAMOTRIGINE, LAMOTRIGINE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

- * ACTAVIS INC
 - DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - METHOXSALEN, METHOXSALEN
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS LABS

- * ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

- * ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 - GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 - GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 - GUAIFENESIN, GUAIFENESIN (OTC)

ACTAVIS LABS FL INC

- * ACTAVIS LABORATORIES FL INC
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CABERGOLINE, CABERGOLINE
 - CARTIA XT, DILTIAZEM HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DALFAMPRIDINE, DALFAMPRIDINE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 - DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 - DUTASTERIDE, DUTASTERIDE
 - FENTANYL CITRATE, FENTANYL CITRATE
 - FLUTAMIDE, FLUTAMIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - KETOPROFEN, KETOPROFEN
 - LEVETIRACETAM, LEVETIRACETAM
 - LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - METAXALONE, METAXALONE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - MIRTAZAPINE, MIRTAZAPINE
 - NAPROXEN SODIUM, NAPROXEN SODIUM
 - NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 - NITROGLYCERIN, NITROGLYCERIN
 - OMEPRAZOLE, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS LABORATORIES FL INC
 OXYCODONE AND ASPIRIN, ASPIRIN
 PALIPERIDONE, PALIPERIDONE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISONE, PREDNISONE
 RAMELTEON, RAMELTEON
 RISPERIDONE, RISPERIDONE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TETRABENAZINE, TETRABENAZINE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS NY INC

* ACTAVIS LABORATORIES NY INC
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONIDINE, CLONIDINE
 EMLA, LIDOCAINE
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LIDOCAINE, LIDOCAINE
 NORINYL 1+50 28-DAY, MESTRANOL
 PROGESTERONE, PROGESTERONE
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 TENUATE, DIETHYLPROPION HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
 AZACITIDINE, AZACITIDINE
 DAPSONE, DAPSONE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 BUSULFAN, BUSULFAN
 DOCETAXEL, DOCETAXEL
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
 ACETASOL HC, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DESOXIMETASONE, DESOXIMETASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS MID ATLANTIC LLC
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - ENULOSE, LACTULOSE
 - FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 - GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 - HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 - HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 - HYDROCORTISONE, HYDROCORTISONE
 - IBUPROFEN, IBUPROFEN (OTC)
 - LEVETIRACETAM, LEVETIRACETAM
 - MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NITROFURANTOIN, NITROFURANTOIN
 - NYSTATIN, NYSTATIN
 - PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - VALNAC, BETAMETHASONE VALERATE
- * ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - IBUPROFEN, IBUPROFEN
 - M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 - PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

- * ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

ACTAVIS TOTOWA

- * ACTAVIS TOTOWA LLC
 - DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 - EPIDRUBICIN HYDROCHLORIDE, EPIDRUBICIN HYDROCHLORIDE
 - FINASTERIDE, FINASTERIDE
 - FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - OXALIPLATIN, OXALIPLATIN
 - PACLITAXEL, PACLITAXEL
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - REPAGLINIDE, REPAGLINIDE
 - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTAVIS TOTOWA TEVA

- * ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - FINASTERIDE, FINASTERIDE

ACTELION PHARMS

- * ACTELION PHARMACEUTICALS LTD
 - TRACLEER, BOSENTAN

ACTELION PHARMS LTD

- * ACTELION PHARMACEUTICALS LTD
 - OPSUMIT, MACITENTAN
 - TRACLEER, BOSENTAN
 - UPTRAVI, SELEXIPAG
 - VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 - VELETRI, EPOPROSTENOL SODIUM
 - VENTAVIS, ILOPROST
 - ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

- * ACTIENT PHARMACEUTICALS LLC
 - THEO-24, THEOPHYLLINE

ADAMAS PHARMA

- * ADAMAS PHARMA LLC
 - GOCOVRI, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

- * ADAMIS PHARMACEUTICALS CORP
 - SYMJEPI, EPINEPHRINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ADAPT**

* ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE

ADARE PHARMS INC

* ADARE PHARMACEUTICALS INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

ADDMEDICA SAS

* ADDMEDICA SAS
SIKLOS, HYDROXYUREA

ADIENNE SA

* ADIENNE SA
TEPADINA, THIOTEPA

AEGERION

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AERIE PHARMS INC

* AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL DIMESYLATE

AETERNA ZENTARIS

* AETERNA ZENTARIS GMBH
MACRILEN, MACIMORELIN ACETATE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

AJANTA PHARMA

* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
LANSOPRAZOLE, LANSOPRAZOLE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

AKTEN, LIDOCAINE HYDROCHLORIDE
 AKTOB, TOBRAMYCIN
 ALFENTA, ALFENTANIL HYDROCHLORIDE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC, AMINOCAPROIC ACID
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN, BACITRACIN
 BAL, DIMERCAPROL
 BALANCED SALT, CALCIUM CHLORIDE
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CALCITRIOL, CALCITRIOL
 CAPASTAT SULFATE, CAPREOMYCIN SULFATE
 CARBOPLATIN, CARBOPLATIN
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ENDOSOL EXTRA, CALCIUM CHLORIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IC-GREEN, INDOCYANINE GREEN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LATANOPROST, LATANOPROST
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PYRAZINAMIDE, PYRAZINAMIDE
 RIFAMPIN, RIFAMPIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOLOL, TIMOLOL
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TROPICACYL, TROPICAMIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC*** AKORN INC**

ACETYLCYSTEINE, ACETYLCYSTEINE
 APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DRONABINOL, DRONABINOL
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INAPSINE, DROPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALCON*** ALCON LABORATORIES INC**

BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 MIOSTAT, CARBACHOL
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON PHARMS LTD*** ALCON PHARMACEUTICALS LTD**

BETADINE, POVIDONE-IODINE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)

ALEMBIC LTD*** ALEMBIC LTD**

LITHIUM CARBONATE, LITHIUM CARBONATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD*** ALEMBIC PHARMACEUTICALS LTD**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALEMBIC PHARMACEUTICALS LTD**

CELECOXIB, CELECOXIB
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DESVENLAFAXINE, DESVENLAFAXINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 THEOPHYLLINE, THEOPHYLLINE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ALIMERA SCIENCES INC

*** ALIMERA SCIENCES INC**
 ILUVIEN, FLUOCINOLONE ACETONIDE

ALKEM

*** ALKEM LABORATORIES LTD**
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

*** ALKEM LABORATORIES LTD**
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 CAPECITABINE, CAPECITABINE
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALKEM LABORATORIES LTD
 LAMOTRIGINE, LAMOTRIGINE
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ALKERMES

* ALKERMES INC
 VIVITROL, NALTREXONE

ALKERMES INC

* ALKERMES INC
 ARISTADA, ARIPIPIRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLEGIS

* ALLEGIS HOLDINGS LLC
 PRIMISOL, TRIMETHOPRIM HYDROCHLORIDE

ALLERGAN

* ALLERGAN
 ACULAR LS, KETOROLAC TROMETHAMINE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 BLEPH-10, SULFACETAMIDE SODIUM
 GENOPTIC, GENTAMICIN SULFATE
 ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
 ACULAR, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACZONE, DAPSONE
 ALOCRIL, NEDOCROMIL SODIUM
 ALPHAGAN P, BRIMONIDINE TARTRATE
 AVAGE, TAZAROTENE
 AZELEX, AZELAIC ACID
 COMBIGAN, BRIMONIDINE TARTRATE
 ELESTAT, EPINASTINE HYDROCHLORIDE
 LASTACRAFT, ALCAFTADINE
 LATISSE, BIMATOPROST
 LUMIGAN, BIMATOPROST
 OCUFLOX, OFLOXACIN
 OZURDEX, DEXAMETHASONE
 POLYTRIM, POLYMYXIN B SULFATE
 RESTASIS MULTIDOSE, CYCLOSPORINE
 RESTASIS, CYCLOSPORINE
 TAZORAC, TAZAROTENE
 ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
 BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLEPHAMIDE, PREDNISOLONE ACETATE
 FML FORTE, FLUOROMETHOLONE
 FML, FLUOROMETHOLONE
 OCUFEN, FLURBIPROFEN SODIUM
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ALLERGAN HOLDINGS**

* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERGAN INC

* ALLERGAN INC
ACZONE, DAPSONE
RHOFADOLINE, OXYMETAZOLINE HYDROCHLORIDE

ALLERGAN SALES LLC

* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE
BREVICON 28-DAY, ETHINYL ESTRADIOL
CONDYLOX, PODOFILOX
CORDRAN, FLURANDRENOLIDE
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
ESTRACE, ESTRADIOL
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE
MICROZIDE, HYDROCHLOROTHIAZIDE
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
RAPAFLO, SILODOSIN
SAVELLA, MILNACIPRAN HYDROCHLORIDE
TRELSTAR, TRIPTORELIN PAMOATE

ALLERQUEST

* ALLERQUEST LLC
PRE-PEN, BENZYL PENICILLIN POLYLYSINE

ALLIED PHARMA INC

* ALLIED PHARMA INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

ALLOS

* ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

ALPHARMA PHARMS

* ALPHARMA PHARMACEUTICALS LLC
EMBEDA, MORPHINE SULFATE

ALRA

* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
OFLOXACIN, OFLOXACIN

* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

* ALVOGEN GROUP HOLDINGS LLC
ADALAT CC, NIFEDIPINE

* ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
VORICONAZOLE, VORICONAZOLE

ALVOGEN MALTA

* ALVOGEN MALTA OPERATIONS LTD
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BUDESONIDE, BUDESONIDE
CARBIDOPA, CARBIDOPA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MELPHALAN, MELPHALAN
NAPRELAN, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SPECTAZOLE, ECONAZOLE NITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK LLC
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

AM ANTIBIOTICS

* AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

AMAG PHARMA USA

* AMAG PHARMA USA INC
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
INTRAROSA, PRASTERONE

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMERIGEN PHARMS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMERIGEN PHARMACEUTICALS LTD
 CARBIDOPA, CARBIDOPA
 INDAPAMIDE, INDAPAMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN

* AMGEN INC
 SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
 CORLANOR, IVABRADINE HYDROCHLORIDE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATOVAQUONE, ATOVAQUONE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 LORAZEPAM, LORAZEPAM
 MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC

ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 IBUPROFEN, IBUPROFEN (OTC)
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PARICALCITOL, PARICALCITOL
 SPIRONOLACTONE, SPIRONOLACTONE
 TOBRAMYCIN, TOBRAMYCIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN, VALSARTAN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH

BUMETANIDE, BUMETANIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 CLOFARABINE, CLOFARABINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS CO GMBH
 NADOLOL, NADOLOL
 OXAPROZIN, OXAPROZIN
 PARICALCITOL, PARICALCITOL
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

AMNEAL PHARMS LLC

* AMNEAL PHARMACEUTICALS LLC
 ACTIVELLA, ESTRADIOL
 AZATHIOPRINE, AZATHIOPRINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REPREXAIN, HYDROCODONE BITARTRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOTRETINOIN, ISOTRETINOIN
 PROGESTERONE, PROGESTERONE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
 AMPHADASE, HYALURONIDASE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
 CORTROSYN, COSYNTROPIN
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

AMRING PHARMS

* AMRING PHARMACEUTICALS INC
 BROMFENAC SODIUM, BROMFENAC SODIUM
 LATANOPROST, LATANOPROST
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
 EUCRISA, CRISABOROLE
 KERYDIN, TAVABOROLE

ANBEX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANBEX INC

IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB CO LTD

* ANBISON LABORATORY CO LTD

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM**ANCHEN PHARMS**

* ANCHEN PHARMACEUTICALS INC

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ANCHEN PHARMACEUTICALS TAIWAN INC

DIVALPROEX SODIUM, DIVALPROEX SODIUM

* ANCHEN PHARMACEUTICALS, INC

ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE**ANDA REPOSITORY**

* ANDA REPOSITORY LLC

BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
PRIMIDONE, PRIMIDONE**ANDRX LABS LLC**

* ANDRX LABS LLC

FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC

CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE**ANI PHARMS INC**

* ANI PHARMACEUTICALS INC

ALPRAZOLAM, ALPRAZOLAM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ETODOLAC, ETODOLAC
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLIPIZIDE, GLIPIZIDE
GLUCAMIDE, CHLORPROPAMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LITHOBID, LITHIUM CARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ANI PHARMACEUTICALS INC**

LORAZEPAM, LORAZEPAM
 METHAZOLAMIDE, METHAZOLAMIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NILUTAMIDE, NILUTAMIDE
 NIZATIDINE, NIZATIDINE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RISPERIDONE, RISPERIDONE
 TESTOSTERONE, TESTOSTERONE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALPROIC ACID, VALPROIC ACID
 VANCOGIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANTARES PHARMA INC*** ANTARES PHARMA INC**

OTREXUP, METHOTREXATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

ANTIBIOTICE*** ANTIBIOTICE SA**

AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTRIM PHARMS LLC*** ANTRIM PHARMACEUTICALS LLC**

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

APEX PHARMS INC*** APEX PHARMACEUTICALS INC**

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI*** ASTELLAS PHARMA GLOBAL DEVELOPMENT INC**

MYRBETRIQ, MIRABEGRON

APICORE US*** APICORE US LLC**

TETRABENAZINE, TETRABENAZINE

APIL*** ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD**

ACTONEL, RISEDRONATE SODIUM
 ASACOL HD, MESALAMINE
 ATELVIA, RISEDRONATE SODIUM
 DELZICOL, MESALAMINE
 ENABLEX, DARIFENACIN HYDROBROMIDE
 ESTROSTEP FE, ETHINYL ESTRADIOL
 FEMCON FE, ETHINYL ESTRADIOL
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LO MINASTRIN FE, ETHINYL ESTRADIOL
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 NOR-QD, NORETHINDRONE
 NORCO, ACETAMINOPHEN
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 SARAFEM, FLUOXETINE HYDROCHLORIDE
 TAYTULLA, ETHINYL ESTRADIOL

APOLLO PHARMS INC*** APOLLO PHARMACEUTICALS INC**

PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******APOPHARMA INC**

* APOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

* APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMIVUDINE, LAMIVUDINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APOTEX CORP

* APOTEX CORP
AZITHROMYCIN, AZITHROMYCIN
CABERGOLINE, CABERGOLINE
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******APOTEX INC**

* APOTEX INC
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALKERAN, MELPHALAN
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE, ATOVAQUONE
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BICALUTAMIDE, BICALUTAMIDE
 BIMATOPROST, BIMATOPROST
 BIVALIRUDIN, BIVALIRUDIN
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BUDESONIDE, BUDESONIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CICLOPIROX, CICLOPIROX
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DASATINIB, DASATINIB
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 EZETIMIBE, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMIQUIMOD, IMIQUIMOD
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOVASTATIN, LOVASTATIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NABUMETONE, NABUMETONE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OXCARBAZEPINE, OXCARBAZEPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
 ACYCLOVIR, ACYCLOVIR
 ALLOPURINOL, ALLOPURINOL
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CARVEDILOL, CARVEDILOL
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DILTIZAC, DILTIAZEM HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 LEFLUNOMIDE, LEFLUNOMIDE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 MIRTAZAPINE, MIRTAZAPINE
 OXAPROZIN, OXAPROZIN
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUNISOLIDE, FLUNISOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
RISPERIDONE, RISPERIDONE
- * APOTEX INC.
DILTIZAC, DILTIAZEM HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

- * APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO PHARMA LLC

- * APPCO PHARMA LLC
BUDESONIDE, BUDESONIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
LAMIVUDINE, LAMIVUDINE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

APRECIA PHARMS

- * APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

AQUA PHARMS

- * AQUA PHARMACEUTICALS
ACTICLATE CAP, DOXYCYCLINE HYCLATE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE
VERDESO, DESONIDE
- * AQUA PHARMACEUTICALS LLC
FLUOROPLEX, FLUOROURACIL
XOLEGEL, KETOCONAZOLE

AQUA PHARMS LLC

- * AQUA PHARMACEUTICALS LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ALTABAX, RETAPAMULIN
VELTIN, CLINDAMYCIN PHOSPHATE

ARALEZ PHARMS

- * ARALEZ PHARMACEUTICALS TRADING DAC
TOPROL-XL, METOPROLOL SUCCINATE
YOSPRALA, ASPIRIN
ZONTIVITY, VORAPAXAR SULFATE

ARALEZ PHARMS INC

- * ARALEZ PHARMACEUTICALS INC
FIBRICOR, FENOFIBRIC ACID

ARBOR PHARMS LLC

- * ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
CETYLEV, ACETYLCYSTEINE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ARBOR PHARMACEUTICALS LLC
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 EDARBI, AZILSARTAN KAMEDOXOMIL
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
 ERY-TAB, ERYTHROMYCIN
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROMYCIN, ERYTHROMYCIN
 EVEKEO, AMPHETAMINE SULFATE
 GLIADEL, CARMUSTINE
 HORIZANT, GABAPENTIN ENACARBIL
 NYMALIZE, NIMODIPINE
 PCE, ERYTHROMYCIN
 SKLICE, IVERMECTIN
 SOTYLIZE, SOTALOL HYDROCHLORIDE
 TRIPTODUR KIT, TRIPTORELIN PAMOATE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
 THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
 ALUNBRIG, BRIGATINIB
 ICLUSIG, PONATINIB HYDROCHLORIDE

ARISE PHARMS

* ARISE PHARMACEUTICALS LLC
 IBUPROFEN, IBUPROFEN (OTC)

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
 ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
 DUTASTERIDE, DUTASTERIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN (OTC)
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

ASPEN GLOBAL

* ASPEN GLOBAL INC
 MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CYCLESSA, DESOGESTREL
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 LEUKERAN, CHLORAMBUCIL
 MYLERAN, BUSULFAN
 THIOGUANINE, THIOGUANINE

ASTELLAS

* ASTELLAS PHARMA US INC
 ADENOCARD, ADENOSINE
 AMBISOME, AMPHOTERICIN B
 ASTAGRAF XL, TACROLIMUS
 CRESEMBA, ISAVUCONAZONIUM SULFATE
 LEXISCAN, REGADENOSON
 MYCAMINE, MICAFUNGIN SODIUM
 PROGRAF, TACROLIMUS
 VESICARE, SOLIFENACIN SUCCINATE
 XTANDI, ENZALUTAMIDE

ASTRAZENECA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ASTRAZENECA LP
 - PULMICORT FLEXHALER, BUDESONIDE
 - SYMBICORT, BUDESONIDE
- * ASTRAZENECA PHARMACEUTICALS LP
 - ATACAND HCT, CANDESARTAN CILEXETIL
 - ATACAND, CANDESARTAN CILEXETIL
 - FASLODEX, FULVESTRANT
 - ZOMIG, ZOLMITRIPTAN
 - ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
 - CALQUENCE, ACALABRUTINIB
 - SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

- * ASTRAZENECA AB
 - BYDUREON BCISE, EXENATIDE
 - BYDUREON PEN, EXENATIDE SYNTHETIC
 - BYDUREON, EXENATIDE SYNTHETIC
 - BYETTA, EXENATIDE SYNTHETIC
 - FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
 - KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 - ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 - QTERN, DAPAGLIFLOZIN PROPANEDIOL
 - SYMLIN, PRAMLINTIDE ACETATE
 - XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL

ASTRAZENECA LP

- * ASTRAZENECA LP
 - NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

- * ASTRAZENECA PHARMACEUTICALS LP
 - ALVESCO, CICLESONIDE
 - ARIMIDEX, ANASTROZOLE
 - BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
 - BRILINTA, TICAGRELOR
 - CASODEX, BICALUTAMIDE
 - DALIRESP, ROFLUMILAST
 - EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
 - IRESSA, GEFITINIB
 - LYNPARZA, OLAPARIB
 - MOVANTIK, NALOXEGOL OXALATE
 - NEXIUM IV, ESOMEPRAZOLE SODIUM
 - NEXIUM, ESOMEPRAZOLE MAGNESIUM
 - OMNARIS, CICLESONIDE
 - PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 - PULMICORT RESPULES, BUDESONIDE
 - RHINOCORT ALLERGY, BUDESONIDE (OTC)
 - SEROQUEL, QUETIAPINE FUMARATE
 - TAGRISSE, OSIMERTINIB MESYLATE
 - TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 - ZETONNA, CICLESONIDE

ATHENEX INC

- * ATHENEX INC
 - BUMETANIDE, BUMETANIDE
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIPYRIDAMOLE, DIPYRIDAMOLE
 - DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 - FAMOTIDINE, FAMOTIDINE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - VALPROATE SODIUM, VALPROATE SODIUM

ATLAS PHARMS LLC

- * ATLAS PHARMACEUTICALS LLC
 - IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ATLAS PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
CUPRIMINE, PENICILLAMINE
EDECIN, ETHACRYNATE SODIUM
EDECIN, ETHACRYNIC ACID
LACRISERT, HYDROXYPROPYL CELLULOSE
LODOSYN, CARBIDOPA
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE

ATON PHARMA VPNA

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DEMSEK, METYROSINE

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROBINDO PHARMA LTD**

LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD*** AUROBINDO PHARMA LIMITED**

DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

*** AUROBINDO PHARMA LTD**

ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AFIRMELLE, ETHINYL ESTRADIOL
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ARIPIRAZOLE, ARIPIRAZOLE
 ATHENTIA NEXT, LEVONORGESTREL (OTC)
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AUROVELA 1.5/30, ETHINYL ESTRADIOL
 AUROVELA 1/20, ETHINYL ESTRADIOL
 AUROVELA 24 FE, ETHINYL ESTRADIOL
 AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
 AUROVELA FE 1/20, ETHINYL ESTRADIOL
 AYUNA, ETHINYL ESTRADIOL
 AZITHROMYCIN, AZITHROMYCIN
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AUROBINDO PHARMA LTD
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CEFIXIME, CEFIXIME
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYONANZ, ETHINYL ESTRADIOL
 DALFAMPRIDINE, DALFAMPRIDINE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ
 ENTACAPONE, ENTACAPONE
 ENTECAVIR, ENTECAVIR
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 ETOMIDATE, ETOMIDATE
 EZETIMIBE, EZETIMIBE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 INCASSIA, NORETHINDRONE
 INDOMETHACIN, INDOMETHACIN
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KALLIGA, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LO SIMPESSE, ETHINYL ESTRADIOL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METRONIDAZOLE, METRONIDAZOLE
 MILI, ETHINYL ESTRADIOL
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 NEVIRAPINE, NEVIRAPINE
 NEXESTA FE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 REPAGLINIDE, REPAGLINIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROBINDO PHARMA LTD**

RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIMPESE, ETHINYL ESTRADIOL
 SPIRONOLACTONE, SPIRONOLACTONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-MILI, ETHINYL ESTRADIOL
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN

*** AUROBINDO PHARMA LTD INC**

ZIDOVUDINE, ZIDOVUDINE

AUROLIFE PHARMA LLC*** AUROLIFE PHARMA LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DUTASTERIDE, DUTASTERIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA LLC*** AUSTARPHARMA LLC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM
 METHOCARBAMOL, METHOCARBAMOL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS INC*** AUXILIUM PHARMACEUTICALS INC**

TESTOPEL, TESTOSTERONE
 THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC*** AUXILIUM PHARMACEUTICALS LLC**

DILATRATE-SR, ISOSORBIDE DINITRATE
 EDEX, ALPROSTADIL
 ROBAXIN, METHOCARBAMOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUXILIUM PHARMACEUTICALS LLC
 ROBAXIN-750, METHOCARBAMOL
 SEMPREX-D, ACRIVASTINE
 STRIANT, TESTOSTERONE
 TESTIM, TESTOSTERONE
 THEO-24, THEOPHYLLINE

AVACOR PRODS

* AVACOR PRODUCTS LLC
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVADEL LEGACY

* AVADEL LEGACY PHARMACEUTICALS LLC
 VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

AVADEL PHARMS

* AVADEL PHARMACEUTICALS USA INC
 ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM

AVADEL SPECLT

* AVADEL SPECIALTY PHARMACEUTICALS LLC
 NOCTIVA, DESMOPRESSIN ACETATE

AVANIR PHARMS

* AVANIR PHARMACEUTICALS
 ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
 * AVANIR PHARMACEUTICALS INC
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 INDOMETHACIN, INDOMETHACIN
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
 PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
 IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
 PYTEST KIT, UREA, C-14
 PYTEST, UREA, C-14

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
 CLONIDINE, CLONIDINE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC
 AMYVID, FLORBETAPIR F-18

AVONDALE PHARMS

* AVONDALE PHARMACEUTICALS LLC
 NIACOR, NIACIN

AYTU BIOSCIENCE INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AYTU BIOSCIENCE INC
NATESTO, TESTOSTERONE

**** B ******B BRAUN**

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC*** B BRAUN MEDICAL INC**

CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ MEDICAL LLC*** BAJAJ MEDICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

BARR*** BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLONAZEPAM, CLONAZEPAM
 DANAZOL, DANAZOL
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIDANOSINE, DIDANOSINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BARR LABORATORIES INC
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 ONDANSETRON, ONDANSETRON
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PORTIA-28, ETHINYL ESTRADIOL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 SPRINTEC, ETHINYL ESTRADIOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM

* BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS DIV TEVA

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 BUDESONIDE, BUDESONIDE
 OXYBUTYNIN, OXYBUTYNIN

BARR LABS INC

* BARR LABORATORIES INC
 ACITRETIN, ACITRETIN
 CLOZAPINE, CLOZAPINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 ESTRADIOL, ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 TRETINOIN, TRETINOIN
 TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
 ALAWAY, KETOTIFEN FUMARATE (OTC)
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALREX, LOTEPIREDNOL ETABONATE
 BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 ISTALOL, TIMOLOL MALEATE
 LATANOPROST, LATANOPROST
 LOTEMAX, LOTEPIREDNOL ETABONATE
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 OFLOXACIN, OFLOXACIN
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 PROLENSA, BROMFENAC SODIUM
 RETISERT, FLUOCINOLONE ACETONIDE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VITRASE, HYALURONIDASE
 VYZULTA, LATANOPROSTENE BUNOD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAUSCH AND LOMB INC
 - ZIRGAN, GANCICLOVIR
 - ZYLET, LOTEPIREDNOL ETABONATE
- * BAUSCH AND LOMB PHARMACEUTICALS INC
 - BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 - BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 - CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 - DEXASPORIN, DEXAMETHASONE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - FLUNISOLIDE, FLUNISOLIDE
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 - LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 - NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 - NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 - NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 - NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 - NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 - OFLOXACIN, OFLOXACIN
 - OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 - OTICAIR, HYDROCORTISONE
 - PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 - PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 - TIMOLOL MALEATE, TIMOLOL MALEATE
 - TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 - TOBRAMYCIN, TOBRAMYCIN
 - TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 - TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

- * BAUSCH AND LOMB INC
 - BEPREVE, BEPOTASTINE BESILATE
 - LOTEMAX, LOTEPIREDNOL ETABONATE
 - LUMIFY, BRIMONIDINE TARTRATE (OTC)

BAXTER HLTHCARE

- * BAXTER HEALTHCARE CORP
 - ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 - AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 - ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 - BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - BREVIBLOC, ESMOLOL HYDROCHLORIDE
 - CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 - CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
 - CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 - CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 - CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 - CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 - CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

FORANE, ISOFLURANE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 IFEX, IFOSFAMIDE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
 - SUPRANE, DESFLURANE
 - TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 - TIS-U-SOL, MAGNESIUM SULFATE
 - TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 - TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 - VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
 - PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP
 - BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 - CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 - CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPROFLOXACIN, CIPROFLOXACIN
 - CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
 - CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 - FUROSEMIDE, FUROSEMIDE
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - LEVOFLOXACIN, LEVOFLOXACIN
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 - NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 - PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
- * BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
 - ALEVE, NAPROXEN SODIUM (OTC)
 - ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

- * BAYER HEALTHCARE PHARMACEUTICALS INC
 - ALIQOPA, COPANLISIB DIHYDROCHLORIDE

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
 - CHILDREN'S CLARITIN, LORATADINE (OTC)
 - CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 - CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 - CLARITIN HIVES RELIEF, LORATADINE (OTC)
 - CLARITIN REDITABS, LORATADINE (OTC)
 - CLARITIN, LORATADINE (OTC)
 - CLARITIN-D 24 HOUR, LORATADINE (OTC)
 - CLARITIN-D, LORATADINE (OTC)
 - LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 - MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 - MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 - MYCELEX-7, CLOTRIMAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAYER HEALTHCARE LLC
ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIQUAT
ANGELIQ, DROSPIRENONE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
DESONATE, DESONIDE
EOVIST, GADOXETATE DISODIUM
FINACEA , AZELAIC ACID
FINACEA, AZELAIC ACID
GADAVIST, GADOBUTROL
KYLEENA, LEVONORGESTREL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
PRECOSE, ACARBOSE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
CEFTRIAZONE, CEFTRIAZONE SODIUM

BEDFORD LABS

* BEDFORD LABORATORIES

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BEDFORD LABORATORIES

LORAZEPAM PRESERVATIVE FREE, LORAZEPAM

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC

CEPHALEXIN, CEPHALEXIN

DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC

* BELCHER PHARMACEUTICALS LLC

CEFIXIME, CEFIXIME

EPINEPHRINE, EPINEPHRINE

SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

TACROLIMUS, TACROLIMUS

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

METHOCARBAMOL, METHOCARBAMOL

SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC

CARVEDILOL, CARVEDILOL

BI-COASTAL PHARMA

* BI-COASTAL PHARMA INTERNATIONAL LLC

DUVOID, BETHANECHOL CHLORIDE

BIO NUCLEONICS

* BIO NUCLEONICS INC

STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC

* BIO PHARM INC

CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

RISPERIDONE, RISPERIDONE

BIO-PHARM INC

* BIO-PHARM INC

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,

LACTULOSE, LACTULOSE

MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

BIOCON LIMITED

* BIOCON LIMITED

SIMVASTATIN, SIMVASTATIN

BIOCON LTD

* BIOCON LTD

ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC

RAPIVAB, PERAMIVIR

BIOFRONTERA

* BIOFRONTERA BIOSCIENCE GMBH

AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC

* BIOGEN IDEC INC

SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC

* BIOGEN IDEC INC

TECFIDERA, DIMETHYL FUMARATE

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC

KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA

AMMONIA N 13, AMMONIA N-13

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

- * BIONPHARMA INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BEXAROTENE, BEXAROTENE
 CALCITRIOL, CALCITRIOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DUTASTERIDE, DUTASTERIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NIMODIPINE, NIMODIPINE
 PARICALCITOL, PARICALCITOL
 PROGESTERONE, PROGESTERONE
 TETRABENAZINE, TETRABENAZINE
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL
 ZONISAMIDE, ZONISAMIDE

BLAIREX

- * BLAIREX LABORATORIES INC
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE EARTH

- * BLUE EARTH DIAGNOSTICS LTD
 AXUMIN, FLUCICLOVINE F-18

BOEHRINGER INGELHEIM

- * BOEHRINGER INGELHEIM
 CATAPRES, CLONIDINE HYDROCHLORIDE
 CATAPRES-TTS-1, CLONIDINE
 CATAPRES-TTS-2, CLONIDINE
 CATAPRES-TTS-3, CLONIDINE
 GILOTRIF, AFATINIB DIMALEATE
 GLYXAMBI, EMPAGLIFLOZIN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICARDIS, TELMISARTAN
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
- * BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 AGGRENOX, ASPIRIN
 APTIVUS, TIPRANAVIR
 ATROVENT HFA, IPRATROPIUM BROMIDE
 ATROVENT, IPRATROPIUM BROMIDE
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 JARDIANCE, EMPAGLIFLOZIN
 JENTADUETO XR, LINAGLIPTIN
 JENTADUETO, LINAGLIPTIN
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MOBIC, MELOXICAM
 OFEV, NINTEDANIB ESYLATE
 PERSANTINE, DIPYRIDAMOLE
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
 SPIRIVA, TIOTROPIUM BROMIDE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 SYNJARDY XR, EMPAGLIFLOZIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 SYNJARDY, EMPAGLIFLOZIN
 TRADJENTA, LINAGLIPTIN
 TWYNSTA, AMLODIPINE BESYLATE
 VIRAMUNE XR, NEVIRAPINE
 VIRAMUNE, NEVIRAPINE

BOSCOGEN

* BOSCOGEN INC
 ACYCLOVIR, ACYCLOVIR
 REPAGLINIDE, REPAGLINIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 E-Z-HD, BARIUM SULFATE
 E-Z-PAQUE, BARIUM SULFATE
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 READI-CAT 2 SMOOTHIES, BARIUM SULFATE
 READI-CAT 2, BARIUM SULFATE
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 SINOGRAFIN, DIATRIZOATE MEGLUMINE
 TAGITOL V, BARIUM SULFATE
 VARIBAR NECTAR, BARIUM SULFATE
 VARIBAR, BARIUM SULFATE

BRAEBURN PHARMS INC

* BRAEBURN PHARMACEUTICALS INC
 PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

BRAINTREE

* BRAINTREE LABORATORIES INC
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRECKENRIDGE PHARMACEUTICAL INC
 MEFENAMIC ACID, MEFENAMIC ACID
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MELOXICAM, MELOXICAM
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 OMEPRAZOLE, OMEPRAZOLE
 OXCARBAZEPINE, OXCARBAZEPINE
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE , POLYETHYLENE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
 AMMONIA N 13, AMMONIA N-13

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
 AZACTAM, AZTREONAM
 BARACLUDE, ENTECAVIR
 LYSODREN, MITOTANE
 PRAVACHOL, PRAVASTATIN SODIUM

* BRISTOL MYERS SQUIBB CO
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM
 DROXIA, HYDROXYUREA
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 REYATAZ, ATAZANAVIR SULFATE
 SPRYCEL, DASATINIB
 SUSTIVA, EFAVIRENZ
 VIDEX EC, DIDANOSINE

* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
 ELIQUIS, APIXABAN
 ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE
 ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB PHARMA CO
 COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
 DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
 EVOTAZ, ATAZANAVIR SULFATE
 VIDEX, DIDANOSINE

**** C ******CADILA PHARMS LTD**

* CADILA PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 GEMFIBROZIL, GEMFIBROZIL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 OFLOXACIN, OFLOXACIN
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TELMISARTAN, TELMISARTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CADILA PHARMACEUTICALS LTD

VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS

ADAPALENE, ADAPALENE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES

AMMONIA N 13, AMMONIA N-13

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT

SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC

SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

GEMFIBROZIL, GEMFIBROZIL

CARLSBAD

* CARLSBAD TECHNOLOGY INC

ACYCLOVIR, ACYCLOVIR

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

DICLOFENAC SODIUM, DICLOFENAC SODIUM

FAMOTIDINE, FAMOTIDINE

GLIMEPIRIDE, GLIMEPIRIDE

LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

* CARLSBAD TECHNOLOGY INC

ACYCLOVIR, ACYCLOVIR

CARMEL BIOSCIENCES

* CARMEL BIOSCIENCES INC

PREXXARTAN, VALSARTAN

CASPER PHARMA LLC

* CASPER PHARMA LLC

CASPORYN HC, HYDROCORTISONE

FURADANTIN, NITROFURANTOIN

NEOSPORIN, BACITRACIN ZINC

PERMAPEN, PENICILLIN G BENZATHINE

ROBINUL FORTE, GLYCOPYRROLATE

ROBINUL, GLYCOPYRROLATE

TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE

ZYLOPRIM, ALLOPURINOL

CATALENT

* CATALENT PHARMA SOLUTIONS LLC

VALPROIC ACID, VALPROIC ACID

CEDIPROF INC

* CEDIPROF INC

LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS

* CELATOR PHARMACEUTICALS INC

VYXEOS, CYTARABINE

CELERITY PHARMS

* CELERITY PHARMACEUTICALS LLC

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN

CELGENE

* CELGENE CORP

ISTODAX, ROMIDEPSIN

POMALYST, POMALIDOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CELGENE CORP**

REVLIMID, LENALIDOMIDE
 THALOMID, THALIDOMIDE
 VIDAZA, AZACITIDINE

CELGENE CORP*** CELGENE CORP**

IDHIFA, ENASIDENIB MESYLATE
 OTEZLA, APREMILAST

CEPHALON*** CEPHALON INC**

ACTIQ, FENTANYL CITRATE
 FENTORA, FENTANYL CITRATE
 GABITRIL, TIAGABINE HYDROCHLORIDE
 NUVIGIL, ARMODAFINIL
 PROVIGIL, MODAFINIL
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRISENOX, ARSENIC TRIOXIDE

CEREXA*** CEREXA INC**

TEFLARO, CEFTAROLINE FOSAMIL

*** CEREXA INC A SUB OF FOREST LABORATORIES LLC**

AVYCAZ, AVIBACTAM SODIUM

CFT PHARMS LLC*** CFT PHARMACEUTICALS LLC**

VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

CHANGZHOU PHARM*** CHANGZHOU PHARMACEUTICAL FACTORY**

ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL LIFE SCI*** CHARTWELL LIFE SCIENCE LLC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULES*** CHARTWELL MOLECULES LLC**

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DISULFIRAM, DISULFIRAM
 GEMFIBROZIL, GEMFIBROZIL
 NABUMETONE, NABUMETONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX*** CHARTWELL RX SCIENCES LLC**

CALCIUM ACETATE, CALCIUM ACETATE
 CILOSTAZOL, CILOSTAZOL
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 INDOMETHACIN, INDOMETHACIN
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

CHARTWELL TETRA*** CHARTWELL TETRA LLC**

TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM*** CHATTEM INC**

SELSUN, SELENIUM SULFIDE
 UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMI SPA*** CHEMI SPA**

DECITABINE, DECITABINE
 TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR*** CHEMISCHE FABRIK KREUSSLER & CO. GMBH**

ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL*** CHEMO RESEARCH SL**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CHEMO RESEARCH SL
 BENZNIDAZOLE, BENZNIDAZOLE
 ECOZA, ECONAZOLE NITRATE
 NUVESSA, METRONIDAZOLE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

CHEPLAPHARM

* CHEPLAPHARM ARZNEIMITTEL GMBH
 XENICAL, ORLISTAT

CHIESI USA INC

* CHIESI USA INC
 BETHKIS, TOBRAMYCIN
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE, NICARDIPINE HYDROCHLORIDE
 CLEVIPREX, CLEVIDIPINE
 CUROSURF, PORACTANT ALFA
 KENGREAL, CANGRELOR
 ZYFLO CR, ZILEUTON
 ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS

* CINTEX SERVICES LLC
 FLURANDRENOLIDE, FLURANDRENOLIDE

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
 CONZIP, TRAMADOL HYDROCHLORIDE
 LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
 NEVIRAPINE, NEVIRAPINE
 RISPERIDONE, RISPERIDONE
 ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 BUDESONIDE, BUDESONIDE
 CARBOPLATIN, CARBOPLATIN
 CARVEDILOL, CARVEDILOL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DECITABINE, DECITABINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FAMCICLOVIR, FAMCICLOVIR
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

FLUTAMIDE, FLUTAMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 STAVUDINE, STAVUDINE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
 ETHYOL, AMIFOSTINE
 FOSCAVIR, FOSCARNET SODIUM
 TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLOVER PHARMS

* CLOVER PHARMACEUTICALS CORP
 AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC

* CLOVIS ONCOLOGY INC
 RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC

* CMP DEVELOPMENT LLC
 CAROSPIR, SPIRONOLACTONE

CMP PHARMA INC

* CMP PHARMA INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 ISONIAZID, ISONIAZID
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SPS, SODIUM POLYSTYRENE SULFONATE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CNTY LINE PHARMS

* COUNTY LINE PHARMACEUTICALS LLC
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CICLOPIROX, CICLOPIROX
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUOCINONIDE, FLUOCINONIDE
 LIDEX, FLUOCINONIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 TAMBOCOR, FLECAINIDE ACETATE
 TRANDATE, LABETALOL HYDROCHLORIDE
 UREX, METHENAMINE HIPPURATE

COLGATE PALMOLIVE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

- * COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
- COLGATE PALMOLIVE CO**
- * COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE
- COLGATE-PALMOLIVE CO**
- * COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE
- COLLEGIUM PHARM INC**
- * COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE
- COMBE**
- * COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)
- CONCORDIA LABS INC**
- * CONCORDIA LABORATORIES INC
PHOTOFRIN, PORFIMER SODIUM
- CONCORDIA PHARMS INC**
- * CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
KAPVAY, CLONIDINE HYDROCHLORIDE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
PARNATE, TRANLYCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
- CONTRACT PHARMACAL**
- * CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PROFEN, IBUPROFEN (OTC)
- COOPERSURGICAL**
- * COOPERSURGICAL INC
PARAGARD T 380A, COPPER
- CORCEPT THERAP**
- * CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE
- CORDEN PHARMA**
- * CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE
- COREPHARMA**
- * COREPHARMA LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
- COVIS PHARMA BV**
- * COVIS PHARMA BV
ALTOPREV, LOVASTATIN
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CPDC**

- * CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV

- * CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CRANE PHARMS LLC

- * CRANE PHARMACEUTICALS LLC
DAPTOMYCIN, DAPTOMYCIN

CROSSMEDIKA SA

- * CROSSMEDIKA SA
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

CROWN LABS

- * CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

- * CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CSPC NBP PHARM CO

- * CSPC NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE

CSPC OUYI PHARM CO

- * CSPC OUYI PHARMACEUTICAL CO LTD
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS

- * CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

- * CUBIST PHARMACEUTICALS LLC
CUBICIN RF, DAPTOMYCIN
CUBICIN, DAPTOMYCIN
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

- * CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

CUSTOPHARM INC

- * CUSTOPHARM INC
ACETAMINOPHEN, ACETAMINOPHEN
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

CUTANEA

- * CUTANEA LIFE SCIENCES INC
AKTIPAK, BENZOYL PEROXIDE

CUTIS HEALTH LLC

- * CUTIS HEALTH LLC
DORAL, QUAZEPAM

CYCLE PHARMS LTD

- * CYCLE PHARMACEUTICALS LTD
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CYCLE PHARMACEUTICALS LTD
NITYR, NITISINONE

CYNDEA PHARMA

* CYNDEA PHARMA SL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

CYPRESS PHARM

* CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
ELIPHOS, CALCIUM ACETATE
REZIRA, HYDROCODONE BITARTRATE
VITUZ, CHLORPHENIRAMINE MALEATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**** D ******DAEWOONG PHARM CO**

* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO

* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
EVOXAC, CEVIMELINE HYDROCHLORIDE
MORPHABOND ER, MORPHINE SULFATE
ROXYBOND, OXYCODONE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVA INTL INC

* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

* DEPOMED INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******* DEPOMED INC**

CAMBIA, DICLOFENAC POTASSIUM
 GRALISE, GABAPENTIN
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO*** DEPROCO INC**

LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 SCANDONEST L, LEVONORDEFIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEVA HOLDING AS*** DEVA HOLDING AS**

ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD*** DEXCEL LTD**

DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA*** DEXCEL PHARMA TECHNOLOGIES LTD**

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 PERIOCHIP, CHLORHEXIDINE GLUCONATE

DFB ONCOLOGY LTD*** DFB ONCOLOGY LTD**

DOCETAXEL, DOCETAXEL

DIAGNOSTIC GREEN*** DIAGNOSTIC GREEN GMBH**

INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS*** DIALYSIS SUPPLIES INC**

NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC*** DIGESTIVE CARE INC**

PERTZYE, PANCRELIPASE (AMYLASE)

DORC*** DORC INTERNATIONAL BV**

MEMBRANEBLUE, TRYPAN BLUE
 VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS*** DOUGLAS PHARMACEUTICALS AMERICA LTD**

MYORISAN, ISOTRETINOIN

DOW PHARM*** DOW PHARMACEUTICAL SCIENCES**

ACANYA, BENZOYL PEROXIDE
 ATRALIN, TRETINOIN
 JUBLIA, EFINAACONAZOLE
 ONEXTON, BENZOYL PEROXIDE
 OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA*** DR REDDYS LABORATORIES LOUISIANA LLC**

IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LOPURIN, ALLOPURINOL
 SSD AF, SILVER SULFADIAZINE
 SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC*** DR REDDYS LABORATORIES INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******* DR REDDYS LABORATORIES INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMOXIL, AMOXICILLIN
 AUGMENTIN '125', AMOXICILLIN
 AUGMENTIN '250', AMOXICILLIN
 AUGMENTIN '875', AMOXICILLIN
 AUGMENTIN XR, AMOXICILLIN
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LAROTID, AMOXICILLIN
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NITROGLYCERIN, NITROGLYCERIN
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROGESTERONE, PROGESTERONE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

DR REDDYS LABS INTL

*** DR REDDYS LABORATORIES INTERNATIONAL SA**
 RAMELTEON, RAMELTEON

DR REDDYS LABS LTD

*** DR REDDYS LABORATORIES LIMITED**
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

*** DR REDDYS LABORATORIES LTD**
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZACITIDINE, AZACITIDINE
 BIVALIRUDIN, BIVALIRUDIN
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOFARABINE, CLOFARABINE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DECITABINE, DECITABINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOCETAXEL, DOCETAXEL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******* DR REDDYS LABORATORIES LTD**

ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESZOPICLONE, ESZOPICLONE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOLIRA, MINOCYCLINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 TACROLIMUS, TACROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 TETRABENAZINE, TETRABENAZINE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZAFIRLUKAST, ZAFIRLUKAST
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZENATANE, ISOTRETINOIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 HABITROL, NICOTINE (OTC)
 MERCAPTOPYRINE, MERCAPTOPYRINE

DRAximAGE

* DRAximAGE INC
 DTPA, TECHNETIUM TC-99M PENTETATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DUCHESNAY

* DUCHESNAY INC
 BONJESTA, DOXYLAMINE SUCCINATE
 DICLEGIS, DOXYLAMINE SUCCINATE
 OSPHENA, OSPHEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
 AVIANE-28, ETHINYL ESTRADIOL
 CRYSELLE, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ENPRESSE-28, ETHINYL ESTRADIOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VELIVET, DESOGESTREL

DURAMED RES

* DURAMED RESEARCH INC
 AYGESTIN, NORETHINDRONE ACETATE

DUSA

* DUSA PHARMACEUTICALS INC
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******EAGLE PHARMS**

* EAGLE PHARMACEUTICALS INC
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 RYANODEX, DANTROLENE SODIUM

EASTMAN KODAK

* EASTMAN KODAK CO
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ECI PHARMACEUTICALS LLC
 METHIMAZOLE, METHIMAZOLE
 PARICALCITOL, PARICALCITOL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 VALPROIC ACID, VALPROIC ACID

ECLAT PHARMS LLC

* ECLAT PHARMACEUTICALS LLC
 BLOXIVERZ, NEOSTIGMINE METHYLSULFATE

ECOLAB

* ECOLAB INC
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
 DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

* ECR PHARMA
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
 CARBIDOPA, CARBIDOPA
 ETHACRYNIC ACID, ETHACRYNIC ACID
 IVERMECTIN, IVERMECTIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
 METHERGINE, METHYLERGONOVINE MALEATE

EGALET

* EGALET CORP
 ARYMO ER, MORPHINE SULFATE

EGALET US INC

* EGALET US INC
 OXAYDO, OXYCODONE HYDROCHLORIDE
 SPRIX, KETOROLAC TROMETHAMINE

EI INC

* EI INC
 THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
 ACIPHEX, RABEPRAZOLE SODIUM
 ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
 ARICEPT, DONEPEZIL HYDROCHLORIDE
 BANZEL, RUFINAMIDE
 BELVIQ XR, LORCASERIN HYDROCHLORIDE
 BELVIQ, LORCASERIN HYDROCHLORIDE
 FYCOMPA, PERAMPANEL
 HALAVEN, ERIBULIN MESYLATE
 HEXALEN, ALTRETAMINE
 LENVIMA, LENVATINIB MESYLATE
 PANRETIN, ALITRETINOIN
 SALAGEN, PILOCARPINE HYDROCHLORIDE

ELEFSEE PHARMS INTL

* ELEFSEE PHARMACEUTICALS INTERNATIONAL LTD
 LAZANDA, FENTANYL CITRATE

ELI LILLY AND CO

* ELI LILLY AND CO
 BASAGLAR, INSULIN GLARGINE
 EFFIENT, PRASUGREL HYDROCHLORIDE
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 PROZAC, FLUOXETINE HYDROCHLORIDE
 VERZENIO, ABEMACICLIB

ELI LILLY CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELI LILLY CO
 ADCIRCA, TADALAFIL
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC
 DANTROLENE SODIUM, DANTROLENE SODIUM
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 ISRADIPINE, ISRADIPINE
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA

* EMCURE PHARMACEUTICALS LTD INDIA
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
 ACARBOSE, ACARBOSE
 ACETAZOLAMIDE SODIUM , ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BICNU, CARMUSTINE
 CIDOFOVIR, CIDOFOVIR
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 ETOMIDATE, ETOMIDATE
 FUROSEMIDE, FUROSEMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RIFAMPIN, RIFAMPIN
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO

* EMD SERONO INC
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 OVIDREL, CHORIOGONADOTROPIN ALFA
 SAIZEN, SOMATROPIN RECOMBINANT
 SEROSTIM, SOMATROPIN RECOMBINANT
 ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC

* EMD SERONO INC
 CETROTIDE, CETRORELIX

EMERALD INTL LTD

* EMERALD INTERNATIONAL LTD
 BACLOFEN, BACLOFEN

EMMAUS MEDCL

* EMMAUS MEDICAL INC
 ENDARI, L-GLUTAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EMMAUS MEDICAL INC

NUTRESTORE, L-GLUTAMINE

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC

SUPPRELIN LA, HISTRELIN ACETATE

VALSTAR PRESERVATIVE FREE, VALRUBICIN

VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC

DELATESTRYL, TESTOSTERONE ENANTHATE

FORTESTA, TESTOSTERONE

FROVA, FROVATRIPTAN SUCCINATE

OPANA, OXYMORPHONE HYDROCHLORIDE

PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC

AVEED, TESTOSTERONE UNDECANOATE

COLY-MYCIN S, COLISTIN SULFATE

MEGACE ES, MEGESTROL ACETATE

NASCOBAL, CYANOCOBALAMIN

VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ENDO VENTURES LTD

* ENDO VENTURES LTD IRELAND

SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

EPI HLTH

* EPI HEALTH LLC

SITAVIG, ACYCLOVIR

EPIC PHARMA

* EPIC PHARMA INC

MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC

BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE

CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE

SULINDAC, SULINDAC

TRANDOLAPRIL, TRANDOLAPRIL

URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC

ESTRADIOL, ESTRADIOL

SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE

DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

GABAPENTIN, GABAPENTIN

GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE

GLYBURIDE, GLYBURIDE

GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE

MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE

MORPHINE SULFATE, MORPHINE SULFATE

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

PHENYTOIN, PHENYTOIN

PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

SULINDAC, SULINDAC

TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******ESSENTIAL ISOTOPES**

* ESSENTIAL ISOTOPES LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
 DROPERIDOL, DROPERIDOL
 MORPHINE SULFATE, MORPHINE SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
 IDKIT:HP, CITRIC ACID

EXELA HOLDINGS

* EXELA HOLDINGS INC
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
 CAFFEINE CITRATE, CAFFEINE CITRATE
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 GANCICLOVIR, GANCICLOVIR
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POTASSIUM ACETATE, POTASSIUM ACETATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
 COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
 CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

* EXELTIS USA INC
 ESTRASORB, ESTRADIOL HEMIHYDRATE

EYEVANCE PHARMS

* EYEVANCE PHARMACEUTICALS LLC
 ZERVIAE, CETIRIZINE HYDROCHLORIDE

LILLY

* ELI LILLY AND CO
 ALIMTA, PEMETREXED DISODIUM
 CIALIS, TADALAFIL
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 EVISTA, RALOXIFENE HYDROCHLORIDE
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GLUCAGON, GLUCAGON RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELI LILLY AND CO
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 ZYPREXA ZYDIS, OLANZAPINE
 ZYPREXA, OLANZAPINE

**** F ******FDC LTD**

* FDC LTD
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 LATANOPROST, LATANOPROST
 OFLOXACIN, OFLOXACIN
 TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

* FOUNDATION CONSUMER HEALTHCARE LLC
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
 TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

FERRER INTERNACIONAL

* FERRER INTERNACIONAL SA
 XEPI, OZENOXACIN

FERRING

* FERRING PHARMACEUTICALS INC
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE
 BRAVELLE, UROFOLLITROPIN
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 ENDOMETRIN, PROGESTERONE
 FIRMAGON, DEGARELIX ACETATE
 MENOPUR, MENOTROPINS (FSH)
 MINIRIN, DESMOPRESSIN ACETATE
 ZOMACTON, SOMATROPIN RECOMBINANT

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
 CERVIDIL, DINOPROSTONE
 CLENPIQ, CITRIC ACID
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DDAVP, DESMOPRESSIN ACETATE
 LYSTEDA, TRANEXAMIC ACID
 PREPOPIK, CITRIC ACID
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

FLAMEL IRELAND LTD

* FLAMEL IRELAND LIMITED
 AKOVAZ, EPHEDRINE SULFATE

FLAMINGO PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FLAMINGO PHARMACEUTICALS LTD
 METRONIDAZOLE, METRONIDAZOLE
 PIROXICAM, PIROXICAM

FLEXION THERAPS INC

* FLEXION THERAPEUTICS INC
 ZILRETTA, TRIAMCINOLONE ACETONIDE

FOREST LABS

* FOREST LABORATORIES INC
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CELEXA, CITALOPRAM HYDROBROMIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 THYROLAR-0.25, LIOTRIX (T4
 THYROLAR-0.5, LIOTRIX (T4
 THYROLAR-1, LIOTRIX (T4
 THYROLAR-2, LIOTRIX (T4
 THYROLAR-3, LIOTRIX (T4

FOREST LABS INC

* FOREST LABORATORIES INC
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE
 CARAFATE, SUCRALFATE
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 RECTIV, NITROGLYCERIN
 ULTRESA, PANCRELIPASE (AMYLASE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 VIOKACE, PANCRELIPASE (AMYLASE
 ZENPEP, PANCRELIPASE (AMYLASE

FOREST LABS LLC

* FOREST LABORATORIES LLC
 BYVALSON, NEBIVOLOL HYDROCHLORIDE
 CANASA, MESALAMINE
 LINZESS, LINACLOTIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 SAPHRIS, ASENAPINE MALEATE
 VIIBRYD, VILAZODONE HYDROCHLORIDE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMCINONIDE, AMCINONIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CUTIVATE, FLUTICASONE PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FOUGERA PHARMACEUTICALS INC
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 OXISTAT, OXICONAZOLE NITRATE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 TACROLIMUS, TACROLIMUS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
 ANASTROZOLE, ANASTROZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ASTRAMORPH PF, MORPHINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACITRACIN, BACITRACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BORTEZOMIB, BORTEZOMIB
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM GLUCONATE, CALCIUM GLUCONATE
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CEFOTETAN, CEFOTETAN DISODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KANAMYCIN SULFATE, KANAMYCIN SULFATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANNITOL 25%, MANNITOL
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 SMOFLIPID 20%, FISH OIL
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** G ******G AND W LABS**

* G AND W LABORATORIES INC
 ACEPHEN, ACETAMINOPHEN (OTC)
 CICLOPIROX, CICLOPIROX
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 INDOMETHACIN, INDOMETHACIN
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

* G AND W LABORATORIES INC
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BETA-VAL, BETAMETHASONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* G AND W LABORATORIES INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 IMIQUIMOD, IMIQUIMOD
 MESALAMINE, MESALAMINE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MYKACET, NYSTATIN
 NYSTATIN, NYSTATIN
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TAZAROTENE, TAZAROTENE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
 CLOBEX, CLOBETASOL PROPIONATE
 EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
 CLOBEX, CLOBETASOL PROPIONATE
 * GALDERMA LABORATORIES LP
 CAPEX, FLUOCINOLONE ACETONIDE
 CLOBEX, CLOBETASOL PROPIONATE
 DESOWEN, DESONIDE
 DIFFERIN, ADAPALENE
 DIFFERIN, ADAPALENE (OTC)
 EPIDUO, ADAPALENE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 MIRVASO, BRIMONIDINE TARTRATE
 ORACEA, DOXYCYCLINE
 SOOLANTRA, IVERMECTIN
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 VECTICAL, CALCITRIOL

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
 SYNERA, LIDOCAINE

GALEN UK

* GALEN LTD
 ADASUVE, LOXAPINE

GASTROENTERO

* GASTROENTERO LOGIC LLC
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS

* GATE PHARMACEUTICALS
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 LINEZOLID, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******GATOR PHARMS**

* GATOR PHARMACEUTICALS INC
COLPREP KIT, MAGNESIUM SULFATE

GAVIS PHARMS

* GAVIS PHARMACEUTICALS LLC
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GAVIS PHARMS LLC

* GAVIS PHARMACEUTICALS LLC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

GD SEARLE

* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
INSPIRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GEDEON RICHTER USA

* GEDEON RICHTER USA INC
FINASTERIDE, FINASTERIDE

GEMINI LABS LLC

* GEMINI LABORATORIES LLC
OXANDRIN, OXANDROLONE
PRANDIN, REPAGLINIDE

GENENTECH

* GENENTECH INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GENENTECH INC
 ERIVEDGE, VISMODEGIB
 NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT

GENENTECH INC

* GENENTECH INC
 COTELLIC, COBIMETINIB FUMARATE
 ESBRIET, PIRFENIDONE

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
 GOPRELTO, COCAINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENZYME

* GENZYME CORP
 CEREZYME, IMIGLUCERASE
 CLOLAR, CLOFARABINE
 MOZOBIL, PLERIXAFOR
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENVELA, SEVELAMER CARBONATE
 THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORP
 CAPRELSA, VANDETANIB
 CERDELGA, ELIGLUSTAT TARTRATE
 HECTOROL, DOXERCALCIFEROL

GILEAD

* GILEAD SCIENCES INC
 ATRIPLA, EFAVIRENZ
 CAYSTON, AZTREONAM
 EMTRIVA, EMTRICITABINE
 HEPSERA, ADEFOVIR DIPIVOXIL
 LETAIRIS, AMBRISENTAN
 RANEXA, RANOLAZINE
 TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
 COMPLERA, EMTRICITABINE
 DESCOVY, EMTRICITABINE
 EPCLUSA, SOFOSBUVIR
 GENVOYA, COBICISTAT
 HARVONI, LEDIPASVIR
 ODEFSEY, EMTRICITABINE
 SOVALDI, SOFOSBUVIR
 STRIBILD, COBICISTAT
 TYBOST, COBICISTAT
 VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VOSEVI, SOFOSBUVIR
 ZYDELIG, IDELALISIB

GLAND PHARMA LTD

* GLAND PHARMA LTD
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 AZITHROMYCIN, AZITHROMYCIN
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CISPLATIN, CISPLATIN
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 FLUOROURACIL, FLUOROURACIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLAND PHARMA LTD**

HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 MEROPENEM, MEROPENEM
 MESNA, MESNA
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACITAXEL, PACLITAXEL
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

*** GLASSHOUSE PHARMACEUTICALS LTD CANADA**
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

GLAXO GRP ENGLAND

*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**
 INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

GLAXO GRP LTD

*** GLAXO GROUP LTD DBA GLAXOSMITHKLINE**
 FLOVENT HFA, FLUTICASONE PROPIONATE

*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 BREO ELLIPTA, FLUTICASONE FUROATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE

GLAXOSMITHKLINE

*** GLAXOSMITHKLINE**
 ABREVA, DOCOSANOL (OTC)
 AVODART, DUTASTERIDE
 BACTROBAN, MUPIROCIN CALCIUM
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 CEFTIN, CEFUROXIME AXETIL
 EPIVIR-HBV, LAMIVUDINE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 JALYN, DUTASTERIDE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALARONE, ATOVAQUONE
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 RELENZA, ZANAMIVIR
 VALTREX, VALACYCLOVIR HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 ZYBAN, BUPROPION HYDROCHLORIDE

*** GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC**
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)

*** GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND**
 ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 ARNUITY ELLIPTA, FLUTICASONE FUROATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
TRELEGY ELLIPTA, FLUTICASONE FUROATE

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

* GLAXOSMITHKLINE CONSUMER HEALTH
TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
COMMIT, NICOTINE POLACRILEX (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
TAVIST-1, CLEMASTINE FUMARATE (OTC)
VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE

* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK GENERICS LTD
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MARLISSA, ETHINYL ESTRADIOL
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN, NAPROXEN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VIORELE, DESOGESTREL
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
 INDOMETHACIN, INDOMETHACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
- GLENMARK PHARMS**
- * GLENMARK PHARMACEUTICALS INC USA
 CICLOPIROX, CICLOPIROX
 CLOTRIMAZOLE, CLOTRIMAZOLE
 MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- * GLENMARK PHARMACEUTICALS SA
 CALCIPOTRIENE, CALCIPOTRIENE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 DESONIDE, DESONIDE
 LINEZOLID, LINEZOLID
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
- GLENMARK PHARMS INC**
- * GLENMARK PHARMACEUTICALS INC USA
 CALCIPOTRIENE, CALCIPOTRIENE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MUPIROCIN, MUPIROCIN CALCIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
- GLENMARK PHARMS LTD**
- * GLENMARK PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 APREPITANT, APREPITANT
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS LTD
 EZETIMIBE, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 GABAPENTIN, GABAPENTIN
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE, LIDOCAINE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NITROGLYCERIN, NITROGLYCERIN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXCARBAZEPINE, OXCARBAZEPINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 RUFINAMIDE, RUFINAMIDE
 TELMISARTAN, TELMISARTAN
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VORICONAZOLE, VORICONAZOLE

GLOBAL ISOTOPES LLC

* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

GRANULES INDIA

* GRANULES INDIA LTD
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD

* GRANULES INDIA LTD
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)

GUARDIAN PHARMS

* GUARDIAN PHARMACEUTICALS
 GUAIFENESIN, GUAIFENESIN (OTC)

GUERBET

* GUERBET LLC
 DOTAREM, GADOTERATE MEGLUMINE
 LIPIODOL, ETHIODIZED OIL

HANFORD GC

* GC HANFORD MANUFACTURING CO
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP

* G POHL BOSKAMP GMBH AND CO KG
 GONITRO, NITROGLYCERIN

**** H ******HAEMONETICS**

* HAEMONETICS CORP
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******HALOCARBON PRODS**

* HALOCARBON PRODUCTS CORP
 ISOFLURANE, ISOFLURANE
 SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

* HALOZYME THERAPEUTICS INC
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS

* HAMELN PHARMA PLUS GMBH
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

HAMELN RDS GMBH

* HAMELN RDS GMBH
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HANDA PHARMS LLC

* HANDA PHARMACEUTICALS LLC
 LAMOTRIGINE, LAMOTRIGINE

HANSAMED INC

* HANSAMED INC
 ULTACAN FORTE, ARTICAINA HYDROCHLORIDE
 ULTACAN, ARTICAINA HYDROCHLORIDE

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
 FLUCONAZOLE, FLUCONAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HAUPT PHARMA

* HAUPT PHARMA INC
 DUTASTERIDE, DUTASTERIDE

HEC PHARM USA INC

* HEC PHARM USA INC
 CLARITHROMYCIN, CLARITHROMYCIN

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
 AKYNZEO, NETUPITANT
 ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
 NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
 CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIFLUNISAL, DIFLUNISAL
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHIMAZOLE, METHIMAZOLE
 NIFEDIPINE, NIFEDIPINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 ALPRAZOLAM, ALPRAZOLAM
 CALCIUM ACETATE, CALCIUM ACETATE
 CARISOPRODOL AND ASPIRIN, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HERITAGE PHARMACEUTICALS INC**

DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FELODIPINE, FELODIPINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDOMETHACIN, INDOMETHACIN
 KETOPROFEN, KETOPROFEN
 LEFLUNOMIDE, LEFLUNOMIDE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 NYSTATIN, NYSTATIN
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

*** HERON THERAPEUTICS INC**
 CINVANTI, APREPITANT
 SUSTOL, GRANISETRON

HETERO LABS LTD III

*** HETERO LABS LTD UNIT III**
 ABACAVIR SULFATE, ABACAVIR SULFATE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

*** HETERO LABS LTD UNIT V**
 ACYCLOVIR, ACYCLOVIR
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 FAMCICLOVIR, FAMCICLOVIR
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HETERO LABS LTD UNIT V
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TETRABENAZINE, TETRABENAZINE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CICLOPIROX, CICLOPIROX
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CORMAX, CLOBETASOL PROPIONATE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 EMBELINE E, CLOBETASOL PROPIONATE
 EMBELINE, CLOBETASOL PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
 FLUNISOLIDE, FLUNISOLIDE
 PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
 FAMOTIDINE, FAMOTIDINE
 GATIFLOXACIN, GATIFLOXACIN
 LORAZEPAM, LORAZEPAM
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
 BROMFENAC SODIUM, BROMFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HI-TECH PHARMACAL CO INC
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - DESONIDE, DESONIDE
 - IBUPROFEN, IBUPROFEN
 - LEVETIRACETAM, LEVETIRACETAM
 - MEGESTROL ACETATE, MEGESTROL ACETATE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 - PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 - TRIFLURIDINE, TRIFLURIDINE

HIGH TECH PHARMA

- * HIGH TECHNOLOGY PHARMACAL CO INC
 - VALPROIC ACID, VALPROIC ACID

HIKMA

- * HIKMA FARMACEUTICA LDA
 - CEFOTAXIME, CEFOTAXIME SODIUM
- * HIKMA PHARMACEUTICALS
 - AMOXICILLIN, AMOXICILLIN
 - CEFACTOR, CEFACTOR
 - CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 - CEPHALEXIN, CEPHALEXIN
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - GLYBURIDE (MICRONIZED), GLYBURIDE

HIKMA FARMACEUTICA

- * HIKMA FARMACEUTICA (PORTUGAL) SA
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 - BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 - CEFOXITIN, CEFOXITIN SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPROFLOXACIN, CIPROFLOXACIN
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROGESTERONE, PROGESTERONE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA
 - CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA
 - CEFOTETAN, CEFOTETAN DISODIUM
 - CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - ETOMIDATE, ETOMIDATE
 - METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 - OXYTOCIN, OXYTOCIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HIKMA FARMACEUTICA PORTUGAL SA
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- * HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

- * HIKMA INTERNATIONAL PHARMACEUTICALS LLC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHOCARBAMOL, METHOCARBAMOL
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

- * HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

- * HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GEMFIBROZIL, GEMFIBROZIL
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LETROZOLE, LETROZOLE
MODAFINIL, MODAFINIL
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
- * HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL
- * HIKMA PHARMACEUTICALS LLC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
FOLIC ACID, FOLIC ACID
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
OLANZAPINE, OLANZAPINE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
ZALEPLON, ZALEPLON

HILL DERMAC

- * HILL DERMACEUTICALS INC
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

- * HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU PHARM CO

- * HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
- * HISUN PHARMACEUTICAL HANGZHOU CO LTD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
SIMVASTATIN, SIMVASTATIN

HOFFMANN LA ROCHE

- * HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
INVIRASE, SAQUINAVIR MESYLATE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

- * HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE

HONG KONG

- * HONG KONG KING-FRIEND INDUSTRIAL CO LTD
CYTARABINE, CYTARABINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

HOPE PHARMS

- * HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON PHARMA

- * HORIZON PHARMA INC
DUEXIS, FAMOTIDINE
RAYOS, PREDNISONE
- * HORIZON PHARMA IRELAND LTD
PENNSAID, DICLOFENAC SODIUM
- * HORIZON PHARMA RHEUMATOLOGY LLC
MIGERGOT, CAFFEINE

HORIZON PHARMA INC

- * HORIZON PHARMA INC
BUPHENYL, SODIUM PHENYL BUTYRATE

HORIZON PHARMA USA

- * HORIZON PHARMA USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
VIMOVO, ESOMEPRAZOLE MAGNESIUM

HORIZON THERAPS INC

- * HORIZON THERAPEUTICS INC
RAVICTI, GLYCEROL PHENYL BUTYRATE

HOSPIRA

- * HOSPIRA INC
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AQUASOL A, VITAMIN A PALMITATE
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CORLOPAM, FENOLDOPAM MESYLATE
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% , DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 LTA II KIT, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 25%, MANNITOL
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TALWIN, PENTAZOCINE LACTATE
 TAZICEF, CEFTAZIDIME
 THAM, TROMETHAMINE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 VITAMIN K1, PHYTONADIONE
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* HOSPIRA WORLDWIDE, INC

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA WORLDWIDE, INC
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NITROPRESS, SODIUM NITROPRUSSIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ARGATROBAN, ARGATROBAN
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BIVALIRUDIN, BIVALIRUDIN
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 DOCETAXEL, DOCETAXEL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAXIPIPE, CEFEPIME HYDROCHLORIDE
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MILRINONE LACTATE, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIPENT, PENTOSTATIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 PARICALCITOL, PARICALCITOL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 SODIUM BICARBONATE, SODIUM BICARBONATE
 TACROLIMUS, TACROLIMUS
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
 OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HOUSTON CYCLOTRON

* HOUSTON CYCLOTRON PARTNERS LP
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HQ SPECIALTY PHARMA CORP
 CISPLATIN, CISPLATIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HRA PHARMA

* HRA PHARMA LLC
 METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
 DUTASTERIDE, DUTASTERIDE
 IBUPROFEN, IBUPROFEN (OTC)

ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 COPEGUS, RIBAVIRIN
 FUZEON, ENFUVIRTIDE
 KLONOPIN, CLONAZEPAM
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 VALIUM, DIAZEPAM

**** I ******IBA MOLECULAR N AM**

* IBA MOLECULAR NORTH AMERICA INC
 AMMONIA N 13, AMMONIA N-13

ICU MEDICAL INC

* ICU MEDICAL INC
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOSYN 10% (PH6), AMINO ACIDS
 AMINOSYN 10%, AMINO ACIDS
 AMINOSYN 3.5% M, AMINO ACIDS
 AMINOSYN 3.5%, AMINO ACIDS
 AMINOSYN 5%, AMINO ACIDS
 AMINOSYN 7% (PH6), AMINO ACIDS
 AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN 7%, AMINO ACIDS
 AMINOSYN 8.5% (PH6), AMINO ACIDS
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN 8.5%, AMINO ACIDS
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 10%, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 7%, AMINO ACIDS
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 8.5%, AMINO ACIDS
 AMINOSYN-HBC 7%, AMINO ACIDS
 AMINOSYN-HF 8%, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 AMINOSYN-RF 5.2%, AMINO ACIDS
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* ICU MEDICAL INC

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDENTI PHARMS INC

* IDENTI PHARMACEUTICALS INC

FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******IDT AUSTRALIA LTD**

* IDT AUSTRALIA LTD
 PINDOLOL, PINDOLOL
 TEMOZOLOMIDE, TEMOZOLOMIDE

IMPAX LABS

* IMPAX LABORATORIES INC
 ACARBOSE, ACARBOSE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC

* IMPAX LABORATORIES INC
 ACITRETIN, ACITRETIN
 ADRENACLICK, EPINEPHRINE
 ALBENZA, ALBENDAZOLE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EMVERM, MEBENDAZOLE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FELBAMATE, FELBAMATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX LABORATORIES INC
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RYTARY, CARBIDOPA
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP

* INCYTE CORP
 JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 SUBLOCADE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
 ALLOPURINOL, ALLOPURINOL
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 GLIMEPIRIDE, GLIMEPIRIDE

INGENUS PHARMS LLC

* INGENUS PHARMACEUTICALS LLC
 CARBOPLATIN, CARBOPLATIN
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INGENUS PHARMS NJ

* INGENUS PHARMACEUTICALS NJ LLC
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARISOPRODOL, CARISOPRODOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PROBENECID AND COLCHICINE, COLCHICINE

INJECTALIA

* INJECTALIA SRL
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOGENIX

* INNOGENIX LLC
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

INNOPHARMA LICENSING

* INNOPHARMA LICENSING LLC
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
 FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA (IBSA)
 TIROSINT, LEVOTHYROXINE SODIUM

INSYS DEV CO INC

* INSYS DEVELOPMENT CO INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INSYS DEVELOPMENT CO INC
 SUBSYS, FENTANYL
 SYNDROS, DRONABINOL

INTAS PHARMS USA

* INTAS PHARMACEUTICALS USA
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

INTERCEPT PHARMS INC

* INTERCEPT PHARMACEUTICALS INC
 OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
 NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC

* INTERGEL PHARMACEUTICALS INC
 DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS

* INTERPHARMA PRAHA AS
 ORALTAG, IOHEXOL

INTERSECT ENT INC

* INTERSECT ENT INC
 SINUVA, MOMETASONE FUROATE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
 MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 * INTERNATIONAL MEDICATION SYSTEMS LTD
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
 LORAZEPAM, LORAZEPAM
 SODIUM BICARBONATE, SODIUM BICARBONATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FOLIC ACID, FOLIC ACID
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 GEMFIBROZIL, GEMFIBROZIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INVAGEN PHARMACEUTICALS INC
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 MEPROBAMATE, MEPROBAMATE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 OLANZAPINE, OLANZAPINE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 ILOPERIDONE, ILOPERIDONE
 LANSOPRAZOLE, LANSOPRAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TELMISARTAN, TELMISARTAN

IPCA LABS LTD

* IPCA LABORATORIES LTD
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 INCRELEX, MECASERMIN RECOMBINANT
 ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******IROKO PHARMS**

* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

IROKO PHARMS LLC

* IROKO PHARMACEUTICALS LLC
TIVORBEX, INDOMETHACIN
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

IRONWOOD PHARMS INC

* IRONWOOD PHARMACEUTICALS INC
DUZALLO, ALLOPURINOL
ZURAMPIC, LESINURAD

ISO TEX

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX PHARMS INC

* IVAX PHARMACEUTICALS INC
OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
OXAPROZIN, OXAPROZIN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SIMVASTATIN, SIMVASTATIN
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******J AND J CONSUMER INC**

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 MOTRIN IB, IBUPROFEN (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 SINE-AID IB, IBUPROFEN (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 TYLENOL, ACETAMINOPHEN (OTC)
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
 DAPSONE, DAPSONE
 PASER, AMINOSALICYLIC ACID

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
 ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
 AXERT, ALMOTRIPTAN MALATE
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVEGA, PALIPERIDONE
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKAMET, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 LEVAQUIN, LEVOFLOXACIN
 MICRONOR, NORETHINDRONE
 MODICON 28, ETHINYL ESTRADIOL
 NIZORAL, KETOCONAZOLE
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 PANCREAZE, PANCRELIPASE (AMYLASE)
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JANSSEN PHARMACEUTICALS INC
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 SPORANOX, ITRACONAZOLE
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TOPAMAX, TOPIRAMATE
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 VERMOX, MEBENDAZOLE
 XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
 EDURANT, RILPIVIRINE HYDROCHLORIDE
 OLYSIO, SIMEPREVIR SODIUM
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR ETHANOLATE
 YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
 INTELENCE, ETRAVIRINE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
 SIRTURO, BEDAQUILINE FUMARATE

JAVELIN PHARMS INC

* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF HOSPIRA INC
 DYLOJECT, DICLOFENAC SODIUM

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
 XYREM, SODIUM OXYBATE

JAZZ PHARMS III

* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
 FAZACLO ODT, CLOZAPINE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
 DEFITELIO, DEFIBROTIDE SODIUM

JAZZ PHARMS INTL

* JAZZ PHARMACEUTICALS INTERNATIONAL LTD
 PRIALT, ZICONOTIDE ACETATE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 GABAPENTIN, GABAPENTIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
 AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
- * JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

JUBILANT CADISTA

- * JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISON, PREDNISON
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE INC
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131
- * JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

- * JUBILANT GENERICS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JUBILANT GENERICS LTD
 SPIRONOLACTONE, SPIRONOLACTONE
 TELMISARTAN, TELMISARTAN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 ZOLMITRIPTAN, ZOLMITRIPTAN

JUBILANT HOLLISTERSTR

* JUBILANT HOLLISTERSTIER LLC
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 DIGOXIN, DIGOXIN
 METHOCARBAMOL AND ASPIRIN, ASPIRIN
 UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

* KW GRIFFEN CO
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
 RIBASPHERE, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN

KAI PHARMS INC

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
 PARSABIV, ETELCALCETIDE

KALEO INC

* KALEO INC
 AUVI-Q, EPINEPHRINE
 EVZIO, NALOXONE HYDROCHLORIDE

KASTLE THERAPS LLC

* KASTLE THERAPEUTICS LLC
 KYNAMRO, MIPOMERSEN SODIUM

KEN LIFESCIENCE

* KEN LIFESCIENCE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
 AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KINEDEXE UK

* KINEDEXE UK LTD
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

KING PHARMS

* KING PHARMACEUTICALS INC
 SYNERCID, DALFOPRISTIN

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
 CYTOMEL, LIOTHYRONINE SODIUM
 LEVOXYL, LEVOTHYROXINE SODIUM **
 TUSSIGON, HOMATROPINE METHYLBROMIDE

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
 SKELAXIN, METAXALONE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
 ALTACE, RAMIPRIL
 BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
 BICILLIN C-R, PENICILLIN G BENZATHINE
 BICILLIN L-A, PENICILLIN G BENZATHINE
 CORZIDE, BENDROFLUMETHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KING PHARMACEUTICALS LLC
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 SILVADENE, SILVER SULFADIAZINE
 TAPAZOLE, METHIMAZOLE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
 IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
 LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KREMERS URBAN PHARMS

* KREMERS URBAN PHARMACEUTICALS INC
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OMEPRAZOLE, OMEPRAZOLE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 TEMOZOLOMIDE, TEMOZOLOMIDE

KRKA TOVARNA ZDRAVIL

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
 LANSOPRAZOLE, LANSOPRAZOLE

KVK TECH

* KVK TECH INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 KALEXATE, SODIUM POLYSTYRENE SULFONATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
 FARESTON, TOREMIFENE CITRATE
 SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
 KYBELLA, DEOXYCHOLIC ACID

**** L ******L PERRIGO CO**

* L PERRIGO CO
 CIMETIDINE, CIMETIDINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* L PERRIGO CO**

JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARM CO

* LA JOLLA PHARMACEUTICAL CO
 GIAPREZA, ANGIOTENSIN II

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
 ELLA, ULIPRISTAL ACETATE

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABS LEON FARMA

* LABORATORIOS LEON FARMA SA
 ALTAVERA, ETHINYL ESTRADIOL
 ELIFEMME, ETHINYL ESTRADIOL
 ESTARYLLA, ETHINYL ESTRADIOL
 INTROVALE, ETHINYL ESTRADIOL
 ISIBLOOM, DESOGESTREL
 JAIMIESS, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORYNA, DROSPIRENONE
 SYEDA, DROSPIRENONE
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 VIENVA, ETHINYL ESTRADIOL
 VOLNEA, DESOGESTREL

LABS LICONSA

* LABORATORIOS LICONSA SA
 LANSOPRAZOLE, LANSOPRAZOLE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 LANIAZID, ISONIAZID
 LANORINAL, ASPIRIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE
 PROBALAN, PROBENECID

* LANNETT HOLDINGS INC
 BACLOFEN, BACLOFEN
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT HOLDINGS INC
URSODIOL, URSODIOL

LANNETT CO INC

* LANNETT CO INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
MONOKET, ISOSORBIDE MONONITRATE
NIACIN, NIACIN
SUMATRIPTAN, SUMATRIPTAN

LANNETT HOLDINGS INC

* LANNETT HOLDINGS INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CODEINE SULFATE, CODEINE SULFATE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METAXALONE, METAXALONE
MORPHINE SULFATE, MORPHINE SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC

* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LEADING PHARMA LLC
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

LEO LABS

* LEO LABORATORIES LTD
 PICATO, INGENOL MEBUTATE

LEO PHARMA AS

* LEO PHARMA AS
 DOVONEX, CALCIPOTRIENE
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 PROTOPIC, TACROLIMUS
 TACLONEX, BETAMETHASONE DIPROPIONATE

LEXICON PHARMS INC

* LEXICON PHARMACEUTICALS INC
 XERMELO, TELOTRISTAT ETIPRATE

LG CHEM LTD

* LG CHEM LTD
 FACTIVE, GEMIFLOXACIN MESYLATE
 VALTROPIN, SOMATROPIN RECOMBINANT

LIBERTY PHARMA INC

* LIBERTY PHARMA INC
 PRASUGREL, PRASUGREL HYDROCHLORIDE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
 CONRAY 30, IOTHALAMATE MEGLUMINE
 CONRAY 43, IOTHALAMATE MEGLUMINE
 CONRAY, IOTHALAMATE MEGLUMINE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
 OPTIMARK, GADOVERSETAMIDE
 OPTIRAY 240, IOVERSOL
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFESTAR PHARMA

* LIFESTAR PHARMA LLC
 RISPERIDONE, RISPERIDONE

LNK

* LNK INTERNATIONAL INC
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC

* LNK INTERNATIONAL INC
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
 ANTHELIOS 20, AVOBENZONE (OTC)
 ANTHELIOS 40, AVOBENZONE (OTC)
 ANTHELIOS SX, AVOBENZONE (OTC)
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LOTUS PHARMACEUTICAL CO LTD
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 ROWEEPRA, LEVETIRACETAM

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ADENOSINE, ADENOSINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOSPORINE, CYCLOSPORINE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXFERRUM, IRON DEXTRAN
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 ETOMIDATE, ETOMIDATE
 FOMEPIZOLE, FOMEPIZOLE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCARNITINE, LEVOCARNITINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROGESTERONE, PROGESTERONE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 VENOFER, IRON SUCROSE
 ZIDOVUDINE, ZIDOVUDINE

LUITPOLD PHARMS INC

* LUITPOLD PHARMACEUTICALS INC
 BUSULFAN, BUSULFAN
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 DACTINOMYCIN, DACTINOMYCIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 INJECTAFER, FERRIC CARBOXYMALTOSIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 NANDROLONE DECANOATE, NANDROLONE DECANOATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUITPOLD PHARMACEUTICALS INC
 OXALIPLATIN, OXALIPLATIN
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

* LUNDBECK NA LTD
 NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

* LUNDBECK PHARMACEUTICALS LLC
 CARNEXIV, CARBAMAZEPINE
 ONFI, CLOBAZAM
 SABRIL, VIGABATRIN

LUPIN

* LUPIN INC
 SOLOSEC, SECNIDAZOLE

* LUPIN LTD
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOVASTATIN, LOVASTATIN
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
 ANTARA (MICRONIZED), FENOFIBRATE
 DESOXIMETASONE, DESOXIMETASONE
 MIBELAS 24 FE, ETHINYL ESTRADIOL
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 TOBRAMYCIN, TOBRAMYCIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LUPIN LTD

* LUPIN LIMITED
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 AMABELZ, ESTRADIOL
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ARMODAFINIL, ARMODAFINIL
 AZITHROMYCIN, AZITHROMYCIN
 BEKYREE, DESOGESTREL
 BIMATOPROST, BIMATOPROST
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN, CIPROFLOXACIN
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DAYSEE, ETHINYL ESTRADIOL
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAYOSIM, ETHINYL ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FYAVOLV, ETHINYL ESTRADIOL
 GATIFLOXACIN, GATIFLOXACIN
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KAITLIB FE, ETHINYL ESTRADIOL
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NIACIN, NIACIN
 NIKKI, DROSPIRENONE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE, OMEPRAZOLE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

RIFABUTIN, RIFABUTIN
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUPRAX, CEFIXIME
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TESTOSTERONE, TESTOSTERONE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TYDEMY, DROSPIRENONE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS*** LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL*** LYMOL MEDICAL CORP**

SCLEROSOL, TALC
 TALC, TALC

LYNE*** LYNE LABORATORIES INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LEVOCARNITINE, LEVOCARNITINE
 NYSTATIN, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO*** L PERRIGO CO**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TAB-PROFEN, IBUPROFEN (OTC)
 TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP***** MASSACHUSETTS GENERAL HOSP**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MACLEODS PHARMS LTD**

* MACLEODS PHARMACEUTICALS LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CELECOXIB, CELECOXIB
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FAMCICLOVIR, FAMCICLOVIR
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

MAGNA PHARMS

* MAGNA PHARMACEUTICALS INC
 ZOLPIMIST, ZOLPIDEM TARTRATE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
 H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSPITAL PRODUCTS IP LTD
 INOMAX, NITRIC OXIDE
 UVADEX, METHOXSALEN

MALLINCKRODT IP

* MALLINCKRODT IP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MALLINCKRODT IP
OFIRMEV, ACETAMINOPHEN

MALLINKRODT NUCLEAR

* MALLINCKRODT NUCLEAR MEDICINE LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

MANNKIND

* MANNKIND CORP
AFREZZA, INSULIN RECOMBINANT HUMAN

MARINA BIOTECH

* MARINA BIOTECH INC
PRESTALIA, AMLODIPINE BESYLATE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
DUTASTERIDE, DUTASTERIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
CROTAN, CROTAMITON

MAYER LABS INC

* MAYER LABORATORIES INC
TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN

* MAYNE PHARMA LLC
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FABIOR, TAZAROTENE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MAYNE PHARMA LLC**

FENTANYL-75, FENTANYL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 SORILUX, CALCIPOTRIENE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIVORA-28, ETHINYL ESTRADIOL
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC*** MAYNE PHARMA INC**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
 DOFETILIDE, DOFETILIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MCGUFF*** MCGUFF PHARMACEUTICALS INC**

ASCOR, ASCORBIC ACID

MCNEIL*** MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC**

IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS*** MCNEIL CONSUMER HEALTHCARE**

SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF*** MAYO CLINIC PET RADIOCHEMISTRY FACILITY**

AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MEDAC PHARMA INC*** MEDAC PHARMA INC**

RASUVO, METHOTREXATE

MEDEFIL INC*** MEDEFIL INC**

SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICINES360*** MEDICINES360**

LILETTA, LEVONORGESTREL

MEDICIS*** MEDICIS PHARMACEUTICAL CORP**

ALDARA, IMIQUIMOD
 AMMONUL, SODIUM BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEDICIS PHARMACEUTICAL CORP
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 LOPROX, CICLOPIROX
 LUZU, LULICONAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 MINITRAN, NITROGLYCERIN
 SOLODYN, MINOCYCLINE HYDROCHLORIDE
 VANOS, FLUOCINONIDE
 ZIANA, CLINDAMYCIN PHOSPHATE
 ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
 VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 LOPROX, CICLOPIROX
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALAR, FLUOCINOLONE ACETONIDE

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE
 MONISTAT 3, MICONAZOLE NITRATE (OTC)
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 7, MICONAZOLE NITRATE (OTC)
 NIX, PERMETHRIN (OTC)
 TAGAMET HB, CIMETIDINE (OTC)

MELINTA

* MELINTA SUBSIDIARY CORP
 BAXDELA, DELAFLOXACIN MEGLUMINE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
 CANCIDAS, CASPOFUNGIN ACETATE
 EMEND, APREPITANT
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 PRIMAXIN, CILASTATIN SODIUM
 PROSCAR, FINASTERIDE
 ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
 PRINIVIL, LISINAPRIL
 PROPECIA, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC

* MERCK AND CO INC
 EMEND, FOSAPREPITANT DIMEGLUMINE
 FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
 ASMANEX HFA, MOMETASONE FUROATE
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 BELSOMRA, SUVOREXANT
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX D 24 HOUR, DESLORATADINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 COZAAR, LOSARTAN POTASSIUM
 CRIXIVAN, INDINAVIR SULFATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS HD, RALTEGRAVIR POTASSIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NASONEX, MOMETASONE FUROATE
 NOXAFIL, POSACONAZOLE
 PREVYMIS, LETERMIVIR
 REBETOL, RIBAVIRIN
 SEGLUROMET, ERTUGLIFLOZIN
 SINEMET CR, CARBIDOPA
 SINEMET, CARBIDOPA
 STEGLATRO, ERTUGLIFLOZIN
 STELUJAN, ERTUGLIFLOZIN
 STROMECTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 ZEPATIER, ELBASVIR

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRO PHARM

* MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE

METHAPHARM

* METHAPHARM INC
 PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
 STENDRA, AVANAFIL

MICRO LABS

* MICRO LABS LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 PIROXICAM, PIROXICAM
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TELMISARTAN, TELMISARTAN

MICRO LABS LTD

* MICRO LABS LTD
 NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CROMOLYN SODIUM, CROMOLYN SODIUM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MICRO LABS LTD INDIA
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US

* MIDATECH PHARMA US INC
ORAVIG, MICONAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
ZUPLENZ, ONDANSETRON

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOAZONE, CHLORZOAZONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOAZONE, CHLORZOAZONE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
NINLARO, IXAZOMIB CITRATE
VELCADE, BORTEZOMIB

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA

* MISSION PHARMACAL CO
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
FLOWTUSS, GUAIFENESIN
HYCOFENIX, GUAIFENESIN
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)

MIST PHARMS LLC

* MIST PHARMACEUTICALS LLC
NITROMIST, NITROGLYCERIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MITSUBISHI TANABE**

* MITSUBISHI TANABE PHARMA CORP
RADICAVA, EDARAVONE

MOBERG PHARMA NORTH

* MOBERG PHARMA NORTH AMERICA LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
EMEND, APREPITANT
SINGULAIR, MONTELUKAST SODIUM
ZOCOR, SIMVASTATIN

MSN LABS PVT LTD

* MSN LABORATORIES PRIVATE LTD
CLOFARABINE, CLOFARABINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC

* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
MINOXIDIL, MINOXIDIL
PREDNISONE, PREDNISONE

MYLAN

* MYLAN PHARMACEUTICALS
FENOFIBRATE, FENOFIBRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
* MYLAN PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
AVITA, TRETINOIN
AZATHIOPRINE, AZATHIOPRINE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETOPOSIDE, ETOPOSIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 STAVUDINE, STAVUDINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 URSODIOL, URSODIOL
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

MYLAN ASI

* MYLAN ASI LLC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
 SULFAMYLLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ALOPRIM, ALLOPURINOL SODIUM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 AZACITIDINE, AZACITIDINE
 CARBOPLATIN, CARBOPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN INSTITUTIONAL LLC
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CIDOFOVIR, CIDOFOVIR
 COSYNTROPIN, COSYNTROPIN
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DURACLON, CLONIDINE HYDROCHLORIDE
 ENLON, EDROPHONIUM CHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FOMEPIZOLE, FOMEPIZOLE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 PENTOSTATIN, PENTOSTATIN
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 RIMSO-50, DIMETHYL SULFOXIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
 ARIXTRA, FONDAPARINUX SODIUM
 CARBAMAZEPINE, CARBAMAZEPINE
 MIACALCIN, CALCITONIN SALMON
 PIROXICAM, PIROXICAM
 SUCRALFATE, SUCRALFATE
 THEOPHYLLINE, THEOPHYLLINE

MYLAN LABS

* MYLAN LABORATORIES LTD
 NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
 ADENOSINE, ADENOSINE
 AMIFOSTINE, AMIFOSTINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOFARABINE, CLOFARABINE
 CYANOCOBALAMIN, CYANOCOBALAMIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN LABORATORIES LTD
 CYTARABINE, CYTARABINE
 DACTINOMYCIN, DACTINOMYCIN
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PARICALCITOL, PARICALCITOL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN LABORATORIES LTD**

VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC*** MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACITRETIN, ACITRETIN
 ACYCLOVIR, ACYCLOVIR
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMNESTEEM, ISOTRETINOIN
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 AVITA, TRETINOIN
 BACLOFEN, BACLOFEN
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CABERGOLINE, CABERGOLINE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPECITABINE, CAPECITABINE
 CAPTOPRIL, CAPTOPRIL
 CELECOXIB, CELECOXIB
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYTARABINE, CYTARABINE
 DENAVIR, PENCICLOVIR
 DESLORATADINE, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DISULFIRAM, DISULFIRAM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ELIMITE, PERMETHRIN
 EPLERENONE, EPLERENONE
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 ERYGEL, ERYTHROMYCIN
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESTRADIOL, ESTRADIOL
 ESZOPICLONE, ESZOPICLONE
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EXEMESTANE, EXEMESTANE
 EXTINA, KETOCONAZOLE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FINASTERIDE, FINASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 FLUOROURACIL, FLUOROURACIL
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 GABAPENTIN, GABAPENTIN
 GLATIRAMER ACETATE, GLATIRAMER ACETATE
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ITRACONAZOLE, ITRACONAZOLE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LUXIQ, BETAMETHASONE VALERATE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NABUMETONE, NABUMETONE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLUX E, CLOBETASOL PROPIONATE
 OLUX, CLOBETASOL PROPIONATE
 PALIPERIDONE, PALIPERIDONE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PERPHENAZINE, PERPHENAZINE
 PHENYTOIN, PHENYTOIN
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISON, PREDNISON
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 REPAGLINIDE, REPAGLINIDE
 RILUZOLE, RILUZOLE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 RUFINAMIDE, RUFINAMIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TOLAZAMIDE, TOLAZAMIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAVOPROST, TRAVOPROST
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAZOLAM, TRIAZOLAM
 TRILYTE, POLYETHYLENE GLYCOL 3350
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VORICONAZOLE, VORICONAZOLE
 VUSION, MICONAZOLE NITRATE
 ZIDOVUDINE, ZIDOVUDINE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONALON, DOXEPIN HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR
- * MYLAN PHARMACEUTICALS INC.
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 NIZATIDINE, NIZATIDINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECIALITY LP

- * MYLAN SPECIALTY LP
 ACCUNEB, ALBUTEROL SULFATE
 AEROSPAN HFA, FLUNISOLIDE
 ANADROL-50, OXYMETHOLONE
 ASTELIN, AZELASTINE HYDROCHLORIDE
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 AVC, SULFANILAMIDE
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 CESAMET, NABILONE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 CORTIFOAM, HYDROCORTISONE ACETATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DEMADEX, TORSEMIDE
 DEPEN, PENICILLAMINE
 DIPENTUM, OLSALAZINE SODIUM
 DYMISTA, AZELASTINE HYDROCHLORIDE
 EDLUAR, ZOLPIDEM TARTRATE
 ELESTRIN, ESTRADIOL
 EPIFOAM, HYDROCORTISONE ACETATE
 EPIPEN JR., EPINEPHRINE
 EPIPEN, EPINEPHRINE
 FELBATOL, FELBAMATE
 GASTROCROM, CROMOLYN SODIUM
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 MUSE, ALPROSTADIL
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 ROWASA, MESALAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN SPECIALTY LP
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL

MYLAN SPECLT

- * MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES INC
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
XULANE, ETHINYL ESTRADIOL

MYLAN TEORANTA

- * MYLAN TEORANTA
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

**** N ******NAMIGEN LLC**

- * NAMIGEN LLC
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

NANG KUANG PHARM CO

- * NANG KUANG PHARMACEUTICAL CO LTD
LINEZOLID, LINEZOLID

NANJING KING-FRIEND

- * NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CARBOPLATIN, CARBOPLATIN

NAPO PHARMS INC

- * NAPO PHARMACEUTICALS INC
FULYZAQ, CROFELEMER

NATCO PHARMA

- * NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

- * NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
- * NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

- * NAVINTA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NAVINTA LLC**

BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 FAMOTIDINE, FAMOTIDINE
 FOMEPIZOLE, FOMEPIZOLE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 METHOCARBAMOL, METHOCARBAMOL
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

NCM USA BRONX LLC*** NCM USA BRONX LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAP INC*** NEOS THERAPEUTICS INC**

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS*** NEOS THERAPEUTICS**

ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC*** NEOS THERAPEUTICS INC**

ADZENYS ER, AMPHETAMINE
 COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON*** NEPHRON CORP**

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

*** NEPHRON PHARMACEUTICALS CORP**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE

NESHER PHARMS*** NESHER PHARMACEUTICALS USA LLC**

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 MICRO-K 10, POTASSIUM CHLORIDE
 MICRO-K, POTASSIUM CHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEUROCRINE*** NEUROCRINE BIOSCIENCES INC**

INGREZZA, VALBENZAZINE TOSYLATE

NEW HAVEN PHARMS*** NEW HAVEN PHARMACEUTICALS INC**

DURLAZA, ASPIRIN

NEW RIVER*** NEW RIVER PHARMACEUTICALS INC**

PROFERDEX, IRON DEXTRAN

NEWGEN PHARMS LLC*** NEWGEN PHARMACEUTICALS LLC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

NEXGEN PHARMA*** NEXGEN PHARMA INC**

BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHENODIOL, CHENODIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NEXGEN PHARMA INC**

POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC*** NEXGEN PHARMA INC**BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350**NEXTWAVE PHARMS***** NEXTWAVE PHARMACEUTICALS INC**

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS*** NEXUS PHARMACEUTICALS INC**ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE**NIAGARA PHARMS***** NIAGARA PHARMACEUTICALS INC**

PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA*** NODEN PHARMA DAC**TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE**NORTEC DEV ASSOC***** NORTEC DEVELOPMENT ASSOC INC**

PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR HLTHCARE*** NORTHSTAR HEALTHCARE HOLDINGS LTD**ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE**NORTON WATERFORD***** NORTON WATERFORD LTD**

QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC*** NOSTRUM LABORATORIES INC**ACETAZOLAMIDE, ACETAZOLAMIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL, CARISOPRODOL
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN
PINDOLOL, PINDOLOL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE**NOSTRUM PHARMS LLC***** NOSTRUM PHARMACEUTICALS LLC**METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE**NOVA LABS LTD***** NOVA LABORATORIES LTD**

PURIXAN, MERCAPTOPYRINE

NOVARTIS*** NOVARTIS CONSUMER HEALTH INC**LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)*** NOVARTIS PHARMACEUTICALS CORP**

AFINITOR, EVEROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 COARTEM, ARTEMETHER
 DESFERAL, DEFEROXAMINE MESYLATE
 DIOVAN HCT, HYDROCHLOROTHIAZIDE
 DIOVAN, VALSARTAN
 EXELON, RIVASTIGMINE
 EXELON, RIVASTIGMINE TARTRATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXFORGE, AMLODIPINE BESYLATE
 EXJADE, DEFERASIROX
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 GILENYA, FINGOLIMOD
 GLEEVEC, IMATINIB MESYLATE
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LESCOL XL, FLUVASTATIN SODIUM
 LOPRESSOR, METOPROLOL TARTRATE
 LOTREL, AMLODIPINE BESYLATE
 MYFORTIC, MYCOPHENOLIC ACID
 NEORAL, CYCLOSPORINE
 RECLAST, ZOLEDRONIC ACID
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 STARLIX, NATEGLINIDE
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TOBI PODHALER, TOBRAMYCIN
 TRILEPTAL, OXCARBAZEPINE
 VIVELLE-DOT, ESTRADIOL
 VOLTAREN, DICLOFENAC SODIUM
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
 AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE
 TOBI, TOBRAMYCIN

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
 ALCaine, PROPARACAINE HYDROCHLORIDE
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ARGATROBAN, ARGATROBAN
 ARRANON, NELARABINE
 AZOPT, BRINZOLAMIDE
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE
 CILLOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 DUREZOL, DIFLUPREDNATE
 EMADINE, EMEDASTINE DIFUMARATE
 ENTRESTO, SACUBITRIL
 FARYDAK, PANOBINOSTAT LACTATE
 FLAREX, FLUOROMETHOLONE ACETATE
 FLUORESCITE, FLUORESCEIN SODIUM
 Hycamtin, TOPOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 ILEVRO, NEPAFENAC
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE
 ISOPTO ATROPINE, ATROPINE SULFATE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 JADENU SPRINKLE, DEFERASIROX
 JADENU, DEFERASIROX
 KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
 KISQALI, RIBOCICLIB SUCCINATE
 MAXIDEX, DEXAMETHASONE
 MAXITROL, DEXAMETHASONE
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
 MYDRIACYL, TROPICAMIDE
 NATACYN, NATAMYCIN
 NEVANAC, NEPAFENAC
 OMNIPRED, PREDNISOLONE ACETATE
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAZEO, OLOPATADINE HYDROCHLORIDE
 PROMACTA, ELTROMBOPAG OLAMINE
 RYDAPT, MIDOSTAURIN
 SIGNIFOR LAR, PASIREOTIDE PAMOATE
 SIMBRINZA, BRIMONIDINE TARTRATE
 TAFINLAR, DABRAFENIB MESYLATE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TOBRADEX ST, DEXAMETHASONE
 TOBRADEX, DEXAMETHASONE
 TOBEX, TOBRAMYCIN
 TRAVATAN Z, TRAVOPROST
 TRISENCE, TRIAMCINOLONE ACETONIDE
 TYKERB, LAPATINIB DITOSYLATE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 XTORO, FINAFLOXACIN
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZYKADIA, CERITINIB

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
 NORETHINDRONE, NORETHINDRONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ELINEST, ETHINYL ESTRADIOL
 FALMINA, ETHINYL ESTRADIOL
 HER STYLE, LEVONORGESTREL (OTC)
 INDOMETHACIN, INDOMETHACIN
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LERIBANE, ETHINYL ESTRADIOL
 LEVONEST, ETHINYL ESTRADIOL
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MELAMISA, DROSPIRENONE
 MONO-LINYAH, ETHINYL ESTRADIOL
 NIFEDIPINE, NIFEDIPINE
 NORETHINDRONE, NORETHINDRONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVAST LABORATORIES LTD**

PHILITH, ETHINYL ESTRADIOL
 PIMTREA, DESOGESTREL
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 SETLAKIN, ETHINYL ESTRADIOL
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRI-LINYAH, ETHINYL ESTRADIOL
 WERA, ETHINYL ESTRADIOL
 YAELA, DROSPIRENONE

NOVATECH SA

* NOVATECH SA
 STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CARBIDOPA, CARBIDOPA
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FAMOTIDINE, FAMOTIDINE
 FLUCYTOSINE, FLUCYTOSINE
 FLUOCINONIDE, FLUOCINONIDE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MISOPROSTOL, MISOPROSTOL
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN, NITROFURANTOIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,
 PHENELZINE SULFATE, PHENELZINE SULFATE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
 TEMAZEPAM, TEMAZEPAM
 TINIDAZOLE, TINIDAZOLE
 TRIMETHOPRIM, TRIMETHOPRIM
 VORICONAZOLE, VORICONAZOLE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVEN

* NOVEN PHARMACEUTICALS INC
 MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
 COMBIPATCH, ESTRADIOL
 DAYTRANA, METHYLPHENIDATE

NOVITIUM PHARMA

* NOVITIUM PHARMA LLC
 DAPSONE, DAPSONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******NOVO NORDISK**

* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
FIASP FLEXTOUCH, INSULIN ASPART
FIASP, INSULIN ASPART
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
OZEMPIC, SEMAGLUTIDE
RYZODEG 70/30, INSULIN ASPART
SAXENDA, LIRAGLUTIDE RECOMBINANT
TRESIBA, INSULIN DEGLUDEC
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT
XULTOPHY 100/3.6, INSULIN DEGLUDEC

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NU PHARM

* NU PHARM INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUVO PHARM

* NUVO PHARMACEUTICAL INC
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE

NUVO PHARM INC

* NUVO PHARMACEUTICAL INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NXDC

* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

NYCOMED US

* NYCOMED US INC
TERCONAZOLE, TERCONAZOLE

**** O ******OAK PHARMS**

* OAK PHARMACEUTICALS INC
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN

* OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC

* OAK PHARMACEUTICALS INC
ZIOPTAN, TAFLUPROST
* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
 COSOPT, DORZOLAMIDE HYDROCHLORIDE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OC PHARMA

* OC PHARMA LLC
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
 ANTABUSE, DISULFIRAM
 NYSTATIN, NYSTATIN
 SURMONTIL, TRIMIPRAMINE MALEATE
 URECHOLINE, BETHANECHOL CHLORIDE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
 IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUPROHM, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
 EZETIMIBE, EZETIMIBE
 VALSARTAN, VALSARTAN

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
 LINDANE, LINDANE

OMEROS

* OMEROS CORP
 OMIDRIA, KETOROLAC TROMETHAMINE

ONY

* ONY INC
 INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
 KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL

* OPKO IRELAND GLOBAL HOLDINGS LTD
 RAYALDEE, CALCIFEDIOL

OPTNOSE US

* OPTNOSE US INC
 XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
 ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ESZOPICLONE, ESZOPICLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORCHID HEALTHCARE

FELODIPINE, FELODIPINE
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MODAFINIL, MODAFINIL
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFAINE HYDROCHLORIDE, TERBINAFAINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON

OREXIGEN

* OREXIGEN THERAPEUTICS INC
 CONTRAVE, BUPROPION HYDROCHLORIDE

OREXO US INC

* OREXO US INC
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC
 BRIDION, SUGAMMADEX SODIUM
 NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
 DESOGEN, DESOGESTREL
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 GANIRELIX ACETATE, GANIRELIX ACETATE
 NEXPLANON, ETONOGESTREL
 PREGNYL, GONADOTROPIN, CHORIONIC
 REMERON SOLTAB, MIRTAZAPINE
 REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
 CARISOPRODOL, CARISOPRODOL
 MIGLITOL, MIGLITOL
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

ORION CORP ORION

* ORION CORP ORION PHARMA
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
 COMTAN, ENTACAPONE
 STALEVO 100, CARBIDOPA
 STALEVO 125, CARBIDOPA
 STALEVO 150, CARBIDOPA
 STALEVO 200, CARBIDOPA
 STALEVO 50, CARBIDOPA
 STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
 BENZONATATE, BENZONATATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 LEVETIRACETAM, LEVETIRACETAM
 METRONIDAZOLE, METRONIDAZOLE

ORPHAN EUROPE

* ORPHAN EUROPE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

- * ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID
- * ORPHAN EUROPE SARL
CYSTADANE, BETAINE HYDROCHLORIDE

OSI PHARMS

- * OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

- * OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM

- * OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP

- * OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

OSMOTICA PHARM US

- * OSMOTICA PHARMACEUTICAL US LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

- * OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

- * OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

- * OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
REXULTI, BREXPIPRAZOLE

OUTLOOK PHARMS

- * OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

- * OXFORD PHARMACEUTICALS LLC
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

**** P ******P AND L DEV LLC**

- * P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

- * PACIFIC PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
- * PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

- * PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

PADDOCK LLC

- * PADDOCK LABORATORIES LLC
ATOVAQUONE, ATOVAQUONE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PANACEA BIOTEC LTD

- * PANACEA BIOTEC LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM

- * PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

- * PAR PHARMACEUTICAL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PROPAPFENONE HYDROCHLORIDE, PROPAPFENONE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
- * PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 CABERGOLINE, CABERGOLINE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
 CLONAZEPAM, CLONAZEPAM
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 ESTAZOLAM, ESTAZOLAM
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTAMIDE, FLUTAMIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYUREA, HYDROXYUREA
 IBUPROFEN, IBUPROFEN (OTC)
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LAMOTRIGINE, LAMOTRIGINE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXANDROLONE, OXANDROLONE
 PIMOZIDE, PIMOZIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANYLCPROMINE SULFATE, TRANYLCPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 ACCOLATE, ZAFIRLUKAST
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ANTIZOL, FOMEPIZOLE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 ENTECAVIR, ENTECAVIR
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PRAZIQUANTEL, PRAZIQUANTEL
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADRENALIN, EPINEPHRINE
 ARGATROBAN, ARGATROBAN
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 CORPHEDRA, EPHEDRINE SULFATE
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETOMIDATE, ETOMIDATE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 GANCICLOVIR, GANCICLOVIR SODIUM
 KETALAR, KETAMINE HYDROCHLORIDE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 PITOCIN, OXYTOCIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIOSTAT, LIOETHYRONINE SODIUM
 VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 CEREBYX, FOSPHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 NARDIL, PHENELZINE SULFATE
 NEURONTIN, GABAPENTIN
 ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS

* PARKE-DAVIS DIVISION OF PFIZER INC
 DILANTIN, PHENYTOIN SODIUM
 ZARONTIN, ETHOSUXIMIDE

PERNIX IRELAND LTD

* PERNIX IRELAND LTD
 TREXIMET, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PERNIX IRELAND PAIN

* PERNIX IRELAND PAIN LIMITED
ZOHYDRO ER, HYDROCODONE BITARTRATE

PERNIX THERAPS LLC

* PERNIX THERAPEUTICS LLC
SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO

* PERRIGO CO
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)

PERRIGO CO

* PERRIGO CO OF TENNESSEE INC
CICLOPIROX, CICLOPIROX
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS LTD
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NITROGLYCERIN, NITROGLYCERIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO NEW YORK INC
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 ENTOCORT EC, BUDESONIDE
 EVAMIST, ESTRADIOL
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 TRETINOIN, TRETINOIN

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
 SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN, NAPROXEN
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 FLURANDRENOLIDE, FLURANDRENOLIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TESTOSTERONE, TESTOSTERONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PETNET

* PETNET SOLUTIONS INC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PETNET SOLUTIONS INC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
INLYTA, AXITINIB
LYRICA, PREGABALIN
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE
ZMAX, AZITHROMYCIN

PFIZER

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN

* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN

* PFIZER INC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CADUET, AMLODIPINE BESYLATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
ELELYSO, TALIGLUCERASE ALFA
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LIPITOR, ATORVASTATIN CALCIUM
LORATADINE, LORATADINE (OTC)
MERREM, MEROPENEM
NORVASC, AMLODIPINE BESYLATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
SONATA, ZALEPLON
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
ZITHROMAX, AZITHROMYCIN

* PFIZER LABORATORIES DIV PFIZER INC
CARDURA, DOXAZOSIN MESYLATE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PFIZER LABORATORIES DIV PFIZER INC
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
- * PFIZER PHARMACEUTICALS INC
DILANTIN, PHENYTOIN
ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

- * PFIZER CONSUMER HEALTHCARE
ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

- * PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
ELLENCHE, EPIRUBICIN HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
IBRANCE, PALBOCICLIB
LYRICA CR, PREGABALIN
NICOTROL, NICOTINE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
VIAGRA, SILDENAFIL CITRATE
XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

- * PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PHARMACEUTICAL ASSOCIATES INC
 THEOPHYLLINE, THEOPHYLLINE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACARE

* PHARMACARE LTD
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

PHARMACHEMIE BV

* PHARMACHEMIE BV
 CARBOPLATIN, CARBOPLATIN
 CISPLATIN, CISPLATIN
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
 XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
 AROMASIN, EXEMESTANE
 AZULFIDINE EN-TABS, SULFASALAZINE
 AZULFIDINE, SULFASALAZINE
 BACITRACIN, BACITRACIN
 CAVERJECT IMPULSE, ALPROSTADIL
 CAVERJECT, ALPROSTADIL
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLEOCIN T, CLINDAMYCIN PHOSPHATE
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLEOCIN, CLINDAMYCIN PHOSPHATE
 CORTEF, HYDROCORTISONE
 CORVERT, IBUTILIDE FUMARATE
 CYKLOKAPRON, TRANEXAMIC ACID
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DETROL LA, TOLTERODINE TARTRATE
 DETROL, TOLTERODINE TARTRATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 ESTRING, ESTRADIOL
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
 GENOTROPIN, SOMATROPIN RECOMBINANT
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 HALCION, TRIAZOLAM
 HEMABATE, CARBOPROST TROMETHAMINE
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 MEDROL, METHYLPREDNISOLONE
 MYCOBUTIN, RIFABUTIN
 NICOTROL, NICOTINE
 OGEN 5, ESTROPIPATE
 PREPIDIL, DINOPROSTONE
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROVERA, MEDROXYPROGESTERONE ACETATE
 R-GENE 10, ARGININE HYDROCHLORIDE
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
 SOMAVERT, PEGVISOMANT
 XALATAN, LATANOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PHARMACIA AND UPJOHN CO

XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN SUB PFIZER INC

DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC

COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

PHARMACYCLICS INC

* PHARMACYCLICS INC

IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC

GLYBURIDE, GLYBURIDE
LEVETIRACETAM, LEVETIRACETAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMAFORCE

* PHARMAFORCE INC

FLOXURIDINE, FLOXURIDINE

PHARMALUCENCE

* PHARMALUCENCE INC

AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMASCIENCE INC

* PHARMASCIENCE INC

BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMTAK INC

* PHARMTAK INC

LEVETIRACETAM, LEVETIRACETAM

PHOTOCURE ASA

* PHOTOCURE ASA

CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE

* PIERRE FABRE MEDICAMENT

NAVELBINE, VINORELBINE TARTRATE

PIERRE FABRE DERMA

* PIERRE FABRE DERMATOLOGIE

HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

* PIERREL S.P.A.

ORABLOC, ARTICAINA HYDROCHLORIDE

PII

* PHARMACEUTICS INTERNATIONAL INC

BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCORTISONE, HYDROCORTISONE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PIRAMAL CRITICAL

* PIRAMAL CRITICAL CARE INC

ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

* PIRAMAL CRITICAL CARE LTD

GABLOFEN, BACLOFEN

PIRAMAL ENT

* PIRAMAL ENTERPRISES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL IMAGING

* PIRAMAL IMAGING SA
NEURACEQ, FLORBETABEN F-18

PLD ACQUISITIONS LLC

* PLD ACQUISITIONS LLC
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA

* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
NEOPAP, ACETAMINOPHEN (OTC)

PORTOLA PHARMS INC

* PORTOLA PHARMACEUTICALS INC
BEVYXXA, BETRIXABAN

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA PHARMS LLC

* PRAGMA PHARMACEUTICALS LLC
KEFLEX, CEPHALEXIN

PRECISION DERMAT

* PRECISION DERMATOLOGY INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PRECISION DERMATOLOGY INC
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCOID, HYDROCORTISONE BUTYRATE
 MINOCIN, MINOCYCLINE HYDROCHLORIDE

PRECISION DOSE

* PRECISION DOSE INC
 RISPERIDONE, RISPERIDONE

PRECISION DOSE INC

* PRECISION DOSE INC
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PROMIUS PHARMA**

- * PROMIUS PHARMA LLC
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

- * PROMIUS PHARMA LLC
CLODERM, CLOCORTOLONE PIVALATE
IMPOYZ, CLOBETASOL PROPIONATE
SERNIVO, BETAMETHASONE DIPROPIONATE

PROVENSIS

- * PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

- * PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PROVIDENT PHARM

- * PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PTC THERAP

- * PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC

- * PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH

- * PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM

- * PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC

- * PURACAP PHARMACEUTICAL LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE GMP

- * PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARMA

- * PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP

- * PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ******QILU PHARM CO LTD**

- * QILU PHARMACEUTICAL CO LTD
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAZONE, CEFTRIAZONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN

QOL MEDCL

- * QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUEEN HAMAMATSU PET

- * QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******R-PHARM US LLC**

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

R2 PHARMA LLC

* R2 PHARMA LLC
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

RADIUS HEALTH INC

* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

RANBAXY

* RANBAXY LABORATORIES INC
EURAX, CROTAMITON
HALOG, HALCINONIDE
ULTRAVATE, HALOBETASOL PROPIONATE

RANBAXY LABS LTD

* RANBAXY LABORATORIES LTD
KENALOG, TRIAMCINOLONE ACETONIDE

RECIP

* RECIP AB
THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

* RECKITT BENCKISER LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
INDOCIN, INDOMETHACIN SODIUM
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

RELYPSA INC

* RELYPSA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS INC

* REMPEX PHARMACEUTICALS INC
MINOCIN, MINOCYCLINE HYDROCHLORIDE

REMPEX PHARMS MEDCNS

* REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF THE MEDICINES CO
VABOMERE, MEROPENEM

RENAISSANCE SSA LLC

* RENAISSANCE SSA LLC
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
METHOCARBAMOL, METHOCARBAMOL
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RHODES PHARMACEUTICALS LP
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 LIDOCAINE, LIDOCAINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 QUININE SULFATE, QUININE SULFATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

RISING PHARMS INC

* RISING PHARMACEUTICALS INC
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DUTASTERIDE, DUTASTERIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCORTISONE, HYDROCORTISONE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 METHIMAZOLE, METHIMAZOLE
 PARICALCITOL, PARICALCITOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 ZILEUTON, ZILEUTON

ROCHE PALO

* ROCHE PALO ALTO LLC
 CELLCEPT, MYCOPHENOLATE MOFETIL
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 CYTOVENE, GANCICLOVIR SODIUM

ROCKWELL MEDICAL INC

* ROCKWELL MEDICAL INC
 TRIFERIC , FERRIC PYROPHOSPHATE CITRATE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

* ROMARK LABORATORIES
 ALINIA, NITAZOXANIDE

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
 LEVETIRACETAM, LEVETIRACETAM

RP SCHERER

* RP SCHERER TECHNOLOGIES LLC
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

RTRX

* RETROPHIN INC
 CHOLBAM, CHOLIC ACID

RUBICON RES PVT LTD

* RUBICON RESEARCH PVT LTD
 BACLOFEN, BACLOFEN
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

**** S ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******SAGE PRODS**

* SAGE PRODUCTS INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA

* SAGENT AGILA LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SAGENT AGILA LLC

* SAGENT AGILA LLC
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 GLYDO, LIDOCAINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LINEZOLID, LINEZOLID
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PROPOFOL, PROPOFOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAGENT STRIDES

* SAGENT STRIDES LLC
 ADENOSINE, ADENOSINE
 AZITHROMYCIN, AZITHROMYCIN
 BACITRACIN, BACITRACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SAGENT STRIDES LLC**

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

SALIX PHARMS*** SALIX PHARMACEUTICALS INC**

ANUSOL HC, HYDROCORTISONE
 DIURIL, CHLOROTHIAZIDE
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 PEPCID, FAMOTIDINE
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SALIX PHARMS INC*** SALIX PHARMACEUTICALS INC**

RELISTOR, METHYLNALTREXONE BROMIDE

SAMSON MEDCL*** SAMSON MEDICAL TECHNOLOGIES LLC**

CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ*** SANDOZ**

DOCETAXEL, DOCETAXEL

*** SANDOZ INC**

ALPRAZOLAM, ALPRAZOLAM
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 APREPITANT, APREPITANT
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFERGOT, CAFFEINE
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARVEDILOL, CARVEDILOL
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CILOSTAZOL, CILOSTAZOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC

CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COSYNTROPIN, COSYNTROPIN
 CYCLOSPORINE, CYCLOSPORINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPLERENONE, EPLERENONE
 ETODOLAC, ETODOLAC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 HALOPERIDOL, HALOPERIDOL
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISONIAZID, ISONIAZID
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOLAZONE, METOLAZONE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 OMNITROPE, SOMATROPIN RECOMBINANT
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFADIAZINE, SULFADIAZINE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ INC

* SANDOZ INC
 ACETAMINOPHEN, ACETAMINOPHEN
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BIMATOPROST, BIMATOPROST
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 CARBOPLATIN, CARBOPLATIN
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 CEFIXIME, CEFIXIME
 CEFTRIAXONE, CEFTRIAXONE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 DECITABINE, DECITABINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 ENTECAVIR, ENTECAVIR
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EZETIMIBE, EZETIMIBE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 GATIFLOXACIN, GATIFLOXACIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLATOPA, GLATIRAMER ACETATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LATANOPROST, LATANOPROST
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MAXITROL, DEXAMETHASONE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYDRIACYL, TROPICAMIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEVIRAPINE, NEVIRAPINE
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROGESTERONE, PROGESTERONE
 QOLIANA, BRIMONIDINE TARTRATE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 REPAGLINIDE, REPAGLINIDE
 RIBAVIRIN, RIBAVIRIN
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILODOSIN, SILODOSIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TELMISARTAN, TELMISARTAN
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBREX, TOBRAMYCIN
 TREPROSTINIL, TREPROSTINIL
 TRIFLURIDINE, TRIFLURIDINE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANJA PHARMS CO

* SANJA PHARMACEUTICALS CO
 CARBOPLATIN, CARBOPLATIN
 OXALIPLATIN, OXALIPLATIN

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
 JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA, FEXOFENADINE HYDROCHLORIDE
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 AMARYL, GLIMEPIRIDE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBIEN, ZOLPIDEM TARTRATE
 APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
 APIDRA, INSULIN GLULISINE RECOMBINANT
 ARAVA, LEFLUNOMIDE
 AUBAGIO, TERIFLUNOMIDE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVAPRO, IRBESARTAN
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLOMID, CLOMIPHENE CITRATE
 DIABETA, GLYBURIDE
 ELOXATIN, OXALIPLATIN
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 LANTUS, INSULIN GLARGINE RECOMBINANT
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOVENOX, ENOXAPARIN SODIUM
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NICODERM CQ, NICOTINE (OTC)
 PLAVIX, CLOPIDOGREL BISULFATE
 PRIFTIN, RIFAPENTINE
 PRIMAQUINE, PRIMAQUINE PHOSPHATE
 RIFADIN, RIFAMPIN
 RIFAMATE, ISONIAZID
 RIFATER, ISONIAZID
 TAXOTERE, DOCETAXEL

SANOFI US

* SANOFI US

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANOFI US**

ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

SANOFI US SERVICES*** SANOFI US SERVICES INC**

TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US*** SANOFI-AVENTIS US LLC**

ADLYXIN, LIXISENATIDE
 ADMELOG SOLOSTAR, INSULIN LISPRO
 ADMELOG, INSULIN LISPRO
 SOLIQUA 100/33, INSULIN GLARGINE
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

SANTARUS INC*** SANTARUS INC**

FENOGLIDE, FENOFIBRATE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 ZEGERID, OMEPRAZOLE

SANTOS BIOTECH*** SANTOS BIOTECH INDUSTRIES INC**

ANASTROZOLE, ANASTROZOLE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE

SAOL THERAPS RES LTD*** SAOL THERAPEUTICS RESEARCH LTD**

LIORESAL, BACLOFEN

SAPTALIS PHARMS*** SAPTALIS PHARMACEUTICALS LLC**

LORAZEPAM, LORAZEPAM

SAREPTA THERAPS INC*** SAREPTA THERAPEUTICS INC**

EXONDYS 51, ETEPLIRSEN

SAVIOR LIFETEC CORP*** SAVIOR LIFETEC CORP**

MEROPENEM, MEROPENEM

SAWAI USA*** SAWAI USA INC**

PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SB PHARMCO*** SB PHARMCO PUERTO RICO INC**

AVANDIA, ROSIGLITAZONE MALEATE

SCHERING*** SCHERING CORP**

INTEGRILIN, EPTIFIBATIDE
 NOXAFIL, POSACONAZOLE
 REBETOL, RIBAVIRIN

SCHERING PLOUGH*** SCHERING PLOUGH HEALTHCARE PRODUCTS INC**

AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)

SCIECURE PHARMA INC*** SCIECURE PHARMA INC**

BUDESONIDE, BUDESONIDE

SCIEGEN PHARMS INC*** SCIEGEN PHARMACEUTICALS INC**

ARIPIPRAZOLE, ARIPIPRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARISOPRODOL, CARISOPRODOL
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SCIEGEN PHARMACEUTICALS INC**

FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

SCIOS LLC*** SCIOS LLC**

NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD*** SEBELA IRELAND LTD**

BRISDELLE, PAROXETINE MESYLATE
 IMURAN, AZATHIOPRINE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 MICORT-HC, HYDROCORTISONE ACETATE
 MOTOFEN, ATROPINE SULFATE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 ONMEL, ITRACONAZOLE
 PEXEVA, PAROXETINE MESYLATE
 PRAMOSONE, HYDROCORTISONE ACETATE
 RIDAURA, AURANOFIN

SECAN PHARMS*** SECAN PHARMACEUTICALS INC**

LEVETIRACETAM, LEVETIRACETAM

SENTYNL THERAPS INC*** SENTYNL THERAPEUTICS INC**

ABSTRAL, FENTANYL CITRATE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT*** SEPTODONT INC**

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING*** SEPTODONT HOLDING SAS**

ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC*** SEPTODONT INC**

ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 LIDOCAINE, LIDOCAINE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA*** SERB SA**

CYANOKIT, HYDROXOCOBALAMIN

SETON PHARM*** SETON PHARMACEUTICAL LLC**

PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS*** SETON PHARMACEUTICALS LLC**

PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANGHAI HENGRUI*** SHANGHAI HENGRUI PHARMACEUTICAL CO LTD**

SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW*** SHENZHEN TECHDOW PHARMACEUTICAL CO LTD**

HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHERTECH LABS LLC

- * SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHILPA MEDICARE

- * SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

- * SHILPA MEDICARE LTD
CAPECITABINE, CAPECITABINE

SHIONOGI INC

- * SHIONOGI INC
PONSTEL, MEFENAMIC ACID
SYMPROIC, NALDEMEDINE TOSYLATE
ULESFIA, BENZYL ALCOHOL

SHIRE

- * SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEV LLC

- * SHIRE DEVELOPMENT LLC
FOSRENOL, LANTHANUM CARBONATE
MYDAYIS, AMPHETAMINE ASPARTATE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
XIIDRA, LIFITEGRAST

SHIRE DEVELOPMENT

- * SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

- * SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

- * SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE

SHIRE ORPHAN THERAP

- * SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

- * SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGMA TAU

- * SIGMA TAU PHARMACEUTICALS INC
ADAGEN, PEGADEMASE BOVINE

SIGMAPHARM LABS LLC

- * SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOALCIFEROL, ERGOALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SIGMAPHARM LABORATORIES LLC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILARX

* SILARX PHARMACEUTICALS INC
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE, LORATADINE (OTC)
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

SILARX PHARMS INC

* SILARX PHARMACEUTICALS INC
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

SILVERGATE PHARMS

* SILVERGATE PHARMACEUTICALS INC
 EPANED KIT, ENALAPRIL MALEATE
 EPANED, ENALAPRIL MALEATE
 QBRELIS, LISINOPRIL
 XATMEP, METHOTREXATE SODIUM

SINOTHERAPEUTICS INC

* SINOTHERAPEUTICS INC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

SKINMEDICA

* SKINMEDICA INC
 VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
 TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 * SMITHKLINE BEECHAM (CORK) LTD IRELAND
 COREG CR, CARVEDILOL PHOSPHATE
 COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
 NIMODIPINE, NIMODIPINE
 * SOFGEN PHARMACEUTICALS LLC
 IBUPROFEN, IBUPROFEN (OTC)
 PROGESTERONE, PROGESTERONE

SOFIE

* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

SOMERSET

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SOMERSET PHARMACEUTICALS INC
 ELDEPRYL, SELEGILINE HYDROCHLORIDE
 EMSAM, SELEGILINE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
 CYANOCOBALAMIN, CYANOCOBALAMIN
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 METHOCARBAMOL, METHOCARBAMOL
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
 FLUOROURACIL, FLUOROURACIL

SPECGX LLC

* SPECGX LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
 ANEXSIA 5/325, ACETAMINOPHEN
 ANEXSIA 7.5/325, ACETAMINOPHEN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 EXALGO, HYDROMORPHONE HYDROCHLORIDE
 FENTANYL CITRATE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

SPECTRA MDCL DEVICES

* SPECTRA MEDICAL DEVICES INC
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPECTRON MRC LLC

* SPECTRON MRC LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS INC
 BELEODAQ, BELINOSTAT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SPECTRUM PHARMACEUTICALS INC
 EVOMELA, MELPHALAN HYDROCHLORIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
 ADDYI, FLIBANSERIN

ST RENATUS

* ST RENATUS LLC
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
 IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS

* STASON PHARMACEUTICALS INC
 PURINETHOL, MERCAPTOPYRINE

STI PHARMA LLC

* STI PHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 DEXAMETHASONE, DEXAMETHASONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
 DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
 SORIATANE, ACITRETIN

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACARBOSE, ACARBOSE
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 DUTASTERIDE, DUTASTERIDE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 IMIQUIMOD, IMIQUIMOD
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOXSALEN, METHOXSALEN
 METRONIDAZOLE, METRONIDAZOLE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NEVIRAPINE, NEVIRAPINE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TACROLIMUS, TACROLIMUS
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRONGBRIDGE US INC
KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BENZONATATE, BENZONATATE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
EXELDERM, SULCONAZOLE NITRATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HALOG, HALCINONIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LITHIUM CARBONATE, LITHIUM CARBONATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** s ******* SUN PHARMACEUTICAL INDUSTRIES INC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NIMODIPINE, NIMODIPINE
 OXAPROZIN, OXAPROZIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 RISPERIDONE, RISPERIDONE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS LTD*** SUN PHARMACEUTICAL INDUSTRIES LTD**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SUN PHARMACEUTICAL INDUSTRIES LTD
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RILUZOLE, RILUZOLE
 RIOMET, METFORMIN HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOPIRAMATE, TOPIRAMATE
 ULTRAVATE, HALOBETASOL PROPIONATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- SUN PHARM INDUSTRIES**
- * SUN PHARMACEUTICAL INDUSTRIES INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MORPHINE SULFATE, MORPHINE SULFATE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
 QUALAQUIN, QUININE SULFATE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SYNALGOS-DC, ASPIRIN
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMIFOSTINE, AMIFOSTINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BROMSITE, BROMFENAC SODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DECITABINE, DECITABINE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 ODOMZO, SONIDEGIB PHOSPHATE
 OXALIPLATIN, OXALIPLATIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TETRABENAZINE, TETRABENAZINE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SUN PHARMA GLOBAL FZE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * SUN PHARMA GLOBAL INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

SUNOVION

- * SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

- * SUNOVION PHARMACEUTICALS INC
APTIOM, ESLICARBAZEPINE ACETATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE
SEEBRI, GLYCOPYRROLATE
UTIBRON, GLYCOPYRROLATE
ZONEGRAN, ZONISAMIDE

SUNOVION RESP

- * SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNRISE PHARM INC

- * SUNRISE PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

SUNSTAR AMERICAS

- * SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

- * SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
TOKENDI XR, TOPIRAMATE

SUVEN LIFE

- * SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

SVC PHARMA

- * SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN

- * SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNERGY PHARMS

- * SYNERGY PHARMACEUTICALS INC
TRULANCE, PLECANATIDE

SYNTHON PHARMS

- * SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ******ACME LABS**

- * THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******GEN HOSP**

* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES

* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP

* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSENI, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT

TALON THERAP

* TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TARO PHARMACEUTICAL INDUSTRIES LTD
 PHENYTOIN, PHENYTOIN

* TARO PHARMACEUTICALS USA INC
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DAPSONE, DAPSONE
 DERMABET, BETAMETHASONE VALERATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 KETOZOLE, KETOCONAZOLE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 PHENYTOIN, PHENYTOIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TAZAROTENE, TAZAROTENE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERCONAZOLE, TERCONAZOLE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 U-CORT, HYDROCORTISONE ACETATE

TARO PHARM

* TARO PHARMACEUTICAL INDUSTRIES LTD
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 DESLORATADINE, DESLORATADINE
 DESONIDE, DESONIDE
 FELBAMATE, FELBAMATE
 FLUOROURACIL, FLUOROURACIL
 GABAPENTIN, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 METRONIDAZOLE, METRONIDAZOLE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OVIDE, MALATHION
 TERIL, CARBAMAZEPINE
 WARFARIN SODIUM, WARFARIN SODIUM

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
 AMCINONIDE, AMCINONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESLORATADINE, DESLORATADINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
 PLIAGLIS, LIDOCAINE

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)

TASMAN PHARMA

* TASMAN PHARMA INC
 VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
 FLOLIPID, SIMVASTATIN

TECH ORGANIZED

* TECHNOLOGY ORGANIZED LLC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 NEVIRAPINE, NEVIRAPINE

TEDOR PHARM

* TEDOR PHARMA INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEDOR PHARMA INC

* TEDOR PHARMA INC
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
 LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
 CEFOTAN, CEFOTETAN DISODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TELIGENT OU
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
 FORTAZ, CEFTAZIDIME
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
 ZINACEF, CEFUROXIME SODIUM

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLURANDRENOLIDE, FLURANDRENOLIDE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE, LIDOCAINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TERSERA THERAPS LLC

* TERSERA THERAPEUTICS LLC
 ERGOMAR, ERGOTAMINE TARTRATE
 ZOLADEX, GOSERELIN ACETATE

TESARO INC

* TESARO INC
 VARUBI, ROLAPITANT HYDROCHLORIDE
 ZEJULA, NIRAPARIB TOSYLATE

TEVA

* TEVA NEUROSCIENCE INC
 AZILECT, RASAGILINE MESYLATE

* TEVA PHARMACEUTICALS USA INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL, CAPTOPRIL
 CARVEDILOL, CARVEDILOL
 CEFACLOR, CEFACLOR
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPITOL, CARBAMAZEPINE
 ESZOPICLONE, ESZOPICLONE
 ETODOLAC, ETODOLAC
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALZIN, ZINC ACETATE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MUPIROCIN, MUPIROCIN
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORAP, PIMOZIDE
 OXAPROZIN, OXAPROZIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA INC**

OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM*** TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC**

AUSTEDO, DEUTETRABENAZINE
 DIAMOX, ACETAZOLAMIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 VANTRELA ER, HYDROCODONE BITARTRATE
 ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL*** TEVA PARENTERAL MEDICINES INC**

DAPTOMYCIN, DAPTOMYCIN
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM*** TEVA PHARMACEUTICAL INDUSTRIES LTD**

AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
 ARMONAIR RESPICLICK, FLUTICASONE PROPIONATE

TEVA PHARMS*** TEVA PHARMACEUTICALS USA**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 AZITHROMYCIN, AZITHROMYCIN
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUDESONIDE, BUDESONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA**

CEFDINIR, CEFDINIR
 CEFPROZIL, CEFPROZIL
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FAMCICLOVIR, FAMCICLOVIR
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEFLUNOMIDE, LEFLUNOMIDE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROGESTERONE, PROGESTERONE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANDAZOLE, METRONIDAZOLE
 VORICONAZOLE, VORICONAZOLE
 ZALEPLON, ZALEPLON

TEVA PHARMS INTL*** TEVA PHARMACEUTICALS INTERNATIONAL GMBH**

AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 SYNRIPO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ENTECAVIR, ENTECAVIR
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANSOPRAZOLE, LANSOPRAZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LINEZOLID, LINEZOLID
LOGILIA, ULIPRISTAL ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TEVA PHARMACEUTICALS USA
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * TEVA PHARMACEUTICALS USA INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CAPECITABINE, CAPECITABINE
 DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METRONIDAZOLE, METRONIDAZOLE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
- THE FEINSTEIN INST**
- * THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- THE MEDICINES CO**
- * THE MEDICINES CO
 ANGIOMAX, BIVALIRUDIN
 IONSYS, FENTANYL HYDROCHLORIDE
 ORBACTIV, ORITAVANCIN DIPHOSPHATE
- THE PHARMA NETWORK**
- * THE PHARMA NETWORK LLC
 BENZONATATE, BENZONATATE
- THE PHARMANETWORK**
- * THE PHARMANETWORK LLC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
- THEPHARMANETWORK LLC**
- * THEPHARMANETWORK LLC
 BENZONATATE, BENZONATATE
 ISONIAZID, ISONIAZID
 NIMODIPINE, NIMODIPINE
 THERMAZENE, SILVER SULFADIAZINE
- THERATECHNOLOGIES**
- * THERATECHNOLOGIES INC
 EGRIFTA, TESAMORELIN ACETATE
- THERAVANCE BIOPHARMA**
- * THERAVANCE BIOPHARMA R AND D INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* THERAVANCE BIOPHARMA R AND D INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

TOLMAR

* TOLMAR INC
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM , DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT PHARMA INC

* TORRENT PHARMA INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN

* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TORRENT PHARMACEUTICALS LTD
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FELODIPINE, FELODIPINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 VALSARTAN, VALSARTAN

TRIS PHARMA INC

* TRIS PHARMA INC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DYANAVAL XR, AMPHETAMINE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 KARBINAL ER, CARBINOXAMINE MALEATE
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TWI PHARMS INC

* TWI PHARMACEUTICALS INC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TWI PHARMACEUTICALS INC
 MEGESTROL ACETATE, MEGESTROL ACETATE
 NIFEDIPINE, NIFEDIPINE

**** U ******UCB INC**

* UCB INC
 BRIVIACT, BRIVARACETAM
 KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEUPRO, ROTIGOTINE
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 VIMPAT, LACOSAMIDE
 ZAROXOLYN, METOLAZONE

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RADIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNICHEM

* UNICHEM LABORATORIES LTD
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MELOXICAM, MELOXICAM
 ZALEPLON, ZALEPLON

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

* UNICHEM LABORATORIES LTD
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PIROXICAM, PIROXICAM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)

* UNICHEM PHARMACEUTICALS (USA) INC
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******UNIQUE PHARM LABS**

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FLUCONAZOLE, FLUCONAZOLE
 GLIPIZIDE, GLIPIZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
 RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
 ORENITRAM, TREPROSTINIL DIOLAMINE
 REMODULIN, TREPROSTINIL
 TYVASO, TREPROSTINIL

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV NORTH DAKOTA

* UNIV NORTH DAKOTA
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER-SMITH LABS

* UPSHER-SMITH LABORATORIES LLC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 EXEMESTANE, EXEMESTANE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 Klor-CON M10, POTASSIUM CHLORIDE
 Klor-CON M15, POTASSIUM CHLORIDE
 Klor-CON M20, POTASSIUM CHLORIDE
 Klor-CON, POTASSIUM CHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OXANDROLONE, OXANDROLONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PACERONE, AMIODARONE HYDROCHLORIDE
 PENTOXIL, PENTOXIFYLLINE
 PREVALITE, CHOLESTYRAMINE
 QUDEXY XR, TOPIRAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UPSHER-SMITH LABORATORIES LLC
 SORINE, SOTALOL HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 VOGELXO, TESTOSTERONE

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
 CLAFORAN, CEFOTAXIME SODIUM
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DRISDOL, ERGOCALCIFEROL
 HIPREX, METHENAMINE HIPPURATE
 LASIX, FUROSEMIDE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 LOPRESSOR, METOPROLOL TARTRATE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
 APOKYN, APOMORPHINE HYDROCHLORIDE
 REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC

* US WORLDMEDS LLC
 CORGARD, NADOLOL
 XADAGO, SAFINAMIDE MESYLATE

USL PHARMA

* USL PHARMA LLC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 FLUOXYMESTERONE, FLUOXYMESTERONE
 JANTOVEN, WARFARIN SODIUM

USPHARMA

* USPHARMA LTD
 NITRO-DUR, NITROGLYCERIN

USV NORTH AMERICA

* USV NORTH AMERICA INC
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ******VALEANT**

* VALEANT PHARMACEUTICALS INTERNATIONAL
 ANCOBON, FLUCYTOSINE
 BONTRIL PDM, PHENDIMETRAZINE TARTRATE
 D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
 BENZACLIN, BENZOYL PEROXIDE
 DERMATOP E EMOLLIENT, PREDNICARBATE
 ELIDEL, PIMECROLIMUS
 PENLAC, CICLOPIROX
 RETIN-A, TRETINOIN
 XERESE, ACYCLOVIR
 ZOVIRAX, ACYCLOVIR

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
 ATIVAN, LORAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

- * VALEANT INTERNATIONAL BARBADOS SRL
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
VASERETIC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
- * VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE
- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
MINITRAN, NITROGLYCERIN
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC

- * VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

VALEANT PHARMS INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
GIAZO, BALSALAZIDE DISODIUM
UCERIS, BUDESONIDE

VALEANT PHARMS LLC

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
IPRIVASK, DESIRUDIN RECOMBINANT
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
MINITRAN, NITROGLYCERIN
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******* VALEANT PHARMACEUTICALS NORTH AMERICA LLC**

RETIN-A, TRETINOIN
 SECONAL SODIUM, SECOBARBITAL SODIUM
 TIAZAC, DILTIAZEM HYDROCHLORIDE
 VASOTEC, ENALAPRIL MALEATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 XENAZINE, TETRABENAZINE

VALIDUS PHARMS*** VALIDUS PHARMACEUTICALS LLC**

BUMEX, BUMETANIDE
 EQUETRO, CARBAMAZEPINE
 NIFEDIPINE, NIFEDIPINE
 ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC*** VALIDUS PHARMACEUTICALS INC**

MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC*** VANDA PHARMACEUTICALS INC**

FANAPT, ILOPERIDONE
 HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC*** VELOXIS PHARMACEUTICALS INC**

ENVARUS XR, TACROLIMUS

VERNALIS R AND D LTD*** VERNALIS R AND D LTD**

MOXATAG, AMOXICILLIN
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

VEROSCIENCE*** VEROSCIENCE LLC**

CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS*** VERTEX PHARMACEUTICALS INC**

KALYDECO, IVACAFTOR

VERTEX PHARMS INC*** VERTEX PHARMACEUTICALS INC**

KALYDECO, IVACAFTOR
 ORKAMBI, IVACAFTOR

VERTICAL PHARMS LLC*** VERTICAL PHARMACEUTICALS LLC**

DIVIGEL, ESTRADIOL

VIB*** VALEANT INTERNATIONAL BERMUDA**

ZOVIRAX, ACYCLOVIR

VICURON*** VICURON PHARMACEUTICALS INC**

ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS*** VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE**

VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE*** VIIV HEALTHCARE CO**

COMBIVIR, LAMIVUDINE
 EPIVIR, LAMIVUDINE
 EPZICOM, ABACAVIR SULFATE
 JULUCA, DOLUTEGRAVIR SODIUM
 LEXIVA, FOSAMPRENAVIR CALCIUM
 RESCRIPTOR, DELAVIRDINE MESYLATE
 RETROVIR, ZIDOVUDINE
 SELZENTRY, MARAVIROC
 TIVICAY, DOLUTEGRAVIR SODIUM
 TRIUMEQ, ABACAVIR SULFATE
 TRIZIVIR, ABACAVIR SULFATE
 ZIAGEN, ABACAVIR SULFATE

VINTAGE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VINTAGE PHARMACEUTICALS LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 RISPERIDONE, RISPERIDONE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
 ALPRAZOLAM, ALPRAZOLAM
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 GILDAGIA, ETHINYL ESTRADIOL
 GILDESS 24 FE, ETHINYL ESTRADIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 KIMIDESS, DESOGESTREL
 LEVETIRACETAM, LEVETIRACETAM
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CARISOPRODOL, CARISOPRODOL
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VINTAGE PHARMACEUTICALS INC
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SULFASALAZINE, SULFASALAZINE
 TORSEMIDE, TORSEMIDE

VINTAGE PHARMS LLC

* VINTAGE PHARMACEUTICALS LLC
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 DUTASTERIDE, DUTASTERIDE
 EMOQUETTE, DESOGESTREL
 FELODIPINE, FELODIPINE
 GILDESS 1.5/30, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 LETROZOLE, LETROZOLE
 MEFENAMIC ACID, MEFENAMIC ACID
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYZILRA, ETHINYL ESTRADIOL
 ORSYTHIA, ETHINYL ESTRADIOL
 PERCOCET, ACETAMINOPHEN
 PREVIFEM, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

VIRTUS PHARM

* VIRTUS PHARMACEUTICAL INC
 ACARBOSE, ACARBOSE

VIRTUS PHARMS

* VIRTUS PHARMACEUTICALS LLC
 DAPSONE, DAPSONE
 LEVETIRACETAM, LEVETIRACETAM
 PROMETRIUM, PROGESTERONE
 TRANEXAMIC ACID, TRANEXAMIC ACID

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LACTULOSE, LACTULOSE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PREDNISOLONE, PREDNISOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VISTAPHARM INC
VALPROIC ACID, VALPROIC ACID

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS LLC
LIDOCAINE, LIDOCAINE

VIVA HLTHCARE

* VIVA HEALTHCARE FZ LLC
GLIMEPIRIDE, GLIMEPIRIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
SIMVASTATIN, SIMVASTATIN
TRANEXAMIC ACID, TRANEXAMIC ACID

VIVIMED GLOBAL

* VIVIMED GLOBAL GENERICS PTE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METRONIDAZOLE, METRONIDAZOLE

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WARNER CHILCOTT LLC

* WARNER CHILCOTT CO LLC
CHOLEDYL SA, OXTRIPHYLLINE

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WATSON LABORATORIES INC
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEPROBAMATE, MEPROBAMATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLDOPA, METHYLDOPA
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MIRTAZAPINE, MIRTAZAPINE
 NABUMETONE, NABUMETONE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NATEGLINIDE, NATEGLINIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TELMISARTAN, TELMISARTAN
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- * WATSON LABS INC
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

- * WATSON LABORATORIES INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 PERPHENAZINE, PERPHENAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN

WATSON LABS TEVA*** WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC**

AFEDITAB CR, NIFEDIPINE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 BICALUTAMIDE, BICALUTAMIDE
 EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 GLIPIZIDE, GLIPIZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ISRADIPINE, ISRADIPINE
 LEVOFLOXACIN, LEVOFLOXACIN
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PROBENECID, PROBENECID
 SIMVASTATIN, SIMVASTATIN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON PHARMS INC*** WATSON PHARMACEUTICALS INC**

TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WATSON PHARMS TEVA*** WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC**

RIFAMPIN, RIFAMPIN

WELLSTAT THERAP*** WELLSTAT THERAPEUTICS CORP**

VISTOGARD, URIDINE TRIACETATE
 XURIDEN, URIDINE TRIACETATE

WES PHARMA INC*** WES PHARMA INC**

HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WEST WARD PHARM CORP*** WEST WARD PHARMACEUTICAL CORP**

PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARM CORP*** WEST-WARD PHARMACEUTICAL CORP**

CEFOTETAN, CEFOTETAN DISODIUM

WEST-WARD PHARMS INT*** WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD**

ACARBOSE, ACARBOSE
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMRINONE LACTATE, INAMRINONE LACTATE
 ANASTROZOLE, ANASTROZOLE
 ATIVAN, LORAZEPAM
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAFKIT, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CARBOPLATIN, CARBOPLATIN
 CEFOXITIN, CEFOXITIN SODIUM
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 CISPLATIN, CISPLATIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLADRIBINE, CLADRIBINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CODEINE SULFATE, CODEINE SULFATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYCLOSPORINE, CYCLOSPORINE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE, DEXAMETHASONE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DISULFIRAM, DISULFIRAM
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DURAMORPH PF, MORPHINE SULFATE
 DUTASTERIDE, DUTASTERIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 EXEMESTANE, EXEMESTANE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 INFUMORPH, MORPHINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LORAZEPAM INTENSOL, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOSTATIN, PENTOSTATIN
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROBAXIN, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET, ACETAMINOPHEN
RUFINAMIDE, RUFINAMIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 TINIDAZOLE, TINIDAZOLE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
 CARISOPRODOL, CARISOPRODOL
 PERPHENAZINE, PERPHENAZINE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

WINDLAS HLTHCARE

* WINDLAS HEALTHCARE PVT LTD
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE

WOCKHARDT

* WOCKHARDT EU OPERATIONS (SWISS) AG
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 LINDANE, LINDANE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

* WOCKHARDT LTD
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL, LISINAPRIL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT LTD**

ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

WOCKHARDT BIO AG*** WOCKHARDT BIO AG**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXAMETHASONE, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 GENERLAC, LACTULOSE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID

WOCKHARDT EU OPERATN*** WOCKHARDT EU OPERATIONS SWISS AG**

PHENYTOIN, PHENYTOIN

WOCKHARDT LTD*** WOCKHARDT LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WOCKHARDT LTD
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENTACAPONE, ENTACAPONE
 FAMOTIDINE, FAMOTIDINE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

* WOCKHARDT USA INC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 * WOCKHARDT USA LLC
 LANSOPRAZOLE, LANSOPRAZOLE

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC

* WRASER PHARMACEUTICALS LLC
 TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON

* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS INC

* WYETH PHARMACEUTICALS INC
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTONIX, PANTOPRAZOLE SODIUM
 TRECATOR, ETHIONAMIDE
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 ZOSYN, PIPERACILLIN SODIUM

WYETH PHARMS PFIZER

* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
 DUAVEE, BAZEDOXIFENE ACETATE

**** X ******X GEN PHARMS**

* X GEN PHARMACEUTICALS INC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 AMPHOTERICIN B, AMPHOTERICIN B
 BACIIM, BACITRACIN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NYSTATIN, NYSTATIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ******X-GEN PHARMS INC**

- * X-GEN PHARMACEUTICALS INC
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

- * XELLIA PHARMACEUTICALS APS
BACITRACIN, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

XIAMEN LP PHARM CO

- * XIAMEN LP PHARMACEUTICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

XSPIRE PHARMA

- * XSPIRE PHARMA
NALFON, FENOPROFEN CALCIUM
- * XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

- * XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**** Y ******YABAO PHARM**

- * YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YAOPHARMA CO LTD

- * YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YUNG SHIN PHARM

- * YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACTOR, CEFACOLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** Z ******ZAMBON SPA**

- * ZAMBON SPA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
- * ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZEVACOR PHARMA INC

- * ZEVACOR PHARMA INC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ZHEJIANG HISUN PHARM

- * ZHEJIANG HISUN PHARMACEUTICAL CO LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZO SKIN HEALTH

- * ZO SKIN HEALTH
TRETINOIN, TRETINOIN

ZYDUS HLTHCARE

- * ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS HEALTHCARE USA LLC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 AZATHIOPRINE, AZATHIOPRINE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 LAMOTRIGINE, LAMOTRIGINE
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ACYCLOVIR, ACYCLOVIR
 ALLOPURINOL, ALLOPURINOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARVEDILOL, CARVEDILOL
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESOXIMETASONE, DESOXIMETASONE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FELBAMATE, FELBAMATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE, OMEPRAZOLE
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZYPITAMAG, PITAVASTATIN MAGNESIUM

ZYDUS WORLDWIDE

* ZYDUS WORLDWIDE DMCC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

38TH EDITION - 2018 - APPROVED DRUG PRODUCTS LIST

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL, FOAM	OINTMENT, AUGMENTED
AEROSOL, METERED	PASTE
CAPSULE	PATCH
CAPSULE, DELAYED REL PELLETS	PELLET
CAPSULE, DELAYED RELEASE	POWDER
CAPSULE, EXTENDED RELEASE	POWDER, EXTENDED RELEASE
CAPSULE, PELLET	POWDER, METERED
CLOTH	RING
CONCENTRATE	SHAMPOO
CREAM	SOLUTION
CREAM, AUGMENTED	SOLUTION FOR SLUSH
ELIXIR	SOLUTION, EXTENDED RELEASE
EMULSION	SOLUTION, GEL FORMING/DROPS
ENEMA	SOLUTION, METERED
FILM	SOLUTION/DROPS
FILM, EXTENDED RELEASE	SPONGE
FOR SOLUTION	SPRAY
FOR SUSPENSION	SPRAY, METERED
FOR SUSPENSION, DELAYED RELEASE	SUPPOSITORY
FOR SUSPENSION, EXTENDED RELEASE	SUSPENSION
GAS	SUSPENSION, EXTENDED RELEASE
GEL	SUSPENSION/DROPS
GEL, AUGMENTED	SWAB
GEL, METERED	SYRUP
GRANULE	SYSTEM
GRANULE, DELAYED RELEASE	SYSTEM, EXTENDED RELEASE
GUM, CHEWING	TABLET
IMPLANT	TABLET, CHEWABLE
INHALANT	TABLET, COATED PARTICLES
INJECTABLE	TABLET, DELAYED RELEASE
INJECTABLE, LIPID COMPLEX	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INJECTABLE, LIPOSOMAL	TABLET, EFFERVESCENT
INJECTION, EXTENDED RELEASE	TABLET, EXTENDED RELEASE
INSERT	TABLET, EXTENDED RELEASE, CHEWABLE
INSERT, EXTENDED RELEASE	TABLET, FOR SUSPENSION
INTRAUTERINE DEVICE	TABLET, ORALLY DISINTEGRATING
JELLY	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
LIQUID	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
LOTION	TAPE
LOTION, AUGMENTED	TROCHE/LOZENGE
LOTION/SHAMPOO	
OIL	
OIL/DROPS	
OINTMENT	

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
ENDOTRACHEL	NASAL
FOR RX COMPOUNDING	OPHTHALMIC
IMPLANTATION	ORAL
INHALATION	ORAL-21
INJECTION	ORAL-28
INTRA-ANAL	OTIC
INTRACRANIAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVITREAL	VAGINAL
IONTOPHORESIS	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information concerning the listed drug products.

Exclusivity

During relevant exclusivity periods, certain abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the FD&C Act (505(b)(2) applications) may not be submitted or approved as described below. This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for periods of exclusivity. This *Addendum* also identifies those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act, and those drugs that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. Please note that beginning with the publication of the 38th edition of the Orange Book, individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. In previous editions of the Orange Book, Orphan Drug Exclusivity was not described with any specificity.

The exclusivities identified in the *Addendum* do not prevent the submission or approval of an application submitted pursuant to Section 505(b)(1) of the FD&C Act that would otherwise be blocked if it had been submitted pursuant to Section 505(b)(2) or 505(j), except in the case of Orphan Drug Exclusivity. Drugs that may qualify for periods of exclusivity include:

- (1) A new chemical entity, submitted in a new drug application under Section 505(b) of the FD&C Act and approved after September 24, 1984. A new chemical entity is an active ingredient that contains "no active ingredient (including any ester or salt of the active ingredient)" that has been approved by FDA in any other application submitted under Section 505(b) of the FD&C Act. No subsequent ANDA or 505(b)(2) application for a drug that contains the same active moiety may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. See Sections 505(j)(5)(F)(ii) and 505(c)(3)(E)(ii) of the FD&C Act.
- (2) A new drug application approved after September 24, 1984, for a drug product containing "an active ingredient (including any ester or salt of

the active ingredient)" that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, a subsequent ANDA or a 505(b)(2) application may not be approved for the exclusivity-protected "conditions of approval of such drug" before the expiration of *three years* from the date of approval of the original application. If an NDA has exclusivity only for a new indication or use, this exclusivity generally does not preclude the approval of an ANDA or 505(b)(2) application for indications and uses not covered by the exclusivity, assuming the proposed drug product will be safe and effective as labeled. See Sections 505(j)(5)(F)(iii) and 505(c)(3)(E)(iii) of the FD&C Act.

- (3) A supplement to a new drug application for a drug containing a previously approved "active ingredient (including any ester or salt of the active ingredient)" approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. A subsequent ANDA or 505(b)(2) application may not be approved for an exclusivity-protected change approved in the supplement for *three years* from the date of approval of the supplement. See Sections 505(j)(5)(F)(iv) and 505(c)(3)(E)(iv) of the FD&C Act.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using Form FDA 3542a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of the date of approval on Form FDA 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement."¹ In November 2017, the Agency began including in the [Orange Book](#) the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent. Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. Form FDA 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; method-of-use patents that claim one or more approved methods of using the approved drug product; and certain other patents as detailed on

¹ Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see section 505(x)(1) and (2) of the FD&C Act).

Form FDA 3542.² This information, as provided by the sponsor on Form FDA 3542, will be published as described above. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under Section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act).

Upon approval of an NDA, patent numbers and expiration dates for patent information submitted to FDA on Form FDA 3542 will be published daily in the [Orange Book](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

² See 21 CFR 314.53(c)(2)(ii)(M), (N)(2) and (N)(3).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107	001				PC	Mar 14, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977	001	6294540	May 14, 2018	DS DP U-65		
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978	001	6294540	May 14, 2018	DS DP U-65		
		6641843	Feb 04, 2019	DP		
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551	001	6294540	May 14, 2018	DS DP U-1572	NCE	Aug 12, 2018
		6294540*PED	Nov 14, 2018			
		8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652	001	6294540	May 14, 2018	DS DP U-257		
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205	001	6294540	May 14, 2018	DS DP U-65		
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743	001	7803770	Mar 26, 2028	U-2009	NCE	Apr 28, 2022
		8148333	Nov 08, 2027	DP		
		8748382	Oct 03, 2027	U-2009		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	004	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001	8822438	Aug 24, 2027	U-1579		
		8822438	Aug 24, 2027	U-1580		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	002	8822438	Aug 24, 2027	U-1579		
		8822438	Aug 24, 2027	U-1580		
<u>ACALABRUTINIB - CALOQUENCE</u>						
N 210259	001	9290504	Jul 11, 2032	DS DP	NCE	Oct 31, 2022
		9758524	Jul 11, 2032	U-2145		
		9796721	Jul 01, 2036	DS DP U-2145		
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001	6028222	Aug 05, 2017	DP	M-196	Jan 27, 2020
		6028222*PED	Feb 05, 2018		PED	Jul 27, 2020
		6992218	Jun 06, 2021	DP		
		6992218*PED	Dec 06, 2021			
		9399012	Sep 11, 2031	U-1882		
		9399012*PED	Mar 11, 2032			
		9610265	Nov 13, 2028	U-2000		
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802	001	5972916	Jul 14, 2017	U-296		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001	6488962	Jun 20, 2020	DP		
		7976870	Jun 01, 2027	U-1498		
		8372432	Mar 11, 2029	DP U-1499		
		8377453	Nov 19, 2029	DP U-1499		
		8394408	Mar 11, 2029	DP		
		8597681	Dec 21, 2030	DP		
		8658631	May 16, 2032	DP		
		8668929	Mar 11, 2029	U-1499		
		8741885	May 16, 2032	DP U-1499		
		8980319	Dec 21, 2030	DP		
		8992975	May 16, 2032	DP		
		9050335	May 16, 2032	DP		
		9468636	May 16, 2032	U-1499		
<u>ACETYL CYSTEINE - ACETADOTE</u>						
N 021539	001	8148356	May 21, 2026	DP		
		8399445	Aug 24, 2025	U-1373		
		8653061	Aug 24, 2025	U-1373		
		8722738	Apr 06, 2032	U-1373		
		9327028	Jul 21, 2031	U-1839		
<u>ACETYL CYSTEINE - CETYLEV</u>						
N 207916	001	8747894	May 08, 2032	DP U-1373		
		9427421	May 08, 2032	DP		
		9561204	May 08, 2032	U-1373		
<u>ACETYL CYSTEINE - CETYLEV</u>						
N 207916	002	8747894	May 08, 2032	DP U-1373		
		9427421	May 08, 2032	DP		
		9561204	May 08, 2032	U-1373		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	6681768	Aug 07, 2022	DP		
		7078412	Jul 16, 2020	DS DP U-1263		
		8051851	Apr 22, 2027	DP		
		9056100	Jul 07, 2020	DP U-1263		
		9333195	Jul 07, 2020	DP U-1263		
		RE46417	Sep 05, 2020	DS DP U-1263		
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	8592434	Jun 16, 2030	DP U-1460		
		8747896	Jun 03, 2027	DP U-1460		
		8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	6514980	Jul 24, 2018	DP U-1006		
		6514980	Jul 24, 2018	DP U-1484		
		7223387	Nov 13, 2022	DP U-1006		
		7223387	Nov 13, 2022	DP U-1484		
<u>ADAPALENE - DIFFERIN</u>						
N 020380	002				RTO	Jul 08, 2019
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	7579377	Feb 23, 2025	U-818		
		7737181	Aug 29, 2024	DP		
		7834060	Mar 12, 2023	U-1078		
		7838558	Mar 12, 2023	DP		
		7868044	Mar 12, 2023	U-1078		
		8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	7998467	May 31, 2028	DP U-1078		
		8435502	Sep 15, 2026	DP U-1078		
		8709392	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790	001				PC	Jan 23, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	7820186	Nov 23, 2025	DP		
		7964202	Sep 01, 2024	DP U-1078		
		8071644	Jul 18, 2027	DP U-1078		
		8080537	Jul 18, 2027	U-1078		
		8105618	Dec 23, 2022	U-1078		
		8129362	Jul 18, 2027	U-1078		
		8241649	Dec 23, 2022	DP		
		8445543	Jul 12, 2027	U-1078		
		8809305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001	8445543	Dec 23, 2022	U-1078	NP	Jul 15, 2018
		8703820	Mar 12, 2023	U-1078		
		8729127	Mar 12, 2023	U-1078		
		8785420	Dec 23, 2022	U-1078		
		8809305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
		9381179	Mar 12, 2023	U-1078		
		9387187	Mar 12, 2023	U-1078		
		9814690	Dec 23, 2022	DP U-1078		
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N 021449	001	6451340	Jul 23, 2018	DS DP U-470		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS	ODE-115	Apr 15, 2023
		8545884	Dec 19, 2029	DP	ODE-50	Jul 12, 2020
		9539258	Nov 09, 2026	U-1950		
		RE43431	Jan 22, 2022	DS		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS	ODE-115	Apr 15, 2023
		8545884	Dec 19, 2029	DP	ODE-50	Jul 12, 2020
		9539258	Nov 09, 2026	U-1950		
		RE43431	Jan 22, 2022	DS		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003	6251912	Jul 29, 2018	DS DP U-1067	I-730	Apr 15, 2019
		8426586	Oct 10, 2029	DS	NCE	Jul 12, 2018
		8545884	Dec 19, 2029	DP	ODE-115	Apr 15, 2023
		9539258	Nov 09, 2026	U-1950	ODE-50	Jul 12, 2020
		RE43431	Jan 22, 2022	DS		
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899	001	6723303	Apr 20, 2021	DP		
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949	001	6702997	Dec 28, 2021	U-558		
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949	002	6702997	Dec 28, 2021	U-558		
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001 7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001 6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001 6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP		NPP	Apr 28, 2019
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950	001 6632842	Dec 28, 2021		U-532		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001 6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134	001 8664215	Dec 23, 2027		U-1493		
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001 9126931	May 29, 2031	DS		I-756	Nov 06, 2020
	9365514	Mar 04, 2032	DP		NCE	Dec 11, 2020
	9440922	Jun 09, 2030	DP		ODE	Nov 06, 2024
					ODE-105	Dec 11, 2022
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575	001 5994329	Jul 17, 2018			Y	
	6015801	Jul 17, 2018			Y	
	6225294	Jul 17, 2018			Y	
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344	001 7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762	001 5994329	Jul 17, 2018		U-647	Y	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287	001 6149940	Aug 22, 2017				
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985	001 5559111	Jul 21, 2018	DS DP	U-3		
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985	002	5559111	Jul 21, 2018	DS DP U-3		
		5559111*PED	Jan 21, 2019			
		8617595	Feb 19, 2026	DP		
		8617595*PED	Aug 19, 2026			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 210709	001				NP PED	Nov 14, 2020 May 14, 2021
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	004	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	005	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	001	5559111	Jul 21, 2018	DS DP U-3		
		5559111*PED	Jan 21, 2019			
		8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	002	5559111	Jul 21, 2018	DS DP U-3		
		5559111*PED	Jan 21, 2019			
		8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	003	5559111	Jul 21, 2018	DS DP U-3		
		5559111*PED	Jan 21, 2019			
		8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	004	5559111	Jul 21, 2018	DS DP U-3		
		5559111*PED	Jan 21, 2019			
		8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	001	5559111	Jul 21, 2018	DS DP U-3		
		8168616	Jul 03, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	002	5559111	Jul 21, 2018	DS DP U-3		
		8168616	Jul 03, 2026	DP		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029		U-2104	
		8283369	Nov 26, 2028		U-2104	
		8357713	Nov 26, 2028	DP	U-2104	
		8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029		U-2104	
		9216179	Aug 01, 2031		U-2104	
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002	8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029		U-2104	
		8283369	Nov 26, 2028		U-2104	
		8357713	Nov 26, 2028	DP	U-2104	
		8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029		U-2104	
		9216179	Aug 01, 2031		U-2104	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001	6890898	Feb 02, 2019		U-1335	M-177
		7078381	Feb 02, 2019		U-1335	NCE
		7459428	Feb 02, 2019		U-1336	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	002	6890898	Feb 02, 2019		U-1335	M-177
		7078381	Feb 02, 2019		U-1335	NCE
		7459428	Feb 02, 2019		U-1336	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	003	6890898	Feb 02, 2019		U-1335	M-177
		7078381	Feb 02, 2019		U-1335	NCE
		7459428	Feb 02, 2019		U-1336	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001	6890898	Feb 02, 2019		U-1335	M-177
		7078381	Feb 02, 2019		U-1335	NCE
		7459428	Feb 02, 2019		U-1336	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002	6890898	Feb 02, 2019	U-1335	M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001	6329404	Jun 19, 2021	DP U-1334	M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002	6329404	Jun 19, 2021	DP U-1334	M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003	6329404	Jun 19, 2021	DP U-1334	M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004	6329404	Jun 19, 2021	DP U-1334	M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005	6329404	Jun 19, 2021	DP U-1334	M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006	6890898	Feb 02, 2019	U-1335	M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335	NCE	Jan 25, 2018
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726	003	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726	004	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>ALVIMOPAN - ENTEREG</u>						
N 021775	001	6469030	Nov 29, 2020	U-879		
		8112290	Jul 31, 2030	U-1443	Y	
		8645160	Jun 18, 2029	U-1485	Y	
		8946262	Feb 12, 2030	U-1655		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	001	8389578	Jan 22, 2028	U-2105	NP	Aug 24, 2020
		8741343	Dec 02, 2030	U-2106	ODE-153	Aug 24, 2024
		8796337	Nov 23, 2025	U-2106		
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025	U-2106		
		8895616	Nov 23, 2025	U-2106		
		8895617	Nov 23, 2025	U-2106		
		8895618	Nov 23, 2025	DP		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	002	8389578	Jan 22, 2028	U-2105	NP	Aug 24, 2020
		8741343	Dec 02, 2030	U-2106	ODE	Aug 24, 2024
		8796337	Nov 23, 2025	U-2106		
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025	U-2106		
		8895616	Nov 23, 2025	U-2106		
		8895617	Nov 23, 2025	U-2106		
		8895618	Nov 23, 2025	DP		
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081	001	8377933	Dec 11, 2027	U-1754	I-716	Oct 02, 2018
		9474752	Dec 11, 2027	U-1754		
		9549926	Oct 14, 2031	U-1965		
		RE42462	Jul 29, 2018	DS		
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081	002	8377933	Dec 11, 2027	U-1754	I-716	Oct 02, 2018
		9474752	Dec 11, 2027	U-1754		
		9549926	Oct 14, 2031	U-1965		
		RE42462	Jul 29, 2018	DS		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	001	5994409	Dec 08, 2017	U-305		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	002	5994409	Dec 08, 2017	U-305		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965	001	5954703	Oct 31, 2017	U-289		
		6709446	May 01, 2018	U-289		
		7723910	Jun 17, 2019	U-289		
		8216289	May 01, 2018	U-289		
		8758418	May 01, 2018	U-289		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001 6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630	001				ODE-146	Jun 06, 2024
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	001 6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	002 6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	003 6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	001 6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	002 6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	003 6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	001 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	002 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	003 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	004 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	005 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	006 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	007 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	008 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	009 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	010 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	011 6455574	Aug 11, 2018		U-552		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	002 6162802	Dec 19, 2017		U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	003 6162802	Dec 19, 2017		U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	004 6162802	Dec 19, 2017		U-367		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	005	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	006	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	007	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001	6696481	Apr 15, 2023	DS DP U-3	NP	Jan 21, 2018
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002	6696481	Apr 15, 2023	DS DP U-3	NP	Jan 21, 2018
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003	6696481	Apr 15, 2023	DS DP U-3	NP	Jan 21, 2018
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	002	6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	003	6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	004	6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	005	6395728	Jul 08, 2019	DP		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	6544555	Oct 13, 2020	DS DP U-897		
		6669948	Oct 13, 2020	DS DP U-897		
		6723341	Oct 13, 2020	DS DP U-897		
		8299052	May 07, 2027	U-1304		
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020	U-926		
		7217430	Apr 04, 2020	DP U-926		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001 7250176	Apr 04, 2020	U-926			
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325	001 8709491	Jun 28, 2032	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006 8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147	001 8062667	Mar 29, 2029	DP		NP	Oct 19, 2018
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522	007 6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522	008 6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522	009 6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522	010 6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522	011 6384020	Jul 06, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522	012	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522	013	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303	001	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303	002	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303	003	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303	004	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303	005	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303	006	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	001	6913768	May 24, 2023	DP U-2025	NP	Jun 20, 2020
		8846100	Aug 24, 2029	DP		
		9173857	May 12, 2026	U-2025		
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	002	6913768	May 24, 2023	DP U-2025	NP	Jun 20, 2020
		8846100	Aug 24, 2029	DP		
		9173857	May 12, 2026	U-2025		
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	003	6913768	May 24, 2023	DP U-2025	NP	Jun 20, 2020
		8846100	Aug 24, 2029	DP		
		9173857	May 12, 2026	U-2025		
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	003 RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	004 6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724	001 6406713	Jun 18, 2019	DS			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007	001 6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007	002 6730679	Nov 11, 2017	DP			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632	001 5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632	002 5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>APIXABAN - ELIQUIS</u>						
N 202155	001 6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-691	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		NCE	Dec 28, 2017
	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155	002 6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-691	Aug 21, 2017
	6967208	Nov 21, 2026	DS DP U-1200		NCE	Dec 28, 2017
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437	001 6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437	002	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
<u>APREMILAST - OTEZLA</u>						
N 205437	003	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
<u>APREPITANT - EMEND</u>						
N 021549	001	6096742	Jul 01, 2018	DS DP U-1743	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1744		
		6096742	Jul 01, 2018	DS DP U-745		
		8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 021549	002	6096742	Jul 01, 2018	DS DP U-1743	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1744		
		6096742	Jul 01, 2018	DS DP U-745		
		8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 021549	003	6096742	Jul 01, 2018	DS DP U-1743	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1744		
		6096742	Jul 01, 2018	DS DP U-745		
		8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 207865	001	6096742	Jul 01, 2018	DS DP U-1916	NPP	Aug 28, 2018
		8258132	Sep 26, 2027	DP U-1916		
<u>APREPITANT - CINVANTI</u>						
N 209296	001	9561229	Sep 18, 2035	DP U-2161		
		9808465	Sep 18, 2035	U-2161		
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912	001	6472563	Nov 09, 2021	DS		
		6667344	Jun 22, 2021	DP		
		6720453	Nov 09, 2021	DS		
		6814953	Jun 22, 2021	U-793		
		7145036	Nov 09, 2021	DS		
		7348362	Jun 22, 2021	DP U-793		
		7462645	Jun 22, 2021	U-793		
		7465756	Jun 22, 2021	DP		
		7473710	Jun 22, 2021	U-793		
		7541385	Jun 22, 2021	U-793		
		8110706	Nov 09, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434	001	7589106	Sep 26, 2027	DP U-1163		
		7687516	Sep 26, 2027	DP U-1164		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	001	7053092	Jan 28, 2022	U-839	I-700	Dec 12, 2017
		8017615	Jun 16, 2024	DP	ODE-80	Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9359302	Sep 25, 2022	DS DP U-1859		
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	002	7053092	Jan 28, 2022	U-839	I-700	Dec 12, 2017
		8017615	Jun 16, 2024	DP	ODE-80	Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9359302	Sep 25, 2022	DS DP U-1859		
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	003	7053092	Jan 28, 2022	U-839	I-700	Dec 12, 2017
		8017615	Jun 16, 2024	DP	ODE-80	Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9359302	Sep 25, 2022	DS DP U-1859		
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	004	7053092	Jan 28, 2022	U-839	I-700	Dec 12, 2017
		8017615	Jun 16, 2024	DP	ODE-80	Dec 12, 2021
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9359302	Sep 25, 2022	DS DP U-1859		
		9387182	Dec 25, 2023	U-1529		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	6977257	Apr 24, 2022		DP	I-700	Dec 12, 2017
	6977257*PED	Oct 24, 2022			ODE-80	Dec 12, 2021
	7053092	Jan 28, 2022		U-839		
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027		U-1529		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9358207	Apr 12, 2020		DP		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		ODE-80	Dec 12, 2021
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866 001	7115587	Jul 21, 2024	DP	U-764	I-700	Dec 12, 2017
	7115587*PED	Jan 21, 2025			ODE-80	Dec 12, 2021
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024		U-1632	M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338427	Mar 15, 2025	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024		U-1632	M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338427	Mar 15, 2025	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027		U-1529		
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022		U-543		
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026		U-1749		
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023		U-1529		
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027		U-1529		
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022		U-543		
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026		U-1749		
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023		U-1529		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027		U-1529		
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022		U-543		
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026		U-1749		
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023		U-1529		
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027		U-1529		
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022		U-543		
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026		U-1749		
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
	9526726	Mar 19, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030		U-543		
	9034867	Nov 07, 2032	DP	U-543		
	9193685	Oct 24, 2033	DP	U-543		
	9452131	Mar 19, 2035		U-543		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023		DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023		DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023		DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023		DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023		DP		
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018		U-573		
	6855339	Nov 10, 2018		U-617		
	6861076	Nov 10, 2018		U-617		
	6884439	Nov 10, 2018		U-651		
	6982096	Nov 10, 2018		U-651		
	8273379	Nov 10, 2018		U-1291		
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018		U-2204		
	6855339	Nov 10, 2018		U-2204		
	6861076	Nov 10, 2018		U-2204		
	6884439	Nov 10, 2018		U-2204		
	6982096	Nov 10, 2018		U-2204		
	8273379	Nov 10, 2018		U-2204		
<u>ASCORBIC ACID - ASCOR</u>						
N 209112 001					ODE	Oct 02, 2024
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020		DP U-1960	D-166	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1961	I-597	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1962	M-158	Mar 17, 2018
	5763476	Jun 09, 2020		DP U-1963	NPP	Mar 17, 2018
	5763476	Jun 09, 2020		DP U-326	PED	Sep 17, 2018
	5763476*PED	Dec 09, 2020			PED	Sep 17, 2018
	7741358	Apr 06, 2026	DS DP	U-1064		
	7741358	Apr 06, 2026	DS DP	U-1960		
	7741358	Apr 06, 2026	DS DP	U-1961		
	7741358	Apr 06, 2026	DS DP	U-1962		
	7741358	Apr 06, 2026	DS DP	U-1963		
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020		DP U-1960	D-166	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1961	I-597	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1962	M-158	Mar 17, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-1963		NPP	Mar 17, 2018
	5763476	Jun 09, 2020	DP U-326		PED	Sep 17, 2018
	5763476*PED	Dec 09, 2020			PED	Sep 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	8865187	Mar 23, 2022	DP			
	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 001					PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 002					PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 003					PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 004					PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	003	5849911*PED 6087383 6087383*PED	Dec 20, 2017 Dec 21, 2018 Jun 21, 2019	DS DP		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	004	5849911*PED 6087383 6087383*PED	Dec 20, 2017 Dec 21, 2018 Jun 21, 2019	DS DP		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352	001	5849911*PED 6087383 6087383*PED	Dec 20, 2017 Dec 21, 2018 Jun 21, 2019	DS DP	NPP PED	Sep 24, 2018 Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353	001	5849911*PED 6087383 6087383*PED 8148374	Dec 20, 2017 Dec 21, 2018 Jun 21, 2019 Sep 03, 2029	DS DP DS DP U-1279	NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	001				M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	002				M-204	Jun 23, 2020
<u>AVANAFIL - STENDRA</u>						
N 202276	001	6656935 7501409	Apr 27, 2025 May 05, 2023	DS DP U-155 DP	D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276	002	6656935 7501409	Apr 27, 2025 May 05, 2023	DS DP U-155 DP	D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276	003	6656935 7501409	Apr 27, 2025 May 05, 2023	DS DP U-155 DP	D-140	Sep 17, 2017
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	7112592 7612087 8178554 8471025 8835455 8969566 9284314 9695122	Feb 24, 2022 Nov 12, 2026 Jul 24, 2021 Aug 12, 2031 Oct 08, 2030 Jun 15, 2032 Jun 15, 2032 Jun 15, 2032	DS DP U-282 DP DS DP U-282 DS DP DS DS DS		
<u>AXITINIB - INLYTA</u>						
N 202324	001	6534524 7141581 8791140	Apr 29, 2025 Jun 30, 2020 Dec 14, 2030	DS DP U-1220 DS		
<u>AXITINIB - INLYTA</u>						
N 202324	002	6534524 7141581 8791140	Apr 29, 2025 Jun 30, 2020 Dec 14, 2030	DS DP U-1220 DS		
<u>AZELAIC ACID - FINACEA</u>						
N 021470	001	6534070	Nov 18, 2018			
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	6730288 7700076 8435498 8722021 8900554 9211259 9265725	Sep 08, 2019 Sep 18, 2027 Mar 01, 2024 Oct 24, 2023 Oct 24, 2023 Jan 26, 2029 Dec 08, 2027	DP DP U-1727 DP DP U-1796 DP	NP	Jul 29, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073	Jun 04, 2028	DP		NPP	Feb 20, 2018
	8518919	Nov 22, 2025	U-1430		NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-1667		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-644		PED	Aug 20, 2018
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-81			
	8163723*PED	Feb 29, 2024				
	8168620	Feb 24, 2026	DP			
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					PC	Mar 26, 2018
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784 001	6268489	Jul 31, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZMAX</u>						
N 050797	001	6268489	Jul 31, 2018	DS		
		6984403	Feb 14, 2024	DP U-282		
		7887844	Feb 14, 2024	DP		
<u>AZITHROMYCIN - AZASITE</u>						
N 050810	001	6159458	Nov 04, 2017	DP U-709		
		6239113	Mar 31, 2019	U-709		
		6569443	Mar 31, 2019	DP U-709		
		6861411	Nov 25, 2018	U-709		
		7056893	Mar 31, 2019	DP U-709		
<u>AZTREONAM - CAYSTON</u>						
N 050814	001	7208141	Dec 20, 2021	DP U-1031		
		7214364	Dec 20, 2021	DP		
		7427633	Dec 20, 2021	DP U-1031		
		8399496	Dec 20, 2021	DP U-1377		
<u>BACLOFEN - KEMSTRO</u>						
N 021589	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>BACLOFEN - KEMSTRO</u>						
N 021589	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610	001	7452872	Aug 24, 2026	U-141		
		7625884	Aug 24, 2026	U-141		
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205	001	6197341	Mar 13, 2018	DP U-1229		
		7452872	Aug 24, 2026	U-1229		
		7625884	Aug 24, 2026	U-1229		
		8497256	Jun 23, 2031	U-1229		
		9192616	Aug 02, 2026	U-1229		
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	5998402	Apr 04, 2018	DS DP U-594	NCE	Oct 13, 2018
		6479535	May 06, 2019	DP U-594		
		6479535	May 06, 2019	DP U-904		
		7683051	Mar 10, 2027	DS DP U-594		
		7683051	Mar 10, 2027	DS DP U-904		
		8815934	May 06, 2019	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911	001	6446627	Dec 18, 2017	DP		
		9463289	May 18, 2031	DP		
		9808587	May 18, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911	002	6446627	Dec 18, 2017	DP		
		9463289	May 18, 2031	DP		
		9808587	May 18, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	001	7780038	Jan 24, 2027	DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	002	7780038	Jan 24, 2027	DP	NS	Dec 17, 2017
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921	001	6446627	Dec 18, 2017	DP		
		7637260	Aug 25, 2020	DP		
		8132712	Sep 07, 2028	DP		
		8931476	Jul 17, 2031	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921	002	6446627	Dec 18, 2017	DP		
		7637260	Aug 25, 2020	DP		
		8132712	Sep 07, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921	002 8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001 7498343	Dec 01, 2026	DS DP U-1321		NCE	Dec 28, 2017
	8546428	Mar 19, 2029	DS DP U-1321		ODE-38	Dec 28, 2019
<u>BELINOSTAT - BELEODAO</u>						
N 206256	001 6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE-68	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001 8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	002 8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	003 8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	004 8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194	001 8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	8791270*PED	Jul 12, 2026				
	9000021	Mar 15, 2033		U-1542		
	9034908	Mar 15, 2033		U-1542		
	9144568	Mar 15, 2033		U-1542		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE ODE-154	Aug 29, 2022 Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					NCE ODE-154	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	8288434	Aug 05, 2029	DP U-1033			
	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	9504704	Jun 03, 2029	DP U-124			
	9504704	Jun 03, 2029	DP U-134			
	9504704	Jun 03, 2029	DP U-818			
	9504704	Jun 03, 2029	DP U-916			
	9561208	Jun 03, 2029	DP U-916			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129 001	5858383	Aug 11, 2017	U-970			
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
	9655907	Aug 31, 2030	DP U-1858			
	9775851	Aug 31, 2030	DP U-1858			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589	001	6753013	Jan 27, 2020	DP U-1761	NP	Oct 16, 2018
		9119781	Jun 10, 2031	DP U-1761		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852	001	6753013	Jan 27, 2020	DP U-193	NPP	Dec 23, 2017
		6753013	Jan 27, 2020	DP U-88		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185	001	6753013	Jan 27, 2020	DP U-1761	NPP	Aug 29, 2017
		6753013	Jan 27, 2020	DP U-193		
		6753013	Jan 27, 2020	DP U-88		
		6787529	Jan 27, 2020	DP U-1761		
		6787529	Jan 27, 2020	DP U-193		
		6787529	Jan 27, 2020	DP U-88		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BEXAROTENE - TARGRETIN</u>						
N 021055	001				M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	7851504	Jun 13, 2027	DS DP		
		8278353	Mar 16, 2025	DP		
		8299118	Mar 16, 2025	U-1295		
		8309605	Mar 16, 2025	U-1293		
		8309605	Mar 16, 2025	U-1294		
		8338479	Mar 16, 2025	DP U-1295		
		8524777	Mar 16, 2025	U-1235		
		8586630	Mar 16, 2025	U-1458		
		8772338	Mar 16, 2025	DP U-1528		
		8933120	Mar 16, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	8933127	Mar 16, 2025	DP		
		9155716	Mar 16, 2025	DP U-1528		
		9241918	Mar 16, 2025	DP U-1814		
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	8038988	Aug 25, 2023	DS DP U-1208	M-140	Sep 04, 2017
		8101161	May 25, 2024	U-1217		
		8101161	May 25, 2024	U-1218		
		8263054	Jan 15, 2023	U-1277		
		8541466	Jan 31, 2021	U-1217		
		8632760	Jan 15, 2023	U-1487		
		8758733	Jan 15, 2023	U-1487		
		8906962	Jan 31, 2021	U-1217		
		8986715	Jan 15, 2023	U-1217		
		9216183	Jan 15, 2023	U-1487		
		9226931	Jan 15, 2023	U-1799		
		9579270	Jan 31, 2021	U-1975		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551	003	7291324	Oct 22, 2022	U-837		
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786	001	6350468	Dec 14, 2018	U-932		
		6350468	Dec 14, 2018	U-956		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873	001	7582727	Jul 27, 2028	DP		
		7598343	Jul 27, 2028	DP		
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258	001	7772178	Nov 11, 2027	DP U-1128		
		8119602	Mar 17, 2027	U-1233		
		RE43298	Dec 22, 2024	DS DP U-1128		
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001	5780454*PED	Nov 03, 2017		D-141	Oct 08, 2017
		6713446	Jan 25, 2022	DS DP	D-142	Oct 08, 2017
		6713446*PED	Jul 25, 2022		I-695	Oct 08, 2017
		6958319	Jan 25, 2022	DS DP	M-139	Aug 08, 2017
		6958319*PED	Jul 25, 2022		M-165	Sep 14, 2018
					ODE-76	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004	001	8962572	Nov 03, 2032	DP		
<u>BOSENTAN - TRACLEER</u>						
N 021290	001				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290	002				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279	001	7959945	Dec 28, 2027	DP	NP	Sep 05, 2020
		8309126	May 15, 2026	DP	ODE	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001	6002008	Mar 27, 2018	DS DP U-1284	I-759	Dec 19, 2020
		7417148	Jan 23, 2026	U-1283	NCE	Sep 04, 2017
		7767678	Nov 23, 2026	DS DP	ODE-30	Sep 04, 2019
		7919625	Dec 11, 2025	DP		
		RE42376	Apr 13, 2024	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	6002008	Mar 27, 2018	DS DP U-1284		I-759	Dec 19, 2020
	7417148	Jan 23, 2026	U-1283		NCE	Sep 04, 2017
	7767678	Nov 23, 2026	DS DP		ODE-30	Sep 04, 2019
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	6002008	Mar 27, 2018	DS DP U-1284		I-759	Dec 19, 2020
	7417148	Jan 23, 2026	U-1283		ODE-30	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	003	9012462	Feb 06, 2031	DS	NCE	Apr 28, 2022
		9273077	May 21, 2029	U-1927	ODE-142	Apr 28, 2024
		9611283	Apr 10, 2034	U-1927		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262	001	6562873	Jul 10, 2021			
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
<u>BRIMONIDINE TARTRATE - QOLIANA</u>						
N 021764	001	7265117	Aug 19, 2025	DP		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001	6562873	Jul 10, 2021	DP		
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		8858961	Sep 02, 2023	DP		
		8858961*PED	Mar 02, 2024			
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
		9687443	Jul 10, 2021	DP		
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	7439241	Aug 25, 2025	U-1428		
		8053427	Jun 13, 2031	DP U-1428		
		8163725	Jun 13, 2031	DP		
		8231885	May 24, 2025	DP		
		8410102	May 24, 2025	U-1428		
		8426410	May 24, 2025	U-1428		
		8513247	Mar 25, 2031	DP U-1428		
		8513249	Mar 25, 2031	DP U-1428		
		8859551	May 25, 2024	U-1428		
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144	001				NP	Dec 22, 2020
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251	001	6316441	Dec 07, 2019	U-778		
		9044484	Oct 30, 2030	DP		
		9421265	Jun 17, 2030	DP		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	7030149	Apr 19, 2022	U-849		
		7320976	Apr 19, 2022	U-849		
		7323463	Jan 19, 2023	DP	Y	
		7642258	Apr 19, 2022	DS DP U-1024		
		8133890	Apr 19, 2022	U-1235		
		8354409	Apr 19, 2022	DP U-1371		
		8748425	Apr 19, 2022	DP U-1524		
		9474751	Apr 19, 2022	DP U-1524		
		9770453	Apr 19, 2022	DP U-2131		
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	001	6784197	Feb 21, 2021	DS DP U-1815	NCE	May 12, 2021
		6784197	Feb 21, 2021	DS DP U-2130		
		6911461	Feb 21, 2021	DS DP U-1815		
		6911461	Feb 21, 2021	DS DP U-2130		
		8492416	Feb 21, 2021	U-1815		
		8492416	Feb 21, 2021	U-2130		
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	002	6784197	Feb 21, 2021	DS DP U-1815	NCE	May 12, 2021
		6784197	Feb 21, 2021	DS DP U-2130		
		6911461	Feb 21, 2021	DS DP U-1815		
		6911461	Feb 21, 2021	DS DP U-2130		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			
	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			
	9700555	Apr 30, 2032	DP U-2186			
	9700555	Apr 30, 2032	DP U-2187			
	9700555	Apr 30, 2032	DP U-2188			
	9700555	Apr 30, 2032	DP U-2189			
	9700555	Apr 30, 2032	DP U-2190			
	9700555	Apr 30, 2032	DP U-2191			
	9700555	Apr 30, 2032	DP U-2192			
	9700555	Apr 30, 2032	DP U-2193			
	9700555	Apr 30, 2032	DP U-2194			
	9700555	Apr 30, 2032	DP U-2195			
	9700555	Apr 30, 2032	DP U-2196			
	9700555	Apr 30, 2032	DP U-2197			
	9700555	Apr 30, 2032	DP U-2198			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 001	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 002	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 003	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178	Apr 29, 2019
					NPP	Apr 29, 2019
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 001	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 002	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325			
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
	9320716	Jun 09, 2020	DP U-1325			
	9532954	Jun 09, 2020	DP U-1325			
	RE43799	Jun 09, 2020	DP U-1325			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N 205613	001				NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	001	6123924	Sep 26, 2017	DP	M-210	Sep 11, 2020
		7367333	Nov 11, 2018	DP	M-214	Dec 20, 2020
		7367333*PED	May 11, 2019		NPP	Jan 27, 2020
		7587988	Apr 10, 2026	DP	PED	Jul 27, 2020
		7587988*PED	Oct 10, 2026			
		7759328	Jan 29, 2023	DP U-2001		
		7759328	Jan 29, 2023	DP U-2002		
		7759328	Jan 29, 2023	DP U-2122		
		7759328*PED	Jul 29, 2023			
		7967011	Aug 11, 2021	DP		
		7967011*PED	Feb 11, 2022			
		8143239	Jan 29, 2023	DP U-2001		
		8143239	Jan 29, 2023	DP U-2002		
		8143239	Jan 29, 2023	DP U-2122		
		8143239*PED	Jul 29, 2023			
		8387615	Nov 10, 2024	DP		
		8387615*PED	May 10, 2025			
		8528545	Oct 16, 2028	DP		
		8528545*PED	Apr 16, 2029			
		8575137	Jan 29, 2023	DP U-2001		
		8575137	Jan 29, 2023	DP U-2002		
		8575137	Jan 29, 2023	DP U-2122		
		8575137*PED	Jul 29, 2023			
		8616196	Apr 07, 2029	DP		
		8616196*PED	Oct 07, 2029			
		8875699	Nov 10, 2024	DP		
		8875699*PED	May 10, 2025			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	002	6123924	Sep 26, 2017	DP	M-210	Sep 11, 2020
		7367333	Nov 11, 2018	DP	M-214	Dec 20, 2020
		7367333*PED	May 11, 2019			
		7587988	Apr 10, 2026	DP		
		7587988*PED	Oct 10, 2026			
		7759328	Jan 29, 2023	DP U-2001		
		7759328	Jan 29, 2023	DP U-2002		
		7759328	Jan 29, 2023	DP U-2122		
		7759328*PED	Jul 29, 2023			
		7897646	Sep 09, 2018	U-2002		
		7897646	Sep 09, 2018	U-2122		
		7897646*PED	Mar 09, 2019			
		7967011	Aug 11, 2021	DP		
		7967011*PED	Feb 11, 2022			
		8143239	Jan 29, 2023	DP U-2001		
		8143239	Jan 29, 2023	DP U-2002		
		8143239	Jan 29, 2023	DP U-2122		
		8143239*PED	Jul 29, 2023			
		8387615	Nov 10, 2024	DP		
		8387615*PED	May 10, 2025			
		8461211	Sep 09, 2018	U-2002		
		8461211	Sep 09, 2018	U-2122		
		8461211*PED	Mar 09, 2019			
		8528545	Oct 16, 2028	DP		
		8528545*PED	Apr 16, 2029			
		8575137	Jan 29, 2023	DP U-2001		
		8575137	Jan 29, 2023	DP U-2002		
		8575137	Jan 29, 2023	DP U-2122		
		8575137*PED	Jul 29, 2023			
		8616196	Apr 07, 2029	DP		
		8616196*PED	Oct 07, 2029			
		8875699	Nov 10, 2024	DP		
		8875699*PED	May 10, 2025			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	8182835	Sep 18, 2018	DP U-1246		
		8834921	Sep 18, 2018	DP U-1587		
		9585838	Dec 24, 2021	DP		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002	8182835	Sep 18, 2018	DP U-1246		
		8834921	Sep 18, 2018	DP U-1587		
		9205052	Sep 18, 2018	U-1246		
		9585838	Dec 24, 2021	DP		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	001	9642850	Sep 29, 2017	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		
		RE41571	Sep 29, 2017	U-1072		
		RE41571	Sep 29, 2017	U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	002	9642850	Sep 29, 2017	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		
		RE41571	Sep 29, 2017	U-1072		
		RE41571	Sep 29, 2017	U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	003	9642850	Sep 29, 2017	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		
		RE41571	Sep 29, 2017	U-1072		
		RE41571	Sep 29, 2017	U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	004	9642850	Sep 29, 2017	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		
		RE41571	Sep 29, 2017	U-1072		
		RE41571	Sep 29, 2017	U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	005	9642850	Sep 29, 2017	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		
		RE41571	Sep 29, 2017	U-1072		
		RE41571	Sep 29, 2017	U-1556		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	001	8921387	Jan 06, 2032	DP U-2173		
		8921387	Jan 06, 2032	DP U-2174		
		8975270	Sep 05, 2031	DP U-2175		
		8975270	Sep 05, 2031	DP U-2206		
		9272044	Jun 06, 2031	U-2176		
		9272044	Jun 06, 2031	U-2177		
		9272044	Jun 06, 2031	U-2178		
		9272044	Jun 06, 2031	U-2209		
		9498432	Jun 06, 2031	DP U-2179		
		9782402	Jun 06, 2031	DP U-2176		
		9782402	Jun 06, 2031	DP U-2180		
		9782402	Jun 06, 2031	DP U-2207		
		9782402	Jun 06, 2031	DP U-2208		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	7579019	Jan 22, 2020	U-1769		NP	Oct 23, 2018
	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
	9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
	9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
	9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLY</u>						
N 204242	006 9439900	Sep 18, 2032	DP	Y		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	001 7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	002 7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	003 7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	001 7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	002 7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	003 7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	001 6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	002 6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497	001 7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001 7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	8916195	Feb 02, 2030	U-1639		
		9107837	Jun 04, 2027	U-1639		
		9125868	Nov 08, 2027	U-1585		
		9248123	Jan 13, 2032	U-1808		
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
N 019881	001	5993856	Nov 17, 2017	DP U-457		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001	5847170	Mar 26, 2021	DS DP	M-201	May 17, 2020
		5847170*PED	Sep 26, 2021		M-209	Sep 14, 2020
		7241907	Dec 10, 2025	DS	PED	Nov 17, 2020
		7241907*PED	Jun 10, 2026			
		8927592	Oct 27, 2030	U-1630		
		8927592*PED	Apr 27, 2031			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	001	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617	ODE-33	Nov 29, 2019
		9717720	Feb 10, 2032	DP		
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	002	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617	ODE-33	Nov 29, 2019
		9717720	Feb 10, 2032	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001	7579473	Aug 14, 2026	DS DP	I-760	Dec 19, 2020
		8497284	Sep 24, 2024	U-1220	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP	NP	Apr 25, 2019
		9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002	7579473	Aug 14, 2026	DS DP	I-760	Dec 19, 2020
		8497284	Sep 24, 2024	U-1220	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP	NP	Apr 25, 2019
		9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003	7579473	Aug 14, 2026	DS DP	I-760	Dec 19, 2020
		8497284	Sep 24, 2024	U-1220	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP	NP	Apr 25, 2019
		9724342	Jul 09, 2033	DP		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	6582727	Aug 22, 2020	DP	NP	Jun 17, 2019
		8207149	Apr 25, 2028	U-1871		
		8361488	Jul 19, 2028	DP		
		8426391	Aug 27, 2028	DP U-1872		
		8778373	Apr 25, 2028	U-1873		
		8906410	Feb 02, 2027	DP		
		9408858	Apr 25, 2028	U-1888		
		9498486	Apr 25, 2028	U-1920		
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001	8263580	Sep 27, 2028	DP U-1280		
		8629128	May 26, 2026	DP U-1280		
		8629128	May 26, 2026	DP U-1767		
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001	6440392	Feb 02, 2021	DP U-227		
		RE40812	Feb 02, 2021	DP		
		RE43580	Feb 02, 2021	DP U-227		
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	001	6051567	Aug 02, 2019			
		6265392	Aug 02, 2019			
		6274169	Aug 02, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	002	6051567				
		Aug 02, 2019				
		6265392				
		Aug 02, 2019				
		6274169				
		Aug 02, 2019				
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160	002	6576665				
		Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003	6576665				
		Apr 03, 2021				
		6875445		DP		
		Jul 30, 2021				
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581	001	8591938				
		Feb 23, 2030		DP U-1469		
		8592480			U-1469	
		Jul 20, 2027				
		9089528			U-1469	
		Jul 20, 2027				
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958	001	5989588				
		Sep 30, 2017		DP U-349		
		5989588*PED				
		Mar 30, 2018				
		6814978			DP	
		Aug 26, 2021				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823	001	5994329				
		Jul 17, 2018		U-353		
		6015801			U-353	
		Jul 17, 2018				
		6165513			DP	
		Jun 10, 2018				
		6432932			U-595	
		Jul 17, 2018				
		6465443			DP	
		Aug 14, 2018				
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193	001	7084130				
		Nov 29, 2021		DP U-891		
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026	001				ODE-85	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER</u>						
N 207026	002				ODE-85	Jan 13, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001	7943582				
		Feb 26, 2029		DS DP U-493	I-733	May 20, 2019
		7943788			M-197	Feb 01, 2020
		Jul 14, 2027		DS DP		
		8222219			U-493	
		Jul 30, 2024				Mar 29, 2018
		8513202		DS DP U-493	NCE	
		Dec 03, 2027				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	7943582				
		Feb 26, 2029		DS DP U-493	I-733	May 20, 2019
		7943788			M-197	Feb 01, 2020
		Jul 14, 2027		DS DP		
		8222219			U-493	
		Jul 30, 2024				Mar 29, 2018
		8513202		DS DP U-493	NCE	
		Dec 03, 2027				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001	7943582				
		Feb 26, 2029		DS DP U-493	I-735	May 20, 2019
		7943788			M-197	Feb 01, 2020
		Jul 14, 2027		DS DP		
		8222219			U-493	
		Jul 30, 2024				Aug 08, 2017
		8513202		DS DP U-493	NCE	Mar 29, 2018
		Dec 03, 2027				
		8785403			DP	
		Jul 30, 2024				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002	7943582				
		Feb 26, 2029		DS DP U-493	I-735	May 20, 2019
		7943788			M-197	Feb 01, 2020
		Jul 14, 2027		DS DP		
		8222219			U-493	
		Jul 30, 2024				Aug 08, 2017
		8513202		DS DP U-493	NCE	Mar 29, 2018
		Dec 03, 2027				
		8785403			DP	
		Jul 30, 2024				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003	7943582				
		Feb 26, 2029		DS DP U-493	I-735	May 20, 2019
		7943788			M-197	Feb 01, 2020
		Jul 14, 2027		DS DP		
		8222219			U-493	
		Jul 30, 2024				Aug 08, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003	8513202	Dec 03, 2027	DS DP U-493	NCE	Mar 29, 2018
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	M-197	Feb 01, 2020
		8222219	Jul 30, 2024	U-493	NC	Aug 08, 2017
		8513202	Dec 03, 2027	DS DP U-493	NCE	Mar 29, 2018
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	6114313	Dec 11, 2017	DP U-1715	NCE	Jun 22, 2020
		6130208	Jun 29, 2018	DP U-1715		
		8680052	Mar 09, 2033	U-1715		
		8759316	May 13, 2029	U-1715		
		9295687	Jul 10, 2035	DP		
		9427448	Nov 10, 2030	U-1926		
		9439921	Jul 10, 2035	DP		
		9700575	Jul 10, 2035	DP		
<u>CAPSAICIN - OUTENZA</u>						
N 022395	001	6239180	Jun 04, 2021	DP		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	001	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	002	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	003	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	7635773	Mar 13, 2029	DP	ODE-124	Oct 07, 2023
		8410077	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	9750822	Mar 13, 2029	DP		
		9770407	Nov 10, 2028	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485	001	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485	002	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485	003	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485	004	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485	005	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485	006	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	7094427	May 29, 2022	DP U-1645	NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	7094427	May 29, 2022	DP U-1645	NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	7094427	May 29, 2022	DP U-1645	NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP	Jan 09, 2018
					ODE-84	Jan 09, 2022
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025		U-1260	I-723	Jan 21, 2019
	7737112	Dec 07, 2027		DP	NCE	Jul 20, 2017
	8129346	Apr 14, 2025		U-1260	ODE-27	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025		DP		
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033		DP		
	9511109	Oct 21, 2029		U-1924		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025		U-1260	I-723	Jan 21, 2019
	7737112	Dec 07, 2027		DP	NCE	Jul 20, 2017
	8129346	Apr 14, 2025		U-1260	ODE-27	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025		DP		
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033		DP		
	9511109	Oct 21, 2029		U-1924		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
	7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
	7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	003	7737142	Mar 27, 2027	DS DP U-1750	M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP	NCE	Sep 17, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	004	7737142	Mar 27, 2027	DS DP U-1750	M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP	NCE	Sep 17, 2020
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132	001				PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132	002				PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132	003				PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132	004				PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	001	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	002	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	003	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	004	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	001	9636407	Dec 21, 2032	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	002	9636407	Dec 21, 2032	DP		
<u>CEFIXIME - SUPRAX</u>						
N 202091	001	9233112	Dec 14, 2028	DP U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676	NPP	May 27, 2019
		6906055	Dec 15, 2021	DS DP	NPP	May 27, 2019
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676	NPP	May 27, 2019
		6906055	Dec 15, 2021	DS DP	NPP	May 27, 2019
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	7129232	Oct 21, 2024	DS DP U-36	NCE	Dec 19, 2019
		8476425	Sep 27, 2032	DS	GAIN	Dec 19, 2024
		8685957	Sep 27, 2032	DS	U-36	
		8906898	May 28, 2034	DS DP		
		8968753	Mar 14, 2034		U-1672	
		8968753	Mar 14, 2034		U-1673	
		9320740	Mar 14, 2034	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	7129232	Oct 21, 2024	DS DP U-36	NCE	Dec 19, 2019
		8476425	Sep 27, 2032	DS	GAIN	Dec 19, 2024
		8685957	Sep 27, 2032	DS U-36		
		8906898	May 28, 2034	DS DP		
		8968753	Mar 14, 2034		U-1672	
		8968753	Mar 14, 2034		U-1673	
		9320740	Mar 14, 2034	DP		
<u>CERITINIB - ZYKADIA</u>						
N 205755	001	7153964	Feb 26, 2021	DS DP	M-199	May 26, 2020
		7893074	Apr 25, 2026	DS DP	NCE	Apr 29, 2019
		7964592	Jan 13, 2027	DS DP	ODE-145	May 26, 2024
		8039479	Jun 29, 2030	DS DP	ODE-66	Apr 29, 2021
		8188276	Jan 31, 2023	DS DP		
		8377921	Nov 20, 2027		U-1179	
		8399450	Nov 20, 2027	DS DP		
		8703787	Feb 02, 2032		U-1179	
		8835430	Jan 31, 2023	DS DP		
		9018204	Jan 31, 2023	DS DP		
		9309229	Jan 18, 2032	DS DP		
		9416112	Jan 31, 2023	DS DP		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621	003	6455533	Jul 02, 2018	DP U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621	004	6455533	Jul 02, 2018	DP U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621	005	6455533	Jul 02, 2018	DP U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621	006	6455533	Jul 02, 2018	DP U-295		
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694	001	8829005	Mar 15, 2030		U-1680	NDF
		8829005*PED	Sep 15, 2030			PED
		9254286	Jul 09, 2032	DP		
		9254286*PED	Jan 09, 2033			
		9750684	Mar 15, 2030	DP		
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150	002	6469009	Jul 13, 2019	DP U-295		
		7014867	Jun 10, 2022	DP		
		7226614	Jun 10, 2022		U-295	
<u>CETRORELIX - CETROTIDE</u>						
N 021197	001	6319192	Apr 23, 2019		U-426	
<u>CETRORELIX - CETROTIDE</u>						
N 021197	002	6319192	Apr 23, 2019		U-426	
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669	001	7066916	Feb 17, 2024		U-737	
		7427574	Apr 25, 2026	DP		
		7595021	May 12, 2023	DP U-1022		
		7717889	Feb 27, 2025	DP U-1022		
		7935093	Oct 02, 2027	DP U-1022		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	001	6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	002	6729786	Mar 14, 2023	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 004	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 006	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					NP	Sep 26, 2020
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
	9107921	Jan 03, 2032	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441 001	7863287	Feb 28, 2027	DP			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE ODE-91	Mar 17, 2020 Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE ODE-91	Mar 17, 2020 Mar 17, 2022
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155 001					NCE W	Sep 12, 2017 Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 002	7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 002	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	5482934	Oct 24, 2017	DS DP U-1002			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	5482934	Oct 24, 2017	DS DP U-1002			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1355			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	5482934	Oct 24, 2017	DS DP U-557		
		6767901	Oct 21, 2020	DP		
		6939559	Apr 21, 2019	DP		
		7235247	Apr 21, 2019	DP		
		8371292	Feb 01, 2028	U-1356		
		8383611	Oct 20, 2020	DP		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	5482934	Oct 24, 2017	DS DP U-1002		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1357		
<u>CICLOPIROX - CICLOPIROX</u>						
N 020519	001	7018656	Sep 05, 2018	DP		
<u>CICLOPIROX - LOPROX</u>						
N 021159	001	7981909	Sep 16, 2017	U-1162		
		8227490	Sep 16, 2017	U-1256		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001	6011068	Mar 08, 2018	DS DP	M-200	May 23, 2020
		7829595	Sep 22, 2026	DP U-1098	ODE-78	Nov 21, 2021
		9375405	Sep 22, 2026	DP	ODE-8	Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	002	6011068	Mar 08, 2018	DS DP	M-200	May 23, 2020
		7829595	Sep 22, 2026	DP U-1098	ODE-78	Nov 21, 2021
		9375405	Sep 22, 2026	DP	ODE-8	Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	003	6011068	Mar 08, 2018	DS DP	M-200	May 23, 2020
		7829595	Sep 22, 2026	DP U-1098	ODE-78	Nov 21, 2021
		9375405	Sep 22, 2026	DP	ODE-8	Feb 25, 2018
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001	8318817	Apr 27, 2030	U-1792	NP	Dec 10, 2018
		9205048	Apr 21, 2029	U-1793		
		9220796	Jul 01, 2035	DP		
		9233068	Dec 11, 2029	DP		
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744	001	6488962	Jun 20, 2020	DP		
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251	001	8932610	Mar 24, 2030	DP U-1578	NC	Apr 29, 2019
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	001	7709022	Jun 23, 2021	DP		
		8187632	Jun 23, 2021	DP		
		8187632*PED	Dec 23, 2021			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	002	7709022	Jun 23, 2021	DP		
		8187632	Jun 23, 2021	DP		
		8187632*PED	Dec 23, 2021			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	6284804	Aug 10, 2020			
		6359016	Aug 10, 2020			
		8846650	Jun 04, 2025	DP U-1578		
		9149486	Sep 13, 2022	DP U-1578		
		9345714	Sep 13, 2022	DP U-1578		
		9402805	Sep 13, 2022	DP U-1578		
		9402805	Sep 13, 2022	DP U-1679		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535	001	8450338	Oct 10, 2028	DP		
		8481083	Oct 10, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CIENPIO</u>						
N 209589	001 9827231	Jun 23, 2034	DP U-2162			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001 5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002 5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003 5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767	001 6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782	001 6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793	001 5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
	9789057	Dec 02, 2026	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801	001 7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802	001 6387383	Aug 03, 2020	DP U-916			
<u>CLOBAZAM - ONFI</u>						
N 202067	001				ODE-17	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067	002				ODE-17	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067	003				ODE-17	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993	001				ODE-18	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535	001 6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644	001 7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835	001 5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001 6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483	001 9855334	Mar 11, 2035	DP		NP	Nov 28, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029	001				PC	Nov 05, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOFARABINE - CLOLAR</u>						
N 021673	001 5661136	Jan 14, 2018	U-626			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	003				M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	004				M-149	Nov 20, 2017
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	001 6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	002 6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	001 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	002 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	003 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	004 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	005 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	006 6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094	001 8148374	Sep 03, 2029	DS DP U-1279		NCE NP	Aug 27, 2017 Sep 24, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395	001 7470506	Jun 23, 2019	U-1660		NCE	Aug 27, 2017
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE43596*PED	Nov 09, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001 5914331	Jul 02, 2017	DS		NCE	Aug 27, 2017
	5914331*PED	Jan 02, 2018			NCE	Nov 05, 2020
	6642245	Nov 04, 2020	U-257		NPP	Sep 25, 2020
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7176220	Aug 27, 2026	DS DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICICSTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	7390791	May 07, 2022	DS DP		
		7635704	Oct 26, 2026	DS DP U-257		
		7803788	Feb 02, 2022		U-257	
		8148374	Sep 03, 2029	DS DP U-1279		
		8633219	Apr 24, 2030	DP U-257		
		8754065	Aug 15, 2032	DS DP U-257		
		8981103	Oct 26, 2026	DS DP		
		9296769	Aug 15, 2032	DS DP U-257		
<u>COBICICSTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	5914331	Jul 02, 2017	DS		I-704 Dec 17, 2017
		5922695	Jul 25, 2017	DS	U-257	NCE Aug 27, 2017
		5935946	Jul 25, 2017	DS DP U-257		NPP Jan 27, 2020
		5977089	Jul 25, 2017	DS DP U-257		
		6043230	Jul 25, 2017		U-257	
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
		7176220	Aug 27, 2026	DS DP U-257		
		7635704	Oct 26, 2026	DS DP U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
		8592397	Jan 13, 2024	DP U-257		
		8633219	Apr 24, 2030	DP U-257		
		8716264	Jan 13, 2024	DP U-257		
		8981103	Oct 26, 2026	DS DP		
		9457036	Jan 13, 2024	DP U-257		
		9744181	Jan 13, 2024	DP U-257		
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192	001	7803839	Feb 01, 2027	DS DP		NCE Nov 10, 2020
		8362002	Oct 05, 2026		U-1776	ODE-101 Nov 10, 2022
<u>COLCHICINE - COLCRYS</u>						
N 022352	001	7601758	Feb 10, 2029		U-1007	
		7619004	Dec 03, 2028		U-1020	
		7820681	Feb 17, 2029		U-1020	
		7906519	Feb 17, 2029		U-1116	
		7915269	Feb 17, 2029		U-1007	
		7935731	Dec 03, 2028		U-1116	
		7964647	Oct 06, 2028		U-1007	
		7964648	Oct 06, 2028		U-1161	
		7981938	Oct 06, 2028		U-1166	
		8093296	Oct 06, 2028		U-1007	
		8093297	Oct 06, 2028		U-1161	
		8093298	Oct 06, 2028		U-1116	
		8097655	Oct 06, 2028		U-1020	
		8415395	Oct 06, 2028		U-1007	
		8415396	Oct 06, 2028		U-1007	
		8440721	Feb 17, 2029		U-1007	
		8440722	Feb 17, 2029		U-1020	
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	8927607	Aug 22, 2033		U-1020	
		9399036	Aug 22, 2033		U-1020	
		9555029	Aug 22, 2033		U-1020	
		9675613	Aug 22, 2033		U-1020	
		9789108	Aug 22, 2033		U-1020	
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176	001	7229613	Apr 17, 2022		U-851	
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	001	7229613	Apr 17, 2022		U-493	
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	002	7229613	Apr 17, 2022		U-493	
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697	001	5723606	Dec 15, 2019	DS DP	U-698	
		5723606	Dec 15, 2019	DS DP	U-868	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697	001	5723606	Dec 15, 2019	DS DP U-698		
		5723606	Dec 15, 2019	DS DP U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697	002	5723606	Dec 15, 2019	DS DP U-698		
		5723606	Dec 15, 2019	DS DP U-868		
<u>COPANLISIB DIHYDROCHLORIDE - ALIOOPA</u>						
N 209936	001	7511041	May 13, 2024	DS DP	NCE	Sep 14, 2022
		8466283	Oct 22, 2029	DS DP U-2124	ODE-155	Sep 14, 2024
		9636344	Mar 29, 2032	U-2124		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372	008				ODE-3	Oct 15, 2017
<u>CRISABOROLE - EUCRISA</u>						
N 207695	001	8039451	Jun 11, 2026	DS DP	NCE	Dec 14, 2021
		8168614	Jan 20, 2030	U-1932		
		8501712	Feb 16, 2027	U-1932		
		9682092	Feb 16, 2027	U-1932		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001	7230098	Aug 26, 2025	DS	M-163	Sep 14, 2018
		7825137	May 12, 2027	U-1179	ODE-111	Mar 11, 2023
		7858643	Oct 08, 2029	DS DP	ODE-15	Aug 26, 2018
		8217057	Nov 06, 2029	DS DP		
		8785632	Mar 01, 2025	DS		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002	7230098	Aug 26, 2025	DS	M-163	Sep 14, 2018
		7825137	May 12, 2027	U-1179	ODE-111	Mar 11, 2023
		7858643	Oct 08, 2029	DS DP	ODE-15	Aug 26, 2018
		8217057	Nov 06, 2029	DS DP		
		8785632	Mar 01, 2025	DS		
<u>CROFELEMER - FULYZAQ</u>						
N 202292	001	7323195	Jun 07, 2018	DP	NCE	Dec 31, 2017
		7341744	Jun 16, 2018	U-1319		
		8574634	Jan 11, 2018	U-1319		
		8962680	Oct 31, 2031	U-1319		
		9585868	Oct 31, 2031	DS U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642	001	7229636	Aug 01, 2024	DP U-817		
		7404489	Mar 12, 2024	DP		
		7879349	Aug 01, 2024	DP U-1152		
		8003353	Aug 01, 2024	U-817		
		8940714	Feb 26, 2024	U-1152		
		9415007	Jul 28, 2024	U-1896		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	001	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	002	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		M-216	Dec 22, 2020
	8026284*PED	Mar 22, 2028			NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE-45	Apr 30, 2020
	9173851*PED	Dec 17, 2034			ODE-97	Aug 14, 2022
	9192590	Jan 26, 2027	U-1399		PED	Oct 30, 2020
	9192590*PED	Jul 26, 2027			PED	Jun 22, 2021
	9198882	Jan 26, 2027	U-1399		PED	Feb 14, 2023
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		M-216	Dec 22, 2020
	8026284*PED	Mar 22, 2028			NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE-45	Apr 30, 2020
	9173851*PED	Dec 17, 2034			ODE-97	Aug 14, 2022
	9192590	Jan 26, 2027	U-1399		PED	Oct 30, 2020
	9192590*PED	Jul 26, 2027			PED	Jun 22, 2021
	9198882	Jan 26, 2027	U-1399		PED	Feb 14, 2023
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					ODE-31	Oct 02, 2019
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		M-168	Nov 20, 2018
	7866474	Aug 31, 2027	DP	Y		
	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		M-168	Nov 20, 2018
	7866474	Aug 31, 2027	DP	Y		
	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		NS	Nov 20, 2018
	7866474	Aug 31, 2027	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031		U-1759		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP	U-1406	I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP	U-2031	M-170	Nov 20, 2018
	7994185	Jan 20, 2030	DS DP	U-2032	NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP	U-1406	ODE-147	Jun 22, 2024
	8415345	Jan 20, 2030	DS DP	U-2031	ODE-47	May 29, 2020
	8415345	Jan 20, 2030	DS DP	U-2032	ODE-58	Jan 09, 2021
	8703781	Oct 15, 2030	DS DP	U-1713		
	8835443	Sep 13, 2025		U-2026		
	8835443	Sep 13, 2025		U-2027		
	8952018	Oct 15, 2030		U-2027		
	9233956	May 04, 2029		U-1811		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP	U-1406	I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP	U-2031	M-170	Nov 20, 2018
	7994185	Jan 20, 2030	DS DP	U-2032	NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP	U-1406	ODE-147	Jun 22, 2024
	8415345	Jan 20, 2030	DS DP	U-2031	ODE-47	May 29, 2020
	8415345	Jan 20, 2030	DS DP	U-2032	ODE-58	Jan 09, 2021
	8703781	Oct 15, 2030	DS DP	U-1713		
	8835443	Sep 13, 2025		U-2026		
	8835443	Sep 13, 2025		U-2027		
	8952018	Oct 15, 2030		U-2027		
	9233956	May 04, 2029		U-1811		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
	8629171	Jun 13, 2031	DS DP	U-1724	D-162	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP	U-1724	I-726	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP	U-1725	I-727	Feb 05, 2019
	8900566	Aug 08, 2027		U-1724	NCE	Jul 24, 2020
	8900566	Aug 08, 2027		U-1725		
	9421192	Aug 08, 2027	DS	U-1724		
	9421192	Aug 08, 2027	DS	U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
	8629171	Jun 13, 2031	DS DP	U-1724	D-162	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP	U-1724	I-726	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP	U-1725	I-727	Feb 05, 2019
	8900566	Aug 08, 2027		U-1724	NCE	Jul 24, 2020
	8900566	Aug 08, 2027		U-1725		
	9421192	Aug 08, 2027	DS	U-1724		
	9421192	Aug 08, 2027	DS	U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS	U-1724		
	9421192	Aug 08, 2027	DS	U-1725		
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023		U-1517	D-154	Jan 20, 2019
	7115564	Nov 14, 2023	DP		NCE	May 23, 2019
	7119061	Nov 14, 2023	DP		GAIN	May 23, 2024
	8143212	Nov 14, 2023		U-1517		
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018		U-1030		
	8007826	May 26, 2027		U-1030		
	8354437	Dec 22, 2026		U-1030		
	8440703	Apr 08, 2025		U-1030		
	8663685	Jan 18, 2025		U-1030		
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP		ODE-69	Jul 22, 2021
	8110225	Dec 24, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001 8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	001 6414126	Oct 04, 2020	DS DP U-2139		M-157	Mar 11, 2018
	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6479065	Aug 10, 2020	DP	Y	NCE	Jan 08, 2019
	6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6667061	May 25, 2020	DP	Y		
	6824822	Oct 09, 2022	DP	Y		
	6872700	Jan 14, 2020	U-654	Y		
	6936590	Oct 04, 2020	U-493			
	6956026	Jan 07, 2018	U-687	Y		
	7223440	Aug 31, 2021	DP	Y		
	7456254	Jun 30, 2025	DP U-1223			
	7456254	Jun 30, 2025	DP U-2139			
	7563871	Apr 15, 2024	DP	Y		
	7612176	Apr 13, 2025	DP U-1223	Y		
	7741269	Jan 07, 2018	U-1224	Y		
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8216180	Jan 11, 2028	DP	Y		
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2153			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8690837	May 19, 2029	DP	Y		
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP	Y		
	8827963	Feb 04, 2029	DP	Y		
	8906851	Aug 18, 2026	U-1313			
	8906851	Aug 18, 2026	U-2139			
	8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP	Y		
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	002 6414126	Oct 04, 2020	DS DP U-2139		M-157	Mar 11, 2018
	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6479065	Aug 10, 2020	DP	Y	NCE	Jan 08, 2019
	6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6667061	May 25, 2020	DP	Y		
	6824822	Oct 09, 2022	DP	Y		
	6872700	Jan 14, 2020	U-654	Y		
	6936590	Oct 04, 2020	U-493			
	6956026	Jan 07, 2018	U-687	Y		
	7223440	Aug 31, 2021	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-1223			
	7456254	Jun 30, 2025	DP U-2139			
	7563871	Apr 15, 2024	DP	Y		
	7612176	Apr 13, 2025	DP U-1223	Y		
	7741269	Jan 07, 2018	U-1224	Y		
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8216180	Jan 11, 2028	DP	Y		
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2153			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8690837	May 19, 2029	DP	Y		
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP	Y		
	8827963	Feb 04, 2029	DP	Y		
	8906851	Aug 18, 2026	U-1313			
	8906851	Aug 18, 2026	U-2139			
	8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP	Y		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPSONE - ACZONE</u>						
N 207154 001	9161926	Nov 18, 2033	DP		NS	Feb 24, 2019
	9517219	Nov 18, 2033	U-1033			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	8003673	Sep 04, 2028	U-1180		M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003	9138456	Nov 23, 2030	DP		M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	002	8597876*PED				
		Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	003	7470506			U-1209	
		7470506			U-1305	
		7470506			U-935	
		7700645	DS DP			
		8518987	DS DP			
		8518987*PED				
		8597876			U-1305	
		8597876*PED				
		Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	004	7470506			U-1209	
		7470506			U-1305	
		7470506			U-935	
		7700645	DS DP			
		8518987	DS DP			
		8518987*PED				
		8597876			U-1305	
		8597876*PED				
		Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	005	7470506			U-1209	
		7470506			U-1305	
		7470506			U-935	
		7700645	DS DP			
		8518987	DS DP			
		8518987*PED				
		8597876			U-1305	
		8597876*PED				
		Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	006	7470506			U-1209	
		7470506			U-1305	
		7470506			U-935	
		7700645	DS DP			
		8518987	DS DP			
		8518987*PED				
		8597876			U-1305	
		8597876*PED				
		Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895	001	7470506			U-1209	
		7470506			U-1305	
		7700645	DS DP			
		8518987	DS DP			
		8518987*PED				
		8597876			U-1305	
		8597876*PED				
		Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	7148359		DP	D-163	Apr 22, 2019
		7364752		DP	NCE	Dec 19, 2019
		8188104	DS DP	U-1636		
		8268349		DP		
		8399015		DP		
		8420596	DS DP			
		8466159			U-1637	
		8492386			U-1840	
		8501238	DS DP	U-1636		
		8642538	DS DP	U-1638		
		8680106			U-1637	
		8685984			U-1840	
		8686026		DP		
		8691938	DS DP			
		9006387			U-1687	
		9044480			U-1638	
		9139536			U-1753	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	9629841	Oct 18, 2033	DP U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624	001	7148359	Jul 19, 2019	DP	NCE	Dec 19, 2019
		7364752	Nov 10, 2020	DP		
		8188104	May 17, 2029	DS DP U-1636		
		8268349	Aug 25, 2024	DP		
		8399015	Aug 25, 2024	DP		
		8420596	Apr 10, 2031	DS DP		
		8466159	Sep 04, 2032	U-1637		
		8492386	Sep 04, 2032	U-1840		
		8501238	Sep 17, 2028	DS DP U-1636		
		8642538	Sep 10, 2029	DS DP U-1638		
		8680106	Sep 04, 2032	U-1637		
		8685984	Sep 04, 2032	U-1840		
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030	U-1687		
		9044480	Apr 10, 2031	U-1638		
		9139536	Nov 09, 2028	U-1753		
		9333204	Jan 02, 2035	DP U-1889		
		9744170	Jan 02, 2035	DP U-1889		
<u>DASATINIB - SPRYCEL</u>						
N 021986	001	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	002	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	003	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	004	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	005	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986	006	6596746	Jun 28, 2020	DS DP U-748	NPP	Nov 09, 2020
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DEFERASIROX - EXJADE</u>						
N 021882	001	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	002	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	003	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	001	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP		
<u>DEFERASIROX - JADENU</u>						
N 206910	002	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP		
<u>DEFERASIROX - JADENU</u>						
N 206910	003	6465504	Apr 05, 2019	DS DP	ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP		
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001	6465504	Apr 05, 2019	DS DP		
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002	6465504	Apr 05, 2019	DS DP		
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003	6465504	Apr 05, 2019	DS DP		
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001	7049328	Jun 28, 2021	U-735	ODE-16	Oct 14, 2018
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001	7049328	Jun 28, 2021	U-735	ODE-16	Oct 14, 2018
		8703156	Oct 29, 2029	DP U-735		
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001				NCE ODE-112	Mar 30, 2021 Mar 30, 2023
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				NCE ODE-130	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				NCE ODE-130	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	003				NCE ODE-130	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	004				NCE ODE-130	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				NCE ODE-130	Feb 09, 2022 Feb 09, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	5925730	May 18, 2021	DS DP U-943			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	5925730	May 18, 2021	DS DP U-943			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
	RE46617	Dec 28, 2029	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
	7728143	Nov 20, 2027	DS		GAIN	Jun 19, 2027
	8252813	Oct 02, 2026	DP U-2028			
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705 002	6177101	Jun 07, 2019				
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
<u>DESLORATADINE - CLARINEX</u>						
N 021165 001	6100274	Jul 07, 2019				
	7405223	Jul 07, 2019	U-886			
<u>DESLORATADINE - CLARINEX</u>						
N 021300 001	6514520	Jun 01, 2018	DP			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 001	6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 002	6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP U-1017			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex-D 12 Hour</u>						
N 021313	001	6100274	Jul 07, 2019	DP		
		6709676	Feb 18, 2021	DP U-707		
		7618649	Dec 19, 2020	DP U-1017		
		8187630	Dec 19, 2020	DP U-1017		
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex D 24 Hour</u>						
N 021605	001	6100274	Jul 07, 2019	DP		
		6979463	Mar 28, 2022	DP		
		7618649	Dec 19, 2020	DP U-1017		
		7820199	Mar 28, 2022	DP		
<u>DES Mopressin Acetate - Noctiva</u>						
N 201656	001	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		7799761	Sep 26, 2024	DP		
		9539302	Jun 15, 2030	DP		
<u>DES Mopressin Acetate - Noctiva</u>						
N 201656	002	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		9539302	Jun 15, 2030	DP		
<u>DES Onide - Desonate</u>						
N 021844	001	6387383	Aug 03, 2020	DS DP U-783		
<u>DES Onide - Verdeso</u>						
N 021978	001	6730288	Sep 08, 2019	DP		
		7029659	Sep 08, 2019	DP		
		8460641	Nov 05, 2028	DP U-1412		
		8962000	Aug 31, 2025	DP U-1412		
		9492384	Aug 31, 2025	DP U-1412		
<u>DES Oximetasone - Topicort</u>						
N 204141	001	5990100	Mar 24, 2018	DP U-1408		
		8277780	Sep 01, 2028	DP U-1408		
		8715624	May 26, 2026	DP U-1408		
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204003	001				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204003	002				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204028	001				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204028	002				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204065	002				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204065	003				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204082	001				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204083	001				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204095	001				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204095	002				PC	Aug 28, 2017
<u>DES Venlafaxine Succinate - Desvenlafaxine Succinate</u>						
A 204172	001				PC	Aug 28, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	001	6673838	Mar 01, 2022	DS	U-1364	
		6673838	Mar 01, 2022	DS	U-860	
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	002	6673838	Mar 01, 2022	DS	U-1364	
		6673838	Mar 01, 2022	DS	U-860	
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	003	6673838	Mar 01, 2022	DS	U-1364	
		6673838	Mar 01, 2022	DS	U-860	
		8269040	Jul 05, 2027	DS		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP	U-1846	
		9550780	Sep 18, 2033	DS DP	U-1995	
		9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP	U-1846	
		9550780	Sep 18, 2033	DS DP	U-1995	
		9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP	U-1846	
		9550780	Sep 18, 2033	DS DP	U-1995	
		9814708	Sep 18, 2033	DP		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	6726918	Oct 20, 2020	DP	U-1204	ODE-2
		6726918	Oct 20, 2020	DP	U-1205	Sep 24, 2017
		6899717	Nov 01, 2023		U-1206	
		7033605	Oct 20, 2020	DP		
		7767223	Nov 28, 2021	DP		
		8034366	Jan 09, 2023	DP	U-1204	
		8034366	Jan 09, 2023	DP	U-1205	
		8034370	Jan 09, 2023	DP		
		8043628	Oct 20, 2020		U-1205	
		8063031	Oct 20, 2020	DP		
		8088407	Oct 20, 2020		U-1205	
		8506987	Jan 09, 2023		U-1204	
		8506987	Jan 09, 2023		U-1205	
		9012437	Oct 20, 2020		U-1205	
		9192511	Jan 09, 2023	DP		
		9283178	Oct 20, 2020		U-1205	
		9592242	Oct 20, 2020		U-1989	
		9592242	Oct 20, 2020		U-1990	
		9775849	Oct 20, 2020		U-1989	
		9775849	Oct 20, 2020		U-1990	
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818	001	7795316	Aug 03, 2028	DP	U-1082	
		8101582	Dec 19, 2027	DP	U-1082	
		8450287	Dec 19, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018		DP		
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019		DP		
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019		DP		
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026		DP		
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023		DP		
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028		DP		
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026		DP		
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026		DP		
	9241910	Mar 10, 2029		DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032		DP		
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032		DP		
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032		DP		
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032		DP		
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 005					PC	Jul 04, 2017
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 007					PC	Jul 04, 2017
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 001	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 002	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 003	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 004	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 005	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 006	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020	U-829			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE-96	Aug 07, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001	8679544				
		Apr 23, 2030	DP		I-692	Aug 22, 2017
		8999387		U-55		
		Apr 23, 2030	DP			
		9017721		DP		
		Apr 23, 2030	DP			
		9173854		U-55		
		Apr 23, 2030	DP			
		9180095		DP		
		Apr 23, 2030	U-55			
		9180096		DP		
		Apr 23, 2030	U-55			
		9186328		DP		
		Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	002	8679544				
		Apr 23, 2030	DP		I-692	Aug 22, 2017
		8999387		U-55		
		Apr 23, 2030	DP			
		9017721		DP		
		Apr 23, 2030	DP			
		9173854		U-55		
		Apr 23, 2030	DP			
		9180095		DP		
		Apr 23, 2030	U-55			
		9180096		DP		
		Apr 23, 2030	U-55			
		9186328		DP		
		Apr 23, 2030	U-55			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234	001	5607690				
		Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001	7759394				
		Jun 16, 2026	DS DP	U-436		
		8097651		DS DP	U-436	
		Jun 16, 2026		U-436		
		8927604		DP		
		Jun 16, 2026		DP		
		9827197		DP		
		Jun 16, 2026		DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001	6287594				
		Jan 15, 2019	DP			
		6365180		DP	U-980	
		Jul 15, 2019		U-1035		
		7662858		U-1111		
		Feb 24, 2029		U-980		
		7884095		U-980		
		Feb 24, 2029		U-980		
		7939518		U-1482		
		Feb 24, 2029		U-1482		
		8110606		U-1482		
		Feb 24, 2029		U-1482		
		8623920		U-1482		
		Feb 24, 2029		U-1482		
		9561200		U-1482		
		Feb 24, 2029		U-1482		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001	8217078				
		Jul 10, 2029		U-1248		
		8546450		U-1435		
		Aug 09, 2030		U-1436		
		8546450		U-1477		
		Aug 09, 2030		U-1435		
		8618164		U-1435		
		Jul 10, 2029		U-1435		
		8741956		U-1435		
		Jul 10, 2029		U-1435		
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001	6407079				
		Jun 18, 2019	DP		NP	Dec 23, 2017
		8946292		U-1659		
		Mar 22, 2027		U-1659		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	8217078				
		Jul 10, 2029		U-1477		
		8252838		DP	U-1489	
		Apr 21, 2028		U-1435		
		8546450		U-1436		
		Aug 09, 2030		U-1488		
		8546450		U-1477		
		Aug 09, 2030		U-1435		
		8563613		DP	U-1488	
		Oct 17, 2027		U-1477		
		8618164		U-1435		
		Jul 10, 2029		U-1614		
		8741956		DP	U-1488	
		Jul 10, 2029		U-1488		
		8871809		U-1614		
		Oct 17, 2027		U-1488		
		9066913		DP	U-1488	
		Oct 17, 2027		U-1488		
		9101591		DP	U-1488	
		Oct 17, 2027		U-1488		
		9132110		DP	U-1488	
		Oct 17, 2027		U-1488		
		9168304		U-1488		
		Oct 17, 2027		U-1488		
		9168305		U-1488		
		Oct 17, 2027		U-1488		
		9220784		U-1488		
		Oct 17, 2027		U-1488		
		9339551		U-1488		
		Oct 17, 2027		U-1488		
		9339552		DP	U-1488	
		Oct 17, 2027		U-1614		
		9370501		U-1614		
		Jul 10, 2029		U-1614		
		9375412		U-1614		
		Jul 10, 2029		U-1614		
		9415029		U-1614		
		Jul 10, 2029		U-1614		
		9539335		U-1614		
		Oct 17, 2027		U-1614		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001	8071577	May 13, 2026	DP U-1		
		8153616	Jan 30, 2028	U-1240		
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212	001	6114319	May 18, 2019	DP	ODE-26	Jun 13, 2019
		6114319*PED	Nov 18, 2019		PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	004	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	005	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	006	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394	001	8263647	May 30, 2022	DP		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393	001	8883849	Jan 17, 2022		U-1618	
		9155718	Jan 17, 2022	DP		
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168	001	6419953	Dec 18, 2018			
		6511678	Dec 18, 2018			
		6528090	Dec 18, 2018	DP		
		6528091	Dec 18, 2018	U-106		
		6713086	Dec 18, 2018	DP U-579		
		6720004	Dec 18, 2018	DP		
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168	002	6511678	Dec 18, 2018			
		6528090	Dec 18, 2018	DP		
		6713086	Dec 18, 2018	DP U-579		
		6720004	Dec 18, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168	002	6511678	Dec 18, 2018			
		6528090	Dec 18, 2018	DP		
		6713086	Dec 18, 2018	DP U-579		
		6720004	Dec 18, 2018	DP		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	8940786	Sep 30, 2033	DP U-1789		
		9308195	Sep 30, 2033	DP		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	8940786	Sep 30, 2033	DP U-1789		
		9308195	Sep 30, 2033	DP		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	8940786	Sep 30, 2033	DP U-1789		
		9308195	Sep 30, 2033	DP		
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	001	6124363	Oct 09, 2018			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	002	6124363	Oct 09, 2018			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	003	6124363	Oct 09, 2018			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP	M-166	Jul 30, 2018
					NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP	NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP	NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192	001	6838464	Feb 26, 2021	DS DP	NC	Nov 21, 2020
		7067522	Dec 20, 2019	DS DP	NCE	Aug 12, 2018
		7125879	Apr 21, 2025	DS DP U-257		
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001	8481565	Oct 04, 2026	DP		
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001	8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	003	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	004	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DORIPENEM - DORIBAX</u>						
N 022106	001 8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N 022106	002 8247402	Mar 30, 2021	DS DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001 6211229	Feb 17, 2020		U-620		
	7915307	Aug 24, 2027		U-620		
	8513299	Sep 07, 2030		U-620		
	9107898	May 01, 2028		U-620		
	9486437	May 18, 2027		U-620		
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027		U-620		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002 6211229	Feb 17, 2020		U-620		
	7915307	Aug 24, 2027		U-620		
	8513299	Sep 07, 2030		U-620		
	9107898	May 01, 2028		U-620		
	9486437	May 18, 2027		U-620		
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027		U-620		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001 7211267	Apr 05, 2022		U-925		
	7232572	Apr 05, 2022		U-925		
	7749532	Dec 19, 2027	DP	U-1063		
	8206740	Dec 24, 2025	DP	U-925		
	8394405	Apr 07, 2024	DP	U-925		
	8394406	Apr 07, 2024	DP	U-925		
	8470364	Apr 07, 2024	DP	U-925		
	8603506	Apr 05, 2022		U-1063		
	8709478	Apr 07, 2024		U-1063		
	9241946	Apr 05, 2022		U-1063		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	001 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	002 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	003 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	004 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	005 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	006 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP	U-918		
	9446057	Dec 23, 2034	DP	U-918		
	9511031	Oct 23, 2034	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008 6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	9295652	Oct 23, 2034	DP	U-918	
		9446057	Dec 23, 2034	DP	U-918	
		9511031	Oct 23, 2034	DP		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876	001	6340695	Jun 21, 2021	DP	U-1382	
		7560122	Jan 25, 2019	DP		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661	001	7560122	Jan 25, 2019	DP		
		9089489	Feb 18, 2033	DP	U-1382	
		9375404	Feb 18, 2033	DP	U-1382	
		9526703	Feb 18, 2033	DP	U-1382	
<u>DRONABINOL - SYNDROS</u>						
N 205525	001	8222292	Aug 06, 2028	DS	DP	
		9345771	Aug 06, 2028	DS	DP	
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001	7323493	Jun 19, 2018	DP		
		8318800	Jun 19, 2018	DP		
		8410167	Apr 16, 2029		U-1387	
		8410167	Apr 16, 2029		U-1388	
		8602215	Jun 30, 2031		U-1473	
		9107900	Apr 16, 2029		U-1726	
		9107900	Apr 16, 2029		U-1728	
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	001	8906890	Oct 22, 2031	DP		
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	002	6933395	Aug 11, 2017	DS		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098	001	6787531	Aug 31, 2020	DP		
		6933395	Aug 11, 2017	DS		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676	001	6787531	Aug 31, 2020	DP		
		6933395	Aug 11, 2017	DP		
		6958326	Dec 20, 2021	DP		
		6987101	Dec 22, 2017		U-758	
		7163931	Dec 20, 2021		U-1	
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	6441168	Jul 30, 2022	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	6441168	Apr 17, 2020	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROXIDOPA - NORTHERA</u>						
N 203202	001				NCE	Feb 18, 2019
					ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	002				NCE	Feb 18, 2019
					ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	003				NCE	Feb 18, 2019
					ODE-61	Feb 18, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	5993830	Jan 16, 2018	DP U-1449			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE ODE-144	May 05, 2022 May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFFAVIRENZ - SUSTIVA</u>						
N 021360	002	6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS	U-1170	
		5922695	Jul 25, 2017	DS	U-750	
		5935946	Jul 25, 2017	DS DP	U-1170	
		5935946	Jul 25, 2017	DS DP	U-750	
		5977089	Jul 25, 2017	DS DP	U-1170	
		5977089	Jul 25, 2017	DS DP	U-750	
		6043230	Jul 25, 2017		U-1170	
		6043230	Jul 25, 2017		U-750	
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6642245	Nov 04, 2020		U-1170	
		6642245	Nov 04, 2020		U-750	
		6703396	Mar 09, 2021	DS DP		
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
		8592397	Jan 13, 2024	DP	U-1170	
		8592397	Jan 13, 2024	DP	U-750	
		8598185	Apr 28, 2029	DP		
		8716264	Jan 13, 2024	DP	U-257	
		9018192	Jun 13, 2026		U-1170	
		9018192	Jun 13, 2026		U-750	
		9457036	Jan 13, 2024	DP	U-257	
		9545414	Jun 13, 2026	DP	U-1170	
		9545414	Jun 13, 2026	DP	U-750	
		9744181	Jan 13, 2024	DP	U-257	
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	7214506	Oct 05, 2021		U-281	NCE Jun 06, 2019
		8039494	Jul 08, 2030		U-281	
		8486978	Oct 24, 2030	DP		
		9302009	Oct 24, 2030	DP		
		9566272	Jan 03, 2028		U-1969	
		9662394	Oct 02, 2034	DP		
		9861698	Jul 08, 2030	DP		
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261	001	7973040	Jul 24, 2029	DS DP	U-1813	NCE Jan 28, 2021
		8871759	May 04, 2031	DS DP	U-1813	
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	001	6110940	Aug 29, 2017			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	002	6110940	Aug 29, 2017			
<u>ELIPLUSTAT TARTRATE - CERDELGA</u>						
N 205494	001	6916802	Apr 29, 2022		U-1571	NCE Aug 19, 2019
		7196205	Apr 29, 2022	DS		ODE-73 Aug 19, 2021
		7615573	Apr 29, 2022		U-1571	
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	001	6280959	Oct 30, 2018	DS DP	U-1306	D-149 Jun 11, 2018
		6280959	Oct 30, 2018	DS DP	U-1575	I-711 Jun 11, 2018
		6280959	Oct 30, 2018	DS DP	U-1714	ODE-75 Aug 26, 2021
		6280959	Oct 30, 2018	DS DP	U-930	PED Dec 11, 2018
		6280959*PED	Apr 30, 2019			PED Dec 11, 2018
		7160870	Nov 20, 2022	DS DP	U-1306	PED Feb 26, 2022
		7160870	Nov 20, 2022	DS DP	U-1575	
		7160870	Nov 20, 2022	DS DP	U-1714	
		7160870	Nov 20, 2022	DS DP	U-930	
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021		U-1306	
		7332481	May 24, 2021		U-1575	
		7332481	May 24, 2021		U-1714	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-1306		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE-75	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-930		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-1306		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE-75	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-930		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-1306		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE-75	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-930		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-1306		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE-75	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-930		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	6280959*PED	Apr 30, 2019			I-711	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		ODE-74	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Dec 11, 2018
	7332481	May 24, 2021	U-1736		PED	Dec 11, 2018
	7332481*PED	Nov 24, 2021			PED	Feb 26, 2022
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	7635704	Oct 26, 2026	DS DP U-257		NP	Sep 24, 2017
	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	7635704	Oct 26, 2026	DS DP U-257		NP	Sep 24, 2017
	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6890898	Feb 02, 2019	U-1652		I-739	Dec 02, 2019
	7078381	Feb 02, 2019	U-1651		NC	Jan 30, 2018
	7407955	May 02, 2025	DS DP		NCE	Aug 01, 2019
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6890898	Feb 02, 2019	U-1652		I-739	Dec 02, 2019
	7078381	Feb 02, 2019	U-1651		NC	Jan 30, 2018
	7407955	May 02, 2025	DS DP		NCE	Aug 01, 2019
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	002	8883805	Nov 26, 2025	DP		
		9173859	May 04, 2027	DP U-1772		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	001	7579449	Nov 05, 2025	DS	I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP	M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	002	7579449	Nov 05, 2025	DS	I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP	M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	003	7579449	Nov 05, 2025	DS	I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP	M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	004	7579449	Nov 05, 2025	DS	I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP	M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	001	6488962	Jun 20, 2020	DP	I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS	NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	002	6488962	Jun 20, 2020	DP	I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS	NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	003	6488962	Jun 20, 2020	DP	I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS	NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	004	6488962	Jun 20, 2020	DP	I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS	NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500	001	5914331	Jul 02, 2017	DS		
		6642245	Nov 04, 2020		U-257	
		6642245	Nov 04, 2020		U-541	
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896	001	5914331	Jul 02, 2017	DS		
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351	001	5914331	Jul 02, 2017	DS	M-206	Aug 21, 2020
		5914331*PED	Jan 02, 2018		M-207	Aug 21, 2020
		6642245	Nov 04, 2020		U-257	
		6642245*PED	May 04, 2021		NCE	Nov 05, 2020
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		6838464	Feb 26, 2021	DS DP		
		7067522	Dec 20, 2019	DS DP		
		7125879	Apr 21, 2025	DS DP U-257		
		7390791	May 07, 2022	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5914331	Jul 02, 2017	DS		NCE	Nov 05, 2020
	5914331*PED	Jan 02, 2018			NPP	Sep 25, 2020
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-1170			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8716264	Jan 13, 2024	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1892			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	9855214	Nov 06, 2032	DP			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1892			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE-151	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE-151	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	6599530	Sep 14, 2018	DP U-219			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-693	Sep 10, 2017
	8183274	Aug 24, 2026	U-1281		NCE	Aug 31, 2017
	8183274	Aug 24, 2026	U-1588			
	9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430	002	7449012	Sep 11, 2025	DP		
		7794432	Sep 11, 2025	DP		
		8048035	Sep 11, 2025	DP		
		8870827	Sep 11, 2025	DP		
		9586010	Sep 11, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800	001	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800	002	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800	003	7905352	Apr 12, 2027	DP		
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800	004	7905352	Apr 12, 2027	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	001	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	003	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025		U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
		9833573	Nov 23, 2024		U-2172	
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200	001	9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035		U-1829	
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640	001	9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035		U-1829	
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029	001	9283197	Aug 15, 2034	DP	U-1828	
		9283197	Aug 15, 2034	DP	U-1829	
		9283197	Aug 15, 2034	DP	U-1830	
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504	001	6629968	Jun 30, 2020	DS DP		
		6635045	Jun 29, 2021	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N 021437	001	6410054	Dec 08, 2019	U-3		
		6410054	Dec 08, 2019	U-537		
		6410524	Nov 05, 2019	U-467		
		6495165	Dec 08, 2019	U-3		
		6495165	Dec 08, 2019	U-537		
		6534093	Dec 08, 2019	U-3		
		6534093	Dec 08, 2019	U-537		
		6558707	Dec 08, 2019	DP U-537		
		6747020	Nov 05, 2019	U-587		
		7157101	Dec 08, 2019	DP U-664		
<u>EPLERENONE - INSPRA</u>						
N 021437	002	6410054	Dec 08, 2019	U-3		
		6410054	Dec 08, 2019	U-537		
		6410524	Nov 05, 2019	U-467		
		6495165	Dec 08, 2019	U-3		
		6495165	Dec 08, 2019	U-537		
		6534093	Dec 08, 2019	U-3		
		6534093	Dec 08, 2019	U-537		
		6558707	Dec 08, 2019	DP U-537		
		6747020	Nov 05, 2019	U-587		
		7157101	Dec 08, 2019	DP U-664		
<u>EPLERENONE - INSPRA</u>						
N 021437	003	6410054	Dec 08, 2019	U-3		
		6410054	Dec 08, 2019	U-537		
		6410524	Nov 05, 2019	U-467		
		6495165	Dec 08, 2019	U-3		
		6495165	Dec 08, 2019	U-537		
		6534093	Dec 08, 2019	U-3		
		6534093	Dec 08, 2019	U-537		
		6558707	Dec 08, 2019	DP U-537		
		6747020	Nov 05, 2019	U-587		
		7157101	Dec 08, 2019	DP U-664		
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	001	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	002	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532	001	6214865	Jul 20, 2023	DS	I-721	Jan 28, 2019
		6469182	Jun 16, 2019		ODE-107	Jan 28, 2023
		6469182	Jun 16, 2019		U-1096	
		7470720	Jun 16, 2019	DP	U-1812	
		8097648	Jan 22, 2021		U-1096	
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	001	5747498	Nov 08, 2018	DS DP	U-659	
		5747498*PED	May 08, 2019			D-164
		6900221	Nov 09, 2020	DS DP	U-1046	May 20, 2019
		6900221	Nov 09, 2020	DS DP	U-1403	Jun 01, 2019
		6900221	Nov 09, 2020	DS DP	U-659	Oct 18, 2019
		6900221	Nov 09, 2020	DS DP	U-875	
		6900221*PED	May 09, 2021			
		7087613	Nov 09, 2020		U-1045	
		7087613	Nov 09, 2020		U-1403	
		7087613	Nov 09, 2020		U-659	
		7087613*PED	May 09, 2021			
		RE41065	Nov 08, 2018	DS DP		
		RE41065*PED	May 08, 2019			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	002	5747498	Nov 08, 2018	DS DP	U-659	
		5747498*PED	May 08, 2019			D-164
		6900221	Nov 09, 2020	DS DP	U-1046	May 20, 2019
						M-181
						Jun 01, 2019
						Oct 18, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-1403			
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-1046		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001					NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002					NCE	Dec 19, 2022
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041		D-150	Aug 27, 2018
	8372431	Apr 17, 2030	DP		I-715	Aug 27, 2018
	9206135	Apr 21, 2026	DS		NCE	Nov 08, 2018
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041		D-150	Aug 27, 2018
	8372431	Apr 17, 2030	DP		I-715	Aug 27, 2018
	9206135	Apr 21, 2026	DS		NCE	Nov 08, 2018
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041		D-150	Aug 27, 2018
	8372431	Apr 17, 2030	DP		I-715	Aug 27, 2018
	9206135	Apr 21, 2026	DS		NCE	Nov 08, 2018
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041		D-150	Aug 27, 2018
	8372431	Apr 17, 2030	DP		I-715	Aug 27, 2018
	9206135	Apr 21, 2026	DS		NCE	Nov 08, 2018
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153	001	7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153	002	6147103	Oct 09, 2018			
		6166213	Oct 09, 2018			
		6191148	Oct 09, 2018			
		6369085	May 25, 2018	DS DP	U-729	
		6369085	May 25, 2018	DS DP	U-770	
		6428810	Nov 03, 2019		DP U-469	
		6428810	Nov 03, 2019		DP U-729	
		6428810	Nov 03, 2019		DP U-770	
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	001	6369085	May 25, 2018	DS DP	U-1207	
		6369085	May 25, 2018	DS DP	U-729	
		6369085	May 25, 2018	DS DP	U-773	
		6428810	Nov 03, 2019		DP U-1207	
		6428810	Nov 03, 2019		DP U-729	
		6428810	Nov 03, 2019		DP U-773	
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	002	6369085	May 25, 2018	DS DP	U-1207	
		6369085	May 25, 2018	DS DP	U-729	
		6369085	May 25, 2018	DS DP	U-773	
		6428810	Nov 03, 2019		DP U-1207	
		6428810	Nov 03, 2019		DP U-729	
		6428810	Nov 03, 2019		DP U-773	
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	003	6369085	May 25, 2018	DS DP	U-1207	
		6428810	Nov 03, 2019		DP U-1207	
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	004	6369085	May 25, 2018	DS DP	U-1207	
		6428810	Nov 03, 2019		DP U-1207	
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101	001	6369085	May 25, 2018	DS DP	U-858	
		6428810	Nov 03, 2019		DP U-858	
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	6369085	May 25, 2018	DS DP	U-1509	
		6369085	May 25, 2018	DS DP	U-1875	
		6369085*PED	Nov 25, 2018			
		6428810	Nov 03, 2019		DP U-1509	
		6428810	Nov 03, 2019		DP U-1874	
		6428810*PED	May 03, 2020			
		7411070	May 25, 2018	DS		
		7411070*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920	001	6369085	May 25, 2018	DS DP	U-1784	
		6369085*PED	Nov 25, 2018			
		6428810	Nov 03, 2019		DP U-1785	
		6428810*PED	May 03, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920	001	7411070	May 18, 2018	DS		
		7411070*PED	Nov 18, 2018			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	001	6369085	May 25, 2018	DS DP	U-1053	NPP Jul 06, 2020
		6926907	Feb 28, 2023	DP	U-1052	
		7411070	May 25, 2018	DS	U-1053	
		7745466	Oct 13, 2018	DP	U-1053	
		8557285	May 31, 2022	DP		
		8852636	May 31, 2022	DP	U-1052	
		8858996	May 31, 2022	DP	U-1052	
		8945621	Oct 17, 2031		U-1661	
		9161920	May 31, 2022		U-1760	
		9198888	May 31, 2022		U-1781	
		9220698	Mar 10, 2031		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
		9707181	May 31, 2022	DP		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	002	6369085	May 25, 2018	DS DP	U-1053	NPP Jul 06, 2020
		6926907	Feb 28, 2023	DP	U-1052	
		7411070	May 25, 2018	DS	U-1053	
		7745466	Oct 13, 2018	DP	U-1053	
		8557285	May 31, 2022	DP		
		8852636	May 31, 2022	DP	U-1052	
		8858996	May 31, 2022	DP	U-1052	
		8945621	Oct 17, 2031		U-1661	
		9161920	May 31, 2022		U-1760	
		9198888	May 31, 2022		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
		9707181	May 31, 2022	DP		
<u>ESTRADIOL - VAGIFEM</u>						
N 020908	002	5860946	Jul 01, 2017	DP		
		7018992	Sep 17, 2022		U-1023	
<u>ESTRADIOL - MENOSTAR</u>						
N 021674	001	5891868	Nov 21, 2017	DP	U-594	
		6692763	Nov 21, 2017	DP	U-594	
<u>ESTRADIOL - ELESTRIN</u>						
N 021813	001	7198801	Jun 25, 2022	DP		
		7470433	Aug 03, 2021	DP		
<u>ESTRADIOL - EVAMIST</u>						
N 022014	001	6978945	Jul 31, 2022	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	001	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	002	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	003	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	004	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	005	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9724310	Jul 10, 2028	DS DP		
		9730900	Jul 10, 2028	DP	U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	001	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	002	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	003	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040	001	6747019	Mar 20, 2020		U-311	
		7320970	Mar 30, 2020	DP	U-844	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	001	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	002	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	003	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	004	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	005	6660726	Mar 08, 2021	DS DP	U-904	
		6660726	Mar 08, 2021	DS DP	U-905	
		6855703	Feb 12, 2021	DS DP	U-904	
		6855703	Feb 12, 2021	DS DP	U-905	
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325	001	8377880	Jul 29, 2030	DS DP		
		8999932	Jul 29, 2030	DS DP	U-2014	
		9278995	Jul 29, 2030	DS		
		9701712	Jul 29, 2030	DS DP	U-2014	
		9820938	Jun 27, 2034	DP		
					NCE	Feb 07, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025		U-1904	Y	NCE
	9018368	Jun 28, 2025	DS DP			ODE-122
	9243245	Oct 27, 2028	DS	U-2097		Sep 19, 2021
	9243245	Oct 27, 2028	DS	U-2098		Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034		U-1918		
	9506058	Mar 14, 2034		U-1919		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025		U-1904	Y	NCE
	9018368	Jun 28, 2025	DS DP			ODE-122
	9243245	Oct 27, 2028	DS	U-2097		Sep 19, 2021
	9243245	Oct 27, 2028	DS	U-2098		Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034		U-1918		
	9506058	Mar 14, 2034		U-1919		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241 001	6214815	Jun 09, 2019		U-112		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024		U-828		
	7615545	Jun 15, 2023		U-1		
	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023		U-1		
	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187 001	5989581	Apr 08, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946 001	6156742	Dec 05, 2020		U-374		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864 001	6500814	Sep 03, 2018		U-1		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP			
	8450299	Oct 07, 2025		U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490 001	6667050	Apr 06, 2019	DP	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573 001	6667050	Apr 06, 2019	DP	U-828		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287	001				PC	Sep 11, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501	001	7704984	Feb 02, 2029	U-1090		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667	001	6667050	Apr 06, 2019	DP U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA</u>						
N 204426	001	6652880	Mar 29, 2020	DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654	001	6667050	Apr 06, 2019	DP U-1		
		7704984	Feb 02, 2029	U-1		
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE-64	Apr 04, 2021
<u>ETONOGESTREL - IMPLANON</u>						
N 021529	001	9757552	Jul 28, 2030	DP U-1		
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	8722037	Sep 28, 2027	DP		
		8888745	Aug 28, 2026	DP		
		9757552	Jul 28, 2030	DP U-1		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	001	6878717	Nov 05, 2019	U-1016		
		6878717	Nov 05, 2019	U-1237		
		6878717	Nov 05, 2019	U-256		
		7037917	Dec 13, 2020	DS DP U-1016		
		7037917	Dec 13, 2020	DS DP U-1237		
		7037917	Dec 13, 2020	DS DP U-256		
		7887845	Mar 25, 2019	DP		
		8003789	Nov 01, 2019	DS DP		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002	6878717	Nov 05, 2019	U-1016		
		6878717	Nov 05, 2019	U-1237		
		6878717	Nov 05, 2019	U-256		
		7037917	Dec 13, 2020	DS DP U-1016		
		7037917	Dec 13, 2020	DS DP U-1237		
		7037917	Dec 13, 2020	DS DP U-256		
		7887845	Mar 25, 2019	DP		
		8003789	Nov 01, 2019	DS DP		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	003	6878717	Nov 05, 2019	U-1016		
		6878717	Nov 05, 2019	U-1237		
		6878717	Nov 05, 2019	U-256		
		7037917	Dec 13, 2020	DS DP U-1237		
		7887845	Mar 25, 2019	DP		
		8003789	Nov 01, 2019	DS DP		
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001	5665772	Sep 09, 2019	DS DP U-1049		
		5665772	Sep 09, 2019	DS DP U-1365		
		5665772*PED	Mar 09, 2020			
		6239124	Jul 29, 2017	U-1049		
		6239124*PED	Jan 29, 2018			
		6455518	Jul 29, 2017	U-1049		
		6455518	Jul 29, 2017	U-1365		
		6455518*PED	Jan 29, 2018			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002	5665772	Sep 09, 2019	DS DP U-1049		
		5665772	Sep 09, 2019	DS DP U-1365		
		5665772*PED	Mar 09, 2020			
		6239124	Jul 29, 2017	U-1049		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002	6239124*PED	Jan 29, 2018			
		6455518	Jul 29, 2017	U-1049		
		6455518	Jul 29, 2017	U-1365		
		6455518*PED	Jan 29, 2018			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003	5665772	Sep 09, 2019	DS DP	U-1049	
		5665772	Sep 09, 2019	DS DP	U-1365	
		5665772*PED	Mar 09, 2020			
		6239124	Jul 29, 2017		U-1049	
		6239124*PED	Jan 29, 2018			
		6455518	Jul 29, 2017		U-1049	
		6455518	Jul 29, 2017		U-1365	
		6455518*PED	Jan 29, 2018			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001	5665772	Sep 09, 2019	DS DP		I-724 Feb 26, 2019
		7297703	Dec 06, 2019	DP		ODE-108 Feb 26, 2023
		7741338	Dec 06, 2019	DP		ODE-11 May 05, 2018
		8410131	Nov 01, 2025		U-1368	ODE-24 Apr 26, 2019
		8410131*PED	May 01, 2026			ODE-4 Oct 29, 2017
		8436010	Feb 22, 2022		U-1396	PED Apr 29, 2018
		8436010*PED	Aug 22, 2022			PED Nov 05, 2018
		8778962	Feb 18, 2022		U-1541	PED Oct 26, 2019
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028		U-1681	
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002	5665772	Sep 09, 2019	DS DP		I-724 Feb 26, 2019
		7297703	Dec 06, 2019	DP		ODE-108 Feb 26, 2023
		7741338	Dec 06, 2019	DP		ODE-11 May 05, 2018
		8410131	Nov 01, 2025		U-1368	ODE-24 Apr 26, 2019
		8410131*PED	May 01, 2026			ODE-4 Oct 29, 2017
		8436010	Feb 22, 2022		U-1396	PED Apr 29, 2018
		8436010*PED	Aug 22, 2022			PED Nov 05, 2018
		8778962	Feb 18, 2022		U-1541	PED Oct 26, 2019
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028		U-1681	
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003	5665772	Sep 09, 2019	DS DP		I-724 Feb 26, 2019
		7297703	Dec 06, 2019	DP		ODE-108 Feb 26, 2023
		7741338	Dec 06, 2019	DP		ODE-11 May 05, 2018
		8410131	Nov 01, 2025		U-1368	ODE-24 Apr 26, 2019
		8410131*PED	May 01, 2026			ODE-4 Oct 29, 2017
		8436010	Feb 22, 2022		U-1396	PED Apr 29, 2018
		8436010*PED	Aug 22, 2022			PED Nov 05, 2018
		8778962	Feb 18, 2022		U-1541	PED Oct 26, 2019
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028		U-1681	
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004	5665772	Sep 09, 2019	DS DP		I-724 Feb 26, 2019
		7297703	Dec 06, 2019	DP		ODE-108 Feb 26, 2023
		7741338	Dec 06, 2019	DP		ODE-11 May 05, 2018
		8410131	Nov 01, 2025		U-1368	ODE-24 Apr 26, 2019
		8410131*PED	May 01, 2026			ODE-4 Oct 29, 2017
		8436010	Feb 22, 2022		U-1396	PED Apr 29, 2018
		8436010*PED	Aug 22, 2022			PED Nov 05, 2018
		8778962	Feb 18, 2022		U-1541	PED Oct 26, 2019
		8778962*PED	Aug 18, 2022			
		9006224	Jul 01, 2028		U-1681	
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	5665772	Sep 09, 2019	DS DP		ODE-4 Oct 29, 2017
		7297703	Dec 06, 2019	DP		PED Apr 29, 2018
		8617598	Sep 27, 2022	DP		
		8617598*PED	Mar 27, 2023			
		8778962	Feb 18, 2022		U-1541	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	8778962*PED				Aug 18, 2022
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	5665772	DS DP		ODE-4	Oct 29, 2017
		7297703		DP	PED	Apr 29, 2018
		8617598		DP		
		8617598*PED				
		8778962		U-1541		
		8778962*PED				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	5665772	DS DP		ODE-4	Oct 29, 2017
		7297703		DP	PED	Apr 29, 2018
		8617598		DP		
		8617598*PED				
		8778962		U-1541		
		8778962*PED				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210	001	6479065		DP	NP	Oct 20, 2020
		6667061		DP		
		6824822		DP		
		6872700		U-654		
		6956026		U-687		
		7223440		DP		
		7456254		DP U-1223		
		7563871		DP		
		7612176		DP U-1223		
		7741269		U-1224		
		8329648		U-1313		
		8329648		U-2154		
		8329648		U-2155		
		8329648		U-2156		
		8431685		DP U-412		
		8461105		DP U-412		
		8895033		DP U-1313		
		8895033		DP U-2157		
		8895033		DP U-2158		
		8906851		U-1313		
		9238076		DP U-412		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	001	6872700		U-654	M-148	Nov 24, 2017
		6902744		DP		
		6956026		U-1074		
		6956026		U-1623		
		6956026		U-687		
		7297761		DP		
		7521423		DP		
		7741269		U-1074		
		7741269		U-1108		
		7741269		U-653		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	002	6872700		U-654	M-148	Nov 24, 2017
		6902744		DP		
		6956026		U-1074		
		6956026		U-1623		
		6956026		U-687		
		7297761		DP		
		7521423		DP		
		7741269		U-1074		
		7741269		U-1108		
		7741269		U-653		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	6414126	DS DP	U-2139	M-162	Sep 24, 2018
		6414126	DS DP	U-493	M-212	Oct 20, 2020
		6479065		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020		U-654		
	6936590	Oct 04, 2020		U-493		
	6956026	Jan 07, 2018		U-687		
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018		U-1224		
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026		U-1313		
	8361972	Mar 21, 2028		U-2139		
	8361972	Mar 21, 2028		U-493		
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030		U-1522		
	8716251	Mar 21, 2028	DP			
	8906851	Aug 18, 2026		U-1313		
	9198925	Oct 04, 2020		U-2139		
	9198925	Oct 04, 2020		U-493		
	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2139			
	6414126	Oct 04, 2020	DS DP U-493			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020		U-654		
	6936590	Oct 04, 2020		U-493		
	6956026	Jan 07, 2018		U-687		
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018		U-1224		
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8216180	Jan 12, 2028	DP			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026		U-1313		
	8361972	Mar 21, 2028		U-2139		
	8361972	Mar 21, 2028		U-493		
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030		U-1522		
	8690837	May 19, 2029	DP			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8906851	Aug 18, 2026		U-1313		
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020		U-2139		
	9198925	Oct 04, 2020		U-493		
	9238076	Apr 15, 2024	DP U-412			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200	002 9320853	Mar 25, 2028	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445	001 7030106	Jan 25, 2022	DP			
	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801	002 6814978	Aug 26, 2021	DP			
<u>FAMOTIDINE - FLUXID</u>						
N 021712	001 6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N 021712	002 6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519	001 8067033	Jul 18, 2026	DP			
	8067451	Jul 18, 2026	DP U-1196			
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001 5614520	Mar 25, 2019	DS DP U-954		M-205	Aug 15, 2020
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002 5614520	Mar 25, 2019	DS DP U-954		M-205	Aug 15, 2020
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - TRICOR</u>						
N 021203	001 6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N 021203	003 6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	001 6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	002 6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001 6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001	7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	002	6277405	Jan 09, 2018	DS		
		6375986	Sep 21, 2020	DP	U-615	
		6652881	Jan 09, 2018	DS		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	001	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	003	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	004	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	005	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
		9314447	May 31, 2033	DP	U-1447	
		9314447	May 31, 2033	DP	U-1448	
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	001	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	001	7569612	Aug 20, 2027		U-1000	
		7741373	Aug 20, 2027		U-1059	
		7741374	Aug 20, 2027		U-1060	
		7741374	Aug 20, 2027		U-1061	
		7915247	Aug 20, 2027		U-1000	
		7915247	Aug 20, 2027		U-1059	
		7915247	Aug 20, 2027		U-1061	
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002	7569612	Aug 20, 2027		U-1000	
		7741373	Aug 20, 2027		U-1059	
		7741374	Aug 20, 2027		U-1060	
		7741374	Aug 20, 2027		U-1061	
		7915247	Aug 20, 2027		U-1000	
		7915247	Aug 20, 2027		U-1059	
		7915247	Aug 20, 2027		U-1061	
<u>FENTANYL - SUBSYS</u>						
N 020788	001	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030		U-55	
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP	U-55	
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP	U-55	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788	001	9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	002	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	003	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	004	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	006	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	007	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
		8835459	Jan 25, 2027	DP		
		8835460	Jan 25, 2027	DP U-55		
		9241935	Jan 25, 2027	DP		
		9289387	Jan 25, 2027	DP U-55		
		9642797	Jan 25, 2027	DP U-55		
		9642844	Jan 25, 2027	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	001	6200604	Mar 26, 2019	U-767		
		6974590	Mar 26, 2019	U-767		
		7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		
		8092832	Dec 30, 2024	DP		
		8728441	Mar 26, 2019	U-1514		
		8753611	Mar 26, 2019	U-1514		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	7579019	Jan 22, 2020		U-767		
	9597288	Jul 23, 2027	DP	U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	7579019	Jan 22, 2020		U-767		
	9597288	Jul 23, 2027	DP	U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	7579019	Jan 22, 2020		U-767		
	9597288	Jul 23, 2027	DP	U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	7579019	Jan 22, 2020		U-767		
	9597288	Jul 23, 2027	DP	U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	7579019	Jan 22, 2020		U-767		
	9597288	Jul 23, 2027	DP	U-767		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	005 7579019	Jan 22, 2020				
	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	001 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	002 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	003 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	004 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	005 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510	006 6759059	Sep 24, 2019				
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	001 6432440	Apr 20, 2018				
	8216604	Oct 03, 2024	DP U-1169			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	002 6432440	Apr 20, 2018				
	8216604	Oct 03, 2024	DP U-1169			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569	003 9731869	Jan 26, 2032				
			DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338	001 6169920	Jan 02, 2018				
	6181963	Nov 02, 2019	DP U-736			
	6195582	Jan 28, 2019	DP			
	6881208	Apr 19, 2022	DP U-736			
	6975902	Apr 01, 2024	U-736			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	DP			
	8428709	Jun 11, 2032	U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	DP			
	9731121	Oct 17, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	001 7612109	Feb 05, 2024				
	7754702	Feb 13, 2027	DS DP			
	8895612	Jan 08, 2027	DP U-1432			
	9376505	Oct 20, 2023	DP U-1620			
			DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026			U-1577	
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP		U-1577	
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024			U-1577	
	8901349	Feb 18, 2024			U-1577	
	9050316	Feb 18, 2024			U-1577	
	9328133	Feb 18, 2024	DS DP		U-1577	
	9387191	Jul 21, 2030	DP			
	9757416	Feb 18, 2024	DS DP		U-1577	
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	7816404	Apr 17, 2029			DP U-1656	
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020			U-1422	
	8591864	Mar 08, 2020	DP			
	8926947	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	6858650	Jul 03, 2022	DS		U-913	
	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027			DP U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
	8088398	Jun 07, 2027			DP U-913	
	8338478	May 11, 2019	DS DP		U-913	
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	6858650	Jul 03, 2022	DS		U-913	
	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027			DP U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
	8088398	Jun 07, 2027			DP U-913	
	8338478	May 11, 2019	DS DP		U-913	
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	6723348	Nov 26, 2021	DP		U-1466	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	6723348	Nov 26, 2021	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786 002	6039974	Jul 31, 2018	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704 002	6613357	Dec 25, 2020	DP		U-1159	
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7378508	Jul 31, 2027	DS DP			
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027			U-319	
	8586551	Jul 15, 2023	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FIDAXOMICIN - DIFICID</u>						
N 201699	001 8859510	Jul 31, 2027	U-319			
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001 8536167	Aug 08, 2031	U-1679		NCE	Dec 17, 2019
	9119859	Jul 02, 2030	U-1679		PED	Jun 17, 2020
	9504691	Nov 21, 2033	DP U-1679			
<u>FINASTERIDE - PROSCAR</u>						
N 020180	001 5942519	Oct 23, 2018	U-280			
<u>FINGOLIMOD - GILENYA</u>						
N 022527	001 5604229	Feb 18, 2019	DS U-1086			
	6004565	Sep 23, 2017	U-1086			
	8324283	Mar 29, 2026				
	9187405	Jun 25, 2027	U-1086			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	001				NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	002				NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	003				NCE	Jul 13, 2021
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001 7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
	9468639	Oct 16, 2022	U-1734			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677	001 7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	001 7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	002 7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	003 7687052	Apr 30, 2027	DS DP			
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001 5808146	Nov 09, 2018	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273	001 7148207	Dec 20, 2022	DP U-944			
	7547776	Dec 10, 2018	DS			
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737	001 6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE - ILLUVIEN</u>						
N 201923	001 6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001 7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	7915243	Mar 22, 2026	DP		
		7939516	May 04, 2025	DP		
		8247395	Oct 22, 2022	DP		
		8653053	Oct 25, 2022	DP		
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001	6765001	Dec 21, 2021	DP		
		7220424	Jan 07, 2023	U-861		
		7794738	Sep 11, 2022	U-1084		
		8232264	Mar 09, 2023	DP		
<u>FLUOROURACIL - CARAC</u>						
N 020985	001	6670335	Jun 02, 2021	DP	U-68	
<u>FLUOROURACIL - TOLAK</u>						
N 022259	001	7169401	Jul 18, 2023	DP	NP	Sep 18, 2018
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	001	6960577	Nov 01, 2017	U-963		
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	003	6960577	Nov 01, 2017	U-963		
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	006	6960577	Nov 01, 2017	U-963		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	001	6960577	Nov 01, 2017	U-962	M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	002	6960577	Nov 01, 2017	U-962	M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	003	6960577	Nov 01, 2017	U-962	M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	004	6960577	Nov 01, 2017	U-962	M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	005	6960577	Nov 01, 2017	U-962	M-142	Oct 10, 2017
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	001	7270800	Sep 03, 2025	DS DP	U-336	NCE
		7351401	Jan 24, 2023	DS DP	U-336	
		8236282	May 21, 2024	DS DP		
		8691185	Jan 24, 2023		U-336	
		8916131	Sep 16, 2028	DP		
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	002	7270800	Sep 03, 2025	DS DP	U-336	NCE
		7351401	Jan 24, 2023	DS DP	U-336	
		8236282	May 21, 2024	DS DP		
		8691185	Jan 24, 2023		U-336	
		8916131	Sep 16, 2028	DP		
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051	002	6858596	Aug 03, 2021	DP	U-1890	
		7101866	Aug 03, 2021	DS DP	U-1890	
		7541350	Aug 03, 2021	DP	U-1890	
		8062264	Apr 05, 2026	DP		
		8147461	Oct 15, 2028	DP		
		8347879	Jul 15, 2028	DP		
		8752543	Apr 05, 2026	DP		
		9320862	Nov 06, 2024	DP		
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001	7101866	Aug 03, 2021	DS DP	U-1559	NP
		7629335	Aug 03, 2021	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	7101866	Aug 03, 2021	DS DP U-1559		NP	Aug 20, 2017
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	6537983	Aug 03, 2021	DP U-2125		NCE	May 10, 2018
	6759398	Aug 03, 2021	DP U-2125		NCE	Dec 18, 2018
	6878698	Aug 03, 2021	U-2134			
	7101866	Aug 03, 2021	DS DP U-2126			
	7439393	May 21, 2025	DS DP U-2127			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750762	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691		M-202	May 15, 2020
	6759398	Aug 03, 2021	DP U-1401		NCE	May 10, 2018
	6759398	Aug 03, 2021	DP U-1691			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	6537983	Aug 03, 2021	DP U-1691		M-202	May 15, 2020
	6759398	Aug 03, 2021	DP U-1691		NCE	May 10, 2018
	7101866	Aug 03, 2021	DS DP U-1691		NP	Apr 30, 2018
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Jun 14, 2027	DP	U-1691	
		8534281	Aug 10, 2029	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		RE44874	Mar 23, 2023	DS DP	U-1691	
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152	001	7300669	Oct 20, 2019	DP	U-835	NPP Jan 16, 2018
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021	U-581		Y
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434	001				M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	003	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022	001	6715485	Mar 03, 2020	DP	NP	Sep 18, 2020
		7975690	Dec 29, 2025	U-2133		
		8327844	Oct 08, 2023	U-2133		
		8522778	May 11, 2022	DP		
		8550073	Oct 22, 2029	DP		
		8555878	Mar 20, 2020	DP		
		8978647	Aug 06, 2030	DP		
		9072857	Apr 10, 2021	DP		
		9468727	Jul 30, 2020	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077	001				M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077	002				M-214	Dec 20, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077	003				M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	003	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP U-645		
		9216260	Jun 28, 2031	DP		
		9415008	Oct 06, 2034	DP U-645		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	002	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP	U-645	
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	003	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP	U-645	
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192	001	6242003	Apr 13, 2020			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	001	7465462	May 10, 2020	DP	U-929	
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	002	7465462	May 10, 2020	DP	U-929	
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378	004	7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378	005	7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	001	5929028	Jan 14, 2018	DP	U-1366	
		5929028	Jan 14, 2018	DP	U-567	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
		7563763	Aug 23, 2019		U-993	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	002	5929028	Jan 14, 2018	DP	U-1366	
		5929028	Jan 14, 2018	DP	U-567	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
		7563763	Aug 23, 2019		U-993	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-1366			
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-993			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-1366			
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-993			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 001	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 002	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 003	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS DP			
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020	U-762			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP U-813			
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP U-813			
	8623922	Jun 22, 2021	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
	9463161	May 28, 2030	DP U-1841			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	6068832	Aug 27, 2017	DP U-1068		M-214	Dec 20, 2020
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	6068832	Aug 27, 2017	DP U-1068		M-214	Dec 20, 2020
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548 001	6436989	Dec 24, 2017	DS DP U-257			
	6514953	Jul 15, 2019	DS DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116	001 6436989	Dec 24, 2017	DS DP U-257			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	001 5691336	Mar 04, 2019	DS DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	002 5691336	Mar 04, 2019	DS DP		D-155	Feb 01, 2019
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244	001 6204257	Jul 01, 2022	DS DP U-945			
	6872838	Aug 07, 2018	DS			
<u>FULVESTRANT - FASLODEX</u>						
N 021344	001 6774122	Jan 09, 2021		U-1826	I-725	Feb 19, 2019
	6774122	Jan 09, 2021		U-2108	I-749	Aug 25, 2020
	6774122	Jan 09, 2021		U-2163		
	6774122	Jan 09, 2021		U-596		
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021		U-1826		
	7456160	Jan 09, 2021		U-2108		
	7456160	Jan 09, 2021		U-2163		
	7456160	Jan 09, 2021		U-596		
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021		U-1826		
	8329680	Jan 09, 2021		U-2108		
	8329680	Jan 09, 2021		U-2163		
	8329680	Jan 09, 2021		U-596		
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021		U-1826		
	8466139	Jan 09, 2021		U-2108		
	8466139	Jan 09, 2021		U-2163		
	8466139	Jan 09, 2021		U-596		
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - NEURONTIN</u>						
N 021129	001 7256216	May 28, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544	001 6488962	Jun 20, 2020	DP		ODE-6	Jan 28, 2018
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
	8333992	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN - GRALISE</u>						
N 022544	002 6488962	Jun 20, 2020	DP		ODE-6	Jan 28, 2018
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
	8333992	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	001 6818787	Nov 06, 2022	DS DP		ODE-25	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP	U-1247		
	8114909	Apr 11, 2026		U-1231		
	8686034	Jan 24, 2025		U-1231		
	8686034	Jan 24, 2025		U-1247		
	8795725	Jun 10, 2029	DP	U-1231		
	8795725	Jun 10, 2029	DP	U-1247		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	002 6818787	Nov 06, 2022	DS DP		ODE-25	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP	U-1247		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	6676929	May 04, 2020	DP			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001	6039931	Nov 13, 2021	U-1239		M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 001	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 002	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 003	7160559	Dec 20, 2019	DP			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE-120	Jun 01, 2021 Jun 01, 2023
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493 001	6333045	Aug 20, 2019	DP		Y	
	6333045*PED	Feb 20, 2020				
<u>GEFITINIB - IRESSA</u>						
N 206995 001					NP ODE-95	Jul 13, 2018 Jul 13, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GEFITINIB - IRESSA</u>						
N 206995	001				NP ODE-95	Jul 13, 2018 Jul 13, 2022
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158	001	6262071	Sep 21, 2019	U-513		
		6331550	Sep 21, 2019	U-511		
		6340689	Sep 14, 2019	U-512		
		6455540	Sep 21, 2019	U-511		
		6723734	Mar 20, 2018	DS DP		
		6803376	Sep 21, 2019	DS DP U-608		
		6803376	Sep 21, 2019	DS DP U-609		
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003	8232250	Aug 19, 2030	U-441		
		8399413	Aug 19, 2030	U-441		
		8969302	Aug 19, 2030	U-441		
		9155776	Aug 19, 2030	U-441		
		9402874	Aug 19, 2030	U-441		
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001	8648037	Jan 19, 2032	DS DP U-2141	NCE	Aug 03, 2022
		8937150	May 18, 2032	DS DP		
		9321807	Jun 05, 2035	DS		
		9586978	Jun 10, 2030	U-2141		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	001	7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	002	7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	001	7358366	Apr 19, 2020	DS		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	002	7358366	Apr 19, 2020	DS		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	003	7358366	Apr 19, 2020	DS		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	004	7358366	Apr 19, 2020	DS		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	005	7358366	Apr 19, 2020	DS		
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	001	RE44459	Mar 26, 2019	U-1431		
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	002	RE44459	Mar 26, 2019	U-1431		
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	003	RE44459	Mar 26, 2019	U-1431		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	001	6303146	Jul 14, 2019	U-412		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	002	6303146	Jul 14, 2019	U-412		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	003	6303146	Jul 14, 2019	U-412		
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	5968979	Jul 28, 2018	DS DP U-1378	NPP	Apr 28, 2020
		8404215	Mar 09, 2032	U-1383	ODE	Apr 28, 2024
		8642012	Sep 22, 2030	U-1383	ODE-42	Feb 01, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284	001 9095559	Mar 09, 2032	U-1383			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
	9561197	Sep 22, 2030	U-1383			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571	001 7638552	Aug 20, 2023	U-1076		ODE-1	Jul 28, 2017
	7816396	Aug 20, 2023	U-1076			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923	001 7229607	Apr 09, 2021	U-1773		NP	Oct 29, 2018
	7736670	Jun 27, 2021	DP			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8182838	Oct 20, 2028	DP			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8956661	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437	001 6962151	Oct 27, 2020	DP		NP	Dec 05, 2020
	7316067	Sep 06, 2022	DP			
	7458372	Nov 18, 2024	DP			
	7931212	Nov 25, 2025	DP			
	8511581	Nov 08, 2023	DP			
	9168556	Sep 01, 2032	DP			
	9265900	Dec 07, 2028	DP			
	9604018	May 16, 2033	DP			
	9789270	Oct 30, 2030	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930	001 6878721	Feb 25, 2025	DS DP U-1773		NP	Oct 29, 2018
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	7820694	Jun 02, 2020	DP U-1773			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8067437	Jun 02, 2020	U-1773			
	8182838	Oct 20, 2028	DP			
	8283362	Jun 02, 2020	DP U-1773			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8658673	Jun 02, 2020	DP U-1773			
	8796307	Jun 02, 2020	DP			
	8956661	Jun 27, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726	001 7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578	001 7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSQ</u>						
N 022198	001 7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445	001 6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GRANISETRON - SUSTOL</u>						
N 022445	001	6613355	Jun 28, 2021	DP	NDF	Aug 09, 2019
		6790458	May 11, 2021	DP		
		8252304	Sep 28, 2024	DP		
		8252305	Sep 28, 2024	U-1891		
		8715710	Sep 28, 2024	DP		
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	001	6372252	Apr 28, 2020	U-489		
		6955821	Apr 28, 2020	DP U-489		
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	002	6372252	Apr 28, 2020	U-489		
		6955821	Apr 28, 2020	DP U-489		
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474	001	9549907	Nov 13, 2035	DS DP	U-2023	
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	001	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP	U-494	PED
		6811794*PED	Jan 04, 2023			May 19, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP	U-494	PED
		6811794*PED	Jan 04, 2023			May 19, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP	U-494	PED
		6811794*PED	Jan 04, 2023			May 19, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP	U-494	PED
		6811794*PED	Jan 04, 2023			May 19, 2018
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183	001	8962028	Jun 19, 2033	DP	U-1775	NP
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001	7348361	Nov 06, 2020	DP	U-1087	
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058	001	8062652	Jun 16, 2026	U-1197		
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859	001	7767429	Sep 23, 2027	DS DP		
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727	001	6465463	Sep 08, 2020	U-71		
		6784177	Sep 08, 2020	U-71		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	001	6358986				Jan 10, 2020
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	002	6358986				Jan 10, 2020
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	6228398		DP		Nov 01, 2019
		6902742		DP		Nov 01, 2019
		9132096		DP		Sep 12, 2034
		9265760			U-1810	Jul 25, 2033
		9326982			U-1810	Jul 25, 2033
		9333201			U-1810	Jul 25, 2033
		9339499			U-1810	Jul 25, 2033
		9421200			U-1810	Jul 25, 2033
		9433619			U-1810	Jul 25, 2033
		9452163			U-55	Sep 12, 2034
		9486451			U-55	Sep 12, 2034
		9610286			U-1810	Jul 25, 2033
		9713611		DP	U-55	Sep 12, 2034
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	6228398		DP		Nov 01, 2019
		6902742		DP		Nov 01, 2019
		9132096		DP		Sep 12, 2034
		9265760			U-1810	Jul 25, 2033
		9326982			U-1810	Jul 25, 2033
		9333201			U-1810	Jul 25, 2033
		9339499			U-1810	Jul 25, 2033
		9421200			U-1810	Jul 25, 2033
		9433619			U-1810	Jul 25, 2033
		9452163			U-55	Sep 12, 2034
		9486451			U-55	Sep 12, 2034
		9610286			U-1810	Jul 25, 2033
		9713611		DP	U-55	Sep 12, 2034
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	6228398		DP		Nov 01, 2019
		6902742		DP		Nov 01, 2019
		9132096		DP		Sep 12, 2034
		9265760			U-1810	Jul 25, 2033
		9326982			U-1810	Jul 25, 2033
		9333201			U-1810	Jul 25, 2033
		9339499			U-1810	Jul 25, 2033
		9421200			U-1810	Jul 25, 2033
		9433619			U-1810	Jul 25, 2033
		9452163			U-55	Sep 12, 2034
		9486451			U-55	Sep 12, 2034
		9610286			U-1810	Jul 25, 2033
		9713611		DP	U-55	Sep 12, 2034
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	6228398		DP		Nov 01, 2019
		6902742		DP		Nov 01, 2019
		9132096		DP		Sep 12, 2034
		9265760			U-1810	Jul 25, 2033
		9326982			U-1810	Jul 25, 2033
		9333201			U-1810	Jul 25, 2033
		9339499			U-1810	Jul 25, 2033
		9421200			U-1810	Jul 25, 2033
		9433619			U-1810	Jul 25, 2033
		9452163			U-55	Sep 12, 2034
		9486451			U-55	Sep 12, 2034
		9610286			U-1810	Jul 25, 2033
		9713611		DP	U-55	Sep 12, 2034
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	6228398		DP		Nov 01, 2019
		6902742		DP		Nov 01, 2019
		9132096		DP		Sep 12, 2034

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033		U-1810		
	9326982	Jul 25, 2033		U-1810		
	9333201	Jul 25, 2033		U-1810		
	9339499	Jul 25, 2033		U-1810		
	9421200	Jul 25, 2033		U-1810		
	9433619	Jul 25, 2033		U-1810		
	9452163	Sep 12, 2034		U-55		
	9486451	Sep 12, 2034		U-55		
	9610286	Jul 25, 2033		U-1810		
	9713611	Sep 12, 2034	DP	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019		DP		
	6902742	Nov 01, 2019		DP		
	9132096	Sep 12, 2034		DP		
	9265760	Jul 25, 2033		U-1810		
	9326982	Jul 25, 2033		U-1810		
	9333201	Jul 25, 2033		U-1810		
	9339499	Jul 25, 2033		U-1810		
	9421200	Jul 25, 2033		U-1810		
	9433619	Jul 25, 2033		U-1810		
	9452163	Sep 12, 2034		U-55		
	9486451	Sep 12, 2034		U-55		
	9610286	Jul 25, 2033		U-1810		
	9713611	Sep 12, 2034	DP	U-55		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	6733783	Oct 30, 2021		DP	U-1556	
	8309060	Nov 20, 2023		DP	U-1556	
	8361499	Oct 30, 2021		DP		
	8529948	Aug 06, 2022		DP		
	8551520	Oct 30, 2021		DP		
	8647667	Oct 30, 2021		DP		
	8808740	Dec 21, 2031		DP	U-1556	
	9023401	Oct 30, 2020		DP		
	9056052	Oct 30, 2020		DP		
	9060940	Oct 30, 2020			U-1556	
	9084816	Aug 24, 2027		DP		
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027		DP		
	9198863	Oct 30, 2020		DP		
	9205056	Oct 30, 2020		DP		
	9289391	Oct 30, 2020		DP		
	9486412	Aug 24, 2027		DP		
	9486413	Aug 24, 2027		DP		
	9492389	Aug 24, 2027		DP		
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9517236	Oct 30, 2020		DP		
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031		DP		
	9572804	Oct 30, 2020		DP		
	9669023	Oct 30, 2020		DP		
	9669024	Oct 30, 2020		DP		
	9675610	Jun 16, 2023		DP		
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
	9750703	Dec 21, 2031		DP		
	9763933	Aug 24, 2027		DP		
	9770416	Aug 24, 2027		DP		
	9775809	Aug 24, 2027		DP		
	9861584	Dec 21, 2031		DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	6733783	Oct 30, 2021		DP	U-1556	
	8309060	Nov 20, 2023		DP	U-1556	
	8361499	Oct 30, 2021		DP		
	8529948	Aug 06, 2022		DP		
	8551520	Oct 30, 2021		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	005	9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	006	6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	007	6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2021	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	007	9675611	Oct 30, 2020	U-1556		
		9682077	Oct 30, 2020	U-1556		
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	001	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	002	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	003	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	004	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	005	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCORTISONE BUTYRATE - LOCROID</u>						
N 022076	001	7378405	Dec 19, 2026	DP		
		7981877	Jan 23, 2025	DP		
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305	001	7381427	Jun 08, 2022	U-2205	NP	Dec 14, 2020
		9675639	Jul 04, 2035	DP U-2205		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	001	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	002	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	003	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	004	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	005	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	002	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	003	6589960	Nov 09, 2020	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	001	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	002	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	003	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	004	6589960	Nov 09, 2020	DP		
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945	001				ODE-7	Feb 03, 2018
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945	002				ODE-7	Feb 03, 2018
<u>HYDROXYUREA - SIKLOS</u>						
N 208843	001				NP	Dec 21, 2020
<u>HYDROXYUREA - SIKLOS</u>						
N 208843	002				NP	Dec 21, 2020
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	001	6294196	Oct 07, 2019	DP		
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	002	6294196	Oct 07, 2019	DP		
		7192938	May 06, 2023	U-798		
		7410957	May 06, 2023	U-887		
		7718634	May 06, 2023	U-642		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	7514444	Dec 28, 2026	DS DP	D-165	May 06, 2019
		8008309	Dec 28, 2026	DS DP	I-689	Jul 28, 2017
		8476284	Dec 28, 2026		I-702	Jan 29, 2018
		8476284	Dec 28, 2026		U-1456	Jan 29, 2018
		8476284	Dec 28, 2026		U-1650	Mar 04, 2019
		8476284	Dec 28, 2026		U-1946	May 06, 2019
		8476284	Dec 28, 2026		U-1947	May 06, 2019
		8497277	Dec 28, 2026		U-1456	Jan 18, 2020
		8497277	Dec 28, 2026		U-1491	Jan 18, 2020
		8497277	Dec 28, 2026		U-1650	Aug 02, 2020
		8497277	Dec 28, 2026		NCE	Nov 13, 2018
		8497277	Dec 28, 2026		U-1946	Mar 04, 2023
		8497277	Dec 28, 2026		U-1947	Mar 04, 2023
		8697711	Dec 28, 2026	DS DP	ODE-109	May 06, 2023
		8703780	Dec 28, 2026		ODE-117	Jan 18, 2024
		8735403	Dec 28, 2026	DS DP	ODE-128	Aug 02, 2024
		8754090	Jun 03, 2031		ODE-152	Nov 13, 2020
		8754091	Dec 28, 2026	DP	ODE-55	Feb 12, 2021
		8952015	Dec 28, 2026		ODE-60	Jul 28, 2021
		8952015	Dec 28, 2026		ODE-72	Jan 29, 2022
		8952015	Dec 28, 2026		ODE-86	
		8952015	Dec 28, 2026			
		8952015	Dec 28, 2026			
		8952015	Dec 28, 2026			
		8952015	Dec 28, 2026			
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031		U-1456	
		8999999	Jun 03, 2031		U-1683	
		8999999	Jun 03, 2031		U-1684	
		9125889	Jun 03, 2031		U-1745	
		9181257	Dec 28, 2026	DS DP		
		9296753	Oct 30, 2033	DS DP		
		9540382	Aug 18, 2033		U-1456	
		9540382	Aug 18, 2033		U-1650	
		9540382	Aug 18, 2033		U-1684	
		9540382	Aug 18, 2033		U-1946	
		9540382	Aug 18, 2033		U-1947	
		9713617	Jun 03, 2033	DP		
		9725455	Jun 03, 2033			
		9795604	Oct 24, 2034	DS	U-2150	
		9801881	Jun 03, 2031		U-1491	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	9801883	Jun 03, 2031	U-2159		
		9814721	Jun 03, 2031	U-1947		
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472	001	6251426	Jun 25, 2018			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001	6727286	Nov 27, 2021	DP U-981		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	6727286	Nov 27, 2021	DP U-981	D-152	Nov 20, 2018
		8735452	Sep 30, 2029	U-981	NPP	Nov 20, 2018
		8871810	Sep 30, 2029	U-1599		
		9012508	Sep 14, 2030	U-981		
		9114068	Sep 30, 2029	U-1735		
		9138404	Sep 30, 2029	U-1756		
		9295639	Sep 30, 2029	U-1756		
		9649284	Sep 30, 2029	U-2018		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903	001	6342530	Nov 14, 2020	DP U-1127		
		6342530	Nov 14, 2020	DP U-794		
		6344479	Mar 20, 2021	DS DP U-794	Y	
		8415337	Mar 02, 2032	DS DP		
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128	001	6211246	Jun 10, 2019			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150	001	5648333	Jul 15, 2019	DS DP U-1187	ODE-14	Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321	001	6248726	Jun 19, 2018	U-495		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001	8188146	Jan 27, 2020	DS DP	NCE	Jul 26, 2017
		8293727	Feb 09, 2030	U-1287		
		8293728	Feb 09, 2030	U-1287		
		8298554	Apr 29, 2030	DP		
		8314086	Feb 09, 2030	U-1287		
		8318715	Feb 09, 2030	U-1287		
		8357677	Feb 09, 2030	U-1287		
		8367652	Feb 09, 2030	U-1287		
		8377920	Feb 09, 2030	U-1287		
		8399446	Feb 09, 2030	U-1287		
		8415335	Feb 09, 2030	U-1287		
		8426399	Feb 09, 2030	U-1287		
		8431560	Feb 09, 2030	U-1287		
		8440650	Feb 09, 2030	U-1287		
		8445003	Apr 29, 2030	U-1287		
		8445013	Apr 29, 2030	U-1287		
		8501225	Apr 29, 2030	U-1287		
		8518929	Apr 29, 2030	U-1287		
		8524698	Apr 29, 2030	U-1287		
		8546372	Apr 29, 2030	U-1287		
		8551521	Apr 29, 2030	U-1287		
		8563608	Apr 29, 2030	U-1287		
		8617593	Apr 29, 2030	U-1478		
		8617594	Apr 29, 2030	U-1287		
		8623406	Apr 29, 2030	U-1478		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	002	8188146	Jan 27, 2020	DS DP	NCE	Jul 26, 2017
		8293727	Feb 09, 2030	U-1287		
		8293728	Feb 09, 2030	U-1287		
		8298554	Apr 29, 2030	DP		
		8314086	Feb 09, 2030	U-1287		
		8318715	Feb 09, 2030	U-1287		
		8357677	Feb 09, 2030	U-1287		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	002	8367652	Feb 09, 2030	U-1287		
		8377920	Feb 09, 2030	U-1287		
		8399446	Feb 09, 2030	U-1287		
		8415335	Feb 09, 2030	U-1287		
		8426399	Feb 09, 2030	U-1287		
		8440650	Feb 09, 2030	U-1287		
		8445003	Apr 29, 2030	U-1287		
		8445013	Apr 29, 2030	U-1287		
		8501225	Apr 29, 2030	U-1287		
		8518929	Apr 29, 2030	U-1287		
		8524698	Apr 29, 2030	U-1287		
		8546372	Apr 29, 2030	U-1287		
		8551521	Apr 29, 2030	U-1287		
		8563608	Apr 29, 2030	U-1287		
		8617593	Apr 29, 2030	U-1287		
		8617594	Apr 29, 2030	U-1287		
		8623406	Apr 29, 2030	U-1287		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	001	6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		6949535	Apr 24, 2021	DS U-1560	ODE-70	Jul 23, 2021
		8138195	Apr 24, 2021	DS DP U-1549	ODE-71	Jul 23, 2021
		8492389	Apr 24, 2021	DS DP		
		8637533	Apr 24, 2021	DS DP		
		8865730	Mar 05, 2033	DS DP U-1615		
		8980901	May 12, 2025	U-1678		
		9149477	May 12, 2025	U-1757		
		9469643	Sep 02, 2033	DS		
		9492449	Mar 11, 2030	U-1914		
		RE44599	Jul 21, 2025	U-1558		
		RE44599	Jul 21, 2025	U-1615		
		RE44638	Aug 05, 2025	DS DP		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		6949535	Apr 24, 2021	DS U-1560	ODE-70	Jul 23, 2021
		8138195	Apr 24, 2021	DS DP U-1549	ODE-71	Jul 23, 2021
		8492389	Apr 24, 2021	DS DP		
		8637533	Apr 24, 2021	DS DP		
		8865730	Mar 05, 2033	DS DP U-1615		
		8980901	May 12, 2025	U-1678		
		9149477	May 12, 2025	U-1757		
		9469643	Sep 02, 2033	DS		
		9492449	Mar 11, 2030	U-1914		
		RE44599	Jul 21, 2025	U-1558		
		RE44599	Jul 21, 2025	U-1615		
		RE44638	Aug 05, 2025	DS DP		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jul 16, 2018	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	6894051	May 23, 2019	DS DP	U-649	
		6958335	Dec 19, 2021		U-791	
		RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	001	6894051	May 23, 2019	DS DP	U-649	ODE-40 Jan 25, 2020
		6958335	Dec 19, 2021		U-1883	
		6958335	Dec 19, 2021		U-791	
		6958335*PED	Jun 19, 2022			
		7544799	Jul 16, 2018	DS DP		Y
		7544799*PED	Jan 16, 2019			
		RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	002	6894051	May 23, 2019	DS DP	U-649	ODE-40 Jan 25, 2020
		6958335	Dec 19, 2021		U-1883	
		6958335	Dec 19, 2021		U-791	
		6958335*PED	Jun 19, 2022			
		7544799	Jul 16, 2018	DS DP		Y
		7544799*PED	Jan 16, 2019			
		RE43932	Jul 16, 2018	DS DP		
		RE43932*PED	Jan 16, 2019			
<u>IMIQUIMOD - ALDARA</u>						
N 020723	001	7696159	Apr 01, 2024	DS	U-1047	
		7696159	Apr 01, 2024	DS	U-1048	
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	8236816	Dec 11, 2029		U-68	
		8299109	Dec 11, 2029		U-68	
		8598196	Aug 18, 2029		U-1455	
		8598196	Aug 18, 2029		U-172	
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	002	8222270	Dec 11, 2029		U-68	
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383	001	6878721	Feb 25, 2025	DS DP	U-1168	
		8067437	Jun 02, 2020		U-1168	
		8479730	Oct 11, 2028		DP	
		8658673	Jun 02, 2020	DS DP	U-1168	
		8796307	Jun 02, 2020	DS DP		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	001	6645961	Mar 04, 2018	DP		
		6689761	Feb 10, 2021		U-554	
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	003	6645961	Mar 04, 2018	DP		
		6689761	Feb 10, 2021		U-554	
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	005	6645961	Mar 04, 2018	DP		
		6689761	Feb 10, 2021		U-554	
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	006	6645961	Mar 04, 2018	DP		
		6689761	Feb 10, 2021		U-554	
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314	001	6123916	Sep 26, 2017		U-1125	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6432452	Aug 19, 2018	U-68		M-169	Nov 19, 2018
	6787161	Aug 19, 2018	U-68			
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6432452	Aug 19, 2018	U-68			
	6787161	Aug 19, 2018	U-68			
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
	7686786	Aug 03, 2026	DP			
	8324157	Jun 25, 2030	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Jan 20, 2026	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986	003	RE43834				
		Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986	004	RE41956				
		Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	5866538*PED				
		Dec 20, 2017				
		6899699	DP			
		Jan 02, 2022				
		8672898	DP			
		Jan 02, 2022				
		8684969	DP			
		Oct 20, 2025				
		8920383	DP			
		Jul 17, 2026				
		9108002	DP			
		Jan 20, 2026				
		9132239	DP			
		Feb 01, 2032				
		9457154	DP			
		Sep 27, 2027				
		9486588	DP			
		Jan 02, 2022				
		9687611	DP			
		Feb 27, 2027				
		9775953	DP			
		Jul 17, 2026				
		RE46363	DP			
		Aug 03, 2026				
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313	001	6899699			NCE	Sep 25, 2020
		Jan 02, 2022				
		7615532	DS DP		NPP	Dec 16, 2019
		May 25, 2025				
		8672898	DP			
		Jan 02, 2022				
		8684969	DP			
		Oct 20, 2025				
		8920383	DP			
		Jul 17, 2026				
		9108002	DP			
		Jan 20, 2026				
		9132239	DP			
		Feb 01, 2032				
		9457154	DP			
		Sep 27, 2027				
		9486588	DP			
		Jan 02, 2022				
		9687611	DP			
		Feb 27, 2027				
		9775953	DP			
		Jul 17, 2026				
		RE46363	DP			
		Aug 03, 2026				
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314	001	6899699			NCE	Sep 25, 2020
		Jan 02, 2022				
		7615532	DS DP		NPP	Dec 16, 2019
		May 25, 2025				
		8672898	DP			
		Jan 02, 2022				
		8684969	DP			
		Oct 20, 2025				
		8920383	DP			
		Jul 17, 2026				
		9108002	DP			
		Jan 20, 2026				
		9132239	DP			
		Feb 01, 2032				
		9457154	DP			
		Sep 27, 2027				
		9486588	DP			
		Jan 02, 2022				
		9687611	DP			
		Feb 27, 2027				
		9775953	DP			
		Jul 17, 2026				
		RE46363	DP			
		Aug 03, 2026				
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314	002	6899699			NCE	Sep 25, 2020
		Jan 02, 2022				
		7615532	DS DP		NPP	Dec 16, 2019
		May 25, 2025				
		8672898	DP			
		Jan 02, 2022				
		8684969	DP			
		Oct 20, 2025				
		8920383	DP			
		Jul 17, 2026				
		9108002	DP			
		Jan 20, 2026				
		9132239	DP			
		Feb 01, 2032				
		9457154	DP			
		Sep 27, 2027				
		9486588	DP			
		Jan 02, 2022				
		9687611	DP			
		Feb 27, 2027				
		9775953	DP			
		Jul 17, 2026				
		RE46363	DP			
		Aug 03, 2026				
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583	001	6268343			NC	Nov 21, 2019
		Aug 22, 2022	DS DP			
		6458924	DS DP		NCE	Sep 25, 2020
		Aug 22, 2017				
		6899699	DP			
		Jan 02, 2022				
		7235627	DS			
		Aug 22, 2017				
		7615532	DS DP			
		May 25, 2025				
		8672898	DP			
		Jan 02, 2022				
		8684969	DP			
		Oct 20, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583	001	8846618	Jun 27, 2022	DS DP		
		8920383	Jul 17, 2026	DP		
		8937042	May 05, 2029	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536	001	5750497	Jun 16, 2019	DS DP	U-668	
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536	002	5750497	Jun 16, 2019	DS DP	U-668	
		6004297	Jan 28, 2019	DP		
		9265893	Sep 23, 2032	DP		
		RE41956	Jan 21, 2021	DP		
		RE43834	Jan 28, 2019	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536	003	5750497	Jun 16, 2019	DS DP	U-668	
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536	004	5750497	Jun 16, 2019	DS DP	U-668	
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	5750497	Jun 16, 2019	DS DP	U-668	
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>INSULIN GLARGINE - BASAGLAR</u>						
N 205692	001				NP	Dec 16, 2018
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081	001	7476652	Jul 23, 2023	DP		
		7713930	Jun 13, 2023	DP		
		7918833	Sep 23, 2027	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024		U-1832	
		9233211	Mar 02, 2024	DP		
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		
		9561331	Aug 28, 2024	DP		
		9604008	Mar 02, 2024	DP		
		9604009	Aug 16, 2024	DP		
		9610409	Mar 02, 2024	DP		
		9623189	Aug 19, 2024	DP		
		9775954	Mar 02, 2024	DP		
		9827379	Mar 02, 2024	DP	U-2146	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	7918833	Sep 23, 2027	DP		NC	Nov 21, 2019
	8512297	Sep 15, 2024	DP		NCE	Jul 27, 2021
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1923		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526764	Oct 09, 2029	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9775954	Mar 02, 2024	DP			
	9821032	May 09, 2032		U-2182		
	9827379	Mar 02, 2024	DP	U-2146		
	RE45313	Jul 12, 2020	DS DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 002	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1832		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO - ADMELOG</u>						
N 209196 001					NP	Dec 11, 2020
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002					NP	Dec 11, 2020
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP	U-1707		
	6034054	Jun 11, 2018	DP	U-1708		
	6551992	Jun 11, 2018	DP	U-1707		
	6551992	Jun 11, 2018	DP	U-1708		
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 001	6257233	May 14, 2019		U-704		
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 002	6257233	May 14, 2019		U-704		
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6444226	Jun 29, 2020	DP	U-1534		
	6652885	Jun 29, 2020		U-1535		
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020		U-1535		
	7943178	Jun 29, 2020	DP	U-1535		
	7943572	Aug 10, 2026		U-1539		
	8119593	Aug 11, 2029		U-1537		
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1621		
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029		U-1537		
	8636001	Jul 12, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP	U-1788		
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP	U-1861		
	9511198	Feb 16, 2030		U-1929		
	9511198	Feb 16, 2030		U-1930		
	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP	U-1534		
	6652885	Jun 29, 2020		U-1535		
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020		U-1535		
	7943178	Jun 29, 2020	DP	U-1535		
	7943572	Aug 10, 2026		U-1539		
	8119593	Aug 11, 2029		U-1537		
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1621		
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029		U-1537		
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP	U-1788		
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP	U-1861		
	9511198	Feb 16, 2030		U-1929		
	9511198	Feb 16, 2030		U-1930		
	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP	U-1534		
	6652885	Jun 29, 2020		U-1535		
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020		U-1535		
	7943178	Jun 29, 2020	DP	U-1535		
	7943572	Aug 10, 2026		U-1539		
	8119593	Aug 11, 2029		U-1537		
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1621		
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029		U-1537		
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP	U-1788		
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP	U-1861		
	9511198	Feb 16, 2030		U-1929		
	9511198	Feb 16, 2030		U-1930		
	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351 002					I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808 002					I-752	Apr 05, 2020
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 001	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 002	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	8329213	May 02, 2025	DS DP		ODE-99	Oct 22, 2022
	8703181	May 02, 2025		U-1434		
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033		U-1848		
	9364473	Jun 12, 2033		U-1856		
	9452162	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1848		
	9492442	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1917		
	9717724	Jun 12, 2033		U-1848		
	9717724	Jun 12, 2033		U-2091		
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025		U-1848		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001 9782349	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001 6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001 6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	001 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	002 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	003 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	004 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	005 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	006 7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657	001 6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966	001 6407079	Jun 18, 2019				
<u>ITRACONAZOLE - ONMEL</u>						
N 022484	001 8486456	Oct 03, 2028	DP U-1054			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	001 7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	001	7879842	Feb 22, 2026	DS DP U-1694		
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	002	7361649	Apr 17, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361650	Apr 14, 2026	DS DP U-1694		
		7867996	Feb 22, 2026	DS DP U-1694		
		7879842	Feb 22, 2026	DS DP U-1694		
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	7495103	May 20, 2027	DS DP	I-705	Dec 30, 2017
		8324242	Aug 05, 2027	U-1311	NPP	Jul 31, 2020
		8324242	Aug 05, 2027	U-1906	ODE-20	Jan 31, 2019
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8410274	Dec 28, 2026	DP		
		8754224	Dec 28, 2026	DS DP		
		9670163	Dec 28, 2026	DP U-1311		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	7495103	May 20, 2027	DS DP	NPP	Jul 31, 2020
		8324242	Aug 05, 2027	U-1311	ODE-20	Jan 31, 2019
		8324242	Aug 05, 2027	U-1906		
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8410274	Dec 28, 2026	DP		
		8754224	Dec 28, 2026	DS DP		
		8883206	Feb 27, 2033	DP		
		9670163	Dec 28, 2026	DP U-1311		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	7495103	May 20, 2027	DS DP	NPP	Jul 31, 2020
		8324242	Aug 05, 2027	U-1311	ODE-20	Jan 31, 2019
		8324242	Aug 05, 2027	U-1906		
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8410274	Dec 28, 2026	DP		
		8754224	Dec 28, 2026	DS DP		
		8883206	Feb 27, 2033	DP		
		9670163	Dec 28, 2026	DP U-1311		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	7495103	May 20, 2027	DS DP	NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-1973	ODE-123	Sep 28, 2023
		8324242	Aug 05, 2027	U-1311	ODE-93	Jul 02, 2022
		8324242	Aug 05, 2027	U-1911		
		8410274	Dec 28, 2026	DP		
		8507534	Sep 20, 2030	DS DP		
		8653103	Dec 04, 2028	DP		
		8716338	Sep 20, 2030	DP U-1718		
		8716338	Sep 20, 2030	DP U-1910		
		8741933	Nov 08, 2026	U-1717		
		8741933	Nov 08, 2026	U-1909		
		8754224	Dec 28, 2026	DS DP		
		8846718	Dec 04, 2028	U-1717		
		8846718	Dec 04, 2028	U-1908		
		8993600	Dec 11, 2030	DP		
		9150552	Dec 04, 2028	U-1908		
		9192606	Sep 29, 2029	DP U-1912		
		9216969	Nov 08, 2026	DS DP		
		9670163	Dec 28, 2026	DP U-1911		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	7495103	May 20, 2027	DS DP	NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-1973	NPP	Sep 28, 2019
		8324242	Aug 05, 2027	U-1911	ODE-123	Sep 28, 2023
		8410274	Dec 28, 2026	DP	ODE-93	Jul 02, 2022
		8507534	Sep 20, 2030	DS DP		
		8653103	Dec 04, 2028	DP		
		8716338	Sep 20, 2030	DP U-1910		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	8741933				
		8754224				
		8846718				
		8993600				
		9150552				
		9192606				
		9216969				
		9670163				
<u>IVERMECTIN - SKLICE</u>						
N 202736	001	6103248				
		8791153				
		8927595				
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255	001	5952372				
		6133310				
		7550440				
		8080530				
		8093219				
		8415311				
		8470788				
		8815816				
		9089587				
		9233117				
		9233118				
		9782425				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	001	6670384				
		6670384				
		7022330				
		7125899				
		7312237				
		RE41393				
		RE41911				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002	6670384				
		6670384				
		7022330				
		7125899				
		7312237				
		RE41393				
		RE41911				
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001	7442830				
		7687662				
		8003819				
		8530694				
		8546608				
		8859504				
		8871745				
		9175017				
		9233115				
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	002	7442830				
		7687662				
		8003819				
		8530694				
		8546608				
		8859504				
		8871745				
		9175017				
		9233115				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027		U-1779		
	9175017	Jun 16, 2029		U-1778		
	9233115	Aug 12, 2024		U-1778		
<u>KETOCONAZOLE - EXTINA</u>						
N 021738 001	7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024		U-1251		
	8377982	May 28, 2024		U-1363		
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024		U-1441		
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024		DP		
	8906950	May 28, 2024		U-1626		
	8946281	May 28, 2024		U-1662		
	9216167	May 28, 2024		U-1800		
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382 001	6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028		DP		
	8992952	Aug 05, 2024		DP		
	9192571	Mar 07, 2028		DP		
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023		U-1518	NPP	Dec 08, 2020
	8173707*PED	Jan 30, 2024			PED	Jun 08, 2021
	8586633	Jul 30, 2023		DP		
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033		DP		
	9066856*PED	Apr 23, 2034				
	9278101	Jul 30, 2023		U-1518		
	9278101*PED	Jan 30, 2024				
	9399040	Jul 30, 2023		DP		
	9399040*PED	Jan 30, 2024				
	9486406	Oct 23, 2033		DP		
	9486406*PED	Apr 23, 2034				
	9855246	Oct 23, 2033		DP		
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					I-748	Jul 07, 2020
					ODE-150	Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS	U-1567	D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS	U-2140	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
					NPP	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS	U-1567	D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS	U-2140	D-144	Aug 29, 2017
					I-696	Aug 29, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002				NPP	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003	RE38551	Mar 17, 2022	DS U-1567	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS U-2140	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
					NPP	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004	RE38551	Mar 17, 2022	DS U-1567	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS U-2140	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
					NPP	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1568	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
					M-217	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022255	001	RE38551	Mar 17, 2022	DS U-1567	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS U-2140	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
					NPP	Nov 03, 2020
<u>LAMIVUDINE - EPIVIR</u>						
N 020596	001	6004968	Mar 20, 2018	DP U-248		
		6004968*PED	Sep 20, 2018			
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004	001	6004968	Mar 20, 2018			
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713	Oct 21, 2022		U-1663	
		7217713*PED	Apr 21, 2023			
		7435734	Oct 21, 2022		U-1663	
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP	U-1663	
		7754731*PED	Sep 11, 2029			
		7820660	Apr 25, 2023	DS		
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	005				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	006				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	002				M-159	May 18, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	002	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	003	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	004	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
		9339504	Jul 02, 2028	DP U-1596		
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	001	5595760	Mar 08, 2020	DP U-831	I-701 I-754 ODE-156 ODE-82	Dec 19, 2017 Sep 15, 2020 Sep 15, 2024 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	002	5595760	Mar 08, 2020	DP U-831	I-701 I-754 ODE-156 ODE-82	Dec 19, 2017 Sep 15, 2020 Sep 15, 2024 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	003	5595760	Mar 08, 2020	DP U-831	I-701 I-754 ODE-156 ODE-82	Dec 19, 2017 Sep 15, 2020 Sep 15, 2024 Dec 16, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-1429			
	6391874	Jul 11, 2017	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6828320	Jul 11, 2017	U-1429			
	6828320	Jul 11, 2017	U-800			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Sep 18, 2029	DS DP			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	6211233	Jun 17, 2018	DS DP			
	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		D-153	Nov 12, 2018
	8088368	May 12, 2030	DS DP		D-158	Feb 12, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	8273341	May 12, 2030	U-1470		D-159	Feb 12, 2019
	8334270	Mar 21, 2028	DS DP U-1470		D-160	Feb 12, 2019
	8580765	Mar 21, 2028	DS DP U-1470		I-718	Nov 12, 2018
	8618076	Dec 11, 2030	DS DP U-1470		I-719	Nov 12, 2018
	8633309	Mar 26, 2029	DS DP U-1470		I-720	Nov 12, 2018
	8735372	Mar 21, 2028	U-1470		NCE	Oct 10, 2019
	8822430	May 12, 2030	DS DP U-1470		NPP	Nov 12, 2018
	8841278	May 12, 2030	DP U-1470		NPP	Apr 07, 2020
	8889159	Mar 26, 2029	DP U-1470		ODE-136	Apr 07, 2024
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9393256	Sep 14, 2032	U-1470			
	9511056	May 12, 2030	DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561976	Aug 28, 2018	U-1210		ODE-88	Feb 17, 2022
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS		NCE	Dec 22, 2020
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935	001	8962630	Dec 09, 2029	U-1981		
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029	U-1981		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	003	7429559	Jan 13, 2019	DP		
		8815801	Jun 28, 2022	DP		
		8921326	Feb 05, 2031	DP	U-1666	
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088	001	6113938	Jul 24, 2018			
		6375978	Dec 17, 2018			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	
		9254307	Oct 28, 2018	DS DP		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	
		8470359	Oct 15, 2023	DS DP	U-621	
		8486455	Oct 28, 2018	DS DP		
		8840916	Nov 13, 2020	DP		
		9283282	Oct 28, 2018	DS DP		
		9539333	Nov 13, 2020	DS DP	U-621	
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	
		8470359	Oct 15, 2023	DS DP	U-621	
		8486455	Oct 28, 2018	DS DP		
		8840916	Nov 13, 2020	DP		
		9283282	Oct 28, 2018	DS DP		
		9539333	Nov 13, 2020	DS DP	U-621	
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731	001	6565874	Oct 28, 2018	DP	U-621	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018		U-621	
		8470359	Oct 15, 2023	DS DP	U-621	
		8486455	Oct 28, 2018	DS DP		
		8840916	Nov 13, 2020	DP		
		9283282	Oct 28, 2018	DS DP		
		9539333	Nov 13, 2020	DS DP	U-621	
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004	6451289	Mar 21, 2021	DP	M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001	7256310	Oct 08, 2024	DS DP	U-636	M-156
		8765153	Dec 08, 2023	DP		Mar 12, 2018
<u>LEVETIRACETAM - ROWEEPRA</u>						
A 090906	003				PC	Sep 13, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 002	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP	U-1850		
	9463160	Feb 20, 2018	DP			
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP	U-1850		
	9463160	Feb 20, 2018	DP			
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP	U-1850		
	9463160	Feb 20, 2018	DP			
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP	U-1850		
	9463160	Feb 20, 2018	DP			
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182 001	6335369	Jan 18, 2021		U-433		
	6429230	Jan 18, 2021		U-433		
	6696493	Jan 18, 2021		U-433		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721 001	6806256	Feb 26, 2022	DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP		ODE-10	Apr 29, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP		ODE-10	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP		ODE-10	Apr 29, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031		U-839	NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031		U-839	NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031		U-839	NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031		U-839	NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP	U-2003		
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	7252839	Nov 13, 2023	DP			
	9615965	Sep 16, 2029	DP	U-2003		
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
	9615965	Sep 16, 2029	DP	U-2003		
	9668912	Apr 01, 2031	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	8540665	Oct 22, 2029		U-1438		
	9358338	Apr 27, 2035		U-1870		
	9370622	Sep 28, 2035		U-1870		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP		U-1523	
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623 001	6465709	Jul 07, 2020	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	6528086	Sep 28, 2019	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIFITEGRAST - XIIDRA</u>						
N 208073	001	8168655				
		May 09, 2029		U-1880		
		8367701		DP U-1880		
		8592450		U-1880		
		8927574		DP		
		9085553		DP		
		9216174		DP		
		9353088		DP		
		9447077		U-1900		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001	7304036				
		Aug 30, 2026	DS DP	U-1278	NCE	Aug 30, 2017
		7304036		DS DP		
		Aug 30, 2026	DS DP	U-1516		
		7371727		DS		
		Jan 28, 2024	DS			
		7704947		DS DP		
		Jan 28, 2024	DS DP			
		7745409		DS DP		
		Jan 28, 2024	DS DP			
		8080526		DS DP		
		Jan 28, 2024	DS DP			
		8110553		U-1278		
		Jan 28, 2024				
		8748573		U-1515		
		Oct 30, 2031				
		8748573		U-1516		
		Oct 30, 2031				
		8802628		DP		
		Nov 17, 2031				
		8933030		DP		
		Feb 17, 2031				
		9708371		DP U-1515		
		Aug 16, 2033				
		9708371		DP U-1516		
		Aug 16, 2033				
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002	7304036				
		Aug 30, 2026	DS DP	U-1278	NCE	Aug 30, 2017
		7304036		DS DP		
		Aug 30, 2026	DS DP	U-1516		
		7371727		DS		
		Jan 28, 2024	DS			
		7704947		DS DP		
		Jan 28, 2024	DS DP			
		7745409		DS DP		
		Jan 28, 2024	DS DP			
		8080526		DS DP		
		Jan 28, 2024	DS DP			
		8110553		U-1278		
		Jan 28, 2024				
		8748573		U-1515		
		Oct 30, 2031				
		8748573		U-1516		
		Oct 30, 2031				
		8802628		DP		
		Nov 17, 2031				
		8933030		DP		
		Feb 17, 2031				
		9708371		DP U-1515		
		Aug 16, 2033				
<u>LINACLOTIDE - LINZESS</u>						
N 202811	003	7304036				
		Aug 30, 2026	DS DP	U-1516	NCE	Aug 30, 2017
		7371727		DS	NS	Jan 25, 2020
		Jan 28, 2024	DS			
		7704947		DS DP		
		Jan 28, 2024	DS DP			
		7745409		DS DP		
		Jan 28, 2024	DS DP			
		8080526		DS DP		
		Jan 28, 2024	DS DP			
		8110553		U-1516		
		Jan 28, 2024				
		8933030		DP U-1516		
		Feb 17, 2031				
		9708371		DP U-1516		
		Aug 16, 2033				
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	6890898				
		Feb 02, 2019		U-1270		
		6890898		U-493		
		Feb 02, 2019				
		7078381		U-1270		
		Feb 02, 2019				
		7078381		U-493		
		Feb 02, 2019				
		7407955		DS DP		
		May 02, 2025	DS DP			
		7459428		U-1270		
		Feb 02, 2019				
		7459428		U-493		
		Feb 02, 2019				
		8119648		U-1270		
		Aug 12, 2023				
		8119648		U-774		
		Aug 12, 2023				
		8178541		U-1244		
		Aug 12, 2023				
		8178541		U-1245		
		Aug 12, 2023				
		8178541		U-1270		
		Aug 12, 2023				
		8178541		U-775		
		Aug 12, 2023				
		8673927		U-1503		
		May 04, 2027				
		8846695		U-1503		
		Jun 04, 2030				
		8853156		U-1642		
		Mar 05, 2031				
		8883805		DP		
		Nov 26, 2025	DP			
		9173859		DP U-1503		
		May 04, 2027	DP			
		9173859		DP U-1768		
		May 04, 2027	DP			
		9486526		U-1915		
		Aug 05, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	6890898	Feb 02, 2019	U-1270			
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	8119648	Aug 12, 2023	U-1270			
	8119648	Aug 12, 2023	U-774			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503	Y		
	8853156	Mar 05, 2031	U-1642			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1503			
	9173859	May 04, 2027	DP U-1768			
	9486526	Aug 05, 2029	U-1915			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	6890898	Feb 02, 2019	U-1039		M-146	Jul 30, 2017
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6890898	Feb 02, 2019	U-1039		M-146	Jul 30, 2017
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6890898	Feb 02, 2019	U-1039		M-146	Jul 30, 2017
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6488962	Jun 20, 2020	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6488962	Jun 20, 2020	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019	DP		I-750	Aug 25, 2020
	6268343	Aug 22, 2022	DS DP U-968		M-176	Apr 22, 2019
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	8846618	Jun 27, 2022	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS		M-188	Oct 14, 2019
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP	U-727		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	9707176	Nov 11, 2030	DP			
	9821032	May 09, 2032	U-2200			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	9707176	Nov 11, 2030	DP			
	9821032	May 09, 2032	U-2200			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE-36	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE-36	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE-36	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE-36	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE-36	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	005	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE-36	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE-36	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448	001	6814978	Aug 26, 2021	DP		
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPATOM RELIEF</u>						
N 021140	001	6103260	Jul 17, 2017	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226	001	6232333	Nov 07, 2017			
		6458818	Nov 07, 2017			
		6521651	Nov 07, 2017	DP		
		7141593	May 22, 2020	DP		
		7432294	May 22, 2020	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251	001	6911214	Nov 28, 2021	DP U-895		
		8501219	Nov 28, 2021	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	001	7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP U-688		
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024	U-688		
		8377952	Oct 22, 2027	U-1372		
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8470347	Sep 17, 2026	DP		
		8470347*PED	Mar 17, 2027			
		8691878	Aug 25, 2024	U-1513		
		8691878*PED	Feb 25, 2025			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	002	7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP U-688		
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024	U-688		
		8377952	Oct 22, 2027	U-1372		
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8470347	Sep 17, 2026	DP		
		8470347*PED	Mar 17, 2027			
		8691878	Aug 25, 2024	U-1513		
		8691878*PED	Feb 25, 2025			
<u>LOMATADINE - CLARITIN</u>						
N 020641	002	6132758	Jun 01, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252			
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1762			
	9169213	Dec 06, 2032	U-1763			
	9169213	Dec 06, 2032	U-1764			
	9169213	Dec 06, 2032	U-1765			
	9770455	Aug 31, 2031	U-2110			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252			
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524	001	8546379	Apr 10, 2023	DS DP	U-1253	
		8546379	Apr 10, 2023	DS DP	U-1254	
		8546379	Apr 10, 2023	DS DP	U-1255	
		8575149	Apr 10, 2023		U-1452	
		8697686	Dec 20, 2025	DS DP		
		8946207	Jun 16, 2024	DP		
		8980881	Dec 20, 2025		U-1252	
		8980881	Dec 20, 2025		U-1253	
		8980881	Dec 20, 2025		U-1254	
		8980881	Dec 20, 2025		U-1255	
		8999970	Feb 07, 2033		U-1688	
		8999970	Feb 07, 2033		U-1689	
		8999970	Feb 07, 2033		U-1692	
		9169213	Dec 06, 2032		U-1884	
		9169213	Dec 06, 2032		U-1885	
		9169213	Dec 06, 2032		U-1886	
		9169213	Dec 06, 2032		U-1887	
		9770455	Aug 31, 2031		U-2110	
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	001	5916595	Dec 12, 2017			
		6080778	Mar 23, 2018		U-456	
		6485748	Dec 12, 2017	DP		
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	002	5916595	Dec 12, 2017			
		6080778	Mar 23, 2018		U-456	
		6485748	Dec 12, 2017	DP		
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	003	5916595	Dec 12, 2017			
		6080778	Mar 23, 2018		U-456	
		6485748	Dec 12, 2017	DP		
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	004	5916595	Dec 12, 2017			
		6080778	Mar 23, 2018		U-456	
		6485748	Dec 12, 2017	DP		
<u>LOXAPINE - ADASUVE</u>						
N 022549	001	6716416	May 20, 2022	DP		
		7052679	Oct 26, 2021	DP		
		7078020	Oct 26, 2021	DP	U-1375	
		7090830	Oct 26, 2021	DP		
		7458374	Aug 18, 2024	DP		
		7537009	Oct 28, 2024	DP		
		7585493	Oct 26, 2021	DP		
		7601337	Oct 26, 2021	DP		
		8074644	Jul 25, 2022	DP		
		8173107	Oct 26, 2021	DP		
		8235037	Oct 26, 2021	DP		
		8387612	Oct 23, 2026	DP		
		8955512	Oct 26, 2021	DP		
		8991387	May 21, 2024	DP		
		9370629	May 20, 2024	DP		
		9439907	Oct 26, 2021	DP		
		9440034	Oct 26, 2021	DP		
		9687487	Oct 26, 2021	DS DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	6414016	Sep 05, 2020		U-1392	
		6414016	Sep 05, 2020		U-717	
		6583174	Oct 16, 2020	DP		
		6982283	Dec 04, 2022		U-1391	
		7064148	Aug 30, 2022		U-1404	
		7064148	Aug 30, 2022		U-739	
		7417067	Oct 16, 2020	DP		
		8026393	Oct 25, 2027	DP		
		8071613	Sep 05, 2020		U-1203	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8071613	Sep 05, 2020			U-1393	
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022			U-1214	
	8097653	Nov 14, 2022			U-1394	
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP		U-1345	
	8389542	Nov 14, 2022	DP		U-1395	
	8748481	Sep 01, 2025			U-1520	
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	6414016	Sep 05, 2020			U-874	
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022			U-739	
	7064148	Aug 30, 2022			U-873	
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024			U-1085	
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020			U-1202	
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025			U-1519	
	8779187	Jan 23, 2027	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP		NCE	Nov 14, 2018
	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP		U-540	
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		M-195	Jan 27, 2020
	5532372*PED	Jan 02, 2019			NPP	Jan 27, 2020
	8729085	May 26, 2026	DP		PED	Jul 27, 2020
	8729085*PED	Nov 26, 2026			PED	Jul 27, 2020
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026			U-1770	
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031			U-1822	
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP		U-543	
	9815827	Feb 20, 2024			U-2166	
	9815827	Feb 20, 2024			U-543	
	9827242	May 23, 2031			U-2199	
	9827242	May 23, 2031			U-2201	
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		NPP	Jan 27, 2020
	5532372*PED	Jan 02, 2019			PED	Jul 27, 2020
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026			U-1770	
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031			U-1822	
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP		U-543	
	9815827	Feb 20, 2024			U-2166	
	9815827	Feb 20, 2024			U-543	
	9827242	May 23, 2031			U-2199	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	002	9827242	May 23, 2031	U-2201		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	003	5532372	Jul 02, 2018	DS	M-195	Jan 27, 2020
		5532372*PED	Jan 02, 2019		NPP	Jan 27, 2020
		8729085	May 26, 2026	DP	PED	Jul 27, 2020
		8729085*PED	Nov 26, 2026		PED	Jul 27, 2020
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026	U-1770		
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	004	5532372	Jul 02, 2018	DS		
		5532372*PED	Jan 02, 2019			
		8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026	U-1770		
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005	5532372	Jul 02, 2018	DS	M-195	Jan 27, 2020
		5532372*PED	Jan 02, 2019		NPP	Jan 27, 2020
		8729085	May 26, 2026	DP	PED	Jul 27, 2020
		8729085*PED	Nov 26, 2026		PED	Jul 27, 2020
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026	U-1770		
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP U-543		
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598	001				NCE	Dec 20, 2022
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	7094781	Oct 12, 2022	DS DP	NCE	Oct 18, 2018
		8268847	Apr 18, 2029	U-1446	ODE-54	Oct 18, 2020
		8367685	Oct 04, 2028	DP U-1445		
		9265762	May 29, 2027	DP U-1820		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	7094781	Oct 12, 2022	DS DP	NCE	Oct 18, 2018
		8268847	Apr 18, 2029	U-1446	ODE-54	Oct 18, 2020
		8367685	Oct 04, 2028	DP U-1445		
		9265762	May 29, 2027	DP U-1820		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910	001	5945449	Oct 31, 2017	DP U-785		
		7300674	Mar 04, 2023	DP U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910	002	5945449	Oct 31, 2017	DP U-785		
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001	6946149	Mar 07, 2023	DP U-837		
<u>MALATHION - OVIDE</u>						
N 018613	001	7560445	Feb 01, 2027	DS DP U-986		
		7977324	Aug 14, 2026	DP		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001	6586430	Dec 01, 2019	DS DP U-824	NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824	NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002	6586430	Dec 01, 2019	DS DP U-824	NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824	NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	003	6586430	Dec 01, 2019	DS DP U-824	NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824	NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	004	6586430	Dec 01, 2019	DS DP U-824	NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824	NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 208984	001	6586430	Dec 01, 2019	DS DP U-824	NP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824		
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MEBENDAZOLE - VERMOX</u>						
N 208398	001				NS	Oct 19, 2019
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839	001	5681814	Sep 18, 2017	DP		
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001	7838564	Mar 07, 2026	DP	ODE-51	Aug 23, 2020
		7872050	Jul 08, 2029	U-1427		
		8450375	Mar 07, 2026	DP		
		8501818	Mar 07, 2026	DP		
		8501819	Mar 07, 2026	U-1427		
		9382191	Mar 07, 2026	DP		
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N 021583	001	6495534	May 15, 2020	DP		
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001	6592903	Sep 21, 2020	DP		
		7101576	Apr 22, 2024	U-755		
		9040088	Apr 22, 2024	U-755		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001	9101540	Apr 22, 2024	DP U-755		
		9101549	Apr 22, 2024	U-755		
		9107827	Apr 22, 2024	U-755		
<u>MELOXICAM - MOBIC</u>						
N 021530	001	6184220	Mar 25, 2019	DP		
<u>MELOXICAM - VIVLODEX</u>						
N 207233	001	9526734	Mar 31, 2033	DP	NP	Oct 22, 2018
		9649318	Mar 31, 2035	DP		
		9808468	Mar 31, 2035	U-2160		
		9808468	Mar 31, 2035	U-2165		
<u>MELOXICAM - VIVLODEX</u>						
N 207233	002	9526734	Mar 31, 2033	DP	NP	Oct 22, 2018
		9649318	Mar 31, 2035	DP		
		9808468	Mar 31, 2035	U-2160		
		9808468	Mar 31, 2035	U-2165		
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	8410077	Mar 13, 2029	DP	ODE-110	Mar 10, 2023
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001	6353029	Aug 24, 2020			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919	001				ODE-65	Apr 28, 2021
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776	001	8680136	Aug 17, 2031	DS DP		
		9694025	Aug 08, 2031	U-2120		
<u>MESALAMINE - MESALAMINE</u>						
A 091640	001				PC	Jan 14, 2018
<u>MESALAMINE - SFROWASA</u>						
N 019618	002	7645801	Jul 24, 2027	DS DP		
<u>MESALAMINE - CANASA</u>						
N 021252	001				M-187	Sep 02, 2019
<u>MESALAMINE - CANASA</u>						
N 021252	002	8217083	Jun 06, 2028	DP		
		8436051	Jun 06, 2028	DP		
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001	6893662	Nov 15, 2021	DP U-141		
		8580302	Nov 15, 2021	DP		
		9089492	Nov 15, 2021	DP		
<u>MESALAMINE - LIALDA</u>						
N 022000	001	6773720	Jun 08, 2020	DP		
<u>MESALAMINE - APRISO</u>						
N 022301	001	6551620	Apr 20, 2018	DS DP U-907		
		8337886	Apr 20, 2018	DP U-1310		
		8496965	Apr 20, 2018	DP		
		8865688	May 01, 2030	U-1310		
		8911778	Apr 20, 2018	DP U-1310		
		8940328	Apr 20, 2018	DP		
		8956647	Apr 20, 2018	DP		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001	6649180	Apr 13, 2020	DP		
<u>METAXALONE - SKELAXIN</u>						
N 013217	003	7122566	Feb 06, 2026	U-915		
		7714006	Dec 03, 2021	U-1050		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	001	6475521				
		Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	004	6475521				
		Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001	6099859		DP		
		Mar 20, 2018		DP		
	6495162	Mar 20, 2018				
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002	6099859		DP		
		Mar 20, 2018		DP		
	6495162	Mar 20, 2018				
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001	6890957		DP		
		Sep 14, 2023				
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	001	6488962	DS DP			
		Jun 20, 2020	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002	6488962	DS DP			
		Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001	9101660		DP		
		Jan 22, 2027		DP		
	9320714	Feb 03, 2029				
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002	9101660		DP		
		Jan 22, 2027		DP		
	9320714	Feb 03, 2029				
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	6099859		DP		
		Mar 20, 2018		DP		
	6495162	Mar 20, 2018				
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-1120			
	7919116	Mar 20, 2018	U-973			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	002	6099859		DP		
		Mar 20, 2018		DP		
	6495162	Mar 20, 2018				
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-1120			
	7919116	Mar 20, 2018	U-973			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	002 9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	001 7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	002 7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	003 7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	004 7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	005 7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	001 8628799	Jul 13, 2025	DP		M-175	Apr 05, 2019
	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
	RE44186	Jul 31, 2023	DS DP	U-1097		
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002 9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1097	M-198	Feb 27, 2020
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003 9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1097	M-198	Feb 27, 2020
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001 6699871	Jul 26, 2022	DS DP	U-802		
	6890898	Feb 02, 2019		U-1996		
	7078381	Feb 02, 2019		U-1996		
	7125873	Jul 26, 2022	DP	U-1036		
	7125873	Jul 26, 2022	DP	U-1038		
	7125873	Jul 26, 2022	DP	U-803		
	7326708	Nov 24, 2026	DS DP	U-802		
	7459428	Feb 02, 2019		U-1996		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002 6699871	Jul 26, 2022	DS DP	U-802		
	6890898	Feb 02, 2019		U-1996		
	7078381	Feb 02, 2019		U-1996		
	7125873	Jul 26, 2022	DP	U-1036		
	7125873	Jul 26, 2022	DP	U-1038		
	7125873	Jul 26, 2022	DP	U-803		
	7326708	Nov 24, 2026	DS DP	U-802		
	7459428	Feb 02, 2019		U-1996		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001 6699871	Jul 26, 2022	DS DP	U-1227		
	6890898	Feb 02, 2019		U-1996		
	7078381	Feb 02, 2019		U-1996		
	7125873	Jul 26, 2022	DP	U-1227		
	7326708	Nov 24, 2026	DS DP	U-1227		
	7459428	Feb 02, 2019		U-1996		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVQ</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVQ</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVQ</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776	004	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	005	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	006	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	007	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	008	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	009	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	010	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400	001	9259427	Jan 02, 2033	DP	ODE-137 ODE-138	Apr 25, 2024 Apr 25, 2024
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630	001				ODE-113	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	001	6559158	Nov 03, 2017	U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	002	6559158	Nov 03, 2017	U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	003	8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271	001	6559158	Nov 03, 2017	U-1185	NP	Jul 19, 2019
		8420663	Sep 30, 2029	U-1185		
		8524276	Mar 10, 2031	DP		
		8956651	Mar 10, 2031	DP		
		9180125	Sep 30, 2029	DP U-1185		
		9314461	Mar 10, 2031	DP		
		9492445	Sep 30, 2029	DP U-1185		
		9724343	Sep 30, 2029	DP U-1185		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	001	6210705	Sep 30, 2018	DP U-727		
		6348211	Sep 30, 2018	DP U-727		
		8632802	Oct 07, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025		U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025		U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025		U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018	DP	U-727		
	6348211	Sep 30, 2018	DP	U-727		
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025		U-2024		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-1693		
	9000038	Jul 31, 2017		U-666		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP	U-666		
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-1693		
	9000038	Jul 31, 2017		U-666		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP	U-666		
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121	003	8629179	Jul 31, 2017	DP		
		8629179*PED	Jan 31, 2018			
		9000038	Jul 31, 2017		U-1693	
		9000038	Jul 31, 2017		U-666	
		9000038*PED	Jan 31, 2018			
		9029416	Jul 31, 2017	DP	U-666	
		9144549	Jul 31, 2017		U-1747	
		9144549	Jul 31, 2017		U-1748	
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121	004	6919373	Jul 31, 2017		U-666	
		6930129	Jul 31, 2017		U-666	
		8163798	Jul 31, 2017	DP		
		8629179	Jul 31, 2017	DP		
		8629179*PED	Jan 31, 2018			
		9000038	Jul 31, 2017		U-1693	
		9000038	Jul 31, 2017		U-666	
		9000038*PED	Jan 31, 2018			
		9029416	Jul 31, 2017	DP	U-666	
		9144549	Jul 31, 2017		U-1747	
		9144549	Jul 31, 2017		U-1748	
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	001	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	002	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	003	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	004	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	001	6228398	Nov 01, 2019	DP	U-472	
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	002	6228398	Nov 01, 2019	DP	U-472	
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	003	6228398	Nov 01, 2019	DP	U-472	
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	004	6228398	Nov 01, 2019	DP	U-472	
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	001	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	002	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUIILLIVANT XR</u>						
N 202100	001	8062667	Mar 29, 2029	DP		
		8287903	Feb 15, 2031	DP		
		8465765	Feb 15, 2031	DP	U-1415	
		8563033	Feb 15, 2031	DP	U-1415	
		8778390	Feb 15, 2031	DP	U-1543	
		8956649	Feb 15, 2031	DP	U-1665	
		9040083	Feb 15, 2031	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	001	6419960	Dec 16, 2019	DP		
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
		9801823	Dec 16, 2019	DP		
					NP	Apr 17, 2018
				Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 001	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 002	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 003	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 002	6413549	Jul 11, 2017	DP			
<u>METRONIDAZOLE - METROGEL</u>						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806 001	7456207	Sep 22, 2024	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308 001	6153635	Nov 28, 2020			Y	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE-140	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643		ODE-22	Feb 17, 2019
	9829495	Aug 15, 2036	U-1643			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 001	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 002	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 003	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 004	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE-63	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
	9278105	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	6682348	Mar 29, 2022	DP			
	7699609	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 002	5908838	Feb 19, 2018	U-917			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 003	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	006	5908838	Feb 19, 2018			
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
		8722650	Jun 24, 2025			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	007	5908838	Feb 19, 2018			
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
		8722650	Jun 24, 2025			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	008	5908838	Feb 19, 2018			
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
		8722650	Jun 24, 2025			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	001	5908838	Feb 19, 2018			
		7541347	Apr 02, 2027			
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	003	5908838	Feb 19, 2018			
		7541347	Apr 02, 2027			
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	005	5908838	Feb 19, 2018			
		7541347	Apr 02, 2027			
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025			
		7919483	Mar 07, 2027			
		8252776	Jun 24, 2025			
		8268804	Jun 24, 2025			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812	001	6946120	Apr 20, 2019	DP		
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812	002	6946120	Apr 20, 2019	DP		
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568	001	6166197	Dec 26, 2017	DS		
		7015315	Mar 21, 2023	DS		
		7101993	Sep 05, 2023	DS		
		7407943	Aug 01, 2021			
		7511131	Jan 29, 2027	DS		
					NCE	Jan 29, 2018
					ODE-41	Jan 29, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023		U-1527		
	RE44872	Nov 04, 2023		U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023		U-1527		
	RE44872	Nov 04, 2023		U-1527		
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP		ODE-21	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
	9539241	Jan 02, 2028	DS DP	U-2095		
	9649428	May 21, 2029		U-2095		
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
<u>MOMETASONE FUROATE - NASONEX</u>						
N 020762 001	6127353	Oct 03, 2017	DS DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 001	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 002	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	6068832	Aug 27, 2017	DP	U-645		
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	6068832	Aug 27, 2017	DP	U-645		
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001					NP	Dec 08, 2020
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409 001	8007830	Oct 24, 2022	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	6610327	Oct 29, 2019	DP U-298		M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	6548079	Jul 25, 2020	DP U-298		M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N 021598 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	U-709			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
<u>MUPIROCIN - CENTANY</u>						
N 050788 001	6013657	Jul 08, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	001 6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	002 6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599	002				M-191	Nov 10, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286	001 8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033		U-540		
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854	001 9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP	U-1185		
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760	001 7056500	Jun 29, 2024	DP	U-1185	NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760	002 7056500	Jun 29, 2024	DP	U-1185	NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001 7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP	U-1907		
	9517307	Jul 18, 2034	DP	U-1925		
	9724471	May 23, 2027	DP	U-2092		
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411	001 9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP	U-1903		
	9561177	Mar 16, 2035	DP	U-1903		
	9629965	Mar 16, 2035	DP	U-1903		
	9775838	Mar 16, 2035		U-1903		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411	002	9480644	Mar 16, 2035	DP	U-1903	
		9707226	Mar 16, 2035	DP	U-1903	
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862	001	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8627816	Feb 04, 2032	DP		
		8926594	Mar 31, 2026	DP		
		8939943	Feb 28, 2031	DP		
		9022022	Feb 28, 2031	DP		
		9056170	Nov 23, 2024	DP		
		9238108	Feb 20, 2027	DP		
		9278182	Feb 01, 2026	DP		
		9474869	Feb 28, 2031	DP	U-1907	
		9517307	Jul 18, 2034	DP	U-1925	
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	001	6277384	Dec 22, 2018	DP		NC Jul 23, 2017
		6696066	Dec 22, 2018	DP		
		8673355	Dec 22, 2018	DP		
		8822487	Dec 22, 2018	DP		
		8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP	U-1556	
		9056051	May 10, 2022	DP	U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP	U-1556	
		9161937	May 10, 2022	DP	U-1556	
		9168252	May 10, 2022	DP	U-1556	
		9205082	Dec 22, 2018	DP	U-1556	
		9283216	May 10, 2022	DP	U-1819	
		9283221	May 10, 2022	DP	U-1819	
		9345701	May 10, 2022	DP	U-1819	
		9474750	Dec 22, 2018	DP	U-1556	
		9511066	May 10, 2022		U-1921	
		9522919	Mar 30, 2025	DS DP		
		9555000	Apr 04, 2023	DP	U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	002	6277384	Dec 22, 2018	DP		NC Jul 23, 2017
		6696066	Dec 22, 2018	DP		
		8673355	Dec 22, 2018	DP		
		8822487	Dec 22, 2018	DP		
		8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP	U-1556	
		9056051	May 10, 2022	DP	U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP	U-1556	
		9161937	May 10, 2022	DP	U-1556	
		9168252	May 10, 2022	DP	U-1556	
		9205082	Dec 22, 2018	DP	U-1556	
		9283216	May 10, 2022	DP	U-1819	
		9283221	May 10, 2022	DP	U-1819	
		9345701	May 10, 2022	DP	U-1819	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	002	9474750	Dec 22, 2018	DP U-1556		
		9511066	May 10, 2022	U-1921		
		9522919	Mar 30, 2025	DS DP		
		9555000	Apr 04, 2023	DP U-1556		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	003	6277384	Dec 22, 2018	DP	NC	Jul 23, 2017
		6696066	Dec 22, 2018	DP		
		8673355	Dec 22, 2018	DP		
		8822487	Dec 22, 2018	DP		
		8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP U-1556		
		9056051	May 10, 2022	DP U-1556		
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP U-1556		
		9161937	May 10, 2022	DP U-1556		
		9168252	May 10, 2022	DP U-1556		
		9205082	Dec 22, 2018	DP U-1556		
		9283216	May 10, 2022	DP U-1819		
		9283221	May 10, 2022	DP U-1819		
		9345701	May 10, 2022	DP U-1819		
		9474750	Dec 22, 2018	DP U-1556		
		9511066	May 10, 2022	U-1921		
		9522919	Mar 30, 2025	DS DP		
<u>NALTREXONE - VIVITROL</u>						
N 021897	001	6194006	Dec 30, 2018	DP		
		6264987	May 19, 2020	DP		
		6331317	Nov 12, 2019	DP		
		6379703	Dec 30, 2018	DP		
		6379704	May 19, 2020	DP		
		6395304	Nov 12, 2019	DP		
		6495164	May 25, 2020	DP		
		6495166	Nov 12, 2019	DP		
		6534092	May 19, 2020	DP		
		6537586	Nov 12, 2019	DP		
		6596316	Dec 30, 2018	DP		
		6667061	May 25, 2020	DP		
		6713090	Nov 12, 2019	DP		
		6939033	Nov 12, 2019	DP		
		7799345	May 25, 2020	DP		
		7919499	Oct 15, 2029	U-1123		
		7919499	Oct 15, 2029	U-1124		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	001	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	002	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	003	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	004	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	005	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	006	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920	001	9693978	Mar 03, 2026	DP		
		9693979	Mar 03, 2026	DP		
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001	6060499	Aug 14, 2017	DP U-867		
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017	DP U-867		
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025	DP U-867		
		7332183*PED	Apr 02, 2026			
		8022095	Aug 14, 2017	DP U-867		
		8022095*PED	Feb 14, 2018			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	002	5872145	Aug 14, 2017	DP U-1719	NP	May 14, 2018
		5872145*PED	Feb 14, 2018		PED	Nov 14, 2018
		6060499	Aug 14, 2017	DP U-1719		
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017	DP U-1719		
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025	DP U-1719		
		7332183*PED	Apr 02, 2026			
<u>NATEGLINIDE - STARLIX</u>						
N 021204	001	6559188	Sep 15, 2020	DP U-827		
		6641841	Nov 14, 2017	DP U-214		
		6844008	Nov 14, 2017	DP U-214		
		6878749	Sep 15, 2020	DP		
<u>NATEGLINIDE - STARLIX</u>						
N 021204	002	6559188	Sep 15, 2020	DP U-827		
		6641841	Nov 14, 2017	DP U-214		
		6844008	Nov 14, 2017	DP U-214		
		6878749	Sep 15, 2020	DP		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	002	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	003	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	004	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	005	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302	001	7803838	Aug 29, 2026	DP	NC	Jun 03, 2019
		7838552	Oct 04, 2027	U-185		
<u>NEPAFENAC - NEVANAC</u>						
N 021862	001	7834059	Jan 31, 2027	U-1095		
		8071648	Dec 02, 2025	DP		
		8324281	Dec 02, 2025	DP		
<u>NEPAFENAC - ILEVRO</u>						
N 203491	001	6403609	Jul 17, 2018	DP		
		7947295	Jun 08, 2024	DP		
		8921337	Mar 31, 2032	DP		
		9662398	Dec 01, 2030	DP		
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001	6288082	Sep 24, 2019	DS DP U-2043	NCE	Jul 17, 2022
		7399865	Dec 29, 2025	DS DP		
		7982043	Oct 08, 2025	U-2043		
		8518446	Nov 20, 2030	DP U-2043		
		8790708	Nov 05, 2030	DP U-2043		
		9139558	Oct 15, 2028	U-2043		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001	9211291				
		Mar 24, 2030		U-2043		
		9630946				
		Oct 15, 2028		U-2043		
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254	001	8394826				
		Nov 10, 2030	DS DP	U-1524	NCE	Dec 18, 2022
		8450344				
		Jul 11, 2026	DS DP	U-1524		
		9096569				
		Jul 11, 2026	DS DP	U-1524		
		9415043				
		Mar 14, 2034	DS			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	6297375				
		Feb 22, 2020	DS		NCE	Oct 10, 2019
		8623826				
		Nov 18, 2030		U-528		
		8951969				
		Nov 18, 2030	DP			
		9186357				
		Nov 18, 2030		U-528		
		9271975				
		Sep 09, 2031		U-528		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152	001	8460704				
		Mar 12, 2029		U-1409		
<u>NIACIN - NIASPAN</u>						
N 020381	002	6469035				
		Mar 15, 2018		U-1142		
		6469035				
		Mar 15, 2018		U-1143		
		6469035				
		Mar 15, 2018		U-1144		
		6469035				
		Mar 15, 2018		U-1145		
		6469035				
		Mar 15, 2018		U-768		
<u>NIACIN - NIASPAN</u>						
N 020381	003	6469035				
		Mar 15, 2018		U-1142		
		6469035				
		Mar 15, 2018		U-1143		
		6469035				
		Mar 15, 2018		U-1144		
		6469035				
		Mar 15, 2018		U-1145		
		6469035				
		Mar 15, 2018		U-768		
<u>NIACIN - NIASPAN</u>						
N 020381	004	6469035				
		Mar 15, 2018		U-1142		
		6469035				
		Mar 15, 2018		U-1143		
		6469035				
		Mar 15, 2018		U-1144		
		6469035				
		Mar 15, 2018		U-1145		
		6469035				
		Mar 15, 2018		U-768		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	7612102				
		Dec 26, 2027	DP			
		7659291				
		Apr 18, 2027		U-1029		
		8455524				
		Apr 18, 2027		U-1029		
		9364564				
		Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	7612102				
		Dec 26, 2027	DP			
		7659291				
		Apr 18, 2027		U-1029		
		8455524				
		Apr 18, 2027		U-1029		
		9364564				
		Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	7612102				
		Dec 26, 2027	DP			
		7659291				
		Apr 18, 2027		U-1029		
		8455524				
		Apr 18, 2027		U-1029		
		9364564				
		Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	005	7612102				
		Dec 26, 2027	DP			
		7659291				
		Apr 18, 2027		U-1029		
		8455524				
		Apr 18, 2027		U-1029		
		9364564				
		Dec 26, 2027	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165	004	8075911				
		May 22, 2021	DP			
		8663680				
		Feb 13, 2020	DP			
		8999379				
		Feb 13, 2020		U-1686		
		9205059				
		Dec 15, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CO</u>						
N 020165	005	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
		9205059	Dec 15, 2019	DP		
<u>NICOTINE - NICODERM CO</u>						
N 020165	006	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
		9205059	Dec 15, 2019	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002	8323683	Apr 30, 2028			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002	8323683	Apr 30, 2028	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	001	7169791	Jul 04, 2023	DS DP	U-836	
		8163904	Aug 23, 2028	DS DP		
		8293756	Sep 25, 2027	DP		
		8389537	Jul 18, 2026	DS DP	U-1374	
		8415363	Jul 18, 2026	DS DP	U-1407	
		8501760	Jul 18, 2026	DS DP		
		9061029	Apr 07, 2032	DP	U-1374	
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	002	7169791	Jul 04, 2023	DS DP	U-836	
		8163904	Aug 23, 2028	DS DP		
		8293756	Sep 25, 2027	DP		
		8389537	Jul 18, 2026	DS DP	U-1374	
		8415363	Jul 18, 2026	DS DP	U-1407	
		8501760	Jul 18, 2026	DS DP		
		9061029	Apr 07, 2032	DP	U-1374	
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE-46	May 10, 2020
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	6762180	Dec 10, 2020	DS DP	NCE	Oct 15, 2019
		7119093	Feb 21, 2024	DS DP	ODE-77	Oct 15, 2021
		7989474	Apr 06, 2024	U-1677		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	6762180	Dec 10, 2020	DS DP	NCE	Oct 15, 2019
		7119093	Feb 21, 2024	DS DP	ODE-77	Oct 15, 2021
		7989474	Apr 06, 2024	U-1677		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447	001	8071623	Mar 22, 2030	DS DP	NCE	Mar 27, 2022
		8436185	Apr 24, 2029	DS	ODE-133	Mar 27, 2024
<u>NITAZOXANIDE - ALINIA</u>						
N 021498	001	5965590	Jul 03, 2017	U-523		
<u>NITISINONE - ORFADIN</u>						
N 021232	001				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232	002				D-169	Sep 01, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - ORFADIN</u>						
N 021232	003				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232	004				D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356	001 9301932	Feb 28, 2033	DP U-1836		D-169	Sep 01, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002 6125846*PED	Nov 16, 2017				
	8282966	Jun 30, 2029		U-1286		
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029		U-1286		
	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029		U-1286		
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029		U-1286		
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003 6125846*PED	Nov 16, 2017			M-167	Oct 09, 2018
	8282966	Jun 30, 2029		U-1286		
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029		U-1286		
	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029		U-1286		
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029		U-1286		
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
	9770570	May 03, 2036		U-2148		
	9770570*PED	Nov 03, 2036				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705	002 7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	001 6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	002 6500456	Sep 16, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	003 6500456	Sep 16, 2018				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424	001 9101592	Mar 11, 2032	DP			
<u>NIZATIDINE - AXID</u>						
N 021494	001 6930119	Jul 17, 2022	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	001 6166197	Dec 26, 2017	DS		NCE	Dec 23, 2021
	6210892	Oct 07, 2018		U-1942	ODE-127	Dec 23, 2023
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
	9717750	Jun 17, 2030		U-1942		
	9717750	Jun 17, 2030		U-1943		
	9717750	Jun 17, 2030		U-2093		
	9717750	Jun 17, 2030		U-2094		
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	001 7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022		U-1854	ODE-119	May 27, 2023
	8377916	Feb 21, 2022		U-1854		
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	002 7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022		U-1854	ODE-119	May 27, 2023
	8377916	Feb 21, 2022		U-1854		
	9238673	Jun 17, 2033	DP			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	001 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	002 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	003 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	004 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	005 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	006 6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	001 6960577	Nov 01, 2017		U-964		
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	002 6960577	Nov 01, 2017		U-964		
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	003 6960577	Nov 01, 2017		U-964		
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	004 6960577	Nov 01, 2017		U-964		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	001 6169084	Sep 30, 2018	DS DP	U-1026		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	002	6169084	Sep 30, 2018	DS DP U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	003	6169084	Sep 30, 2018	DS DP U-1026		
<u>OLAPARIB - LYNPARZA</u>						
N 206162	001	7151102	Apr 29, 2022	DS DP	NCE	Dec 19, 2019
		7449464	Oct 11, 2024	DS DP	ODE-83	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		
		8143241	Aug 12, 2027	U-1634		
		8247416	Sep 24, 2028	DS		
		8859562	Aug 04, 2031	U-1634		
		8912187	Mar 12, 2024	U-1634		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	7151102	Apr 29, 2022	DS DP	NCE	Dec 19, 2019
		7449464	Oct 11, 2024	DS DP	NP	Aug 17, 2020
		7981889	Oct 11, 2024	DS DP	ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2102		
		8143241	Aug 12, 2027	U-2103		
		8475842	Dec 31, 2029	DP		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2102		
		8912187	Mar 12, 2024	U-2101		
		8912187	Mar 12, 2024	U-2102		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	002	7151102	Apr 29, 2022	DS DP	NCE	Dec 19, 2019
		7449464	Oct 11, 2024	DS DP	NP	Aug 17, 2020
		7981889	Oct 11, 2024	DS DP	ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2102		
		8143241	Aug 12, 2027	U-2103		
		8475842	Dec 31, 2029	DP		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2102		
		8912187	Mar 12, 2024	U-2101		
		8912187	Mar 12, 2024	U-2102		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001	6846413	Aug 28, 2018	DP	NCE	Jul 31, 2019
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP U-1547		
		7056916	Dec 07, 2023	DS DP		
		7220742	May 12, 2025	DS DP U-1547		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP U-1547		
		7491719	Nov 10, 2023	DS DP		
		7727984	Nov 10, 2023	DS		
		7786111	Nov 10, 2023	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025	U-1547		
		8044046	Nov 10, 2023	U-1547		
		8733341	Oct 16, 2030	DP		
		9027967	Mar 31, 2027	DP		
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	6846413	Aug 28, 2018	DP	M-173	Mar 18, 2019
		6846413*PED	Feb 28, 2019		NC	May 21, 2018
		6977042	Aug 28, 2018	DP	NCE	Jul 31, 2019
		6977042*PED	Feb 28, 2019			
		6988496	Feb 23, 2020	DP		
		6988496*PED	Aug 23, 2020			
		7056916	Dec 07, 2023	DS DP		
		7220742	May 12, 2025	DS DP U-1703		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001 7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025		U-1702		
	8044046	Nov 10, 2023		U-1702		
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP	U-1702		
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848	001				PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545	001 6995186	Nov 12, 2023	DP	U-765		
	7402609	Jun 19, 2022	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861	001 7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022		U-726		
	8399508*PED	Mar 17, 2023				
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276	001 8791154	May 19, 2032	DP	U-1680	NP	Jan 30, 2018
	9533053	May 19, 2032	DP		PED	Jul 30, 2018
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585	001 6987103	Oct 26, 2026		U-1300	NCE	Oct 26, 2017
	RE45128	Mar 16, 2019	DS DP	U-1576	ODE-32	Oct 26, 2019
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931	001 7148359	Jul 19, 2019	DP		I-743	Jul 24, 2018
	7148359*PED	Jan 19, 2020			NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP		NP	Jul 24, 2018
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP	U-1638		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977	001				NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060	001 5792795	May 13, 2018	DP		NCE	May 05, 2019
	5948818	May 13, 2018	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP	U-1511		
	9012501	Feb 07, 2025	DP	U-1511		
	9050308	Jan 04, 2033		U-1511		
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP	U-1511		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	001	6147103				
		6150380				
		6166213				
		6191148				
		Oct 09, 2018				
		Nov 10, 2018				
		Oct 09, 2018				
		Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	002	6147103				
		6150380				
		6166213				
		6191148				
		Oct 09, 2018				
		Nov 10, 2018				
		Oct 09, 2018				
		Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	003	6147103				
		6150380				
		6166213				
		6191148				
		Oct 09, 2018				
		Nov 10, 2018				
		Oct 09, 2018				
		Oct 09, 2018				
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032	001	9023391				
		Aug 16, 2025		DP		
<u>OMEPRAZOLE MAGNESIUM - OMEPRAZOLE MAGNESIUM</u>						
A 204152	001				PC	May 30, 2018
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229	001	6403616				
		6428810				
		Nov 15, 2019				
		Nov 03, 2019				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	001	6428810				
		6428810				
		Nov 03, 2019		DP U-1817		
		Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	002	6428810				
		Nov 03, 2019		DP U-864		
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	001	8580830				
		9095577				
		Nov 23, 2029		DP		
		Jul 13, 2030		DP		
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	002	8580830				
		9095577				
		Nov 23, 2029		DP		
		Jul 13, 2030		DP		
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334	001	5840684				
		5998581				
		8420592				
		9649352				
		9682061				
		Nov 24, 2017		DS DP U-1569		NCE
		Nov 12, 2017		DS		GAIN
		Aug 29, 2029				Aug 06, 2019
		Jul 16, 2035		DP		Aug 06, 2024
		Apr 26, 2030		U-1569		
<u>ORLISTAT - XENICAL</u>						
N 020766	001	6004996				
		Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887	001	6004996				
		Jan 06, 2018		DP		
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	001	8946235				
		9732058				
		Aug 08, 2032		DS DP U-1777		NCE
		Jul 25, 2032		DS DP U-1777		ODE-102
		Nov 13, 2020				Nov 13, 2020
		Nov 13, 2022				Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	002	8946235				
		9732058				
		Aug 08, 2032		DS DP U-1777		NCE
		Jul 25, 2032		DS DP U-1777		ODE-102
		Nov 13, 2020				Nov 13, 2020
		Nov 13, 2022				Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505	001	6245819				
		8236861				
		8236861				
		8470890				
		8470890				
		8642079				
		Jul 21, 2025		U-1370		NCE
		Aug 11, 2026		U-1369		Feb 26, 2018
		Aug 11, 2026		U-1370		
		Feb 13, 2024		U-1369		
		Feb 13, 2024		U-1370		
		Jul 09, 2028		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPEMIFENE - OSPHENA</u>						
N 203505	001	8772353	Feb 13, 2024	U-1369		
		8772353	Feb 13, 2024	U-1370		
		9241915	Feb 13, 2024	U-1369		
		9241915	Feb 13, 2024	U-1370		
		9566252	Jul 21, 2020	U-1370		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	001	5872147	Dec 05, 2017	U-585		
		6090799	Jul 18, 2017	U-585		
		6576659	Dec 05, 2017	U-585		
		6828313	Dec 05, 2017	U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	002	5872147	Dec 05, 2017	U-585		
		6090799	Jul 18, 2017	U-585		
		6576659	Dec 05, 2017	U-585		
		6828313	Dec 05, 2017	U-585		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	001	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	002	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	003	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285	001	7037525	Feb 12, 2018	U-724		
		8119148	Dec 19, 2020	DP U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001	7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	U-1298		
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	U-1298		
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002	7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	U-1298		
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	U-1298		
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003	7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027	U-1298		
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027	U-1298		
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351	002	6743441	Apr 26, 2020	DP U-318		
		7081249	Apr 26, 2020	DP U-318		
		7081250	Apr 26, 2020	DP U-318		
		7081251	Apr 26, 2020	DP U-318		
		7081252	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	DS DP U-318		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN - OXYTROL FOR WOMEN</u>						
N 202211	001	6743441	Apr 26, 2020	DP U-1329		
		7081249	Apr 26, 2020	DP U-1329		
		7081250	Apr 26, 2020	DP U-1329		
		7081251	Apr 26, 2020	DP U-1329		
		7081252	Apr 26, 2020	DP U-1329		
		7179483	Apr 26, 2020	U-1329		
<u>OXYBUTYNYNIN - GELNIOUE 3%</u>						
N 202513	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		7198801	Jun 25, 2022	DP		
		8241662	Apr 26, 2020	U-318		
<u>OXYBUTYNYNIN CHLORIDE - GELNIOUE</u>						
N 022204	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		8241662	Apr 26, 2020	U-318		
		8920392	Mar 26, 2031	U-1644		
		9259388	Nov 06, 2029	U-1644		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	002	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	U-1556		
		9592200	Jul 07, 2023	DP		
		9682075	Dec 10, 2030	DP U-1556		
		9737530	Sep 02, 2036	DP U-1556		
		9763883	Jul 07, 2023	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	7674799	Mar 30, 2025	DP	Y	NPP Aug 13, 2018
		7674800	Mar 30, 2025	DS	Y	
		7683072	Mar 30, 2025	DS	Y	
		7776314	Apr 19, 2025	DP	Y	
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	002	7674799	Mar 30, 2025	DP	Y	NPP Aug 13, 2018
		7674800	Mar 30, 2025	DS	Y	
		7683072	Mar 30, 2025	DS	Y	
		7776314	Apr 19, 2025	DP	Y	
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
		9675610	Jun 16, 2023	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775808	Aug 24, 2027	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	7674799	Mar 30, 2025	DP	Y	NPP Aug 13, 2018
		7674800	Mar 30, 2025	DS	Y	
		7683072	Mar 30, 2025	DS	Y	
		7776314	Apr 19, 2025	DP	Y	
		8309060	Nov 20, 2023	DP U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	8309060	Nov 20, 2023	DP U-1556		NPP	Aug 13, 2018
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	7674799	Mar 30, 2025	DP	Y	NPP	Aug 13, 2018
	7674800	Mar 30, 2025	DS	Y		
	7683072	Mar 30, 2025	DS	Y		
	7776314	Apr 19, 2025	DP	Y		
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	8309060	Nov 20, 2023	DP U-1556		NPP	Aug 13, 2018
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	8309060	Nov 20, 2023	DP U-1556		NPP	Aug 13, 2018
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	7276250	Feb 04, 2023	DP U-826			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	007	7276250	Feb 04, 2023	DP U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	001	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	002	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	003	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	004	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	005	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	006	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027	U-1598		
		8871779	Nov 22, 2029	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OZENOXACIN - XEPI</u>						
N 208945 001					NCE	Dec 11, 2022
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026		U-1434	ODE-52	Sep 06, 2020
	7820788	Oct 27, 2024	DP	U-1092		
	7820788	Oct 27, 2024	DP	U-1290		
	7820788	Oct 27, 2024	DP	U-1434		
	7923536	Dec 09, 2023		U-1117		
	7923536	Dec 09, 2023		U-1290		
	7923536	Dec 09, 2023		U-1434		
	8034375	Aug 13, 2026		U-1290		
	8138229	Dec 09, 2023	DP	U-1092		
	8138229	Dec 09, 2023	DP	U-1290		
	8138229	Dec 09, 2023	DP	U-1434		
	8268348	Feb 21, 2026		U-1290		
	8314156	Dec 09, 2023		U-1290		
	8314156	Dec 09, 2023		U-1434		
	8853260	Oct 10, 2020	DP	U-1092		
	8853260	Oct 10, 2020	DP	U-1290		
	8853260	Oct 10, 2020	DP	U-1434		
	9101543	Feb 21, 2026		U-1434		
	9393318	Mar 04, 2032		U-1290		
	9511046	Jan 12, 2034		U-1434		
	9597409	Mar 04, 2032		U-1290		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023		U-1998		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023		U-1998		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023		U-1998		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	6555544	Nov 10, 2018	DP	U-543	I-698	Nov 12, 2017
	9439906	Jan 26, 2031		U-1901	M-215	Dec 20, 2020
	9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	6555544	Nov 10, 2018	DP	U-543	I-698	Nov 12, 2017
	9439906	Jan 26, 2031		U-1901	M-215	Dec 20, 2020
	9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	6555544	Nov 10, 2018	DP	U-543	I-698	Nov 12, 2017
	9439906	Jan 26, 2031		U-1901	M-215	Dec 20, 2020
	9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	6555544	Nov 10, 2018	DP	U-543	I-698	Nov 12, 2017
	9439906	Jan 26, 2031		U-1901	M-215	Dec 20, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	004	9439906		Jan 26, 2031	U-543	
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	005	6555544	DP	Nov 10, 2018	U-543	I-698
		9439906		Jan 26, 2031	U-1901	M-215
		9439906		Jan 26, 2031	U-543	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	001	6077843*PED		Nov 12, 2017		NP
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	002	6077843*PED		Nov 12, 2017		NP
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	003	6077843*PED		Nov 12, 2017		NP
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	004	6077843*PED		Nov 12, 2017		NP
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	7947724		Jan 30, 2024	DP	
		7947724*PED		Jul 30, 2024		
		7947725		Jan 30, 2024	DP	
		7947725*PED		Jul 30, 2024		
		7960424		Jan 30, 2024	DP	
		7960424*PED		Jul 30, 2024		
		8518981		Jan 30, 2024	DP	
		8518981*PED		Jul 30, 2024		
		8598218		Jan 30, 2024	DP	
		8598218*PED		Jul 30, 2024		
		8598219		Jan 30, 2024	DP	
		8598219*PED		Jul 30, 2024		
		8729094		Jan 30, 2024	DP	U-528
		8729094*PED		Jul 30, 2024		
		9066980		Jan 30, 2024	DP	U-528
		9066980*PED		Jul 30, 2024		
		9125905		Jan 30, 2024	DP	
		9125905*PED		Jul 30, 2024		
		9173942		Jan 30, 2024	DP	
		9173942*PED		Jul 30, 2024		
		9439854		Jan 30, 2024	DP	
		9439854*PED		Jul 30, 2024		
		9457020		Jan 30, 2024	DP	
		9457020*PED		Jul 30, 2024		
		9457021		Jan 30, 2024	DP	
		9457021*PED		Jul 30, 2024		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	7947724		Jan 30, 2024	DP	
		7947724*PED		Jul 30, 2024		
		7947725		Jan 30, 2024	DP	
		7947725*PED		Jul 30, 2024		
		7960424		Jan 30, 2024	DP	
		7960424*PED		Jul 30, 2024		
		8518981		Jan 30, 2024	DP	
		8518981*PED		Jul 30, 2024		
		8598218		Jan 30, 2024	DP	
		8598218*PED		Jul 30, 2024		
		9173942		Jan 30, 2024	DP	
		9173942*PED		Jul 30, 2024		
		9439854		Jan 30, 2024	DP	
		9439854*PED		Jul 30, 2024		
		9457020		Jan 30, 2024	DP	
		9457020*PED		Jul 30, 2024		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	001	7658918		Feb 20, 2028	DP	
		8221747		Feb 20, 2028	DP	
		8246950		Feb 20, 2028	U-1274	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028	DP	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 001	9198871	Feb 07, 2030	DP	U-1787		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 002	9198871	Feb 07, 2030	DP	U-1787		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	003	9198871	Feb 07, 2030	DP U-1787		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	004	9198871	Feb 07, 2030	DP U-1787	M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	005	9198871	Feb 07, 2030	DP U-1787	M-93	Jul 29, 2019
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	001	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	002	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	003	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE-89	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001	6780881	Nov 17, 2021	DP		
		7351723	Nov 17, 2021	DP		
		8754108	Nov 17, 2021	DP		
		8754108*PED	May 17, 2022			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001	7544370	Jun 07, 2026	DP		
		7550153	Sep 30, 2024	U-859		
		7553498	Sep 30, 2024	U-859		
		7838027	Sep 30, 2024	DP U-859		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	001	6136799	Apr 08, 2018			
		6361758	Apr 08, 2018	DP		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	002	6136799	Apr 08, 2018			
		6361758	Apr 08, 2018	DP		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	003	6136799	Apr 08, 2018			
		6136799*PED	Oct 08, 2018			
		6361758	Apr 08, 2018	DP		
		6361758*PED	Oct 08, 2018			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	001	6063927	Apr 23, 2019			
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	002	6063927	Apr 23, 2019			
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	003	6063927	Apr 23, 2019			
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	004	6063927	Apr 23, 2019			
		6172233	Jan 15, 2018			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	7598271	May 04, 2025	DS		
		8658663	Apr 06, 2029	DS DP	U-904	
		8946251	Aug 04, 2026	DS DP	U-904	
		9393237	Aug 04, 2026		U-904	
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE-34	Dec 14, 2019
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE-34	Dec 14, 2019
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE-34	Dec 14, 2019
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	001	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023		U-1629	Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	002	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023		U-1629	Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	003	7473761	Dec 14, 2026	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023		U-1629	Dec 15, 2021
		9351923	May 23, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	001	7556799				
		Feb 27, 2025		U-1766	NCE	Oct 21, 2020
		8147873		DP		
		8216560		U-1766		
		8282913		DP		
		8287847		U-1766		
		8337824	DS	U-1766		
		8475780		U-1766		
		8778324		U-1766		
		8889115		U-1766		
		9492476		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	002	7556799				
		Feb 27, 2025		U-1766	NCE	Oct 21, 2020
		8147873		DP		
		8216560		U-1766		
		8282913		DP		
		8287847		U-1766		
		8337824	DS	U-1766		
		8475780		U-1766		
		8778324		U-1766		
		8889115		U-1766		
		9492476		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	003	7556799				
		Feb 27, 2025		U-1766	NCE	Oct 21, 2020
		8147873		DP		
		8216560		U-1766		
		8282913		DP		
		8287847		U-1766		
		8337824	DS	U-1766		
		8475780		U-1766		
		8778324		U-1766		
		8889115		U-1766		
		9492476		U-1766		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	001	7105530				
		Oct 19, 2023	DS DP		ODE-23	Apr 26, 2019
		7262203		DS DP		
		8114885		DS DP		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530				
		Oct 19, 2023	DS DP		ODE-23	Apr 26, 2019
		7262203		DS DP		
		8114885		DS DP		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	001	7084245				
		May 12, 2024	DS DP	U-1238		
		7414105		DS DP	U-1238	
		7528104		DS DP		
		7550433		U-1238		
		7919118	DS DP			
		7919461		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	002	7084245				
		May 12, 2024	DS DP	U-1238		
		7414105		DS DP	U-1238	
		7528104		DS DP		
		7550433		U-1238		
		7919118	DS DP			
		7919461		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	003	7084245				
		May 12, 2024	DS DP	U-1238		
		7414105		DS DP	U-1238	
		7528104		DS DP		
		7550433		U-1238		
		7919118	DS DP			
		7919461		U-1238		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	7772209	Nov 24, 2021			U-1077	
	7772209	Nov 24, 2021			U-1296	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	7772209	Nov 24, 2021			U-1296	
<u>PENCICLOVIR - DENAVIR</u>						
N 020629 001	6469015	Oct 22, 2019			U-501	
	6579981	Jun 17, 2020			U-501	
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	6503745	Nov 05, 2019	DS		NCE	Dec 19, 2019
	6562861	Dec 17, 2018	DS		NPP	Sep 20, 2020
	8778997	May 07, 2027			U-1627	
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	6949571	Jun 08, 2021	DS DP U-2088		NCE	Oct 22, 2017
	6949571	Jun 08, 2021	DS DP U-2089			
	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	6949571	Jun 08, 2021	DS DP U-2088		NCE	Oct 22, 2017
	6949571	Jun 08, 2021	DS DP U-2089			
	8772497	May 16, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		6949571	Jun 08, 2021	DS DP U-2088	NCE	Oct 22, 2017
		6949571	Jun 08, 2021	DS DP U-2089		
		8772497	May 16, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		6949571	Jun 08, 2021	DS DP U-2088	NCE	Oct 22, 2017
		6949571	Jun 08, 2021	DS DP U-2089		
		8772497	May 16, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		6949571	Jun 08, 2021	DS DP U-2088	NCE	Oct 22, 2017
		6949571	Jun 08, 2021	DS DP U-2089		
		8772497	May 16, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	006	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		6949571	Jun 08, 2021	DS DP U-2088	NCE	Oct 22, 2017
		6949571	Jun 08, 2021	DS DP U-2089		
		8772497	May 16, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 208277	001	6949571	Jun 08, 2021	DS DP U-106	NCE	Oct 22, 2017
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		8772497	May 16, 2026	DS		
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	8658205	Jun 18, 2019	DP		
		8685441	Jan 13, 2019	U-665		
		9545457	Jan 13, 2019	U-665		
		9789210	Mar 16, 2037	U-665		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	6149938	Jul 23, 2018	DP		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	6149938	Jul 23, 2018	DP		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	6149938	Jul 23, 2018	DP U-1243		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	001	7056890	Jun 14, 2020	DP U-1262		
		7553818	Jun 14, 2020	U-1262		
		7659256	Jun 14, 2020	DP U-1262		
		7674776	Jun 14, 2020	DP U-1262		
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029	U-1262		
		8895057	Jun 09, 2028	U-1262		
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028	U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	002	7056890	Jun 14, 2020	DP U-1262		
		7553818	Jun 14, 2020	U-1262		
		7659256	Jun 14, 2020	DP U-1262		
		7674776	Jun 14, 2020	DP U-1262		
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029	U-1262		
		8895057	Jun 09, 2028	U-1262		
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	002	9011906				
		Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	003	7056890				
		Jun 14, 2020	DP U-1262			
		7553818				
		Jun 14, 2020	U-1262			
		7659256				
		Jun 14, 2020	DP U-1262			
		7674776				
		Jun 14, 2020	DP U-1262			
		8580298				
		May 15, 2029	DP			
		8580299				
		Jun 14, 2029	U-1262			
		8895057				
		Jun 09, 2028	U-1262			
		8895058				
		Jun 09, 2028	DP			
		9011905				
		Jun 09, 2028	DP			
		9011906				
		Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	004	7056890				
		Jun 14, 2020	DP U-1262			
		7553818				
		Jun 14, 2020	U-1262			
		7659256				
		Jun 14, 2020	DP U-1262			
		7674776				
		Jun 14, 2020	DP U-1262			
		8580298				
		May 15, 2029	DP			
		8580299				
		Jun 14, 2029	U-1262			
		8895057				
		Jun 09, 2028	U-1262			
		8895058				
		Jun 09, 2028	DP			
		9011905				
		Jun 09, 2028	DP			
		9011906				
		Jun 09, 2028	U-1262			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159	001	6764678				
		May 11, 2021	U-967		NPP	Mar 18, 2019
		6872390				
		May 11, 2021	DP			
		7229630				
		Jun 20, 2023	DP			
		7569230				
		Oct 17, 2023	U-967			
		7575757				
		Apr 21, 2025	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	001	8859623				
		Nov 14, 2033	U-1594			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	002	8859623				
		Nov 14, 2033	U-1594			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	001	6756393				
		Mar 06, 2021	DS DP		NCE	Apr 29, 2021
		6815458				
		Mar 06, 2021	DS DP U-1843			
		7115634				
		Oct 06, 2021	DS DP			
		7601740				
		Jun 17, 2027	DS DP			
		7659285				
		Aug 24, 2026	U-1844			
		7732615				
		Jun 03, 2028	DS DP			
		7858789				
		Dec 13, 2020	DS DP			
		7923564				
		Sep 26, 2025	DS DP			
		8110574				
		Dec 13, 2020	DS DP			
		8618130				
		Jan 15, 2024	U-1845			
		8921393				
		Jan 15, 2024	U-1846			
		9296694				
		Mar 06, 2021	DS DP			
		9566271				
		Jan 15, 2024	U-1974			
		9765053				
		Jul 27, 2022	U-1974			
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302	001	6423722				
		Jun 26, 2018				
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	001	6900184				
		Apr 14, 2023	DP U-282			
		7915229				
		Apr 14, 2023	DP			
		8133883				
		Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	002	6900184				
		Apr 14, 2023	DP U-282			
		7915229				
		Apr 14, 2023	DP			
		8133883				
		Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	003	6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	004	6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	001	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	002	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	003	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535	001	7566729	Apr 22, 2029	U-1600	NCE	Oct 15, 2019
		7635707	Apr 22, 2029	U-1609	ODE-77	Oct 15, 2021
		7696236	Dec 18, 2027	U-1601		
		7767225	Sep 22, 2026	DP U-1602		
		7767700	Dec 18, 2027	U-1601		
		7816383	Jan 08, 2030	U-1603		
		7910610	Jan 08, 2030	U-1604		
		7988994	Sep 22, 2026	DP U-1602		
		8013002	Jan 08, 2030	U-1603		
		8084475	Jan 08, 2030	U-1605		
		8318780	Jan 08, 2030	U-1606		
		8383150	Sep 22, 2026	DP U-1607		
		8420674	Dec 18, 2027	DP U-1608		
		8592462	Apr 22, 2029	U-1609		
		8609701	Apr 22, 2029	U-1610		
		8648098	Jan 08, 2030	U-1611		
		8753679	Sep 22, 2026	DP U-1602		
		8754109	Jan 08, 2030	U-1612		
		8778947	Aug 30, 2033	U-1613		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	001	7566729	Apr 22, 2029	U-2077	NCE	Oct 15, 2019
		7566729	Apr 22, 2029	U-2078	ODE-77	Oct 15, 2021
		7635707	Apr 22, 2029	U-2072		
		7635707	Apr 22, 2029	U-2073		
		7635707	Apr 22, 2029	U-2074		
		7635707	Apr 22, 2029	U-2075		
		7635707	Apr 22, 2029	U-2076		
		7635707	Apr 22, 2029	U-2083		
		7767700	Dec 18, 2027	U-2080		
		7816383	Jan 08, 2030	U-2042		
		7816383	Jan 08, 2030	U-2050		
		7910610	Jan 08, 2030	U-2048		
		7910610	Jan 08, 2030	U-2049		
		8013002	Jan 08, 2030	U-2047		
		8013002	Jan 08, 2030	U-2082		
		8084475	Jan 08, 2030	U-2052		
		8084475	Jan 08, 2030	U-2054		
		8318780	Jan 08, 2030	U-2046		
		8318780	Jan 08, 2030	U-2081		
		8383150	Sep 22, 2026	DP U-1607		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE-77	Oct 15, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE ODE-77	Oct 15, 2019 Oct 15, 2021
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	003	8754109	Jan 08, 2030	U-2053		
		8778947	Aug 30, 2033	U-2044		
		8778947	Aug 30, 2033	U-2045		
		9561217	Jan 25, 2022	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	001	5856336	Dec 25, 2020	DS	U-998	
		7022713	Feb 19, 2024		U-998	
		8557993	Feb 02, 2024	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	002	5856336	Dec 25, 2020	DS	U-998	
		7022713	Feb 19, 2024		U-998	
		8557993	Feb 02, 2024	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	003	5856336	Dec 25, 2020	DS	U-998	
		7022713	Feb 19, 2024		U-998	
		8557993	Feb 02, 2024	DS	DP	
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379	001	8829186	Jan 19, 2031	DS	DP	
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379	002	8829186	Jan 19, 2031	DS	DP	
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379	003	8829186	Jan 19, 2031	DS	DP	
<u>PLECANATIDE - TRULANCE</u>						
N 208745	001	7041786	Mar 25, 2023	DS		NCE
		7799897	Jun 09, 2022	DS		Jan 19, 2022
		8637451	Mar 28, 2022		U-1964	
		9610321	Sep 11, 2031		U-1999	
		9616097	Jul 02, 2032	DP		
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311	001	6987102	Jul 22, 2023		U-936	
		7897590	Jul 22, 2023		U-936	
		RE42152	Dec 10, 2018	DP		
<u>POLIDOCANOL - VARITHENA</u>						
N 205098	001	6572873	May 26, 2020		U-1461	
		6846412	Jul 19, 2022	DP		
		6942165	May 26, 2020	DP		
		7025290	May 26, 2020	DP	U-1461	
		7357336	May 26, 2020		U-1461	
		7604185	May 26, 2020	DS	DP	U-1462
		7731986	Nov 17, 2024	DS	DP	U-1463
		7814943	Nov 19, 2027	DP	U-1461	
		7842282	May 26, 2020		U-1461	
		7842283	May 26, 2020	DP		
		8122917	Sep 09, 2024	DP		
		8323677	May 26, 2020	DS		
		8734833	May 26, 2020	DS	DP	
		9480652	May 12, 2032	DP		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	001	6045501	Aug 28, 2018	U-1361	I-707	Apr 23, 2018
		6315720	Oct 23, 2020	U-1361	NCE	Feb 08, 2018
		6561976	Aug 28, 2018	U-1361	ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361		
		6755784	Oct 23, 2020	U-1361		
		6908432	Aug 28, 2018	U-1361		
		8198262	Oct 19, 2024	U-1360		
		8204763	Aug 28, 2018	U-1361		
		8315886	Oct 23, 2020	U-1361		
		8589188	Aug 28, 2018	U-1361		
		8626531	Oct 23, 2020	U-1361		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	6045501	Aug 28, 2018	U-1361		I-707	Apr 23, 2018
	6315720	Oct 23, 2020	U-1361		NCE	Feb 08, 2018
	6561976	Aug 28, 2018	U-1361		ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	6045501	Aug 28, 2018	U-1361		I-707	Apr 23, 2018
	6315720	Oct 23, 2020	U-1361		NCE	Feb 08, 2018
	6561976	Aug 28, 2018	U-1361		ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	6045501	Aug 28, 2018	U-1361		I-707	Apr 23, 2018
	6315720	Oct 23, 2020	U-1361		NCE	Feb 08, 2018
	6561976	Aug 28, 2018	U-1361		ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-1283		ODE-35	Dec 14, 2019
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-1283		ODE-35	Dec 14, 2019
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	002	9493470	Dec 12, 2033	DS DP U-1700		
		9493470	Dec 12, 2033	DS DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	003	8114874	Dec 22, 2026	DS DP	NCE	Dec 14, 2017
		9029533	Dec 22, 2026	U-1283	ODE-35	Dec 14, 2019
		9029533	Dec 22, 2026	U-1699		
		9029533	Dec 22, 2026	U-1700		
		9029533	Dec 22, 2026	U-1701		
		9029533	Dec 22, 2026	U-836		
		9493470	Dec 12, 2033	DS DP U-1700		
		9493470	Dec 12, 2033	DS DP U-1948		
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003	001	5661151	Jul 19, 2019	DS DP U-760		
		6958337	Oct 05, 2018	DS DP U-760		
		8263600	Apr 01, 2022	DP		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053	001	5661151	Jul 19, 2019	DS DP U-1454		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596	001	5661151	Jul 19, 2019	DS DP U-1454		
		8410077	Mar 13, 2029	DP		
		9023790	Jul 04, 2031	DP U-1698		
		9358297	Jun 24, 2031	DP U-1454		
		9493582	Feb 27, 2033	DP		
		9750822	Mar 13, 2029	DP		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	001	6028071	Jul 16, 2022	DS DP U-1004		
		7622470	May 31, 2025	U-1015		
		8299078	May 31, 2025	U-1004		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	002	6028071	Jul 16, 2022	DS DP U-1004		
		7622470	May 31, 2025	U-1015		
		8299078	May 31, 2025	U-1004		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	001	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	002	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	003	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	005	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	006	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	007	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	001	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8268806	Mar 19, 2031	DP		NCE	Nov 16, 2021
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028	U-1922			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726*PED	Oct 14, 2017			M-182	Jul 12, 2019
	8404703	Jan 02, 2023	U-1381		PED	Jan 12, 2020
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726*PED	Oct 14, 2017			M-182	Jul 12, 2019
	8404703	Jan 02, 2023	U-1381		PED	Jan 12, 2020
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 001	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	002	6071523	Jun 03, 2018	DP		
		6399079	Jun 03, 2018	DP		
		6656482	Jun 03, 2018	DP		
		7799331	Oct 11, 2028	DP U-1068		
		7799331	Oct 11, 2028	DP U-139		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	001	6740341	Nov 24, 2019	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	002	6740341	Nov 24, 2019	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	003	6740341	Nov 24, 2019	DP		
<u>PREDNISONE - RAYOS</u>						
N 202020	001	6488960	Mar 14, 2020	DP U-1267		
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	002	6488960	Mar 14, 2020	DP U-1267		
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024			
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	003	8168218	Jan 07, 2028	DP U-1269		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREGABALIN - LYRICA</u>						
N 021446	001	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446	002	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446	003	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446	004	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446	005	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	
		6197819	Dec 30, 2018	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446	005 RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	006 6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	007 6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	008 6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 022488	001 6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA CR</u>						
N 209501	001 6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501	002 6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501	003 6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PROGESTERONE - ENDOMETRIN</u>						
N 022057	001 7300664	Nov 17, 2019	U-856			
	7320800	Nov 17, 2019	U-856			
	7393543	Nov 17, 2019	DP U-880			
<u>PROPOFOL - DIPRIVAN</u>						
N 019627	002 8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	001 6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	002 6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410	001 8338489	Oct 16, 2028	U-1496		ODE-62	Mar 14, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUAZEPAM - DORAL</u>						
N 018708 001	7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N 018708 003	7608616	Jun 03, 2028	U-1012			
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			NS	May 26, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RAMELTEON - ROZEREM</u>						
N 021782 001	6034239	Jul 22, 2019	DS DP U-674			
<u>RAMIPRIL - ALTACE</u>						
N 019901 001	7368469	Aug 30, 2020	U-871			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RAMIPRIL - ALTACE</u>						
N 019901	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	004	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	001	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	004	7368469	Aug 30, 2020	U-871		
<u>RANOLAZINE - RANEXA</u>						
N 021526	001	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP		Y
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RANOLAZINE - RANEXA</u>						
N 021526	002	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP		
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823	001				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823	002				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	001				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	002				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001	7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	002	7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP	U-219	
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	6403567	Apr 10, 2022	DS DP	U-869	
		6642210	Jun 22, 2019	DS DP	U-869	
		7144872	Jun 22, 2019	DS DP	U-116	
		7144872	Jun 22, 2019	DS DP	U-869	
		7144872	Jun 22, 2019	DS DP	U-870	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	7183264	Jun 22, 2019	DP	U-116	
		7183264	Jun 22, 2019	DP	U-869	
		7183264	Jun 22, 2019	DP	U-870	
		7582617	Jun 22, 2019		U-1003	
		7655636	Jun 22, 2019		U-869	
		7655637	Jun 22, 2019	DS DP	U-869	
		7683037	Jun 22, 2019		U-1042	
		8106029	Jun 22, 2019		U-1042	
		8106183	Feb 02, 2027	DS		
		8133879	Jun 22, 2019	DP		
		8183226	Jun 22, 2019		U-116	
		8470801	Jun 22, 2019		U-116	
		8536150	Jun 22, 2019		U-116	
		9045519	Jun 22, 2019	DP		
		9085601	Feb 02, 2027	DP		
		9289446	Jun 22, 2019	DP	U-116	
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001	7351834	Jun 28, 2022	DS		I-744 Apr 27, 2020
		8637553	Feb 16, 2031	DS DP		NCE Sep 27, 2017
		8680124	Jun 02, 2030		U-1506	ODE-139 Apr 27, 2024
		9458107	Apr 08, 2031	DP		ODE-44 Feb 25, 2020
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	001	5866591	Sep 10, 2017	DP		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	002	5866591	Sep 10, 2017	DP		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	003	5866591	Sep 10, 2017	DP		
<u>RETAPAMULIN - ALTABAX</u>						
N 022055	001	7875630	Feb 14, 2027	DS		
		8207191	Aug 30, 2024		U-805	
		RE43390	Apr 12, 2021	DS DP	U-805	
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859	001	6150337	Nov 21, 2017		U-400	
<u>RIBAVIRIN - REBETOL</u>						
N 020903	001	6172046	Sep 21, 2017		U-1014	
		6172046	Sep 21, 2017		U-377	
		6472373	Sep 21, 2017		U-1014	
		6472373	Sep 21, 2017		U-479	
<u>RIBAVIRIN - REBETOL</u>						
N 020903	002	6172046	Sep 21, 2017		U-1014	
		6172046	Sep 21, 2017		U-377	
		6472373	Sep 21, 2017		U-1014	
		6472373	Sep 21, 2017		U-479	
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001	6172046	Sep 21, 2017		U-1014	
		6172046	Sep 21, 2017		U-521	
		6472373	Sep 21, 2017		U-521	
		6790837	Apr 05, 2023	DP		
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001	8324225	Jun 17, 2028	DS DP		NCE Mar 13, 2022
		8415355	Feb 19, 2031	DS DP		
		8685980	May 25, 2030	DS DP		
		8962630	Dec 09, 2029		U-1981	
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029		U-1981	
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001					NP Apr 15, 2019
					ODE-116	Apr 15, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				ODE-121	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				NP ODE-116 ODE-121	Apr 15, 2019 Apr 15, 2023 Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	7045620	Jun 19, 2024	DS DP		
		7612199	Jun 19, 2024	DS DP		
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7928115	Jul 24, 2029		U-1121	
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP		
		8518949	Feb 27, 2026	DP		
		8741904	Feb 27, 2026	DS	U-1526	
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
		9271968	Feb 27, 2026	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	6861053	Aug 11, 2019		U-1707	I-709 May 27, 2018
		6861053	Aug 11, 2019		U-1708	
		7045620	Jun 19, 2024	DS		
		7452857	Aug 11, 2019		U-1707	
		7452857	Aug 11, 2019		U-1708	
		7605240	Aug 11, 2019		U-1707	
		7605240	Aug 11, 2019		U-1708	
		7612199	Jun 19, 2024	DS DP		
		7718608	Aug 11, 2019		U-1707	
		7718608	Aug 11, 2019		U-1708	
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7915275	Feb 23, 2025		U-1707	
		7915275	Feb 23, 2025		U-1708	
		7935799	Aug 11, 2019		U-1707	
		7935799	Aug 11, 2019		U-1708	
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP	U-1707	
		8193196	Sep 02, 2027	DS DP	U-1708	
		8309569	Jul 18, 2029		U-1707	
		8309569	Jul 18, 2029		U-1708	
		8518949	Feb 27, 2026	DP		
		8642573	Oct 02, 2029		U-1481	
		8741904	Feb 27, 2026	DS	U-1526	
		8741904	Feb 27, 2026	DS	U-1707	
		8741904	Feb 27, 2026	DS	U-1708	
		8829017	Jul 24, 2029		U-1562	
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
		8946252	Jul 24, 2029		U-1481	
		8969398	Oct 02, 2029		U-1481	
		9271968	Feb 27, 2026	DP		
		9421195	Mar 10, 2030		U-1481	
		9629828	Jul 24, 2029		U-1994	
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001	6838464	Feb 26, 2021	DS DP	NPP	Aug 26, 2018
		7067522	Dec 20, 2019	DS DP		
		7125879	Apr 21, 2025	DS DP	U-1153	
		7125879	Apr 21, 2025	DS DP	U-1307	
		7125879	Apr 21, 2025	DS DP	U-1740	
		7638522	Apr 14, 2023	DP		
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE-53	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 001	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 002	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 003	5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 004	6165513	Jun 10, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP	U-662		
	7645460	Jan 09, 2028	DP	U-662		
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6596316	Dec 30, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N 020945 001	6232333	Nov 07, 2017				
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		D-168	Oct 27, 2020
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	7592339	Dec 11, 2020		U-2142		
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-1956		
	9539218	Feb 17, 2034		U-1957		
	9539218	Feb 17, 2034		U-2143		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-1956		
	9539218	Feb 17, 2034		U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167	Y	
	7592339	Dec 11, 2020		U-1200	Y	
	7592339	Dec 11, 2020		U-1301	Y	
	7592339	Dec 11, 2020		U-1302	Y	
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	9415053	Nov 13, 2024	DP U-1302		
		9415053	Nov 13, 2024	DP U-1303		
		9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1957		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	001	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	002	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	005	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115	M-208	Aug 31, 2020
		8431154	Feb 19, 2023	DP		
		8536206	Mar 08, 2024	U-1115		
		8604064	Mar 08, 2024	U-1115		
		8618142	Mar 08, 2024	DP		
		9468598	Feb 19, 2023	DP		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	7049320	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP		
		7981905	Apr 04, 2027	U-1741		
		8178550	Apr 04, 2027	DS DP		
		8361500	Oct 09, 2029	DP		
		8404702	Apr 04, 2027	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399	001	7049320	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7981905	Apr 04, 2027	U-1741		
		8178550	Apr 04, 2027	DS DP		
		8404702	Apr 04, 2027	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
		9101615	Jul 14, 2032	U-1741		
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393	001	7608280	Aug 22, 2021	DS	ODE-12	Jun 16, 2018
		7611724	Aug 22, 2021	DS		
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	001	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	002	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	003	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	004	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	005	7927624	Dec 02, 2021	DP U-20	M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1807		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-618			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	002	7413747				
		Mar 18, 2019	DP			
		8246979				
		Sep 01, 2027	DP U-1272			
		8246979				
		Sep 01, 2027	DP U-1273			
		8246980				
		Nov 27, 2025	DP			
		8617591				
		Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	003	6699498				
		Nov 27, 2020	DP			
		6884434				
		Mar 30, 2021	DP			
		7413747				
		Mar 18, 2019	DP			
		8246979				
		Sep 01, 2027	DP U-1272			
		8246979				
		Sep 01, 2027	DP U-1273			
		8246980				
		Nov 27, 2025	DP			
		8617591				
		Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	004	6699498				
		Nov 27, 2020	DP			
		6884434				
		Mar 30, 2021	DP			
		7413747				
		Mar 18, 2019	DP			
		8246979				
		Sep 01, 2027	DP U-1272			
		8246979				
		Sep 01, 2027	DP U-1273			
		8246980				
		Nov 27, 2025	DP			
		8617591				
		Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	005	6699498				
		Nov 27, 2020	DP			
		6884434				
		Mar 30, 2021	DP			
		7413747				
		Mar 18, 2019	DP			
		8246979				
		Sep 01, 2027	DP U-1272			
		8246979				
		Sep 01, 2027	DP U-1273			
		8246980				
		Nov 27, 2025	DP			
		8617591				
		Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	006	6699498				
		Nov 27, 2020	DP			
		6884434				
		Mar 30, 2021	DP			
		7413747				
		Mar 18, 2019	DP			
		8246979				
		Sep 01, 2027	DP U-1272			
		8246979				
		Sep 01, 2027	DP U-1273			
		8246980				
		Nov 27, 2025	DP			
		8617591				
		Jul 22, 2023	DP U-1474			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	001	6495541				
		Jan 10, 2020	DS DP			
		7351701				
		Jul 23, 2024	U-2012		NCE	Dec 19, 2021
		7531530			ODE-126	Dec 19, 2023
		Jul 23, 2024	U-2012			
		8071579				
		Aug 12, 2027	U-2012			
		8143241				
		Aug 12, 2027	U-2012			
		8754072				
		Feb 10, 2031	DS DP			
		8859562				
		Aug 04, 2031	U-2012			
		9045487				
		Feb 10, 2031	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	002	6495541				
		Jan 10, 2020	DS DP			
		7351701				
		Jul 23, 2024	U-2012		NCE	Dec 19, 2021
		7531530			ODE-126	Dec 19, 2023
		Jul 23, 2024	U-2012			
		8071579				
		Aug 12, 2027	U-2012			
		8143241				
		Aug 12, 2027	U-2012			
		8754072				
		Feb 10, 2031	DS DP			
		8859562				
		Aug 04, 2031	U-2012			
		9045487				
		Feb 10, 2031	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003	6495541				
		Jan 10, 2020	DS DP			
		7351701				
		Jul 23, 2024	U-2012		NCE	Dec 19, 2021
		7531530			ODE-126	Dec 19, 2023
		Jul 23, 2024	U-2012			
		8071579				
		Aug 12, 2027	U-2012			
		8143241				
		Aug 12, 2027	U-2012			
		8754072				
		Feb 10, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003	8859562				
		Aug 04, 2031		U-2012		
	9045487	Feb 10, 2031	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911	001	6740669	DS DP			
	6740669*PED	Nov 14, 2022				
	7750028	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911	002	6740669	DS DP			
	6740669*PED	Nov 14, 2022				
	7750028	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911	003	6740669	DS DP			
	6740669*PED	Nov 14, 2022				
	7750028	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367	001	6740669	DS DP			
	6740669*PED	Nov 14, 2022				
	7750028	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	7598257	DS DP	U-1201	I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP	U-1622	ODE-19	Nov 16, 2018
	8415362	Dec 24, 2027	DS DP		ODE-79	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	7598257	DS DP	U-1201	I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP	U-1622	ODE-19	Nov 16, 2018
	8415362	Dec 24, 2027	DS DP		ODE-79	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	7598257	DS DP	U-1201	I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP	U-1622	ODE-19	Nov 16, 2018
	8415362	Dec 24, 2027	DS DP		ODE-79	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9662335	Dec 12, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		ODE-19	Nov 16, 2018
	8415362	Dec 24, 2027	DS DP		ODE-79	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		ODE-19	Nov 16, 2018
	8415362	Dec 24, 2027	DS DP		ODE-79	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023		U-1723		
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026		U-1723		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023		U-1723		
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026		U-1723		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023		U-1723		
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026		U-1723		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027		U-1993		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027		U-1993		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024		U-989		
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024		U-1010		
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001	7947681	Nov 17, 2024	U-1156	Y	
		7947681*PED	May 17, 2025			
		8003126	Nov 16, 2025			
		8003126*PED	May 16, 2026			
		8067416	Nov 17, 2024	U-989		
		8067416*PED	May 17, 2025			
		8318745	Nov 17, 2024	DP		
		8318745*PED	May 17, 2025			
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1156		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828	001	6352717	Nov 16, 2019			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001	7951400	Nov 30, 2028	DP	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1837	M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-995		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002	7951400	Nov 30, 2028	DP	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1837	M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-995		
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363	001				NCE GAIN	Sep 15, 2022 Sep 15, 2027
<u>SELEGILINE - EMSAM</u>						
N 021336	001	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	002	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	003	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	6899699	Jan 02, 2022	DP		NCE	Dec 05, 2022
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Jan 29, 2029	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990	001 6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127	001 7985418	Oct 27, 2025	DP		NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	001 9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	002 9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	001 6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	002 6733780	Oct 18, 2020	DP			
<u>SEVOFLURANE - ULTANE</u>						
N 020478	001 6074668	Jan 09, 2018				
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342	001				PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342	002				PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342	003				PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	001 6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	002 6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	003 6469012	Oct 22, 2019	U-155			
<u>SILODOSIN - RAPAFLU</u>						
N 022206	001 5387603	Dec 01, 2018	DS DP			
<u>SILODOSIN - RAPAFLU</u>						
N 022206	002 5387603	Dec 01, 2018	DS DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001 7671032	May 19, 2025	DS DP		D-151	Oct 05, 2018
	8148399	Sep 05, 2029	DS DP U-1467		I-697	Nov 05, 2017
	8349869	Jul 28, 2026	DS DP U-1467		I-717	Oct 05, 2018
	8741926	Jul 28, 2026	DS U-1467		M-171	Feb 26, 2019
	8754106	Jul 28, 2026	DS U-1467		M-179	May 20, 2019
	9040562	Jul 28, 2026	DS DP U-1467		NCE	Nov 22, 2018
	9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	001 9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	002 9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	001 6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020	U-172			
	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5989591	Mar 11, 2018	DP		ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5989591	Mar 11, 2018	DP		ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5989591	Mar 11, 2018	DP		ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5989591	Mar 11, 2018	DP		ODE-92	May 28, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE-5	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOLE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419		ODE-5	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444	001	9345724	Mar 29, 2031	DS DP U-2015		
		9585912	Mar 29, 2031	DS DP		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	6780889	Jul 04, 2020	DP		
		7262219	Jul 04, 2020	DP		
		7668730	Jun 16, 2024	U-1110		
		7765106	Jun 16, 2024	U-1069		
		7765107	Jun 16, 2024	U-1070		
		7851506	Dec 22, 2019	U-1101		
		7851506	Dec 22, 2019	U-1102		
		7895059	Dec 17, 2022	U-1110		
		8263650	Dec 22, 2019	DP U-1101		
		8263650	Dec 22, 2019	DP U-1102		
		8324275	Dec 22, 2019	U-1101		
		8324275	Dec 22, 2019	U-1102		
		8457988	Dec 17, 2022	U-1110		
		8589182	Dec 17, 2022	U-1110		
		8731963	Dec 17, 2022	U-1110		
		8772306	Mar 15, 2033	U-1532		
		8859619	Dec 22, 2019	DP		
		8952062	Dec 22, 2019	U-1101		
		8952062	Dec 22, 2019	U-1102		
		9050302	Mar 15, 2033	U-1532		
		9486426	Mar 15, 2033	U-1532		
		9539330	Dec 22, 2019	DP		
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892	001	7687075	Jun 22, 2028	DS DP		
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923	001	8496973	Mar 29, 2031	DS DP U-1419	ODE-5	Jan 14, 2018
		9345724	Mar 29, 2031	DS DP U-2015		
		9585912	Mar 29, 2031	DS DP		
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671	001	7964580	Mar 26, 2029	DS DP U-1470	NCE	Dec 06, 2018
		8334270	Mar 21, 2028	DS DP U-1470	NPP	Apr 07, 2020
		8580765	Mar 21, 2028	DS DP U-1470	ODE-135	Apr 07, 2024
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
		9284342	Sep 13, 2030	DS DP U-1470		
		9549941	Mar 26, 2029	U-1958		
<u>SOFOSEBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001	7964580	Mar 26, 2029	DS DP U-1470	NCE	Dec 06, 2018
		8334270	Mar 21, 2028	DS DP U-1470	NCE	Jun 28, 2021
		8575135	Nov 16, 2032	DS DP U-1470	NPP	Aug 01, 2020
		8580765	Mar 21, 2028	DS DP U-1470		
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8735372	Mar 21, 2028	U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		8921341	Nov 16, 2032	DS DP U-1470		
		8940718	Nov 16, 2032	DS DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
		9284342	Sep 13, 2030	DS DP U-1470		
		9757406	Jan 30, 2034	DP		
<u>SOFOSEBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195	001	7964580	Mar 26, 2029	DS DP U-2039	NCE	Jul 18, 2022
		7964580	Mar 26, 2029	DS DP U-2040		
		8334270	Mar 21, 2028	DS DP U-2039		
		8334270	Mar 21, 2028	DS DP U-2040		
		8575135	Nov 05, 2033	DS DP U-2039		
		8575135	Nov 05, 2033	DS DP U-2040		
		8580765	Mar 21, 2028	DS DP U-2039		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSEBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195	001	8580765	Mar 21, 2028	DS DP U-2040		
		8618076	Dec 11, 2030	DS DP U-2039		
		8618076	Dec 11, 2030	DS DP U-2040		
		8633309	Mar 26, 2029	DS DP U-2039		
		8633309	Mar 26, 2029	DS DP U-2040		
		8735372	Mar 21, 2028	DS DP U-2039		
		8735372	Mar 21, 2028	DS DP U-2040		
		8889159	Mar 26, 2029	DS DP U-2039		
		8889159	Mar 26, 2029	DS DP U-2040		
		8921341	Nov 16, 2032	DS DP U-2039		
		8921341	Nov 16, 2032	DS DP U-2040		
		8940718	Nov 16, 2032	DS DP U-2039		
		8940718	Nov 16, 2032	DS DP U-2040		
		9085573	Mar 21, 2028	DS DP U-2039		
		9085573	Mar 21, 2028	DS DP U-2040		
		9284342	Sep 13, 2030	DS DP U-2039		
		9284342	Sep 13, 2030	DS DP U-2040		
		9296782	Jul 17, 2034	DS DP		
		9585906	Mar 21, 2028	DS DP U-2039		
		9585906	Mar 21, 2028	DS DP U-2040		
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	001	6017927	Nov 19, 2018	DS DP		
		6017927*PED	May 19, 2019			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	002	6017927	Nov 19, 2018	DS DP		
		6017927*PED	May 19, 2019			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	001	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	002	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	003	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	005	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	008	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	009	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	004	6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	005	6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	006	6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	007	6004297	Jan 28, 2019	DP		
		8841252	Dec 26, 2017	DP		
		RE41956	Jan 21, 2021	DP		
		RE43834	Jan 28, 2019	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148	008	6899699	Jan 02, 2022	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148	009	6899699	Jan 02, 2022	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148	010	6899699	Jan 02, 2022	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148	011	6899699	Jan 02, 2022	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266	001	8063043	Sep 15, 2029	DS DP	NCE	Jul 24, 2020
		8178563	Feb 06, 2029	DS	U-1722	
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	7235576	Jan 12, 2020	DS DP	ODE-56	Nov 22, 2020
		7351834	Jan 12, 2020	DS		
		7897623	Jan 12, 2020	DP		
		8124630	Jan 12, 2020		U-1459	
		8618141	Feb 11, 2023		U-1480	
		8841330	Jan 12, 2020		U-1696	
		8877933	Dec 24, 2027	DS DP	U-1624	
		9737488	Sep 10, 2028	DP	U-1480	
		9737488	Sep 10, 2028	DP	U-1696	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001 9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108	001 9724297	Aug 31, 2035	DP U-2096			
<u>SPINOSAD - NATROBA</u>						
N 022408	001 6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478	001 9757394	Oct 28, 2036	DP U-2109			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001 6174442	Dec 19, 2018	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001 5686060	Nov 11, 2019	DS DP		I-728 NCE	Mar 31, 2019 Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001 7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377	001 7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278	001 6745071	Feb 21, 2023	DP			
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001	6715485	Mar 03, 2020	DP		
		7975690	Aug 18, 2025	DP U-1809		
		8047202	Jul 02, 2023	DP		
		8327844	Oct 03, 2023	U-1809		
		8550073	Oct 22, 2029	DP		
		8555877	Mar 03, 2020	DP		
		8590530	Sep 15, 2025	DP U-1809		
		8875704	Apr 07, 2028	DP U-1809		
		8899229	Aug 18, 2030	DP		
		8978647	Dec 06, 2030	DP		
		9108015	Sep 15, 2025	DP		
		9119932	Apr 23, 2024	DP		
		9649456	Oct 21, 2030	DP U-1719		
		9649456	Oct 21, 2030	DP U-2010		
		9649456	Oct 21, 2030	DP U-2011		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	001	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171		
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020	U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	002	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171		
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020	U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171		
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020	U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	004	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171		
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020	U-883		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001	7951797	Nov 20, 2029	DS DP U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002	7951797	Nov 20, 2029	DS DP U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003	7951797	Nov 20, 2029	DS DP U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004	7951797	Nov 20, 2029	DS DP U-620	NCE	Aug 13, 2019
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	001	6440458	Mar 25, 2019	DP		
		6576259	Mar 25, 2019	DP U-1420		
		6884433	Mar 25, 2019	DP U-1420		
		8551522	Mar 25, 2019	DP		
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	002	6440458	Mar 25, 2019	DP		
		6576259	Mar 25, 2019	DP U-1420		
		6884433	Mar 25, 2019	DP U-1420		
		8551522	Mar 25, 2019	DP		
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	003	6440458	Mar 25, 2019	DP		
		6576259	Mar 25, 2019	DP U-1420		
		6884433	Mar 25, 2019	DP U-1420		
		8551522	Mar 25, 2019	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
	8486993	Aug 30, 2024	DP	U-1752		
	8586084	Aug 30, 2024		U-1752		
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024		U-1752		
	8664239	May 30, 2028		U-1752		
	8685998	May 30, 2028	DP	U-1752		
	8889185	Aug 30, 2024		U-1752		
	8889186	Aug 30, 2024		U-1752		
	9161907	Aug 30, 2024	DP	U-1752		
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
	8486993	Aug 30, 2024	DP	U-1752		
	8586084	Aug 30, 2024		U-1752		
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024		U-1752		
	8664239	May 30, 2028		U-1752		
	8685998	May 30, 2028	DP	U-1752		
	8889185	Aug 30, 2024		U-1752		
	8889186	Aug 30, 2024		U-1752		
	9161907	Aug 30, 2024	DP	U-1752		
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
	8486993	Aug 30, 2024	DP	U-1752		
	8586084	Aug 30, 2024		U-1752		
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024		U-1752		
	8664239	May 30, 2028		U-1752		
	8685998	May 30, 2028	DP	U-1752		
	8889185	Aug 30, 2024		U-1752		
	8889186	Aug 30, 2024		U-1752		
	9161907	Aug 30, 2024	DP	U-1752		
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP		Y	
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP	U-1184		
	6821975	Nov 19, 2020	DS DP	U-533		
	6821975	Nov 19, 2020	DS DP	U-614		
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020		U-1184		
	6943166	Apr 26, 2020		U-155		
	6943166	Apr 26, 2020		U-614		
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP	U-1184		
	7182958	Apr 26, 2020	DP	U-155		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP	U-533		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 002	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP			
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP			
	7182958*PED	Oct 26, 2020				
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TALC - STERITALC</u>						
N 205555 001					ODE-143	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					ODE-143	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE-143	May 01, 2024
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8227230	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8741620	Feb 24, 2024	DS DP			
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807 001	6127425	Jun 26, 2018	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 001	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 002	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP		Y	
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP		Y	
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP		Y	
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP		Y	
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP		Y	
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001	7994364	Jun 27, 2025	DS DP U-1289			
	RE39593	Aug 05, 2022	DS DP U-1289			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	5856529	Dec 09, 2018	DS DP U-2149	NCE	Jan 31, 2019
		9060995	Jan 25, 2033	U-1710	ODE-59	Jan 31, 2021
		9539234	Jan 25, 2033	U-1934		
		9549913	Jan 25, 2033	U-1486		
		9730910	May 17, 2034	U-2085		
		RE46604	Jan 25, 2033	U-2147		
<u>TAVABOROLE - KERIDIN</u>						
N 204427	001	7582621	May 26, 2027	U-2016	NCE	Jul 07, 2019
		9549938	Feb 16, 2026	U-1951		
		9566289	Feb 16, 2026	DP		
		9566290	Feb 16, 2026	U-1970		
		9572823	Feb 16, 2026	U-1970		
<u>TAZAROTENE - FABIOR</u>						
N 202428	001	8808716	Feb 24, 2030	DP		
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858	001				ODE-29	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928	001	6056941	Jul 28, 2019	DP		
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML</u>						
N 020372	002	9549999	Mar 10, 2030	DP		
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001	6409990	May 12, 2020	DS	NCE	Mar 13, 2018
		9439985	Sep 27, 2033	DS DP	ODE-67	Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001	7816379	Feb 23, 2028	DS DP U-282	NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282	GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001	7816379	Feb 23, 2028	DS DP U-282	NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282	GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282		
<u>TEDEGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001	5789379	Apr 14, 2020	DS DP U-1320	NCE	Dec 21, 2017
		7056886	Sep 18, 2022	DP U-1320	ODE-37	Dec 21, 2019
		7847061	Nov 01, 2025	U-1320		
		9060992	Nov 01, 2025	U-1320		
		9539310	Nov 01, 2025	U-1320		
		9545434	Nov 01, 2025	U-1320		
		9545435	Nov 01, 2025	U-1320		
		9555079	Nov 01, 2025	U-1320		
		9572867	Nov 01, 2025	U-1320		
		9592273	Nov 01, 2025	U-1320		
		9592274	Nov 01, 2025	U-1320		
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001	7820671	Feb 25, 2025	DS DP		
		8431615	May 30, 2028	U-1398		
		8529882	Aug 31, 2021	U-1398		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001	6635618	Sep 11, 2023	DS DP U-728		
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021	U-1005		
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP U-728		
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021	U-282		
		8101575	May 01, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001	8158580	May 01, 2021	DP		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002	6635618	Sep 11, 2023	DS DP	U-728	
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021		U-1005	
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP	U-728	
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021		U-282	
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELBIVUDINE - TYZEKA</u>						
N 022011	001	6395716	Aug 10, 2019		U-782	
		6444652	Aug 10, 2019		U-782	
		6566344	Aug 10, 2019		U-782	
		6569837	Oct 25, 2020		U-782	
		6569837	Oct 25, 2020		U-999	
		7589079	Sep 11, 2023	DS DP	U-999	
		7795238	Aug 10, 2019		U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELBIVUDINE - TYZEKA</u>						
N 022154	001	6395716	Aug 10, 2019		U-999	
		6444652	Aug 10, 2019		U-999	
		6566344	Aug 10, 2019		U-999	
		6569837	Oct 25, 2020		U-999	
		7795238	Aug 10, 2019		U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELITHROMYCIN - KETEK</u>						
N 021144	001	5635485	Apr 01, 2018	DS DP	U-578	
<u>TELITHROMYCIN - KETEK</u>						
N 021144	002	5635485	Apr 01, 2018	DS DP	U-578	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	001	6358986	Jan 10, 2020			
<u>TELMISARTAN - MICARDIS</u>						
N 020850	002	6358986	Jan 10, 2020			
		7998953	Jun 06, 2020		U-1177	
		8003679	Oct 06, 2022		U-1176	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	003	6358986	Jan 10, 2020			
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794	001	7553840	Dec 11, 2027	DS		
		7709493	Dec 11, 2027	DS	U-1979	
		7968559	Dec 11, 2027		U-1979	
		8193204	Feb 27, 2031	DS		
		8653094	Dec 19, 2028		U-1979	
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	6987108	Sep 08, 2023	DP		
		7786118	Feb 21, 2023	DP		
		8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	5362718	Feb 15, 2019	DS DP		
		5362718*PED	Aug 15, 2019		Y	
		8026276	Jan 20, 2026	DP		
		8299116	Jul 25, 2023	DP		
		8455539	Jul 25, 2023	DP		
		8455539*PED	Jan 25, 2024			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSTIROLIMUS - TORISEL</u>						
N 022088	001	8722700	Jul 25, 2023	DP		
		8722700*PED	Jan 25, 2024			
		8791097	May 10, 2032	U-1550		
		8791097	May 10, 2032	U-1551		
		8791097*PED	Nov 10, 2032			
		RE44768	Feb 15, 2019	DS DP		
		RE44768*PED	Aug 15, 2019			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464	001	7390791	May 07, 2022	DS DP	NCE	Nov 05, 2020
		7803788	Feb 02, 2022	U-999	NP	Nov 11, 2019
		8754065	Aug 15, 2032	DS DP U-999		
		9296769	Aug 15, 2032	DS DP U-999		
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	001	5922695	Jul 25, 2017	DS	U-1275	PED
		5922695	Jul 25, 2017	DS	U-248	
		5922695	Jul 25, 2017	DS	U-250	
		5922695	Jul 25, 2017	DS	U-256	
		5922695	Jul 25, 2017	DS	U-999	
		5935946	Jul 25, 2017	DS DP	U-1275	
		5935946	Jul 25, 2017	DS DP	U-248	
		5935946	Jul 25, 2017	DS DP	U-250	
		5935946	Jul 25, 2017	DS DP	U-256	
		5935946	Jul 25, 2017	DS DP	U-999	
		5977089	Jul 25, 2017	DS DP	U-1275	
		5977089	Jul 25, 2017	DS DP	U-248	
		5977089	Jul 25, 2017	DS DP	U-250	
		5977089	Jul 25, 2017	DS DP	U-256	
		5977089	Jul 25, 2017	DS DP	U-999	
		6043230	Jul 25, 2017		U-1275	
		6043230	Jul 25, 2017		U-248	
		6043230	Jul 25, 2017		U-250	
		6043230	Jul 25, 2017		U-256	
		6043230	Jul 25, 2017		U-999	
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	002	5922695	Jul 25, 2017	DS	U-1275	PED
		5922695	Jul 25, 2017	DS	U-248	
		5922695	Jul 25, 2017	DS	U-250	
		5922695	Jul 25, 2017	DS	U-256	
		5922695	Jul 25, 2017	DS	U-999	
		5935946	Jul 25, 2017	DS DP	U-1275	
		5935946	Jul 25, 2017	DS DP	U-248	
		5935946	Jul 25, 2017	DS DP	U-250	
		5935946	Jul 25, 2017	DS DP	U-256	
		5935946	Jul 25, 2017	DS DP	U-999	
		5977089	Jul 25, 2017	DS DP	U-1275	
		5977089	Jul 25, 2017	DS DP	U-248	
		5977089	Jul 25, 2017	DS DP	U-250	
		5977089	Jul 25, 2017	DS DP	U-256	
		5977089	Jul 25, 2017	DS DP	U-999	
		6043230	Jul 25, 2017		U-1275	
		6043230	Jul 25, 2017		U-248	
		6043230	Jul 25, 2017		U-250	
		6043230	Jul 25, 2017		U-256	
		6043230	Jul 25, 2017		U-999	
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	003	5922695	Jul 25, 2017	DS	U-1275	PED
		5922695	Jul 25, 2017	DS	U-248	
		5922695	Jul 25, 2017	DS	U-250	
		5922695	Jul 25, 2017	DS	U-256	
		5922695	Jul 25, 2017	DS	U-999	
		5935946	Jul 25, 2017	DS DP	U-1275	
		5935946	Jul 25, 2017	DS DP	U-248	
		5935946	Jul 25, 2017	DS DP	U-250	
		5935946	Jul 25, 2017	DS DP	U-256	
		5935946	Jul 25, 2017	DS DP	U-999	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5977089	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-250			
	5922695	Jul 25, 2017	DS U-256			
	5922695	Jul 25, 2017	DS U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-250			
	5922695	Jul 25, 2017	DS U-256			
	5922695	Jul 25, 2017	DS U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318	001	7163684	Aug 19, 2019			U-790
		7351414	Aug 19, 2019			U-865
		7517334	Mar 25, 2025			DP
		7550434	Dec 08, 2018			DP U-982
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318	002	6770623	Dec 08, 2018			DP U-982
		6977077	Aug 19, 2019			U-982
		6977077	Aug 19, 2019			U-994
		7144861	Dec 08, 2018			DP
		7163684	Aug 19, 2019			U-983
		7163684	Aug 19, 2019			U-994
		7351414	Aug 19, 2019			U-984
		7351414	Aug 19, 2019			U-994
		7517334	Mar 25, 2025			DP
		7550434	Dec 08, 2018			DP U-982
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505	001	5861379	May 26, 2020	DS DP		U-1100
		7144577	Jul 14, 2020			U-1100
		7316997	Aug 14, 2023			U-1100
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505	002	7144577	Jul 14, 2020			U-1100
		7316997	Aug 14, 2023			U-1100
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791	001	6348210	Nov 10, 2019			U-440
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	001	6503894	Aug 30, 2020			U-490
		9125816	Aug 30, 2020			U-490
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-490
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	002	6503894	Aug 30, 2020			U-490
		9125816	Aug 30, 2020			U-490
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-490
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	003	6503894	Aug 30, 2020			U-490
		9125816	Aug 30, 2020			U-490
		9125816*PED	Mar 02, 2021			
		9132089	Aug 30, 2020			U-490
		9132089*PED	Mar 02, 2021			
<u>TESTOSTERONE - TESTIM</u>						
N 021454	001	7320968	Jan 18, 2025			U-843
		7608605	Apr 21, 2023			U-1009
		7608606	Apr 21, 2023			U-1009
		7608607	Apr 21, 2023			U-1009
		7608608	Apr 21, 2023			U-1009
		7608609	Apr 21, 2023			U-1009
		7608610	Apr 21, 2023			U-1009
		7935690	Apr 21, 2023			U-1009
		8063029	Apr 21, 2023			U-843
		8178518	Apr 21, 2023			DP
<u>TESTOSTERONE - FORTESTA</u>						
N 021463	001	6319913	Nov 09, 2018			U-490
		6579865	Nov 09, 2018			DP
<u>TESTOSTERONE - STRIANT</u>						
N 021543	001	6248358	Aug 23, 2019			U-527

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020				
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020				
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020				
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027				U-1386
	8435944	Sep 27, 2027				U-1390
	8784878	Jul 13, 2023	DP			U-1545
	8807861	Feb 26, 2027	DP			U-1563
	8993520	Jun 02, 2026				U-1390
	9180194	Jun 02, 2026				U-1390
	9289586	Feb 26, 2027				U-1390
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP			U-1531
	9295675	Feb 11, 2034	DP			U-1531
	9662340	Feb 11, 2034	DP			U-1531
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP			U-1531
	9295675	Feb 11, 2034	DP			U-1531
	9662340	Feb 11, 2034	DP			U-1531

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785	002	7874984	Aug 28, 2018	U-732		
		7874984	Aug 28, 2018	U-733		
		7959566	Oct 23, 2020	U-1155		
		8204763	Aug 28, 2018	U-1249		
		8315886	Oct 23, 2020	U-1249		
		8589188	Aug 28, 2018	U-1465		
		8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	003	6045501	Aug 28, 2018	U-371		
		6045501	Aug 28, 2018	U-731		
		6315720	Oct 23, 2020	U-442		
		6315720	Oct 23, 2020	U-731		
		6561976	Aug 28, 2018	U-371		
		6561976	Aug 28, 2018	U-731		
		6561977	Oct 23, 2020	U-371		
		6561977	Oct 23, 2020	U-731		
		6755784	Oct 23, 2020	U-371		
		6755784	Oct 23, 2020	U-731		
		6869399	Oct 23, 2020	U-371		
		6869399	Oct 23, 2020	U-731		
		6869399	Oct 23, 2020	U-732		
		6869399	Oct 23, 2020	U-733		
		6908432	Aug 28, 2018	U-371		
		6908432	Aug 28, 2018	U-731		
		7141018	Oct 23, 2020	U-371		
		7141018	Oct 23, 2020	U-731		
		7141018	Oct 23, 2020	U-732		
		7141018	Oct 23, 2020	U-733		
		7230012	Dec 09, 2023	DP		
		7435745	Nov 03, 2017	U-899		
		7874984	Aug 28, 2018	U-1109		
		7874984	Aug 28, 2018	U-371		
		7874984	Aug 28, 2018	U-442		
		7874984	Aug 28, 2018	U-732		
		7874984	Aug 28, 2018	U-733		
		7959566	Oct 23, 2020	U-1155		
		8204763	Aug 28, 2018	U-1249		
		8315886	Oct 23, 2020	U-1249		
		8589188	Aug 28, 2018	U-1465		
		8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	6045501	Aug 28, 2018	U-731		
		6315720	Oct 23, 2020	U-731		
		6561976	Aug 28, 2018	U-731		
		6561977	Oct 23, 2020	U-731		
		6755784	Oct 23, 2020	U-731		
		6869399	Oct 23, 2020	U-731		
		6908432	Aug 28, 2018	U-731		
		7141018	Oct 23, 2020	U-731		
		7435745	Nov 03, 2017	U-899		
		7874984	Aug 28, 2018	U-1109		
		7874984	Aug 28, 2018	U-371		
		7874984	Aug 28, 2018	U-442		
		7874984	Aug 28, 2018	U-732		
		7874984	Aug 28, 2018	U-733		
		7959566	Oct 23, 2020	U-1155		
		8204763	Aug 28, 2018	U-1249		
		8315886	Oct 23, 2020	U-1249		
		8589188	Aug 28, 2018	U-1465		
		8626531	Oct 23, 2020	U-1465		
<u>THIOTEPA - TEPADINA</u>						
N 208264	001				I-747	Jan 26, 2020
					ODE-129	Jan 26, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPADINA</u>						
N 208264	002				I-747 ODE-129	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	6251910	Jul 15, 2018	DS	I-714	Sep 03, 2018
		6525060	Dec 02, 2019	DS DP U-1171	Y	
		6525060	Dec 02, 2019	DS DP U-1860	Y	
		6525060	Dec 02, 2019	DS DP U-1862	Y	
		6525060	Dec 02, 2019	DS DP U-1863	Y	
		7250419	Dec 02, 2019	DS DP U-1171		
		7250419	Dec 02, 2019	DS DP U-1860		
		7250419	Dec 02, 2019	DS DP U-1864		
		7250419	Dec 02, 2019	DS DP U-1865		
		7250419	Dec 02, 2019	DS DP U-1866		
		7250419	Dec 02, 2019	DS DP U-1867		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		
		RE46276	Oct 30, 2024	DS DP U-1935		
		RE46276	Oct 30, 2024	DS DP U-1936		
		RE46276	Oct 30, 2024	DS DP U-1937		
		RE46276	Oct 30, 2024	DS DP U-1938		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	6251910	Jul 15, 2018	DS	NS	Sep 03, 2018
		6525060	Dec 02, 2019	DS DP U-1171	Y	
		6525060	Dec 02, 2019	DS DP U-1860	Y	
		6525060	Dec 02, 2019	DS DP U-1862	Y	
		6525060	Dec 02, 2019	DS DP U-1863	Y	
		7250419	Dec 02, 2019	DS DP U-1171		
		7250419	Dec 02, 2019	DS DP U-1860		
		7250419	Dec 02, 2019	DS DP U-1864		
		7250419	Dec 02, 2019	DS DP U-1865		
		7250419	Dec 02, 2019	DS DP U-1866		
		7250419	Dec 02, 2019	DS DP U-1867		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		
		RE46276	Oct 30, 2024	DS DP U-1935		
		RE46276	Oct 30, 2024	DS DP U-1936		
		RE46276	Oct 30, 2024	DS DP U-1937		
		RE46276	Oct 30, 2024	DS DP U-1938		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821	001	7879828	Feb 05, 2029	DP		
		8372995	Oct 08, 2030	DP		
		8975242	Oct 24, 2028	DP		
		9254328	Mar 13, 2026	DP		
		9694078	Mar 13, 2026	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	001	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	002	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516	001	6335335	Nov 02, 2018	DP		
		6645963	Nov 16, 2018	DP		
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395	001	6777423	Sep 24, 2021	DS DP		
		6777423*PED	Mar 24, 2022			
		6908928	Sep 24, 2021	DS DP U-566		
		6908928	Sep 24, 2021	DS DP U-762		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP	U-566		
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS	DP		
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS	DP		
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP	U-1186		
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS	DP	U-566	
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	6846413	Aug 28, 2018	DP		NP	Sep 24, 2017
	6846413*PED	Feb 28, 2019			NPP	Feb 15, 2020
	6977042	Aug 28, 2018	DP		PED	Mar 24, 2018
	6977042*PED	Feb 28, 2019			PED	Aug 15, 2020
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
	RE39820	Jan 30, 2018	DS	DP	U-1593	
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	6846413	Aug 28, 2018	DP		NP	Sep 15, 2018
	6846413*PED	Feb 28, 2019			NPP	Feb 15, 2020
	6977042	Aug 28, 2018	DP		PED	Mar 15, 2019
	6977042*PED	Feb 28, 2019			PED	Aug 15, 2020
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
	RE39820	Jan 30, 2018	DS	DP		
	RE39820*PED	Jul 30, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	001	6479500				
		Mar 16, 2020		U-1751	NCE	Sep 22, 2020
		9527833	DS DP			
		Jun 17, 2034				
		RE46284		U-1751		
		Dec 16, 2026				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	002	6479500				
		Mar 16, 2020		U-1751	NCE	Sep 22, 2020
		9527833	DS DP			
		Jun 17, 2034				
		RE46284		U-1751		
		Dec 16, 2026				
<u>TIPRANA VIR - APTIVUS</u>						
N 021814	001	5852195				
		Jun 22, 2019	DS			
		6147095		U-670		
		Oct 29, 2019				
		6231887	DP			
		Jul 27, 2018				
<u>TIPRANA VIR - APTIVUS</u>						
N 022292	001	5852195				
		Jun 22, 2019	DS			
		6147095		U-670		
		Oct 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	001	5978698				
		Oct 08, 2017				
		6136794				
		Jan 29, 2019				
		6770660		U-1444		
		May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	002	5978698				
		Oct 08, 2017		U-1897		
		6136794		U-1898		
		Jan 29, 2019				
		6770660		U-1444		
		May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	001	5978698				
		Oct 08, 2017				
		6136794				
		Jan 29, 2019				
		6770660		U-1444		
		May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	002	5978698				
		Oct 08, 2017				
		6136794				
		Jan 29, 2019				
		6770660		U-1444		
		May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	003	5978698				
		Oct 08, 2017				
		6136794				
		Jan 29, 2019				
		6770660		U-1444		
		May 01, 2023				
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688	001	7368102				
		Dec 19, 2022	DP	U-909		
		7442388		DP		
		May 10, 2020				
		7516741		DP		
		Jan 11, 2024				
		7559325		DP		
		Oct 27, 2025				
		8069851		DP		
		Sep 24, 2024				
		8349294		DP		
		May 10, 2020				
		8715623		DP	U-909	
		Dec 19, 2022				
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820	001	6987094				
		Sep 22, 2022	DP			
		7696178		DP		
		Mar 17, 2023				
		7939502		U-1324		
		Jun 14, 2022				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001	6956041				
		Dec 08, 2020	DP		I-761	Dec 14, 2020
		6965027		DS	NCE	Nov 06, 2017
		Mar 25, 2023				
		7091208		U-247		
		Dec 08, 2020				
		7265221		DS		
		Dec 08, 2020				
		7301023		DS		
		May 23, 2022				
		RE41783		DS		
		Dec 08, 2025				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	6956041				
		Dec 08, 2020	DP		I-761	Dec 14, 2020
		6965027		DS	NCE	Nov 06, 2017
		Mar 25, 2023				
		7091208		U-247		
		Dec 08, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	7265221	Dec 08, 2020	DS		
		7301023	May 23, 2022	DS		
		RE41783	Dec 08, 2025	DS		
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	001	6630162	Nov 11, 2019	DP U-544		
		6770295	Aug 26, 2019	DP U-544		
		6911217	Nov 11, 2019	DP U-544		
		6911217*PED	May 11, 2020			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	002	6630162	Nov 11, 2019	DP U-544		
		6770295	Aug 26, 2019	DP U-544		
		6911217	Nov 11, 2019	DP U-544		
		6911217*PED	May 11, 2020			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001	5753677	May 19, 2020		U-978	
		8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002	5753677	May 19, 2020		U-978	
		8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003	5753677	May 19, 2020		U-978	
		8501730	Sep 01, 2026	DS		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	001	7125560	Mar 01, 2019		U-766	
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	002	7125560	Mar 01, 2019		U-766	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844	003	7125560	Mar 01, 2019		U-766	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
		9555005	Mar 19, 2033	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	001	8158645	Dec 10, 2024	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	002	8158645	Dec 10, 2024	DP		
<u>TRABECTEDIN - YONDELIS</u>						
N 207953	001	8895557	Jan 07, 2028	DP	NCE ODE-100	Oct 23, 2020 Oct 23, 2022
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	001	6339105	Oct 12, 2019	U-435		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	002	6339105	Oct 12, 2019	U-435		
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693	001	6106861	Dec 05, 2017	DP		
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	001	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	002	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	003	6607748	Jun 29, 2020	DP		
		7988998	Oct 27, 2023	DP		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	001	7858118	Apr 11, 2022	DP U-1104		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	002	7858118	Apr 11, 2022	DP U-1104		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	003	7858118	Apr 11, 2022	DP U-1104		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	7378423	Sep 13, 2025	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	M-170	Nov 20, 2018
		8703781	Oct 15, 2030	DS DP U-1712	NCE	May 29, 2018
		8703781	Oct 15, 2030	DS DP U-2033	ODE-148	Jun 22, 2024
		8835443	Sep 13, 2025	U-1581	ODE-48	May 29, 2020
		8835443	Sep 13, 2025	U-1582	ODE-57	Jan 08, 2021
		8835443	Sep 13, 2025	U-2020		
		8835443	Sep 13, 2025	U-2037		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	7378423	Sep 13, 2025	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	NCE	May 29, 2018
		8703781	Oct 15, 2030	DS DP U-1712	ODE-148	Jun 22, 2024
		8703781	Oct 15, 2030	DS DP U-2033	ODE-48	May 29, 2020
		8835443	Sep 13, 2025	U-1581	ODE-57	Jan 08, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	8835443	Sep 13, 2025	U-1582		
		8835443	Sep 13, 2025	U-2020		
		8835443	Sep 13, 2025	U-2037		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003	7378423	Sep 13, 2025	DS DP	I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP	M-170	Nov 20, 2018
		8703781	Oct 15, 2030	DS DP	NCE	May 29, 2018
		8703781	Oct 15, 2030	DS DP	ODE-148	Jun 22, 2024
		8835443	Sep 13, 2025	U-1581	ODE-48	May 29, 2020
		8835443	Sep 13, 2025	U-1582	ODE-57	Jan 08, 2021
		8835443	Sep 13, 2025	U-2020		
		8835443	Sep 13, 2025	U-2037		
		8952018	Oct 15, 2030	U-2020		
		9155706	Jan 28, 2032	DP		
		9271941	Jan 28, 2032	DP		
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430	001	7947739	Mar 04, 2025	DP		
		8022106	Mar 04, 2025	U-1182		
		8273795	Mar 04, 2025	U-1182		
		8487005	Mar 04, 2025	DP U-1182		
		8791160	Mar 04, 2025	DP U-1182		
		8809394	Mar 04, 2025	DP U-1182		
		8957113	Mar 04, 2025	DP U-1182		
		9060939	Mar 04, 2025	DP		
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994	001	8268299	Oct 13, 2029	DP		
		8323630	Sep 20, 2027	DP		
		8388941	Sep 20, 2027	DP		
<u>TRAVOPROST - IZBA</u>						
N 204822	001	8178582	Oct 10, 2029	DP		
		8722735	Oct 10, 2029	DP		
		8754123	May 19, 2029	DP		
		9144561	Mar 13, 2029	DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	001	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	002	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	003	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	004	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	001	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP	U-796	
		8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	002	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP	U-796	
		8133893	Mar 13, 2029	DS DP		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	001	6765117	Oct 24, 2017	DS		
		7999007	Mar 29, 2029	DP	U-1437	
		8497393	Dec 15, 2028	DS		
		8653137	Sep 05, 2028	U-1437		
		8658694	Sep 05, 2028	U-1437		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029		DP U-1437		
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
	9199908	May 24, 2024		U-1771		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	6521212	Nov 13, 2018		U-1018		
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			
	9339507	Mar 10, 2028		DP		
	9358240	May 05, 2028		U-1849		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024		DP		
	8349892	Jan 22, 2031		DP		
	8410169	Feb 13, 2030		DP		
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029		DP		
	9050311	May 24, 2024	DS	DP		
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026		DP U-1877		
	9422223	May 24, 2024		DP		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		
	8211880	Mar 10, 2029		U-1258		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845	001	8828440	Aug 04, 2031	DP	NP	Oct 06, 2020
		9555048	Aug 04, 2031	U-2151		
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326	001	6017922	May 18, 2018			
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326	002	6017922	May 18, 2018			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956	001				NP ODE-149	Jun 29, 2020 Jun 29, 2024
<u>TROGLITAZONE - PRELAY</u>						
N 020719	001	5859037	Nov 13, 2017	U-251		
		6011049	Nov 13, 2017	U-301		
<u>TROGLITAZONE - PRELAY</u>						
N 020719	002	5859037	Nov 13, 2017	U-251		
		6011049	Nov 13, 2017	U-301		
<u>TROGLITAZONE - PRELAY</u>						
N 020719	003	5859037	Nov 13, 2017	U-251		
		6011049	Nov 13, 2017	U-301		
<u>TROSPPIUM CHLORIDE - SANCTURA XR</u>						
N 022103	001	7410978	Feb 01, 2025	DP		
		7759359	Nov 04, 2024	U-1071		
		7763635	Nov 04, 2024	U-1071		
		7781448	Nov 04, 2024	U-1071		
		7781449	Nov 04, 2024	U-1071		
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001	8426392	Jun 12, 2030	U-1389		
		8512745	Jun 02, 2030	DP		
		8735380	Feb 20, 2029	DP		
		8962603	Jun 12, 2030	U-1657		
		9283233	Apr 13, 2030	U-1821		
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001	7488827	Dec 18, 2027	DS DP	M-172	Feb 24, 2019
		7498440	Apr 27, 2025	DS DP	NCE	Dec 18, 2018
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8183257	Jul 27, 2025	U-1476		
		8201556	Feb 05, 2029	DP		
		8309572	Apr 27, 2025	U-1476		
		8534281	Aug 10, 2029	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001	7439393	May 21, 2025	DS DP	U-1476	
		7488827	Dec 18, 2027	DS DP	NCE	May 10, 2018
		7498440	Apr 27, 2025	DS DP	NCE	Dec 18, 2018
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8183257	Jul 27, 2025	U-1476		
		8309572	Apr 27, 2025	U-1476		
		8511304	Jun 14, 2027	DP	U-1476	
		8534281	Aug 10, 2029	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		9750726	Nov 29, 2030	DP		
		RE44874	Mar 23, 2023	DS DP	U-1476	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214	001	6458836	Jul 09, 2021	U-1315		
		6458836	Jul 09, 2021	U-333		
		6770675	Nov 24, 2018	DP U-1322		
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159	001	6258795	Jul 10, 2018	DP	NCE	Sep 04, 2020
		7776838	Aug 17, 2027	U-1791	NP	Dec 11, 2018
					ODE-104	Dec 11, 2022
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169	001	6258795	Jul 10, 2018	DP	NCE	Sep 04, 2020
					ODE-98	Sep 04, 2022
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241	001	8039627	Oct 06, 2029	DS DP	NCE	Apr 11, 2022
		8357697	Nov 08, 2027	U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241	002	8039627	Oct 06, 2029	DS DP	NCE	Apr 11, 2022
		8357697	Nov 08, 2027	U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304	001				D-148	Apr 23, 2018
					NPP	Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257	001	8889109	Dec 11, 2027	DP	D-148	Apr 23, 2018
		9642911	Dec 11, 2027	DP	NPP	Apr 23, 2018
<u>VANDETANIB - CAPRELSA</u>						
N 022405	001	8067427	Aug 08, 2028	DP	ODE-9	Apr 06, 2018
		RE42353	Jun 27, 2022	DS DP		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	002	8067427	Aug 08, 2028	DP	ODE-9	Apr 06, 2018
		RE42353	Jun 27, 2022	DS DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	001	6362178	Oct 31, 2018	DS DP U-533		
		7696206	Oct 31, 2018	DS DP U-533		
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	002	6362178	Oct 31, 2018	DS DP U-533		
		7696206	Oct 31, 2018	DS DP U-533		
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	003	6362178	Oct 31, 2018	DS DP U-533		
		7696206	Oct 31, 2018	DS DP U-533		
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	004	6362178	Oct 31, 2018	DS DP U-533		
		7696206	Oct 31, 2018	DS DP U-533		
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179	001	6362178	Oct 31, 2018	U-155		
		7696206	Oct 31, 2018	U-155		
		8613950	Dec 23, 2028	DP		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6410550	May 10, 2020	DS DP U-56	M-143	Oct 15, 2017
		6890927	May 06, 2022	DS DP U-56	M-144	Oct 15, 2017
		7265119	Aug 03, 2022	DS DP U-56	M-183	Aug 12, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001				M-192	Dec 16, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002	6410550	May 10, 2020	DS DP U-56	M-143	Oct 15, 2017
		6890927	May 06, 2022	DS DP U-56	M-144	Oct 15, 2017
		7265119	Aug 03, 2022	DS DP U-56	M-183	Aug 12, 2019
					M-192	Dec 16, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	001	9375478	Jan 30, 2035	U-1857		
		9687526	Jan 30, 2035	U-1857		
		9744209	Jan 30, 2035	U-1857		
		9744239	Jan 30, 2035	U-1857		
		9750785	Jan 30, 2035	DP		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	002	9375478	Jan 30, 2035	U-1857		
		9687526	Jan 30, 2035	U-1857		
		9744209	Jan 30, 2035	U-1857		
		9744239	Jan 30, 2035	U-1857		
		9750785	Jan 30, 2035	DP		
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429	001	7504509	Oct 22, 2026	DS DP	I-757	Nov 06, 2020
		7863288	Jun 20, 2029	DS DP	M-184	Aug 31, 2019
		8143271	Jun 21, 2026	DS DP	ODE	Nov 06, 2024
		8470818	Aug 02, 2026		U-1418	
		8470818	Aug 02, 2026		U-2164	Aug 17, 2018
		8741920	Jul 27, 2030	DS DP		
		9447089	Jun 06, 2032	DP		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	001	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE-114	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	002	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE-114	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE-114	Apr 11, 2023
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N 202497	001	6723338	Mar 31, 2020	U-1271	ODE-28	Aug 09, 2019
		7247316	Sep 25, 2020	DP		
		7887836	Mar 31, 2020	U-1271		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388	001	7888364	Nov 11, 2028	DS DP		
		9278961	Dec 15, 2028		U-1825	
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	7235567	Jun 13, 2021	DS DP		
		7304078	Apr 06, 2024	DS DP	U-1512	NCE May 08, 2019
<u>VORICONAZOLE - VFEND</u>						
N 021267	001	6632803	Jun 02, 2018	DP		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025		U-892	
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023	DP		
		7732490	Mar 04, 2023		U-892	
		7851509	Feb 21, 2024	DP	U-892	
		8067472	Mar 04, 2023		U-892	
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023		U-892	
		8450372	Mar 18, 2028		U-892	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	001	7144884	Oct 02, 2022	DS DP	U-1439	NCE Sep 30, 2018
		8476279	Oct 02, 2022		DP U-1439	
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027		U-1668	
		9227946	Jun 15, 2027		U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	002	7144884	Oct 02, 2022	DS DP	U-1439	NCE Sep 30, 2018
		8476279	Oct 02, 2022		DP U-1439	
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027		U-1668	
		9227946	Jun 15, 2027		U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	003	7144884	Oct 02, 2022	DS DP	U-1439	NCE Sep 30, 2018
		8476279	Oct 02, 2022		DP U-1439	
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027		U-1668	
		9227946	Jun 15, 2027		U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	004	7144884	Oct 02, 2022	DS DP	U-1439	NCE Sep 30, 2018
		8476279	Oct 02, 2022		DP U-1439	
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027		U-1668	
		9227946	Jun 15, 2027		U-1668	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	001	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	002	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	003	8653033	Oct 01, 2024		U-48	
		8653033	Oct 01, 2024		U-55	
		8765680	Oct 01, 2024		U-48	
		8765680	Oct 01, 2024		U-55	
		9707270	Oct 01, 2024		U-2084	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	003	8653033	Oct 01, 2024	U-48		
		8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
		9707270	Oct 01, 2024	U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	004	8653033	Oct 01, 2024	U-48		
		8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
		9707270	Oct 01, 2024	U-2084		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	001	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	002	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	003	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	004	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483	001	6150366	May 27, 2019	DP	U-719	
		6245766	Dec 18, 2018	U-601		
		7175855	May 18, 2020	DP		
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	002	8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
		8324189	May 29, 2025	U-53		
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003	7932241	Feb 05, 2028	DP		
		8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
		8324189	May 29, 2025	U-53		
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001	7932241	Feb 05, 2028	DP		
		8052987	Oct 27, 2023	U-1199		
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003	6750237	Nov 28, 2020	DP	NPP	Jun 12, 2018
		6750237*PED	May 28, 2021			
		7220767	Nov 28, 2020	DP		
		7220767*PED	May 28, 2021			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004	6750237	Nov 28, 2020	DP	NPP	Jun 12, 2018
		7220767	Nov 28, 2020	DP		
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	001	6514531	Dec 01, 2019	DP		
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	002	6514531	Dec 01, 2019	DP		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001	6761910	Sep 24, 2019	DP	U-674	
		8512747	Sep 24, 2019	U-674		
		9265720	Feb 25, 2031	U-674		
		9597281	Apr 06, 2027	U-674		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	6761910	Sep 24, 2019	DP U-674			
	8512747	Sep 24, 2019	U-674			
	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	6761910	Sep 24, 2019	DP U-674			
	8512747	Sep 24, 2019	U-674			
	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	7632517	Oct 01, 2017	U-70			
	8236285	Aug 07, 2032	DS DP U-70			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 001	7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 002	7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d) (5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 117

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-26 ONCE WEEKLY APPLICATION
- D-27 BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
- D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
- D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
- D-30 5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
- D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
- D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ".1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPIENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
- D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
- D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
- D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
- D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
- D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
- D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
- D-130 DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
- D-131 EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
- D-132 45MG FOR 6 MONTH ADMINISTRATION
- D-133 NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
- D-134 INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
- D-135 UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
- D-136 ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
- D-137 NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
- D-138 80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- D-139 ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
- D-140 REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
- D-141 DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
- D-142 DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
- D-143 INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
- D-144 LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
- D-145 UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
- D-146 CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
- D-147 ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
- D-148 EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
- D-149 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
- D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
- D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
- D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
- D-154 ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
- D-155 SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- D-156 DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
- D-157 UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
- D-158 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
- D-159 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
- D-160 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
- D-161 DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
- D-162 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
- D-163 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
- D-164 UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
- D-165 DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- D-166 BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
- D-167 ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAÏVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
- D-168 NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- D-169 ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

EXCLUSIVITY INDICATION

- I-1 DYSMENORRHEA
- I-2 CHOLANGIOPANCREATOGRAPHY
- I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-5	HYSTEOSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-43 HERPES SIMPLEX ENCEPHALITIS

I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY

I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS

I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING

I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

I-48 PEDIATRIC ANGIOCARDIOGRAPHY

I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI

I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER

I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

I-52 PEDIATRIC EXCRETORY UROGRAPHY

I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

I-54 RENAL CONCENTRATION CAPACITY TEST

I-55 HYPERTENSION

I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE

I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER

I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS

I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE

I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE

I-61 FEMALE ANDROGENETIC ALOPECIA

I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION

I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS

I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

I-66 UNCOMPLICATED GONORRHEA

I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER

I-68 CENTRAL PRECOCIOUS PUBERTY

I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY

I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

I-71 VARICELLA INFECTIONS (CHICKENPOX)

I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE

I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES

I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS

I-76 PREVENTION OF OSTEOPOROSIS

I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM

I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY

I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM

I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

FOLLOWING KNEE REPLACEMENT SURGERY

- I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
- I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
- I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
- I-122 PSORIASIS OF THE SCALP
- I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
- I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
- I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
- I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
- I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
- I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
- I-129 TREATMENT OF ALCOHOL DEPENDENCE
- I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
- I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
- I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
- I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
- I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
- I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
- I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
- I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO₂) IS LESS THAN OR EQUAL TO 55 TORR
- I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
- I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
- I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
- I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]

I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE

I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT

I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE

I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES

I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER

I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS

I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY

I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE

I-163 TREATMENT OF PHOTOPHOBIA

I-164 CHRONIC BACTERIAL PROSTATITIS

I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

I-166 TREATMENT OF BULIMIA

I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS

I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)

I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER

I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS

I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD

I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES

I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY

I-174 PELVIC INFLAMMATORY DISEASE

I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS

I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS

I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN

I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE

I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)

I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION

I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME

I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11

I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)

I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

	PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

TYPE 2 DIABETES

- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER

I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS

I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

I-321 JUVENILE RHEUMATOID ARTHRITIS

I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

I-323 COLORECTAL CANCER

I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS

I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

I-326 GENERALIZED ANXIETY DISORDER

I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER

I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE

I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD

I-331 TREATMENT OF MODERATE ACNE VULGARIS

I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)

I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)

I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE

I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS

I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME

I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA

I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS

I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-341 BREAST CANCER COMBINATION THERAPY

I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-343 USE OF COREG FOR SEVERE HEART FAILURE

I-344 ACNE VULGARIS

I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER

I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)

I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE

I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)

I-349 ACUTE CORONARY SYNDROME

I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY

I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS

I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)

I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS

I-354 MANAGEMENT OF POST HERPETIC NEURALGIA

I-355 PREMENSTRUAL DYSPHORIC DISORDER

I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME

I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-358 TREATMENT OF PANIC DISORDER

I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY

I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR

I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES

I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE

I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING

I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY

I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

I-372 NOSOCOMIAL PNEUMONIA

I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN >= 2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECCURANCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-401	LONGER-TERM EFFICACY OF ARIPIPIRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION \leq 40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES

I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS

I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI

I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER

I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER

I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES

I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE

I-491 INFLUENZA PROPHYLAXIS

I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES

I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA

I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE

I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY

I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES

I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER

I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY

I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.

I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY

I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME

I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES

I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-508 PREMENSTRUAL DYSPHONIC DISORDER

I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)

I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)

I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY

I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)

I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)

I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY

I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)

I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED

I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL

I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY

I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.

I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCLARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE

I-524 GENERALIZED ANXIETY DISORDER (GAD)

I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS

I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS

I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
- I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
- I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-566 MANAGEMENT OF FIBROMYALGIA
- I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
- I-569 TREATMENT OF CHRONIC HEPATITIS B
- I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
- I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

YEARS AT HIGH RISK

- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
- I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
- I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
- I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
- I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
- I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
- I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
- I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA
- I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
- I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
- I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
- I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
- I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
- I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
- I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
- I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
- I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
- I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
- I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
- I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
- I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
- I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
- I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
- I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
- I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
- I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
- I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
- I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
- I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
- I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
- I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
- I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
- I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
- I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
- I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 117

EXCLUSIVITY INDICATION

- I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
- I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
- I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
- I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
- I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-751 TREATMENT OF TARDIVE DYSKINESIA
- I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
- I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
- I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
- I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
- I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
- I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
- I-760 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- I-761 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

TRIAL

- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES

M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008

M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL

M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

M-119 LABELING CHANGES REGARDING MISSED DOSES

M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS

M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43

M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL

M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS

M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE

M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086

M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004

M-128 CLINICAL TRIAL STUDY RESULTS

M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE

M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT

M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
- M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
- M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
- M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
- M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
- M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
- M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
- M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
- M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
- M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
- M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
- M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
- M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
- M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
- M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
- M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
- M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
- M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
- M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
- M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"
- M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
- M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
- M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
- M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
- M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
- M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
- M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
- M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
- M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
- M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
- M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
- M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
- M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
- M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
- M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
- M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
- M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
- M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
- M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
- M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
- M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
- M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
- M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

REQUIREMENT 1857-2

- M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
- M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
- M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE
- M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17
- M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
- M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
- M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
- M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
- M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
- M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
- M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.
- M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569
- M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT
- M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY
- M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY
- M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
- M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
- M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE
- M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
- M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

PATIENTS WITH SCHIZOPHRENIA

- M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
- M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED
- M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
- M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

ORPHAN DRUG EXCLUSIVITY

- ODE-1 TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
- ODE-2 FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- ODE-3 TO TREAT INFANTILE SPASMS
- ODE-4 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
- ODE-5 FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
- ODE-6 FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
- ODE-7 TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
- ODE-8 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARYHYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- ODE-9 TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-10 FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- ODE-11 TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-12 TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-13 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAFV600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-14 TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
- ODE-15 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
- ODE-16 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
- ODE-17 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
- ODE-18 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
- ODE-19 TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
- ODE-20 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
- ODE-21 AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-22 FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
- ODE-23 ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- ODE-24 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
- ODE-25 MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
- ODE-26 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- ODE-27 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- ODE-28 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- ODE-29 LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
- ODE-30 TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
- ODE-31 TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
- ODE-32 TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
- ODE-33 TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
- ODE-34 TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-35 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
- ODE-36 ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- ODE-37 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-38 PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
- ODE-39 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
- ODE-40 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
- ODE-41 ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- ODE-42 USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-43 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
- ODE-44 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
- ODE-45 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-46 IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
- ODE-47 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
- ODE-48 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
- ODE-49 TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- ODE-50 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLS) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
- ODE-51 TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
- ODE-52 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
- ODE-53 TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
- ODE-54 TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENERD PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
- ODE-55 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-56 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
- ODE-57 TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
- ODE-58 DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
- ODE-59 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- ODE-60 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-61 TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
- ODE-62 TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
- ODE-63 TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
- ODE-64 SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
- ODE-65 TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
- ODE-66 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
- ODE-67 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- ODE-68 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- ODE-69 TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

RISK

- ODE-70 RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
- ODE-71 RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-72 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-73 LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
- ODE-74 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
- ODE-75 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
- ODE-76 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
- ODE-77 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- ODE-78 TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
- ODE-79 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- ODE-80 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
- ODE-81 TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
- ODE-82 TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
- ODE-83 USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- ODE-84 TREATMENT OF MOTOR FLUCUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
- ODE-85 AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALZABLE SUBSTANCES
- ODE-86 TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
- ODE-87 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
- ODE-88 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
- ODE-89 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
- ODE-90 TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
- ODE-91 TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
- ODE-92 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
- ODE-93 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
- ODE-94 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-95 FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-96 TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-97 TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
- ODE-98 TREATMENT OF HEREDITARY OROTIC ACIDURIA
- ODE-99 FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
- ODE-100 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
- ODE-101 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
- ODE-102 FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
- ODE-103 USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-104 EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
- ODE-105 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-106 FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
- ODE-107 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
- ODE-108 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-109 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
- ODE-110 FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
- ODE-111 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
- ODE-112 FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
- ODE-113 FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
- ODE-114 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-115 TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSED AFTER PLATINUM-BASED CHEMOTHERAPY
- ODE-116 TREATMENT OF PROGRESSIVE KERATOCONUS
- ODE-117 FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-118 AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
- ODE-119 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
- ODE-120 FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 117

ORPHAN DRUG EXCLUSIVITY

- TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
- ODE-146 OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
- ODE-147 DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-148 TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-149 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
- ODE-150 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
- ODE-151 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-152 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
- ODE-153 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPMINERGIC MEDICATIONS
- ODE-154 FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
- ODE-155 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-156 TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
- U-5 METHOD OF PRODUCING BRONCHODILATION
- U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
- U-7 INCREASING CARDIAC CONTRACTILITY
- U-8 ACUTE MYOCARDIAL INFARCTION
- U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
- U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
- U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
- U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
- U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
- U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
- U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-16 USE IN LUNG SCANNING PROCEDURES
- U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
- U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
- U-19 TREATMENT OF INFLAMMATION
- U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
- U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CYTOSTATICALLY ACTIVE ALKYLATING AGENTS

- U-22 METHOD OF COMBATting PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
- U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
- U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
- U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
- U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
- U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
- U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
- U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
- U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
- U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
- U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
- U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
- U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
- U-36 METHODS OF TREATING BACTERIAL ILLNESSES
- U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
- U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
- U-39 ANGINA PECTORIS
- U-40 METHOD OF TREATMENT OF BURNS
- U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
- U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
- U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-44 RELIEF OF NAUSEA AND VOMITING
- U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
- U-46 TREATMENT OF PANIC DISORDER
- U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
- U-48 ANALGESIA
- U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
- U-50 USE IN TREATING INFLAMMATORY DERMATOSES
- U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
- U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-53 HYPERCALCEMIA OF MALIGNANCY
- U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
- U-55 TREATMENT OF PAIN
- U-56 AID TO SMOKING CESSATION
- U-57 OPHTHALMIC USE OF NORFLOXACIN
- U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
- U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
- U-60 NASAL ADMINISTRATION OF BUTORPHANOL
- U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY

U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE

U-64 TREATMENT OF VIRAL INFECTIONS

U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV

U-66 TRIPHASIC REGIMEN

U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL

U-68 TREATMENT OF ACTINIC KERATOSIS

U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS

U-70 TREATMENT OF TRANSIENT INSOMNIA

U-71 METHOD OF TREATMENT OF HEART FAILURE

U-72 TREATMENT OF MIGRAINE

U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT

U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS

U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM

U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-78 ULCERATIVE COLITIS

U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD

U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PSYCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PESSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

U-132 INHIBITING HIV PROTEASE

U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS

U-185 METHOD OF TREATING HYPERTENSION

U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT

U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER

U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE

U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR

U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

U-192 USE IN TREATING ALLERGIC REACTIONS

U-193 PSORIASIS

U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE

U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON

U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS

U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA

U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-205 METHOD FOR TREATING HEARTBURN

U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION

U-207 USE AS NASAL SPRAY

U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION

U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE

U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE

U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

AND METHOD FOR TREATING HYPERLIPIDEMIA

U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT

U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS

U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE

U-217 METHOD OF PRODUCING ANESTHESIA

U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT

U-219 TREATMENT OF PARKINSON'S DISEASE

U-220 METHOD OF DIAGNOSIS

U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION

U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL

U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS

U-224 CONTROLLING INTRAOCULAR PRESSURE

U-225 METHOD FOR DELIVERY

U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

U-227 NASAL ADMINISTRATION

U-228 ASTHMA

U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)

U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

U-231 USE IN PARKINSON'S DISEASE

U-232 METHOD OF TREATING MIGRAINE

U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS

U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY

U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS

U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....

U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID

U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS

U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION

U-243 TOPICAL ADMINISTRATION

U-244 PLATELET AGGREGATION INHIBITORS

U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-246 PHOSPHATE BINDING

U-247 TREATMENT OF RHEUMATOID ARTHRITIS

U-248 TREATMENT OF HIV

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE

U-250 TREATMENT OF HEPATITIS B INFECTION

U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES

U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE

U-253 ORAL TRANSMUCOSAL USE

U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN

U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS

U-257 TREATMENT OF HIV INFECTION

U-258 TREATMENT OF NEURODEGENERATIVE DISEASES

U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE

U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION

U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE

U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE

U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN

U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN

U-265 USE AS LAXATIVE

U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS

U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

U-268 ACROMEGALY

U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS

U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT

U-271 METHOD OF TREATING TUMORS

U-272 METHOD OF TREATING CARCINOMA

U-273 CUTANEOUS T-CELL LYMPHOMA

U-274 ZANAMIVIR FOR INHALATION

U-275 METHOD OF USE OF THE DRUG SUBSTANCE

U-276 METHOD OF USE OF LEVOBUPIVACAINE

U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)

U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT

U-279 METHOD OF USE OF THE APPROVED PRODUCT

U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE

U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS

U-282 METHOD OF TREATING BACTERIAL INFECTIONS

U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE

U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS

U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA

U-286 DEPRESSION

U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS

U-288 THERAPY OF INFLUENZA

U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP

U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)

U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN

U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE

U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID

U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS

U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY

U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS

U-298 METHOD OF COMBATING BACTERIA IN A PATIENT

U-299 TREATMENT OF ADENOMATOUS POLYPS

U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS

U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS

U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION

U-305 METHODS FOR USING THE DRUG PRODUCT

U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY

U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA

U-309 TREATING SJOEGREN SYNDROME

U-310 TREATMENT OF XEROSTOMIA

U-311 HORMONE REPLACEMENT

U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER

U-313 TREATMENT OF CONGESTIVE HEART FAILURE

U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT

U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER

U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-319 TREATMENT OF MICROBIAL INFECTIONS

U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

U-322 TREATMENT OF ALZHEIMER'S DEMENTIA

U-323 USE AS A BILE ACID SEQUESTRANT

U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE

U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-330 TREATMENT OF NAUSEA AND VOMITING

U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM

U-333 METHOD OF TREATING OCULAR HYPERTENSION

U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR

U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS

U-336 DIAGNOSTIC RADIOIMAGING

U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI

U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME

U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER

U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR

U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS

U-348 METHOD OF USE FOR INHIBITING HIV INFECTION

U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION

U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR

U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABLIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPATHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMINISTRATION OF INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL (PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

SEGMENT OF THE GLOBE.

- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-685 EXPECTORANT AND COUGH SUPPRESSANT

U-686 EXPECTORANT AND NASAL DECONGESTANT

U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.

U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA

U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA

U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT

U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB

U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION

U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

U-707 ALLERGIC RHINITIS

U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549

U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA

U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

U-726 ALLERGIC RHINITIS

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

AND VASOMOTOR RHINITIS

- U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
- U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
- U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
- U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
- U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
- U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
- U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
- U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
- U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
- U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
- U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
- U-745 TREATMENT OR PREVENTION OF EMESIS
- U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
- U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
- U-749 METHOD OF CONTRACEPTION
- U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS
- U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
- U-752 SUNSCREEN
- U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
- U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
- U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
- U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
- U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
- U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
- U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
- U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
- U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-763 ADMINISTRATION OF ARIPIPIRAZOLE BY INJECTION
- U-764 TREATMENT OF SCHIZOPHRENIA
- U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
- U-766 TREATMENT OF SEIZURES
- U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
- U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT
- U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
- U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
- U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
- U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
- U-780 A METHOD FOR THE TREATMENT OF CANCER
- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD

U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYONATREMIA
- U-869 METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)
- U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
- U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
- U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
- U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
- U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
- U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS

U-952 USE AS AN ANALGESIC

U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

U-955 PROPHYLACTIC TREATMENT OF MIGRAINE

U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE

U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHYLIZED IXABEPILONE WITH SOLVENT (DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
- U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
- U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
- U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIDIUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SALIVARRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CONTAINING DOCETAXEL

- U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS
- U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
- U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1131 TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
- U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

PATENT AND EXCLUSIVITY TERMS

ADB 81 of 117

PATENT USE

- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
- U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1176 TREATMENT OR PREVENTION OF STROKE
- U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
- U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
- U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS

PATENT AND EXCLUSIVITY TERMS

ADB 82 of 117

PATENT USE

U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN

U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION

U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE

U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)

U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE

U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN

U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN

U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)

U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)

U-1193 METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)

U-1194 METHOD FOR TREATING INSOMNIA

U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA

U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-1204 TREATMENT OF UVEITIS

U-1205 TREATMENT OF MACULAR EDEMA

U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX

U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS

U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER

U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
- U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
- U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
- U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
- U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
- U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
- U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
- U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
- U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
- U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
- U-1254 METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
- U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
- U-1256 TREATMENT OF SEBORRHEIC DERMATITIS
- U-1257 TREATMENT OF OPHTHALMIC DISORDERS
- U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES
- U-1259 PROPHYLAXIS OF HIV-1 INFECTION
- U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
- U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
- U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
- U-1264 TREATMENT OF A RESPIRATORY DISEASE
- U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
- U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
- U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
- U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
- U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
- U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
- U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

DELIVERY SYSTEM

- U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
- U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
- U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
- U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
- U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
- U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
- U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
- U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
- U-1284 A METHOD OF TREATING A NEOPLASM
- U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
- U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
- U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
- U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
- U-1290 TREATMENT OF LUNG CANCER
- U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
- U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT
- U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
- U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
- U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
- U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
- U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)
- U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
- U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
- U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
- U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
- U-1308 MULTIPLE MYELOMA
- U-1309 BONE METASTASES
- U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- U-1311 METHOD OF TREATING CYSTIC FIBROSIS
- U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA
- U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
- U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- U-1322 METHOD OF REDUCING OCULAR HYPERTENSION
- U-1323 REDUCING THE RISK OF STROKE
- U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
- U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
- U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
- U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
- U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
- U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
- U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
- U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
- U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

INHIBITOR AND METFORMIN

- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
- U-1347 TREATMENT OF A SKIN DISORDER
- U-1348 TREATMENT OF OSTEOARTHRITIS
- U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
- U-1351 TREATMENT OF ACUTE PAIN
- U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
- U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
- U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
- U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
- U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
- U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

PATENT AND EXCLUSIVITY TERMS

ADB 88 of 117

PATENT USE

U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY

U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN

U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN

U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB

U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

U-1370 TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE

U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA

U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION

U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS

U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)

U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER

U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE

U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS

U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF

U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS

U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1389 ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF

U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION

U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
- U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
- U-1398 METHOD OF TREATING CHRONIC HEPATITIS C
- U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
- U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
- U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
- U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
- U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES
- U-1406 TREATMENT OF MELANOMA
- U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
- U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
- U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
- U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
- U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1412 TREATMENT OF ATOPIC DERMATITIS
- U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
- U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
- U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
- U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
- U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS
- U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
- U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
- U-1420 METHOD OF ONCE A DAY ADMINISTRATION
- U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
- U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
- U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
- U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
- U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
- U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
- U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
- U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
- U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
- U-1434 TREATMENT OF PANCREATIC CANCER
- U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
- U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY

U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT

U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT

U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1455 TREATMENT OF PERIANAL WARTS

U-1456 TREATMENT OF MANTLE CELL LYMPHOMA

U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM

U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1459 TREATMENT OF CARCINOMA OF THE THYROID

U-1460 TREATMENT OF HERPES LABIALIS

U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE

U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1467 METHOD OF TREATING HEPATITIS C

U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

U-1470 FOR THE TREATMENT OF HEPATITIS C

U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.

U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA

U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)

U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER

U-1487 METHOD OF INCREASING EYELASH GROWTH

U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN

U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS

U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.

U-1496 METHOD TO TREAT HEMANGIOMA.

U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM

U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM

U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4

U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR

U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED

U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER

U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.

U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA

U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL

U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.

U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
- U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
- U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
- U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
- U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
- U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
- U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
- U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
- U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
- U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
- U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
- U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
- U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
- U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
- U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
- U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
- U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
- U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
- U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
- U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
- U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
- U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.

U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

U-1552 FOR HEALING OF ALL GRADES OF EROSION ESOPHAGITIS (EE)

U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)

U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER

U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE

U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.

U-1564 A METHOD OF TREATING GAUCHER'S DISEASE

U-1565 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-1567 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1

U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.

U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

U-1576 TREATMENT OF LEUKEMIA

U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS

U-1578 TREATMENT OF ACUTE OTITIS MEDIA

U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CHEMOTHERAPY

- U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
- U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
- U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
- U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
- U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
- U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
- U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
- U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
- U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
- U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
- U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
- U-1594 DILATION OF THE PUPIL
- U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
- U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- U-1597 TREATMENT OF DIABETIC MACULAR EDEMA
- U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
- U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
- U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
- U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
- U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
- U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
- U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE
- U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
- U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN

U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN

U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER

U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT

U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.

U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.

U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVIR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN

U-1643 TREATING CUSHING'S SYNDROME

U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN

U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)

U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)

U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN

U-1659 MANAGEMENT OF PAIN

U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

U-1662 A METHOD OF TREATING OCULAR PAIN

U-1663 TREATMENT OF HIV-1 INFECTION

U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1

U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER

U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE

U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS

U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION

U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS

U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS

U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1681 TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC

U-1682 TREATMENT OF BACTERIAL VAGINOSIS

U-1683 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR

U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT

U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

U-1697 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.

U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN

U-1702 TREATMENT OF COPD

U-1703 TREATMENT OF RESPIRATORY COMPLAINTS

U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES

U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE

U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.

U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE

U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

U-1712 MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR

U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE

U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.

U-1719 ACUTE TREATMENT OF MIGRAINE

U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA

U-1721 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2

U-1722 TREATMENT OF BASAL CELL CARCINOMA

U-1723 TREATMENT OF HEART FAILURE

U-1724 METHOD OF INHIBITING HEPATITIS C VIRUS

U-1725 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY

U-1726 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1727 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1728 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1729 REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)

U-1730 REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM

U-1731 TEMPORARY RELIEF OF MINOR ACHES AND PAINS

U-1732 TEMPORARY REDUCTION OF FEVER

U-1733 TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE

U-1734 USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

U-1735 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

U-1736 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1737 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE

U-1738 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-1739 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1740 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY

U-1741 PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1742 ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1743 FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

U-1745 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA

U-1746 MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY

U-1747 FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD

U-1748 FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1749 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-1750 TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

U-1752 PROPHYLAXIS OF ORGAN REJECTION

U-1753 TREATMENT OF HCV INFECTION USING DASABUVIR

U-1754 FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

U-1755 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

U-1756 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

U-1757 INHIBITION ON PI3K KINASE

U-1758 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION

U-1759 METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB

U-1760 RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

U-1761 PLAQUE PSORIASIS

U-1762 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1763 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1764 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1765 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1766 TREATMENT OF HYPERKALEMIA

U-1767 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN

U-1769 TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE

U-1770 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA

U-1771 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION

U-1772 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1773 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1774 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

U-1775 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS

U-1776 METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA

U-1777 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

U-1778 METHOD FOR TREATING MULTIPLE MYELOMA

U-1779 METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS

U-1780 METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA

U-1781 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

U-1782 FOR HEAD LICE INFESTATIONS

U-1783 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED

U-1784 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED

U-1785 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED

U-1786 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

U-1787 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

U-1788 TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN

U-1789 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

U-1790 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA

U-1791 EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

U-1792 TREATMENT OF OTIC INFECTION OR INFLAMMATION

U-1793 TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1794 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK

U-1795 REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

U-1796 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1797 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG

U-1798 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN

U-1799 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES

U-1800 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT

U-1801 REDUCTION OF SERUM URIC ACID LEVELS

U-1802 TREATMENT OF GOUT

U-1803 TREATMENT OF HYPERURICEMIA

U-1804 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT

U-1805 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS

PATENT AND EXCLUSIVITY TERMS

ADB 102 of 117

PATENT USE

- U-1806 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
- U-1807 TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- U-1808 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- U-1809 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
- U-1810 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-1811 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
- U-1812 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
- U-1813 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
- U-1814 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
- U-1815 TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-1816 TREATMENT OF A UREA CYCLE DISORDER
- U-1817 PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-1818 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1819 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
- U-1820 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1821 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-1822 TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
- U-1823 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
- U-1824 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1825 METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
- U-1826 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1827 A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
- U-1828 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
- U-1829 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
- U-1830 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
- U-1831 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
- U-1832 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1833 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1834 TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

PATIENTS UNDERGOING CATARACT SURGERY

- U-1835 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-1836 TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
- U-1837 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
- U-1838 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1839 COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
- U-1840 TREATMENT OF HCV INFECTION USING PARITAPREXAVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
- U-1841 USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-1842 METHOD OF TREATING EPILEPSY
- U-1843 TREATMENT OF PSYCHOSIS
- U-1844 TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
- U-1845 TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
- U-1846 TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
- U-1847 METHOD OF TREATING A BACTERIAL INFECTION
- U-1848 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
- U-1849 METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
- U-1850 METHOD OF ADMINISTERING LEVETIRACETAM
- U-1851 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1852 METHOD OF TREATING TYPE 2 DIABETES
- U-1853 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
- U-1854 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
- U-1855 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
- U-1856 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-1857 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
- U-1858 TREATMENT OF PLAQUE PSORIASIS
- U-1859 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1860 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1861 USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
- U-1862 TREATMENT OF POST-MYOCARDIAL INFARCTION
- U-1863 TREATMENT OF STROKE
- U-1864 TREATMENT OF MYOCARDIAL INFARCTION
- U-1865 TREATMENT OF THROMBOTIC STROKE
- U-1866 TREATMENT OF STABLE AND UNSTABLE ANGINA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1867 METHOD OF INHIBITING PLATELET AGGREGATION

U-1868 TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION

U-1869 TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE

U-1870 ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1871 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D

U-1872 USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY

U-1873 ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE

U-1874 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8

U-1875 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3

U-1876 METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH

U-1877 METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL

U-1878 FOR OPIOID DEPENDENCE

U-1879 METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY

U-1880 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

U-1881 IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR

U-1882 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY

U-1883 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)

U-1884 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1885 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1886 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1887 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1888 USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE

U-1889 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

U-1890 OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))

U-1891 TREATMENT OR PREVENTION OF NAUSEA AND VOMITING

U-1892 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION

U-1893 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS

U-1894 COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-1895 METHOD OF TREATING PROSTATE CANCER

U-1896 SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES

PATENT AND EXCLUSIVITY TERMS

ADB 105 of 117

PATENT USE

U-1897 METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1898 METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1899 TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1900 TREATMENT OF THE SIGNS SYMPTOMS OF DRY EYE DISEASE (DED)

U-1901 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

U-1902 TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS

U-1903 USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

U-1904 (I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1905 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1906 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1907 USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE

U-1908 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR

U-1909 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR

U-1910 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338

U-1911 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR

U-1912 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606

U-1913 TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1914 IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-1915 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN

U-1916 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)

U-1917 TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1918 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1919 RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1920 USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4

U-1921 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT

U-1922 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

MENOPAUSE

- U-1923 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1924 KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-1925 USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
- U-1926 METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
- U-1927 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- U-1928 RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
- U-1929 TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
- U-1930 METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
- U-1931 PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
- U-1932 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
- U-1933 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
- U-1934 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CY1A2 INHIBITOR
- U-1935 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
- U-1936 TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1937 TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1938 TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1939 ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
- U-1940 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
- U-1941 TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
- U-1942 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
- U-1943 TREATMENT OF SPINAL MUSCULAR ATROPHY
- U-1944 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
- U-1945 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
- U-1946 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
- U-1947 TREATMENT OF MARGINAL ZONE LYMPHOMA
- U-1948 A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
- U-1949 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-1950 TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 107 of 117

PATENT USE

U-1951 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL

U-1952 FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

U-1953 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

U-1954 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

U-1955 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

U-1956 FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

U-1957 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

U-1958 FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN

U-1959 TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM

U-1960 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS

U-1961 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)

U-1962 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS

U-1963 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS

U-1964 ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT

U-1965 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3

U-1966 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17

U-1967 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-1968 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-1969 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES

U-1970 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES

U-1971 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

U-1972 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

U-1973 METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

U-1974 TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS

U-1975 METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST

U-1976 METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2005 REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
- U-2006 REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
- U-2007 TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
- U-2008 TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
- U-2009 METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
- U-2010 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
- U-2011 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
- U-2012 A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
- U-2013 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- U-2014 A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
- U-2015 SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
- U-2016 TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
- U-2017 TREATMENT OF OPIOID DEPENDENCE
- U-2018 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
- U-2019 METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
- U-2020 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- U-2021 METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
- U-2022 METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
- U-2023 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
- U-2024 METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
- U-2025 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-2026 TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
- U-2027 TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
- U-2028 TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
- U-2029 PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
- U-2030 PROPHYLAXIS OF VENOUS THROMBOSIS
- U-2031 TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- U-2032 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2033 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
- U-2034 INHIBITING COAGULATION
- U-2035 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
- U-2036 A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
- U-2037 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
- U-2038 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- U-2039 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
- U-2040 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
- U-2041 TREATMENT OF PARTIAL-ONSET SEIZURES
- U-2042 DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2043 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
- U-2044 DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2045 ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2046 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
- U-2047 ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2048 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2049 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2050 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2051 DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2052 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2053 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2054 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2055 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2056 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2057 DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

PATENT AND EXCLUSIVITY TERMS

ADB 111 of 117

PATENT USE

- U-2058 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
- U-2059 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
- U-2060 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
- U-2061 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2062 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
- U-2063 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2064 DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2065 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2066 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
- U-2067 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2068 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
- U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
- U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
- U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF

PATENT AND EXCLUSIVITY TERMS

ADB 112 of 117

PATENT USE

- U-2078 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2079 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2080 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2081 DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
- U-2082 MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2083 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
- U-2084 TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
- U-2085 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
- U-2086 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
- U-2087 TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
- U-2088 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
- U-2089 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
- U-2090 FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2091 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-2092 METHOD FOR CONFIRMING DOSE DELIVERY
- U-2093 TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
- U-2094 TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
- U-2095 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
- U-2096 SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
- U-2097 TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2098 INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2099 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
- U-2100 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
- U-2101 MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 113 of 117

PATENT USE

- U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
- U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
- U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
- U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
- U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
- U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
- U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
- U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
- U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
- U-2116 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
- U-2117 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
- U-2118 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
- U-2119 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
- U-2120 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT

PATENT AND EXCLUSIVITY TERMS

ADB 114 of 117

PATENT USE

INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS

- U-2121 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
- U-2122 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2123 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
- U-2124 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- U-2125 THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
- U-2126 USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2127 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2128 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLININUM, VIA INHALATION
- U-2129 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLININUM, VIA TOPICAL APPLICATION
- U-2130 TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-2131 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
- U-2132 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
- U-2133 METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
- U-2134 THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
- U-2135 AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
- U-2136 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-2137 TREATMENT OF POSTHERPETIC NEURALGIA
- U-2138 TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
- U-2139 TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
- U-2140 METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2141 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
- U-2142 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- U-2143 AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
- U-2144 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-2145 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-2146 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE

PATENT AND EXCLUSIVITY TERMS

ADB 115 of 117

PATENT USE

U-2147 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME

U-2148 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE

U-2149 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON

U-2150 TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

U-2151 METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE

U-2152 TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-2153 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2154 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2155 REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2156 REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2157 TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE

U-2158 DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION

U-2159 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

U-2160 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM

U-2161 TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

U-2162 FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY

U-2163 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCOCLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

U-2164 ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

U-2165 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM

U-2166 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-2167 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2168 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2170 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2171 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISH OF RECURRENT RCC FOLLOWING NEPHRECTOMY

U-2172 METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)

U-2173 TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE

U-2174 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH

U-2175 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY

U-2176 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE

U-2177 TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE

U-2178 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2179 IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION

U-2180 TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

U-2181 TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE

U-2182 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2183 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13

U-2184 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14

U-2185 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27

U-2186 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28

U-2187 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39

U-2188 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

U-2189 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52

U-2190 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53

U-2191 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64

U-2192 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65

U-2193 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75

U-2194 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76

U-2195 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER

U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

- U-2203 A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
- U-2204 TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-2205 TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
- U-2206 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
- U-2207 TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
- U-2208 TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
- U-2209 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
- U-2210 TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
- U-2211 TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
- U-2212 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2213 REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2214 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
- U-2215 ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2216 ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2217 TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2218 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2219 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
- U-2220 A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIIIMORELIN
- U-2221 TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 MG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
- U-2222 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
- U-2223 METHOD OF TREATING ANGINA PECTORIS